{
  "evaluation_metadata": {
    "evaluator_name": "LLM-as-Judge Evaluator (Model: claude-haiku-4-5)",
    "evaluator_model": "claude-haiku-4-5",
    "model_evaluated": "gpt-oss-120b-reasoning",
    "experiment": "e2_page_window",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions_in_experiment": 1000
  },
  "evaluation_results": [
    {
      "question_id": 77,
      "question": "How did the gross benefit obligation and the actuarial losses for LMT's nonqualified defined benefit pension plans evolve between 2023 and 2024?",
      "original_answer": "In 2023, the gross benefit obligation for LMT's nonqualified defined benefit pension plans was $1.0 billion with actuarial losses totaling $347 million. By 2024, the gross benefit obligation decreased to $905 million, and the actuarial losses declined to $303 million. This indicates a reduction in both the liability and the associated actuarial losses over the period.",
      "llm_answer": "The gross benefit obligation for the non‑qualified defined‑benefit pension plans fell from **$1.0 billion at year‑end 2023** to **$905 million at year‑end 2024**.  Likewise, the actuarial losses (including unrecognized prior‑service credits) declined from **$347 million in 2023** to **$303 million in 2024**【LMT_10k_2023.pdf, p.86‑87】【LMT_10k_2024.pdf, p.87‑88】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative data matches the ground truth exactly: (1) Gross benefit obligation 2023: $1.0 billion ✓, (2) Gross benefit obligation 2024: $905 million ✓, (3) Actuarial losses 2023: $347 million ✓, (4) Actuarial losses 2024: $303 million ✓. The multi-hop synthesis is sound, correctly comparing the two years and identifying the trend of reduction in both metrics. The answer properly identifies the company (LMT), the specific pension plan type (nonqualified defined benefit), and the time period (2023-2024). The LLM provides appropriate source citations (LMT_10k_2023.pdf and LMT_10k_2024.pdf with page numbers), which adds credibility. The wording is clear and professional, with proper formatting of dollar amounts. The conclusion that 'this indicates a reduction in both the liability and the associated actuarial losses' is logically sound and matches the ground truth interpretation. Minor note: The LLM includes parenthetical clarification about 'unrecognized prior-service credits' which is a reasonable contextual addition not contradicting the ground truth. No calculation errors detected. The answer fully addresses all components of the multi-part question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1182,
        "completion_tokens": 346,
        "total_tokens": 1529
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did General Motors' long-term rate of return assumptions on U.S. pension plan assets evolve between 2022 and 2024, and what does this indicate about the company's strategic asset mix adjustments?",
      "original_answer": "In 2022, General Motors reported that the weighted-average long-term rate of return on U.S. pension plan assets decreased from 5.6% at December 31, 2020, to 5.4% at December 31, 2021. By contrast, in 2024, the company indicated that the weighted-average long-term rate of return on U.S. pension plan assets increased from 6.3% at December 31, 2023, to 6.5% at December 31, 2024. This indicates a notable shift in the company's strategic asset mix, moving from a more conservative assumption in 2022 to a more optimistic projection in 2024, likely reflecting changes in capital market assumptions and investment strategies aimed at improving funded status.",
      "llm_answer": "GM’s assumed long‑term return on U.S. pension‑plan assets rose from about **5.38 % for the 2022 year‑end** to roughly **6.27 % at year‑end 2024** (see the “Expected rate of return on plan assets” rows in the 2024 filing)【GM_10k_2024.pdf†p.86‑90】.  The December 2024 investment‑policy study raised the weighted‑average long‑term rate of return and was accompanied by a shift in the strategic asset mix—equity allocation increased (from 9 % to 11 %) and “Other” assets (private‑equity, real‑estate, hedge‑fund strategies) grew (from 23 % to 29 %) while debt fell—signaling GM’s move to higher‑return, higher‑risk assets to improve funded status and reduce volatility【GM_10k_2024.pdf†p.86‑90】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant discrepancies with the ground truth. (1) QUANTITATIVE ACCURACY FAILURES: The LLM states the rate was '5.38% for 2022 year-end' and '6.27% at year-end 2024', but the ground truth indicates: 2022 showed 5.4% (at Dec 31, 2021), and 2024 showed 6.5% (at Dec 31, 2024). The LLM's 6.27% figure is incorrect—it should be 6.5%. The 5.38% figure is also inaccurate; the ground truth references 5.4% for 2021 and 5.6% for 2020. (2) TEMPORAL CONFUSION: The LLM conflates different years. The ground truth clearly distinguishes between 2022 filing data (showing 2020-2021 comparisons) and 2024 filing data (showing 2023-2024 comparisons). The LLM appears to have mixed these periods. (3) ASSET MIX DETAILS: The LLM provides specific asset allocation percentages (equity 9% to 11%, Other 23% to 29%) that are not mentioned in the ground truth. While these details may be from the filing, they represent additional information not in the ground truth answer and cannot be verified against it. (4) MULTI-HOP REASONING: The LLM correctly identifies the strategic shift from conservative to optimistic assumptions and mentions the connection to asset mix changes, which aligns with the ground truth's conclusion. However, this correct reasoning is undermined by the incorrect numerical values. (5) SEMANTIC ISSUES: The ground truth presents a clear 2022 vs 2024 comparison showing evolution over time. The LLM attempts this but with wrong numbers, making the comparison factually incorrect. The ground truth's key insight—movement from 5.4% (2022) to 6.5% (2024)—is not accurately captured. The LLM's answer would mislead readers about the actual magnitude and timing of GM's assumption changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 473,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Chevron's relationship with PDC Energy evolved between 2023 and 2024, and what specific operational and financial impacts were attributed to this change?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, and as a result, PDC was excluded from Chevron’s internal control assessment due to the business combination. By 2024, the integration had progressed to the point where Chevron reported a $2.2 billion increase in U.S. upstream earnings attributed to legacy PDC assets, and a 19% increase in net oil-equivalent production driven by the full-year contribution from PDC. This reflects a shift from acquisition to operational integration and performance contribution.",
      "llm_answer": "In 2023 Chevron completed a business‑combination that made PDC Energy a wholly‑owned subsidiary; the 2023 filing notes that PDC was excluded from internal‑control testing because it was newly acquired and that its assets and revenues represented roughly 5 % of Chevron’s total assets and 1 % of total revenue (2023 10‑K, pp. 28‑32). By the 2024 filing the legacy PDC assets were fully integrated, delivering a full‑year of production that added about 250 k barrels of oil‑equivalent per day and $2.2 billion of sales volume, which helped lift U.S. upstream earnings by $3.5 billion (2024 10‑K, pp. 42‑46).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant quantitative errors that undermine its credibility. CRITICAL ERRORS: (1) The LLM states U.S. upstream earnings increased by $3.5 billion, but the ground truth specifies $2.2 billion - this is a major factual error of $1.3 billion. (2) The LLM introduces a new metric ('250k barrels of oil-equivalent per day') and '$2.2 billion of sales volume' that are not mentioned in the ground truth and appear to conflate different metrics. The ground truth clearly states '$2.2 billion increase in U.S. upstream earnings' - not sales volume. (3) The LLM provides page references (pp. 28-32, pp. 42-46) that cannot be verified against the ground truth and may be fabricated. CORRECT ELEMENTS: The LLM correctly identifies that Chevron acquired PDC Energy in 2023, that PDC was excluded from internal control testing as a newly acquired entity, that integration progressed by 2024, and that there was a 19% increase in net oil-equivalent production (though not explicitly stated in the LLM answer, the 250k BOE/day figure may relate to this). The contextual framing of the evolution from acquisition to integration is appropriate. MULTI-HOP REASONING: The LLM demonstrates understanding of the multi-hop nature (2023 acquisition → 2024 integration) but fails in precise synthesis of the financial impacts. The conflation of 'sales volume' with 'earnings increase' suggests confusion about what metrics were actually reported. The answer is partially responsive to the question but the quantitative inaccuracies are disqualifying for a financial analysis context where precision is paramount.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 442,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did Southern Company's treatment and valuation of energy-related derivatives change between 2022 and 2024, particularly in terms of unrealized gains (losses) and their presentation in financial statements?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred, specifically as of December 31, 2021, and 2020. By 2024, the company shifted its disclosure focus to the fair value of energy-related derivatives, interest rate derivatives, and foreign currency derivatives, which were presented as either assets or liabilities in the balance sheets, typically under 'Other' or separately as 'Risk Management Activities'. This indicates a change in both the valuation approach and the presentation of these instruments in financial disclosures.",
      "llm_answer": "In the 2022 filing Southern Company reported separate unrealized‑gain figures for its energy‑related derivatives – a $155 million pre‑tax gain on regulatory hedges at 12/31/2021 and a $34 million gain recorded in OCI (with a $17 million gain recognized in earnings) for cash‑flow hedges. By the 2024 filing the company no longer disclosed those gains; instead the fair value of the derivatives is presented net as assets and liabilities on the balance sheet (e.g., $75 million of regulatory‑hedge assets versus $122 million of liabilities and $8 million of cash‑flow‑hedge assets versus $490 million of liabilities) and it notes that any reclassification from AOCI to earnings for cash‑flow hedges is immaterial. This reflects a shift from explicit unrealized‑gain reporting to net balance‑sheet presentation of derivative fair value.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer provides specific dollar amounts and derivative classifications that cannot be verified against the ground truth provided. Critical issues: (1) QUANTITATIVE PROBLEMS: The LLM cites very specific numbers ($155M regulatory hedge gain at 12/31/2021, $34M OCI gain, $17M earnings gain, $75M regulatory-hedge assets, $122M liabilities, $8M cash-flow-hedge assets, $490M liabilities) that are presented with high confidence but are not confirmed in the ground truth. The ground truth only describes a general shift in disclosure approach without providing these specific figures. Without access to actual 10-K filings, these numbers cannot be verified and may be fabricated. (2) ENTITY/METRIC ACCURACY: The LLM correctly identifies Southern Company and the 2022-2024 timeframe, and correctly identifies the types of derivatives (energy-related, interest rate, foreign currency). However, the specific derivative classifications and their treatment are presented with unwarranted specificity. (3) REASONING QUALITY: The LLM does correctly identify the core conceptual shift described in the ground truth - from explicit unrealized-gain reporting to net balance-sheet presentation. This multi-hop synthesis is sound in principle. However, the addition of specific unverified numbers undermines the answer's credibility. (4) COMPLETENESS: The answer addresses the main question about changes between 2022 and 2024, but the ground truth is somewhat vague about specific metrics, making it difficult to assess whether the LLM's detailed numbers are accurate or speculative. The ground truth mentions 'typically under Other or separately as Risk Management Activities' but the LLM provides exact balance sheet line items without confirmation. (5) MAJOR CONCERN: The LLM appears to have generated specific financial figures that sound plausible but cannot be verified against the provided ground truth. This is a significant risk in financial analysis where precision is critical.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 534,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Chevron's financial relationship with Tengizchevroil evolve between 2022 and 2024, particularly in terms of its investment carrying value and equity earnings?",
      "original_answer": "In 2022, Chevron disclosed that its carrying value of its investment in Tengizchevroil (TCO) was about $100 higher than its underlying equity in TCO's net assets, with a significant portion of the investment tied to a $4,500 loan to fund the FGP/WPMP development. By 2024, Chevron's financial stake in Tengizchevroil had grown substantially, with its investment and advances reaching $27,368 million in 2024, compared to $26,954 million in 2023. Additionally, Chevron's equity in earnings from TCO declined from $4,386 million in 2022 to $3,033 million in 2024, indicating a reduction in profitability from the venture over this period.",
      "llm_answer": "Chevron’s book‑value stake in Tengizchevroil rose modestly – the investment was $27,368 million at 31 Dec 2024, up from $26,954 million a year earlier【CVX_10k_2024.pdf†p82】.  At the same time, its share of TCO’s earnings fell, dropping from $4,386 million in 2022 to $3,033 million in 2024【CVX_10k_2024.pdf†p86】.  The 2024 filing notes the carrying amount now exceeds the underlying equity in TCO by about $73 million, reflecting a small premium on the investment.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop financial question about Chevron's relationship with Tengizchevroil. STRENGTHS: (1) All key financial figures are correct: $27,368 million (2024), $26,954 million (2023), $4,386 million (2022 earnings), and $3,033 million (2024 earnings). (2) The multi-hop synthesis is sound - the answer correctly traces the evolution across the 2022-2024 period by comparing investment values and equity earnings. (3) The modest increase in investment carrying value ($414 million from 2023 to 2024) is accurately characterized. (4) The significant decline in equity earnings ($1,353 million decrease from 2022 to 2024) is correctly identified and presented. (5) The answer appropriately notes the carrying amount premium of approximately $73 million. MINOR CONSIDERATIONS: The original answer mentions a $4,500 million loan for FGP/WPMP development and a $100 million carrying value premium from 2022, which the LLM answer does not include. However, the question specifically asks about the evolution 'between 2022 and 2024,' and the LLM answer provides the most relevant 2024 comparison data ($73 million premium). The omission of the 2022 loan detail is a minor gap, but the core financial evolution is accurately captured. The LLM answer is more focused on the 2023-2024 period while still addressing the broader 2022-2024 timeframe through the earnings comparison. All numbers are formatted correctly and calculations are accurate. The reasoning demonstrates proper multi-hop synthesis across investment values and earnings metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 442,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Walmart's ownership stake in Alert Innovation evolve between fiscal 2023 and fiscal 2024, and what specific transaction occurred to change its relationship with the entity?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, which was previously consolidated as a variable interest entity, resulting in Walmart becoming a 100% owner. However, by fiscal 2024, Walmart had subsequently sold and deconsolidated Alert Innovation, indicating a complete exit from the entity. This marks a full transformation from full ownership to no ownership within a single fiscal year.",
      "llm_answer": "In fiscal 2023 Walmart bought Alert Innovation for about $0.4 billion, converting the company from a variable‑interest entity into a wholly‑owned subsidiary (100 % ownership). The 2024 filing reports no further change, so Walmart remained a 100 % owner through fiscal 2024. The ownership shift was driven by the $0.4 billion acquisition of Alert Innovation.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERROR: The LLM answer fundamentally misses the key evolution in Walmart's ownership stake between fiscal 2023 and fiscal 2024. (1) QUANTITATIVE ACCURACY: The $0.4 billion acquisition amount is correct, and the 100% ownership percentage in fiscal 2023 is accurate. However, the LLM fails to capture the critical transaction that occurred in fiscal 2024. (2) MAJOR FACTUAL ERROR - OWNERSHIP EVOLUTION: The ground truth clearly states that by fiscal 2024, Walmart had 'subsequently sold and deconsolidated Alert Innovation, indicating a complete exit from the entity.' The LLM incorrectly claims 'The 2024 filing reports no further change, so Walmart remained a 100% owner through fiscal 2024.' This is the opposite of what actually happened. The question specifically asks about how ownership 'evolved' between the two years, and the critical evolution is the complete exit/sale in fiscal 2024. (3) MISSING TRANSACTION: The LLM completely fails to identify the sale/deconsolidation transaction that occurred in fiscal 2024, which is the core answer to the question about what 'specific transaction occurred to change its relationship with the entity.' (4) MULTI-HOP REASONING FAILURE: The LLM failed to synthesize the multi-year information correctly. It only captured the fiscal 2023 acquisition but missed the fiscal 2024 sale, which is essential to answering how the ownership stake 'evolved' between the two years. (5) SEMANTIC MISMATCH: The LLM's statement that ownership remained at 100% through fiscal 2024 directly contradicts the ground truth that Walmart had completely exited the entity by fiscal 2024 (0% ownership). This is a fundamental factual error, not a wording difference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 463,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions change from fiscal year 2022 to 2023, and what does this indicate about the company's exposure management strategy?",
      "original_answer": "In fiscal year 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in Accumulated Other Comprehensive Income (AOCI) with $32.5 million expected to be reclassified into earnings within 12 months. By fiscal year 2023, Starbucks had shifted its position significantly, reporting foreign currency - other derivative assets of $1.9 million in current assets and $1.7 million in long-term assets, while carrying derivative liabilities of $4.7 million in current liabilities and $4.1 million in long-term liabilities. This indicates a substantial reduction in overall foreign currency - other derivative exposure and a shift from unrealized gains in equity to more balanced short- and long-term asset and liability positions.",
      "llm_answer": "- **2022:** Starbucks held foreign‑currency‑other derivative assets of **$39.9 m (prepaid) + $33.5 m (long‑term) = $73.4 m** and only **$0.3 m** of related liabilities (SBUX 10‑K 2022, pp. 64‑68).  \n- **2023:** The same line‑item fell to **$8.9 m + $6.9 m = $15.8 m** in assets, while liabilities rose to **$7.4 m (accrued) + $3.6 m (long‑term) = $11.0 m** (SBUX 10‑K 2023, pp. 70‑74).  \n\nThe net foreign‑currency‑other position shrank from roughly **$73 m** of assets to about **$5 m** net (assets – liabilities), indicating that Starbucks has largely unwound its non‑transactional currency hedges and is moving to a tighter, more balanced exposure‑management strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significantly incorrect numbers that do not match the ground truth data. (1) QUANTITATIVE ACCURACY FAILURES: The LLM reports 2022 foreign currency derivative assets of $73.4M ($39.9M + $33.5M), but ground truth shows $55.3M in AOCI. The LLM reports 2023 assets of $15.8M ($8.9M + $6.9M), but ground truth shows $1.9M current + $1.7M long-term = $3.6M total. The LLM reports 2023 liabilities of $11.0M ($7.4M + $3.6M), but ground truth shows $4.7M current + $4.1M long-term = $8.8M total. All numerical values are substantially different from the ground truth. (2) CALCULATION ERRORS: While the LLM's arithmetic is internally consistent (e.g., $39.9M + $33.5M does equal $73.4M), the underlying source numbers are wrong, making the calculations meaningless. The net position calculation ($73M to $5M) is based on incorrect inputs. (3) ENTITY/METRIC CONFUSION: The LLM appears to be citing different line items or balance sheet categories than what the ground truth identifies. The ground truth specifically references AOCI positions and current/long-term asset/liability classifications, while the LLM references 'prepaid' and 'accrued' categories that don't align with the ground truth structure. (4) MULTI-HOP REASONING: While the LLM attempts to synthesize year-over-year change and draw conclusions about exposure management strategy (which is appropriate), the foundation is built on incorrect data, making the conclusion unreliable. The directional insight (reduction in exposure, shift to balanced positions) may be conceptually sound, but it's based on wrong numbers. (5) MISSING KEY DETAIL: The ground truth specifically mentions the $32.5M expected to be reclassified within 12 months in 2022, which the LLM completely omits. This is an important detail for understanding the company's exposure management.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 504,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Medtronic's treatment of A Preferred Shares evolve between fiscal years 2022 and 2024, and what specific action was taken regarding these shares in 2022?",
      "original_answer": "In fiscal year 2022, Medtronic redeemed 1,872 A Preferred Shares for $0.075 million during the third quarter, and no A Preferred Shares were outstanding by April 29, 2022. By fiscal year 2024, no A Preferred Shares remained outstanding, indicating that the company did not reissue or reintroduce this class of shares after the redemption in 2022. This shows a discontinuation of the A Preferred Shares following their redemption.",
      "llm_answer": "In FY 2022 Medtronic eliminated its A Preferred Shares by redeeming the 1,872 shares then outstanding for $0.075 million, leaving none outstanding at April 29, 2022. By FY 2024 the company still reports that no A Preferred Shares are issued or outstanding, showing that after the redemption the shares have not been re‑issued.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and addresses all key aspects of the question. Quantitative verification: (1) Share count of 1,872 shares - CORRECT, (2) Redemption amount of $0.075 million - CORRECT, (3) Date reference (April 29, 2022 for FY2022 end) - CORRECT, (4) FY2024 status (no shares outstanding) - CORRECT. Multi-hop reasoning: The answer correctly synthesizes information across two fiscal years (2022 and 2024) and identifies the evolution: redemption in 2022 followed by no reissuance by 2024. The answer properly identifies the specific action (redemption of 1,872 shares for $0.075 million in Q3 2022) and confirms the discontinuation status in 2024. Minor observation: The LLM uses slightly different phrasing ('eliminated' vs 'redeemed') but this is semantically equivalent and actually more concise. The statement about shares 'not being re-issued' in the LLM answer directly parallels the ground truth's 'did not reissue or reintroduce.' All factual content matches the ground truth, calculations are accurate, and the multi-hop synthesis across fiscal years is sound. The answer is complete, addressing both the specific 2022 action and the 2024 status evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1192,
        "completion_tokens": 335,
        "total_tokens": 1527
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did Comcast's financial relationship with Atairos evolve between 2022 and 2023, particularly in terms of equity income (losses) driven by fair value adjustments on underlying investments?",
      "original_answer": "In 2022, Comcast's equity in net income (losses) from investees, particularly Atairos, showed a loss of $(434) million due to fair value adjustments on its underlying investments. In contrast, by 2023, Atairos generated income of $1.1 billion for Comcast, reflecting a significant turnaround. This change indicates a substantial improvement in the performance of Atairos's underlying investments over the period.",
      "llm_answer": "In 2022 Comcast’s equity‑in‑investees line was a $ 537 million loss, driven largely by a $(434) million loss on its Atairos investment from fair‑value adjustments on Atairos’ underlying holdings (2022 10‑K, p.46‑47). By 2023 that position had reversed to a $ 789 million gain, with Atairos generating a $1.1 billion fair‑value gain, turning the overall equity‑in‑investees line positive (2023 10‑K, p.37‑38). This reflects a swing from a loss in 2022 to a sizable gain in 2023.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy with correct identification of the key financial metrics and the evolution of Comcast's relationship with Atairos between 2022 and 2023. STRENGTHS: (1) Correctly identifies the $(434) million loss from Atairos in 2022 due to fair value adjustments - this matches the ground truth exactly. (2) Correctly identifies the $1.1 billion gain in 2023 from Atairos - this matches ground truth. (3) Properly synthesizes the multi-hop information showing the turnaround from loss to gain. (4) Provides additional context about the broader equity-in-investees line ($537M loss in 2022, $789M gain in 2023), which adds useful detail. (5) Correctly cites source documents (2022 and 2023 10-Ks with page numbers). MINOR ISSUES: (1) The ground truth focuses specifically on 'equity in net income (losses) from investees' and the Atairos component, while the LLM answer provides broader context about the total equity-in-investees line. This is not incorrect but represents a slightly different framing. (2) The ground truth states Atairos 'generated income of $1.1 billion' while the LLM specifies this as a '$1.1 billion fair-value gain' - both are semantically equivalent and accurate. (3) The LLM provides more granular detail about the overall equity-in-investees position, which enhances understanding but wasn't explicitly requested. QUANTITATIVE VERIFICATION: All numbers check out - $(434)M loss in 2022, $1.1B gain in 2023, and the directional change from loss to gain is correct. The additional figures ($537M and $789M) appear reasonable as broader line items. MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years and identifies the causal relationship (fair value adjustments on underlying investments). The logic is sound and the conclusion about the turnaround is well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 503,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure slightly declined to 296 billion cubic feet. This minor decrease suggests limited growth or a strategic reallocation of resources in the region during that period.",
      "llm_answer": "COP’s direct natural‑gas reserves in the Asia Pacific/Middle East fell modestly from 312 billion cubic feet (BCF) in 2023 to 296 BCF in 2024 (undeveloped volumes stayed at 7 BCF)【150】, while its equity‑affiliate holdings in the same region rose from 5,275 BCF to 5,870 BCF (undeveloped grew from 1,717 BCF to 2,681 BCF)【144】.  Together, total regional reserves increased from roughly 7.3 trillion cubic feet in 2023 to about 8.9 trillion cubic feet in 2024.  The decline in company‑owned reserves offset by a strong boost in affiliate assets signals a strategic pivot toward expanding partnership‑based exposure in the Asia‑Pacific/Middle‑East gas market.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core fact from the ground truth: COP's direct natural gas reserves in Asia Pacific/Middle East declined from 312 BCF (2023) to 296 BCF (2024). However, the answer introduces significant additional information about equity-affiliate holdings and total regional reserves that is NOT present in the ground truth answer. While this additional detail may be factually accurate from the source documents, it goes beyond what was established as the correct answer and introduces unverified numbers (5,275 BCF to 5,870 BCF for affiliates; 7.3 TCF to 8.9 TCF total). The ground truth explicitly states the answer should focus on the direct reserves decline and what it indicates about strategic positioning. The LLM's interpretation that this represents a 'strategic pivot toward expanding partnership-based exposure' is a reasonable inference but differs from the ground truth's more cautious assessment of 'limited growth or strategic reallocation.' The quantitative accuracy is compromised because the affiliate and total reserve figures cannot be verified against the ground truth, and the calculation from BCF to TCF (multiplying by 1,000) appears to have potential errors that cannot be confirmed. The answer demonstrates good multi-hop reasoning in attempting to synthesize affiliate data with direct reserves, but this synthesis goes beyond the scope of the ground truth answer. The core direct reserves numbers (312→296 BCF) are correct, which prevents a lower score, but the introduction of unverified additional data and a different strategic interpretation reduces overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 446,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the revenue performance of ENBREL in Canada evolve between 2022 and 2024, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ENBREL in Canada generated $113 million in revenue, which declined to $47 million in 2023, and further dropped to $28 million in 2024. This indicates a consistent downward trend in revenue, suggesting a shrinking market presence or reduced demand for ENBREL in Canada over this period.",
      "llm_answer": "ENBREL’s Canadian sales fell sharply, from **$73 million in 2022** to **$47 million in 2023** (a 36 % drop) and then to **$28 million in 2024** (a further 40 % drop)【AMGN_10k_2023.pdf p.73】【AMGN_10k_2024.pdf p.71】. This consecutive, accelerating decline indicates a weakening market position in Canada and a clearly negative sales trajectory for ENBREL.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERROR IN PRIMARY METRIC: The LLM provided an incorrect 2022 revenue figure for ENBREL in Canada. Ground truth shows $113 million in 2022, but the LLM stated $73 million - a $40 million discrepancy (35% understatement). This is a fundamental factual error that undermines the entire answer. The 2023 ($47 million) and 2024 ($28 million) figures are correct. CALCULATION VERIFICATION: The LLM's percentage calculations are mathematically accurate given their stated numbers (36% drop from $73M to $47M ≈ correct; 40% drop from $47M to $28M ≈ correct), but these calculations are based on the wrong 2022 baseline. The correct percentage decline from 2022-2023 should be calculated from $113M to $47M (58% decline), not from $73M. MULTI-HOP REASONING: The LLM correctly synthesized information across multiple years and documents (AMGN 10-K filings 2023 and 2024), and the qualitative interpretation of a 'weakening market position' and 'negative sales trajectory' is sound and matches the ground truth conclusion. COMPLETENESS: The answer addresses both parts of the question (revenue evolution and market trajectory implications), but the foundational data error compromises the entire analysis. The reasoning about consecutive, accelerating decline is logically sound but based on incorrect numbers. CONTEXTUAL RELEVANCE: The answer appropriately contextualizes the data within the broader question about market trajectory, making relevant inferences about market position.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1159,
        "completion_tokens": 409,
        "total_tokens": 1569
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Qualcomm's approach to linking human capital advancements with executive compensation evolved from fiscal 2023 to fiscal 2024, and what specific performance modifier range was applied in fiscal 2024?",
      "original_answer": "In fiscal 2023, Qualcomm indicated that human capital advancements would be considered in determining executives' fiscal 2024 bonus. By fiscal 2024, this approach evolved into a more defined structure where progress toward human capital advancements served as a non-financial performance modifier that could adjust executives' bonus payouts by a multiplier ranging from 0.9 to 1.1. This represents a shift from a general consideration to a quantified performance modifier in executive compensation.",
      "llm_answer": "Qualcomm kept human‑capital progress as a non‑financial performance factor in its executive‑bonus formula, a practice that was already in place in fiscal 2023. In fiscal 2024 the company formalized the modifier, allowing the bonus to be adjusted by a multiple of **0.9 to 1.1**【QCOM_10k_2024.pdf†L1-L3】. This range represents the specific performance‑modifier applied to executives’ bonuses for FY 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the specific performance modifier range of 0.9 to 1.1 for fiscal 2024, which matches the ground truth exactly. (2) The numeric values are accurate and properly formatted. (3) The company (Qualcomm) and fiscal years (2023, 2024) are correctly identified. (4) The answer appropriately references the non-financial performance modifier concept. WEAKNESSES: (1) The LLM's characterization of the evolution is incomplete and somewhat misleading. The ground truth emphasizes a clear SHIFT from fiscal 2023 (where human capital advancements were merely 'considered') to fiscal 2024 (where they became a 'more defined structure' with a 'quantified performance modifier'). The LLM states the practice was 'already in place in fiscal 2023' and only 'formalized' in 2024, which understates the evolution described in the ground truth. (2) The LLM fails to adequately capture the key distinction: in FY2023, human capital was a general consideration; in FY2024, it became a specific, quantified modifier with defined bounds (0.9-1.1). The answer suggests continuity rather than evolution. (3) The multi-hop reasoning is incomplete—the answer doesn't fully synthesize the year-over-year comparison that the question specifically asks about ('evolved from fiscal 2023 to fiscal 2024'). The ground truth emphasizes this evolution as a meaningful change in approach, while the LLM presents it as a minor formalization of an existing practice. CALCULATION/VERIFICATION: The modifier range (0.9 to 1.1) is correct. No calculation errors present. MULTI-HOP SYNTHESIS: Partially successful—the answer identifies both years and the modifier, but fails to properly synthesize the nature of the change between them.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 473,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has the therapeutic scope of Breyanzi evolved between 2022 and 2024, based on the specific indications and approvals documented in those years?",
      "original_answer": "In 2022, Breyanzi was associated with trials for 3L+ Chronic Lymphocytic Leukemia (TRANSCEND-CLL-004) and 3L+ Follicular Lymphoma (TRANSCEND-FL), both with expected timing in 2023/24. By 2024, Breyanzi received FDA accelerated approvals for two distinct indications: relapsed or refractory Follicular Lymphoma (FL) after at least two prior lines of therapy (approved in May 2024), and relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) after at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor (approved in March 2024). This reflects a shift from being in late-stage trials to having concrete accelerated approvals in specific patient populations.",
      "llm_answer": "In the 2022 filing Breyanzi was listed only for relapsed or refractory large B‑cell lymphoma, representing a single B‑cell cancer indication (BMY_10k_2022.pdf p.18‑22). By the 2024 filing the product had added FDA accelerated approvals for relapsed or refractory CLL/SLL (March 2024) and FL (May 2024), an FDA approval for relapsed or refractory MCL (May 2024), and a Japanese approval for FL (August 2024), expanding its therapeutic scope to multiple B‑cell malignancies (BMY_10k_2024.pdf p.44‑46).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) FACTUAL INACCURACY - The LLM claims Breyanzi was 'listed only for relapsed or refractory large B-cell lymphoma' in 2022, but the ground truth explicitly states it was associated with trials for BOTH 3L+ CLL (TRANSCEND-CLL-004) and 3L+ FL (TRANSCEND-FL) in 2022. This is a fundamental mischaracterization of the 2022 baseline. (2) INCOMPLETE/INCORRECT 2024 APPROVALS - The LLM lists an 'FDA approval for relapsed or refractory MCL (May 2024)' which is NOT mentioned in the ground truth. The ground truth only documents CLL/SLL (March 2024) and FL (May 2024) FDA accelerated approvals. The MCL approval appears to be fabricated or confused with another product. (3) JAPANESE APPROVAL - The LLM mentions 'Japanese approval for FL (August 2024)' which is not in the ground truth answer, suggesting either hallucination or information from outside the specified scope. (4) MISSING CRITICAL CONTEXT - The LLM fails to emphasize that the 2022 indications were in 'late-stage trials with expected timing in 2023/24,' whereas 2024 shows 'concrete accelerated approvals.' The ground truth explicitly frames this as a shift from trials to approvals. (5) APPROVAL DATES - While the March 2024 (CLL/SLL) and May 2024 (FL) dates are correct, the addition of MCL and Japanese approvals introduces unverified information. The multi-hop reasoning is partially sound (comparing 2022 vs 2024 scope), but the factual foundation is compromised by the incorrect 2022 baseline and unsubstantiated 2024 additions. The answer demonstrates some understanding of the evolution concept but fails on accuracy of specific indications and approvals.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 451,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the financial performance of Disney's Resorts and Vacations segment evolved from 2023 to 2024, and how does this compare to the overall revenue growth of the Parks & Experiences segment?",
      "original_answer": "The Resorts and Vacations segment saw an increase in revenue from $7,949 million in 2023 to $8,375 million in 2024, representing a 5% growth. This growth was slightly below the overall Parks & Experiences revenue growth of 5%, which increased from $32,549 million in 2023 to $34,151 million in 2024. The Resorts and Vacations segment remained a significant contributor to the overall Parks & Experiences division, maintaining a consistent proportion of total revenue despite the modest growth difference.",
      "llm_answer": "Disney’s Resorts & Vacations revenue increased from $7.9 billion in FY 2023 to $8.4 billion in FY 2024 – a rise of roughly 5 % (up $426 million).  The broader Parks & Experiences segment grew from $32.5 billion to $34.2 billion in the same period, also about 5 % (up $1.6 billion), so the Resorts & Vacations line expanded at a rate essentially in line with overall segment growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and addresses all components of the multi-hop question effectively. QUANTITATIVE VERIFICATION: (1) Resorts & Vacations 2023: $7.9B matches $7,949M (ground truth) - acceptable format variation; (2) Resorts & Vacations 2024: $8.4B matches $8,375M - acceptable format variation; (3) Growth calculation: $8,375M - $7,949M = $426M, which the LLM correctly states; (4) Growth percentage: $426M / $7,949M = 5.36%, reasonably rounded to 5%; (5) Parks & Experiences 2023: $32.5B matches $32,549M - acceptable format variation; (6) Parks & Experiences 2024: $34.2B matches $34,151M - acceptable format variation; (7) Parks & Experiences growth: $34,151M - $32,549M = $1,602M, which the LLM correctly rounds to $1.6B; (8) Parks & Experiences growth percentage: $1,602M / $32,549M = 4.92%, reasonably rounded to 5%. MULTI-HOP REASONING: The LLM successfully synthesized information across two related segments (Resorts & Vacations and Parks & Experiences) and correctly compared their growth rates. The conclusion that both segments grew at essentially the same rate (~5%) is accurate and well-supported. COMPLETENESS: The answer addresses all parts of the question: (1) evolution of Resorts & Vacations from 2023-2024, (2) comparison to overall Parks & Experiences growth, and (3) contextual assessment of the relationship. MINOR OBSERVATION: The ground truth states the growth was 'slightly below' the overall segment growth, while the LLM states it was 'essentially in line with' overall segment growth. Given that both round to 5% (5.36% vs 4.92%), the LLM's characterization of 'essentially in line' is reasonable and arguably more precise than 'slightly below,' though this is a minor semantic difference that doesn't affect factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 481,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has the structure and value of CVS's forward contracts associated with accelerated share repurchase (ASR) transactions evolved between 2023 and 2024?",
      "original_answer": "In 2023, CVS executed a $2.0 billion ASR with Citibank, N.A., which was accounted for as an initial treasury stock transaction of $1.6 billion and a forward contract of $0.4 billion. The forward contract was classified as an equity instrument and recorded within capital surplus, with the final 20% of shares received in February 2023. In 2024, CVS entered into a larger $3.0 billion ASR with Morgan Stanley, accounted for as an initial treasury stock transaction of $2.6 billion and a forward contract of $0.4 billion. The forward contract was similarly classified and recorded, but the remaining 15% of shares were received later, in March 2024. Despite the increase in the ASR size, the forward contract value remained constant at $0.4 billion, indicating a shift in the proportion of the ASR allocated to the forward contract component.",
      "llm_answer": "In both years CVS used the same two‑step ASR structure – an initial treasury‑stock purchase for the bulk of the notional amount and a separate forward contract for the balance that is first recorded in capital surplus as an equity instrument and then re‑classified to treasury stock when the final shares are delivered. In 2023 the forward contracts were $0.4 billion for the $2.0 billion Citibank ASR (20 % of the notional) and $0.3 billion for the $1.5 billion Barclays ASR (20 % of the notional) 【73†L31-L38】【73†L39-L46】, while in 2024 the company entered a larger $3.0 billion Morgan Stanley ASR with a $0.4 billion forward contract (about 15 % of the notional) 【173†L31-L38】【173†L39-L45】. Thus, the structure stayed the same, but the forward‑contract amount remained at $0.4 billion even as the overall ASR size grew, reducing the forward component’s percentage of the total transaction.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: The LLM answer introduces a significant factual error by mentioning a $1.5 billion Barclays ASR with a $0.3 billion forward contract in 2023 that does not appear in the ground truth. The ground truth explicitly states CVS executed only a $2.0 billion ASR with Citibank in 2023, not multiple ASRs. This is a critical multi-hop synthesis error. QUANTITATIVE ACCURACY ISSUES: (1) The LLM correctly identifies the 2023 Citibank ASR as $2.0 billion with $0.4 billion forward contract, but incorrectly adds a non-existent Barclays transaction. (2) The 2024 Morgan Stanley ASR is correctly stated as $3.0 billion with $0.4 billion forward contract. (3) The percentage calculations are approximately correct for the transactions mentioned (20% for 2023 Citibank, 13.3% for 2024 Morgan Stanley), but the inclusion of the fabricated Barclays transaction undermines accuracy. STRUCTURAL ANALYSIS: The LLM correctly identifies the two-step ASR structure (initial treasury stock + forward contract recorded in capital surplus) and the reclassification process. However, the core comparison between 2023 and 2024 is compromised by the spurious Barclays reference. GROUND TRUTH VERIFICATION: The original answer clearly states only two ASRs: (1) 2023 Citibank $2.0B with $0.4B forward, and (2) 2024 Morgan Stanley $3.0B with $0.4B forward. The LLM's introduction of a Barclays transaction is a hallucination that significantly damages the answer's credibility. The correct insight about forward contract value remaining constant at $0.4B while the proportion decreased is present but overshadowed by the factual error. MULTI-HOP REASONING: The model failed to correctly synthesize the available information, instead introducing extraneous data not supported by the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 486,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Duke Energy's disclosure regarding the Master Retirement Trust's pension asset valuation methodology evolve from 2023 to 2024, particularly in terms of transparency around fair value categorization?",
      "original_answer": "In 2023, Duke Energy disclosed the allocation percentages of the Master Retirement Trust among its subsidiaries and noted that certain investments measured at fair value using the net asset value per share practical expedient were not categorized in the fair value hierarchy. In 2024, the company maintained the same allocation percentages but added a new disclosure element — a reconciliation of beginning and ending balances of the Master Retirement Trust's qualified pension and other post-retirement assets, specifically those valued using significant unobservable inputs (Level 3). This represents a significant increase in transparency regarding the fair value categorization of pension assets.",
      "llm_answer": "Both the 2023 and 2024 10‑K filings explain that the Master Retirement Trust’s pension assets are valued using the fair‑value hierarchy – Level 1, Level 2 and Level 3 – and that a “Not Categorized” bucket exists for investments measured with a net‑asset‑value‑per‑share practical expedient. The 2024 filing repeats the same methodology description and footnote, presenting a comparable breakdown of assets by level, so the company’s transparency around fair‑value categorization remained essentially unchanged from 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core conclusion. The ground truth explicitly states that Duke Energy ADDED a significant new disclosure element in 2024 — a reconciliation of beginning and ending balances of Level 3 assets — representing a 'significant increase in transparency.' The LLM answer directly contradicts this by claiming transparency 'remained essentially unchanged from 2023.' This is a critical factual error that misrepresents the evolution of Duke Energy's disclosures. While the LLM correctly identifies that both years discuss the fair value hierarchy (Level 1, 2, 3) and the 'Not Categorized' bucket for net asset value per share practical expedient investments, it fails to recognize the key differentiator: the 2024 addition of Level 3 reconciliation disclosures. The LLM's statement that '2024 filing repeats the same methodology description and footnote' is contradicted by the ground truth's explicit mention of new reconciliation elements in 2024. The answer demonstrates incomplete multi-hop synthesis — it identified some overlapping elements between years but missed the critical new disclosure that represents the evolution being asked about. The quantitative accuracy score reflects that while some descriptive elements are correct (fair value hierarchy levels, NAV practical expedient), the fundamental conclusion about whether transparency changed is wrong. The qualitative accuracy is low because the reasoning fails to identify and synthesize the key differentiating disclosure element across the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 428,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did Pfizer's financial obligations and revenue recognition related to Paxlovid change between 2023 and 2024, particularly concerning the U.S. government's inventory return and the creation of the U.S. Strategic National Stockpile?",
      "original_answer": "In 2023, Pfizer recorded a non-cash revenue reversal of $3.5 billion related to the expected return of 6.5 million EUA-labeled Paxlovid treatment courses previously purchased by the U.S. government. In 2024, this estimate was adjusted based on the actual return of 5.1 million treatment courses, resulting in a favorable final adjustment of $771 million. Additionally, in 2024, Pfizer recognized $442 million of revenue in connection with the creation of the U.S. Strategic National Stockpile (SNS) of 1.0 million Paxlovid treatment courses for future pandemic preparedness. These developments reflect a shift from revenue reversal and inventory transition in 2023 to revenue recognition and strategic stockpile establishment in 2024.",
      "llm_answer": "In 2023 Pfizer recorded a $3.5 billion non‑cash revenue reversal for Paxlovid, reflecting the expected return of roughly 6.5 million EUA‑labeled treatment courses from the U.S. government and creating a volume‑based credit to fund a patient‑assistance program. In 2024 that estimate was revised – a $771 million favorable adjustment was booked for the 5.1 million courses actually returned, and the company recognized $442 million of revenue for supplying a U.S. Strategic National Stockpile of 1 million courses (at no cash cost), which helped cut Paxlovid‑related deferred revenue from $5.1 billion at year‑end 2023 to $2.2 billion at year‑end 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct with strong quantitative accuracy. All key financial figures are accurate: $3.5 billion revenue reversal in 2023, 6.5 million EUA-labeled courses, $771 million favorable adjustment in 2024, 5.1 million courses actually returned, $442 million revenue for SNS, and 1.0 million courses in the stockpile. The deferred revenue figures ($5.1 billion at end 2023, $2.2 billion at end 2024) are correctly cited and provide additional context not in the ground truth. The multi-hop reasoning is sound, correctly synthesizing the transition from 2023 revenue reversal to 2024 adjustments and SNS recognition. The answer properly identifies all entities (Pfizer, U.S. government, SNS) and time periods. One minor issue: the LLM introduces the concept of 'volume-based credit to fund a patient-assistance program' which is not mentioned in the ground truth, though this appears to be additional context rather than contradictory information. The answer also adds the detail about 'at no cash cost' for the SNS supply, which is a reasonable inference but not explicitly stated in the ground truth. The core narrative of the shift from revenue reversal in 2023 to revenue recognition and strategic stockpile establishment in 2024 is clearly conveyed. The answer is well-structured and provides comprehensive coverage of the question's requirements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 382,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the financial performance of ERLEADA evolved between 2022 and 2023, and what does this indicate about its role in J&J's oncology portfolio?",
      "original_answer": "ERLEADA's sales increased from $1,881 million in 2022 to $2,387 million in 2023, representing a 26.9% growth. This indicates that ERLEADA has become a more prominent contributor to J&J's oncology segment, which saw overall growth of 10.5% in 2023. The strong performance of ERLEADA contrasts with the decline in other key oncology products like IMBRUVICA and ZYTIGA, suggesting that ERLEADA is playing an increasingly important role in sustaining J&J's oncology revenue.",
      "llm_answer": "ERLEADA’s sales rose from $1.9 billion in 2022 to $2.4 billion in 2023 – a 26.9% increase (27.5% operational growth, offset only slightly by currency ‑0.6%)【JNJ_10k_2023.pdf page 31】.  This strong jump helped lift total oncology sales 10.5% and was attributed to continued share‑gain and market growth in metastatic castration‑resistant prostate cancer, signalling that ERLEADA is becoming a key growth driver and increasingly central product within J&J’s oncology portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. Quantitative verification: ERLEADA sales figures are correct ($1.9B in 2022 = $1,881M, $2.4B in 2023 = $2,387M with appropriate rounding), and the 26.9% growth calculation is accurate. The operational growth rate of 27.5% with -0.6% currency impact is additional detail not in the ground truth but appears consistent with the overall 26.9% reported growth. The oncology segment growth of 10.5% is correctly cited. Multi-hop reasoning is sound: the answer correctly synthesizes ERLEADA's performance relative to J&J's overall oncology portfolio and appropriately contextualizes it as a growth driver. The mention of share-gain in metastatic castration-resistant prostate cancer provides additional relevant context about the mechanism of growth. The answer addresses both parts of the question: (1) financial performance evolution with specific numbers and percentages, and (2) role in J&J's oncology portfolio with appropriate comparative analysis. The semantic equivalence is maintained throughout - the conclusion that ERLEADA is becoming increasingly central/important to the oncology portfolio matches the ground truth's assertion of its growing prominence. Minor note: The LLM provides slightly more operational detail (currency impact breakdown) than the ground truth, which enhances rather than detracts from accuracy. The citation to source material adds credibility. No calculation errors detected, all entities correctly identified, and the reasoning properly synthesizes information across the multi-hop question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 435,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the global sales performance of ERLEADA evolve from 2022 to 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA reported worldwide sales of $1,291 million, with a significant growth rate of 70.0% compared to the previous year. By 2023, the product's global sales increased further to $2,387 million, reflecting a 26.9% growth from 2022. This indicates that ERLEADA continued to experience strong market adoption and revenue expansion, albeit at a slower growth rate compared to the prior year, suggesting a maturing growth phase in its lifecycle.",
      "llm_answer": "ERLEADA’s worldwide sales jumped from $1.9 billion in 2022 to $2.4 billion in 2023 – a 26.9% increase (operational growth 27.5%)【JNJ_10k_2023.pdf page 29】. This strong rise reflects continued share‑gain and market‑growth momentum for the drug in metastatic castration‑resistant prostate cancer, indicating an accelerating market trajectory.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains major factual errors that fundamentally undermine its credibility. (1) 2022 Sales Figure: LLM states $1.9 billion, but ground truth is $1,291 million ($1.291 billion) - this is a 47% overstatement. (2) 2023 Sales Figure: LLM states $2.4 billion, but ground truth is $2,387 million ($2.387 billion) - this is a 0.5% overstatement (minor). (3) Growth Rate Calculation: LLM correctly identifies 26.9% growth, which matches ground truth. However, this correct percentage is based on incorrect 2022 baseline figure. The correct calculation should be: ($2,387M - $1,291M) / $1,291M = 84.8% growth, NOT 26.9%. The 26.9% figure in ground truth represents 2023 growth from 2022, but the LLM's 2022 baseline is wrong. (4) Prior Year Context: Ground truth mentions 70.0% growth in 2022 compared to prior year, which the LLM completely omits. This is essential context for understanding the market trajectory evolution. (5) Reasoning Quality: The LLM's conclusion about 'accelerating market trajectory' directly contradicts the ground truth's assessment of 'maturing growth phase' with 'slower growth rate compared to prior year.' The LLM misinterprets the data direction. (6) Multi-hop Synthesis: The LLM fails to synthesize the year-over-year comparison properly - it should have noted the deceleration from 70% (2022) to 26.9% (2023), not characterized it as acceleration. The answer demonstrates poor data verification and incorrect interpretation of market dynamics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1193,
        "completion_tokens": 419,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did NVDA's debt management strategy evolve regarding the 0.584% Notes Due 2024 between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a balance of $1,250 million for the 0.584% Notes Due 2024, with an effective interest rate of 0.66%. By fiscal year 2024, NVDA disclosed in its 10-K filing that it repaid these notes in fiscal year 2025, resulting in no remaining balance for this instrument as of January 26, 2025. This indicates a shift in NVDA's debt management strategy, where it chose to retire the obligation before or shortly after the due date rather than rolling it over or extending it.",
      "llm_answer": "In FY 2023 NVIDIA reported $1.25 billion of 0.584 % notes due 2024, with a remaining term of about 0.4 years and an effective interest rate of 0.66 %【NVDA_10k_2023.pdf p.70‑71】. By FY 2024 the same $1.25 billion remained on the balance sheet and the filing disclosed no early redemption or refinancing of those notes (the only early repayment disclosed was of the 0.309 % notes due 2023)【NVDA_10k_2024.pdf p.70‑71】, indicating that the company chose to hold the low‑cost 0.584 % notes through their scheduled maturity.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer directly contradicts the ground truth on the core finding. Ground truth states that by FY 2024, NVDA disclosed the notes were repaid in fiscal year 2025 with no remaining balance as of January 26, 2025. The LLM claims the $1.25 billion 'remained on the balance sheet' in FY 2024 with no early redemption disclosed. This is factually incorrect. The LLM misread or misinterpreted the FY 2024 10-K filing - the ground truth explicitly states the notes were repaid (resulting in zero balance), while the LLM states they remained. QUANTITATIVE ACCURACY: The FY 2023 numbers are correct ($1.25 billion, 0.584%, 0.66% effective rate). However, the critical error is the FY 2024 status - the LLM incorrectly reports the balance remained at $1.25 billion when it should be $0 (fully repaid). QUALITATIVE ACCURACY: The reasoning is fundamentally flawed. The LLM concludes NVDA 'chose to hold the low-cost 0.584% notes through their scheduled maturity,' but the ground truth shows they actually repaid the notes in FY 2025 before or at maturity. This represents a complete misunderstanding of the debt management strategy evolution. MULTI-HOP REASONING: The LLM failed to properly synthesize the FY 2023 vs FY 2024 comparison. It correctly identified FY 2023 data but incorrectly assessed FY 2024 status, missing the key strategic shift from holding to repaying. CONTEXTUAL RELEVANCE: The answer addresses the right question topic but arrives at the wrong conclusion about how the strategy evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 418,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Honeywell's investment in Mortgage/Asset-backed securities evolve between 2022 and 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, Honeywell reported $982 million invested in Mortgage/Asset-backed securities under U.S. Plans. By 2023, this amount had significantly decreased to $10 million under Non-U.S. Plans. This represents a reduction of $972 million, or over 98%, indicating a major shift in Honeywell's investment strategy concerning Mortgage/Asset-backed securities.",
      "llm_answer": "Honeywell cut its mortgage‑backed securities holdings. The U.S. pension plan’s mortgage/asset‑backed securities fell from $1,119 million in 2022 to $676 million in 2023, and the non‑U.S. plan’s balance fell from $31 million to $10 million, a combined drop of about $464 million.【2023‑10‑K U.S. Plans table – 2023 = 676 M, 2022 = 1,119 M】【2023‑10‑K Non‑U.S. Plans table – 2023 = 10 M, 2022 = 31 M】",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer contains fundamentally incorrect numbers that contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURE: The LLM reports U.S. Plans 2022 value as $1,119 million, but ground truth states $982 million - a $137 million discrepancy. The LLM reports U.S. Plans 2023 value as $676 million, but ground truth indicates the 2023 amount was $10 million (under Non-U.S. Plans). The LLM reports Non-U.S. Plans 2022 as $31 million, but ground truth shows no such figure for 2022. (2) CALCULATION ERROR: The LLM calculates a combined drop of $464 million ($1,119M - $676M = $443M for U.S., plus $31M - $10M = $21M for Non-U.S., totaling $464M). However, the ground truth shows a reduction of $972 million (from $982M to $10M), representing a 98% decrease. The LLM's calculation is mathematically consistent with its stated numbers but those numbers are wrong. (3) MULTI-HOP REASONING FAILURE: The LLM appears to have confused or misidentified which plan held which amounts in which years. Ground truth clearly states 2022 had $982M under U.S. Plans and 2023 had $10M under Non-U.S. Plans. The LLM's narrative of a gradual decline across both plans does not match the actual dramatic shift described in ground truth. (4) ENTITY/METRIC CONFUSION: The LLM correctly identifies Honeywell and mortgage/asset-backed securities, but misattributes the values to the wrong plan categories and years. (5) MAGNITUDE MISREPRESENTATION: Ground truth shows a 98% reduction; LLM shows approximately 41% reduction - a fundamentally different picture of the investment strategy change. The LLM answer is internally consistent but factually incorrect against the ground truth source data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1185,
        "completion_tokens": 462,
        "total_tokens": 1647
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role in the company's funding mix and their fair value classification?",
      "original_answer": "In 2022, securitized debt obligations were described as a key component of Capital One's diversified funding strategy, used alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances to maintain access to wholesale funding sources. By 2023, the company disclosed that the carrying value of securitized debt obligations was $18,043 million, with an estimated fair value of $18,067 million, all classified under Level 2 of the fair value hierarchy. This indicates that while the company continued to rely on securitized debt obligations as a funding source, the 2023 data provides more specific transparency into their valuation and classification, showing a shift toward more detailed disclosure and potentially more structured risk management.",
      "llm_answer": "Capital One’s securitized‑debt program grew modestly from 2022 to 2023.  At year‑end 2022 the company held $16.973 billion of securitized debt obligations (fair‑value $16.918 billion) and measured them at Level 2 of the fair‑value hierarchy; by year‑end 2023 the carrying amount had risen to $18.043 billion (fair‑value $18.067 billion) and remained classified as Level 2 【COF_10k_2022.pdf pp.111‑115】【COF_10k_2023.pdf pp.208‑212】.  The increase lifted the share of securitized debt in total long‑term funding from roughly 35 % of long‑term debt in 2022 to about 37 % in 2023, indicating a slightly larger role in the company’s funding mix.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. STRENGTHS: (1) All key financial figures are correct: 2022 carrying value $16.973B (fair value $16.918B) and 2023 carrying value $18.043B (fair value $18.067B) match the ground truth data. (2) Fair value classification as Level 2 for both years is accurate. (3) The calculation of the increase from approximately 35% to 37% of long-term debt is mathematically sound and demonstrates proper multi-hop synthesis. (4) The answer directly addresses all three components of the question: evolution of securitized debt, role in funding mix, and fair value classification. (5) The narrative effectively captures the shift from general description (2022) to specific quantitative disclosure (2023). (6) Source citations are provided with specific page references. MINOR CONSIDERATIONS: The ground truth answer emphasizes 'more detailed disclosure and potentially more structured risk management' as a qualitative shift, while the LLM answer focuses more on the quantitative growth and percentage changes. However, the LLM answer's emphasis on 'modest growth' and 'slightly larger role' is semantically consistent with the ground truth's characterization of continued reliance with enhanced transparency. The LLM answer actually provides MORE specific quantitative detail than the ground truth (including 2022 figures and percentage calculations), which strengthens rather than weakens the response. No calculation errors detected. All entities (Capital One, securitized debt obligations, fair value hierarchy levels) correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 435,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did JPMorgan's treatment of CECL capital transition provisions under U.S. capital rules evolve from 2023 to 2024, and what was the quantitative change in the CECL-related capital benefit during this period?",
      "original_answer": "In 2023, JPMorgan reported a $1.4 billion benefit from the CECL capital transition provisions included in its CET1 capital. By 2024, this benefit had decreased to $720 million, reflecting a phased reduction in the CECL-related capital benefit as the provisions were being phased in under U.S. capital rules. The capital metrics indicated that the CECL benefit was fully phased in by January 1, 2025.",
      "llm_answer": "In the 2023 filing JPMorgan said its CET1 capital reflected a **$1.4 billion** benefit from the CECL capital‑transition provision under U.S. capital rules. The 2024 filing shows that the same provision now contributed only **$720 million**, indicating the benefit was being phased out and **declined by about $680 million** from 2023 to 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of all key numbers: $1.4 billion benefit in 2023, $720 million in 2024, and the calculated decline of $680 million. The multi-hop synthesis across 2023 and 2024 filings is sound, and the calculation ($1.4B - $720M = $680M) is accurate. Entity identification is correct (JPMorgan, CET1 capital, CECL capital-transition provision). The answer correctly characterizes the phased reduction in the benefit. However, there is one minor omission: the ground truth specifies that the CECL benefit was 'fully phased in by January 1, 2025,' which provides important context about the completion of the phase-in period. The LLM answer states the benefit was 'being phased out' which is slightly imprecise terminology—the benefit was being phased in (reduced) as part of a transition period, not phased out entirely. This is a semantic nuance rather than a factual error. The answer addresses all quantitative aspects of the question and provides clear, logical reasoning connecting the two years' data. The minor contextual gap regarding the January 1, 2025 completion date prevents a perfect score, but the core answer is substantively correct and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1201,
        "completion_tokens": 347,
        "total_tokens": 1548
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did the terms and capacity of Salesforce's Revolving Loan Credit Agreement evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Salesforce had a $3.0 billion unsecured revolving credit facility under the Revolving Loan Credit Agreement, which was scheduled to mature in December 2025. By fiscal 2024, this agreement was replaced with a new $5.0 billion unsecured revolving credit facility that matures in October 2029. The increase in capacity and the extension of the maturity date reflect a strategic enhancement of the company’s credit resources.",
      "llm_answer": "In fiscal 2023 Salesforce’s revolving‑loan credit agreement already gave the company an unsecured $3.0 billion revolving credit facility that matures in December 2025 and had no borrowings outstanding, having been amended for administrative purposes in April 2022 【CRM_10k_2023.pdf†p.51‑55】. By fiscal 2024 the same $3.0 billion capacity and maturity remained unchanged, and the agreement was further amended in May 2023 (also an immaterial administrative change) 【CRM_10k_2024.pdf†p.49‑53】. Thus, the borrowing capacity stayed at $3 billion, with only minor administrative amendments to the terms between the two years.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth on all major factual points. CRITICAL ERRORS: (1) CAPACITY CHANGE: LLM claims the capacity remained at $3.0 billion between fiscal 2023 and 2024, but ground truth clearly states it increased from $3.0 billion to $5.0 billion - this is a major factual error on the primary metric being asked about. (2) MATURITY DATE CHANGE: LLM claims the maturity date remained December 2025, but ground truth states it was extended to October 2029 - another critical error on a key term evolution. (3) AGREEMENT REPLACEMENT: Ground truth indicates the agreement was REPLACED with a new facility, not merely amended. LLM characterizes this as 'the same $3.0 billion capacity and maturity remained unchanged' which is completely inaccurate. (4) NATURE OF CHANGES: LLM describes only 'minor administrative amendments' when the actual evolution involved a substantial increase in borrowing capacity ($2 billion increase) and a 4-year extension of maturity - these are material strategic enhancements, not administrative changes. The LLM appears to have misread or misinterpreted the 10-K filings, possibly confusing fiscal 2023 data with fiscal 2024 data or failing to identify the new agreement entirely. The answer fails to address the core question about how the terms and capacity 'evolved' - it incorrectly claims no evolution occurred. This represents a complete failure to synthesize the multi-hop information correctly across the two fiscal years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 416,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did UPS's relationship with Coyote evolve between 2022 and 2024, and what financial impact did this change have on UPS in 2024?",
      "original_answer": "In 2022, UPS had an active business relationship with Coyote, operating it as a branded subsidiary that provided truckload brokerage services in the U.S. and Europe. Coyote was integrated into UPS’s broader supply chain offerings, leveraging the UPS fleet and third-party carrier networks to provide customized transportation solutions. However, by 2024, UPS had completed the divestiture of Coyote, recording a pre-tax gain of $156 million ($152 million after tax) as a result of the transaction. This change marks a full transition from a strategic business unit to a divested asset, reflecting a shift in UPS's supply chain strategy.",
      "llm_answer": "In 2022 UPS’s truck‑load brokerage was run through its Coyote‑branded subsidiaries, i.e., Coyote was an owned part of UPS’s Supply Chain Solutions business【5†L31-L38】. By 2024 UPS had sold the business – the divestiture was completed in Q3 2024 and generated a pre‑tax gain of $156 million (about $152 million after tax) that was recorded as other expense in 2024【31†L1-L7】. This gain provided a positive boost to UPS’s 2024 earnings.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and addresses the core question effectively. STRENGTHS: (1) All financial figures are accurate - the $156 million pre-tax gain and $152 million after-tax gain match the ground truth exactly. (2) The timeline is correct - 2022 shows Coyote as an active branded subsidiary, and 2024 shows completion of divestiture in Q3. (3) The multi-hop synthesis is sound, correctly connecting the evolution from owned business unit to divested asset. (4) The characterization of Coyote's 2022 role as a truckload brokerage subsidiary within Supply Chain Solutions is accurate. (5) The financial impact is properly identified as a positive earnings boost. MINOR WEAKNESSES: (1) The LLM answer omits some contextual detail from the ground truth about Coyote's specific service offerings (e.g., 'customized transportation solutions' leveraging UPS fleet and third-party carrier networks). However, this is a minor omission that doesn't affect the core answer. (2) The phrase 'recorded as other expense in 2024' is slightly awkward phrasing - the gain would typically be recorded as other income/gain, not expense, though the intent is clear. (3) The answer could have been slightly more explicit about the strategic shift this represents. Overall, the answer correctly answers both parts of the multi-part question: (a) how the relationship evolved (from owned subsidiary to divested), and (b) the financial impact ($156M pre-tax gain). The quantitative accuracy is excellent with all numbers correct. The qualitative reasoning about the business evolution is sound, though slightly less detailed than the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 449,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Union Pacific's relationship with chassis evolved between 2023 and 2024, particularly in terms of total units and ownership structure?",
      "original_answer": "In 2023, Union Pacific had a total of 48,340 chassis units, with 30,635 owned and 17,705 leased. By 2024, the total number of chassis dropped significantly to 5,553 units, with only 4,356 owned and 1,197 leased. This represents a transformation in Union Pacific's relationship with chassis, shifting from a heavy reliance on both owned and leased chassis to a much smaller, still mixed but significantly reduced footprint. The drastic reduction in total chassis units indicates a strategic shift in how the company manages this asset class.",
      "llm_answer": "In 2023 Union Pacific reported **48,340 chassis** – 30,635 owned and 17,705 leased【UNP_10k_2023.pdf p. 20】. By 2024 the chassis fleet had shrunk to **5,553 units**, of which 4,356 were owned and 1,197 leased【UNP_10k_2024.pdf p. 20】. Thus total chassis fell dramatically and, while both owned and leased numbers dropped, the owned share now makes up a larger proportion of the much smaller fleet.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. All quantitative data is correct: 2023 figures (48,340 total, 30,635 owned, 17,705 leased) and 2024 figures (5,553 total, 4,356 owned, 1,197 leased) match the ground truth exactly. The multi-hop synthesis is sound - the answer correctly identifies the dramatic reduction across both years and both ownership categories. The observation about the owned share becoming a larger proportion of the smaller fleet is mathematically accurate (owned went from 63.4% to 78.4% of total). The answer addresses all parts of the question: total units, ownership structure, and the evolution between years. The reasoning about the strategic shift is appropriate and well-supported by the data. Minor note: The LLM includes source citations (page references) which adds credibility but isn't required. The wording is clear and semantically equivalent to the ground truth, conveying the same essential information about the transformation in Union Pacific's chassis relationship. No calculation errors or factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 310,
        "total_tokens": 1543
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Boeing's treatment and disclosure of aluminum agreements evolved between 2022 and 2024, particularly in terms of their classification as derivatives and the time horizon for these agreements?",
      "original_answer": "In 2022, Boeing disclosed that its aluminum agreements were classified as derivatives but were not designated for hedge accounting treatment, with changes in fair value recorded in earnings immediately. The agreements were described in the context of long-term strategic sourcing objectives and non-U.S. business requirements. By 2024, the disclosure evolved to indicate that these aluminum agreements were now part of a broader set of commodity contracts hedging forecasted transactions through 2028. This represents a shift from purely strategic sourcing to a more structured hedging strategy with a defined time horizon extending to 2028.",
      "llm_answer": "In the 2022 Form 10‑K (see the “Derivatives” note on pages 78‑82) Boeing disclosed that its agreements to buy and sell aluminum are accounted for as **derivatives**, but they are **not designated for hedge accounting** and are intended to meet the company’s **long‑term strategic sourcing objectives**. The 2024 Form 10‑K (pages 109‑113) repeats the same treatment – the aluminum contracts are still classified as **derivative instruments** (non‑hedged) and are described as serving **long‑term strategic sourcing objectives and non‑U.S. business requirements** – only the disclosure is now placed under a dedicated “Derivative Instruments Not Receiving Hedge Accounting Treatment” heading, with no substantive change in classification or time‑horizon language.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERROR IN CORE CLAIM: The LLM answer fundamentally contradicts the ground truth on the key evolution between 2022 and 2024. The ground truth explicitly states that by 2024, aluminum agreements 'were now part of a broader set of commodity contracts hedging forecasted transactions through 2028' - representing a shift to 'a more structured hedging strategy with a defined time horizon extending to 2028.' The LLM answer claims there was 'no substantive change in classification or time-horizon language' and that 2024 disclosure 'repeats the same treatment' as 2022. This is factually incorrect and represents a failure to identify the key evolution the question asks about. The LLM correctly identifies: (1) 2022 classification as derivatives, (2) non-designated hedge accounting status, (3) strategic sourcing objectives language, and (4) page references appear reasonable. However, the LLM completely misses or denies the critical 2024 evolution regarding the 2028 time horizon and the shift to hedging forecasted transactions. The LLM's assertion that disclosure is 'only' reorganized under a new heading with 'no substantive change' directly contradicts the ground truth's description of an actual substantive evolution in how these agreements are characterized (from purely strategic sourcing to structured hedging with defined time horizon). This is a multi-hop synthesis failure - the model failed to identify and synthesize the key differences between 2022 and 2024 filings. The quantitative accuracy score is high because page numbers and years are correct, but the qualitative accuracy is very low because the core analytical finding is wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 454,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Procter & Gamble's exposure to currency rate risk evolved between the fiscal years ended June 30, 2023 and June 30, 2024, particularly in terms of its hedging instruments and confidence in mitigating near-term exchange rate fluctuations?",
      "original_answer": "Procter & Gamble's exposure to currency rate risk remained materially unchanged between the fiscal years ended June 30, 2023 and June 30, 2024. The company continued to use forward contracts and currency swaps with maturities of less than 18 months to manage exchange rate risk. Additionally, P&G maintained its assessment that, at a 95% confidence level based on historical currency rate movements, the impact of a near-term change in currency rates would not materially affect its financial statements in either reporting period.",
      "llm_answer": "Procter & Gamble’s currency‑rate risk profile was essentially unchanged from FY 2023 to FY 2024.  In both years the company continued to rely on a natural‑hedge strategy supplemented by short‑term forward contracts and currency swaps (generally < 18 months) and, as disclosed in the “Hedging and Derivative Financial Instruments” sections of the 2023 and 2024 10‑Ks, management said that, based on its 95 %‑confidence VaR model, a near‑term move in exchange rates would not materially affect its financial statements.  The filing notes that market‑risk exposures “have not changed materially versus the previous reporting period,” indicating no increase in exposure and sustained confidence in its hedging approach.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key claims: (1) Currency risk exposure remained materially unchanged - CORRECT, both answers state this explicitly. (2) Hedging instruments - CORRECT, both mention forward contracts and currency swaps with maturities less than 18 months. (3) 95% confidence level - CORRECT, LLM properly identifies this as a VaR (Value-at-Risk) model metric. (4) Impact assessment - CORRECT, both state that near-term exchange rate changes would not materially affect financial statements. (5) Multi-hop synthesis - EXCELLENT, the LLM successfully synthesized information across both FY 2023 and FY 2024 10-K filings, comparing the two periods and identifying continuity in approach. The LLM adds valuable context by mentioning 'natural-hedge strategy' as a supplementary approach and directly quotes the filing language about market-risk exposures not changing materially, which strengthens the answer. All numeric values (95% confidence, <18 months maturity) are accurate. The reasoning is sound and demonstrates proper understanding of derivative financial instruments and risk management. Minor note: The LLM uses 'VaR model' terminology which is technically accurate but not explicitly stated in the ground truth answer - this is an enhancement rather than an error. The answer fully addresses all parts of the multi-part question regarding evolution of exposure, hedging instruments, and confidence in mitigation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 407,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How has Adobe's positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its functional scope and integration with other Adobe products?",
      "original_answer": "In 2022, Frame.io was listed among Adobe's trademarks, indicating it was an established product within Adobe's portfolio but with no detailed description of its functionality or integration. By 2024, Frame.io was actively described as a 'cloud-native creative collaboration platform' with expanded capabilities such as real-time upload, review and approval, frame-accurate commenting, and Camera to Cloud functionality. It was also integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and positioned as part of Adobe GenStudio for large-scale content production. This reflects a significant evolution from a trademarked asset to a core collaborative tool deeply embedded in Adobe's creative workflow.",
      "llm_answer": "In the 2022 10‑K (pages 95‑99), Adobe described Frame.io as a cloud‑native creative‑collaboration platform that enables real‑time upload, review, frame‑accurate commenting and “Camera‑to‑Cloud” footage capture, and is directly integrated with Premiere Pro, After Effects, Photoshop, Lightroom and Workfront. By the 2024 10‑K (pages 10‑14), Adobe expanded Frame.io’s functional scope to also support still images, design files, PDFs and marketing‑campaign workflows, and positioned it within Adobe GenStudio—alongside Adobe Express and Firefly Services—thereby deepening its integration across the broader Adobe ecosystem.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The LLM claims that in the 2022 10-K, Frame.io was already described as a 'cloud-native creative-collaboration platform' with detailed functionality (real-time upload, review, frame-accurate commenting, Camera-to-Cloud, and integration with Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront). However, the ground truth explicitly states that in 2022, Frame.io was ONLY 'listed among Adobe's trademarks' with 'no detailed description of its functionality or integration.' This is a major contradiction. The LLM has essentially collapsed the 2022-2024 evolution into a single description and attributed 2024 characteristics to 2022. The LLM does correctly identify some 2024 enhancements (support for still images, design files, PDFs, marketing-campaign workflows, and positioning within Adobe GenStudio), but this partial correctness cannot offset the fundamental mischaracterization of the 2022 baseline. The multi-hop reasoning fails because the LLM did not properly distinguish between the two time periods and their different levels of detail/integration. The answer suggests continuity where the ground truth indicates significant evolution and expansion. Page references (95-99 for 2022, 10-14 for 2024) cannot be verified but the characterization of 2022 content is demonstrably incorrect based on the ground truth provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 406,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between the 2022 and 2023 fiscal years, particularly in terms of the carrying value of its investment and the nature of its financial disclosures?",
      "original_answer": "In the 2022 filing, AMD disclosed that the carrying value of its investment in the ATMP JV was $69 million as of December 25, 2021, and $63 million as of December 26, 2020. Additionally, AMD provided detailed figures regarding purchases from and resales to the ATMP JV, including purchases of $1.1 billion in 2021 and $831 million in 2020. In contrast, the 2023 filing omits any mention of the carrying value of the investment and specific transaction figures, only reiterating the structural details of the relationship, such as AMD's 15% equity interest and the accounting method used. This indicates a reduction in the level of financial disclosure regarding the ATMP JV, even though the nature of the relationship and AMD's equity stake remained unchanged.",
      "llm_answer": "AMD’s equity‑method investment in the ATMP joint venture grew from about **$83 million at the end of fiscal 2022 to roughly $99 million at the end of fiscal 2023**, a rise of roughly $16 million (AMD 2023 10‑K, Note 7). In the 2022 filing the JV was described in a brief Note 4 that gave only historical purchase, payable, receivable and equity‑income figures (e.g., 2021/2020 data) and a carrying amount of $69 million/$63 million (AMD 2022 10‑K, Note 4), whereas the 2023 filing places the JV in a separate Note 7 and provides **more granular, year‑by‑year disclosures** – detailed 2023/2022 purchase volumes ($1.7 billion each), payables ($363 m vs $463 m), receivables ($9 m vs $2 m), equity‑income ($16 m vs $14 m) and the updated carrying value (AMD 2023 10‑K, Note 7).",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains fundamental factual errors that directly contradict the ground truth. (1) CRITICAL QUANTITATIVE ERRORS: The LLM claims the carrying value grew from $83 million (fiscal 2022) to $99 million (fiscal 2023), but the ground truth explicitly states the 2022 filing showed carrying values of $69 million (Dec 25, 2021) and $63 million (Dec 26, 2020). The LLM provides completely different numbers with no basis in the ground truth. The $16 million increase calculation is based on these incorrect figures. (2) DIRECTIONAL CONTRADICTION: The ground truth indicates a REDUCTION in disclosure level from 2022 to 2023 (2022 had detailed figures; 2023 omitted carrying value and transaction figures). The LLM claims the opposite - that 2023 provides 'more granular, year-by-year disclosures' with updated carrying values. This is a fundamental misreading of the ground truth. (3) MISSING KEY FACTS: The ground truth emphasizes that the 2023 filing OMITS the carrying value and specific transaction figures, only reiterating structural details. The LLM incorrectly states that 2023 provides updated carrying values and detailed transaction volumes ($1.7 billion). (4) STRUCTURAL CONFUSION: While the LLM correctly identifies the 15% equity interest and notes the move from Note 4 to Note 7, it mischaracterizes the nature of the disclosure change as an expansion rather than a reduction. (5) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the comparison between 2022 and 2023 filings, arriving at conclusions opposite to the ground truth regarding disclosure trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 438,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did Honeywell's revenue from Commercial Aviation Original Equipment evolve between 2023 and 2024, and what does this indicate about its position in the aerospace sector?",
      "original_answer": "Honeywell's revenue from Commercial Aviation Original Equipment decreased from $2,397 million in 2023 to $2,223 million in 2024. This decline suggests a contraction in this segment despite overall growth in the Aerospace Technologies division, indicating a potential weakening in original equipment demand or supply constraints in this specific product line.",
      "llm_answer": "Honeywell’s Commercial Aviation Original‑Equipment revenue fell from **$2,397 million in 2023 to $2,223 million in 2024** – a decrease of about $174 million (≈7 %). Despite the dip, the segment still generated more than $2.2 billion, showing that Honeywell remains a sizable OEM supplier in the aerospace market, even as overall original‑equipment sales faced modest pressure. (Source: Note 3 revenue tables in the 2023 and 2024 10‑K filings).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct financial figures and calculations. Verification of key metrics: (1) 2023 revenue of $2,397 million - CORRECT; (2) 2024 revenue of $2,223 million - CORRECT; (3) Decline calculation of $174 million - CORRECT ($2,397M - $2,223M = $174M); (4) Percentage decline of ~7% - CORRECT (174/2,397 ≈ 7.26%). The LLM properly identified the segment, years, and sourced the information from Note 3 of the 10-K filings. Multi-hop synthesis is sound: the answer correctly combines revenue data across two years and draws appropriate conclusions about market position. The LLM adds valuable context by noting that despite the decline, Honeywell remains a significant OEM supplier with over $2.2 billion in revenue, which aligns with the ground truth's indication of 'potential weakening in original equipment demand.' Minor differences from ground truth: (1) The LLM provides more specific percentage calculation (7%) while ground truth uses vaguer language ('decline'); (2) The LLM emphasizes Honeywell's continued market strength despite the dip, whereas ground truth focuses more on the contraction aspect. Both interpretations are valid and complementary. The LLM answer is slightly more comprehensive by quantifying the percentage decline and providing additional context about market position, while still capturing the core insight about segment weakness. No calculation errors detected. All entities (Honeywell, Commercial Aviation Original Equipment, years 2023-2024) correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1207,
        "completion_tokens": 425,
        "total_tokens": 1632
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How did the global revenue contribution from Heart Failure Devices evolve between 2023 and 2024, and what was the percentage change in this segment's total revenue?",
      "original_answer": "In 2023, the global revenue from Heart Failure Devices was $1,161 million, while in 2024, this figure increased to $1,279 million. This represents a 10.2% increase in total revenue for the Heart Failure Devices segment. The growth was consistent across both U.S. and international markets, with minimal impact from exchange rate fluctuations, indicating strong underlying demand and market expansion.",
      "llm_answer": "The Heart Failure Devices line generated **$1.161 billion** of global revenue in 2023 and **$1.279 billion** in 2024, a rise of roughly **$118 million**. This increase corresponds to a **≈10.2 %** year‑over‑year growth in the segment’s total revenue【ABT_10k_2023.pdf: pages 51‑55】【ABT_10k_2024.pdf: pages 27‑31】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and correct multi-hop synthesis. Verification of key metrics: (1) 2023 revenue of $1.161 billion ($1,161 million) - CORRECT; (2) 2024 revenue of $1.279 billion ($1,279 million) - CORRECT; (3) Dollar increase calculation: $1,279M - $1,161M = $118M - CORRECT; (4) Percentage change calculation: ($118M / $1,161M) × 100 = 10.16% ≈ 10.2% - CORRECT. The LLM properly formatted numbers using billion notation (equivalent to million values provided in ground truth), which is an acceptable format variation. The answer correctly identifies the segment (Heart Failure Devices), the time period (2023-2024), and synthesizes the revenue evolution across both years. The citation references to ABT 10-K filings (2023 and 2024) are appropriately included. Minor deduction: The ground truth mentions 'consistent growth across U.S. and international markets' and 'minimal impact from exchange rate fluctuations,' which the LLM answer does not explicitly address. However, the core quantitative question is fully answered with complete accuracy, and the omission of contextual details about geographic distribution and FX impact is minor given that the primary question focuses on revenue evolution and percentage change, both of which are comprehensively addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1182,
        "completion_tokens": 365,
        "total_tokens": 1547
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How has IBM's treatment of the 0.300% Notes due 2028 evolved between the 2022 and 2023 filings?",
      "original_answer": "In the 2022 filing, the 0.300% Notes due 2028 were referenced as part of a list of debt instruments, with their rights defined in Exhibit 4.1 to Form 8-K filed February 10, 2020, and incorporated by reference. By 2023, the 0.300% Notes due 2028 were formally listed in the table of registered securities with a specific trading symbol (IBM 28B) and explicitly called out as a distinct class of notes registered on the New York Stock Exchange. This reflects a shift from general incorporation by reference to explicit disclosure and formal registration.",
      "llm_answer": "IBM’s handling of the 0.300 % Notes due 2028 was unchanged between the two reports. In both the 2022 and 2023 Form 10‑K the notes are still disclosed as a registered security under Section 12(b) (ticker IBM 28B) and are presented on the balance sheet as long‑term debt, with no securities listed under Section 12(g) or a new current‑portion classification.",
      "correctness_score": 2,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect on the core claim. The ground truth explicitly states there WAS an evolution in treatment between 2022 and 2023: from general incorporation by reference in 2022 to explicit disclosure with formal registration and trading symbol in 2023. The LLM claims the treatment was 'unchanged between the two reports,' which directly contradicts the ground truth. This is a critical factual error on the main question. While the LLM correctly identifies some details (ticker IBM 28B, Section 12(b) registration, long-term debt classification), it misses the key evolution that the question asks about. The LLM's statement that notes were 'still disclosed as a registered security under Section 12(b)' in both years oversimplifies the actual change from incorporation by reference to explicit listing. The answer fails to capture the shift from implicit/referenced disclosure to explicit/formal registration that represents the actual evolution between filings. The reasoning is flawed because it assumes consistency where the ground truth documents a meaningful change in disclosure treatment and formality.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 323,
        "total_tokens": 1537
      },
      "error": null
    },
    {
      "question_id": 158,
      "question": "How has Apple's financial performance in the Rest of Asia Pacific region evolved from 2022 to 2023, based on changes in net sales and operating income?",
      "original_answer": "In 2022, Apple's Rest of Asia Pacific segment reported net sales of $29,375 million and operating income of $11,569 million. In 2023, these figures increased to $29,615 million in net sales and $12,066 million in operating income. This represents a moderate growth in both metrics, with net sales rising by $240 million (0.8%) and operating income increasing by $497 million (4.3%).",
      "llm_answer": "Apple’s Rest of Asia Pacific segment saw net sales climb modestly from $29.375 billion in 2022 to $29.615 billion in 2023, while operating income rose more sharply from $11.569 billion to $12.066 billion over the same period. These figures indicate that the region’s sales were roughly flat year‑over‑year, but profitability improved noticeably.【Note 13 – Segment Information and Geographic Data】",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy across all dimensions. (1) QUANTITATIVE VERIFICATION: All financial figures are correct - net sales 2022: $29.375B (matches $29,375M), net sales 2023: $29.615B (matches $29,615M), operating income 2022: $11.569B (matches $11,569M), operating income 2023: $12.066B (matches $12,066M). The LLM correctly converted millions to billions format, which is an acceptable variation. (2) CALCULATIONS: The LLM implicitly validates the year-over-year changes - sales increase of $240M (0.8%) and operating income increase of $497M (4.3%) are both accurate, though the LLM does not explicitly state these percentage changes. (3) MULTI-HOP SYNTHESIS: The answer correctly synthesizes data across two fiscal years (2022-2023) and two metrics (net sales and operating income) for the Rest of Asia Pacific segment. (4) REASONING QUALITY: The characterization is sound - 'roughly flat' for 0.8% sales growth and 'noticeably improved' for 4.3% operating income growth are appropriate qualitative assessments. The observation that profitability improved more sharply than sales is logically sound and demonstrates understanding of the underlying metrics. (5) MINOR OMISSION: The LLM does not explicitly state the absolute dollar changes ($240M for sales, $497M for operating income) or the percentage changes (0.8% and 4.3%), which were included in the ground truth answer. However, this is a minor omission that does not affect the core correctness of the response. The inclusion of a citation reference adds credibility. Overall, the answer is factually accurate, well-reasoned, and appropriately addresses the question about financial performance evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1195,
        "completion_tokens": 461,
        "total_tokens": 1657
      },
      "error": null
    },
    {
      "question_id": 169,
      "question": "How has the vesting period for stock options issued under the 2007 Omnibus Incentive Plan evolved between grants made prior to 2022 and those made after December 31, 2021, based on disclosures in the 2022 and 2024 10-K filings?",
      "original_answer": "In the 2022 10-K filing, stock options granted prior to 2022 under the 2007 Omnibus Incentive Plan generally vested pro rata over a five-year period, while those granted after December 31, 2021, under the amended and restated plan, generally vested pro rata over a four-year period. The 2024 10-K confirms that stock options granted prior to 2022 continued to vest pro rata over a five-year period, and those granted after December 31, 2021, also continued to vest pro rata over a four-year period. This indicates a consistent reduction in the vesting period from five to four years for post-2021 grants, showing a structural change in the incentive plan's vesting terms over time.",
      "llm_answer": "The 2022 10‑K notes that stock options granted **prior to 2022** under the 2007 Omnibus Incentive Plan “generally vest pro rata over a five‑year period” (and terminate ten years from grant) 【DHR_10k_2022.pdf page 114‑118】. The 2024 10‑K, reflecting the amended and restated plan, states that options granted **after December 31 2021** now “generally vest pro rata over a four‑year period” (still with a ten‑year termination) 【DHR_10k_2024.pdf page 94‑98】. Thus, the vesting schedule was shortened by one year—from five years to four years—for post‑2021 grants.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains a critical structural error in how it presents the information. While the individual facts are correct (5-year vesting for pre-2022 grants, 4-year vesting for post-2021 grants), the LLM incorrectly attributes these vesting periods to different time periods in the two filings. Specifically: (1) The LLM states the 2022 10-K discusses pre-2022 grants (5-year vesting) and the 2024 10-K discusses post-2021 grants (4-year vesting), implying these are different time periods being discussed in different filings. However, the ground truth indicates BOTH filings discuss BOTH time periods - the 2022 10-K covers both pre-2022 (5-year) and post-2021 (4-year) grants, and the 2024 10-K also covers both periods with the same vesting schedules. (2) The LLM's phrasing 'reflecting the amended and restated plan, states that options granted after December 31 2021 now' suggests the 2024 10-K is introducing new information, when in fact both filings consistently report the same vesting structure. (3) The quantitative facts are accurate: 5-year vs 4-year vesting, one-year reduction, 10-year termination period. (4) The multi-hop reasoning fails because the LLM did not properly synthesize that BOTH filings contain information about BOTH time periods, showing consistency across years rather than evolution. The ground truth explicitly states 'The 2024 10-K confirms that stock options granted prior to 2022 continued to vest pro rata over a five-year period, and those granted after December 31, 2021, also continued to vest pro rata over a four-year period,' emphasizing the consistency and confirmation across both filings. The LLM's answer suggests a temporal progression that doesn't match the actual disclosure structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 475,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How has CVS's approach to validating the fair value estimates for its Level 2 debt securities evolved from 2022 to 2023, particularly in terms of price adjustments and secondary source comparisons?",
      "original_answer": "In 2022, CVS obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December 31, 2021 or 2020. The company compared selected sample prices quarterly to secondary sources and reviewed variances over a specified threshold. In 2023, the company maintained the same validation methodology, obtaining one price per Level 2 debt security without any adjustments at December 31, 2023 or 2022, and continued to compare prices quarterly to secondary sources. Despite maintaining the same process, the emphasis on consistent internal validation by the investment team appears to have remained stable, indicating a sustained but unchanging approach to fair value estimation.",
      "llm_answer": "In the 2022 filing CVS explained that it obtains one price for each Level 2 debt security, makes no year‑end adjustments (for 2021 and 2020), and validates those prices by quarterly sampling and comparing them to a secondary source, reviewing any variance that exceeds a set threshold. The 2023 filing repeats the same practice—still using a single price per security, still making no adjustments at December 31, 2023 (or 2022), and still performing the quarterly secondary‑source price‑comparison review—so the validation approach has essentially remained unchanged, merely applied to the newer reporting period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about CVS's fair value validation approach evolution from 2022 to 2023. STRENGTHS: (1) All key factual elements are correct: single price per Level 2 debt security, no adjustments at year-end (2023, 2022, 2021, 2020), quarterly secondary source comparisons, variance threshold reviews. (2) Quantitative accuracy is perfect—all dates and periods are correctly identified and applied. (3) The multi-hop synthesis is sound: the answer correctly identifies the 2022 methodology, the 2023 methodology, and accurately concludes they are essentially unchanged. (4) The answer properly addresses the core question about evolution (or lack thereof) in the validation approach. (5) Semantic equivalence is maintained throughout—'quarterly sampling and comparing' and 'quarterly secondary-source price-comparison review' convey the same meaning as the ground truth. MINOR CONSIDERATIONS: The LLM answer is slightly more concise than the ground truth in describing the validation process, but this is not a deficiency—it captures all essential information without unnecessary elaboration. The phrase 'merely applied to the newer reporting period' effectively conveys the continuity of approach. The answer correctly emphasizes that despite maintaining the same process, there was no evolution or change, which directly answers the implicit question about whether the approach evolved. No factual errors, calculation errors, or entity misidentifications are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 427,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How did CVS's classification and valuation methodology for privately-placed equity securities evolve between 2022 and 2023, particularly in terms of fair value determination and unobservable inputs?",
      "original_answer": "CVS maintained a consistent classification of privately-placed equity securities as Level 3 in both 2022 and 2023, indicating no active market for these securities. However, the company emphasized in both years that it uses an internal analysis of financial statements and cash flow projections to determine fair value. In 2022, the significant unobservable inputs included earnings and revenue multiples, discount for lack of marketability, and comparability adjustments. In 2023, the same unobservable inputs were referenced, but with an added emphasis on the potential impact of changes in these inputs on fair value measurements, suggesting a more detailed sensitivity analysis or increased scrutiny of these inputs in the valuation process.",
      "llm_answer": "Both in 2022 and in 2023 CVS continued to treat privately‑placed equity securities as Level 3 assets. The fair value is still derived from an internal analysis of each investment’s financial statements and cash‑flow projections, relying on unobservable inputs such as earnings and revenue multiples, a discount for lack of marketability and comparability adjustments. The 2023 filing repeats the same language as the 2022 filing, indicating no change in classification or valuation methodology【CVS_10k_2022.pdf pp. 146‑150】【CVS_10k_2023.pdf pp. 151‑155】.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies the core facts: CVS classified privately-placed equity securities as Level 3 in both 2022 and 2023, used internal analysis of financial statements and cash flow projections, and relied on earnings/revenue multiples, discount for lack of marketability, and comparability adjustments as unobservable inputs. The numeric/factual elements are accurate. However, the answer has a significant weakness in addressing the question's core inquiry about 'evolution' between the two years. The LLM states 'The 2023 filing repeats the same language as the 2022 filing, indicating no change in classification or valuation methodology,' which directly contradicts the ground truth's key finding. The ground truth explicitly notes that while classification remained consistent, there was an evolution in emphasis: 2023 added 'an added emphasis on the potential impact of changes in these inputs on fair value measurements, suggesting a more detailed sensitivity analysis or increased scrutiny of these inputs.' This is a meaningful evolution that the LLM completely missed. The LLM's conclusion that there was 'no change' is therefore partially incorrect - there was a methodological evolution in terms of emphasis and scrutiny, even if the core classification and inputs remained the same. The answer addresses the multi-hop synthesis adequately by comparing both years, but fails to capture the nuanced evolution that the question specifically asks about. The citation references appear reasonable but the interpretation of what those citations show is incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 435,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 184,
      "question": "How did the total net revenue from Alphagan/Combigan change between 2023 and 2024, and what was the trend in its international revenue during this period?",
      "original_answer": "The total net revenue from Alphagan/Combigan decreased from $272 million in 2023 to $248 million in 2024, reflecting an 8.8% decline. During the same period, its international revenue slightly increased from $151 million in 2023 to $153 million in 2024, representing a 1.5% growth.",
      "llm_answer": "Alphagan/Combigan’s total net revenue fell from $272 million in 2023 to $248 million in 2024 – a decline of roughly $24 million (about 9 %). However, its international component edged higher, rising from $151 million in 2023 to $153 million in 2024 (a modest increase).【2023 table – Alphagan/Combigan Total $272 M, International $151 M】【2024 table – Alphagan/Combigan Total $248 M, International $153 M】",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key metrics: (1) Total revenue 2023: $272M ✓, 2024: $248M ✓ - matches ground truth exactly. (2) Revenue decline calculation: $272M - $248M = $24M ✓, percentage decline: ($24M/$272M) × 100 = 8.82% ≈ 8.8-9% ✓ (LLM stated \"about 9%\" which is acceptable rounding). (3) International revenue 2023: $151M ✓, 2024: $153M ✓ - matches exactly. (4) International growth calculation: ($153M - $151M)/$151M × 100 = 1.32% ≈ 1.5% ✓ (LLM described as \"modest increase\" which is semantically equivalent). The LLM correctly synthesized multi-hop information across two fiscal years, comparing both total and international revenue trends. All entities (Alphagan/Combigan product, years 2023-2024, revenue metrics) are correctly identified. The answer addresses both parts of the question: total revenue change and international revenue trend. Minor note: LLM stated \"about 9%\" while ground truth specifies \"8.8%\" - this is a negligible difference in rounding and does not constitute a material error. The inclusion of source citations in brackets demonstrates transparency. Overall, the answer is factually correct, complete, well-reasoned, and directly relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1173,
        "completion_tokens": 348,
        "total_tokens": 1521
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Chevron's relationship with PDC Energy evolved from 2023 to 2024, and what specific operational impact did this change have on Chevron's overall production performance?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, Inc. (PDC), and as a result, PDC was excluded from Chevron's internal control assessment over financial reporting due to the timing of the acquisition. By 2024, Chevron's relationship with PDC had evolved from a newly acquired entity to an integral operational component, as evidenced by the 7% increase in Chevron's worldwide oil-equivalent production, which was attributed in part to the full-year contribution from legacy PDC operations. This indicates that PDC Energy transitioned from being a recent acquisition in 2023 to a key contributor to Chevron's production growth in 2024.",
      "llm_answer": "In 2023 Chevron completed a business‑combination acquisition of PDC Energy, treating the company as a newly‑acquired, wholly‑owned subsidiary and even excluding PDC from its internal‑control assessment for that year. By 2024 PDC’s assets and production were fully integrated into Chevron’s consolidated operations, and the “legacy” PDC output helped lift Chevron’s worldwide oil‑equivalent production to 3.3 million bbl/d – roughly a 7 % increase (about 0.2‑0.3 million bbl/d) over 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. (1) CORRECTNESS: All factual information is correct - the 2023 acquisition of PDC Energy, its exclusion from internal control assessment in 2023, full integration by 2024, and the 7% production increase are all accurately stated. The answer correctly identifies PDC's transition from newly-acquired to fully-integrated operational component. (2) QUANTITATIVE ACCURACY: All numbers are correct - 3.3 million bbl/d production figure, 7% increase, and the 0.2-0.3 million bbl/d range are all accurate. The calculations are sound and properly contextualized. (3) MULTI-HOP REASONING: The answer successfully synthesizes information across 2023-2024 timeline, connecting the acquisition event to operational integration to production impact. It properly traces the evolution of the relationship and links it to measurable performance outcomes. (4) ENTITY ACCURACY: Chevron and PDC Energy are correctly identified, years are accurate (2023 and 2024), and metrics (oil-equivalent production, bbl/d) are properly used. (5) COMPLETENESS: The answer addresses both parts of the question - how the relationship evolved AND what specific operational impact occurred. The LLM answer actually provides slightly more specific detail (the 3.3 million bbl/d figure and the 0.2-0.3 million bbl/d range) than the ground truth while maintaining perfect alignment. Minor note: The LLM uses 'business-combination acquisition' terminology which is more precise SEC filing language, enhancing rather than detracting from accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 429,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has UPS's investment in cold-chain logistics capabilities evolved from 2023 to 2024, and what specific acquisitions contributed to this change?",
      "original_answer": "In 2023, UPS expanded its cold-chain logistics capabilities through the acquisition of Bomi Group and MNX Global Logistics, aiming to enhance its healthcare logistics services. By 2024, this strategic focus intensified with the acquisition of Frigo-Trans and Biotech & Pharma Logistics in Germany for approximately $440 million, signaling a significant increase in international investment in complex cold-chain logistics. This represents a shift from general expansion to targeted, high-value international acquisitions in the cold-chain sector.",
      "llm_answer": "UPS began expanding its cold‑chain logistics in 2023 by acquiring Bomi Group and MNX Global Logistics, which added temperature‑sensitive and healthcare‑focused capabilities to its network (UPS_10k_2023.pdf). In 2024 the company continued that push, announcing the purchase of Frigo‑Trans and Biotech & Pharma Logistics to further boost its complex cold‑chain services, especially internationally (UPS_10k_2024.pdf).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the four acquisitions (Bomi Group, MNX Global Logistics, Frigo-Trans, and Biotech & Pharma Logistics) and the general timeline (2023 vs 2024 expansion). The qualitative reasoning about the shift from general expansion to targeted international acquisitions is sound and well-articulated. However, there is a critical omission: the LLM answer fails to include the specific acquisition price of approximately $440 million for the 2024 German acquisitions (Frigo-Trans and Biotech & Pharma Logistics), which is explicitly stated in the ground truth and represents a key quantitative detail demonstrating the 'significant increase in international investment.' This is a material omission for a financial question where specific dollar amounts are part of the ground truth answer. The answer demonstrates good multi-hop synthesis across 2023 and 2024 filings and correctly characterizes the strategic evolution, but the missing financial metric reduces the completeness and quantitative accuracy of the response. The citation format (referencing specific PDFs) adds credibility but doesn't compensate for the missing $440 million figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 331,
        "total_tokens": 1571
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Linde plc's non-employee director restricted stock unit award program evolved between 2022 and 2024, particularly in terms of governance structure and long-term shareholder alignment mechanisms?",
      "original_answer": "In 2022, Linde plc introduced the Non-Employee Director Restricted Stock Unit Award under the 2021 Linde plc Long Term Incentive Plan, establishing a framework for equity-based compensation tied to long-term performance metrics. This initiative was part of a broader suite of incentive programs aimed at aligning director interests with those of shareholders. By 2024, the company expanded this framework by introducing the Linde plc Non-employee Director Deferral Program, adopted by the Board of Directors on July 30, 2024. This deferral program enhances governance by allowing directors to defer receipt of stock units, thereby reinforcing long-term alignment with shareholder value creation. The evolution from a basic restricted stock unit award to a more sophisticated deferral mechanism indicates Linde’s strategic emphasis on strengthening board accountability and promoting sustained corporate governance standards.",
      "llm_answer": "In the 2022 Form 10‑K (pages 103‑107), Linde’s non‑employee director RSU awards were granted under the 2021 Long‑Term Incentive Plan, with the Compensation Committee approving annual awards that vest over a three‑year service period and are tied to total‑shareholder‑return relative to a peer group. By the 2024 filing (pages 94‑98), the plan was amended (first amendment effective Jan 29 2024) and a separate Non‑Employee Director Deferral Program was adopted (July 30 2024), shifting a portion of the RSUs into a deferred component that vests only upon meeting longer‑term performance metrics such as return on capital and extended TSR, and placing the program under direct Board approval while retaining Compensation Committee oversight—thereby tightening governance and deepening alignment with long‑term shareholder value.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies key structural elements: (1) 2021 Long-Term Incentive Plan as the underlying framework, (2) July 30, 2024 adoption date for the Non-Employee Director Deferral Program, (3) January 29, 2024 amendment date, (4) the evolution from basic RSU awards to a more sophisticated deferral mechanism, and (5) the governance shift involving Board approval with Compensation Committee oversight. The answer demonstrates sound multi-hop reasoning by synthesizing information across 2022 and 2024 filings and correctly identifies the strategic intent around shareholder alignment.\n\nWEAKNESSES AND ERRORS: (1) QUANTITATIVE INACCURACY - The LLM introduces specific performance metrics (TSR relative to peer group in 2022; return on capital and extended TSR in 2024) that are not explicitly confirmed in the ground truth. The ground truth mentions 'long-term performance metrics' generically but does not specify these particular metrics. The claim about 'three-year service period' vesting is also not confirmed in the ground truth. (2) PAGE REFERENCES - The LLM cites specific page numbers (103-107 for 2022, 94-98 for 2024) which cannot be verified against the ground truth and may be inaccurate. (3) DETAIL OVERREACH - The answer provides more granular detail about performance metrics and vesting structures than the ground truth supports, suggesting potential hallucination or over-specification. (4) MISSING CONTEXT - While the LLM correctly notes the deferral program's adoption, it doesn't emphasize as clearly that this represents an expansion of the framework (as stated in ground truth: 'expanded this framework').\n\nMULTI-HOP REASONING: The synthesis across 2022 and 2024 filings is logically sound and correctly identifies the progression from basic RSU awards to a more sophisticated deferral mechanism. The connection between governance structure changes and shareholder alignment is appropriately made.\n\nSEMANTIC EQUIVALENCE: The core message aligns with the ground truth - evolution toward more sophisticated governance and long-term alignment - but the specific performance metrics introduced by the LLM are not substantiated by the ground truth, creating a factual accuracy concern.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 597,
        "total_tokens": 2049
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did General Motors' financial and legal relationship with Stellantis evolve between 2022 and 2024, particularly regarding indemnification obligations and investment gains?",
      "original_answer": "In 2022, General Motors reported a gain of $0.2 billion related to Stellantis N.V. (Stellantis) warrants, indicating a positive financial relationship. However, by 2024, the relationship had evolved into a more complex and potentially costly one. GM had agreed to indemnify Stellantis for certain liabilities tied to pre-sale emissions claims, product liabilities, and recalls related to the 2017 sale of the Opel/Vauxhall business. Additionally, GM faced potential future liabilities from ongoing investigations into Opel’s historical conduct in Europe. Unlike the earlier gains, GM's 2024 disclosures highlighted contingent liabilities and legal risks rather than financial benefits from its relationship with Stellantis.",
      "llm_answer": "In the 2022 Form 10‑K GM noted that, under the 2017 sale of its Opel/Vauxhall business, General Motors Holdings LLC had agreed to indemnify Stellantis for losses arising from any inaccuracy of the representations, warranties or covenants in that agreement, with the obligations limited by time‑limits, thresholds and caps and no material loss estimated (GM_10k_2022.pdf: pp. 34‑36). That filing also disclosed a $0.2 billion gain from Stellantis N.V. warrants (GM_10k_2022.pdf: p. 34). By the 2024 Form 10‑K the same indemnification commitments remained unchanged—still subject to the same limits and only an immaterial indemnity for certain recalls—and the filing makes no new disclosure of material Stellantis‑related investment gains, implying the earlier warrant gain was a one‑time item (GM_10k_2024.pdf: p. 93).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both accurate and problematic elements. CORRECT ELEMENTS: (1) The $0.2 billion warrant gain in 2022 is accurately cited; (2) The indemnification obligations related to the 2017 Opel/Vauxhall sale are correctly identified; (3) The characterization that indemnification commitments remained unchanged between 2022 and 2024 is supported; (4) The document citations and page references appear reasonable. PROBLEMATIC ELEMENTS: (1) The LLM states 'the filing makes no new disclosure of material Stellantis-related investment gains' in 2024, but the ground truth indicates the 2024 disclosures 'highlighted contingent liabilities and legal risks' - the LLM's phrasing suggests merely an absence of gains rather than an active shift toward highlighting risks and liabilities; (2) The LLM characterizes the indemnification as having 'only an immaterial indemnity for certain recalls' in 2024, but the ground truth mentions 'pre-sale emissions claims, product liabilities, and recalls' plus 'ongoing investigations into Opel's historical conduct in Europe' - the LLM appears to understate the scope and potential significance of these liabilities; (3) The LLM's conclusion that the warrant gain was 'a one-time item' is reasonable but somewhat speculative - the ground truth simply notes the absence of new gains in 2024 without explicitly characterizing the 2022 gain as one-time. MULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2024 filings and correctly identifies the evolution from gains to indemnification obligations. However, it understates the complexity and potential costliness of the 2024 relationship by not adequately emphasizing the expanded scope of liabilities (emissions, product liability, recalls, ongoing investigations). The answer is partially correct but misses important nuances about the nature of the evolved relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 513,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolved from 2022 to 2024, particularly in terms of their financial presentation and categorization?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of energy-related derivatives not designated as hedging instruments on the statements of income for prior years (2021, 2020, and 2019), indicating a focus on income statement impacts. By 2024, the company shifted its disclosure to emphasize the fair value of energy-related derivatives as either assets or liabilities on the balance sheets, specifically categorized under 'Other' or 'Risk Management Activities'. This represents a shift from income-focused reporting to balance sheet-oriented transparency.",
      "llm_answer": "In the 2022 Form 10‑K Southern Company disclosed energy‑related derivatives chiefly through tables that showed the pre‑tax gains or losses on cash‑flow and fair‑value hedges and their impact on AOCI and earnings, with only a brief description of the three accounting methods (cash‑flow hedge, fair‑value hedge, not designated) and no separate balance‑sheet line for “regulatory” hedges【SO_10k_2022.pdf p.325‑329】. By the 2024 filing the company had added a formal three‑method framework that isolates “regulatory hedges” as a distinct category, presents assets and liabilities for each derivative type (regulatory, cash‑flow/fair‑value, and non‑designated) on the balance sheet, reports net natural‑gas volumes and longest hedge dates, and notes that reclassifications from AOCI to earnings are immaterial【SO_10k_2024.pdf p.281‑285】. This reflects a shift from primarily income‑statement impact reporting to a more granular balance‑sheet presentation and clearer categorization of energy‑related derivatives.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of Southern Company's energy-related derivatives disclosure from 2022 to 2024. STRENGTHS: (1) Correctly identifies the shift from income-statement focus (2022) to balance-sheet orientation (2024), matching the ground truth's central thesis. (2) Accurately captures the key methodological changes: introduction of 'regulatory hedges' as a distinct category, more granular balance-sheet presentation, and clearer categorization framework. (3) Provides specific page references (p.325-329 for 2022, p.281-285 for 2024) that add credibility and specificity. (4) Correctly notes the three accounting methods (cash-flow hedge, fair-value hedge, not designated) and their evolution. (5) Mentions immaterial AOCI reclassifications, showing attention to detail. (6) The semantic meaning aligns well with ground truth: both describe a shift from income-focused to balance-sheet-oriented transparency. MINOR CONSIDERATIONS: (1) The LLM answer is more detailed and specific than the ground truth (mentions natural gas volumes, hedge dates, AOCI immateriality), which could be viewed as either enhanced context or potential over-specification. However, these details appear consistent with typical 10-K disclosures and don't contradict the ground truth. (2) The ground truth emphasizes categorization under 'Other' or 'Risk Management Activities' on balance sheets, while the LLM answer focuses more on the three-method framework and regulatory hedges distinction. Both perspectives are complementary rather than contradictory. (3) No quantitative errors detected in dates (2022, 2024) or the characterization of changes. The multi-hop reasoning correctly synthesizes information across two filing years and identifies the evolution pattern. The answer successfully addresses all parts of the question regarding treatment, disclosure, financial presentation, and categorization evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 530,
        "total_tokens": 1931
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did GILD's strategic relationship with Arcus evolve between 2023 and 2024, particularly in terms of equity ownership and governance influence?",
      "original_answer": "In 2023, GILD owned approximately 19.9% of Arcus' issued and outstanding voting stock and had two designees on Arcus' board of directors. In January 2024, GILD made an additional $320 million equity investment in Arcus, increasing its ownership to 33%, and expanded its board representation to three designees. This represents a significant increase in both financial commitment and governance influence over Arcus within a year.",
      "llm_answer": "In 2023 Gilead owned about 14.8 million Arcus shares – roughly 19.9 % of the voting stock – and had **two** of its own directors sitting on Arcus’s board. In January 2024 Gilead invested an additional $320 million, raising its stake to **approximately 33 %** and expanding its board representation to **three** designees, thereby increasing both its equity ownership and governance influence.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative data points are correct: (1) 2023 ownership of 19.9% of voting stock - verified correct; (2) 2023 board representation of two designees - verified correct; (3) January 2024 additional investment of $320 million - verified correct; (4) 2024 ownership increased to approximately 33% - verified correct; (5) 2024 board representation expanded to three designees - verified correct. The LLM successfully synthesized multi-hop information across two time periods (2023 and 2024), correctly identifying the evolution of both equity ownership and governance influence. The answer includes the helpful detail of mentioning '14.8 million Arcus shares' which provides additional context without contradicting the ground truth. The reasoning is sound: the model correctly identified that the January 2024 investment represented a significant increase in both financial commitment and governance influence. The wording differs slightly from the ground truth (e.g., 'Gilead' vs 'GILD', 'directors' vs 'designees' in one instance) but these are semantic equivalences that do not affect accuracy. The answer directly addresses all components of the multi-part question regarding how the strategic relationship evolved between 2023 and 2024, particularly in equity ownership and governance influence. No calculation errors or factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 392,
        "total_tokens": 1597
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maturity date and borrowing capacity of the 2021 Multicurrency Credit Facility evolved between 2022 and 2023?",
      "original_answer": "In 2022, the 2021 Multicurrency Credit Facility had a maximum borrowing capacity of $6.0 billion with a maturity date of June 30, 2025. By 2023, the borrowing capacity remained at $6.0 billion, but the maturity date was extended to July 1, 2026. This reflects a one-year extension of the facility’s term without any increase in the total commitment amount, indicating a strategic move to maintain financial flexibility over a longer horizon.",
      "llm_answer": "In the 2022 Form 10‑K the 2021 Multicurrency Credit Facility was described as having a maturity of June 30 2025 and a total commitment (borrowing capacity) of $6.0 billion 【AMT_10k_2022.pdf p. 48‑49】.  The 2023 Form 10‑K shows that the same facility’s maturity was later extended to July 1 2026, while the commitment remained unchanged at $6.0 billion 【AMT_10k_2023.pdf p. 50‑52】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and directly addresses the multi-hop question about the evolution of the 2021 Multicurrency Credit Facility between 2022 and 2023. (1) CORRECTNESS: All factual information is correct. The 2022 maturity date of June 30, 2025 matches the ground truth exactly. The 2023 maturity date extension to July 1, 2026 is correct. The borrowing capacity of $6.0 billion for both years is accurate. (2) QUANTITATIVE ACCURACY: All numbers and dates are precise and correctly formatted. The dollar amount ($6.0 billion) is consistent across both years as stated. The dates are exact matches to the ground truth (June 30, 2025 and July 1, 2026). (3) QUALITATIVE ACCURACY: The LLM correctly synthesized information from two separate 10-K filings (2022 and 2023) and properly identified the key evolution: a one-year maturity extension without capacity increase. The reasoning is sound and the multi-hop synthesis is complete. (4) CONTEXTUAL RELEVANCE: The answer directly answers the question about how the facility evolved, providing the before-and-after comparison requested. The inclusion of source citations (page numbers) adds credibility. Minor note: The ground truth answer includes interpretive commentary about 'strategic move to maintain financial flexibility,' which the LLM answer omits, but this is not a factual error—it's an optional interpretive element. The core factual content is complete and accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1199,
        "completion_tokens": 399,
        "total_tokens": 1598
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Chevron's utilization of imported crude oil in U.S. refining operations evolved between 2023 and 2024, and what changes in refinery capacity utilization accompanied this trend?",
      "original_answer": "Chevron's reliance on imported crude oil in U.S. refining operations remained consistent at approximately 60% of refinery inputs in both 2023 and 2024. However, the utilization of U.S. refineries changed: in 2023, crude unit distillation capacity utilization averaged 90.8%, while in 2024 it decreased to 86.6%. This indicates that while the company's dependency on imported crude oil remained stable, the overall operational intensity of its U.S. refineries declined slightly in 2024.",
      "llm_answer": "Chevron’s share of imported crude in its U.S. refineries stayed essentially unchanged – about 60 percent of total U.S. refinery inputs in both 2023 and 2024. However, refinery utilization slipped: U.S. crude‑unit capacity utilization fell from roughly 90.8 percent in 2023 to about 86.6 percent in 2024 (overall refinery utilization dropped from 89.8 percent to 87.9 percent)【CVX_10k_2023.pdf†15-18】【CVX_10k_2024.pdf†16-19】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key claims: (1) Imported crude oil percentage: Both answers correctly state ~60% in 2023 and 2024 - CORRECT. (2) Crude-unit distillation capacity utilization: LLM states 90.8% (2023) and 86.6% (2024), matching ground truth exactly - CORRECT. (3) Overall refinery utilization: LLM provides additional detail (89.8% to 87.9%) not in ground truth, but this is supplementary information that enhances rather than contradicts the answer. (4) Multi-hop synthesis: The answer correctly synthesizes information across two years and two different metrics (imported crude percentage and capacity utilization), showing proper understanding of the relationship between stable import dependency and declining operational intensity. (5) Entity accuracy: Chevron correctly identified, years correct (2023-2024), metrics properly labeled. (6) Reasoning: The conclusion that 'while the company's dependency on imported crude oil remained stable, the overall operational intensity of its U.S. refineries declined slightly in 2024' is logically sound and well-supported. The LLM answer uses slightly different wording ('slipped' vs 'decreased') but conveys identical meaning. The inclusion of overall refinery utilization figures (89.8% to 87.9%) is additional context that strengthens the answer without introducing errors. Minor deduction only because the ground truth doesn't explicitly mention these overall utilization figures, though their inclusion is factually accurate and contextually valuable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 427,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did UPS's hedging position in British Pound Sterling evolve between 2023 and 2024, and what does this shift indicate about the company's currency risk management strategy?",
      "original_answer": "In 2023, UPS reported a British Pound Sterling (GBP) hedge position of 663 million units, which decreased to 536 million units in 2024. This represents a reduction of 127 million units, or approximately 19.15%. The decrease indicates a strategic move to reduce exposure to GBP, suggesting that UPS may have reassessed its currency risk related to the British Pound and opted for a more conservative hedging approach or a lower anticipated risk in that currency during the later year.",
      "llm_answer": "UPS’s GBP hedge fell from a notional $663 million at December 31 2023 to $536 million at December 31 2024. The roughly $127 million (≈19 %) reduction shows UPS scaled back its pound‑denominated hedge, likely to align the hedge with lower forecasted GBP cash‑flows and to fine‑tune its currency‑risk management rather than maintain a larger, more aggressive exposure.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of the key metrics and numbers. Quantitative verification: (1) 2023 GBP hedge position: 663 million units vs. LLM's '$663 million' - the ground truth specifies 'units' while LLM uses '$' notation, but this is a minor notation difference that doesn't affect factual accuracy; (2) 2024 position: 536 million units vs. LLM's '$536 million' - same notation variance; (3) Reduction calculation: 127 million units (663-536=127) matches LLM's '$127 million'; (4) Percentage reduction: 19.15% in ground truth vs. '≈19%' in LLM - the approximation is reasonable and accurate. The LLM correctly synthesizes the multi-hop information by comparing positions across two years and drawing conclusions about strategy. The reasoning about 'scaling back' and 'aligning with lower forecasted GBP cash-flows' is logically sound and semantically equivalent to the ground truth's interpretation about 'reassessing currency risk' and 'more conservative hedging approach.' The main minor issue is the notation difference (units vs. dollar amounts) - the ground truth explicitly states 'million units' while the LLM presents these as dollar amounts with '$' symbols. This could be interpreted as either a notation preference or a potential conflation of notional amounts with units, though the numerical values themselves are correct. The answer fully addresses both parts of the question: the evolution of the position and what it indicates about strategy. All entities (UPS, GBP, years 2023-2024) are correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 434,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the fair value of money market investments held by Bank of America evolved between 2023 and 2024, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "The fair value of money market investments held by Bank of America increased from $1.2 billion at December 31, 2023, to $1.3 billion at December 31, 2024. This indicates a modest growth in the company's short-term investment holdings, suggesting a slight expansion in liquidity management or short-term capital deployment strategies over the year.",
      "llm_answer": "Bank of America’s money‑market holdings rose from a fair‑value of **$1.2 billion at 12/31/2023** to **$1.3 billion at 12/31/2024** – an increase of roughly **$100 million**. This modest uptick shows the bank is marginally expanding its short‑term, highly liquid assets, signaling a continued emphasis on liquidity and low‑risk, short‑duration investments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. (1) QUANTITATIVE VERIFICATION: All numbers are correct - $1.2 billion at 12/31/2023, $1.3 billion at 12/31/2024, and the calculated difference of $100 million ($1.3B - $1.2B = $0.1B = $100M). Dates are accurate and properly formatted. (2) COMPLETENESS: The answer addresses both parts of the multi-part question - it provides the evolution of fair value AND interprets what this shift indicates about strategy. (3) ENTITY ACCURACY: Bank of America is correctly identified, the metric (fair value of money market investments) is precise, and fiscal years are correct. (4) REASONING QUALITY: The multi-hop synthesis is sound - the model correctly extracted the two data points from different fiscal years and synthesized them into a coherent narrative about liquidity strategy. The interpretation that a modest increase signals 'continued emphasis on liquidity and low-risk, short-duration investments' is logically sound and semantically equivalent to the ground truth's 'modest growth...suggesting a slight expansion in liquidity management.' (5) MINOR DIFFERENCES: The LLM uses slightly more detailed language ('highly liquid assets,' 'low‑duration investments') compared to the ground truth's more concise phrasing, but this represents appropriate elaboration rather than error. The characterization of the increase as 'marginal' and 'modest' aligns perfectly with the ground truth's 'modest growth.' No calculation errors, no factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1186,
        "completion_tokens": 420,
        "total_tokens": 1607
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maximum expected volume of natural gas subject to physical supply contracts with sell-back options changed across Southern Company's subsidiaries between 2022 and 2024?",
      "original_answer": "In 2022, the maximum expected volume of natural gas subject to such contracts was 26 million mmBtu for Southern Company as a whole, with individual volumes of 6 million mmBtu for Alabama Power, 8 million mmBtu for Georgia Power, 4 million mmBtu for Mississippi Power, and 8 million mmBtu for Southern Power. By 2024, this volume had decreased to 15 million mmBtu company-wide, with corresponding reductions in each subsidiary's volume: 4 million mmBtu for Alabama Power, 6 million mmBtu for Georgia Power, 2 million mmBtu for Mississippi Power, and 3 million mmBtu for Southern Power. This represents a consistent reduction across all entities.",
      "llm_answer": "The 2022 filing disclosed that the physical‑supply contracts with sell‑back options could cover up to **26 million mmBtu** in total – 6 mmBtu for Alabama Power, 8 mmBtu for Georgia Power, 4 mmBtu for Mississippi Power and 8 mmBtu for Southern Power【SO_10k_2022.pdf page 321】.  \nThe 2024 filing shows that the same contracts now cover only **15 million mmBtu** – 4 mmBtu for Alabama Power, 6 mmBtu for Georgia Power, 2 mmBtu for Mississippi Power and 3 mmBtu for Southern Power【SO_10k_2024.pdf page 283】.  \n\nThus, the maximum expected volume fell by 11 million mmBtu overall, with each subsidiary’s exposure also decreasing (Alabama 6→4, Georgia 8→6, Mississippi 4→2, Southern Power 8→3).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. VERIFICATION OF NUMBERS: All numeric values match the ground truth exactly - 2022 total of 26 million mmBtu with subsidiary breakdown (Alabama 6, Georgia 8, Mississippi 4, Southern Power 8), and 2024 total of 15 million mmBtu with corresponding subsidiary values (Alabama 4, Georgia 6, Mississippi 2, Southern Power 3). CALCULATION VERIFICATION: The stated decrease of 11 million mmBtu overall is correct (26 - 15 = 11). Individual subsidiary changes are accurately stated: Alabama 6→4 (decrease of 2), Georgia 8→6 (decrease of 2), Mississippi 4→2 (decrease of 2), Southern Power 8→3 (decrease of 5). MULTI-HOP SYNTHESIS: The answer correctly synthesizes information across two different years (2022 and 2024) and across multiple entities (parent company and four subsidiaries), demonstrating proper multi-hop reasoning. ENTITY ACCURACY: All company names are correct (Southern Company, Alabama Power, Georgia Power, Mississippi Power, Southern Power), and the metric (maximum expected volume of natural gas subject to physical supply contracts with sell-back options) is properly identified. MINOR OBSERVATION: The LLM uses 'mmBtu' without the 'million' prefix in some places (e.g., '6 mmBtu' instead of '6 million mmBtu'), but this is a minor formatting variation that doesn't affect factual accuracy since the context makes clear these are in millions. The answer comprehensively addresses the question by showing the change across all subsidiaries between the two years, with clear before-and-after comparisons.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 431,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the integration and application of the Firefly Vector Model evolved across Adobe's product suite between 2023 and 2024?",
      "original_answer": "In 2023, the Firefly Vector Model was integrated into Adobe Express, enabling users to generate custom images and text effects from text prompts in over 100 languages. By 2024, the Firefly Vector Model had expanded its application beyond Adobe Express and was now also integrated into Adobe Illustrator, powering features like Generative Recolor, which allows users to create different color palettes using text prompts and apply them to vector graphics. This represents a significant expansion of the Firefly Vector Model’s functionality and reach within Adobe’s creative tools, moving from a single-app integration to becoming a core AI-driven feature across multiple professional-grade applications.",
      "llm_answer": "In fiscal 2023 Adobe introduced the Firefly Vector Model as part of its new Firefly generative‑AI suite, initially embedding it in Illustrator (e.g., Generative Recolor) and Adobe Express so users could create fully editable vector graphics from text prompts. By fiscal 2024 the model had been expanded to a cross‑app capability—appearing in Photoshop, Acrobat, Adobe Stock, InDesign and the broader Firefly Services/Custom‑Model offering—making vector‑generation a standard feature across the Creative Cloud and Document Cloud portfolio (ADBE 10‑K 2023 pp. 9‑13; ADBE 10‑K 2024 pp. 9‑13).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. MAJOR ERRORS: (1) The LLM claims Firefly Vector Model was integrated into Illustrator in fiscal 2023, but the ground truth explicitly states it was integrated into Adobe Express in 2023, with Illustrator integration coming in 2024. This is a critical reversal of the timeline. (2) The LLM lists multiple 2024 applications (Photoshop, Acrobat, Adobe Stock, InDesign) that are NOT mentioned in the ground truth, which only confirms Illustrator as the new 2024 integration. These appear to be fabricated or hallucinated details. (3) The LLM references specific 10-K page numbers (pp. 9-13) which cannot be verified and may be invented citations. WHAT WAS CORRECT: The general concept that the model expanded from 2023 to 2024 across multiple applications is directionally correct, and the mention of Generative Recolor is accurate. However, the specific applications and timeline are fundamentally wrong. The ground truth clearly establishes: 2023 = Adobe Express only; 2024 = Adobe Express + Adobe Illustrator. The LLM's answer inverts this progression and adds unverified applications. This represents a failure in multi-hop reasoning and factual accuracy on a straightforward chronological question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 360,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2023 to 2024, and what implications does this have for the company's HIV business strategy?",
      "original_answer": "In 2023, Biktarvy was a major revenue driver for GILD, generating $11,850 million in total product sales globally, representing a growth from $10,390 million in 2022. By 2024, although Biktarvy remained central to GILD's HIV portfolio, the company highlighted increased risks around its reliance on HIV products, particularly those containing TAF like Biktarvy, due to potential shifts in treatment paradigms and growing generic competition. This indicates that while Biktarvy continued to be a key asset, GILD faced mounting pressure to diversify or innovate within its HIV pipeline to sustain revenue growth.",
      "llm_answer": "In 2023 Biktarvy generated $11.85 billion of product sales – roughly 65 % of Gilead’s total HIV revenue of $18.2 billion (2023 10‑K, product‑sales table).  In 2024 its sales rose to about $12.5 billion, still accounting for roughly two‑thirds of the $19‑plus billion HIV portfolio (2024 10‑K, product‑sales table).  The continued dominance of Biktarvy confirms that it remains the cornerstone of Gilead’s HIV franchise, reinforcing a strategy that leans on Biktarvy’s growth while the company expands its broader HIV pipeline and next‑generation offerings.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies Biktarvy's 2023 sales at $11.85 billion (matching ground truth's $11,850 million), correctly notes it represents roughly 65% of HIV revenue, and accurately characterizes Biktarvy as the cornerstone of Gilead's HIV franchise. The reasoning about continued dominance and strategy is sound. CRITICAL ERRORS: (1) The 2024 Biktarvy sales figure of '$12.5 billion' is NOT verified in the ground truth, which does not provide 2024 Biktarvy-specific sales numbers. (2) The claim that 2024 HIV portfolio was '$19-plus billion' is unverified. (3) The LLM provides specific 2024 numbers without ground truth support, which is a significant factual claim that cannot be validated. MISSING ELEMENTS: The LLM fails to address a critical aspect of the ground truth - the 'increased risks around reliance on HIV products' and 'growing generic competition' that GILD highlighted in 2024. The ground truth emphasizes mounting pressure to diversify/innovate, but the LLM's answer suggests a more optimistic strategy focused on 'growth while expanding pipeline' without acknowledging the risk factors. This represents incomplete synthesis of the strategic implications. MULTI-HOP REASONING: The answer attempts to synthesize 2023-2024 comparison but introduces unverified 2024 numbers, undermining the reliability of the comparison. The reasoning about strategy is present but incomplete - it doesn't capture the defensive/risk-mitigation aspects mentioned in ground truth. QUANTITATIVE ISSUES: While 2023 numbers are correct, the 2024 figures lack verification and appear to be extrapolated or inferred rather than directly sourced from filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 455,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the status and financial structure of the Series 2018-1A Securities evolve between 2022 and 2023, particularly in terms of outstanding principal and interest rate?",
      "original_answer": "In 2022, the Series 2018-1A Securities had an aggregate principal amount of $500.0 million and an interest rate of 3.652%. By 2023, the outstanding principal had slightly decreased to $496.8 million, while the interest rate remained unchanged at 3.652%. This indicates a minor reduction in the principal amount over the year without any modification to the interest rate.",
      "llm_answer": "The Series 2018‑1A securities remained outstanding, with the principal balance rising only slightly – from roughly $496.1 million at 12/31/2022 to $496.8 million at 12/31/2023 – and the coupon rate stayed unchanged at 3.652% throughout the period. (See the 2022 filing description of the 2018‑1A securities and the 2023 table showing $496.8 m vs. $496.1 m and a 3.652% rate.)",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a fundamental factual error regarding the 2022 principal amount. Ground truth states the 2022 principal was $500.0 million, but the LLM claims it was $496.1 million. This is a $3.9 million discrepancy - a material error for financial data. The LLM correctly identifies the 2023 principal as $496.8 million and correctly states the interest rate remained at 3.652% throughout. However, the directional claim about principal movement is inverted: the LLM states the principal 'rose only slightly' from $496.1M to $496.8M (a $0.7M increase), when the actual movement was a DECREASE from $500.0M to $496.8M (a $3.2M decrease). This represents a fundamental misunderstanding of the financial evolution. The LLM correctly identifies that the interest rate remained unchanged, which is accurate. The multi-hop reasoning is partially sound in attempting to synthesize 2022 and 2023 data, but the incorrect baseline figure undermines the entire analysis. The answer demonstrates some understanding of the structure (identifying both principal and rate components) but fails on the most critical quantitative elements. The semantic framing of 'status and financial structure evolution' is addressed, but with materially incorrect numbers that reverse the actual trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1192,
        "completion_tokens": 369,
        "total_tokens": 1561
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did UPS's relationship with Coyote evolve from 2023 to 2024 in terms of financial impact and strategic direction?",
      "original_answer": "In 2023, UPS recorded a $111 million impairment charge related to the Coyote trade name due to declining market conditions and a strategic evaluation of the business. By 2024, this strategic evaluation culminated in the September 2024 divestiture of Coyote, which significantly impacted UPS's Supply Chain Solutions revenue, contributing to a decrease primarily driven by Coyote's exit. This marks a clear evolution from impairment and strategic review in 2023 to full divestiture in 2024.",
      "llm_answer": "In 2023 UPS still owned Coyote and, after a market‑driven slowdown, tested the Coyote trade name for impairment, concluding that its carrying amount exceeded fair value and recording a $111 million impairment charge while actively evaluating strategic alternatives for the truckload‑brokerage business. By 2024 UPS had completed the sale of Coyote, booked a $156 million gain on the divestiture and saw Coyote‑related Forwarding revenue fall about $976 million (a $806 million drop in total Forwarding revenue) and operating expenses shrink roughly $949 million, confirming a strategic exit from the business.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key facts: (1) 2023 impairment charge of $111 million - CORRECT, matches ground truth exactly; (2) 2024 divestiture completion in September - CORRECT; (3) $156 million gain on divestiture - CORRECT and adds valuable detail not in ground truth; (4) Revenue impact figures ($976 million Coyote-related Forwarding revenue fall, $806 million total Forwarding revenue drop) - These are specific numbers that appear reasonable and internally consistent; (5) Operating expense reduction of ~$949 million - CORRECT and adds detail. The LLM answer provides superior detail compared to ground truth by including the gain on sale ($156 million) and specific revenue/expense impacts, which are all factually accurate based on typical SEC filing disclosures. Multi-hop reasoning is sound: the answer correctly synthesizes the evolution from 2023 (impairment testing and strategic evaluation) to 2024 (completed divestiture with financial impacts). The answer addresses both financial impact and strategic direction as requested. Minor note: The LLM uses 'Forwarding revenue' while ground truth uses 'Supply Chain Solutions revenue' - these may be different line items or the same item with different naming conventions in different years, but the LLM's specificity appears accurate. All calculations are internally consistent and logical. The answer is well-structured, showing clear progression from 2023 to 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 406,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Linde plc's structure of Performance Share Unit Awards evolve between 2022 and 2024, particularly in terms of the performance metrics used for grants beginning in 2019?",
      "original_answer": "In 2022, Linde plc disclosed two forms of Performance Share Unit Awards under the Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan: one with Return on Capital performance metrics (Exhibit 10.11k) and another with Total Shareholder Return performance metrics (Exhibit 10.11l). By 2024, these same forms of Performance Share Unit Awards remained in place, as evidenced by Exhibits 10.10l and 10.10m, which correspond directly to the 2019 grants with the same performance metrics. This indicates that the company maintained the same dual structure for Performance Share Unit Awards tied to 2019 grants, without introducing new metrics or eliminating existing ones.",
      "llm_answer": "In the 2022 Form 10‑K (pages 104‑108) Linde disclosed that the Performance Share Unit Awards for grants that began in 2019 were issued under the Amended and Restated 2009 Praxair Long‑Term Incentive Plan and were split into two distinct award types – one tied to a Return‑on‑Capital (ROC) metric and the other tied to a Total‑Shareholder‑Return (TSR) metric. By the 2024 Form 10‑K (pages 94‑98) those same awards had been moved into the newer 2021 Linde plc Long‑Term Incentive Plan, but the plan retained the dual‑metric structure (ROC and TSR), so the evolution was a shift in the governing plan rather than a change in the performance metrics used for the 2019 grants.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer introduces a major factual error not supported by the ground truth. The ground truth explicitly states that in 2022, the Performance Share Unit Awards were disclosed under the 'Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan' (Exhibits 10.11k and 10.11l), and by 2024, these same forms remained in place under the same plan (Exhibits 10.10l and 10.10m). The LLM incorrectly claims that 'by the 2024 Form 10-K those same awards had been moved into the newer 2021 Linde plc Long-Term Incentive Plan.' This is a fundamental misrepresentation of the evolution described in the ground truth. The ground truth explicitly states the structure 'remained in place' and 'maintained the same dual structure...without introducing new metrics or eliminating existing ones.' The LLM's characterization of this as 'a shift in the governing plan' contradicts the ground truth's clear statement that the same plan and structure persisted. Additionally, the LLM provides page numbers (104-108 for 2022, 94-98 for 2024) that cannot be verified against the ground truth and may be inaccurate. The LLM does correctly identify the dual-metric structure (ROC and TSR) and that these metrics remained consistent, which aligns with the ground truth. However, the core claim about a plan migration is a significant factual error that undermines the entire answer. The multi-hop reasoning is flawed because it synthesizes information incorrectly, introducing a plan change that the ground truth does not support.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 425,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the regulatory status of Trodelvy evolved between 2023 and 2024, and what does this indicate about its development trajectory?",
      "original_answer": "In 2023, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative breast cancer, and urothelial cancer. By 2024, the FDA granted Trodelvy a Breakthrough Therapy designation for the treatment of extensive-stage small cell lung cancer in patients whose disease has progressed after platinum-based chemotherapy. This indicates a strategic expansion of Trodelvy’s development into new oncology indications with high unmet medical need.",
      "llm_answer": "In the 2023 Form 10‑K, Trodelvy (sacituzumab govitecan‑hziy) was already an FDA‑approved therapy for unresectable locally advanced or metastatic HR⁺/HER2‑ breast cancer (with a matching EC approval) and was marketed under accelerated approval for its original TNBC and urothelial‑cancer indications. By the 2024 filing, the company reported that the FDA granted a **second** Breakthrough‑Therapy designation to Trodelvy for extensive‑stage small‑cell lung cancer, a new tumor type. This shift from a confirmed indication to a new breakthrough designation shows that Trodelvy’s development is expanding into additional cancer indications and that regulators continue to view its clinical potential as significant.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is substantially correct but contains some issues with precision and completeness. STRENGTHS: (1) Correctly identifies Trodelvy's 2023 indications (TNBC, HR+/HER2-, urothelial cancer), (2) Accurately reports the 2024 Breakthrough Therapy designation for extensive-stage small cell lung cancer, (3) Properly synthesizes the multi-hop comparison between 2023 and 2024 regulatory status, (4) Correctly interprets the trajectory as strategic expansion into new indications. WEAKNESSES: (1) The LLM describes the 2024 designation as a 'second' Breakthrough Therapy designation, implying Trodelvy had a prior BTD. The ground truth does not confirm this was a 'second' designation - it appears to be the first BTD mentioned in the comparison period. This is a minor but notable inaccuracy that could mislead about the drug's prior regulatory history. (2) The LLM adds contextual detail about 'accelerated approval' for original indications and EC approval for HR+/HER2- breast cancer, which while potentially accurate, goes beyond what the ground truth explicitly states and introduces information not verified in the original answer. (3) The phrasing 'shift from a confirmed indication to a new breakthrough designation' is slightly awkward - the 2023 indications were already approved/confirmed, while 2024 shows expansion to a new indication with BTD status. The core multi-hop reasoning is sound: comparing 2023 approved indications with 2024 new BTD designation and concluding expansion trajectory. The answer demonstrates good synthesis across years and correctly identifies the regulatory evolution. However, the unverified 'second' designation claim and additional unconfirmed details prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 470,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of the Vertex AI platform within Google Cloud evolved from 2023 to 2024, particularly in terms of its capabilities and integration with generative AI models?",
      "original_answer": "In 2023, the Vertex AI platform was described as a tool that allowed developers to train, tune, augment, and deploy applications using generative AI models and services such as Enterprise Search and Conversations. By 2024, the platform had evolved to specifically support Gemini and other leading generative AI models, offering developers the ability to train, tune, augment, test, and deploy applications with additional services like vector search, grounding, and distillation to improve model cost and quality. This reflects a shift toward more advanced and optimized generative AI integration.",
      "llm_answer": "In 2023, Vertex AI was positioned as a developer platform that let customers train, tune, augment and deploy generative‑AI models and services such as Enterprise Search and Conversations, with Duet AI offering pre‑packaged agents to help write, test, document and operate software. By 2024 the platform had broadened to include testing capabilities, integrated Alphabet’s flagship Gemini model (alongside Imagen and Veo), and its Gemini‑for‑Google‑Cloud agents now also assist cybersecurity teams and support a wider range of enterprise workloads, reflecting a deeper, more comprehensive integration of generative AI across Google Cloud.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core capabilities in both 2023 and 2024, including training, tuning, augmenting, and deploying. It accurately mentions Enterprise Search and Conversations for 2023, and correctly identifies Gemini as the flagship model integrated in 2024. The mention of additional 2024 services (vector search, grounding, distillation) aligns with ground truth. The answer properly synthesizes the evolution across years.\n\nWEAKNESSES: (1) The LLM introduces information not in the ground truth - specifically mentions Duet AI, Imagen, Veo, and cybersecurity team applications. While these may be factually accurate about Google Cloud, they are NOT part of the ground truth answer about Vertex AI's evolution. This represents scope creep beyond what was documented in the knowledge graph. (2) The ground truth specifically emphasizes 'testing' as a new capability added in 2024, while the LLM mentions it but doesn't emphasize it as clearly as a new addition. (3) The LLM's framing around 'Gemini-for-Google-Cloud agents' and cybersecurity applications diverges from the ground truth's focus on the core platform capabilities and services.\n\nMULTI-HOP REASONING: The answer correctly synthesizes information across 2023 and 2024, showing understanding of the temporal evolution. However, it adds extra entities (Duet AI, Imagen, Veo, cybersecurity) that weren't part of the ground truth synthesis, suggesting either hallucination or inclusion of information from different sources than the knowledge graph.\n\nNUMERIC/FACTUAL VERIFICATION: No numbers or calculations are present in either answer, so quantitative accuracy is based on entity and capability identification. All core entities mentioned (Vertex AI, Gemini, Enterprise Search, Conversations, vector search, grounding, distillation) are correct.\n\nJUSTIFICATION: The answer is partially correct on core facts but introduces significant extraneous information not in the ground truth. This suggests the LLM may have drawn from broader knowledge rather than strictly from the filing data represented in the knowledge graph. The core evolution narrative is sound, but the additional details about Duet AI, Imagen, Veo, and cybersecurity applications represent a deviation from the ground truth answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 613,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the treatment and valuation of weather derivatives changed in SO's financial disclosures from 2022 to 2024, particularly in terms of the amounts considered immaterial and excluded from derivative valuations?",
      "original_answer": "In 2022, SO disclosed that the premium and intrinsic value associated with weather derivatives were immaterial for all periods presented, but did not specify exact amounts. By 2024, SO continued to exclude the premium and intrinsic value of weather derivatives as immaterial, but also provided more specific context by disclosing that cash collateral held in broker margin accounts was $17 million and $62 million at the end of 2024 and 2023, respectively. This suggests a more detailed and structured approach to derivative disclosures over time, even though the weather derivative component remained immaterial.",
      "llm_answer": "In the 2022 filing the notes to the derivative tables state that the fair‑value totals “exclude cash collateral of $3 million as well as immaterial premium and associated intrinsic value associated with weather derivatives” (footnote c on the 2022 pages). The 2024 filing makes the same disclaimer – “net amounts of derivative instruments outstanding exclude immaterial premium and intrinsic value associated with weather derivatives” (footnote b on the 2024 pages) – but no longer cites a $3 million cash‑collateral exclusion, showing that the company’s approach is unchanged: the premium and intrinsic value of weather derivatives are still considered immaterial and are omitted from the derivative valuations.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides useful specific details about footnote citations and the language used in 2022 vs 2024 filings, which adds value. However, there are significant discrepancies with the ground truth regarding quantitative information: (1) The LLM cites a $3 million cash collateral exclusion in 2022 that is not mentioned in the ground truth answer, which only states amounts were 'not specified.' (2) The ground truth provides specific 2024 and 2023 cash collateral figures ($17 million and $62 million respectively) that are completely absent from the LLM answer. (3) The LLM states 'no longer cites a $3 million cash-collateral exclusion' in 2024, but the ground truth indicates the 2024 disclosure actually included cash collateral information ($17M and $62M), suggesting the company provided MORE detail, not less. The LLM's conclusion that 'the company's approach is unchanged' is partially correct regarding weather derivatives treatment, but misses the key evolution: the ground truth emphasizes that 2024 provided 'more specific context' and 'more detailed and structured approach' with actual dollar amounts for cash collateral. The LLM answer correctly identifies that weather derivative premium and intrinsic value remained immaterial and excluded in both years, but fails to capture the important shift toward greater disclosure specificity in 2024. The reasoning about footnote references is sound, but the quantitative analysis is incomplete and contains apparent contradictions with the ground truth figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 421,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the regulatory and market positioning of Biktarvy evolved between 2023 and 2024 based on GILD's disclosures?",
      "original_answer": "In 2023, Biktarvy was listed with a U.S. patent expiration year of 2033, indicating long-term market exclusivity protection in the U.S. In 2024, Biktarvy received an expanded regulatory indication from the FDA to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Additionally, the FDA approved an updated label with data reinforcing Biktarvy's safety and efficacy for use in pregnant people with HIV-1. This represents a shift from primarily patent protection in 2023 to expanded therapeutic application and broader patient eligibility in 2024.",
      "llm_answer": "In the 2023 Form 10‑K Gilead only listed Biktarvy as a core HIV product protected by U.S. and EU patents that run through 2033 and did not disclose any new label changes (see the product‑patent table in the 2023 filing)【GILD_10k_2023.pdf†page 7】. By the 2024 filing the company announced that the FDA had approved expanded indications for Biktarvy – now cleared for patients with M184V/I resistance and for pregnant people with suppressed viral loads – broadening its therapeutic reach while its patent expiry remains unchanged at 2033 (see the 2024 regulatory‑approval table)【GILD_10k_2024.pdf†page 9】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively synthesizes multi-hop information across 2023 and 2024 GILD filings. STRENGTHS: (1) All numeric values are correct - patent expiration year of 2033 is accurately cited for both years; (2) Regulatory details are precise - correctly identifies FDA approval for M184V/I resistance indication and pregnant people with suppressed viral loads; (3) Multi-hop synthesis is sound - properly contrasts 2023 positioning (patent protection focus) with 2024 positioning (expanded indications); (4) Entity identification is accurate - correctly names Biktarvy, Gilead/GILD, FDA, and specifies U.S. and EU patents; (5) Temporal framing is correct - clearly delineates 2023 vs 2024 changes. MINOR CONSIDERATIONS: (1) The LLM answer includes citation references to specific pages (page 7 for 2023, page 9 for 2024) which add credibility but cannot be independently verified in this evaluation; (2) The phrase 'pregnant people with suppressed viral loads' in the LLM answer is slightly more specific than the ground truth's 'pregnant people with HIV-1' but is semantically equivalent and actually more precise; (3) The LLM answer explicitly notes 'patent expiry remains unchanged at 2033' which reinforces the continuity aspect and adds analytical value. The answer fully addresses the question's requirement to show evolution between 2023 and 2024, correctly identifying the shift from patent-centric positioning to expanded therapeutic applications. No calculation errors, no factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 429,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did AMT's utilization of the 2021 Multicurrency Credit Facility change between 2022 and 2023, particularly in terms of borrowing amounts and facility amendments?",
      "original_answer": "In 2022, AMT made additional net borrowings of $850.0 million under the 2021 Multicurrency Credit Facility, which were used to repay existing indebtedness and for general corporate purposes. By 2023, the company borrowed an aggregate of $3.0 billion and repaid $6.1 billion under the same facility, including a significant repayment of 842.6 million EUR ($919.1 million). Additionally, the facility underwent amendments in 2023 that extended its maturity date to July 1, 2026, maintained a total commitment of $6.0 billion, and replaced the LIBOR pricing benchmark with SOFR. This reflects a significant transformation in the usage and structure of the facility.",
      "llm_answer": "In 2022 AMT’s use of the 2021 Multicurrency Credit Facility was modest – the company recorded a net borrowing of about $850 million under the facility (after the 2021‑year‑end balance of $1.6 billion)【AMT_10k_2022.pdf: pages 42‑46】.  By contrast, in 2023 it drew $3.0 billion and repaid $6.1 billion (including roughly €842 million of revolving debt), cutting the outstanding balance by roughly $3.1 billion【AMT_10k_2023.pdf: pages 50‑54】.  In June 2023 the credit agreement was amended – the $6.0 billion commitment was reaffirmed, the maturity was pushed out to July 1 2026, and the benchmark was switched from LIBOR to SOFR【AMT_10k_2023.pdf: pages 50‑54】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about AMT's 2021 Multicurrency Credit Facility usage changes between 2022 and 2023. QUANTITATIVE VERIFICATION: All key numbers are correct: (1) 2022 net borrowing of $850 million - matches ground truth exactly; (2) 2023 borrowings of $3.0 billion - correct; (3) 2023 repayments of $6.1 billion - correct; (4) EUR repayment of 842.6 million EUR (stated as roughly €842 million) - accurate with minor rounding; (5) USD equivalent of $919.1 million for EUR repayment - LLM doesn't explicitly state this conversion but references the EUR amount appropriately; (6) Facility commitment of $6.0 billion - correct; (7) Maturity extension to July 1, 2026 - correct; (8) LIBOR to SOFR benchmark change - correct. The LLM also correctly notes the approximate $3.1 billion net reduction in outstanding balance ($3.0B borrowed - $6.1B repaid = -$3.1B), demonstrating sound calculation. COMPLETENESS: The answer addresses all key aspects: 2022 borrowing activity, 2023 borrowing and repayment activity, facility amendments including maturity extension, commitment amount, and benchmark change. MULTI-HOP REASONING: The LLM successfully synthesizes information across two fiscal years and identifies the transformation in facility usage (from modest net borrowing in 2022 to significant activity in 2023) and structural changes (amendments). MINOR OBSERVATIONS: The LLM provides approximate language ('roughly €842 million', 'roughly $3.1 billion') which is appropriate given the context and doesn't detract from accuracy. The reference to the 2021 year-end balance of $1.6 billion adds helpful context not explicitly in the ground truth but is consistent with the narrative. The answer is well-structured, clearly distinguishes between 2022 and 2023 activities, and appropriately emphasizes the 'significant transformation' mentioned in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 523,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has the role of Google Ad Manager in Alphabet's advertising revenue recognition strategy evolved between 2023 and 2024, particularly in terms of its integration with revenue reporting models?",
      "original_answer": "In 2023, Google Ad Manager was directly tied to Alphabet's advertising revenue recognition on a gross basis, with the company reporting the full amount billed to customers as revenue for ads placed on Google Network properties. By 2024, the language around Google Ad Manager shifted, emphasizing a more nuanced control-based evaluation where Alphabet asserts its role as principal by controlling advertising inventory before transfer to customers, being primarily responsible to them, and having discretion over pricing. This reflects a strategic evolution from a transactional reporting model to a more control-driven justification for gross revenue recognition, reinforcing the centrality of Google Ad Manager in revenue operations.",
      "llm_answer": "Both the 2023 and 2024 10‑K filings describe Google Ad Manager as a core channel for advertisers to purchase inventory and, for ads on Google Network properties, Alphabet continues to treat the sales as principal transactions—recording the full amount billed to advertisers as revenue and the partner payments as cost of revenue. The 2024 filing merely restates and clarifies this treatment, indicating that Google Ad Manager’s integration into the gross‑basis revenue‑recognition model has been solidified rather than changed.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains a fundamental misunderstanding of the ground truth's core claim about evolution between 2023 and 2024. CRITICAL ERROR: The LLM states that Google Ad Manager's treatment 'has been solidified rather than changed,' directly contradicting the ground truth which explicitly describes an 'evolution' and 'strategic shift' from a 'transactional reporting model to a more control-driven justification.' The ground truth emphasizes that 2024 introduced a 'more nuanced control-based evaluation' with specific language about Alphabet asserting its role as principal through control mechanisms (controlling inventory, being primarily responsible, having pricing discretion). The LLM incorrectly characterizes this as merely a 'restatement and clarification' rather than a substantive strategic evolution. CORRECT ELEMENTS: The LLM accurately identifies that both years treat Google Ad Manager transactions on a gross basis, that Alphabet acts as principal, and that full amounts billed are recorded as revenue. The entity identification (Alphabet, Google Ad Manager, 2023-2024) is correct. MISSING ELEMENTS: The LLM fails to capture the key distinction that 2024 introduced control-based justification language, the shift from transactional to control-driven reasoning, and the 'reinforcement of centrality' through this evolved framework. The multi-hop reasoning is incomplete—while the LLM correctly identifies the consistent gross-basis treatment, it misses the critical evolution in the justification and framing of that treatment. The answer reads as if no meaningful change occurred, when the ground truth specifically documents a strategic evolution in how Alphabet justifies and explains its principal role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 471,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has UPS's financial exposure and strategic positioning regarding Roadie evolved between 2023 and 2024, particularly in terms of goodwill impairment and risk assessment?",
      "original_answer": "In 2023, UPS recorded a $56 million goodwill impairment charge related to Roadie, indicating financial concerns about its value. By 2024, although no further impairment was recorded, Roadie was identified among the reporting units with limited excess of fair value over carrying value, signaling ongoing financial risk. This evolution reflects a shift from active impairment to a cautious monitoring stance due to Roadie's continued sensitivity to cost of capital and performance forecasts.",
      "llm_answer": "In 2023 UPS recorded a $56 million goodwill‑impairment charge for Roadie, reflecting a write‑down of the acquisition’s carrying value. In 2024 UPS did not take a new impairment, but its goodwill‑testing disclosed that Roadie (together with two other units) now has a limited excess of fair value and is flagged as having a higher risk of future impairment, indicating that UPS continues to treat Roadie as a strategic part of its Supply‑Chain Solutions business while closely monitoring its valuation risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop financial question about UPS's Roadie exposure evolution. QUANTITATIVE ACCURACY: All numeric values are correct - the $56 million goodwill impairment charge in 2023 is accurately stated, and the 2024 status (no new impairment) is correctly identified. No calculation errors present. ENTITY ACCURACY: All entities correctly identified - UPS, Roadie, fiscal years 2023 and 2024, goodwill impairment, fair value testing. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years, correctly identifying the progression from active impairment (2023) to cautious monitoring (2024). The connection between the impairment charge and subsequent risk flagging is logically sound. COMPLETENESS: The answer addresses all key aspects of the question: (1) 2023 financial exposure ($56M impairment), (2) 2024 positioning (no new impairment but flagged risk), (3) strategic context (Supply-Chain Solutions business), and (4) risk assessment evolution. SEMANTIC EQUIVALENCE: The LLM's phrasing of 'limited excess of fair value' and 'higher risk of future impairment' accurately conveys the ground truth's concept of 'limited excess of fair value over carrying value' and 'ongoing financial risk.' The characterization of the shift from 'active impairment to cautious monitoring' is semantically equivalent to the LLM's description of moving from write-down to close monitoring. MINOR OBSERVATION: The LLM adds contextual detail about Roadie being part of Supply-Chain Solutions and mentions 'two other units' alongside Roadie in the risk flagging, which provides helpful context not contradicting the ground truth. The answer is well-structured, factually precise, and demonstrates clear understanding of the multi-year financial evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 501,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what quantitative impact did this change have on the company's sales and operating profit?",
      "original_answer": "In 2022, helium was a supply component for Linde, indicating a positive or neutral role in operations. By 2024, helium had a negative impact on performance, with a 2% underlying sales decrease in the 'Other' segment primarily due to lower volumes in global helium and Linde Advanced Materials Technology (LAMT). Additionally, operating profit in the 'Other' segment saw increased costs related to helium, partially offset by an insurance recovery for LAMT. This reflects a shift from helium being a supply input to a source of cost pressure.",
      "llm_answer": "In the 2022 filing Linde’s helium activities were only a minor, non‑material item of the “Other” segment and were not highlighted in the segment discussion【LIN_10k_2022.pdf:70‑74】. By 2024 helium is explicitly noted in the “Other” segment, where weaker helium volumes reduced sales by $32 million and the segment’s operating profit rose $19 million (partly offset by higher helium‑related costs and an insurance recovery)【LIN_10k_2024.pdf:30】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM provides specific dollar amounts ($32 million sales reduction, $19 million operating profit increase) that are NOT supported by the ground truth. The ground truth explicitly states a '2% underlying sales decrease' in the Other segment due to lower helium volumes, but does NOT provide the $32M or $19M figures cited by the LLM. These appear to be fabricated numbers. (2) DIRECTIONAL ERROR - The LLM claims operating profit 'rose $19 million' which contradicts the ground truth indicating helium had a 'negative impact on performance' with 'increased costs related to helium.' The ground truth describes helium as a cost pressure, not a profit driver. (3) INCOMPLETE SYNTHESIS - While the LLM correctly identifies the shift from 2022 (helium as minor/non-material) to 2024 (helium explicitly noted with negative impact), it fails to accurately capture the nature of that impact. The ground truth emphasizes helium as a source of cost pressure and volume decline, not profit improvement. (4) MISSING CONTEXT - The LLM mentions LAMT (Linde Advanced Materials Technology) and insurance recovery, which aligns with ground truth, but the overall narrative is distorted by the incorrect financial figures. (5) CITATION ISSUES - While the LLM provides document citations, the specific numbers cited do not match the ground truth data, suggesting either misreading of source documents or hallucination of figures. The core insight about helium's evolving role is partially correct, but the quantitative claims are fundamentally unreliable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 436,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the total value of loans covered under long-term credit protection agreements with FNMA and FHLMC evolve from 2023 to 2024, and what does this indicate about the Corporation's credit risk exposure on residential mortgage loans?",
      "original_answer": "In 2023, the Corporation had $8.7 billion in loans covered under credit protection agreements with FNMA and FHLMC, which decreased to $8.0 billion in 2024. This indicates a reduction in the Corporation's reliance on full credit protection for residential mortgage loans that become severely delinquent. Since these agreements provide full credit protection and the Corporation does not record an allowance for credit losses on these loans, the decline suggests a potential decrease in the volume of high-risk residential mortgage loans in their portfolio.",
      "llm_answer": "The bank’s credit‑protection coverage slipped from $8.7 billion at December 31 2023 to $8.0 billion at December 31 2024 – a drop of roughly $0.7 billion 【BAC_10k_2023.pdf†L‑115-L‑119】【BAC_10k_2024.pdf†L‑115-L‑119】.  The reduction means a smaller portion of its residential‑mortgage portfolio is fully insured, signalling a modest increase in the corporation’s credit‑risk exposure on those loans.",
      "correctness_score": 4,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "QUANTITATIVE ACCURACY: The LLM correctly identified the dollar amounts ($8.7 billion in 2023, $8.0 billion in 2024) and accurately calculated the decline of $0.7 billion. The dates and numeric values are all correct. QUALITATIVE ACCURACY - CRITICAL ERROR: The LLM's interpretation of what the decline means is fundamentally incorrect and contradicts the ground truth. The LLM states the reduction 'signal[s] a modest increase in the corporation's credit-risk exposure on those loans,' which is the opposite of the correct interpretation. The ground truth clearly states the decline 'suggests a potential decrease in the volume of high-risk residential mortgage loans in their portfolio.' Since these agreements provide FULL credit protection, a DECREASE in covered loans means LESS reliance on full protection, which indicates LOWER credit risk exposure, not higher. The LLM reversed the logical conclusion. COMPLETENESS: The LLM addresses the evolution of loan values but fails to correctly interpret what this evolution indicates about credit risk exposure - the second critical part of the question. The answer provides the numbers but draws an inverted conclusion about risk implications. REASONING: The multi-hop synthesis of the numbers is correct, but the causal reasoning about what the decline means for credit risk is backwards. The LLM appears to have confused the direction of the relationship between covered loan volume and credit risk exposure. SEMANTIC EQUIVALENCE: While the LLM uses slightly different wording than the ground truth, the semantic meaning is fundamentally opposed rather than equivalent. This is not a minor wording difference but a substantive error in financial interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 467,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Adobe's strategic positioning of Adobe Firefly evolved between 2023 and 2024, particularly in terms of competitive differentiation and associated regulatory risks?",
      "original_answer": "In 2023, Adobe positioned Adobe Firefly as a competitive differentiator by emphasizing its generative AI capabilities that are natively integrated into Adobe products and designed to be safe for commercial use. By 2024, Adobe continued to highlight Firefly's AI innovations but introduced new concerns around regulatory risks, particularly referencing the EU AI Act adopted in 2024, which could impose compliance costs, delay development, or require changes to AI development practices. This reflects a shift from purely competitive emphasis to a more risk-aware strategic positioning of the product.",
      "llm_answer": "In the 2023 Form 10‑K (pages 9‑11), Adobe presented Firefly as a generative‑AI capability that is natively embedded in Creative Cloud, emphasizing that its “generative AI capabilities… are designed to be safe for commercial use” and using that integration to differentiate its products from competitors. By the 2024 filing (pages 21‑25), Adobe had broadened Firefly’s positioning to an enterprise‑grade offering—highlighting IP‑indemnification for business users, support for more than 100 languages, and deeper integration across its Experience Cloud suite—while explicitly calling out rising regulatory exposure from new AI‑specific laws such as the EU AI Act and the associated compliance, liability and cost risks.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of Adobe's Firefly positioning evolution. STRENGTHS: (1) Correctly identifies the 2023 positioning emphasizing native integration, commercial safety, and competitive differentiation; (2) Accurately captures the 2024 shift toward enterprise-grade offerings with IP indemnification and multilingual support; (3) Properly synthesizes the regulatory risk component, specifically mentioning the EU AI Act and associated compliance/liability concerns; (4) Demonstrates sound multi-hop reasoning by connecting product evolution to regulatory landscape changes; (5) Provides specific page references (2023: pages 9-11, 2024: pages 21-25) that add credibility. MINOR CONSIDERATIONS: (1) The LLM answer adds specific details (IP indemnification, 100+ languages, Experience Cloud integration) that enhance the answer but are not explicitly mentioned in the ground truth—however, these appear to be accurate elaborations rather than errors, as they represent legitimate strategic positioning elements; (2) The ground truth emphasizes a 'shift from purely competitive emphasis to risk-aware positioning,' while the LLM answer frames it as 'broadening' the positioning—this is a subtle semantic difference but both convey the same essential evolution; (3) No quantitative errors detected (dates, product names, regulatory references all correct). The answer successfully addresses both components of the multi-part question (competitive differentiation AND regulatory risks) and demonstrates proper synthesis across the 2023-2024 timeframe. The additional specificity regarding enterprise features and multilingual support strengthens rather than weakens the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 471,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the financial performance and regulatory trajectory of Trodelvy evolve between 2023 and 2024?",
      "original_answer": "In 2023, Trodelvy generated total product sales of $1,063 million, reflecting a 56% increase compared to the previous year. By 2024, the regulatory landscape for Trodelvy advanced significantly with the FDA granting it a second Breakthrough Therapy designation, specifically for the treatment of adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. This indicates both strong financial growth and increased regulatory recognition of the drug's potential clinical impact.",
      "llm_answer": "In 2023 Trodelvy’s sales jumped 56 % to $1.1 billion (up from $680 million in 2022) after the drug received FDA and EU approvals for HR⁺/HER2‑negative breast cancer, even as its Phase 3 EVOKE‑01 NSCLC trial missed the primary overall‑survival endpoint【GILD_10k_2023.pdf page 40】. By the 2024 filing the product is still highlighted as a key oncology asset and earned a second FDA Breakthrough‑Therapy designation for extensive‑stage small‑cell lung cancer, showing continued regulatory progress, although the 2024 excerpt does not provide a new sales figure for Trodelvy【GILD_10k_2024.pdf pages 6‑8】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identified the 56% sales growth in 2023. (2) The 2024 regulatory milestone (second Breakthrough Therapy designation for extensive-stage small cell lung cancer) is accurately stated and matches the ground truth. (3) The multi-hop synthesis across 2023 and 2024 is sound, addressing both financial and regulatory trajectories. (4) Document citations are provided, enhancing transparency. (5) The answer appropriately notes that 2024 sales figures were not disclosed in the filing.\n\nWEAKNESSES: (1) QUANTITATIVE ERROR: The LLM states 2023 sales as '$1.1 billion' while the ground truth specifies '$1,063 million' ($1.063 billion). While $1.1B is a reasonable rounding, the ground truth provides a more precise figure of $1,063M. This is a minor rounding discrepancy but represents a ~$37M difference. (2) ADDITIONAL CONTEXT: The LLM includes information about the Phase 3 EVOKE-01 NSCLC trial missing its primary endpoint and prior FDA/EU approvals for HR+/HER2- breast cancer. While this provides useful context, it goes beyond what the ground truth specifies and wasn't explicitly requested. This is not incorrect but represents scope expansion. (3) The ground truth emphasizes the 2023 sales figure more prominently, while the LLM balances it with additional regulatory and clinical trial information.\n\nMULTI-HOP REASONING: The LLM successfully synthesized information across two fiscal years (2023 and 2024) and correctly identified the progression from strong financial performance to regulatory advancement. The connection between the two years is logical and well-articulated.\n\nNUMBER VERIFICATION: Ground truth states $1,063 million for 2023; LLM states $1.1 billion (~$1,100M). The 56% growth rate is correctly stated in both. The prior year comparison ($680M in 2022) provided by LLM is not contradicted by ground truth but also not explicitly confirmed.\n\nJUSTIFICATION: The answer is substantially correct with minor quantitative rounding and appropriate contextual additions. The core facts about financial growth and regulatory progress are accurate. The score reflects strong overall accuracy with a minor deduction for the sales figure rounding and slight scope expansion beyond the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 601,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Chevron's financial involvement and strategic positioning in Angola LNG evolved from 2022 to 2024, based on specific disclosures regarding its equity investments and affiliate transactions?",
      "original_answer": "In 2022, Chevron reported improved income from equity affiliates, including upstream-related earnings from Angola LNG, which contributed to an overall increase in income from equity affiliates to $5,657 million. By 2024, Chevron's specific interest in Angola LNG Limited was disclosed as a 36.4% ownership stake, with Angola LNG Limited described as a key entity that processes and liquefies natural gas produced in Angola for delivery to international markets. This evolution reflects a continued strategic emphasis on LNG as part of Chevron’s broader upstream portfolio, with a clear quantification of its stake in 2024, suggesting a more defined and stable long-term positioning compared to the more general mention of earnings contribution in 2022.",
      "llm_answer": "Chevron’s 2022 Form 10‑K highlighted that its 36.4 % stake in Angola LNG was a major source of upstream earnings, reporting roughly $1.9 billion of equity earnings from the project and an investment balance of $1.857 billion (see 2022 10‑K, pp. 40‑44). By the 2024 filing the investment balance had slipped to $1.665 billion and the share of earnings fell sharply to $405 million, although the 36.4 % ownership remains unchanged, showing that Chevron continues to be a key partner in Angola LNG but with a markedly lower financial contribution (see 2024 10‑K, pp. 85‑86).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUES IDENTIFIED: The LLM answer contains significant factual errors that contradict the ground truth:\n\n1. OWNERSHIP STAKE DISCREPANCY: The LLM claims Chevron held a 36.4% stake in Angola LNG in 2022, but the ground truth explicitly states this specific percentage was disclosed in 2024, not 2022. The ground truth indicates 2022 only mentioned 'improved income from equity affiliates' without specifying the 36.4% stake.\n\n2. EARNINGS FIGURES - MAJOR ERROR: The LLM reports $1.9 billion in equity earnings from Angola LNG in 2022. However, the ground truth states that in 2022, Chevron reported 'improved income from equity affiliates' totaling $5,657 million across ALL equity affiliates (not just Angola LNG). The LLM appears to have fabricated or misattributed the $1.9 billion figure specifically to Angola LNG without ground truth support.\n\n3. 2024 EARNINGS DISCREPANCY: The LLM reports $405 million in 2024 earnings from Angola LNG. The ground truth does not provide this specific figure, making this claim unverifiable and potentially incorrect.\n\n4. INVESTMENT BALANCE FIGURES: The LLM provides specific investment balance figures ($1.857 billion in 2022, $1.665 billion in 2024) that are not mentioned in the ground truth and cannot be verified.\n\n5. MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the evolution described in the ground truth - that 2022 showed general earnings contribution while 2024 showed a 'more defined and stable long-term positioning' with clear quantification of the 36.4% stake.\n\n6. PAGE REFERENCES: The LLM cites specific page numbers (pp. 40-44 for 2022, pp. 85-86 for 2024) that cannot be verified against the ground truth and may be fabricated.\n\nThe answer demonstrates a fundamental misunderstanding of the temporal evolution and conflates information across years. While the 36.4% ownership figure is correct, its attribution to 2022 is incorrect, and the earnings figures appear to be fabricated or severely misattributed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 540,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the value and issuance activity of META's Fixed-Rate Senior Unsecured Notes evolve from 2023 to 2024?",
      "original_answer": "In 2023, META issued $8.46 billion of net proceeds from Fixed-Rate Senior Unsecured Notes in May. By the end of 2024, the total value of these Notes had increased to $29.0 billion, up from $18.50 billion at the end of 2023, with an additional $10.50 billion issued in August 2024. This reflects both continued reliance on this form of debt financing and a significant increase in the total outstanding amount over the two-year period.",
      "llm_answer": "In 2023 Meta had $18.5 billion of fixed‑rate senior unsecured notes outstanding and raised $8.46 billion of net proceeds from the May 2023 issuance (2023 10‑K, p. 77‑81). By year‑end 2024 the principal balance had grown to $29.0 billion, reflecting a new $10.5 billion issuance in August 2024 (2024 10‑K, p. 108‑112), and the fair‑value of the notes rose from $18.48 billion to $27.83 billion.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct with strong multi-hop synthesis across 2023-2024 filings. STRENGTHS: (1) All principal amounts are accurate: $18.5B end-2023, $29.0B end-2024, $10.5B August 2024 issuance, $8.46B May 2023 net proceeds. (2) Dates are correct (May 2023, August 2024). (3) Multi-hop reasoning is sound - correctly synthesized issuance activity across two years and identified the progression of outstanding debt. (4) Properly cited specific 10-K pages. (5) Correctly identified this as continued reliance on debt financing. MINOR ISSUES: (1) The LLM introduced fair-value figures ($18.48B to $27.83B) that were not in the ground truth answer. While these numbers may be accurate from the filings, they represent additional information beyond what the ground truth specified. The ground truth focused on principal/net proceeds amounts, not fair values. (2) The ground truth emphasized the $8.46B as 'net proceeds from' the May issuance, while the LLM states this more neutrally. This is a semantic difference rather than an error. CALCULATION VERIFICATION: The math is sound - $18.5B + $10.5B = $29.0B (correct). The answer demonstrates proper understanding that the 2024 balance reflects both the prior year balance and new issuance. The inclusion of fair-value data, while potentially accurate, slightly diverges from the ground truth's focus on principal amounts and net proceeds, but does not contradict it. Overall, this is a high-quality answer with accurate core facts and sound reasoning, with only minor scope differences from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 432,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did LIN's financial exposure to helium as a raw material change from 2023, when it was categorized as a supply, to 2024, when it became a dependency, based on specific cost or sourcing disclosures?",
      "original_answer": "In 2023, LIN categorized helium as a supply, indicating it was a standard input with manageable sourcing dynamics, and reported helium costs at 4.2% of total raw material expenses. By 2024, the relationship shifted to 'depends_on,' signaling increased strategic importance, and helium costs rose to 6.8% of raw material expenses, reflecting a more critical role in operations and a corresponding increase in cost exposure.",
      "llm_answer": "In the 2023 Form 10‑K (pages 70‑74) Linde treated helium only as a routine “supply” and gave no separate cost figure for it. By the 2024 filing (pages 59‑63) the company re‑classified helium as a “dependency” and disclosed that the raw‑materials‑and‑supplies line – which includes helium – fell to **$529 million** in 2024 from **$614 million** a year earlier, signalling a tighter sourcing position and a now‑material financial exposure to helium price risk.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its credibility. CRITICAL ISSUES: (1) MISSING KEY METRICS: The ground truth provides specific helium cost percentages (4.2% in 2023, 6.8% in 2024), which are the core quantitative evidence requested in the question. The LLM completely omits these percentages, which are essential to answering 'based on specific cost or sourcing disclosures.' (2) INCORRECT DOLLAR AMOUNTS: The LLM cites $529M (2024) and $614M (2023) for 'raw-materials-and-supplies' but provides no source verification. These figures appear to be for a broader category, not helium-specific costs. The ground truth indicates helium costs were 4.2% of total raw material expenses in 2023 and 6.8% in 2024, which would translate to different absolute values depending on total raw material expenses. (3) DIRECTIONAL CONTRADICTION: The LLM states raw materials fell from $614M to $529M (a decrease), yet claims this signals 'tighter sourcing position' and 'material financial exposure.' This logic is contradictory—a decrease in total raw material costs would typically indicate less exposure, not more. The ground truth shows helium's PERCENTAGE of costs INCREASED (4.2% to 6.8%), indicating growing relative importance despite potentially lower absolute costs. (4) INCOMPLETE SYNTHESIS: The LLM correctly identifies the classification shift from 'supply' to 'dependency' but fails to quantify the financial exposure change using the specific percentages provided in the ground truth. (5) PAGE REFERENCES: The LLM cites specific page numbers (70-74 for 2023, 59-63 for 2024) without verification, which cannot be confirmed. WHAT WAS CORRECT: The LLM correctly identifies that helium was reclassified from 'supply' to 'dependency' between 2023 and 2024, and correctly notes this represents increased strategic importance. However, the quantitative support for this claim is either missing or incorrect. The answer fails to provide the specific cost percentages that form the backbone of the ground truth answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 549,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what was the percentage change in the amount approved for such activities?",
      "original_answer": "In 2022, PayPal had $3.8 billion approved to fund credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, the approved amount decreased to $3.0 billion, representing approximately 39% of European customer balances. This indicates a reduction in the absolute amount approved for credit activities, even though the percentage slightly increased, signaling a more conservative approach to utilizing customer balances for credit funding.",
      "llm_answer": "PayPal’s share of European customer balances that it can use for credit grew modestly – the balances designated for credit represented about 37 % of the eligible European pool at 12/31/2022 and about 39 % at 12/31/2023.  At the same time, the dollar amount approved for those credit activities fell from $3.8 billion in 2022 to $3.0 billion in 2023, a decline of roughly 21 % ((3.0‑3.8)/3.8 ≈ ‑21 %)【PYPL_10k_2023.pdf, p.48】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative data is correct: (1) 2022 approved amount: $3.8 billion ✓, (2) 2022 percentage: 37% ✓, (3) 2023 approved amount: $3.0 billion ✓, (4) 2023 percentage: 39% ✓. The calculation of the percentage change is accurate: (3.0-3.8)/3.8 = -0.2105 ≈ -21% ✓. The LLM correctly synthesizes the multi-hop information by: (a) identifying the evolution of both absolute dollar amounts and percentages, (b) noting the apparent paradox that the percentage increased while the absolute amount decreased, and (c) interpreting this as a more conservative approach. The answer directly addresses all parts of the question: how the utilization evolved (both in absolute and percentage terms) and what the percentage change was. The reasoning is sound and the semantic meaning matches the ground truth perfectly. Minor note: The LLM uses slightly different phrasing ('share' and 'designated for credit' vs 'approved to fund') but this is semantically equivalent and actually clarifies the concept. The citation to the source document adds credibility. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 320,
        "total_tokens": 1561
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Starbucks' exposure to foreign currency - other instruments evolve between 2023 and 2024, particularly in terms of their fair value and the expected reclassification impact on earnings?",
      "original_answer": "In 2023, Starbucks reported a fair value of $1,164 million for foreign currency - other instruments, with a net gain of $39.6 million included in AOCI. By 2024, the fair value decreased to $920 million, and the net gain included in AOCI dropped to $11.5 million. Additionally, the amount expected to be reclassified from AOCI into earnings within 12 months declined from $55.3 million in 2023 to $9.5 million in 2024, indicating a reduced short-term earnings impact from these instruments.",
      "llm_answer": "Starbucks’ foreign‑currency‑other hedge portfolio shrank dramatically – the fair‑value of designated foreign‑currency‑other derivative assets fell from roughly $55 million in 2023 (prepaid $32 m + long‑term $22.9 m) to only about $3.6 million in 2024, while the related liabilities rose from $2 million to $8.8 million, turning a net positive fair‑value position into a modest net liability【SBUX_10k_2023.pdf p.70】【SBUX_10k_2024.pdf p.70】.  At the same time, the amount of foreign‑currency‑other gains sitting in AOCI dropped from $39.6 million in 2023 to $11.5 million in 2024, and Starbucks now expects to reclassify only about $9.5 million of those gains into earnings over the next 12 months (down from the $23.6 million actually reclassified in 2023)【SBUX_10k_2024.pdf p.69】【SBUX_10k_2023.pdf p.69】【SBUX_10k_2024.pdf p.71】【SBUX_10k_2023.pdf p.71】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and misinterpretations of the ground truth data. Critical issues: (1) FAIR VALUE NUMBERS ARE WRONG: The LLM claims fair value fell from 'roughly $55 million' (prepaid $32M + long-term $22.9M) to $3.6M in 2024, but the ground truth states the fair value was $1,164 million in 2023 and $920 million in 2024 - a massive discrepancy of over 20x. The LLM appears to have confused component line items with the total fair value metric. (2) AOCI GAINS ARE PARTIALLY CORRECT: The LLM correctly identifies AOCI gains of $39.6M (2023) and $11.5M (2024), matching ground truth exactly. (3) RECLASSIFICATION AMOUNT ERROR: The LLM states $9.5M expected reclassification in 2024 (correct) but incorrectly references '$23.6 million actually reclassified in 2023' when the ground truth specifies $55.3 million expected to be reclassified from AOCI into earnings within 12 months in 2023 (not actual reclassified amount). The LLM conflates different metrics. (4) MULTI-HOP REASONING FAILURE: While the LLM attempts to synthesize across multiple data points, it fundamentally misidentifies the primary fair value metric, suggesting it extracted component balance sheet items rather than the consolidated fair value figure from the derivatives/hedging disclosure. (5) SEMANTIC ISSUES: The framing of 'turning a net positive fair-value position into a modest net liability' is not supported by the ground truth, which focuses on the overall fair value decline from $1,164M to $920M. The answer demonstrates partial understanding of AOCI and reclassification concepts but fails on the core quantitative accuracy of the main fair value metric.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 457,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the fair value of energy-related derivatives held by Alabama Power and Georgia Power evolve from 2022 to 2023, and what was the directional change in their asset versus liability positions?",
      "original_answer": "In 2022, Alabama Power reported energy-related derivatives with a fair value of $55 million in assets and $11 million in liabilities, while Georgia Power reported $75 million in assets and $8 million in liabilities. By 2023, Alabama Power's energy-related derivatives decreased to $15 million in assets but increased significantly to $110 million in liabilities. Similarly, Georgia Power's derivatives were valued at $13 million in assets and $124 million in liabilities in 2023. This indicates a substantial shift toward liability exposure for both entities over the period.",
      "llm_answer": "In the 2022 filing the company did not break out energy‑related derivative fair values for Alabama Power or Georgia Power – only the combined Southern Company totals were disclosed ($199 million of assets and $210 million of liabilities)【SO_10k_2022.pdf†L31-L38】. By 2023, Alabama Power reported $15 million of these derivatives as assets and $110 million as liabilities, and Georgia Power reported $13 million of assets and $124 million of liabilities, putting both subsidiaries in a net‑liability position (liabilities now exceed assets)【SO_10k_2023.pdf†L71-L78】【SO_10k_2023.pdf†L85-L92】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES: The LLM answer contains a significant factual error regarding 2022 data. The ground truth clearly states that Alabama Power reported $55M in assets and $11M in liabilities, and Georgia Power reported $75M in assets and $8M in liabilities in 2022. The LLM claims these breakouts were not disclosed in 2022 and only combined Southern Company totals were available ($199M assets, $210M liabilities). This is factually incorrect - the original answer explicitly provides subsidiary-level 2022 data. The 2023 figures are correct: Alabama Power $15M assets/$110M liabilities, Georgia Power $13M assets/$124M liabilities. The LLM's reasoning about the shift toward liability exposure is sound, but it fails to capture the complete evolution from 2022 to 2023 because it incorrectly states 2022 subsidiary data was unavailable. The multi-hop synthesis is incomplete - the question asks how derivatives 'evolved from 2022 to 2023,' requiring year-over-year comparison for both entities. The LLM only provides 2023 subsidiary data and 2022 combined data, making a proper evolution analysis impossible. The qualitative observation about the shift to net-liability positions is correct but undermined by the missing 2022 subsidiary breakdown. The answer demonstrates partial understanding but fails on the core requirement of comparing subsidiary-level data across both years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 384,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the asset allocation strategy for the U.S. Retiree Health Care Plan evolve from 2022 to 2023, particularly in terms of the percentage distribution between fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan allocated 65% to fixed income securities and cash equivalents and 35% to equity securities. By 2023, the allocation to fixed income securities increased to 80%, while equity securities decreased to 20%. This represents a shift toward a more conservative investment strategy in 2023 compared to 2022.",
      "llm_answer": "In 2022 the U.S. Retiree Health Care Plan was invested roughly 65 % in fixed‑income securities (and cash equivalents) and 35 % in equity securities. By the end of 2023 the mix had shifted to about 80 % fixed‑income and 20 % equity, showing a move toward a more conservative, fixed‑income‑heavy allocation【TXN_10k_2023.pdf pages 47‑51】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. (1) CORRECTNESS: All factual information matches the ground truth perfectly. The 2022 allocation (65% fixed income/cash equivalents, 35% equity) and 2023 allocation (80% fixed income, 20% equity) are stated correctly. The characterization of the shift as 'more conservative' is accurate and appropriate. (2) QUANTITATIVE ACCURACY: All percentages are correct with no calculation errors. The year-over-year changes are accurately represented (fixed income +15 percentage points, equity -15 percentage points). Number formatting is consistent and clear. (3) QUALITATIVE ACCURACY: The multi-hop reasoning is sound - the model correctly synthesized the asset allocation data across two fiscal years and properly identified the strategic shift. The terminology used ('fixed-income-heavy allocation,' 'conservative') is semantically equivalent to the ground truth. (4) ENTITY ACCURACY: The U.S. Retiree Health Care Plan is correctly identified, and the fiscal years (2022 and 2023) are accurate. The source citation (TXN_10k_2023.pdf pages 47-51) is appropriately included. (5) MINOR NOTES: The use of 'roughly' and 'about' in the LLM answer is slightly more cautious than the ground truth's definitive statements, but this is a reasonable stylistic choice that doesn't detract from accuracy. The answer fully addresses all parts of the multi-part question regarding the evolution of asset allocation strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1185,
        "completion_tokens": 404,
        "total_tokens": 1589
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has the regulatory approval status of Trodelvy evolved between 2022 and 2023, and what new indications were granted in 2023?",
      "original_answer": "In 2022, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies and for metastatic urothelial cancer after platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. By 2023, Trodelvy received additional approvals: it was granted EC approval and FDA approval for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. This represents a significant expansion of the drug’s therapeutic applications.",
      "llm_answer": "In the 2022 Form 10‑K Trodelvy (sacituzumab govitecan‑hziy) was listed as an FDA‑approved, accelerated‑approval product for two indications – (i) metastatic triple‑negative breast cancer after ≥2 prior systemic therapies and (ii) metastatic urothelial cancer after platinum‑based chemotherapy and a PD‑1/PD‑L1 inhibitor【GILD_10k_2022.pdf page 6】. In the 2023 Form 10‑K the company reported that Trodelvy received new approvals as monotherapy for adult patients with unresectable or metastatic hormone‑receptor‑positive/HER2‑negative (HR+/HER2‑) breast cancer (both European Commission and FDA approvals)【GILD_10k_2023.pdf page 38】, adding this HR+/HER2‑ breast‑cancer indication to its label.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key facts: (1) 2022 indications correctly identified - TNBC after ≥2 prior systemic therapies and metastatic urothelial cancer after platinum-based chemotherapy and PD-1/PD-L1 inhibitor match the ground truth exactly; (2) 2023 new indication correctly identified - HR+/HER2- breast cancer with both EC and FDA approvals, matching ground truth; (3) The answer correctly notes the requirement for endocrine-based therapy and at least two additional systemic therapies in the metastatic setting (implied in the LLM's reference to 'at least two additional systemic therapies'); (4) Multi-hop reasoning is sound - the answer successfully synthesizes information from 2022 and 2023 10-K filings to show the evolution of regulatory approvals. Minor observation: The LLM answer uses slightly abbreviated language ('endocrine-based therapy' is implicit in the HR+/HER2- context) compared to the ground truth's explicit mention, but this is a semantic equivalence issue rather than a factual error. The answer directly addresses both parts of the question (how status evolved AND what new indications were granted) with proper sourcing to specific documents and pages. All entity names (Trodelvy, sacituzumab govitecan-hziy), years (2022, 2023), and regulatory bodies (FDA, EC) are correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 379,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Meta's disclosure regarding user perception as a risk factor evolve between 2023 and 2024, particularly in terms of the nature of risks highlighted and their potential impact on business operations?",
      "original_answer": "In 2023, Meta emphasized user perception risks related to privacy, safety, content quality, and regulatory changes, specifically noting concerns around decreased user sentiment and engagement due to data practices and content policies. In 2024, while user perception was still acknowledged, the focus shifted toward broader operational and financial risks, such as integration challenges from acquisitions, tax liabilities, and investor sentiment. The explicit mention of user perception as a direct risk factor was notably reduced in 2024, indicating a strategic shift in how Meta communicated its risk profile.",
      "llm_answer": "In the 2023 Form 10‑K (pages 15‑19) Meta warned that if users did not view its products as useful, reliable and trustworthy, it could lose users and ad impressions; the filing listed many sources of negative sentiment – competition from rivals, ad overload, technical glitches, and concerns about privacy, safety, content and overall user‑experience – that could erode the active‑user base and hurt revenue. By the 2024 Form 10‑K (pages 33‑37) the company broadened the risk, emphasizing that adverse public perception of its policies, content‑moderation decisions, AI features and data‑use practices could directly depress user growth and engagement, reduce advertising demand, and trigger heightened regulatory, litigation and reputational fallout, thereby creating a more immediate material impact on its business operations.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. CRITICAL ISSUES: (1) PAGE NUMBERS ARE INCORRECT - The LLM cites pages 15-19 for 2023 and pages 33-37 for 2024, but these specific page references cannot be verified and appear to be fabricated. (2) DIRECTIONAL CONTRADICTION - The ground truth states that 'explicit mention of user perception as a direct risk factor was notably reduced in 2024,' indicating a DECREASE in emphasis. However, the LLM answer claims the company 'broadened the risk' in 2024 and emphasized it MORE directly, which is the opposite of what the ground truth indicates. (3) CHARACTERIZATION ERROR - The ground truth indicates a 'strategic shift' away from user perception risks toward 'broader operational and financial risks, such as integration challenges from acquisitions, tax liabilities, and investor sentiment.' The LLM answer instead portrays an EXPANSION of user perception risks in 2024, missing this key strategic shift entirely. (4) MISSING KEY CONTEXT - The LLM fails to mention the shift toward acquisition integration challenges, tax liabilities, and investor sentiment that characterized the 2024 disclosure. (5) INCOMPLETE SYNTHESIS - While the LLM correctly identifies some 2023 risk factors (privacy, safety, content quality), it fails to properly synthesize the evolution showing REDUCED emphasis on user perception in 2024. The answer demonstrates a fundamental misunderstanding of the directional change in Meta's risk disclosure between these two years. The LLM appears to have invented specific page numbers and mischaracterized the nature of the evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 456,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has the notional amount of Lockheed Martin's variable interest rate swaps evolved from 2021 to 2024, and what does this indicate about the company's interest rate risk management strategy?",
      "original_answer": "In 2021, the notional amount of Lockheed Martin's variable interest rate swaps was $500 million, while by 2024, it had increased to $1.3 billion. This indicates a significant shift in the company's interest rate risk management strategy, with a growing emphasis on converting fixed-rate borrowings to variable-rate borrowings, likely in response to changes in the interest rate environment and the company's borrowing profile over the period.",
      "llm_answer": "Lockheed Martin’s aggregate notional amount of outstanding interest‑rate swaps grew from **$500 million at 12/31/2021** to **$1.3 billion at 12/31/2023 and again $1.3 billion at 12/31/2024**【LMT_10k_2022.pdf p.64‑68】【LMT_10k_2024.pdf p.50‑54】. This more‑than‑doubling of swap notional indicates the company has substantially expanded its swap program to hedge a larger share of its debt exposure and to more actively manage interest‑rate risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: All key numbers are correct - $500 million at 12/31/2021 and $1.3 billion at 12/31/2024 match the ground truth exactly. The LLM also correctly notes the intermediate 2023 value of $1.3 billion, providing additional detail beyond the ground truth. The characterization of this as 'more-than-doubling' is mathematically accurate ($500M to $1.3B = 160% increase). ENTITY ACCURACY: Lockheed Martin correctly identified, fiscal years properly specified (2021, 2023, 2024), and the metric (notional amount of variable interest rate swaps) is correctly identified. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple 10-K filings (2022 and 2024 documents cited) to track the evolution over time. STRATEGIC INTERPRETATION: The LLM's interpretation that this indicates 'substantially expanded swap program to hedge a larger share of its debt exposure and to more actively manage interest-rate risk' is semantically equivalent to the ground truth's statement about 'growing emphasis on converting fixed-rate borrowings to variable-rate borrowings' and 'response to changes in the interest rate environment.' Both convey the same strategic shift. MINOR CONSIDERATIONS: The LLM provides slightly more specific detail (including 2023 data point) and cites specific document pages, which adds credibility. The wording differs slightly from ground truth but conveys the same core meaning and conclusions. No calculation errors detected. All dates and figures are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 433,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did PayPal's approach to its Seller Protection Programs evolve between 2022 and 2023, particularly in terms of financial provisions for transaction losses?",
      "original_answer": "In 2022, PayPal acknowledged the risk of losses from its Seller Protection Programs and noted that historical loss rates ranged between 0.09% and 0.15% of TPV, with the potential for increased losses due to macroeconomic conditions such as the ongoing impacts of the COVID-19 pandemic. By 2023, PayPal provided more structured financial disclosures, showing that the allowance for transaction losses was $64 million (down from $66 million in 2022), indicating a slight decrease in expected losses. This shift reflects a more defined and quantified approach to managing seller protection risk in 2023 compared to the more qualitative risk assessment in 2022.",
      "llm_answer": "In 2022 PayPal described its seller‑protection coverage as part of its broader buyer‑ and seller‑protection programs, reporting a transaction‑loss allowance of $66 million and a provision for transaction and credit losses of $1.170 billion (2022 10‑K, pp. 49‑53). By 2023 the company provided a more granular accounting, raising the provision to $1.192 billion, seeing realized losses fall to $1.313 billion, and ending the year with a $64 million allowance for transaction losses (combined allowance $282 million with negative balances), indicating a modest increase in reserves while actual losses declined (2023 10‑K, pp. 111‑115).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) The $66 million allowance for transaction losses in 2022 is accurate. (2) The $64 million allowance for transaction losses in 2023 is accurate. (3) The directional finding that allowances decreased from 2022 to 2023 is correct. (4) The answer appropriately identifies this as a shift toward more structured financial disclosures. PROBLEMATIC ELEMENTS: (1) The LLM introduces additional metrics ($1.170 billion provision for 2022, $1.192 billion for 2023, $1.313 billion realized losses, $282 million combined allowance) that are not mentioned in the ground truth answer. While these may be accurate figures from the 10-K filings, they represent a significant expansion beyond what the ground truth identifies as the key evolution. (2) The ground truth specifically emphasizes the 2022 historical loss rates (0.09%-0.15% of TPV) and the qualitative risk assessment language, neither of which appears in the LLM answer. (3) The ground truth frames the evolution as moving from 'qualitative risk assessment' to 'more defined and quantified approach,' but the LLM frames it as moving from 'broader buyer-and-seller-protection programs' to 'more granular accounting.' (4) The LLM's mention of 'negative balances' and 'combined allowance $282 million' introduces complexity not addressed in the ground truth. MULTI-HOP REASONING: The LLM correctly synthesizes information across 2022 and 2023 filings and identifies the year-over-year comparison. However, it diverges from the ground truth's specific focus on the evolution of the approach to financial provisions for transaction losses by introducing additional metrics. QUANTITATIVE ACCURACY: While the core numbers ($66M→$64M) are correct, the introduction of unverified additional figures and the 'combined allowance $282 million with negative balances' language creates uncertainty about whether all cited numbers are accurate or properly contextualized. The ground truth does not mention these additional figures, suggesting either they are extraneous or the LLM is providing a more comprehensive but potentially less focused answer than intended.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 584,
        "total_tokens": 1910
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Starbucks' derivative asset and liability positions in foreign currency - other change from fiscal year 2023 to fiscal year 2024, and what was the magnitude of this change on the balance sheet?",
      "original_answer": "In fiscal year 2023, Starbucks reported a derivative asset of $1,164 million under 'Foreign currency - other.' By fiscal year 2024, this amount significantly decreased to $1.9 million in derivative assets under the same category. Additionally, the derivative liability for 'Foreign currency - other' increased from $2.0 million in 2023 to $4.7 million in 2024. This indicates a major reduction in the company's foreign currency derivative assets and a moderate increase in liabilities tied to foreign currency over this period.",
      "llm_answer": "Starbucks’ foreign‑currency‑other derivative assets collapsed from $32.0 million (current) and $22.9 million (long‑term) in FY 2023 to just $1.9 million and $1.7 million in FY 2024 – a reduction of roughly $51 million【SBUX_10k_2024.pdf†L10-L11】. At the same time, the related liabilities rose from $2.0 million (accrued) in FY 2023 to $4.7 million (accrued) plus $4.1 million (long‑term) in FY 2024 – an increase of about $7 million, resulting in a net swing of roughly $58 million on the balance sheet【SBUX_10k_2024.pdf†L23-L24】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant numerical discrepancies that contradict the ground truth. (1) ASSET POSITION ERRORS: Ground truth states derivative assets were $1,164 million in FY2023 and $1.9 million in FY2024. The LLM claims $32.0M (current) + $22.9M (long-term) = $54.9M in FY2023, which is dramatically different from the $1,164M stated in ground truth. The FY2024 figures of $1.9M and $1.7M in the LLM answer don't match the ground truth's single $1.9M figure. (2) LIABILITY POSITION ERRORS: Ground truth clearly states derivative liabilities were $2.0M in FY2023 and $4.7M in FY2024. The LLM introduces additional components ($4.1M long-term in FY2024) not mentioned in the ground truth, and calculates a $7M increase when the ground truth shows only a $2.7M increase ($4.7M - $2.0M). (3) CALCULATION ERRORS: The LLM's claimed $51M reduction in assets is incorrect - if using ground truth numbers, the reduction would be $1,162.1M ($1,164M - $1.9M). The $58M net swing calculation is also incorrect based on ground truth figures. (4) MULTI-HOP SYNTHESIS: While the LLM attempts to break down current vs. long-term components and calculate net balance sheet impact, it does so with fundamentally wrong base numbers. The ground truth provides a clear, single total for each position, not bifurcated current/long-term breakdowns. The LLM appears to have confused or misread the source data entirely. The answer demonstrates poor quantitative accuracy with material numerical errors that undermine the entire response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 425,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial impact of energy-related derivatives on natural gas cost and revenue hedging positions evolve from 2022 to 2023?",
      "original_answer": "In 2022, energy-related derivatives had a negative impact of $117 million on natural gas revenues and a $27 million negative impact on the cost of natural gas. In 2023, the impact shifted positively with a $59 million gain on the cost of natural gas, while the revenue impact remained neutral at $0. This indicates a transformation in the role and effectiveness of these derivatives in managing natural gas exposure.",
      "llm_answer": "In 2022 the company’s energy‑related cash‑flow hedges produced a $37 million gain that reduced the reported natural‑gas cost, while non‑designated energy derivatives created a $65 million loss on natural‑gas cost and a negative impact on natural‑gas revenue. By 2023 the cash‑flow hedge result reversed to a $44 million loss on natural‑gas cost, the non‑designated derivatives swung to a $59 million gain on natural‑gas cost, and the natural‑gas revenue line showed essentially no gain or loss. (SO_10k_2023.pdf p. 293; SO_10k_2023.pdf p. 295)",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresents the ground truth data. Critical issues: (1) QUANTITATIVE ERRORS: The LLM reports a $37 million gain on natural gas cost in 2022, but ground truth shows a $27 million negative impact. The LLM reports a $65 million loss on natural gas cost in 2022, but ground truth shows only the $27 million negative impact total. The LLM reports a $44 million loss on natural gas cost in 2023, but ground truth shows a $59 million gain. These are fundamental number errors. (2) STRUCTURAL MISUNDERSTANDING: The LLM breaks down the derivatives into 'cash-flow hedges' ($37M gain) and 'non-designated derivatives' ($65M loss), which doesn't align with the ground truth's simpler categorization of total impacts. The ground truth shows: 2022 = -$117M revenue impact, -$27M cost impact; 2023 = $0 revenue impact, +$59M cost impact. (3) INCOMPLETE SYNTHESIS: The LLM appears to have confused or misinterpreted the derivative components, creating a narrative about hedges reversing that doesn't match the ground truth evolution. The ground truth shows a clear shift from negative to positive/neutral, while the LLM's breakdown suggests offsetting gains and losses that don't reconcile to the stated totals. (4) MULTI-HOP REASONING: While the LLM attempts to synthesize information across years, it fails to correctly identify the actual year-over-year changes. The core finding that derivatives shifted from negative to positive impact is partially captured, but the specific numbers are wrong. (5) CITATION ISSUE: The LLM cites specific pages (293, 295) but the numbers provided don't match the ground truth, suggesting either misreading or hallucination of source data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 468,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Walmart's treatment of its Deferred Compensation Matching Plan evolve between the 2023 and 2024 10-K filings, particularly in terms of its documentation status and effective date?",
      "original_answer": "In the 2023 10-K filing, the Deferred Compensation Matching Plan was newly introduced as 'Walmart Inc. Deferred Compensation Matching Plan, as amended and restated effective November 8, 2023.' By the 2024 10-K filing, the plan was no longer labeled as newly introduced but was instead referenced as being 'incorporated by reference' to the 2024 Annual Report on Form 10-K, indicating that it had become an established, ongoing plan. The effective date remained unchanged at November 8, 2023, suggesting no substantive changes to the plan’s implementation timeline, but its treatment shifted from being newly introduced to being formally integrated into the company's long-term compensation framework.",
      "llm_answer": "In the 2023 Form 10‑K Walmart listed the Deferred Compensation Matching Plan as Exhibit 10.1*—a document filed with the report—showing it was “as amended and restated effective November 8, 2023”【WMT_10k_2023.pdf†81-L84】. In the 2024 Form 10‑K the plan is no longer attached; it is “incorporated by reference to Exhibit 10.1” of the 2024 filing, but the amendment’s effective date remains November 8, 2023【WMT_10k_2024.pdf†82-L85】.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct dates (November 8, 2023) and proper identification of the plan evolution. The quantitative elements are entirely accurate - the effective date is correct and consistently referenced across both filings. The multi-hop reasoning is sound: the answer correctly synthesizes information showing the plan's transition from being filed as Exhibit 10.1 in 2023 to being incorporated by reference in 2024, while maintaining the same effective date. The answer effectively captures the key distinction between the two filings' treatment of the plan. Minor areas for improvement: (1) The LLM answer uses more technical/procedural language ('filed with the report,' 'incorporated by reference to Exhibit 10.1') rather than the ground truth's broader characterization of the shift from 'newly introduced' to 'established, ongoing plan' status. (2) The ground truth emphasizes the conceptual shift in how the plan is treated within the company's compensation framework, while the LLM answer focuses more on the mechanical/documentary differences. (3) The LLM answer could have been slightly more explicit about what 'incorporated by reference' means in terms of the plan's status evolution. However, these are relatively minor semantic/framing differences - the core factual content is accurate and the multi-hop synthesis correctly identifies the evolution between the two years. The answer appropriately addresses all parts of the question regarding documentation status and effective date.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 425,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the disclosure and treatment of LTIP Units evolved between 2023 and 2024, particularly in terms of their dilutive effect and accrual policy?",
      "original_answer": "In 2023, LTIP Units were described as potentially dilutive securities that are convertible into units and exchangeable for common stock, with no material dilutive effect reported for the years 2023, 2022, and 2021. The company stated it does not adjust net income attributable to common stockholders or weighted average shares outstanding due to no dilutive impact. In 2024, the disclosure simplified, stating that LTIP Units are potentially dilutive but again noting no material dilutive effect for the years 2024, 2023, and 2022. Additionally, the accrual policy remained consistent, stating that distributions are accrued when declared. The treatment of LTIP Units remained stable with no significant change in dilutive impact or accrual policy.",
      "llm_answer": "Both the 2023 and 2024 filings list LTIP units as “potentially dilutive securities” but state that they had **no material dilutive effect** – the 2023 note says this for 2023‑2021, and the 2024 note repeats the same conclusion for 2024‑2022. The accrual policy is unchanged: the company **accrues dividends (for common stock) or distributions (for the partnership) only when declared** and does not adjust net income or weighted‑average shares/units for LTIP‑related allocations. The 2024 filing simply updates the language to include the current year, confirming the same treatment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. (1) CORRECTNESS: All factual claims are correct - LTIP Units are described as potentially dilutive securities in both years, no material dilutive effect is reported for 2023-2021 in the 2023 filing and 2024-2022 in the 2024 filing, and the accrual policy (distributions accrued when declared) remains unchanged. The answer correctly identifies that the treatment remained stable with no significant changes. (2) QUANTITATIVE ACCURACY: No specific dollar amounts or percentages were required for this question, but the year ranges cited (2023-2021 for 2023 filing, 2024-2022 for 2024 filing) are accurate and properly formatted. (3) QUALITATIVE ACCURACY: The multi-hop reasoning is sound - the answer correctly synthesizes information across both 2023 and 2024 filings, identifies the key similarities (no material dilutive effect, unchanged accrual policy), and notes the evolution (simplified disclosure language in 2024 while maintaining same treatment). The answer properly addresses all components of the question: disclosure evolution, dilutive effect treatment, and accrual policy. (4) ENTITY ACCURACY: LTIP Units are correctly identified throughout, years are accurate, and the financial metrics/terms (dilutive effect, accrual policy, distributions) are properly used. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same information as the ground truth, using slightly different but equivalent phrasing (e.g., 'simplified disclosure' vs 'simplified' in ground truth). Minor note: The LLM adds helpful clarification about dividends vs distributions terminology, which enhances clarity without introducing inaccuracy. The answer fully addresses the multi-part question about evolution, dilutive effect, and accrual policy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 486,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Meta's compliance approach to the EU-U.S. Data Privacy Framework (EU-U.S. DPF) evolved between 2023 and 2024, particularly in response to regulatory actions and decisions?",
      "original_answer": "In 2023, Meta was in the process of implementing steps to comply with corrective orders from the Irish Data Protection Commission (IDPC) following a EUR €1.2 billion fine and a directive to suspend unlawful data transfers to the U.S. under Standard Contractual Clauses (SCCs). At that time, the EU-U.S. DPF had just been finalized, and Meta viewed its implementation as a key milestone to address data transfer compliance. By 2024, Meta had implemented compliance measures with the corrective orders and was actively engaging with regulators on new compliance models, such as the 'subscription for no ads' alternative introduced in November 2023. In 2024, the European Commission opened formal proceedings into the compliance of this model with the Digital Markets Act (DMA), issuing preliminary findings in July 2024 that suggested non-compliance. This reflects a shift from foundational compliance with the EU-U.S. DPF framework to navigating more complex regulatory scrutiny around specific business models under evolving EU laws.",
      "llm_answer": "In the 2023 Form 10‑K Meta reported that it was “implementing steps to comply” with the newly‑adopted EU‑U.S. Data‑Privacy Framework and the July‑2023 EU adequacy decision, and was working to satisfy the Irish regulator’s corrective orders (while appealing the IDPC’s SCC ruling). By the 2024 filing Meta’s tone had shifted – it now flags the risk that the EU‑U.S. DPF could be invalidated, says it is relying on other transfer tools such as SCCs and is concentrating on broader GDPR, DMA and EU‑consumer‑law compliance, while continuing active engagement with regulators to mitigate any disruption to its European services.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key elements of Meta's evolving compliance approach but has significant gaps and some inaccuracies compared to the ground truth:\n\nSTRENGTHS:\n1. Correctly identifies the 2023 context: EU-U.S. DPF implementation and IDPC corrective orders\n2. Accurately notes the shift in tone between 2023 and 2024 filings\n3. Correctly references the July 2023 EU adequacy decision\n4. Properly identifies the broader regulatory landscape (GDPR, DMA, EU consumer law)\n5. Correctly notes Meta's engagement with regulators\n\nSIGNIFICANT GAPS AND ERRORS:\n1. MISSING CRITICAL DETAIL: The ground truth specifically mentions the EUR €1.2 billion fine from IDPC - the LLM answer completely omits this quantitative fact\n2. MISSING KEY DEVELOPMENT: The ground truth explicitly discusses the 'subscription for no ads' alternative introduced in November 2023 as a compliance model - the LLM answer does not mention this specific business model innovation\n3. MISSING REGULATORY ACTION: The ground truth mentions the European Commission's formal proceedings into the 'subscription for no ads' model and July 2024 preliminary findings of non-compliance - while the LLM vaguely references DMA compliance concerns, it doesn't specifically connect these to the subscription model or cite the July 2024 preliminary findings\n4. INCOMPLETE SYNTHESIS: The ground truth shows a clear progression from foundational EU-U.S. DPF compliance to navigating complex regulatory scrutiny around specific business models. The LLM answer focuses more on transfer mechanisms (SCCs) rather than the business model evolution\n5. TONE CHARACTERIZATION: While the LLM correctly identifies a shift in tone, it frames it primarily as risk-flagging about DPF invalidation, whereas the ground truth frames it as a shift from foundational framework compliance to navigating more complex regulatory scrutiny\n\nQUANTITATIVE ACCURACY: The LLM answer lacks specific numbers (missing the €1.2 billion fine) and dates (missing November 2023 subscription model launch, July 2024 preliminary findings). The dates mentioned (July 2023, 2023/2024 filings) are correct but incomplete.\n\nMULTI-HOP REASONING: The LLM answer demonstrates adequate multi-hop reasoning in connecting 2023 and 2024 filings and identifying regulatory evolution, but fails to fully synthesize the specific business model response (subscription for no ads) and its regulatory consequences.\n\nSEMANTIC EQUIVALENCE: While the LLM captures the general evolution narrative, it misses the specific causal chain: fine → corrective orders → EU-U.S. DPF as solution → subscription model as alternative → DMA scrutiny of that model.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 706,
        "total_tokens": 2128
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Linde's approach to green hydrogen production evolved between 2023 and 2024, particularly in terms of production methods and emphasis on renewable energy sources?",
      "original_answer": "In 2023, Linde described green hydrogen as being produced primarily through electrolysis using renewable energy or from steam methane reforming of biomethane, and it was presented as one of the company's clean energy offerings alongside blue hydrogen. By 2024, the company had expanded its description to emphasize green hydrogen as 'renewable hydrogen' produced by electrolysis using renewable energy and water as feedstock, and it was clearly differentiated from low-carbon (blue) hydrogen. Additionally, in 2024, Linde placed more emphasis on the carbon intensity metric to differentiate production methods, indicating a more refined and strategic framing of green hydrogen within the broader context of clean energy solutions.",
      "llm_answer": "In the 2023 filing Linde defined “green” hydrogen as being made either by electro‑lysis powered with renewable electricity **or** by steam‑methane reforming of biomethane, reflecting a broader mix of low‑carbon feedstocks. By the 2024 filing the company had narrowed its definition, stressing that green hydrogen is now produced primarily through renewable‑energy‑driven electro‑lysis (using water as feedstock) and dropping the biomethane route, thereby placing a stronger emphasis on clean‑electricity sources.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key evolution points but contains a significant factual error that undermines accuracy. CORRECT ELEMENTS: (1) The 2023 description correctly identifies electrolysis with renewable energy as one method; (2) The 2024 emphasis on electrolysis using renewable energy and water as feedstock is accurate; (3) The general direction of evolution toward clearer differentiation is correct; (4) The identification of years (2023 vs 2024) is accurate. CRITICAL ERROR: The LLM states that by 2024 Linde 'dropped the biomethane route' and no longer includes steam-methane reforming of biomethane in its green hydrogen definition. However, the ground truth indicates that in 2024, Linde still maintained green hydrogen could be produced from steam methane reforming of biomethane - this was not eliminated, only de-emphasized relative to the electrolysis pathway. The ground truth shows the company 'expanded its description' rather than narrowed it by removing options. MISSING ELEMENT: The LLM answer does not adequately address the ground truth's emphasis on carbon intensity metrics as a key differentiator in 2024's framing. The ground truth specifically notes 'more emphasis on the carbon intensity metric to differentiate production methods,' which the LLM answer omits entirely. REASONING ASSESSMENT: The multi-hop synthesis is partially sound - the model correctly identified the temporal comparison and production method evolution, but mischaracterized the nature of the change (narrowing vs. expanding/refining). The semantic interpretation of 'evolution' was partially incorrect, treating it as elimination rather than refinement and strategic emphasis shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 460,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Southern Company's relationship with Sequent evolve between 2022 and 2023, and what were the financial implications of this change?",
      "original_answer": "Southern Company's relationship with Sequent evolved from a business ownership relationship in 2022 to a completed divestiture in 2023. In 2022, Southern Company Gas completed the sale of Sequent to Williams Field Services Group for $159 million, recognizing a pre-tax gain of $121 million. Additionally, the sale resulted in $85 million of additional tax expense due to changes in state apportionment rates. By 2023, Sequent was no longer part of Southern Company's portfolio, and the financial impact of the sale was fully reflected in the company's financial statements, with the gain from the sale reported as a $121 million pre-tax benefit. This marked a complete transformation in the relationship, shifting from operational integration to full separation.",
      "llm_answer": "In the 2022 Form 10‑K Southern Company Gas reported that it had sold its Sequent subsidiary to Williams Field Services Group for $159 million, recognizing a pre‑tax gain of $121 million (about $92 million after tax) but also incurring $85 million of additional tax expense (see 2022 10‑K, footnote h on pages 55‑59). By the 2023 Form 10‑K the wholesale‑gas‑services segment that previously included Sequent was eliminated from the segment reporting, indicating the divestiture was complete and Sequent‑related revenues were no longer part of the company’s results (see 2023 10‑K, footnote a on pages 300‑304).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-supported. Verification of key facts: (1) Sale price of $159 million - CORRECT; (2) Pre-tax gain of $121 million - CORRECT; (3) $85 million additional tax expense - CORRECT; (4) After-tax gain calculation of ~$92 million - CORRECT (121M - 85M = 36M, but the LLM states 'about $92 million after tax' which appears to reference a different calculation method, though this is a minor discrepancy); (5) Timeline: 2022 sale completion, 2023 elimination from segment reporting - CORRECT. The LLM successfully synthesizes multi-hop information: it identifies the 2022 transaction details from the 2022 10-K and then cross-references the 2023 10-K to confirm the divestiture's completion and removal from segment reporting. The answer directly addresses both parts of the question: (a) how the relationship evolved (from ownership to divestiture), and (b) financial implications (sale price, gain, tax expense). The citation of specific footnotes and page numbers adds credibility. Minor weakness: The after-tax calculation of $92 million is not clearly explained - the ground truth states '$121 million pre-tax benefit' but doesn't explicitly state the after-tax amount, so the LLM's calculation may be based on additional context. The answer is semantically equivalent to the ground truth, conveying the same essential information about the transformation from operational integration to full separation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 399,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Walmart's relationship with the Allswell brand evolved between 2023 and 2024, and what does this indicate about its strategic positioning within the company's private brand portfolio?",
      "original_answer": "In 2023, Walmart introduced the Allswell brand as part of its private brand offerings, indicating its initial entry into the market. By 2024, the brand was not only retained but explicitly listed among other mature private brands like 'bettergoods,' 'Equate,' and 'Great Value,' suggesting that Allswell has transitioned from a newly introduced brand to a more established part of Walmart's private label strategy. This evolution indicates that Allswell has likely gained traction and is being positioned as a core component of Walmart’s private brand portfolio.",
      "llm_answer": "In the 2023 Form 10‑K Walmart listed Allswell as one of its private‑brand lines, and the 2024 Form 10‑K lists Allswell again – the brand was retained rather than added or dropped. This steady presence, even as Walmart introduced new private labels (e.g., “bettergoods”) in 2024, shows that Allswell remains a core part of the company’s private‑brand strategy, underscoring Walmart’s intent to grow a diversified, value‑focused private‑brand portfolio while keeping established brands like Allswell in play.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and addresses the core question effectively. STRENGTHS: (1) Correctly identifies that Allswell was listed in both 2023 and 2024 10-K filings, establishing continuity; (2) Accurately notes the brand was retained rather than dropped, which is the key factual claim; (3) Properly synthesizes the multi-hop reasoning by comparing Allswell's status across two years and relating it to strategic positioning; (4) Correctly identifies other private brands (bettergoods, Equate, Great Value) as comparables; (5) Appropriately concludes that retention indicates core strategic importance. MINOR ISSUES: (1) The LLM states Allswell was 'listed' in 2023, while the ground truth says it was 'introduced' in 2023 - this is a subtle semantic difference suggesting Allswell may have been new in 2023, whereas the LLM's wording is slightly ambiguous about whether it was newly introduced or already established; (2) The LLM says 'bettergoods' was 'introduced' in 2024, but the ground truth lists it as a 'mature private brand' alongside Allswell in 2024, which could suggest bettergoods existed before 2024 - this is a minor inconsistency in characterization; (3) The LLM's phrasing 'even as Walmart introduced new private labels' could be misinterpreted as suggesting bettergoods was new in 2024, when the ground truth implies it was already established. QUANTITATIVE ACCURACY: No numerical errors; dates (2023, 2024) are correct. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and correctly draws the conclusion that retention indicates strategic importance. The logic is sound: presence in both years + retention despite portfolio changes = core strategic positioning. SEMANTIC EQUIVALENCE: The LLM answer conveys essentially the same information as the ground truth, with the core insight (Allswell transitioned from new to established/core) being present, though expressed differently.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 528,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the strategic importance of Embedded Processing products evolved from 2022 to 2023 based on TXN's revenue composition and strategic emphasis?",
      "original_answer": "In 2022, Embedded Processing products were described as one of two core segments, positioned alongside Analog as a key part of the business, though no specific revenue figures were disclosed. By 2023, Embedded Processing remained a strategic focus area, and notably, it partially offset a decline in Analog revenue, contributing to a $17.52 billion total revenue. This indicates that while Embedded Processing maintained its strategic importance, it also played a more pronounced compensatory role in the revenue mix during a year of overall revenue decline.",
      "llm_answer": "In 2023 Texas Instruments’ embedded‑processing segment grew 3 % to $3.37 billion, while total revenue fell 12.5 % to $17.52 billion, lifting the segment’s share of revenue from roughly 16 % in 2022 (≈ $3.26 billion of $20.0 billion) to about 19 % in 2023. The MD&A repeatedly stresses that “analog and embedded processing products” are the core of TI’s strategy, and the rising revenue mix shows embedded processing is becoming an even more important growth engine within that strategic focus.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer provides strong quantitative support with specific revenue figures and calculations. Verification of key numbers: (1) 2023 Embedded Processing revenue of $3.37 billion - correct; (2) Total 2023 revenue of $17.52 billion - matches ground truth exactly; (3) 12.5% total revenue decline calculation - correct (from ~$20.0B to $17.52B); (4) 3% growth in Embedded Processing - mathematically sound ($3.26B to $3.37B ≈ 3.4%, close enough given rounding); (5) Revenue share calculations - 16% in 2022 ($3.26B/$20.0B = 16.3%) and 19% in 2023 ($3.37B/$17.52B = 19.2%) are accurate. The LLM successfully synthesizes multi-hop information: comparing 2022 vs 2023, calculating growth rates, determining revenue mix shifts, and connecting this to strategic emphasis. The answer goes beyond the ground truth by providing specific percentage growth (3%) and revenue share calculations, which adds analytical depth. Minor difference: The ground truth emphasizes Embedded Processing's 'compensatory role' offsetting Analog decline, while the LLM frames it as 'becoming an even more important growth engine.' Both interpretations are valid - the LLM's framing is actually more precise given the 3% growth while total revenue fell 12.5%. The LLM correctly identifies the strategic positioning from MD&A language. The answer is well-structured, quantitatively rigorous, and demonstrates sound multi-hop reasoning across years and metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 397,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has Chevron's involvement in Angola LNG evolved from 2022 to 2024, and what does this indicate about its strategic positioning in the LNG market?",
      "original_answer": "In 2022, Chevron's involvement in Angola LNG was referenced in the context of its production volumes, indicating operational participation. By 2024, Chevron's stake in Angola LNG Limited was explicitly stated as a 36.4% interest, highlighting a more defined and structured investment approach. This evolution suggests a strategic shift toward securing a stable position in the LNG market through formalized equity stakes.",
      "llm_answer": "In 2022 Chevron’s balance‑sheet showed a $1.857 billion carrying value for its stake in Angola LNG Limited and a share of earnings of roughly $1.86 billion; by 2024 the investment value had slipped to $1.665 billion and its equity earnings fell sharply to $405 million, although the company still holds a 36.4 % ownership interest. The drop in both the investment balance and earnings indicates Chevron is scaling back its financial exposure to Angola LNG while preserving a sizable ownership stake, signaling a strategic choice to maintain a foothold in LNG but to re‑balance its LNG portfolio toward other, higher‑value opportunities.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and introduces information not supported by the ground truth. Critical issues: (1) QUANTITATIVE ERRORS: The LLM provides specific dollar amounts ($1.857 billion in 2022, $1.665 billion in 2024, earnings of $1.86 billion and $405 million) that are NOT mentioned in the ground truth answer. These numbers appear to be fabricated or hallucinated, as the original answer makes no reference to carrying values or specific earnings figures. (2) UNSUPPORTED CLAIMS: The LLM claims Chevron is 'scaling back its financial exposure' and 'rebalancing its LNG portfolio toward other, higher-value opportunities' - these interpretations are not supported by the ground truth, which simply notes a 'strategic shift toward securing a stable position in the LNG market through formalized equity stakes.' (3) INCOMPLETE SYNTHESIS: While the LLM correctly identifies the 36.4% ownership interest in 2024, it fails to properly address the core evolution described in the ground truth - the shift from production volume references in 2022 to explicit equity stake definition in 2024. (4) REASONING FLAW: The LLM's conclusion about 'scaling back' contradicts the ground truth's characterization of a 'more defined and structured investment approach.' The LLM appears to have invented financial metrics to support a narrative not present in the source material. The answer demonstrates poor multi-hop reasoning by introducing unsupported quantitative claims rather than synthesizing the actual documented evolution of Chevron's strategic positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 433,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the financial contribution and production status of the CH-53K program evolved between 2021 and 2024, and what does this indicate about its role within Lockheed Martin's RMS division?",
      "original_answer": "In 2021, the CH-53K program contributed to a $540 million increase in RMS net sales, driven by higher production volume alongside the Black Hawk and CRH programs. Additionally, it contributed to a $140 million increase in operating profit due to higher risk retirements and production volume. By 2024, the CH-53K program was described as being in a 'production ramp-up' phase, contributing $1.1 billion to higher product sales within RMS, indicating a shift from early-stage production and risk retirement to a more mature, high-volume production phase. This evolution shows that the CH-53K has transitioned from a developing program with growing financial impact to a key growth driver within RMS.",
      "llm_answer": "In 2021 the CH‑53K was a major driver of RMS growth – it contributed roughly $540 million of the segment’s net‑sales increase and about $140 million of the operating‑profit boost, reflecting higher production volume and risk‑retirements on the Sikorsky helicopter line【LMT_10k_2022.pdf p.48‑51】. By 2024 the filing again highlights “higher production volume on the CH‑53K program” as a key factor behind RMS product‑sales growth, indicating the helicopter’s production is still ramping up and that the CH‑53K remains a core, growth‑enabling program within Lockheed Martin’s RMS division【LMT_10k_2024.pdf p.34‑35】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and appropriate multi-hop synthesis across the 2021-2024 period. STRENGTHS: (1) All quantitative data is correct - the $540 million net sales increase, $140 million operating profit increase for 2021, and the $1.1 billion contribution to higher product sales in 2024 are all accurately cited. (2) The multi-hop reasoning is sound - the answer correctly synthesizes information from multiple years and documents to show the CH-53K's evolution from early production to mature ramp-up phase. (3) Entity identification is accurate - correctly identifies Lockheed Martin, RMS division, and the CH-53K program. (4) The semantic meaning matches the ground truth: both convey that CH-53K transitioned from a developing program to a key growth driver. (5) Document citations are appropriately included. MINOR WEAKNESSES: (1) The LLM answer is slightly less explicit about the 'production ramp-up' phase terminology used in 2024 filings - it says 'production is still ramping up' which is semantically equivalent but less precise than the ground truth's direct reference to the 'production ramp-up' phase descriptor. (2) The answer could have been slightly more explicit about the shift from 'risk retirements' to 'mature production' as a key indicator of program maturation, though this is implied. (3) The answer doesn't explicitly state the $1.1 billion figure as clearly as the ground truth does - it references 'higher production volume on the CH-53K program' contributing to growth but doesn't quantify it as $1.1 billion. However, this appears to be a citation/reference issue rather than a factual error. Overall, the answer successfully addresses all parts of the multi-part question with accurate numbers, proper synthesis across years, and sound reasoning about the program's evolution and strategic importance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 505,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did PayPal's use of macroeconomic factors in its loss curves for revolving consumer credit products evolve between 2022 and 2023?",
      "original_answer": "In 2022, PayPal applied macroeconomic factors such as forecasted trends in unemployment and benchmark credit card charge-off rates to its revolving consumer credit loss curves, using a single scenario deemed most appropriate for the economic conditions. By 2023, the company updated its expected credit loss models for revolving consumer receivables to include forecasted trends in household disposable income and retail e-commerce sales, replacing unemployment rates after the first quarter of 2023. This reflects a shift in the macroeconomic indicators used to inform loss curves for this segment.",
      "llm_answer": "In the 2022 filing, PayPal built its revolving‑consumer‑credit loss curves using a single external scenario that projected only unemployment trends and benchmark credit‑card charge‑off rates, applying those factors over a roughly 2‑year supportable forecast period. By the 2023 filing, the models were revised to incorporate additional macro variables—household disposable‑income and retail e‑commerce sales (while still using unemployment through Q1 2023)—and the forecast horizon for revolving products was extended to about 5 years.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the core evolution of PayPal's macroeconomic factors between 2022 and 2023, correctly identifying the shift from unemployment/charge-off rates to household disposable income and retail e-commerce sales. However, there are significant issues with quantitative accuracy: (1) The LLM introduces a specific claim about forecast periods ('roughly 2-year' in 2022 and 'about 5 years' in 2023) that is NOT present in the ground truth answer. This is a factual addition not supported by the original answer and represents a potential hallucination. (2) The ground truth states unemployment was replaced 'after the first quarter of 2023,' while the LLM says it was 'still using unemployment through Q1 2023'—these are semantically equivalent but the LLM's phrasing is slightly less precise about the timing of the replacement. (3) The LLM correctly identifies the macroeconomic variables (unemployment, charge-off rates, household disposable income, retail e-commerce sales) and the general evolution. The multi-hop reasoning is sound in synthesizing the 2022 vs 2023 comparison. However, the introduction of unsupported quantitative claims about forecast horizons significantly undermines the answer's reliability. The answer is partially correct on the core facts but adds unverified details that lower confidence in its accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 375,
        "total_tokens": 1656
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Starbucks' foreign currency debt-related gains or losses included in AOCI change from 2023 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2023, Starbucks reported a foreign currency debt-related loss of $6.3 million included in OCI before reclassifications, while in 2024, the company reported a gain of $135.2 million in AOCI related to foreign currency debt. This indicates a significant shift from a loss to a substantial gain, suggesting a reversal in the company's exposure to foreign currency fluctuations over this period.",
      "llm_answer": "Starbucks’ net gain on foreign‑currency‑denominated debt that is recorded in AOCI slipped from **$140.2 million in 2023 to $135.2 million in 2024**, a decline of about $5 million. The smaller gain suggests that the company’s hedging program still produces a positive result, but the benefit narrowed, indicating a modest increase in exposure to adverse foreign‑currency movements in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM reports 2023 value as $140.2 million, but ground truth states it was a LOSS of $6.3 million. This is a fundamental factual error - the sign is wrong (gain vs. loss) and the magnitude is completely incorrect ($140.2M vs. $6.3M loss). The 2024 figure of $135.2 million is correct. (2) CALCULATION ERROR - The LLM calculates a $5 million decline from $140.2M to $135.2M, which is arithmetically correct for those numbers, but since the 2023 baseline is wrong, the entire comparison is invalid. The actual change is from a $6.3M loss to a $135.2M gain - a swing of approximately $141.5 million in the positive direction. (3) MULTI-HOP REASONING - The LLM completely misses the critical insight that the ground truth emphasizes: a reversal from a loss to a gain, indicating a significant shift in foreign currency exposure. Instead, the LLM incorrectly frames this as a modest decline in gains. (4) ENTITY/METRIC ACCURACY - While the company (Starbucks) and metric (foreign currency debt in AOCI) are correct, the characterization of 2023 as a gain rather than a loss is a fundamental error that undermines the entire analysis. (5) SEMANTIC MEANING - The LLM's conclusion about 'modest increase in exposure to adverse foreign-currency movements' contradicts the ground truth's finding of a 'significant shift' and 'reversal.' The answer demonstrates a complete misunderstanding of the year-over-year comparison and its implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 411,
        "total_tokens": 1620
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the fair value of energy-related derivatives for Alabama Power and Georgia Power change between 2022 and 2023, and what was the overall trend in their combined liabilities related to these derivatives?",
      "original_answer": "In 2022, Alabama Power reported a net liability of $144 million related to derivatives in non-designated hedging relationships, including energy-related derivatives. In 2023, Alabama Power had $15 million in assets and $110 million in liabilities related to energy-related derivatives, resulting in a net liability of $95 million. Georgia Power had $13 million in assets and $124 million in liabilities related to energy-related derivatives in 2023, yielding a net liability of $111 million. Therefore, the combined net liability for energy-related derivatives across both entities decreased from $255 million in 2022 to $206 million in 2023, indicating a reduction in exposure.",
      "llm_answer": "In 2023 Alabama Power reported $15 million of energy‑related derivative assets and $110 million of derivative liabilities, while Georgia Power reported $13 million of assets and $124 million of liabilities 【SO_10k_2023.pdf p.279‑283】. The prior‑year filing showed a total of $210 million of energy‑related derivative liabilities for the group (the subsidiaries’ 2022 amounts were not broken out) 【SO_10k_2022.pdf p.325‑329】, so the two utilities’ combined liabilities rose from $210 million in 2022 to $234 million in 2023, indicating an overall increase.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains fundamental factual and calculation errors that directly contradict the ground truth. (1) WRONG CONCLUSION ON TREND: The LLM states liabilities 'rose from $210 million in 2022 to $234 million in 2023, indicating an overall increase,' but the ground truth shows a DECREASE from $255 million to $206 million. This is the opposite of what actually occurred. (2) INCORRECT 2022 BASELINE: The LLM claims 2022 total liabilities were $210 million, but ground truth shows $255 million ($144M Alabama Power + implied $111M Georgia Power). The LLM failed to properly synthesize 2022 data for both entities. (3) INCORRECT 2023 CALCULATION: The LLM calculates 2023 combined liabilities as $234 million ($110M + $124M), which is arithmetically correct for those two numbers, but this ignores the $15M and $13M in ASSETS that should be netted. The ground truth properly nets these to show net liabilities of $95M (Alabama) and $111M (Georgia), totaling $206M net liability. The LLM treated only the liability side without accounting for offsetting assets. (4) INCOMPLETE MULTI-HOP SYNTHESIS: While the LLM correctly identified 2023 figures for both companies, it failed to properly synthesize the 2022 comparison data and misunderstood the net liability calculation methodology. (5) SEMANTIC REVERSAL: The answer's conclusion about trend direction is completely inverted from reality—a critical error for a question specifically asking about trend analysis. The only correct elements are the 2023 individual company figures ($15M, $110M, $13M, $124M), but the overall analysis, calculations, and conclusions are substantially wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 453,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Walmart's financial relationship with Alert Innovation evolve between fiscal 2023 and fiscal 2024, particularly in terms of acquisition and subsequent disposition activities?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, bringing its ownership to approximately 100%. However, in fiscal 2024, Walmart sold and deconsolidated the Alert Innovation entity, signaling a complete exit from the investment. This represents a full evolution from acquisition to divestiture within a one-year span.",
      "llm_answer": "In fiscal 2023 Walmart completed a $0.4 billion acquisition of Alert Innovation, buying out the remaining non‑controlling interest and taking the company to roughly 100 % ownership (“completed a $0.4 billion acquisition of Alert Innovation…bringing our ownership to approximately 100 %” – 2023 10‑K). By fiscal 2024 no further Alert Innovation‑related purchase or sale was reported (the 2024 “Purchase and Sale of Subsidiary Stock” section discusses only Flipkart/PhonePe transactions), indicating Walmart simply held the investment through 2024; the eventual disposition of Alert Innovation was disclosed as occurring later, in fiscal 2025.",
      "correctness_score": 2,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERROR: The LLM answer directly contradicts the ground truth on the core factual claim. Ground truth states that in fiscal 2024, Walmart 'sold and deconsolidated the Alert Innovation entity,' representing a complete exit. The LLM answer claims 'no further Alert Innovation-related purchase or sale was reported' in fiscal 2024 and that 'Walmart simply held the investment through 2024' with disposition occurring in fiscal 2025. This is a fundamental factual error that misrepresents the entire evolution of the financial relationship. The quantitative accuracy is acceptable (the $0.4 billion acquisition amount and 100% ownership figures are correct), but the qualitative accuracy is severely compromised by the incorrect characterization of fiscal 2024 activities. The LLM failed to identify that the key evolution the question asks about—from acquisition to disposition—occurred between fiscal 2023 and fiscal 2024, not between fiscal 2024 and fiscal 2025. The answer demonstrates poor multi-hop reasoning by failing to correctly synthesize the disposition activity that occurred in fiscal 2024 according to the ground truth. The LLM appears to have misread or misinterpreted the 10-K filings, leading to an answer that is semantically opposite to the correct answer on the most important aspect of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 370,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the regulatory approval status of Trodelvy evolve between 2022 and 2023, and what does this indicate about Gilead's oncology strategy?",
      "original_answer": "In 2022, Trodelvy was part of Gilead's marketed product portfolio and contributed to growth in the oncology franchise, though no specific regulatory updates were mentioned. By 2023, Trodelvy received both FDA and EC approvals for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who had received prior endocrine-based therapy and at least two additional systemic therapies. This regulatory progress indicates a strategic focus by Gilead on expanding the therapeutic applications of Trodelvy and strengthening its position in the oncology market, particularly in breast cancer treatment.",
      "llm_answer": "In the 2022 Form 10‑K, Trodelvy was already FDA‑approved for urothelial cancer and for triple‑negative breast cancer (TNBC), with additional European‑Commission and Health‑Canada authorizations for TNBC and ongoing NSCLC studies (GILD_10k_2022, p. 38). By the 2023 Form 10‑K, Gilead had added FDA and European‑Commission approvals for Trodelvy in hormone‑receptor‑positive/HER2‑negative breast cancer, while its Phase 3 EVOKE‑01 NSCLC trial failed to meet its primary overall‑survival endpoint (GILD_10k_2023, p. 39‑40). This evolution shows Gilead is actively expanding Trodelvy’s label into new breast‑cancer indications, reflecting a strategy to broaden its oncology portfolio despite mixed trial outcomes.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of Trodelvy's regulatory evolution between 2022 and 2023. STRENGTHS: (1) Correctly identifies that by 2023, Trodelvy received FDA and EC approvals for HR+/HER2- breast cancer (matching ground truth), (2) Accurately notes the prior 2022 approvals for urothelial cancer and TNBC, (3) Properly synthesizes multi-hop information across two 10-K filings, (4) Correctly identifies the EVOKE-01 NSCLC trial failure as context for mixed outcomes, (5) Appropriately concludes that Gilead's strategy involves expanding Trodelvy's label into new breast cancer indications. MINOR ISSUES: (1) The LLM answer provides additional context about 2022 approvals (urothelial cancer, TNBC, EC/Health Canada authorizations) that goes beyond the ground truth's focus on the 2022-2023 evolution, though this is not incorrect—it's supplementary detail. (2) The ground truth specifically states the 2023 approval was for 'HR+/HER2- breast cancer who had received prior endocrine-based therapy and at least two additional systemic therapies,' while the LLM answer states 'hormone-receptor-positive/HER2-negative breast cancer' without explicitly mentioning the prior therapy requirements. This is a minor omission of clinical specificity but doesn't affect the core regulatory status assessment. (3) The LLM answer includes information about the EVOKE-01 trial failure, which adds valuable context about Gilead's mixed outcomes but wasn't explicitly mentioned in the ground truth. MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years and two 10-K filings, properly identifying the progression of regulatory approvals and connecting this to Gilead's strategic positioning. The logic linking regulatory expansion to oncology strategy strengthening is sound. ENTITY ACCURACY: All entities (Trodelvy, Gilead, FDA, EC, cancer types, trial names) are correctly identified. No calculation errors present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 536,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Simon Property Group's financial relationship with ABG evolved between 2023 and 2024, particularly in terms of capital transactions and strategic positioning?",
      "original_answer": "In 2023, Simon Property Group (SPG) engaged in multiple capital transactions with ABG, including recognizing a non-cash pre-tax gain of $36.4 million from a dilution of ownership in ABG during the second quarter and an additional $145.8 million gain in the third quarter due to further dilution from SPARC Group issuing equity. Additionally, SPG had a long-standing strategic partnership with ABG dating back to 2021, involving licensing ventures such as Forever 21, Brooks Brothers, and Eddie Bauer, which resulted in significant gains. In 2024, SPG no longer reported active capital transactions with ABG, such as gains from dilution or new equity investments. Instead, the 2024 filing only referenced historical transactions, such as the 2021 sale of a portion of SPG’s ABG interest for a pre-tax gain of $18.8 million and the 2022 acquisition of Reebok assets alongside a strategic partnership. This indicates a shift from active financial engagement and restructuring with ABG in 2023 to a more stable, historically referenced relationship in 2024.",
      "llm_answer": "In 2023 Simon’s link to ABG was still that of a minority partner – the company’s stake was repeatedly diluted by ABG‑initiated capital transactions (Q2, Q3 and Q4) that produced non‑cash deemed‑disposal gains of $36.4 million, $12.4 million and $10.3 million, and a partial cash sale in Q4 that generated a $157.1 million pre‑tax gain and left Simon with roughly a 9.6 % ownership (see 2023 10‑K pp. 70‑74). By contrast, in 2024 Simon exited the relationship entirely, selling its remaining ABG interest for $1.2 billion and recording a $414.8 million pre‑tax gain (with $103.7 million tax expense), signalling a shift from a strategic partnership to a full divestiture (see 2024 10‑K pp. 72‑76).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR DISCREPANCIES IDENTIFIED: The LLM answer contains significant factual errors that contradict the ground truth:\n\n1. QUANTITATIVE ERRORS (Critical):\n   - LLM claims Q2 2023 gain of $36.4M (matches ground truth), but then adds Q3 gain of $12.4M and Q4 gain of $10.3M - these figures are NOT in the ground truth\n   - Ground truth states Q3 2023 gain was $145.8M from SPARC Group equity issuance, NOT $12.4M\n   - LLM claims Q4 2023 partial cash sale generated $157.1M gain - ground truth does not mention this specific transaction or amount\n   - LLM states final 2024 sale was for $1.2 billion with $414.8M pre-tax gain - ground truth does NOT mention a 2024 sale at all\n   - LLM claims 9.6% ownership after Q4 2023 - ground truth does not provide this specific percentage\n\n2. FUNDAMENTAL CONTRADICTION:\n   - Ground truth explicitly states: \"In 2024, SPG no longer reported active capital transactions with ABG\" and \"the 2024 filing only referenced historical transactions\"\n   - LLM claims SPG \"exited the relationship entirely\" in 2024 with a $1.2B sale and $414.8M gain\n   - These are directly contradictory - ground truth shows NO 2024 transactions, LLM shows major 2024 divestiture\n\n3. MISSING CONTEXT:\n   - LLM fails to mention the strategic partnership context (Forever 21, Brooks Brothers, Eddie Bauer licensing ventures) that ground truth emphasizes\n   - LLM omits the 2021 and 2022 historical transactions mentioned in ground truth\n\n4. REASONING QUALITY:\n   - While the LLM correctly identifies the shift from active engagement to different positioning, it does so based on fabricated 2024 transaction data\n   - The multi-hop synthesis is logically structured but built on incorrect premises\n\n5. SEMANTIC ALIGNMENT:\n   - The overall narrative structure (2023 active transactions → 2024 shift) is directionally similar but the specific facts are wrong\n   - Ground truth shows shift to \"historically referenced relationship,\" not complete exit\n\nThe LLM answer appears to have hallucinated specific financial figures and a major 2024 transaction that do not appear in the ground truth knowledge graph. This is a critical failure for a financial analysis task where accuracy is paramount.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 596,
        "total_tokens": 2038
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Chevron's relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2024, particularly in terms of financial reporting and investment value?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was included in Chevron’s consolidated financial disclosures, specifically in Note 8 on page 70 of the 10-K filing, indicating it was a consolidated subsidiary. By 2024, the company was reported as an equity method investee under 'Downstream' in the Investments and Advances section, with a disclosed investment value of $8,571 million as of December 31, 2024, up from $7,765 million in 2023. This reflects a shift from full consolidation to an equity method investment, suggesting a structural or ownership change in Chevron’s relationship with the entity.",
      "llm_answer": "Chevron continued to report that it owns 50 % of Chevron Phillips Chemical Company LLC (with a $669 million loan to fund the Golden Triangle Polymers Project) in both the 2022 and 2024 10‑K filings【CVX_10k_2022.pdf:34】【CVX_10k_2024.pdf:85】.  In 2022 the affiliate generated $867 million of equity earnings and was reflected as a relatively modest investment balance, while by 2024 the carrying amount of the investment had risen to $8.571 billion (up from $7.765 billion in 2023) and equity earnings increased to $903 million, indicating a substantially larger financial stake in the joint venture【CVX_10k_2024.pdf:85】.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant issues in addressing the core question about the evolution of Chevron's relationship with Chevron Phillips Chemical Company LLC between 2022 and 2024.\n\nCRITICAL ERRORS:\n1. FUNDAMENTAL MISCHARACTERIZATION: The LLM states that Chevron Phillips Chemical was reported the same way in both 2022 and 2024 (as a 50% equity method investment), but the ground truth explicitly states there was a SHIFT from full consolidation in 2022 to equity method investment by 2024. This is the core evolution the question asks about, and the LLM completely missed it.\n\n2. ACCOUNTING TREATMENT ACCURACY: The ground truth clearly indicates that in 2022, Chevron Phillips Chemical was a \"consolidated subsidiary\" (Note 8, page 70), not an equity method investee. By 2024, it became an equity method investee. The LLM failed to capture this structural change entirely.\n\nQUANTITATIVE VERIFICATION:\n- Investment value 2024: $8,571 million ✓ (correct, matches ground truth)\n- Investment value 2023: $7,765 million ✓ (correct, matches ground truth)\n- 50% ownership: ✓ (correct)\n- $669 million loan for Golden Triangle Polymers Project: Mentioned in LLM but not in ground truth (cannot verify as error)\n- 2024 equity earnings $903 million: Mentioned in LLM but not in ground truth (cannot verify as error)\n- 2022 equity earnings $867 million: Mentioned in LLM but not in ground truth (cannot verify as error)\n\nMULTI-HOP REASONING FAILURE:\nThe question specifically asks about how the relationship \"evolved\" between 2022 and 2024. The ground truth identifies a key evolution: consolidation → equity method investment. The LLM presents the relationship as static (\"continued to report... in both 2022 and 2024\"), which fundamentally misses the evolution narrative.\n\nCOMPLETENESS ISSUES:\n- Failed to identify the shift from consolidated subsidiary to equity method investee\n- Failed to note the structural/ownership change implied by the accounting treatment shift\n- Did not address the financial reporting methodology change\n\nWHAT WAS CORRECT:\n- The investment values for 2023 and 2024 are accurate\n- The 50% ownership percentage is correct\n- The general upward trend in investment value is noted\n\nThe answer demonstrates partial understanding of the financial numbers but fundamentally fails to address the core evolution in the relationship that the question asks about.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 641,
        "total_tokens": 1953
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did the status and financial impact of Meta's Facilities Consolidation Strategy evolve between the end of 2023 and the end of 2024?",
      "original_answer": "At the end of 2023, Meta had 'substantially completed' its facilities consolidation initiatives as part of the 2022 Restructuring, indicating the process was still ongoing. By the end of 2024, the company reported that it had 'completed the 2022 restructuring initiatives,' which included the facilities consolidation strategy, showing the process had reached full completion. Additionally, the 2024 disclosure included a financial summary of the 2022 Restructuring pre-tax charges across three years (2022–2024), indicating a retrospective quantification of the financial impact that was not explicitly detailed in 2023.",
      "llm_answer": "By December 31 2023 Meta said the 2022 facilities‑consolidation effort was “substantially completed” but still carried a large restructuring bill – roughly $2.5 billion of pre‑tax charges (about $177 M in cost‑of‑revenue, $1.58 B in R&D, $396 M in marketing and $352 M in G&A). By December 31 2024 the company reported the consolidation was fully completed, and the only remaining impact was $389 million of pre‑tax charges for the year, all of which were attributed to the facilities‑consolidation work.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its credibility. While it correctly identifies the key qualitative evolution (from 'substantially completed' in 2023 to 'fully completed' in 2024), it introduces specific financial numbers that cannot be verified against the ground truth and appear to be fabricated. The ground truth explicitly states that the 2024 disclosure included 'a financial summary of the 2022 Restructuring pre-tax charges across three years (2022–2024)' but does NOT provide the specific breakdown numbers the LLM cites ($2.5B total with $177M cost-of-revenue, $1.58B R&D, $396M marketing, $352M G&A for 2023, or $389M for 2024). The LLM appears to have hallucinated these specific dollar amounts. The qualitative aspects are correct (status progression from substantially completed to fully completed), but the quantitative claims are unsubstantiated and likely incorrect. The answer does address the multi-part nature of the question (status evolution AND financial impact), but the financial impact portion is compromised by unverified numbers. The reasoning structure is sound, but the factual foundation is weak. This represents a critical failure in financial accuracy where specific numbers are presented with confidence but lack verification in the source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 368,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2024, particularly in terms of strategic focus and program status?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a key growth area that was dependent on U.S. Government authorization and funding, indicating that the programs were still in a development phase with uncertain future funding. By 2024, the company was actively producing hypersonic strike weapons under multiple programs with the U.S. Air Force and Army, showing a shift from a funding-dependent future initiative to an active production program. This evolution reflects a significant advancement in the maturity and strategic importance of hypersonics within Lockheed Martin's portfolio.",
      "llm_answer": "In the 2022 Form 10‑K, Lockheed Martin described hypersonics as a “key growth area” but warned that the ability to expand those programs depended on U.S.‑government funding and the transition of development work into production. By the 2024 filing, the company is naming concrete hypersonics development efforts in both its Missiles & Fire Control and Space segments—multiple Air Force, Army and Navy strike‑weapon projects—signaling that hypersonics has moved from a strategic priority subject to budget risk to an active, multi‑segment portfolio of ongoing programs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2022 characterization of hypersonics as a 'key growth area' with funding dependency and development phase status. (2) Accurately captures the 2024 evolution showing active production of hypersonic strike weapons across multiple programs (Air Force, Army, Navy). (3) Properly synthesizes the multi-hop information showing progression from funding-dependent future initiative to active production portfolio. (4) Correctly identifies the strategic shift from budget-risk dependent to established multi-segment programs. (5) Appropriately references both Missiles & Fire Control and Space segments, adding specificity beyond ground truth without contradicting it. QUANTITATIVE ACCURACY: No numeric values, dates, or calculations present in either answer, so this dimension is not applicable but scores full marks as no errors exist. QUALITATIVE ACCURACY: The reasoning is sound and multi-hop synthesis is correct - the model successfully connected 2022 filing information (development phase, funding uncertainty) with 2024 filing information (active production, multiple programs) to show evolution. MINOR CONSIDERATIONS: The LLM answer adds slightly more detail about segment identification (Missiles & Fire Control, Space) and mentions Navy programs alongside Air Force and Army, which represents appropriate elaboration rather than error. The semantic equivalence is excellent - 'key growth area' matches, 'funding-dependent' matches, 'active production' matches the ground truth's 'actively producing.' The answer fully addresses the question's request for evolution in strategic focus and program status from 2022 to 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 478,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolve from 2022 to 2023, particularly in terms of their designation and financial impact?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred. By 2023, the company expanded its disclosure to include the pre-tax effects of energy-related derivatives not designated as hedging instruments on its statements of income, covering the years 2023, 2022, and 2021. This indicates a shift from focusing only on regulatory hedging instruments to providing a broader view of its energy-related derivative activities.",
      "llm_answer": "Southern Company kept its energy‑related contracts classified as regulatory‑hedging instruments (including deferred) in both years, but the net unrealized result swung from modest gains in 2022 (e.g., a $9 million gain for the parent, $23 million for Alabama Power and $27 million for the gas subsidiary) to large losses in 2023 (e.g., a $257 million loss for the parent, $95 million loss for Alabama Power and $46 million loss for the gas subsidiary).  The cash‑flow hedge accounting reflected the same reversal, moving from small OCI and earnings gains in 2022 (e.g., a $3 million OCI gain and a $34 million earnings gain for the parent) to sizable OCI and earnings losses in 2023 (e.g., an $81 million OCI loss and a $44 million earnings loss for the parent, and a $63 million OCI loss for the gas unit).  By contrast, energy‑related derivatives that were not designated as hedges improved from a $76 million loss in 2022 to a $59 million gain in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer provides extensive specific financial numbers and detailed breakdowns by subsidiary, but fundamentally misses the core point of the ground truth answer. The ground truth emphasizes a DISCLOSURE EVOLUTION - a shift from reporting only regulatory hedging instruments in 2022 to expanding disclosures in 2023 to include non-designated derivatives. The LLM answer instead focuses on the FINANCIAL PERFORMANCE SWING (gains to losses) without addressing the disclosure/designation evolution that is central to the question. Critical issues: (1) The LLM provides highly specific numbers ($9M, $23M, $27M gains in 2022; $257M, $95M, $46M losses in 2023; $3M OCI gain, $34M earnings gain, etc.) that cannot be verified against the ground truth and appear to be fabricated or hallucinated - the ground truth does not provide these specific subsidiary-level breakdowns. (2) The LLM completely misses the key disclosure change: the ground truth explicitly states that 2023 expanded to include 'pre-tax effects of energy-related derivatives not designated as hedging instruments on its statements of income, covering the years 2023, 2022, and 2021.' The LLM mentions non-designated derivatives only briefly at the end ($76M loss in 2022 to $59M gain in 2023) without connecting this to the disclosure evolution. (3) The LLM's framing of 'regulatory-hedging instruments (including deferred)' in both years suggests continuity, but the ground truth indicates a shift in what was disclosed/reported. (4) The question asks about 'treatment and disclosure' evolution - the LLM focuses almost entirely on financial results rather than how the company's treatment and disclosure practices changed. The answer demonstrates detailed financial analysis but fails to address the fundamental disclosure/designation shift that defines the evolution from 2022 to 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 503,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Gilead's intellectual property strategy regarding Truvada evolve between 2022 and 2023, particularly in terms of patent disclosures?",
      "original_answer": "In 2022, Gilead highlighted the October 2020 loss of exclusivity of Truvada in the United States as a transitory headwind, indicating that the product was no longer protected under patent, which likely affected revenue. In 2023, Gilead provided structured disclosures regarding the patent expiration dates of its principal products, including Truvada, focusing on the actual or estimated expiration dates in the U.S. and the EU. This represents a shift from acknowledging a past loss of exclusivity to proactively disclosing future intellectual property timelines for key products.",
      "llm_answer": "In the 2022 Form 10‑K Gilead noted that Truvada had lost U.S. exclusivity in October 2020 and, while it listed the drug in its product portfolio, it did not disclose any active or pending patents covering Truvada (the patent‑expiration tables on pages 35‑39 contain no Truvada entries). The 2023 Form 10‑K likewise lists Truvada (and Truvada for PrEP) among its marketed products but again provides no new patent disclosures for the drug (the patent‑expiration tables on pages 7‑11 likewise omit Truvada), indicating that Gilead’s IP approach for Truvada remained unchanged—focused on managing generic competition rather than pursuing additional patent protection.",
      "correctness_score": 3,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) CORE CONTRADICTION: The ground truth states that in 2023, Gilead 'provided structured disclosures regarding the patent expiration dates of its principal products, including Truvada,' representing a shift toward proactive IP timeline disclosure. The LLM answer directly contradicts this by claiming the 2023 10-K 'likewise omits Truvada' from patent-expiration tables and that 'Gilead's IP approach for Truvada remained unchanged.' This is a fundamental mischaracterization of the evolution described in the ground truth. (2) MISINTERPRETATION OF STRATEGY SHIFT: The ground truth emphasizes an evolution from 'acknowledging a past loss of exclusivity' (2022) to 'proactively disclosing future intellectual property timelines' (2023). The LLM answer frames this as 'unchanged' and 'focused on managing generic competition rather than pursuing additional patent protection,' which misses the key strategic shift in disclosure practices. (3) NUMERIC ACCURACY: The LLM correctly identifies October 2020 as the loss of exclusivity date and correctly references page numbers (35-39 for 2022, 7-11 for 2023), showing some attention to detail. However, these correct details are used to support an incorrect overall conclusion. (4) MULTI-HOP REASONING FAILURE: The question asks about evolution 'between 2022 and 2023.' The LLM fails to identify the actual evolution (shift from retrospective acknowledgment to prospective disclosure) and instead concludes there was no meaningful change. This represents a failure in comparative analysis across the two years. (5) SEMANTIC MISALIGNMENT: While the LLM answer is well-structured and specific, it conveys the opposite message from the ground truth regarding whether Gilead's IP strategy evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 497,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did SPG's use of the Supplemental Facility evolve between 2022 and 2024, particularly in terms of borrowing and repayment activities?",
      "original_answer": "In 2022, SPG borrowed $1.05 billion under the Supplemental Facility in January 2022, which was used to fund the early extinguishment of nine mortgages with a principal balance of $1.16 billion. This borrowing was repaid shortly after issuance. By 2024, SPG again utilized the Supplemental Facility, borrowing €750.0 million ($815.4 million U.S. dollar equivalent) in November 2023, which was repaid on November 17, 2023. Additionally, in 2024, SPG issued new senior unsecured notes to redeem other outstanding notes at maturity, indicating a shift in financing strategy. The evolution shows a continued reliance on the Supplemental Facility for short-term financing needs but with a more structured approach to repayment and refinancing.",
      "llm_answer": "In 2022 the Operating Partnership used the Supplemental Facility only once – it drew $1.05 billion on December 14, 2021 and then paid that entire amount back on January 12, 2022 with proceeds from a $1.2 billion senior‑note issuance【SPG_10k_2022.pdf p.71‑73】. By the 2024 filing the focus had shifted to repayment: the only activity reported was the repayment of the remaining €750 million of Euro‑denominated borrowings under the Supplemental Facility on November 17, 2023 (after an interest‑rate swap in early 2023), with no new draws disclosed, indicating the facility was being wound down【SPG_10k_2024.pdf p.68‑70】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) CRITICAL DATE ERROR: LLM states the $1.05 billion was drawn on December 14, 2021 and repaid January 12, 2022, but ground truth clearly states this occurred in January 2022 (the draw and repayment both happened in 2022, not spanning 2021-2022). This is a significant factual error affecting the 2022 narrative. (2) MISSING KEY INFORMATION: Ground truth explicitly states the $1.05 billion was used to fund early extinguishment of nine mortgages with $1.16 billion principal balance - the LLM omits this crucial detail about the purpose of the borrowing. (3) INCOMPLETE 2024 ANALYSIS: Ground truth mentions that in 2024 SPG issued new senior unsecured notes to redeem other outstanding notes at maturity, indicating a shift in financing strategy. The LLM completely omits this important evolution point. (4) CURRENCY CONVERSION ERROR: Ground truth specifies €750.0 million = $815.4 million USD equivalent. LLM mentions €750 million but does not provide the USD equivalent conversion, missing a key quantitative detail. (5) PARTIAL CREDIT FOR CORRECT ELEMENTS: The LLM correctly identifies the November 17, 2023 repayment date and the €750 million amount, and correctly characterizes the shift toward facility wind-down. (6) REASONING QUALITY: While the LLM attempts to synthesize information across years, it fails to capture the complete evolution narrative, particularly the strategic shift from short-term financing for mortgage extinguishment to structured refinancing with new note issuances. The multi-hop synthesis is incomplete and misses the strategic context provided in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 445,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the role of cash buffer needs in MetLife's capital management strategy evolved from 2022 to 2024, particularly in terms of liquidity levels and their impact on capital allocation decisions?",
      "original_answer": "In 2022, MetLife maintained a short-term liquidity position of $12.4 billion and a total liquid asset base of $223.0 billion, reflecting a strong buffer to meet business requirements under both normal and stress scenarios. The company emphasized its belief in having ample liquidity and highlighted active monitoring and adjustment of liquidity and capital plans. By 2024, the narrative shifted to a more cautious tone, noting that maintaining or increasing cash buffers could limit capital available for innovation, acquisitions, and shareholder returns. This indicates that while liquidity remained a strategic priority, the implications of holding larger cash buffers became more pronounced, potentially constraining other capital deployment opportunities.",
      "llm_answer": "In the 2022 Form 10‑K MetLife stressed that it kept a sizable cash‑buffer – a short‑term liquidity position of $12.4 billion and total liquid assets of $223 billion – and warned that any increase in that buffer would directly reduce the capital it could deploy for growth, acquisitions or shareholder returns. The 2024 filing repeats the same emphasis on cash‑buffer needs, noting that liquidity remains ample (still well over $200 billion of cash and liquid assets) and that the size of the buffer continues to be a key lever in deciding how much capital can be allocated to other strategic uses. Thus, while the overall approach has not changed, MetLife’s 2024 disclosures show a continued, perhaps slightly larger, liquidity cushion that still constrains the amount of capital available for non‑buffer purposes.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUES: (1) FACTUAL ERROR ON 2022 NARRATIVE: The LLM claims that in 2022 MetLife 'warned that any increase in that buffer would directly reduce the capital it could deploy for growth, acquisitions or shareholder returns.' However, the ground truth states that in 2022, MetLife 'emphasized its belief in having ample liquidity' with no mention of warnings about buffer constraints. The cautious tone about cash buffers limiting capital allocation only emerged in 2024 according to the ground truth. This is a fundamental mischaracterization of the 2022 position. (2) INCORRECT EVOLUTION NARRATIVE: The LLM states 'while the overall approach has not changed' and describes only a 'continued, perhaps slightly larger, liquidity cushion.' This contradicts the ground truth which explicitly describes a 'shift to a more cautious tone' from 2022 to 2024 - a meaningful evolution in how MetLife framed the trade-offs between cash buffers and capital allocation. The LLM failed to capture this key evolution. (3) QUANTITATIVE ACCURACY: The specific numbers are correct ($12.4 billion short-term liquidity, $223 billion total liquid assets for 2022; reference to 'over $200 billion' for 2024). However, the LLM provides no specific 2024 figures to enable proper comparison. (4) MULTI-HOP REASONING FAILURE: The question asks how the role 'evolved' from 2022 to 2024. The ground truth shows a clear evolution: from emphasis on ample liquidity (2022) to recognition that larger buffers constrain other opportunities (2024). The LLM incorrectly suggests continuity rather than evolution. (5) MISSING CONTEXT: The ground truth emphasizes that the 2024 narrative became 'more pronounced' regarding constraints on capital deployment - this represents a meaningful shift in strategic emphasis that the LLM downplayed as 'perhaps slightly larger' and 'not changed.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 503,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did Starbucks' exposure to 'Foreign currency - other' derivatives evolve between 2022 and 2023, particularly in terms of asset and liability classifications?",
      "original_answer": "In 2022, Starbucks reported 'Foreign currency - other' derivative liabilities of $0.3 million under accrued liabilities and no corresponding asset value. By 2023, the company had a derivative asset of $1.9 million under prepaid expenses and other current assets and a derivative liability of $4.7 million under accrued liabilities for the same category. This indicates a significant increase in exposure and a shift toward a more balanced treatment across asset and liability classifications.",
      "llm_answer": "In 2022 Starbucks reported designated “foreign‑currency‑other” derivative assets of $39.9 million in prepaid/current assets and $33.5 million in other long‑term assets (≈ $73.4 million total) and only $0.3 million of accrued‑liability exposure【SBUX_10k_2022.pdf p.68】. By 2023 the asset balance had collapsed to $1.9 million (current) and $1.7 million (long‑term) – about $3.6 million – while the liability side grew to $4.7 million (accrued) plus $4.1 million (long‑term), roughly $8.8 million, shifting the net position from a sizable asset to a net liability【SBUX_10k_2023.pdf p.71】.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significantly incorrect numbers that contradict the ground truth. Ground truth states: (1) 2022: $0.3M liability only, no asset value mentioned; (2) 2023: $1.9M asset (current), $4.7M liability (current). The LLM claims: (1) 2022: $39.9M current assets + $33.5M long-term assets (~$73.4M total) plus $0.3M liability; (2) 2023: $1.9M current + $1.7M long-term assets (~$3.6M) plus $4.7M current + $4.1M long-term liabilities (~$8.8M). CRITICAL ISSUES: (1) The 2022 asset figures ($39.9M and $33.5M) are completely absent from the ground truth, which explicitly states 'no corresponding asset value' for 2022. (2) The LLM introduces long-term liability figures ($4.1M in 2023) not mentioned in ground truth. (3) The LLM's total calculations ($73.4M in 2022 assets, $3.6M in 2023 assets, $8.8M in 2023 liabilities) are fabricated and contradict the ground truth's simpler, more modest figures. (4) The narrative of 'asset balance collapsed' is misleading since 2022 had no reported assets according to ground truth. MULTI-HOP REASONING: The LLM failed to correctly synthesize the year-over-year comparison. While it attempted to show evolution across 2022-2023 and asset/liability classifications, the underlying numbers are fundamentally wrong. SEMANTIC ISSUES: The LLM's conclusion about 'shifting from sizable asset to net liability' is contradicted by ground truth, which shows minimal 2022 assets and a more modest 2023 position. The answer demonstrates fabrication of specific dollar amounts with false citation references (p.68, p.71) that cannot be verified against the actual ground truth data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 450,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has The Coca-Cola Company's relationship with Coca-Cola FEMSA evolved from 2023 to 2024, particularly in terms of its strategic engagement and financial stake?",
      "original_answer": "In 2023, Coca-Cola FEMSA was one of The Coca-Cola Company's five largest independent bottling partners, operating in multiple countries including Mexico, Brazil, and Argentina, and collectively these top five bottlers accounted for 42% of Coca-Cola's worldwide unit case volume. By 2024, the relationship had evolved significantly, as Coca-Cola FEMSA transitioned from being a key bottler to becoming an equity method investee in which The Coca-Cola Company held a 28% ownership stake. This shift indicates a deeper financial commitment and alignment beyond the traditional bottler-concentrate supplier model.",
      "llm_answer": "In the 2023 filing Coca‑Cola FEMSA was described only as a major independent bottling partner – one of the five largest bottlers that together accounted for 42 % of the Company’s worldwide unit‑case volume – and the relationship was framed by the standard bottler’s agreements with no disclosed equity ownership【5†L1-L9】. By the 2024 filing the relationship had deepened: Coca‑Cola now reports an equity‑method investment in Coca‑Cola FEMSA, owning 28 % of its outstanding shares as of 31 Dec 2024, reflecting a more strategic, financially‑aligned partnership【85†L1-L8】【86†L1-L8】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. QUANTITATIVE VERIFICATION: All numbers are correct - 42% of worldwide unit case volume for top five bottlers in 2023 (matches ground truth), 28% ownership stake in 2024 (matches ground truth), and the date of December 31, 2024 is accurate. ENTITY ACCURACY: Coca-Cola FEMSA correctly identified, The Coca-Cola Company correctly referenced, years 2023 and 2024 properly distinguished. MULTI-HOP REASONING: The answer successfully synthesizes the evolution across two years: (1) 2023 status as independent bottler with no equity ownership, (2) 2024 transition to equity method investee with 28% stake. The logical progression from traditional bottler relationship to strategic financial partnership is clearly articulated. COMPLETENESS: The answer addresses all aspects of the question - strategic engagement (from bottler to equity investee), financial stake (28% ownership), and the evolution between the two years. SEMANTIC EQUIVALENCE: The phrasing \"equity-method investment\" and \"28% of outstanding shares\" accurately conveys the ground truth's \"28% ownership stake\" and \"equity method investee\" concepts. The characterization of the shift as indicating \"deeper financial commitment and alignment\" is semantically equivalent to the ground truth's description of \"a deeper financial commitment and alignment beyond the traditional bottler-concentrate supplier model.\" MINOR OBSERVATION: The LLM includes citation markers (【5†L1-L9】, etc.) which adds credibility but is not part of the core answer evaluation. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 440,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Intel's strategic positioning of FPGAs evolved between 2022 and 2024, particularly in terms of their role within adjacent products and their broader production focus?",
      "original_answer": "In 2022, Intel positioned FPGAs as part of its 'adjacent products' within the Client Computing Group (CCG), Data Center Group (DCG), and Internet of Things Group (IOTG), indicating a supporting role within comprehensive platform solutions. By 2024, FPGAs were explicitly listed under direct product definitions, signaling a shift toward a more central production focus. This reflects a transformation in the strategic importance of FPGAs, moving from a supplementary role to a core product offering.",
      "llm_answer": "In the 2022 filing Intel still treated FPGAs as a “adjacent product” – a non‑platform offering in the Programmable Solutions Group that complemented its core CPU/SoC platforms (see the definition of Adjacent products and FPGA on pages 111‑115 of the 2022 10‑K). By the 2024 filing the company has moved FPGAs into the core compute family, listing them as one of the four xPU architectures (CPU, GPU, AI accelerator, FPGA) and tying them to its broader IDM‑IFS production strategy, signaling a shift from a peripheral role to a central production focus (see the definitions of FPGA, xPU and IDM IFS on pages 100‑104 of the 2024 10‑K).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the core directional shift in Intel's FPGA positioning from 2022 to 2024 (from adjacent/supplementary to more central), which aligns with the ground truth. However, there are significant discrepancies in entity identification and specific details that undermine accuracy:\n\n1. ENTITY ACCURACY ISSUES: The LLM identifies FPGAs as being in the 'Programmable Solutions Group' in 2022, while the ground truth explicitly states they were positioned within 'Client Computing Group (CCG), Data Center Group (DCG), and Internet of Things Group (IOTG).' This is a material factual error regarding organizational structure.\n\n2. TERMINOLOGY DISCREPANCY: The ground truth uses 'adjacent products' as the 2022 classification, and the LLM correctly identifies this term. However, the LLM adds 'non-platform offering in the Programmable Solutions Group' which contradicts the ground truth's statement that FPGAs were part of CCG, DCG, and IOTG.\n\n3. 2024 POSITIONING: The LLM's description of FPGAs being listed as one of four xPU architectures (CPU, GPU, AI accelerator, FPGA) and tied to IDM-IFS strategy is more detailed than the ground truth but appears consistent with the directional shift described. However, the ground truth states FPGAs were 'explicitly listed under direct product definitions' without mentioning the specific xPU framework.\n\n4. PAGE REFERENCES: The LLM provides specific page citations (pages 111-115 for 2022, pages 100-104 for 2024) which cannot be verified against the ground truth and may be inaccurate.\n\n5. CORE CONCEPT: Both answers correctly identify the strategic shift from supplementary/adjacent to more central/core positioning, which is the fundamental insight required.\n\nThe answer demonstrates understanding of the directional change but contains organizational structure errors and potentially inaccurate supporting details that reduce confidence in the overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 522,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did ConocoPhillips' financial activity related to the Lower 48 region evolve from 2022 to 2023, particularly in terms of asset acquisition and depreciation, depletion, and amortization expenses?",
      "original_answer": "In 2022, ConocoPhillips noted that purchases in the Lower 48 were driven by the Concho acquisition, indicating a strategic expansion in that region. The depreciation, depletion, amortization, and impairments expense for the Lower 48 was $4,854 million. In 2023, the company's expense for the same category in the Lower 48 increased to $5,729 million, showing a significant rise of $875 million. This increase suggests continued investment and asset utilization in the Lower 48 following the acquisition.",
      "llm_answer": "ConocoPhillips stepped up its investment in the Lower 48 in 2023.  Capital spending for the region rose to **$6.49 billion** in 2023 from **$5.63 billion** in 2022 – an increase of roughly $0.86 billion (≈15 %)【COP_10k_2023.pdf p.134】.  At the same time, depreciation, depletion and amortization (DD&A) for the Lower 48 grew to **$5.73 billion** in 2023 versus **$4.85 billion** in 2022, an uplift of about $0.88 billion (≈18 %)【COP_10k_2023.pdf p.133】.  This shows both higher asset acquisition and higher DD&A expenses for the Lower 48 between 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key numbers: (1) DD&A expenses match ground truth exactly - $4.85B (2022) vs $5.73B (2023), with increase of $0.88B, which aligns with the ground truth's $4,854M and $5,729M (difference of $875M, essentially identical when accounting for rounding). (2) Capital spending figures ($6.49B and $5.63B) are provided but not mentioned in the ground truth, which only addresses DD&A. However, these appear to be accurate supplementary data from the 10-K that enriches the answer. (3) Percentage calculations are correct: ($5.73-$4.85)/$4.85 ≈ 18.1% and ($6.49-$5.63)/$5.63 ≈ 15.3%. (4) The answer successfully synthesizes multi-hop information by comparing 2022 and 2023 data across two distinct financial metrics (capital spending and DD&A). (5) The answer goes beyond the ground truth by including capital spending data, which directly addresses the 'asset acquisition' aspect of the question more explicitly than the ground truth. (6) Entity identification is correct (ConocoPhillips, Lower 48 region, fiscal years 2022-2023). (7) The reasoning is sound - the answer correctly interprets increased DD&A as a result of continued investment and asset utilization. Minor note: The ground truth mentions the Concho acquisition as context for 2022 purchases, which the LLM answer does not explicitly reference, but this is a minor contextual omission that doesn't affect the core factual accuracy of the financial metrics presented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 412,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial impact on gross margins?",
      "original_answer": "In 2022, Emerson completed the acquisition of AspenTech, contributing approximately $6.0 billion in cash, paying $87.69 per share to Heritage AspenTech stockholders, and retaining $168 million in AspenTech's balance sheet. The acquisition positively impacted gross margins by 0.6 percentage points in 2023. By 2024, Emerson owned 55% of AspenTech on a fully diluted basis, and AspenTech continued to operate under its former name and ticker symbol 'AZPN.' The acquisition's financial impact persisted, contributing to a gross margin increase of 1.8 percentage points to 50.8% in 2024, despite a negative impact from acquisition-related inventory step-up amortization of $231 million, which reduced margins by 1.3 percentage points.",
      "llm_answer": "After the May 2022 transaction, Emerson contributed two software businesses and about $6 billion in cash and emerged as the 55 % owner of the newly‑formed AspenTech (the other 45 % held by former Heritage AspenTech shareholders) and generated $356 million of sales, which helped lift Emerson’s gross margin by roughly 0.6 percentage point in 2023 【EMR_10k_2022.pdf page 55‑56】. By fiscal 2024 Emerson’s stake had risen to roughly 57 % and the company announced a proposal to buy the remaining shares, while gross margin continued to improve to 50.8 % (up 1.8 points) – the 2023 margin gain already reflected the AspenTech contribution, and the 2024 increase was driven mainly by other acquisitions and pricing effects【EMR_10k_2024.pdf page 24‑27】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the May 2022 acquisition timing, the ~$6 billion cash contribution, the 0.6 percentage point gross margin improvement in 2023, the 50.8% gross margin in 2024, and the 1.8 percentage point improvement in 2024. The answer appropriately synthesizes multi-hop information across 2022-2024 and correctly notes that AspenTech continued operating under its former name and ticker. The contextual framing of ownership structure evolution is relevant and well-presented.\n\nCRITICAL ERRORS: (1) Ownership percentage discrepancy: The LLM states Emerson's stake 'had risen to roughly 57%' by 2024, but the ground truth clearly states 55% on a fully diluted basis in 2024. This is a material factual error on a key metric. (2) Missing key financial detail: The ground truth specifies the $87.69 per share price paid to Heritage AspenTech stockholders, which the LLM omits entirely. (3) Missing critical margin impact detail: The ground truth explicitly mentions the negative impact from acquisition-related inventory step-up amortization of $231 million, which reduced margins by 1.3 percentage points in 2024. This is a significant omission that affects understanding of the margin composition. (4) Incomplete ownership context: The ground truth mentions Emerson 'retaining $168 million in AspenTech's balance sheet,' which provides important context about the transaction structure that the LLM lacks.\n\nPARTIAL ACCURACY: The LLM correctly identifies that the 2024 margin improvement was 'driven mainly by other acquisitions and pricing effects,' which aligns with the ground truth's implication that the $231 million inventory step-up was a headwind. However, the LLM doesn't explicitly quantify this headwind.\n\nMULTI-HOP REASONING: The answer demonstrates sound multi-hop synthesis by connecting the 2022 acquisition details to 2023 margin impact to 2024 ownership and margin evolution. The logical flow is coherent and addresses the evolution question appropriately.\n\nQUANTITATIVE ISSUES: The 57% vs 55% ownership discrepancy is a clear numerical error. The omission of the $231 million inventory step-up amortization and its 1.3 percentage point margin impact represents incomplete quantitative disclosure of material financial impacts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 609,
        "total_tokens": 1988
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has the treatment and availability of shares under the 2015 Director Stock Plan evolved between 2022 and 2024, particularly in terms of share recovery and issuance mechanics?",
      "original_answer": "In 2022, the 2015 Director Stock Plan specified that each share issued under the plan reduced the number of shares remaining for issuance by one, and shares recovered from expired, forfeited, or cash-settled awards were again available for issuance. By 2024, the plan had a total of 35,395,894 shares authorized for issuance as of January 1, 2015, with 37,608,213 shares recovered for issuance between 2015 and 2024. However, 42,343,146 shares were covered by new awards and reinvested dividends since 2015, leaving 30,660,961 shares available for future issuance. This reflects a net reduction in available shares over time despite ongoing share recovery, indicating a shift in the balance between new issuances and recovered shares.",
      "llm_answer": "The 2015 Director Stock Plan still treats any shares that become free‑floating because an award is terminated, forfeited, settled in cash, exchanged, or used for tax‑withholding as “recovered” and therefore available for re‑issuance, and a share‑settled Stock Appreciation Right is counted only for the net shares actually issued (MET 10‑K 2022 p.336; MET 10‑K 2024 p.312).  Between the 2022 and 2024 filings the cumulative recovered pool grew from about 31.5 million shares to 37.6 million shares, while shares tied up in new awards and imputed dividend credits rose from roughly 32.9 million to 42.3 million, shrinking the remaining pool of shares that can be issued under the plan from 34.07 million (2022) to 30.66 million (2024) (MET 10‑K 2022 p.335; MET 10‑K 2024 p.311).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the question. QUANTITATIVE VERIFICATION: All key numbers are correct and match the ground truth: (1) Recovered shares grew from ~31.5M (2022) to 37.6M (2024) - matches ground truth's 37,608,213 figure; (2) New awards/dividends rose from ~32.9M (2022) to 42.3M (2024) - matches ground truth's 42,343,146; (3) Available shares decreased from 34.07M (2022) to 30.66M (2024) - matches ground truth's 30,660,961. The calculations are internally consistent and accurate. QUALITATIVE ASSESSMENT: The LLM answer provides superior detail on the mechanics of share recovery (terminated, forfeited, cash-settled, exchanged, tax-withholding scenarios) and specifically notes the SAR net-share treatment, which adds valuable context beyond the ground truth. The multi-hop synthesis correctly traces the evolution between 2022 and 2024 across three key metrics. ENTITY ACCURACY: Correctly identifies MET (MetLife) 10-K filings for both 2022 and 2024, with accurate page references. MINOR CONSIDERATIONS: The ground truth mentions the 35,395,894 shares authorized as of January 1, 2015, which the LLM answer does not explicitly state, though this is a baseline figure less relevant to the 'evolution between 2022 and 2024' focus of the question. The LLM answer's emphasis on the mechanics and the trend analysis is more directly responsive to the question's focus on 'evolution' and 'mechanics.' The answer demonstrates sound multi-hop reasoning by synthesizing data across two filing years and explaining the underlying drivers of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 438,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Starbucks' relationship with the Global Coffee Alliance evolved from fiscal year 2022 to fiscal year 2023 in terms of strategic emphasis and revenue contribution?",
      "original_answer": "In fiscal year 2022, the Global Coffee Alliance contributed to the growth of the Channel Development segment, which saw a $250 million increase in revenue driven by product sales and royalty income from the alliance. By fiscal year 2023, the strategic emphasis on the Global Coffee Alliance had evolved, with Starbucks explicitly highlighting its licensing relationship with Nestlé under the alliance as a core channel for product distribution, indicating a deeper integration and ongoing importance to Starbucks' global licensing and product expansion strategy. This evolution reflects a shift from viewing the alliance primarily as a revenue driver to positioning it as a strategic enabler of global product reach and brand extension.",
      "llm_answer": "Starbucks continued to treat its partnership with the Global Coffee Alliance as a core growth lever for the Channel Development segment.  In fiscal 2022 the alliance generated $216 million of product‑sales and royalty revenue – about 0.7 % of total net revenues – and was highlighted as a primary driver of “Other” revenue growth【SBUX_10k_2022.pdf pp. 29‑33】.  In fiscal 2023 the company again stressed the alliance, with product‑sales and royalty revenue rising to roughly $226 million, a modest increase in both absolute dollars and its share of total revenue【SBUX_10k_2023.pdf pp. 4‑8】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR DISCREPANCIES IDENTIFIED: (1) QUANTITATIVE ERRORS - The LLM provides specific revenue figures ($216M in FY2022, $226M in FY2023) that directly contradict the ground truth, which states the Channel Development segment saw a $250 million increase in FY2022 from the Global Coffee Alliance. The LLM's numbers are significantly lower and appear to reference different metrics or be factually incorrect. The ground truth does not provide the specific $216M or $226M figures cited by the LLM. (2) INCOMPLETE SYNTHESIS - The LLM fails to capture the key evolution described in the ground truth: the shift from viewing the alliance 'primarily as a revenue driver' to positioning it as 'a strategic enabler of global product reach and brand extension.' The LLM treats the relationship as consistently important but misses the qualitative shift in strategic emphasis. (3) MISSING CONTEXT - The LLM does not mention the explicit highlighting of the Nestlé licensing relationship as a core channel in FY2023, which is central to understanding the evolved strategic emphasis. (4) CALCULATION VERIFICATION - The LLM's claim that $216M represents '0.7% of total net revenues' cannot be verified against the ground truth and appears to be an unsupported assertion. (5) MULTI-HOP REASONING - While the LLM attempts to compare FY2022 to FY2023, it fails to synthesize the strategic evolution component that is essential to answering the question about how the relationship 'evolved.' The answer reads as a simple year-over-year comparison rather than an analysis of strategic evolution. The LLM provides specific numbers that appear fabricated or sourced incorrectly, contradicting the ground truth's $250M figure for FY2022.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 467,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has NEE's financial stake and involvement in the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's equity method investments totaled $6,159 million, and the Mountain Valley Pipeline was listed among key equity method investees alongside NEP OpCo, Sabal Trail, and Silver State South Solar, with NEE's interest ranging from approximately 32% to 55%. By 2023, NEE's total equity method investments were $6,156 million, with its interest in the principal entities, including the Mountain Valley Pipeline, ranging from approximately 32.8% to 52.6%. The shift from a broader range (32%–55%) in 2022 to a narrower range (32.8%–52.6%) in 2023 suggests a slight adjustment in ownership stakes, potentially reflecting a more refined or strategic investment posture. Additionally, in 2023, the Mountain Valley Pipeline was specifically noted in the context of Nonrecurring Fair Value Measurements, indicating a possible revaluation or change in financial treatment.",
      "llm_answer": "In the 2022 filing NEE disclosed that it recorded a first‑quarter‑2022 impairment that completely wrote off its equity‑method investment in the Mountain Valley Pipeline, effectively ending its financial stake in the project. By the 2023 filing the pipeline still appears among its equity‑method investees, but with an approximately $2.4 billion negative balance that reflects the prior write‑down, indicating NEE has largely withdrawn from the venture while retaining the accounting impact of the loss—an approach that underscores a strategy of cutting exposure to under‑performing, non‑core assets.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth on multiple critical points: (1) MAJOR FACTUAL ERROR - The LLM claims NEE recorded a complete write-off/impairment of its Mountain Valley Pipeline investment in Q1 2022, but the ground truth shows NEE maintained equity method investments totaling $6,159 million in 2022 with the Mountain Valley Pipeline listed as a key investee with 32-55% ownership interest. There is no mention of a complete write-off in the ground truth. (2) QUANTITATIVE INACCURACY - The LLM introduces a '$2.4 billion negative balance' figure that does not appear in the ground truth and appears to be fabricated. The ground truth provides specific ownership percentages (32%-55% in 2022, 32.8%-52.6% in 2023) and total equity method investment amounts ($6,159M in 2022, $6,156M in 2023), none of which match the LLM's narrative. (3) CONTRADICTORY NARRATIVE - The ground truth indicates NEE maintained consistent involvement in the Mountain Valley Pipeline across both years with slight adjustments in ownership stakes, suggesting strategic refinement. The LLM claims NEE 'largely withdrew' from the venture, which directly contradicts the ground truth showing the pipeline remained among principal equity method investees in 2023. (4) MISINTERPRETATION OF FINANCIAL TREATMENT - The LLM mischaracterizes the 2023 mention of 'Nonrecurring Fair Value Measurements' as evidence of withdrawal, when the ground truth simply notes this as a possible revaluation or change in financial treatment, not a write-off. (5) FAILED MULTI-HOP SYNTHESIS - The LLM failed to correctly synthesize the evolution of NEE's stake across 2022-2023, instead fabricating a narrative about impairment and withdrawal that has no basis in the provided ground truth. The answer demonstrates fundamental misunderstanding of the actual financial data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 506,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Medtronic's InterStim Therapy product line evolved between 2022 and 2024 in terms of neurostimulator offerings and therapeutic indications?",
      "original_answer": "In 2022, InterStim therapy was described with a range of neurostimulators including InterStim II, InterStim Micro, and InterStim X, targeting symptoms of overactive bladder, urinary retention, and bowel incontinence. By 2024, the product line continued to include InterStim II and InterStim X, now specifically labeled as 'recharge-free' neurostimulators, and retained its focus on overactive bladder and urinary retention, but expanded its therapeutic scope to include 'chronic fecal incontinence.' This reflects a refinement in product positioning and a broadening of clinical applications over the two-year period.",
      "llm_answer": "In 2022 Medtronic’s InterStim Therapy was anchored by the newly launched InterStim Micro rechargeable neurostimulator (paired with SureScan MRI‑compatible leads) used to treat overactive bladder and urinary retention (and related pelvic‑floor symptoms)【MDT_10k_2022.pdf p.42】【MDT_10k_2022.pdf p.41】. By 2024 the line had expanded to include InterStim II and InterStim X recharge‑free neurostimulators alongside the InterStim Micro, and the therapeutic scope was broadened to explicitly cover chronic fecal (bowel) incontinence in addition to overactive bladder and urinary retention【MDT_10k_2024.pdf p.40】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "ANALYSIS: The LLM answer contains both accurate and problematic elements when compared to the ground truth.\n\nCORRECT ELEMENTS:\n1. Correctly identifies InterStim II and InterStim X as products in the line\n2. Correctly notes these are 'recharge-free' neurostimulators by 2024\n3. Correctly identifies therapeutic indications: overactive bladder, urinary retention, and chronic fecal incontinence\n4. Correctly synthesizes the expansion of therapeutic scope from 2022 to 2024\n5. Appropriately cites 2022 and 2024 10-K filings\n\nPROBLEMATIC ELEMENTS:\n1. FACTUAL ERROR - The LLM states InterStim Micro was \"newly launched\" in 2022 and describes it as a \"rechargeable neurostimulator.\" The ground truth indicates InterStim Micro was present in 2022 but does NOT mention it being newly launched or rechargeable. The ground truth specifically notes that by 2024, InterStim II and InterStim X are labeled as 'recharge-free,' implying InterStim Micro may have different charging characteristics, but this is not explicitly confirmed.\n2. INCOMPLETE PRODUCT EVOLUTION - The LLM states the line \"had expanded to include InterStim II and InterStim X...alongside the InterStim Micro\" by 2024, but the ground truth indicates InterStim Micro was present in 2022 and is NOT mentioned in 2024. This suggests InterStim Micro may have been discontinued or de-emphasized, not carried forward.\n3. CHARACTERIZATION DISCREPANCY - The ground truth describes a \"refinement in product positioning\" with InterStim II and InterStim X becoming specifically labeled as 'recharge-free' by 2024, suggesting a shift away from InterStim Micro. The LLM's framing of \"expansion\" to include these products alongside Micro is misleading.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes information across 2022 and 2024 filings and identifies the therapeutic scope expansion. However, it mischaracterizes the product line evolution by suggesting all three products coexist in 2024 when the ground truth suggests a transition away from InterStim Micro.\n\nNUMERIC/DATE ACCURACY: All years (2022, 2024) are correct. No calculations required.\n\nJUSTIFICATION: The answer demonstrates partial understanding but contains a significant factual error regarding InterStim Micro's status in 2024 and its charging characteristics. The core therapeutic indication expansion is correct, but the product portfolio evolution is misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 642,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Simon Property Group's financial stake and strategic relationship with Authentic Brands Group (ABG) evolve from 2022 to 2024?",
      "original_answer": "In 2022, Simon Property Group held a 1.37% interest in ABG and had merged Forever 21 operations into SPARC Group after increasing its stake to 50% alongside ABG. By 2024, Simon sold a portion of its ABG stake, realizing a pre-tax gain of $18.8 million, and later acquired additional interests in ABG for $100 million in cash, indicating a dynamic evolution in their financial relationship.",
      "llm_answer": "In 2022 Simon owned a non‑controlling interest of about 10 % in Authentic Brands Group (ABG) and was expanding the partnership – it contributed its Forever 21 and Brooks Brothers licensing assets to ABG, bought a 49 % stake in the Eddie Bauer licensing venture, and entered a long‑term strategic agreement to be ABG’s core licensee and operating partner for Reebok in the United States (2022 10‑K, pp. 68‑70). By 2024 Simon had been unwinding that relationship – a partial sale in Q4 2023 reduced its ownership to roughly 9.6 % (and triggered a deemed‑disposal gain), and in Q1 2024 it sold the remaining stake for $1.2 billion, realizing a $414.8 million pretax gain and ending its equity and strategic ties with ABG (2024 10‑K, pp. 73‑75).",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains fundamental factual errors that contradict the ground truth across multiple dimensions:\n\n1. QUANTITATIVE ACCURACY - CRITICAL ERRORS:\n   - LLM claims 2022 ownership was ~10%, but ground truth states 1.37%\n   - LLM claims Q4 2023 partial sale reduced ownership to ~9.6%, but ground truth doesn't mention this figure\n   - LLM claims Q1 2024 sale was for $1.2 billion with $414.8M pretax gain - these numbers are NOT in the ground truth\n   - Ground truth mentions $18.8M gain from partial sale and $100M acquisition, neither of which appear in LLM answer\n   - The $1.2B sale price and $414.8M gain are dramatically different from ground truth figures\n\n2. ENTITY/TRANSACTION ACCURACY:\n   - LLM incorrectly describes 2022 activities (Forever 21/Brooks Brothers licensing contributions, Eddie Bauer 49% stake, Reebok strategic agreement) - ground truth only mentions Forever 21 merger into SPARC Group with 50% stake increase\n   - LLM describes a complete exit by Q1 2024, but ground truth indicates a more nuanced evolution with both a sale (realizing $18.8M gain) AND a subsequent $100M acquisition\n   - The narrative of \"unwinding\" the relationship doesn't match ground truth's description of \"dynamic evolution\"\n\n3. MULTI-HOP REASONING:\n   - LLM failed to correctly synthesize the 2022-2024 evolution\n   - The answer presents a linear unwinding narrative rather than the more complex dynamic relationship described in ground truth\n   - Missing the key detail that Simon both sold AND acquired ABG interests\n\n4. CONTEXTUAL ISSUES:\n   - While the answer addresses the general question about evolution from 2022-2024, the specific facts are largely incorrect\n   - The answer is well-structured and cites specific 10-K pages, but the underlying data appears to be fabricated or from incorrect sources\n   - The magnitude of errors (10% vs 1.37%, $1.2B vs $100M) suggests fundamental misunderstanding or hallucination\n\nThe LLM answer is internally coherent and well-written, but factually incorrect on nearly every quantitative measure and several key qualitative details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 567,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has ConocoPhillips' investment activity in the Lower 48 region evolved from 2021 to 2023, particularly in terms of depreciation, depletion, and amortization expenses?",
      "original_answer": "ConocoPhillips' depreciation, depletion, and amortization (DD&A) expenses in the Lower 48 region increased from $4,067 million in 2021 to $5,729 million in 2023, indicating a significant rise in asset utilization or investment activity. This reflects a growing emphasis on the Lower 48 as a core operational area for the company.",
      "llm_answer": "ConocoPhillips’ depreciation, depletion and amortization (DD&A) expense for its Lower 48 segment has risen each year – $4.067 billion in 2021, $4.854 billion in 2022 and $5.729 billion in 2023 – indicating a steady increase in investment activity in that region【COP_10k_2023.pdf:131-135】.  The growth in DD&A mirrors higher capital‑expenditure outlays for the Lower 48, which climbed from $3.129 billion in 2021 to $5.630 billion in 2022 and $6.487 billion in 2023【COP_10k_2023.pdf:131-135】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Quantitative verification: DD&A figures are correct - $4.067 billion (2021), $4.854 billion (2022), $5.729 billion (2023). The ground truth provides only 2021 ($4,067M) and 2023 ($5,729M) figures, while the LLM adds the 2022 intermediate value ($4.854B), which represents a valuable addition showing the year-by-year progression. The format variation ($4,067M vs $4.067B) is acceptable and correctly converted. Capital expenditure figures provided by LLM ($3.129B in 2021, $5.630B in 2022, $6.487B in 2023) are additional supporting data not in the ground truth but appear to be from the same source document. Multi-hop reasoning is sound: the LLM correctly synthesizes DD&A trends with capital expenditure trends to demonstrate the relationship between investment activity and depreciation expenses. The answer directly addresses the question's focus on how investment activity evolved from 2021-2023, particularly regarding DD&A expenses. The LLM goes beyond the ground truth by providing the 2022 intermediate year and connecting DD&A to capital expenditures, which strengthens the analysis. Minor note: The ground truth uses 'million' while LLM uses 'billion' - both are correct representations of the same values. The citation reference provided adds credibility. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 376,
        "total_tokens": 1587
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Verizon's (VZ) treatment and valuation approach for international bonds evolved from 2023 to 2024 based on their 10-K disclosures?",
      "original_answer": "In 2023, Verizon described that international bonds were valued using matrix prices with input from independent third-party valuation sources as part of the broader fixed income securities category. By 2024, international bonds were specifically itemized in a detailed table with a total value of $12 million, broken down into $10 million in Level 1 and $2 million in Level 2 inputs. This represents a shift from a general description in 2023 to a more transparent and segmented valuation approach in 2024, indicating a more refined disclosure strategy and possibly a more structured approach to valuing international bonds.",
      "llm_answer": "Verizon still classifies international bonds as fixed‑income assets and values them at fair value using market‑based matrix prices with independent third‑party inputs – the same methodology described in both the 2023 and 2024 Form 10‑K disclosures (VZ 10‑K 2023 pp. 91‑95; VZ 10‑K 2024 pp. 93‑97).  What changed was the amount and hierarchy level of the holdings: the pension‑plan international‑bond portfolio dropped from $341 million in 2023 (mostly Level 2 with a $3 million Level 1 component) to $113 million in 2024 (entirely Level 2), while the discount rate used for pension‑liability calculations rose from 5.0% to 5.8% (affecting liability measurement).",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. (1) CRITICAL QUANTITATIVE ERRORS: The LLM claims international bonds were valued at $341 million in 2023 and $113 million in 2024, with specific Level 1/Level 2 breakdowns. However, the ground truth states the 2024 valuation was $12 million total ($10M Level 1, $2M Level 2). This is a massive discrepancy - the LLM's numbers are off by orders of magnitude (341M vs 12M, 113M vs 12M). These are not minor rounding differences but fundamental factual errors. (2) METHODOLOGY ACCURACY: The LLM correctly identifies that both years used matrix prices with third-party inputs, which aligns with the ground truth. However, this correct observation is overshadowed by the incorrect valuation amounts. (3) DISCLOSURE EVOLUTION MISSED: The ground truth emphasizes a key shift from 2023 to 2024 - a move from general description to specific itemization in a detailed table with transparent segmentation. The LLM completely misses this important disclosure evolution and instead focuses on pension plan holdings and discount rates, which are not mentioned in the ground truth answer. (4) MULTI-HOP REASONING: The LLM appears to have synthesized information from different sections of the filings (pension plans, discount rates) but failed to correctly identify the specific international bonds valuation data that the question asks about. The answer addresses pension-plan international bonds rather than the specific international bonds valuation treatment discussed in the ground truth. (5) CONTEXTUAL MISALIGNMENT: The question asks about 'treatment and valuation approach' evolution, which the ground truth correctly identifies as a shift toward more transparent and segmented disclosure. The LLM's focus on pension holdings and discount rates is tangential to the core question about valuation methodology evolution and disclosure transparency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 520,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Emerson's relationship with AspenTech evolve between 2022 and 2024, particularly in terms of financial stake and operational integration?",
      "original_answer": "In 2022, Emerson had a financial stake in AspenTech valued at $8,326 million, as shown in the balance sheet following acquisitions and currency adjustments. By 2024, Emerson's relationship had transformed significantly: it contributed the AspenTech Industrial Software Business along with $6.0 billion in cash to form 'New AspenTech,' retaining a 55% ownership stake in the newly structured company. This indicates a strategic restructuring rather than a simple financial investment, with increased operational integration and a formalized majority ownership.",
      "llm_answer": "In 2022 Emerson created “New AspenTech” by contributing its Open Systems International and Geological Simulation Software businesses and about $6 billion in cash, emerging with a 55 % equity stake that was reported as a separate AspenTech segment (including related goodwill and a $240 million revolving loan on Emerson’s balance sheet). By 2024 Emerson’s ownership had risen to roughly 57 % and it announced a $240‑per‑share cash offer to buy the remaining shares, moving toward full acquisition while AspenTech’s results, financing and hedging activities are now fully consolidated within Emerson’s AspenTech segment.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that fundamentally contradict the ground truth: (1) TIMING ERROR - The LLM states 'In 2022 Emerson created New AspenTech' but the ground truth indicates the 2022 stake was $8,326 million as a financial investment, with the restructuring/contribution to 'New AspenTech' occurring by 2024. The LLM conflates the 2022 and 2024 events. (2) BUSINESS CONTRIBUTION ERROR - The LLM claims Emerson contributed 'Open Systems International and Geological Simulation Software businesses' to form New AspenTech, but the ground truth states it was 'the AspenTech Industrial Software Business' - these are different assets. (3) OWNERSHIP PERCENTAGE ERROR - The LLM claims ownership 'rose to roughly 57%' by 2024, but the ground truth explicitly states it was 55% in 2024. The 57% figure appears fabricated. (4) ACQUISITION CLAIM ERROR - The LLM discusses a '$240-per-share cash offer to buy remaining shares' and 'moving toward full acquisition,' but the ground truth describes a 'strategic restructuring' with 'formalized majority ownership' at 55%, not an acquisition announcement. (5) MISSING KEY FACT - The LLM fails to mention the critical 2022 baseline of $8,326 million valuation, which is essential to understanding the evolution. (6) CONSOLIDATION CLAIM - The LLM states 'AspenTech's results, financing and hedging activities are now fully consolidated,' but the ground truth indicates a 55% ownership stake structure, not full consolidation. The answer demonstrates poor multi-hop synthesis, confusing the 2022 financial stake with the 2024 restructuring, and introducing unsupported claims about acquisition offers and ownership percentages that contradict the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 470,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Starbucks' position in interest rate swaps evolve between 2022 and 2023, particularly in terms of their classification and associated liabilities?",
      "original_answer": "In 2022, Starbucks had an interest rate swap classified as a long-term liability with a value of $34.0 million. By 2023, the company's interest rate swaps were categorized under both current and long-term liabilities, with $0.4 million listed under accrued liabilities (current) and $19.2 million under other long-term liabilities. This reflects a shift in the classification and a net decrease in the overall liability associated with interest rate swaps from $34.0 million in 2022 to $19.6 million in 2023.",
      "llm_answer": "In fiscal 2022 Starbucks reported 1,100 interest‑rate‑swap contracts that were classified as designated derivatives with no asset on the balance sheet and a liability of $34 million in other‑long‑term liabilities plus $12 million in accrued liabilities (about $46 million total)【SBUX_10k_2022.pdf p. 68】. By fiscal 2023 the swap portfolio had fallen to 350 contracts, and the swaps are now shown as a $0.4 million asset and a $41.4 million other‑long‑term liability, with the accrued‑liability component removed – a re‑classification that reduced the overall liability amount【SBUX_10k_2023.pdf p. 73】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant discrepancies with the ground truth across multiple dimensions:\n\n1. FISCAL 2022 NUMBERS - CRITICAL ERRORS:\n   - LLM claims: $34M in other-long-term liabilities + $12M in accrued liabilities = ~$46M total\n   - Ground truth: $34.0M in long-term liability ONLY (no $12M accrued component mentioned)\n   - The LLM incorrectly adds a $12M accrued liability component that doesn't match the ground truth\n   - This is a fundamental misreading of the 2022 position\n\n2. FISCAL 2023 NUMBERS - CRITICAL ERRORS:\n   - LLM claims: $0.4M asset + $41.4M other-long-term liability\n   - Ground truth: $0.4M in accrued liabilities (current) + $19.2M in other long-term liabilities = $19.6M total\n   - The LLM's $41.4M figure is completely incorrect and doesn't match ground truth\n   - The LLM incorrectly characterizes the $0.4M as an asset when it should be current liability\n   - The LLM completely misses the $19.2M long-term liability figure\n\n3. TREND ANALYSIS - INCORRECT:\n   - Ground truth shows: $34.0M (2022) → $19.6M (2023) = net DECREASE of $14.4M\n   - LLM's numbers would suggest: ~$46M (2022) → $41M (2023) = different trend entirely\n   - The LLM's conclusion about \"reduced overall liability amount\" is directionally correct but based on wrong numbers\n\n4. ADDITIONAL DETAILS:\n   - LLM adds information about contract counts (1,100 → 350) not in ground truth, which may be accurate but cannot be verified\n   - LLM correctly identifies the shift from single classification to dual classification (current + long-term)\n   - LLM correctly notes the reclassification aspect\n\n5. CLASSIFICATION ACCURACY:\n   - Ground truth: 2022 = long-term only; 2023 = current + long-term (correct in LLM)\n   - However, the specific liability amounts are fundamentally wrong\n\nThe LLM answer demonstrates understanding of the conceptual shift in classification but fails dramatically on the specific financial figures, which are the core quantitative facts required to answer this question accurately. The $41.4M figure in 2023 is particularly egregious as it's nearly double the correct $19.6M total.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 579,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did NextEra Energy Resources' financial commitment and involvement in the Mountain Valley Pipeline evolve from 2022 to 2023?",
      "original_answer": "In 2022, NextEra Energy Resources recorded an impairment charge of approximately $0.8 billion related to its equity method investment in the Mountain Valley Pipeline, which was fully written off due to the very low probability of pipeline completion. By 2023, despite the ongoing challenges, NEE's subsidiary NEER maintained a 32.8% equity investment in the joint venture and committed to a 20-year natural gas transportation agreement with an annual obligation of approximately $70 million, subject to the completion of construction.",
      "llm_answer": "In the 2022 Form 10‑K, NextEra Energy Resources wrote off its Mountain Valley Pipeline equity investment – eliminating the roughly $0.6 billion carrying amount and recording a $0.2 billion liability for estimated future asset‑retirement‑obligation costs, reflecting a very low probability that the pipeline will be completed【NEE_10k_2022.pdf p. 90‑94】. By the 2023 filing, the company still held a 32.8 % equity stake and disclosed new commitments – including planned equity contributions in 2024 and a 20‑year natural‑gas transportation agreement worth about $70 million per year – that are contingent on the pipeline’s construction, showing continued but conditional involvement【NEE_10k_2023.pdf p. 107‑111】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a significant factual error regarding the 2022 impairment charge. Ground truth states NextEra recorded an impairment charge of approximately $0.8 billion, but the LLM claims a $0.6 billion carrying amount was eliminated with a $0.2 billion liability recorded. This totals only $0.8 billion in combined write-offs/liabilities, but the framing is misleading - the ground truth specifically identifies $0.8 billion as the impairment charge itself, not a split between carrying amount and liability. The LLM's breakdown of $0.6B + $0.2B appears to mischaracterize the nature of the charge. CORRECT ELEMENTS: (1) The 32.8% equity stake in 2023 is accurate; (2) The $70 million annual obligation for the 20-year natural gas transportation agreement is correct; (3) The characterization of low probability of completion in 2022 is accurate; (4) The conditional nature of 2023 commitments is correctly identified. MULTI-HOP REASONING: The answer appropriately synthesizes information across 2022 and 2023 filings and correctly identifies the evolution from write-off to maintained investment with new contingent commitments. However, the quantitative misstatement of the 2022 charge undermines the accuracy of the comparison. MISSING/UNCLEAR ELEMENTS: The LLM mentions 'planned equity contributions in 2024' which is not explicitly stated in the ground truth, suggesting potential over-interpretation or addition of details not confirmed. The ground truth emphasizes the impairment charge as the key 2022 metric, while the LLM's framing of carrying amount + liability is a different accounting presentation that may not accurately reflect what was reported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 466,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has The Coca-Cola Company's investment in equity and debt securities related to its captive insurance company reinsuring group annuity insurance contracts evolved between 2023 and 2024?",
      "original_answer": "In 2023, The Coca-Cola Company reported that its captive insurance company reinsuring group annuity insurance contracts held $1,643 million in equity and debt securities as part of its solvency capital funds. By 2024, this amount increased to $1,883 million, indicating a growth in the company's investment in these securities over the year.",
      "llm_answer": "The captive insurance company’s solvency‑capital portfolio grew in both equity and debt holdings. At year‑end 2023 the captive held $1.643 billion of equity securities and $1.378 billion of debt securities; by year‑end 2024 those amounts had risen to $1.883 billion of equity and $1.643 billion of debt 【KO_10k_2023.pdf†L78-L82】【KO_10k_2024.pdf†L79-L83】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURE: The ground truth states total equity and debt securities were $1,643 million in 2023 and $1,883 million in 2024. However, the LLM breaks this down as: 2023 - $1.643B equity + $1.378B debt = $3.021B total (not $1.643B), and 2024 - $1.883B equity + $1.643B debt = $3.526B total (not $1.883B). These breakdowns are mathematically inconsistent with the ground truth totals. (2) FUNDAMENTAL MISINTERPRETATION: The ground truth refers to combined 'equity and debt securities' totals, not separate equity and debt line items. The LLM appears to have fabricated separate equity and debt breakdowns ($1.378B debt in 2023, $1.643B debt in 2024) that are not supported by the ground truth and create internal mathematical inconsistencies. (3) MULTI-HOP SYNTHESIS FAILURE: While the LLM correctly identifies the 2023 total ($1.643B) and 2024 total ($1.883B) in its equity figures, it then adds unsupported debt figures that contradict the original answer's structure. (4) SEMANTIC MISALIGNMENT: The original answer treats the $1,643M and $1,883M as combined totals for 'equity and debt securities.' The LLM reinterprets these as separate equity amounts and introduces debt amounts that cannot be verified against the ground truth. The answer demonstrates partial understanding (correct year-over-year growth direction and some correct numbers) but fails on factual accuracy due to the introduction of unverified debt security figures that create mathematical inconsistencies with the stated totals.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1184,
        "completion_tokens": 449,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of production status and strategic positioning within Intel's product roadmap?",
      "original_answer": "In 2022, Intel was incurring higher period charges related to the ramp-up of Intel 4, indicating early-stage production challenges and investment. By 2024, Intel 4 had transitioned to high-volume manufacturing in Ireland and became the process node for the high-volume Intel Core Ultra processor, marking its strategic importance in Intel's product roadmap. This evolution shows a shift from initial investment and production ramp-up in 2022 to full-scale production and product integration by 2024.",
      "llm_answer": "In the 2022 filing Intel still classified the Intel 4 node as an early‑ramp‑up technology, noting “higher period charges primarily associated with the ramp up of Intel 4” and no high‑volume production (INTC_10k_2022.pdf p.24). By the 2024 filing Intel reported that Intel 4 had moved to high‑volume manufacturing in Ireland, is already shipping in the Intel Core Ultra client family, and is positioned to represent an increasing share of the company’s processor output and roadmap going forward (INTC_10k_2024.pdf p.10).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness in addressing the multi-hop question about Intel's Intel 4 process node evolution from 2022 to 2024. (1) CORRECTNESS: All factual claims are accurate and well-supported. The 2022 characterization of Intel 4 as early-stage with 'higher period charges primarily associated with the ramp up of Intel 4' and no high-volume production is correct. The 2024 transition to high-volume manufacturing in Ireland and integration into Intel Core Ultra processors is accurately stated. The answer correctly identifies the strategic shift from investment/ramp-up to full-scale production. (2) QUANTITATIVE ACCURACY: No specific numbers or calculations are required for this qualitative question, but the answer appropriately avoids making unsupported numerical claims. The temporal progression (2022 to 2024) is correctly maintained. (3) MULTI-HOP REASONING: The answer successfully synthesizes information across two different filing years (2022 and 2024) and correctly identifies the evolution trajectory. It properly connects production status changes to strategic positioning within the product roadmap, demonstrating sound multi-hop synthesis. (4) ENTITY ACCURACY: Intel and Intel 4 are correctly identified; the Intel Core Ultra processor is correctly named; Ireland is correctly identified as the manufacturing location; the fiscal years 2022 and 2024 are correct. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same essential information as the ground truth, using slightly more specific details (citing page numbers, mentioning Ireland explicitly, noting Core Ultra family). The wording differs but the meaning is semantically equivalent and actually more detailed. Minor note: The answer includes specific document citations (page numbers) which adds credibility but goes slightly beyond the ground truth level of detail—this is a positive enhancement rather than an error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 524,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Emerson's strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial integration?",
      "original_answer": "In 2022, AspenTech was described as a strategic partner of Emerson, with no mention of ownership stakes or integration into Emerson's financials. By 2024, Emerson had merged its industrial software business with AspenTech, creating 'New AspenTech,' and retained a 55% ownership stake in the newly formed entity. This marked a significant shift from a partnership to a partially owned subsidiary structure. Additionally, AspenTech's financials were now integrated into Emerson's results, with the acquisition positively impacting gross margins by 0.6 percentage points in 2023 and influencing SG&A expenses in 2024 due to the deeper integration.",
      "llm_answer": "In 2022 Emerson contributed two of its own industrial‑software businesses and roughly $6 billion in cash to create a new AspenTech, emerging as a 55 % owner of the stand‑alone software company【EMR_10k_2022.pdf p9】. By 2024 Emerson’s stake had risen to about 57 % and it announced a $240‑per‑share cash offer to acquire the remaining shares, moving the partnership toward full ownership and fully consolidating AspenTech’s software and control revenues (which added ~3 % of sales in 2023 and drove a 48 % jump in the Software & Control segment in 2024)【EMR_10k_2024.pdf p24‑p27】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant inaccuracies that contradict the ground truth. (1) OWNERSHIP STRUCTURE ERROR: The LLM claims Emerson had a 55% stake in 2022 and 57% by 2024, but the ground truth explicitly states 'In 2022, AspenTech was described as a strategic partner of Emerson, with no mention of ownership stakes.' The 55% ownership was achieved in 2024 after the merger, not in 2022. (2) TIMELINE CONFUSION: The LLM conflates the 2022 partnership with the 2024 merger structure. In 2022, Emerson contributed businesses and cash to create 'New AspenTech' as a strategic partnership, not as a 55% ownership stake. The 55% ownership structure only emerged by 2024 after the formal merger. (3) FINANCIAL INTEGRATION DETAILS: The LLM mentions a $240-per-share acquisition offer and a 48% jump in Software & Control segment, but the ground truth focuses on gross margin impact (0.6 percentage points in 2023) and SG&A expense impacts in 2024. The LLM's specific metrics don't align with the ground truth's stated financial impacts. (4) CASH CONTRIBUTION: The LLM mentions '$6 billion in cash' which is not mentioned in the ground truth and cannot be verified. (5) MULTI-HOP REASONING: While the LLM attempts to show evolution from 2022 to 2024, it fundamentally mischaracterizes the 2022 relationship as already involving ownership when it was purely a partnership. The correct evolution should show: 2022 (partnership, no ownership) → 2024 (55% ownership, financial integration). The LLM reverses this logic by claiming ownership existed in 2022. The answer demonstrates poor synthesis of the multi-hop information across years and misses the critical distinction between the partnership phase and the ownership/integration phase.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 478,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of its manufacturing readiness and performance improvements?",
      "original_answer": "In 2022, Intel 4 was newly introduced as part of a restructured naming convention for manufacturing process nodes, signaling its position as a next-generation node following Intel 7. By 2024, Intel 4 had transitioned from a conceptual roadmap item to a fully realized product, with high-volume manufacturing ramped up in Ireland. Intel 4, as the company's first EUV lithography node, delivered a 20% performance-per-watt improvement over Intel 7 and was used in the production of the Intel Core Ultra processor, which began shipping in 2023. This represents a significant evolution from its initial naming in 2022 to full-scale production and performance quantification by 2024.",
      "llm_answer": "In the 2022 filing Intel only announced “Intel 4” as a new EUV‑based node in its renamed process‑node roadmap (see the naming‑change table on page 113), indicating it was still in development. By the 2024 filing Intel reported that Intel 4 had moved to high‑volume manufacturing in Ireland, powered the first high‑volume client product (the Core Ultra series) and delivers roughly a 20% performance‑per‑watt improvement over Intel 7 (see pages 8‑12), showing the node’s transition from a planned roadmap item to a production‑ready, performance‑enhancing technology.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: All numeric values are correct - the 20% performance-per-watt improvement over Intel 7 is accurately stated, and the timeline progression (2022 announcement to 2024 production) is correct. No calculation errors or numeric discrepancies. ENTITY ACCURACY: All entities correctly identified - Intel, Intel 4 process node, Intel 7, Core Ultra processor, Ireland manufacturing facility, and EUV lithography technology are all properly referenced. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple filing years (2022 vs 2024) and correctly traces the evolution from conceptual roadmap item to production reality. The connection between the naming convention change, EUV technology introduction, manufacturing readiness, and performance metrics is logically sound. COMPLETENESS: The answer addresses both key aspects of the question - manufacturing readiness (development → high-volume manufacturing in Ireland) and performance improvements (20% per-watt gain). The mention of Core Ultra as the first high-volume client product adds appropriate context. SEMANTIC EQUIVALENCE: The LLM's phrasing ('moved to high-volume manufacturing,' 'production-ready, performance-enhancing technology') conveys the same meaning as the ground truth ('transitioned from a conceptual roadmap item to a fully realized product'). Minor differences in wording are stylistic and do not affect accuracy. MINOR OBSERVATION: The LLM includes specific page references (pages 113, 8-12) which adds credibility and traceability but is not contradicted by the ground truth. The answer is comprehensive, accurate, and well-structured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 476,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has the role and positioning of InterStim Micro evolved within MDT's Pelvic Health therapies between 2022 and 2024?",
      "original_answer": "In 2022, InterStim Micro was listed as one of several neurostimulators within MDT's Pelvic Health product portfolio, which also included InterStim X and InterStim II, used to treat overactive bladder, urinary retention, and fecal incontinence. By 2024, InterStim Micro was specifically highlighted as the rechargeable neurostimulator option, differentiated from the recharge-free InterStim X and InterStim II. This indicates a more defined strategic positioning of InterStim Micro as the rechargeable variant within the broader InterStim therapy lineup, with an emphasis on its continued global growth and adoption.",
      "llm_answer": "In the 2022 Form 10‑K the InterStim Micro is listed simply as one of the Pelvic‑Health neurostimulators (alongside InterStim X and InterStim II) used to treat overactive bladder, non‑obstructive urinary retention and chronic fecal incontinence【2022 p.9】. By the 2024 filing, InterStim Micro is highlighted as the **rechargeable** neurostimulator within the InterStim therapy suite, positioned next to the recharge‑free InterStim X and InterStim II and emphasized for its continued acceptance and growth in the Pelvic‑Health market【2024 p.40】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. CORRECTNESS: The answer accurately captures the evolution of InterStim Micro's positioning from 2022 to 2024, correctly identifying it as one of several neurostimulators in 2022 and highlighting its specific differentiation as the rechargeable option by 2024. The key distinction between rechargeable (InterStim Micro) and recharge-free (InterStim X and InterStim II) variants is accurately conveyed. QUANTITATIVE ACCURACY: No numerical data is required for this question, but the answer correctly references the appropriate filing years (2022 and 2024) and cites specific page numbers (2022 p.9 and 2024 p.40), demonstrating proper source attribution. QUALITATIVE ACCURACY: The multi-hop reasoning is sound - the answer synthesizes information across two different filing years to show the evolution of product positioning. The characterization of InterStim Micro's role shift from generic listing to strategic differentiation as the rechargeable variant is accurate and well-reasoned. The mention of 'continued acceptance and growth' aligns with the ground truth's emphasis on 'continued global growth and adoption.' CONTEXTUAL RELEVANCE: The answer directly addresses the question about how InterStim Micro's role and positioning evolved, providing clear before-and-after comparison. Minor note: The LLM uses bold formatting for 'rechargeable' which adds emphasis but is stylistic rather than substantive. The answer is comprehensive, accurate, and properly synthesizes multi-hop information from multiple filing years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 442,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the disclosure around the dilutive effect of LTIP Units evolved from 2022 to 2024, particularly in terms of material impact across reporting periods?",
      "original_answer": "In 2022, the disclosure stated that LTIP units were exchangeable for common stock and that no securities had a material dilutive effect for the years ended December 31, 2021, 2020, and 2019. By 2024, the disclosure simplified to state that no securities had a material dilutive effect for the years ended December 31, 2024, 2023, and 2022, without explicitly referencing the exchangeability of LTIP units into common stock. This indicates a reduction in the level of detail provided about LTIP units' conversion features, while maintaining the same conclusion regarding dilution impact.",
      "llm_answer": "The 2022 10‑K’s per‑share/unit note listed LTIP units as “potentially dilutive securities” but said that “no securities had a material dilutive effect for the years ended December 31 2021, 2020 and 2019.” The 2024 10‑K repeats the same language—identifying LTIP units as potentially dilutive and stating that “no securities had a material dilutive effect for the years ended December 31 2024, 2023 and 2022.” Thus, the disclosure was merely updated to cover the newer fiscal years; the conclusion that LTIP units have not produced a material dilutive impact remains unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies the years covered in both 2022 and 2024 disclosures (2021/2020/2019 vs 2024/2023/2022) and accurately states that both years concluded no securities had material dilutive effects. However, there is a critical discrepancy in characterizing the evolution of disclosure. The ground truth explicitly states that the 2024 disclosure SIMPLIFIED and REDUCED the level of detail by no longer explicitly referencing the exchangeability of LTIP units into common stock. The LLM answer contradicts this by claiming the 2024 disclosure 'repeats the same language' and identifies LTIP units as 'potentially dilutive securities,' which misses the key point about the reduction in detail. The LLM characterizes the change as merely 'updated to cover newer fiscal years' rather than acknowledging the actual simplification in disclosure content. This represents a failure to properly synthesize the multi-hop comparison between 2022 and 2024 disclosures. The quantitative elements (years and conclusion about no material dilution) are correct, but the qualitative assessment of how the disclosure evolved is fundamentally incorrect. The answer addresses the question but reaches an inaccurate conclusion about the nature of the disclosure evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 356,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has MetLife's approach to managing cash buffer needs in relation to stock repurchases evolved from 2022 to 2024, particularly in terms of remaining repurchase authorization and liquidity considerations?",
      "original_answer": "In 2022, MetLife had $1.5 billion remaining under its $3.0 billion common stock repurchase authorization as of December 31, 2021, indicating a significant but partially utilized capacity for returning capital to shareholders. By 2024, the company emphasized increased caution around cash buffer needs, noting that maintaining or increasing liquidity buffers could limit capital available for repurchases, acquisitions, and innovation. This reflects a shift from a more active repurchase posture in 2022 to a more conservative liquidity strategy in 2024, influenced by regulatory, market, and internal capital considerations.",
      "llm_answer": "MetLife’s 2022 10‑K disclosed that after authorizing a $3 billion share‑repurchase program, $1.5 billion was still available at year‑end and the company stressed that it “maintains a buffer of cash and other liquid assets, and may increase it,” which could limit buy‑backs【MET_10k_2022.pdf†L48-L52】. By the 2024 filing the remaining authorization had been trimmed to roughly $0.6 billion of the authorized amount and the company again emphasized preserving liquidity and the ability to raise its cash buffer, signalling a more cautious, liquidity‑driven stance toward repurchases【MET_10k_2024.pdf†L31-L35】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about MetLife's evolving approach to cash buffers and stock repurchases from 2022 to 2024. STRENGTHS: (1) Correctly identifies the $3 billion authorization program and $1.5 billion remaining in 2022, matching ground truth exactly. (2) Accurately captures the shift to a more conservative stance by 2024, with remaining authorization reduced to approximately $0.6 billion. (3) Properly synthesizes the key insight that MetLife emphasized maintaining/increasing liquidity buffers as a constraint on repurchases in both years, showing the evolution from more active to more cautious posture. (4) Correctly identifies the regulatory, market, and internal capital considerations driving this shift. (5) Appropriately uses citations to support claims. MINOR WEAKNESSES: (1) The phrase 'roughly $0.6 billion' introduces slight imprecision - while this appears to be accurate based on the 2024 filing reference, the ground truth doesn't explicitly state this figure, so verification is limited. (2) The answer could have been slightly more explicit about the percentage of authorization utilized (50% in 2022 vs. approximately 80% by 2024), though this is a minor omission. (3) The answer doesn't explicitly mention 'December 31, 2021' as the reference date for the 2022 disclosure, though this is a minor contextual detail. QUANTITATIVE VERIFICATION: $3B authorization - correct; $1.5B remaining in 2022 - correct; ~$0.6B remaining in 2024 - appears correct based on filing references; the math (3B - 1.5B = 1.5B used by 2022; 3B - 0.6B = 2.4B used by 2024) is logically sound. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and two different 10-K filings, correctly identifying the evolution in strategy and the underlying drivers. The comparison between 2022 and 2024 positions is clear and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 524,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions evolve from fiscal year 2022 to 2023, and what specific changes occurred in their balance sheet classifications?",
      "original_answer": "In fiscal year 2022, Starbucks reported foreign currency - other derivative assets of $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings. By fiscal year 2023, the foreign currency - other derivative assets on the balance sheet were reported as $1.9 million in prepaid expenses and other current assets and $1.7 million in other long-term assets as of October 1, 2023, while derivative liabilities were $4.7 million in accrued liabilities and $4.1 million in other long-term liabilities. This represents a significant reduction in asset positions compared to the prior year, with a shift in balance sheet classification.",
      "llm_answer": "Starbucks’ designated “foreign‑currency‑other” derivative assets fell from $39.9 million in prepaid/other current assets and $33.5 million in other long‑term assets (total ≈ $73.4 million) at FY 2022‑10‑02 to $32.0 million and $22.9 million respectively (total ≈ $54.9 million) at FY 2023‑10‑01【SBUX_10k_2022.pdf page 68‑69】【SBUX_10k_2023.pdf page 73‑74】. The related liability rose from $0.3 million in accrued liabilities in FY 2022 to $2.0 million in accrued liabilities in FY 2023, with no long‑term liability component in either year【SBUX_10k_2022.pdf page 68‑69】【SBUX_10k_2023.pdf page 73‑74】. The balance‑sheet classification stayed the same—assets split between prepaid/current assets and other long‑term assets, and liabilities recorded as accrued liabilities—though the amounts in each category declined for assets and increased for liabilities.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains fundamentally incorrect financial data that does not match the ground truth. Critical issues: (1) QUANTITATIVE ERRORS - The LLM reports FY2022 foreign currency derivative assets of $39.9M (current) + $33.5M (long-term) = $73.4M total, but the ground truth shows $103.9M in OCI before reclassifications. The FY2023 figures are also wrong: LLM states $32.0M current + $22.9M long-term, but ground truth shows only $1.9M current + $1.7M long-term. This is a massive discrepancy (LLM reports ~$54.9M vs. ground truth ~$3.6M). (2) LIABILITY MISSTATEMENT - LLM claims FY2023 liabilities were only $2.0M in accrued liabilities with no long-term component, but ground truth clearly shows $4.7M in accrued liabilities AND $4.1M in other long-term liabilities (total $8.8M). The LLM completely missed the long-term liability position. (3) TREND ANALYSIS ERROR - LLM claims assets 'declined' from FY2022 to FY2023, which is directionally correct but based on wrong numbers. The actual decline is far more dramatic than LLM suggests (from ~$103.9M to ~$3.6M). (4) MISSING KEY CONTEXT - Ground truth mentions $22.0M reclassified from AOCI to earnings in FY2022, which LLM completely omits. (5) BALANCE SHEET CLASSIFICATION - While LLM correctly identifies that assets are split between current and long-term, and liabilities exist in accrued liabilities, the statement that there was 'no long-term liability component in either year' is factually incorrect for FY2023. The LLM appears to have referenced incorrect pages or misread the financial statements entirely. The numbers provided do not reconcile with standard Starbucks 10-K disclosures for derivative positions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 459,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Procter & Gamble's global cash management strategy evolved in relation to its restructuring activities and corporate-level financial performance between fiscal 2022 and fiscal 2024?",
      "original_answer": "In fiscal 2022, Procter & Gamble incurred restructuring costs within its historical range of $250 to $500 million before tax, with $147 million in restructuring accruals as of June 30, 2022. Corporate net earnings improved by $872 million to $485 million, partly due to tax benefits and lower restructuring charges. By fiscal 2024, restructuring costs increased significantly to $659 million before tax, including $216 million in non-cash foreign currency translation losses. Corporate net earnings decreased by $1.0 billion, largely due to the $1.4 billion impairment charge of the Gillette intangible asset and incremental restructuring charges. This indicates a shift toward more aggressive restructuring actions, particularly in Enterprise Markets like Nigeria, which impacted both cash flow and earnings. The global cash management strategy remained focused on liquidity and tax considerations, but faced increased pressure from these restructuring activities and impairment charges.",
      "llm_answer": "Between fiscal 2022 and fiscal 2024 Procter & Gamble kept the same overarching cash‑management framework—using operating cash flow first to fund dividends, share‑repurchases, acquisitions and, when needed, debt—while the scale of cash generation rose from $16.7 billion in 2022 to $19.8 billion in 2024, giving a larger cash buffer (foreign‑subsidiary cash grew from $5.8 billion to $6.1 billion). At the same time, restructuring outlays grew markedly, from a $250‑$500 million annual spend (≈65 % cash‑settled) in 2022 to $659 million in 2024 (≈64 % cash‑settled) as the company liquidated operations in markets such as Nigeria, and corporate earnings swung from a $485 million profit in 2022 to a $1.43 billion loss in 2024 due to an intangible‑asset impairment and higher restructuring charges. The stronger cash position allowed the firm to absorb the larger restructuring costs and corporate loss while still sustaining its dividend and share‑repurchase program and preserving liquidity.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with excellent multi-hop synthesis and contextual relevance. STRENGTHS: (1) Correctly identifies the core evolution of P&G's cash management strategy between fiscal 2022-2024, showing both continuity in framework and changes in scale. (2) Accurately cites operating cash flow figures ($16.7B in 2022 to $19.8B in 2024) and foreign subsidiary cash ($5.8B to $6.1B). (3) Correctly states restructuring costs increased to $659 million in 2024 and provides cash-settlement percentages (≈65% and ≈64%). (4) Accurately identifies the corporate earnings swing from $485 million profit in 2022 to a loss in 2024, attributing it to the Gillette intangible asset impairment and restructuring charges. (5) Properly synthesizes the relationship between improved cash generation, increased restructuring costs, and the company's ability to maintain dividends and share repurchases. (6) Correctly mentions Nigeria as a specific market impacted by restructuring. MINOR ISSUES: (1) The LLM states corporate earnings swung to a '$1.43 billion loss' in 2024, while the ground truth indicates a '$1.0 billion decrease' in corporate net earnings with a '$1.4 billion impairment charge' being a component. The phrasing could be interpreted as conflating the impairment charge with the total loss, though the magnitude is approximately correct. (2) The ground truth mentions '$147 million in restructuring accruals as of June 30, 2022' which the LLM does not explicitly address, though this is a minor detail. (3) The ground truth notes '$216 million in non-cash foreign currency translation losses' in 2024 restructuring costs, which the LLM does not mention. MULTI-HOP REASONING: Excellent synthesis connecting cash flow generation, restructuring activities, corporate earnings impacts, and strategic implications across the two-year period. The answer correctly identifies how improved cash position enabled the company to absorb larger restructuring costs while maintaining shareholder returns. Overall, the answer is substantively correct with strong analytical framework, though missing some specific line-item details from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1505,
        "completion_tokens": 583,
        "total_tokens": 2089
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has NVIDIA's positioning and application of Omniverse evolved between 2022 and 2023, particularly in terms of its integration with enterprise solutions and simulation technologies?",
      "original_answer": "In 2022, NVIDIA Omniverse was positioned primarily as a virtual world simulation and collaboration platform for 3D workflows, emphasizing its availability as a software subscription for enterprise use and free for individuals. It was highlighted in use cases such as virtual car showrooms, surgical training, and architectural walkthroughs, and was integrated with DRIVE Sim software for automotive simulation and validation. By 2023, Omniverse had evolved into a more robust development platform and operating system for building virtual world simulation applications. It was increasingly tied to industrial enterprises for digitalizing complex physical assets and processes, including digital twins of factories and real-time 3D product configurators. Additionally, it was more explicitly linked to NVIDIA's accelerated computing infrastructure both on-premises and in the cloud, indicating a broader integration with enterprise-grade simulation and AI workflows.",
      "llm_answer": "In the 2022 filing NVIDIA presented Omniverse as a subscription‑based virtual‑world simulation and collaboration platform for 3‑D workflows, noting its early enterprise deployments in virtual car showrooms, surgical‑training, architectural walkthroughs and digital‑twin simulations of factories and autonomous robots. By the 2023 filing the company had re‑branded it as “Omniverse Enterprise,” positioning it as an enterprise‑grade suite that underpins the metaverse and 3‑D internet, tightly integrated with NVIDIA’s cloud (vGPU) and AI‑accelerated infrastructure and promoted as a core tool for large‑scale simulation, digital‑twin and cross‑industry digitalization.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of NVIDIA's Omniverse evolution between 2022 and 2023, with mostly accurate characterization of the platform's positioning. STRENGTHS: (1) Correctly identifies 2022 positioning as subscription-based virtual-world simulation and collaboration platform for 3D workflows; (2) Accurately notes early enterprise use cases (virtual car showrooms, surgical training, architectural walkthroughs, digital twins); (3) Correctly captures 2023 evolution toward enterprise-grade positioning with 'Omniverse Enterprise' branding; (4) Properly identifies integration with cloud infrastructure (vGPU) and AI acceleration; (5) Accurately reflects shift toward industrial digitalization and digital twins. WEAKNESSES: (1) The LLM mentions 'digital-twin simulations of factories and autonomous robots' in 2022, but the ground truth indicates these were primarily 2023 developments - this represents a minor chronological misplacement; (2) The LLM introduces 'Omniverse Enterprise' branding as a 2023 development, which is accurate, but the ground truth doesn't explicitly confirm this specific branding terminology in the filings; (3) Missing explicit mention of DRIVE Sim integration noted in ground truth for 2022; (4) The phrase 'underpins the metaverse and 3D internet' in the LLM answer is not explicitly confirmed in the ground truth, which focuses more on industrial/enterprise applications. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and multiple application domains (automotive, healthcare, architecture, manufacturing), demonstrating proper multi-hop synthesis. The comparison between 2022 and 2023 positioning is logically sound and addresses the evolution question. No numerical calculations were required, so quantitative accuracy is based on factual correctness of dates and entity names, which are accurate. The semantic meaning aligns well with the ground truth despite some minor wording differences and one chronological imprecision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 544,
        "total_tokens": 1962
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did AMT's financial commitments related to communications sites evolve from 2023 to 2024, particularly in terms of anticipated spending and future obligations?",
      "original_answer": "In 2023, AMT anticipated spending approximately $450 million related to data center assets as part of its construction plans for 2,500 to 3,500 communications sites globally. By 2024, the company disclosed a much larger financial commitment, with an estimated undiscounted future cash outlay of $4.5 billion for asset retirement obligations tied to leased sites hosting communications infrastructure. This indicates a significant increase in long-term financial exposure related to communications sites, shifting from near-term capital allocation planning in 2023 to a more mature and substantial obligation structure in 2024.",
      "llm_answer": "In 2023 AMT’s discretionary capital projects were $849.3 million, which included the construction of 3,198 communications sites worldwide [49]. For 2024 the company now expects to spend $790‑$820 million on discretionary projects—supporting the build‑out of roughly 2,500‑3,500 sites (and about $450 million of data‑center spend) [54]—and it reports future operating‑lease obligations of $986.9 million in 2025 (decreasing to $924.9 million in 2026, etc.) that reflect ongoing commitments for its communications‑site portfolio [58].",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and fails to address the core question about the evolution of AMT's financial commitments from 2023 to 2024. Critical issues: (1) WRONG NUMBERS: The LLM cites $849.3M for 2023 discretionary capital projects and $790-$820M for 2024, but the ground truth specifies $450M in anticipated spending for data center assets in 2023. The LLM's numbers appear to reference different metrics (total discretionary projects vs. data center specific spending). (2) MISSING KEY METRIC: The ground truth's central finding is the $4.5 billion undiscounted future cash outlay for asset retirement obligations in 2024—a massive and material commitment that the LLM completely omits. This is the most important evolution from 2023 to 2024. (3) WRONG OBLIGATION FIGURES: The LLM mentions $986.9M in 2025 operating-lease obligations, but this does not match the $4.5B asset retirement obligation figure that represents the key evolution. These appear to be different obligation types, and the LLM conflates them. (4) INCOMPLETE SYNTHESIS: The question asks about evolution from 2023 to 2024 in anticipated spending and future obligations. The LLM provides some 2023-2024 capex comparison but completely misses the dramatic shift from $450M near-term capex planning to $4.5B long-term retirement obligations—the core narrative of the ground truth. (5) CONTEXTUAL MISALIGNMENT: The ground truth emphasizes a shift from 'near-term capital allocation planning' to 'mature and substantial obligation structure,' but the LLM's answer focuses on discretionary capex trends rather than the fundamental change in obligation structure. The LLM answer is partially responsive but fundamentally incorrect on the key metrics and fails to capture the material evolution in financial commitments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 491,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has ExxonMobil's characterization of asset divestitures in relation to strategic objectives evolved between 2023 and 2024, particularly in terms of the language used to describe the proceeds from these transactions?",
      "original_answer": "In 2023, ExxonMobil described proceeds from asset sales as part of 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments,' emphasizing a disciplined review process to ensure assets align with strategic goals. By 2024, the company refined its language, referring more broadly to 'proceeds from asset sales and returns of investments,' maintaining the same strategic alignment rationale but streamlining the description. This evolution indicates a more consolidated framing of divestiture proceeds without specific mention of subsidiaries or equipment sales, suggesting a possible shift toward a more generalized narrative around asset management.",
      "llm_answer": "In the 2023 filing ExxonMobil said that cash‑flow‑from‑operations‑and‑asset‑sales includes “proceeds associated with sales of subsidiaries, property, plant and equipment, and sales and returns of investments,” noting that assets are divested when they no longer meet the corporation’s strategic objectives. By the 2024 filing the language had been streamlined to “proceeds from asset sales and returns of investments,” still emphasizing that divestitures occur when assets no longer serve strategic goals, but using a broader, less‑granular description of the proceeds. This shift reflects a move toward a more concise characterization of divestiture proceeds while retaining the strategic‑objective framing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing the evolution of ExxonMobil's language regarding asset divestitures between 2023 and 2024. (1) CORRECTNESS: The answer correctly identifies the 2023 language as 'proceeds associated with sales of subsidiaries, property, plant and equipment, and sales and returns of investments' and the 2024 language as 'proceeds from asset sales and returns of investments.' Both the original answer and LLM answer convey the same core finding: a shift from granular to consolidated framing. (2) QUANTITATIVE ACCURACY: No numeric values are involved in this question, so this dimension is not applicable. The dates (2023 vs 2024) are correctly referenced. (3) QUALITATIVE ACCURACY: The LLM answer accurately synthesizes the multi-hop comparison across two years and correctly identifies the strategic objective framing as consistent across both periods. The reasoning that this represents 'a move toward a more concise characterization' while 'retaining the strategic-objective framing' is sound and matches the ground truth's interpretation. (4) ENTITY ACCURACY: ExxonMobil is correctly identified, and the fiscal years are properly referenced. (5) SEMANTIC EQUIVALENCE: The LLM answer uses slightly different phrasing than the original (e.g., 'streamlined' vs 'refined,' 'less-granular' vs 'more consolidated') but conveys the same essential meaning. The LLM adds a minor contextual detail about 'cash-flow-from-operations-and-asset-sales' which provides helpful context without contradicting the ground truth. The answer fully addresses the question's focus on language evolution and strategic objective alignment. Minor deduction only for the addition of 'cash-flow-from-operations-and-asset-sales' terminology which, while not incorrect, wasn't explicitly mentioned in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 498,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2023, based on the changes in consolidated asset and liability amounts?",
      "original_answer": "In 2022, Comcast's consolidated balance sheet included $9.7 billion in assets and $8.1 billion in liabilities related to Universal Beijing Resort. By 2023, these figures had decreased to $7.8 billion in assets and $7.2 billion in liabilities. This indicates a reduction in both the scale of assets and liabilities associated with the Universal Beijing Resort, suggesting either asset depreciation, debt repayment, or a strategic reduction in the resort's financial footprint within Comcast's consolidated statements.",
      "llm_answer": "Comcast’s consolidated exposure to Universal Beijing Resort has slipped modestly.  The balance‑sheet assets tied to the resort fell from about $8.6 billion in 2022 to $7.8 billion in 2023, while the related liabilities dropped from roughly $7.8 billion to $7.2 billion over the same period, indicating a reduction in both the asset base and the liability obligations【CMCSA_10k_2022.pdf p. 106】【CMCSA_10k_2023.pdf p. 85】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains significant factual errors in the asset figures. Ground truth states 2022 assets were $9.7 billion, but LLM reports $8.6 billion - a $1.1 billion discrepancy (11% error). The 2023 asset figure of $7.8 billion is correct. For liabilities, the LLM reports 2022 at $7.8 billion (correct per ground truth) and 2023 at $7.2 billion (correct). The LLM got 2 of 4 key numbers wrong. REASONING QUALITY: The qualitative interpretation is sound - the LLM correctly identifies the trend of reduction in both assets and liabilities, and appropriately characterizes this as a reduction in financial exposure. The multi-hop synthesis across 2022 and 2023 filings is logically structured. COMPLETENESS: The answer addresses the core question about how exposure evolved from 2022 to 2023, with year-over-year comparison. ENTITY ACCURACY: Correctly identifies Comcast and Universal Beijing Resort, proper fiscal years. MAJOR ISSUE: The 2022 asset figure error ($8.6B vs $9.7B) is a material factual mistake that undermines the credibility of the answer, even though the directional analysis and 2023 figures are accurate. This is not a minor formatting difference but a substantive numerical error that would mislead readers about the magnitude of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 364,
        "total_tokens": 1600
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the nature of Customer Demand Volatility as a risk factor for Caterpillar evolved between 2023 and 2024, particularly in relation to its impact on financial performance and supply chain stability?",
      "original_answer": "In 2023, Customer Demand Volatility was described as being primarily driven by economic uncertainties, including the lingering effects of a global pandemic, which led to inflationary pressures, supply chain disruptions, and labor inefficiencies, all of which limited Caterpillar's ability to meet customer demand. By 2024, while the risk remained, the focus shifted slightly to include broader commodity price changes, material price increases, and significant disruptions to supply chains or shortages of labor and material as key contributors to financial performance risks. This evolution indicates a broadening of the risk profile to include more systemic supply-side challenges alongside demand volatility.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K risk‑factor sections describe “customer‑demand volatility” in essentially the same way – as a source of revenue, earnings and cash‑flow uncertainty that can trigger excess inventories, higher operating costs and pressure on profitability, and that can also disrupt the supply chain (e.g., “lead volatility in customer demand…and cause supply‑chain disruptions” and “when demand … is less than we expect, we may experience excess inventories and our profitability may suffer”)【CAT_10k_2023.pdf pp. 11‑15】【CAT_10k_2024.pdf pp. 11‑15】. The 2024 filing does not materially change the framing of the risk; it reiterates the same concerns about financial performance and supply‑chain stability.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IN CORE ANALYSIS: The LLM answer fundamentally contradicts the ground truth on the key question. The ground truth explicitly states that the risk profile EVOLVED between 2023 and 2024, with a SHIFT in focus from pandemic-driven economic uncertainties to broader commodity price changes, material price increases, and systemic supply-side challenges. The LLM answer incorrectly claims the 2024 filing 'does not materially change the framing of the risk' and that it 'reiterates the same concerns' - this is factually wrong according to the knowledge graph. The LLM failed to identify the evolution/shift that is central to the question. QUANTITATIVE ACCURACY: The LLM correctly identifies the years (2023, 2024) and company (Caterpillar). No specific numbers are provided in either answer, so no calculation errors exist. QUALITATIVE ACCURACY: The LLM correctly identifies that both years discuss customer demand volatility's impact on revenue, earnings, cash flow, excess inventories, operating costs, and supply chain disruptions. However, it completely misses the critical distinction: the NATURE of the risk evolved. The 2023 focus was on pandemic/economic uncertainty effects, while 2024 broadened to include commodity prices, material costs, and systemic supply-side challenges. This is a fundamental failure in multi-hop reasoning and synthesis. CONTEXTUAL RELEVANCE: The question specifically asks HOW the nature of the risk 'evolved' - implying change. The LLM's conclusion that there was no material change directly contradicts the ground truth and fails to address the core question. The answer is contextually misaligned with what the question seeks to understand.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 461,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value and valuation methodology of Net derivative assets (liabilities) evolve from 2022 to 2024?",
      "original_answer": "In 2022, the fair value of Net derivative assets (liabilities) was $19 million as of December 31, 2021, with changes in value primarily tied to derivative activity such as issuances ($68 million), settlements ($-37 million), and transfers ($6 million). By 2024, the fair value had increased significantly to $58 million as of December 31, 2023. Additionally, the valuation methodology shifted from being primarily based on realized and unrealized gains/losses reported in net income to being assessed using discounted cash flows with a focus on observable inputs like swap rates (3-5%, weighted average of 4%). This indicates both a material increase in value and a methodological shift toward more transparent and observable valuation techniques.",
      "llm_answer": "The fair‑value balance of net derivative assets (liabilities) grew sharply, from $19 million at year‑end 2022 to $58 million at year‑end 2023 and to $69 million at year‑end 2024. The valuation approach remained a discounted‑cash‑flow model that relies on swap‑rate assumptions as the key unobservable input, but the assumed swap‑rate range widened—from 1‑2% (weighted‑average ≈ 1%) in 2022, to 3‑5% (average ≈ 4%) in 2023, and was centered at 4% in 2024—and the 2024 filing notes that the new Level‑3 positions were primarily term SOFR‑indexed interest‑rate derivatives.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) QUANTITATIVE ERRORS - The LLM introduces a $69 million figure for year-end 2024 that is NOT in the ground truth. The ground truth only provides data through 2023 ($58 million as of December 31, 2023). The LLM appears to have fabricated or hallucinated a 2024 value. (2) SWAP RATE DISCREPANCY - The LLM claims swap rates were 1-2% (weighted average ~1%) in 2022, but the ground truth states the methodology shift resulted in 3-5% (weighted average 4%) rates. The ground truth does not mention 1-2% rates for 2022. This is a significant factual error. (3) INCOMPLETE GROUND TRUTH COVERAGE - The ground truth mentions derivative activity details (issuances $68M, settlements -$37M, transfers $6M) from 2022, which the LLM completely omits. (4) METHODOLOGICAL SHIFT MISCHARACTERIZATION - The ground truth indicates a shift FROM realized/unrealized gains/losses TO discounted cash flows with observable inputs. The LLM suggests the DCF model was used throughout, which contradicts the ground truth's description of a methodological evolution. (5) LEVEL-3 CLASSIFICATION - The LLM introduces Level-3 classification and SOFR-indexed derivatives for 2024, which are not mentioned in the ground truth and appear to be unsupported additions. CORRECT ELEMENTS: The LLM correctly identifies the $19M (2022) and $58M (2023) figures and the general upward trend. The mention of swap rates as key inputs and the 3-5% range with 4% weighted average for 2023 is correct. OVERALL: The answer contains significant fabrications (2024 data, 1-2% rates), omits key details (derivative activity breakdown), and misrepresents the methodological evolution. The introduction of unsupported 2024 data and Level-3 classifications suggests hallucination beyond the ground truth scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 485,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has NVIDIA's GeForce NOW cloud gaming offering evolved from 2022 to 2023 in terms of its positioning within the company's broader GPU and cloud platform ecosystem?",
      "original_answer": "In 2022, GeForce NOW was positioned as a cloud platform enabling gamers to access interactive graphics applications from nearly any device, emphasizing its role in extending NVIDIA’s graphics leadership and ecosystem reach. It was mentioned alongside other cloud platforms like vGPU for enterprise use. By 2023, GeForce NOW was more specifically integrated into the broader NVIDIA accelerated computing platform narrative, and its positioning shifted to emphasize cloud gaming as part of a suite of GPU-driven services, including AI training platforms like NVIDIA DGX Cloud. This evolution reflects a more strategic alignment of GeForce NOW with NVIDIA’s expanding cloud infrastructure and software offerings, particularly in the context of gaming as a service.",
      "llm_answer": "In the 2022 filing, GeForce NOW is presented mainly as a cloud‑gaming service that lets users play PC games on under‑powered devices and is mentioned alongside vGPU as part of NVIDIA’s cloud platforms that bring interactive graphics to any device (NVDA_10k_2022 pp. 9‑13). By the 2023 filing, GeForce NOW is positioned as a core element of the Graphics segment’s game‑streaming service and related infrastructure, emphasizing its integration with NVIDIA’s broader GPU‑driven cloud and accelerated‑computing ecosystem (NVDA_10k_2023 pp. 4‑8).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the 2022 positioning of GeForce NOW as a cloud gaming service enabling access from various devices, with accurate mention of vGPU as a parallel cloud platform offering. (2) Accurately captures the 2023 evolution showing GeForce NOW integrated into the broader GPU-driven cloud and accelerated computing ecosystem. (3) Properly synthesizes the multi-hop comparison across two fiscal years, showing understanding of how positioning shifted from standalone cloud platform to integrated component of broader strategy. (4) Correctly identifies the Graphics segment context in 2023 and the connection to NVIDIA's accelerated computing narrative. (5) Appropriately cites document sources with page ranges, demonstrating proper multi-document synthesis. MINOR AREAS FOR IMPROVEMENT: (1) The LLM answer could have been slightly more explicit about the connection to AI training platforms like DGX Cloud mentioned in the ground truth, though this is a minor omission. (2) The phrase 'game-streaming service' in the LLM answer is semantically equivalent to 'cloud gaming' in the ground truth, so this is acceptable. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts were required for this qualitative question about positioning evolution, so this dimension scores high. QUALITATIVE ACCURACY: The reasoning correctly identifies the shift from positioning GeForce NOW as an extension of graphics leadership to viewing it as part of a broader accelerated computing platform strategy. The multi-hop synthesis across 2022 and 2023 filings is sound. CONTEXTUAL RELEVANCE: The answer directly addresses the question about evolution of positioning within the broader ecosystem and appropriately contextualizes GeForce NOW within NVIDIA's strategic narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 512,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors influenced this change?",
      "original_answer": "In 2022, Inlyta had total global revenue of $1,003 million, while in 2023, its revenue increased to $1,036 million, representing a 3% growth. This growth was primarily driven by continued adoption of Inlyta in combination with immune checkpoint inhibitors for the first-line treatment of advanced renal cell carcinoma (RCC) in the U.S., and growth in emerging markets. However, this increase was partially offset by lower volumes and lower net prices in certain European markets.",
      "llm_answer": "Inlyta’s revenue grew modestly from $1,003 million in 2022 to $1,036 million in 2023 (U.S. $618 M → $642 M, + 4%; International $385 M → $394 M, + 3%)【PFE_10k_2023.pdf:44】. The uplift was driven by stronger U.S. uptake of Inlyta in first‑line combination regimens with immune‑checkpoint inhibitors for advanced renal‑cell carcinoma, while lower volumes and reduced net‑price pressure in certain European markets partially offset the growth【PFE_10k_2023.pdf:44】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Quantitative verification: Total revenue figures are correct ($1,003M in 2022 → $1,036M in 2023). The breakdown by geography is accurate: U.S. $618M → $642M (+3.9%, rounded to +4% in LLM answer) and International $385M → $394M (+2.3%, rounded to +3% in LLM answer). The overall growth calculation is correct: ($1,036M - $1,003M) / $1,003M = 3.3%, which matches the ground truth's stated 3% growth (minor rounding difference acceptable). The LLM provides additional granular detail by breaking down U.S. vs. International performance, which adds value beyond the ground truth summary. Qualitative accuracy: The answer correctly identifies the primary growth driver (U.S. uptake of Inlyta in first-line combination with immune checkpoint inhibitors for advanced RCC) and the offsetting factor (lower volumes and reduced net-price pressure in European markets). The multi-hop reasoning is sound—the answer synthesizes information about both geographic performance and the clinical/market factors driving changes. Entity accuracy is perfect: correct drug name (Inlyta), correct indication (advanced renal cell carcinoma/RCC), correct time period (2022-2023), and correct company context (Pfizer, as evidenced by the 10-K citation). The only minor observation is that the LLM rounds the U.S. growth to +4% when the precise calculation is +3.9%, but this is within acceptable rounding conventions. The answer directly addresses all parts of the question: revenue evolution (with specific numbers) and factors influencing the change (both positive and negative drivers).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 443,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the treatment and valuation of network location intangibles evolved from 2023 to 2024, particularly in terms of amortization assumptions and impairment review processes?",
      "original_answer": "In 2023, the company amortized network location intangibles on a straight-line basis over their estimated useful lives, with a weighted average amortization period of 15 years as of December 31, 2023. The focus was on the relationship between these intangibles and tower assets, particularly in terms of potential revenue growth from leasing excess capacity. By 2024, the company expanded its disclosures to include a more detailed impairment review process for network location intangibles, assessing impairment on an individual tower basis and identifying specific triggers such as lack of tenant leases or expenses exceeding revenues. Additionally, while amortization remained a key treatment, the company's broader discussion of asset retirement obligations in 2024, including a $470 million increase in liability due to revised settlement dates, indirectly impacts the valuation and useful life assumptions for these intangible assets.",
      "llm_answer": "In 2023 the Company amortized acquired network‑location intangibles on a straight‑line basis over the shorter of the ground‑lease term—generally up to 20 years—with a weighted‑average remaining amortization period of about 15 years, and it reviewed those intangibles for impairment on a tower‑by‑tower basis using undiscounted future‑cash‑flow recoverability tests (and discounted‑cash‑flow measurement when a loss was indicated) (2023 p.101, p.104). In 2024 the Company extended the useful life of its towers to 30 years and, prospectively, began amortizing network‑location intangibles over the longer remaining tower life, cutting depreciation and amortization expense, while keeping the same individual‑tower impairment monitoring and testing methodology (2024 p.94, p.96).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides some correct information but contains significant discrepancies with the ground truth. CORRECT ELEMENTS: (1) The 2023 weighted-average amortization period of 15 years is correctly stated; (2) The tower-by-tower impairment review methodology is correctly identified for both years; (3) The general amortization approach (straight-line basis) is correct; (4) The mention of undiscounted and discounted cash flow testing is accurate. CRITICAL ERRORS: (1) The LLM states the 2023 useful life was 'up to 20 years' but the ground truth indicates the weighted average amortization period was 15 years - this conflates the maximum term with the actual weighted average; (2) The LLM claims the company 'extended the useful life of its towers to 30 years' in 2024, which is a major factual claim not supported by the ground truth. The ground truth makes no mention of extending tower useful lives to 30 years; (3) The LLM states this change 'cut depreciation and amortization expense' but provides no supporting evidence from the ground truth; (4) MISSING KEY INFORMATION: The ground truth specifically mentions a $470 million increase in asset retirement obligation liability due to revised settlement dates in 2024, which indirectly impacts valuation and useful life assumptions - the LLM completely omits this important detail. MULTI-HOP REASONING: The LLM fails to synthesize the connection between ARO changes and their impact on intangible asset valuation. The answer addresses impairment review processes adequately but misses the broader context of how 2024 changes (particularly ARO adjustments) affected overall asset valuation strategy. The claim about extending tower lives to 30 years appears to be either fabricated or misinterpreted from the source documents, representing a fundamental factual error that significantly undermines the answer's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 510,
        "total_tokens": 1947
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, particularly in terms of its upstream growth portfolio and production capacity?",
      "original_answer": "In 2023, ExxonMobil highlighted Guyana as a key component of its upstream growth portfolio, noting four additional discoveries on the Stabroek Block and the startup of the Prosperity FPSO vessel, which brought production to nearly 440 kbd in the fourth quarter. By 2024, Guyana was formally categorized under 'Advantaged Assets' within the updated earnings drivers, reflecting its strategic elevation alongside the Permian and LNG projects as a core contributor to earnings through volume/mix growth. This shift indicates a transition from a discovery and early production phase in 2023 to a more mature, financially impactful asset in 2024.",
      "llm_answer": "In the 2023 Form 10‑K ExxonMobil highlighted Guyana as a fast‑moving growth hub – four new Stabroek discoveries, the Payara FPSO coming on‑line in late‑2023, three FPSOs delivering >390 kb/d (≈440 kb/d in Q4) and the Yellowtail and Uaru projects each slated for ~250 kb/d, with a plan for six FPSOs on the block by 2027. In the 2024 filing the company still treats Guyana as a core upstream growth driver, now grouped with Permian and LNG as an “advantaged growth project,” indicating continued strategic priority but without the detailed capacity milestones that dominated the 2023 discussion.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the overall strategic evolution of Guyana from 2023 to 2024 and correctly identifies the key shift toward 'advantaged growth project' categorization. However, there are significant quantitative inaccuracies that lower the overall score:\n\nCORRECT ELEMENTS:\n- Correctly identifies four Stabroek discoveries in 2023\n- Correctly notes the transition to 'advantaged growth project' grouping with Permian and LNG in 2024\n- Correctly captures the shift from detailed capacity milestones in 2023 to more strategic framing in 2024\n- Appropriately synthesizes the multi-hop comparison across 2023 and 2024 filings\n\nINCORRECT/PROBLEMATIC ELEMENTS:\n1. FPSO NAMING ERROR: The LLM states 'Payara FPSO coming on-line in late-2023' but the ground truth references 'Prosperity FPSO vessel' as the startup in 2023. This is a factual error regarding which vessel came online.\n2. PRODUCTION CAPACITY CONFUSION: The LLM states 'three FPSOs delivering >390 kb/d (≈440 kb/d in Q4)' which is confusing and potentially inaccurate. The ground truth clearly states production reached 'nearly 440 kbd in the fourth quarter' as a single metric, not three FPSOs at that level.\n3. FUTURE CAPACITY PROJECTIONS: The LLM introduces 'Yellowtail and Uaru projects each slated for ~250 kb/d' and 'six FPSOs on the block by 2027' - while these may be accurate details from 2023 filings, they are not mentioned in the ground truth answer and their accuracy cannot be verified against the provided reference.\n4. MISSING GROUND TRUTH DETAIL: The ground truth specifically mentions 'Prosperity FPSO vessel' startup, which the LLM incorrectly attributes to 'Payara FPSO.'\n\nMULTI-HOP REASONING: The answer correctly synthesizes information across 2023 and 2024 filings and identifies the strategic evolution. The reasoning about the transition from 'discovery and early production phase' to 'mature, financially impactful asset' is implicitly captured through the discussion of categorization changes.\n\nQUANTITATIVE ACCURACY: The production numbers (390-440 kb/d) are approximately correct, but the presentation is confusing. The FPSO vessel name error and unverified future projections reduce quantitative accuracy.\n\nOVERALL: The answer demonstrates good understanding of the strategic shift but contains a critical factual error (Payara vs. Prosperity) and introduces unverified details not in the ground truth, which prevents a higher score despite correct overall framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 657,
        "total_tokens": 1969
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the X1 platform's integration with third-party streaming services evolved between 2022 and 2023, and what does this evolution indicate about Comcast's strategy in reducing cord-cutting and increasing average revenue per user (ARPU)?",
      "original_answer": "In 2022, the X1 platform integrated third-party streaming services such as Disney+ and Netflix, and provided access to Peacock's premium tier, with Comcast earning commission revenue from the sale of these services. By 2023, the X1 platform continued to support third-party integrations but now included Xumo Play, NBC, and Sky as part of the NOW TV service, which was specifically marketed to residential broadband customers. This expansion indicates a strategic pivot toward enhancing the value of broadband subscriptions and bundling streaming access to retain customers and potentially increase ARPU through deeper content integration and commission-generating partnerships.",
      "llm_answer": "In 2022 the X1 platform’s streaming integration was limited to the Flex streaming device, which gave customers voice‑activated search and access to a handful of third‑party apps – Peacock’s premium tier, Disney+ and Netflix – and generated commission revenue from those DTC services. By 2023 Flex was rebranded as the Xumo Stream Box and X1 now also powers the newly launched NOW service, adding a broader slate of streaming partners (including free channels from Xumo Play, NBC and Sky) and the ad‑supported Peacock tier, while still earning commissions on DTC sales. This deeper, more bundled integration signals Comcast’s strategy to keep cord‑cutters inside its ecosystem and to monetize streaming content through higher‑value bundles and commissions, thereby curbing churn and boosting ARPU.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive coverage of the question. STRENGTHS: (1) Correctly identifies 2022 streaming integrations (Peacock premium tier, Disney+, Netflix) and commission revenue model; (2) Accurately describes 2023 evolution including Xumo Play, NBC, Sky, and NOW TV service; (3) Properly identifies the Flex-to-Xumo Stream Box rebranding; (4) Correctly notes the addition of ad-supported Peacock tier in 2023; (5) Effectively synthesizes the strategic implications regarding cord-cutting reduction, ecosystem retention, and ARPU enhancement through bundling and commissions; (6) Multi-hop reasoning is sound, connecting product evolution to business strategy. MINOR CONSIDERATIONS: (1) The LLM answer provides slightly more granular detail than the ground truth (e.g., mentioning Flex device specifically, ad-supported Peacock tier, rebranding details), which adds value but represents a minor expansion beyond the ground truth scope; (2) The ground truth mentions 'residential broadband customers' as a specific target, while the LLM answer frames it more broadly as 'cord-cutters' - both are strategically accurate but represent slightly different emphasis; (3) The LLM answer's characterization of 2022 integration as 'limited' is a reasonable interpretation but not explicitly stated in ground truth. NUMERIC/DATE VERIFICATION: All years (2022, 2023) are correct; all service names (Disney+, Netflix, Peacock, Xumo Play, NBC, Sky, NOW TV) are accurate; no calculations required. The answer correctly conveys the evolution from basic third-party integrations to deeper bundled offerings. The strategic analysis (churn reduction, ARPU boost, ecosystem retention) aligns well with ground truth conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 477,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Caterpillar's relationship with FG Wilson evolved between 2023 and 2024 in terms of its distribution network coverage for electric power generation systems?",
      "original_answer": "In 2023, FG Wilson's electric power generation systems were distributed through a network of 110 distributors covering 109 countries. By 2024, this distribution network had slightly contracted to 108 distributors, now covering 158 countries. This indicates a minor reduction in the number of distributors but an expansion in the geographic reach of the network. The change suggests a strategic shift toward optimizing distributor efficiency while broadening market access.",
      "llm_answer": "In the 2023 filing Caterpillar said the FG Wilson electric power‑generation systems were sold through a worldwide network of **110 distributors covering 109 countries**. By the 2024 filing the network had **108 distributors but now reached 158 countries**, showing a slight reduction in the number of distributors while dramatically expanding the geographic coverage of the FG Wilson distribution channel.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. All quantitative data matches the ground truth exactly: 2023 had 110 distributors covering 109 countries, and 2024 had 108 distributors covering 158 countries. The multi-hop synthesis is sound, correctly identifying the relationship between Caterpillar and FG Wilson across two fiscal years and accurately comparing the distribution network metrics. The answer properly characterizes the strategic shift as a 'slight reduction in the number of distributors while dramatically expanding geographic coverage,' which aligns with the ground truth's interpretation. The LLM correctly sourced information from both 2023 and 2024 filings and synthesized the comparison effectively. Minor note: The LLM uses slightly different phrasing ('dramatically expanding' vs. 'expansion') but this is semantically equivalent and actually enhances clarity. The answer directly addresses all aspects of the question regarding how the relationship evolved in terms of distribution network coverage. No calculation errors, no missing data points, and proper entity identification throughout.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 320,
        "total_tokens": 1544
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Capital One's exposure to securitized debt obligations change between 2022 and 2024, particularly in terms of the carrying value and fair value of these obligations?",
      "original_answer": "In 2022, Capital One reported that the assets and liabilities of consolidated VIEs, including securitized debt obligations, were primarily composed of loan receivables and debt securities issued by the VIEs, with the liabilities reported under 'securitized debt obligations' on the consolidated balance sheets. By 2024, the carrying value of 'Securitized debt obligations' was $18,043 million, with a fair value of $18,067 million, all categorized under Level 2 of the fair value hierarchy. This indicates that Capital One maintained a significant exposure to securitized debt obligations, with a slight increase in fair value relative to carrying value, suggesting stable valuation and continued involvement in securitization activities.",
      "llm_answer": "Capital One’s securitized‑debt exposure fell sharply. In the 2022 filing the company reported securitized debt obligations with a carrying amount of $18,043 million and an estimated fair value of $18,067 million (COF 10‑K 2022, pp. 177‑181). By December 31 2024 the carrying amount had declined to $14,264 million and the estimated fair value to $14,335 million (COF 10‑K 2024, pp. 218‑222), a reduction of roughly $3.8 billion in carrying value and $3.7 billion in fair value.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains fundamental factual errors that directly contradict the ground truth. (1) NUMBER REVERSAL: The LLM claims 2022 values were $18,043M carrying value and $18,067M fair value, but then states these DECLINED to $14,264M and $14,335M by 2024. However, the ground truth explicitly states that the 2024 values were $18,043M carrying value and $18,067M fair value - meaning the LLM has reversed the years. The LLM incorrectly attributes 2024's actual values to 2022. (2) DIRECTIONAL ERROR: The LLM concludes securitized debt exposure 'fell sharply' with a $3.8B reduction, but the ground truth indicates Capital One 'maintained a significant exposure' with stable valuations. The LLM's narrative of decline is factually incorrect. (3) CALCULATION VERIFICATION: The LLM calculates $18,043M - $14,264M = $3.779B (approximately $3.8B), which is arithmetically correct for those numbers, but since the underlying year assignments are wrong, the calculation is meaningless. (4) MULTI-HOP SYNTHESIS FAILURE: The LLM failed to correctly synthesize information across the 2022 and 2024 filings. It appears to have confused which values belong to which year. (5) MISSING CONTEXT: The LLM completely misses the ground truth's key insight about fair value being slightly higher than carrying value and the Level 2 fair value hierarchy classification. The answer fundamentally misrepresents Capital One's securitization trajectory by claiming a sharp decline when the actual position remained stable at approximately $18B.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 424,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has McDonald's use of line of credit agreements evolved between 2023 and 2024 in relation to its financing activities and cash flow management?",
      "original_answer": "In 2023, McDonald's cash used for financing activities totaled $4.4 billion, a decrease of $2.2 billion compared to 2022, primarily due to increased bond issuances. The company's cash and equivalents balance was $4.6 billion at the end of 2023, reflecting sufficient liquidity supported by cash from operations and access to commercial paper borrowings and line of credit agreements. In 2024, cash used for financing activities increased to $7.5 billion, a rise of $3.1 billion compared to 2023, driven by decreased bond issuances. The company's cash and equivalents balance dropped to $1.1 billion at year-end 2024, with the prior year's higher balance attributed to the timing of debt issuances that funded 2024's required cash outflows. The company continued to rely on its line of credit agreements and commercial paper to meet short-term funding needs. This indicates a shift from surplus liquidity and bond financing in 2023 to a more cash-constrained environment in 2024, with greater reliance on existing credit facilities.",
      "llm_answer": "In 2023 McDonald’s treated its $4 billion committed line of credit as a short‑term liquidity back‑stop, with cash used for financing activities of $4.4 billion and ample cash on hand ($4.6 billion). By 2024 financing outflows had risen to $7.5 billion, cash on hand fell to $1.1 billion, and the board replaced the 2022 $15 billion borrowing authority with a new $15 billion program effective 2025—while still relying on its line of credit for short‑term funding—showing a shift toward greater use of borrowing capacity to manage cash flow.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies key financial metrics: cash used for financing activities of $4.4B (2023) and $7.5B (2024), cash balances of $4.6B (2023) and $1.1B (2024). The directional analysis is sound—showing a shift from surplus liquidity to cash-constrained environment. The mention of reliance on line of credit agreements and commercial paper for short-term funding is accurate. WEAKNESSES: (1) The LLM introduces a specific '$4 billion committed line of credit' figure that is not present in the ground truth, which only references 'line of credit agreements' without specifying amounts. This is a factual addition not supported by the source material. (2) The LLM mentions a '$15 billion borrowing authority' replacement effective 2025, which is not mentioned in the ground truth at all. This appears to be unsupported information. (3) The LLM omits the ground truth's specific comparison that 2023 financing activities decreased $2.2B from 2022, and that 2024 increased $3.1B from 2023—these year-over-year comparisons provide important context. (4) The ground truth explicitly states the 2024 cash drop was 'attributed to the timing of debt issuances that funded 2024's required cash outflows'—the LLM doesn't capture this nuance about bond issuance timing. MULTI-HOP REASONING: The LLM attempts to synthesize the evolution across years but introduces unsupported details about borrowing authority changes. The core comparison between 2023 and 2024 is present but incomplete. CALCULATION VERIFICATION: All stated numbers are accurate where they appear in ground truth, but the LLM adds numbers not in the source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 449,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the role of the Worldwide Business Conduct Manual in reinforcing internal controls evolved between 2022 and 2024, and what does this indicate about Procter & Gamble's approach to governance?",
      "original_answer": "In 2022, the Worldwide Business Conduct Manual was described as reinforcing the company's commitment to conducting business with integrity and within the letter and spirit of the law, emphasizing its role in supporting internal controls through policies, segregation of duties, and employee development. In 2024, while the core description remained similar, the manual was more specifically tied to governance frameworks such as the oversight activities of the Global Leadership Council and the responsibilities of the Disclosure Committee in evaluating significant business activities. This indicates a shift toward emphasizing structured governance mechanisms alongside ethical conduct, suggesting a more integrated approach to internal control over time.",
      "llm_answer": "Both the 2022 and 2024 filings state that P&G’s Worldwide Business Conduct Manual is a cornerstone that “reinforces” its internal‑control system and codifies a commitment to conduct business with integrity and within the law. In the 2024 report the manual’s role is sharpened – the Audit Committee is now described as reviewing “critical accounting policies and estimates” (versus “significant accounting policies” in 2022) – indicating that the manual is being used to drive more granular, high‑risk oversight. This evolution signals a deepening, more proactive governance approach, with P&G tightening its internal‑control oversight and risk management while maintaining its ethical framework.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains both correct and incorrect elements. CORRECT ELEMENTS: (1) Both 2022 and 2024 filings do describe the Worldwide Business Conduct Manual as reinforcing internal controls and emphasizing integrity/legal compliance - this matches the ground truth. (2) The general conclusion about evolution toward more structured governance is directionally aligned with the ground truth. SIGNIFICANT ERRORS: (1) The LLM introduces a specific claim about the Audit Committee reviewing 'critical accounting policies and estimates' in 2024 versus 'significant accounting policies' in 2022 - this specific comparison is NOT present in the ground truth and appears to be fabricated or misattributed. (2) The ground truth specifically mentions the Global Leadership Council and Disclosure Committee as key governance mechanisms tied to the manual's role in 2024, but the LLM answer completely omits these entities and instead focuses on the Audit Committee and accounting policies language. (3) The ground truth emphasizes a shift toward 'structured governance mechanisms' and 'integrated approach,' while the LLM frames it as 'granular, high-risk oversight' of accounting policies - these are different governance emphases. MULTI-HOP REASONING: The LLM failed to properly synthesize the key governance framework evolution described in the ground truth (Global Leadership Council oversight, Disclosure Committee responsibilities). Instead, it introduced accounting policy language that is not substantiated in the provided ground truth. The reasoning about 'critical' vs 'significant' accounting policies appears to be an unsupported inference or error. COMPLETENESS: The answer addresses the evolution question but misses critical governance mechanisms (Global Leadership Council, Disclosure Committee) that are central to the ground truth's explanation of P&G's governance approach. The answer is partially responsive but fundamentally incomplete in capturing the actual governance evolution described.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 540,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Exxon's strategic positioning in Guyana evolved between 2023 and 2024, as reflected in its long-lived asset disclosures and earnings driver definitions?",
      "original_answer": "In 2023, Exxon disclosed $9,689 million in long-lived assets in Guyana, indicating it was already a significant contributor among non-U.S. assets. By 2024, Guyana was explicitly named as part of Exxon's 'Advantaged Assets' under the new 'Advantaged Volume Growth' earnings driver, which includes key growth projects like Guyana and LNG. This evolution shows that Guyana transitioned from being a quantitatively notable asset in 2023 to a strategically emphasized growth engine in 2024.",
      "llm_answer": "In the 2023 filing Exxon reported $9.7 billion of long‑lived assets in Guyana (up from $6.8 billion in 2022), showing a rapidly expanding upstream footprint there. By the 2024 filing the company’s earnings‑driver definitions list Guyana as an “Advantaged Asset” (alongside Permian and LNG), signaling that Guyana has been elevated from a sizable asset base to a core, high‑value growth platform in Exxon’s strategic plan.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution narrative - Guyana transitioning from a quantitatively significant asset to a strategically emphasized growth engine. The qualitative characterization of Guyana as an 'Advantaged Asset' and core growth platform is accurate. The 2024 positioning within earnings driver definitions is correctly captured. The semantic equivalence of the strategic positioning is well-conveyed.\n\nWEAKNESSES - QUANTITATIVE ERRORS: (1) The LLM states $9.7 billion for 2023 Guyana long-lived assets, but ground truth specifies $9,689 million ($9.689 billion). While the rounding to $9.7B is reasonable, the LLM introduces an unsupported comparison to 2022 ($6.8 billion) that does not appear in the ground truth. This is a factual error - the ground truth makes no mention of 2022 comparisons. (2) The LLM adds context about 2022 ($6.8 billion) that cannot be verified against the provided ground truth, potentially introducing fabricated data points.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes the two-part evolution (2023 asset disclosure + 2024 earnings driver definition), properly connecting quantitative positioning to strategic emphasis. However, the addition of the 2022 comparison breaks the multi-hop chain by introducing unverified information.\n\nENTITY ACCURACY: Correctly identifies Exxon, Guyana, Permian, and LNG. Correctly identifies the 'Advantaged Assets' and 'Advantaged Volume Growth' earnings driver concept (though the LLM uses slightly different phrasing).\n\nCRITICAL ISSUE: The introduction of the $6.8 billion 2022 figure without ground truth support is a significant concern. While the core answer about 2023-2024 evolution is sound, the unsupported historical comparison reduces confidence in the response's factual grounding. The quantitative accuracy score reflects this error, while the qualitative accuracy remains higher because the strategic narrative is correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 527,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Capital One's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, based on the disclosed figures and descriptions?",
      "original_answer": "In 2022, Capital One identified securitized debt obligations as part of its diversified funding mix, which also included deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. While no specific dollar value was disclosed in 2022, the company emphasized the strategic importance of securitized debt obligations in maintaining access to wholesale funding. By 2024, Capital One disclosed that its securitized debt obligations had a carrying value of $14,264 million and an estimated fair value of $14,335 million. This represents a concrete quantification of the instrument's role in the company's capital structure, showing an increased transparency and continued use of this funding source.",
      "llm_answer": "In the 2022 filing Capital One emphasized that securitized debt was a primary driver of its long‑term funding, issuing $6.25 billion of new securitized debt in 2021 and raising total long‑term debt by $2.4 billion to $42.3 billion, supported by shelf‑registration capacity of $25 billion for credit‑card and $20 billion for auto‑loan securitizations. By the 2024 filing the outstanding balance of securitized debt obligations had slipped to $14.3 billion (down from $18.0 billion a year earlier), showing a clear contraction in the reliance on securitizations as a funding source.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations that fundamentally contradict the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM cites $6.25 billion in 2021 securitized debt issuance and $2.4 billion long-term debt increase to $42.3 billion, but these figures are not verified against the ground truth and appear to be from 2022 filings discussing 2021 activity, not directly addressing the 2022-2024 evolution requested. More critically, the LLM states securitized debt 'slipped to $14.3 billion (down from $18.0 billion a year earlier)' - the ground truth confirms the 2024 figure of $14,264 million ($14.3 billion), but provides no evidence of an $18.0 billion figure in 2023, making this comparison unverifiable and potentially incorrect. (2) INCOMPLETE SYNTHESIS: The ground truth explicitly states 'no specific dollar value was disclosed in 2022' for securitized debt obligations, yet the LLM provides 2022 figures without acknowledging this disclosure gap. The LLM fails to properly synthesize the key finding that 2024 represents the first concrete quantification of this instrument. (3) MISCHARACTERIZATION: The LLM concludes there is a 'clear contraction in reliance on securitizations,' but the ground truth emphasizes 'continued use' and 'increased transparency' - these are opposite interpretations. The LLM's narrative of declining reliance contradicts the ground truth's emphasis on strategic importance and continued utilization. (4) MISSING CONTEXT: The LLM omits the ground truth's important point about the 2024 disclosure representing increased transparency and concrete quantification after 2022's lack of specific dollar values. (5) MULTI-HOP REASONING: While the LLM attempts to compare years, it does so with unverified figures and reaches a conclusion opposite to the ground truth's assessment. The answer demonstrates poor synthesis of the actual evolution described in the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 525,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has NVIDIA's Omniverse platform evolved in terms of its positioning and enterprise adoption between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Omniverse was described as 'real-time 3D design collaboration and virtual world simulation software' aimed at empowering creators to collaborate across leading design applications. By fiscal year 2023, Omniverse had evolved into a more robust enterprise-focused development platform and operating system for building virtual world simulation applications. It was made available as a software subscription for enterprise use and offered free for individual users, with industrial enterprises adopting its 3D and simulation technologies to digitalize complex physical assets and environments, including digital twins of factories and real-time 3D product configurators. This indicates a strategic shift from a creative collaboration tool to a broader enterprise simulation and digital twin platform.",
      "llm_answer": "In FY 2022 NVIDIA described Omniverse as a virtual‑world simulation and collaboration platform for 3‑D workflows that is sold as a software subscription for enterprise (free for individuals) and highlighted early industrial‑enterprise use cases such as digital twins, real‑time product configurators and testing of autonomous robots and vehicles (NVDA 10‑K 2022 pp. 9‑13). By FY 2023 the company repositioned Omniverse as a real‑time 3‑D design‑collaboration and virtual‑world simulation software with a dedicated “Omniverse Enterprise” offering for building and operating metaverse and 3‑D internet applications, signalling a more formal enterprise‑grade product and broader adoption across multiple industries (NVDA 10‑K 2023 pp. 4‑8).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IN TEMPORAL SEQUENCING AND FACTUAL ACCURACY: The LLM answer fundamentally reverses the chronological evolution described in the ground truth. (1) MAJOR FACTUAL ERROR - FY 2022 POSITIONING: The LLM claims FY 2022 described Omniverse as 'virtual-world simulation and collaboration platform' with enterprise subscription model and industrial use cases (digital twins, product configurators, autonomous robots). However, the ground truth explicitly states FY 2022 positioned it as 'real-time 3D design collaboration and virtual world simulation software' aimed at empowering creators - a creative collaboration focus, NOT an enterprise platform. The LLM incorrectly attributes FY 2023 characteristics (enterprise subscription, industrial adoption) to FY 2022. (2) MAJOR FACTUAL ERROR - FY 2023 POSITIONING: The LLM describes FY 2023 as introducing 'Omniverse Enterprise' offering for 'metaverse and 3-D internet applications' - this is not supported by the ground truth. The ground truth states FY 2023 evolved into 'enterprise-focused development platform and operating system' with subscription for enterprise/free for individuals, and adoption for digital twins and product configurators. The LLM's mention of 'metaverse and 3-D internet applications' is not in the ground truth. (3) REVERSED EVOLUTION NARRATIVE: The ground truth describes a shift FROM creative collaboration TO enterprise simulation/digital twins. The LLM presents this backwards, placing enterprise characteristics in FY 2022 and then adding 'metaverse' language in FY 2023. (4) CITATION ISSUES: While the LLM provides page references, the actual content cited does not match the claims made. The ground truth clearly indicates the evolution was from creator-focused to enterprise-focused, not the other way around. (5) MISSING KEY DISTINCTION: The ground truth emphasizes the strategic shift from 'creative collaboration tool' to 'enterprise simulation and digital twin platform' - the LLM fails to capture this core evolution narrative and instead conflates characteristics across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 557,
        "total_tokens": 1942
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Pfizer's financial relationship with Viatris evolved between 2022 and 2023, particularly in terms of net amounts due under their various agreements?",
      "original_answer": "In 2022, the net amounts due to Viatris under the agreements were $94 million as of December 31, 2022. By 2023, this amount had decreased to $33 million as of December 31, 2023. This indicates a significant reduction in the net financial obligations between the two companies over the period, suggesting a winding down or stabilization of transitional financial arrangements established post-separation.",
      "llm_answer": "Pfizer reported that the net amount it owed Viatris under the separation‑distribution, agency, MSA and TSA arrangements was **$94 million as of December 31 2022**. In the 2023 filing the balance had fallen to **$33 million as of December 31 2023**, showing a sizable decline in Pfizer’s net obligations to Viatris over the year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-aligned with the ground truth. (1) CORRECTNESS: All key facts are correct - the $94 million balance as of December 31, 2022 and the $33 million balance as of December 31, 2023 are accurately stated. The LLM correctly identifies these as net amounts due under the separation-distribution, agency, MSA and TSA arrangements. (2) QUANTITATIVE ACCURACY: Both dollar amounts are precisely correct with no calculation errors. The year-over-year comparison ($94M to $33M) is accurate, representing a $61 million reduction. Date formatting is acceptable (\"December 31 2022\" vs \"December 31, 2022\" - minor punctuation difference). (3) QUALITATIVE ACCURACY: The LLM demonstrates sound multi-hop reasoning by synthesizing information across two fiscal years and correctly identifying the relationship evolution. The characterization of the decline as \"sizable\" is appropriate given the 65% reduction. The LLM correctly attributes the amounts to the specific agreements mentioned. (4) CONTEXTUAL RELEVANCE: The answer directly addresses the question about how Pfizer's financial relationship with Viatris evolved between 2022 and 2023. The LLM captures the key insight about the reduction in net obligations. Minor note: The ground truth includes interpretive language about \"winding down or stabilization of transitional financial arrangements,\" which the LLM omits. However, the LLM's statement that the decline shows \"a sizable decline in Pfizer's net obligations\" conveys similar meaning. This is a very minor omission that doesn't significantly detract from the answer's quality.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1185,
        "completion_tokens": 445,
        "total_tokens": 1630
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, and what specific changes in project activity or classification reflect this evolution?",
      "original_answer": "In 2023, ExxonMobil's operations in Guyana were characterized by active exploration and development, with 12.6 net exploratory and development wells completed, and key projects such as Payara, Yellowtail, and Uaru underway. By 2024, Guyana was formally classified as part of ExxonMobil's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, signaling a strategic elevation of its importance alongside the Permian Basin and LNG. This reclassification reflects a shift from operational reporting to strategic prioritization, indicating increased emphasis on Guyana as a core growth asset.",
      "llm_answer": "In 2023 ExxonMobil presented Guyana mainly as an active development area – it held 4.6 million offshore acres, completed 12.6 exploratory‑development wells, put the Payara development into production, kept work on Yellowtail going and simply “funded” the Uaru project【XOM_10k_2023.pdf p. 22】. By the 2024 filing the company had lifted Guyana into a strategic priority, naming it an “Advantaged Asset” (alongside Permian and LNG) and folding its Guyana projects into the “Advantaged growth projects” category, which signals a higher‑level focus and treats projects such as Payara, Yellowtail and the now‑under‑development Uaru as core growth drivers【XOM_10k_2024.pdf p. 35】. This shift from a descriptive operational update to an explicit “Advantaged” classification, together with the progression of Uaru from funded to a growth‑project status, reflects the evolving strategic emphasis on Guyana.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: All numeric values are correct - 4.6 million offshore acres, 12.6 exploratory-development wells completed in 2023. The numbers match the ground truth exactly. ENTITY ACCURACY: All entities correctly identified - ExxonMobil, Guyana, Payara, Yellowtail, Uaru projects, Permian Basin, LNG, and the specific years (2023 vs 2024). MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years, correctly identifying the progression from operational reporting (2023) to strategic classification (2024). The connection between the reclassification as 'Advantaged Asset' and the 'Advantaged Volume Growth' earnings driver is properly established. COMPLETENESS: The answer addresses all parts of the question - it explains the 2023 baseline (exploration/development phase with specific well counts and projects), the 2024 evolution (formal classification as Advantaged Asset), and the specific changes reflecting this evolution (reclassification, project status progression from 'funded' to 'under-development'). SEMANTIC EQUIVALENCE: The LLM's phrasing 'shift from a descriptive operational update to an explicit Advantaged classification' effectively captures the same meaning as the ground truth's 'shift from operational reporting to strategic prioritization.' The characterization of Uaru's progression from 'funded' to 'under-development' as part of growth projects is semantically equivalent to the ground truth's description. MINOR OBSERVATIONS: The LLM provides slightly more granular detail about the 4.6 million offshore acres and the specific status of each project, which adds value without contradicting the ground truth. The citation format with page numbers adds credibility. No calculation errors detected. No factual inaccuracies identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 513,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the weighted-average interest rate and face value of senior notes with maturities greater than 10 years evolve from 2022 to 2023?",
      "original_answer": "In 2022, the weighted-average interest rate for senior notes with maturities greater than 10 years was 3.67%, with a face value of $54.536 billion. In 2023, the interest rate remained unchanged at 3.8%, but the face value slightly decreased to $53.4 billion. This indicates a slight reduction in long-term debt in this category, while the interest rate stayed stable.",
      "llm_answer": "The weighted‑average interest rate on the senior notes with maturities > 10 years was unchanged at **3.8 %** from 2022 to 2023, while the face‑value of those notes rose modestly from **$52.8 billion** at year‑end 2022 to **$53.4 billion** at year‑end 2023【CMCSA_10k_2023.pdf†L1-L2】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) FACE VALUE 2022 INCORRECT: LLM states $52.8 billion for 2022, but ground truth shows $54.536 billion - this is a $1.736 billion discrepancy (3.2% error). (2) INTEREST RATE 2022 INCORRECT: LLM claims 3.8% for both years, but ground truth shows 3.67% in 2022 and 3.8% in 2023 - the LLM failed to capture the rate change. (3) DIRECTIONAL ERROR: LLM states face value 'rose modestly' from $52.8B to $53.4B, but ground truth shows it 'slightly decreased' from $54.536B to $53.4B. This is a fundamental mischaracterization of the trend. (4) WHAT WAS CORRECT: The 2023 figures are accurate ($53.4B face value and 3.8% rate), and the company identification (Comcast/CMCSA) is correct. (5) MULTI-HOP SYNTHESIS: The LLM failed to properly synthesize the year-over-year evolution, missing the interest rate increase from 3.67% to 3.8% and misrepresenting the face value trend. The answer demonstrates incomplete data extraction from the source document. The question specifically asks how these metrics 'evolved' from 2022 to 2023, requiring accurate comparison of both years - the LLM provided only one correct year's data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1160,
        "completion_tokens": 325,
        "total_tokens": 1485
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the nuclear decommissioning trusts managed by Alabama Power and Georgia Power shift their domestic equity investment allocations and valuation methodologies between 2023 and 2024, particularly in terms of Level 1 and Level 2 input classifications?",
      "original_answer": "In 2023, Alabama Power reported $396 million in domestic equity investments under Level 1 inputs and $169 million under Level 2 inputs, totaling $565 million. Georgia Power reported $255 million in Level 1 and $1 million in Level 2, totaling $256 million. By 2024, Alabama Power’s domestic equity investments increased to $443 million in Level 1 and $208 million in Level 2, totaling $651 million. Georgia Power saw its Level 1 domestic equity investments rise to $321 million while Level 2 remained at $1 million, totaling $322 million. This indicates a strategic shift toward higher allocations in domestic equities, particularly through more actively traded (Level 1) instruments, which may reflect a more transparent or liquid investment approach in line with evolving trust management strategies.",
      "llm_answer": "Both subsidiaries kept the same domestic‑equity mix and the same valuation hierarchy from 2023 to 2024. Alabama Power’s nuclear‑decommissioning trust still reported $651 million of domestic equity – $443 million measured with Level 2 observable inputs and $208 million with Level 3 unobservable inputs – and Georgia Power’s trust still reported $322 million – $321 million at Level 2 and $1 million at Level 3. No portion of the domestic‑equity holdings was re‑classified to Level 1 in either year.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect on multiple critical dimensions: (1) QUANTITATIVE ERRORS - The LLM completely misclassifies the fair value hierarchy levels. Ground truth shows Alabama Power 2024: $443M Level 1 and $208M Level 2, but LLM claims $443M Level 2 and $208M Level 3. Similarly, Georgia Power 2024: Ground truth shows $321M Level 1 and $1M Level 2, but LLM claims $321M Level 2 and $1M Level 3. The LLM has systematically swapped Level 1 for Level 2 and Level 2 for Level 3 across both companies. (2) DIRECTIONAL ANALYSIS ERROR - The LLM claims 'no portion was re-classified to Level 1 in either year,' which directly contradicts the ground truth showing significant increases in Level 1 allocations from 2023 to 2024 (Alabama: $396M→$443M; Georgia: $255M→$321M). (3) MISSING YEAR-OVER-YEAR COMPARISON - The LLM only presents 2024 data and fails to show the 2023 baseline figures, making it impossible to assess the 'shift' requested in the question. (4) INCORRECT CONCLUSION - The LLM's statement that valuations remained the same is false; the data shows a clear strategic shift toward Level 1 (more liquid/observable) instruments. (5) SEMANTIC MISALIGNMENT - The question specifically asks about shifts in allocations and methodologies between 2023-2024, but the LLM provides no 2023 data and incorrectly claims no changes occurred. This is a comprehensive failure to accurately synthesize and report the multi-hop financial data from the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 406,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has NVIDIA's strategic positioning of CUDA evolved from 2022 to 2023 in terms of its role within the company's full-stack computing platform and its integration across different end markets?",
      "original_answer": "In 2022, CUDA was positioned as a fundamental building block of NVIDIA's accelerated computing platform, supporting a variety of end markets such as Gaming, Data Center, Professional Visualization, and Automotive through a unified underlying architecture. It was described as essential for leveraging GPU capabilities across these markets. By 2023, CUDA's role had evolved into being the foundational programming model within NVIDIA's full-stack computing infrastructure, extending its integration beyond traditional markets into domain-specific verticals such as healthcare, telecom, automotive, and manufacturing. Additionally, in 2023, CUDA was positioned as the base layer supporting hundreds of domain-specific software libraries, SDKs, and APIs, which were not explicitly emphasized in 2022. This indicates a strategic shift from CUDA being a foundational component to becoming the core enabler of a broader, more vertically integrated software stack aimed at accelerating deployment across computationally intensive workloads.",
      "llm_answer": "In the 2022 Form 10‑K NVIDIA framed CUDA as a **fundamental building block** of its accelerated‑computing platform – the common programming model that unifies the GPU architecture across all of its diverse end‑markets and underpins a large developer ecosystem (“leveraging our GPUs and CUDA as the fundamental building blocks” [2022 p. 8]; “almost 3 million developers worldwide using CUDA” [2022 p. 9]).  \n\nBy the 2023 filing the company had elevated CUDA to the **foundational layer of a broader full‑stack** – the core programming model that runs on every NVIDIA GPU and is now explicitly coupled with the CUDA‑X collection of acceleration libraries, SDKs, APIs and domain‑specific frameworks, serving as the common software spine that integrates GPUs and solutions across data‑center, AI, graphics, automotive and other markets (“foundational CUDA programming model that runs on all NVIDIA GPUs… hundreds of domain‑specific libraries, SDKs, APIs” [2023 p. 2]; “large body of software, including the CUDA parallel programming model, the CUDA‑X collection… domain‑specific application frameworks” [2023 p. 5]).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent alignment with the ground truth across all dimensions. QUANTITATIVE ACCURACY: The specific numbers cited (3 million developers in 2022, page references to 2022 p. 8-9 and 2023 p. 2, 5) are accurate and properly sourced. The answer correctly identifies the evolution timeline from 2022 to 2023. QUALITATIVE ACCURACY: The LLM successfully captures the core strategic evolution: (1) 2022 positioning as 'fundamental building block' supporting diverse end-markets with unified architecture, (2) 2023 elevation to 'foundational layer of broader full-stack' with explicit coupling to CUDA-X libraries and domain-specific frameworks. The answer correctly identifies the shift from a foundational component to a core enabler of vertically integrated software stack. MULTI-HOP REASONING: The answer properly synthesizes information across two fiscal years and demonstrates understanding of how CUDA's role expanded from supporting traditional markets (Gaming, Data Center, Professional Visualization, Automotive) to domain-specific verticals (healthcare, telecom, manufacturing). The connection between CUDA and the hundreds of domain-specific libraries/SDKs/APIs is correctly established as a 2023 emphasis. COMPLETENESS: All aspects of the question are addressed - the evolution of strategic positioning, CUDA's role within the full-stack platform, and integration across different end markets. The answer provides specific textual evidence from both 2022 and 2023 filings. SEMANTIC EQUIVALENCE: The LLM's phrasing ('fundamental building block' → 'foundational layer of broader full-stack') accurately conveys the ground truth's characterization of the strategic shift. Minor differences in wording (e.g., 'domain-specific verticals' vs 'domain-specific application frameworks') are semantically equivalent and reflect appropriate variation in expression. No factual errors or calculation mistakes detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1548,
        "completion_tokens": 523,
        "total_tokens": 2072
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did Pfizer's financial obligations and contractual relationships with Viatris evolve from 2022 to 2023, particularly in terms of transitional service agreements and net amounts owed?",
      "original_answer": "In 2022, Pfizer disclosed that amounts recorded under transitional service agreements (TSAs) and master services agreements (MSAs) with Viatris were not material to operations, and the TSA services were largely completed by the end of 2022. By 2023, services under the TSAs were fully completed as of December 31, 2023, and the net amounts due to Viatris under the agreements decreased from $94 million in 2022 to $33 million in 2023. This reflects a reduction in intercompany financial obligations and the winding down of transitional support following the 2020 spin-off of the Upjohn Business into Viatris.",
      "llm_answer": "By the end of 2022 Pfizer still carried a sizable liability to Viatris under the post‑spin‑off agreements – net amounts due to Viatris were $94 million – and the company was still performing services under the transitional service agreements (TSAs). By December 31 2023 the TSAs were “largely completed” and the outstanding balance had fallen to $33 million, showing that the transitional obligations had been substantially wound‑down.【PFE_10k_2023.pdf p.71‑73】",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the key financial figures ($94 million in 2022, $33 million in 2023), properly names both companies (Pfizer and Viatris), correctly identifies the relevant agreements (TSAs and MSAs), and accurately describes the overall trend of winding down obligations. The answer appropriately contextualizes this within the 2020 spin-off. The semantic meaning aligns well with the ground truth regarding the evolution of financial obligations.\n\nCRITICAL ERRORS: (1) MAJOR FACTUAL ERROR - The LLM states that by December 31, 2023, TSAs were 'largely completed' when the ground truth explicitly states they were 'fully completed' as of that date. This is a significant mischaracterization of the completion status. (2) TEMPORAL INCONSISTENCY - The LLM reverses the timeline by stating 'By the end of 2022...the company was still performing services under the TSAs' and then 'By December 31 2023 the TSAs were largely completed.' However, the ground truth indicates that TSAs were 'largely completed by the end of 2022' and 'fully completed' by end of 2023. The LLM's phrasing suggests more work remained in 2022 than actually did.\n\nMINOR ISSUES: The LLM omits mention of MSAs (master services agreements) being disclosed as immaterial, which was part of the 2022 disclosure. The answer also doesn't explicitly mention the 2020 spin-off context, though it's implied.\n\nNUMERIC VERIFICATION: Both dollar amounts are correct ($94M in 2022, $33M in 2023), and the reduction calculation is accurate. The dates (2022, 2023, December 31) are correct.\n\nMULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and correctly identifies the relationship between the spin-off event and the subsequent wind-down of obligations. However, the temporal characterization of completion status undermines the quality of this synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 510,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the relationship between retail deregulation pressures and Duke Energy's environmental regulation compliance costs evolved from 2022 to 2023?",
      "original_answer": "In 2022, Duke Energy highlighted that retail deregulation could result in unrecovered costs, including those related to above-market purchased power commitments from qualifying facilities (QFs) under PURPA, which could hinder the recovery of environmental compliance costs through regulatory rate structures. By 2023, the company noted increased regulatory emphasis on environmental compliance, including EPA regulations on CO2 emissions and cooling water intake structures, as well as new state-level carbon reduction goals more aggressive than the company’s own plans. These developments suggest that deregulation pressures have compounded the challenge of recovering rising environmental compliance costs, as competitive market conditions limit the ability to pass on these expenses to customers.",
      "llm_answer": "In the 2022 Form 10‑K Duke Energy warned that retail‑deregulation pressure could create stranded‑asset and unrecovered‑cost risks, but it still expected to recover its environmental‑compliance spending through the normal ratemaking process. By the 2023 filing the company had sharpened that view, noting that new, more aggressive EPA and state climate rules are driving higher compliance costs and that, if deregulation erodes its regulated‑rate base, the timing and amount of cost recovery could be further delayed or limited—making the interaction between deregulation pressure and environmental‑cost recovery more acute.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy and effectively captures the evolution of Duke Energy's position on deregulation and environmental compliance costs from 2022 to 2023. STRENGTHS: (1) Correctly identifies the 2022 concern about stranded assets and unrecovered costs from deregulation, (2) Accurately notes the 2023 shift toward recognizing more aggressive EPA and state climate rules, (3) Properly synthesizes the multi-hop relationship showing how deregulation pressures compound environmental cost recovery challenges, (4) Uses appropriate terminology (stranded-asset risks, ratemaking process, regulated-rate base erosion), (5) No quantitative errors or date inaccuracies. MINOR DIFFERENCES FROM GROUND TRUTH: (1) The LLM answer mentions 'stranded-asset and unrecovered-cost risks' in 2022, while the ground truth specifically references 'above-market purchased power commitments from qualifying facilities (QFs) under PURPA' - this is a slight loss of specificity but not factually incorrect, (2) The LLM answer frames the 2023 development as 'sharpened view' and 'more acute' interaction, which captures the essence of the ground truth's 'compounded challenge' but uses slightly different framing, (3) The ground truth mentions specific EPA regulations on 'CO2 emissions and cooling water intake structures' while the LLM generalizes to 'EPA and state climate rules' - again, less specific but semantically equivalent. MULTI-HOP REASONING: The LLM correctly synthesizes information across two years and two regulatory domains (deregulation and environmental compliance), showing how they interact. The logic is sound: deregulation creates cost recovery risks, and when combined with rising environmental compliance costs driven by stricter regulations, the problem becomes more acute. This matches the ground truth's conclusion about compounded challenges. OVERALL ASSESSMENT: The answer is substantively correct and demonstrates solid understanding of the multi-hop relationship. The minor loss of specificity (not mentioning PURPA QFs or specific EPA regulations) does not materially affect the accuracy of the core answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 576,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did the retail share of Skoal oral tobacco products change between 2023 and 2024, and how does this contrast with the pricing strategy applied to Skoal during 2023?",
      "original_answer": "The retail share of Skoal oral tobacco products decreased from 9.3% in 2023 to 7.6% in 2024, reflecting a decline in market presence. This contrasts with the pricing strategy in 2023, where multiple price increases were applied to Skoal products, including a $0.11 per can increase effective January 23, 2024 (announced in 2023), following earlier increases of $0.09, $0.09, and $0.08 per can in May, February, and January 2022, respectively. The cumulative effect of these increases may have impacted consumer demand, contributing to the drop in retail share.",
      "llm_answer": "Skoal’s retail share fell from 9.3 % in 2023 to 7.6 % in 2024 – a drop of about 1.7 share points【MO_10k_2024.pdf:48】. In contrast, the 2023 pricing strategy for Skoal was to raise its list price, with multiple $0.09‑$0.10‑per‑can increases (January, April and August 2023)【MO_10k_2023.pdf:45‑46】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) RETAIL SHARE NUMBERS: The LLM correctly states the retail share decline from 9.3% to 7.6% (a 1.7 percentage point drop), which matches the ground truth. (2) PRICING STRATEGY - MAJOR DISCREPANCY: The LLM claims price increases of '$0.09-$0.10-per-can increases (January, April and August 2023)' but the ground truth specifies: a $0.11 per can increase effective January 23, 2024 (announced in 2023), PLUS earlier increases of $0.09, $0.09, and $0.08 per can in May, February, and January 2022 respectively. The LLM has fundamentally misidentified the timing and amounts of price increases. It appears to have confused 2023 pricing actions with 2022 actions, and failed to capture the $0.11 increase that was the most recent/relevant to the 2023-2024 period. (3) INCOMPLETENESS: The LLM fails to mention the cumulative effect of price increases on consumer demand, which is explicitly noted in the ground truth as a potential explanation for the retail share decline. This is a key analytical insight that connects the two parts of the question. (4) MULTI-HOP REASONING: While the LLM attempts to contrast retail share decline with pricing strategy, it does so with incorrect pricing data, undermining the validity of the comparison. The ground truth explicitly notes that cumulative price increases 'may have impacted consumer demand, contributing to the drop in retail share' - this causal reasoning is absent from the LLM answer. (5) SOURCING: The LLM cites specific document pages, but the pricing information cited appears to be inaccurate based on the ground truth data provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 442,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did Amgen's investment in 'Other short-term interest-bearing securities' evolve between 2023 and 2024, and what does this indicate about the company's short-term investment strategy?",
      "original_answer": "Amgen's investment in 'Other short-term interest-bearing securities' remained unchanged at $138 million in both 2023 and 2024. This stability suggests that the company maintained a consistent approach to this segment of its short-term investment portfolio over the two-year period.",
      "llm_answer": "Amgen reported $138 million of “Other short‑term interest‑bearing securities” at the end of 2023, which fell to $135 million at the end of 2024 – a $3 million (≈2 %) decrease. The slight decline indicates the company’s short‑term investment portfolio remained essentially unchanged, reflecting a strategy that prioritizes safety of principal and ample liquidity rather than large reallocations of cash.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL FACTUAL ERROR: The LLM answer contains a fundamental numerical inaccuracy that directly contradicts the ground truth. The ground truth clearly states that Amgen's 'Other short-term interest-bearing securities' remained UNCHANGED at $138 million in both 2023 and 2024. However, the LLM claims the value fell from $138 million in 2023 to $135 million in 2024, representing a $3 million decrease. This is factually incorrect. (1) QUANTITATIVE ACCURACY FAILURE: The 2024 figure of $135 million is wrong (should be $138 million); the calculated decrease of $3 million is wrong (should be $0); the percentage change of 2% is wrong (should be 0%). These are not minor rounding differences but substantive numerical errors. (2) MULTI-HOP REASONING: While the LLM correctly identified the 2023 figure ($138 million) and attempted to synthesize a year-over-year comparison, it failed at the core task by providing an incorrect 2024 figure. (3) INTERPRETATION ISSUE: The LLM's interpretation that a $3 million decrease 'remained essentially unchanged' is internally inconsistent and contradicts its own stated numbers. The ground truth's interpretation that no change indicates a 'consistent approach' is more logically sound. (4) CONTEXTUAL RELEVANCE: The question asks about evolution and strategy implications. The LLM does attempt to address strategy (safety of principal, liquidity), but this interpretation is based on incorrect data. The correct answer (no change) actually better supports the stated strategy conclusion. The LLM answer demonstrates a significant failure in factual accuracy on the primary quantitative metrics, which is the most critical aspect of financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1180,
        "completion_tokens": 461,
        "total_tokens": 1642
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the nature of General Dynamics' involvement in Abrams Main Battle Tank Upgrades evolved from 2022 to 2024, particularly in terms of contract scope and value?",
      "original_answer": "In 2022, General Dynamics received a $360 million contract from the Army for Abrams main battle tank upgrades, mission control units, and systems technical support. By 2024, the company's involvement had evolved to include both production and support services, as evidenced by a $350 million contract for Abrams upgrades, engineering and logistics support, and system and sustainment technical support services. Additionally, a separate $285 million contract was awarded for producing Abrams tanks in the SEPv3 configuration for Romania. This indicates a shift from primarily upgrade-focused contracts to a broader scope that includes both upgrades and production of new configurations, with an increase in total contract value.",
      "llm_answer": "In the 2022 Form 10‑K GD disclosed a **$360 million** Army award for Abrams main‑battle‑tank upgrades that centered on **mission‑control units and systems technical support**【GD_10k_2022.pdf†page=42】. By the 2024 filing the award was a **$350 million** contract that added **engineering, logistics and sustainment technical‑support services** to the upgrade work【GD_10k_2024.pdf†page=44】. Thus, the contract value slipped slightly while the scope broadened from mainly mission‑control and technical support to a more comprehensive engineering‑logistics‑sustainment package.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identified the two main contracts ($360M in 2022 and $350M in 2024) and accurately characterized the scope evolution from mission-control/technical support to a broader engineering-logistics-sustainment package. The numbers are correct and the directional analysis (slight value decrease, scope broadening) is accurate. The citations to specific pages in the 10-K filings add credibility.\n\nWEAKNESSES: The LLM answer is INCOMPLETE regarding the full scope of General Dynamics' Abrams involvement evolution. The ground truth explicitly mentions a separate $285 million contract for producing Abrams tanks in SEPv3 configuration for Romania, which represents a significant expansion of the company's involvement beyond upgrades into new tank production. This is a material omission that affects the completeness of the answer to the multi-hop question about how involvement 'evolved' from 2022 to 2024. The ground truth characterizes this as 'a shift from primarily upgrade-focused contracts to a broader scope that includes both upgrades and production of new configurations, with an increase in total contract value' - but the LLM only addresses the upgrade contracts and misses the production dimension entirely.\n\nQUANTITATIVE ACCURACY: The two main contract values ($360M and $350M) are correct. However, the LLM's conclusion that 'contract value slipped slightly' is incomplete because it ignores the $285M Romania production contract, which would actually show an increase in total contract value when all three contracts are considered together.\n\nQUALITATIVE ACCURACY: The reasoning about scope broadening is sound for the upgrade contracts, but the failure to synthesize the Romania production contract represents a significant gap in multi-hop reasoning. The question asks about evolution of 'involvement' broadly, not just upgrade contracts.\n\nCONTEXTUAL RELEVANCE: The answer addresses the core question but incompletely. It captures the upgrade contract evolution but misses the production dimension that the ground truth identifies as a key part of the evolution narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 569,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did AIG's financial relationship with Corebridge evolve from 2023 to 2024, particularly in terms of borrowing arrangements and income recognition?",
      "original_answer": "In 2023, AIG disclosed that Corebridge had the ability to continue borrowing through February 25, 2025, indicating an ongoing financial arrangement. By 2024, AIG's relationship with Corebridge had transformed, as AIG began recognizing equity method income tied to Corebridge’s stock price changes and dividends received since June 9, 2024. This shift reflects a change from a borrowing-based relationship to one focused on equity-based returns.",
      "llm_answer": "In 2023 AIG still guaranteed Corebridge’s borrowings – its balance‑sheet listed Corebridge senior unsecured notes, junior subordinated debt and a $1.5 bn DDTL facility (with a guarantee‑reimbursement and collateral agreement that would require AIG to repay any Corebridge payments)【2023 10‑K p. 111】. After Corebridge was deconsolidated in June 2024, AIG removed those guarantees and the borrowing is no longer on its books; the company now holds a minority equity stake and records Corebridge dividends and fair‑value changes as equity‑method income in net investment income (and recognized a $4.8 bn loss on deconsolidation)【2024 10‑K pp. 107‑109】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. STRENGTHS: (1) Correctly identifies the 2023 borrowing arrangements including specific debt instruments (senior unsecured notes, junior subordinated debt) and the $1.5 billion DDTL facility with guarantee-reimbursement structure. (2) Accurately captures the June 2024 deconsolidation event as the pivotal transition point. (3) Correctly describes the shift from guarantee obligations to equity method accounting. (4) Provides specific financial impact ($4.8 billion loss on deconsolidation) that demonstrates deep understanding of the transaction. (5) Properly synthesizes information across 2023 and 2024 10-Ks showing multi-hop reasoning. (6) Correctly identifies the new income recognition method (equity-method income in net investment income, including dividends and fair-value changes). MINOR CONSIDERATIONS: The LLM answer is more detailed and specific than the ground truth (which is appropriate for a comprehensive answer), including specific debt types and the deconsolidation loss. The ground truth mentions 'February 25, 2025' as a borrowing continuation date, which the LLM doesn't explicitly reference, but this is a minor detail that doesn't contradict the answer. The core narrative of evolution from borrowing guarantees to equity-based returns is accurately captured. All dates (2023, June 2024, 2024) are correct. The financial figures provided ($1.5 bn, $4.8 bn) appear reasonable and specific. The answer directly addresses both components of the question: borrowing arrangements (2023) and income recognition (2024).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 446,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2022, Tesla was actively selling the Solar Roof and improving installation efficiency through collaboration with real estate developers and builders. The company emphasized its engineering efforts to combine aesthetics, durability, and power generation. By 2024, however, Tesla's 10-K highlights that the future of the Solar Roof (alongside other products) 'depends in large part' on overcoming production ramp challenges, including bottlenecks, supplier risks, and cost control. This reflects a shift from product development and sales emphasis to a more complex production and dependency landscape.",
      "llm_answer": "In the 2022 Form 10‑K (pages 4‑8) Tesla presented Solar Roof as a newly engineered, premium‑glass‑tile system integrated with its own inverter and Powerwall, and it warned that the product’s production ramp could be delayed. By the 2024 filing (pages 15‑19) the company still cites production bottlenecks but now emphasizes that Solar Roof’s output is heavily dependent on third‑party glass‑tile suppliers and on coordinating with its broader energy‑generation platform, and it is pursuing builder partnerships and scaling manufacturing capacity to mitigate those challenges.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Tesla's Solar Roof evolution between 2022 and 2024, with mostly accurate characterization of the shift in focus. Strengths: (1) Correctly identifies the 2022 emphasis on product engineering, aesthetics, durability, and power generation; (2) Accurately captures the 2024 shift toward production challenges and dependencies; (3) Properly identifies third-party supplier risks and glass-tile supplier dependencies as key 2024 concerns; (4) Correctly notes builder partnerships and manufacturing scaling as mitigation strategies; (5) Appropriately cites page ranges from 10-K filings. Minor weaknesses: (1) The LLM answer mentions specific page numbers (pages 4-8 for 2022, pages 15-19 for 2024) which cannot be verified against the ground truth and may be inaccurate - the ground truth does not provide page citations; (2) The LLM adds detail about 'premium-glass-tile system integrated with its own inverter and Powerwall' which, while plausible, goes slightly beyond what the ground truth explicitly states about 2022 positioning; (3) The ground truth emphasizes that Solar Roof's future 'depends in large part' on overcoming production challenges, which the LLM captures but could have emphasized more strongly as a key strategic shift. Multi-hop reasoning is sound: the answer correctly synthesizes information across two different years and identifies the evolution from development/sales focus to production/dependency concerns. The semantic equivalence is strong - both answers convey the same fundamental narrative of evolution from engineering emphasis to production-challenge focus. No calculation errors or factual contradictions with ground truth are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 468,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the retail share of Skoal in the U.S. oral tobacco market changed between 2023 and 2024, and what does this indicate about its competitive positioning?",
      "original_answer": "In 2023, Skoal held a 9.3% retail share in the U.S. oral tobacco market, which decreased to 7.6% in 2024. This decline indicates a weakening in Skoal's competitive positioning within the oral tobacco segment over this period. The drop in market share for Skoal contrasts with the growth seen in other products like on!, which increased from 6.8% to 8.3% during the same timeframe.",
      "llm_answer": "Skoal’s retail share fell from 9.3 percent in 2023 to 7.6 percent in 2024—a decline of about 1.7 percentage points. This drop signals that Skoal is losing ground to competing oral‑tobacco brands and its competitive positioning in the U.S. market has weakened.【MO_10k_2024.pdf p. 48‑49】",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies the key quantitative facts: Skoal's retail share declined from 9.3% in 2023 to 7.6% in 2024, representing a 1.7 percentage point drop (calculation verified: 9.3 - 7.6 = 1.7). The interpretation that this signals weakening competitive positioning is accurate and well-reasoned. However, the answer is incomplete relative to the ground truth. The original answer provides important comparative context by noting that on! increased from 6.8% to 8.3% during the same period, which strengthens the narrative about Skoal's relative competitive decline. This comparative analysis is a key part of understanding what the market share change 'indicates about competitive positioning'—it shows not just that Skoal declined, but that competitors gained ground. The LLM answer addresses the first part of the question (how has the share changed) thoroughly and accurately, but only partially addresses the second part (what does this indicate about competitive positioning) by omitting the comparative context with competing brands. The answer is factually sound but lacks the fuller analytical perspective provided in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1169,
        "completion_tokens": 329,
        "total_tokens": 1498
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the risk associated with the concentration of device share among premium tier companies evolved between 2023 and 2024, particularly in terms of its potential impact on Qualcomm's pricing power and revenue stability?",
      "original_answer": "In 2023, Qualcomm highlighted that the concentration of device share among a few premium tier companies was contributing to a trend of deriving a significant portion of revenues from a small number of customers, particularly Chinese OEMs. This concentration was noted to potentially result in lower prices for Qualcomm's products due to the purchasing power of these companies. In 2024, the risk factor remained present, but the emphasis shifted slightly to underscore the broader implications of this concentration, including the potential for even greater pricing pressure and revenue fluctuation due to the timing and success of customer product introductions. The continued reliance on a small group of customers, especially those developing their own integrated circuits or using competitors, suggests that the risk has not only persisted but potentially intensified, increasing its impact on Qualcomm's pricing power and revenue stability.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K’s risk‑factor sections stress that the premium‑tier handset market is becoming more concentrated among a few OEMs. The 2024 filing explicitly reiterates that this trend “may continue” and adds that the strong purchasing power of those few companies “may result in lower prices for our products, which could have an adverse effect on our revenues and margins,” indicating that the risk to Qualcomm’s pricing power and revenue stability has persisted—and is now reaffirmed rather than diminished—between the two years.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core facts: (1) concentration of device share among premium-tier OEMs in both 2023 and 2024, (2) the purchasing power of these companies leading to lower prices, (3) adverse effects on revenues and margins, and (4) the persistence of this risk across both years. The answer accurately cites the 2024 filing's language about the risk potentially continuing and its impact on pricing power and revenue stability. No quantitative errors are present (no specific numbers were required to be cited). The multi-hop reasoning is sound—the answer synthesizes information from both 2023 and 2024 filings to show evolution (or persistence) of the risk. However, the LLM answer has a notable omission: it does not explicitly mention the 2023 emphasis on Chinese OEMs specifically, which the ground truth highlights as a key detail. Additionally, the ground truth emphasizes that the risk has 'intensified' and notes the broader implications including 'timing and success of customer product introductions' as a 2024 addition, whereas the LLM answer characterizes the change more conservatively as 'reaffirmed rather than diminished.' The LLM's characterization is not incorrect but is less precise about the nature of the evolution (intensification vs. reaffirmation). The answer is well-structured and directly addresses the question about how the risk evolved, but misses some nuanced details about the specific evolution between years that the ground truth captures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 413,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "Given Amgen's approach to managing short-term liquidity, how did its allocation to money market mutual funds evolve between 2023 and 2024?",
      "original_answer": "Amgen's allocation to money market mutual funds remained unchanged at $10,266 million in both 2023 and 2024. The disclosed investment values for money market mutual funds under available-for-sale investments were identical in both years, indicating no shift in this portion of the company's short-term investment strategy.",
      "llm_answer": "Amgen’s short‑term liquidity policy stresses safety of principal, prudent liquidity and low‑risk, one‑year‑or‑less securities such as money‑market mutual funds (“The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk” – 2023 & 2024 10‑K notes). Accordingly, its money‑market mutual‑fund holdings rose from $10.266 billion at year‑end 2023 to $10.354 billion at year‑end 2024 – an increase of about $88 million. 【2023‑10K p. 131‑132】【2024‑10K p. 131‑132】",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL FACTUAL ERROR: The LLM answer contains a fundamental numerical inaccuracy that directly contradicts the ground truth. The LLM claims Amgen's money market mutual fund holdings increased from $10.266 billion (2023) to $10.354 billion (2024), representing an $88 million increase. However, the ground truth explicitly states that allocations remained UNCHANGED at $10,266 million in both 2023 and 2024. This is a major discrepancy - the LLM fabricated an increase that did not occur. The LLM's numbers ($10.266B and $10.354B) appear to be invented or misread from the source documents. The correct answer is that there was NO evolution or change in the allocation between the two years. While the LLM correctly identified the investment policy objectives and appropriately cited the 10-K pages, it fundamentally failed on the core quantitative requirement of the question. The calculation of $88 million difference is mathematically consistent with the LLM's stated figures ($10.354B - $10.266B = $0.088B), but both the starting and ending figures are incorrect according to the ground truth. This represents a complete failure to answer the specific question asked about how the allocation 'evolved' - the correct answer is that it did not evolve at all. The contextual framing about liquidity policy is relevant but cannot compensate for the factual error on the primary metric being evaluated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 389,
        "total_tokens": 1603
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has General Dynamics' participation in the Capital Construction Fund evolved between 2022 and 2024, particularly in terms of the amount of U.S. government accounts receivable pledged to the fund?",
      "original_answer": "In 2022, General Dynamics had U.S. government accounts receivable pledged to the Capital Construction Fund (CCF) of $295 million as of December 31, 2021. By 2024, the amounts pledged to the CCF had increased to $315 million on December 31, 2023, and $333 million on December 31, 2024. This indicates a steady increase in GD's participation in the CCF over the period, reflecting a growing utilization of the tax deferral benefits offered by the program.",
      "llm_answer": "General Dynamics’ involvement in the Capital Construction Fund has been expanding. In its 2022 filing the company reported that it had pledged $295 million of U.S. government accounts receivable to the fund (2022 10‑K note) and the 2024 filing shows that the pledged amount rose to $315 million at year‑end 2023 and further to $333 million at year‑end 2024 (2024 10‑K note). Thus, the amount of receivables pledged to the CCF increased from $295 million in 2022 to $315 million in 2023 and $333 million in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. Verification of key facts: (1) All dollar amounts are correct - $295 million (2022/end of 2021), $315 million (end of 2023), and $333 million (end of 2024). (2) All dates are correctly identified and properly contextualized. (3) The multi-hop synthesis is sound - the answer correctly traces the evolution of GD's CCF participation across the three-year period by extracting data from multiple 10-K filings. (4) The narrative accurately conveys the 'steady increase' trend, with increases of $20 million (2022-2023) and $18 million (2023-2024). Minor observation: The LLM answer slightly simplifies the date attribution by stating '$295 million in 2022' when technically this represents the December 31, 2021 balance reported in the 2022 10-K, whereas the ground truth is more precise about this distinction. However, this is a very minor semantic difference that doesn't affect the substantive accuracy. The answer correctly identifies the Capital Construction Fund, explains the context (tax deferral benefits), and demonstrates proper understanding of the multi-year evolution requested in the question. All calculations and comparisons are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 341,
        "total_tokens": 1595
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of its tax implications and investment income following the IPO and subsequent deconsolidation?",
      "original_answer": "In 2023, AIG's ownership in Corebridge dropped below 80% after Corebridge's IPO on September 19, 2022, resulting in the tax deconsolidation of Corebridge from AIG’s U.S. federal income tax group. This deconsolidation had significant tax implications, including restrictions on future consolidated tax filings for five years and the retention of Corebridge's net operating losses and tax credit carryforwards by Corebridge entities. By 2024, AIG no longer consolidated Corebridge's financials, and instead, AIG reported its investment in Corebridge under the equity method, recognizing $X in equity method income for the period from June 10, 2024, to December 31, 2024, based on dividends received and changes in Corebridge's stock price. This marks a shift from a consolidated tax and financial reporting relationship to a more arms-length investment relationship.",
      "llm_answer": "After Corebridge’s September 2022 IPO, AIG’s ownership fell below the 80 % threshold, triggering a tax de‑consolidation that removed Corebridge’s net operating losses and tax‑credit carryforwards from AIG’s consolidated U.S. tax group and barred joint filing for five years (2023 10‑K). In 2024, after the June 9 de‑consolidation, AIG re‑classified its remaining stake as an equity‑method investment, reporting $601 million of equity‑method income and $5.2 billion of net investment income (down from $11.1 billion in 2023) and incurring a $545 million tax expense on a $3.0 billion pre‑tax gain, which together produced a $4.8 billion after‑tax loss on the Corebridge sale.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates good understanding of the overall narrative arc (IPO → ownership drop below 80% → tax deconsolidation → shift to equity method accounting) and correctly identifies key dates and structural changes. However, there are significant quantitative accuracy issues that prevent a higher score.\n\nCORRECT ELEMENTS:\n- IPO date (September 2022) and ownership drop below 80% threshold correctly identified\n- Tax deconsolidation triggered by ownership drop is accurate\n- Five-year restriction on consolidated tax filings is correct\n- Retention of NOLs and tax credits by Corebridge entities is accurate\n- June 2024 deconsolidation date (June 9 vs June 10 in ground truth - minor discrepancy)\n- Shift from consolidated to equity method accounting is correctly described\n- The multi-hop reasoning connecting IPO → ownership drop → tax implications → accounting change is sound\n\nPROBLEMATIC ELEMENTS:\n1. QUANTITATIVE ISSUES: The LLM provides specific numbers ($601 million equity method income, $5.2 billion net investment income, $11.1 billion 2023 comparison, $545 million tax expense, $3.0 billion pre-tax gain, $4.8 billion after-tax loss) that are NOT in the ground truth answer. The ground truth explicitly states \"$X in equity method income\" - indicating the specific number was either unknown or intentionally redacted. The LLM appears to have fabricated or hallucinated these specific figures.\n\n2. SCOPE CREEP: The LLM introduces information about the Corebridge sale (pre-tax gain, tax expense, after-tax loss) that goes beyond what the ground truth addresses. While this may be factually accurate from the 10-K, it represents additional detail not in the ground truth answer.\n\n3. DATE DISCREPANCY: June 9 vs June 10, 2024 - minor but worth noting.\n\nMULTI-HOP REASONING: The synthesis across multiple concepts (IPO → ownership threshold → tax implications → accounting method change) is logically sound and well-structured. The answer correctly connects the causal chain.\n\nSEMANTIC EQUIVALENCE: The core narrative matches the ground truth, but the introduction of unverified specific numbers undermines confidence in the answer's accuracy. The ground truth's use of \"$X\" suggests these numbers may not have been reliably extractable or were intentionally variable.\n\nThe answer would score higher if it either: (1) matched the ground truth's use of \"$X\" for the equity method income figure, or (2) if those specific numbers could be verified as correct from the source documents. As presented, the quantitative claims appear unsupported by the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 690,
        "total_tokens": 2088
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Tesla's approach to Solar Roof production and its dependencies evolved from 2022 to 2024, particularly in terms of operational strategy and supply chain challenges?",
      "original_answer": "In 2022, Tesla emphasized improving Solar Roof installation capabilities by onboarding and training new installers and collaborating with real estate developers to reduce installation time and costs. The company also highlighted the need to maintain adequate battery cell supply and hire additional skilled electricians to support the ramp. By 2024, Tesla's focus had shifted to broader manufacturing and supply chain risks, with Solar Roof production now described as being dependent on the company's ability to manage global component procurement, avoid bottlenecks, and maintain cost-effective production amid potential supplier failures and inflationary pressures. The evolution reflects a shift from localized installer development to systemic supply chain and production scalability concerns.",
      "llm_answer": "In 2022 Tesla’s Solar‑Roof plan centered on a low‑cost, online ordering model and on‑boarding and training new installers, while partnering with developers to shorten install times and stressing the need for adequate battery‑cell supply and additional skilled electricians to support the ramp‑up (TSLA 10‑K 2022, pp. 32‑36). By 2024 the company has folded Solar‑Roof into a broader capital‑expenditure program that ramps the product alongside new Model S/X vehicles and Megapack, treating it as a large‑scale manufacturing effort and explicitly calling out industry‑wide component shortages, supplier constraints and the risk of production delays as key supply‑chain challenges (TSLA 10‑K 2024, pp. 15‑19). This marks a shift from an early‑stage installer‑focused rollout to a more integrated, capital‑intensive scaling strategy with heightened supply‑chain risk awareness.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the 2022 focus on installer onboarding, training, developer partnerships, battery cell supply needs, and skilled electrician hiring - all matching ground truth. (2) Accurately captures the 2024 shift toward broader manufacturing/supply chain risks, component procurement challenges, supplier failures, and inflationary pressures. (3) Properly synthesizes the evolution narrative from localized installer development to systemic supply chain concerns. (4) Appropriately references SEC 10-K filings with page ranges, demonstrating proper sourcing. (5) Uses semantically equivalent language ('folded Solar-Roof into broader capital-expenditure program' effectively conveys the shift to systemic concerns). (6) Correctly identifies all entities (Tesla/TSLA, Solar Roof, Model S/X, Megapack) and time periods (2022 vs 2024). MINOR CONSIDERATIONS: (1) The LLM adds contextual detail about 'low-cost, online ordering model' in 2022 and 'capital-intensive scaling strategy' in 2024 that, while reasonable inferences, are not explicitly confirmed in the ground truth statement. However, these additions are consistent with and enhance the core narrative without contradicting it. (2) The specific page references (pp. 32-36 for 2022, pp. 15-19 for 2024) cannot be verified against the ground truth but appear plausible for 10-K filings. (3) No quantitative metrics (percentages, dollar amounts, production volumes) are provided in either answer, so quantitative accuracy is assessed as high based on the absence of numerical errors. The multi-hop reasoning is sound: the answer successfully synthesizes information across two different years and filing documents to show an evolution in strategy. The answer fully addresses all parts of the multi-part question regarding operational strategy and supply chain challenges.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 524,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Duke Energy's estimated total cost to permanently close all coal ash basins in North Carolina and South Carolina evolved from 2022 to 2023, and what does this indicate about the company's progress under the Coal Ash Act?",
      "original_answer": "In 2022, Duke Energy estimated the total cost to permanently close all coal ash basins in North Carolina and South Carolina to be approximately $8 billion to $9 billion. By 2023, this estimate had decreased to approximately $7 billion to $8 billion, indicating a downward adjustment in projected costs. Additionally, the amount already spent on these closures increased from approximately $3.1 billion through 2021 (as reported in 2022) to approximately $4 billion through 2023. This evolution suggests that Duke Energy has made measurable progress in implementing closure plans under the Coal Ash Act, with more basins excavated and cost estimates refined over time.",
      "llm_answer": "- In the 2022 Form 10‑K Duke Energy said the total undiscounted cost to permanently close all coal‑ash basins in North Carolina and South Carolina was about **$8 billion to $9 billion**, of which roughly **$3.1 billion had been spent** through 2021 [DUK_10k_2022.pdf:71].  \n- In the 2023 Form 10‑K the estimate was revised lower to **approximately $7 billion to $8 billion**, with **about $4 billion already spent** through 2023 [DUK_10k_2023.pdf:70].  \n\nThe reduction in the projected total cost and the increase in spend indicate that Duke Energy is making measurable progress in closing the ash basins under the Coal Ash Act, shrinking the remaining remediation burden and accelerating the closure schedule.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. QUANTITATIVE VERIFICATION: All financial figures are correct - 2022 estimate of $8-9 billion matches ground truth, 2023 estimate of $7-8 billion matches ground truth, $3.1 billion spent through 2021 is accurate, and $4 billion spent through 2023 is accurate. The directional changes (cost estimate decreased, spending increased) are correctly identified. COMPLETENESS: The answer addresses all key components of the multi-part question: (1) 2022 cost estimate, (2) 2023 cost estimate, (3) evolution/change between years, (4) spending progress, and (5) implications for Coal Ash Act progress. ENTITY ACCURACY: Duke Energy correctly identified, North Carolina and South Carolina correctly specified, Coal Ash Act properly referenced, fiscal years 2022 and 2023 correctly applied. MULTI-HOP REASONING: The answer successfully synthesizes information across two separate 10-K filings (2022 and 2023) and correctly draws the logical conclusion that the reduction in total estimated cost combined with increased actual spending demonstrates measurable progress. The reasoning that 'shrinking the remaining remediation burden' and 'accelerating the closure schedule' follows logically from the data presented. MINOR OBSERVATION: The LLM answer includes specific PDF page references [DUK_10k_2022.pdf:71] and [DUK_10k_2023.pdf:70], which adds credibility and traceability, though these weren't explicitly required. The characterization of progress as 'measurable' and the interpretation of cost refinement are semantically equivalent to the ground truth. No calculation errors detected. The answer is clear, well-organized, and directly responsive to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 467,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did the retail share of the 'on!' oral tobacco product evolved between 2023 and 2024, and what does this indicate about its market position relative to the overall oral tobacco product segment during this period?",
      "original_answer": "The retail share of the 'on!' oral tobacco product increased from 6.8% in 2023 to 8.3% in 2024. This indicates that 'on!' gained market share during this period. In contrast, the total oral tobacco product segment saw a decline in retail share, dropping from 42.5% in 2023 to 37.5% in 2024. This divergence suggests that 'on!' strengthened its position within the broader oral tobacco market between these years.",
      "llm_answer": "The retail share of Altria’s on! product rose from 6.8 % in 2023 to 8.3 % in 2024—a 1.5‑percentage‑point gain【MO_10k_2024.pdf page 48】. This increase occurred as the overall oral‑tobacco‑products segment’s retail share fell from 42.5 % to 37.5 %, showing that on! improved its relative market position even as the broader segment lost share【MO_10k_2024.pdf page 48】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. (1) QUANTITATIVE ACCURACY: All numbers are correct - on! retail share increased from 6.8% (2023) to 8.3% (2024), representing a 1.5 percentage-point gain (correctly calculated). The oral tobacco segment decline from 42.5% to 37.5% is also accurate. (2) COMPLETENESS: The answer addresses both parts of the multi-part question: the evolution of on!'s retail share AND what this indicates about its market position relative to the broader segment. (3) ENTITY ACCURACY: Correctly identifies Altria's on! product, the correct years (2023-2024), and the correct metrics (retail share percentages). (4) REASONING & SYNTHESIS: The multi-hop reasoning is sound - the model correctly synthesizes that while on! gained share, the overall segment lost share, demonstrating on!'s relative strengthening. The logical conclusion that on! 'improved its relative market position even as the broader segment lost share' is accurate and well-reasoned. (5) SEMANTIC EQUIVALENCE: The answer conveys the same information as the ground truth with slightly more concise wording ('strengthened its position' vs 'improved its relative market position') but maintains semantic equivalence. Minor note: The answer attributes information to 'MO_10k_2024.pdf page 48' which adds helpful sourcing but is not required for correctness. The only minor deviation is the slightly different phrasing of the conclusion, but this is a stylistic choice that doesn't affect accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 414,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Qualcomm's reliance on Chinese OEMs for revenue evolved from 2023 to 2024, and what implications does this have for its business stability?",
      "original_answer": "In 2023, Qualcomm derived a significant portion of its revenues from a small number of Chinese OEMs, highlighting its dependency on their device share growth in China and other regions. By 2024, this dependency persisted, with the company continuing to emphasize that it derives a significant portion of its revenues from these same OEMs. This ongoing reliance indicates that any political, economic, or market shifts affecting Chinese OEMs could continue to pose a risk to Qualcomm's revenue stability, particularly given the persistent U.S./China trade and national security tensions mentioned in both filings.",
      "llm_answer": "In its 2023 filing Qualcomm already warned that a “significant portion of our revenues… comes from a small number of Chinese OEMs,” but the 2024 filing adds that those OEMs have been gaining device share and that the company still earned roughly $560 million of Huawei sales before the export‑license was revoked, underscoring that Chinese OEMs remain a material source of revenue. The heightened concentration – now coupled with growing geopolitical and trade‑policy risks – makes Qualcomm’s cash‑flow and earnings more vulnerable to U.S./China restrictions, threatening the stability of its business.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES: (1) UNVERIFIED SPECIFIC NUMBER: The LLM claims Qualcomm 'earned roughly $560 million of Huawei sales before the export-license was revoked.' This specific dollar amount is NOT present in the ground truth answer and cannot be verified from the provided context. This is a major factual claim that introduces potentially false quantitative data. (2) HUAWEI REFERENCE: The ground truth makes no mention of Huawei specifically or any export license revocation. The LLM has introduced a specific company name and business event that is not corroborated by the ground truth, suggesting either hallucination or information from outside the verified knowledge graph. (3) PARTIAL ALIGNMENT: The LLM correctly identifies that Qualcomm warned about 'significant portion of revenues from a small number of Chinese OEMs' in both 2023 and 2024, which matches the ground truth. (4) CORRECT RISK ASSESSMENT: The LLM appropriately identifies geopolitical and trade-policy risks to business stability, which aligns with the ground truth's mention of 'U.S./China trade and national security tensions.' (5) MULTI-HOP REASONING: The LLM attempts to synthesize evolution from 2023 to 2024 and implications for business stability, which is appropriate for the question structure. However, the introduction of unverified specific numbers undermines the credibility of the entire response. The ground truth emphasizes 'persistent' dependency without quantifying changes, while the LLM adds specificity that cannot be confirmed. VERDICT: While the qualitative reasoning about geopolitical risks and OEM dependency is sound, the introduction of the unverified $560 million Huawei figure is a significant factual error that substantially reduces the answer's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 479,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did Amgen's composition of total available-for-sale investments evolve between 2022 and 2023, particularly in terms of specific security types held?",
      "original_answer": "In 2022, Amgen reported total available-for-sale investments of $4,335 million, which included $1,676 million in marketable securities alongside $2,659 million in cash and cash equivalents. By 2023, Amgen no longer held any marketable securities or U.S. Treasury bills, and instead, the entire $10,404 million in total available-for-sale investments was composed of $10,266 million in money market mutual funds and $138 million in other short-term interest-bearing securities. This reflects a strategic shift toward more liquid and short-term interest-bearing instruments.",
      "llm_answer": "Amgen’s total available‑for‑sale investments more than doubled, rising from $4.3 billion at year‑end 2022 to $10.4 billion at year‑end 2023. In 2022 the portfolio consisted of $1.7 billion of U.S. Treasury bills and $2.7 billion of money‑market mutual funds; by 2023 the Treasury bills were gone, money‑market mutual funds expanded to $10.3 billion and a new $138 million of other short‑term interest‑bearing securities was added.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a fundamental factual error regarding the composition of 2022 investments. The ground truth states that in 2022, Amgen held $1,676 million in marketable securities and $2,659 million in cash and cash equivalents (totaling $4,335 million). However, the LLM incorrectly claims the 2022 portfolio consisted of '$1.7 billion of U.S. Treasury bills and $2.7 billion of money-market mutual funds.' This is a significant mischaracterization - the ground truth identifies the 2022 components as 'marketable securities' and 'cash and cash equivalents,' NOT as Treasury bills and money-market mutual funds. The LLM appears to have confused the 2023 composition (which includes money-market mutual funds) with the 2022 composition. The 2023 figures are correctly stated ($10.3 billion in money-market mutual funds, $138 million in other short-term interest-bearing securities, totaling $10.4 billion), and the overall trend of growth from $4.3B to $10.4B is accurate. The LLM correctly identifies that Treasury bills were eliminated by 2023. However, the misidentification of what comprised the 2022 portfolio is a major factual error that undermines the core answer to a question specifically asking about how the composition evolved. The semantic understanding of 'shift toward more liquid instruments' is present but the specific security types for 2022 are wrong, making the comparison invalid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 401,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the presence of Shake Shack as a tenant evolved across SPG's premium outlet properties between 2022 and 2023?",
      "original_answer": "In 2022, Shake Shack was listed as a tenant at Woodbury Common Premium Outlets in New York. By 2023, Shake Shack not only remained at Woodbury Common but also expanded its presence to Las Vegas Outlets North Premium in Nevada. This indicates a strategic expansion of Shake Shack’s footprint within SPG's portfolio of properties over the two years.",
      "llm_answer": "In the 2022 Form 10‑K, Shake Shack was listed only at two premium‑outlet locations – Woodbury Common Premium Outlets in New York and the Las Vegas Outlets in Nevada 【SPG_10k_2022.pdf†p33‑37】. The 2023 Form 10‑K shows the same two properties still featuring Shake Shack, with no new outlets added or any removed 【SPG_10k_2023.pdf†p32‑36】. Thus, the brand’s presence across SPG’s premium‑outlet portfolio remained unchanged between 2022 and 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth. According to the original answer (ground truth), Shake Shack's presence EVOLVED between 2022 and 2023: it was at only Woodbury Common in 2022, then expanded to include Las Vegas Outlets North Premium in 2023. However, the LLM claims Shake Shack was already at BOTH locations in 2022 and remained unchanged through 2023. This is a critical factual error that misrepresents the core finding of the question - that there was strategic expansion. The LLM incorrectly states 'the brand's presence across SPG's premium-outlet portfolio remained unchanged between 2022 and 2023,' which directly contradicts the ground truth showing expansion from 1 to 2 locations. The quantitative error is significant: the LLM reports 2 locations in 2022 when the ground truth shows only 1 location in 2022. The multi-hop reasoning failed because the model did not correctly synthesize the year-over-year comparison across the two 10-K filings. While the answer is contextually relevant to the question asked and addresses the right companies/properties, the factual content is substantially wrong, making this a poor response despite appropriate structure and citation format.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1190,
        "completion_tokens": 346,
        "total_tokens": 1537
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the classification of retirement annuity contracts within the fair value hierarchy evolve between 2022 and 2024, and what does this indicate about GD's valuation methodology for these assets?",
      "original_answer": "In 2022, retirement annuity contracts were part of Level 3 assets, indicating that their fair value was determined using unobservable inputs. By 2024, these contracts remained in Level 3, but the disclosure noted that investments valued using net asset value (NAV) as a practical expedient were now included in the tables for reconciliation to total plan assets, which was not explicitly stated in 2022. This suggests a refinement in disclosure practices rather than a change in hierarchy classification, indicating that while the valuation methodology remained complex and less observable, GD improved transparency in how these assets are reported.",
      "llm_answer": "In the 2022 Form 10‑K GD reported its retirement‑annuity contracts as Level 3 assets (valued using significant unobservable inputs) with a fair‑value balance of $35 million【GD_10k_2022.pdf p. 91‑93】. The 2024 filing still classifies these contracts as Level 3 (now $22 million)【GD_10k_2024.pdf p. 91‑93】, indicating GD continues to rely on internal, model‑based assumptions rather than observable market prices to value the contracts.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies that retirement annuity contracts remained classified as Level 3 assets in both 2022 and 2024, and accurately describes the valuation methodology (unobservable inputs/model-based assumptions). However, there are significant issues: (1) QUANTITATIVE ACCURACY: The specific dollar amounts cited ($35 million in 2022 and $22 million in 2024) cannot be verified against the ground truth, which does not provide these exact figures. The page references (p. 91-93) are cited but without confirmation of accuracy. (2) COMPLETENESS: The LLM answer addresses the classification evolution and methodology but FAILS to address the key refinement mentioned in the ground truth - the 2024 disclosure improvement regarding NAV as a practical expedient and its inclusion in reconciliation tables. This is a material omission that represents a significant part of what the ground truth identifies as the evolution between years. (3) REASONING: The LLM correctly synthesizes that the classification remained stable (Level 3) and explains the valuation approach, but misses the disclosure methodology evolution that the ground truth emphasizes as the actual 'evolution' between 2022 and 2024. The ground truth indicates the change was in transparency/disclosure practices, not in hierarchy classification itself. (4) ENTITY ACCURACY: GD (General Dynamics) is correctly identified. The years 2022 and 2024 are correct. (5) SEMANTIC EQUIVALENCE: The description of Level 3 valuation methodology is semantically equivalent to the ground truth's description. However, the answer is incomplete because it doesn't capture the disclosure refinement that represents the actual evolution. The answer reads as partially correct but incomplete in addressing what actually evolved between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 491,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of potential equity dilution and income recognition?",
      "original_answer": "In 2023, AIG had a stake in Corebridge that included a potential equity dilution mechanism tied to Blackstone's right to exchange its ownership interest in Corebridge for AIG common shares, which would have introduced up to 24.1 million additional shares in 2022 (and 4.4 million in 2023) had the IPO not occurred before 2024. However, since the IPO occurred on September 19, 2022, this exchange right was terminated. By 2024, AIG's relationship with Corebridge had shifted from a stakeholding to an equity method investment, where AIG reported income based on dividends received and changes in Corebridge's stock price from June 9, 2024 onwards. This reflects a transformation from a potential equity dilution scenario to a post-divestiture equity income model.",
      "llm_answer": "In 2023 AIG still consolidated Corebridge, owning 52.2 % of its stock and reporting $3.6 billion of net income attributable to AIG shareholders; a Blackstone exchange option that could have diluted AIG’s equity was excluded from diluted EPS (4.4 million potential shares) because it would have been anti‑dilutive (2023 10‑K, p. 240). By 2024 AIG had de‑consolidated Corebridge, its stake fell to 22.7 %, and Corebridge is now accounted for under the equity‑method, generating $601 million of equity‑method income (and a $4.8 billion loss on de‑consolidation) with no remaining dilutive share‑exchange right (2024 10‑K, pp. 107‑108).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. STRENGTHS: (1) Correctly identifies the 2023 consolidation status (52.2% ownership) and 2024 de-consolidation (22.7% ownership), showing clear evolution; (2) Accurately cites the 4.4 million potential shares from the Blackstone exchange option in 2023 and correctly notes it was excluded from diluted EPS as anti-dilutive; (3) Properly identifies the shift from consolidation to equity method accounting; (4) Correctly reports $3.6 billion net income attributable to AIG shareholders in 2023 and $601 million equity-method income in 2024; (5) Includes the $4.8 billion loss on de-consolidation, which is a material detail; (6) Correctly notes the IPO occurred September 19, 2022, and that the exchange right was terminated; (7) Provides specific page citations (2023 10-K p. 240; 2024 10-K pp. 107-108) enhancing credibility; (8) Multi-hop reasoning is sound, synthesizing ownership changes, accounting method changes, and income recognition across two fiscal years. MINOR CONSIDERATIONS: The LLM answer is more detailed and specific than the ground truth (includes specific income figures and loss on de-consolidation), but these additions are factually accurate and enhance rather than detract from the answer. The ground truth mentions the IPO occurred before 2024 and that the exchange right was terminated, which the LLM implicitly confirms by noting no remaining dilutive share-exchange right in 2024. All quantitative data points are verifiable and correct. The answer directly addresses both components of the question: equity dilution evolution and income recognition changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 458,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2024, based on its debt disclosures and consolidation treatment?",
      "original_answer": "In 2022, Comcast disclosed that Universal Beijing Resort had $3.6 billion in debt as of December 31, 2021, and $2.5 billion as of December 31, 2020. By 2024, Comcast clarified that Universal Beijing Resort had $3.4 billion in debt outstanding as of December 31, 2024, and $3.5 billion as of December 31, 2023. This indicates that the debt levels stabilized after earlier reductions, and Comcast now consolidates Universal Beijing Resort as a variable interest entity (VIE), with its assets and liabilities fully included in Comcast’s consolidated balance sheets at $7.3 billion in assets and $7.0 billion in liabilities as of 2024.",
      "llm_answer": "In the 2022 Form 10‑K, Universal Beijing Resort’s debt was shown as a “Debt not guaranteed” item of $3.6 billion, meaning Comcast’s exposure was limited to its 30 % equity stake and the debt was off the consolidated balance sheet. By the 2024 filing the resort’s outstanding debt had slipped to roughly $3.4 billion and Comcast now consolidates the VIE, reporting the resort’s assets and liabilities on its balance sheet while still noting that its maximum loss risk is confined to its 30 % equity interest. This reflects a modest decline in the underlying debt and a shift from a non‑guaranteed, off‑balance‑sheet exposure to a fully‑consolidated VIE exposure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general narrative of Comcast's evolving financial exposure to Universal Beijing Resort and correctly identifies the shift from off-balance-sheet to consolidated VIE treatment. However, there are significant quantitative discrepancies that undermine accuracy:\n\nCORRECT ELEMENTS:\n- Correctly identifies debt levels: $3.6 billion (2021/2022), $3.4 billion (2024), $3.5 billion (2023)\n- Correctly identifies the shift from non-consolidated to consolidated VIE treatment\n- Correctly notes the consolidation includes assets and liabilities on balance sheet\n- Appropriately characterizes the debt decline as 'modest'\n- Correctly identifies the 30% equity stake reference\n\nINCORRECT/PROBLEMATIC ELEMENTS:\n1. CRITICAL ERROR: The LLM states the debt was 'off the consolidated balance sheet' in 2022 and that Comcast's exposure was 'limited to its 30% equity stake.' The ground truth indicates that by 2024, Comcast consolidates Universal Beijing Resort as a VIE with full consolidation. The LLM's characterization of 2022 treatment as off-balance-sheet may be accurate for that year, but the answer conflates the accounting treatment across years without clearly distinguishing when the consolidation change occurred.\n\n2. MISSING CRITICAL DETAIL: The ground truth specifies consolidated balance sheet amounts ($7.3 billion in assets and $7.0 billion in liabilities as of 2024), which the LLM completely omits. This is a significant omission for understanding the full financial exposure.\n\n3. AMBIGUOUS STATEMENT: The phrase 'while still noting that its maximum loss risk is confined to its 30% equity interest' is confusing and potentially contradictory. If the VIE is fully consolidated, Comcast's exposure extends beyond just the 30% equity stake to the full consolidated amounts. This statement suggests incomplete understanding of VIE consolidation mechanics.\n\n4. INCOMPLETE TEMPORAL ANALYSIS: The answer doesn't clearly establish the timeline of when the consolidation treatment changed (between 2022 and 2024), which is central to understanding the 'evolution' requested in the question.\n\nMULTI-HOP REASONING: The answer attempts to synthesize information across years and connect debt levels to consolidation treatment, but the reasoning is incomplete and contains logical inconsistencies regarding the relationship between equity stake percentage and consolidated exposure.\n\nOVERALL: The answer demonstrates partial understanding but lacks precision on key quantitative details (missing balance sheet amounts) and contains potentially misleading statements about the nature of consolidated VIE exposure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 701,
        "total_tokens": 2025
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the structure of aircraft trade-in commitments changed between 2022 and 2023, particularly in terms of customer eligibility and risk exposure?",
      "original_answer": "In 2022, the Aerospace segment had outstanding options with 'some customers' to trade in aircraft as partial consideration for new aircraft purchases, indicating a broader or less-specific customer eligibility. By 2023, the eligibility was narrowed to 'some Gulfstream customers,' suggesting a more specific subset of customers was offered trade-in options. Additionally, while both years acknowledged the risk associated with adverse market changes affecting trade-in values, 2023 introduced a more specific framing by highlighting Gulfstream, a key business jet brand, which may indicate a strategic focus or increased risk concentration in that segment. Despite these structural changes, both years reported that the estimated change in fair market values from the commitment date was 'not material.'",
      "llm_answer": "In the 2022 filing the trade‑in provisions were described generally as “outstanding options with some customers” of the Aerospace segment, while the 2023 filing narrows the pool by stating that “some Gulfstream customers hold options” to trade in aircraft, indicating a more specific eligibility criterion. The mechanics of the commitments – a fair‑market‑value determination roughly 45 days before delivery or a guaranteed pre‑set value that can reduce revenue if market values fall – are unchanged, and the risk of adverse market‑value changes remains disclosed as non‑material.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing the core structural changes in aircraft trade-in commitments between 2022 and 2023. STRENGTHS: (1) Correctly identifies the narrowing of customer eligibility from 'some customers' in 2022 to 'some Gulfstream customers' in 2023, which is the primary structural change. (2) Accurately notes that both years reported non-material changes in fair market values. (3) Correctly describes the mechanics of the commitments (fair-market-value determination ~45 days before delivery or guaranteed pre-set value). (4) Properly synthesizes the multi-hop information across two years and identifies the risk exposure element. (5) No quantitative errors or incorrect dates/numbers. MINOR WEAKNESSES: (1) The LLM answer does not explicitly mention that the narrowing to 'Gulfstream customers' may indicate 'strategic focus or increased risk concentration' as noted in the ground truth. While the LLM states the narrowing indicates 'more specific eligibility criterion,' it doesn't elaborate on the potential strategic or risk concentration implications that the ground truth emphasizes. (2) The ground truth notes that the 2023 framing 'may indicate a strategic focus or increased risk concentration in that segment' - the LLM answer is more neutral/descriptive and doesn't explore this interpretive dimension. (3) The LLM answer could have been slightly more explicit about what 'risk exposure' means in this context (adverse market changes affecting trade-in values). OVERALL ASSESSMENT: The answer is factually accurate, addresses the multi-part question about structural changes and risk exposure, correctly identifies entities and years, and demonstrates sound multi-hop reasoning. The omission of strategic/risk concentration interpretation is a minor gap that prevents a perfect score, but the core factual content is correct and well-synthesized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 513,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2022 and 2024, particularly in terms of its production status and strategic positioning within Tesla's product lineup?",
      "original_answer": "In 2022, Tesla had only announced the Tesla Semi as part of its planned electric vehicles, indicating it was in the conceptual and development phase. By 2024, Tesla had moved the Tesla Semi into 'pilot production' at its Nevada facility, signaling a significant advancement in its development and a step closer to commercialization. This evolution reflects Tesla's strategic shift from merely planning the vehicle to actively preparing it for market entry.",
      "llm_answer": "In the 2022 Form 10‑K Tesla’s Semi was mentioned only as a “commercial electric vehicle” among its announced future models, with no production activity described【TSLA_10k_2022.pdf p.5】. By the 2024 filing the Semi had progressed to “pilot production” at the Nevada facility and is highlighted as one of the newer vehicle models (alongside Cybertruck and next‑generation platforms) that Tesla is expanding capacity for, showing its shift from a concept to early manufacturing and a strategic pillar of the lineup【TSLA_10k_2024.pdf p.34‑36】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2022 status as conceptual/announced phase with no production activity, matching the ground truth characterization of 'conceptual and development phase'. (2) Accurately captures the 2024 progression to 'pilot production' at Nevada facility, which is the critical evolution point. (3) Properly synthesizes multi-hop information by comparing the two time periods and showing the strategic shift from planning to manufacturing. (4) Correctly identifies the Tesla Semi's positioning within the broader product lineup alongside Cybertruck and next-generation platforms. (5) Uses appropriate terminology ('commercial electric vehicle,' 'pilot production,' 'early manufacturing') that aligns with SEC filing language. (6) Provides specific document references with page numbers, enhancing credibility. MINOR CONSIDERATIONS: The LLM answer is slightly more detailed than the ground truth (mentioning Cybertruck and next-generation platforms), but this additional context is accurate and relevant to understanding Tesla's strategic positioning. The phrase 'strategic pillar of the lineup' in the LLM answer is a reasonable inference from the ground truth's 'strategic positioning within Tesla's product lineup.' No numerical errors, date errors, or factual inaccuracies detected. The multi-hop reasoning correctly synthesizes information across 2022 and 2024 filings to show the evolution trajectory.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 420,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the valuation allowance related to Altria's investment in Cronos evolve between 2022 and 2024, and what does this indicate about the company's expectations regarding the realizability of associated deferred tax assets?",
      "original_answer": "Between 2022 and 2024, the valuation allowance related to Altria's investment in Cronos increased from $379 million in 2022 to $402 million in 2024. This indicates that Altria continued to maintain significant uncertainty regarding the realizability of deferred tax assets associated with the Cronos investment, as the company still did not expect the temporary difference to reverse in the foreseeable future. The steady increase in the allowance suggests a cautious stance by Altria in recognizing the full value of these assets.",
      "llm_answer": "The valuation allowance tied to Altria’s Cronos investment rose from $379 million at year‑end 2022 to $397 million at year‑end 2023 and to $402 million at year‑end 2024 (MO_10k_2024.pdf p.84). The incremental increase shows the company still views a portion of the Cronos‑related deferred tax assets as unlikely to be realized, maintaining a modest but growing reserve for potential non‑realization.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: All numbers are correct - $379 million (2022), $397 million (2023), and $402 million (2024). The progression is accurate and properly cited to MO_10k_2024.pdf p.84. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) how the valuation allowance evolved between 2022-2024, and (2) what this indicates about Altria's expectations regarding deferred tax asset realizability. The LLM provides the intermediate 2023 figure ($397 million), which adds helpful detail beyond the ground truth's 2022-2024 comparison. ENTITY ACCURACY: Correctly identifies Altria, Cronos investment, deferred tax assets, and valuation allowance. REASONING: The multi-hop synthesis is sound - the answer correctly connects the increasing allowance amounts to Altria's cautious stance on asset realization. The interpretation that the company 'still views a portion of the Cronos-related deferred tax assets as unlikely to be realized' accurately reflects the underlying tax accounting principle. SEMANTIC EQUIVALENCE: The LLM's phrasing 'modest but growing reserve for potential non-realization' conveys the same meaning as the ground truth's 'steady increase in the allowance suggests a cautious stance.' Minor difference: The ground truth emphasizes 'continued uncertainty' and 'did not expect the temporary difference to reverse in the foreseeable future,' while the LLM focuses on the incremental nature of the increase. Both interpretations are valid and complementary. The citation to source material adds credibility. No calculation errors detected. The answer is well-structured and directly responsive to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 467,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the financial treatment and valuation impact of Amgen's investment in BeiGene evolve between 2023 and 2024?",
      "original_answer": "In 2023, Amgen changed the accounting method for its investment in BeiGene from the equity method to fair value, resulting in gains recognized in connection with this revaluation. By 2024, the investment contributed net unrealized losses within Amgen's Other income (expense), net, reflecting a shift from gains in 2023 to losses in 2024 due to market or valuation changes. This evolution shows a reversal in the financial benefit derived from the BeiGene investment over the two years.",
      "llm_answer": "In 2023 Amgen switched its BeiGene stake from the equity‑method to a fair‑value approach, so the change in fair value was recorded as a gain in other income (the 2023 “Other income (expense), net” increase was “primarily due to gains recognized in connection with recording our BeiGene investment at fair value”)【AMGN_10k_2023.pdf†p78】. By 2024 the same fair‑value accounting remained, but the investment’s fair value moved lower, producing net unrealized losses that offset other income (the 2024 “Other income (expense), net” change was “primarily due to current‑year net unrealized losses on our strategic equity investments…the 2023 net unrealized gains…were principally composed of amounts recognized on our BeiGene investment”)【AMGN_10k_2024.pdf†p78】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. It correctly identifies: (1) the 2023 accounting method change from equity method to fair value for BeiGene investment; (2) the resulting gains recognized in 2023 within Other income (expense), net; (3) the continuation of fair-value accounting in 2024; (4) the shift to net unrealized losses in 2024. The answer properly synthesizes the multi-hop information across two years and two 10-K filings, showing the evolution from gains to losses. The cited quotes from the 10-K documents (pages 78 of both 2023 and 2024 filings) are accurate and directly support the narrative. The reasoning is sound: the same investment was revalued under the same accounting method, but market conditions caused the fair value to decline, resulting in the reversal from gains to losses. No quantitative errors are present. The answer is more detailed and better sourced than the ground truth, providing specific document citations and direct quotes. The only minor consideration is that the answer could have been slightly more explicit about the 'reversal' concept mentioned in the ground truth, though this is clearly implied in the narrative. The semantic equivalence is excellent - the LLM answer conveys all the essential information from the ground truth while adding valuable supporting detail and documentation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 378,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the positioning and market strategy for Disney+ Hotstar evolved between 2023 and 2024, particularly in terms of its regional branding and service structure?",
      "original_answer": "In 2023, Disney+ Hotstar was described as a DTC service primarily in India that offered general entertainment, family, and sports programming. It was positioned as a distinct regional brand within Disney’s broader Direct-to-Consumer portfolio. By 2024, while still branded as Disney+ Hotstar in India and Southeast Asia, the company had merged its previously separate Star+ and Disney+ services in Latin America into a single Disney+ product offering by the end of June 2024. This indicates a strategic shift toward consolidating regional streaming services under the Disney+ brand umbrella, streamlining offerings, and possibly enhancing content integration across markets.",
      "llm_answer": "In the 2023 filing Disney+ Hotstar was described as a direct‑to‑consumer service “primarily in India that offers general entertainment, family and sports programming” (2023 10‑K, pp. 2‑6). By the 2024 filing the company still brands the service as Disney+ Hotstar in India and certain Southeast Asian markets, but stresses that it is a “stand‑alone service” and is not part of any multi‑product offering, while the separate Disney+ and Star+ services were merged into a single Disney+ product offering worldwide (2024 10‑K, pp. 55‑59). This shows a shift toward consolidating the global DTC portfolio while retaining the Hotstar brand for the Indian market.",
      "correctness_score": 5,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains both accurate and inaccurate elements. CORRECT ELEMENTS: (1) Accurate description of Disney+ Hotstar in 2023 as a DTC service in India offering general entertainment, family, and sports programming; (2) Correct identification that Disney+ Hotstar remained branded as such in India and Southeast Asia in 2024; (3) Correct identification of the merger of Star+ and Disney+ services; (4) Correct general timeframe (end of June 2024 for Latin America consolidation). SIGNIFICANT ERRORS: (1) The LLM states that Disney+ Hotstar is described as a 'stand-alone service' and 'is not part of any multi-product offering' - this contradicts the ground truth which indicates it was part of Disney's broader DTC portfolio and the strategic shift was toward consolidation under the Disney+ umbrella, not isolation; (2) The LLM claims the merger of Disney+ and Star+ occurred 'worldwide' when the ground truth specifically indicates this consolidation happened in Latin America by end of June 2024, not globally; (3) The LLM mischaracterizes the strategic direction - the ground truth emphasizes consolidation under the Disney+ brand umbrella globally, while the LLM suggests Hotstar remains separate/stand-alone. MULTI-HOP REASONING: The LLM failed to properly synthesize the key strategic insight - that the evolution represents a shift toward consolidating regional services under the Disney+ brand globally, while maintaining regional branding where appropriate (Hotstar in India/Southeast Asia). Instead, it incorrectly positioned Hotstar as isolated rather than integrated into the broader consolidation strategy. The page citations appear fabricated or imprecise. The answer partially addresses the question but contains material misinterpretations of the strategic positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 487,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did PayPal's approach to its Protection Programs evolve between 2023 and 2024, particularly in terms of risk exposure and loss recovery mechanisms?",
      "original_answer": "In 2023, PayPal disclosed that the costs associated with its protection programs were recorded in 'transaction and credit losses' during the period the payment transaction was completed, and it did not provide a separate service to customers under these programs. By 2024, PayPal introduced more detailed disclosures around its protection programs, highlighting that it incurs substantial losses from these programs due to customer disputes and faces challenges in recovering losses from merchants, especially in cases involving fraud or merchant insolvency. Additionally, PayPal noted that it may face increased exposure due to evolving fraud schemes and potential regulatory changes affecting chargeback requirements. This indicates a shift toward more explicit risk acknowledgment and a broader understanding of potential financial impact.",
      "llm_answer": "In the 2023 Form 10‑K PayPal said that its merchant‑ and consumer‑protection programs are “intended to protect both merchants and consumers from loss primarily due to fraud and counter‑party performance” and that it “estimate[s] and record[s] associated costs in transaction and credit losses during the period the payment transaction is completed” (2023 10‑K, p. 75). By the 2024 filing the discussion had shifted to a risk‑focused narrative: the company still provides purchase and seller protection, but now stresses that “we incur substantial losses from our protection programs…while we may seek to recover losses from the merchant, we ultimately may not be able to fully recover such losses” and warns that regulatory or card‑network changes could increase its exposure (2024 10‑K, pp. 22‑26). Thus, PayPal moved from an accounting‑centric description of the programs in 2023 to a stronger emphasis on the ongoing loss exposure and the limited ability to recover those losses in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the 2023 approach focusing on accounting treatment ('transaction and credit losses' during payment transaction completion) and the 2024 shift toward risk disclosure; (2) Accurately captures the key evolution: from accounting-centric description to risk-focused narrative; (3) Properly synthesizes multi-hop information across two fiscal years showing the progression; (4) Correctly identifies specific concerns in 2024 (substantial losses, limited merchant recovery, regulatory/card-network risks); (5) Provides specific page references (2023 10-K p. 75, 2024 10-K pp. 22-26) that add credibility; (6) Uses direct quotes appropriately to support claims. MINOR CONSIDERATIONS: The LLM answer is slightly more detailed and specific than the ground truth (includes page numbers and direct quotes), but this represents added value rather than inaccuracy. The semantic meaning is fully preserved and enhanced. The characterization of the shift from 'accounting-centric' to 'risk-focused' is an apt interpretation that matches the ground truth's description of 'shift toward more explicit risk acknowledgment.' All factual claims are verifiable and accurate. The multi-hop reasoning correctly synthesizes the evolution across the two years and identifies the key differences in disclosure approach and risk emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1459,
        "completion_tokens": 398,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has NextEra Energy's relationship with solar generation facilities evolved from 2022 to 2024, particularly in terms of ownership structure and financial exposure?",
      "original_answer": "In 2022, NextEra Energy Resources was actively divesting ownership stakes in solar generation facilities, including the sale of a 100% ownership interest in a 100 MW solar facility in Arizona and the sale of a 90% ownership interest in a portfolio that included four solar facilities. These transactions resulted in significant cash proceeds and the recognition of gains. By 2024, the company's relationship had transformed into a more complex structure involving equity stakes and consolidated variable interest entities (VIEs). For example, NextEra consolidated eight VIEs owning solar generation facilities with approximately 765 MW of capacity and held a 10% direct ownership interest in additional solar facilities. This shift indicates a strategic move from outright ownership and divestiture to a more diversified and financially leveraged stake through VIEs, with increased financial exposure through guarantees and credit support.",
      "llm_answer": "In the 2022 filing, NextEra Energy kept a controlling interest in solar projects but sold Class B membership interests to third‑party investors, reporting those interests as non‑controlling (or redeemable) and carrying contract liabilities that could require repayment if the “flip” date or a solar production‑tax‑credit condition was not met. By the 2024 filing, the solar assets are largely held through consolidated VIEs—some with 50‑67 % ownership and others with a 10 % stake—so the full assets and liabilities of the VIEs appear on the balance sheet, with financial exposure limited to the VIE‑level, non‑recourse debt. This reflects a shift from a hybrid ownership model with contingent liabilities to a more direct, consolidated ownership structure with defined VIE‑related exposure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures some correct elements but contains significant discrepancies with the ground truth:\n\nCORRECT ELEMENTS:\n- Correctly identifies the shift from one ownership structure to another between 2022 and 2024\n- Accurately describes the 2024 structure involving consolidated VIEs\n- Correctly notes the move toward consolidated ownership with defined VIE-related exposure\n- Appropriately identifies the concept of non-recourse debt at VIE level\n- Correctly characterizes the general strategic shift in financial exposure\n\nINCORRECT/MISSING ELEMENTS:\n1. QUANTITATIVE ERRORS: The LLM mentions \"50-67% ownership\" and \"10% stake\" for 2024 VIEs, but the ground truth specifies \"approximately 765 MW of capacity\" for eight consolidated VIEs and \"10% direct ownership interest in additional solar facilities.\" The percentage ranges (50-67%) are not mentioned in the ground truth and appear to be inaccurate or unsupported.\n\n2. INCOMPLETE 2022 DESCRIPTION: The LLM describes a \"hybrid ownership model with contingent liabilities\" involving Class B membership interests and \"flip\" dates, which differs from the ground truth's description of specific divestitures (100% sale of 100 MW Arizona facility, 90% sale of four-facility portfolio). The LLM's characterization of 2022 structure is partially correct but emphasizes different aspects than the ground truth.\n\n3. MISSING SPECIFIC TRANSACTIONS: The ground truth explicitly mentions concrete 2022 transactions (100 MW Arizona facility sale, 90% portfolio sale) that generated cash proceeds and gains. The LLM answer does not reference these specific transactions.\n\n4. MISSING 765 MW CAPACITY METRIC: The ground truth provides a specific capacity figure (765 MW) for the eight consolidated VIEs in 2024, which the LLM answer omits entirely.\n\n5. VAGUE OWNERSHIP PERCENTAGES: The LLM's mention of \"50-67% ownership\" lacks specificity and doesn't match the ground truth's clearer structure of consolidated VIEs plus 10% direct ownership.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes the evolution across years and identifies the structural shift, but the specific details of the synthesis are incomplete or partially inaccurate. The reasoning about moving from hybrid to consolidated structure is sound, but the supporting details don't fully align with the ground truth.\n\nOVERALL: The answer demonstrates understanding of the general trend but lacks precision in quantitative details and misses specific transaction information from 2022. The 2024 description is closer to accurate but still contains unsupported percentage figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 696,
        "total_tokens": 2133
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did ACN's investment in Mutual Fund Debt Securities evolve from 2022 to 2023, and what was the change in valuation methodology as reflected in the fair value hierarchy levels?",
      "original_answer": "In 2022, ACN reported Mutual Fund Debt Securities valued at $379,989 with the entire amount categorized under Level 2 of the fair value hierarchy. In 2023, this investment decreased to $253,025, and the valuation remained entirely under Level 2. The decrease in value indicates a reduction in exposure to Mutual Fund Debt Securities over the year, while the valuation methodology remained consistent, relying on observable market data.",
      "llm_answer": "ACN’s mutual‑fund debt‑security holding was $379.989 million at August 31 2022 and was measured using Level 2 inputs (quoted prices for similar instruments). By August 31 2023 the balance was $382.0 million and the assets were re‑classified to Level 1 (quoted prices for identical instruments), indicating a shift to a more observable‑price valuation methodology.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM provides completely incorrect numbers. Ground truth shows 2023 value of $253,025 (in thousands, equivalent to $253.025 million), but LLM states $382.0 million - this is a massive error representing a 51% overstatement. The 2022 figure of $379.989 million is correct in the LLM answer. (2) VALUATION METHODOLOGY - The LLM claims a reclassification from Level 2 to Level 1, but ground truth explicitly states the valuation remained entirely under Level 2 in both years. This is a fundamental factual error about the fair value hierarchy classification. (3) DIRECTION OF CHANGE - Ground truth shows a DECREASE from $379,989 to $253,025 (a decline of approximately 33%), but LLM incorrectly states an INCREASE from $379.989 million to $382.0 million. This reverses the actual trend. (4) MULTI-HOP SYNTHESIS - The LLM failed to correctly synthesize the year-over-year comparison and the hierarchy level consistency. The answer demonstrates poor data accuracy on the core numerical facts and mischaracterizes the key finding about valuation methodology consistency. The only correct element is the 2022 starting value and its Level 2 classification. The answer is fundamentally unreliable for investment analysis purposes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1207,
        "completion_tokens": 359,
        "total_tokens": 1566
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Chevron's financial stake and involvement in Tengizchevroil evolved between 2022 and 2023?",
      "original_answer": "In 2022, Chevron's carrying value of its investment in Tengizchevroil was $23,727 million with a reported equity in earnings of $1,238 million. By 2023, Chevron disclosed that its carrying value was approximately $80 million higher than its underlying equity in Tengizchevroil's net assets, indicating a more complex valuation approach. Additionally, Chevron highlighted that it provided a loan of $4,500 million to Tengizchevroil to fund the Future Growth Project and Wellhead Pressure Management Project (FGP/WPMP). This shows a significant deepening of Chevron's financial involvement and strategic commitment to the partnership in 2023 compared to 2022.",
      "llm_answer": "Chevron’s 50 % equity interest in Tengizchevroil (TCO) showed a modest rise in the carrying amount of the investment – from $26.534 billion at 12/31/2022 to $26.954 billion at 12/31/2023 – while its share of TCO’s earnings fell from $4.386 billion in 2022 to $3.375 billion in 2023. The loan that Chevron has to TCO for the FGP/WPMP development remained unchanged at a principal balance of $4.5 billion throughout the period【CVX_10k_2023.pdf:80‑84】.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant numerical discrepancies that contradict the ground truth. (1) CARRYING VALUE ERRORS: Ground truth states 2022 carrying value was $23,727 million ($23.727 billion), but LLM claims $26.534 billion - a difference of ~$2.8 billion (12% error). For 2023, ground truth indicates ~$23,807 million (approximately $80 million higher than underlying equity), but LLM states $26.954 billion - another massive discrepancy of ~$3.1 billion. (2) EARNINGS ERRORS: Ground truth reports 2022 equity in earnings of $1,238 million, but LLM claims $4.386 billion - a 254% overstatement. For 2023, ground truth does not provide a specific earnings figure, but LLM claims $3.375 billion without corroboration. (3) LOAN AMOUNT: LLM correctly identifies the $4.5 billion loan for FGP/WPMP, which matches ground truth. (4) EQUITY INTEREST: LLM mentions 50% equity interest, which is reasonable but not explicitly verified in ground truth. (5) MULTI-HOP REASONING: While LLM attempts to synthesize the evolution between years, the fundamental numerical errors undermine the entire analysis. The LLM appears to have confused or misread the carrying values by approximately 10-12%, which is a critical error for financial analysis. Ground truth emphasizes the strategic deepening of involvement through the loan provision; LLM focuses on carrying value changes but with wrong numbers. The answer fails on quantitative accuracy, which is the primary requirement for financial questions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 417,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Disney's relationship with ABC Network evolved between 2023 and 2024, particularly in terms of its strategic positioning within Disney's broader entertainment ecosystem?",
      "original_answer": "In 2023, ABC Network was positioned as a core component of Disney's 'Linear Networks' within the Entertainment segment, specifically highlighting its domestic footprint through eight owned ABC television stations and its role in content distribution. By 2024, ABC Network's role had evolved, with its programming becoming more integrated into Disney's direct-to-consumer platforms, such as Hulu and Disney+. Specifically, content from ABC Network was made available on Hulu's SVOD service one day after its linear airing. This shift indicates a strategic move toward digital integration and away from traditional linear distribution. Additionally, while ABC Network was still referenced in the context of affiliate fees in 2023, 2024 emphasized its contribution to streaming services rather than standalone linear revenue.",
      "llm_answer": "In the 2023 filing Disney still described ABC Network as a core “Linear Networks” asset in the Entertainment segment – a broadcast outlet that airs primetime, daytime, news and sports (the sports day‑part is branded ESPN on ABC) and distributes its programming to roughly 245 local affiliates plus eight owned stations that reach almost 100 % of U.S. households. By the 2024 filing the language is largely the same, but Disney now stresses ABC’s strategic role as a near‑universal distribution hub that links its linear broadcast business with ESPN sports programming and feeds its Direct‑to‑Consumer platforms (Hulu, Disney+), using ABC to drive advertising, affiliate‑fee revenue and cross‑segment content synergies across Disney’s broader entertainment ecosystem.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer provides some accurate details but has significant issues with completeness and alignment to the ground truth. STRENGTHS: (1) Correctly identifies ABC Network as part of Linear Networks in Entertainment segment in both 2023 and 2024; (2) Accurately mentions eight owned ABC stations; (3) Correctly references the ~245 local affiliates and near-universal U.S. household reach; (4) Properly identifies ESPN on ABC as sports programming; (5) Correctly notes the shift toward DTC platforms (Hulu, Disney+). WEAKNESSES: (1) The LLM answer emphasizes continuity ('language is largely the same') rather than the strategic evolution highlighted in the ground truth - the ground truth specifically emphasizes a shift FROM traditional linear distribution TO digital integration; (2) Missing the specific detail about ABC content being made available on Hulu's SVOD service one day after linear airing - this is a concrete example of the integration strategy; (3) The LLM frames the evolution as ABC becoming a 'distribution hub' linking linear and DTC, but the ground truth emphasizes a more fundamental repositioning where ABC's role shifted from standalone linear revenue to streaming contribution; (4) The LLM mentions 'affiliate-fee revenue' continuing in 2024, while the ground truth suggests the emphasis shifted away from affiliate fees toward streaming services; (5) The LLM's characterization of 'largely the same' language between filings contradicts the ground truth's assertion of meaningful strategic evolution. QUANTITATIVE ACCURACY: The numbers provided (245 affiliates, 8 owned stations, ~100% household reach) appear reasonable and are not contradicted by the ground truth, though the ground truth doesn't provide these specific figures for verification. MULTI-HOP REASONING: The LLM successfully synthesizes information across 2023 and 2024 filings but fails to capture the directional shift in strategic positioning that is central to the question. The answer reads more as a description of ABC's dual role rather than an evolution narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 555,
        "total_tokens": 1960
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has General Dynamics' positioning of the ASCOD vehicle within its Land Systems portfolio evolved between 2022 and 2023, and what does this indicate about potential shifts in production focus or investment allocation?",
      "original_answer": "In 2022, General Dynamics explicitly stated it was 'producing and upgrading' the ASCOD vehicle, indicating active development and enhancement of the platform. By 2023, the company's disclosure shifted to simply 'offering' the ASCOD, without specific mention of production or upgrades. This change in language suggests a potential shift in focus away from active investment or development of the ASCOD platform, possibly reallocating resources to other vehicle programs like the Piranha 5 and AJAX, which are explicitly called out in both years with continued production and international deployments.",
      "llm_answer": "In both the 2022 and 2023 10‑K filings General Dynamics continues to list the ASCOD as a product of its European Land Systems (ELS) unit, describing it as “a highly versatile tracked combat vehicle with multiple versions, including the Spanish Pizarro and the Austrian Ulan.” The language and placement are unchanged from 2022 to 2023, indicating that the ASCOD remains a portfolio offering rather than a newly emphasized production line, and suggesting no significant shift in manufacturing focus or additional investment allocation for this vehicle during that period.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer fundamentally contradicts the ground truth on the core finding. Ground truth identifies a significant shift in language from 2022 ('producing and upgrading') to 2023 ('offering'), which indicates a potential reallocation of resources away from ASCOD. The LLM claims the language and placement are 'unchanged from 2022 to 2023,' which is factually incorrect according to the ground truth. This is a critical error in multi-hop reasoning - the LLM failed to identify the key linguistic shift that forms the basis of the answer. The LLM correctly identifies ASCOD as part of European Land Systems and provides accurate descriptive details (Spanish Pizarro, Austrian Ulan variants), but these details, while accurate, do not address the core question about how positioning evolved. The LLM's conclusion that there is 'no significant shift' directly contradicts the ground truth's finding of a meaningful shift in disclosure language suggesting resource reallocation. The quantitative accuracy is high (no numbers to verify, dates are correct), but the qualitative accuracy is severely compromised because the LLM missed the essential finding about the change in language between years and failed to synthesize the multi-hop comparison across 2022 and 2023 filings. The answer demonstrates a failure to detect and interpret the nuanced but important shift in corporate disclosure language that indicates strategic repositioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 398,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has PayPal's utilization of European customer balances for credit activities evolved between 2023 and 2024, and what does this shift indicate about the company's credit funding strategy?",
      "original_answer": "In 2023, PayPal had approved $3.0 billion of European customer balances for credit activities, representing approximately 39% of balances made available for corporate use. By 2024, the approved amount had decreased to $2.0 billion, or 26% of European customer balances. This indicates a strategic shift toward reducing reliance on customer balances for credit funding, potentially in favor of external financing sources, as evidenced by PayPal's multi-year agreement to sell consumer installment receivables, which saw $20.8 billion in loans sold in 2024 compared to $5.5 billion in 2023.",
      "llm_answer": "PayPal’s use of European customer balances to fund credit fell sharply – the amount it had approved for designation dropped from $3.0 billion (about 39 % of the European balances) at 12/31/2023 to $2.0 billion (about 26 %) at 12/31/2024【PYPL_10k_2023.pdf page 69】【PYPL_10k_2024.pdf page 45】. The decline in both absolute dollars and percentage of balances indicates the company is scaling back reliance on internal European deposits for credit financing, suggesting a shift toward alternative or more conservative funding sources for its credit products.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identified all key quantitative data points: $3.0 billion (39%) in 2023 and $2.0 billion (26%) in 2024 for European customer balances approved for credit activities. The dates (12/31/2023 and 12/31/2024) are accurate, and the document citations are provided. The core observation about declining reliance on European customer balances is correct.\n\nWEAKNESSES: The LLM answer is INCOMPLETE on a critical dimension. The ground truth explicitly mentions PayPal's multi-year agreement to sell consumer installment receivables as evidence of the strategic shift, with specific numbers: $20.8 billion in loans sold in 2024 vs. $5.5 billion in 2023. This is a crucial multi-hop synthesis element that demonstrates HOW the company is shifting its funding strategy (from customer balances to receivables sales). The LLM answer mentions 'alternative or more conservative funding sources' but fails to provide the specific evidence of this shift.\n\nQUANTITATIVE ACCURACY: All stated numbers are correct (7/10 because the answer is incomplete - it doesn't include the receivables sales data that would fully support the strategic shift claim).\n\nQUALITATIVE ACCURACY: The reasoning about scaling back reliance is sound, but the answer lacks the multi-hop synthesis needed to fully explain the strategic shift. The LLM correctly identifies the trend but doesn't complete the analysis by showing what PayPal is doing instead (5/10 - partial reasoning).\n\nCONTEXTUAL RELEVANCE: The answer addresses the first part of the question (how utilization evolved) but only partially addresses the second part (what this indicates about credit funding strategy). The answer would be stronger with the receivables sales data (6/10).\n\nOVERALL: This is a partially correct answer that gets the primary numbers right but fails to complete the multi-hop synthesis required by the question. The missing receivables sales comparison is a significant omission that prevents full understanding of PayPal's strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 545,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the valuation and categorization of equity securities within NEE's Special Use Funds evolve between 2022 and 2024, and what does this indicate about changes in transparency or investment composition?",
      "original_answer": "In 2022, NEE's Special Use Funds reported equity securities at a carrying amount of $906 million (with an estimated fair value of $907 million) for NEE and $672 million (with an estimated fair value of $672 million) for FPL, without detailed categorization by valuation levels. By 2024, the equity securities in the Special Use Funds had grown significantly, with NEE holding $2,614 million in Level 1 equity securities and FPL holding $1,028 million in Level 1 equity securities, alongside more granular disclosures that included Level 2 and Level 3 valuations. This indicates a substantial increase in equity investments and a shift toward more transparent and detailed reporting of asset valuation methodologies.",
      "llm_answer": "In the 2022 filing, equity securities in Nextera’s nuclear‑decommissioning special‑use funds were reported only at Level 1 (quoted market prices) and Level 2 (commingled‑fund holdings) – $2.538 bn + $2.973 bn = $5.511 bn for NEE (and $0.862 bn + $2.690 bn = $3.552 bn for FPL) – with no Level 3 component. By the 2024 filing, the same funds show a Level 3 slice ($229 m for NEE, $204 m for FPL), a new $665 m of equity securities recorded at cost because their fair values are not readily determinable, and total equity holdings have risen to $6.164 bn and $4.219 bn respectively. This evolution indicates that the special‑use funds now contain more illiquid or less observable equity positions and that Nextera is providing greater disclosure of those lower‑visibility assets.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains fundamentally incorrect information that contradicts the ground truth across multiple dimensions:\n\n1. QUANTITATIVE ACCURACY - CRITICAL ERRORS:\n   - Ground truth 2022: NEE $906M equity securities (fair value $907M), FPL $672M\n   - LLM claims 2022: NEE $5.511B ($2.538B + $2.973B), FPL $3.552B ($0.862B + $2.690B)\n   - These numbers are completely wrong and off by a factor of 5-6x\n   - Ground truth 2024: NEE $2,614M Level 1, FPL $1,028M Level 1\n   - LLM claims 2024: NEE $6.164B total, FPL $4.219B total\n   - Again, LLM numbers are 2-4x larger than ground truth\n   - LLM introduces specific figures ($229M Level 3 for NEE, $204M for FPL, $665M at cost) that do not appear in the ground truth and cannot be verified\n\n2. ENTITY/CATEGORIZATION ERRORS:\n   - Ground truth clearly states 2022 had NO detailed categorization by valuation levels (no Level 1/2/3 breakdown)\n   - LLM incorrectly claims 2022 already had Level 1 and Level 2 categorization\n   - This is a fundamental misrepresentation of the evolution described in the ground truth\n   - Ground truth indicates the shift TO detailed categorization occurred between 2022-2024\n   - LLM reverses this timeline by claiming detailed categorization existed in 2022\n\n3. MULTI-HOP REASONING:\n   - The question asks about evolution between 2022-2024\n   - Ground truth shows: simple reporting (2022) → detailed Level 1/2/3 categorization (2024)\n   - LLM shows: detailed categorization (2022) → more detailed with Level 3 (2024)\n   - LLM fundamentally misunderstands the nature of the evolution\n\n4. SEMANTIC ISSUES:\n   - LLM's conclusion about \"greater disclosure of lower-visibility assets\" may be directionally reasonable\n   - However, this conclusion is built on completely incorrect foundational numbers and categorizations\n   - The introduction of Level 3 and cost-basis valuations in LLM's narrative contradicts ground truth which shows Level 1 dominance in 2024\n\n5. SPECIFIC CALCULATION VERIFICATION:\n   - LLM's 2022 sum: $2.538B + $2.973B = $5.511B ✓ (arithmetic correct)\n   - LLM's 2024 sum: appears to be total but components not clearly broken down\n   - However, the underlying numbers themselves are wrong, making correct arithmetic irrelevant\n\nThe LLM answer appears to have fabricated or severely misremembered the actual financial figures from the filings, creating a narrative that is internally somewhat coherent but factually divorced from the ground truth by orders of magnitude in dollar amounts and fundamental mischaracterization of the 2022 baseline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 683,
        "total_tokens": 2071
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the scope and utilization of Accenture's share purchase program evolve from fiscal 2022 to fiscal 2023, particularly in terms of shares acquired under the public program versus those acquired through employee-related transactions?",
      "original_answer": "In fiscal 2022, Accenture purchased 1,964,612 Class A ordinary shares under the publicly announced open-market share purchase program for an aggregate price of $576 million. Additionally, 97,251 shares were acquired through employee-related transactions, such as share withholding for payroll tax obligations, which do not affect the aggregate available authorization. In fiscal 2023, there is no mention of shares purchased under the public program, but the company continued acquiring shares through employee-related transactions under equity share plans. This indicates a shift where the public share purchase program saw reduced or no activity, while employee-related share acquisitions remained consistent.",
      "llm_answer": "In fiscal 2022 Accenture bought 1,964,612 shares under its publicly announced open‑market share‑purchase program and 97,251 shares in employee‑related withholding transactions (about 5 % of the total repurchases)【ACN_10k_2022.pdf p31】. In fiscal 2023 the same pattern persisted – the public program continued to dominate, repurchasing roughly 2 million shares (the overwhelming share of all purchases) while employee‑related transactions remained modest, amounting to only a few‑tens of thousands of shares【ACN_10k_2023.pdf p81‑85】. The Board’s total repurchase authority was increased to $6.129 billion in FY 2022 and stayed at that level in FY 2023, indicating that the program’s scope remained large while utilization stayed focused on the public open‑market purchases.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual error that contradicts the ground truth. The ground truth explicitly states 'In fiscal 2023, there is no mention of shares purchased under the public program,' indicating the public program had NO activity in FY2023. However, the LLM claims 'In fiscal 2023 the same pattern persisted – the public program continued to dominate, repurchasing roughly 2 million shares.' This is a direct contradiction and represents a major factual error. QUANTITATIVE ACCURACY ISSUES: (1) FY2022 numbers are correct: 1,964,612 shares at $576M and 97,251 employee-related shares are accurately stated. (2) The LLM's claim of 'roughly 2 million shares' in FY2023 under the public program is unsupported by the ground truth, which indicates zero public program activity in FY2023. (3) The percentage calculation of ~5% for employee transactions in FY2022 is approximately correct (97,251/2,061,863 ≈ 4.7%), but this detail, while accurate, doesn't address the core evolution question. (4) The board authorization figures ($6.129 billion) are not verified against the ground truth provided. MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the key evolution described in the ground truth - the SHIFT from public program activity in FY2022 to NO public program activity in FY2023, with only employee-related transactions continuing. Instead, the LLM incorrectly characterized FY2023 as showing 'the same pattern' as FY2022. SEMANTIC MISALIGNMENT: The ground truth emphasizes a significant change ('shift where the public share purchase program saw reduced or no activity'), but the LLM describes continuity ('the same pattern persisted'). This represents a fundamental misunderstanding of the question's core requirement to explain how the program 'evolved.' The answer demonstrates poor document synthesis and contradicts the explicit ground truth statement about FY2023 public program activity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 530,
        "total_tokens": 1924
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did Chevron's financial reporting relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of its consolidation status and investment accounting approach?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was consolidated into Chevron’s financial statements, as indicated by the inclusion of 'Note 8: Summarized Financial Data - Chevron Phillips Chemical Company LLC' among other consolidated subsidiaries. However, in 2023, Chevron explicitly stated that its investment in Chevron Phillips Chemical Company LLC was accounted for using the equity method, and it was no longer consolidated under Chevron U.S.A. Inc.'s financial data. This reflects a significant structural change where Chevron transitioned from consolidating the entity to reporting its investment under the equity method, altering how its financial performance is reflected in Chevron’s consolidated results.",
      "llm_answer": "Chevron’s 50 % stake in Chevron Phillips Chemical Company LLC was not consolidated in either filing; it was treated as a joint‑venture investment accounted for under the equity method. The 2022 10‑K notes that the CPChem interest “is accounted for using the equity method” (Note 6, 2022 pages 30‑34), and the 2023 10‑K repeats the same equity‑method treatment while adding a separate Note 8 that presents CPChem’s full financial summary and points to Note 15 for the investment discussion (Note 8, 2023 pages 73‑77).",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is fundamentally contradictory to the ground truth and contains critical factual errors: (1) CORE FACTUAL ERROR: The LLM claims CPChem was NOT consolidated in either 2022 or 2023 and was always under equity method treatment. The ground truth explicitly states that in 2022, CPChem WAS consolidated into Chevron's financial statements (evidenced by 'Note 8: Summarized Financial Data - Chevron Phillips Chemical Company LLC' among consolidated subsidiaries), but in 2023 it transitioned to equity method accounting and was no longer consolidated. This is a fundamental mischaracterization of the evolution being asked about. (2) QUANTITATIVE ERROR: The LLM introduces a '50% stake' figure that is not mentioned in the ground truth and appears to be an unsupported claim about ownership percentage. (3) MULTI-HOP REASONING FAILURE: The question specifically asks about how the relationship 'evolved between 2022 and 2023' - implying a change. The ground truth identifies a clear transition from consolidated (2022) to equity method (2023). The LLM completely misses this evolution by claiming the same treatment in both years. (4) CITATION ISSUES: While the LLM provides specific note references and page numbers, these appear to be fabricated or misinterpreted, as they contradict the documented ground truth about consolidation status changing between years. (5) SEMANTIC MISMATCH: The LLM's answer describes a static situation (same treatment both years) when the ground truth describes a dynamic change (consolidation to equity method). The answer fails to address the core premise of the question - the evolution/change in the relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 453,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Hydra-70 rockets in General Dynamics' Combat Systems segment evolved from 2022 to 2023, particularly in terms of contract involvement and production capacity expansion?",
      "original_answer": "In 2022, General Dynamics received a $175 million contract for the production of Hydra-70 rockets as part of its Combat Systems segment. By 2023, the company's role had evolved significantly, with OTS (Orbital Technologies Corporation, part of Combat Systems) maintaining a market-leading position in the supply of Hydra-70 rockets and expanding its production capacity. Specifically, OTS received awards to increase metal parts production capacity for munitions from 18,000 to 86,000 rounds per month by 2025, which includes Hydra-70 rockets as part of its broader munitions portfolio.",
      "llm_answer": "In the 2022 filing the Hydra‑70 rockets appear only as a discrete $175 million Army contract to produce the rockets, indicating a single, contract‑specific role in the Combat Systems segment【GD_10k_2022.pdf page 44】. By the 2023 filing Hydra‑70 rockets are described as a core product in OTS’s munitions portfolio, and the segment announced awards to expand metal‑parts capacity from 18,000 to 86,000 rounds per month (by 2025) and propellant capacity from 4 million to 16 million lb per year (by 2028), reflecting a shift from a single contract to a broad production‑capacity expansion【GD_10k_2023.pdf page 13】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the question. QUANTITATIVE VERIFICATION: All numbers are correct - $175 million contract in 2022, metal parts capacity expansion from 18,000 to 86,000 rounds per month by 2025, and propellant capacity expansion from 4 million to 16 million lb per year by 2028. The LLM answer actually provides MORE detail than the ground truth by including the propellant capacity expansion metrics, which represents additional valuable context. MULTI-HOP SYNTHESIS: The answer correctly synthesizes information across 2022 and 2023 filings, identifying the evolution from a single discrete contract to a broader strategic capacity expansion. The identification of OTS (Orbital Technologies Corporation) as the relevant business unit is accurate and adds helpful context. ENTITY ACCURACY: General Dynamics, Combat Systems segment, OTS, and Hydra-70 rockets are all correctly identified. Years (2022, 2023) and timelines (by 2025, by 2028) are accurate. REASONING QUALITY: The logical progression from 'single contract-specific role' to 'core product with broad capacity expansion' effectively captures the evolution requested in the question. The characterization of the shift is semantically sound and well-supported by the data. MINOR CONSIDERATIONS: The LLM answer includes document citations (page numbers) which, while helpful for verification, go slightly beyond what was in the ground truth, but this is a positive addition rather than an error. The ground truth mentions 'market-leading position' which the LLM answer doesn't explicitly state, but this is a minor omission that doesn't affect the core factual accuracy of the response. Overall, the answer is comprehensive, accurate, and effectively addresses all aspects of the multi-hop question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 493,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has PayPal's treatment of the Global Restricted Stock Unit Award Grant Notice evolved between the 2023 and 2024 filings, particularly in terms of its documentation status and associated agreements?",
      "original_answer": "In the 2023 filing, the Global Restricted Stock Unit Award Grant Notice was listed as Exhibit 10.07+ and was associated with the PayPal Holdings, Inc. 2015 Equity Incentive Award Plan, with its form incorporated by reference from 10-12B/A filed on May 14, 2015. By 2024, the same form of the Global Restricted Stock Unit Award Grant Notice (Exhibit 10.07+) remained in place, still referencing the 2015 plan and incorporated by reference from the same 10-12B/A filing on May 14, 2015. However, in the 2024 filing, there was an updated form of the Global Performance Based Restricted Stock Unit Award Grant Notice (Exhibit 10.08+), which was now filed under the amended and restated plan and was linked to a more recent 10-Q filing on April 30, 2024. This indicates that while the base RSU grant notice remained unchanged, the performance-based variant saw active revision and documentation updates in 2024.",
      "llm_answer": "In the 2023 Form 10‑K the Global Restricted Stock Unit (GRSU) Award Grant Notice (Exhibit 10.07+) was listed as an exhibit **incorporated by reference** – it was not filed with the 10‑K and was tied to the “2015 Equity Incentive Award Plan, Amended and Restated” (Exhibit 10.03+, filed 5/31/2023) 【PYPL_10k_2023.pdf†124】. The 2024 Form 10‑K treats the same GRSU notice the same way (still incorporated by reference, not attached) but now points to an updated “2015 Equity Incentive Award Plan, as Amended and Restated” (Exhibit 10.03+, filed 5/28/2024), reflecting an amendment to the underlying agreement while the notice’s documentation status remains unchanged 【PYPL_10k_2024.pdf†122】【PYPL_10k_2024.pdf†121】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) EXHIBIT NUMBER ERROR: The LLM states the Global Restricted Stock Unit Award Grant Notice is Exhibit 10.07+, but provides no verification this matches the ground truth's Exhibit 10.07+ designation - this appears correct by coincidence. (2) INCORPORATION BY REFERENCE CLAIM: The LLM claims the notice was 'incorporated by reference' in both years, but the ground truth explicitly states it was 'incorporated by reference from 10-12B/A filed on May 14, 2015' - a specific source document the LLM does not mention. (3) PLAN REFERENCE ERROR: The LLM incorrectly identifies the underlying plan as '2015 Equity Incentive Award Plan, Amended and Restated' with dates of 5/31/2023 and 5/28/2024. The ground truth references the same plan but does not specify these amendment dates for the base RSU notice - the LLM appears to have confused or conflated information. (4) MISSING CRITICAL DISTINCTION: The ground truth emphasizes that the Global Performance Based Restricted Stock Unit Award Grant Notice (Exhibit 10.08+) was updated in 2024 with a more recent 10-Q filing reference (April 30, 2024), showing active revision of the performance-based variant. The LLM completely omits this important distinction between the base RSU notice (unchanged) and the performance-based variant (updated). (5) INCOMPLETE SYNTHESIS: The question asks about evolution 'particularly in terms of its documentation status and associated agreements' - the LLM addresses documentation status (incorporated by reference) but fails to properly synthesize the key evolution: that while the base notice remained static, the performance-based variant saw active updates in 2024. The LLM's answer is partially coherent but misses the core insight of the ground truth regarding the differential treatment of the two notice types.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 512,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Opdivo within Bristol-Myers Squibb's portfolio evolved from 2022 to 2024, based on its revenue performance and new regulatory approvals?",
      "original_answer": "In 2022, Opdivo generated $7,523 million in revenue, indicating it was a major contributor to Bristol-Myers Squibb's oncology portfolio. By 2024, Opdivo received a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. This regulatory expansion demonstrates a strategic evolution in Opdivo’s therapeutic application and reinforces its continued importance in the company's oncology pipeline, despite not showing a significant revenue increase from earlier years.",
      "llm_answer": "Opdivo was already a major revenue driver in the 2022 filing, delivering $7.5 billion in net product sales (about 16 % of total revenue) 【BMY_10k_2022.pdf p108‑p110】. By 2024 BMS had broadened its role from a high‑selling drug to a platform therapy, securing a suite of new approvals—including the sub‑cutaneous Opdivo Qvantig formulation, FDA and EU approvals for urothelial carcinoma, resectable NSCLC, and an Opdivo‑Yervoy combination—thereby expanding its indication set and reinforcing its strategic importance in the oncology portfolio 【BMY_10k_2024.pdf p43‑p47】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with some notable strengths and minor weaknesses: (1) QUANTITATIVE ACCURACY: The 2022 revenue figure of $7.5 billion is correct (ground truth states $7,523 million, LLM rounds to $7.5B - acceptable format variation). The 16% of total revenue calculation appears reasonable but cannot be independently verified from the ground truth provided. The March 2024 urothelial carcinoma approval is correctly identified. (2) COMPLETENESS: The LLM answer goes beyond the ground truth by mentioning additional approvals (subcutaneous Opdivo Qvantig formulation, EU approvals, resectable NSCLC, Opdivo-Yervoy combination). While the ground truth only explicitly mentions the March 2024 urothelial carcinoma approval, the LLM's additional details suggest broader research of the 2024 filing. However, the ground truth specifically notes 'despite not showing a significant revenue increase from earlier years,' which the LLM answer does not explicitly address - this is a notable omission regarding the revenue trajectory. (3) ENTITY ACCURACY: All entities are correctly identified (Bristol-Myers Squibb/BMS, Opdivo, FDA, years 2022-2024). (4) REASONING: The multi-hop synthesis is sound - the LLM correctly connects 2022 revenue data with 2024 regulatory approvals to show portfolio evolution. The characterization of Opdivo's evolution from 'major revenue driver' to 'platform therapy' is logical and well-supported. (5) SEMANTIC EQUIVALENCE: The answer conveys the core message effectively, though with different emphasis than ground truth. The ground truth emphasizes 'continued importance despite not showing significant revenue increase,' while the LLM emphasizes 'broadened role' and 'expanding indication set.' The LLM's mention of multiple new approvals (beyond just urothelial carcinoma) adds value but may exceed what can be verified from the provided ground truth. Minor deduction for not explicitly addressing the revenue stagnation aspect mentioned in ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 543,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Chevron's financial involvement and strategic support for Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of project funding and investment structure?",
      "original_answer": "In 2022, Chevron highlighted its 50% ownership in Chevron Phillips Chemical Company LLC (CPChem), emphasizing ongoing investments in global manufacturing facilities and expansion projects, such as the planned 1-hexene unit in Old Ocean, Texas, and a C3 splitter at Cedar Bayou, with targeted start-ups in 2023. By 2023, Chevron's involvement had evolved to include a direct loan of $387 million to fund a portion of the Golden Triangle Polymers Project in Orange, Texas, in which CPChem owns 51%. This indicates a shift from general equity ownership and project announcements in 2022 to more direct financial support and structured investment in specific projects in 2023.",
      "llm_answer": "In 2022 Chevron owned 50 % of CPChem and backed its expansion plans – notably the announced Old Ocean 1‑hexene unit and Cedar Bayou C3‑splitter slated to start‑up in 2023 – with a $6.843 billion investment balance (see the 2022 chemicals‑operations section). By 2023 that balance had risen to $7.765 billion and now includes a $387 million loan to fund the Golden Triangle Polymers Project in Orange, Texas, indicating Chevron moved from a pure equity stake to a mixed equity‑plus‑project‑loan structure and deepened its strategic financing of CPChem’s growth (see Note 15 in the 2023 filing).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key financial metrics and strategic evolution. STRENGTHS: (1) Correctly identifies Chevron's 50% ownership in CPChem in 2022 and the specific expansion projects (Old Ocean 1-hexene unit, Cedar Bayou C3-splitter with 2023 start-ups). (2) Accurately cites the $387 million loan to Golden Triangle Polymers Project in Orange, Texas in 2023, matching ground truth exactly. (3) Provides investment balance figures ($6.843 billion in 2022, $7.765 billion in 2023) that add specificity beyond the ground truth. (4) Correctly characterizes the strategic shift from pure equity ownership to mixed equity-plus-loan structure. (5) Properly synthesizes multi-hop information across 2022 and 2023 filings. MINOR CONSIDERATIONS: (1) The investment balance figures ($6.843B and $7.765B) are not mentioned in the ground truth, though they appear to be from actual filings and are contextually appropriate. (2) The answer goes slightly beyond the ground truth by providing these balance sheet figures, which enhances rather than detracts from accuracy. (3) All core facts align with ground truth: ownership percentages, project names, locations, loan amount, and the strategic evolution narrative. QUANTITATIVE VERIFICATION: The $387 million loan figure is exact match to ground truth. The 50% ownership and 51% CPChem stake in Golden Triangle are correctly stated. No calculation errors detected. MULTI-HOP REASONING: Successfully synthesizes information across 2022 and 2023 periods, correctly identifying the evolution in Chevron's financial involvement structure. The comparison between years is logically sound and well-articulated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 464,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did PayPal's protection programs evolve between 2023 and 2024 in terms of financial commitments and disclosures regarding transaction loss reserves?",
      "original_answer": "In 2023, PayPal disclosed that it estimated and recorded costs associated with protection programs in transaction and credit losses, but did not specify the exact amounts for the allowance for transaction losses or negative customer balances. In 2024, PayPal provided more detailed disclosures, including specific figures: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, and the allowance for negative customer balances rose from $218 million to $256 million. This indicates a significant increase in PayPal's financial commitments and potential risk exposure under its protection programs in 2024 compared to the prior year.",
      "llm_answer": "In the 2023 filing PayPal only described its merchant‑ and consumer‑protection programs in general terms, stating that the costs are estimated and recorded as “transaction and credit losses” (see 2023 pages 75‑79). By the 2024 filing the company added a dedicated “PROTECTION PROGRAMS” note that quantifies the reserves – reporting an allowance for transaction losses of $86 million (up from $64 million) and an allowance for negative customer balances of $256 million (up from $218 million) and providing a reconciliation of the beginning balance, provisions, realized losses and recoveries (see 2024 pages 108‑112). This shows a shift to more detailed disclosure and a larger financial commitment to cover potential transaction losses.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. QUANTITATIVE VERIFICATION: All financial figures are correct - allowance for transaction losses increased from $64 million (2023) to $86 million (2024), and allowance for negative customer balances increased from $218 million to $256 million. These exact numbers match the ground truth. COMPLETENESS: The answer addresses both key aspects of the question: (1) the evolution of financial commitments (showing the dollar increases), and (2) the evolution of disclosures (describing the shift from general descriptions to detailed quantified reserves with reconciliation). ENTITY ACCURACY: Correctly identifies PayPal, the correct years (2023 and 2024), and the correct financial metrics (allowance for transaction losses and allowance for negative customer balances). MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years, comparing disclosure approaches and quantifying the changes. The logic is sound - it shows both the increased financial commitment (larger reserve amounts) and improved disclosure quality (dedicated note with reconciliation details). SEMANTIC EQUIVALENCE: The LLM answer conveys the same core information as the ground truth, using slightly different but equivalent phrasing (e.g., 'shift to more detailed disclosure' vs. 'provided more detailed disclosures'). The inclusion of specific page references (2023 pages 75-79, 2024 pages 108-112) adds helpful context not in the ground truth but does not contradict it. Minor note: The LLM answer provides slightly more operational detail about the reconciliation components (beginning balance, provisions, realized losses and recoveries) which enhances understanding without introducing any inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 480,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has McDonald's strategic framing of its relationship with franchisees changed between 2022 and 2024, particularly in terms of franchising as a core business model and the role of franchisee co-investment?",
      "original_answer": "In 2022, McDonald's described its relationship with franchisees in neutral, structural terms, emphasizing the division of responsibilities such as franchised arrangements and license agreements, and presenting franchisees as co-participants in operating restaurants. By 2024, the framing evolved significantly, with franchising being described as 'paramount' to delivering food quality, customer experience, and profitability. The 2024 filing also emphasized the importance of franchisee co-investment, noting that it enables McDonald's to achieve high restaurant performance. This represents a shift from a descriptive to a more strategic and value-laden framing of the franchisee relationship.",
      "llm_answer": "In the 2022 filing McDonald’s described franchising as one element of its restaurant system and noted that it “may share in the cost of certain restaurant improvements with its franchisees” as a occasional cost‑sharing arrangement. By the 2024 filing the company re‑positions franchising as the central pillar of its strategy—stating it is “primarily a franchisor” and that “franchising is paramount” to its growth—and frames franchisee co‑investment as a deliberate partnership, emphasizing that ownership of real estate combined with franchisee co‑investment “enables it to achieve restaurant performance levels that are among the highest in the industry.”",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. (1) CORRECTNESS: The answer accurately captures the strategic shift in McDonald's framing between 2022 and 2024. Both the original and LLM answers identify the same core evolution: from neutral/structural language in 2022 to strategic/value-laden language in 2024. The LLM provides specific textual evidence ('primarily a franchisor,' 'franchising is paramount') that directly supports this characterization. (2) QUANTITATIVE ACCURACY: No numeric values are present in either answer, so this dimension is not applicable. The answer correctly references the two time periods (2022 and 2024) without error. (3) ENTITY ACCURACY: McDonald's is correctly identified throughout. The key concepts (franchising, franchisee co-investment, real estate ownership, restaurant performance) are all accurately referenced and properly contextualized. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across two different filing years and identifies the strategic shift in how the company frames its relationship with franchisees. The reasoning correctly connects the 2022 cost-sharing language to the 2024 emphasis on co-investment as enabling high performance. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same essential information as the ground truth while providing more specific textual evidence. The ground truth uses 'neutral, structural terms' and 'co-participants' for 2022, while the LLM specifies 'one element' and 'occasional cost-sharing'—both characterizations are semantically equivalent and accurate. The 2024 framing is captured identically in both answers regarding 'paramount' language and the connection between co-investment and performance. Minor strength: The LLM answer provides slightly more concrete textual evidence from the filings, making it marginally more substantive than the ground truth while remaining fully accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 529,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the FDA's authorization of Marlboro HeatSticks evolved between 2022 and 2023, and what does this indicate about Altria's regulatory progress with heated tobacco products?",
      "original_answer": "In 2022, the FDA had not yet authorized Marlboro HeatSticks and was considering them on a case-by-case basis regarding graphic health warnings. By 2023, the FDA had authorized PMTAs for three new tobacco-flavored varieties of Marlboro HeatSticks in January 2023, marking a significant regulatory milestone. This indicates that Altria made notable progress in securing FDA approval for its heated tobacco product line, which is a key part of its innovation strategy.",
      "llm_answer": "In the 2022 filing Altria reported that the FDA had **not yet authorized** Marlboro HeatSticks – the agency had taken no action to exempt them from graphic‑warning rules and the products remained barred by an ITC cease‑and‑desist order. By the 2023 filing, the FDA had **authorized PMTAs for three new tobacco‑flavored Marlboro HeatSticks** (January 2023), showing that Altria’s heated‑tobacco line is moving from a non‑authorized, restricted status toward FDA‑cleared market entry. This progression reflects tangible regulatory headway for Altria’s heated‑tobacco products.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive synthesis of multi-hop information across 2022 and 2023 filings. QUANTITATIVE ACCURACY: All dates and numbers are correct - the answer accurately identifies that in 2022 Marlboro HeatSticks were not authorized, and in January 2023 the FDA authorized PMTAs for three new tobacco-flavored varieties. No calculation errors present. ENTITY ACCURACY: Correctly identifies Altria, Marlboro HeatSticks, FDA, PMTAs, and ITC cease-and-desist order. All entities properly contextualized. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years, comparing the regulatory status evolution and drawing appropriate conclusions about Altria's regulatory progress. The logic is sound - moving from non-authorized/restricted status to FDA-cleared authorization represents tangible progress. COMPLETENESS: Addresses both parts of the question (how authorization evolved AND what it indicates about regulatory progress). The answer goes slightly beyond the ground truth by mentioning the ITC cease-and-desist order, which adds relevant context without contradicting the original answer. SEMANTIC EQUIVALENCE: The LLM's phrasing ('moving from non-authorized, restricted status toward FDA-cleared market entry' and 'tangible regulatory headway') conveys the same meaning as the ground truth's 'significant regulatory milestone' and 'notable progress.' Minor difference: The LLM uses 'toward FDA-cleared market entry' while ground truth says 'marking a significant regulatory milestone' - both accurately characterize the progression, though the LLM's phrasing is slightly more cautious ('toward' vs. 'marking'). This is a negligible semantic difference that doesn't affect correctness. The answer is well-structured, clear, and demonstrates strong understanding of the multi-hop synthesis required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 510,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did the valuation of mutual fund equity securities held by ACN evolve between 2022 and 2023, and what does this shift indicate about the company's investment positioning in this category?",
      "original_answer": "In 2022, ACN reported $239,293 (in millions) in mutual fund equity securities. By 2023, this figure decreased to $196,226 (in millions), indicating a reduction of $43,067 (in millions). This decline suggests a strategic shift or reallocation away from mutual fund equity securities during the period.",
      "llm_answer": "The fair‑value of mutual‑fund equity securities held in Accenture’s defined‑benefit and post‑retirement plans was about $239 million in both 2022 (Level 1 $4.9 million + Level 2 $234.3 million) and 2023 (now recorded entirely at Level 2 with no Level 1 component)【ACN_10k_2022.pdf†page87】【ACN_10k_2023.pdf†page81】.  This unchanged dollar amount but shift to a fully Level 2 classification shows the company maintained a stable exposure to mutual‑fund equities while moving the valuation to more observable market inputs, reflecting a consistent yet more market‑driven investment positioning in this asset class.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer is fundamentally incorrect on the core quantitative facts. (1) MAJOR NUMBER ERROR: The LLM states mutual fund equity securities were 'about $239 million' in both 2022 and 2023, but the ground truth shows $239,293 MILLION in 2022 and $196,226 MILLION in 2023 - a difference of over 1,000x in magnitude. The LLM appears to have confused millions with the actual reported figures in millions. (2) CALCULATION ERROR: The LLM claims the dollar amount was 'unchanged' when in fact there was a $43,067 million DECREASE from 2022 to 2023 - this is a massive decline that the LLM completely missed. (3) MISINTERPRETATION: The LLM focuses on Level 1 vs Level 2 classification changes (valuation methodology) rather than the actual dollar value evolution, which is the primary question. While the Level 1/Level 2 detail may be accurate, it is irrelevant to answering the core question about how the valuation evolved in dollar terms. (4) FAILED MULTI-HOP SYNTHESIS: The LLM failed to properly synthesize the year-over-year comparison across the 2022 and 2023 filings. The ground truth clearly shows a significant strategic shift (reduction of $43,067 million), but the LLM incorrectly concluded the positioning was 'stable' and 'unchanged.' (5) SEMANTIC FAILURE: The conclusion that the company 'maintained a stable exposure' directly contradicts the actual 18% decline in mutual fund equity holdings. This represents a fundamental misunderstanding of the data and the question being asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 416,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Chevron's involvement in Angola LNG Limited evolved from 2022 to 2023, particularly in terms of its operational focus and investment emphasis?",
      "original_answer": "In 2022, Chevron operated and held a 36.4% interest in Angola LNG Limited, emphasizing its role in processing and liquefying associated natural gas from multiple fields and operators in Angola. The company was also involved in developing non-associated gas resources to supply the Angola LNG plant. By 2023, Chevron continued to hold the same 36.4% interest, but the disclosure shifted focus to its broader portfolio of equity affiliates and non-equity investments, with Angola LNG Limited being listed alongside other major investments like Tengizchevroil and Chevron Phillips Chemical Company LLC. This indicates a shift in disclosure emphasis from operational development to financial stake and integration within Chevron’s global portfolio.",
      "llm_answer": "In the 2022 Form 10‑K Chevron emphasized the **operational role** of its 36.4 % stake in Angola LNG Limited – describing the Soyo plant as the world’s first LNG facility fed by associated‑gas and noting that Chevron was actively developing non‑associated offshore gas to supply the plant. In the 2023 filing the language is pared back to a simple statement of ownership and the plant’s processing function, and the **investment emphasis** shifted – the equity‑method investment in Angola LNG fell to $1.76 billion in 2023 from $1.96 billion in 2022, indicating a move from capital‑intensive development toward maintaining the existing stake.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about Chevron's Angola LNG involvement evolution from 2022 to 2023. STRENGTHS: (1) Correctly identifies the 36.4% ownership stake in both years; (2) Accurately cites the investment values ($1.96 billion in 2022 declining to $1.76 billion in 2023), showing proper synthesis of financial data across years; (3) Effectively captures the shift in disclosure emphasis from operational development focus to financial stake integration; (4) Correctly describes the Soyo plant as the world's first LNG facility fed by associated gas; (5) Properly synthesizes the multi-hop reasoning showing how operational language changed while investment values declined. MINOR CONSIDERATIONS: (1) The LLM answer provides slightly more specific financial detail ($1.76B and $1.96B values) than the ground truth explicitly states, though these appear to be accurate supporting details that strengthen the answer; (2) The ground truth mentions Angola LNG being listed alongside other major investments (Tengizchevroil, Chevron Phillips Chemical) as part of the disclosure shift, which the LLM answer doesn't explicitly mention, though this is a minor contextual detail rather than a core factual error; (3) The LLM answer's characterization of the shift as moving 'from capital-intensive development toward maintaining the existing stake' is a reasonable inference supported by the declining investment value and changed disclosure language, though the ground truth frames it more neutrally as a shift in 'disclosure emphasis.' QUANTITATIVE VERIFICATION: The 36.4% stake is correct for both years; the investment value decline from $1.96B to $1.76B is accurately stated and properly used to support the narrative of shifting emphasis. The answer correctly synthesizes information across two fiscal years and multiple disclosure sections. Overall, this is a high-quality answer that accurately addresses the question with appropriate supporting detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 546,
        "total_tokens": 1893
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did MMM's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, MMM held $14 million in Certificates of Deposit/Time Deposits, as disclosed in the fair value measurements. By 2023, this amount increased to $49 million, indicating a significant growth in this category of investment. This represents an increase of $35 million, or approximately 250%, from the prior year.",
      "llm_answer": "MMM’s certificates of deposit/time‑deposit holdings grew from $21 million at year‑end 2022 to $49 million at year‑end 2023, a rise of $28 million (roughly a 133% increase)【MMM_10k_2023.pdf page 62】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains significant factual errors in the primary numbers. Ground truth states 2022 balance was $14 million, but LLM reports $21 million - a $7 million discrepancy (50% error). The 2023 figure of $49 million is correct in both answers. The calculated change is therefore wrong: LLM states $28 million increase, but ground truth shows $35 million increase - a $7 million error in the delta calculation. The percentage increase is also incorrect: LLM calculates 133% ((28/21)*100), but ground truth shows 250% ((35/14)*100). While the LLM correctly identified the direction of change (increase) and the 2023 ending balance, the 2022 starting balance is fundamentally wrong, cascading into incorrect calculations. The question asks about evolution from 2022 to 2023 and magnitude of change - both core requirements are answered but with wrong numbers. The answer is contextually relevant and addresses the multi-part question structure, but the quantitative foundation is severely compromised. The citation to page 62 of the 2023 10-K is appropriate, but the data extracted appears to be incorrect or from a different disclosure section than the ground truth source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1125,
        "completion_tokens": 343,
        "total_tokens": 1468
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of the percentage of franchised restaurants between 2021 and 2024?",
      "original_answer": "In 2021, 93% of McDonald's restaurants were franchised, while by 2024, this percentage increased to approximately 95%. This indicates a slight but deliberate shift toward further reliance on franchisees to operate McDonald's restaurants, reinforcing the company's strategic emphasis on franchising as a core business model.",
      "llm_answer": "In 2021, McDonald’s had 37,295 franchised restaurants out of 40,031 total locations – about 93% of its restaurants were franchised. By year‑end 2024, the company reported roughly 95% of its 43,477 restaurants were franchised. Thus, the proportion of franchised restaurants has risen modestly from 93% to about 95% over the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Quantitative verification: (1) 2021 data - 37,295 franchised out of 40,031 total = 93.2%, correctly rounded to 93%; (2) 2024 data - approximately 95% of 43,477 restaurants franchised, which aligns with ground truth; (3) The percentage increase from 93% to 95% is correctly identified. The LLM answer goes beyond the ground truth by providing absolute restaurant counts (37,295 in 2021, 43,477 in 2024), which adds valuable context and demonstrates the calculation basis. Multi-hop reasoning is sound: the answer correctly synthesizes data across two years and identifies the trend of increasing franchising. The conclusion about 'modest' increase and strategic emphasis on franchising matches the ground truth interpretation. Minor note: The LLM states '95%' while ground truth says 'approximately 95%' - this is a negligible difference and both are semantically equivalent. All entities (McDonald's, franchised restaurants, years 2021-2024) are correctly identified. The answer directly addresses the question about how the relationship evolved in terms of franchised percentage. No calculation errors detected. The additional detail about absolute numbers strengthens rather than detracts from the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1160,
        "completion_tokens": 354,
        "total_tokens": 1515
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the effective date and structure of the 2015 Stock Compensation Plan for Non-Employee Directors evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was described as 'amended and restated effective March 31, 2021.' By 2023, the plan was further amended and restated, with a new effective date of 'October 26, 2022.' This indicates that the plan underwent at least one additional amendment during the 2022–2023 period, reflecting a structural or procedural update to the plan’s terms.",
      "llm_answer": "In the 2022 Form 10‑K the “2015 Stock Compensation Plan for Non‑Employee Directors” was described as “as amended and restated effective March 31 2021” and the plan provided **703,256 shares** that could be issued to directors 【MO_10k_2022.pdf, p.113‑117】. By the 2023 Form 10‑K the same plan had been further amended and restated, now **effective October 26 2022**, and the share pool was reduced to **589,927 shares** 【MO_10k_2023.pdf, p.107‑111】. Thus the plan’s effective date moved forward and the number of shares authorized under the plan was lowered.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. It correctly identifies the key evolution of the 2015 Stock Compensation Plan for Non-Employee Directors between 2022 and 2023: (1) The effective date changed from March 31, 2021 (as stated in 2022 10-K) to October 26, 2022 (as stated in 2023 10-K) - both dates match the ground truth exactly. (2) The LLM provides additional quantitative detail beyond the ground truth by specifying the share pool changes: 703,256 shares in 2022 reduced to 589,927 shares in 2023. While the ground truth does not explicitly mention these share numbers, they represent accurate supplementary information from the filings that strengthens the answer. (3) The multi-hop reasoning is sound - the answer correctly synthesizes information across two different 10-K filings (2022 and 2023) to show the evolution of the plan. (4) The answer directly addresses all aspects of the question: effective date evolution (March 31, 2021 → October 26, 2022) and structural changes (share pool reduction). (5) The citation format with page references adds credibility and traceability. The only minor consideration is that the ground truth focuses on the effective date and structural updates, while the LLM adds share pool information - this is additive rather than contradictory, making it a strength rather than a weakness. All dates and numbers are factually correct based on standard SEC filing conventions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 397,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did Accenture's financial relationship with Duck Creek Technologies evolve between fiscal years 2022 and 2023, particularly in terms of investment valuation and reported financial impact?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with a carrying amount of $138,902, and was accounted for using the equity method. By fiscal 2023, the investment resulted in a $253 million gain, which was specifically called out in the financial statements as impacting the adjusted earnings per share and effective tax rate calculations. This indicates a shift from a long-term equity stake to a more active financial realization event.",
      "llm_answer": "In fiscal 2022 Accenture’s equity‑method investment in Duck Creek Technologies (about a 16 % ownership) was carried at $138.9 million, with an estimated fair value of $223.2 million [2022 p. 70]. In fiscal 2023 the company recorded a $253 million gain on that investment, reflecting a substantial appreciation in value and a material boost to earnings (shown in the effective‑tax‑rate and EPS adjustments) [2023 p. 38].",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: All numbers are correct - fiscal 2022 carrying amount of $138.9 million (matches $138,902 in thousands), fair value of $223.2 million (matches $223,166 in thousands), 16% ownership percentage, and fiscal 2023 $253 million gain. Number format variations are appropriately handled ($138.9M vs $138,902 in thousands). COMPLETENESS: The answer addresses all key aspects of the question - the evolution between fiscal years 2022 and 2023, investment valuation changes, and reported financial impact. ENTITY ACCURACY: Correctly identifies Accenture, Duck Creek Technologies, fiscal years 2022 and 2023, and the equity method accounting treatment. MULTI-HOP REASONING: Successfully synthesizes information across two fiscal years showing the progression from a long-term equity stake (2022) to a realized gain event (2023), with proper connection to EPS and tax rate impacts. MINOR OBSERVATIONS: The LLM answer uses slightly different phrasing than the ground truth (e.g., 'shift from a long-term equity stake to a more active financial realization event' vs 'recorded a $253 million gain'), but the semantic meaning is equivalent and accurate. The inclusion of page references [2022 p. 70] and [2023 p. 38] adds credibility. The answer clearly conveys the substantial appreciation and material financial impact. No calculation errors detected. All factual claims are supported by the ground truth data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 410,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has the therapeutic application of Breyanzi evolved between 2022 and 2024, and what specific new indications were approved in 2024 that expand its market potential?",
      "original_answer": "In 2022, Breyanzi was indicated for the treatment of adult patients with certain types of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. By 2024, Breyanzi received two new approvals: in March 2024 for the treatment of adult patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, and in May 2024 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. These new indications significantly expand the patient populations eligible for Breyanzi treatment.",
      "llm_answer": "In the 2022 filing Breyanzi was described only as a CD‑19‑directed CAR‑T therapy for adult patients with relapsed or refractory **large B‑cell lymphoma** who had received ≥ two prior lines of systemic therapy【BMY_10k_2022.pdf†page 70】. By 2024 the label had broadened dramatically: the FDA approved Breyanzi for **relapsed/refractory mantle‑cell lymphoma (MCL)** (May 2024) and for **relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)** (March 2024)【BMY_10k_2024.pdf†page 45】, and added **follicular lymphoma (FL)** approvals – an FDA accelerated approval for FL after ≥ two prior lines (May 2024) and a Japanese approval for high‑risk FL after one prior line (August 2024)【BMY_10k_2024.pdf†page 44‑46】. These new indications expand Breyanzi’s market from a single large‑B‑cell lymphoma indication to multiple B‑cell malignancies, markedly increasing its commercial potential.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a significant factual error regarding mantle-cell lymphoma (MCL). The ground truth explicitly states that in 2024, Breyanzi received approvals for: (1) CLL/SLL in March 2024, and (2) follicular lymphoma (FL) in May 2024. The LLM incorrectly claims MCL was approved in May 2024, which is NOT mentioned in the ground truth. This is a major factual error that contradicts the original answer. CORRECT ELEMENTS: (1) 2022 indication for relapsed/refractory large B-cell lymphoma after ≥2 prior lines is accurate; (2) March 2024 CLL/SLL approval is correct; (3) May 2024 FL approval is correct; (4) The characterization of Breyanzi as CD-19-directed CAR-T therapy is accurate and adds helpful context; (5) The overall narrative about market expansion is sound. ADDITIONAL ISSUES: The LLM introduces information about Japanese approval for FL in August 2024 and mentions 'high-risk FL after one prior line,' which is NOT in the ground truth answer. While this may be factually accurate from the 10-K filings, it goes beyond what was confirmed in the ground truth and introduces unverified details. The LLM also cites specific page numbers from 10-K filings, which adds specificity but cannot be verified against the ground truth. MULTI-HOP REASONING: The synthesis across 2022 and 2024 filings is attempted but compromised by the MCL error. The comparison of market expansion is logical but built on incomplete/incorrect data. QUANTITATIVE ACCURACY: Dates are mostly correct (March 2024, May 2024) but the MCL approval date is incorrectly attributed. The prior therapy line requirements (≥2) are correctly stated where mentioned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 457,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has 3M's approach to estimating and recording insurance receivables related to legal proceedings under ASC 450 evolved between 2022 and 2023, particularly in relation to respirator mask/asbestos litigation?",
      "original_answer": "In 2022, 3M referenced its compliance with ASC 450 for recording liabilities related to legal proceedings but did not specifically mention the methodology for estimating insurance receivables. By 2023, the company explicitly described applying the loss recovery and/or gain contingency models under ASC 450 and ASC 610-30 to estimate insurance receivables, including analysis of policy terms, case law, and claim nature. Additionally, the number of individual claimants in respirator mask/asbestos litigation increased from approximately 4,028 in 2022 to 4,042 in 2023, indicating a growing exposure that likely influenced the more detailed approach to insurance receivables in 2023.",
      "llm_answer": "Both the 2022 and 2023 10‑K state that 3M estimates insurance receivables by analysing policy terms, exclusions, relevant case law, its experience with similar claims and the nature of each claim, and records a receivable when the amount is deemed recognizable under ASC 450 (and ASC 610‑30) – for insured matters with an accrued liability and also for insured expenses where no liability is recorded【34†L31-L38】【78†L31-L38】.  The 2023 filing adds that, while the receivable for the respirator‑mask/asbestos litigation remains immaterial, the company is actively pursuing coverage from insolvent insurers and expects to collect “substantially all” of the remaining insurance recoveries – a more explicit, proactive stance that was not detailed in the 2022 disclosure【82†L31-L38】.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies that both 2022 and 2023 filings describe similar methodologies for estimating insurance receivables (analyzing policy terms, exclusions, case law, experience, claim nature). It accurately notes the ASC 450 and ASC 610-30 framework. The observation about 2023 adding more explicit language regarding pursuing coverage from insolvent insurers and expecting to collect 'substantially all' remaining recoveries is a valid evolution in disclosure. The answer demonstrates good qualitative understanding of the disclosure changes.\n\nCRITICAL ERRORS: (1) QUANTITATIVE FAILURE - The LLM answer completely omits the specific claimant numbers that are central to the ground truth answer. The ground truth explicitly states the number of individual claimants increased from approximately 4,028 in 2022 to 4,042 in 2023. This is a concrete, verifiable metric that directly supports the claim about 'growing exposure.' The LLM's failure to include these numbers represents a significant gap in quantitative accuracy. (2) INCOMPLETE EVOLUTION NARRATIVE - The ground truth emphasizes that in 2022, 3M 'did not specifically mention the methodology for estimating insurance receivables,' but by 2023 it 'explicitly described' the loss recovery and gain contingency models. The LLM answer contradicts this by stating 'Both the 2022 and 2023 10-K state that 3M estimates insurance receivables by analysing...' This suggests the methodologies were equally explicit in both years, which contradicts the ground truth's assertion of evolution in specificity and detail.\n\nMULTI-HOP REASONING: The LLM answer addresses the evolution but misses the causal connection between growing claimant numbers (4,028→4,042) and the more detailed approach to insurance receivables estimation. The ground truth explicitly links these: 'a growing exposure that likely influenced the more detailed approach.' The LLM identifies the proactive stance change but doesn't connect it to the quantitative growth in litigation exposure.\n\nSEMANTIC ISSUES: The LLM's statement that 'Both the 2022 and 2023 10-K state' the same methodology contradicts the ground truth's assertion of evolution from no specific mention to explicit description. This is a material semantic difference that affects the core answer to how the approach 'evolved.'\n\nOVERALL ASSESSMENT: The answer captures some qualitative evolution in disclosure but fails on quantitative specificity (missing claimant numbers) and mischaracterizes the degree of methodological description in 2022 vs. 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 682,
        "total_tokens": 2063
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did PepsiCo's relationship with Naked evolve between 2022 and 2023, particularly in terms of its operational involvement and financial stake?",
      "original_answer": "In 2022, PepsiCo sold its Tropicana, Naked, and other select juice brands to PAI Partners while retaining a 39% noncontrolling interest in a newly formed joint venture, The Beachbody Company (TBG), which operates across North America and Europe. Additionally, PepsiCo acted as the exclusive distributor for TBG's portfolio of brands, including Naked, for small-format and foodservice customers via chilled direct-store-delivery. By 2023, PepsiCo no longer directly distributed Naked products and instead primarily disclosed its relationship through its retained 39% noncontrolling interest in TBG, with no further operational involvement in the distribution of Naked products. This represents a shift from active distribution to a purely financial stake.",
      "llm_answer": "In 2022 PepsiCo sold the Naked juice brand (along with Tropicana) to PAI Partners, but retained a 39 % non‑controlling interest in the newly‑formed joint‑venture (Tropicana Brands Group) and remained the exclusive U.S. distributor for the venture’s small‑format and food‑service sales【PEP_10k_2022.pdf†page 9】. By the 2023 filing PepsiCo’s position was unchanged – it still owned the 39 % stake and continued to act as the joint‑venture’s exclusive distributor, so neither its operational involvement nor its financial stake shifted between the two years【PEP_10k_2023.pdf†page 6】.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERROR: The LLM answer fundamentally contradicts the ground truth on the core question about how the relationship evolved. The LLM claims 'neither its operational involvement nor its financial stake shifted between the two years' and that PepsiCo 'continued to act as the joint-venture's exclusive distributor' in 2023. However, the ground truth explicitly states that 'By 2023, PepsiCo no longer directly distributed Naked products' and that the relationship shifted 'from active distribution to a purely financial stake.' This is a major factual error that directly contradicts the premise of the question about evolution/change. QUANTITATIVE ACCURACY: The 39% noncontrolling interest figure is correct, and the 2022 transaction details (sale to PAI Partners, retention of 39% stake, exclusive distributor role) are accurate. However, the entity name is slightly off - the ground truth refers to 'The Beachbody Company (TBG)' while the LLM calls it 'Tropicana Brands Group.' QUALITATIVE ACCURACY: The LLM failed to identify the key evolution that occurred between 2022 and 2023 - the cessation of PepsiCo's distribution role. The answer misses the critical shift from operational involvement (distribution) to purely financial involvement (equity stake). The multi-hop reasoning is flawed because it incorrectly synthesizes the 2023 information, claiming continuity where the ground truth shows discontinuity. CONTEXTUAL RELEVANCE: The answer addresses the question structure but provides the wrong answer to the substantive question about how the relationship evolved. The question specifically asks about evolution 'between 2022 and 2023,' and the correct answer is that there WAS significant evolution (loss of distribution role), while the LLM incorrectly claims there was NO evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 489,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the accounting treatment or disclosure around the ExtraBucks Rewards program evolved between 2023 and 2024, particularly regarding the recognition of revenue and the determination of performance obligations?",
      "original_answer": "In 2023, the ExtraBucks Rewards program was described as creating an additional performance obligation at the time of the initial transaction, with revenue allocated based on relative standalone selling prices that consider historical redemption patterns. Revenue was recognized as the rewards were redeemed, and unredeemed rewards were reflected as a contract liability. In 2024, the disclosure remained consistent in terms of revenue recognition timing and contract liability treatment, but the language around performance obligations became more refined, emphasizing that the determination of an additional performance obligation was specifically tied to customers who accumulate ExtraBucks based on historical spending levels. The 2024 filing also included more structured language around how the Company allocates transaction prices and evaluates standalone selling prices, suggesting a more mature and formalized approach to the program’s accounting treatment.",
      "llm_answer": "Both the 2023 and 2024 filings continue to treat ExtraBucks Rewards as a distinct performance‑obligation. The company allocates part of the transaction price to the rewards based on their relative standalone selling price (using historical redemption patterns) and recognises that portion of revenue only when the rewards are redeemed, while the un‑redeemed portion is recorded as a contract liability 【2023 p. 129‑133】. The 2024 filing does not change the underlying policy but expands the disclosure – it now provides a detailed reconciliation of the contract‑liability balance (showing earnings, redemptions, breakage and acquired liabilities) and quantifies the liability for 2024 versus 2023, giving more transparency on the program’s financial impact 【2024 p. 123‑127】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the ExtraBucks Rewards accounting treatment and its evolution between 2023 and 2024. STRENGTHS: (1) Correctly identifies that both years treat ExtraBucks as a distinct performance obligation; (2) Accurately describes the revenue recognition methodology using relative standalone selling prices based on historical redemption patterns; (3) Correctly states that unredeemed rewards are recorded as contract liabilities; (4) Properly identifies the key evolution: 2024 expanded disclosure with detailed reconciliation of contract liability balances including earnings, redemptions, breakage, and acquired liabilities; (5) Appropriately cites page ranges for both years (2023 p. 129-133, 2024 p. 123-127); (6) Correctly notes the underlying policy remained consistent while disclosure became more detailed and transparent. MINOR GAPS: (1) The LLM answer does not explicitly mention the 'more refined language' around performance obligations tied to 'customers who accumulate ExtraBucks based on historical spending levels' that the ground truth emphasizes - this represents a subtle but meaningful refinement in how the determination of performance obligations was articulated; (2) Does not explicitly characterize the 2024 approach as 'more mature and formalized' though the expanded reconciliation disclosure implicitly conveys this; (3) Could have been more explicit about the quantification aspect ('quantifies the liability for 2024 versus 2023') though this is mentioned. QUANTITATIVE ACCURACY: No specific dollar amounts or percentages were provided in either answer, so this dimension is not directly testable. The page citations appear reasonable for 10-K filings. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and correctly identifies both continuity and evolution in accounting treatment. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The LLM answer conveys the essential information from the ground truth with appropriate emphasis on the key differences between years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1452,
        "completion_tokens": 562,
        "total_tokens": 2014
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Netflix's reliance on integrated payment partners evolved between 2023 and 2024, based on the specific details provided in the cost of revenues section for each year?",
      "original_answer": "In 2023, Netflix specifically mentioned that payment processing fees paid to integrated payment partners were part of other operating costs within the cost of revenues. In 2024, the company continued to reference payment processing fees paid to integrated payment partners as part of other operating costs, but the overall structure of the cost of revenues section was streamlined, removing some of the granular details about these fees. This indicates that while the relationship persisted, the level of explicit detail about the financial impact of integrated payment partners decreased, suggesting a shift in disclosure strategy rather than a substantive discontinuation of the relationship.",
      "llm_answer": "In 2023 Netflix’s cost of revenues – which includes the payment‑processing fees it pays to its integrated payment partners – was $19.7 billion, or 58 % of total revenue. By 2024 the total cost of revenues rose to $21.0 billion but fell to 54 % of revenue, meaning the portion of costs tied to payment‑processing (and thus reliance on integrated payment partners) grew more slowly than revenue and now represents a smaller share of the company’s overall cost structure.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer fundamentally misinterprets the question and provides incorrect information. Key issues: (1) MISALIGNMENT WITH GROUND TRUTH: The ground truth states that Netflix's disclosure strategy changed - payment processing fees were mentioned in 2023 but the 2024 disclosure was 'streamlined' with 'removal of granular details.' The LLM answer inverts this, claiming payment processing fees grew as a portion of costs, which contradicts the ground truth's focus on disclosure changes rather than substantive cost changes. (2) QUANTITATIVE ERRORS: The LLM provides specific cost of revenues figures ($19.7B in 2023, $21.0B in 2024) and percentage calculations (58% vs 54%) that are not verified in the ground truth and appear to be fabricated or misattributed. The ground truth makes no mention of these specific dollar amounts or percentages. (3) MISINTERPRETATION OF QUESTION: The question asks about 'evolution' based on 'specific details provided in the cost of revenues section' - this is asking about disclosure changes and detail levels, not about absolute cost changes or percentage shifts. The LLM completely misses this nuance. (4) FAILED MULTI-HOP SYNTHESIS: The ground truth explicitly states the relationship 'persisted' but disclosure became less granular. The LLM instead creates a narrative about payment processing costs growing slower than revenue, which is not supported by the ground truth. (5) SEMANTIC MISMATCH: The ground truth emphasizes a 'shift in disclosure strategy' while the LLM focuses on cost structure changes - these are fundamentally different conclusions. The answer demonstrates a failure to understand the core insight about changing transparency/disclosure practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 466,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has 3M's approach to managing PFAS contamination in Minnesota evolved from 2022 to 2023, particularly in response to regulatory changes and new health-based standards?",
      "original_answer": "In 2022, 3M had substantially completed remediation work at the Cottage Grove site and was continuing operational and maintenance activities at Oakdale and Woodbury sites in Minnesota under the May 2007 Settlement Agreement and Consent Order. The company was also addressing PFAS discharges at its Decatur, Alabama facility under a 2020 interim Consent Order with ADEM, which included obligations for on-site and off-site investigations and future capital improvements. By 2023, the Minnesota Department of Health issued updated, more stringent Health Based Values (HBVs) for PFOA and PFOS in January 2024, prompting 3M to evaluate the potential impact on its obligations under the SACO. Additionally, MPCA issued a Notice of Violation in March 2023 alleging PFAS in stormwater discharge at 3M’s Hutchinson facility, and in December 2022, MPCA issued an order addressing stormwater from the Cottage Grove facility. In January 2024, MPCA proposed a new Clean Water Act permit for Cottage Grove with significantly revised, often below-quantification-level limits on PFAS, indicating a tightening regulatory environment that 3M is actively engaging with.",
      "llm_answer": "In 2022 3M’s Minnesota program was centered on the May 2007 Settlement Agreement and Consent Order with the MPCA – it completed remediation at the Oakdale, Woodbury and Cottage Grove sites, continued operational monitoring, and provided alternative drinking water whenever PFAS concentrations exceeded the existing health‑based values (HBVs) or health‑risk limits (HRLs) [MMM_10k_2022.pdf:125‑129]. By 2023 the focus shifted to new regulatory requirements: 3M developed a storm‑water PFAS management plan after MPCA direction, responded to a March 2023 MPCA Notice of Violation for PFAS in storm‑water discharge, and is reviewing a draft Clean Water Act permit with tighter PFAS limits and the Minnesota Department of Health’s more stringent HBVs issued in January 2024, prompting the company to evaluate and adjust its obligations [MMM_10k_2023.pdf:96‑100].",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key facts but contains significant errors and omissions when compared to the ground truth. STRENGTHS: (1) Correctly identifies the May 2007 Settlement Agreement and Consent Order as the framework; (2) Correctly dates the March 2023 MPCA Notice of Violation for Hutchinson facility; (3) Correctly references January 2024 Minnesota Department of Health HBVs; (4) Correctly mentions the draft Clean Water Act permit for Cottage Grove with tighter PFAS limits; (5) Appropriately captures the shift from remediation completion to regulatory compliance focus. CRITICAL ERRORS AND OMISSIONS: (1) FACTUAL ERROR - States 3M 'completed remediation at the Oakdale, Woodbury and Cottage Grove sites' in 2022, but ground truth states 'substantially completed remediation work at the Cottage Grove site' only, with Oakdale and Woodbury continuing 'operational and maintenance activities' (not completed remediation); (2) MISSING CONTEXT - Fails to mention the Decatur, Alabama facility and the 2020 interim Consent Order with ADEM, which is a significant part of 3M's PFAS management approach; (3) INCOMPLETE TIMELINE - Omits the December 2022 MPCA order addressing stormwater from Cottage Grove facility, which is relevant to the 2022-2023 evolution; (4) VAGUE ATTRIBUTION - References 'MPCA direction' for stormwater plan development without specificity; (5) SEMANTIC ISSUE - The phrase 'completed remediation at...Cottage Grove' contradicts the ground truth's more nuanced 'substantially completed' language, suggesting full completion rather than ongoing work. MULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2023 documents and identifies the regulatory evolution, but misses the geographic scope (Decatur, Alabama) and oversimplifies the remediation status. The answer demonstrates reasonable understanding of the progression but lacks precision on key factual details that distinguish between completed and ongoing activities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1508,
        "completion_tokens": 534,
        "total_tokens": 2042
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did PepsiCo's use of foreign currency derivatives evolve between 2022 and 2023, and what does this indicate about its foreign exchange risk management strategy?",
      "original_answer": "In 2022, PepsiCo reported a total notional value of $3.0 billion for its foreign currency derivatives, while in 2023, this value increased to $3.8 billion. This indicates a strategic expansion in the use of foreign currency derivatives to manage foreign exchange risk, likely in response to increased exposure or volatility in international markets. Additionally, the company emphasized the use of these derivatives to offset changes in the underlying hedged items, resulting in no material net impact on earnings in 2023.",
      "llm_answer": "PepsiCo’s foreign‑currency hedging program grew substantially – the notional amount of its foreign‑currency derivatives rose from **$3.0 billion at year‑end 2022 to $3.8 billion at year‑end 2023**, and the notional of debt used as net‑investment hedges edged up from **$2.9 billion to $3.0 billion** over the same period【PEP_10k_2023.pdf:101‑105】. The increase in both the overall derivative exposure and the dedicated net‑investment hedge amount signals that PepsiCo is expanding and deepening its hedging activities to more fully offset its growing foreign‑exchange risk.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of all key financial metrics. Quantitative verification: (1) Foreign currency derivatives notional value correctly stated as $3.0 billion (2022) to $3.8 billion (2023) - matches ground truth exactly; (2) Net-investment hedge debt notional correctly stated as $2.9 billion (2022) to $3.0 billion (2023) - this additional detail goes beyond the ground truth but is accurate and relevant. The LLM successfully synthesizes multi-hop information by connecting the derivative amounts to the strategic implication of expanded hedging activities. The reasoning is sound: the increase in both metrics logically supports the conclusion about deepening hedging activities and growing FX risk management. The answer addresses the core question about evolution between 2022-2023 and provides interpretation of what this indicates about strategy. Minor deduction: The ground truth mentions 'no material net impact on earnings in 2023,' which the LLM answer does not include. However, the LLM provides additional context about net-investment hedges that adds value and is not contradictory. The answer is well-structured, cites sources appropriately, and uses proper formatting for numbers. All entities (PepsiCo, years, metrics) are correctly identified. The semantic meaning aligns with ground truth regarding strategic expansion in response to FX exposure/volatility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 397,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has ExxonMobil's approach to capitalizing on improving living standards evolved between 2022 and 2023, particularly in terms of chemical production capacity additions and geographic focus?",
      "original_answer": "In 2022, ExxonMobil highlighted the completion of a joint venture ethane cracker near Corpus Christi, Texas, and plans for up to 500,000 metric tons annually of advanced recycling capacity in Baytown, Texas, by 2026, as part of its strategy to meet growing demand driven by improving living standards. By 2023, the company shifted focus toward expanding performance polymers and linear alpha olefins capacity in Baytown, Texas, and advancing a 100% foreign-owned petrochemical complex in Dayawan, China, with over 2.5 million metric tons per year of polyethylene and polypropylene capacity. This reflects a strategic evolution from domestic advanced recycling and integrated U.S. projects to high-performance product expansions and significant foreign investment in China to meet local demand.",
      "llm_answer": "In the 2022 filing (see pages 66‑68), ExxonMobil said it would capture demand from rising living standards by restarting U.S. Gulf‑Coast growth projects (e.g., Baytown and Baton Rouge) and by taking a final investment decision on a multi‑billion‑dollar chemical complex in China’s Dayawan Petrochemical Industrial Park. By the 2023 filing (see pages 58‑60), the company had moved from planning to execution – launching a 400 k mt/yr performance‑polymers line and a 350 k mt/yr linear‑alpha‑olefins unit in Baytown, while still investing in the Dayawan complex – reinforcing a dual geographic focus on North America and China to meet the same improving‑living‑standards trend.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the overall strategic evolution and geographic shift correctly, but contains significant quantitative discrepancies that undermine accuracy. CORRECT ELEMENTS: (1) The identification of 2022 focus on U.S. Gulf Coast projects (Baytown, Baton Rouge) and the Dayawan China complex decision is accurate; (2) The 2023 shift to execution phase with Baytown expansions is correct; (3) The dual geographic focus on North America and China is accurately identified; (4) The connection to improving living standards is properly maintained throughout. QUANTITATIVE ERRORS: (1) The LLM states 'performance-polymers line' at 400 k mt/yr and 'linear-alpha-olefins unit' at 350 k mt/yr for 2023 Baytown - these specific numbers are not verified in the ground truth, which does not provide these exact capacity figures; (2) The ground truth specifies 'over 2.5 million metric tons per year of polyethylene and polypropylene capacity' for Dayawan, but the LLM does not quantify the Dayawan capacity at all; (3) The 2022 advanced recycling capacity of 'up to 500,000 metric tons annually' mentioned in ground truth is completely omitted from the LLM answer; (4) The ethane cracker completion near Corpus Christi is not mentioned in the LLM answer. MULTI-HOP REASONING: The LLM successfully synthesizes the evolution across 2022-2023 and connects both years to the improving living standards theme. The reasoning about moving from planning to execution is sound and well-articulated. MISSING CONTEXT: The LLM fails to mention the advanced recycling capacity plans (500k mt/yr by 2026) and the Corpus Christi ethane cracker completion, which are material omissions from the ground truth. The answer is directionally correct on strategy but incomplete on specific capacity additions and projects.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 488,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did 3M's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "In 2022, 3M held $21 million in Certificates of Deposit/Time Deposits, which increased to $49 million in 2023 — more than doubling. This indicates a strategic shift toward increasing liquidity or reallocating short-term cash holdings into more stable or higher-yielding instruments within this category.",
      "llm_answer": "3M’s balance‑sheet shows that its holdings of certificates of deposit / time deposits grew from **$21 million at year‑end 2022 to $49 million at year‑end 2023** – an increase of more than double【MMM_10k_2023.pdf Note 12, “Certificates of deposit/time deposits $ 49 $ 21”】.  This rise signals that the company is shifting a larger portion of its cash into short‑term, low‑risk, highly liquid assets, indicating a more conservative short‑term investment approach aimed at preserving liquidity.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-supported. (1) QUANTITATIVE ACCURACY: All numbers are correct - $21 million in 2022 and $49 million in 2023 match the ground truth exactly. The characterization of this as 'more than double' is accurate (49/21 = 2.33x). (2) COMPLETENESS: The answer addresses both parts of the question - the evolution of CD/Time Deposits holdings and what this indicates about strategy. (3) ENTITY ACCURACY: Correctly identifies 3M, the specific financial metric (Certificates of Deposit/Time Deposits), and the correct fiscal years (2022 and 2023). The citation to Note 12 of the 2023 10-K is appropriate. (4) REASONING: The multi-hop synthesis is sound - the model correctly extracted the two data points from different years and synthesized them into a coherent narrative about strategic shift. (5) SEMANTIC EQUIVALENCE: The LLM's interpretation that this indicates 'a more conservative short-term investment approach aimed at preserving liquidity' is semantically equivalent to the ground truth's statement about 'increasing liquidity or reallocating short-term cash holdings into more stable or higher-yielding instruments.' Both convey the same strategic intent. Minor difference: The LLM provides slightly more specific interpretation (conservative approach, liquidity preservation) while the ground truth is more general (liquidity increase or reallocation). This is not a deficiency but rather appropriate elaboration. The answer is well-structured, properly cited, and factually sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1206,
        "completion_tokens": 419,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Mastercard's approach to proprietary insights evolved from 2022 to 2023, particularly in terms of data responsibility and trust-building language?",
      "original_answer": "In 2022, Mastercard described its proprietary insights as being based on the 'principled use of consumer and merchant data.' By 2023, the language evolved to emphasize 'principled and responsible use of secure consumer and merchant data.' This shift indicates a stronger emphasis on data security and trust as a core component of their proprietary insights strategy. The change in phrasing reflects a broader narrative around cybersecurity and stakeholder confidence in how Mastercard manages sensitive data.",
      "llm_answer": "In the 2022 filing Mastercard said its proprietary‑insight services “draw on Mastercard’s principled use of consumer and merchant data” and are meant to let parties “transact easily and with confidence” (2022 Business Overview, pp. 69‑73). By the 2023 filing the language was sharpened to stress a “principled and responsible use of secure consumer and merchant data” and added “securely” to the trust‑building phrase – “transact securely, easily and with confidence” (2023 Business Overview, pp. 47‑51). This reflects a shift toward explicitly emphasizing data responsibility and security.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and provides more detailed evidence than the ground truth. Key strengths: (1) Correctly identifies the 2022 language as 'principled use of consumer and merchant data' and the 2023 evolution to 'principled and responsible use of secure consumer and merchant data' - matching the ground truth exactly. (2) Adds valuable specificity by citing page numbers (2022: pp. 69-73; 2023: pp. 47-51) and document sections (Business Overview), which enhances credibility without contradicting the ground truth. (3) Provides additional context by noting the expansion of trust-building language from 'transact easily and with confidence' to 'transact securely, easily and with confidence,' which reinforces the core finding about emphasis on security. (4) The multi-hop reasoning is sound - correctly synthesizing the evolution across two years and identifying the shift toward data responsibility and security. (5) No quantitative errors or calculation issues present. Minor consideration: The LLM answer goes slightly beyond the ground truth by including the additional phrase evolution ('securely' added to trust language), but this is complementary rather than contradictory and strengthens the overall narrative about the shift toward security emphasis. The semantic meaning is fully aligned with the ground truth's conclusion about 'stronger emphasis on data security and trust as a core component.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 398,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did the factors influencing the accounting estimates for pension and retiree medical plans evolve between 2022 and 2023, and what does this indicate about the changing external environment affecting these plans?",
      "original_answer": "In 2022, the accounting estimates for pension and retiree medical plans were influenced by uncertainties related to the ongoing impacts of the COVID-19 pandemic. By 2023, this had evolved, and the estimates were instead influenced by business and economic uncertainty stemming from the ongoing conflicts in Ukraine and the Middle East, as well as a high interest rate and inflationary cost environment. This indicates a shift in the external risk factors affecting the company's pension and retiree medical plans from health-related disruptions to broader macroeconomic and geopolitical concerns.",
      "llm_answer": "In the 2022 10‑K the company noted that the key uncertainties driving its pension‑ and retiree‑medical‑plan estimates were the COVID‑19 pandemic and the associated economic volatility (PEP 2022 ‑ Critical Accounting Policies and Estimates). By the 2023 filing, the discussion had shifted to “the ongoing conflicts in Ukraine and the Middle East, a high‑interest‑rate environment and inflationary cost pressures” as the primary sources of uncertainty (PEP 2023 ‑ Critical Accounting Policies and Estimates). This evolution signals that the external environment affecting the plans has moved from pandemic‑related risk to broader geopolitical and macro‑economic challenges, which are likely to alter discount‑rate, inflation and health‑care cost assumptions used in the estimates.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about pension and retiree medical plan accounting estimates evolution. STRENGTHS: (1) Correctly identifies the 2022 factors (COVID-19 pandemic and associated economic volatility) and 2023 factors (Ukraine/Middle East conflicts, high interest rates, inflationary pressures), matching the ground truth exactly. (2) Properly synthesizes information across two fiscal years (2022 and 2023) to show the evolution. (3) Accurately identifies the company as PEP (PepsiCo) and correctly cites the relevant sections (Critical Accounting Policies and Estimates). (4) The reasoning is sound - correctly identifies this as a shift from health-related disruptions to macroeconomic/geopolitical concerns. (5) Goes beyond the ground truth by adding relevant context about how these changes would affect specific assumptions (discount rates, inflation, healthcare costs), which is logically sound and demonstrates deeper understanding. (6) No quantitative errors - all dates and entities are correct. MINOR CONSIDERATIONS: The LLM answer includes slightly more interpretive detail about the implications (mentioning specific assumptions affected) compared to the ground truth, but this is appropriate elaboration that enhances rather than contradicts the answer. The semantic meaning is fully aligned with the original answer. All factual claims are verifiable and accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 403,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has ExxonMobil's undeveloped acreage position in the Other Americas region evolved between 2022 and 2023, and what does this indicate about the company's exploration potential in that region?",
      "original_answer": "ExxonMobil's undeveloped acreage in the Other Americas region decreased from 25,096 gross and 11,977 net thousands of acres in 2022 to 24,221 gross and 11,548 net thousands of acres in 2023. This indicates a reduction in the total acreage under evaluation, suggesting that some properties may have been relinquished or transitioned to developed status, while the company continues to focus on properties with higher exploration potential.",
      "llm_answer": "ExxonMobil’s undeveloped land base in the Other Americas slipped from ≈25,096 gross and 11,977 net thousand acres in 2022 to ≈24,221 gross and 11,548 net thousand acres in 2023 – a drop of about 875 gross and 429 net thousand acres【XOM_10k_2023.pdf page 24‑25】. The modest reduction indicates the company has shed a small portion of its acreage (likely through development or relinquishment) but still holds a large undeveloped portfolio, pointing to continued exploration potential in the region.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All numbers are correct - 2022 figures (25,096 gross, 11,977 net thousand acres), 2023 figures (24,221 gross, 11,548 net thousand acres), and calculated differences (875 gross, 429 net thousand acres) are all accurate. The calculations are mathematically sound: 25,096 - 24,221 = 875 and 11,977 - 11,548 = 429. ENTITY ACCURACY: Company (ExxonMobil), region (Other Americas), years (2022-2023), and metrics (gross/net undeveloped acreage) are all correctly identified. MULTI-HOP REASONING: The answer successfully synthesizes the year-over-year comparison and draws appropriate conclusions about exploration potential. The interpretation that the reduction indicates properties were relinquished or transitioned to developed status aligns with the ground truth. COMPLETENESS: The answer addresses both parts of the question - the evolution of acreage position and what it indicates about exploration potential. The characterization of the reduction as 'modest' is appropriate given the ~3.5% decrease in gross acreage. MINOR OBSERVATIONS: The use of the approximation symbol (≈) is slightly informal but acceptable given the context. The citation to source material adds credibility. The semantic meaning matches the ground truth perfectly - both convey that acreage decreased modestly while the company maintains significant exploration potential. No factual errors or calculation mistakes detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 412,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How did the treatment and financial impact of non-functional currency denominated items evolve from 2022 to 2023, particularly in terms of the use of foreign currency contracts not designated in hedging relationships?",
      "original_answer": "In 2022, MMM used foreign exchange forward and option contracts not designated in hedging relationships to offset the impacts of changes in value of various non-functional currency denominated items, including certain intercompany financing balances, with a gross notional amount of $3.7 billion. By 2023, the company continued to use such contracts for the same purpose but shifted focus to derivatives not designated as hedging instruments, with fair value gains and losses directly impacting earnings. This indicates a shift from primarily designated hedging strategies to a more direct financial exposure management approach.",
      "llm_answer": "3M kept using foreign‑currency forwards and options that are not designated as hedges to offset changes in non‑functional‑currency items, and because they are non‑designated the fair‑value gains or losses flow through earnings. The pretax loss on those non‑designated foreign‑currency contracts shrank dramatically—from a $76 million loss in 2022 to a $9 million loss in 2023—while the net gain on all non‑designated derivatives fell from $45 million in 2022 to $21 million in 2023, reflecting a much smaller adverse impact from non‑functional‑currency items.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core concept that 3M (MMM) used non-designated foreign currency contracts to offset non-functional currency items, with fair value gains/losses flowing through earnings. The qualitative understanding of the shift and mechanism is sound. However, there are significant quantitative accuracy issues: (1) The LLM provides specific loss figures ($76M in 2022, $9M in 2023) and net gain figures ($45M in 2022, $21M in 2023) that are NOT present in the ground truth answer. The ground truth only mentions a $3.7 billion gross notional amount for 2022 contracts and does not provide these specific loss/gain figures. (2) The LLM's claim about a 'dramatic shrink' from $76M to $9M loss cannot be verified against the ground truth, which contains no such numbers. (3) The ground truth emphasizes the shift from 'primarily designated hedging strategies to a more direct financial exposure management approach,' while the LLM focuses on the magnitude of losses/gains without explicitly addressing this strategic shift. The LLM answer appears to have introduced specific financial metrics that may come from the source documents but are not reflected in the ground truth answer provided. This creates a factual accuracy problem - either these numbers are incorrect, or the ground truth is incomplete. Given the strict evaluation criteria for numbers and calculations, the introduction of unverified specific figures significantly reduces the correctness score. The answer is partially correct in concept but problematic in its quantitative claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 432,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the role and emphasis of Cyber and Intelligence Solutions evolved within Mastercard's value proposition between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were mentioned as part of a broader list of value-added services, grouped alongside consulting fees, loyalty programs, gateway services, and other payment-related offerings. This suggests a supporting role within the company's portfolio. By 2023, the Cyber and Intelligence Solutions were more prominently positioned as a core component of Mastercard’s value proposition, explicitly described as enabling secure, easy, and confident transactions across the global payments ecosystem. This indicates a strategic shift toward elevating the importance of cybersecurity within Mastercard’s overall service offering.",
      "llm_answer": "In the 2022 filing, cyber and intelligence solutions were presented as one line‑item within “Other revenues,” described mainly as fee‑based services that “prevent, detect and respond to fraud and … ensure the safety of transactions” (2022 10‑K, Other revenues section). By the 2023 filing, the Business Overview elevates them to a headline component of Mastercard’s value‑added services, stating that “cyber and intelligence solutions … allow all parties to transact securely, easily and with confidence” and linking them to broader digital‑identity and open‑banking capabilities (2023 10‑K, Business Overview). This shift shows the offering moving from a peripheral revenue source to a strategic pillar of Mastercard’s value proposition.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core narrative of Cyber and Intelligence Solutions' evolution from 2022 to 2023. STRENGTHS: (1) Correctly identifies the 2022 positioning as a line-item within 'Other revenues' with a supporting/peripheral role, (2) Accurately captures the 2023 elevation to a headline component in the Business Overview, (3) Provides specific quoted language from both filings that supports the evolution narrative ('prevent, detect and respond to fraud' in 2022; 'transact securely, easily and with confidence' in 2023), (4) Correctly synthesizes the multi-hop comparison across two fiscal years, (5) Appropriately characterizes the shift as moving from 'peripheral revenue source to strategic pillar,' which aligns with ground truth's 'supporting role' to 'core component' framing. MINOR CONSIDERATIONS: (1) The LLM answer adds contextual details about 'digital-identity and open-banking capabilities' that are not explicitly mentioned in the ground truth, though this appears to be legitimate additional context from the 2023 filing rather than an error, (2) The specific quoted phrases appear authentic to SEC filings but cannot be independently verified against the exact source documents in this evaluation. QUANTITATIVE ACCURACY: No numerical data, percentages, or dollar amounts are present in either answer, so this dimension is not applicable but scores high due to absence of errors. QUALITATIVE ACCURACY: The reasoning is sound - the answer correctly identifies the shift in positioning and provides supporting evidence through quoted language. The multi-hop synthesis (comparing 2022 vs 2023 across different filing sections) is executed properly. CONTEXTUAL RELEVANCE: The answer directly addresses the question about evolution of role and emphasis, providing clear before/after comparison with specific evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 510,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the treatment or disclosure of Income Tax Expense and Accruals evolved in the list of critical accounting policies between 2022 and 2023?",
      "original_answer": "In 2022, 'income tax expense and accruals' was explicitly listed as one of the critical accounting policies and estimates, indicating its significance in financial reporting. By 2023, while still listed as a critical accounting policy, it was moved to a subsection under 'Our Critical Accounting Policies and Estimates' with a more structured presentation of related notes, such as Note 5 - Income Taxes, which provided deeper transparency into tax-related disclosures. This evolution reflects a shift toward more detailed and organized reporting of tax-related matters in 2023.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K filings list “income tax expense and accruals” as a critical accounting policy, and the wording is essentially unchanged. In 2022 (PEP 10‑K 2022 pp. 57‑61) the company says it bases its annual tax rate on income, statutory rates and transfer‑pricing, uses significant judgment, establishes reserves for uncertain positions and adjusts them as audits, new laws or other facts change; the 2023 filing (PEP 10‑K 2023 pp. 31‑35) repeats the same description of an estimated effective tax rate, judgment‑driven tax‑position evaluation and reserve‑adjustment process. Thus, the treatment and disclosure of income‑tax expense and accruals did not materially evolve between 2022 and 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer directly contradicts the ground truth on the core finding. Ground truth states that income tax expense and accruals evolved between 2022 and 2023, specifically: (1) it was explicitly listed as a critical accounting policy in 2022, and (2) by 2023 it was moved to a subsection under 'Our Critical Accounting Policies and Estimates' with more structured presentation and deeper transparency through related notes like Note 5. The LLM answer claims 'the treatment and disclosure of income-tax expense and accruals did not materially evolve between 2022 and 2023,' which is factually incorrect according to the ground truth. While the LLM correctly identifies that both years list it as a critical accounting policy and notes similar substantive content (tax rate estimation, judgment, reserves), it misses the structural reorganization that constitutes the actual evolution. The LLM also cites specific page numbers (2022 pp. 57-61, 2023 pp. 31-35) without verification against the actual filings, and these page references cannot be confirmed as accurate. The answer focuses on content similarity rather than addressing the actual structural and organizational changes that occurred. The fundamental error is concluding 'no material evolution' when the ground truth explicitly describes a meaningful shift in presentation structure and organization of tax-related disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 386,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Intel's development and positioning of the Universal Chiplet Interconnect Express standard evolved between 2023 and 2024 in the context of its broader systems of chips strategy?",
      "original_answer": "In 2023, Intel introduced the Universal Chiplet Interconnect Express (UCIe) standard and demonstrated it in silicon, marking the initial phase of its strategic push to enable optimized systems of chips. By 2024, Intel had progressed beyond the demonstration phase and was actively producing based on this standard, integrating it into its broader advanced semiconductor assembly and test offerings. This evolution reflects Intel's deepening commitment to the UCIe standard as a core component of its systems of chips strategy, aimed at enhancing system performance and accelerating customer designs through advanced packaging technologies and system-level standards.",
      "llm_answer": "In the 2023 filing Intel reported that the Universal Chiplet Interconnect Express (UCIe) standard had been **demonstrated in silicon in 2023** and was being advanced as a key part of its “systems‑of‑chips” capabilities and advanced‑packaging strategy 【35‑39】. By the 2024 filing Intel reiterated that it **continues to drive the UCIe standard**, now embedding it in its Intel Foundry’s advanced packaging and services portfolio and positioning it as a cornerstone of its broader Open System Foundry/IDM 2.0 “systems‑of‑chips” roadmap to accelerate customers’ designs and improve system performance 【20‑24】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2023 milestone of UCIe demonstration in silicon, matching the ground truth exactly. (2) Accurately captures the 2024 progression from demonstration to active production/integration phase. (3) Properly synthesizes the multi-hop connection between UCIe development and Intel's broader systems-of-chips strategy. (4) Correctly identifies the strategic context including advanced packaging, Intel Foundry services, and Open System Foundry/IDM 2.0 positioning. (5) Accurately conveys the evolution trajectory and strategic intent. (6) No quantitative errors - dates and temporal progression are correct. MINOR CONSIDERATIONS: (1) The LLM answer includes additional contextual details about Intel Foundry's advanced packaging portfolio and IDM 2.0 roadmap that, while accurate and relevant, go slightly beyond the ground truth's more concise framing. However, this represents enrichment rather than error. (2) The citation markers [35-39] and [20-24] suggest source documentation but cannot be verified against the ground truth provided. (3) The phrasing 'continues to drive' in 2024 is semantically equivalent to the ground truth's 'actively producing based on this standard.' The answer successfully demonstrates multi-hop reasoning by connecting: (a) 2023 demonstration phase → (b) 2024 production integration → (c) broader systems-of-chips strategy context. All factual claims are accurate and the synthesis is logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 429,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the accounting treatment and completion timeline of CVS's Accelerated Share Repurchase (ASR) transactions evolved between the 2023 and 2024 10-K filings?",
      "original_answer": "In 2023, CVS completed a $2.0 billion ASR with Citibank, receiving 17.4 million shares initially (80% of the notional amount) and an additional 5.4 million shares in February 2023, concluding the transaction. The forward contract portion was reclassified from capital surplus to treasury stock upon completion. In 2024, CVS completed a $3.0 billion ASR with Morgan Stanley, initially receiving 31.4 million shares (85% of the notional amount) and an additional 8.3 million shares in March 2024. Similar to 2023, the forward contract was reclassified from capital surplus to treasury stock after the final shares were received. The accounting treatment remained consistent, but the scale and timeline of completion evolved, with the 2024 ASR taking two months to conclude compared to one month in 2023.",
      "llm_answer": "In the 2023 filing the ASRs were recorded as a two‑part transaction – an initial treasury‑stock purchase for most of the notional amount and a forward contract for the remainder that was classified as an equity instrument in capital surplus and then re‑classified to treasury stock when the final shares arrived in February of the next year (e.g., the $2.0 bn Citibank ASR was booked $1.6 bn treasury stock + $0.4 bn forward, with the forward moved to treasury stock in Feb 2023; the $1.5 bn Barclays ASR was booked $1.2 bn + $0.3 bn, with the re‑classification in Feb 2022)【2023 10‑K】.  \n\nThe 2024 filing uses the same accounting model for the larger $3.0 bn Morgan Stanley ASR – $2.6 bn as an initial treasury‑stock transaction and a $0.4 bn forward contract recorded in capital surplus – but the final share delivery occurred in March 2024 rather than February, extending the completion timeline by about one month【2024 10‑K】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - Critical numerical errors: LLM states 2023 Citibank ASR was booked as '$1.6 bn treasury stock + $0.4 bn forward' but ground truth shows 17.4M shares initially (80% of $2.0B = $1.6B) and 5.4M additional shares (20% of $2.0B = $0.4B) - the dollar amounts are correct but LLM fails to mention the actual share counts (17.4M and 5.4M) which are key metrics. For 2024, LLM states '$2.6 bn as initial treasury-stock transaction and $0.4 bn forward' but ground truth shows 31.4M shares initially (85% of $3.0B = $2.55B, not $2.6B) and 8.3M additional shares (15% of $3.0B = $0.45B, not $0.4B). These are calculation errors. (2) ENTITY/DATE ERRORS - LLM references a Barclays ASR with reclassification in 'Feb 2022' which is inconsistent with the 2023 filing context and appears to be an error not mentioned in ground truth. (3) TIMELINE DISCREPANCY - Ground truth states 2023 ASR took 'one month' to conclude (initial in Jan, final in Feb 2023) and 2024 took 'two months' (initial in Jan, final in March 2024). LLM states 2024 'extended the completion timeline by about one month' compared to 2023, which contradicts the ground truth that 2024 took longer (2 months vs 1 month). (4) MISSING SHARE COUNTS - LLM completely omits the specific share quantities (17.4M, 5.4M for 2023; 31.4M, 8.3M for 2024) which are critical details for understanding the transaction evolution. (5) ACCOUNTING TREATMENT - While LLM correctly identifies the two-part structure and reclassification mechanism, it fails to accurately capture the percentage allocations (80%/20% for 2023, 85%/15% for 2024) and the actual share delivery mechanics. The answer demonstrates partial understanding of the accounting model but contains significant quantitative errors and omissions that undermine its accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 495,
        "total_tokens": 1931
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did UPS's financial exposure and reporting approach related to the Central States Pension Fund evolve from 2022 to 2023, particularly in terms of actuarial estimates and sensitivity analysis?",
      "original_answer": "In 2022, UPS disclosed a $2.3 billion pre-tax actuarial loss related to potential coordinating benefits for the Central States Pension Fund, as part of broader pension obligation disclosures. By 2023, the company's reporting shifted focus to sensitivity analysis, referencing a 25 basis point change in expected and actual returns on assets as a key assumption affecting pension liabilities, with an explicit cross-reference to Note 5 for details on the Central States Pension Fund liability. This indicates a shift from quantifying a specific obligation to emphasizing the sensitivity of returns on the overall liability.",
      "llm_answer": "In the 2022 Form 10‑K UPS reported a $2.3 billion pre‑tax actuarial loss for “coordinating benefits attributable to the Central States Pension Fund,” reflecting its best‑estimate of additional benefits that might be required before discount‑rate effects were applied. By the 2023 filing the company no longer gave a separate loss figure; it points to note 5 for the potential CSPF liability and adds a 25‑basis‑point discount‑rate sensitivity analysis that quantifies how changes in assumptions would affect pension obligations (e.g., a $1.55 billion reduction in projected benefit obligation for a 25‑bp increase) and net periodic benefit cost, showing a shift to a more explicit, scenario‑based reporting of exposure.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and provides more detailed context than the ground truth. Key strengths: (1) Correctly identifies the $2.3 billion pre-tax actuarial loss in 2022 for coordinating benefits related to CSPF; (2) Accurately notes the shift away from separate loss figures in 2023; (3) Correctly references the 25 basis point sensitivity analysis; (4) Provides additional helpful detail about the $1.55 billion reduction in projected benefit obligation for a 25-bp increase, which represents a concrete example of the sensitivity analysis mentioned in the ground truth; (5) Properly synthesizes the multi-hop evolution from 2022 to 2023 reporting approaches. Minor considerations: The LLM answer goes slightly beyond the ground truth by providing the specific $1.55 billion figure and explaining the mechanics of the sensitivity analysis more explicitly. While this additional detail is accurate and relevant, the ground truth focuses more on the conceptual shift (from 'quantifying a specific obligation to emphasizing sensitivity'). The LLM's characterization of the shift as 'scenario-based reporting' is semantically equivalent to the ground truth's description. All numeric values are correct, the temporal progression is accurate, and the multi-hop reasoning correctly connects 2022 and 2023 reporting approaches. The answer fully addresses all parts of the question regarding financial exposure evolution, reporting approach changes, actuarial estimates, and sensitivity analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 416,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Mastercard's positioning and emphasis on its Cyber and Intelligence Solutions evolved between 2022 and 2023, particularly in terms of the value proposition communicated to stakeholders?",
      "original_answer": "In 2022, Mastercard described its Cyber and Intelligence Solutions as part of its value-added services that 'allow all parties to transact easily and with confidence' and emphasized principled use of consumer and merchant data. By 2023, the company expanded this messaging, positioning the solutions as central to enabling secure transactions and confidence in the payments ecosystem, while also linking them to strategic investments in new networks like open banking and digital identity. This reflects a broader integration of cyber solutions into the company's overall infrastructure narrative.",
      "llm_answer": "In the 2022 filing Mastercard presented its Cyber & Intelligence Solutions as a core “value‑added service … to allow all parties to transact **easily and with confidence**,” and even called the solutions a primary driver of revenue growth (“the remaining increase was driven primarily by our Cyber & Intelligence … solutions”)【2022 Business Overview】【2022 MD&A】.  \n\nBy the 2023 filing the messaging had shifted to a stronger security focus – the solutions are now described as “designed to allow all parties to transact **securely, easily and with confidence**, … drawing on our principled and **responsible** use of **secure** consumer and merchant data”【2023 Business Overview】 – positioning them less as a pure growth engine and more as a trusted, secure foundation for the ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the 2022 positioning using the exact phrase 'easily and with confidence' from the original answer; (2) Accurately captures the 2023 evolution with the expanded messaging including 'securely, easily and with confidence'; (3) Properly synthesizes the shift from growth-driver framing to security/trust foundation positioning; (4) Correctly identifies the emphasis on 'principled and responsible use' of data in 2023; (5) Appropriately notes the integration into broader ecosystem narrative; (6) Uses proper citation formatting to indicate source documents. MINOR CONSIDERATIONS: (1) The LLM adds interpretive framing ('less as a pure growth engine and more as a trusted, secure foundation') that goes slightly beyond the ground truth's statement about 'linking them to strategic investments in new networks like open banking and digital identity' - however, this interpretation is logically sound and represents a reasonable synthesis of the messaging shift; (2) The ground truth mentions 'strategic investments in new networks like open banking and digital identity' which the LLM does not explicitly address, though this is a relatively minor omission that doesn't undermine the core answer; (3) No quantitative errors or date inaccuracies present. The answer successfully addresses all parts of the multi-part question (positioning evolution, emphasis changes, value proposition communication) and demonstrates sound multi-hop reasoning across the 2022-2023 comparison. The semantic equivalence is strong, with the LLM capturing the essential evolution in Mastercard's messaging while providing specific textual evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 477,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did PepsiCo's presentation of the 4.450% Senior Note due 2046 evolve between its 2022 and 2023 SEC filings, particularly in terms of exhibit referencing and associated documentation dates?",
      "original_answer": "In the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12, incorporated by reference from PepsiCo's Form 8-K filed on October 14, 2015. In the 2023 filing, the same note was reclassified as Exhibit 4.13 and referenced the Form 8-K filed on February 24, 2016. This indicates a shift in how PepsiCo organized or updated its capital structure disclosures, potentially reflecting revised documentation or administrative reclassification over time.",
      "llm_answer": "In PepsiCo’s 2022 Form 10‑K the 4.450 % Senior Note due 2046 was listed twice (Exhibit 4.11 and Exhibit 4.13) and each entry was incorporated by reference to an 8‑K filed on October 14 2015 and February 24 2016. In the 2023 Form 10‑K the 4.450 % due 2046 no longer appears; instead a 4.450 % note (now due 2033) is shown as Exhibit 4.6 and is incorporated by reference to a February 15 2023 8‑K, reflecting a shift from the older 2015‑2016 exhibit references to a more recent filing and a different maturity.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that fundamentally contradict the ground truth: (1) EXHIBIT NUMBERS: Ground truth states the 2022 filing showed Exhibit 4.12, but LLM claims it was listed as both Exhibit 4.11 and 4.13 - both incorrect. Ground truth states 2023 filing showed Exhibit 4.13, but LLM claims it no longer appears and instead shows a different note (4.450% due 2033) as Exhibit 4.6 - this is a complete misidentification. (2) DATES: LLM correctly identifies October 14, 2015 and February 24, 2016 as referenced dates in the 2022 filing, but then introduces a February 15, 2023 date that is not mentioned in the ground truth for the 2023 filing. (3) MATURITY DATES: Ground truth consistently refers to the 4.450% Senior Note due 2046 in both years. LLM incorrectly claims the 2023 filing shows a 4.450% note due 2033 instead - this is a significant factual error suggesting confusion between different debt instruments. (4) CORE CLAIM: Ground truth indicates the same note (due 2046) was reclassified from Exhibit 4.12 to 4.13 between years. LLM claims the note no longer appears and a different maturity date note appears instead - this fundamentally misrepresents the evolution described in the question. (5) MULTI-HOP REASONING: The LLM failed to correctly synthesize the exhibit number changes and incorrectly introduced a different debt instrument entirely, suggesting either hallucination or severe misreading of source documents. The answer does not accurately track how the same financial instrument's presentation evolved across the two filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 436,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Intel's relationship with Positive Technologies evolved between 2023 and 2024, particularly in terms of their engagement under OFAC licensing following the U.S. sanctions?",
      "original_answer": "In 2023, Intel disclosed that it had communicated with Positive Technologies regarding IT security research and coordinated disclosure of vulnerabilities, and that it resumed such communications under an OFAC license following the sanctions. By 2024, Intel's relationship had evolved from mere disclosure of past communication to an explicit statement of intent to continue these interactions in accordance with the OFAC license. While both years clarify that there were no gross revenues or net profits associated with these activities, the 2024 filing reflects a more forward-looking and sustained partnership posture with Positive Technologies under the sanctioned conditions.",
      "llm_answer": "Intel’s disclosures show that the relationship has not changed. In the 2023 Form 10‑K Intel explained that, after Positive Technologies was designated on April 15 2021, the company resumed communications with the firm under an OFAC license and “plan to continue these communications” with no gross revenues or net profits (INTC_10k_2023.pdf p. 69‑70). The 2024 Form 10‑K repeats the same statement – Intel still engages Positive Technologies under the same OFAC license and intends to keep those communications ongoing, again with no revenue or profit (INTC_10k_2024.pdf p. 52‑53).",
      "correctness_score": 3,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IN CORE REASONING: The LLM answer fundamentally contradicts the ground truth on the central question. The ground truth explicitly states the relationship 'evolved' with a 'shift from mere disclosure of past communication to an explicit statement of intent to continue' - representing a meaningful change in posture from 2023 to 2024. The LLM answer incorrectly claims 'the relationship has not changed' and that Intel 'repeats the same statement' in both years. This is a major factual error on the primary question asked. QUANTITATIVE ACCURACY: The dates (April 15, 2021 for designation) and the statement that there were no gross revenues or net profits are correct. Page numbers cited (69-70 for 2023, 52-53 for 2024) appear plausible though cannot be independently verified. QUALITATIVE ACCURACY: The LLM correctly identifies the OFAC license framework and the basic facts about communications resumption. However, it completely misses the evolution in Intel's disclosure posture - the ground truth indicates 2024 reflects a 'more forward-looking and sustained partnership posture' versus 2023's more retrospective framing. The LLM's assertion that both years contain identical language is contradicted by the ground truth's characterization of different disclosure approaches. CONTEXTUAL RELEVANCE: The answer addresses the right entities (Intel, Positive Technologies, OFAC) and timeframe (2023-2024) but fails to answer the actual question about how the relationship 'evolved.' The question specifically asks about evolution/change, and the LLM provides an answer about stasis, which is semantically opposite to what was asked. This represents a fundamental misunderstanding of the multi-hop synthesis required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 472,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has the balance of CVS's 4.78% Senior Notes due March 2038 evolved between 2023 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "The balance of CVS's 4.78% Senior Notes due March 2038 remained stable at $5,000 million in both 2023 and 2024, indicating that the company did not retire or issue additional amounts of this particular debt instrument during the period. This stability contrasts with other senior notes, such as the 2.7% senior notes due August 2040, which decreased from $1,250 million in 2023 to $367 million in 2024, suggesting selective debt management and refinancing activity in other long-term obligations.",
      "llm_answer": "The $5.0 billion of 4.78 % senior notes due March 2038 was $5,000 million at both December 31 2023 (2023 10‑K table) and December 31 2024 (2024 10‑K table), showing no change in that tranche. This unchanged balance indicates that CVS has neither retired nor added to this long‑dated issuance, leaving it as a stable pillar of its long‑term debt mix while the overall debt portfolio has grown through other issuances.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) All primary numbers are correct - the 4.78% Senior Notes balance of $5,000 million ($5.0 billion) is accurately stated for both 2023 and 2024. (2) The core finding that the balance remained unchanged is correct. (3) The dates (March 2038 maturity, December 31 2023 and 2024) are accurate. (4) The quantitative accuracy is high with proper number formatting and no calculation errors. WEAKNESSES: (1) The LLM answer is INCOMPLETE - it fails to address the comparative context provided in the ground truth. The original answer specifically mentions the 2.7% senior notes due August 2040 declining from $1,250 million to $367 million, which provides important context about selective debt management and refinancing activity. This comparative analysis is essential to fully answer 'what does this indicate about the company's long-term debt structure?' (2) The LLM answer states 'the overall debt portfolio has grown through other issuances' but provides no supporting evidence or specific examples from the filings. (3) The ground truth explicitly contrasts the stability of the 4.78% notes with the decline in other senior notes to illustrate selective debt management - the LLM answer mentions this concept but doesn't provide the concrete comparative data. (4) The qualitative reasoning is somewhat generic ('stable pillar') without the specific comparative analysis that demonstrates the company's strategic debt management approach. The answer is factually correct on the primary metric but lacks the multi-hop synthesis and comparative context that would fully address what the stability indicates about long-term debt structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 451,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has the status of the 0.835% Notes due 2032 evolved between the 2022 and 2024 SEC filings for Exxon Mobil Corporation?",
      "original_answer": "In the 2022 filing, the 0.835% Notes due 2032 were listed among other notes with distinct trading symbols, including the 0.142% Notes due 2024 (XOM24B), indicating a broader set of publicly traded debt instruments. By 2024, the 0.835% Notes due 2032 remained listed with the trading symbol XOM32, but the 0.142% Notes due 2024 no longer appeared in the 2024 filing, suggesting that the 2024 notes were either redeemed or no longer publicly traded. Therefore, while the 0.835% Notes due 2032 remained a consistent part of Exxon Mobil's publicly disclosed debt structure, the removal of the 2024 notes indicates a change in the company's short-to-intermediate term debt composition.",
      "llm_answer": "In the 2022 Form 10‑K, Exxon Mobil’s securities register listed the 0.835% Notes due 2032 (ticker XOM32) as an outstanding NYSE‑listed security. The 2024 Form 10‑K again includes the 0.835% Notes due 2032 (ticker XOM32) in its securities register, indicating the notes remain outstanding and their status has not changed.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains accurate numeric and entity information but fundamentally fails to address the core question about how the status 'evolved' between 2022 and 2024. CORRECT ELEMENTS: (1) The 0.835% Notes due 2032 with ticker XOM32 is correctly identified in both filings, (2) The notes remained outstanding in both years - this is factually accurate, (3) Numeric values and ticker symbols are correct. CRITICAL DEFICIENCY: The ground truth answer emphasizes a significant evolution in debt composition - specifically that the 0.142% Notes due 2024 (XOM24B) appeared in 2022 but disappeared by 2024, indicating redemption or delisting. This is a key multi-hop insight showing how the company's short-to-intermediate debt structure changed. The LLM answer completely omits this comparative analysis and instead states 'the status has not changed,' which contradicts the ground truth's finding of compositional evolution. The question explicitly asks 'how has the status...evolved,' requiring a comparison showing changes in the broader debt portfolio. The LLM narrowly focuses only on the 0.835% Notes themselves (which did remain consistent) while missing the broader context of portfolio changes that constitute the actual 'evolution' being asked about. This represents a failure in multi-hop reasoning - the model needed to synthesize information about multiple debt instruments across two years to properly answer the question. The answer is incomplete and misses the essential insight about debt composition changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 420,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has American Express's investment strategy toward U.S. Government treasury obligations evolved between 2022 and 2024, particularly in terms of fair value allocation and maturity distribution?",
      "original_answer": "In 2022, American Express held U.S. Government treasury obligations exclusively in short-term instruments with a fair value of $477 million and no long-term exposure. By 2024, the company shifted its strategy to include both short-term ($189 million) and intermediate-term ($98 million) treasury obligations, indicating a more diversified maturity profile. This reflects a transformation in the company's investment approach, expanding beyond less than 12-month instruments to include holdings maturing within 1 to 5 years.",
      "llm_answer": "In the 2022 filing (covering 2021), American Express reported U.S. Government Treasury securities with an estimated fair value of about **$1.7 billion** (cost $1.68 bn, fair value $1.704 bn)【AXP_10k_2022.pdf p.119】. Those holdings were split **≈49 % due within 1 year ($832 m), 51 % due in 1‑5 years ($862 m) and a small $10 m tranche in the 5‑10‑year bucket**【AXP_10k_2022.pdf p.121】.  \n\nBy the 2024 filing (covering 2023), the Treasury portfolio had been trimmed to roughly **$0.29 billion** of fair‑value holdings (cost $289 m, fair value $287 m)【AXP_10k_2024.pdf p.124】, with **≈66 % ($189 m) maturing within 1 year and the remainder ($98 m) in the 1‑5‑year range, eliminating any longer‑dated Treasury exposure**【AXP_10k_2024.pdf p.127】.  \n\nThus, the company sharply reduced its Treasury allocation and shifted the maturity profile toward shorter‑term obligations.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer is fundamentally incorrect and contradicts the ground truth on nearly every key metric:\n\n1. QUANTITATIVE ACCURACY FAILURES:\n   - 2022 Fair Value: LLM claims $1.7 billion; Ground truth is $477 million (3.6x overstatement)\n   - 2024 Fair Value: LLM claims $0.29 billion ($287-289m); Ground truth is $287 million (matches numerically but context is wrong)\n   - 2022 Maturity Distribution: LLM claims 49% short-term ($832m) and 51% intermediate ($862m); Ground truth shows EXCLUSIVELY short-term ($477m) with ZERO long-term exposure\n   - 2024 Maturity Distribution: LLM correctly states $189m short-term and $98m intermediate (matches ground truth)\n\n2. ENTITY/PERIOD CONFUSION:\n   - LLM references \"2022 filing (covering 2021)\" and \"2024 filing (covering 2023)\" - this is confusing and appears to misalign fiscal year reporting\n   - Ground truth clearly states 2022 vs 2024 comparison\n   - The LLM appears to be analyzing different fiscal years than requested\n\n3. CORE NARRATIVE FAILURE:\n   - Ground truth: 2022 had ONLY short-term treasuries ($477m), 2024 added intermediate-term exposure\n   - LLM narrative: 2022 already had diversified maturity (49/51 split), 2024 shifted toward shorter-term\n   - These are opposite conclusions about the strategic evolution\n\n4. MULTI-HOP REASONING:\n   - The LLM failed to correctly synthesize the 2022 vs 2024 comparison\n   - The directional change in strategy is inverted from ground truth\n   - The magnitude of holdings is dramatically overstated for 2022\n\n5. SPECIFIC CALCULATION ERRORS:\n   - 2022: $832m + $862m + $10m = $1.704bn (LLM's math is internally consistent but based on wrong source data)\n   - The ground truth shows $477m total for 2022, not $1.7bn\n   - This suggests the LLM may have pulled data from a different section or misidentified the relevant treasury holdings\n\nThe LLM answer appears to have accessed different pages or sections of the filings than the ground truth knowledge graph, resulting in completely different baseline numbers and an inverted narrative about strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 566,
        "total_tokens": 1926
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Amazon's introduction and subsequent treatment of the 2.500% Note due 2050 evolve between 2022 and 2024?",
      "original_answer": "In 2022, the 2.500% Note due 2050 was introduced as part of an Officers' Certificate dated June 3, 2020, and was listed alongside other notes in Exhibit 4.5. By 2024, the 2.500% Note due 2050 was reintroduced in Exhibit 4.6, which was an exact replication of Exhibit 4.5 from 2020, indicating that Amazon continued to maintain this long-term debt instrument without modification. The reintroduction in 2024 reaffirmed the note's role in Amazon's capital structure.",
      "llm_answer": "Amazon first disclosed the 2.500 % senior unsecured note due 2050 in its 2022 Form 10‑K, where it appears in Exhibit 4.6 (the June 3 2020 Officers’ Certificate) alongside other notes (0.400 % due 2023, 0.800 % due 2025, etc.)【2022 10‑K pp. 69‑73】. In the 2024 Form 10‑K the same note is still listed in Exhibit 4.6 (unchanged from the June 3 2020 certificate)【2024 10‑K pp. 72‑76】, indicating Amazon continued to treat the 2.500 % Note due 2050 as an outstanding debt instrument with no amendment, redemption or removal reported.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN EXHIBIT IDENTIFICATION: The LLM answer contains a fundamental factual error regarding exhibit numbering. The ground truth states the note was listed in Exhibit 4.5 in 2022 and reintroduced in Exhibit 4.6 in 2024. However, the LLM claims the note appears in Exhibit 4.6 in the 2022 Form 10-K, which contradicts the ground truth. This is a significant error because the question specifically asks about the evolution of treatment between years, and the exhibit numbering change (4.5 to 4.6) is a key part of that evolution. The LLM incorrectly states both years reference Exhibit 4.6, missing the critical distinction that the exhibit number changed between 2022 and 2024. CORRECT ELEMENTS: The LLM correctly identifies the note as 2.500% senior unsecured note due 2050, correctly notes it originated from the June 3, 2020 Officers' Certificate, correctly identifies it as appearing in both 2022 and 2024 filings, and correctly concludes there was no amendment, redemption, or removal. The page number citations appear reasonable though cannot be independently verified. MULTI-HOP REASONING: The LLM demonstrates understanding that the note persisted across both years without modification, which is correct. However, the failure to accurately track the exhibit number change represents a failure in the detailed synthesis required for this multi-hop question. The ground truth emphasizes the reintroduction in a different exhibit (4.6 vs 4.5) as significant to understanding the evolution, which the LLM misses entirely. SEMANTIC ISSUES: While the LLM's conclusion about continuity is correct, the specific factual error about exhibit numbering undermines the credibility of the answer and suggests incomplete or inaccurate source material review.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 480,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the number of amendments to the Citibank, N.A. Co-Branded Credit Card Agreement evolve between 2022 and 2023?",
      "original_answer": "In 2022, the most recent amendment to the Citibank, N.A. Co-Branded Credit Card Agreement was the Eighth Amendment, filed on March 10, 2022. By 2023, the agreement had undergone further modifications, with the Twelfth Amendment being filed on October 11, 2023, indicating a total of four additional amendments during this period. This demonstrates a continued evolution and refinement of the agreement terms over the 12-month period.",
      "llm_answer": "The 2022 Form 10‑K lists ten amendments to the Citibank, N.A. Co‑Branded Credit Card Agreement (the tenth amendment, 10.8.10, was filed on 12/29/2022)【COST_10k_2022.pdf†p66】.  \nThe 2023 Form 10‑K adds an eleventh amendment (10.8.11, filed 3/9/2023) and a twelfth amendment (10.8.12, filed 10/11/2023)【COST_10k_2023.pdf†p68】, raising the total to twelve.  \n\nThus, the number of amendments grew from ten in 2022 to twelve in 2023 – an increase of two amendments.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL DISCREPANCY: The LLM answer directly contradicts the ground truth on the key factual claims. Ground truth states: (1) In 2022, the most recent amendment was the Eighth Amendment (filed March 10, 2022), and (2) By 2023, the Twelfth Amendment was filed (October 11, 2023), representing four additional amendments between 2022 and 2023. The LLM answer claims: (1) In 2022, there were ten amendments total with the tenth filed on 12/29/2022, and (2) In 2023, eleventh and twelfth amendments were added, for a total of twelve. This is a fundamental factual error - the LLM reports the 2022 baseline as ten amendments when ground truth indicates it was eight amendments. The LLM's calculation of 'two amendments added' (from ten to twelve) is mathematically correct given its premises, but those premises are wrong. The date for the Twelfth Amendment (10/11/2023) matches ground truth, but the Eighth Amendment date (3/10/2022 vs LLM's implicit claim of earlier) and the count of amendments in 2022 do not align. The LLM appears to have misread or misinterpreted the source documents regarding the baseline number of amendments in 2022. The question asks about evolution 'between 2022 and 2023,' and while the LLM does address this temporal comparison, it does so with incorrect baseline numbers. The contextual relevance is adequate (it addresses the right agreement and time period), but the quantitative accuracy is severely compromised by the incorrect amendment counts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 408,
        "total_tokens": 1624
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration with new computing architectures and software ecosystems?",
      "original_answer": "In 2022, NVIDIA emphasized CUDA as a foundational building block across its target markets, including Gaming, Data Center, Professional Visualization, and Automotive, highlighting its role in enabling accelerated computing and deep learning. CUDA was positioned as a core component of the company's unified architecture, supporting a wide range of applications through internal and third-party software stacks. By 2024, NVIDIA had significantly expanded the scope of CUDA's integration, describing it as part of a broader full-stack computing platform that includes the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific application frameworks. Additionally, CUDA was now explicitly tied to NVIDIA's expanded data center platform, which now includes CPUs (introduced in fiscal 2024) alongside GPUs and DPUs, showing a strategic evolution toward deeper integration with heterogeneous computing architectures and enterprise-grade AI ecosystems.",
      "llm_answer": "In the 2022 filing NVIDIA described CUDA as the foundational programming model that runs on all its GPUs and serves as the core building block of a unified architecture across its markets, backed by a large ecosystem of roughly 3 million developers and extensive libraries/SDKs [2022 p.7‑9; 2022 p.10]. By the 2024 filing CUDA had been further integrated into a heterogeneous data‑center stack that now includes CPUs and DPUs, the new Blackwell architecture, and the expanded CUDA‑X collection, with the developer community growing to nearly 6 million, reflecting deeper ties to new hardware and broader software ecosystems [2024 p.4‑5; 2024 p.6].",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively synthesizes multi-hop information across 2022 and 2024 filings. STRENGTHS: (1) Correctly identifies CUDA's foundational role in 2022 across unified architecture; (2) Accurately captures the 2024 evolution toward heterogeneous computing with CPUs and DPUs; (3) Properly mentions CUDA-X collection expansion; (4) Developer community growth from ~3 million to ~6 million is correctly stated; (5) References to Blackwell architecture appropriately contextualize 2024 developments; (6) Multi-hop synthesis is sound, comparing 2022 positioning against 2024 integration. MINOR CONSIDERATIONS: (1) The LLM answer includes specific page references (2022 p.7-9, etc.) which add credibility but cannot be verified against the ground truth provided; (2) The mention of 'Blackwell architecture' in the LLM answer is not explicitly mentioned in the ground truth, though it represents a reasonable inference about 2024 developments and doesn't contradict the ground truth; (3) The ground truth emphasizes 'enterprise-grade AI ecosystems' while the LLM answer focuses more on hardware integration - both perspectives are valid but slightly different emphases. QUANTITATIVE VERIFICATION: Developer count progression (3 million to 6 million) is accurate and represents a meaningful metric of ecosystem growth. REASONING QUALITY: The LLM correctly identifies the evolution from 2022's emphasis on unified architecture to 2024's heterogeneous computing platform integration, which aligns with the ground truth's narrative arc. The answer appropriately synthesizes information about software (CUDA-X) and hardware (CPUs, DPUs) integration. Overall, this is a high-quality answer with accurate core facts and sound multi-hop reasoning, with only minor variations in emphasis rather than factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 501,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Pfizer's financial relationship with Paxlovid evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual obligations?",
      "original_answer": "In 2023, Paxlovid generated $1.279 billion in revenue, but this figure was significantly impacted by a non-cash revenue reversal of $3.5 billion due to the expected return of 6.5 million treatment courses of EUA-labeled U.S. government inventory. By 2024, this reversal was adjusted favorably by $771 million as only 5.1 million treatment courses were actually returned, and an additional $442 million in revenue was recorded in connection with the creation of the U.S. Strategic National Stockpile (SNS). Furthermore, as of December 31, 2024, Pfizer reported approximately $1 billion in remaining performance obligations related to Paxlovid supply contracts, indicating ongoing but reduced commercial activity compared to the prior year. This evolution reflects a shift from a high-volume, government-driven revenue model in 2023 to a more stable, contracted future delivery model in 2024.",
      "llm_answer": "In 2023 Pfizer reported only $1.279 billion of Paxlovid revenue—a 92 % decline from 2022—and booked a $3.5 billion non‑cash revenue reversal for the expected return of 6.5 million EUA‑labeled treatment courses, leaving $5.1 billion of deferred revenue (about $2.6 billion current) tied to government supply contracts (PFE 2023 10‑K, pp. 42‑46). By 2024 the drug had moved to commercial markets, driving Paxlovid revenue up to $5.7 billion (including $442 million from a U.S. strategic stockpile and a $771 million favorable adjustment), while deferred revenue fell to $2.2 billion ($1.4 billion current, $785 million non‑current) and remaining performance obligations for Paxlovid were about $1 billion at year‑end, reflecting the fulfillment of most prior contractual obligations (PFE 2024 10‑K, pp. 107‑111).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) MAJOR FACTUAL ERROR - LLM claims 2024 Paxlovid revenue was $5.7 billion, but ground truth states only $1.279 billion in 2023 with no 2024 revenue figure provided in the original answer. The LLM appears to have fabricated or misattributed a 2024 revenue number. (2) DEFERRED REVENUE DISCREPANCY - LLM cites $5.1 billion deferred revenue in 2023 and $2.2 billion in 2024, but ground truth makes no mention of these deferred revenue figures. The ground truth only mentions $1 billion in remaining performance obligations for 2024. (3) CALCULATION VERIFICATION - The 92% decline claim from 2022 cannot be verified against ground truth (2022 data not provided). (4) CORRECT ELEMENTS - LLM accurately captured: 2023 revenue of $1.279 billion, $3.5 billion revenue reversal, 6.5 million treatment courses expected return, $771 million favorable adjustment in 2024, $442 million SNS revenue, and approximately $1 billion remaining performance obligations at end of 2024. (5) MULTI-HOP REASONING - While the LLM attempted to synthesize the evolution between years, it introduced significant fabricated numbers (particularly the $5.7 billion 2024 revenue figure) that contradict or extend beyond the ground truth. The answer conflates deferred revenue with remaining performance obligations, which are distinct accounting concepts. (6) SEMANTIC ISSUES - The characterization of 'moving to commercial markets' in 2024 is not supported by ground truth, which emphasizes government-driven activity and SNS contracts. The answer demonstrates partial understanding but contains material factual errors that undermine credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 450,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the availability and structure of shares under the 2003 Incentive Program evolved between 2022 and 2024?",
      "original_answer": "In 2022, the 2003 Incentive Program had 65,754,069 shares available for award. By 2024, the total maximum number of shares that could be issued under the program was increased to 220 million, with 47 million remaining available for awards by the end of 2024. This indicates a significant expansion in the program's capacity, although actual usage had grown moderately over time, with restricted stock units granted increasing from 9,392 thousand in 2022 to 10,393 thousand in 2024.",
      "llm_answer": "In 2022 the 2003 Incentive Program still had roughly 65.8 million shares available for future awards (65,754,069 shares) 【XOM_10k_2022.pdf p. 42‑43, footnote (2)】. By the end of 2024 that pool had been reduced to about 47 million shares 【XOM_10k_2024.pdf p. 100‑101, Note 15】. The program’s structure has not changed – it continues to be capped at 220 million shares and permits grants of stock options, stock‑appreciation rights, restricted stock and other awards, with options/SARs priced at no less than market value and a maximum ten‑year life 【XOM_10k_2024.pdf p. 100‑101, Note 15】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct with strong quantitative accuracy. Verification of key numbers: (1) 2022 shares available: 65,754,069 (LLM states ~65.8 million) - CORRECT with appropriate rounding; (2) 2024 shares remaining: 47 million - CORRECT; (3) Total program cap: 220 million - CORRECT. The answer accurately identifies the evolution of the program between 2022 and 2024, showing the reduction in available shares from 65.8M to 47M. The structural details about the program (capped at 220M shares, permits various award types, options/SARs pricing requirements, 10-year maximum life) are accurate and relevant. However, the LLM answer omits one important detail from the ground truth: the restricted stock units granted increased from 9,392 thousand in 2022 to 10,393 thousand in 2024. This represents actual usage data that demonstrates how the program was utilized over the period, which is relevant to understanding the evolution of the program. The LLM correctly synthesizes multi-hop information across the 2022 and 2024 10-K filings, properly comparing the available shares and explaining the program structure. The reasoning is sound and the citations are appropriately placed. The omission of RSU grant data prevents a perfect score, as this contextual information about actual program usage would have provided a more complete picture of how the program evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 385,
        "total_tokens": 1643
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has AdSense's role within Google's advertising revenue streams evolved between 2022 and 2024, particularly in relation to the company's broader advertising technology portfolio?",
      "original_answer": "In 2022, AdSense was explicitly cited as a key growth driver within the Google Network, contributing to an $8.6 billion year-over-year revenue increase alongside AdMob and Google Ad Manager. By 2024, while AdSense remained part of the Google Network, it was no longer specifically quantified as a growth lever. Instead, newer AI-powered advertising products like Demand Gen and Performance Max were highlighted as central to advertiser success, suggesting a strategic shift where AdSense became a more foundational, mature offering within Google's broader advertising technology stack.",
      "llm_answer": "In the 2022 Form 10‑K (pages 35‑36) Google highlighted AdSense as a distinct growth engine for its Google Network segment – it was named alongside AdMob and Google Ad Manager as a driver of the $8.6 billion network‑revenue increase, even as the filing noted a modest decline in AdSense‑related impressions. By the 2024 filing (pages 7‑8), AdSense is no longer singled out; the discussion treats it as part of the broader “Google Network” and focuses on AI‑powered, integrated ad‑tech solutions (e.g., Demand Gen, Performance Max), indicating that AdSense’s role has been absorbed into a more unified advertising technology portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY (10/10): All specific numbers are correct - the $8.6 billion year-over-year revenue increase is accurately cited, and the fiscal years (2022 vs 2024) are correctly identified. The answer properly references the specific 10-K filing pages (35-36 for 2022, 7-8 for 2024), adding credibility and specificity. QUALITATIVE ACCURACY (9/10): The multi-hop reasoning is sound and well-synthesized. The answer correctly identifies the three key products mentioned in 2022 (AdSense, AdMob, Google Ad Manager), accurately notes the shift away from explicit quantification of AdSense by 2024, and properly identifies the newer AI-powered products (Demand Gen, Performance Max) as the strategic focus. The characterization of AdSense's evolution from 'distinct growth engine' to 'foundational, mature offering' is semantically equivalent to the ground truth's description of it becoming 'absorbed into a more unified advertising technology portfolio.' The mention of 'modest decline in AdSense-related impressions' adds nuanced context that aligns with the filing data. CONTEXTUAL RELEVANCE (10/10): The answer directly addresses all aspects of the multi-part question: (1) AdSense's role evolution, (2) the 2022-2024 timeframe, and (3) the relationship to the broader advertising technology portfolio. MINOR CONSIDERATIONS: The answer uses slightly different phrasing ('absorbed into' vs 'became a more foundational, mature offering') but these are semantically equivalent and both accurately capture the strategic shift. The inclusion of specific page numbers and the note about impression declines demonstrates thorough engagement with source material. No factual errors, calculation mistakes, or entity misidentifications detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 499,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did the UPS Retirement Plan's benefit accrual structure evolve between 2022 and 2023, and what specific changes were made to future benefit accruals for non-union participants?",
      "original_answer": "In 2022, the UPS Retirement Plan was described as noncontributory and covering substantially all eligible employees hired before July 1, 2016, who were not part of a collective bargaining unit or certain employees covered by a collective bargaining agreement. The plan provided retirement benefits based on average compensation and was subject to IRS limits. It was also disclosed that the plan would cease accruals of additional benefits for future service and compensation for non-union participants effective January 1, 2023. In 2023, this cessation of accruals was confirmed as effective, and the plan was described with the same eligibility and benefit structure but explicitly stated that no further accruals would occur for non-union participants. This marks a transformational change in the plan's structure, as the accrual freeze was implemented as planned, shifting the plan from an active benefit-accruing structure to a closed one for non-union employees. The change represents a significant strategic shift in UPS's retirement benefit policy.",
      "llm_answer": "In the 2022 filing the UPS Retirement Plan still accrued benefits for non‑union participants, but it disclosed that “the UPS Retirement Plan and the UPS Excess Coordinating Benefit Plan will cease accruals of additional benefits for future service and compensation for non‑union participants effective January 1, 2023”【UPS_10k_2022.pdf page 92‑93】. By the 2023 filing the plan had already implemented that change – “the plan ceased accruals of additional benefits for future service and compensation for non‑union participants effective January 1, 2023”【UPS_10k_2023.pdf page 81‑82】, ending all future benefit accruals for non‑union participants.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and addresses the core question effectively. STRENGTHS: (1) All dates are accurate - correctly identifies the January 1, 2023 effective date for the accrual freeze in both 2022 and 2023 filings; (2) Correctly identifies the specific change: cessation of benefit accruals for non-union participants; (3) Properly synthesizes the multi-hop information by comparing the 2022 disclosure (forward-looking statement about planned change) with the 2023 confirmation (implementation of that change); (4) Accurately cites both the UPS Excess Coordinating Benefit Plan alongside the main UPS Retirement Plan; (5) Correctly characterizes the evolution from an accruing plan to a frozen plan for non-union employees. MINOR WEAKNESSES: (1) The answer could have been slightly more explicit about the plan's original structure (noncontributory, covering eligible employees hired before July 1, 2016, not part of collective bargaining units) to provide fuller context about what changed; (2) Could have emphasized more strongly that this represents a 'transformational' or 'strategic shift' in retirement policy, though the answer does convey the significance of the change; (3) Doesn't explicitly mention the IRS limits aspect mentioned in ground truth, though this is a minor detail. The answer demonstrates sound multi-hop reasoning by correctly connecting the 2022 forward-looking disclosure with the 2023 implementation confirmation, showing clear understanding of how the plan evolved between the two years. The semantic meaning aligns well with the ground truth despite slightly different wording.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 446,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Amazon's utilization and structure of its short-term credit facilities evolved between 2022 and 2024, particularly in terms of credit capacity, interest rate terms, and outstanding borrowings?",
      "original_answer": "In 2022, Amazon had a $7.0 billion unsecured revolving credit facility with an interest rate of benchmark rate plus 0.50% and a commitment fee of 0.04%, and no borrowings were outstanding under this facility. Additionally, Amazon had $7.2 billion in unused letters of credit as of December 31, 2021. By 2024, Amazon had significantly expanded its credit capacity by entering into a new $15.0 billion unsecured revolving credit facility with a lower interest rate of benchmark rate plus 0.45% and a reduced commitment fee of 0.03%. In addition, Amazon introduced a new $5.0 billion unsecured 364-day revolving credit facility in October 2024, which also carried a rate of SOFR plus 0.45% and a 0.03% commitment fee. Notably, there were still no borrowings outstanding under the main Credit Agreement or the Short-Term Credit Agreement as of December 31, 2024. However, Amazon had $147 million and $151 million in borrowings under other short-term credit facilities as of December 31, 2023 and 2024, respectively, which were included in 'Accrued expenses and other.' The company also increased its unused letters of credit to $8.3 billion by the end of 2024.",
      "llm_answer": "In 2022 Amazon’s short‑term financing consisted of a $1.0 billion secured revolving credit facility (LIBOR + 1.40%, 0.50% commitment fee) with $338 million and $803 million of borrowings in 2020‑21, and a $7.0 billion unsecured revolving credit facility (benchmark + 0.50%, 0.04% fee) that had no borrowings (2022 10‑K, p.56). By 2024 the secured facility had been repaid and terminated (it had carried SOFR + 1.25% with a 0.45% fee and $682 million outstanding as of Dec 31 2023) and Amazon expanded its unsecured revolving capacity to $15 billion (benchmark + 0.45%, 0.03% fee) and added a $5 billion 364‑day revolving facility (same terms), both with zero utilization, while other short‑term facilities showed only $147‑$151 million of working‑capital borrowings (2024 10‑K, pp.56‑58). This reflects roughly doubled credit capacity, narrower interest spreads, and a drop in outstanding short‑term debt from roughly $800 million to essentially zero on the primary facilities.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant inaccuracies that contradict the ground truth:\n\n1. SECURED FACILITY MISREPRESENTATION: The LLM claims Amazon had a $1.0 billion secured revolving credit facility in 2022 with LIBOR + 1.40% and mentions $338M/$803M borrowings in 2020-21, plus $682M outstanding as of Dec 31, 2023. The ground truth makes NO mention of any secured facility or these borrowing amounts. This appears to be fabricated or confused with another company's data.\n\n2. INCORRECT 2022 BASELINE: The LLM correctly identifies the $7.0 billion unsecured facility with benchmark + 0.50% and 0.04% fee, but the secured facility information is entirely wrong and not supported by ground truth.\n\n3. 2024 EXPANSION PARTIALLY CORRECT: The LLM correctly states the $15.0 billion facility (benchmark + 0.45%, 0.03% fee) and $5.0 billion 364-day facility (SOFR + 0.45%, 0.03% fee) were added, with zero utilization on main facilities. However, the context about the secured facility being \"repaid and terminated\" is misleading since no such facility existed in the ground truth.\n\n4. OTHER SHORT-TERM FACILITIES: The LLM correctly identifies $147-$151 million in other short-term borrowings for 2023-2024, matching ground truth.\n\n5. LETTERS OF CREDIT: The LLM fails to mention the increase in unused letters of credit from $7.2 billion (2021) to $8.3 billion (2024), which is part of the ground truth answer.\n\n6. MULTI-HOP SYNTHESIS FAILURE: The LLM incorrectly synthesized information by introducing a secured facility that doesn't exist in the ground truth, fundamentally misrepresenting Amazon's credit structure evolution.\n\n7. CALCULATION/COMPARISON ERROR: The claim about \"drop in outstanding short-term debt from roughly $800 million to essentially zero\" is based on the false secured facility data and doesn't align with ground truth.\n\nThe answer demonstrates partial understanding of the 2024 structure but is severely compromised by fabricated 2022-2023 data about a secured facility that doesn't appear in the actual filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1546,
        "completion_tokens": 556,
        "total_tokens": 2103
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Costco's use of variable-priced contracts for energy purchases evolved between 2022 and 2023, and what does this indicate about its commodity price risk management strategy?",
      "original_answer": "In 2022, Costco entered into variable-priced contracts for some purchases of electricity and natural gas, as well as fuel for its gas stations, on an index basis. These contracts met the definition of derivatives but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. By 2023, Costco continued this approach but specifically called out natural gas and fuel for gas stations as key components of its variable-priced contract usage. This indicates a continued reliance on variable-priced contracts as part of its commodity price risk management, with no significant shift away from index-based pricing mechanisms. The strategy remains consistent, showing stability in how Costco manages exposure to energy price fluctuations.",
      "llm_answer": "In the 2022 filing Costco said it “enter[s] into variable‑priced contracts for some purchases of **electricity and natural gas**, in addition to some fuel for its gas stations” (2022 10‑K, Commodity‑Price Risk, p. 31). The 2023 filing notes it “also enters into variable‑priced contracts for some purchases of **natural gas**, in addition to fuel for its gas stations” (2023 10‑K, Derivatives, p. 47), no longer mentioning electricity. This shift suggests Costco is moving electricity purchases into fixed‑price contracts while retaining index‑based contracts for natural‑gas, indicating a tighter, more targeted commodity‑price risk‑management strategy that leans on fixed pricing where feasible.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IN FACTUAL ACCURACY: The LLM answer makes a fundamental misrepresentation of Costco's energy contract strategy. The ground truth clearly states that in 2023, Costco 'continued this approach' and 'specifically called out natural gas and fuel for gas stations as key components' - indicating CONTINUITY, not change. The LLM incorrectly interprets the absence of electricity mention in the 2023 filing as evidence of a 'shift' away from electricity contracts toward fixed-price contracts. This is a major logical error. The ground truth explicitly states 'no significant shift away from index-based pricing mechanisms' and 'The strategy remains consistent.' The LLM's conclusion that Costco is 'moving electricity purchases into fixed-price contracts' directly contradicts the ground truth's assertion of strategy stability. ENTITY/DOCUMENT ACCURACY: The LLM correctly identifies the years (2022, 2023) and companies (Costco), and correctly notes the presence of natural gas and fuel for gas stations in both years. However, the interpretation of what the 2023 filing's omission of electricity means is fundamentally wrong. REASONING FLAW: The LLM commits a logical error by inferring a strategic shift from a change in disclosure language rather than recognizing that the ground truth indicates consistent strategy. The ground truth's emphasis on 'continued reliance' and 'stability' is completely opposite to the LLM's characterization of a 'tighter, more targeted' strategy shift. COMPLETENESS: While the LLM addresses the evolution question, it provides an incorrect answer about the nature of that evolution. The question asks what the evolution 'indicates about' risk management strategy - the LLM's answer indicates a misunderstanding of Costco's actual strategy consistency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 487,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the strategic positioning and commercial role of NVIDIA AI Enterprise evolved within NVIDIA's data center offerings between 2022 and 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, indicating its foundational role in NVIDIA's AI and accelerated computing strategy. By 2024, the product had evolved into a more prominent commercial offering, described as a 'comprehensive suite of enterprise-grade AI software' that is actively licensed and integrated into broader data center solutions. This shift reflects NVIDIA's move from positioning it as a strategic initiative to a key monetization vehicle within its full-stack data center platform, alongside offerings like NVIDIA DGX Cloud and the expansion into CPUs and DPUs.",
      "llm_answer": "In the 2022 Form 10‑K, NVIDIA AI Enterprise was described as a stand‑alone “operating system for enterprise‑AI applications” that was sold primarily through paid‑license agreements and bundled with NVIDIA vGPU software for graphics‑rich virtual desktops and workstations (NVDA 2022 10‑K, pp. 78‑82). By the 2024 filing, the company had moved AI Enterprise into the core of its data‑center compute stack—listing it alongside GPUs, the Grace CPU, DPUs and DGX Cloud as an integral software component of its compute offerings and still offering it under paid licenses, signaling a deeper strategic integration and broader commercial role within NVIDIA’s full‑stack data‑center portfolio (NVDA 2024 10‑K, pp. 4‑8).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about NVIDIA AI Enterprise's evolution between 2022 and 2024. STRENGTHS: (1) Correctly identifies the 2022 positioning as a stand-alone 'operating system for enterprise-AI applications' with paid-license agreements and vGPU bundling; (2) Accurately describes the 2024 evolution into a core data center compute stack component alongside GPUs, Grace CPU, DPUs, and DGX Cloud; (3) Properly synthesizes the shift from strategic initiative to monetization vehicle; (4) Correctly cites relevant 10-K filing pages (2022: pp. 78-82; 2024: pp. 4-8); (5) Maintains semantic equivalence with ground truth regarding 'comprehensive suite of enterprise-grade AI software' and 'full-stack data center platform'; (6) Accurately captures the licensing model continuity across both periods. MINOR AREAS FOR IMPROVEMENT: (1) The LLM provides slightly more granular detail about vGPU bundling in 2022 than the ground truth explicitly states, though this appears to be accurate supplementary information from the filings rather than an error; (2) Could have emphasized more explicitly the 'monetization vehicle' language from the ground truth, though the concept is clearly conveyed through 'deeper strategic integration and broader commercial role.' MULTI-HOP REASONING: The answer successfully synthesizes information across two different fiscal years and multiple product offerings (GPUs, CPUs, DPUs, DGX Cloud, vGPU) to demonstrate the evolution. The logic flow is sound and the comparison between 2022 and 2024 positioning is clear and accurate. No calculation errors or factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 460,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Pfizer's contractual obligations related to Paxlovid evolve between 2023 and 2024, and what does this indicate about the company's future revenue expectations for the product?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of Paxlovid labeled under Emergency Use Authorization (EUA) from the U.S. government. This indicated uncertainty and potential decline in demand for Paxlovid. By 2024, however, remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, signaling a stabilization and expectation of future revenue from existing contracts. This shift from a large revenue reversal to a defined forward-looking contractual obligation suggests improved demand forecasting and a more stable outlook for Paxlovid in 2024 compared to the uncertainty in 2023.",
      "llm_answer": "Pfizer’s Paxlovid contracts fell sharply – deferred revenue tied to the drug (and Comirnaty) dropped from $5.1 billion at 12/31/2023 (‑ $2.6 billion current, $2.5 billion non‑current) to $2.2 billion at 12/31/2024 (‑ $1.4 billion current, $785 million non‑current) and the remaining performance‑obligation balance for Paxlovid is now about $1 billion (2024)【PFE_10k_2024.pdf p.107‑108】【PFE_10k_2024.pdf p.110】.  This reduction shows that most of the earlier government‑pre‑pay contracts have been satisfied and that future Paxlovid revenue is expected to be lower and spread over the next several years as the product shifts to commercial sales.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides relevant information about Paxlovid contractual obligations but contains significant discrepancies with the ground truth and lacks critical context. STRENGTHS: (1) Correctly identifies the $1 billion remaining performance obligation for Paxlovid as of 12/31/2024, matching ground truth; (2) Appropriately discusses the shift from government pre-pay contracts to commercial sales; (3) Correctly notes the decline in deferred revenue from 2023 to 2024; (4) Provides proper document citations. CRITICAL ISSUES: (1) The LLM conflates deferred revenue for both Paxlovid AND Comirnaty combined ($5.1B to $2.2B) rather than isolating Paxlovid-specific obligations, which is a significant analytical error; (2) Completely omits the ground truth's key finding: the $3.5 billion non-cash revenue reversal in Q4 2023 related to expected return of 6.5 million treatment courses under EUA - this is a crucial data point showing demand uncertainty; (3) The LLM's interpretation that 'most earlier government pre-pay contracts have been satisfied' is reasonable but doesn't capture the severity of the 2023 reversal event; (4) The answer focuses on deferred revenue trends rather than the more significant story of the revenue reversal and its implications for demand forecasting. QUANTITATIVE ACCURACY: The $1 billion figure is correct, but the deferred revenue numbers ($5.1B, $2.2B) appear to be combined product figures rather than Paxlovid-specific, making the quantitative analysis partially incorrect. REASONING: The multi-hop synthesis is incomplete - the answer should have connected the 2023 reversal event to the 2024 stabilization to show the evolution more clearly. The conclusion about future revenue expectations is reasonable but lacks the evidentiary foundation of the revenue reversal that ground truth emphasizes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 499,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "Compare and contrast how Google's exposure to new regulatory costs in international markets evolved between 2022 and 2024, particularly in terms of the scope and nature of regulatory challenges described?",
      "original_answer": "In 2022, Google highlighted that an evolving foreign policy landscape could subject the company to 'new regulatory costs and challenges,' specifically mentioning data transfers between the EU and the UK, as well as new customer requirements. By 2024, the scope of regulatory challenges expanded significantly. The 2024 filing not only reiterated the exposure to 'new regulatory costs and challenges' but also introduced elements like 'uncertainty regarding regulatory outcomes' and the risk of 'other liabilities under local laws that may not offer due process or clear legal precedent.' This indicates a shift from primarily data-related regulatory concerns in 2022 to broader, more unpredictable regulatory risks in 2024, reflecting an increased complexity in Google's international regulatory environment.",
      "llm_answer": "In the 2022 Form 10‑K, Google’s international‑risk disclosure warned that an “evolving foreign‑policy landscape” could generate “new regulatory costs and challenges,” but the discussion was narrowly framed around data‑transfer issues (e.g., EU‑UK personal‑data flows) and new customer‑requirement obligations. By the 2024 Form 10‑K the same bullet had broadened dramatically: it now lists sanctions, import‑export controls, political unrest, longer payment cycles, potential litigation, uncertainty about regulatory outcomes, and other liabilities under local laws that may lack due‑process, together with anti‑corruption and labor‑law complexities—showing that Google’s exposure to regulatory costs in overseas markets has grown from a limited data‑privacy focus to a far wider, more complex set of geopolitical and compliance challenges.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensiveness in addressing the multi-hop comparison question. STRENGTHS: (1) Correctly identifies both 2022 and 2024 filings as sources; (2) Accurately captures the 2022 scope as narrowly focused on data-transfer issues (EU-UK personal data flows) and new customer requirements; (3) Correctly identifies the 2024 expansion to include sanctions, import-export controls, political unrest, payment cycles, litigation risks, regulatory uncertainty, local law liabilities, anti-corruption, and labor-law complexities; (4) Properly synthesizes the evolution from 'limited data-privacy focus' to 'far wider, more complex set of geopolitical and compliance challenges'; (5) Uses appropriate terminology ('evolving foreign-policy landscape,' 'new regulatory costs and challenges') that matches the ground truth; (6) Maintains semantic equivalence with the original answer while providing more specific detail about the expanded 2024 risks. MINOR CONSIDERATIONS: The LLM answer is actually more detailed and comprehensive than the ground truth, listing specific regulatory categories (sanctions, import-export controls, political unrest, longer payment cycles, potential litigation, anti-corruption, labor-law complexities) that provide concrete examples of the 'broader, more unpredictable regulatory risks' mentioned in the ground truth. This additional specificity enhances rather than detracts from accuracy. The multi-hop reasoning is sound—correctly comparing and contrasting the two years while identifying the qualitative shift in regulatory exposure. No numerical errors, date errors, or entity misidentifications present. The answer directly addresses all aspects of the question regarding scope, nature, and evolution of regulatory challenges.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 488,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has UPS's approach to funding postretirement medical benefits evolved between 2022 and 2023, particularly in terms of the sources used for expected benefit payments?",
      "original_answer": "In 2022, UPS indicated that expected benefit payments for postretirement medical benefits would be paid from both plan trusts and corporate assets. In 2023, the language remained unchanged, indicating continuity in the funding approach. Therefore, there was no change in the sources used for expected benefit payments for postretirement medical benefits between the two years.",
      "llm_answer": "UPS’s funding policy for post‑retirement medical benefits did not change from 2022 to 2023. In both years the company states that expected benefit payments for post‑retirement medical benefits will be paid from **plan trusts and corporate assets** (2022 filing p. 108‑109; 2023 filing p. 90‑91). The sources used for these payments remain the same.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and directly addresses the question. Strengths: (1) Correctly identifies that UPS's funding approach for postretirement medical benefits did not change between 2022 and 2023; (2) Accurately states the sources as 'plan trusts and corporate assets' in both years, matching the ground truth exactly; (3) Properly synthesizes the multi-hop comparison across two fiscal years; (4) Provides specific page references (2022 filing p. 108-109; 2023 filing p. 90-91) that add credibility, though these cannot be independently verified against the ground truth; (5) Uses clear, professional language that conveys the same semantic meaning as the ground truth. Minor consideration: The LLM includes page citations which, while helpful for verification purposes, are not explicitly mentioned in the ground truth answer. However, this addition enhances rather than detracts from the answer's quality. The core finding—no change in funding sources between the two years, with both years using plan trusts and corporate assets—is completely accurate and well-articulated. The answer fully addresses all aspects of the question regarding the evolution (or lack thereof) of UPS's funding approach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1186,
        "completion_tokens": 342,
        "total_tokens": 1529
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the role and scope of NVIDIA AI Enterprise evolved from its introduction in 2022 to its broader supply and integration in 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, described as a software suite aimed at simplifying the deployment of AI applications across data centers and enterprise environments. By 2024, the platform had evolved into a more comprehensive and integrated solution, including components such as NVIDIA NIM, NVIDIA NeMo, and AI Blueprints, with specific performance improvements like a 2.5x increase in token throughput. This reflects a shift from a foundational offering to a full-stack, production-grade generative AI platform with enhanced capabilities and broader deployment options.",
      "llm_answer": "In the 2022 Form 10‑K, NVIDIA AI Enterprise was announced as a new, paid‑license software suite within the Compute & Networking segment, described as “a comprehensive suite of enterprise‑grade AI software” that includes NIM, NeMo and AI Blueprints to simplify development and deployment of generative‑AI applications on NVIDIA hardware【NVDA_10k_2022.pdf page 6】. By the 2024 filing, the same suite had become a core part of the Data Center platform—listed alongside GPUs, CPUs, DPUs and networking solutions, bundled with DGX Cloud and vGPU offerings, and supplied to OEMs, system integrators and cloud partners—showing a much broader supply footprint and deeper integration across NVIDIA’s ecosystem【NVDA_10k_2024.pdf page 6‑7】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution of NVIDIA AI Enterprise from 2022 to 2024 and correctly identifies key components (NIM, NeMo, AI Blueprints) and the shift toward broader integration. However, there are significant discrepancies with the ground truth: (1) QUANTITATIVE ACCURACY ISSUE: The ground truth specifically mentions a '2.5x increase in token throughput' as a performance improvement by 2024, which the LLM answer completely omits. This is a concrete, measurable metric that should have been included. (2) COMPONENT DESCRIPTION DISCREPANCY: The LLM answer states that NIM, NeMo, and AI Blueprints were part of the 2022 introduction, but the ground truth indicates these were added by 2024 as part of the evolution. The 2022 description was simply 'a software suite aimed at simplifying deployment' without specifying these components. This is a material factual error in the multi-hop synthesis. (3) CHARACTERIZATION: The LLM describes the 2022 offering as 'comprehensive suite of enterprise-grade AI software' which may overstate the initial scope compared to the ground truth's more modest 'software suite aimed at simplifying deployment.' (4) POSITIVE ASPECTS: The LLM correctly identifies the shift from foundational offering to broader integration, correctly names the segment (Compute & Networking), and accurately describes the 2024 expansion to OEMs, system integrators, and cloud partners. The multi-hop reasoning across 2022 and 2024 filings is sound in structure. The main weakness is the omission of the specific 2.5x token throughput metric and the misplacement of component introductions in the timeline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 448,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has ExxonMobil's proved reserves through equity companies evolved from 2022 to 2024, and what does this indicate about its strategic positioning in different regions?",
      "original_answer": "In 2022, ExxonMobil's total proved reserves from equity companies amounted to 14 million barrels gross (1 million net) across the United States, Europe, Africa, and Asia. By 2024, these reserves had significantly increased to 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas, with the majority of this growth concentrated in Asia. This indicates a major strategic shift toward strengthening its upstream presence in the Asia region through equity companies.",
      "llm_answer": "ExxonMobil’s equity‑company proved reserves were essentially flat, staying at roughly 3 billion barrels of oil‑equivalent at year‑end 2022 (≈2.99 billion boe) and again at year‑end 2024 (≈2.99 billion boe) (2022 10‑K, pp. 20‑24; 2024 10‑K, pp. 8‑12). The regional mix has not shifted markedly – more than 90 % of equity‑company reserves are in Asia (≈2.8 billion boe), with only modest stakes in Africa (≈0.14 billion boe) and Europe (≈0.05 billion boe) and virtually no U.S. equity holdings, indicating a continued strategic emphasis on joint‑venture assets in Asian markets while keeping equity exposure elsewhere limited.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth on nearly every factual dimension. Critical errors: (1) QUANTITATIVE ERRORS - The LLM claims reserves were 'roughly 3 billion barrels of oil-equivalent' (≈2.99 billion boe) in both 2022 and 2024, but ground truth shows 2022 had only 14 million barrels gross (1 million net), and 2024 had 467 million barrels crude oil + 120 million barrels NGL + 5,367 billion cubic feet natural gas. The LLM's numbers are off by orders of magnitude (claiming ~3,000 million boe vs actual 467-600 million boe range). (2) DIRECTIONAL ERROR - LLM claims reserves were 'essentially flat' when ground truth shows 'significantly increased' from 2022 to 2024. This is a fundamental mischaracterization of the trend. (3) REGIONAL ANALYSIS ERROR - While LLM correctly identifies Asia as dominant, it claims 90% of reserves are in Asia (~2.8 billion boe), which is inconsistent with the actual 2024 figures dominated by natural gas (5,367 bcf) concentrated in Asia. The regional percentages appear fabricated. (4) MISSING SPECIFICITY - LLM fails to break down reserves by commodity type (crude oil, NGL, natural gas) as provided in ground truth, instead using only BOE equivalents. (5) STRATEGIC INTERPRETATION - While LLM correctly notes Asia emphasis, it misses the 'major strategic shift' and 'significant increase' that characterizes the actual evolution. The answer appears to reference incorrect page numbers and data that don't match the actual 10-K filings. This is a complete failure to accurately synthesize the multi-hop financial information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 439,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of their role in revenue generation and cost structure?",
      "original_answer": "In 2022, Google Network Partners played a central role in the revenue generation process as Google acted as the principal for ads placed on Google Network properties, reporting advertising revenues on a gross basis, with payments to partners recorded as cost of revenues. By 2024, Google continued to pay Google Network partners, but the focus of the financial reporting shifted to emphasize the net cash flow impact, noting that payments to these partners were a primary use of cash from operating activities. This reflects a more cost-centric framing of the relationship in the later year.",
      "llm_answer": "In the 2022 10‑K, Alphabet said that ads on Google Network properties are accounted for on a gross basis – the full amount billed to advertisers is recorded as revenue and the amounts paid to Google Network partners are reflected in cost of revenues (TAC) (2022 pp. 53‑57). The 2024 10‑K keeps the same accounting treatment but explicitly notes that payments to Google Network partners are a primary cash outflow from operating activities, underscoring that the partners still generate a large share of advertising revenue while remaining a significant cost component (2024 pp. 40‑44).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop financial question about Google Network Partners' evolving role between 2022 and 2024. STRENGTHS: (1) Correctly identifies the 2022 accounting treatment - gross basis revenue recognition with partner payments as TAC (cost of revenues), which matches the ground truth. (2) Accurately captures the 2024 shift in emphasis toward cash flow impact and cost structure framing, consistent with ground truth. (3) Properly synthesizes the multi-hop relationship: both years maintain the same accounting treatment but differ in reporting emphasis. (4) Correctly cites page ranges (2022 pp. 53-57, 2024 pp. 40-44) which adds credibility. (5) Uses appropriate financial terminology (TAC, operating activities, cost component). (6) Addresses both parts of the question: revenue generation role AND cost structure evolution. MINOR CONSIDERATIONS: The LLM answer adds slightly more specific detail about TAC terminology and page citations compared to the ground truth, but this represents enhancement rather than error. The phrase 'partners still generate a large share of advertising revenue while remaining a significant cost component' is a reasonable inference from the ground truth's description of the shift in framing. No quantitative errors detected. The semantic meaning aligns perfectly with the ground truth - both convey that the relationship shifted from a principal/revenue-focused framing in 2022 to a cost/cash-flow-focused framing in 2024, while maintaining the same underlying accounting treatment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 436,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has UPS's foreign currency exchange risk management strategy evolved between 2022 and 2023, particularly in terms of the financial impact of undesignated foreign currency forward contracts on earnings volatility?",
      "original_answer": "In 2022, UPS disclosed that foreign currency exchange forward contracts were used to economically offset foreign currency remeasurement and settlement risk for certain balance sheet assets and liabilities, and that changes in their fair value affected earnings directly. For 2023, UPS expanded the disclosure to emphasize that undesignated derivative settlements are now explicitly linked to earnings volatility, with a specific focus on how these contracts impact income statement recognition. The 2023 filing also introduced a more structured presentation of fair value changes and settlements for these contracts, with amounts for both 2023 and 2022 now reported side-by-side in millions, indicating a more transparent and systematic approach to disclosing the financial effects of these instruments.",
      "llm_answer": "UPS trimmed the earnings impact of its undesignated foreign‑currency forward contracts, signaling a tighter risk‑management approach. In 2022 the company booked a $69 million loss on non‑designated foreign‑currency forwards (recorded in investment income), which amplified earnings volatility, but in 2023 that loss fell to just $7 million, reflecting a shift toward more contracts being designated as cash‑flow hedges (or being terminated) and thereby reducing volatility.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and introduces specific numbers that cannot be verified against the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM provides specific dollar amounts ($69 million loss in 2022, $7 million in 2023) that are not mentioned in the original answer or ground truth. These numbers appear to be fabricated or misattributed, as the ground truth makes no reference to specific loss amounts. The claim that losses 'fell to just $7 million' is presented as fact but lacks verification. (2) INCOMPLETE SYNTHESIS: The ground truth emphasizes that UPS expanded disclosure in 2023 to explicitly link undesignated derivative settlements to earnings volatility and introduced more structured presentation of fair value changes. The LLM answer misses this key evolution in disclosure strategy and instead focuses on a narrative about 'trimming earnings impact' and shifting to designated hedges. (3) REASONING FLAWS: The LLM's conclusion that the reduction in losses reflects 'a shift toward more contracts being designated as cash-flow hedges (or being terminated)' is speculative and not supported by the ground truth. The ground truth discusses disclosure changes and presentation improvements, not necessarily a change in hedging strategy. (4) ENTITY/METRIC CONFUSION: The LLM mentions 'investment income' as the line item for recording these losses, but this specific detail is not confirmed in the ground truth. (5) MISSING CONTEXT: The LLM fails to address the core evolution described in the ground truth—the shift from general disclosure about offsetting risk to explicit linkage with earnings volatility and more transparent side-by-side reporting. The answer reads as a plausible-sounding narrative about risk management but lacks grounding in the actual filing disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 495,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the role of the membership format in Costco's profitability strategy evolved between 2022 and 2023, particularly in terms of its impact on member loyalty and fee revenue?",
      "original_answer": "In 2022, the membership format was described as 'an integral part of our business and has a significant effect on our profitability,' with an emphasis on growth in the membership base, increasing Executive member penetration, and sustaining high renewal rates as key drivers of profitability. By 2023, the language evolved to underscore that the membership format 'is an integral part of our business and profitability,' indicating a more consolidated role in the company's financial model. Additionally, in 2023, Costco introduced a new concern about the potential adverse impact of lower renewal rates in newer markets on the worldwide renewal rate, which was not explicitly mentioned in 2022. This suggests that while the membership model remained central to profitability, the company faced emerging challenges in sustaining renewal rates as it expanded into newer markets.",
      "llm_answer": "In the 2022 filing Costco stressed that its membership format is “an integral part of our business and has a significant effect on our profitability,” noting that the model is built to “reinforce member loyalty and provide continuing fee revenue” and that growth in the membership base, executive‑member penetration and high renewal rates directly drive profitability (2022 MD&A § Membership format)【COST_10k_2022.pdf†p21】. By the 2023 filing the same fundamentals remained – the format still “reinforces member loyalty and provides continuing fee revenue” and growth in the base and executive upgrades continue to be key profit levers – but Costco added a new caution that “our worldwide renewal rate may be adversely impacted by lower renewal rates in newer markets,” reflecting a more nuanced view of loyalty risk while still emphasizing fee‑revenue growth (2023 MD&A § Membership format)【COST_10k_2023.pdf†p22】. The 2022 highlights also quantified the impact, reporting a 9% rise in membership‑fee revenue to $4.224 billion, and the 2023 discussion continues to treat fee revenue as a core profitability driver, albeit without a specific percentage, underscoring the ongoing importance of the membership model for both loyalty and fee income.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly captures the evolution of language from 2022 ('has a significant effect') to 2023 ('is an integral part'), accurately reflecting the consolidation of the membership model's role. (2) Accurately identifies the core themes in both years: member loyalty reinforcement, fee revenue generation, membership base growth, and executive member penetration. (3) Correctly identifies the new concern introduced in 2023 about lower renewal rates in newer markets adversely impacting worldwide renewal rates. (4) The quantitative data provided (9% rise in membership-fee revenue to $4.224 billion in 2022) is accurate and appropriately contextualized. (5) Multi-hop reasoning is sound: the answer synthesizes information across two years and two filings to show both continuity and evolution in strategy. (6) The characterization of the 2023 perspective as 'more nuanced' regarding loyalty risk is semantically equivalent to the ground truth's description of 'emerging challenges.' MINOR CONSIDERATIONS: (1) The LLM provides slightly more detail than the ground truth (e.g., specific MD&A section references and page numbers), which adds value rather than detracting. (2) The statement about 2023 'without a specific percentage' is accurate and appropriately notes the difference from 2022. (3) All entity references (Costco, years 2022-2023, membership format, renewal rates, fee revenue) are correctly identified. The answer fully addresses the multi-part question regarding evolution, member loyalty impact, and fee revenue impact between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1538,
        "completion_tokens": 454,
        "total_tokens": 1993
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration within the broader data center platform and software ecosystem?",
      "original_answer": "In 2022, CUDA was primarily positioned as a key component of NVIDIA's AI ecosystem, with nearly 3 million developers using CUDA and other software tools to deploy AI and accelerated computing technologies. It was described as central to NVIDIA's partnerships and developer programs, including the Deep Learning Institute and Inception program. By 2024, CUDA had evolved into a more deeply integrated part of a full-stack computing platform, specifically within the data center. It was described as the foundation of the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific frameworks, emphasizing its role in enabling end-to-end optimized computing across GPUs, CPUs, and DPUs. This reflects a strategic shift from promoting CUDA as a developer-focused tool to positioning it as a core infrastructure layer for enterprise-scale computing solutions.",
      "llm_answer": "In the 2022 filing NVIDIA presented CUDA as the “foundational CUDA programming model” that runs on every GPU and serves as the fundamental building block of its accelerated‑computing platform, unifying software across markets and supporting a developer base of “almost 3 million” users【NVDA_10k_2022.pdf p9‑10】. By the 2024 filing CUDA is described as part of a broader data‑center stack that now includes CPUs, DPUs and networking, and is woven into AI Enterprise, DGX Cloud and the CUDA‑X libraries, with the ecosystem growing to “over 5.9 million” developers, reflecting deeper integration of CUDA throughout the full‑stack data‑center platform【NVDA_10k_2024.pdf p4‑6】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the question. QUANTITATIVE VERIFICATION: The developer numbers are correct - 2022 shows \"almost 3 million\" developers (matching ground truth's \"nearly 3 million\"), and 2024 shows \"over 5.9 million\" developers (accurate growth metric). Both numeric values align with the original answer. QUALITATIVE ACCURACY: The LLM correctly identifies the strategic evolution from 2022 to 2024: (1) 2022 positioning emphasizes CUDA as foundational programming model and accelerated-computing platform with developer focus; (2) 2024 positioning emphasizes broader data-center stack integration including CPUs, DPUs, and networking, plus integration with AI Enterprise, DGX Cloud, and CUDA-X libraries. This accurately reflects the shift from developer-focused tool to enterprise infrastructure layer described in the ground truth. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years and demonstrates the evolution through specific product/ecosystem references (AI Enterprise, DGX Cloud, CUDA-X). The comparison is logically sound and well-structured. COMPLETENESS: The answer addresses all key aspects of the question - the evolution of CUDA's approach, its integration within data center platform, and its role in the broader software ecosystem. MINOR CONSIDERATIONS: The LLM answer uses slightly different phrasing than ground truth (e.g., \"woven into\" vs. \"deeply integrated\") but conveys equivalent semantic meaning. The citation format with page numbers adds credibility. No factual errors detected. The answer is well-organized and directly responsive to the multi-part question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 462,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2023 to 2024, particularly in terms of expected future revenue and product delivery timelines?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled Paxlovid from U.S. government inventory. By the end of 2024, Pfizer reported remaining performance obligations for Paxlovid at approximately $1 billion, with expected product delivery and revenue realization scheduled from 2025 through 2028, indicating a shift from uncertain returns and revenue reversals to a more defined forward-looking revenue outlook based on firm contracts.",
      "llm_answer": "In 2023 Pfizer’s Paxlovid commitments were almost entirely government‑sponsored contracts that produced a $3.5 billion non‑cash revenue reversal for an estimated 6.5 million EUA‑labeled treatment courses and left $5.1 billion of deferred revenue (about $2.6 bn current and $2.5 bn non‑current) 【2023 10‑K p.5】. By 2024, after amending those agreements, the company recorded a $771 million favorable adjustment for 5.1 million returned courses, recognized $442 million of revenue for a U.S. Strategic National Stockpile of 1 million courses, and now reports roughly $1 billion of remaining performance‑obligation revenue for Paxlovid with deliveries scheduled from 2025 through 2028, while deferred revenue fell to $2.2 billion 【2024 10‑K p.108‑110】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides substantial detail and addresses the core question about Paxlovid's financial evolution from 2023 to 2024, but contains significant quantitative discrepancies that undermine accuracy. CORRECT ELEMENTS: (1) The $3.5 billion non-cash revenue reversal in 2023 Q4 is accurate; (2) The 6.5 million treatment courses estimate is correct; (3) The ~$1 billion remaining performance obligations for 2025-2028 delivery matches ground truth; (4) The overall narrative of shift from uncertain returns to defined forward-looking revenue is sound; (5) The mention of 2024 amendments and adjustments is appropriate context. PROBLEMATIC ELEMENTS: (1) The $5.1 billion deferred revenue figure for 2023 is NOT supported by the ground truth answer, which does not mention this amount; (2) The $771 million favorable adjustment for 5.1 million returned courses is not mentioned in ground truth; (3) The $442 million revenue for 1 million SNS courses is not in ground truth; (4) The $2.2 billion deferred revenue for 2024 is not mentioned in ground truth. MULTI-HOP REASONING: The LLM correctly synthesizes the evolution across years and identifies the shift from reversals to forward obligations, which is sound. However, the introduction of specific numbers ($5.1B, $771M, $442M, $2.2B) that don't appear in the ground truth suggests either hallucination or citation of information not validated in the knowledge graph. The core answer structure is logical and addresses the question comprehensively, but the additional financial details create factual uncertainty. The answer is more detailed than ground truth but potentially less reliable due to unverified figures. CALCULATION VERIFICATION: No explicit calculations are performed that can be verified as erroneous, but the sourcing of specific dollar amounts is questionable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 497,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2022 and 2024, based on its disclosures around reserves development and advantaged asset reporting?",
      "original_answer": "In 2022, ExxonMobil reported that Guyana was a key contributor to extensions and discoveries, adding approximately 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves. By 2024, Guyana was explicitly listed as one of the core 'Advantaged Assets' in the company's updated earnings drivers, signaling a strategic shift to highlight Guyana's role in driving earnings through volume growth. This evolution reflects a transition from Guyana being primarily a reserves growth region to being a recognized source of advantaged production and earnings visibility.",
      "llm_answer": "In the 2022 Form 10‑K ExxonMobil reported that extensions and discoveries “primarily in the United States, Brazil, and **Guyana**” added about 1.3 billion oil‑equivalent barrels of proved undeveloped reserves (see XOM_10k_2022 p. 16). By the 2024 Form 10‑K, Guyana is listed as one of the company’s “**advantaged assets**” in the Advantaged Volume Growth driver—grouped with Permian and LNG—signaling that the project has moved from early‑stage reserve‑building to a core, high‑value growth asset (see XOM_10k_2024 p. 35‑36).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive synthesis of multi-hop information across ExxonMobil's 2022 and 2024 10-K filings. STRENGTHS: (1) Quantitative accuracy is excellent—the 1.3 billion oil-equivalent barrels figure is correctly cited and properly attributed to 2022 extensions and discoveries; (2) Entity identification is precise—correctly identifies ExxonMobil, Guyana, Permian, and LNG as relevant assets; (3) Multi-hop reasoning is sound—effectively synthesizes the evolution from 2022 (reserves growth focus) to 2024 (advantaged assets classification); (4) The characterization of the strategic shift from 'early-stage reserve-building' to 'core, high-value growth asset' accurately captures the semantic meaning of the ground truth's 'transition from reserves growth region to recognized source of advantaged production and earnings visibility'; (5) Page citations (p. 16 for 2022, p. 35-36 for 2024) add credibility and specificity; (6) The grouping of Guyana with Permian and LNG in the Advantaged Volume Growth driver is contextually appropriate and demonstrates understanding of the company's strategic positioning. MINOR CONSIDERATIONS: The LLM answer uses slightly different phrasing than the ground truth ('Advantaged Volume Growth driver' vs. 'core Advantaged Assets in earnings drivers'), but this represents semantic equivalence rather than factual error. The answer fully addresses all components of the multi-part question regarding how Guyana's strategic emphasis evolved between 2022 and 2024, with proper attention to both reserves development and advantaged asset reporting dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 447,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the planned utilization of the ATR 72-600F aircraft evolve from 2022 to 2024, and what does this indicate about its role in the company's fleet strategy?",
      "original_answer": "In 2022, the ATR 72-600F was projected to have a decreasing role in the company's fleet, with planned units dropping from 11 in 2023 to just 1 by 2026. By 2024, however, the company's projections showed a shift, with ATR 72-600F units remaining steady at 7 for 2025 and declining only slightly to 3 by 2026. This indicates that while the aircraft was initially expected to phase out more rapidly, it continued to play a more sustained, albeit reduced, role in the fleet strategy.",
      "llm_answer": "In the 2022 filing FedEx said it was committed to 24 ATR 72‑600F turboprops – 11 slated for 2023, 6 for 2024, 6 for 2025 and 1 for 2026 (FDX_10k_2022.pdf, p. 115). By the 2024 filing the commitment had been cut to just 10 aircraft, all pushed back to later deliveries (7 in 2025 and 3 in 2026) with no ATR 72‑600Fs scheduled for 2023‑2024 (FDX_10k_2024.pdf, p. 118). This downsizing and postponement shows FedEx is scaling back the ATR 72‑600F’s role, treating it as a smaller, less‑central component of its fleet strategy in favor of other aircraft types.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides specific numbers and sources but contains significant quantitative discrepancies with the ground truth. QUANTITATIVE ISSUES: (1) 2022 projections - LLM states '11 slated for 2023, 6 for 2024, 6 for 2025 and 1 for 2026' (total 24), but ground truth shows '11 in 2023 to just 1 by 2026' without specifying intermediate years. The LLM's breakdown differs from what can be verified. (2) 2024 projections - LLM claims '7 in 2025 and 3 in 2026' which matches the ground truth exactly. (3) Total commitment - LLM states the 2024 commitment was 'cut to just 10 aircraft' (7+3), which is mathematically correct but the ground truth indicates 'ATR 72-600F units remaining steady at 7 for 2025 and declining only slightly to 3 by 2026' - the characterization of this as a 'cut' may be accurate but the ground truth emphasizes 'more sustained' role. QUALITATIVE ASSESSMENT: The LLM correctly identifies the multi-hop comparison between 2022 and 2024 filings and synthesizes the evolution appropriately. The reasoning that this represents 'scaling back' and treating it as 'smaller, less-central' aligns with the ground truth's characterization of 'reduced role.' However, the ground truth emphasizes the shift from 'more rapid phase-out' to 'more sustained' role, while the LLM emphasizes 'downsizing and postponement' - these are somewhat different interpretations of the same data. MULTI-HOP REASONING: The LLM successfully synthesizes information across two filing years (2022 and 2024) and correctly identifies the directional change. The logic is sound regarding the postponement of deliveries. MAIN CONCERN: The specific 2022 numbers provided by the LLM (11, 6, 6, 1) cannot be fully verified against the ground truth statement, which only mentions the endpoints (11 in 2023, 1 by 2026). This creates uncertainty about whether the intermediate year figures are accurate. The answer is partially correct in structure and reasoning but has quantitative precision issues.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 535,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has NVIDIA's approach to offering Omniverse evolved between 2022 and 2024, particularly in terms of its integration with other AI and simulation platforms?",
      "original_answer": "In 2022, NVIDIA Omniverse was primarily described as a virtual world simulation and collaboration platform for 3D workflows, available as a software subscription for enterprise use and free for individual use. It was highlighted as being integrated with VR and AR in enterprise applications such as virtual car showrooms and surgical training. By 2024, NVIDIA's offering of Omniverse had evolved into a more comprehensive development platform and operating system for building and running virtual world simulation applications. It was now emphasized as being used by industrial enterprises to digitalize complex physical assets and processes—such as building digital twins of factories and testing autonomous robots and vehicles—powered by NVIDIA's accelerated computing infrastructure both on-premises and in the cloud. This represents a shift from general 3D collaboration to a more specialized, enterprise-focused simulation and digital twin platform.",
      "llm_answer": "In the 2022 filing NVIDIA presented Omniverse mainly as a subscription‑based virtual‑world simulation and collaboration platform for 3‑D design, VR/AR and creative workflows – a tool for designers and artists that also offered an Avatar AI component for conversational use (NVDA_10k_2022.pdf p.7‑11). By the 2024 filing the company had repositioned Omniverse as an enterprise development platform and operating system that powers digital twins, synthetic‑data generation for AI model training and testing of autonomous robots and vehicles, tightly integrated with NVIDIA’s AI‑accelerated data‑center, cloud and DRIVE simulation solutions (NVDA_10k_2024.pdf p.4‑8).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: No numeric values, dates, or calculations are present in either answer, so this dimension is not applicable but receives full marks as there are no errors. ENTITY ACCURACY: Both answers correctly identify NVIDIA, Omniverse, and the 2022-2024 timeframe. The LLM properly cites specific document sources (NVDA_10k_2022.pdf and NVDA_10k_2024.pdf with page ranges), adding credibility. COMPLETENESS & MULTI-HOP REASONING: The LLM answer successfully synthesizes the evolution across two years by: (1) describing 2022 positioning as subscription-based virtual-world simulation for 3D design/VR/AR/creative workflows, (2) noting the Avatar AI component, and (3) contrasting with 2024 repositioning as enterprise development platform/OS for digital twins, synthetic data generation, and autonomous vehicle testing. This mirrors the ground truth's core narrative of shifting from general 3D collaboration to specialized enterprise-focused simulation. SEMANTIC EQUIVALENCE: The LLM answer conveys equivalent information to the ground truth: - 2022: 'subscription-based virtual-world simulation and collaboration platform' matches ground truth's description - 2024: 'enterprise development platform and operating system' for 'digital twins' and 'autonomous robots and vehicles' matches ground truth's characterization - Integration with 'AI-accelerated data-center, cloud and DRIVE simulation solutions' aligns with ground truth's mention of 'accelerated computing infrastructure both on-premises and in the cloud' MINOR DIFFERENCES: The LLM answer includes additional specific details (Avatar AI component, synthetic-data generation, DRIVE solutions) not explicitly mentioned in the ground truth, but these are complementary rather than contradictory and enhance the answer's informativeness. The LLM also provides document citations which add transparency. No factual errors or contradictions were identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 544,
        "total_tokens": 1951
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has the role of Google Play in generating non-advertising revenue evolved between 2022 and 2023?",
      "original_answer": "In 2022, Google Play was introduced as part of the company's broader strategy to expand non-advertising revenues, specifically through the sales of apps, in-app purchases, and digital content. By 2023, Google Play had transitioned into a more defined revenue stream under 'platforms,' where it was explicitly tied to revenues from app sales and in-app purchases. This evolution indicates a strategic shift toward solidifying Google Play’s role as a key monetization platform rather than just a component of diversification. The change reflects a more structured categorization and likely a stronger contribution to revenue stability within the ecosystem.",
      "llm_answer": "In the 2022 filing Google Play was described as part of “Google other” revenues—sales of apps, in‑app purchases and digital content—and the company noted that non‑advertising revenues, including Google Play, were growing (2022 pp. 28‑32). The 2023 filing again highlights Google Play as the primary source of “platforms” revenue within Google Subscriptions, Platforms and Devices and stresses that non‑advertising revenue continued to rise, indicating that Google Play’s contribution to the non‑advertising mix has become more prominent year‑over‑year (2023 pp. 31‑35).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and effectively addresses the multi-hop question about Google Play's evolution between 2022 and 2023. STRENGTHS: (1) Correctly identifies the 2022 positioning of Google Play within 'Google other' revenues as part of non-advertising revenue diversification; (2) Accurately describes the 2023 shift where Google Play became explicitly categorized under 'platforms' revenue within the Subscriptions, Platforms and Devices segment; (3) Properly synthesizes the multi-hop information showing the evolution from a component of broader diversification to a more defined, prominent revenue stream; (4) Appropriately cites page ranges from both 2022 (pp. 28-32) and 2023 (pp. 31-35) filings, demonstrating cross-document synthesis; (5) Correctly characterizes the strategic shift toward solidifying Google Play's role as a key monetization platform. MINOR WEAKNESSES: (1) The LLM answer could have been slightly more explicit about the 'transition' or 'evolution' language to more directly mirror the ground truth's emphasis on 'strategic shift'; (2) The phrase 'primary source of platforms revenue within Google Subscriptions, Platforms and Devices' is accurate but could have been clearer that this represents a more structured categorization compared to 2022. QUANTITATIVE ACCURACY: No specific financial figures or percentages are provided in either answer, so this dimension focuses on date accuracy (2022 vs 2023 correctly distinguished) and page citations (appear reasonable for 10-K filings). QUALITATIVE ACCURACY: The reasoning correctly identifies the multi-hop synthesis required (comparing 2022 positioning to 2023 positioning) and draws appropriate conclusions about increased prominence and structural definition. CONTEXTUAL RELEVANCE: The answer directly addresses how Google Play's role evolved, which is precisely what the question asks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 511,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has AIG's use of expected loss ratio methods in workers' compensation reserving evolved between 2022 and 2023, particularly in relation to guaranteed cost and excess of deductible business?",
      "original_answer": "In 2022, AIG generally gave significant weight to expected loss ratio methods for guaranteed cost business only in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that changes in claims strategy and loss mitigation efforts were accelerating settlements, increasing paid losses along the latest diagonals. In 2023, the reserving methodology remained broadly consistent, with AIG continuing to use a combination of loss development, frequency/severity, and expected loss ratio methods. However, the 2023 filing emphasized that incurred and paid losses were now presented net of reinsurance and undiscounted, which may reflect a refinement in reporting transparency rather than a change in reserving philosophy. Additionally, the increased proportion of large deductible business continued to slow the reporting pattern of claims in 2023, consistent with the trend noted in 2022.",
      "llm_answer": "In the 2022 filing (AIG 10‑K p. 258) the company said it “generally use[s] a combination of loss‑development, frequency/severity and **expected loss‑ratio methods**” and that **for guaranteed‑cost business the expected‑loss‑ratio approach is given significant weight only in the most recent accident year**, whereas **for excess‑of‑deductible business it may be given significant weight in the most recent five accident years**, with the ratios adjusted for tail‑factor changes, legal‑cost trends, rate changes, inflation and market conditions.  \n\nIn the 2023 filing (AIG 10‑K p. 200) AIG still notes the same mix of methods but no longer spells out those distinct weighting rules for guaranteed‑cost versus excess‑of‑deductible policies, instead presenting a more unified reserving approach while still highlighting the continued growth of large‑deductible business.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and correctly identifies the key evolution in AIG's workers' compensation reserving methodology between 2022 and 2023. STRENGTHS: (1) Correctly cites specific page numbers (p. 258 for 2022, p. 200 for 2023) and accurately quotes the methodological mix (loss-development, frequency/severity, and expected loss-ratio methods). (2) Accurately captures the 2022 distinction: guaranteed-cost business received significant weight in most recent accident year only, while excess-of-deductible business received significant weight in most recent five accident years. (3) Correctly identifies the key evolution: 2023 filing no longer spells out these distinct weighting rules and presents a more unified approach. (4) Appropriately notes the continued growth of large-deductible business as a contextual factor. (5) Multi-hop reasoning is sound - correctly synthesizes information across two years and two business segments. MINOR GAPS: (1) The LLM answer omits some contextual details from the ground truth, specifically: the mention of changes in claims strategy and loss mitigation efforts accelerating settlements and increasing paid losses along latest diagonals (2022), and the specific note about incurred and paid losses being presented net of reinsurance and undiscounted (2023). (2) The LLM characterizes the 2023 change as a shift to 'more unified reserving approach' which is a reasonable interpretation but slightly less precise than the ground truth's emphasis on reporting transparency refinement. (3) Does not explicitly mention tail-factor adjustments, legal-cost trends, rate changes, inflation and market conditions mentioned in the 2022 filing. However, these omissions are relatively minor contextual details rather than core factual errors. The answer successfully addresses the main question about how the methodology evolved and the key differences between the two years. No numerical errors detected. The semantic meaning aligns well with the ground truth despite some wording differences.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1480,
        "completion_tokens": 553,
        "total_tokens": 2033
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Cisco's product category segmentation evolved between fiscal 2022 and fiscal 2024, particularly in relation to the Collaboration category?",
      "original_answer": "In fiscal 2022, Cisco introduced a product revenue segmentation that included 'Collaboration' as one of six distinct categories, which also included Secure, Agile Networks; Internet for the Future; End-to-End Security; Optimized Application Experiences; and Other Products. By fiscal 2024, Cisco restructured its product categories into four main areas, retaining 'Collaboration' but now grouping it alongside Networking, Security, and a new category called Observability. This indicates a consolidation and realignment of product offerings, with the introduction of Observability as a distinct area and the removal or reclassification of Optimized Application Experiences and Internet for the Future.",
      "llm_answer": "Cisco’s product‑category reporting was streamlined. In fiscal 2022 the company presented six categories – Secure Agile Networks, Internet for the Future, Collaboration, End‑to‑End Security, Optimized Application Experiences and Other Products 【CSCO_10k_2022.pdf†L71-L78】. Effective fiscal 2024 it consolidated those into four categories – Networking, Security, Collaboration and Observability – and restated prior periods to the new layout 【CSCO_10k_2024.pdf†L71-L78】. The Collaboration segment remained a distinct category, but its revenue fell from $4.47 billion in FY 2022 to $4.11 billion in FY 2024 (a roughly 9% decline) 【CSCO_10k_2022.pdf†L73-L77】【CSCO_10k_2024.pdf†L73-L77】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. STRENGTHS: (1) Correctly identifies the six fiscal 2022 categories (Secure Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, Other Products) matching the ground truth exactly. (2) Accurately describes the fiscal 2024 consolidation into four categories (Networking, Security, Collaboration, Observability) with proper identification of Observability as new. (3) Correctly notes that Collaboration remained a distinct category through both periods. (4) Provides specific revenue figures for Collaboration: $4.47B (FY2022) and $4.11B (FY2024), with accurate calculation of the 9% decline (($4.47B - $4.11B) / $4.47B ≈ 8.05%, which rounds to approximately 9% as stated). (5) Mentions the important detail that prior periods were restated to the new layout, showing understanding of accounting practices. (6) Properly synthesizes multi-hop information across two fiscal years and two different 10-K filings. MINOR CONSIDERATIONS: The revenue decline calculation is stated as 'roughly 9%' which is slightly rounded (actual is ~8%), but this is acceptable given the 'roughly' qualifier and is not a material error. The answer fully addresses the evolution question by showing both the structural change (6 to 4 categories) and the specific impact on Collaboration (revenue decline while maintaining category status). All entities, dates, and metrics are correctly identified and synthesized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 414,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Amgen's disclosure regarding the 3.125% 2025 Notes evolved from 2022 to 2023 in terms of financial presentation and associated interest rate framework?",
      "original_answer": "In 2022, Amgen reported a carrying value of $1,000 million for the 3.125% 2025 Notes within its debt table, but no specific interest rate framework was disclosed. By 2023, Amgen included the 3.125% 2025 Notes in a new table that explicitly outlined the interest rate mechanism, identifying it as SOFR + 2.1%. This evolution reflects a shift from a purely quantitative disclosure in 2022 to a more detailed qualitative and quantitative presentation in 2023, including the interest rate benchmark and spread.",
      "llm_answer": "In the 2022 Form 10‑K Amgen listed the $1 billion 3.125 % 2025 senior notes in its debt schedule (under “Other current assets and accrued liabilities”) and disclosed that the related interest‑rate swap gave those notes an effective rate of **LIBOR + 1.8 %**【source: AMGN 10‑K 2022, debt table showing “3.125% notes due 2025 … $1,000” and swap table showing “3.125% 2025 Notes … LIBOR + 1.8%】.  \nThe 2023 Form 10‑K still shows the same $1 billion of 3.125 % 2025 notes in its debt tables, but the swap disclosure now reports an effective rate of **SOFR + 2.1 %**, reflecting the transition from LIBOR to the Secured Overnight Financing Rate and a slightly higher spread【source: AMGN 10‑K 2023, swap table showing “3.125% 2025 Notes … SOFR + 2.1%】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM reports LIBOR + 1.8% for 2022, but the ground truth states NO specific interest rate framework was disclosed in 2022. The LLM appears to have fabricated or misattributed swap information that was not in the original 2022 filing. This is a major factual error. (2) The LLM correctly identifies SOFR + 2.1% for 2023, which matches the ground truth. (3) ENTITY/PRESENTATION ACCURACY - The LLM incorrectly places the notes under 'Other current assets and accrued liabilities' when they should be in the debt table. The ground truth explicitly states the 2022 disclosure was 'within its debt table.' (4) MULTI-HOP REASONING - The LLM does attempt to synthesize the evolution across years, but the 2022 data is fundamentally incorrect, undermining the entire comparison. The ground truth emphasizes that 2022 had NO interest rate framework disclosed, while 2023 introduced explicit SOFR + 2.1% disclosure. The LLM's narrative of 'transition from LIBOR to SOFR' is not supported by the ground truth, which shows no LIBOR disclosure in 2022. (5) COMPLETENESS - While the LLM addresses both years, the core factual content for 2022 is wrong, making the answer substantially incorrect despite addressing the right time periods and company. The $1 billion carrying value is correct, but the interest rate framework disclosure for 2022 is entirely inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 391,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure had decreased to 296 billion cubic feet. This indicates a reduction in the company's natural gas holdings in the region over the two-year period, suggesting a potential strategic shift or divestment in that geographic area.",
      "llm_answer": "COP’s proved natural‑gas inventory in the Asia Pacific/Middle East fell from **326 billion cubic feet (BCF) at year‑end 2022** to **296 BCF at year‑end 2024** – a drop of roughly 30 BCF (≈ 9 %).  The undeveloped portion remained very small, rising only from **4 BCF in 2022 to 7 BCF in 2024** (COP_10k_2024.pdf: pages 143‑147).  This downward trend, together with the modest undeveloped base and limited new extensions, signals that the region is a mature, non‑growth part of COP’s portfolio, indicating the company is not pursuing expansion there but is instead concentrating its strategic focus on higher‑potential assets elsewhere.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and goes beyond the ground truth in several ways. QUANTITATIVE VERIFICATION: All key numbers are correct - 326 BCF in 2022, 296 BCF in 2024, representing a 30 BCF decrease (9% decline). The calculation is accurate: (326-296)/326 = 9.2%, appropriately rounded to ~9%. Additional data on undeveloped reserves (4 BCF in 2022 to 7 BCF in 2024) is provided with correct figures. ENTITY ACCURACY: COP correctly identified, years 2022 and 2024 correct, natural gas reserves metric correctly specified as 'proved natural-gas inventory.' MULTI-HOP REASONING: The answer successfully synthesizes the reserve data across two years and draws logical conclusions about strategic positioning. The interpretation that the region represents a 'mature, non-growth part of COP's portfolio' is a sound inference from the declining reserves and modest undeveloped base. COMPLETENESS: The answer addresses both parts of the question - the evolution of reserves (with specific numbers and percentage change) and strategic implications. The LLM provides additional context about undeveloped reserves and source documentation (COP_10k_2024.pdf pages 143-147), which adds credibility without contradicting the ground truth. SEMANTIC EQUIVALENCE: The LLM's characterization of 'potential strategic shift or divestment' aligns with the ground truth's similar language, and the additional interpretation about concentration on 'higher-potential assets elsewhere' is a reasonable extension of the data. Minor deduction from perfect score (9 vs 10) only because the ground truth uses simpler language ('potential strategic shift or divestment') while the LLM provides more detailed interpretation - this is actually a strength but represents a slight deviation from the ground truth's more measured tone.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 494,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did the repurchase activity of Class C Capital Stock by Alphabet change between 2022 and 2023, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023, the repurchase amount increased to $62.2 billion. Additionally, in April 2023, the Board authorized an additional $70.0 billion for share repurchases, with $36.3 billion remaining available as of December 31, 2023. This indicates a continued and expanding emphasis on returning capital to shareholders through share repurchases, with a notable increase in the scale of buybacks year-over-year.",
      "llm_answer": "Alphabet’s buy‑back of its non‑voting Class C stock slipped in volume – it repurchased 469 million shares in 2022 versus 450 million in 2023 – but the cash outlay rose slightly, from about $52.6 billion to $52.9 billion (see the “Share repurchases” table). The lower share count combined with a higher dollar amount reflects a continued, aggressive buy‑back program that uses excess cash to return value to shareholders even as the share price rises, signalling that capital allocation remains focused on shareholder returns.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significantly incorrect financial figures that contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURES: The ground truth states Alphabet repurchased $59.3 billion in 2022 and $62.2 billion in 2023. The LLM claims $52.6 billion in 2022 and $52.9 billion in 2023 - these are substantially different numbers (off by ~$6.7B in 2022 and ~$9.3B in 2023). The LLM also provides share count data (469M vs 450M shares) that is not mentioned in the ground truth and appears to be incorrect or from a different context. (2) INCOMPLETE SYNTHESIS: The LLM completely omits the critical 2023 Board authorization of an additional $70.0 billion for share repurchases and the $36.3 billion remaining available as of December 31, 2023. This is a major omission that fails to capture the full picture of Alphabet's capital allocation strategy expansion. (3) ENTITY/METRIC CONFUSION: While the LLM correctly identifies Class C stock, it focuses on share count rather than the dollar amounts that are central to the question and ground truth. (4) REASONING QUALITY: The LLM's interpretation about share price rises and lower share counts is reasonable logic, but it's built on incorrect foundational numbers. The conclusion about shareholder returns focus is directionally correct but undermined by the factual errors. (5) MISSING CONTEXT: The ground truth emphasizes the year-over-year increase ($59.3B to $62.2B) and the new authorization as indicators of 'continued and expanding emphasis' - the LLM misses this expansion narrative entirely by providing lower numbers and omitting the new authorization. The answer demonstrates some understanding of capital allocation strategy but fails fundamentally on the quantitative accuracy that is essential for financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 491,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has AIG's use of frequency/severity methods evolved between 2022 and 2023, particularly in terms of the lines of business where they are applied and the reasoning behind their usage?",
      "original_answer": "In 2022, AIG primarily used frequency/severity methods for short-tail classes such as U.S. Property, and explicitly avoided using them for aviation exposures due to the high severity and varying mix of claims year to year. By 2023, AIG expanded the application of frequency/severity methods to include U.S. Workers' Compensation, a long-tail line of business, as part of a combination of methods that also included loss development and expected loss ratio methods. This reflects a strategic shift toward using frequency/severity methods in more complex, long-tail environments, especially where risk-sharing features and large deductible business have increased.",
      "llm_answer": "In the 2022 filing AIG said that frequency‑severity techniques were used only for short‑tail, relatively predictable classes – “such as U.S. Property” (and similar program‑property lines) – and were expressly **not** used for high‑severity, variable‑mix lines like aviation because “the claims are driven by severity”【AIG_10k_2022.pdf†271-L30-L34】.  \n\nIn the 2023 filing the company reports that it now applies a **combination of loss‑development, frequency‑severity and expected‑loss‑ratio methods to U.S. Workers’ Compensation**, a long‑tail line whose mix of risk‑sharing features and growing large‑deductible business makes it useful to model both claim frequency and severity【AIG_10k_2023.pdf†200-L1-L5】.  \n\nThus, AIG’s use of frequency‑severity methods has expanded from short‑tail property lines in 2022 to also include workers’ compensation in 2023, shifting the rationale from handling predictable, short‑tail losses to capturing both claim count and severity in a more complex, long‑tail line.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and comprehensiveness in addressing the multi-hop question about AIG's evolution in frequency/severity methods between 2022 and 2023. STRENGTHS: (1) Correctly identifies the 2022 application to short-tail classes (U.S. Property) with proper citation; (2) Accurately notes the explicit exclusion of aviation due to high severity and variable claim mix; (3) Correctly identifies the 2023 expansion to U.S. Workers' Compensation, a long-tail line; (4) Properly synthesizes the combination of methods used in 2023 (loss-development, frequency-severity, and expected-loss-ratio); (5) Accurately captures the reasoning shift from predictable short-tail losses to complex long-tail environments; (6) Correctly identifies the contextual factors (risk-sharing features, large deductible business) driving the 2023 approach; (7) Provides appropriate citations to source documents. QUANTITATIVE ACCURACY: No numerical values are present in either the question or answer, so this dimension is not applicable but receives full marks as no errors exist. QUALITATIVE ACCURACY: The multi-hop reasoning is sound - the answer successfully synthesizes information across two years and two different lines of business, correctly identifying the strategic shift. The entity identification is precise (AIG, U.S. Property, aviation, U.S. Workers' Compensation). MINOR CONSIDERATIONS: The answer is slightly more detailed and structured than the ground truth, but this represents added clarity rather than inaccuracy. The semantic meaning aligns perfectly with the original answer. The answer effectively conveys the evolution from 2022 to 2023 and the reasoning behind the changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 465,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Amgen's financial relationship with BeiGene evolved from 2022 to 2023, particularly in terms of cost recovery, product sales, and profit and loss sharing?",
      "original_answer": "In 2022, Amgen recovered $199 million in R&D costs from BeiGene, recorded product sales of $64 million, and recognized $53 million in profit and loss sharing expenses. In 2023, these figures changed to $109 million in cost recovery, $125 million in product sales, and $40 million in profit and loss sharing expenses. This indicates a decrease in cost recovery and profit-sharing expenses, but a significant increase in product sales to BeiGene. The shift suggests a maturation of the collaboration, with more product sales occurring in 2023, while the level of R&D cost sharing declined.",
      "llm_answer": "In 2022 Amgen recovered $199 million in net R&D‑cost recoveries from BeiGene, logged $64 million of product sales to BeiGene and incurred $53 million of profit‑and‑loss‑share expense; in 2023 those figures changed to $109 million recovered, $125 million of product sales and $40 million of profit‑and‑loss‑share expense, indicating lower cost recovery, higher sales and reduced sharing expense (2023 10‑K, BeiGene section, pages 129‑133).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. All quantitative data points are correct: 2022 figures ($199M cost recovery, $64M product sales, $53M P&L sharing) and 2023 figures ($109M cost recovery, $125M product sales, $40M P&L sharing) match the ground truth exactly. The answer correctly synthesizes the multi-hop relationship evolution across two fiscal years, identifying the key trends: decreased cost recovery ($199M→$109M), increased product sales ($64M→$125M), and reduced P&L sharing expenses ($53M→$40M). The reasoning is sound and logically connects these changes to the maturation of the collaboration. The LLM appropriately cites the source (2023 10-K, BeiGene section, pages 129-133), adding credibility. The wording is slightly more concise than the ground truth but conveys identical semantic meaning. The only minor distinction is that the LLM uses 'net R&D-cost recoveries' terminology while the ground truth uses 'cost recovery,' but these are semantically equivalent. The answer fully addresses all components of the multi-part question regarding cost recovery, product sales, and profit/loss sharing evolution from 2022 to 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 332,
        "total_tokens": 1592
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what specific changes occurred in terms of revisions, production, and purchases during this period?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. During this period, revisions in 2023 added 9 billion cubic feet, but production subtracted 25 billion cubic feet in 2024. Additionally, there were no purchases reported directly affecting this region in 2024, indicating a reduction in active reserve growth strategies compared to earlier years.",
      "llm_answer": "COP’s Asia Pacific/Middle East natural‑gas reserves fell from 326 BCF at year‑end 2022 to 312 BCF in 2023 and to 296 BCF in 2024. The region recorded modest upward revisions of +6 BCF in 2022 and +9 BCF in 2023, but a ‑2 BCF revision in 2024; production reduced the reserve base by 24 BCF, 25 BCF and 51 BCF respectively, and there were no purchases in any of the three years [COP_10k_2024.pdf: pages 144‑145].",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides a detailed year-by-year breakdown with specific numbers, but contains significant quantitative errors that undermine its accuracy. CORRECT ELEMENTS: (1) Starting reserve of 326 BCF in 2022 is correct; (2) Ending reserve of 296 BCF in 2024 is correct; (3) The 2023 revision of +9 BCF is correct; (4) No purchases in any year is correct; (5) The overall trend and structure of the answer is sound. CRITICAL ERRORS: (1) The 2023 intermediate figure of 312 BCF cannot be verified from the ground truth and appears inconsistent with the stated changes; (2) Production figures are problematic: LLM states 24 BCF, 25 BCF, and 51 BCF for 2022, 2023, and 2024 respectively, but the ground truth only specifies 25 BCF production in 2024 and does not provide 2022 or 2023 production figures; (3) The 2022 revision of +6 BCF is not mentioned in the ground truth; (4) The -2 BCF revision in 2024 is not mentioned in the ground truth. MULTI-HOP REASONING: The LLM correctly synthesized the overall decline from 326 to 296 BCF and identified the key drivers (revisions, production, purchases), but the year-by-year breakdown introduces unsupported details. The answer goes beyond what the ground truth explicitly states by providing production figures for 2022 and 2023 that cannot be verified. The ground truth focuses on the 2023 revision (+9 BCF) and 2024 production (-25 BCF) as the specific changes during the period, while the LLM provides a more granular but partially inaccurate breakdown. The answer demonstrates good structure and reasoning quality but fails on quantitative precision for intermediate years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 445,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did FedEx's planned usage of the B767F aircraft evolve from 2022 to 2024, and what does this indicate about its strategic fleet planning?",
      "original_answer": "In 2022, FedEx projected using 14 B767F aircraft in both 2023 and 2024, with a planned reduction to 10 by 2025. By 2024, the projections had changed, showing a decrease to 11 B767F aircraft for 2025 and only 3 by 2026. This indicates a strategic shift toward a more accelerated reduction in the planned use of B767F aircraft, reducing reliance on this model over time.",
      "llm_answer": "- In the 2022 Form 10‑K FedEx’s purchase‑commitment table showed a plan for **14 Boeing 767‑300F (B767F) freighters in 2023 and another 14 in 2024** – 28 B767Fs slated for delivery over the two‑year period【FDX_10k_2022.pdf, p.38】.  \n- By the 2024 Form 10‑K the same table was revised to **only 11 B767Fs scheduled for 2025 and 3 for 2026**, with no further B767F deliveries indicated【FDX_10k_2024.pdf, p.115】.  \n\nThis cut‑back signals that FedEx is de‑emphasizing the 767F in its future fleet, likely shifting toward newer, more fuel‑efficient aircraft (e.g., B777F) and aligning capacity with evolving demand and cost‑efficiency objectives.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a fundamental factual error regarding the 2022 projections. The ground truth states FedEx projected 14 B767F aircraft for BOTH 2023 AND 2024 (14 per year, not 28 total). The LLM incorrectly states '14 Boeing 767-300F (B767F) freighters in 2023 and another 14 in 2024 – 28 B767Fs slated for delivery over the two-year period.' This misrepresents the data by doubling the annual commitment. The correct interpretation is 14 units per year, not 28 total. The 2024 projections (11 for 2025, 3 for 2026) are correctly stated. MULTI-HOP REASONING: The LLM correctly identifies the evolution from 2022 to 2024 and attempts to synthesize the strategic implications. However, the foundational numbers are wrong, which undermines the entire analysis. SEMANTIC ACCURACY: The conclusion about 'accelerated reduction' and 'de-emphasizing the 767F' aligns with the ground truth's assessment of strategic shift, and the mention of shifting toward B777F is reasonable contextual inference. However, the quantitative foundation is flawed. COMPLETENESS: The answer addresses both the evolution question and strategic implications, but the incorrect baseline numbers (2022 projections) significantly compromise the answer's reliability. The comparison between 2022 and 2024 projections is logically structured but built on incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 385,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did AIG's use of Expected Loss Ratio Methods evolve between 2022 and 2023, particularly in terms of the lines of business and the reasoning behind their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to the high severity nature of claims and varying mix across years. By 2023, AIG applied Expected Loss Ratio Methods more broadly, particularly in U.S. Workers' Compensation, a long-tail line of business, where they used a combination of methods including Expected Loss Ratio, to account for extended loss emergence periods and complex risk-sharing features in policies. This reflects a shift from a focus on short-term forecasting in high-severity contexts to a broader application in long-tail, structurally complex lines.",
      "llm_answer": "In the 2022 filing AIG noted that expected‑loss‑ratio (ELR) methods were used almost exclusively for aviation exposures – combined with loss‑development techniques and applied to set reserves for the latest accident year (2022 p.272‑273). By the 2023 filing the ELR approach had been broadened to multiple lines (e.g., U.S. Workers’ Compensation, U.S. Excess Casualty and other short‑tail property/special‑risk businesses) and is now employed whenever loss‑development patterns are inconsistent, losses emerge very slowly, or there is limited loss history, with the ratios based on older years’ ultimate loss ratios adjusted for rate changes, inflation, loss trends and market conditions (2023 p.200‑202; 2023 p.202‑203).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing the evolution of AIG's Expected Loss Ratio Methods between 2022 and 2023. STRENGTHS: (1) Correctly identifies that in 2022, ELR methods were used primarily for aviation exposures combined with loss-development techniques for the latest accident year - this matches the ground truth. (2) Accurately describes the 2023 expansion to multiple lines including U.S. Workers' Compensation, which is explicitly mentioned in the ground truth. (3) Provides specific page references (2022 p.272-273, 2023 p.200-202, p.202-203) that add credibility and demonstrate multi-hop synthesis across filing documents. (4) Correctly characterizes the shift in application scope and reasoning. (5) The additional detail about application criteria (loss-development patterns inconsistent, slow emergence, limited history) and adjustment factors (rate changes, inflation, loss trends, market conditions) provides valuable context that aligns with the ground truth's characterization of the evolution. MINOR WEAKNESSES: (1) The ground truth emphasizes the shift from 'short-term forecasting in high-severity contexts' to 'long-tail, structurally complex lines,' while the LLM answer mentions 'short-tail property/special-risk businesses' alongside Workers' Compensation - this is a slight inconsistency, as Workers' Compensation is explicitly a long-tail line. The inclusion of 'short-tail' businesses alongside the long-tail Workers' Compensation line could be seen as partially contradicting the ground truth's characterization of the shift. (2) The ground truth emphasizes the 'complex risk-sharing features in policies' for 2023, which the LLM answer doesn't explicitly mention, though it does reference 'structurally complex' applications implicitly. QUANTITATIVE ACCURACY: No specific numbers or calculations are involved in this question, so this dimension is less critical. Page references appear reasonable for SEC filings. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2023 filings, comparing methodologies and their applications across years. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The core message matches the ground truth - ELR methods expanded from aviation-focused to broader application in long-tail lines with more sophisticated reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 628,
        "total_tokens": 1989
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has Cisco's positioning around Enterprise Data Center Transformation evolved between 2022 and 2024, particularly in relation to its strategic alliances and competitive landscape?",
      "original_answer": "In 2022, Cisco highlighted that the enterprise data center was undergoing a fundamental transformation due to the convergence of technologies like computing, networking, storage, and software, with strategic alliance partners sometimes acquiring or aligning with competitors, reducing business with Cisco. By 2024, Cisco continued to emphasize this transformation but expanded its focus on strategic alliances aimed at industry advancement and new market creation, while also updating its competitive landscape to include new entrants like Nvidia Corporation, signaling a shift in market dynamics and alliance strategies.",
      "llm_answer": "In the 2022 filing Cisco described the enterprise data‑center as undergoing a “fundamental transformation” and positioned its strategic alliances (e.g., Apple, Google, Microsoft, AWS and others) as a way to co‑develop end‑to‑end solutions, while noting that rivals were also forming alliances and acquisitions that heighten competition (2022 p.13). By the 2024 filing Cisco still stresses the same transformation but adds that many of its alliance partners may also partner with competitors, turning some collaborators into competitive threats and making the data‑center market more contested (2024 p.9‑10). This reflects a shift from viewing alliances mainly as growth enablers to recognizing them as both collaborative and competitive forces in an increasingly crowded landscape.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Cisco's positioning evolution between 2022 and 2024, with mostly accurate core facts and sound multi-hop reasoning. STRENGTHS: (1) Correctly identifies the 'fundamental transformation' theme as consistent across both years; (2) Accurately captures the shift in alliance strategy from growth enablers to recognizing competitive tensions; (3) Properly synthesizes the evolution in competitive landscape; (4) Appropriately references page numbers (2022 p.13, 2024 p.9-10) showing document grounding; (5) Correctly identifies specific alliance partners (Apple, Google, Microsoft, AWS); (6) Accurately conveys the semantic meaning that alliance partners may also work with competitors. WEAKNESSES: (1) The ground truth specifically mentions 'Nvidia Corporation' as a new entrant in the 2024 competitive landscape, but the LLM answer does not explicitly name this new competitor, instead using the more general phrase 'increasingly crowded landscape'; (2) The LLM answer provides specific company examples (Apple, Google, Microsoft, AWS) for 2022 alliances that are not explicitly mentioned in the ground truth, which could be accurate but represents additional detail not verified against the knowledge graph; (3) Minor semantic difference: ground truth emphasizes 'new market creation' as part of 2024 strategy, while LLM focuses more on the competitive/contested nature without explicitly mentioning market creation. QUANTITATIVE ACCURACY: No calculations or specific financial metrics are involved in this question, so this dimension is less critical. The years (2022, 2024) are correctly referenced. MULTI-HOP REASONING: The answer successfully synthesizes information across two different filing years and correctly identifies the evolution in strategic thinking. The logic connecting alliance dynamics to competitive landscape changes is sound. CONTEXTUAL RELEVANCE: The answer directly addresses all parts of the question regarding positioning evolution, strategic alliances, and competitive landscape changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 554,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the effective interest rate and notional amount associated with the 3.125% 2025 Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 3.125% 2025 Notes were part of a $5.2 billion principal amount on which new interest rate swaps were entered into after the termination of previous swaps, indicating a dynamic hedging strategy due to low interest rates. By 2023, the notional amount of the 3.125% 2025 Notes under interest rate swaps had decreased to $1.0 billion, with an effective interest rate of SOFR + 2.1%. This reflects a reduction in the hedged notional exposure and a shift in the interest rate environment.",
      "llm_answer": "The swap notional tied to the 3.125 % 2025 Notes stayed at $1 billion in both years, but the underlying benchmark changed – the effective rate was LIBOR + 1.8 % in 2022, and by 2023 it had been reset to SOFR + 2.1 %【AMGN_10k_2022.pdf p. 133】【AMGN_10k_2023.pdf p. 144】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that contradict the ground truth: (1) NOTIONAL AMOUNT ERROR: The LLM claims the swap notional 'stayed at $1 billion in both years,' but the ground truth explicitly states it was $5.2 billion in 2022 and decreased to $1.0 billion by 2023. This is a fundamental misrepresentation of the evolution requested in the question. (2) EFFECTIVE RATE ERROR: The LLM states the 2022 rate was 'LIBOR + 1.8%' but the ground truth does not mention LIBOR + 1.8% for 2022. The ground truth indicates new swaps were entered into in 2022 after termination of previous swaps, but does not specify LIBOR + 1.8% as the 2022 effective rate. The 2023 rate of SOFR + 2.1% is correct. (3) INCOMPLETE SYNTHESIS: The LLM failed to capture the key evolution - the significant reduction in notional amount from $5.2B to $1.0B between the two years, which is central to answering 'how did...evolve.' (4) MISSING CONTEXT: The ground truth mentions a 'dynamic hedging strategy due to low interest rates' and the shift in interest rate environment, which provides important context for understanding the changes. The LLM answer oversimplifies the situation by suggesting stability ('stayed at $1 billion') when the actual story is one of significant reduction in hedged exposure. The answer demonstrates a fundamental misunderstanding of the multi-hop synthesis required to properly compare 2022 and 2023 positions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1185,
        "completion_tokens": 398,
        "total_tokens": 1583
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Cisco's strategic positioning of AppDynamics within its product portfolio evolved from 2022 to 2024, particularly in terms of its emphasis within observability offerings?",
      "original_answer": "In 2022, Cisco explicitly introduced AppDynamics as a key component of its full-stack observability strategy, positioning it alongside Intersight and ThousandEyes to provide application performance monitoring capabilities. However, by 2024, Cisco restructured its product revenue reporting to include a new category called 'Observability,' which subsumed offerings like AppDynamics. This shift indicates a more formalized and integrated strategic emphasis on observability as a standalone pillar within Cisco's broader portfolio.",
      "llm_answer": "In the 2022 10‑K Cisco described AppDynamics as a distinct “application‑performance‑monitoring” component of its full‑stack observability strategy, listed together with Intersight and ThousandEyes 【CSCO_10k_2022.pdf p.3‑4】. By the 2024 filing the company has folded AppDynamics into a newly created “Observability” product category (the Observability Suite) and is emphasizing the whole observability portfolio—reporting a 27% year‑over‑year revenue increase for that category—showing a shift from a single‑product focus to a broader, integrated observability offering.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies the 2022 positioning of AppDynamics as a distinct APM component within full-stack observability strategy alongside Intersight and ThousandEyes - this matches the ground truth exactly. (2) Accurately captures the 2024 restructuring where AppDynamics was subsumed into a new 'Observability' product category, showing the shift from single-product to integrated portfolio emphasis. (3) The 27% year-over-year revenue increase for the Observability category is a specific quantitative detail that adds credibility and demonstrates multi-hop synthesis across filing documents. (4) The semantic framing of the evolution (from 'distinct component' to 'integrated offering') aligns well with the ground truth's characterization of 'more formalized and integrated strategic emphasis.' (5) Document citations (CSCO_10k_2022.pdf p.3-4) provide transparency. MINOR CONSIDERATIONS: (1) The LLM introduces the specific term 'Observability Suite' which is not explicitly mentioned in the ground truth, though this appears to be accurate terminology from the actual filings. (2) The ground truth emphasizes this as a 'restructured product revenue reporting' change, while the LLM frames it as a strategic portfolio shift - both interpretations are valid and complementary. (3) The 27% YoY revenue growth figure is not mentioned in the ground truth but appears to be factually accurate from the 2024 filing and strengthens the answer. QUANTITATIVE VERIFICATION: The 27% figure is specific and verifiable; no calculation errors detected. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2024 filings, comparing positioning strategies and showing the evolution. The logic is sound and the conclusion about the shift from single-product to integrated emphasis is well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 519,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the effective interest rate and notional amount associated with the 4.663% 2051 Notes evolve from 2022 to 2023?",
      "original_answer": "In 2022, the 4.663% 2051 Notes were part of a $5.2 billion principal amount of notes that were hedged using interest rate swaps, with the swaps terminated and replaced at then-current interest rates. In 2023, the notional amount of the 4.663% 2051 Notes was $1.5 billion, and the effective interest rate was SOFR + 4.3%. This indicates a continuation of the hedging strategy but with updated interest rate terms and a more specific disclosure of the notional amount and rate for the 2051 Notes.",
      "llm_answer": "In 2022 the 4.663 % 2051 Notes were reported to have a fixed effective interest rate of **5.6 %** and were hedged with **$1.5 billion** of swap notional [AMGN 10‑K 2022 – “effective interest rates … 4.663 % 2051 Notes … 5.6 %” and the swap‑notional table showing $1,500 m]​. By the 2023 filing the effective rate had changed to a **floating SOFR + 4.3 %** while the notional amount stayed at **$1.5 billion** [AMGN 10‑K 2023 – “4.663 % 2051 Notes … $1,500 … SOFR + 4.3 %”].",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM claims the 2022 effective interest rate was 5.6%, but the ground truth does not support this specific number for 2022. The ground truth states the notes were part of a $5.2 billion principal amount that was hedged, not that the 2022 effective rate was 5.6%. The LLM appears to have fabricated or misattributed this 5.6% figure. (2) NOTIONAL AMOUNT DISCREPANCY - The LLM states the 2022 swap notional was $1.5 billion, but the ground truth indicates in 2022 the notes were part of a $5.2 billion principal amount of hedged notes. The $1.5 billion figure is only confirmed for 2023. This is a critical error in the 2022 data. (3) MULTI-HOP REASONING - The LLM failed to properly synthesize the evolution from 2022 to 2023. The ground truth shows: 2022 had $5.2B principal with swaps terminated/replaced at then-current rates (specific 2022 effective rate not clearly stated in ground truth), while 2023 had $1.5B notional with SOFR + 4.3%. The LLM incorrectly applied the $1.5B figure to both years. (4) CORRECT ELEMENTS - The LLM correctly identified: (a) the 2023 effective rate as SOFR + 4.3%, (b) the 2023 notional amount as $1.5 billion, (c) that this represents a change from fixed to floating rate, (d) the continuation of hedging strategy. (5) MISSING CONTEXT - The LLM did not adequately explain the significant reduction from $5.2B (2022) to $1.5B (2023) in the notional amounts, which is a key part of how the notes 'evolved.' The answer presents a false continuity when there was actually a substantial change in the hedged amount.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 439,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of the lines of business and segmentation criteria applied?",
      "original_answer": "In 2022, AIG referenced the use of expected loss ratio methods in a general sensitivity analysis related to loss reserve assumptions, without specifying detailed segmentation or particular lines of business. By 2023, AIG explicitly applied expected loss ratio methods to U.S. Workers' Compensation, a long-tail line of business, and introduced more granular segmentation criteria such as risk-sharing features, state and industry subsets, deductible size, and claim handling entities. This indicates a more structured and detailed application of the method in 2023 compared to 2022.",
      "llm_answer": "AIG still relies on expected‑loss‑ratio techniques for its long‑tail lines, but the way it applies them became more granular in 2023. In the 2022 filing the method was described broadly – it was used for U.S. Workers’ Compensation, U.S. Excess and Other Casualty, U.S. Financial Lines and run‑off lines, generally in combination with loss‑development approaches and applied to “expected‑loss‑ratio years.” By 2023 the company broke those lines out further – workers’‑comp reserves are now split into guaranteed‑cost versus excess‑of‑deductible business and then segmented by state, industry, deductible size and whether the claim is handled by AIG or a third‑party administrator, while excess‑casualty emphasizes higher attachment points and continues to give excess‑of‑deductible business significant weight for the most recent five accident years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and contradictions with the ground truth. Key issues: (1) The LLM claims that in 2022, expected loss ratio methods were applied to 'U.S. Workers' Compensation, U.S. Excess and Other Casualty, U.S. Financial Lines and run-off lines,' but the ground truth explicitly states that in 2022, AIG 'referenced the use of expected loss ratio methods in a general sensitivity analysis related to loss reserve assumptions, without specifying detailed segmentation or particular lines of business.' This is a fundamental contradiction - the LLM incorrectly attributes specific line-of-business applications to 2022 that the ground truth says were NOT specified in that year. (2) The ground truth indicates that U.S. Workers' Compensation was explicitly applied in 2023, not 2022. The LLM's claim that workers' comp was already being used in 2022 contradicts this. (3) The LLM introduces specific segmentation details for 2022 (guaranteed-cost vs. excess-of-deductible, state, industry, deductible size) that the ground truth attributes only to 2023. (4) The LLM's description of 2023 segmentation criteria (state, industry, deductible size, claim handling entities) aligns with the ground truth, but this is overshadowed by the incorrect 2022 characterization. (5) The core evolution narrative is inverted - the LLM suggests the methods were already applied to specific lines in 2022 and just became 'more granular' in 2023, whereas the ground truth indicates the methods were applied generally in 2022 and then explicitly applied to specific lines with detailed segmentation in 2023. The LLM failed to correctly synthesize the multi-hop comparison between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 466,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did PepsiCo's engagement with the 2.850% Senior Notes due 2026 evolve between 2023 and 2024, particularly in terms of its broader debt issuance strategy as reflected in the additional notes introduced in 2024?",
      "original_answer": "In 2023, PepsiCo referenced the 2.850% Senior Notes due 2026 as part of a broader set of debt instruments, including other senior notes with varying interest rates and maturity dates. By 2024, the company introduced a significantly expanded range of senior notes, including higher-yielding instruments such as the 7.00% Senior Notes due 2029 and the 5.50% Senior Notes due 2035, indicating a more diversified and long-term debt issuance strategy. This evolution suggests that PepsiCo not only maintained its commitment to the 2.850% Senior Notes due 2026 but also broadened its capital structure by incorporating a wider spectrum of debt instruments with different risk-return profiles.",
      "llm_answer": "In the 2023 Form 10‑K PepsiCo’s Board resolution listed the 2.850 % Senior Notes due 2026 as one of a broad set of senior‑note authorizations (PEP 10‑K 2023 pp. 130‑131). The 2024 Form 10‑K again authorizes the same 2.850 % Senior Notes due 2026, but the resolution now also adds a number of new series—e.g., 2.375 % and 2.625 % Senior Notes due 2026, 4.500 % Senior Notes due 2029, 4.800 % Senior Notes due 2034, 5.250 % Senior Notes due 2054, among others—showing that PepsiCo expanded its debt‑issuance program in 2024 to diversify maturities and coupon rates while still keeping the 2.850 % notes active.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates partial correctness with significant discrepancies in the specific debt instruments cited. STRENGTHS: (1) Correctly identifies that PepsiCo maintained the 2.850% Senior Notes due 2026 across both 2023 and 2024; (2) Accurately captures the core narrative that PepsiCo expanded its debt issuance program in 2024 with new series of notes; (3) Properly synthesizes the multi-hop comparison between years; (4) Correctly notes the diversification strategy across maturities and coupon rates; (5) Provides specific page references (pp. 130-131) for 2023 filing. CRITICAL ERRORS: (1) The LLM cites specific debt instruments (2.375%, 2.625%, 4.500%, 4.800%, 5.250%) that do NOT match the ground truth examples (7.00% due 2029, 5.50% due 2035). This is a significant quantitative accuracy failure; (2) The ground truth explicitly mentions 7.00% Senior Notes due 2029 and 5.50% Senior Notes due 2035 as examples of 'higher-yielding instruments,' but the LLM provides different coupon rates and maturity dates; (3) The LLM's cited rates (4.500%, 4.800%) are actually LOWER than the 2.850% baseline in some cases, contradicting the ground truth's characterization of 'higher-yielding instruments.' REASONING ASSESSMENT: The multi-hop synthesis is sound in structure—comparing 2023 to 2024 and identifying expansion—but the specific financial data points are incorrect. The LLM appears to have fabricated or misremembered specific debt instrument details rather than accurately extracting them from the filings. This represents a fundamental failure in quantitative accuracy despite correct overall narrative structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 447,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Cisco's exposure to channel partner financing guarantees evolved between fiscal years 2022 and 2024, and what does this indicate about the company's financial risk management strategy?",
      "original_answer": "In fiscal year 2022, Cisco disclosed that the volume of channel partner financing was $27.9 billion, with a balance of financing subject to guarantees amounting to $1.4 billion as of July 30, 2022. By fiscal year 2024, while the company continued to provide financing guarantees, the specific volume of channel partner financing and the balance subject to guarantees were no longer explicitly quantified in the disclosures. This shift indicates a potential strategic move toward reducing transparency around these financial commitments, which may reflect a broader risk management approach to limit visibility into contingent liabilities. However, the absence of updated figures prevents definitive conclusions about the actual change in exposure.",
      "llm_answer": "Cisco’s net exposure to channel‑partner financing guarantees fell from about $179 million at FY 2022 year‑end (maximum potential payments of $188 million less $9 million of deferred revenue) to roughly $114 million at FY 2024 year‑end (maximum potential payments of $127 million less $13 million of deferred revenue)【2022‑10K‑p92‑96】【2024‑10K‑p50‑54】. The decline in guaranteed amounts indicates that Cisco is tightening its contingent‑liability exposure on partner financing, reflecting a more conservative financial‑risk‑management approach.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains fundamentally incorrect numbers and misrepresents the ground truth data. Critical issues: (1) QUANTITATIVE ERRORS: The LLM cites specific net exposure figures ($179M in FY2022, $114M in FY2024) with detailed calculations involving maximum potential payments and deferred revenue offsets. However, the ground truth explicitly states that in FY2022, the balance of financing subject to guarantees was $1.4 billion (not $179M), and that by FY2024, these figures were 'no longer explicitly quantified in the disclosures.' The LLM's precise calculations ($188M - $9M = $179M, $127M - $13M = $114M) appear to be fabricated or sourced from incorrect sections of the filings. (2) CONTRADICTION WITH GROUND TRUTH: The ground truth indicates a shift toward REDUCED TRANSPARENCY (figures no longer disclosed), while the LLM claims to have found specific updated figures for FY2024 that supposedly show a decline. This is directly contradictory. (3) MISSING KEY CONTEXT: The LLM fails to address the ground truth's important finding that the FY2022 volume of channel partner financing was $27.9 billion with $1.4 billion subject to guarantees - vastly larger than the LLM's cited figures. (4) REASONING FLAW: The LLM concludes Cisco is 'tightening contingent-liability exposure' based on a supposed decline in guaranteed amounts, but this reasoning is built on incorrect numbers. The ground truth suggests the actual strategic shift is toward opacity rather than quantifiable risk reduction. (5) CITATION ISSUES: While the LLM provides document references, the specific page ranges cited do not appear to support the numbers presented. The answer demonstrates a fundamental failure to accurately synthesize multi-hop information from the actual SEC filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 481,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has the status and interest rate structure of the 2.45% 2030 Notes evolved between 2022 and 2023?",
      "original_answer": "In 2022, Amgen disclosed that it had entered into interest rate swap contracts with an aggregate notional amount of $1.0 billion with respect to the 2.45% 2030 Notes, effectively converting the fixed-rate interest to a floating LIBOR-based coupon. By 2023, the 2.45% 2030 Notes remained outstanding with a notional amount of $1.0 billion, but the interest rate structure had transitioned from LIBOR to SOFR, now stated as SOFR + 1.3%. This reflects a continuation of the note's existence but with a modified floating-rate benchmark.",
      "llm_answer": "The 2.45 % 2030 senior notes remained on Amgen’s balance sheet at their full $1.25 billion principal amount in both 2022 and 2023, with no redemption or repurchase disclosed 【source 2022‑table showing “2.45% notes due 2030 … 1,250 | 1,250”】.  While the coupon stayed at 2.45 %, the interest‑rate‑swap hedge on $1 billion of those notes shifted from a LIBOR‑plus‑1.0 % effective rate in 2022 【source 2022‑swap “2.45% 2030 Notes | 1,000 | LIBOR + 1.0%”】 to a SOFR‑plus‑1.3 % effective rate in 2023 【source 2023‑swap “2.45% 2030 Notes | 1,000 | SOFR + 1.3%”】, reflecting the transition from LIBOR to SOFR.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and incorrect information. CORRECT ELEMENTS: (1) The company is Amgen, correctly identified; (2) The notes are the 2.45% 2030 Notes; (3) The notional amount of the interest rate swap is $1.0 billion in both years; (4) The transition from LIBOR to SOFR is correctly identified; (5) The 2023 rate of SOFR + 1.3% is correct; (6) The multi-hop reasoning connecting the swap structure changes across years is sound. INCORRECT/PROBLEMATIC ELEMENTS: (1) CRITICAL ERROR - The LLM states the principal amount is $1.25 billion in both 2022 and 2023, but the ground truth indicates the notional amount of the swap is $1.0 billion. The LLM conflates the total principal of the notes ($1.25B) with the swap notional ($1.0B), which are different concepts; (2) The 2022 swap rate is stated as LIBOR + 1.0% in the LLM answer, but the ground truth says LIBOR-based coupon without specifying the exact spread. The LLM provides a specific spread (1.0%) that may not be verified; (3) The LLM emphasizes that the coupon remained at 2.45% while the swap changed the effective rate, which is a nuanced but correct understanding of how interest rate swaps work. MULTI-HOP REASONING: The LLM correctly synthesizes information across 2022 and 2023 filings to show the evolution of the interest rate structure. The reasoning that the swap converts the fixed rate to floating is sound. However, the conflation of principal amount ($1.25B) with swap notional ($1.0B) represents a significant conceptual error that affects the accuracy of the answer. The answer would benefit from clearer distinction between the total note principal and the hedged portion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 455,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has FedEx's relationship with Pass-Through Certificates evolved between 2022 and 2023, particularly regarding its financial guarantees and obligations?",
      "original_answer": "In 2022, FedEx Express had issued $970 million of Pass-Through Certificates, Series 2020-1AA, which were fully and unconditionally guaranteed by FedEx. These certificates were secured by 19 Boeing aircraft with a net book value of $1.8 billion. However, in 2023, FedEx clarified that pass-through certificates associated with leveraged operating leases were not direct obligations of, nor guaranteed by, FedEx or FedEx Express. This indicates a shift from direct financial guarantees in 2022 to a position of no direct financial obligation in 2023.",
      "llm_answer": "Between 2022 and 2023 FedEx’s relationship with its $970 million Series 2020‑1AA Pass‑Through Certificates did not change materially. In both filings the payment obligations of FedEx Express on the certificates were “fully and unconditionally guaranteed by FedEx,” yet the certificates themselves were still described as “not direct obligations of, or guaranteed by, FedEx or FedEx Express,” with payments funded through leveraged operating leases. The only noticeable update was a slight reduction in the collateral’s net book value – the 19 Boeing aircraft backing the certificates fell from about $1.8 billion at May 31 2022 to $1.7 billion at May 31 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains fundamental factual errors that contradict the ground truth. (1) CORE CONTRADICTION: The LLM claims the relationship 'did not change materially' between 2022 and 2023, directly contradicting the ground truth which explicitly states there was 'a shift from direct financial guarantees in 2022 to a position of no direct financial obligation in 2023.' This is the central claim of the question and the LLM got it backwards. (2) CONTRADICTORY STATEMENTS: The LLM states that in both years the certificates were 'fully and unconditionally guaranteed by FedEx,' yet simultaneously claims they were 'not direct obligations of, or guaranteed by, FedEx or FedEx Express.' These two statements are logically incompatible - the LLM appears to have confused the distinction between the payment obligations of FedEx Express (which were guaranteed) versus the certificates themselves (which were not direct obligations). The ground truth clarifies this distinction: in 2022 FedEx provided direct guarantees, but in 2023 FedEx clarified that pass-through certificates were NOT guaranteed by FedEx. (3) TEMPORAL ERROR: The LLM references a May 31, 2024 date for collateral value ($1.7 billion), but the question and ground truth only address 2022 and 2023. This introduces an unsupported data point outside the scope. (4) QUANTITATIVE ISSUES: While the $970 million and $1.8 billion figures are correct for 2022, the introduction of a $1.7 billion figure for 2024 is not part of the ground truth comparison. (5) MULTI-HOP REASONING FAILURE: The LLM failed to properly synthesize the key evolution: the shift in FedEx's position regarding its financial guarantees and obligations between the two years. The answer misses the critical distinction that 2023 represented a clarification that FedEx had no direct obligation, whereas 2022 showed direct guarantees. This is a fundamental misunderstanding of the question's core requirement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 524,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Mastercard's use of risk mitigation arrangements to manage gross settlement exposure evolve from 2023 to 2024, and what does this indicate about the company's risk management strategy?",
      "original_answer": "In 2023, Mastercard had $75,023 million in gross settlement exposure, with $12,167 million covered by risk mitigation arrangements. By 2024, gross settlement exposure increased to $78,385 million, and the company applied $13,466 million in risk mitigation arrangements, reflecting an increase in both total exposure and the amount mitigated. This indicates that Mastercard's risk management strategy became more robust over time, as it increased its use of mitigation tools in response to growing settlement exposure.",
      "llm_answer": "In 2023 Mastercard applied $12.2 billion of risk‑mitigation arrangements (cash collateral, letters of credit, guarantees, etc.) against a gross settlement exposure of $75.0 billion; by year‑end 2024 those arrangements had risen to $13.5 billion while gross exposure grew to $78.4 billion【MA_10k_2023.pdf†page 110‑114】【MA_10k_2024.pdf†page 103‑107】. The increase in mitigation coverage as exposure rose shows the company is actively scaling its collateral and credit‑enhancement safeguards, reflecting a disciplined, proactive risk‑management approach that continuously adjusts protections to match evolving settlement risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. QUANTITATIVE VERIFICATION: All financial figures are correct - 2023 gross settlement exposure of $75.0 billion (matches $75,023 million), 2023 risk mitigation of $12.2 billion (matches $12,167 million), 2024 gross settlement exposure of $78.4 billion (matches $78,385 million), and 2024 risk mitigation of $13.5 billion (matches $13,466 million). Number formatting variations ($75.0B vs $75,023M) are appropriately handled. MULTI-HOP SYNTHESIS: The answer correctly synthesizes information across two fiscal years and two 10-K filings, properly comparing the evolution of both metrics. ENTITY ACCURACY: Mastercard correctly identified, fiscal years 2023-2024 properly specified, and risk mitigation arrangements accurately characterized (cash collateral, letters of credit, guarantees). REASONING QUALITY: The answer goes beyond the ground truth by providing additional context about the types of mitigation arrangements and offering a more nuanced interpretation of the strategy (\"disciplined, proactive risk-management approach\"). The conclusion that the company is \"actively scaling its collateral and credit-enhancement safeguards\" logically follows from the data showing mitigation arrangements increasing alongside exposure. MINOR CONSIDERATIONS: The LLM answer includes source citations (page numbers) which adds credibility but weren't in the ground truth. The interpretation of what this indicates about risk management strategy is slightly more detailed and sophisticated than the ground truth's simpler statement that the strategy \"became more robust,\" but this represents value-added analysis rather than error. All core facts, calculations, and multi-hop reasoning are sound and accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 482,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Nike's liabilities related to foreign exchange forwards and options designated as hedging instruments change between 2022 and 2024, and what does this indicate about the company's exposure or strategy?",
      "original_answer": "In 2022, Nike reported $37 million in liabilities for foreign exchange forwards and options designated as hedging instruments under accrued liabilities, and $11 million under deferred income taxes and other liabilities, totaling $48 million. By 2024, the liability under accrued liabilities for the same category increased to $110 million, while the amount under deferred income taxes and other liabilities decreased to $5 million, resulting in a total of $115 million. This represents a significant increase in total liabilities for designated hedging instruments related to foreign exchange forwards and options, indicating a potential increase in Nike's foreign exchange risk exposure or a strategic shift in hedging activity.",
      "llm_answer": "Nike’s liabilities for foreign‑exchange forwards and options that were formally designated as hedging instruments grew from $48 million at May 31 2022 ( $37 million accrued + $11 million deferred ) to $115 million at May 31 2024 ( $110 million accrued + $5 million deferred ), an increase of about $67 million. The rise signals that Nike has expanded its currency‑hedging program, likely to cover larger foreign‑currency exposures from its worldwide business and to adopt a more proactive risk‑management strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All numbers are correct - 2022 total of $48M ($37M accrued + $11M deferred), 2024 total of $115M ($110M accrued + $5M deferred), and the calculated increase of $67M. The dates (May 31, 2022 and May 31, 2024) are accurate. The arithmetic is correct throughout. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) how the liabilities changed between 2022 and 2024, with specific breakdowns by category, and (2) what this indicates about Nike's exposure or strategy. ENTITY ACCURACY: Nike is correctly identified, the specific financial metrics (foreign exchange forwards and options designated as hedging instruments) are properly categorized, and the balance sheet line items (accrued liabilities vs. deferred income taxes and other liabilities) are accurate. MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years and two balance sheet categories, properly comparing the shifts in liability composition (accrued liabilities increased while deferred liabilities decreased). INTERPRETATION: The LLM's interpretation that the increase signals expanded currency-hedging programs and proactive risk management is reasonable and consistent with the ground truth's assessment of increased foreign exchange risk exposure or strategic shift. The wording differs slightly from the ground truth but conveys equivalent meaning. Minor note: The ground truth uses slightly more cautious language ('potential increase' and 'or a strategic shift'), while the LLM is more definitive ('expanded its currency-hedging program'), but both interpretations are reasonable given the data. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 476,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the representation of Bounty within P&G's Baby, Feminine & Family Care segment evolve between the 2022 and 2023 10-K filings, and what does this suggest about its brand visibility?",
      "original_answer": "In the 2022 10-K filing, Bounty was mentioned as part of P&G's Family Care business within the Baby, Feminine & Family Care segment, but it was not explicitly listed among the key brands. In contrast, the 2023 10-K filing explicitly included Bounty among the major brands under the Family Care category. This change suggests an increase in Bounty's brand visibility within P&G's portfolio, though the filings do not provide specific market share or sales figures to quantify this shift. The explicit mention in 2023 indicates a possible strategic move to highlight Bounty's role, though no direct strategic intent is stated in the evidence provided.",
      "llm_answer": "In the 2022 10‑K, Bounty was listed as a distinct major brand in the Baby, Feminine & Family Care segment and the narrative called the family‑care business “predominantly a North‑American business comprised primarily of the Bounty paper‑towel … brand, with North‑America market share over 40 %.” The 2023 filing repeats the same description and market‑share figure, but the tabular “major brands” list now shows Bounty grouped with Tampax (e.g., “Tampax Bounty”) rather than as a separate entry. This continuity—Bounty’s unchanged market‑share claim and continued prominence in the segment narrative—suggests its brand visibility and strategic importance have remained strong and stable.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that directly contradict the ground truth. Key issues: (1) CONTRADICTS GROUND TRUTH ON 2022 REPRESENTATION: The LLM claims Bounty was 'listed as a distinct major brand' in 2022, but the ground truth explicitly states it was 'not explicitly listed among the key brands' in 2022. This is a fundamental factual error. (2) CONTRADICTS GROUND TRUTH ON 2023 REPRESENTATION: The LLM claims Bounty is 'grouped with Tampax (e.g., \"Tampax Bounty\")' in 2023, but the ground truth states Bounty was 'explicitly included...among the major brands' as a separate entry in 2023. The grouping claim is unsupported and contradicts the ground truth's assertion of explicit separate listing. (3) INCORRECT CONCLUSION ON VISIBILITY CHANGE: The LLM concludes visibility 'remained strong and stable,' but the ground truth indicates an INCREASE in visibility from 2022 (not listed) to 2023 (explicitly listed). This is a fundamental misinterpretation of the evolution described. (4) UNVERIFIED MARKET SHARE CLAIM: The LLM cites a '40%' North American market share figure and specific narrative language that cannot be verified against the ground truth provided. While the ground truth acknowledges the filings don't provide specific market share figures to quantify the shift, the LLM's citation of specific percentages and exact quotes suggests either fabrication or reliance on information not in the ground truth. (5) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the year-over-year comparison. The core finding should be that Bounty moved from implicit/unlisted status (2022) to explicit listing (2023), suggesting increased visibility. Instead, the LLM inverted this narrative. The answer demonstrates poor factual accuracy on the central claim and misses the key insight about the evolution of Bounty's representation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 507,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has Oracle's approach to its hardware business, particularly Oracle Engineered Systems, evolved between fiscal 2022 and fiscal 2023 in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle's hardware business, which includes Oracle Engineered Systems, was described in terms of its contractual activities and revenue recognition, with an emphasis on the timing of revenue recognition for cloud and license contracts. By fiscal 2023, Oracle introduced a more detailed explanation of how hardware and related software are treated as a combined performance obligation, with revenue recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve and develop new hardware products and services, which was not explicitly mentioned in 2022. This indicates a shift toward a more strategic focus on innovation and integration of hardware and software components within the hardware business.",
      "llm_answer": "Oracle kept the same accounting treatment for its hardware business—including Oracle Engineered Systems—recognizing revenue at the point in time the hardware and its related software are delivered (the policy described in the 2022 filing on pages 103‑107 and reiterated in the 2023 filing on pages 41‑45). However, the strategic focus shifted: hardware fell from roughly a 7% share of total revenue in fiscal 2022 to about 6% in fiscal 2023, and Oracle now emphasizes continued R&D, indirect‑channel sales and ratable hardware‑support contracts, positioning hardware as a complementary, lower‑margin component of its broader cloud‑centric strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its credibility. MAJOR ISSUES: (1) QUANTITATIVE ERRORS - The LLM provides specific revenue percentages (7% in fiscal 2022 declining to 6% in fiscal 2023) that are not supported by the ground truth and appear to be fabricated. The ground truth makes no mention of these specific percentages. (2) PAGE REFERENCES - The LLM cites specific page numbers (pages 103-107 for 2022 and pages 41-45 for 2023) without verification. These citations cannot be confirmed against the ground truth and may be inaccurate. (3) INCOMPLETE ALIGNMENT WITH GROUND TRUTH - While the LLM correctly identifies that revenue recognition remained consistent (point-of-delivery for hardware and related software), it goes beyond the ground truth by adding unsupported claims about revenue share percentages and strategic positioning. (4) PARTIAL CORRECTNESS - The LLM does correctly capture: (a) the consistent revenue recognition policy across both years, (b) the emphasis on R&D investments in 2023, (c) the shift toward cloud-centric strategy. However, these correct elements are mixed with unverified quantitative claims. (5) MULTI-HOP REASONING - The answer attempts to synthesize information about both accounting treatment and strategic emphasis, which is appropriate to the question, but the synthesis includes fabricated metrics. The ground truth emphasizes a shift in disclosure detail and strategic focus on innovation, while the LLM adds specific revenue percentages and channel strategy details not mentioned in the ground truth. VERDICT: The answer demonstrates partial understanding of the evolution but introduces specific numbers and claims that cannot be verified and likely contradict the actual filings. The fabrication of revenue percentages is a critical error that significantly reduces credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 503,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the sales performance of the product ERLEADA evolve between 2022 and 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA generated $1,881 million in sales, and by 2023, its sales increased to $2,387 million, representing a 26.9% growth. This indicates a strong upward trajectory for ERLEADA in the market, suggesting increased adoption or improved commercial performance over the period.",
      "llm_answer": "In 2022 ERLEADA generated about **$1.9 billion** in sales, and in 2023 that rose to roughly **$2.4 billion** – a **≈27 % increase** (operations growth 27.5 %). The company attributes the jump to “continued share gains and market growth” in metastatic castration‑resistant prostate cancer, indicating a strong, upward market trajectory for the product.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. Quantitative verification: 2022 sales of $1.9B (vs. ground truth $1,881M) and 2023 sales of $2.4B (vs. ground truth $2,387M) are correctly rounded representations with acceptable format variation. The growth calculation of ≈27% is accurate (ground truth: 26.9%, LLM: 27% with note of 27.5% operations growth). The answer correctly identifies the product (ERLEADA), years (2022-2023), and financial metrics. Multi-hop synthesis is sound: the LLM synthesized sales figures across two years and calculated the growth rate, then contextualized this within market dynamics (metastatic castration-resistant prostate cancer market). The qualitative assessment of 'strong upward trajectory' aligns with the ground truth interpretation. Minor strengths: the LLM added contextual detail about 'share gains and market growth' which provides additional insight beyond the ground truth while remaining consistent. The only minor deviation is the rounding of exact figures ($1,881M to $1.9B and $2,387M to $2.4B), which is acceptable and standard practice in financial reporting. The answer fully addresses both parts of the question: (1) how sales evolved (with specific numbers and growth rate) and (2) what this indicates about market trajectory (strong upward trajectory with supporting rationale).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1156,
        "completion_tokens": 376,
        "total_tokens": 1533
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the nature of CMCSA's relationship with local broadcast television stations evolved from 2023 to 2024, particularly in terms of competitive positioning and dependency for content distribution?",
      "original_answer": "In 2023, CMCSA's Media segment directly competed with local broadcast television stations for viewers' attention and advertising revenue. By 2024, the relationship shifted to a more interdependent one, where CMCSA's linear television networks became reliant on local broadcast television stations for retransmission consent, which is necessary for distributing broadcast network programming to video service customers. This marks a shift from competition to dependency, reflecting a strategic and operational evolution in how CMCSA interacts with local broadcast stations.",
      "llm_answer": "In the 2023 filing, Comcast described local broadcast television stations as both competitors for content and talent and as indispensable affiliates whose ownership or affiliation was needed to get its network programming to a nationwide audience. By the 2024 filing, the tone had shifted to one of cost‑driven dependence – the company now highlights payments for retransmission‑consent and growing demands from those stations, noting that its ability to distribute network programming hinges on securing and maintaining those affiliation agreements on acceptable terms.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key elements of the relationship evolution but introduces problematic characterizations not supported by the ground truth. STRENGTHS: (1) Correctly identifies the shift from 2023 to 2024; (2) Accurately notes the importance of retransmission consent; (3) Properly identifies CMCSA/Comcast as the subject company; (4) Recognizes the dependency aspect. WEAKNESSES: (1) The 2023 characterization is problematic - the LLM claims CMCSA described stations as 'indispensable affiliates whose ownership or affiliation was needed to get its network programming to a nationwide audience,' but the ground truth indicates 2023 was characterized by DIRECT COMPETITION for viewers and advertising revenue, not dependency. This is a significant semantic error that misrepresents the 2023 baseline; (2) The LLM introduces 'cost-driven dependence' and 'growing demands' language that, while plausible, goes beyond what the ground truth explicitly states about the nature of the shift; (3) The ground truth emphasizes a shift FROM competition TO dependency, but the LLM's 2023 description already implies dependency ('indispensable affiliates'), which contradicts the ground truth's clear delineation of 2023 as competitive positioning; (4) The LLM adds interpretive language about 'tone' and 'cost-driven' that, while potentially accurate, represents inference beyond the ground truth's more straightforward statement of the relationship evolution. MULTI-HOP REASONING: The answer attempts to synthesize information across two years but fails to properly establish the baseline competitive relationship in 2023, which is essential to understanding the evolution. The core insight about the shift to dependency is present but undermined by the mischaracterization of the starting point. QUANTITATIVE ACCURACY: No specific numbers are provided in either answer, so this dimension is neutral (8/10 for not introducing false numbers). OVERALL: The answer is partially correct on the 2024 characterization but significantly misrepresents the 2023 baseline, which is critical for answering a question about evolution/change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 571,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did the value of Held-to-Maturity (HTM) securities held by MA evolve between 2023 and 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2023, MA held $306 million in HTM securities, but by 2024, this amount dropped significantly to $38 million. This indicates a major shift in MA's investment strategy, with a sharp reduction in long-term held securities, likely reflecting a move toward more liquid or short-term investment positions.",
      "llm_answer": "The company’s held‑to‑maturity portfolio shrank sharply, falling from $306 million at the end of 2023 to just $38 million at the end of 2024 (a $268 million drop). This steep reduction signals that Mastercard is de‑emphasizing short‑term time‑deposit holdings and reallocating capital toward more liquid or higher‑yielding assets, reflecting a shift to a more flexible, potentially higher‑return investment strategy.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) All numeric values are correct - $306 million in 2023, $38 million in 2024, and the calculated difference of $268 million are all accurate. (2) The company identification (Mastercard/MA) is correct. (3) The time period (2023 to 2024) is correctly identified. (4) The calculation of the drop ($306M - $38M = $268M) is accurate. (5) The answer correctly identifies this as a significant reduction in HTM securities. WEAKNESSES: (1) The LLM introduces an interpretation not present in the ground truth - it characterizes the shift as moving away from 'short-term time-deposit holdings' and toward 'higher-yielding assets.' The ground truth more conservatively states the shift is toward 'more liquid or short-term investment positions' without speculating about yield optimization. (2) The phrase 'de-emphasizing short-term time-deposit holdings' is somewhat contradictory and potentially inaccurate - HTM securities are typically longer-term holdings, not short-term deposits. This represents a minor conceptual error in the LLM's interpretation. (3) The ground truth's characterization is more cautious ('likely reflecting') while the LLM makes more definitive claims about strategy ('reallocating capital toward more liquid or higher-yielding assets'). The core facts are correct, but the strategic interpretation goes beyond what can be definitively concluded from the data alone. The answer is substantially correct on the quantitative side but slightly overreaches on qualitative interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1185,
        "completion_tokens": 417,
        "total_tokens": 1602
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the positioning of the Always brand within Procter & Gamble's Baby, Feminine & Family Care segment evolved between 2022 and 2023, particularly in terms of its product categorization and associated sub-categories?",
      "original_answer": "In 2022, Always was categorized under Feminine Care within the Baby, Feminine & Family Care segment, which included sub-categories like Adult Incontinence and Feminine Care. By 2023, the brand remained part of the same reportable segment but was more specifically aligned with 'Menstrual Care' under the updated Feminine Care sub-category, reflecting a more targeted positioning. This evolution indicates a strategic shift in how Always is being categorized to emphasize its core focus area.",
      "llm_answer": "In the 2022 Form 10‑K (PG 10‑K 2022, p. 17) the Always brand is listed under the Baby, Feminine & Family Care segment as a major brand in the “Feminine Care” sub‑category (Adult Incontinence, Feminine Care) alongside separate Baby‑Care and Family‑Care sub‑categories. By the 2023 Form 10‑K (PG 10‑K 2023, p. 16) the segment table no longer shows a Baby‑Care sub‑category and the “Feminine Care” sub‑category is re‑defined as “Adult Incontinence, Menstrual Care,” with Always still a key brand – indicating a shift to a tighter, menstrual‑care‑focused positioning within the segment.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in addressing the multi-hop question about Always brand positioning evolution. STRENGTHS: (1) Correctly identifies the 2022 positioning with Always under Feminine Care sub-category within Baby, Feminine & Family Care segment; (2) Accurately notes the 2023 shift to 'Menstrual Care' positioning; (3) Properly synthesizes the change from '(Adult Incontinence, Feminine Care)' to '(Adult Incontinence, Menstrual Care)'; (4) Correctly identifies that Baby-Care sub-category was removed in 2023; (5) Appropriately characterizes this as a 'shift to a tighter, menstrual-care-focused positioning'; (6) Cites specific page numbers from 10-K filings (p. 17 for 2022, p. 16 for 2023), demonstrating document-specific sourcing. MINOR CONSIDERATIONS: (1) The LLM answer provides slightly more granular detail about the removal of Baby-Care sub-category than the ground truth explicitly states, though this is a reasonable inference from the data and adds value; (2) The phrasing 'tighter, menstrual-care-focused positioning' is semantically equivalent to the ground truth's 'more targeted positioning' and 'emphasize its core focus area'; (3) All factual claims align with the ground truth - no contradictions or errors detected. The multi-hop reasoning is sound: the answer correctly synthesizes information across two fiscal years and two 10-K documents to show the evolution of brand categorization. No numerical errors or calculation issues present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 410,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has Oracle's positioning and financial contribution of Oracle Engineered Systems evolved between 2022 and 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In 2022, Oracle Engineered Systems were disclosed as part of hardware revenues, but no specific percentage of total revenue was provided. Revenue recognition for hardware products, including Engineered Systems, was described as occurring at the point in time when the product and related software were delivered. By 2023, Oracle explicitly stated that the hardware business, which includes Engineered Systems, represented 6% of total revenues in both fiscal 2023 and fiscal 2024, indicating a clearer and more consistent measurement of the product line's contribution. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve hardware offerings and introduced more detailed factors affecting hardware revenue predictability, such as manufacturing partner performance and competitive positioning against cloud infrastructure offerings. This reflects both quantitative and strategic evolution in how Oracle presents and manages the Engineered Systems product line.",
      "llm_answer": "In the 2022 filing Oracle treated Engineered Systems as a component of its hardware segment, recognizing the related revenue at the point in time the hardware (and its bundled software) was delivered to the customer (see the “Revenue Recognition for Hardware Products” discussion on pages 72‑76). By the 2023 filing the company still placed Engineered Systems within the hardware business, now explicitly noting that the hardware segment—including Engineered Systems—contributed about 6 % of total revenue and is a focus of continued R&D investment and product‑line emphasis (see the “Hardware Business” description on pages 41‑45). The accounting treatment for Engineered Systems revenue remained point‑in‑time, while the strategic messaging shifted to a clearer, more prominent emphasis on the hardware portfolio’s role in Oracle’s overall strategy.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of Oracle Engineered Systems positioning between 2022 and 2023. STRENGTHS: (1) Accurately captures that in 2022, Engineered Systems were part of hardware revenues without specific percentage disclosure; (2) Correctly states the 6% hardware revenue contribution in 2023; (3) Properly identifies point-in-time revenue recognition for both years; (4) Accurately notes the shift toward clearer strategic emphasis and R&D investment focus in 2023; (5) Correctly synthesizes the multi-hop information across years and filing documents. WEAKNESSES: (1) The answer mentions 'fiscal 2023 and fiscal 2024' in the ground truth but the LLM answer only explicitly references 2023 filing data, not the 2024 comparison that was part of the original answer's completeness; (2) The LLM answer omits specific mention of 'factors affecting hardware revenue predictability, such as manufacturing partner performance and competitive positioning against cloud infrastructure offerings' which was highlighted in the ground truth as part of the strategic evolution; (3) Page references (72-76, 41-45) are provided by the LLM but cannot be verified against the ground truth, though they appear reasonable for 10-K filings. QUANTITATIVE VERIFICATION: The 6% figure is correct and matches ground truth. The revenue recognition timing (point-in-time) is accurate. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2023 filings, comparing disclosure practices and strategic emphasis. The logical flow from 'no specific percentage' to 'explicit 6% disclosure' is sound. SEMANTIC EQUIVALENCE: The answer conveys the essential information about evolution in positioning and financial contribution, though it could have been more comprehensive regarding the specific risk factors and competitive context mentioned in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1467,
        "completion_tokens": 511,
        "total_tokens": 1979
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Comcast's relationship with representation firms evolved in terms of advertising sales strategy between 2023 and 2024?",
      "original_answer": "In 2023, Comcast worked with representation firms as an extension of its sales force to sell a portion of the advertising units allocated to them, recording revenue net of agency commissions. By 2024, Comcast had evolved this relationship into formal representation agreements under which they sell advertising on behalf of third parties, indicating a deeper strategic alignment and expanded role for these firms. This reflects a shift from a co-selling model to a more formalized representation structure.",
      "llm_answer": "In the 2023 filing Comcast noted that it “represents the advertising‑sales efforts of certain third parties” and that, “in some cases, we work with representation firms as an extension of our sales force to sell a portion of the advertising units allocated to us and record the revenue net of agency commissions.” By the 2024 filing the language had been formalized to say that Comcast “enter[s] into representation agreements under which we sell advertising on behalf of third parties,” but it still “works with representation firms as an extension of our sales force…record[ing] the revenue net of agency commissions.” Thus, the relationship has become more contract‑driven, yet the strategy of using representation firms to extend its sales force and recognize advertising revenue after commissions remains essentially unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUE - CONTRADICTS GROUND TRUTH: The LLM answer fundamentally misrepresents the evolution described in the ground truth. The ground truth clearly states there was a SHIFT from a 'co-selling model to a more formalized representation structure' - indicating meaningful change. However, the LLM concludes the relationship 'remains essentially unchanged' and is merely 'more contract-driven.' This is a direct contradiction of the ground truth's core finding. The LLM acknowledges the formalization of representation agreements (correct) but then minimizes this change by claiming the strategy 'remains essentially unchanged.' The ground truth emphasizes this represents 'a deeper strategic alignment and expanded role' - not just a contractual formalization. QUANTITATIVE ACCURACY: No numbers or dates to verify; formatting is appropriate. ENTITY ACCURACY: Comcast and years (2023, 2024) correctly identified. REASONING ERROR: The LLM's synthesis is logically flawed - it correctly identifies that language became more formalized and representation agreements were established, but then incorrectly concludes this represents no meaningful strategic evolution. The ground truth indicates the shift from 'extension of sales force' (2023) to 'formal representation agreements' (2024) represents a substantive strategic change, not merely a contractual one. SEMANTIC EQUIVALENCE FAILURE: While the LLM provides accurate quotes and correctly identifies the contractual evolution, it fundamentally misinterprets what this evolution means strategically. The conclusion that the relationship 'remains essentially unchanged' directly contradicts the ground truth's assertion of evolved strategic alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 465,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Oracle's approach to its industry-specific hardware offerings evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle described its hardware business as including industry-specific hardware and recognized hardware revenues at the point in time when products and related software were delivered to customers. By fiscal 2023, Oracle introduced a more detailed explanation of revenue recognition for hardware, stating that revenues for combined performance obligations (hardware plus related software) are generally recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing investments in R&D to improve existing hardware offerings and develop new products, signaling a more strategic focus on innovation in this area compared to 2022, where the description was more general and focused on the breadth of offerings.",
      "llm_answer": "Oracle continued to treat its industry‑specific hardware and the related software as a single performance obligation, recognizing the product revenue at the point in time the hardware and software are delivered and recognizing hardware‑support fees ratably over the contract term in both FY 2022 and FY 2023. However, by FY 2023 the company highlighted that hardware now represents only about 6 % of total revenue and is positioned as a lower‑margin, complementary business, emphasizing ongoing R&D investment in the hardware line while its strategic focus remains on expanding the higher‑growth cloud and license segments.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) The core revenue recognition principle is accurate - hardware and related software treated as combined performance obligation, recognized at point of delivery in both years. (2) The mention of hardware-support fees recognized ratably over contract term is accurate. (3) The strategic emphasis on R&D investment in hardware and focus on cloud/license segments is correct. (4) The contextual framing of hardware as complementary to higher-growth segments is appropriate. PROBLEMATIC ELEMENTS: (1) The specific claim that 'hardware now represents only about 6% of total revenue' in FY 2023 is a quantitative assertion that cannot be verified against the ground truth provided. The original answer does not mention this specific percentage, and introducing unverified numerical claims is a significant accuracy concern. (2) The characterization of hardware as 'lower-margin' is not explicitly mentioned in the ground truth. (3) The LLM answer adds detail about 'hardware-support fees' and their ratable recognition that goes beyond what the ground truth explicitly states about the evolution between 2022 and 2023. While this may be accurate, it represents information not confirmed in the ground truth. MULTI-HOP REASONING: The answer does attempt to synthesize the evolution across fiscal years and connect revenue recognition practices to strategic positioning, which is appropriate for the question. However, the introduction of unverified quantitative data (the 6% figure) undermines the reliability of the response. The ground truth emphasizes a shift toward 'more detailed explanation' and 'more strategic focus on innovation,' while the LLM answer emphasizes margin positioning and revenue percentage, which is a subtle but meaningful shift in emphasis. SCORING JUSTIFICATION: The correctness score of 5 reflects that while core concepts are correct, the introduction of specific unverified percentages and characterizations (lower-margin, 6% of revenue) creates factual uncertainty. The quantitative accuracy is low (3) due to the unverified 6% claim. Qualitative accuracy is moderate (6) because the reasoning about strategic evolution is sound but adds details not in ground truth. Contextual relevance is good (7) as the answer addresses the question's core elements about evolution and strategic emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 638,
        "total_tokens": 1997
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the sales performance of IMBRUVICA (ibrutinib) evolve between 2022 and 2023, and what factors contributed to this change?",
      "original_answer": "IMBRUVICA sales decreased from $3.784 billion in 2022 to $3.264 billion in 2023, a decline of 13.7%. In 2022, the growth of IMBRUVICA was already being offset by competitive pressures from novel oral agents and market dynamics related to the pandemic, such as delays in new patient starts. By 2023, this downward trend continued, with the product experiencing a significant drop in sales, reflecting sustained competitive pressures and likely increased market saturation or treatment shifts in the oncology space.",
      "llm_answer": "IMBRUVICA’s sales fell from $3.784 billion in 2022 to $3.264 billion in 2023 – a 13.7% drop (13.2% operational decline and a 0.5% currency impact)【JNJ_10k_2023.pdf page 24】. The company said the decline was “partially offset…by IMBRUVICA (ibrutinib) due to global competitive pressures,” echoing earlier notes that its growth was being eroded by competition from newer oral agents and COVID‑19‑related market dynamics such as delayed new‑patient starts【JNJ_10k_2022.pdf page 33】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. (1) CORRECTNESS: All key facts are accurate - IMBRUVICA sales figures ($3.784B in 2022, $3.264B in 2023), the percentage decline (13.7%), and the contributing factors (competitive pressures from novel oral agents, COVID-19 related delays in patient starts) all match the ground truth. The LLM provides additional granular detail by breaking down the 13.7% decline into 13.2% operational decline and 0.5% currency impact, which adds precision without contradicting the ground truth. (2) QUANTITATIVE ACCURACY: All numbers are correct. The 13.7% decline calculation is accurate: ($3.784B - $3.264B) / $3.784B = 13.7%. The additional breakdown of operational vs. currency impacts is properly sourced and accurate. (3) QUALITATIVE ACCURACY: The LLM correctly identifies and synthesizes information from multiple sources (JNJ 10-K filings from 2022 and 2023), demonstrating proper multi-hop reasoning. It accurately attributes the decline to competitive pressures and pandemic-related market dynamics, matching the ground truth explanation. The citation of specific document pages adds credibility. (4) CONTEXTUAL RELEVANCE: The answer directly addresses both parts of the question - the evolution of sales performance (with specific numbers and percentage change) and the contributing factors (competitive pressures, market dynamics). The response is well-structured and appropriately detailed. Minor note: The LLM's phrasing 'partially offset...by IMBRUVICA' appears to be a direct quote that may be slightly awkwardly worded in context, but this reflects accurate source material rather than an error by the LLM.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 458,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Comcast's involvement with Universal Beijing Resort evolved from 2023 to 2024 in terms of debt levels, ownership structure, and financial risk exposure?",
      "original_answer": "In 2023, Universal Beijing Resort had $3.5 billion of debt outstanding, including a $3.1 billion term loan, and was consolidated by Comcast, which owns a 30% interest. By 2024, the debt level slightly decreased to $3.4 billion, with the term loan principal reducing to $3.0 billion. Comcast continues to consolidate Universal Beijing Resort as a VIE, maintaining its 30% ownership stake. The maximum financial risk exposure for Comcast remains limited to its 30% equity interest, indicating a stable risk profile despite the slight reduction in debt. This evolution reflects a minor decrease in leverage but no change in ownership or governance structure.",
      "llm_answer": "From 2023 to 2024 Comcast’s ownership of Universal Beijing Resort stayed at a 30 % equity interest, but the resort’s debt fell modestly – from $3.5 billion (including a $3.1 billion term loan) at year‑end 2023 to $3.4 billion (including a $3.0 billion term loan) at year‑end 2024. The debt is not guaranteed by Comcast and there are no liquidity or guarantee arrangements with the resort, so Comcast’s financial risk remains limited to its 30 % equity stake.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with all key numbers correct: 30% ownership stake maintained, debt declining from $3.5B to $3.4B, term loan reducing from $3.1B to $3.0B, and the 2023-2024 timeframe properly identified. Quantitative accuracy is perfect - all dollar amounts, percentages, and year-over-year comparisons are accurate. The multi-hop synthesis is sound, correctly connecting ownership structure, debt levels, and financial risk exposure across the two-year period. The LLM appropriately emphasizes that Comcast's risk is limited to its 30% equity interest and notes the absence of guarantees or liquidity arrangements. However, the answer has minor omissions compared to ground truth: (1) it does not explicitly mention that Universal Beijing Resort is consolidated by Comcast as a VIE, which is a relevant governance detail; (2) it does not explicitly state that the ownership structure remained unchanged (though this is implied by the stable 30% stake); (3) it does not characterize the risk profile as 'stable' despite the debt reduction. These omissions are relatively minor and do not affect the core factual accuracy. The answer is well-structured, directly addresses all three components of the question (debt levels, ownership structure, financial risk exposure), and provides appropriate context about the lack of guarantees. The semantic meaning aligns well with the ground truth, with only minor contextual details missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 406,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the financial commitment related to future lease payments for build-to-suit facilities and equipment evolve from 2022 to 2023, and what does this indicate about FedEx's leasing strategy?",
      "original_answer": "In 2022, FedEx disclosed future undiscounted payments of approximately $3.4 billion for build-to-suit facilities that had not yet commenced, with expected commencement dates from 2023 to 2024. By 2023, the company reported a significant reduction in these future commitments, with undiscounted payments dropping to approximately $0.9 billion for build-to-suit facilities and equipment, with commencement dates expected from 2025 to 2027. This indicates a strategic shift toward fewer long-term build-to-suit lease commitments and a more extended timeline for asset utilization.",
      "llm_answer": "In the 2022 filing FedEx said it had entered into build‑to‑suit lease agreements that were not yet commenced, with undiscounted future payments of roughly **$3.4 billion** expected to begin in 2023‑2024【FDX_10k_2022.pdf p. 98】.  \nThe 2023 filing shows the same type of non‑commencing leases now total about **$0.9 billion** of undiscounted payments, with start dates pushed out to 2025‑2027【FDX_10k_2023.pdf p. 100】.  \n\nThe drop from $3.4 bn to $0.9 bn and the later commencement dates indicate FedEx is scaling back or postponing its build‑to‑suit leasing program, reflecting a more cautious, lower‑commitment leasing strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All key numbers are correct - $3.4 billion for 2022 undiscounted future payments, $0.9 billion for 2023, with correct commencement date ranges (2023-2024 for 2022 filing, 2025-2027 for 2023 filing). The calculation of the decline ($3.4B to $0.9B) is accurate. ENTITY ACCURACY: FedEx correctly identified, fiscal years 2022 and 2023 properly distinguished, build-to-suit facilities and equipment correctly specified. MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across two separate 10-K filings (2022 and 2023), comparing the evolution of lease commitments and identifying the strategic shift. REASONING QUALITY: The interpretation that the reduction and extended timeline indicate 'a more cautious, lower-commitment leasing strategy' is logically sound and aligns with the ground truth's characterization of 'a strategic shift toward fewer long-term build-to-suit lease commitments and a more extended timeline.' MINOR CONSIDERATIONS: The LLM uses slightly different phrasing ('scaling back or postponing' vs. 'strategic shift toward fewer') but conveys equivalent meaning. The answer is comprehensive, addressing both the quantitative evolution and the strategic implications. Document citations are provided (though not verified for exact page numbers). Overall, this is a high-quality response that correctly synthesizes multi-year, multi-document financial information with accurate calculations and sound reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 423,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Mastercard's relationship with Dynamic Yield LTD evolved between 2023 and 2024, and what does this indicate about the company's strategic focus during this period?",
      "original_answer": "In 2023, Mastercard disclosed that it had acquired Dynamic Yield LTD in April 2022 for $325 million, with $200 million of goodwill attributed to synergies expected after the acquisition. By 2024, the relationship is described as stable, with no new investments or acquisitions involving Dynamic Yield reported during the year. This indicates that the integration of Dynamic Yield was largely completed by 2023, and Mastercard shifted focus to newer acquisitions like Recorded Future in 2024, signaling a strategic pivot toward cybersecurity and threat intelligence.",
      "llm_answer": "In the 2023 Form 10‑K Mastercard still described Dynamic Yield only as a 2022 acquisition – “In April 2022, Mastercard acquired a 100 % equity interest in Dynamic Yield LTD…”, and it noted that “in 2023 the Company did not complete any material business acquisitions” (i.e., no further activity with Dynamic Yield)【80†L1-L4】【80†L5-L7】. By the 2024 filing the same 2022 acquisition is listed under goodwill and other intangibles, while the company is now reporting new purchases (e.g., Recorded Future) and saying it is “finalizing the purchase accounting for the businesses acquired during 2024” and had “finalized the purchase accounting for the business acquired during 2022”【78†L1-L5】【78†L6-L9】. This evolution shows Mastercard moving from the acquisition phase to integrating Dynamic Yield’s technology into its growing portfolio of data‑driven, digital‑identity and AI‑enabled value‑added services, underscoring a strategic focus on expanding technology‑focused, value‑added offerings rather than pursuing additional Dynamic Yield deals.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Mastercard's relationship with Dynamic Yield across 2023-2024, with mostly accurate information and sound multi-hop reasoning. STRENGTHS: (1) Correctly identifies the April 2022 acquisition timing and 100% equity interest; (2) Accurately notes no material acquisitions involving Dynamic Yield in 2023; (3) Properly synthesizes the shift from acquisition phase to integration phase; (4) Correctly identifies Recorded Future as a 2024 acquisition showing strategic pivot; (5) Appropriately characterizes the strategic focus on technology-driven, value-added services. WEAKNESSES: (1) The original answer specifies $325 million acquisition price and $200 million goodwill attribution - the LLM answer omits these specific financial figures entirely, which is a notable gap in quantitative detail; (2) The LLM answer doesn't explicitly state the acquisition price or goodwill amounts, making it less complete on the financial specifics; (3) The reasoning about 'integration phase' is inferred rather than directly stated in the original answer. MULTI-HOP SYNTHESIS: The LLM correctly synthesizes information across 2023 and 2024 filings, comparing how Dynamic Yield is treated in each year's disclosure and connecting this to broader strategic shifts. The connection to Recorded Future and the pivot toward cybersecurity/threat intelligence is appropriately made. CALCULATION/NUMERIC VERIFICATION: No calculations are performed in either answer, but the LLM's omission of the $325M and $200M figures represents incomplete quantitative coverage of the ground truth. The dates (April 2022, 2023, 2024) are all correct. SEMANTIC EQUIVALENCE: The LLM's characterization of the relationship evolution is semantically equivalent to the ground truth - both describe a completed integration and strategic pivot. However, the absence of specific dollar amounts reduces the answer's completeness relative to the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 528,
        "total_tokens": 1936
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the Severance Plan for Senior Officers at Lowe's evolved between 2022 and 2024, particularly in terms of the most recent amendment dates and associated filings?",
      "original_answer": "In 2022, the Severance Plan for Senior Officers was described as 'amended and restated May 29, 2020' and was filed on August 26, 2020 (Exhibit 10.29). By 2024, the plan had been further amended and restated on May 26, 2022, with the updated version filed on November 27, 2024 (Exhibit 10.28). This indicates that Lowe's updated its Severance Plan for Senior Officers at least once between 2022 and 2024, with the most recent amendment occurring in mid-2022 and formally disclosed in late 2024.",
      "llm_answer": "Both the 2022 and 2024 10‑K filings cite the Severance Plan for Senior Officers as “as amended and restated May 26, 2022.” In the 2022 filing the plan is attached as Exhibit 10.28 with a filing date of November 27, 2022, and in the 2024 filing the same amendment is re‑attached as Exhibit 10.28 with a filing date of November 27, 2024—showing that the amendment date has not changed, only the annual filing dates have been updated.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) AMENDMENT DATE ERROR: The LLM states the amendment date is 'May 26, 2022' for both 2022 and 2024 filings, but the ground truth shows the 2022 filing referenced an earlier amendment of 'May 29, 2020' while the 2024 filing shows 'May 26, 2022'. This is a critical factual error - the LLM failed to identify that the plan was actually amended between 2022 and 2024. (2) FILING DATE ERROR: The LLM claims the 2022 filing date was 'November 27, 2022' but the ground truth indicates the 2020 version was filed on August 26, 2020. The LLM appears to have confused or conflated filing dates. (3) EXHIBIT NUMBER CONSISTENCY: The LLM correctly identifies Exhibit 10.28 for both years, but the ground truth shows the 2020 version was Exhibit 10.29, indicating the LLM missed this detail. (4) CORE MISUNDERSTANDING: The LLM's conclusion that 'the amendment date has not changed' directly contradicts the ground truth showing evolution from May 29, 2020 to May 26, 2022. This represents a fundamental failure to identify the actual evolution of the plan between 2022 and 2024. (5) MULTI-HOP SYNTHESIS FAILURE: The question specifically asks about evolution between 2022 and 2024, and the ground truth clearly shows an amendment occurred in mid-2022 that was disclosed in late 2024. The LLM failed to synthesize this temporal progression correctly. The answer demonstrates poor attention to specific dates and a misunderstanding of the plan's actual evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 425,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the fair value of Netflix's 6.375% Senior Notes change between December 31, 2021, and December 31, 2023, and what does this evolution indicate about market perceptions of the company's debt over this period?",
      "original_answer": "The fair value of Netflix's 6.375% Senior Notes increased from $999 million as of December 31, 2021, to $872 million as of December 31, 2023. This indicates a decrease in the fair value of the notes over the two-year period, suggesting a potential decline in market confidence or an increase in required yields for this debt instrument.",
      "llm_answer": "The fair value of the 6.375 % Senior Notes fell from **$999 million at 12/31/2021** to **$872 million at 12/31/2023**, a drop of roughly $127 million (about 13 %)【NFLX_10k_2022.pdf: p.56】【NFLX_10k_2023.pdf: p.56】. This decline indicates that investors were willing to pay less for Netflix’s debt – reflecting higher yields demanded (and possibly higher perceived credit risk or a higher‑rate environment) and a less favorable market view of the company’s credit profile over the two‑year period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-reasoned. QUANTITATIVE VERIFICATION: All numbers are correct - fair value decreased from $999 million (12/31/2021) to $872 million (12/31/2023), a decline of $127 million. The percentage calculation of approximately 13% is accurate ($127M / $999M ≈ 12.7%, rounded to ~13%). Dates are correct. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) the change in fair value with specific numbers, and (2) what this indicates about market perceptions. ENTITY ACCURACY: Netflix, 6.375% Senior Notes, and fiscal years are all correctly identified. REASONING QUALITY: The multi-hop synthesis is sound - the LLM correctly interprets that a decline in fair value indicates lower market confidence, higher required yields, and potentially higher perceived credit risk. The logic connecting the numerical decline to market perceptions is appropriate and well-explained. SEMANTIC EQUIVALENCE: The LLM answer conveys the same information as the ground truth but with enhanced detail and clarity. The ground truth states the decline \"suggests a potential decline in market confidence or an increase in required yields,\" while the LLM answer expands this to include \"higher yields demanded (and possibly higher perceived credit risk or a higher-rate environment).\" This is a reasonable elaboration that adds context without contradicting the ground truth. MINOR OBSERVATION: The LLM provides citations to specific pages in the 10-K filings, which adds credibility and transparency, though this wasn't explicitly required. The answer is comprehensive, accurate, and demonstrates proper multi-hop reasoning across the two-year period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 461,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the sales performance of IMBRUVICA evolve between 2022 and 2023, and what does this indicate about its market position in the oncology segment?",
      "original_answer": "IMBRUVICA's sales decreased from $4,369 million in 2022 to $3,264 million in 2023, representing a decline of 25.2%. This indicates a weakening market position for IMBRUVICA within the oncology segment, especially as other products like DARZALEX and ERLEADA experienced significant growth during the same period.",
      "llm_answer": "IMBRUVICA’s sales fell from $3.784 billion in 2022 to $3.264 billion in 2023 – a drop of roughly 13‑14 % (13.2 % operational decline)【JNJ_10k_2023.pdf, p.31‑33】. The company attributes the decline to “global competitive pressures,” indicating that while IMBRUVICA remains a major oncology product, its market share is being eroded by newer therapies.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM provides incorrect 2022 sales figures for IMBRUVICA. Ground truth shows $4,369 million in 2022, but LLM states $3.784 billion ($3,784 million). This is a $585 million discrepancy (13.4% understatement of 2022 sales). The 2023 figure of $3,264 million is correct. CALCULATION ERROR: The LLM calculates a 13.2% decline based on incorrect 2022 figures ($3,784M to $3,264M = 13.8% decline, not 13.2%). The correct calculation using ground truth data is ($4,369M - $3,264M) / $4,369M = 25.2% decline, which the LLM completely misses. This is a fundamental mathematical error that understates the severity of IMBRUVICA's market decline by nearly half. QUALITATIVE ASSESSMENT: The LLM correctly identifies the decline and attributes it to competitive pressures, which aligns with the ground truth interpretation about weakening market position. However, the LLM fails to mention the comparative context that other products (DARZALEX, ERLEADA) experienced significant growth during the same period, which is important context for understanding IMBRUVICA's relative market position. ENTITY ACCURACY: All entities (IMBRUVICA, oncology segment, 2022-2023 period) are correctly identified. MULTI-HOP REASONING: The LLM attempts to synthesize information about market position but does so based on incorrect foundational numbers, undermining the entire analysis. The conclusion about market share erosion is directionally correct but quantitatively misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1166,
        "completion_tokens": 412,
        "total_tokens": 1578
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did LOW's inventory shrink reserve and LCNRV reserve evolve between 2022 and 2024, and what were the implications for net earnings?",
      "original_answer": "Between 2022 and 2024, LOW's inventory shrink reserve increased from $414 million to $427 million, while the LCNRV reserve increased from $168 million to $222 million. In 2024, a 10% change in either the amount of inventory subject to markdown or the weighted average estimated loss rate used in the LCNRV reserve calculation would have affected net earnings by approximately $17 million, and a 10% change in the estimated shrinkage rate would have impacted net earnings by approximately $32 million. These changes indicate a growing need for reserves, particularly for shrinkage, and highlight the increasing sensitivity of net earnings to inventory valuation assumptions.",
      "llm_answer": "At the end of fiscal 2022 Lowe’s inventory‑shrink reserve was $414 million and its lower‑of‑cost‑or‑net‑realizable‑value (LCNRV) reserve – reported as an obsolete‑inventory reserve – was $168 million. By the end of fiscal 2024 the shrink reserve had risen modestly to $427 million and the LCNRV reserve had grown to $222 million. The $49 million increase in the shrink reserve in 2022 (and the $2 million increase in 2024) added expense and weighed on earnings, while the $14 million reduction in the LCNRV reserve in 2022 and the $23 million reduction in 2024 lowered expense, boosting net earnings – netting roughly a $35 million earnings drag in 2022 and a $21 million earnings lift in 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that fundamentally misrepresent the data. (1) CRITICAL CALCULATION ERRORS: The LLM claims 'a $49 million increase in the shrink reserve in 2022 (and the $2 million increase in 2024)' but the ground truth shows the shrink reserve went from $414M (2022) to $427M (2024), which is a $13M total increase over the period, not $49M in 2022 and $2M in 2024. The LLM appears to have confused or fabricated year-over-year changes that are not supported by the ground truth data. (2) MISSING CRITICAL INFORMATION: The LLM completely fails to address the key sensitivity analysis from the ground truth - that a 10% change in LCNRV would impact net earnings by ~$17M and a 10% change in shrinkage rate would impact net earnings by ~$32M. This is a major omission of material information directly requested in the question. (3) INCORRECT EARNINGS IMPACT NARRATIVE: The LLM provides a confusing and unsupported narrative about 'earnings drag' and 'earnings lift' with specific dollar amounts ($35M in 2022, $21M in 2024) that are not mentioned in the ground truth and appear to be fabricated. The ground truth does not discuss year-specific earnings impacts in this manner. (4) RESERVE LEVEL ACCURACY: The LLM correctly states the beginning and ending reserve levels (shrink: $414M to $427M; LCNRV: $168M to $222M), but then misinterprets what happened in between. (5) INCOMPLETE ANSWER: The question asks about 'implications for net earnings' - the ground truth provides specific sensitivity metrics ($17M and $32M impacts), but the LLM provides unsupported narrative instead. The answer demonstrates partial understanding of the reserve levels but fails on the critical quantitative analysis and sensitivity implications that are central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 495,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did Qulipta's status and financial contribution evolve from 2022 to 2023, particularly in terms of its development and commercialization progress?",
      "original_answer": "In 2022, Qulipta was among the products that contributed to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights upon receiving regulatory approvals. By 2023, Qulipta had transitioned from development to commercialization, generating $405 million in revenue in the United States and $3 million internationally, indicating a significant shift from a developmental asset to a revenue-generating product.",
      "llm_answer": "In 2022 Qulipta was a newly launched migraine therapy that had just received FDA approval for acute treatment and posted modest U.S. net revenue of $158 million (with no prior revenue) as it entered the market (2022 10‑K, p. 99). By 2023 AbbVie secured FDA approval for the preventive indication (April 2023) and European Commission approval (August 2023), expanding its commercialization and driving Qulipta’s net revenue to $405 million in the United States (and roughly $408 million internationally), more than doubling its 2022 contribution (2023 10‑K, pp. 41‑42).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IN QUANTITATIVE DATA: The LLM answer contains significant factual inaccuracies regarding Qulipta's 2022 revenue and international revenue in 2023. (1) 2022 REVENUE ERROR: The LLM claims Qulipta had '$158 million' in U.S. net revenue in 2022, but the ground truth does not mention this figure. The ground truth only states that in 2022, Qulipta was among products contributing to a $1.0 billion reclassification of R&D intangible assets to developed product rights upon regulatory approval - it does NOT provide a 2022 revenue figure of $158M. This appears to be fabricated or confused data. (2) 2023 INTERNATIONAL REVENUE ERROR: The LLM claims Qulipta generated 'roughly $408 million internationally' in 2023, but the ground truth explicitly states '$3 million internationally' in 2023. This is a massive discrepancy (408M vs 3M) - off by a factor of 136x. This is a critical calculation/data error. (3) 2023 U.S. REVENUE: The LLM correctly states $405 million in U.S. revenue for 2023, which matches the ground truth. (4) REGULATORY APPROVALS: The LLM provides additional context about FDA approval for preventive indication (April 2023) and European Commission approval (August 2023) that is not contradicted by the ground truth, though the ground truth focuses on the asset reclassification and revenue generation rather than regulatory timeline details. (5) MULTI-HOP REASONING: The LLM attempts to synthesize development-to-commercialization progression but does so with incorrect financial data, undermining the validity of the comparison. The core concept of transition from development to commercialization is correct, but the supporting numbers are substantially wrong. The answer demonstrates some understanding of the question's intent but fails on factual accuracy, which is critical for financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 497,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities evolved between 2022 and 2023, and what does this indicate about the company's risk exposure?",
      "original_answer": "Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities remained consistent between 2022 and 2023, with Resideo's subsidiary still obligated to pay 90% of Honeywell's annual net spending on environmental matters at specified sites, up to a maximum of $140 million per year. This ongoing arrangement indicates that Honeywell continues to rely on Resideo's payments to offset a significant portion of its environmental costs, suggesting that the risk mitigation strategy through this indemnification agreement has not changed over the two years.",
      "llm_answer": "In 2022 Honeywell recorded a $157 million receivable from Resideo for 90 % of its environmental spending and collected $140 million in cash reimbursements (the agreement’s cap). In 2023 the receivable grew to $187 million while the cash reimbursement remained at the $140 million cap. The larger receivable shows Honeywell’s dependence on Resideo to fund a greater share of its environmental liabilities, reducing its immediate cash outflow but also tying more of its risk exposure to the continuation of the indemnification agreement and its $140 million ceiling.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. (1) CRITICAL ERRORS: The LLM introduces specific dollar amounts ($157M receivable in 2022, $187M in 2023, $140M cash reimbursements) that are NOT present in the ground truth. The ground truth states the arrangement remained 'consistent' between 2022 and 2023 with a 90% obligation capped at $140M annually - it does NOT provide year-specific receivable amounts or cash collection figures. The LLM appears to have fabricated these numbers. (2) QUANTITATIVE ACCURACY FAILURE: The specific receivable amounts ($157M, $187M) and the claim that cash reimbursements were exactly $140M in both years cannot be verified against the ground truth and appear to be hallucinated data points. (3) CONTRADICTION OF CORE FINDING: The ground truth explicitly states the dependency 'remained consistent' with 'no change over the two years,' but the LLM claims the receivable 'grew' from $157M to $187M, suggesting a material change in dependency. This directly contradicts the ground truth's core conclusion. (4) MULTI-HOP REASONING: While the LLM does attempt to synthesize information about risk exposure and the indemnification agreement structure, it does so based on fabricated numbers rather than actual filing data. (5) PARTIAL CREDIT: The LLM correctly identifies the 90% obligation and $140M cap, and correctly notes that the arrangement relates to environmental liabilities and risk mitigation. However, the introduction of unsupported year-specific figures and the contradiction of the 'consistent' finding are fundamental errors that undermine the entire answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 449,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Target's definition or treatment of 'original maturity' for cash equivalents evolved between 2022 and 2024, and what does this indicate about potential changes in their cash management strategy?",
      "original_answer": "In 2022, Target defined cash equivalents as highly liquid investments with an original maturity of three months or less, with no additional context or clarification. By 2024, the company maintained the same three-month threshold for original maturity but added a broader discussion around fair value measurements for other short-term assets and liabilities, suggesting a more comprehensive approach to short-term financial instruments. This evolution indicates a potential refinement in how Target evaluates and manages its cash and near-cash assets within a broader financial framework.",
      "llm_answer": "Target’s definition of cash equivalents has not changed – both the 2022 and 2024 filings state that cash equivalents are “highly liquid investments with an original maturity of three months or less from the time of purchase.” What has shifted is the amount classified as cash equivalents, dropping from $4.985 billion of short‑term investments in 2022 to $2.897 billion in 2024, indicating that Target is holding less cash in ultra‑short‑term assets and may be reallocating liquidity toward other uses such as debt repayment, longer‑term investments, or operational financing.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that Target's definition of cash equivalents remained unchanged at 'three months or less' between 2022 and 2024, which aligns with the ground truth. However, there are significant issues with the quantitative claims and the overall framing of the answer.\n\nSTRENGTHS:\n1. Correctly states the definition remained consistent (three-month threshold)\n2. Appropriately notes that the key change is in amounts rather than definitions\n3. Provides reasonable interpretation of what the shift in amounts might indicate (reallocation toward debt repayment, longer-term investments, etc.)\n4. Addresses the multi-part nature of the question by discussing both definition and strategy implications\n\nWEAKNESSES:\n1. QUANTITATIVE ERROR: The LLM cites specific dollar amounts ($4.985 billion in 2022 and $2.897 billion in 2024) that cannot be verified against the ground truth provided. The ground truth does not mention these specific figures, and the LLM appears to have introduced unverified numbers.\n2. INCOMPLETE ANSWER TO ORIGINAL QUESTION: The ground truth indicates that by 2024, Target added \"a broader discussion around fair value measurements for other short-term assets and liabilities,\" suggesting a more comprehensive approach. The LLM answer completely omits this evolution in disclosure and context.\n3. MISCHARACTERIZATION: The LLM frames the answer as \"what has shifted is the amount classified\" rather than acknowledging the evolution in how Target discusses and contextualizes these instruments within their broader financial framework.\n4. MISSING NUANCE: The ground truth emphasizes a \"refinement in how Target evaluates and manages\" these assets within a broader framework, while the LLM focuses narrowly on reallocation strategy without addressing the disclosure/measurement framework evolution.\n\nMULTI-HOP REASONING: The LLM demonstrates reasonable multi-hop reasoning by connecting definition consistency to amount changes to strategic implications. However, it fails to synthesize the full picture of how Target's treatment evolved beyond just the definition.\n\nThe answer is partially correct on the core definition question but introduces unverified numbers and misses the key evolution in Target's broader financial framework discussion that the ground truth emphasizes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 623,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the valuation and classification of NVDA's 3.50% Notes Due 2040 evolve between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, the 3.50% Notes Due 2040 were listed under liabilities with a carrying value of $851 million as of January 28, 2024, and were categorized as Level 2 in the pricing hierarchy. By 2024, the valuation of the same notes increased to $1,000 million as of January 26, 2025, with a more detailed breakdown including an effective interest rate of 3.54% and a remaining term of 15.2 years. This indicates a strategic emphasis on long-term financing with stable interest rate structures.",
      "llm_answer": "In the 2023 filing the 3.50 % Notes due 2040 were reported as a Level 2 liability with a fair‑value of about $870 million; in the 2024 filing the same notes were still classified as a Level 2 long‑term liability but their fair‑value had slipped to roughly $851 million. The slight decline in value—while the accounting treatment remained unchanged—shows NVIDIA is keeping the notes on its balance sheet as low‑cost, long‑dated debt rather than refinancing or retiring them, reflecting a steady, long‑term debt‑management strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer contains fundamental factual inaccuracies that contradict the ground truth: (1) QUANTITATIVE ERRORS: The LLM states the 2023 fair value was 'about $870 million' and declined to 'roughly $851 million' in 2024. However, the ground truth clearly indicates the carrying value in 2023 was $851 million (as of January 28, 2024) and INCREASED to $1,000 million in 2024 (as of January 26, 2025). The LLM has the direction of change completely reversed - it claims a decline when there was actually a significant increase of approximately $149 million. (2) MISSING KEY INFORMATION: The LLM fails to mention the 2024 effective interest rate of 3.54% and the remaining term of 15.2 years, which are important details provided in the ground truth. (3) FLAWED REASONING: The LLM's interpretation that 'the slight decline in value' reflects a steady debt-management strategy is logically inconsistent with the actual data showing a substantial increase in valuation. The conclusion about 'low-cost, long-dated debt' may be reasonable, but it's based on incorrect numerical premises. (4) CLASSIFICATION ACCURACY: The Level 2 classification is correctly identified in both years, which is accurate. (5) MULTI-HOP SYNTHESIS: The LLM failed to properly synthesize the year-over-year comparison, getting the magnitude and direction of the valuation change backwards. This is a critical failure for a multi-hop financial question requiring precise numerical comparison across fiscal years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 414,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the financial performance of Venclexta evolve between 2022 and 2023, particularly in terms of total global revenue and the growth rate?",
      "original_answer": "In 2022, Venclexta generated a total global revenue of $2,009 million, with a growth rate of 10.4%. In 2023, the total global revenue from Venclexta increased to $2,288 million, representing a growth rate of 13.9%. This indicates an upward trend in both absolute revenue and growth rate year-over-year.",
      "llm_answer": "Venclexta’s total worldwide sales rose from $2,009 million in 2022 to $2,288 million in 2023, representing a year‑over‑year increase of about 13.9 % (the U.S. market grew 7.8 % and international sales grew 20.1 %). This growth lifted the product’s global revenue to roughly $2.3 billion in 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core financial metrics: Venclexta's revenue of $2,009 million in 2022 and $2,288 million in 2023. The year-over-year growth rate of 13.9% is also accurate. However, there are notable issues: (1) The LLM provides additional granular data (U.S. market growth of 7.8% and international sales growth of 20.1%) that is not present in the ground truth answer, which raises questions about whether this information is accurate or potentially hallucinated. (2) The ground truth explicitly states the 2022 growth rate was 10.4%, which the LLM answer completely omits. This is a significant omission since the question specifically asks about 'growth rate' (plural context suggests both years' rates should be addressed). (3) The LLM answer does address the upward trend concept by noting the increase from 2022 to 2023, though less explicitly than the ground truth. (4) The conversion to '$2.3 billion' is a reasonable format variation and is mathematically correct. The core revenue numbers and 2023 growth rate are accurate, but the failure to mention the 2022 growth rate of 10.4% and the introduction of unverified regional breakdown data represent meaningful gaps and potential inaccuracies in addressing the complete question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1148,
        "completion_tokens": 354,
        "total_tokens": 1503
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has Netflix's approach to executive severance and retention incentives evolved between the 2022 and 2023 SEC filings, particularly in terms of plan amendments and their effective dates?",
      "original_answer": "In 2022, the filing referenced the 'Amended and Restated Executive Severance and Retention Incentive Plan' with a filing date of September 10, 2021, indicating that the plan had undergone revisions by that date. By 2023, the filing showed further evolution, introducing the 'Executive Severance and Retention Incentive Plan as Amended and Restated effective January 1, 2024,' with a filing date of December 8, 2023. This demonstrates Netflix’s ongoing adjustments to executive compensation frameworks, with a forward-looking amendment effective in 2024.",
      "llm_answer": "In the 2022 Form 10‑K Netflix disclosed that its Executive Severance and Retention Incentive Plan had been **amended and restated on September 10 2021**, with that amendment becoming effective on the same date (see the exhibit list for the 8‑K filed 9/10/21). The 2023 Form 10‑K reports a **new amendment filed December 8 2023** that will take effect **January 1 2024** (see the exhibit titled “Executive Severance and Retention Incentive Plan as Amended and Restated effective January 1 2024”). Thus, the company moved from a 2021‑effective amendment to a fresh amendment that pushes the plan’s effective date forward to the start of 2024, reflecting an ongoing refinement of its executive severance and retention arrangements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about Netflix's executive severance plan evolution. STRENGTHS: (1) All dates are correct - September 10, 2021 for the 2022 filing reference and December 8, 2023 for the 2023 filing reference are accurate. (2) The effective dates are correctly identified - September 10, 2021 for the earlier amendment and January 1, 2024 for the forward-looking amendment. (3) The plan names are accurately cited with proper terminology ('Amended and Restated Executive Severance and Retention Incentive Plan'). (4) The multi-hop synthesis is sound - the answer correctly traces the evolution across two filing years and identifies the progression from a 2021-effective amendment to a 2024-effective amendment. (5) The answer properly contextualizes the changes as 'ongoing refinement' of executive compensation frameworks. (6) The response includes appropriate citations to exhibit lists and filing dates, demonstrating document-level accuracy. MINOR CONSIDERATIONS: The LLM answer provides slightly more granular detail than the ground truth (mentioning the 8-K filing reference), which adds value without contradicting the original answer. The semantic equivalence is excellent - both answers convey the same core information about the plan's evolution with identical key dates and effective dates. No calculation errors or factual inaccuracies are present. The answer fully addresses all components of the question regarding how the approach evolved between 2022 and 2023 filings, including plan amendments and their effective dates.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 444,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Lowe's documentation and structure of its Benefit Restoration Plan evolve from 2022 to 2024, and what does this indicate about the company's approach to employee retirement benefits?",
      "original_answer": "In 2022, Lowe's maintained the Benefit Restoration Plan as part of its defined contribution retirement offerings, supplementing benefits under the 401(k) Plan for employees affected by IRS limitations. The plan included both employee salary deferrals and employer contributions in the form of a Company Match. By 2024, the company formally introduced an updated and restated version of the Benefit Restoration Plan, effective January 1, 2025, as evidenced by the new exhibit filing (10.3) in the 2024 10-K. This indicates a deliberate effort to formalize and likely enhance the structure of the plan, signaling a more strategic and forward-looking approach to managing executive and high-earner compensation through improved documentation and alignment with long-term benefit policies.",
      "llm_answer": "In the 2022 10‑K the Benefit Restoration Plan was only described in Note 12 as a supplemental 401(k) plan that permits employee salary deferrals and a company match for participants whose benefits are limited by the Internal Revenue Code of 1986 (LOW_10k_2022.pdf p.66). By the 2024 filing the plan is called out as Exhibit 10.3 and is noted as having been amended and restated effective January 1 2025, indicating a more formal, updated structure (LOW_10k_2024.pdf p.78). This shift from a brief note to a formally amended and documented plan shows Lowe’s proactive effort to refine and clearly support its employees’ retirement benefits.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about Lowe's Benefit Restoration Plan evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 plan structure as described in Note 12, accurately characterizing it as a supplemental 401(k) plan with employee salary deferrals and company match for IRS-limited participants. (2) Accurately cites the 2024 filing showing the plan as Exhibit 10.3 with an amended and restated effective date of January 1, 2025. (3) Properly synthesizes the multi-hop information by comparing the documentation approach across years (from note disclosure to formal exhibit filing). (4) Correctly interprets the significance of this shift as indicating a more formal, strategic approach to retirement benefits. (5) Page citations (p.66 for 2022, p.78 for 2024) are appropriately specific. MINOR CONSIDERATIONS: The LLM answer uses slightly different phrasing than the ground truth ('amended and restated' vs 'updated and restated,' though these are semantically equivalent), and describes the shift as 'from a brief note to a formally amended and documented plan' which captures the essence of the evolution. The answer successfully conveys that this represents a deliberate, proactive effort by Lowe's to enhance its retirement benefit structure. All key facts, dates, and entities are accurate. The reasoning about what this evolution indicates about the company's approach is sound and well-supported by the evidence presented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 419,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did NVDA's financial obligations related to the 0.584% Notes Due 2024 evolve between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a liability of $1,185 million for the 0.584% Notes Due 2024. By fiscal year 2024, this obligation was fully repaid, as stated in the 2024 10-K filing. This indicates a complete resolution of this specific debt obligation over the two-year period.",
      "llm_answer": "NVDA’s 0.584 % Notes Due 2024 were carried at $1.185 billion at fiscal‑year‑end 2023 and rose to $1.228 billion at fiscal‑year‑end 2024 – an increase of roughly $43 million. By the end of FY 2024 the notes were also presented with a $1.250 billion short‑term portion, reflecting their imminent maturity.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth on the core facts. (1) CRITICAL ERROR - Numbers: The LLM states the liability was $1.185 billion in FY2023 and rose to $1.228 billion in FY2024, but the ground truth clearly states the obligation was FULLY REPAID by FY2024. The LLM's claim of an increase from $1.185B to $1.228B is factually wrong. (2) CRITICAL ERROR - Core Conclusion: The ground truth explicitly states 'this obligation was fully repaid' and represents 'complete resolution of this specific debt obligation.' The LLM incorrectly suggests the debt remained outstanding and even increased. (3) CALCULATION ERROR: The LLM calculates a $43 million increase ($1.228B - $1.185B), but this calculation is based on false premises since the debt was repaid. (4) MISINTERPRETATION: The LLM's mention of a '$1.250 billion short-term portion' and 'imminent maturity' suggests the debt was still outstanding at FY2024 year-end, which directly contradicts the ground truth that it was fully repaid. (5) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the evolution of this obligation across the two fiscal years - it should have identified the transition from outstanding liability to full repayment, not an increase in the liability. The answer demonstrates a fundamental misunderstanding of the question and provides materially incorrect financial information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1138,
        "completion_tokens": 392,
        "total_tokens": 1530
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the global revenue performance of Mavyret evolve between 2022 and 2023, and what were the trends in its United States and international markets during this period?",
      "original_answer": "In 2022, Mavyret generated total global revenue of $1,541 million, with $755 million from the United States and $786 million from international markets. By 2023, total revenue from Mavyret decreased to $1,430 million, driven by a decline in both U.S. and international markets. Specifically, U.S. revenue dropped to $659 million, a decrease of 12.7%, while international revenue slightly declined to $771 million, a marginal decrease of 1.9%. This indicates a contraction in Mavyret's market performance across both regions, with a more pronounced decline in the U.S. market.",
      "llm_answer": "Mavyret’s total net revenue fell from $1.541 billion in 2022 to $1.430 billion in 2023 – a 7.2 % decline.  The U.S. portion dropped sharply from $755 million to $659 million (≈‑13 %), while the international portion slipped only modestly from $786 million to $771 million (≈‑2 %)【source】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. Verification of key metrics: (1) Total revenue 2022: $1.541 billion ($1,541 million) - CORRECT; (2) Total revenue 2023: $1.430 billion ($1,430 million) - CORRECT; (3) U.S. revenue 2022: $755 million - CORRECT; (4) U.S. revenue 2023: $659 million - CORRECT; (5) International revenue 2022: $786 million - CORRECT; (6) International revenue 2023: $771 million - CORRECT. Calculation verification: (1) Overall decline: ($1,430-$1,541)/$1,541 = -111/1,541 = -7.2% - CORRECT; (2) U.S. decline: ($659-$755)/$755 = -96/755 = -12.7%, LLM states ≈-13% - CORRECT (appropriate rounding); (3) International decline: ($771-$786)/$786 = -15/786 = -1.9%, LLM states ≈-2% - CORRECT (appropriate rounding). The LLM successfully synthesized multi-hop information across years and geographic regions, correctly identifying the more pronounced decline in the U.S. market versus the modest international decline. The answer directly addresses all parts of the question regarding evolution between 2022-2023 and trends in both U.S. and international markets. The use of approximate symbols (≈) for percentages is appropriate given rounding. Minor note: The answer includes a source citation marker that appears incomplete, but this does not affect factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 363,
        "total_tokens": 1585
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Netflix's compliance with covenant limitations related to its Senior Notes evolve between 2022 and 2024, particularly in terms of repayment obligations and the scope of restrictions?",
      "original_answer": "In 2022, Netflix was in compliance with all covenant limitations tied to its Senior Notes, which included restrictions on creating liens, entering into sale and lease-back transactions, incurring additional indebtedness by certain subsidiaries, and merging or transferring substantial assets. These notes included various euro-denominated tranches with principal amounts totaling €5,170 million. By 2024, Netflix remained in compliance with these covenants, but the scope of limitations had slightly evolved—specifically, certain Senior Notes no longer referenced restrictions on sale and lease-back transactions, suggesting a narrowing of covenant scope for some notes. Additionally, in 2024, Netflix repaid $400 million of its 5.750% Senior Notes upon maturity, indicating active debt management and a shift in its debt composition.",
      "llm_answer": "In the 2022 Form 10‑K Netflix described its senior‑note covenants as prohibiting the company from creating new liens, entering sale‑and‑lease‑back transactions, incurring additional indebtedness of subsidiaries, or merging or selling substantially all of its assets, and it reported that it was in compliance with those covenants (no specific note repayment was noted)【NFLX_10k_2022.pdf page 55】. By the 2024 filing the same core restrictions remained—still limiting liens, asset‑transfer actions and, for certain notes, sale‑and‑lease‑backs and subsidiary debt—and the company again confirmed compliance, but it also disclosed that it had repaid the $400 million principal of its 5.750 % senior notes at maturity, showing an evolution from merely maintaining compliance to actively retiring a note series within the covenant framework【NFLX_10k_2024.pdf page 54‑55】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy with correct identification of Netflix's covenant compliance across 2022 and 2024. Key strengths: (1) All numeric values are correct—$400 million repayment amount, 5.750% interest rate on Senior Notes are accurate; (2) Covenant restrictions properly identified in both years (liens, sale-and-lease-back transactions, subsidiary indebtedness, asset transfers/mergers); (3) Multi-hop synthesis is sound—correctly connects 2022 compliance status with 2024 compliance status while noting the debt repayment action; (4) The characterization of evolution from 'maintaining compliance to actively retiring a note series' appropriately captures the shift in debt management strategy. Minor areas for improvement: (1) The LLM notes 'for certain notes, sale-and-lease-backs' in 2024, which aligns with the ground truth's observation about 'certain Senior Notes no longer referenced restrictions on sale and lease-back transactions,' but could have been more explicit about this narrowing of scope; (2) The ground truth mentions euro-denominated tranches totaling €5,170 million in 2022, which the LLM answer does not include—this is a notable omission of specific debt composition detail; (3) The LLM could have been slightly more explicit about the 'narrowing of covenant scope' language used in the ground truth. Overall, the answer correctly addresses the core question about covenant evolution, compliance status, and debt management actions, with accurate financial figures and sound reasoning across the multi-hop synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 430,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Honeywell's approach to the Safety and Retail product line evolve between 2022 and 2023, and what structural change was introduced in 2023 that reflects this evolution?",
      "original_answer": "In 2022, Honeywell reported the Safety and Retail business unit as a standalone component under the Safety and Productivity Solutions segment, generating $2,387 million in revenue. By 2023, the company had realigned its organizational structure, merging the Safety and Retail unit with the Advanced Sensing Technologies unit to form a new business unit called Sensing and Safety Technologies. This structural change, introduced in July 2022 but reported in the 2023 filing, reflects a strategic shift toward integrating sensing capabilities with safety solutions to enhance technological offerings and streamline operations.",
      "llm_answer": "In the 2022 filing Honeywell still reported Safety and Retail as a stand‑alone product line within the Safety and Productivity Solutions segment [HON_10k_2022.pdf p. 67]. By the 2023 filing the company had merged that unit with Advanced Sensing Technologies, creating a new Sensing and Safety Technologies business unit – a structural realignment disclosed in the 2023 10‑K (see the July 2022 realignment note and the 2023 segment table) [HON_10k_2023.pdf p. 66].",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core structural evolution: Safety and Retail was a standalone unit in 2022 that was merged with Advanced Sensing Technologies in 2023 to form Sensing and Safety Technologies. The answer accurately captures the multi-hop synthesis across 2022 and 2023 filings and correctly identifies the July 2022 realignment timing. However, there is a notable omission: the ground truth specifies that Safety and Retail generated $2,387 million in revenue in 2022, which the LLM answer does not include. This is a material quantitative detail that would strengthen the answer's completeness. The LLM correctly identifies the segment (Safety and Productivity Solutions), the business units involved, and the strategic rationale (integrating sensing with safety). The citation format and document references are appropriate. The reasoning about the structural change reflecting a strategic shift toward integration is sound and matches the ground truth's characterization. The minor weakness is the incomplete quantitative detail regarding 2022 revenue, which represents a partial omission rather than an error. The answer would score higher (8-9) if it had included the $2,387 million revenue figure for the 2022 Safety and Retail unit.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 354,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the status and role of Class B-2 Common Stock evolved between 2023 and 2024, particularly in terms of its convertibility and impact on corporate governance?",
      "original_answer": "In 2023, Class B-2 Common Stock was described as part of a structure that would become convertible into Class A Common Stock, with potential dilutive effects on voting power and market price. It also played a role in approving significant corporate actions, indicating a governance influence. By 2024, no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 Common Stock exchange offer, suggesting a strategic shift in equity structure. This indicates a transformation in the role of Class B-2 Common Stock, moving from an active governance and conversion position to a non-outstanding status, reducing its influence on corporate decisions.",
      "llm_answer": "In the 2023 filing Visa’s Class B‑2 common stock was only a convertible class – no B‑2 shares were outstanding – and it was described as “will become convertible into Class A common stock” with limited voting rights that could be exercised on certain significant transactions (e.g., a merger) and whose affirmative vote is required for some consolidations. By the 2024 filing a Class B‑1 exchange offer created 49 B‑2 shares (part of 125 total B‑class shares outstanding), making the securities issued while preserving their convertibility into Class A and their limited but pivotal voting rights that can affect merger‑type decisions, thereby giving B‑2 holders a direct, though constrained, role in corporate governance.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM claims '49 B-2 shares' were created and '125 total B-class shares outstanding' - these specific numbers are not supported by the ground truth and appear to be fabricated. The ground truth makes no mention of these specific share counts. (2) CONTRADICTORY NARRATIVE: The ground truth explicitly states that in 2023, 'no shares of Class B-2 Common Stock were outstanding' and by 2024, 'no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 Common Stock exchange offer.' The LLM reverses this, claiming B-2 shares were non-outstanding in 2023 but then created in 2024 through the exchange offer. This is backwards from the ground truth. (3) INCOMPLETE SYNTHESIS: The ground truth emphasizes a 'transformation' from 'active governance and conversion position to a non-outstanding status, reducing its influence.' The LLM instead describes an increase in B-2 shares and their role, which contradicts the core finding. (4) MISSING KEY INSIGHT: The ground truth's central point is that B-2 stock moved from active to non-outstanding status, indicating a strategic shift away from this class. The LLM misses this critical evolution. (5) COMPANY IDENTIFICATION: The LLM introduces 'Visa' without confirmation this is the correct company from the ground truth context, though this may be acceptable if Visa is indeed the subject. The answer fundamentally misrepresents the direction and magnitude of change in Class B-2 stock status between 2023 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 438,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has The Home Depot's approach to enhancing the ease of shopping experience evolved between 2023 and 2024, particularly in terms of digital and in-store capabilities?",
      "original_answer": "In 2023, The Home Depot focused on improving the ease of shopping experience by investing in mobile app-enabled store navigation, electronic shelf labels, reconfigured service desks, and enhanced self-checkout options. These efforts were aimed at improving store navigation, convenience, and checkout speed. By 2024, the company expanded its focus to include more personalized digital experiences, such as customer product review summaries and enhanced product content, while continuing to invest in digital platforms to improve navigation and 'shopability.' The 2024 strategy placed greater emphasis on leveraging customer data to meet personalized expectations, indicating a shift toward deeper integration of data-driven insights into the shopping journey.",
      "llm_answer": "In fiscal 2023 Home Depot laid the groundwork for a frictionless, interconnected shopping experience by upgrading its digital platforms—adding better search, richer product pages, faster checkout and mobile‑app navigation—and by enhancing stores with way‑finding signage, electronic shelf labels, self‑service lockers, curbside pickup and expanded self‑checkout options. In fiscal 2024 the company accelerated that effort with a $3.5 billion capital‑expenditure program that adds deeper personalization (richer product content, review summaries, data‑driven marketing), further integrates online‑order pickup and curbside services, and scales the same in‑store technologies across new locations, creating an even more seamless digital‑to‑physical shopping journey.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the evolution from 2023 to 2024, capturing the shift from foundational digital/in-store improvements to more personalized, data-driven approaches. It accurately mentions key 2023 initiatives (mobile app navigation, electronic shelf labels, self-checkout, curbside pickup) and 2024 enhancements (personalization, product review summaries, richer product content). The semantic understanding of the progression is sound and well-articulated. The answer demonstrates good multi-hop reasoning by synthesizing the evolution across both years.\n\nWEAKNESSES: The LLM introduces a specific quantitative claim—'$3.5 billion capital-expenditure program'—that is NOT present in the ground truth answer. This is a significant factual addition that cannot be verified against the provided knowledge graph. While this number may be accurate from the actual 10-K filing, it represents information beyond what the ground truth specifies, and introducing unverified financial figures is problematic in financial analysis contexts. The ground truth makes no mention of a specific capex amount.\n\nMULTI-HOP REASONING: The answer correctly synthesizes information across 2023 and 2024, properly identifying the progression and evolution. However, the introduction of the $3.5B figure without ground truth support undermines confidence in the quantitative accuracy.\n\nCOMPLETENESS: The answer addresses all aspects of the question—digital capabilities, in-store capabilities, and the evolution between years. It provides more specific examples than the ground truth (self-service lockers, curbside pickup details) which adds value but also introduces unverified specificity.\n\nSCORING JUSTIFICATION: Correctness score of 6 reflects that while the core narrative and qualitative evolution are correct, the introduction of an unverified $3.5B capex figure represents a material factual claim that cannot be confirmed against ground truth. Quantitative accuracy is 4 due to this unverified number. Qualitative accuracy is 7 because the reasoning and entity identification are sound despite the quantitative issue. Contextual relevance is 8 as the answer directly and thoroughly addresses the question asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 597,
        "total_tokens": 1984
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the structure of the Target Corporation Long-Term Incentive Plan evolved from 2022 to 2024, particularly in terms of the specific forms of equity awards included under the plan?",
      "original_answer": "In 2022, the Long-Term Incentive Plan included forms such as Non-Qualified Stock Options, Restricted Stock Units, Performance-Based Restricted Stock Units, Performance Share Units, Price-Vested Stock Options, Non-Employee Director Non-Qualified Stock Options, and Non-Employee Director Restricted Stock Units. By 2024, the plan introduced new forms of equity awards, including the Cliff-Vested Restricted Stock Unit Agreement and the Performance Award Performance Share Unit Agreement, indicating an expansion in the types of equity compensation vehicles available under the plan.",
      "llm_answer": "By 2022 Target’s Long‑Term Incentive Plan still offered a mixed menu of equity awards – non‑qualified stock options (including price‑vested options), restricted stock units, performance‑based RSUs, performance‑share units, non‑employee director options and RSUs, and even cash‑retention awards (see the exhibit list on page 66 of the 2022 filing)【66†L1-L21】. In the 2024 filing the plan’s award structure had been narrowed to RSU‑type awards only – standard RSUs, performance‑based RSUs, performance‑share units, a new cliff‑vested RSU and a performance‑award PSU – while the non‑qualified stock‑option and cash‑retention components were omitted (see the exhibit list on pages 71‑75 of the 2024 filing)【71†L1-L23】【71†L24-L38】. This reflects a shift from a mixed option/RSU plan to a primarily RSU‑centric long‑term incentive framework.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) INCORRECT CHARACTERIZATION OF 2024 PLAN: The LLM claims the 2024 plan was 'narrowed to RSU-type awards only' and that 'non-qualified stock-option and cash-retention components were omitted.' This directly contradicts the ground truth, which states the plan EXPANDED to include new forms like Cliff-Vested RSU and Performance Award PSU, but does NOT indicate that options were removed. The ground truth explicitly lists options as still being part of the 2022 plan structure and does not state they were eliminated by 2024. (2) MISCHARACTERIZATION OF EVOLUTION: The LLM describes this as a 'shift from a mixed option/RSU plan to a primarily RSU-centric' framework, suggesting contraction rather than expansion. The ground truth indicates EXPANSION ('introduced new forms'), not elimination of existing award types. (3) INCOMPLETE ACCURACY ON 2022: While the LLM correctly identifies most 2022 award types (non-qualified stock options, RSUs, performance-based RSUs, performance share units, director options and RSUs), it adds 'cash-retention awards' which are not mentioned in the ground truth. (4) CORRECT IDENTIFICATION OF NEW 2024 AWARDS: The LLM correctly identifies the two new award types introduced in 2024 (Cliff-Vested RSU and Performance Award PSU), which aligns with ground truth. (5) CITATION ISSUES: The LLM provides specific page references (66, 71-75) that cannot be verified against the ground truth provided, and the citation format suggests confidence in details that may not be accurate. The fundamental error is misinterpreting plan evolution as a narrowing/shift rather than an expansion with new award types added.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 477,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Qulipta's commercial performance evolve from its FDA approval in 2021 through 2023, based on AbbVie's financial disclosures?",
      "original_answer": "Qulipta was approved by the FDA in September 2021 for the preventive treatment of episodic migraine in adults, marking its entry into the market. By 2023, Qulipta had generated $405 million in U.S. revenue and $3 million internationally, totaling $408 million. This indicates a significant commercial trajectory following its approval, especially considering it had no revenue in 2021 and only $158 million in U.S. revenue in 2022. The product demonstrated strong growth, suggesting robust market adoption and positioning within AbbVie's portfolio.",
      "llm_answer": "AbbVie received its first FDA approval for Qulipta (atogepant) in September 2021, and the drug generated its first sales in 2022 – $158 million of U.S. net revenue (no revenue in 2021)【ABBV_10k_2022.pdf†p.58‑62】.  In 2023 Qulipta’s sales more than doubled, reaching $405 million in the United States and $408 million worldwide, a >100 % year‑over‑year increase driven by strong market‑share uptake and the additional FDA approval for chronic migraine (April 2023) and EU approval (August 2023)【ABBV_10k_2023.pdf†p.40‑44】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Quantitative verification: (1) FDA approval date of September 2021 - CORRECT; (2) 2021 revenue of $0 - CORRECT; (3) 2022 U.S. revenue of $158 million - CORRECT; (4) 2023 U.S. revenue of $405 million - CORRECT; (5) 2023 international revenue of $3 million - CORRECT; (6) 2023 total revenue of $408 million - CORRECT (405 + 3 = 408). The LLM correctly calculated the year-over-year growth as >100% (158M to 405M represents 156% growth). Multi-hop reasoning: The answer successfully synthesizes information across multiple years and documents (2022 and 2023 10-K filings), tracking the product's evolution from approval through commercialization. Entity accuracy is strong - correctly identifies Qulipta (atogepant), AbbVie, FDA approvals, and the specific indications (episodic migraine in 2021, chronic migraine in April 2023). The answer goes beyond the ground truth by adding valuable context about the April 2023 chronic migraine approval and August 2023 EU approval, which explains the strong growth trajectory. The only minor distinction is that the LLM specifies the international revenue as part of the $408 million total (implying $3M international), which aligns with the ground truth statement of '$405 million in U.S. revenue and $3 million internationally, totaling $408 million.' The reasoning about market-share uptake and the impact of additional approvals on growth is sound and well-supported by the data presented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 410,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has Netflix's treatment and disclosure of the 2020 Stock Plan evolved between the 2022 and 2024 SEC filings, particularly in terms of its structural description and associated equity compensation activities?",
      "original_answer": "In 2022, the 2020 Stock Plan was referenced primarily through its inclusion in the exhibit list as a filed document (Def 14A, filed April 22, 2020), with no detailed description of its provisions or activities. In contrast, by 2024, the 2020 Stock Plan was not only explicitly described in detail but also linked to specific equity compensation activities, including the granting of incentive stock options, nonstatutory stock options, and restricted stock units (RSUs) with defined vesting schedules and performance-based criteria. This represents a significant shift from mere documentation to a more comprehensive disclosure of the plan's operational role in equity compensation.",
      "llm_answer": "In the 2022 Form 10‑K Netflix described the 2020 Stock Plan simply as a “stockholder‑approved plan that provides for the grant of incentive stock options to employees and for the grant of non‑statutory stock options, stock‑appreciation rights, restricted stock and restricted stock units to employees, directors and consultants.” By the 2024 filing the same core language is retained, but the disclosure now notes that the plan also supports performance‑based RSUs and expands the equity‑compensation tables to show that no new options were granted in 2022, that RSU/PSU grants were paused in 2022‑2023, and that stock‑based compensation expense fell from $575 million in 2022 to $273 million in 2024, with detailed intrinsic‑value and cash‑received data for exercised options.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides a partially correct response with significant issues in quantitative accuracy. STRENGTHS: (1) Correctly identifies the core evolution from basic documentation to more detailed disclosure; (2) Accurately captures the shift toward performance-based RSUs and expanded equity compensation tables; (3) Properly identifies the types of awards (incentive stock options, nonstatutory stock options, RSUs, PSUs); (4) Demonstrates sound multi-hop reasoning by synthesizing information across 2022 and 2024 filings. WEAKNESSES: (1) CRITICAL QUANTITATIVE ERROR - The LLM states stock-based compensation expense fell from $575 million in 2022 to $273 million in 2024. The ground truth does not provide these specific numbers, and the magnitude of this decline (52.6% reduction) is presented as fact without verification. This is a major factual claim that cannot be confirmed against the ground truth provided; (2) The LLM introduces specific operational details (no new options granted in 2022, RSU/PSU grants paused in 2022-2023) that are not mentioned in the ground truth answer, making it impossible to verify their accuracy; (3) The ground truth emphasizes the shift from 'mere documentation' to 'comprehensive disclosure of the plan's operational role,' while the LLM focuses more on specific compensation metrics and expense figures rather than the structural/disclosure evolution itself. MULTI-HOP REASONING: The LLM correctly synthesizes information across two filing years and identifies the evolution in disclosure practices, though it diverges from the ground truth's emphasis on structural description versus operational linkage. The answer is contextually relevant to the question about evolution of treatment and disclosure, but the introduction of unverified financial figures significantly undermines credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 499,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the company's approach to aluminum purchase agreements evolve between 2022 and 2023, particularly in terms of their classification and strategic use of derivative instruments?",
      "original_answer": "In 2022, the company described its aluminum purchase agreements as derivative instruments entered into for long-term strategic sourcing objectives and non-U.S. business requirements. By 2023, the company continued to use these agreements but provided additional clarity that the quantities of aluminum in these contracts offset each other and are priced at prevailing market prices. This evolution indicates a more refined strategy around market pricing alignment and potentially reduced exposure through offsetting positions.",
      "llm_answer": "The company kept the same accounting treatment in both years – its aluminum purchase‑and‑sale agreements were still classified as derivative instruments that do not qualify for hedge accounting and were described as tools to meet long‑term strategic sourcing objectives and non‑U.S. business requirements (2022 p. 119‑123; 2023 p. 101‑105).  However, the scale of those non‑hedged commodity contracts fell sharply, with the notional amount dropping from 760 (2021) to 412 (2022), indicating a reduced reliance on the aluminum agreements while the strategic purpose remained unchanged.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ASPECTS: (1) The accounting treatment remained consistent across 2022-2023 as derivative instruments not qualifying for hedge accounting - this aligns with ground truth. (2) The strategic purpose (long-term sourcing objectives and non-U.S. business requirements) is correctly identified. (3) The general characterization of the evolution is reasonable. SIGNIFICANT ISSUES: (1) QUANTITATIVE ERROR - The LLM introduces specific notional amounts (760 in 2021, 412 in 2022) that are NOT mentioned in the ground truth answer. These numbers appear to be fabricated or from a different source not verified against the knowledge graph. This is a critical factual error. (2) INCOMPLETE ANSWER - The ground truth emphasizes a KEY evolution point: by 2023, the company provided 'additional clarity that the quantities of aluminum in these contracts offset each other and are priced at prevailing market prices.' The LLM answer completely omits this important refinement in strategy and disclosure, which was the core of the evolution narrative. (3) MISDIRECTED FOCUS - Rather than highlighting the 2022-to-2023 evolution (the question's focus), the LLM shifts focus to 2021-to-2022 changes in notional amounts, which is not the primary comparison requested. (4) MISSING STRATEGIC INSIGHT - The ground truth notes 'potentially reduced exposure through offsetting positions' as a strategic implication of the 2023 clarification. The LLM misses this entirely. The answer demonstrates partial understanding of the accounting classification but fails on the core evolution narrative and introduces unverified quantitative data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 459,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the disclosure or treatment of the Directors' Code of Conduct evolved between 2023 and 2024, particularly in terms of its accessibility and scope?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly referenced and posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors-code-of-conduct.pdf. In 2024, the URL for the Directors' Code of Conduct changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf, indicating a shift in how the document is categorized or accessed. Additionally, in 2024, the company introduced a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES,' which was not present in 2023, suggesting an expanded focus on compliance mechanisms beyond the Code itself. These changes reflect a transformation in the presentation and accessibility of the Directors' Code of Conduct, as well as an increased emphasis on insider trading compliance.",
      "llm_answer": "In the 2023 Form 10‑K the company said its Directors’ Code of Conduct “applies to all directors of BNY Mellon” and is posted on its website at a URL in an “inv relations” folder ( https://www.bnymellon.com/.../inv relations/directors‑code‑of‑conduct.pdf ). The 2024 filing repeats the same scope – the code still applies to every director – but updates the link to a clearer “investor‑relations” path ( …/investor‑relations/directors‑code‑of‑conduct.pdf ) and aligns the site branding with the newer bny.com domain, making the code more directly accessible.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies that the Directors' Code of Conduct applies to all directors in both years and accurately captures the URL path change from 'inv relations' to 'investor-relations' and the domain shift from bnymellon.com to bny.com. However, the answer has significant omissions that reduce its completeness. The ground truth explicitly states that in 2024, a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES' was introduced, which was not present in 2023. This represents a material expansion in scope and compliance focus that the LLM answer completely fails to mention. The question specifically asks about 'scope' evolution, and the introduction of this new section is a key indicator of expanded scope. The LLM answer focuses primarily on accessibility improvements (URL changes, domain branding) but misses the substantive scope expansion. While the LLM correctly identifies the accessibility changes and maintains accuracy on the URL path modifications, it fails to address approximately 40% of the ground truth answer's key findings regarding the new insider trading policies section. The answer is partially correct on accessibility but incomplete on scope, which was explicitly asked about in the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 350,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the structure and value of HD's 4.95% Senior Notes evolved between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, HD issued $750 million of 4.95% senior notes due September 30, 2026, at a discount of $1.6 million. By 2024, the carrying amount of these 4.95% senior notes due September 2026 was $747 million as of February 2, 2025, and the company also reported $980 million in 4.95% senior notes due September 2052. This indicates that while the original 2026 notes remained outstanding with only a slight reduction in carrying value, HD expanded its 4.95% senior note structure to a much longer maturity in 2052, suggesting a strategy of extending debt maturities and potentially locking in fixed interest rates over a longer horizon.",
      "llm_answer": "In 2023 Home Depot added a new $750 million tranche of 4.95 % senior notes due September 2026 (issued at a $1.6 million discount) and reported a net carrying amount of about $744 million at year‑end 2023【HD_10k_2023.pdf p.58‑59】. By the close of fiscal 2024 the same issue still carried a $750 million principal but its net carrying amount had risen to roughly $745‑$747 million, reflecting the amortization of the discount and a stable balance【HD_10k_2024.pdf p.60‑61】. The modest increase and the decision to retain the notes indicate that Home Depot is deliberately building a diversified, fixed‑rate, medium‑term debt base to lock in financing costs and support its long‑term liquidity and acquisition strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ISSUES: (1) MAJOR OMISSION - The LLM answer completely fails to mention the $980 million in 4.95% senior notes due September 2052, which is a crucial part of the ground truth answer and directly addresses the question about how the structure 'evolved' between 2023 and 2024. This is a significant multi-hop synthesis failure. (2) QUANTITATIVE ERRORS - The LLM states the carrying amount was 'about $744 million at year-end 2023' but the ground truth indicates $750 million was issued at a $1.6 million discount, resulting in approximately $748.4 million carrying value initially. The LLM's figure of $744 million appears incorrect. (3) CARRYING VALUE DISCREPANCY - The LLM claims the carrying amount 'had risen to roughly $745-$747 million' by fiscal 2024, but the ground truth states it was $747 million as of February 2, 2025 (fiscal 2024 year-end). The LLM's range is imprecise and the direction of change is unclear. (4) INCOMPLETE ANALYSIS - The ground truth explicitly states that HD 'expanded its 4.95% senior note structure to a much longer maturity in 2052,' which is the key strategic insight about debt maturity extension. The LLM completely misses this critical evolution. (5) REASONING QUALITY - While the LLM correctly identifies the 2026 notes and discusses discount amortization, it fails to synthesize the complete picture of HD's debt strategy by omitting the 2052 notes entirely. The conclusion about 'medium-term debt base' is partially correct but incomplete without acknowledging the simultaneous issuance of long-term 2052 notes. CORRECT ELEMENTS: The 2023 issuance details ($750 million, 4.95%, September 2026, $1.6 million discount) are accurate. The discussion of discount amortization is conceptually sound. The general strategic intent about fixed-rate financing is reasonable but incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 496,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did Intel's financial treatment and valuation of its investment in Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of observable price adjustments and net book value?",
      "original_answer": "In 2021, Intel recognized $471 million in observable price adjustments in its investment in Beijing Unisoc Technology Ltd. By the end of 2023, Intel was accounting for its interest in Unisoc as a non-marketable equity security, with a net book value of $1.1 billion as of December 30, 2023 (the same as December 31, 2022). This indicates that while Intel continued to hold the investment without marketability, the valuation remained stable over the two-year period despite the earlier price adjustment.",
      "llm_answer": "Intel initially re‑valued its stake in Beijing Unisoc in 2021 with a $471 million upward “observable price adjustment” to the non‑marketable equity security 【INTC_10k_2022.pdf p.41‑45】.  By the end of 2023 the investment was carried at a net book value of roughly $1.1 billion (the same amount reported at year‑end 2022) and the only observable price adjustments thereafter were modest – $299 million in 2022 and $17 million in 2023 for all non‑marketable equity securities 【INTC_10k_2023.pdf p.94‑98】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT: (1) The $471 million observable price adjustment in 2021 is accurate. (2) The $1.1 billion net book value as of December 30, 2023 (same as December 31, 2022) is correct. (3) The characterization of the investment as a non-marketable equity security is accurate. (4) The general narrative about valuation stability is sound. PROBLEMATIC: (1) The LLM introduces additional information about $299 million in 2022 and $17 million in 2023 observable price adjustments for 'all non-marketable equity securities' - this is NOT part of the ground truth answer and appears to conflate aggregate non-marketable equity security adjustments with the specific Unisoc investment. The ground truth specifically states 'the only observable price adjustments thereafter were modest' but does not provide these specific figures or clarify they apply to all non-marketable securities rather than Unisoc alone. (2) The citation references (p.41-45 and p.94-98) cannot be verified against the ground truth provided. MULTI-HOP REASONING: The answer attempts to synthesize information across 2021-2023 and correctly identifies the evolution from 2021 adjustment to stable 2022-2023 valuation. However, the introduction of aggregate non-marketable equity security figures muddies the specific focus on Unisoc. The core answer structure is sound but the additional quantitative details create ambiguity about whether they apply specifically to Unisoc or to the broader category. QUANTITATIVE ISSUES: While the key numbers ($471M, $1.1B) are correct, the introduction of $299M and $17M figures without clear attribution to Unisoc specifically represents a significant quantitative accuracy concern. These figures may be correct for the broader category but are not established in the ground truth as applying to Unisoc.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 505,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did AbbVie's engagement with Qulipta evolve from 2022 to 2023, particularly in terms of its regulatory and commercial development status?",
      "original_answer": "In 2022, Qulipta was part of a group of products that received regulatory approvals, leading to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights. By 2023, AbbVie had introduced Qulipta with specific regulatory milestones: it received FDA approval in April 2023 for the preventive treatment of chronic migraine in adults and EC approval in August 2023 for the preventive treatment of migraine in adults with four or more migraine days per month. This evolution reflects a shift from asset reclassification to active regulatory and commercial advancement.",
      "llm_answer": "In the 2022 Form 10‑K AbbVie noted that Qulipta had already received regulatory clearance and was re‑classified from an indefinite‑life R&D intangible to a “developed product right,” signaling that the drug was on the market (2022‑10‑K pp. 101‑102). By the 2023 Form 10‑K the company reported new regulatory milestones—FDA approval in April 2023 and European Commission approval in August 2023—and showed that Qulipta generated $405 million of U.S. sales (plus modest international sales) in 2023, indicating continued commercial launch and expansion (2023‑10‑K pp. 38‑40).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about Qulipta's evolution from 2022 to 2023. STRENGTHS: (1) Correctly identifies the 2022 reclassification of R&D intangible assets to developed product rights, matching the ground truth's $1.0 billion figure (though LLM doesn't explicitly state the amount, it correctly characterizes the reclassification). (2) Accurately reports both regulatory milestones: FDA approval in April 2023 and EC approval in August 2023 with correct indications (preventive treatment of chronic migraine/migraine). (3) Provides additional commercial context by citing $405 million in U.S. sales for 2023, which adds valuable information beyond the ground truth and demonstrates the commercial advancement phase. (4) Correctly synthesizes the multi-hop evolution from asset reclassification (2022) to regulatory approvals and commercial launch (2023). (5) Properly cites specific 10-K pages, enhancing credibility. MINOR CONSIDERATIONS: (1) The LLM states Qulipta \"was on the market\" in 2022 based on the reclassification, which is a reasonable inference but slightly differs from the ground truth's more cautious framing of \"reclassification\" without explicitly confirming market presence in 2022. However, this is a minor semantic distinction. (2) The ground truth emphasizes the shift from \"asset reclassification to active regulatory and commercial advancement,\" while the LLM frames it as progression from reclassification to regulatory milestones and commercial sales—semantically equivalent. QUANTITATIVE VERIFICATION: All dates (April 2023, August 2023) are correct; the $405 million sales figure is presented as additional supporting evidence. No calculation errors detected. The answer successfully addresses both the regulatory and commercial development aspects of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 507,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has Boeing's framing and strategic emphasis on 'upgrades and conversions' within the Global Services segment evolved between 2022 and 2023, based on the language used in the 10-K filings?",
      "original_answer": "In 2022, 'upgrades and conversions' were listed as part of a broader set of services under the Global Services segment, grouped alongside supply chain logistics, engineering, maintenance, spare parts, training systems, technical documents, and digital services. The description was general and lacked strategic framing. In 2023, while the service was still included, the context shifted subtly: it was now positioned within a more structured narrative that emphasized the full spectrum of sustaining aerospace platforms and systems, indicating a more integrated and strategic role within the segment. This evolution suggests a more deliberate positioning of 'upgrades and conversions' as a core capability rather than a general service offering.",
      "llm_answer": "In the 2022 Form 10‑K Boeing described Global Services as delivering a “full spectrum of products and services, including … upgrades and conversions” and noted that BGS would “grow market share by leveraging a high level of customer satisfaction and productivity” through those lifecycle services【BA_10k_2022.pdf p.3‑5】【BA_10k_2022.pdf p.6‑7】. The 2023 filing repeats the same phrasing—“upgrades and conversions” remain listed among the full‑spectrum services and the segment again says it will “grow market share by leveraging a high level of customer satisfaction and productivity” with its modifications and upgrades offering【BA_10k_2023.pdf p.1‑3】【BA_10k_2023.pdf p.4‑5】. Thus, Boeing’s framing of upgrades and conversions has stayed essentially unchanged, continuing to present them as core, growth‑driving components of Global Services.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ISSUE: The LLM answer directly contradicts the ground truth on the core finding. Ground truth states that Boeing's framing EVOLVED between 2022 and 2023, with 2023 showing a 'more structured narrative' and 'more deliberate positioning' of upgrades and conversions as a 'core capability.' The LLM answer explicitly claims the framing 'stayed essentially unchanged' and remained 'the same phrasing,' which is the opposite conclusion from the ground truth. This is a fundamental misreading of the question's premise and the filing evolution. QUANTITATIVE ACCURACY: The LLM correctly identifies the years (2022, 2023) and references the appropriate documents with page numbers, which is accurate. No numerical calculations are required here. QUALITATIVE ACCURACY: The LLM failed to detect or articulate the subtle but important shift in strategic positioning that the ground truth identifies. The ground truth emphasizes that in 2023, upgrades and conversions were positioned within 'a more structured narrative' emphasizing 'the full spectrum of sustaining aerospace platforms and systems,' indicating 'a more integrated and strategic role.' The LLM's conclusion that the language remained unchanged misses this evolution entirely. The LLM appears to have focused on surface-level repetition of phrases rather than analyzing the contextual shift in how the service was framed strategically. CONTEXTUAL RELEVANCE: The question explicitly asks about how the framing and strategic emphasis 'evolved' between the two years. The LLM's answer that nothing evolved is fundamentally non-responsive to the question's core inquiry. The question presupposes an evolution; the ground truth confirms it; the LLM denies it. This represents a major failure in understanding what the question is asking. MULTI-HOP REASONING: The LLM needed to synthesize information from both 2022 and 2023 filings and compare them to identify evolution. While the LLM did reference both years, it failed to perform the comparative analysis that would reveal the strategic shift described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 559,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Intel's financial relationship with Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of the valuation and recognition of this investment?",
      "original_answer": "Intel's financial relationship with Beijing Unisoc Technology Ltd. remained consistent in terms of total net book value, which stayed at $1.1 billion as of both December 25, 2021 (from the 2022 filing) and December 30, 2023 (from the 2023 filing). However, in 2021, Intel recognized $471 million in observable price adjustments related to its investment in Unisoc, indicating a revaluation event during that year. This type of valuation adjustment was not explicitly mentioned in the 2023 filing, suggesting a stabilization of the investment's value over time or a lack of significant observable price changes in 2023 compared to 2021.",
      "llm_answer": "Intel’s holding in Beijing Unisoc was accounted for as a non‑marketable equity security. At the end of 2020 the investment was $658 million, but by December 2021 it had risen to $1.1 billion, and Intel recognized a $471 million observable‑price adjustment on the Unisoc stake in 2021 【INTC_10k_2022.pdf†page 50‑54】. The net book value of the investment stayed at $1.1 billion at year‑end 2022 and again at year‑end 2023, indicating that the valuation increase was realized in 2021 and has remained stable since then 【INTC_10k_2023.pdf†page 94‑98】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key facts: (1) Investment valuation progression is correct - $658M at end of 2020, rising to $1.1B by December 2021, with the $471M observable price adjustment in 2021 matching ground truth exactly. (2) The net book value remaining at $1.1B through year-end 2022 and 2023 is accurate. (3) The characterization as a non-marketable equity security is appropriate and adds relevant context. (4) Multi-hop reasoning is sound - the answer correctly synthesizes information across 2021, 2022, and 2023 filings to show the evolution of the investment relationship. (5) The conclusion that the valuation increase occurred in 2021 and remained stable thereafter is logically sound and matches the ground truth's observation about stabilization. Minor note: The LLM provides slightly more detail about the 2020 baseline ($658M) than the ground truth explicitly states, but this is additional accurate information that enhances rather than contradicts the answer. The answer directly addresses both components of the question: the evolution of the financial relationship (showing the 2021 increase and subsequent stability) and the valuation/recognition aspects (documenting the $471M adjustment and stable $1.1B book value). All numbers are formatted correctly and calculations are implicit but accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 379,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role of Self-Service Lockers evolved within Home Depot's interconnected shopping experience between 2023 and 2024?",
      "original_answer": "In 2023, Self-Service Lockers were described as part of Home Depot's investments to improve the customer shopping experience, specifically to enable convenient online order pickup options alongside other features like wayfinding signage and electronic shelf labels. By 2024, Self-Service Lockers were positioned more strategically as part of the company's broader fulfillment network, specifically referenced in the context of leveraging stores as 'convenient customer pickup, return, and delivery fulfillment locations' under interconnected retail programs such as BOSS, BOPIS, BODFS, and BORIS. Additionally, in 2024, approximately 50% of U.S. online orders were fulfilled through a store, highlighting a more integrated and operationally significant role for Self-Service Lockers in the fulfillment process. This reflects a shift from a convenience-focused feature to a core component of the omnichannel delivery strategy.",
      "llm_answer": "In fiscal 2023 Home Depot first highlighted self‑service lockers as a store‑refresh investment that “enable[s] convenient online‑order pickup options” and listed them among the four interconnected retail programs (BOSS, BOPIS, BODFS and BORIS) that let customers pick up or return merchandise at the front‑entrance lockers 【2023 p. 9】【2023 p. 10】. By fiscal 2024 the lockers are still described as a core component of the “interconnected shopping experience,” now emphasized as part of the broader suite of pickup options that complement curbside service and support the BOPIS/BOSS ecosystem, reinforcing their role as a permanent, omnichannel fulfillment channel 【2024 p. 9】【2024 p. 10】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution of Self-Service Lockers from 2023 to 2024 and correctly identifies the key programs (BOSS, BOPIS, BODFS, BORIS). However, there are significant gaps and inaccuracies: (1) CRITICAL OMISSION: The ground truth specifically mentions that 'approximately 50% of U.S. online orders were fulfilled through a store' in 2024 - this quantitative metric is completely absent from the LLM answer, representing a major factual gap. (2) CHARACTERIZATION ISSUE: The LLM states lockers were 'listed among the four interconnected retail programs' in 2023, but the ground truth indicates they were described as 'part of' these programs, not as one of the four programs themselves - this is a subtle but important distinction. (3) INCOMPLETE EVOLUTION NARRATIVE: The ground truth emphasizes a clear shift 'from a convenience-focused feature to a core component of the omnichannel delivery strategy,' while the LLM's description is more static, describing them as 'still described as a core component' without clearly articulating the strategic shift. (4) MISSING CONTEXT: The ground truth mentions 'wayfinding signage and electronic shelf labels' as companion investments in 2023, which provides important context for understanding the broader store-refresh initiative. (5) POSITIVE ELEMENTS: The LLM correctly identifies the fiscal years (2023 and 2024), the four programs, and the general positioning as part of fulfillment/omnichannel strategy. The citation format suggests document references, though these cannot be verified. The reasoning about evolution from convenience to core component is directionally correct but lacks the quantitative support that would strengthen the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 467,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the level of detail and specificity in Costco's disclosure regarding the estimation methods for Insurance/Self-insurance Liabilities evolved from 2023 to 2024?",
      "original_answer": "In 2023, Costco provided a general description of its self-insurance practices and risk management mechanisms, including the use of a captive insurance subsidiary and a reinsurance program, but did not specify the factors used in estimating liabilities. In 2024, the company significantly expanded its disclosure, detailing that liabilities are estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions. Additionally, 2024's disclosure included a discussion of the unpredictability of claim costs and the potential for significant differences between actual and recorded liabilities, which was not present in 2023. This represents a meaningful increase in transparency and specificity.",
      "llm_answer": "In the 2023 filing (pages 44‑48) Costco’s note on Insurance/Self‑insurance Liabilities was fairly high‑level – it said the liabilities are “estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions” and that any adjustments had historically been immaterial. By the 2024 filing (pages 29‑33) the disclosure is more granular: it still cites the same base assumptions but now explicitly calls out inflation, regulatory or legal changes and “unforeseen developments” as sources of variability, stresses that claim costs are “highly unpredictable,” and notes that actual costs could differ significantly from the estimates. Thus, the 2024 discussion adds specific risk drivers and a clearer warning about estimate uncertainty, making the disclosure more detailed and specific than in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual inversion that contradicts the ground truth. The LLM claims that in 2023, Costco ALREADY disclosed 'historical claims experience, demographic factors, severity factors, and other actuarial assumptions' - but the ground truth explicitly states that in 2023, Costco 'did not specify the factors used in estimating liabilities' and only provided 'a general description.' The ground truth indicates this detailed specification of estimation methods was NEW in 2024, not present in 2023. This is a major error that reverses the core finding of the question. The LLM correctly identifies that 2024 added discussion of unpredictability, inflation, regulatory changes, and 'unforeseen developments,' which aligns with ground truth. However, by incorrectly attributing the detailed estimation methodology to 2023, the LLM fundamentally misrepresents the evolution of disclosure. The page number citations (2023: pages 44-48, 2024: pages 29-33) cannot be verified against the ground truth but appear plausible. The characterization of 2024 as 'more granular' is correct, but the baseline comparison is wrong. The LLM correctly notes that adjustments were 'historically immaterial' in 2023, which aligns with ground truth's description of general disclosure. The semantic understanding of what constitutes 'increased transparency' is present, but the factual foundation is inverted, making the answer substantially incorrect despite some accurate elements regarding 2024's enhancements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 426,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How did the financial impact of the Aldevron acquisition on inventory-related costs evolve from 2022 to 2023?",
      "original_answer": "In 2022, the Aldevron acquisition contributed to a $59 million increase in cost of sales due to fair value adjustments to inventory. By 2023, this specific acquisition-related cost associated with Aldevron was no longer present; instead, a new $87 million charge emerged in the second quarter, primarily related to excess inventory in the Biotechnology segment due to reduced demand. This indicates a shift from acquisition-driven inventory adjustments to operational inventory challenges.",
      "llm_answer": "In 2022 the company said the “lower incremental year‑over‑year acquisition‑related charges associated with fair‑value adjustments to inventory in connection with the 2021 Aldevron acquisition” (the $59 million inventory charge that had boosted cost of sales in 2021) were largely absent, tempering the rise in cost of sales. By 2023, inventory costs rose again – the firm recorded a $87 million excess‑inventory charge in Q2 (driven by reduced demand), a much larger inventory‑related expense than the muted Aldevron‑related impact seen in 2022.【80†L31-L38】【44†L31-L38】",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual error that contradicts the ground truth. The LLM states that in 2022, 'the $59 million inventory charge that had boosted cost of sales in 2021' was 'largely absent,' implying the $59M charge occurred in 2021, not 2022. However, the ground truth explicitly states: 'In 2022, the Aldevron acquisition contributed to a $59 million increase in cost of sales due to fair value adjustments to inventory.' This is a critical misplacement of the timing of the $59M charge. The LLM incorrectly attributes this charge to 2021 rather than 2022. The LLM does correctly identify the $87 million excess inventory charge in Q2 2023 and correctly notes it was driven by reduced demand in the Biotechnology segment. The LLM also correctly captures the conceptual shift from acquisition-driven adjustments to operational challenges. However, the mischaracterization of when the $59M charge occurred is a major factual error that undermines the core answer to the question about how the impact 'evolved from 2022 to 2023.' The answer should have clearly stated that 2022 saw the $59M Aldevron-related charge, and 2023 saw the $87M excess inventory charge - a shift in both magnitude and source. The LLM's framing makes it appear the $59M was a 2021 event that was absent in 2022, which is incorrect and creates confusion about the actual year-over-year evolution being asked about.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 398,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the treatment and recognition of shop card liabilities evolved between 2023 and 2024, and what does this indicate about Costco's approach to unclaimed balances?",
      "original_answer": "In both 2023 and 2024, Costco recognized revenue from shop cards upon redemption and accounted for outstanding balances as a liability, net of estimated breakage based on redemption data. However, the specific mention of 'estimated breakage' and the methodology tied to redemption data became more emphasized in 2024, indicating a more refined or formalized approach to tracking and accounting for unclaimed shop card balances. This evolution suggests Costco improved its estimation techniques for unclaimed balances, aligning its liability reporting more closely with actual redemption behavior over time.",
      "llm_answer": "Costco’s 2023 and 2024 filings both state that shop‑card balances are recorded as a liability, net of an estimated breakage amount, and that revenue from the cards is recognized only when the cards are actually redeemed. There was no substantive change in the accounting policy, which shows Costco continues to take a conservative, breakage‑based approach to unclaimed balances—deferring revenue until redemption and estimating the portion that will never be used.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies the core accounting mechanics (revenue recognized upon redemption, liabilities recorded net of estimated breakage) and accurately states that both 2023 and 2024 filings reflect this approach. However, the answer fundamentally misses the key evolution that the ground truth emphasizes. The ground truth explicitly states that 'the specific mention of estimated breakage and the methodology tied to redemption data became more emphasized in 2024, indicating a more refined or formalized approach.' The LLM answer explicitly contradicts this by stating 'There was no substantive change in the accounting policy,' which directly contradicts the ground truth's assertion of an evolution/refinement in 2024. The LLM correctly identifies that Costco uses a conservative, breakage-based approach and defers revenue until redemption, but it fails to recognize the important distinction that the 2024 filing shows more emphasis on the methodology and formalization of the breakage estimation process. This is a critical failure in multi-hop reasoning—the question asks specifically about how treatment 'evolved' between the two years, and the ground truth indicates a meaningful evolution in emphasis and methodology formalization, while the LLM dismisses any substantive change. The quantitative accuracy is high (no numbers to verify, dates are correct), but the qualitative accuracy is low because the LLM missed the core insight about the evolution in approach and emphasis that distinguishes 2024 from 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 423,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has Intel's Foundry Services offering evolved from 2022 to 2023 in terms of strategic partnerships and customer engagement, based on the specific initiatives and agreements mentioned in those years?",
      "original_answer": "In 2022, Intel introduced its Foundry Services as part of the IDM 2.0 strategy, emphasizing plans to build a world-class foundry business with differentiated offerings, including leading-edge packaging and process technology, committed capacity in the US and Europe, and a strong IP portfolio. By 2023, Intel had significantly advanced this offering by securing four design wins on Intel 18A, including a major high-performance computing customer, and five new design wins in advanced packaging, particularly for AI-related designs. Additionally, Intel expanded its IFS Accelerator Ecosystem Alliance program to over 40 strategic agreements and entered into multigenerational agreements with ARM and Synopsys to enable optimized SoC design on Intel 18A. These developments indicate a shift from strategic intent in 2022 to concrete customer engagements and ecosystem partnerships in 2023.",
      "llm_answer": "In 2022 Intel rolled out its new Foundry Services (IFS) under the IDM 2.0 plan, launching the IFS Accelerator Ecosystem Alliance and taking the lead on the first phase of the U.S. Department of Defense’s RAMP‑C program, which established its initial strategic partnerships and early customer foothold. By 2023 the IFS ecosystem had roughly doubled to more than 40 alliances, added multigenerational agreements with ARM and a definitive deal with Synopsys, broadened RAMP‑C collaborations to include marquee customers such as Nvidia, IBM, Microsoft, Boeing and Northrop Grumman, and secured a commercial agreement with Tower for 300‑mm analog‑processing capacity—signaling a markedly deeper and broader partnership and customer‑engagement strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the overall evolution narrative from 2022 to 2023 and correctly identifies several key elements: the IDM 2.0 strategy, the IFS Accelerator Ecosystem Alliance expansion to 40+ partnerships, multigenerational agreements with ARM and Synopsys, and the shift from strategic intent to concrete engagements. However, there are significant factual issues: (1) The LLM introduces RAMP-C program details and specific customer names (Nvidia, IBM, Microsoft, Boeing, Northrop Grumman) and a Tower semiconductor agreement that are NOT mentioned in the ground truth answer. These appear to be either hallucinated or from different source material not validated by the knowledge graph. (2) The ground truth specifically mentions 'four design wins on Intel 18A' and 'five new design wins in advanced packaging' - concrete quantitative achievements that the LLM answer completely omits. (3) The LLM's claim about the ecosystem 'roughly doubling' to 40+ alliances is imprecise - the ground truth states it 'expanded to over 40' without specifying a doubling from a baseline. (4) The LLM correctly identifies the shift from 2022 intent to 2023 execution but misses the specific design win metrics that are central to demonstrating this evolution. The answer demonstrates good qualitative understanding of the strategic progression but introduces unverified information and omits key quantitative achievements that ground the answer in the actual filing data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 405,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the financial impact of DHR's relationship with Aldevron evolve between 2022 and 2023, particularly in terms of goodwill and net cash consideration?",
      "original_answer": "In 2022, DHR preliminarily recorded approximately $6.1 billion of goodwill related to the Aldevron Acquisition. By 2023, the net cash consideration for Aldevron increased to $9.561 billion, indicating a more detailed or revised financial assessment of the acquisition. This evolution shows a significant increase in the financial commitment to the Aldevron relationship, particularly in terms of cash outlay, beyond the initial goodwill estimate provided in 2022.",
      "llm_answer": "In the 2022 Form 10‑K (pages 81‑85) Danaher disclosed that the Aldevron acquisition was recorded with roughly **$6.1 billion of goodwill** and a **net cash consideration of about $9.6 billion**. The 2023 Form 10‑K (pages 72‑76) reports the same figures – **$6.1 billion of goodwill** and **$9.6 billion of net cash consideration** – showing that the financial impact of the Aldevron relationship did not change between 2022 and 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer fundamentally misrepresents the ground truth and reaches the opposite conclusion. (1) QUANTITATIVE ACCURACY ISSUES: The LLM states both 2022 and 2023 had '$9.6 billion of net cash consideration,' but the ground truth explicitly states the net cash consideration 'increased to $9.561 billion' in 2023, implying it was different (lower) in 2022. The LLM provides no 2022 net cash consideration figure from the ground truth, only the $6.1 billion goodwill. The ground truth shows evolution/change; the LLM claims no change. (2) REASONING FAILURE: The question asks 'How did the financial impact...evolve' - this explicitly asks for changes over time. The ground truth answer describes an evolution showing 'a significant increase in the financial commitment.' The LLM concludes 'the financial impact of the Aldevron relationship did not change between 2022 and 2023' - this is the opposite of what the ground truth indicates. (3) MULTI-HOP SYNTHESIS ERROR: The LLM failed to properly synthesize the 2022 vs 2023 comparison. It presents identical figures for both years when the ground truth indicates the net cash consideration figure changed/evolved between years. (4) MISSING CONTEXT: The LLM misses the key insight that the evolution shows 'a more detailed or revised financial assessment' and 'a significant increase in the financial commitment.' The LLM's conclusion that figures 'did not change' directly contradicts the ground truth's emphasis on evolution and increase. The answer is factually incorrect on the core claim about whether change occurred.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 436,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the maturity date of the AT&T Inc. 1.800% Global Notes changed between the 2022 and 2024 SEC filings, and what does this indicate about the company's debt structure evolution?",
      "original_answer": "In the 2022 SEC filing, the AT&T Inc. 1.800% Global Notes were due on September 5, 2026. In the 2024 filing, the same class of notes is listed with a maturity date of September 14, 2039. This indicates a significant shift in the company's debt structure, extending the maturity of this particular note by over 13 years.",
      "llm_answer": "Both the 2022 and 2024 10‑K show AT&T’s 1.800 % Global Notes maturing on September 5 2026 (and a separate 1.800 % series maturing on September 14 2039). The maturity date for the 2026 tranche has not changed, indicating AT&T has kept that medium‑term debt intact, while the ongoing presence of the 2039 tranche reflects a strategic shift to extend the overall debt profile and lock in low‑cost financing for a longer horizon.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains a fundamental factual error that directly contradicts the ground truth. According to the original answer (from the knowledge graph), the 1.800% Global Notes maturity date CHANGED from September 5, 2026 (in 2022 filing) to September 14, 2039 (in 2024 filing). However, the LLM claims these are TWO SEPARATE tranches/series that both exist in both filings - one maturing in 2026 and another in 2039. This is incorrect. The ground truth indicates a single class of notes with a changed maturity date, not two different series. The LLM's interpretation that 'the maturity date for the 2026 tranche has not changed' directly contradicts the ground truth statement that the same notes shifted from 2026 to 2039. The LLM also misses the core finding: this represents a 13+ year extension of the debt maturity, which is a significant structural change. Instead, the LLM frames it as maintaining two separate tranches, which misrepresents the actual debt evolution. The reasoning about 'strategic shift to extend the overall debt profile' is somewhat aligned with the ground truth's implication, but it's based on an incorrect premise about the structure of the notes. Quantitatively, the dates are correct (2026 and 2039 are mentioned), but they are incorrectly contextualized as two separate series rather than a maturity date change for the same notes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1195,
        "completion_tokens": 381,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Target's compliance with its debt leverage covenant evolved between 2023 and 2024, and what changes in credit facility structure may have influenced this compliance?",
      "original_answer": "In 2023, Target stated that it was, and expected to remain, in compliance with its debt leverage covenant, which was part of a $1.0 billion 364-day credit facility that would expire in October 2024, along with a $3.0 billion five-year facility expiring in October 2028. By 2024, Target had renewed its 364-day credit facility, extending its expiration to October 2025, while maintaining the same $3.0 billion five-year facility. The company continued to assert compliance with the debt leverage covenant. The renewal of the 364-day facility likely provided continued flexibility, supporting Target’s ability to remain compliant with the covenant.",
      "llm_answer": "Target said it was “in compliance” with the debt‑leverage covenant in both fiscal years – the 2023 filing notes that it “are, and expect to remain, in compliance” with the covenant [2023 10‑K pp. 52‑56] and the 2024 filing repeats the same statement [2024 10‑K pp. 33‑37].  The underlying credit‑facility structure was refreshed each year: in October 2023 Target added a new $1.0 billion, 364‑day unsecured revolving facility (replacing the prior one) and extended its five‑year $3.0 billion revolving facility to October 2028 [2023 10‑K pp. 52‑56]; in October 2024 it again replaced the 364‑day facility with a new $1.0 billion facility (now expiring in October 2025) while retaining the $3.0 billion facility through 2028, giving a stronger liquidity backstop that supports continued covenant compliance [2024 10‑K pp. 33‑37].",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Quantitative verification: All dollar amounts are correct ($1.0 billion 364-day facility, $3.0 billion five-year facility), and all dates are accurate (October 2024 expiration for 2023 facility, October 2025 for 2024 facility, October 2028 for five-year facility). The answer correctly identifies that Target renewed/replaced the 364-day facility in both years while maintaining the $3.0 billion facility. Multi-hop reasoning is sound: the answer synthesizes information across 2023 and 2024 filings, correctly comparing the evolution of credit facilities and their relationship to covenant compliance. Entity accuracy is perfect - Target is correctly identified, fiscal years are correct, and the debt leverage covenant is properly referenced. The answer goes slightly beyond the ground truth by providing more specific detail about the October 2023 renewal (noting it 'replaced the prior one') and explicitly stating the 2024 facility expires in October 2025, which adds helpful context. The semantic meaning matches the ground truth perfectly - both convey that Target maintained compliance in both years and that the renewal of the 364-day facility supported this compliance. The only minor distinction is that the LLM provides slightly more granular detail about the timing and replacement nature of the facilities, which enhances rather than detracts from accuracy. No calculation errors, no factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 409,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Intel's approach to expanding digital readiness for global populations evolved from 2022 to 2023, particularly in relation to its RISE strategy and external collaboration initiatives?",
      "original_answer": "In 2022, Intel committed to expanding digital readiness through its RISE strategy, focusing on collaborative initiatives with other technology companies via the Alliance for Global Inclusion to create an Inclusion Index with unified goals and metrics. By 2023, this effort had matured into the publication of the third global inclusion index survey, which transitioned into an index system where organizations scoring 50% or higher were formally recognized. Intel was among the 18 recognized organizations out of 27 respondents, indicating a more structured and outcome-focused approach to digital readiness and inclusion. This evolution reflects a shift from establishing collaborative frameworks to measuring and recognizing performance against defined benchmarks.",
      "llm_answer": "In 2022 Intel framed digital‑readiness as a core element of its newly‑named RISE Technology Initiative, scaling AI‑for‑Youth and AI‑for‑Workforce programs in partnership with governments and institutions and funding projects that make technology more inclusive while expanding digital skills. By 2023 the focus shifted to deepening external collaboration—most notably through the Alliance for Global Inclusion and the publication of the third Global Inclusion Index (where Intel earned a spot)—and Intel continued to broaden its digital‑readiness outreach for millions of people, now with clearer metrics and a more formalized partnership ecosystem under the same RISE strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual discrepancies with the ground truth. CRITICAL ERRORS: (1) The LLM introduces 'AI-for-Youth' and 'AI-for-Workforce programs' with no mention in the ground truth, which appears to be fabricated detail. (2) The LLM mentions Intel 'earned a spot' in the Global Inclusion Index but fails to provide the specific quantitative benchmark (50% score threshold) that was central to the ground truth. (3) The LLM omits the crucial metric that Intel was 'among the 18 recognized organizations out of 27 respondents'—this specific numerical comparison is a key factual element of the evolution described. PARTIALLY CORRECT ELEMENTS: (1) Correctly identifies RISE strategy as the framework. (2) Correctly mentions Alliance for Global Inclusion. (3) Correctly references the third Global Inclusion Index publication in 2023. (4) Correctly captures the general evolution from framework-building to measurement/recognition. REASONING ISSUES: The multi-hop synthesis is incomplete—while the LLM captures the general trajectory of evolution, it fails to ground this evolution in the specific quantitative metrics (50% threshold, 18 of 27 organizations) that demonstrate the 'more structured and outcome-focused approach' mentioned in the ground truth. The introduction of AI programs appears to conflate or confuse different initiatives. The answer reads as partially informed but introduces unverified details while omitting critical numerical benchmarks that define the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 425,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did Emerson's relationship with Micromine evolve between 2023 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2023, Emerson (via its AspenTech subsidiary) entered into an agreement to acquire Micromine for AU$900 (approximately $623 USD), but later terminated the agreement due to uncertainty around Russian regulatory approval. This led to a mark-to-market gain of $24 in 2023 related to foreign currency forward contracts tied to the Micromine acquisition. By 2024, AspenTech had terminated all outstanding foreign currency forward contracts associated with the Micromine deal. The termination of the Micromine acquisition represented a shift from a strategic expansion effort in 2023 to a full withdrawal from the transaction, with no further financial commitments or exposures to Micromine reported in 2024.",
      "llm_answer": "Emerson’s AspenTech unit moved from being a prospective buyer of Micromine (the July 2022 acquisition agreement) to cancelling that deal – AspenTech announced on August 1 2023 that the Micromine purchase was terminated because Russian regulatory approval could not be secured.  The termination carried no fee, so the only measurable financial effect was a modest foreign‑currency mark‑to‑market gain of about $24 million in 2023 (from unwinding forward contracts tied to the deal) and the removal of any pending acquisition‑related expense, with no further impact reported in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) Correctly identifies AspenTech as Emerson's subsidiary involved in the Micromine deal; (2) Correctly states the deal was terminated due to Russian regulatory approval issues; (3) Correctly identifies the $24 million mark-to-market gain in 2023 from foreign currency forward contracts; (4) Correctly notes no further impact in 2024; (5) Correctly states termination carried no fee. PROBLEMATIC ELEMENTS: (1) CRITICAL DATE ERROR - The LLM states 'July 2022 acquisition agreement' but the ground truth indicates the agreement was entered into in 2023, not 2022. The August 1, 2023 termination date is correct, but the original agreement date is wrong; (2) MISSING DETAIL - The LLM does not specify the original acquisition price (AU$900 million, approximately $623 USD), which is a key financial detail in the ground truth; (3) INCOMPLETE SYNTHESIS - While the LLM mentions 'removal of any pending acquisition-related expense,' the ground truth more explicitly states that by 2024 'AspenTech had terminated all outstanding foreign currency forward contracts associated with the Micromine deal,' showing complete unwinding of the transaction. The LLM's characterization is somewhat vague on this point. QUANTITATIVE ACCURACY: The $24 million figure is correct, but the missing acquisition price (AU$900M/$623M USD) and the incorrect 2022 date for the original agreement represent significant quantitative/temporal errors. QUALITATIVE ACCURACY: The reasoning about the evolution from prospective buyer to cancellation is sound, and the explanation of financial implications is logical, though incomplete. CONTEXTUAL RELEVANCE: The answer appropriately addresses the question about how the relationship evolved and financial implications, though with the noted gaps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 500,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did the availability of shares under The Home Depot's U.S. Employee Stock Purchase Plan (ESPP) and the average purchase price of shares during the fiscal year change from 2022 to 2023?",
      "original_answer": "In 2022, there were approximately 17 million shares available under the U.S. ESPP, and associates purchased approximately one million shares at an average price of $305.14. In 2023, the number of shares available under the U.S. ESPP decreased to 15 million, and associates again purchased approximately one million shares, but at a lower average price of $277.19. This indicates a reduction in share availability and a notable decrease in the average purchase price during the fiscal year.",
      "llm_answer": "The Home Depot U.S. ESPP’s share pool shrank – the plan had roughly **17 million shares available** at the end of fiscal 2022 (January 30 2022) and only **about 15 million shares available** at the end of fiscal 2023 (January 28 2024)【HD_10k_2022.pdf†L1-L2】【HD_10k_2023.pdf†L1-L2】.  At the same time, the average price paid for ESPP shares fell – the most recent disclosed average price was **$305.14** (for the prior period) and it dropped to **$277.19** in fiscal 2023【HD_10k_2022.pdf†L3-L4】【HD_10k_2023.pdf†L3-L4】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All key quantitative data points are correct: (1) 2022 shares available: 17 million ✓, (2) 2023 shares available: 15 million ✓, (3) 2022 average purchase price: $305.14 ✓, (4) 2023 average purchase price: $277.19 ✓. The answer correctly identifies the multi-hop synthesis required: comparing share availability across two fiscal years AND comparing average purchase prices across two fiscal years. The reasoning is sound - the LLM properly identifies both the decrease in available shares (17M to 15M) and the decrease in average purchase price ($305.14 to $277.19). The fiscal year dates provided (January 30, 2022 and January 28, 2024) are appropriate context markers. The answer directly addresses all parts of the question: how availability changed (decreased) and how average purchase price changed (decreased). The wording is clear and the conclusion appropriately summarizes the findings. Minor note: The answer states shares purchased were \"approximately one million\" in both years, which aligns with the ground truth but this detail is not explicitly emphasized in the LLM response - however, this is a very minor omission that doesn't significantly impact the core answer quality. The citation format with document references adds credibility. Overall, this is a well-synthesized, factually accurate response that properly handles the multi-hop nature of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 397,
        "total_tokens": 1659
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the pattern of impairment triggers and associated charges across DHR's business segments evolved between the 2022 and 2023 filings, and what does this indicate about shifting risks in its intangible asset portfolio?",
      "original_answer": "In the 2022 filing, DHR reported impairment triggers only in the Diagnostics segment during the first quarter of 2021, resulting in a $10 million impairment charge. In contrast, the 2023 filing identified impairment triggers in multiple segments: the Biotechnology segment in the second quarter of 2023, the Diagnostics and Biotechnology segments in the fourth quarter of 2023, and again in the Diagnostics segment in the first quarter of 2021 (which was included for comparative purposes). The impairment charges increased significantly, from $10 million in 2021 (reported in the 2022 filing) to $77 million in 2023 (reported in the 2023 filing). This indicates a notable expansion in both the scope and magnitude of impairment activity, particularly affecting the Biotechnology segment in 2023, which was not previously a focus of impairment events. This evolution suggests growing risks in DHR’s intangible asset portfolio, especially in its Biotechnology segment.",
      "llm_answer": "In the 2022 filing, Danaher reported impairment triggers only in Diagnostics (Q1 2021) and in both Diagnostics and Environmental & Applied Solutions (Q1 & Q3 2020), producing modest charges of $10 million (2021) and $22 million (2020)【DHR_10k_2022.pdf p. 98‑102】. By the 2023 filing, the triggers had shifted to the Biotechnology segment (Q2 2023) and again to Diagnostics (Q4 2023), with a much larger $77 million charge in 2023 and no impairments recorded in 2022【DHR_10k_2023.pdf p. 87‑91】. This evolution shows that risk in Danaher’s intangible‑asset portfolio is moving away from the older Diagnostics/Environmental businesses toward newer, technology‑heavy Biotechnology assets, reflecting heightened integration or market uncertainty in that segment.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM answer introduces significant factual errors not present in the ground truth. It claims impairment triggers in 'Environmental & Applied Solutions (Q1 & Q3 2020)' with '$22 million (2020)' charges - these segments and amounts are NOT mentioned in the original answer and appear to be fabricated. The ground truth only references Diagnostics segment in Q1 2021 with $10 million in the 2022 filing. (2) SEGMENT IDENTIFICATION - The LLM incorrectly adds Environmental & Applied Solutions as an impairment segment, which is not supported by the ground truth. (3) YEAR CONFUSION - The LLM conflates 2020 and 2021 impairments in a confusing manner, stating '$10 million (2021) and $22 million (2020)' without clear temporal organization. (4) CORRECT ELEMENTS - The LLM does correctly identify: (a) The shift from Diagnostics to Biotechnology between filings, (b) The $77 million charge in 2023, (c) The general pattern of increasing impairment magnitude, (d) The interpretation that risk is shifting toward Biotechnology segment. (5) MULTI-HOP REASONING - While the LLM attempts to synthesize across 2022 and 2023 filings, it does so with fabricated intermediate data points. The reasoning about risk migration is sound but built on partially incorrect premises. (6) MISSING CONTEXT - The LLM fails to clearly state that the 2023 filing showed impairments in BOTH Biotechnology AND Diagnostics in Q4 2023, not just Diagnostics. The ground truth indicates multiple segments affected in 2023, which the LLM partially captures but obscures with incorrect 2020 data. The citation format suggests document references but the actual content contradicts the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1450,
        "completion_tokens": 468,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the value of outstanding letters of credit related to trade contracts change between 2022 and 2023, and what does this indicate about the company's involvement in business transactions tied to trade contracts?",
      "original_answer": "The value of outstanding letters of credit related to trade contracts increased from $362 million in 2022 to $598 million in 2023. This significant increase indicates a growing involvement or expansion in business activities tied to trade contracts during this period.",
      "llm_answer": "The company’s outstanding letters of credit grew from **$362 million at January 30 2022** to **$598 million at January 28 2024** (the fiscal‑2023 year), a rise of roughly **$236 million**【HD_10k_2022.pdf†L11-L13】【HD_10k_2023.pdf†L13-L15】. This increase signals that Home Depot is using more letters of credit to back its business dealings—including trade contracts—showing a higher level of activity and exposure in transactions tied to those contracts.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-reasoned. STRENGTHS: (1) All key numbers are correct: $362 million (2022) and $598 million (2023) match the ground truth exactly. (2) The calculation of the increase ($236 million) is accurate ($598M - $362M = $236M). (3) The answer correctly identifies the company as Home Depot and properly synthesizes information across multiple 10-K filings (2022 and 2023). (4) The interpretation that this increase indicates growing involvement in trade contract activities aligns with the ground truth's conclusion about expansion in business activities. (5) The answer addresses both parts of the multi-part question: the change in value AND what it indicates about the company's involvement. MINOR CONSIDERATIONS: (1) The LLM provides slightly more specific date information (January 30, 2022 and January 28, 2024) compared to the ground truth's simpler year references (2022 and 2023), but this is actually more precise and not incorrect. (2) The LLM adds context about Home Depot using letters of credit to 'back its business dealings,' which is a reasonable inference and adds helpful context without contradicting the ground truth. (3) The citation format with document references adds credibility. The answer demonstrates sound multi-hop reasoning by correctly synthesizing data from two separate fiscal year filings and drawing appropriate conclusions about business activity trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 395,
        "total_tokens": 1593
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has the status of the 0.300% Notes due 2028 evolved between the 2023 and 2024 SEC filings, and what does this indicate about IBM's financial instruments disclosures?",
      "original_answer": "In the 2023 filing, the 0.300% Notes due 2028 were disclosed as part of IBM's instruments defining the rights of holders, with specific reference to Exhibit 4.1, filed on February 10, 2020. In the 2024 filing, the 0.300% Notes due 2028 are listed as actively issued financial instruments under the trading symbol IBM28B, registered on the New York Stock Exchange. This indicates a shift from merely disclosing the existence of the instrument in 2023 to formally recognizing it as an actively traded financial instrument in 2024, suggesting increased market engagement or liquidity for this instrument.",
      "llm_answer": "The 0.300 % Notes due 2028 were listed as outstanding, registered securities in both filings – they appear in the 2023 Form 10‑K (IBM_10k_2023.pdf pp. 18‑22) and are again shown in the 2024 Form 10‑K securities table (IBM_10k_2024.pdf p. 1, listed as IBM28B)【IBM_10k_2024.pdf page 1】. Because the note’s status has not changed, IBM’s disclosures demonstrate a consistent, transparent approach to reporting its debt instruments from one year to the next.",
      "correctness_score": 3,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR ERRORS IN CORE REASONING: The LLM answer fundamentally misinterprets the question and contradicts the ground truth. The ground truth explicitly states there WAS a shift/evolution between 2023 and 2024 filings - from disclosure as an instrument defining rights of holders (2023) to recognition as an actively traded financial instrument with trading symbol IBM28B on NYSE (2024). The LLM incorrectly claims 'the note's status has not changed' and that disclosures show 'consistent' reporting, which directly contradicts the ground truth's finding of a meaningful shift in how the instrument is presented. QUANTITATIVE ACCURACY: The LLM correctly identifies the instrument (0.300% Notes due 2028), the trading symbol (IBM28B), the filing years (2023 and 2024), and references appropriate document pages. These numeric/factual details are accurate. QUALITATIVE ACCURACY: The LLM fails at the core analytical task. The question asks how the STATUS EVOLVED - implying change. The ground truth identifies a specific evolution: from passive disclosure to active market recognition. The LLM's conclusion that status 'has not changed' is factually incorrect based on the ground truth. The LLM also misses the key insight about increased market engagement/liquidity indicated by the shift. REASONING FAILURE: The LLM demonstrates poor multi-hop synthesis by failing to recognize the distinction between how the instrument is characterized in each filing year. It treats both years as equivalent when the ground truth clearly indicates a meaningful difference in disclosure approach and market status. CONTEXTUAL RELEVANCE: While the LLM addresses the right instrument and years, it fundamentally misses what the question is asking - the evolution/change - and instead argues for consistency where the ground truth identifies change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 496,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has IBM's treatment of the 1.750% Notes due 2031 evolved between 2023 and 2024, particularly in terms of disclosure and registration on stock exchanges?",
      "original_answer": "In 2023, IBM disclosed the 1.750% Notes due 2031 in its 10-K filing, indicating that the instrument defining the rights of the holders was incorporated by reference as part of an exhibit filed on January 30, 2019. By 2024, the 1.750% Notes due 2031 were not only still referenced but also explicitly registered under a trading symbol (IBM31) on the New York Stock Exchange, reflecting a shift from mere disclosure to formal recognition and active listing on a financial market platform.",
      "llm_answer": "In the 2023 Form 10‑K IBM only referenced the 1.750 % Notes due 2031 by incorporating the instrument that defines the holders’ rights (Exhibits 4.3 & 4.4 to Form 8‑K) and did not list the notes in the Section 12(b) securities table, so no exchange registration was shown【IBM_10k_2023.pdf pp 18‑22】. By the 2024 filing IBM still cites the same exhibits but now includes the notes in the Section 12(b) table with ticker “IBM31” and identifies them as listed on the New York Stock Exchange, reflecting a shift to explicit exchange registration【IBM_10k_2024.pdf pp 1‑5】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensiveness in addressing the multi-hop question about IBM's 1.750% Notes due 2031 evolution between 2023 and 2024. STRENGTHS: (1) All key facts are correct - the notes are accurately identified as 1.750% Notes due 2031, the years 2023 and 2024 are properly distinguished, and the ticker symbol IBM31 is correctly cited. (2) The multi-hop synthesis is sound: the answer correctly traces the evolution from 2023 (disclosure via incorporated exhibits, no Section 12(b) listing) to 2024 (same exhibits cited but now with explicit Section 12(b) registration and NYSE listing). (3) Specific exhibit references (4.3 & 4.4 to Form 8-K, January 30, 2019 date) align with ground truth. (4) The core narrative matches the original answer: shift from mere disclosure to formal exchange registration. (5) Page citations are provided, adding credibility. (6) The distinction between 2023 (no exchange registration shown) and 2024 (explicit NYSE registration with ticker) is clearly articulated. MINOR CONSIDERATIONS: The LLM answer provides slightly more granular detail (specific exhibit numbers, page ranges) than the original answer, which is appropriate for a detailed evaluation. The semantic meaning is fully preserved - both answers convey that IBM moved from passive disclosure to active listing. No numerical errors, calculation errors, or factual inaccuracies detected. The answer directly addresses all components of the question regarding disclosure evolution and stock exchange registration status.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 427,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Eli Lilly's financial relationship with Zyprexa evolve between 2023 and 2024, particularly in terms of revenue recognition and business model approach?",
      "original_answer": "In 2023, Eli Lilly generated $1.45 billion from the sale of the rights for the olanzapine portfolio, including Zyprexa, outside the U.S., indicating a direct revenue stream from product sales. By 2024, the company no longer reported Zyprexa as part of product sales; instead, revenue from the 2023 sale of rights was included in collaboration and other arrangements revenue, signaling a shift from direct product sales to revenue recognition through licensing and collaboration agreements. This change reflects a transformation in the financial relationship from active product sales to post-sale royalty or profit-sharing arrangements.",
      "llm_answer": "In 2023 Lilly reported ≈ $1.7 billion of Zyprexa‑related revenue (U.S. $79 m + outside‑U.S. $1.6 billion) and noted that the amount “includes sale of the rights for the olanzapine portfolio” – it was booked as product revenue 【45†L45-L48】. In the 2024 filing the same proceeds are shown under “collaboration and other revenue,” with the note that this line “includes the 2023 sales of rights for the olanzapine portfolio, including Zyprexa” 【62†L1-L4】, signalling a shift from treating Zyprexa as a sold product to a licensed asset that generates upfront and/or royalty‑type income under a partnership‑based business model.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM reports ~$1.7 billion total Zyprexa revenue in 2023 (U.S. $79M + outside-U.S. $1.6B), but the ground truth states $1.45 billion from the sale of rights outside the U.S. only. The LLM appears to have conflated or misidentified revenue components. The ground truth specifically references $1.45 billion from the 2023 sale of rights outside the U.S., not a combined $1.7 billion figure. This is a significant numerical discrepancy that undermines the answer's reliability. QUALITATIVE ASSESSMENT: The LLM correctly identifies the core conceptual shift - from product sales revenue recognition in 2023 to collaboration/licensing revenue in 2024. The reasoning about the business model transformation (from direct product sales to royalty/profit-sharing arrangements) aligns with the ground truth narrative. However, the incorrect revenue figures and the apparent mixing of different revenue streams (U.S. vs. outside-U.S., product sales vs. rights sales) suggest the LLM may have misread or synthesized the source data. MULTI-HOP REASONING: The LLM does attempt to synthesize information across 2023 and 2024 filings and correctly identifies the revenue classification change. However, the quantitative errors suggest incomplete or inaccurate source synthesis. SPECIFIC ISSUES: (1) The $1.7B figure appears incorrect - should be $1.45B based on ground truth; (2) The breakdown of U.S. $79M + outside-U.S. $1.6B is not supported by the ground truth; (3) The ground truth emphasizes the $1.45B from the sale of rights outside the U.S., not a combined total. The answer demonstrates understanding of the conceptual shift but fails on numerical accuracy, which is critical for financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 472,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the treatment and financial impact of the Mobility Preferred Interests evolve from 2023 to 2024, particularly in terms of redemption obligations and their effect on earnings per share calculations?",
      "original_answer": "In 2023, AT&T reclassified the Mobility Preferred Interests from equity to a liability due to the certainty of redemption, recording $2,670 in current liabilities and $2,670 in noncurrent liabilities. The company ultimately repurchased all remaining interests in April 2023 for $5,414, including accrued distributions. By 2024, the Mobility Preferred Interests were fully retired, and the focus shifted to their impact on earnings per share calculations, where under ASU 2020-06, the ability to settle these interests in stock was reflected in the diluted earnings per share computation for periods prior to the repurchase. This indicates a shift from active financial obligations to retrospective accounting treatment.",
      "llm_answer": "In 2023 AT&T re‑classified its Series A Mobility II preferred interests as a liability, recording roughly $2.7 billion in current liabilities and a matching $2.7 billion in non‑current liabilities for the amount that had to be redeemed within a year, and then fully repurchased the interests in April 2023 for about $5.4 billion, which eliminated the liability but required the interests to be reflected as 71‑72 potentially dilutive shares in the diluted‑EPS calculation for the portion of the year before the repurchase. By 2024 the Series A interests no longer exist; instead AT&T issued Series B redeemable non‑controlling interests that accrue to a $2,000 redemption value, are recorded as a redeemable‑noncontrolling‑interest liability, and are not treated as potentially dilutive, so they have no impact on 2024 diluted earnings‑per‑share.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both accurate and inaccurate information. CORRECT ELEMENTS: (1) The 2023 reclassification from equity to liability is accurate; (2) The $2.7 billion (approximately $2,670 million) in current and noncurrent liabilities is correct; (3) The April 2023 repurchase for approximately $5.4 billion ($5,414 million) is accurate; (4) The recognition of dilutive shares in the diluted EPS calculation for 2023 is correct; (5) The shift to retrospective accounting treatment by 2024 is accurate. PROBLEMATIC ELEMENTS: (1) The LLM introduces information about 'Series A Mobility II preferred interests' and 'Series B redeemable non-controlling interests' that goes beyond the ground truth answer. While this additional detail may be factually accurate from the filings, it expands the scope beyond what was in the original answer and introduces complexity not addressed in the ground truth; (2) The specific mention of '71-72 potentially dilutive shares' is a quantitative detail not present in the ground truth answer, making it difficult to verify; (3) The discussion of Series B interests with a '$2,000 redemption value' is entirely absent from the ground truth answer, suggesting the LLM may have synthesized information beyond what was requested or verified; (4) The statement about Series B interests having 'no impact on 2024 diluted earnings-per-share' contradicts the ground truth's focus on the retrospective impact of the original interests. MULTI-HOP REASONING: The LLM correctly synthesizes the evolution from 2023 to 2024, but introduces unverified additional information about Series B interests that wasn't part of the original answer. The core narrative about the Mobility Preferred Interests' treatment is sound, but the addition of Series B information suggests either hallucination or synthesis beyond the ground truth scope. QUANTITATIVE VERIFICATION: The core numbers ($2.7B, $5.4B) are correct, but the '71-72 shares' figure cannot be verified against the ground truth. The answer demonstrates good understanding of the financial mechanics but introduces unverified quantitative claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 569,
        "total_tokens": 1975
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has IBM's treatment and disclosure of the 0.875% Notes due 2030 evolved between 2023 and 2024, particularly in terms of its listing and registration status?",
      "original_answer": "In 2023, the 0.875% Notes due 2030 were disclosed as part of a list of instruments incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 8, 2022. By 2024, the 0.875% Notes due 2030 were explicitly listed in the table of registered securities with a trading symbol (IBM30A) and registered on the New York Stock Exchange. This indicates a shift from a referenced disclosure to a fully listed and registered financial instrument.",
      "llm_answer": "In the 2023 Form 10‑K IBM already disclosed the 0.875% Notes due 2030 (ticker IBM30A) as a security registered under Section 12(b) of the Exchange Act and listed on the New York Stock Exchange (IBM_10k_2023.pdf p. 18). The 2024 Form 10‑K repeats that same listing and registration (IBM_10k_2024.pdf p. 1) and adds an explicit reference to the instrument defining the notes (Exhibit 4.2 to Form 8‑K), but the notes’ NYSE listing and Section 12(b) registration status remain unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) The ground truth explicitly states that in 2023, the notes were disclosed as part of a list incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 8, 2022 - NOT as a directly listed security in the 2023 10-K. The LLM incorrectly claims the 2023 Form 10-K already disclosed the notes as registered under Section 12(b) and listed on NYSE. (2) The ground truth indicates a shift/evolution from referenced disclosure (2023) to explicit listing in a table of registered securities (2024). The LLM claims the status 'remain unchanged' between years, which directly contradicts the core premise of the question about how treatment 'evolved.' (3) The LLM cites page numbers (p. 18 for 2023, p. 1 for 2024) without verification against actual filings. (4) The LLM mentions Exhibit 4.2 to Form 8-K in 2024, but the ground truth references Exhibit 4.1 to Form 8-K from February 8, 2022 for 2023 disclosure. (5) The fundamental narrative is inverted - the ground truth shows progression from indirect/referenced disclosure to explicit registration/listing, while the LLM presents both years as having the same status. The LLM fails to capture the key evolution that the question asks about.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 362,
        "total_tokens": 1597
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the structure and distribution terms of the Telco Preferred Interests evolve from 2023 to 2024, and what does this indicate about AT&T's approach to financing through preferred equity instruments?",
      "original_answer": "In 2023, the Telco Preferred Interests consisted of $2,000 of Class A-1 preferred interests issued in September 2020, paying a 4.25% annual distribution, and $5,250 of Class A-2 and A-3 preferred interests issued in April 2023, paying a 6.85% annual distribution. By 2024, the total Telco Preferred Interests had grown to $7,250, with the Class A-1 preferred interests still at 4.25% and the Class A-2 and A-3 interests remaining at 6.85%, both subject to reset every seven years. Additionally, in 2024, AT&T clarified that failure to pay distributions would not restrict cash movements or its ability to pay dividends or repurchase shares. The structure remained consistent in terms of redemption rights and noncontrolling interest classification, but the expansion of the instrument in 2024 suggests a continued reliance on preferred equity as a financing strategy.",
      "llm_answer": "In 2023 AT&T’s Telco LLC had three cumulative, non‑convertible preferred series – Class A‑1 paying an initial 4.25 % distribution (reset every 7 years) and Classes A‑2/A‑3 paying an initial 6.85 % distribution (reset on Nov 1 2027 and every 7 years), with $7.25 bn of preferred interests outstanding [2023 pp. 89‑93]. By the 2024 filing the company announced a new Class A‑4 series (to be issued in Q1 2025 for $2.25 bn) that will pay a 5.94 % initial distribution and reset on Nov 1 2028 and every four years, while the original three series and total outstanding amount remained unchanged [2024 pp. 85‑89]. This addition of a new series with a distinct rate and reset schedule shows AT&T is actively expanding its preferred‑equity program, using cumulative preferred interests with tailored yields, reset mechanisms and redemption rights as a flexible, non‑dilutive financing tool.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM states $7.25 bn outstanding in 2023, but the ground truth clearly indicates 2023 had $2,000 + $5,250 = $7,250 million ($7.25 bn) total. However, the LLM then claims this amount 'remained unchanged' into 2024, which contradicts the ground truth stating the total grew to $7,250 by 2024 (implying it was lower in 2023). More critically, the ground truth shows 2023 had $2,000 Class A-1 and $5,250 Class A-2/A-3, totaling $7,250, NOT $7.25bn as stated for 2023. The LLM conflates 2023 and 2024 figures. (2) MAJOR FACTUAL ERROR - The LLM introduces a Class A-4 series announced for Q1 2025 issuance at $2.25bn with 5.94% distribution and 4-year reset. This information is NOT in the ground truth at all. The ground truth makes no mention of any Class A-4 series or future issuances. This appears to be fabricated or confused with different source material. (3) MULTI-HOP REASONING FAILURE - The question asks how the structure 'evolved from 2023 to 2024.' The ground truth shows: 2023 had $7,250 total ($2,000 A-1 + $5,250 A-2/A-3), and 2024 had $7,250 total with the same structure. The LLM fails to properly compare these years and instead introduces non-existent 2025 information. (4) MISSING KEY INFORMATION - The ground truth specifically mentions that in 2024, AT&T clarified that failure to pay distributions would not restrict cash movements or ability to pay dividends/repurchase shares. The LLM completely omits this important clarification. (5) STRUCTURAL CLAIMS - The LLM correctly identifies the instruments as cumulative, non-convertible preferred interests with reset mechanisms, but the specific numbers and evolution narrative are incorrect. The ground truth indicates the structure remained consistent from 2023 to 2024, not that it expanded with a new Class A-4 series.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1452,
        "completion_tokens": 501,
        "total_tokens": 1953
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has Capital One's involvement in multifamily commercial real estate loans evolved between 2022 and 2023, particularly in terms of risk exposure under loss sharing agreements with government-sponsored enterprises?",
      "original_answer": "In 2022, Capital One originated multifamily commercial real estate loans with the intent to sell them to GSEs, entering into loss sharing agreements, which resulted in a liability of $82 million. By 2023, the company continued this practice but the liability recognized on the consolidated balance sheets for these loss sharing agreements increased to $137 million, indicating a significant increase in risk exposure. This evolution reflects a growing involvement in these types of loans and a corresponding rise in the financial obligations tied to their loss sharing agreements.",
      "llm_answer": "In 2022 Capital One’s commercial‑banking segment simply originated and serviced multifamily commercial‑real‑estate loans that it sold to government‑sponsored enterprises, but the filing did not quantify any loss‑sharing liability (2022 10‑K, “Primary Loan Products” p. 96‑100). By 2023 the bank reported a specific loss‑sharing liability on its balance sheet of **$137 million**, up from **$82 million** a year earlier, showing that its risk exposure under those GSE loss‑sharing agreements had increased (2023 10‑K, “Loss Sharing Agreements” p. 215‑219).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and directly addresses the multi-hop question about Capital One's evolving involvement in multifamily commercial real estate loans and GSE loss sharing agreements. STRENGTHS: (1) All key financial figures are correct: $82 million liability in 2022 and $137 million in 2023, matching the ground truth exactly. (2) The year-over-year comparison is accurate, showing the increase in risk exposure. (3) The answer correctly identifies the entities (Capital One, GSEs) and the specific financial metric (loss sharing agreement liability). (4) The multi-hop synthesis is sound - the answer traces the evolution from 2022 to 2023 and explains the relationship between origination/sale activities and the liability amounts. (5) The answer appropriately cites specific sections of the 10-K filings, adding credibility. MINOR CONSIDERATIONS: (1) The LLM notes that the 2022 10-K filing \"did not quantify any loss-sharing liability\" while the ground truth states the liability was $82 million in 2022. This is a slight discrepancy in how the information is presented - the ground truth indicates the $82 million was recognized in 2022, while the LLM suggests it wasn't quantified in the 2022 filing itself. However, the LLM correctly identifies that by 2023, the liability increased to $137 million, which is the key factual point. (2) The semantic meaning is preserved: both answers convey that Capital One's risk exposure under GSE loss sharing agreements increased significantly between 2022 and 2023. The LLM's phrasing about the liability being \"up from $82 million a year earlier\" correctly captures the evolution. Overall, the answer is factually accurate on the critical numbers and demonstrates proper multi-hop reasoning across the two fiscal years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 488,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did Amazon's co-branded credit card programs shift in strategic significance and associated regulatory risks from 2022 to 2023, particularly in terms of new compliance obligations and their potential impact on operating results?",
      "original_answer": "In 2022, Amazon introduced co-branded credit card programs as part of its payment offerings, highlighting the risk that renewal on less favorable terms or termination could adversely affect operating results. The regulatory risks at that time included compliance with payment card association rules such as data security and certification requirements. By 2023, Amazon expanded its offerings and emphasized additional compliance obligations, including data localization rules, which were not mentioned in 2022. This indicates that the co-branded credit card programs became subject to a broader set of regulatory risks, particularly in international jurisdictions, which could increase compliance costs and operational complexity. The potential impact on operating results grew as Amazon now faced risks not only from traditional payment regulations but also from evolving data governance laws, particularly regarding cross-border data transfers tied to these credit card programs.",
      "llm_answer": "In the 2022 Form 10‑K Amazon only flagged its co‑branded credit‑card programs as a risk – “could adversely affect our operating results if renewed on less favorable terms or terminated” – without treating them as a core strategic initiative or noting new regulatory burdens【AMZN_10k_2022.pdf: p.13】. By the 2023 filing the company describes the co‑branded cards as a more strategically important element of its payments ecosystem and warns that “new compliance obligations” (e.g., enhanced authentication and data‑security rules) could increase costs and materially affect operating results if the programs are renegotiated unfavorably or end【AMZN_10k_2023.pdf: p.14】.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the shift in strategic significance from 2022 to 2023, noting that co-branded cards moved from being flagged as a risk to being described as 'more strategically important.' (2) The LLM accurately captures that 2022 focused on renewal/termination risks while 2023 emphasized 'new compliance obligations.' (3) The citation format and page references appear reasonable. (4) The core narrative of increased regulatory burden is present.\n\nWEAKNESSES: (1) CRITICAL OMISSION: The LLM answer fails to mention 'data localization rules' which the ground truth explicitly identifies as a key new compliance obligation introduced in 2023 that was NOT mentioned in 2022. This is a significant factual gap that directly addresses the question's focus on 'new compliance obligations.' (2) The LLM mentions 'enhanced authentication and data-security rules' but the ground truth specifically highlights 'data localization rules' as the distinguishing new regulatory risk - these are different compliance areas. (3) The LLM's characterization of 2022 compliance risks as limited to 'payment card association rules such as data security and certification requirements' is less specific than the ground truth's framing. (4) The LLM does not adequately convey the international/cross-border dimension of the new regulatory risks that the ground truth emphasizes ('particularly in international jurisdictions' and 'cross-border data transfers').\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2023 filings and identifies the shift in strategic positioning. However, it incompletely captures the specific regulatory evolution (data localization being the key new element).\n\nNUMERIC/FACTUAL VERIFICATION: No specific numbers are provided in either answer, so quantitative accuracy is not directly testable. However, the qualitative facts about regulatory obligations are partially incorrect due to the omission of data localization rules.\n\nSEMANTIC EQUIVALENCE: While the LLM conveys a general sense of increased regulatory burden, it misses the specific nature of that burden (data localization) that distinguishes 2023 from 2022, which is central to answering the question about how the programs 'shifted' in regulatory risk.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 611,
        "total_tokens": 2045
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has PM's financial relationship with RBH evolved between 2022 and 2024, particularly regarding the consolidation status and valuation considerations of RBH within PM's financial statements?",
      "original_answer": "In 2022, RBH was deconsolidated from PM's financial statements due to CCAA proceedings initiated in 2019, with its financial results excluded since that time. Additionally, PM faced potential material impacts from unresolved Canadian tobacco litigation, including a CAD 3.1 billion allocation of compensatory damages against RBH. By 2024, PM's relationship with RBH had evolved into holding an equity investment, which required impairment analysis. The audit process emphasized significant judgment around the fair value estimate of the investment, including assumptions on discount rates, sales volumes, operating margins, and the tax treatment of a potential global settlement. This reflects a shift from a deconsolidated subsidiary to a valued equity stake requiring ongoing impairment evaluation.",
      "llm_answer": "In the 2022 Form 10‑K PMI noted that Rothmans, Benson & Hedges (RBH) had been **deconsolidated** from its consolidated financial statements since the March 22 2019 CCAA filing and was reported only as an equity investment, with the deconsolidation reflected in reclassifications of other‑comprehensive earnings. By the 2024 Form 10‑K the company still did not consolidate RBH, but it performed a quantitative valuation of the equity stake, concluded that its fair value ($714 million) was well below the carrying amount, and recorded a **$2.3 billion non‑cash impairment** to reflect the lower valuation.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of PM's relationship with RBH from 2022 to 2024 - deconsolidation in 2019 and the shift to equity investment treatment with impairment analysis. However, there are significant quantitative accuracy issues: (1) The LLM provides specific numbers ($714 million fair value, $2.3 billion impairment) that are NOT present in the ground truth answer. The ground truth does not mention these specific valuations, only that impairment analysis was required. (2) The LLM states RBH was reported 'only as an equity investment' in 2022, but the ground truth indicates it was 'deconsolidated' with financial results excluded - these are related but distinct characterizations. (3) The ground truth mentions the CAD 3.1 billion litigation allocation against RBH, which the LLM completely omits. (4) The ground truth emphasizes 'significant judgment' in fair value estimates and specific assumptions (discount rates, sales volumes, operating margins, tax treatment), which the LLM does not address. Strengths: The LLM correctly identifies the CCAA filing date (March 22, 2019), the deconsolidation status, and the shift to equity investment with impairment considerations. The multi-hop reasoning connecting 2022 and 2024 is sound. Weaknesses: Introduction of specific dollar amounts not in ground truth raises concerns about hallucination. Missing the material litigation context. The answer is more specific than the ground truth but potentially inaccurate on those specifics. The qualitative understanding of the evolution is good, but quantitative precision is compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 443,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the financial performance and strategic positioning of Baqsimi evolve between 2023 and 2024, particularly in terms of revenue contribution and its role within LLY's product portfolio?",
      "original_answer": "In 2023, Baqsimi contributed $677.6 million in total revenue, with $645.7 million from the U.S. and $31.9 million from outside the U.S., indicating it was still a growing product within LLY's portfolio. By 2024, Baqsimi was no longer reported as a direct revenue contributor through product sales; instead, it was disclosed as part of a collaboration and other arrangements, specifically under the 2023 sale of rights. This shift suggests that LLY transitioned Baqsimi from an internally commercialized product to a divested asset, impacting its strategic focus and revenue model. The absence of Baqsimi from direct product revenue in 2024 reflects a significant change in its role and contribution to LLY's financials.",
      "llm_answer": "In 2023 Baqsimi was still a listed product, generating $677.6 million of total revenue (U.S. $645.7 m + outside‑U.S. $31.9 m) and, more importantly, a one‑time $579 million boost from the sale of its U.S. rights 【2023‑48†L31-L38】【2023‑48†L9-L13】. By 2024 the product no longer appears in the product‑revenue breakdown; its only impact is reflected in “collaboration and other revenue,” which the filing notes includes the 2023 rights‑sale for Baqsimi 【2024‑62†L13-L16】, indicating that Lilly has monetized the asset and removed it from its core portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. QUANTITATIVE VERIFICATION: All financial figures are correct - 2023 Baqsimi revenue of $677.6M total ($645.7M U.S. + $31.9M outside U.S.) matches ground truth exactly. The $579M one-time boost from the sale of U.S. rights is accurately cited and properly contextualized as a 2023 transaction. MULTI-HOP REASONING: The answer successfully synthesizes information across 2023 and 2024 filings, correctly identifying the strategic transition from direct product revenue to collaboration/other revenue arrangements. The logic is sound: Baqsimi was divested in 2023 (generating both ongoing product revenue and a one-time sale proceeds), and by 2024 it no longer appears in product revenue but is reflected in collaboration arrangements. ENTITY ACCURACY: Company (LLY/Lilly), product (Baqsimi), years (2023, 2024), and metrics (revenue, U.S./non-U.S. breakdown) are all correctly identified. COMPLETENESS: The answer addresses all aspects of the question - financial performance evolution, strategic positioning shift, revenue contribution changes, and role within the portfolio. The inclusion of the $579M sale proceeds adds important context about the monetization strategy. MINOR CONSIDERATIONS: The answer goes slightly beyond the ground truth by explicitly mentioning the $579M sale proceeds, which enriches the narrative but is not contradicted by the ground truth. The characterization of the transition as 'monetization' and 'removal from core portfolio' aligns perfectly with the ground truth's description of the shift from 'internally commercialized product to divested asset.' The citation format with document references enhances credibility. No calculation errors detected. Semantic equivalence is maintained throughout.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 494,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has the composition of Union Pacific's Total Highway Revenue Equipment changed from 2022 to 2024, particularly in terms of the ratio of owned versus leased containers and chassis?",
      "original_answer": "In 2022, Union Pacific owned 78,837 units and leased 16,004 units of Total Highway Revenue Equipment, with containers making up the majority of owned assets and chassis being heavily leased. By 2024, the company significantly reduced both owned and leased equipment, with owned units dropping to 50,731 and leased units to 1,485. The most notable change was in leased containers, which fell from 1,856 in 2022 to just 288 in 2024, and owned chassis decreased from 29,875 to 4,356. This indicates a strategic shift toward owning fewer assets and leasing even fewer, especially in chassis.",
      "llm_answer": "In the 2022 Form 10‑K (covering Dec 31 2021) Union Pacific reported 48,962 owned containers and 1,856 leased (≈96 % owned) and 29,875 owned chassis and 14,148 leased (≈68 % owned) for a total of 94,841 highway‑revenue units【UNP_10k_2022.pdf†page=22】. By the 2024 Form 10‑K (covering Dec 31 2024) the fleet had shrunk to 52,216 units, with owned containers falling to 46,375 and leased to just 288 (≈99 % owned) and owned chassis dropping sharply to 4,356 while leased chassis were 1,197 (≈78 % owned)【UNP_10k_2024.pdf†page=19】. Thus, the share of owned equipment rose for both containers and chassis, even as the absolute number of owned chassis declined dramatically.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that fundamentally contradict the ground truth. (1) OWNED UNITS DISCREPANCY: Ground truth states 2022 owned = 78,837 units, but LLM reports only 48,962 owned containers + 29,875 owned chassis = 78,837 total (this is correct arithmetic but the LLM presents 48,962 as if it's the only owned container count, missing the full context). More critically, for 2024, ground truth shows owned = 50,731 total, but LLM reports 46,375 owned containers + 4,356 owned chassis = 50,731 (correct arithmetic but incomplete presentation). (2) LEASED UNITS CRITICAL ERROR: Ground truth clearly states 2022 leased = 16,004 units total, but LLM reports 1,856 leased containers + 14,148 leased chassis = 15,004, which is close but still incorrect (should be 16,004). For 2024, ground truth states leased = 1,485 total, but LLM reports 288 leased containers + 1,197 leased chassis = 1,485 (correct sum but the 1,197 leased chassis figure appears incorrect - ground truth implies much lower leased chassis). (3) TOTAL FLEET SIZE ERROR: Ground truth implies 2022 total = 94,841 (78,837 + 16,004), which LLM correctly states. However, for 2024, ground truth total should be 52,216 (50,731 + 1,485), which LLM states but the component breakdown doesn't align with ground truth's assertion that leased containers fell to 288 and owned chassis to 4,356. (4) PERCENTAGE CALCULATIONS: LLM calculates owned percentages (96% containers 2022, 99% containers 2024, 68% chassis 2022, 78% chassis 2024), but these are based on potentially incorrect component numbers. (5) MULTI-HOP REASONING: The LLM correctly identifies the strategic shift toward owning more and leasing less, which aligns with ground truth's conclusion. However, the specific numbers used to support this conclusion contain errors. (6) KEY OMISSION: Ground truth emphasizes that leased containers fell from 1,856 to 288 (a 84% reduction), which LLM does mention correctly. Ground truth also emphasizes owned chassis decreased from 29,875 to 4,356 (an 85% reduction), which LLM mentions but with potentially incorrect leased chassis figures. The fundamental issue is that while the LLM's narrative conclusion about the strategic shift is directionally correct, the underlying numerical support contains discrepancies that undermine confidence in the analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 632,
        "total_tokens": 1955
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role within the company's overall funding structure?",
      "original_answer": "In 2022, securitized debt obligations were explicitly described as one of the company's key funding sources alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. By 2023, while still present in the funding structure at $18.043 billion in carrying value, securitized debt obligations were categorized under Level 2 in the fair value hierarchy, indicating a shift toward more standardized valuation methods. This evolution suggests a more structured and possibly less volatile role for securitized debt obligations in Capital One's funding strategy.",
      "llm_answer": "Capital One’s securitized‑debt program grew modestly but noticeably – the carrying amount of securitized debt obligations rose from about **$16.97 billion at year‑end 2022** to **$18.04 billion at year‑end 2023** (≈ $1.1 billion increase)【COF_10k_2022.pdf p. 68‑69】【COF_10k_2023.pdf p. 208‑212】.  Although deposits still supply the bulk of the firm’s funding, securitized debt – which historically has been roughly 4 % of total funding sources – has taken a slightly larger share of the overall funding mix, indicating a growing reliance on securitization alongside its core deposit base.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides accurate quantitative data and addresses the core question about securitized debt evolution. STRENGTHS: (1) The carrying values are correct - $16.97B (2022) and $18.04B (2023) match the ground truth, with the $1.1B increase calculation accurate. (2) The answer correctly identifies the growth trend and provides specific page references to source documents. (3) The statement about deposits being the bulk of funding is contextually appropriate. (4) The answer addresses the multi-hop synthesis by comparing 2022 and 2023 data. WEAKNESSES: (1) The LLM answer does not mention the Level 2 fair value hierarchy categorization in 2023, which was explicitly noted in the ground truth as a significant shift toward more standardized valuation methods. This is a material omission regarding the 'evolution' aspect of the question. (2) The statement about securitized debt being 'roughly 4% of total funding sources' is not verified in the ground truth and appears to be an inference rather than explicitly stated data. (3) The LLM answer frames the evolution primarily in terms of absolute dollar growth and market share, while the ground truth emphasizes the shift in valuation methodology (Level 2 hierarchy) as the key evolution indicator. (4) The phrase 'growing reliance on securitization' is somewhat speculative - the ground truth suggests a 'more structured and possibly less volatile role' which is a different characterization. The answer is substantially correct on the quantitative side but misses important qualitative aspects of the evolution, particularly the fair value hierarchy shift that indicates a methodological change in how these obligations are valued and treated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 465,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did the nature of LLY's revenue from Zyprexa evolve between 2023 and 2024, particularly in terms of the source and recognition method of that revenue?",
      "original_answer": "In 2023, Zyprexa revenue was primarily derived from the sale of the rights for the olanzapine portfolio. By 2024, the revenue associated with Zyprexa was recognized as part of collaboration and other arrangements, specifically stemming from the 2023 sale of rights for the olanzapine portfolio, and was included in collaboration revenue rather than product sales. This reflects a shift in how Zyprexa-related revenue was categorized and recognized in 2024 compared to 2023.",
      "llm_answer": "In 2023 Zyprexa was reported in the “Net product revenue” line‑item – the table shows $79.4 million (U.S.) and $1,615.4 million (outside the U.S.) and the footnote notes that this amount “includes sale of the rights for the olanzapine portfolio” and is recognized when the product is shipped (i.e., when control passes to the customer)【LLY_10k_2023.pdf p.65‑69】. By 2024 the same Zyprexa‑related cash is shown under “Collaboration and other revenue,” which the filing says “includes … the 2023 sales of rights for the olanzapine portfolio, including Zyprexa” and is recognized at the time the rights are transferred rather than as ongoing product sales【LLY_10k_2024.pdf p.62‑66】.  Thus the source shifted from product sales to a one‑time rights‑sale collaboration, and the recognition moved from shipment‑based product revenue to a sale‑of‑rights timing.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. STRENGTHS: (1) Correctly identifies the core shift in revenue categorization from 2023 to 2024 - from 'Net product revenue' to 'Collaboration and other revenue'. (2) Accurately captures the specific dollar amounts ($79.4M U.S., $1,615.4M outside U.S. for 2023), though these are presented as supporting detail rather than central to the answer. (3) Correctly identifies the underlying transaction: the 2023 sale of rights for the olanzapine portfolio. (4) Accurately describes the recognition method shift: from shipment-based (when control passes to customer) to rights-transfer timing. (5) Properly synthesizes multi-hop information across two 10-K filings (2023 and 2024). (6) Provides appropriate document citations with page numbers. (7) The semantic meaning aligns perfectly with the ground truth - both convey that Zyprexa revenue shifted from product sales categorization to collaboration revenue categorization, reflecting the underlying change from ongoing product sales to a one-time rights sale. MINOR CONSIDERATIONS: The LLM answer provides more granular detail about recognition methods (shipment-based vs. rights-transfer timing) than the ground truth explicitly states, but this is a reasonable inference from the filing data and adds helpful context without contradicting the ground truth. The answer fully addresses both parts of the question: (1) the source of revenue (product sales → rights sale collaboration), and (2) the recognition method (shipment-based → rights-transfer timing). Multi-hop reasoning is sound - correctly connecting the 2023 transaction to its 2024 revenue categorization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 456,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the valuation methodology and classification of Federal Government Securities in the pension plan evolved from 2022 to 2024?",
      "original_answer": "In 2022, Federal Government Securities were valued under the 'Significant Other Observable Inputs (Level 2)' category and totaled $742 million. By 2024, the company clarified that these securities are valued using a bid evaluation process with bid data from independent pricing sources and are explicitly classified as Level 2 investments. This reflects a continuation in classification but adds specificity in methodology explanation.",
      "llm_answer": "Both the 2022 and 2024 10‑K filings state that Federal Government Securities – Treasury bills, notes, bonds and similar securities – are valued using a bid‑evaluation process with bid data from independent pricing sources, and they are classified as Level 2 investments in the fair‑value hierarchy. The description and classification are identical in the two reports, indicating that the valuation methodology and hierarchy level have not changed from 2022 to 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies that Federal Government Securities are classified as Level 2 investments and valued using a bid-evaluation process with independent pricing sources in both years. However, there are significant issues: (1) The LLM states the description and classification are 'identical' and 'have not changed,' which contradicts the ground truth that indicates an 'evolution' from 2022 to 2024. The ground truth explicitly states that 2024 'adds specificity in methodology explanation,' suggesting a change in how the methodology is described/clarified, not just a static continuation. (2) The LLM completely omits the quantitative data point that Federal Government Securities totaled $742 million in 2022, which is a material omission for a complete answer. (3) The LLM fails to capture the nuance that while the classification remained Level 2, there was clarification/evolution in how the methodology was explained between the two years. The ground truth uses the word 'evolved' and notes 'adds specificity,' indicating a change in presentation/explanation even if the underlying classification remained the same. (4) The answer is partially correct on the core classification and methodology but misses the key insight about the evolution in how this information was presented/clarified. The quantitative omission and mischaracterization of 'no change' when the ground truth indicates an evolution in explanation are significant weaknesses.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 405,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did Capital One's credit score data utilization for product segmentation decisions evolve from 2022 to 2023, and what does this indicate about their credit risk modeling strategy?",
      "original_answer": "In 2022, Capital One used credit score data for product segmentation decisions based on historical credit score distributions from 2020 to 2021, as shown in Table 21. In 2023, the company updated its data to reflect credit score distributions from 2022 to 2023 in the same table. This shift indicates a more current and dynamic credit risk modeling strategy, with product segmentation decisions being informed by the most recent borrower behavior and risk profiles, suggesting a proactive approach to managing credit risk in evolving economic conditions.",
      "llm_answer": "In both the 2022 and 2023 10‑K filings Capital One notes that it “uses borrower credit scores for subprime classification, for competitive benchmarking and, in some cases, to drive product‑segmentation decisions” (2022 p. 101; 2023 p. 93). The 2023 credit‑score distribution shows a slight shift toward a larger low‑score share in the credit‑card portfolio (≤660 % rose from 31 % to 32 %) while the auto‑score mix remained flat (53 % >660 in both years) (2022 p. 103; 2023 p. 95). This suggests Capital One is maintaining its reliance on credit‑score data for segmentation but is increasingly targeting lower‑score borrowers, reflecting a more granular, risk‑based approach in its credit‑risk modeling strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer provides relevant information about Capital One's credit score usage but diverges significantly from the ground truth in key ways: (1) FACTUAL DIVERGENCE: The ground truth specifically references Table 21 and states that 2022 used historical data from 2020-2021, while 2023 used data from 2022-2023. The LLM answer does not mention Table 21 or this critical temporal shift in the underlying data periods. This is a fundamental difference in how the evolution is characterized. (2) QUANTITATIVE ISSUES: The LLM provides specific percentages (31% to 32% for credit card ≤660, 53% >660 for auto in both years) with page citations, but these numbers cannot be verified against the ground truth which does not provide these specific figures. The ground truth emphasizes the DATA PERIOD SHIFT (2020-2021 to 2022-2023) as the key evolution, not the percentage point changes in score distributions. (3) INTERPRETATION MISMATCH: The ground truth characterizes the evolution as reflecting 'more current and dynamic' modeling with 'most recent borrower behavior,' emphasizing the temporal update of reference data. The LLM interprets the evolution as 'increasingly targeting lower-score borrowers' based on the 1% shift in credit card portfolio composition. These are different conclusions about strategy. (4) MULTI-HOP REASONING: The ground truth's reasoning is clearer: updated data periods → more current risk profiles → proactive risk management. The LLM's reasoning (slight shift in score distribution → targeting lower-score borrowers) is less directly supported and may misinterpret compositional changes as strategic targeting. (5) MISSING CONTEXT: The LLM does not address the specific data period evolution (2020-2021 to 2022-2023) that appears central to the ground truth's assessment. The answer is partially correct in identifying credit score usage for segmentation but fails to capture the primary evolution mechanism identified in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 531,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Amazon's strategic positioning of AWS evolved from 2022 to 2023 in terms of its role within the company's broader business segments and investment priorities?",
      "original_answer": "In 2022, AWS was positioned primarily as a key area of investment within Amazon's broader technology and content spending, with an emphasis on supporting geographic expansion, new product categories, and internal operational efficiencies. The document highlighted that Amazon was investing in AWS alongside initiatives to build and deploy innovative software and electronic devices, indicating a strategic alignment with internal growth and infrastructure enhancement. By 2023, AWS had evolved into one of Amazon's three core business segments—alongside North America and International—reflecting its elevated strategic importance. The 2023 filing explicitly states that AWS serves developers and enterprises by offering a broad set of on-demand technology services, including compute, storage, database, analytics, and machine learning, and is now a distinct and central pillar of Amazon’s business model. This shift demonstrates a transformation in AWS's role from a strategic investment area to a standalone, mission-critical business segment.",
      "llm_answer": "In the 2022 filing, AWS was described mainly as a **technology‑and‑content investment area** that Amazon funds to support its overall infrastructure – “We seek to invest efficiently in several areas of technology and content, **including AWS**… we are investing in AWS, which offers a broad set of on‑demand technology services” (2022 10‑K pp. 17‑21). By the 2023 filing, AWS had been elevated to a **stand‑alone operating segment**, listed alongside North America and International – “We have organized our operations into three segments: North America, International, and **Amazon Web Services (‘AWS’)**… We serve developers and enterprises … through AWS, which offers a broad set of on‑demand technology services” (2023 10‑K pp. 1‑5). This shift shows AWS moving from a supporting investment focus to a core, separate business unit that receives dedicated strategic and capital priority.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies AWS's 2022 positioning as a technology-and-content investment area within broader infrastructure spending, with accurate characterization of its supporting role. (2) Accurately captures the 2023 evolution where AWS became a standalone operating segment alongside North America and International. (3) Properly synthesizes the multi-hop comparison showing the transformation from 'supporting investment focus' to 'core, separate business unit.' (4) Uses appropriate direct citations from the 10-K filings (page references 17-21 for 2022, 1-5 for 2023) that support the claims. (5) Correctly identifies the three business segments structure in 2023. (6) Accurately describes AWS's service offerings (compute, storage, database, analytics, machine learning services) in both years. MINOR CONSIDERATIONS: The LLM answer is slightly more concise than the ground truth but captures all essential information. The ground truth emphasizes 'geographic expansion, new product categories, and internal operational efficiencies' as 2022 investment priorities, while the LLM focuses more narrowly on infrastructure support—however, this is a matter of emphasis rather than factual error, as infrastructure support encompasses these elements. The semantic meaning is preserved: both convey that AWS moved from a supporting investment area to a mission-critical standalone segment. QUANTITATIVE ACCURACY: No numerical errors detected. MULTI-HOP REASONING: Successfully synthesizes information across 2022 and 2023 filings to demonstrate evolution. ENTITY ACCURACY: All entities (Amazon, AWS, business segments, years) correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1489,
        "completion_tokens": 477,
        "total_tokens": 1966
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Philip Morris International's financial relationship with Rothmans, Benson & Hedges Inc. (RBH) evolved between 2022 and 2024, particularly in terms of its accounting treatment and potential financial exposure?",
      "original_answer": "In 2022, RBH was deconsolidated from Philip Morris International’s financial statements due to its CCAA restructuring, and its financial results were no longer included in PMI’s consolidated financials. At that time, there was a comprehensive stay of Canadian tobacco litigation until March 31, 2022, and no loss accruals were made due to the inability to estimate potential losses. By 2024, PMI’s relationship with RBH had shifted from deconsolidation to an equity investment model. A proposed settlement of CAD 32.5 billion in the Canadian tobacco litigation emerged, prompting PMI to assess its investment in RBH for impairment. As a result, PMI recorded a non-cash impairment charge of $2,316 million in 2024, reflecting a decline in the estimated fair value of its investment. This marks a significant evolution from a deconsolidated entity with uncertain liabilities to a recognized equity investment with a quantified impairment.",
      "llm_answer": "In the 2022 Form 10‑K, PMI disclosed that Rothmans, Benson & Hedges Inc. (RBH) had been de‑consolidated (since the 2019 CCAA filing) and that its remaining equity stake was carried as an investment, with any gains or losses on the investment reported in accumulated other‑comprehensive losses and re‑classifications to earnings (see the “Reclassifications from Other Comprehensive Earnings” and “Deconsolidation of RBH” discussion on pages 111‑115). By the 2024 filing, PMI recognized a non‑cash impairment of $2.316 billion on that RBH equity investment—moving the loss from OCI to a direct earnings charge—because the proposed CAD 32.5 billion settlement plan in the CCAA proceedings signaled that the fair value of the investment was substantially lower, thereby increasing PMI’s potential financial exposure (see “Impairment Related to the Rothmans, Benson & Hedges Equity Investment” on pages 28‑32).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the multi-hop question about PMI's evolving relationship with RBH. QUANTITATIVE ACCURACY: All numeric values are correct - the impairment charge of $2.316 billion (formatted as $2,316 million in ground truth, $2.316 billion in LLM answer - both equivalent), the CAD 32.5 billion settlement amount, and the 2022-2024 timeframe are all accurate. ENTITY ACCURACY: PMI, RBH, and CCAA are correctly identified. MULTI-HOP REASONING: The LLM successfully synthesizes information across multiple years and filing documents, correctly tracing the evolution from: (1) 2022 deconsolidation status with equity investment treatment, (2) OCI accounting treatment in 2022, and (3) 2024 shift to direct earnings impairment charge. The causal link between the CAD 32.5 billion settlement proposal and the impairment assessment is correctly established. COMPLETENESS: The answer addresses all key aspects of the question - accounting treatment evolution, financial exposure quantification, and the timeline. Minor strengths include specific page references (111-115, 28-32) that add credibility. MINOR CONSIDERATIONS: The ground truth mentions \"no loss accruals were made due to the inability to estimate potential losses\" in 2022 and references to \"comprehensive stay of Canadian tobacco litigation until March 31, 2022,\" which the LLM answer does not explicitly include. However, these are contextual details that don't materially affect the core answer about the financial relationship evolution. The LLM's focus on the accounting treatment shift (OCI to earnings charge) and the quantified impairment is semantically equivalent to the ground truth's characterization of the evolution from \"deconsolidated entity with uncertain liabilities to a recognized equity investment with a quantified impairment.\" The answer is well-structured, factually sound, and demonstrates clear understanding of the complex multi-year, multi-entity financial relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1478,
        "completion_tokens": 543,
        "total_tokens": 2021
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2022 to 2024, considering both its revenue contribution and associated product risks?",
      "original_answer": "In 2022, Biktarvy was a major revenue driver for GILD, generating $8,624 million in total product sales globally, indicating its strong market position in the HIV treatment segment. By 2024, while specific revenue figures are not provided, the company's risk disclosures highlight Biktarvy's ongoing importance but also emphasize heightened risks related to the HIV product class, particularly concerning the reliance on TAF-based therapies and potential shifts in treatment paradigms. This evolution suggests that although Biktarvy remains central to GILD's revenue, its commercial outlook has become more vulnerable to competitive and regulatory pressures.",
      "llm_answer": "In 2022 Biktarvy produced $8.6 billion of product sales – about 53 % of Gilead’s $16.3 billion HIV portfolio and a core driver of total revenue.  The 2024 10‑K still positions Biktarvy as one of the company’s top‑selling HIV medicines, with its sales continuing to represent a large share of earnings, while the risk discussion again flags heightened product‑specific risks – notably generic competition, pricing pressure and any shift away from TAF‑based regimens – that could erode that contribution.  Thus, Biktarvy’s commercial importance remains strong, but the same competitive and regulatory vulnerabilities noted in 2022 persist.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct quantitative data and sound multi-hop reasoning. STRENGTHS: (1) The 2022 Biktarvy revenue figure of $8.6 billion ($8,624 million) is accurate and properly formatted. (2) The calculation that Biktarvy represented approximately 53% of GILD's HIV portfolio is mathematically correct ($8.624B / $16.3B ≈ 52.9%, rounds to 53%). (3) The answer correctly identifies Biktarvy as a major revenue driver in 2022 and acknowledges its continued importance in 2024. (4) Risk factors are properly synthesized: generic competition, pricing pressure, and TAF-based therapy shifts are all legitimate concerns mentioned in risk disclosures. (5) The multi-hop reasoning effectively connects 2022 revenue data with 2024 risk evolution. (6) The semantic meaning aligns well with the ground truth regarding vulnerability to competitive and regulatory pressures. MINOR WEAKNESSES: (1) The LLM adds contextual detail about Biktarvy being 'one of the company's top-selling HIV medicines' in 2024, which while reasonable, goes slightly beyond what the ground truth explicitly states (ground truth notes 'specific revenue figures are not provided' for 2024). (2) The phrase 'the same competitive and regulatory vulnerabilities noted in 2022 persist' is slightly interpretive—the ground truth emphasizes 'heightened risks' rather than identical risks persisting. This is a minor semantic distinction. (3) The answer could have been more explicit about the lack of 2024 specific revenue figures, though it does acknowledge Biktarvy's continued importance without providing exact numbers. Overall, the answer successfully addresses the evolution question by showing strong 2022 position with quantified data and 2024 vulnerability with risk context, demonstrating solid multi-hop synthesis across years and metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 501,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has Union Pacific Railroad's financial stake and operational relationship with TTX evolved from 2022 to 2024, particularly in terms of investment value and car hire expenses?",
      "original_answer": "Union Pacific Railroad's financial stake in TTX increased from $1.6 billion in 2021 (referenced in the 2022 filing) to $1.9 billion in 2024. Additionally, UPRR's car hire expenses rose from $375 million in 2021 to $432 million in 2024. These increases indicate a growing financial and operational involvement with TTX over the period.",
      "llm_answer": "Union Pacific’s equity‑method stake in the rail‑car pool TTX grew from roughly **$1.6 billion** (reflecting a 36.79 % economic interest) in the 2022 filing to about **$1.9 billion** (now a 37.03 % interest) in the 2024 filing【UNP_10k_2022.pdf, p.86】【UNP_10k_2024.pdf, p.66】.  At the same time, the expense Union Pacific records for TTX car‑hire rose from **about $375 million** in the 2022 period to **$432 million** in 2024, indicating a larger operational reliance on TTX’s pooled equipment【UNP_10k_2022.pdf, p.86】【UNP_10k_2024.pdf, p.66】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. QUANTITATIVE VERIFICATION: (1) Investment value: $1.6 billion (2022 filing) → $1.9 billion (2024 filing) - CORRECT. The LLM correctly identifies these as equity-method stakes and notes the slight increase in economic interest percentage (36.79% to 37.03%), which adds valuable context. (2) Car hire expenses: $375 million (2022 period) → $432 million (2024) - CORRECT. The LLM properly attributes these to the 2022 and 2024 filings respectively. MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across two separate 10-K filings (2022 and 2024), correctly linking the investment value changes with operational expense changes to demonstrate growing financial and operational involvement. ENTITY ACCURACY: Union Pacific Railroad (UNP) correctly identified, TTX correctly identified as the rail-car pool entity, and the equity-method accounting treatment is properly characterized. MINOR OBSERVATIONS: (1) The LLM references specific page numbers (p.86 for 2022, p.66 for 2024) which adds credibility, though these cannot be independently verified here. (2) The phrase 'in the 2022 period' for car hire expenses is slightly ambiguous (could mean fiscal 2022 or the 2022 filing), but context makes the meaning clear. (3) The inclusion of percentage ownership changes (36.79% to 37.03%) goes beyond the ground truth but is factually accurate and enhances the answer. REASONING QUALITY: The conclusion that these increases 'indicate a larger operational reliance on TTX's pooled equipment' is logically sound and well-supported by the data presented. The answer directly addresses all components of the multi-part question regarding financial stake evolution, operational relationship, investment value, and car hire expenses.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 488,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Tesla's approach to scaling Solar Roof production change from 2022 to 2023, particularly regarding installer training initiatives and supply chain risk management?",
      "original_answer": "In 2022, Tesla emphasized expanding Solar Roof production by on-boarding and training new installers, collaborating with real estate developers, and reducing installation time and costs. The company also highlighted its need to hire additional personnel, particularly skilled electricians, to support the ramp. By 2023, Tesla's focus had shifted toward addressing broader supply chain risks and production ramp challenges, with language indicating that Solar Roof production now depended more on managing supplier reliability, global component constraints, and cost-effective manufacturing processes. The 2023 filing also noted that delays in production ramps could harm the business, signaling a shift from installer-focused growth to a more risk-averse strategy centered on supply chain resilience.",
      "llm_answer": "In 2022 Tesla said it would “continue to improve our installation capabilities and price efficiencies for Solar Roof by on‑boarding and training new installers, as well as collaborating with real‑estate developers and builders… and hire additional personnel, particularly skilled electricians, to support the ramp of Solar Roof” (2022 10‑K pp. 32‑36). By the 2023 filing the narrative had shifted to a risk‑focused view, noting that “we have experienced, and may also experience similar future delays in launching and/or ramping production of … Solar Roof” and warning that “our suppliers may fail to deliver components … or we may be unable to manage these components effectively,” indicating a stronger emphasis on supply‑chain risk management and less explicit mention of new installer‑training programs (2023 10‑K pp. 14‑18).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2022 focus on installer training, onboarding, and hiring skilled electricians - directly quoting the 10-K language about 'on-boarding and training new installers' and 'hire additional personnel, particularly skilled electricians.' (2) Accurately captures the 2023 shift toward supply chain risk management, citing specific language about production delays and supplier reliability concerns. (3) Properly synthesizes the multi-hop comparison showing the transition from installer-focused growth (2022) to risk-averse supply chain strategy (2023). (4) Includes appropriate citations to specific 10-K pages (2022 pp. 32-36, 2023 pp. 14-18), demonstrating document-level accuracy. (5) No quantitative errors - no numbers, dates, or calculations to verify, and all temporal references (2022 vs 2023) are correct. MINOR CONSIDERATIONS: (1) The LLM answer could have slightly more explicitly stated that the 2023 filing showed 'less explicit mention of new installer-training programs' as a direct contrast, though this is implied through the shift in narrative focus. (2) The ground truth mentions 'collaborating with real estate developers' which the LLM includes, and 'reducing installation time and costs' which is implicitly covered through 'price efficiencies.' The semantic equivalence is maintained. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and two separate 10-K filings, correctly identifying the strategic pivot and supporting it with appropriate textual evidence. The reasoning chain (2022 installer focus → 2023 supply chain risk focus) is logically sound and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 480,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has The Coca-Cola Company's relationship with fountain retailers evolved between 2022 and 2023, particularly regarding the manufacturing and distribution of fountain syrups in the United States?",
      "original_answer": "In 2022, The Coca-Cola Company stated that U.S. bottlers were generally not authorized to manufacture fountain syrups, and instead, the Company itself manufactured and sold fountain syrups directly to authorized fountain wholesalers (including some bottlers) and certain fountain retailers. By 2023, the Company clarified that it continues to manufacture fountain syrups in the U.S., but now explicitly states that it sells these syrups to both fountain retailers and authorized fountain wholesalers or bottling partners who then distribute them to fountain retailers. This indicates a more explicit acknowledgment of a tiered distribution model involving bottling partners in 2023, suggesting a potential expansion of their distribution network or clarification of roles.",
      "llm_answer": "The Company’s U.S. fountain‑syrup model was essentially unchanged. In both the 2022 and 2023 10‑K the Company states that it manufactures fountain syrups in the United States and sells them either directly to fountain retailers or through authorized fountain wholesalers (including certain bottling partners), while U.S. bottlers are not permitted to produce fountain syrups 【KO_10k_2022.pdf p.6】 【KO_10k_2023.pdf p.35】. The 2023 filing reiterates that these syrup sales are recorded in the North America operating segment, confirming the same distribution relationship as in 2022.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains accurate factual information about the fountain syrup distribution model but fundamentally misinterprets the question and provides an incomplete analysis of the evolution between 2022 and 2023.\n\nCORRECT ELEMENTS:\n- Accurately states that Coca-Cola manufactures fountain syrups in the U.S.\n- Correctly identifies that U.S. bottlers are not authorized to manufacture fountain syrups\n- Properly notes the dual distribution channels (direct to retailers and through wholesalers/bottling partners)\n- Correctly cites the relevant 10-K filings and page numbers\n- Accurately identifies the North America operating segment classification\n\nCRITICAL ERRORS:\n1. MISINTERPRETATION OF EVOLUTION: The LLM states \"the Company's U.S. fountain-syrup model was essentially unchanged\" and that \"the 2023 filing reiterates that these syrup sales...confirming the same distribution relationship as in 2022.\" This directly contradicts the ground truth, which identifies a meaningful evolution: the 2023 filing provides a MORE EXPLICIT acknowledgment of a tiered distribution model involving bottling partners, suggesting either an expansion or clarification of roles.\n\n2. INCOMPLETE ANALYSIS: The LLM fails to identify the key distinction between 2022 and 2023 filings. The ground truth emphasizes that 2023 \"explicitly states\" and provides \"more explicit acknowledgment\" of the bottling partners' role, whereas 2022 was less clear on this point. The LLM misses this nuance entirely.\n\n3. SEMANTIC MISALIGNMENT: The question asks \"how has...evolved\" (implying change), but the LLM concludes there was no meaningful evolution. While the operational model may be substantively similar, the disclosure and explicit acknowledgment of the distribution structure did evolve between years.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes information across both 2022 and 2023 filings but draws the wrong conclusion about the relationship evolution. The reasoning is logically structured but reaches an incorrect interpretation of what constitutes meaningful change in the disclosure.\n\nQUANTITATIVE ACCURACY: No numerical errors present (8/10 - deduction for not addressing any quantitative aspects of the relationship).\n\nQUALITATIVE ACCURACY: Significant issue with interpretation and synthesis of the evolution narrative (4/10).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 628,
        "total_tokens": 1979
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has IBM's treatment and disclosure of the 0.950% Notes due 2025 evolved from 2022 to 2024, particularly in terms of its financial instrument classification and registration details?",
      "original_answer": "In 2022, the 0.950% Notes due 2025 were disclosed as part of IBM's exhibits in Form 8-K filings, specifically referenced under Exhibit 4.1 filed on May 22, 2017. By 2024, the 0.950% Notes due 2025 were not only still present but were actively listed as a financial instrument with a trading symbol 'IBM25B' on the New York Stock Exchange. This evolution indicates a shift from merely disclosing the instrument to formally registering and listing it for trading.",
      "llm_answer": "In IBM’s 2022 Form 10‑K the 0.950 % notes due 2025 were presented only in the footnote to the consolidated financial statements as “notes payable” (a component of long‑term debt) and the filing did not feature a separate registration table for that issue. By the 2024 filing IBM still classifies the same instrument as a debt security (notes payable) but now includes it in a dedicated “Securities registered pursuant to Section 12(b)” table, identifying the ticker IBM25B and confirming that the notes are listed on the New York Stock Exchange—showing a more explicit registration disclosure while the classification itself remains unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy on key details but differs meaningfully from the ground truth in its characterization of the evolution. CORRECT ELEMENTS: (1) The 0.950% Notes due 2025 are correctly identified with proper percentage formatting; (2) The ticker symbol 'IBM25B' and NYSE listing are accurately stated; (3) The classification as debt/notes payable is correct; (4) The 2022-2024 timeframe is properly addressed; (5) The observation about registration disclosure changes is accurate. DISCREPANCIES: The ground truth emphasizes a shift from 'merely disclosing the instrument' (via Form 8-K Exhibit 4.1 from 2017) to 'formally registering and listing it for trading' by 2024. The LLM answer reframes this as a shift from footnote-only disclosure to inclusion in a 'Securities registered pursuant to Section 12(b)' table, which is a more specific and arguably more accurate characterization of what changed in the 10-K filings themselves. However, the LLM answer doesn't explicitly reference the Form 8-K filing history mentioned in the ground truth. The LLM's interpretation that 'the classification itself remains unchanged' is reasonable and adds nuance, but the ground truth's framing emphasizes the transition from exhibit-based disclosure to active trading registration. MULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2024 filings and correctly identifies the evolution in disclosure practices. The reasoning is sound and logically structured. MINOR ISSUE: The LLM doesn't mention the May 22, 2017 Form 8-K filing date referenced in the ground truth, though this may not be essential to answering the 2022-2024 evolution question. Overall, the answer is substantially correct with strong quantitative accuracy but presents a slightly different narrative framework than the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 502,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has GILD's strategic positioning of Biktarvy evolved from 2022 to 2024, particularly in terms of its financial risk exposure and competitive differentiation within the HIV treatment market?",
      "original_answer": "In 2022, Biktarvy was listed among GILD’s key marketed products, indicating its central role in the company's HIV portfolio and suggesting strong commercial positioning. By 2024, the company highlighted increasing financial risk tied to its reliance on nucleoside-based therapies like Biktarvy, particularly due to the potential shift in HIV treatment paradigms away from TAF-based regimens. This evolution reflects a growing concern over Biktarvy’s long-term competitive differentiation and its ability to sustain revenue, especially in the face of rising generic competition and changing therapeutic preferences.",
      "llm_answer": "In the 2022 Form 10‑K Gilead simply listed Biktarvy as a core HIV product (2022 10‑K p. 61) and warned that its overall reliance on HIV sales – including Biktarvy – left the company vulnerable to market‑share loss, pricing reforms and generic competition (2022 10‑K p. 65). By the 2024 filing the company is positioning Biktarvy as a differentiated, single‑tablet regimen that underpins its growth strategy (2024 10‑K pp. 16‑18) while explicitly noting that pricing reforms, rebate pressures and the prospect of generic entry heighten its financial‑risk exposure (2024 10‑K p. 20). This shift reflects a move from a launch‑focused narrative to a risk‑managed stance that emphasizes defending Biktarvy’s competitive edge while mitigating new financial vulnerabilities.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution of Biktarvy's positioning from 2022 to 2024, capturing the shift from a launch-focused narrative to a risk-managed stance. It accurately identifies key themes: (1) Biktarvy as a core HIV product in 2022, (2) growing financial risk exposure by 2024, (3) competitive pressures from generics and pricing reforms, and (4) the shift in treatment paradigms. The multi-hop synthesis across years is sound, and the semantic meaning aligns well with the ground truth.\n\nWEAKNESSES: (1) QUANTITATIVE ACCURACY ISSUES: The LLM provides specific page citations (2022 10-K p. 61, p. 65; 2024 10-K pp. 16-18, p. 20) that cannot be verified against the ground truth knowledge graph. These citations appear fabricated or at minimum unverifiable, which is a significant concern for factual grounding. (2) INCOMPLETE SYNTHESIS: The ground truth emphasizes 'potential shift in HIV treatment paradigms away from TAF-based regimens' as a specific competitive threat, while the LLM mentions 'changing therapeutic preferences' more generally without the specific TAF-based context. (3) FRAMING DISCREPANCY: The LLM characterizes 2024 positioning as emphasizing Biktarvy as 'differentiated' and 'underpins growth strategy,' which somewhat contradicts the ground truth's emphasis on 'growing concern over Biktarvy's long-term competitive differentiation.' The LLM's framing suggests more confidence in differentiation than the ground truth conveys. (4) MISSING NUANCE: The ground truth specifically highlights concerns about 'ability to sustain revenue,' which the LLM doesn't explicitly address.\n\nMULTI-HOP REASONING: The reasoning connecting 2022 positioning to 2024 risk exposure is logically sound and appropriately synthesizes information across years. However, the specific mechanism (TAF-based regimen shift) is underspecified.\n\nOVERALL ASSESSMENT: The answer captures the essential evolution and demonstrates good qualitative understanding, but the unverifiable page citations and incomplete treatment of specific competitive threats (TAF paradigm shift) reduce confidence in factual accuracy. The core narrative is correct but lacks precision in key details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 592,
        "total_tokens": 1949
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Lockheed Martin's approach to defined contribution retirement savings plans evolve between 2022 and 2023, particularly in terms of pension obligation transfers and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin transferred $4.3 billion of gross defined benefit pension obligations through group annuity contracts, recognizing a noncash pension settlement charge of $1.5 billion. In 2023, instead of another annuity purchase, the company made $414 million in settlement payments to approximately 6,500 former employees who had not yet started receiving benefits. This shift indicates a strategic evolution from transferring large blocks of pension obligations to insurers (as in 2022) to directly settling smaller portions of obligations with individual participants in 2023.",
      "llm_answer": "In the 2022 filing Lockheed Martin noted that salaried employees had already been moved from frozen defined‑benefit plans to an enhanced defined‑contribution retirement‑savings plan (effective 1 Jan 2020) and that the company was still shedding legacy pension liabilities by buying a $4.3 billion group‑annuity contract in Q2 2022, which generated a $1.5 billion non‑cash pension‑settlement charge. By the 2023 filing the strategy had shifted to smaller, voluntary lump‑sum settlements – a $414 million payment to about 6,500 former employees in Q4 2023 that reduced the pension obligation without a comparable large settlement charge – reflecting a move from large annuity purchases to targeted settlements while maintaining the defined‑contribution plan.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of Lockheed Martin's pension strategy evolution. QUANTITATIVE VERIFICATION: All key numbers are correct - $4.3 billion group annuity contract in 2022, $1.5 billion noncash pension settlement charge, $414 million settlement payments in 2023 to approximately 6,500 former employees. Dates are accurate (Q2 2022 for annuity, Q4 2023 for settlements, January 1, 2020 for defined contribution plan transition). MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across multiple years and filing periods, correctly identifying the strategic shift from large annuity purchases to targeted lump-sum settlements. The connection between the 2020 defined contribution plan transition and subsequent pension obligation management is properly contextualized. ENTITY ACCURACY: Lockheed Martin correctly identified, fiscal years properly referenced, financial metrics accurately named (group annuity contracts, noncash pension settlement charge, lump-sum settlements). REASONING QUALITY: The answer correctly interprets the evolution as a strategic shift and explains the rationale (moving from large blocks to smaller targeted settlements). The characterization of the 2023 approach as 'voluntary lump-sum settlements' and noting the absence of a 'comparable large settlement charge' demonstrates nuanced understanding. MINOR CONSIDERATIONS: The answer adds contextual detail about the 2020 defined contribution plan transition that, while accurate and helpful, goes slightly beyond the strict ground truth statement but enhances rather than detracts from accuracy. The phrasing 'without a comparable large settlement charge' is semantically equivalent to the ground truth's implication that 2023 lacked the large charge seen in 2022. All factual content aligns with the original answer's core message about the strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 517,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 2.875% Notes due 2025?",
      "original_answer": "In 2022, IBM listed the 2.875% Notes due 2025 (IBM 25A) among other Notes due in 2025, including the 0.950% Notes due 2025 (IBM 25B) and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 2.875% Notes due 2025 (IBM25A) remained, but the 0.875% Notes due 2025 (IBM 25C) were no longer listed, indicating a shift in the debt composition for that year. The 2.875% Notes due 2025 continued to be a key part of IBM's debt structure in 2024, suggesting a strategic decision to maintain this specific financial instrument while retiring or restructuring others.",
      "llm_answer": "In the 2022 Form 10‑K, IBM’s 2025‑maturing debt consisted of three note series – 2.875% Notes (IBM 25A), 0.950% Notes (IBM 25B) and 0.875% Notes (IBM 25C) – plus a 7.00% debenture (IBM 25) (see the 2022 securities table). By the 2024 filing, the 0.875% Notes are no longer listed, leaving only the 2.875% Notes (IBM 25A), the 0.950% Notes (IBM 25B) and the 7.00% debenture as the instruments due in 2025 (see the 2024 securities table). The 2.875% Notes due 2025 remain a consistent component of IBM’s 2025‑maturity profile across both years.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) Correctly identifies the three note series in 2022: 2.875% Notes (IBM 25A), 0.950% Notes (IBM 25B), and 0.875% Notes (IBM 25C). (2) Correctly notes that by 2024, the 0.875% Notes (IBM 25C) are no longer listed. (3) Correctly identifies that the 2.875% Notes remain in both years. (4) The overall narrative about debt composition evolution is sound. PROBLEMATIC ELEMENTS: (1) The LLM introduces a 7.00% debenture (IBM 25) in the 2022 listing that is not mentioned in the ground truth answer. While this may be factually present in the actual 10-K filings, the ground truth specifically lists only three instruments for 2022, not four. (2) The LLM claims the 7.00% debenture remains in 2024, but the ground truth does not mention this instrument at all in the 2024 comparison. This represents a discrepancy in what instruments are being tracked. (3) The ground truth focuses on the three main note series (25A, 25B, 25C) without mentioning the debenture, suggesting either it wasn't material to the answer or wasn't present in the actual filings. The LLM's introduction of an additional instrument not in the ground truth creates factual uncertainty. MULTI-HOP REASONING: The LLM correctly synthesizes information across 2022 and 2024 filings and identifies the key change (removal of 0.875% Notes). However, the inclusion of the 7.00% debenture without ground truth support weakens the synthesis. QUANTITATIVE ACCURACY: The percentages cited (2.875%, 0.950%, 0.875%, 7.00%) appear correct, but the discrepancy regarding which instruments are actually present in each year reduces confidence. The core finding about the 0.875% Notes being removed is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 474,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the strategic importance and risk profile of Biktarvy within Gilead's HIV portfolio evolved from 2022 to 2024, particularly in light of competitive pressures and changes in the treatment paradigm?",
      "original_answer": "In 2022, Biktarvy was positioned as a key growth driver for Gilead, with the company noting its 'continued growth in all geographies' and attributing part of the 11% revenue increase to its performance. By 2024, however, the strategic importance of Biktarvy appears more precarious. The 2024 10-K highlights increased risks around Gilead's HIV franchise, noting that 'many of our HIV products contain TAF' and that any shift away from nucleoside-based therapies could materially impact sales. This suggests that while Biktarvy was a growth asset in 2022, by 2024 it was increasingly seen as vulnerable to paradigm shifts in HIV treatment, representing a change in both strategic positioning and risk exposure.",
      "llm_answer": "In the 2022 Form 10‑K Gilead portrayed Biktarvy as the centerpiece of its HIV franchise – sales were rising on stronger demand and a higher net price and the drug was credited with offsetting the loss‑of‑exclusivity hit to Truvada and Atripla (GILD_10k_2022.pdf pp. 38‑40). By the 2024 filing, Biktarvy is still a core HIV product, but the company flags a heightened risk profile, noting growing generic‑TAF competition and the possibility that a shift away from nucleoside‑based regimens (e.g., long‑acting agents) could erode its market position (GILD_10k_2024.pdf p. 18).",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Biktarvy's evolving strategic position within Gilead's HIV portfolio from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 positioning of Biktarvy as a growth driver with rising sales and higher net price; (2) Accurately notes the 11% revenue increase attribution (matching ground truth); (3) Properly identifies the offset of LOE impacts on Truvada and Atripla; (4) Correctly characterizes the 2024 risk profile shift, including TAF-related vulnerabilities and paradigm shift risks; (5) Appropriately cites specific document references (page numbers); (6) Demonstrates sound multi-hop reasoning by synthesizing information across 2022 and 2024 filings to show evolution. MINOR WEAKNESSES: (1) The LLM answer emphasizes 'generic-TAF competition' as a specific risk, while the ground truth more broadly references 'any shift away from nucleoside-based therapies' - the LLM's framing is slightly narrower but not incorrect; (2) The ground truth uses the phrase 'increasingly seen as vulnerable to paradigm shifts' while the LLM says 'heightened risk profile' and mentions 'long-acting agents' - these are semantically equivalent but the LLM's specificity about long-acting agents is actually more precise; (3) The LLM characterizes Biktarvy as 'still a core HIV product' in 2024, which is accurate but the ground truth emphasizes the shift from 'growth asset' to 'vulnerable' more explicitly. QUANTITATIVE VERIFICATION: The 11% revenue increase figure is correctly cited and matches ground truth. No calculation errors detected. MULTI-HOP REASONING: The answer successfully synthesizes information across two separate 10-K filings (2022 and 2024) to demonstrate the evolution of strategic importance and risk profile. The logic connecting growth positioning in 2022 to vulnerability in 2024 is sound and well-supported. CONTEXTUAL RELEVANCE: The answer directly addresses all aspects of the multi-part question: strategic importance evolution, risk profile changes, competitive pressures, and treatment paradigm shifts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 558,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the balance of the U.S. litigation escrow account evolve between the end of fiscal year 2022 and the end of fiscal year 2023, and what were the specific deposit contributions during each period?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1,449 million at the end of fiscal year 2022 to $3,089 million at the end of fiscal year 2023. During this time, deposits into the account rose from $1,000 million in fiscal year 2022 to $1,500 million in fiscal year 2023.",
      "llm_answer": "The U.S. litigation escrow account held **$1,449 million at the end of fiscal 2022** (the beginning‑of‑period balance for FY 2023) and grew to **$1,764 million at the end of fiscal 2023**【V_10k_2023.pdf:71】.  The Company deposited **$850 million during FY 2022**【V_10k_2022.pdf:103】 and **$1,000 million during FY 2023**【V_10k_2023.pdf:71】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that fundamentally contradict the ground truth. (1) CRITICAL ERRORS - End of FY2023 Balance: LLM states $1,764 million, but ground truth shows $3,089 million - a difference of $1,325 million (43% understatement). This is a major factual error. (2) Deposit Contributions: LLM reports $850 million for FY2022 and $1,000 million for FY2023, but ground truth shows $1,000 million for FY2022 and $1,500 million for FY2023. Both deposit figures are incorrect. (3) Beginning Balance: LLM correctly identifies $1,449 million at end of FY2022, which matches ground truth. (4) Multi-hop Reasoning: While the LLM attempts to synthesize information across fiscal years and cite sources, the underlying numbers are wrong, making the synthesis fundamentally flawed. The LLM correctly identifies the account name and time periods but fails on the core quantitative data. (5) Completeness: The answer addresses both parts of the question (balance evolution and deposit contributions) but provides incorrect values for most metrics. The magnitude of errors (especially the $1,325 million discrepancy in ending balance) represents a critical failure in financial accuracy that would mislead any user relying on this information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1174,
        "completion_tokens": 354,
        "total_tokens": 1528
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the role of fountain syrups in Coca-Cola's North America operating segment evolved between 2022 and 2023, particularly regarding the company's manufacturing and distribution responsibilities?",
      "original_answer": "In 2022, Coca-Cola explicitly stated that it manufactured fountain syrups in the United States and sold them directly to fountain retailers or to authorized fountain wholesalers or bottling partners for further distribution. By 2023, the company's description shifted: while it still referenced selling fountain syrups in the North America segment, it also indicated that outside the U.S., bottling partners were authorized to manufacture fountain syrups using company concentrates. This suggests a nuanced evolution where Coca-Cola may be emphasizing a more decentralized, authorization-based model, particularly outside the U.S., while maintaining direct control within the U.S. There is no explicit mention of a change in manufacturing responsibilities within North America itself, indicating operational continuity there.",
      "llm_answer": "In 2022 the North America segment described fountain‑syrup sales only as the Company “selling fountain syrups to fountain retailers … or to authorized fountain wholesalers or bottling partners who in turn sell and distribute the fountain syrups to fountain retailers” [KO_10k_2022.pdf p. 36]. By 2023 the filing adds that the Company now **manufactures** those fountain syrups in the United States and then sells them both directly to fountain retailers and through authorized wholesalers or bottling partners, keeping the sales within the North America operating segment [KO_10k_2023.pdf p. 36]. Thus, the role has shifted from a pure sales function to an expanded one that includes internal production as well as distribution.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The LLM claims that in 2023, the company 'now manufactures those fountain syrups in the United States' as a new development, suggesting this was NOT the case in 2022. However, the ground truth explicitly states that in 2022, Coca-Cola 'explicitly stated that it manufactured fountain syrups in the United States.' The LLM has reversed the chronology of events. According to the ground truth, manufacturing in the U.S. was already happening in 2022, not introduced in 2023. The LLM's characterization of the evolution as 'shifted from a pure sales function to an expanded one that includes internal production' is therefore incorrect. The actual evolution, per the ground truth, was more nuanced: in 2022 Coca-Cola manufactured and sold directly; by 2023, while still selling fountain syrups in North America, the company emphasized a more decentralized authorization-based model outside the U.S. where bottling partners manufacture using company concentrates. The LLM failed to capture this key distinction about the geographic/authorization-based shift rather than a manufacturing responsibility shift. The LLM also misrepresents the 2022 description by omitting that it already included manufacturing. This is a critical multi-hop reasoning failure where the model incorrectly synthesized information from the two years' filings, creating a false narrative of change in manufacturing responsibilities when the ground truth indicates operational continuity in North America manufacturing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 435,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 0.950% Notes due 2025?",
      "original_answer": "In 2022, IBM had three sets of notes maturing in 2025: the 2.875% Notes due 2025 (IBM 25A), the 0.950% Notes due 2025 (IBM 25B), and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 0.875% Notes due 2025 were no longer listed, leaving only the 2.875% Notes due 2025 (IBM 25A) and the 0.950% Notes due 2025 (IBM 25B). This indicates a reduction in the diversity of interest rate profiles for debt maturing in 2025, with the removal of the 0.875% instrument.",
      "llm_answer": "In the 2022 Form 10‑K IBM listed four instruments maturing in 2025 – the 2.875% notes, the 0.950% notes, the 0.875% notes and a 7.00% debenture. By the 2024 filing the 0.875% notes (IBM 25C) had disappeared, leaving only the 2.875% and 0.950% notes (IBM 25A and 25B) together with the 7.00% debenture, so the 0.950% Notes due 2025 remained unchanged while the overall 2025 note mix was reduced.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERROR: The LLM answer introduces a 7.00% debenture maturing in 2025 that is NOT mentioned in the ground truth. The ground truth explicitly states IBM had THREE sets of notes in 2022 (2.875%, 0.950%, and 0.875%), not four instruments. The LLM claims there were four instruments in 2022 including a 7.00% debenture, and that this debenture persisted into 2024. This is a significant factual error that contradicts the ground truth. CORRECT ELEMENTS: (1) The 0.875% Notes (IBM 25C) were correctly identified as disappearing between 2022 and 2024; (2) The 2.875% Notes (IBM 25A) and 0.950% Notes (IBM 25B) were correctly identified as remaining in both years; (3) The conclusion that the 0.950% Notes remained unchanged is correct; (4) The observation about reduced diversity is semantically aligned with the ground truth. CRITICAL ISSUES: The introduction of the 7.00% debenture is a fabrication not supported by the ground truth. This represents a fundamental factual error in entity identification. The LLM appears to have conflated or invented debt instruments. The answer correctly identifies the removal of the 0.875% instrument but fails on the basic count and composition of 2022 instruments. The multi-hop reasoning is partially sound (comparing 2022 to 2024) but is built on an incorrect foundation regarding what instruments existed in 2022.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 377,
        "total_tokens": 1590
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Disney's strategic approach to cruise ships evolved between 2022 and 2024 based on disclosures in their 10-K filings?",
      "original_answer": "In 2022, Disney mentioned cruise ships as part of its broader travel and resort experiences, indicating that their success depended on consumer demand for out-of-home entertainment and travel. By 2024, Disney had elevated its approach, explicitly stating plans to 'expand investment in our Experiences segment' and 'additional expansion of our fleet of cruise ships.' This evolution reflects a shift from general dependence on consumer demand to an active investment and growth strategy in cruise ship operations. The 2024 filing also notes that new offerings, such as additional cruise ships, come with increased costs and uncertain returns, signaling a more capital-intensive and strategic focus compared to the more passive mention in 2022.",
      "llm_answer": "In the 2022 10‑K Disney’s cruise strategy was centered on expanding its itinerary footprint – it announced the development of a new Disney Cruise Line destination at Lighthouse Point in the Bahamas, slated to open in 2024. By the 2024 10‑K the focus had broadened to scaling the cruise operation itself – the filing notes “additional expansion of our fleet of cruise ships” and new investments in cruise‑related experiences, while also winding down the under‑performing Star Wars: Galactic Starcruiser, reflecting a shift from a single‑destination add‑on to a wider fleet‑growth and portfolio‑optimization approach.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer provides specific details about Disney's cruise strategy evolution but introduces information not present in the ground truth while omitting key elements from it. STRENGTHS: (1) Correctly identifies the shift from 2022 to 2024 in Disney's cruise approach; (2) Accurately mentions 'additional expansion of our fleet of cruise ships' which matches the ground truth language; (3) Provides concrete examples (Lighthouse Point in Bahamas opening in 2024, Star Wars: Galactic Starcruiser winding down) that add specificity; (4) Correctly identifies the evolution from single-destination focus to fleet-growth strategy. WEAKNESSES: (1) The ground truth emphasizes a shift from 'general dependence on consumer demand' (2022) to 'active investment and growth strategy' (2024), but the LLM answer frames it as 'itinerary footprint expansion' to 'fleet-growth and portfolio-optimization' - a different characterization; (2) The LLM introduces specific details about Lighthouse Point and Star Wars: Galactic Starcruiser that, while potentially accurate, are not mentioned in the ground truth and cannot be verified against it; (3) Missing the ground truth's emphasis on the 2024 filing noting 'increased costs and uncertain returns' as a key distinction; (4) The LLM's framing of 2022 strategy as 'destination add-on' is more specific than the ground truth's broader 'dependence on consumer demand for out-of-home entertainment and travel'; (5) Does not capture the ground truth's point about the shift from 'passive mention' to 'capital-intensive and strategic focus.' MULTI-HOP REASONING: The LLM correctly synthesizes information across 2022 and 2024 filings and identifies an evolution, but the specific nature of that evolution differs from the ground truth. The answer demonstrates good reasoning but may be introducing details from actual filings that diverge from the knowledge graph's characterization. QUANTITATIVE ACCURACY: Dates are correct (2022, 2024, 2024 opening for Lighthouse Point), but no specific financial figures are provided in either answer, so this dimension is less critical here.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 566,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did Lockheed Martin's approach to pension risk transfer transactions evolve from 2022 to 2023, particularly in terms of financial impact and strategic intent?",
      "original_answer": "In 2022, Lockheed Martin detailed a specific pension risk transfer transaction from August 3, 2021, where $4.9 billion of gross defined benefit pension obligations were transferred via group annuity contracts (GACs), resulting in a noncash pension settlement charge of $1.7 billion. The company also noted that since December 2018, it had transferred approximately $11.6 billion in pension obligations, eliminating volatility for around 95,000 retirees. By 2023, the company reiterated its strategic intent to continue evaluating such transactions but shifted focus toward the broader financial and risk implications, including potential future contributions to the pension trust and the possibility of additional noncash settlement charges. The 2023 filing also introduced a nuanced risk: while most GACs relieve Lockheed of pension obligations, some could leave the company liable if the insurer defaults. This reflects a more cautious framing of pension risk transfer, acknowledging residual liability exposure not emphasized in 2022.",
      "llm_answer": "In the 2022 filing (pages 58‑62) Lockheed Martin noted that, after a 2021 purchase of group‑annuity contracts (GACs) that transferred $4.9 billion of pension obligations and produced a $1.7 billion non‑cash settlement charge, it would continue to look for pension‑risk‑transfer opportunities but made no new contributions in 2022 and expected to recover CAS pension costs. By the 2023 filing (pages 17‑21) the company reaffirmed that intent, but added that future GAC deals may be structured so the insurer reimburses the plan while Lockheed Martin still bears benefit‑payment risk, and such transactions could require additional contributions or generate non‑cash settlement charges—showing a more nuanced, earnings‑impact‑aware approach to managing pension volatility.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies all key financial figures ($4.9 billion pension obligations transferred, $1.7 billion noncash settlement charge) and accurately dates the 2021 transaction. The multi-hop synthesis across 2022 and 2023 filings is sound, correctly capturing the evolution from a retrospective discussion of completed transactions to a forward-looking discussion of potential future structures. The answer accurately conveys the shift toward acknowledging earnings impacts and potential future contributions. The characterization of the 2023 approach as 'more nuanced, earnings-impact-aware' aligns well with the ground truth's description of 'more cautious framing.' WEAKNESSES: (1) The LLM answer omits the specific detail that approximately 95,000 retirees had volatility eliminated through the cumulative $11.6 billion in transfers since December 2018—this is a material contextual detail from the ground truth. (2) The LLM answer mentions that 'some GACs could leave the company liable if the insurer defaults' but frames this less explicitly than the ground truth's emphasis on 'residual liability exposure not emphasized in 2022.' The LLM captures the concept but with less emphasis on the shift in risk disclosure between years. (3) The page references (58-62, 17-21) cannot be verified against the ground truth and may be inaccurate, though this is a minor issue if the underlying facts are correct. QUANTITATIVE VERIFICATION: All dollar amounts and the 2021 date are accurate. No calculations are required or performed. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years and correctly identifies the evolution in strategic approach. The logic connecting 2022 retrospective discussion to 2023 forward-looking discussion is sound. SEMANTIC EQUIVALENCE: The core message matches—evolution from completed transaction discussion to nuanced future planning with earnings awareness. The omission of the 95,000 retirees detail and the slightly softer treatment of residual liability exposure prevent a higher score, but the fundamental answer is directionally correct and addresses the main question effectively.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 584,
        "total_tokens": 2040
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Tesla's relationship with its financing partners evolved between 2022 and 2023, particularly in terms of accounts receivable management and leasing program risks?",
      "original_answer": "In 2022, Tesla disclosed that accounts receivable from financing partners could take up to approximately two weeks to settle based on contractual payment terms, directly impacting the company's short-term liquidity and balance sheet fluctuations. By 2023, Tesla highlighted increased complexity and risk in managing its financing programs, noting that its leasing business depends on securing adequate financing or partners, and that residual value risks from leased vehicles could negatively affect profitability. This indicates a shift from a focus on operational cash flow timing in 2022 to a broader concern over credit, compliance, and residual value risks in 2023 as the leasing program scaled.",
      "llm_answer": "In the 2022 filing (TSLA 10‑K pp. 62‑66) Tesla explained that its accounts‑receivable are largely comprised of amounts due from financial institutions and leasing companies, that collections can take up to two weeks after a quarter‑end, and that it maintains an allowance for doubtful accounts while noting that no single partner represents ≥ 10 % of the receivable balance; the filing also warned that the profitability of its vehicle‑leasing program hinges on securing financing and accurately projecting residual values. The 2023 filing (TSLA 10‑K pp. 18‑22) repeats the same reliance on financing partners for receivables and leasing, but adds that Tesla has continued to diversify its financing partners and intensify credit‑risk monitoring, even as the residual‑value and financing‑partner risks to the leasing program remain material. Together, the disclosures show an evolution from a stable partner relationship to a more diversified, actively managed financing‑partner network while the core risks to accounts receivable and leasing persist.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Tesla's financing partner relationships and provides accurate core information, but has some notable issues: (1) CORRECT ELEMENTS: The two-week settlement timeline for accounts receivable is accurately cited from 2022 filings; the mention of no single partner representing ≥10% of receivable balance is accurate; the identification of residual value risks and financing dependency for leasing programs is correct; the characterization of evolution toward diversified financing partners is reasonable. (2) QUANTITATIVE ACCURACY: The specific page references (pp. 62-66 for 2022, pp. 18-22 for 2023) cannot be verified against the ground truth but appear plausible for 10-K filings. The two-week settlement period matches the ground truth. The ≥10% threshold is mentioned in the LLM answer but not in the original answer, suggesting additional detail rather than error. (3) MULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2023 filings, identifying the evolution from operational cash flow timing concerns to broader risk management. However, the original answer emphasizes a shift from 'operational cash flow timing' to 'credit, compliance, and residual value risks,' while the LLM frames it as evolution toward 'diversified, actively managed' networks. These are complementary but slightly different framings. (4) POTENTIAL ISSUES: The LLM introduces the concept of 'diversifying financing partners' and 'intensifying credit-risk monitoring' which are not explicitly mentioned in the ground truth answer. While these may be accurate from the filings, they represent inferences or additional details not confirmed by the original answer. The ground truth emphasizes 'increased complexity and risk' while the LLM emphasizes 'active management' - a subtle but meaningful difference in tone. (5) COMPLETENESS: Both answers address accounts receivable management and leasing program risks across both years, meeting the multi-part question requirements. The LLM provides more specific detail but this comes at the cost of introducing elements not in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 575,
        "total_tokens": 2019
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "What changes occurred in Coca-Cola's fountain syrup distribution strategy between 2022 and 2023, and how did the roles of bottlers and fountain wholesalers evolve during this period?",
      "original_answer": "In 2022, Coca-Cola manufactured and sold fountain syrups directly to authorized fountain wholesalers (including certain authorized bottlers), who then sold or delivered the syrups to retailers. Bottlers in the U.S. were generally not authorized to manufacture fountain syrups. By 2023, the strategy evolved such that outside the United States, bottlers were typically authorized to manufacture fountain syrups using Coca-Cola concentrates, which they could sell to fountain retailers or authorized fountain wholesalers. This represents a shift from a more centralized syrup distribution model to a more integrated one, where bottlers play a more active role in the fountain syrup supply chain, particularly in international markets.",
      "llm_answer": "In 2022 Coca‑Cola’s U.S. model was to manufacture fountain syrups and sell them either straight to fountain retailers or to authorized fountain wholesalers – including a limited group of bottlers, while bottlers were not permitted to produce the syrups themselves (KO 2022 pp. 6‑10). By 2023 the company broadened the channel, selling its syrups to either authorized fountain wholesalers **or** to bottling partners who then distribute the syrups to retailers, giving bottlers a more active distribution role while still using dedicated fountain‑wholesaler partners (KO 2023 pp. 35‑39).",
      "correctness_score": 5,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES WITH ACCURACY: The LLM answer contains significant factual errors that contradict the ground truth. (1) INCORRECT 2022 CHARACTERIZATION: The LLM claims in 2022 Coca-Cola sold syrups 'straight to fountain retailers' - the ground truth explicitly states they sold to 'authorized fountain wholesalers' who then sold to retailers. Direct-to-retailer sales are not mentioned in the ground truth. (2) MISSING CRITICAL GEOGRAPHIC DISTINCTION: The ground truth emphasizes that the key change was OUTSIDE THE UNITED STATES - bottlers were authorized to manufacture syrups internationally. The LLM answer focuses on U.S. model changes and mentions 'bottling partners who then distribute' but fails to clearly distinguish that this authorization was primarily for non-U.S. markets. This is a critical omission that misrepresents the scope of the strategic shift. (3) INCOMPLETE CHARACTERIZATION OF 2023 CHANGE: The ground truth specifies that by 2023, bottlers outside the U.S. were 'typically authorized to manufacture fountain syrups using Coca-Cola concentrates' - this is manufacturing authorization, not just distribution. The LLM answer vaguely mentions 'bottling partners' without clarifying the manufacturing component or the geographic scope. (4) MISCHARACTERIZATION OF WHOLESALER ROLE: The LLM suggests wholesalers remained as 'dedicated fountain-wholesaler partners' in parallel, but the ground truth indicates a shift from centralized to integrated model where bottlers take on more active roles. (5) DATES/ENTITIES: Years (2022, 2023) and company (Coca-Cola) are correct. The page citations provided by LLM cannot be verified against ground truth but appear to be fabricated specificity. POSITIVE ASPECTS: The LLM correctly identifies that bottlers were not authorized to manufacture in 2022 (at least in U.S.), and recognizes a shift toward greater bottler involvement by 2023. The general direction of change is partially correct. However, the failure to emphasize the international/non-U.S. focus of the 2023 changes and the mischaracterization of 2022 direct-to-retailer sales represent fundamental errors in understanding the strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 579,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of receivables and new investment activities?",
      "original_answer": "In 2023, AMD had receivables from the ATMP JV of $9 million, and there was no mention of any direct investment or loan made by AMD to the JV. By 2024, AMD's receivables from the ATMP JV increased to $12 million, and the company entered into a new $100 million one-year term loan agreement with one of the ATMP JVs to support its general corporate purposes. This marks a significant shift from a purely transactional relationship in 2023 to a more financially integrated one in 2024, where AMD is not only a customer but also a creditor and strategic supporter of the JV.",
      "llm_answer": "In 2023 AMD reported a $9 million receivable from the ATMP JV (up from $2 million in 2022) and an investment carrying value of about $99 million 【AMD_10k_2023.pdf p.78】. By the end of 2024 the receivable had risen to $12 million, AMD had extended a $100 million one‑year term loan to the JV and made a $17 million equity contribution, lifting the ATMP JV investment to roughly $149 million 【AMD_10k_2024.pdf p.73‑74】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. CRITICAL ERRORS: (1) The LLM claims AMD had a $99 million investment carrying value in 2023 and increased it to $149 million in 2024 with a $17 million equity contribution. The ground truth explicitly states there was 'no mention of any direct investment or loan made by AMD to the JV' in 2023, and the only new activity in 2024 was the $100 million term loan. The LLM appears to have fabricated the equity investment figures. (2) The LLM references specific page numbers (p.78 for 2023, p.73-74 for 2024) which cannot be verified and may be hallucinated citations. CORRECT ELEMENTS: (1) The $9 million receivable in 2023 is correct. (2) The $12 million receivable in 2024 is correct. (3) The $100 million one-year term loan in 2024 is correct. ANALYSIS: The LLM correctly identified the receivables evolution but fundamentally misrepresented the investment relationship. The ground truth indicates AMD had NO equity investment in the ATMP JV in 2023, only receivables. In 2024, AMD's new involvement was limited to the $100 million term loan, not equity contributions. The LLM's claim of a $17 million equity contribution and investment values of $99M-$149M directly contradicts the ground truth statement that there was 'no mention of any direct investment.' This represents a major factual error in understanding the nature of AMD's financial relationship with the ATMP JV. The multi-hop reasoning is partially sound (comparing 2023 to 2024) but is built on incorrect foundational data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 432,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Lockheed Martin's approach to managing its nonqualified defined benefit pension plans evolve between 2022 and 2023, particularly in terms of pension obligation settlements and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin purchased group annuity contracts to transfer $4.3 billion of gross defined benefit pension obligations and recognized a noncash pension settlement charge of $1.5 billion. In 2023, the company continued its strategy of reducing pension liabilities by making voluntary settlement payments of $414 million to approximately 6,500 former employees, significantly smaller in scale compared to the 2022 transaction. This indicates a shift from large-scale pension obligation transfers to a more targeted approach involving smaller settlements with former employees who had not yet started receiving benefits.",
      "llm_answer": "In 2022 Lockheed Martin addressed its non‑qualified defined‑benefit pension obligations by purchasing group‑annuity contracts that transferred about $4.3 billion of gross pension liabilities to an insurer, which it recorded as a $1.5 billion non‑cash settlement charge. By 2023 the company shifted to a modest cash settlement – paying $414 million to roughly 6,500 former participants – which reduced the benefit obligation but had no impact on its pension expense.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the question. All key financial figures are correct: $4.3 billion in gross pension obligations transferred in 2022, $1.5 billion noncash settlement charge in 2022, and $414 million voluntary settlement payments to approximately 6,500 former employees in 2023. The multi-hop reasoning is sound, correctly synthesizing the evolution of Lockheed Martin's pension management strategy across the two-year period. The answer accurately characterizes the shift from large-scale pension obligation transfers (2022) to more targeted, smaller-scale settlements (2023). The LLM correctly identifies the distinction between the 2022 group annuity contract transaction and the 2023 cash settlement approach. One minor point: the LLM states the 2023 settlement 'had no impact on its pension expense,' which is a reasonable inference but goes slightly beyond what the ground truth explicitly states. The ground truth focuses on the settlement being 'significantly smaller in scale' and representing a 'more targeted approach,' without explicitly addressing pension expense impact. This is a minor elaboration that doesn't contradict the ground truth but adds interpretive detail. The answer is well-structured, clearly explains the evolution of strategy, and maintains semantic equivalence with the original answer while using slightly different phrasing (e.g., 'modest cash settlement' vs. 'voluntary settlement payments'). All entity identifications are correct (Lockheed Martin, defined benefit pension plans, former employees/participants), and the temporal sequencing is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 450,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did AMD's financial relationship with the ATMP JV evolve between 2023 and 2024, particularly in terms of its investment and equity income?",
      "original_answer": "In 2023, AMD recorded $16 million in equity income from the ATMP JV and had a carrying value of $99 million as of the end of the year. In 2024, AMD contributed an additional $17 million to the JV, increasing its investment's carrying value to $149 million by the end of the year. Equity income also rose to $33 million. This indicates a significant increase in both AMD's investment stake and the returns it received from the ATMP JV.",
      "llm_answer": "In 2023 AMD’s 15 % equity interest in the ATMP joint venture was carried at roughly **$99 million** and generated **$16 million of equity‑income** on the consolidated statement of operations【AMD_10k_2023.pdf†p78】. By year‑end 2024 the company had made a $17 million equity contribution, raising the carrying value to about **$149 million**, and the JV’s equity‑income climbed to **$33 million**【AMD_10k_2024.pdf†p73】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative data matches the ground truth exactly: 2023 equity income of $16 million, 2023 carrying value of $99 million, 2024 contribution of $17 million, 2024 carrying value of $149 million, and 2024 equity income of $33 million. The answer correctly identifies the 15% equity interest percentage and properly synthesizes the multi-hop information across 2023 and 2024 filings. The reasoning is sound, showing the evolution of AMD's financial relationship with the ATMP JV through both investment increases and rising equity income returns. The answer includes appropriate source citations (AMD_10k_2023.pdf and AMD_10k_2024.pdf with page numbers), demonstrating proper documentation. The only minor observation is that the LLM uses slightly different phrasing ('roughly' and 'about' for approximate values, 'climbed' for increased) compared to the ground truth's more formal language, but this represents stylistic variation rather than factual error. The answer fully addresses all aspects of the question regarding the evolution of AMD's investment stake and returns from the ATMP JV between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 331,
        "total_tokens": 1543
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Johnson & Johnson's financial stake and ownership relationship with Kenvue evolve between 2023 and 2024, particularly in terms of retained equity and associated gains or losses?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% ownership stake in Kenvue valued at $4.3 billion following the exchange offer, which resulted in a non-cash gain of $21.0 billion, including a $2.8 billion gain on the retained shares. By the end of 2024, the company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock, thereby eliminating its ownership stake and incurring a loss of approximately $0.4 billion in the process. This marks a full exit from Kenvue after initially reducing its stake significantly in 2023.",
      "llm_answer": "In 2023, after the Kenvue IPO (which left Johnson & Johnson with about 89.6 % of the shares) the company sold an additional 80.1 % in an exchange offer, retaining roughly 9.5 % of Kenvue’s common stock. That retained stake was recorded in “other assets” at a fair‑market value of $4.3 billion (later $3.9 billion) and generated a $2.8 billion gain on the retained Kenvue equity, which was part of a total non‑cash gain of $21 billion from the exchange. By 2024, Johnson & Johnson completed a debt‑for‑equity swap of its remaining 182 million Kenvue shares, eliminating its ownership entirely and recognizing an approximately $0.4 billion loss in other (income) expense.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the question. Verification of key facts: (1) 2023 retained stake of 9.5% - CORRECT; (2) $4.3 billion valuation - CORRECT; (3) $2.8 billion gain on retained shares - CORRECT; (4) $21.0 billion total non-cash gain - CORRECT; (5) 2024 debt-for-equity exchange of 182,329,550 shares (LLM states ~182 million) - CORRECT; (6) ~$0.4 billion loss in 2024 - CORRECT. The LLM answer provides additional helpful context not in the ground truth, including: the IPO leaving J&J with 89.6% initially, the 80.1% sold in the exchange offer, the fair value adjustment from $4.3B to $3.9B, and the specific accounting treatment (recorded in 'other assets'). The multi-hop reasoning is sound: the answer correctly synthesizes the evolution from 2023 (post-IPO and exchange offer) through 2024 (complete exit via debt-for-equity swap). The narrative flow clearly shows the progression of J&J's ownership stake reduction. Minor note: The LLM uses '~182 million' while ground truth specifies '182,329,550 shares' - this is an acceptable rounding/format variation. The answer fully addresses all aspects of the question regarding how the financial stake and ownership relationship evolved between the two years, including retained equity values and associated gains/losses. No material factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 379,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. evolve between 2022 and 2023, particularly in terms of its inclusion in guarantee agreements?",
      "original_answer": "AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained consistent between 2022 and 2023, with the company continuing to guarantee certain obligations of Southwestern Bell Telephone Co. in both years. In 2022, the guarantee was listed in Exhibit 4-c, which included multiple entities such as Southwestern Bell Telephone Company. In 2023, the guarantee was again referenced in Exhibit 4-c, maintaining the same inclusion of Southwestern Bell Telephone Co. within the list of guaranteed entities. This indicates no change in the nature or scope of the guarantee.",
      "llm_answer": "In the 2022 Form 10‑K AT&T still listed a guaranty covering certain obligations of Southwestern Bell Telephone Co. (see Exhibit 4‑c in the “Guarantees” section). By the 2023 Form 10‑K that guaranty is no longer shown among the company’s guarantee agreements, indicating the Southwest Bell guarantee relationship had been removed.",
      "correctness_score": 1,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 1,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is fundamentally incorrect on the core factual claim. The ground truth states that AT&T's guarantee relationship with Southwestern Bell Telephone Co. REMAINED CONSISTENT between 2022 and 2023, with the guarantee listed in Exhibit 4-c in both years with NO CHANGE in the nature or scope. However, the LLM answer claims the opposite: that the guarantee was present in 2022 but was REMOVED by 2023 ('that guaranty is no longer shown among the company's guarantee agreements'). This is a direct contradiction of the ground truth. The LLM has inverted the actual finding - it states there was a change when the ground truth explicitly indicates there was no change. While the LLM correctly identifies the relevant exhibit (Exhibit 4-c) and the correct company name (Southwestern Bell Telephone Co.), and properly references both 2022 and 2023 10-K filings, the core conclusion about the evolution of the relationship is completely wrong. The question asks how the relationship 'evolved' and the correct answer is that it did not evolve - it remained consistent. The LLM's answer suggests a discontinuation that did not occur according to the ground truth. This is a critical factual error that makes the answer fundamentally incorrect despite addressing the right documents and time periods.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 364,
        "total_tokens": 1602
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2023, particularly in terms of strategic positioning and program development responsibilities?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a growth area that was dependent on U.S. Government authorization and funding, and was listed among other key development areas like classified programs and next-generation franchise programs. By 2023, the company's role had evolved significantly, with hypersonics programs now explicitly listed among major programs under the Space segment, indicating a more concrete and active role in designing, developing, and building hypersonic strike weapons for the U.S. Army and Navy. This reflects a shift from a potential growth area to a clearly defined and active program portfolio.",
      "llm_answer": "In the 2022 Form 10‑K Lockheed Martin said hypersonics was one of four “growth‑element” priorities and that it was “currently performing on multiple hypersonics programs” with the U.S. Air Force and Army, focusing on testing and expecting those programs to move into early‑production through 2026【LMT_10k_2022.pdf, p.12】. By the 2023 Form 10‑K the company still flagged hypersonics as a strategic growth pillar, but its involvement had broadened: both the Missiles & Fire Control and Space segments now carry “design, develop and build” responsibilities for hypersonic strike weapons for the Air Force, Army **and** the Navy, reflecting a wider cross‑segment strategic positioning and deeper program‑development role【LMT_10k_2023.pdf, p.3‑6】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about Lockheed Martin's hypersonics evolution from 2022 to 2023. STRENGTHS: (1) Correctly identifies 2022 positioning as a 'growth-element' priority with multiple programs underway with U.S. Air Force and Army; (2) Accurately describes 2023 evolution showing broader involvement across Missiles & Fire Control and Space segments; (3) Correctly notes expansion to include Navy in addition to Air Force and Army; (4) Properly synthesizes the shift from potential growth area to active program portfolio with 'design, develop and build' responsibilities; (5) Provides specific document citations and page numbers; (6) Captures the strategic positioning evolution effectively. MINOR CONSIDERATIONS: (1) The LLM answer includes additional detail about 'testing' and 'early-production through 2026' timeline from 2022 filing that, while likely accurate, goes slightly beyond what the ground truth explicitly states; (2) The ground truth emphasizes the shift from 'potential growth area' to 'clearly defined and active program portfolio,' while the LLM answer frames it as 'flagged as strategic growth pillar' in 2023 with 'broadened involvement' - semantically equivalent but slightly different framing; (3) The LLM answer provides more granular detail about segment-level responsibilities (Missiles & Fire Control and Space segments specifically) which adds valuable context not explicitly in the ground truth statement. MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years and multiple business segments, properly comparing and contrasting the evolution. The logic flow from 2022 to 2023 is sound and well-supported. QUANTITATIVE ACCURACY: No specific numbers or calculations are present in either answer, so this dimension is not directly testable, but dates (2022, 2023, 2026) are correct. SEMANTIC EQUIVALENCE: The core message matches the ground truth - evolution from growth area to active program with expanded scope and responsibilities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 558,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did the balance of the U.S. litigation escrow account evolve from fiscal year 2022 to fiscal year 2023, and what were the respective amounts deposited into the account during those years?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1.4 billion as of September 30, 2022, to $3.089 billion as of September 30, 2023. During fiscal year 2022, $850 million was deposited into the account, while in fiscal year 2023, $1.0 billion was deposited.",
      "llm_answer": "The U.S. litigation escrow account grew from roughly $1.4 billion at September 30 2022 to $1.764 billion at September 30 2023. During fiscal 2022 the company deposited $850 million into the escrow, and it deposited $1.0 billion in fiscal 2023【2022】【2023】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a major factual error regarding the September 30, 2023 balance. The ground truth states the balance was $3.089 billion, but the LLM claims it was $1.764 billion - a difference of $1.325 billion (43% understatement). This is a fundamental factual error that cannot be overlooked. CORRECT ELEMENTS: (1) The September 30, 2022 balance of $1.4 billion is correct. (2) Both deposit amounts are correct: $850 million in fiscal 2022 and $1.0 billion in fiscal 2023. (3) The dates and fiscal years are correctly identified. (4) The general characterization of account growth is appropriate in tone. MULTI-HOP REASONING: The LLM correctly synthesized the deposit information across two fiscal years and properly identified the account balance evolution concept. However, the synthesis failed at the critical point of identifying the correct ending balance. CALCULATION VERIFICATION: The deposits ($850M + $1.0B = $1.85B) do not reconcile with either the LLM's stated ending balance ($1.764B) or the ground truth ending balance ($3.089B), suggesting the LLM may have confused or misread source data. The magnitude of the error on the 2023 balance is severe enough to make this answer substantially incorrect despite getting the deposits right. This represents a failure in the primary quantitative accuracy requirement for financial questions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1146,
        "completion_tokens": 387,
        "total_tokens": 1534
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the role and positioning of Outdoor Garden within HD's product strategy evolved from 2022 to 2024, based on its classification and performance metrics?",
      "original_answer": "In 2022, Outdoor Garden was disclosed as a distinct product line with $10,317 million in net sales, accounting for 6.8% of total net sales, indicating its importance as a standalone category. By 2024, Outdoor Garden was grouped under the broader 'Hardlines' merchandising department, suggesting a strategic integration into a larger product segment. This shift reflects a change in how HD positions Outdoor Garden within its overall product portfolio, moving from a separate focus area to a component of a consolidated category.",
      "llm_answer": "In the 2022 filing, Outdoor Garden was listed as a merchandising department within the Hardlines product line (alongside Hardware, Indoor Garden and Tools) and contributed $10.3 billion of net sales – roughly 6.8 % of total net sales. By the 2024 filing the Hardlines line had been re‑structured (now grouping Outdoor Garden with Power and Storage & Organization), and Outdoor Garden still generated about $10.3 billion but its share fell to 6.5 % of net sales, showing a modest dip in relative contribution while remaining a core Hardlines category.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: The LLM answer contains fundamental factual inaccuracies that contradict the ground truth. (1) CLASSIFICATION ERROR - Ground truth states that in 2022, Outdoor Garden was 'disclosed as a distinct product line' (separate from Hardlines), but the LLM claims it was 'listed as a merchandising department within the Hardlines product line' in 2022. This is a critical mischaracterization of the 2022 positioning. (2) STRUCTURAL CHANGE MISREPRESENTATION - The ground truth indicates a shift FROM separate classification TO being grouped under Hardlines by 2024. The LLM reverses this logic, suggesting Outdoor Garden was already within Hardlines in 2022 and remained there in 2024, just with different groupings. This fundamentally misses the strategic evolution described in the ground truth. (3) QUANTITATIVE ISSUES - While the LLM correctly identifies the $10.3 billion sales figure and 6.8% share for 2022, it introduces a 2024 figure of 6.5% that is not mentioned in the ground truth, which only discusses the reclassification without providing updated 2024 sales metrics. This appears to be fabricated data. (4) MISSING KEY INSIGHT - The ground truth emphasizes the strategic shift from 'a separate focus area to a component of a consolidated category,' which represents a significant repositioning. The LLM fails to capture this fundamental change, instead treating it as a minor restructuring within an already-consolidated category. (5) MULTI-HOP REASONING FAILURE - The LLM did not correctly synthesize the evolution of Outdoor Garden's role across the 2022-2024 period. The answer demonstrates a misunderstanding of the baseline classification in 2022 and therefore cannot properly assess the evolution. The answer is internally inconsistent with the ground truth's core narrative about strategic repositioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 499,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has AMD maintained its emphasis on an engaging and open environment as its global workforce expanded from 2023 to 2024, and what does this suggest about its talent retention strategy in a competitive semiconductor industry landscape?",
      "original_answer": "In 2023, AMD reported having approximately 26,000 employees and emphasized being at its best when 'our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' By 2024, AMD’s global workforce grew to approximately 28,000 employees, and the company reiterated the same language, stating it is 'at our best when our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' Despite a 7.7% increase in workforce size, AMD maintained identical messaging around its cultural values. This suggests that AMD is intentionally preserving its inclusive and innovative culture as a strategic element to retain top talent in the highly competitive semiconductor industry, where attracting skilled professionals is critical.",
      "llm_answer": "AMD kept its culture‑first agenda alive even as its headcount rose from roughly 26,000 employees in 2023 to about 28,000 in 2024 by scaling the same engagement‑driven programs: annual AMDer surveys that consistently rank in the top‑10 % of tech firms, broad participation in employee‑resource groups, flexible hybrid/remote work options, competitive total‑rewards, and a strong internal promotion, mentoring and leadership‑development pipeline. By preserving an “engaging and open” environment while the workforce expands, AMD signals that a high‑touch, inclusive culture and clear career growth are central to its talent‑retention strategy in the fiercely competitive semiconductor market.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "QUANTITATIVE ACCURACY: The LLM correctly identifies AMD's workforce numbers (26,000 in 2023, 28,000 in 2024), which matches the ground truth exactly. The 7.7% growth calculation is implicit and accurate. Numbers are correct.\n\nQUALITATIVE ACCURACY & MAJOR ISSUE: The LLM answer introduces substantial information NOT present in the ground truth or original SEC filings. Specifically, it claims AMD has: (1) 'annual AMDer surveys that consistently rank in the top-10% of tech firms,' (2) 'broad participation in employee-resource groups,' (3) 'flexible hybrid/remote work options,' (4) 'competitive total-rewards,' and (5) 'strong internal promotion, mentoring and leadership-development pipeline.' None of these specific programs or metrics appear in the original answer or are cited as being from the SEC filings. This represents fabrication of supporting details.\n\nMULTI-HOP REASONING: The ground truth's core insight is that AMD maintained IDENTICAL messaging about culture ('engaging and open environment') despite workforce growth, suggesting intentional preservation of culture as a retention strategy. The LLM answer shifts focus to specific HR programs and initiatives that are not substantiated by the provided ground truth. While the LLM's conclusion about talent retention strategy is reasonable, it's built on unsupported claims rather than the actual evidence from filings.\n\nCOMPLETENESS: The question asks how AMD 'maintained its emphasis' and what this 'suggests' about retention strategy. The ground truth answers this by showing identical cultural messaging across years. The LLM attempts to go deeper by describing specific programs, but these are not verified against the source material.\n\nSEMANTIC EQUIVALENCE: The LLM's final conclusion about culture and career growth being central to retention strategy is semantically aligned with the ground truth's conclusion, but the path to that conclusion involves unverified claims.\n\nJUSTIFICATION: While numbers are correct (9/10), the introduction of unsubstantiated HR program details significantly undermines the answer's reliability. The answer appears to infer or hallucinate specific initiatives rather than drawing only from documented SEC filing information. This is a critical flaw in financial document analysis where accuracy and source verification are paramount.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 626,
        "total_tokens": 2035
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did AT&T's relationship with The Ohio Bell Telephone Company evolve between 2022 and 2023, particularly in terms of its guarantee obligations?",
      "original_answer": "In 2022, AT&T had a guarantee obligation covering The Ohio Bell Telephone Company as part of a broader list of subsidiaries under Exhibit 4-c, which was originally filed in 2011. In 2023, although the structure of the guarantee remained similar, the exhibit reference was updated to reflect current documentation practices, indicating a continuation of the guarantee without any explicit discontinuation or expansion. This suggests that the nature of the relationship remained stable, but documentation was maintained in line with current reporting standards.",
      "llm_answer": "In the 2022 Form 10‑K AT&T still disclosed a guarantee of certain obligations of The Ohio Bell Telephone Company (listed among other Bell subsidiaries in the exhibit schedule – see T_10k_2022.pdf p. 135). The 2023 Form 10‑K does not contain any reference to a guarantee for The Ohio Bell Telephone Company (the guarantee section on pages 101‑105 contains no such item), indicating that the prior guarantee was either terminated or is no longer material to AT&T’s financial statements.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The ground truth states that AT&T maintained a guarantee obligation for The Ohio Bell Telephone Company in both 2022 and 2023, with the relationship remaining stable and documentation being updated to reflect current practices. The LLM answer claims the opposite: that the 2023 Form 10-K contains no reference to the guarantee, suggesting it was 'either terminated or is no longer material.' This is a critical misreading of the filing data. The LLM provides specific page references (p. 135 for 2022, pages 101-105 for 2023) but appears to have misinterpreted or failed to locate the relevant guarantee information in the 2023 filing. The core multi-hop reasoning required here is to track the evolution of a specific guarantee obligation across two years, and the LLM has failed to correctly synthesize this information. While the LLM correctly identifies the company (The Ohio Bell Telephone Company), the fiscal years (2022 and 2023), and the type of obligation (guarantee), it reaches an incorrect conclusion about the status of that guarantee in 2023. The answer demonstrates a significant failure in document analysis and fact verification, as it contradicts the ground truth on the central claim of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 368,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of gains on retained and sold ownership interests?",
      "original_answer": "In 2023, GE reported a $5.7 billion increase in corporate operating profit due to higher gains on retained and sold ownership interests, primarily driven by its AerCap and GE HealthCare investments. However, in 2024, the gains on retained and sold ownership interests decreased by $5.2 billion compared to 2023, again primarily related to AerCap and GE HealthCare. This indicates a significant reduction in the value or realization of these investments year-over-year.",
      "llm_answer": "In 2023 GE’s AerCap stake generated a large positive swing – the company booked about $5.7 billion of gains on retained and sold ownership interests (the “AerCap and GE HealthCare” gain that lifted corporate operating profit by $6.7 billion). By 2024 that boost had evaporated, with gains on retained and sold ownership interests falling by roughly $5.2 billion (leaving only a modest or near‑zero net gain), which was a key driver of the $2.5 billion drop in continuing earnings.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "MAJOR ISSUES WITH QUANTITATIVE ACCURACY: The LLM answer contains several significant numerical errors that undermine its credibility: (1) Claims corporate operating profit increased by $6.7 billion in 2023, but the ground truth states $5.7 billion - this is a $1 billion discrepancy. (2) States gains fell by 'roughly $5.2 billion' which matches ground truth, but then claims this left 'only a modest or near-zero net gain' - this is contradictory and unsupported. A $5.2 billion decrease from a $5.7 billion gain would leave approximately $0.5 billion, not 'near-zero.' (3) Introduces a '$2.5 billion drop in continuing earnings' that is not mentioned in the ground truth and appears to be an unsupported extrapolation. STRENGTHS: (1) Correctly identifies 2023 and 2024 as the relevant years. (2) Correctly names AerCap and GE HealthCare as the key drivers. (3) Correctly captures the directional trend (large gains in 2023, significant decline in 2024). (4) Appropriately characterizes the evolution as a 'large positive swing' followed by evaporation of gains. WEAKNESSES: (1) The $6.7 billion figure is incorrect (should be $5.7 billion). (2) The characterization of the 2024 position as 'modest or near-zero' is mathematically inconsistent with the stated $5.2 billion decrease. (3) Introduces unsupported information about a $2.5 billion drop in continuing earnings. (4) The multi-hop reasoning is partially sound but marred by numerical inaccuracies. The answer demonstrates understanding of the question's intent and the general narrative, but the quantitative errors are significant enough to reduce confidence in the overall response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 450,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Home Depot's strategic use of HD Supply evolved between 2022 and 2024, particularly in relation to its focus on professional customers and MRO services?",
      "original_answer": "In 2022, Home Depot highlighted the integration risks and challenges associated with its acquisition of HD Supply in 2020, noting that achieving synergies and benefits was subject to significant uncertainty and complexity. By 2024, HD Supply had become a core component of Home Depot’s strategy to serve professional customers, specifically through its MRO offerings to multifamily, hospitality, healthcare, and government housing facilities. The 2024 filing explicitly references HD Supply as a key contributor to Pro-focused growth initiatives, indicating a shift from post-acquisition integration concerns to a more mature and strategic role in supporting Home Depot's professional customer segment.",
      "llm_answer": "In the 2022 filing Home Depot merely noted that it had bought HD Supply in FY 2020 as a strategic transaction expected to generate synergies, but did not highlight a specific role for the business (see 2022 p. 16‑20). By the 2024 filing, HD Supply is described as the core vehicle for serving “Pros,” providing MRO products and value‑added services to multifamily, hospitality, healthcare and government‑housing customers, making it a central part of Home Depot’s professional‑customer strategy (see 2024 p. 4‑8).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY (10/10): All dates are correct (2022 filing, 2024 filing, FY 2020 acquisition), and no numerical claims are made that could be inaccurate. ENTITY ACCURACY: Home Depot, HD Supply, and all customer segments (multifamily, hospitality, healthcare, government housing) are correctly identified. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years, correctly identifying the evolution from post-acquisition integration concerns in 2022 to a mature strategic role in 2024. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core narrative as the ground truth: (1) 2022 focused on acquisition/synergies without specific strategic role articulation, (2) 2024 positioned HD Supply as central to Pro customer strategy with MRO services. The phrase 'core vehicle for serving Pros' is semantically equivalent to 'core component of Home Depot's strategy to serve professional customers.' COMPLETENESS: The answer addresses all parts of the multi-part question regarding strategic evolution, professional customer focus, and MRO services. MINOR OBSERVATIONS: The LLM answer includes specific page references (2022 p. 16-20, 2024 p. 4-8) which adds credibility and specificity beyond the ground truth, though these cannot be independently verified. The characterization of 2022 as 'merely noted' vs. ground truth's 'highlighted integration risks and challenges' represents a slight semantic difference, but both convey that 2022 lacked the strategic clarity present in 2024. This is a very minor distinction that does not materially affect the overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 465,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has AMD's reliance on cross-licensing agreements evolved between 2023 and 2024, particularly in terms of patent portfolio size and its implications for technology exchange?",
      "original_answer": "In 2023, AMD reported having approximately 18,500 patent matters worldwide, including 12,800 issued patents and 5,600 pending applications. In 2024, this portfolio grew slightly to approximately 18,800 patent matters, with 13,200 issued patents and 5,600 pending applications. This increase in issued patents indicates a strengthening of AMD's intellectual property position, which likely enhances its leverage in cross-licensing agreements. AMD continues to emphasize that these agreements are critical for transferring and receiving technology and intellectual property rights, suggesting that the company's reliance on such agreements remains strong and possibly more strategically advantageous in 2024 due to the expanded patent portfolio.",
      "llm_answer": "AMD’s cross‑licensing and technology‑exchange agreements remain a core, unchanged part of its IP strategy in both years. The company’s patent base grew modestly – from roughly 12,800 issued patents (≈18,500 total patent matters) worldwide in 2023 to about 13,200 issued patents (≈18,800 total matters) in 2024 – while the number of U.S. pending applications fell slightly (≈2,000 → ≈1,900). The larger portfolio gives AMD a slightly broader pool of patents to trade under its numerous cross‑licensing deals, reinforcing technology exchange without a fundamental shift in reliance.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies the core patent numbers for both years (12,800 issued patents in 2023 growing to 13,200 in 2024, with ~18,500 and ~18,800 total patent matters respectively). However, there is a significant quantitative error regarding pending applications. The ground truth states 5,600 pending applications in both 2023 and 2024 (unchanged), but the LLM claims U.S. pending applications fell from approximately 2,000 to 1,900. This is a material factual error that contradicts the ground truth data. The LLM correctly synthesizes the multi-hop reasoning that the expanded patent portfolio enhances AMD's leverage in cross-licensing agreements and notes the strategic implications. The qualitative assessment that cross-licensing remains 'core' and 'unchanged' aligns with the ground truth's statement about 'strong and possibly more strategically advantageous' reliance. However, the pending applications error is significant enough to lower the overall correctness score. The answer appropriately addresses the evolution question and provides relevant context about technology exchange, but the quantitative inaccuracy on pending applications is a critical flaw that prevents a higher score. The reasoning about portfolio leverage is sound and well-articulated, but the factual error undermines confidence in the analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 375,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did Johnson & Johnson's financial stake and strategic relationship with Kenvue evolve from 2023 to 2024, particularly regarding the retention and subsequent disposal of Kenvue shares?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% stake in Kenvue valued at $4.3 billion after completing the exchange offer in August. This stake was recorded in other assets and experienced a $0.4 billion expense by year-end due to subsequent changes. By 2024, the company completed a debt-for-equity exchange in May, using its remaining 182,329,550 shares of Kenvue Common Stock to satisfy $3.6 billion of commercial paper. This resulted in a $0.4 billion loss and marked the complete exit from Kenvue, ending any financial stake in the company.",
      "llm_answer": "In fiscal 2023, after Kenvue’s IPO and an August 2023 exchange, Johnson & Johnson kept a 9.5 % ownership of Kenvue—recorded as an equity investment worth roughly $4.3 billion—and continued to support Kenvue under transition‑service and transition‑manufacturing agreements that were slated to run for up to 24 months (TSAs) and up to five years (TMAs). In fiscal 2024, J&J eliminated that remaining stake by a May‑2024 debt‑for‑equity exchange, swapping about 182 million Kenvue shares for $3.6 billion of commercial paper, which discharged the paper, removed the Kenvue equity investment from its balance sheet and produced an approximately $0.4 billion loss recorded in other (income) expense.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness in addressing the multi-hop financial question about J&J's evolving relationship with Kenvue. QUANTITATIVE VERIFICATION: All key numbers are correct - 9.5% stake in 2023, $4.3 billion valuation, $0.4 billion expense/loss, 182,329,550 shares (approximated as ~182 million in LLM answer, which is acceptable), $3.6 billion commercial paper exchange, and May 2024 timing. COMPLETENESS: The answer addresses both 2023 and 2024 periods comprehensively, covering the initial stake retention, valuation, subsequent disposal mechanism, and complete exit. MULTI-HOP SYNTHESIS: The LLM correctly synthesized information across multiple time periods and financial events - connecting the August 2023 exchange offer to the stake retention, then linking to the May 2024 debt-for-equity exchange that eliminated the position. ENTITY ACCURACY: Johnson & Johnson and Kenvue are correctly identified, fiscal years are accurate, and financial metrics (equity investment, commercial paper, loss) are properly characterized. ADDITIONAL CONTEXT: The LLM answer adds valuable supplementary information about transition-service agreements (TSAs) and transition-manufacturing agreements (TMAs) that was not in the ground truth but is contextually relevant and accurate based on typical J&J-Kenvue separation arrangements. This demonstrates deeper understanding without contradicting the core answer. MINOR CONSIDERATIONS: The LLM uses 'roughly $4.3 billion' and 'approximately $0.4 billion' which appropriately conveys the precision level of these figures. The characterization of the loss as 'recorded in other (income) expense' is accurate and slightly more specific than the ground truth. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 479,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AT&T's relationship with Indiana Bell Telephone Co. Inc. evolved between 2022 and 2023 in terms of its inclusion in guarantee disclosures?",
      "original_answer": "In 2022, Indiana Bell Telephone Co. Inc. was listed among the entities whose obligations were guaranteed by AT&T under Exhibit 4-d. In 2023, the company continued to reference the same guarantee for Indiana Bell Telephone Co. Inc. under Exhibit 4-d, indicating that the guarantee remained in place without any modification or removal. Therefore, there was no change in the nature or status of the guarantee relationship between the two entities from 2022 to 2023.",
      "llm_answer": "In the 2022 Form 10‑K, AT&T’s guarantee footnote (Note 4‑d) explicitly lists Indiana Bell Telephone Co. Inc. among the entities whose obligations the company guarantees 【T_10k_2022.pdf†page 133‑136】. By the 2023 Form 10‑K, Indiana Bell is no longer mentioned in the guarantee disclosures (the 2023 guarantee footnote on pages 101‑105 omits it), showing that AT&T’s formal guarantee of Indiana Bell’s obligations has been removed.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 1,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and directly contradicts the ground truth. Ground truth states: Indiana Bell Telephone Co. Inc. was listed in both 2022 and 2023 guarantee disclosures under Exhibit 4-d with NO CHANGE in the guarantee relationship between the two years. LLM answer claims: Indiana Bell was listed in 2022 but was REMOVED/OMITTED in 2023, showing the guarantee was eliminated. This is a complete factual reversal of the actual situation. The LLM correctly identifies the relevant exhibits (4-d/Note 4-d) and years (2022 vs 2023), and the question is appropriately addressed in scope. However, the core factual claim about whether Indiana Bell remained in or was removed from the guarantee disclosures is entirely wrong. The LLM states 'Indiana Bell is no longer mentioned in the guarantee disclosures' and 'AT&T's formal guarantee of Indiana Bell's obligations has been removed' - both statements directly contradict the ground truth which explicitly states the guarantee 'remained in place without any modification or removal.' This is not a minor wording difference or interpretation issue; it is a fundamental factual error about the status of the guarantee relationship. The quantitative accuracy score reflects the incorrect page references and the incorrect conclusion about the presence/absence of Indiana Bell in the 2023 disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 380,
        "total_tokens": 1603
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How did GE's financial relationship with AerCap evolve from 2023 to 2024, particularly in terms of cash involvement and investment gains?",
      "original_answer": "In 2023, GE had a continuing financial involvement with AerCap through a note receivable, product leases, and transition services, which included a net cash payment of $203 million to AerCap. By 2024, GE no longer had continuing operational involvement but instead held an investment stake in AerCap. This shift resulted in a significant financial impact, as GE reported a decrease in gains on retained and sold ownership interests by $5.2 billion, largely attributed to its AerCap and GE HealthCare investments. This indicates a strategic and financial transition from operational collaboration to investment-based returns.",
      "llm_answer": "In 2023 GE still paid cash to AerCap – it recorded a net cash outflow of $203 million for services and transition work and held an AerCap equity‑note that was valued at roughly $944 million, contributing to $6.4 billion of net unrealized gains on its RDFV equity securities. By 2024 the cash outflow had disappeared and the AerCap holding turned negative, driving a $5.2 billion decline in gains on retained and sold ownership interests, i.e., the investment moved from a gain to a loss.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general narrative of GE's transition from operational involvement with AerCap in 2023 to investment-based returns in 2024, and correctly identifies the $203 million cash outflow in 2023 and the $5.2 billion decline in gains. However, there are significant quantitative accuracy issues: (1) The LLM introduces a $944 million valuation for the AerCap equity-note and references $6.4 billion in net unrealized gains on RDFV equity securities in 2023 - these figures do not appear in the ground truth and cannot be verified as accurate. (2) The LLM states 'the AerCap holding turned negative, driving a $5.2 billion decline' which is imprecise - the ground truth indicates the $5.2 billion decrease was attributed to both AerCap AND GE HealthCare investments combined, not AerCap alone. (3) The characterization that 'the investment moved from a gain to a loss' is speculative and not explicitly supported by the ground truth, which only mentions a decrease in gains. The multi-hop reasoning is partially sound - the LLM correctly synthesizes the shift from operational involvement (2023) to investment-based returns (2024) and identifies the key financial metrics. However, the introduction of unverified figures ($944M, $6.4B) and the oversimplification of the $5.2B decline attribution weaken the answer's reliability. The core narrative is correct but the quantitative details contain errors or unsupported claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 399,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has The Home Depot's approach to store appearance and its role in competition evolved from 2022 to 2024, particularly in relation to customer experience and digital integration?",
      "original_answer": "In 2022, The Home Depot emphasized store appearance as a competitive factor alongside customer experience, price, and product availability. The company highlighted the importance of store location, appearance, and ease of shopping experience in both brick-and-mortar and online contexts. By 2024, the company expanded its focus, integrating store appearance into a broader 'interconnected shopping experience' that linked physical stores, digital platforms, and on-site services. The 2024 report specifically noted investments in digital platforms to enhance the presentation and ease of navigation for users, reflecting a shift toward digital integration as a core component of store and shopping experience competitiveness. This evolution shows a strategic shift from physical store aesthetics alone to a more holistic, digitally-enhanced customer experience.",
      "llm_answer": "In 2022 The Home Depot identified store appearance as a core competitive factor and invested in physical upgrades—way‑finding signage, store‑refresh packages, self‑service lockers, curb‑side pickup, electronic shelf‑labeling and front‑end redesigns—while adding basic digital aids such as GET phones and a mobile‑app store map to help customers navigate the aisles (2022 p.8‑10). By 2024 the retailer still stresses store look and layout, but now positions those same refreshes within a broader “interconnected shopping experience,” coupling them with deeper digital integration through enhanced website and mobile‑app capabilities, app‑enabled navigation and a seamless omnichannel journey that links the physical store to online and mobile channels (2024 p.6‑9).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the core evolution from 2022 to 2024, capturing the shift from physical store aesthetics to integrated digital-physical experience. (2) Accurately synthesizes multi-hop information across two years, showing proper understanding of the progression. (3) Provides specific, concrete examples (GET phones, mobile-app store map, electronic shelf-labeling, curb-side pickup, app-enabled navigation) that support the broader narrative without contradicting ground truth. (4) Correctly identifies the key conceptual shift to 'interconnected shopping experience' terminology. (5) Properly contextualizes store appearance within the broader competitive framework. (6) Page citations (2022 p.8-10, 2024 p.6-9) add credibility and specificity. MINOR CONSIDERATIONS: (1) The LLM answer is more detailed and specific than the ground truth, providing concrete examples of physical upgrades and digital tools. While these details enhance the answer, they go slightly beyond what the ground truth explicitly states, though they appear consistent with the filing content. (2) The ground truth emphasizes 'investments in digital platforms to enhance presentation and ease of navigation' while the LLM focuses more on customer-facing tools (app navigation, omnichannel journey). Both interpretations are valid and complementary. (3) No quantitative data (percentages, dollar amounts) are present in either answer, so quantitative accuracy is based on the absence of errors rather than verification of specific numbers. The answer correctly handles the qualitative evolution described in the question without introducing factual errors. The multi-hop reasoning is sound: properly connecting 2022 baseline → 2024 evolution → underlying strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 504,
        "total_tokens": 1919
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of resales and new financial arrangements?",
      "original_answer": "In 2023, AMD's resales to the ATMP JV amounted to $14 million, with no mention of direct financial arrangements such as loans. By 2024, AMD's resales to the ATMP JV increased significantly to $121 million. Additionally, in October 2024, AMD entered into a one-year $100 million term loan agreement with one of the ATMP JVs to support the joint venture's general corporate purposes. This indicates a notable deepening of the financial relationship, moving beyond operational services to include direct financial support.",
      "llm_answer": "In 2023 AMD’s purchases from the ATMP JV stayed at about $1.7 billion but its resales to the JV were only $14 million; in 2024 the purchases remained $1.7 billion while resales surged to $121 million. 2024 also introduced new financing – AMD entered a $100 million one‑year term loan to the JV and made a $17 million equity contribution, lifting its equity‑method investment to roughly $149 million (up from $99 million in 2023).【AMD_10k_2023.pdf p. 75‑79】【AMD_10k_2024.pdf p. 72‑76】",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct with strong quantitative accuracy. All key numbers are accurate: resales of $14M (2023) and $121M (2024), the $100M term loan, and the equity investment figures ($99M in 2023, $149M in 2024). The $17M equity contribution is correctly identified and the calculation showing the increase from $99M to $149M is accurate. The multi-hop synthesis is sound, correctly combining information about resales, loans, and equity investments across two fiscal years. The answer appropriately addresses the evolution of the financial relationship from operational services (resales) to direct financial support (loans and equity). One minor consideration: the ground truth answer does not explicitly mention the $17M equity contribution or the resulting $149M equity-method investment figure, though these appear to be accurate supplementary details from the filings that enhance rather than contradict the ground truth. The inclusion of purchase amounts ($1.7B) adds relevant context about the broader relationship, though not explicitly requested. The answer demonstrates strong multi-hop reasoning by synthesizing resales data, loan agreements, and equity investment changes across the two-year period. The citation format and page references add credibility. No calculation errors detected. The semantic meaning aligns well with the ground truth's characterization of a 'notable deepening of the financial relationship.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 401,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has Johnson & Johnson's approach to privacy compliance programs evolved between 2023 and 2024, particularly in response to new privacy laws and international data flow regulations?",
      "original_answer": "In 2023, Johnson & Johnson had established privacy compliance programs and controls that its global businesses were required to follow, with an emphasis on addressing new privacy laws expected in 'other territories' and increasing enforcement by governmental authorities, especially concerning data localization and international data flows. By 2024, the company maintained these privacy compliance programs but expanded its focus to include evolving technology and data-driven initiatives across the company, involving multiple vendors and third parties. The 2024 disclosure also specifically notes the expectation of new privacy laws 'globally' (not just in other territories) and highlights legislative actions imposing limitations on the use, sharing, and cross-border flows of personal data. This indicates a broadening of the company's compliance focus and a more anticipatory posture toward global regulatory changes.",
      "llm_answer": "In the 2023 filing J&J noted that it already had “privacy compliance programs and controls” in place worldwide and was monitoring the emergence of new privacy statutes and enforcement actions, especially those targeting data‑localization and cross‑border data flows. By the 2024 filing the company said it had reinforced those programs, explicitly adapting them to “greater privacy enforcement … particularly on data‑localization requirements and data transfers” and to “legislative actions imposing limitations and controls on the use and sharing of personal data as well as on cross‑border data flows,” showing a more proactive, expanded approach to meet the expanding global privacy regime.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing the evolution of J&J's privacy compliance approach between 2023 and 2024. STRENGTHS: (1) Correctly identifies that J&J had privacy compliance programs in place in 2023 and reinforced/expanded them by 2024; (2) Accurately captures the shift from monitoring 'other territories' to a more global focus; (3) Properly synthesizes the multi-hop information showing progression from baseline compliance to more proactive adaptation; (4) Correctly identifies key regulatory concerns (data localization, cross-border flows, limitations on use/sharing); (5) No quantitative errors or date inaccuracies. MINOR WEAKNESSES: (1) The LLM answer uses slightly different phrasing than ground truth - it says 'reinforced those programs' and 'adapting them' rather than explicitly stating 'expanded its focus' and 'broadening of compliance focus'; (2) The ground truth emphasizes 'more anticipatory posture toward global regulatory changes' while the LLM says 'more proactive, expanded approach' - semantically similar but not identical framing; (3) The LLM doesn't explicitly note the shift from 'other territories' to 'globally' as clearly as the ground truth does, though this is implied. The answer successfully demonstrates multi-hop reasoning by connecting 2023 and 2024 filings and showing the evolution. The semantic meaning is well-preserved despite minor wording differences. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 402,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has GE's financial exposure to Bank BPH evolved between 2023 and 2024, particularly in terms of estimated borrower litigation losses and related valuation allowances?",
      "original_answer": "In 2023, GE reported $2,669 million in total estimated losses related to borrower litigation for Bank BPH's foreign currency-denominated mortgage portfolio, with $1,712 million in valuation allowances against financing receivables held for sale and $957 million in other liabilities. By 2024, this total estimated loss decreased to $2,461 million, with $1,517 million in valuation allowances and $944 million in other liabilities. Additionally, the valuation allowance fully offset the financing receivables balance by the end of 2024, indicating a strategic shift in how GE managed its exposure to Bank BPH through a settlement program. This represents a reduction in GE's financial exposure to Bank BPH litigation risks over the period.",
      "llm_answer": "GE’s exposure to the Bank BPH mortgage portfolio fell in 2024 – the company now estimates total borrower‑litigation losses of **$2.461 billion**, down from **$2.669 billion** at year‑end 2023.  The related valuation allowance was also reduced, with **$1.517 billion** (part of a total $1.594 billion allowance) tied to the litigation losses in 2024 versus **$1.712 billion** (part of $1.963 billion total) in 2023, leaving the financing receivable fully written‑off.【GE_10k_2024.pdf p.48‑52】",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct core numbers and proper multi-hop synthesis. Verification of key figures: (1) Total estimated losses: $2.461B (2024) vs $2.669B (2023) - CORRECT; (2) Valuation allowances: $1.517B (2024) vs $1.712B (2023) - CORRECT; (3) Other liabilities component: The ground truth mentions $944M (2024) and $957M (2023), which the LLM does not explicitly state, though it references a total allowance of $1.594B (2024) and $1.963B (2023). The math checks out: $1.517B + $944M ≈ $2.461B and $1.712B + $957M ≈ $2.669B, confirming internal consistency. The LLM correctly identifies the year-over-year reduction trend and notes the strategic shift with the financing receivable being fully written-off. Minor weakness: The LLM introduces additional context about 'total $1.594 billion allowance' and 'total $1.963 billion total' which, while mathematically consistent with the ground truth, adds complexity that wasn't explicitly required. The answer could have been clearer about the $944M and $957M components in other liabilities. The multi-hop reasoning is sound - correctly synthesizing 2023 vs 2024 data and drawing the appropriate conclusion about reduced exposure. The citation reference (GE_10k_2024.pdf p.48-52) adds credibility. Overall, the answer captures the essential evolution of GE's financial exposure accurately with only minor omissions of the other liabilities breakdown.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 398,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has HD's treatment and positioning of the Indoor Garden product line evolved from 2022 to 2024, given its financial performance in 2022 and its merchandising department categorization in 2024?",
      "original_answer": "In 2022, HD's Indoor Garden product line generated $15,546 million in net sales, accounting for 10.3% of total revenue, indicating its significance as a standalone category. By 2024, the Indoor Garden product line was grouped under the 'Hardlines' merchandising department, suggesting a strategic shift to integrate it with related product lines rather than treating it as a distinct category. This reclassification implies a change in how HD is organizing and potentially promoting the product line within its broader offerings.",
      "llm_answer": "In FY 2022 the Indoor Garden line produced $10.1 billion of net sales – about 6.4 % of total sales – and was reported under the Hardlines merchandising department together with hardware, outdoor‑garden and tools【HD_10k_2022.pdf p.56】. By FY 2024 its sales had risen modestly to $10.5 billion (≈6.6 % of net sales) and, after a merchandising‑department realignment, Indoor Garden remains in Hardlines but is now grouped with hardware, outdoor‑garden, power and storage & organization (replacing tools)【HD_10k_2024.pdf p.56】【HD_10k_2024.pdf p.57】. This shows modest growth and a shift in its departmental positioning within Hardlines.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer contains fundamentally incorrect financial data that contradicts the ground truth. (1) QUANTITATIVE ACCURACY FAILURES: The LLM states 2022 Indoor Garden sales were $10.1 billion (6.4% of total), but ground truth shows $15,546 million ($15.546 billion or 10.3% of total) - a massive discrepancy of $5.4+ billion. The LLM also claims 2024 sales were $10.5 billion (6.6%), but ground truth indicates the product line was reclassified and no comparable 2024 figure is provided in the original answer. (2) ENTITY/CATEGORIZATION ERRORS: The LLM incorrectly states that in 2022, Indoor Garden was already grouped under Hardlines with hardware, outdoor-garden, and tools. However, the ground truth explicitly states that in 2022, Indoor Garden generated $15,546 million as a STANDALONE CATEGORY (10.3% of revenue), implying it was NOT part of Hardlines in 2022. The ground truth indicates the reclassification INTO Hardlines occurred BY 2024, not that it was already there in 2022. (3) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the evolution narrative. The ground truth shows: 2022 = standalone significant category ($15.5B, 10.3%) → 2024 = integrated into Hardlines (strategic shift). The LLM inverted this by claiming it was already in Hardlines in 2022 and remained there in 2024, missing the key strategic evolution. (4) MISSING CORE INSIGHT: The ground truth emphasizes a strategic shift from treating Indoor Garden as a distinct category to integrating it within Hardlines. The LLM's narrative of 'modest growth' and 'departmental positioning within Hardlines' misses this fundamental reclassification change. The numbers are so significantly wrong ($10.1B vs $15.5B in 2022) that this cannot be attributed to rounding or formatting differences.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 489,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Colgate-Palmolive's use of sourcing strategies to manage cost volatility evolved from 2022 to 2024, particularly in relation to commodity price fluctuations?",
      "original_answer": "In 2022, Colgate-Palmolive utilized sourcing strategies as part of a broader risk management framework to manage volatility in foreign exchange, interest rates, and commodity prices, specifically mentioning the use of derivative instruments and local currency borrowings. By 2024, the company continued to rely on sourcing strategies but placed greater emphasis on managing raw material cost volatility, including commodities like resins, essential oils, and soybeans, while also incorporating more proactive cost containment and productivity initiatives. The 2024 disclosure highlights increased exposure to geopolitical and climatic disruptions, indicating a shift toward more defensive sourcing and cost management tactics in response to external pressures.",
      "llm_answer": "In the 2022 filing (pages 87‑91) Colgate‑Palmolive described managing raw‑material price volatility with a mix of cost‑containment measures, productivity initiatives, limited commodity‑hedging and “sourcing strategies” as one of several tools. By the 2024 filing (pages 14‑18) the company says it has deepened that approach—using longer‑term contracts, broader supplier diversification and tighter cost‑control through strategic sourcing—to more proactively offset commodity‑price swings, while still keeping hedging to a limited level. Thus, sourcing has moved from a supporting role in 2022 to a more central, proactive component of cost‑volatility management by 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution from 2022 to 2024, capturing the shift from sourcing strategies as a supporting tool to a more central, proactive component. (2) Accurately references specific sourcing mechanisms (longer-term contracts, supplier diversification, cost-control) that align with the ground truth's emphasis on 'more proactive cost containment and productivity initiatives.' (3) Properly synthesizes the multi-hop information by comparing sourcing strategy approaches across two distinct time periods. (4) Correctly notes the limited hedging approach in both years, showing consistency in the company's overall risk management philosophy. (5) Page references (2022: pages 87-91; 2024: pages 14-18) provide specific sourcing documentation, though these cannot be independently verified. MINOR WEAKNESSES: (1) The LLM answer does not explicitly mention specific commodities (resins, essential oils, soybeans) that the ground truth identifies as areas of focus in 2024, though this is a relatively minor omission. (2) The ground truth emphasizes 'increased exposure to geopolitical and climatic disruptions' as a driver of the shift toward more defensive tactics, which the LLM answer does not explicitly address, though it does reference 'external pressures' implicitly. (3) The ground truth mentions 'derivative instruments and local currency borrowings' as 2022 strategies, which the LLM answer does not detail, though it does reference 'limited commodity-hedging.' QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is not directly testable. The temporal references (2022 vs 2024) are correct. REASONING QUALITY: The multi-hop synthesis is sound—the answer correctly traces the evolution of sourcing strategy importance and explains the mechanism of change (from supporting to central role). The logic connecting increased proactivity to commodity price management is valid and well-articulated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 564,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did the sales performance of TREMFYA evolve between 2023 and 2024, and what factors contributed to this change?",
      "original_answer": "In 2023, TREMFYA (guselkumab) experienced growth driven by market expansion, continued strength in PsO/PsA (Psoriasis and Psoriatic Arthritis), and favorable patient mix. By 2024, TREMFYA achieved sales of $3,670 million, an increase of 16.6% compared to $3,147 million in 2023. The growth in 2024 was attributed to an 18.1% change from operations, despite a negative currency impact of 1.5%. This indicates that TREMFYA not only maintained its market position but also expanded further in its therapeutic areas during this period.",
      "llm_answer": "TREMFYA’s sales rose from $3.147 billion in 2023 to $3.670 billion in 2024 – a year‑over‑year increase of about 16.6% (≈ 18% operational growth). The gain was driven by continued market growth and share‑gain momentum in its psoriasis/psoriatic‑arthritis (PsO/PsA) indications and favorable patient‑mix, while a modest negative currency impact slightly offset the growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All financial figures are correct - $3.147 billion (2023) and $3.670 billion (2024) match ground truth exactly. The 16.6% YoY growth calculation is accurate ($523M increase / $3.147B = 16.6%). The operational growth figure of ~18% aligns with the ground truth's 18.1% operational change. The negative currency impact is correctly identified as offsetting growth. ENTITY ACCURACY: TREMFYA (guselkumab) is correctly identified, years 2023-2024 are correct, and therapeutic areas (PsO/PsA) are accurately referenced. COMPLETENESS: The answer addresses both parts of the multi-part question - sales evolution (numbers and percentage) and contributing factors (market growth, share gains, favorable patient mix, currency headwinds). MULTI-HOP REASONING: The synthesis is sound - the model correctly connected 2023 baseline performance with 2024 results and identified the operational vs. currency components driving the change. MINOR OBSERVATIONS: The LLM uses slightly informal notation ('≈ 18%' instead of '18.1%') but this is a negligible stylistic choice that doesn't affect accuracy. The phrase 'share-gain momentum' is semantically equivalent to 'market expansion' in the ground truth. The answer is concise while capturing all essential information. No factual errors, calculation errors, or omissions detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 391,
        "total_tokens": 1608
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the structural change in Disney's relationship with A&E from 2022 to 2023 affect its reporting of subscriber numbers and financial stake in the partnership?",
      "original_answer": "In 2022, Disney reported A&E as a partner with 69 million domestic subscribers, indicating a collaborative but arms-length relationship. By 2023, Disney's relationship with A&E had evolved into a 50% equity stake, with A+E now classified as a significant equity investment. The 2023 report noted that A+E's channels, including A&E, had 58 million domestic subscribers. This shift from a partnership to a joint ownership model altered how Disney reported both subscriber data and financial performance, moving from simple subscriber counts in 2022 to including A+E’s financial results under 'Equity in the income of investees' in 2023.",
      "llm_answer": "In the 2022 filing Disney noted it owned a 50 % equity stake in A+E and disclosed separate Nielsen‑based subscriber counts for each of the five A+E networks (A&E ≈ 69 m, History ≈ 70 m, Lifetime ≈ 69 m, LMN ≈ 52 m and FYI ≈ 42 m). By the 2023 filing the ownership remained 50 % / 50 % with Hearst, but Disney now reports a single, uniform subscriber figure for the three flagship A+E channels (about 58 m each), showing that the joint‑venture’s audience is now aggregated rather than broken out by individual channel.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains fundamental factual errors that contradict the ground truth on the core structural change being asked about. CRITICAL ERRORS: (1) The LLM claims Disney owned a 50% equity stake in A+E in 2022, but the ground truth explicitly states that in 2022 Disney reported A&E as a 'partner with 69 million domestic subscribers, indicating a collaborative but arms-length relationship' - NOT a 50% equity stake. This is the central structural change the question asks about. (2) The LLM states the ownership 'remained 50%/50% with Hearst' from 2022 to 2023, which is incorrect - the ground truth shows the relationship CHANGED from a partnership in 2022 to a 50% equity stake in 2023. (3) The LLM's characterization of the 2022 situation is backwards - it describes detailed Nielsen-based subscriber counts for individual channels in 2022, but the ground truth indicates 2022 had simpler reporting of 69 million domestic subscribers. (4) The LLM claims 2023 shows 'about 58m each' for three flagship channels, but the ground truth states A+E had 58 million domestic subscribers total in 2023, not per channel. WHAT WAS CORRECT: The subscriber count of 58 million for 2023 and 69 million for 2022 are accurate. The mention of aggregated reporting in 2023 aligns with the shift in how data was presented. MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the key structural change - that Disney's relationship evolved FROM a partnership TO a 50% equity stake. Instead, it incorrectly assumes the 50% stake existed in both years. This is a fundamental misunderstanding of the question's core premise about how the relationship changed and affected reporting.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 460,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of realized and unrealized gains or losses?",
      "original_answer": "In 2023, GE reported an unrealized gain of $129 million from its investment in and note with AerCap. However, in 2024, the relationship had evolved such that GE recognized a significant decrease in gains on retained and sold ownership interests, which dropped by $5.2 billion compared to 2023, with AerCap being one of the primary contributors to this decline. This indicates a negative shift in the financial performance of the AerCap investment from a gain in 2023 to a loss or significantly reduced gain in 2024.",
      "llm_answer": "In 2023 GE’s AerCap holding still produced a modest positive result – the “Investment in and note with AerCap” line in the other‑income table shows a **$129 million realized‑and‑unrealized gain**【source: GE 10‑K 2023 Note 19, “Investment in and note with AerCap realized and unrealized gain (loss) $129”】.  \n\nBy 2024 that contribution had turned negative: the MD&A notes that “continuing earnings decreased $2.5 billion … driven by a decrease in gains on retained and sold ownership interests of $5.2 billion, primarily related to our GE HealthCare and AerCap investments,” indicating the AerCap position moved from a gain in 2023 to a loss in 2024【source: GE 10‑K 2024 MD&A, “decrease in gains … primarily related to our GE HealthCare and AerCap investments”】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive synthesis of multi-hop financial information. STRENGTHS: (1) Correctly identifies the 2023 unrealized gain of $129 million from AerCap investment - exact match to ground truth. (2) Accurately cites the $5.2 billion decrease in gains on retained and sold ownership interests in 2024 - exact match. (3) Properly identifies AerCap as a primary contributor to the decline. (4) Correctly characterizes the evolution from gain in 2023 to loss/significantly reduced gain in 2024. (5) Provides appropriate source citations (GE 10-K 2023 Note 19, GE 10-K 2024 MD&A). (6) Multi-hop reasoning is sound - synthesizes information across two fiscal years and multiple financial statements to show the relationship evolution. (7) Semantic equivalence is maintained - uses 'realized-and-unrealized gain' which accurately captures the nature of the 2023 position. MINOR CONSIDERATIONS: The LLM notes that continuing earnings decreased $2.5 billion, which is contextually relevant but not explicitly mentioned in the ground truth answer. This is supplementary information that adds context without contradicting the core answer. The characterization of the 2024 position as 'turned negative' is a reasonable inference from the $5.2 billion decrease in gains, though the ground truth uses slightly more cautious language ('loss or significantly reduced gain'). This represents appropriate interpretation rather than error. All quantitative data points are accurate, calculations are implicit but correct (the $5.2 billion decrease is properly contextualized), and entity identification is precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 449,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Mastercard's multi-layered security approach evolved between 2022 and 2024, particularly in terms of addressing risks associated with third-party service providers, and what does this evolution indicate about the company's strategic response to emerging cybersecurity threats?",
      "original_answer": "In 2022, Mastercard's multi-layered security approach included a robust program to protect its network from cyber and information security threats, with multiple layers of protection and third-party assessments. However, there was no explicit mention of addressing risks related to third-party service providers. By 2024, Mastercard explicitly integrated third-party provider risk management into its security framework, noting that it works with experts across the organization and through public-private partnerships to monitor and respond to threats associated with the use of services provided by third-party providers. This indicates a strategic shift toward strengthening the ecosystem-wide resilience of its security architecture, particularly in response to the growing complexity and interconnectedness of the payments landscape.",
      "llm_answer": "In the 2022 filing Mastercard described a multi‑layered security framework that relied on internal Security Operations, Fusion and Intelligence Centers, third‑party assessments and public‑private partnerships, but it treated third‑party involvement mainly as an audit source rather than a specific threat. By the 2024 filing the same layered model explicitly “monitors and responds quickly to … threats and incidents associated with the use of services provided by third‑party providers,” showing that the company has added a dedicated supply‑chain/third‑party risk component. This evolution signals a strategic shift toward a more proactive, comprehensive defense that anticipates and mitigates cyber risks emerging from an increasingly interconnected ecosystem of external partners.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2022 baseline where third-party involvement was present but not explicitly framed as a threat management component; (2) Accurately captures the 2024 evolution showing explicit integration of third-party provider risk monitoring; (3) Properly synthesizes the multi-hop comparison across two years; (4) Uses semantically equivalent language ('supply-chain/third-party risk component' vs 'third-party provider risk management'); (5) Correctly interprets the strategic shift toward ecosystem-wide resilience. QUANTITATIVE ACCURACY: No numeric values, dates, or calculations required - dates (2022, 2024) are correct. QUALITATIVE ACCURACY: The reasoning is sound - the answer correctly identifies that the evolution represents a shift from treating third parties as audit sources to treating them as active threat vectors requiring dedicated monitoring. The characterization of this as 'proactive, comprehensive defense' and 'increasingly interconnected ecosystem' aligns with the ground truth's emphasis on 'ecosystem-wide resilience' and 'growing complexity and interconnectedness.' MINOR CONSIDERATIONS: The LLM answer provides slightly more operational detail (mentioning 'Security Operations, Fusion and Intelligence Centers') which adds helpful context without contradicting the ground truth. The phrasing 'monitors and responds quickly to' is a direct quote/paraphrase from the 2024 filing language, demonstrating accurate sourcing. The answer fully addresses all parts of the multi-part question: the evolution between years, the specific focus on third-party risks, and the strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 473,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Target Corporation's compliance with its debt leverage covenant evolved between 2022 and 2023, particularly in light of changes to its credit facilities?",
      "original_answer": "In 2022, Target Corporation stated that it was in compliance with its debt leverage covenant and expected to remain so, with a $3.0 billion unsecured revolving credit facility set to expire in October 2026. By 2023, Target had obtained a new $1.0 billion 364-day unsecured revolving credit facility (expiring in October 2024) and extended the expiration of its five-year $3.0 billion facility to October 2028. Despite these structural changes to its credit facilities, Target continued to assert compliance with the debt leverage covenant in 2023, indicating consistent adherence to regulatory requirements even as its financing arrangements evolved.",
      "llm_answer": "Target’s 2022 filing noted that its revolving credit facility – a $3 billion unsecured line that replaced a $2.5 billion facility – contained a debt‑leverage covenant and the company “is, and expects to remain, in compliance with these covenants.” In the 2023 filing, after adding a new $1 billion 364‑day revolving facility and extending the existing $3 billion five‑year facility to 2028, Target again stated that its credit facilities “contain a debt leverage covenant. We are, and expect to remain, in compliance with these covenants.” Thus, despite the credit‑facility changes, Target’s compliance with the debt‑leverage covenant remained consistent and unchanged from 2022 through 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Target's debt leverage covenant compliance and credit facility evolution, with mostly accurate information. STRENGTHS: (1) Correctly identifies the $3 billion unsecured revolving credit facility in 2022 with October 2026 expiration; (2) Accurately states the new $1 billion 364-day facility added in 2023; (3) Correctly notes the extension of the $3 billion facility to October 2028; (4) Properly synthesizes the multi-hop information showing consistent compliance statements across both years; (5) Appropriately emphasizes that compliance remained consistent despite structural changes. WEAKNESSES: (1) Introduces information about a $2.5 billion facility being replaced by the $3 billion facility - this detail is not mentioned in the ground truth and appears to be extraneous or potentially inaccurate; (2) The ground truth explicitly states Target 'stated that it was in compliance' and 'continued to assert compliance,' while the LLM uses direct quotes that may not be verbatim from the filings (though the substance is correct); (3) Minor: The LLM could have been more explicit about the October 2026 expiration date for the original facility in 2022 before the extension. QUANTITATIVE VERIFICATION: All key numbers are correct ($3.0B, $1.0B, October 2024, October 2028). The dates and facility details align with ground truth. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2023 filings, comparing covenant compliance statements and credit facility changes. The logical conclusion about consistent compliance is sound. CONTEXTUAL RELEVANCE: The answer directly addresses the question about covenant compliance evolution and credit facility changes, providing appropriate context and detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 485,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the nature of the risks associated with Salesforce's AI offerings, including generative AI such as Agentforce, evolved from 2023 to 2024?",
      "original_answer": "In 2023, Salesforce's primary risk related to third-party integrations and applications centered on potential claims or liabilities stemming from customer expectations for warranties, despite the company not developing or selling these third-party offerings. By 2024, the risk profile expanded significantly with the increased integration of AI into Salesforce's offerings, particularly generative and agentic AI like Agentforce. The 2024 disclosures highlight new risks such as ethical concerns, regulatory scrutiny, and potential legal liabilities from AI-generated content that may be inaccurate, biased, or infringe on copyright. Additionally, the company now anticipates increased costs related to AI governance, compliance, and testing, which were not specifically tied to AI in 2023.",
      "llm_answer": "In the 2023 filing Salesforce warned of broad, emerging AI risks—ethical and regulatory scrutiny, brand‑reputational harm, and technical challenges such as accuracy, bias, toxicity, privacy, security and the high cost of building generative AI (e.g., Einstein GPT) (CRM_10k_2023.pdf pp. 24‑25). By the 2024 filing the discussion had shifted to product‑specific concerns for its new generative‑AI Agentforce, stressing market‑and‑monetization uncertainty, consumption‑based pricing risks and heightened liability for inaccurate or copyrighted AI‑generated content, while still acknowledging the same technical and regulatory issues (CRM_10k_2024.pdf pp. 22‑23).",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of the evolution of Salesforce's AI risk disclosures from 2023 to 2024, with mostly accurate characterization of the risk profile changes. STRENGTHS: (1) Correctly identifies the shift from broad, emerging AI risks in 2023 to more product-specific concerns in 2024; (2) Accurately names Agentforce as the key new product with specific risks; (3) Properly identifies new risk categories in 2024 including copyright/content liability concerns; (4) Correctly notes the persistence of technical and regulatory issues across both years; (5) Appropriately cites specific page numbers from both filings. WEAKNESSES: (1) The 2023 characterization differs from ground truth - the LLM emphasizes broad emerging AI risks and Einstein GPT, while the ground truth specifically states 2023 risks centered on third-party integrations and applications with warranty claims, not Salesforce's own AI products. This is a material difference in the baseline comparison; (2) The LLM mentions 'consumption-based pricing risks' for Agentforce in 2024, which is not explicitly mentioned in the ground truth answer; (3) The ground truth emphasizes that 2023 risks were about third-party offerings (not Salesforce-developed), whereas the LLM discusses Salesforce's own AI offerings in 2023, conflating different risk categories; (4) The ground truth specifically mentions 'increased costs related to AI governance, compliance, and testing' as new in 2024, which the LLM does not explicitly capture. MULTI-HOP REASONING: The answer correctly synthesizes information across two years and identifies the evolution pattern, though the baseline characterization of 2023 risks appears to conflate different risk categories. The comparison structure is sound but built on a partially incorrect foundation regarding what 2023 risks actually were. ENTITY ACCURACY: All company names, product names (Agentforce, Einstein GPT), years, and filing references are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 534,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Lowe's delivery capability for parcel-eligible items evolved between fiscal years 2023 and 2024, and what specific improvements were made?",
      "original_answer": "In fiscal year 2023, most parcel-eligible items could be delivered within two business days at standard shipping rates. By fiscal year 2024, Lowe's improved this capability, enabling delivery of most parcel-eligible items within two business days or less. Additionally, in 2024, Lowe's expanded its delivery capabilities to include next-day delivery for major appliances in nearly every zip code in the United States. This represents a refinement and expansion of their delivery speed and geographic coverage.",
      "llm_answer": "In fiscal 2023 Lowe’s said that most parcel‑eligible items could be ordered and delivered within two business days at standard shipping rates, and that a nationwide expansion of its gig‑network enabled same‑day delivery of certain products. By fiscal 2024 the company tightened that promise to “two business days or less,” further expanded the gig‑provider network for same‑day deliveries, and added next‑day delivery of major appliances to almost every U.S. zip code.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "ANALYSIS: The LLM answer contains both accurate and inaccurate information when compared to the ground truth.\n\nCORRECT ELEMENTS:\n1. Fiscal 2023: Two business days at standard shipping rates - CORRECT\n2. Fiscal 2024: \"Two business days or less\" - CORRECT\n3. Next-day delivery for major appliances to nearly every/almost every U.S. zip code - CORRECT (semantic equivalence: \"nearly every\" = \"almost every\")\n4. Geographic scope and year-over-year progression - CORRECT\n\nINCORRECT/PROBLEMATIC ELEMENTS:\n1. MAJOR ERROR: The LLM introduces information about \"same-day delivery\" in fiscal 2023 via gig-network expansion. The ground truth makes NO mention of same-day delivery capability in 2023.\n2. MAJOR ERROR: The LLM states that in 2024 the company \"further expanded the gig-provider network for same-day deliveries.\" The ground truth does not mention same-day delivery as a 2024 improvement.\n3. The ground truth specifically states the improvements were: (a) refinement from \"within two business days\" to \"within two business days or less\" and (b) expansion to next-day delivery for major appliances. Same-day delivery is not mentioned as part of the evolution.\n\nMULTI-HOP REASONING: The LLM attempted to synthesize information across fiscal years but appears to have introduced information not present in the ground truth. This suggests either hallucination or confusion with other company capabilities.\n\nQUANTITATIVE ACCURACY: The numeric/geographic references (zip codes, business days) are accurate, but the introduction of same-day delivery as a key improvement is factually incorrect per the ground truth.\n\nQUALITATIVE ACCURACY: While the LLM correctly identified the main improvements (tightened promise, next-day appliance delivery), it added significant information about same-day delivery that contradicts or goes beyond the ground truth, representing a material factual error in the synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 522,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial impact of the Dermstore LLC sale evolved from 2022 to 2023 in terms of Target's consolidated revenues and operating income?",
      "original_answer": "The financial impact of the Dermstore LLC sale remained minimal in both years, as Dermstore represented less than 1 percent of Target's consolidated revenues, operating income, and net assets in both 2022 and 2023. The sale, which occurred in February 2021, resulted in a $335 million pretax gain included in Net Other (Income)/Expense, and no significant post-sale financial contribution or change was observed in either year.",
      "llm_answer": "The Dermstore sale, completed in February 2021, produced a $335 million pretax gain but is treated as a non‑recurring item that “represented less than 1 percent of our consolidated revenues, operating income and net assets” 【TGT_10k_2022.pdf p.19‑23】. The 2023 filing repeats the same language, noting the sale still accounts for “less than 1 percent of our consolidated revenues, operating income and net assets” 【TGT_10k_2023.pdf p.22‑26】, indicating the impact remained negligible and unchanged from 2022 to 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-supported. Verification of key facts: (1) Dermstore sale date of February 2021 is correct; (2) $335 million pretax gain figure is accurate; (3) The 'less than 1 percent' characterization for both 2022 and 2023 is correct and properly sourced; (4) The answer correctly identifies this as a non-recurring item. Multi-hop reasoning is sound: the model synthesized information across two 10-K filings (2022 and 2023) to demonstrate that the financial impact remained unchanged and minimal across both years. The answer directly addresses the question's core inquiry about how the impact 'evolved' by correctly concluding it remained negligible and unchanged. The citation format with page ranges is appropriate. Minor consideration: The answer could have been slightly more explicit about the fact that no post-sale contributions occurred in either year (as stated in ground truth), though this is implied by the 'less than 1 percent' and 'unchanged' characterization. The semantic equivalence is strong - the LLM conveys the same essential information as the ground truth through slightly different wording ('remained minimal' vs 'remained negligible and unchanged'), which is acceptable and actually enhances clarity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 353,
        "total_tokens": 1589
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the strategic positioning of Data Cloud evolved between 2023 and 2024, particularly in terms of its role within Salesforce's broader service offerings and competitive landscape?",
      "original_answer": "In 2023, Data Cloud was described as a 'hyperscale, trusted data engine native to Salesforce' that unified enterprise data to deliver a 360-degree view of customers, emphasizing its integration across Salesforce's offerings like Marketing and Analytics. By 2024, Data Cloud was positioned within a broader context of competitive risk, with the filing noting that markets for offerings like Data Cloud are 'relatively new and uncertain,' and that Salesforce faces increasing competition as AI and data platforms evolve. Additionally, in 2024, Salesforce acknowledged limited experience in pricing consumption-based models like that of Data Cloud, signaling a shift from product-centric messaging to one that includes strategic risk and monetization challenges.",
      "llm_answer": "In the 2023 filing Data Cloud was introduced as Salesforce’s “hyperscale, trusted data engine” that pulls together a company’s disconnected enterprise data to create a single, 360‑degree view of the customer and to power AI across the Customer 360 suite (e.g., Sales, Service, Marketing and Commerce). By the 2024 filing the company had sharpened its positioning – tying Data Cloud more tightly to the Einstein 1 Platform, emphasizing its consumption‑based pricing model, and flagging the “relatively new and uncertain” monetization and competitive pressures it faces in the crowded data‑and‑AI market – thereby framing it as a core, revenue‑generating data platform that underpins automation and analytics across all of Salesforce’s service offerings.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with correct identification of key facts and sound multi-hop reasoning across 2023-2024 filings. STRENGTHS: (1) Correctly identifies 2023 positioning as 'hyperscale, trusted data engine' with 360-degree customer view - matches ground truth exactly. (2) Accurately captures 2024 shift to acknowledge 'relatively new and uncertain' markets and competitive pressures - core ground truth elements present. (3) Properly synthesizes evolution from product-centric to risk/monetization-aware messaging. (4) Correctly identifies consumption-based pricing model as key 2024 element. (5) No quantitative errors - no numbers, dates, or calculations to verify. (6) Multi-hop reasoning is sound: correctly traces Data Cloud's role across both years and its integration with broader Salesforce offerings. MINOR GAPS: (1) LLM adds 'Einstein 1 Platform' connection which, while potentially accurate, is not explicitly mentioned in the ground truth answer - this represents a minor addition beyond the provided ground truth rather than an error. (2) Ground truth emphasizes 'limited experience in pricing consumption-based models' as a strategic risk acknowledgment, while LLM frames consumption-based pricing more as a positioning choice rather than explicitly as a risk/challenge area. This is a subtle semantic difference - the LLM captures the concept but with slightly different emphasis. (3) Ground truth mentions Analytics specifically; LLM generalizes to 'analytics across all service offerings' which is semantically equivalent but less specific. OVERALL ASSESSMENT: The answer correctly captures the strategic evolution, accurately identifies both 2023 and 2024 positioning elements, and demonstrates proper synthesis of multi-hop information across years. The minor additions (Einstein 1) and slight emphasis differences do not constitute factual errors but rather represent reasonable interpretations or extensions of the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 534,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has LOW's treatment and accounting of forward interest rate swap contracts evolved between 2023 and 2024, particularly in terms of hedge designation and financial impact?",
      "original_answer": "In 2023, LOW disclosed forward interest rate swap contracts related to its March 2023 Notes with a notional amount of $2.0 billion, from which it received $247 million upon settlement. These contracts were designated as cash flow hedges and their (loss)/gain was recorded in other comprehensive (loss)/income and earnings. By 2024, the company clarified that its fixed-to-floating interest rate swap agreements are accounted for as fair value hedges using the shortcut method, under which the hedges are assumed perfectly effective. This resulted in no net impact on the consolidated statements of earnings from the fair value of the derivatives, indicating a shift in both hedge designation and accounting treatment compared to the prior year.",
      "llm_answer": "In the 2023 Form 10‑K Lowe’s reported $1.29 billion of forward interest‑rate swap contracts classified as cash‑flow hedges, which produced a $311 million gain in other‑comprehensive income and a $1 million net‑interest benefit (2023 pp. 58‑62). By the 2024 filing the company had removed that hedge designation – the forward swaps show a $0 notional and only $850 million of fixed‑to‑floating swaps remain as fair‑value hedges – and the cash‑flow‑hedge OCI turned to a $14 million loss with $15 million of net interest (2024 pp. 56‑60).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations of the ground truth:\n\n1. QUANTITATIVE ERRORS:\n   - LLM claims $1.29 billion forward interest-rate swap contracts in 2023, but ground truth states $2.0 billion notional amount\n   - LLM reports $311 million gain in OCI for 2023, but ground truth indicates $247 million was received upon settlement\n   - LLM states $850 million of fixed-to-floating swaps remain in 2024, which is not mentioned in ground truth\n   - LLM reports $14 million loss and $15 million net interest for 2024, which contradicts ground truth's statement of \"no net impact on consolidated statements of earnings\"\n\n2. HEDGE DESIGNATION ERRORS:\n   - LLM incorrectly states forward swaps show \"$0 notional\" in 2024, suggesting they were removed\n   - Ground truth indicates the 2024 treatment clarified that fixed-to-floating swaps are fair value hedges using shortcut method\n   - LLM mischaracterizes the evolution as a removal of hedge designation, when ground truth shows a clarification/shift from cash flow hedges to fair value hedges\n\n3. ACCOUNTING TREATMENT MISREPRESENTATION:\n   - LLM claims \"cash-flow-hedge OCI turned to a $14 million loss,\" but ground truth states fair value hedges resulted in \"no net impact on consolidated statements of earnings\"\n   - This is a fundamental misunderstanding of the accounting treatment change\n\n4. MULTI-HOP REASONING:\n   - LLM failed to correctly synthesize the key evolution: from 2023 cash flow hedges (with OCI impact) to 2024 fair value hedges using shortcut method (with no earnings impact)\n   - The comparison between years is inaccurate and misleading\n\n5. MISSING KEY INFORMATION:\n   - LLM does not mention the March 2023 Notes specifically\n   - LLM does not explain the shortcut method or perfect effectiveness assumption mentioned in ground truth\n   - LLM does not properly convey that the 2024 treatment represents a clarification of accounting methodology\n\nThe answer demonstrates poor accuracy on nearly all quantitative metrics and fails to correctly characterize the evolution of LOW's hedge accounting between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 578,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has Target's strategy around its owned brands evolved from 2022 to 2023, particularly in terms of portfolio emphasis and strategic objectives?",
      "original_answer": "In 2022, Target highlighted a significant portion of sales coming from its owned brands, listing over 40 such brands across multiple categories, indicating a strong but descriptive presence in the market. By 2023, the company elevated its focus by strategically positioning owned brands as a core element of its overall strategy to 'delight with newness, style, and value,' explicitly aiming to strengthen the portfolio as part of broader efforts to drive traffic, sales, and market share growth. This shift reflects a move from simply showcasing owned brands to actively leveraging them as a strategic differentiator.",
      "llm_answer": "In the 2022 filing Target positioned its private‑label names as a **differentiation pillar**, noting “Differentiating from our competition with our owned brands” and listing a broad portfolio that contributed roughly one‑third of sales【TGT_10k_2022.pdf p. 5】. By the 2023 filing the language shifts to **strengthening and expanding** that portfolio, saying Target will “delight with newness, style, and value by **strengthening our owned brands portfolio**” and using it to drive traffic, sales and market‑share growth【TGT_10k_2023.pdf p. 2】—showing a move from a static differentiator to an active growth engine for the brand mix.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the strategic evolution of Target's owned brands from 2022 to 2023, capturing the shift from positioning them as a differentiator to actively leveraging them as a growth engine. The qualitative analysis is sound and well-supported with specific quotes from both filings.\n\nSTRENGTHS:\n- Correctly identifies 2022 positioning as 'differentiation pillar'\n- Accurately captures 2023 shift to 'strengthening and expanding' language\n- Properly synthesizes the multi-hop comparison across two years\n- Provides relevant quotes with proper citations\n- Semantic meaning aligns well with ground truth about moving from 'showcasing' to 'leveraging'\n- Contextually appropriate and directly addresses the question\n\nWEAKNESSES:\n- QUANTITATIVE DISCREPANCY: States owned brands contributed \"roughly one-third of sales\" in 2022, but ground truth says \"over 40 such brands\" without specifying a sales percentage. The LLM introduces a specific metric (one-third/~33%) that is not explicitly confirmed in the ground truth provided. This is a factual claim that cannot be verified against the stated ground truth.\n- Ground truth mentions \"over 40 such brands\" in 2022, but LLM doesn't reference this specific number\n- Minor: Ground truth emphasizes \"over 40 brands across multiple categories\" as a key 2022 descriptor, which the LLM omits\n\nMULTI-HOP REASONING:\nThe reasoning is sound - the model correctly synthesizes information from two different years and identifies the strategic evolution. The comparison between 2022 and 2023 positioning is logically structured and well-explained.\n\nCALCULATIONS/NUMBERS:\nThe primary concern is the \"one-third of sales\" claim. While this may be accurate from the actual filing, it's not explicitly stated in the ground truth answer provided, creating a verification gap. This prevents a higher quantitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 514,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has GM's approach to software-enabled services evolved from 2022 to 2023, particularly in terms of service offerings and platform deployment, and what does this indicate about the company's investment in scalable digital solutions?",
      "original_answer": "In 2022, GM described its software-enabled services in general terms as part of its broader operations, noting that it 'provides software-enabled services worldwide' and integrates them into its automotive business alongside investments in AV technology and automotive financing. By 2023, GM's approach had evolved significantly, with specific details on its end-to-end software platform that enables over-the-air updates for features like Super Cruise, active safety, infotainment, and EV ownership experience. The 2023 filing highlights that select 2024 models, such as the Cadillac LYRIQ and Chevrolet Silverado EV, were already using this platform, indicating a strategic shift toward scalable, software-defined vehicles. This evolution shows a transition from general involvement in digital services to concrete platform deployment across product lines, reflecting increased investment and operational maturity in software-enabled offerings.",
      "llm_answer": "In the 2022 Form 10‑K (see pages 58‑62) GM presented its software‑enabled services as a core suite – OnStar, Super Cruise and other OTA‑updatable features – delivered through an end‑to‑end software platform that was already in use on a limited set of early models (e.g., the 2022 Cadillac LYRIQ and Bolt EV). By the 2023 filing (see pages 3‑7) the company expanded the portfolio to include new digital functions such as security, climate‑control, personal‑theme and EV‑ownership services, and announced that the same platform is now being rolled out across most of its vehicle line‑up, with the 2024 Cadillac LYRIQ and Chevrolet Silverado EV equipped from launch. This evolution signals GM’s growing commitment to a scalable, over‑the‑air software architecture that can be deployed fleet‑wide, underpinning its strategy to generate recurring digital revenue and support its broader EV and autonomous‑vehicle ambitions.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES IDENTIFIED: (1) FACTUAL ERRORS ON DATES/MODELS: The LLM claims 2022 Cadillac LYRIQ and Bolt EV were using the platform in 2022, but the ground truth indicates the platform details were only described in general terms in 2022, with specific platform deployment occurring in 2023 for select 2024 models. The LLM incorrectly backdates platform deployment to 2022. (2) INCONSISTENT TIMELINE: Ground truth clearly states 2023 filing highlights 'select 2024 models' (Cadillac LYRIQ and Chevrolet Silverado EV) using the platform, indicating these were future deployments announced in 2023. LLM conflates 2022 and 2024 model years, creating confusion about deployment timeline. (3) CHARACTERIZATION MISMATCH: Ground truth emphasizes a 'transition from general involvement in digital services to concrete platform deployment' - a shift from vague to specific. LLM presents 2022 as already having 'end-to-end software platform' in use, contradicting the ground truth's characterization of 2022 as general/non-specific. (4) MISSING KEY DISTINCTION: Ground truth's core insight is the evolution from general statements (2022) to specific platform details and deployment (2023). LLM obscures this distinction by claiming both years had similar platform specificity. (5) ADDITIONAL FEATURES: LLM mentions security, climate-control, personal-theme services in 2023 expansion - these details are not in ground truth and cannot be verified. (6) POSITIVE ELEMENTS: LLM correctly identifies OnStar, Super Cruise, OTA updates, and the strategic shift toward scalable software-defined vehicles. The conclusion about recurring digital revenue and EV/AV ambitions aligns with ground truth intent. MULTI-HOP REASONING: The LLM attempts to synthesize 2022 vs 2023 evolution but fails to accurately capture the fundamental shift in specificity and deployment status that defines the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1488,
        "completion_tokens": 510,
        "total_tokens": 1998
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has the revenue contribution from ThousandEyes within the Optimized Application Experiences/Observability product category evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Optimized Application Experiences category, which included ThousandEyes, saw revenue growth of $75 million (11%), driven by ThousandEyes and Intersight. By fiscal year 2023, the Observability category (which includes ThousandEyes) experienced a revenue increase of $80 million (14%), specifically attributed to growth in ThousandEyes and monitoring and analytics offerings. This shows a continued upward trend in ThousandEyes' revenue contribution, with both absolute and percentage growth increasing from 2022 to 2023.",
      "llm_answer": "In FY 2022 Cisco said the Optimized Application Experiences category grew 11 % (≈ $75 million) and that the increase was “driven by growth in our **ThousandEyes** and Intersight offerings”【CSCO_10k_2022.pdf p.45】. In FY 2023 the renamed Observability category grew 14 % (≈ $80 million), again “driven by growth in our **ThousandEyes** … offerings”【CSCO_10k_2023.pdf p.43】. Thus, ThousandEyes’ revenue contribution rose modestly year‑over‑year, supporting a larger category increase in FY 2023 than in FY 2022.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. All quantitative data is correct: FY 2022 shows 11% growth (~$75 million) for Optimized Application Experiences, and FY 2023 shows 14% growth (~$80 million) for the renamed Observability category. The answer correctly identifies ThousandEyes as a key driver in both years and properly notes the category name change from 'Optimized Application Experiences' to 'Observability.' The multi-hop synthesis is sound—the model correctly extracted information from two different fiscal year filings and compared the evolution of ThousandEyes' contribution across years. The reasoning that 'ThousandEyes' revenue contribution rose modestly year-over-year, supporting a larger category increase in FY 2023 than in FY 2022' is logically sound and matches the ground truth's characterization of 'continued upward trend.' The inclusion of document citations adds credibility. Minor observation: The LLM uses the phrase 'rose modestly' which is a reasonable characterization of the growth pattern, though the ground truth emphasizes 'both absolute and percentage growth increasing.' This is a semantic nuance rather than a factual error. The answer fully addresses the question's request to show how revenue contribution evolved between the two fiscal years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 366,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did the treatment of Amendment No. 4 to the Lockheed Martin Executive Severance Plan evolve between the 2023 and 2024 10-K filings, and what does this indicate about its inclusion in the company's disclosure strategy?",
      "original_answer": "In the 2023 10-K filing, Amendment No. 4 to the Executive Severance Plan was disclosed as part of the exhibit list (Exhibit 10.34) and referenced as being incorporated from the September 2022 10-Q filing. However, in the 2024 10-K filing, Amendment No. 4 is no longer listed as a standalone exhibit but appears instead as part of a sequence that includes earlier amendments (Nos. 2, 3, 4, and 5), with Amendment No. 4 specifically incorporated from the same September 2022 10-Q filing. This indicates that while the amendment itself remained relevant, its treatment shifted from a highlighted disclosure in 2023 to a more integrated part of the broader severance plan history in 2024, suggesting a more consolidated and retrospective approach to disclosure.",
      "llm_answer": "In the 2023 Form 10‑K the amendment is listed as **Exhibit 10.34** – “Amendment No. 4 to the Lockheed Martin Executive Severance Plan…incorporated by reference to the September 25 2022 10‑Q”【LMT_10k_2023.pdf†page=104】. In the 2024 Form 10‑K the same amendment appears as **Exhibit 10.36** (still incorporated by reference to the same 10‑Q)【LMT_10k_2024.pdf†page=105】. The only change is the exhibit number, reflecting a re‑ordering of the exhibit schedule as new items were added, while the continued inclusion shows that Lockheed Martin consistently discloses the amendment as part of its executive severance plan transparency.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) EXHIBIT NUMBER ERROR: The LLM claims Amendment No. 4 appears as Exhibit 10.36 in the 2024 10-K, but the ground truth indicates it should be part of a sequence including amendments 2, 3, 4, and 5 - the specific exhibit number discrepancy is critical and unverified. (2) INCOMPLETE ANALYSIS: The LLM's explanation focuses narrowly on exhibit number changes due to 're-ordering' but misses the core insight from the ground truth - that the treatment fundamentally shifted from a 'highlighted disclosure' (standalone in 2023) to 'integrated part of broader severance plan history' (part of a sequence in 2024). This represents a qualitative change in disclosure strategy, not merely a re-numbering. (3) MISSING STRUCTURAL CHANGE: The ground truth explicitly states Amendment No. 4 'is no longer listed as a standalone exhibit but appears instead as part of a sequence' - the LLM fails to capture this structural reorganization and its significance. (4) OVERSIMPLIFIED CONCLUSION: The LLM concludes this merely reflects 'consistent disclosure' and 're-ordering,' missing the ground truth's insight about a 'more consolidated and retrospective approach to disclosure.' (5) SEMANTIC MISALIGNMENT: While the LLM correctly identifies the September 2022 10-Q incorporation, it fundamentally mischaracterizes the nature of the change. The ground truth indicates a strategic shift in how the amendment is presented (consolidated vs. standalone), while the LLM attributes it to routine exhibit numbering. The answer demonstrates partial understanding of exhibit mechanics but fails to grasp the disclosure strategy evolution that is central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 475,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did JPMorgan's compliance with capital ratio requirements evolve from 2023 to 2024, particularly in terms of its Tier 1 leverage ratio and Standardized CET1 capital ratio?",
      "original_answer": "In 2023, JPMorgan's Standardized CET1 capital ratio was 15.0%, exceeding the requirement of 11.4%. In 2024, the Tier 1 leverage ratio was 7.2%, which was above the requirement of 4.0%. This indicates that JPMorgan maintained compliance with capital ratio requirements across both years, with consistent capital strength relative to evolving regulatory expectations.",
      "llm_answer": "In 2023 JPMorgan reported a Tier 1 leverage ratio of **7.2 %**, well above the 4.0 % regulatory floor, and a Standardized CET1 ratio of **15.0 %**, comfortably exceeding the 11.4 % minimum. By year‑end 2024 the Tier 1 leverage ratio remained unchanged at **7.2 %** (still above the 4.0 % requirement), while the Standardized CET1 ratio rose to **15.7 %**, staying well above the higher 12.3 % requirement for that year【2023 Leverage‑based table – Tier 1 leverage ratio 7.2; CET1 ratio 15.0 %】【2024 Leverage‑based table – Tier 1 leverage ratio 7.2 %; CET1 ratio 15.7 %】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "ANALYSIS: The LLM answer provides more detailed information than the ground truth but contains a critical factual discrepancy that undermines accuracy.\n\nCORRECT ELEMENTS:\n- 2023 Tier 1 leverage ratio: 7.2% ✓ (matches ground truth)\n- 2023 Standardized CET1 ratio: 15.0% ✓ (matches ground truth)\n- 2023 regulatory requirements: 4.0% leverage, 11.4% CET1 ✓\n- 2024 Tier 1 leverage ratio: 7.2% ✓ (stated as unchanged)\n- 2024 Tier 1 leverage requirement: 4.0% ✓\n- Overall compliance narrative: JPMorgan maintained strong capital ratios ✓\n\nINCORRECT/PROBLEMATIC ELEMENTS:\n- 2024 Standardized CET1 ratio: LLM states 15.7%, but ground truth does not provide this figure. The ground truth only specifies 2023 CET1 (15.0%) and 2024 Tier 1 leverage (7.2%), with no 2024 CET1 ratio mentioned.\n- 2024 CET1 requirement: LLM states 12.3%, but ground truth does not provide this figure either.\n- The LLM appears to have extrapolated or inferred 2024 CET1 data that is not in the ground truth.\n\nMULTI-HOP REASONING:\nThe LLM correctly synthesized the evolution narrative (comparing 2023 to 2024) and properly identified the multi-year comparison requirement. However, the synthesis is compromised by introducing unsupported data points for 2024 CET1.\n\nQUANTITATIVE ACCURACY ISSUE:\nWhile the numbers provided are internally consistent and plausible, the 2024 CET1 ratio (15.7%) and its requirement (12.3%) cannot be verified against the ground truth, which only provides 2023 CET1 data and 2024 leverage ratio data. This represents a significant gap between what the LLM claims and what the ground truth supports.\n\nCONCLUSION:\nThe answer demonstrates good understanding of the question structure and provides relevant context, but introduces unverified data for 2024 CET1 metrics that go beyond the ground truth. This is a material accuracy issue for a financial compliance question where precision is critical.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 517,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the role of GM Financial in General Motors' operations evolved between 2022 and 2023, particularly in terms of its integration and financial presentation within the consolidated financial statements?",
      "original_answer": "In 2022, GM Financial was described as a segment through which General Motors provides automotive financing services, with its financials adjusted to reflect the impact of consolidated tax returns and intercompany transactions. By 2023, the description of GM Financial became more detailed, emphasizing that the amounts presented for GM Financial are adjusted for the impact on deferred tax positions and the provision for income taxes due to its inclusion in the consolidated tax return, and that these amounts differ from those presented on a stand-alone basis. This evolution reflects a more explicit focus on the integration and financial alignment of GM Financial with the broader corporate structure.",
      "llm_answer": "In the 2022 filing GM Financial was already shown as a distinct reportable segment (net‑sales ≈ $13.4 bn in 2021) and the footnote explained that its numbers were “adjusted to reflect the impact on GM Financial’s deferred‑tax positions and to eliminate the effect of transactions between GM Financial and the other members of the consolidated group” (GM_10k_2022.pdf pp. 97‑101). By the 2023 filing the segment still appears separately, but the presentation now stresses that GM Financial’s results are evaluated on an **EBT‑adjusted** basis and that its amounts are fully integrated into the consolidated tax return with inter‑segment balances eliminated, signalling a tighter operational and financial integration within GM’s consolidated statements (GM_10k_2023.pdf pp. 61‑65).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer addresses the core question about GM Financial's evolving role between 2022 and 2023, correctly identifying that it remained a reportable segment in both years with increasing emphasis on integration and tax consolidation. However, there are significant issues:\n\nQUANTITATIVE ACCURACY PROBLEMS:\n1. The LLM cites \"net-sales ≈ $13.4 bn in 2021\" - this is problematic because: (a) the question asks about 2022-2023 evolution, not 2021 data, (b) the approximate nature and lack of verification against ground truth is concerning, (c) the ground truth answer does not mention this specific figure, suggesting it may be unsupported or from a different context.\n2. Page references (pp. 97-101 for 2022, pp. 61-65 for 2023) are provided but cannot be verified against the ground truth, which does not cite specific page numbers.\n\nQUALITATIVE ACCURACY:\n1. The LLM correctly identifies the core evolution: from basic segment description in 2022 to more detailed integration emphasis in 2023.\n2. The mention of \"EBT-adjusted basis\" in 2023 is a specific detail not explicitly mentioned in the ground truth, which could be accurate but represents an addition beyond what was verified.\n3. The description of tax consolidation and intercompany transaction elimination aligns with the ground truth's emphasis on \"deferred tax positions\" and \"consolidated tax return.\"\n4. The characterization of \"tighter operational and financial integration\" matches the ground truth's \"more explicit focus on integration and financial alignment.\"\n\nMULTI-HOP REASONING:\nThe LLM successfully synthesizes information across two years and two filings, correctly identifying the progression from 2022 to 2023. However, the introduction of the 2021 net-sales figure appears to be an unnecessary tangent that doesn't directly support the 2022-2023 comparison requested.\n\nSEMANTIC EQUIVALENCE:\nThe core message aligns with ground truth: GM Financial evolved from a basic segment description to one emphasizing deeper integration and tax consolidation. However, the LLM adds specific details (EBT-adjusted basis, specific page numbers) that go beyond the ground truth without clear verification.\n\nKEY ISSUES:\n- Unverified quantitative data (2021 net-sales figure)\n- Page references not confirmed against ground truth\n- Introduction of \"EBT-adjusted\" terminology not explicitly in ground truth\n- Otherwise sound reasoning and appropriate focus on the evolution question",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 659,
        "total_tokens": 2045
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the treatment and disclosure of step-rent provisions in lease accounting evolved between 2022 and 2024, particularly regarding the recognition of periodic rent increases based on price indices or sales volume?",
      "original_answer": "In 2022, the company disclosed that certain leases provided for periodic rent increases based on price indices or the greater of minimum guaranteed amounts or sales volume, and these were accounted for on a straight-line basis. By 2024, the company clarified that such increases, based on price indices or the greater of minimum guaranteed amounts or sales volume, are now recognized as variable lease payments rather than being straight-lined, indicating a shift in accounting treatment. This reflects a more dynamic approach to recognizing lease costs that fluctuate with external factors.",
      "llm_answer": "Both the 2022 and 2024 filings state that step‑rent provisions are recognized on a straight‑line basis over the lease’s original term and any extensions the Company is reasonably certain to exercise. The 2024 filing adds explicit language that periodic rent increases tied to price‑indices or sales‑volume thresholds are accounted for as variable lease payments, whereas the 2022 filing described those escalations but did not label them as variable payments. This reflects a more detailed disclosure of how index‑ or sales‑linked rent escalations are treated in the lease accounting.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL FACTUAL ERROR: The LLM answer directly contradicts the ground truth on the core accounting treatment evolution. Ground truth states that by 2024, step-rent provisions based on price indices or sales volume are NOW recognized as VARIABLE LEASE PAYMENTS (a shift from straight-line treatment). The LLM answer claims both 2022 and 2024 recognize these on a straight-line basis, with 2024 only adding 'explicit language' about variable payments without indicating an actual change in treatment. This is fundamentally incorrect. The LLM mischaracterizes the evolution as merely a disclosure/labeling change rather than an actual accounting treatment change. The ground truth explicitly states 'a shift in accounting treatment' from straight-line to variable lease payment recognition. The LLM's statement that 2024 'adds explicit language that periodic rent increases...are accounted for as variable lease payments' while simultaneously claiming straight-line treatment in both years is internally contradictory and factually wrong. The quantitative accuracy score is high because there are no specific numbers to verify, but the qualitative accuracy is severely compromised by the fundamental misunderstanding of the accounting treatment change. The answer fails to capture the key evolution the question asks about - the shift from straight-line to variable lease payment treatment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 386,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the projected funding obligations for Lockheed Martin's qualified defined benefit pension plans evolve from 2023 to 2024, particularly in terms of the amounts expected to be paid out in 2025 and over the long-term period from 2029 to 2033?",
      "original_answer": "In 2023, Lockheed Martin projected $1,860 million in payments for qualified defined benefit pension plans in 2025 and $10,020 million over the period from 2029 to 2033. By 2024, the projected payment for 2025 increased slightly to $1,860 million, while the long-term projection from 2030 to 2034 decreased to $9,990 million. This indicates a marginal reduction in long-term pension obligations.",
      "llm_answer": "In the 2023 filing Lockheed Martin said it expected to pay **$1.86 billion** in qualified defined‑benefit pension benefits in 2025 and **$10.02 billion** over the 2029‑2033 horizon【LMT_10k_2023.pdf:86】.  \nThe 2024 filing revised the 2025 estimate down to **$1.80 billion**, and now breaks out the long‑term outlook as **$1.99 billion for 2029** plus **$9.99 billion for 2030‑2034** (which together imply roughly $12 billion for the 2029‑2033 period)【LMT_10k_2024.pdf:87】.  \n\nThus, the 2025 projection fell slightly, while the total amount projected for the longer‑term period increased relative to the 2023 estimate.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that contradict the ground truth:\n\n1. QUANTITATIVE ERRORS (Primary Issue):\n   - 2023 2025 projection: LLM states $1.86B (correct format), but ground truth confirms $1,860M ($1.86B) - this matches\n   - 2023 long-term (2029-2033): LLM states $10.02B, ground truth states $10,020M ($10.02B) - this matches\n   - 2024 2025 projection: LLM claims $1.80B, but ground truth states $1,860M ($1.86B) - LLM is WRONG. The ground truth explicitly says the 2025 projection remained at $1,860M (no change), not a decrease to $1.80B\n   - 2024 long-term period: LLM breaks this into $1.99B for 2029 + $9.99B for 2030-2034, claiming this totals ~$12B for 2029-2033. Ground truth states the 2024 projection for 2030-2034 is $9,990M ($9.99B). The LLM's interpretation is fundamentally flawed - it's adding a separate 2029 figure that shouldn't be added to the 2030-2034 range, creating an inflated total\n\n2. DIRECTIONAL ERRORS:\n   - Ground truth: 2025 projection remained \"slightly\" at $1,860M (no change)\n   - LLM: Claims 2025 projection \"fell slightly\" to $1.80B (incorrect direction and magnitude)\n   - Ground truth: Long-term obligations decreased from $10,020M to $9,990M (marginal reduction)\n   - LLM: Claims long-term period \"increased\" to ~$12B (completely wrong direction and magnitude)\n\n3. PERIOD COMPARISON ERRORS:\n   - Ground truth compares 2029-2033 (2023) to 2030-2034 (2024) - different periods but comparable\n   - LLM misinterprets the 2024 data by adding separate year figures, creating confusion about what's actually being compared\n\n4. SYNTHESIS FAILURE:\n   - The LLM failed to correctly synthesize the year-over-year comparison\n   - The conclusion that obligations \"increased\" is the opposite of the ground truth's \"marginal reduction\"\n   - The mathematical interpretation of the 2024 figures is incorrect\n\nThe answer gets the 2023 numbers approximately correct but makes critical errors on the 2024 figures and reaches the opposite conclusion about the trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 551,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did JPMorgan Chase's disclosures about its resolution plan obligations evolve between 2023 and 2024, particularly in terms of its described liquidity risk management strategies and funding cost considerations?",
      "original_answer": "In 2023, JPMorgan Chase emphasized that its resolution plan obligations could lead to higher funding costs and constrained liquidity due to the need to satisfy liquidity coverage ratio and net stable funding ratio requirements, as well as regulatory demands outside the U.S. regarding liquidity pre-positioning in subsidiaries. The firm highlighted the potential need to rely on more expensive or limited alternative funding sources if traditional ones like deposits or Federal Home Loan Bank borrowings were reduced. In 2024, the firm expanded its disclosures to include how resolution plan obligations interacted with dynamic regulatory expectations and systemic events, noting that changes in laws, rules, and regulations—especially in response to economic effects of systemic events—could further impact liquidity and capital requirements. This reflects a shift toward framing resolution-related liquidity risks within a broader context of regulatory evolution and macroeconomic uncertainty.",
      "llm_answer": "Both the 2023 and 2024 10‑K filings say that JPMorgan Chase’s need to satisfy the funding requirements of its resolution plan can push up its funding costs and may force it to tap “alternative, potentially more expensive” sources of liquidity if its traditional sources (deposits and Federal Home‑Loan‑Bank borrowings) are limited. The 2024 filing repeats the same liquidity‑risk framework—market‑wide illiquidity, regulatory‑driven changes, and the need to meet LCR/NSFR—and does not materially change the description of how resolution‑plan obligations are managed or their impact on funding costs.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer correctly identifies the core 2023 framework (higher funding costs, alternative funding sources, LCR/NSFR requirements) and accurately notes that both years mention deposits and FHLB borrowings as traditional sources. However, the answer fundamentally misses the key evolution between 2023 and 2024 that the ground truth emphasizes. The ground truth explicitly states that 2024 disclosures EXPANDED to include 'how resolution plan obligations interacted with dynamic regulatory expectations and systemic events' and noted that 'changes in laws, rules, and regulations—especially in response to economic effects of systemic events—could further impact liquidity and capital requirements.' The LLM dismisses this as 'no material change' and states the 2024 filing 'does not materially change the description,' which directly contradicts the ground truth's characterization of an expansion and shift in framing. The ground truth describes a meaningful evolution toward 'framing resolution-related liquidity risks within a broader context of regulatory evolution and macroeconomic uncertainty,' whereas the LLM characterizes the 2024 disclosure as merely repeating the same framework. This represents a significant failure in multi-hop reasoning and synthesis—the LLM failed to recognize and articulate the substantive evolution in how JPMorgan Chase framed these risks across the two years. The numeric/factual elements about funding costs and alternative sources are correct, but the core analytical finding about the evolution of disclosures is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 431,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How has the financial structure of Optum Rx's pharmacy care services evolved between 2022 and 2023, particularly in terms of revenue recognition and accounts receivable?",
      "original_answer": "In 2022, Optum Rx's pharmacy care services were characterized by a gross revenue reporting model due to the Company's primary obligation to pay network pharmacy providers regardless of payment collection, with revenue recognized at the point of prescription dispensing. By 2023, the financial structure remained aligned with this model but showed an increase in accounts receivable related to products and services, rising from $7.1 billion in 2022 to $8.6 billion in 2023. This indicates a growth in the value of receivables tied to pharmacy care services, suggesting either increased transaction volume or changes in payment timing.",
      "llm_answer": "In 2022 and 2023 Optum Rx’s pharmacy‑care business kept the same revenue‑recognition policy – product revenue is recorded when a prescription is dispensed and services revenue when the related services are performed, with no material prior‑period adjustments or contract assets/liabilities (UNH 10‑K 2023 pp. 44‑48).  The balance‑sheet impact changed, however: accounts receivable for products and services grew from $7.1 billion at 12/31/2022 to $8.6 billion at 12/31/2023, reflecting a sizable increase in billed but unpaid amounts (UNH 10‑K 2023 pp. 44‑48).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: All financial figures are correct - accounts receivable increased from $7.1 billion (12/31/2022) to $8.6 billion (12/31/2023), matching the ground truth exactly. The $1.5 billion increase is accurately characterized as 'sizable.' ENTITY ACCURACY: Correctly identifies Optum Rx, the specific metric (accounts receivable for products and services), and the correct fiscal years (2022-2023). REVENUE RECOGNITION: The LLM correctly states that the revenue recognition policy remained consistent between years - product revenue at dispensing, services revenue when performed. This aligns with the ground truth's description of the 'gross revenue reporting model' and the primary obligation to pay network pharmacy providers. MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across multiple dimensions: (1) revenue recognition policy consistency, (2) balance sheet impact changes, and (3) the interpretation that increased receivables reflect 'billed but unpaid amounts.' MINOR DIFFERENCES: The LLM provides slightly more operational detail (mentioning 'no material prior-period adjustments or contract assets/liabilities') which adds context beyond the ground truth but doesn't contradict it. The ground truth's interpretation that the increase 'suggests either increased transaction volume or changes in payment timing' is semantically equivalent to the LLM's 'billed but unpaid amounts' - both refer to the same underlying phenomenon of growing receivables. DOCUMENTATION: The LLM appropriately cites source material (UNH 10-K 2023 pp. 44-48). Overall, the answer is factually accurate, well-reasoned, and comprehensively addresses all aspects of the multi-part question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 483,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has UPS's quantitative exposure and strategic approach to managing interest rate risk through Floating to Fixed Interest Rate Swaps evolved between 2022 and 2024?",
      "original_answer": "In 2022, UPS disclosed a $28 million notional amount for Floating to Fixed Interest Rate Swaps, indicating limited use of this instrument at that time. By 2024, UPS articulated a broader strategy to 'manage the fixed and floating interest rate mix of its total debt portfolio and related overall cost of borrowing,' suggesting a more intentional and strategic deployment of these swaps. This evolution reflects a shift from a minor, quantitative hedge in 2022 to a more comprehensive interest rate risk management approach in 2024.",
      "llm_answer": "UPS’s floating‑to‑fixed interest‑rate swap exposure was roughly $280 million in 2022 (hedging long‑term debt and producing a $10 million reclassification loss on interest expense and a $‑1 million balance in AOCI for interest‑rate cash‑flow hedges) and remained essentially unchanged at $279 million in 2024 (with $4 million cumulative fair‑value adjustments, a $5 million reclassification loss and no AOCI balance for those hedges)【UPS 10‑K 2022 pp. 136‑140】【UPS 10‑K 2024 pp. 134‑138】. The company’s strategy—designating floating‑to‑fixed swaps as cash‑flow hedges of forecasted interest payments and using fair‑value hedges for fixed‑to‑floating swaps—has stayed consistent, but the 2024 filing shows a modest scaling‑back of hedge activity, reflected in the smaller reclassification loss and the elimination of the AOCI balance.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains a fundamental factual error that contradicts the ground truth. The ground truth states UPS had a $28 million notional amount for Floating to Fixed Interest Rate Swaps in 2022, but the LLM claims $280 million in 2022 and $279 million in 2024. This is a 10x overstatement of the 2022 figure and represents a major quantitative accuracy failure. The LLM also mischaracterizes the evolution: it claims the exposure 'remained essentially unchanged' between 2022 and 2024, when the ground truth indicates a strategic shift from 'limited use' ($28M) to a 'more comprehensive interest rate risk management approach.' The LLM's narrative about 'modest scaling-back of hedge activity' contradicts the ground truth's characterization of evolution toward broader strategic deployment. While the LLM correctly identifies that UPS uses floating-to-fixed swaps as cash-flow hedges and mentions specific accounting impacts (reclassification losses, AOCI balances), these details do not compensate for the core factual errors. The LLM also provides specific page citations that cannot be verified but appear to be fabricated given the magnitude of the numerical discrepancy. The answer fails to capture the key insight from the ground truth: the strategic evolution from a minor quantitative hedge to a more intentional, comprehensive approach to managing the fixed/floating debt mix. The multi-hop reasoning is flawed because it's based on incorrect foundational numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 413,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has GM's financial relationship with LG Energy Solution evolved between 2022 and 2023, particularly in terms of joint venture activities and recall-related costs?",
      "original_answer": "In 2022, GM highlighted its joint venture, Ultium Cells LLC, with LG Energy Solution, as a key part of its EV strategy to mass-produce battery cells across three U.S. plants. By 2023, the relationship had shifted toward financial liabilities, as GM accrued $2.6 billion related to the Chevrolet Bolt EV battery recall, with $1.6 billion recognized as receivables from LG. This marks a transition from strategic collaboration to a more transactional and cost-driven dynamic due to product defects.",
      "llm_answer": "In the 2022 filing GM disclosed that it had just created an equally‑owned U.S. battery‑cell joint venture with LG Energy Solution – Ultium Cells LLC – to mass‑produce cells for its Ultium platform, and that LG ES had agreed to reimburse GM for certain costs of the Chevrolet Bolt EV/EUV recall. By the 2023 filing the venture is now referred to as Ultium Cells Holdings LLC and is fully integrated into GM’s operations, while the Bolt‑recall settlement with LG ES generated a $2.6 billion accrual, a $1.6 billion receivable and a remaining $0.6 billion liability, showing a much larger, quantified financial exposure and reimbursement arrangement.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. STRENGTHS: (1) All key financial figures are correct: $2.6 billion accrual, $1.6 billion receivable, and the additional $0.6 billion liability detail (which ground truth didn't explicitly mention but is accurate). (2) Correctly identifies the joint venture evolution from 2022 (Ultium Cells LLC creation) to 2023 (referred to as Ultium Cells Holdings LLC). (3) Accurately captures the shift from strategic collaboration to cost-driven financial arrangement. (4) Properly synthesizes multi-hop information: 2022 JV formation + 2023 recall costs + LG reimbursement arrangement. (5) Correctly notes LG's agreement to reimburse certain recall costs in 2022. MINOR CONSIDERATIONS: (1) The LLM provides slightly more granular detail than ground truth (the $0.6 billion remaining liability), which is accurate but represents additional information not in the original answer. (2) The naming change from 'Ultium Cells LLC' to 'Ultium Cells Holdings LLC' is mentioned but not explicitly confirmed in ground truth, though this appears to be accurate based on SEC filing conventions. (3) The phrase 'fully integrated into GM's operations' is interpretive language not explicitly stated in ground truth, though semantically reasonable. QUANTITATIVE VERIFICATION: All dollar amounts ($2.6B, $1.6B, $0.6B) are correct and properly contextualized. The sum ($2.6B + $1.6B = $4.2B total exposure) is mathematically sound. MULTI-HOP REASONING: Excellent synthesis connecting 2022 JV formation → 2023 recall costs → LG reimbursement structure. The answer correctly identifies this as a relationship evolution from strategic to transactional. Overall, this is a high-quality answer with accurate numbers, proper entity identification, and sound multi-hop reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 498,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has the revenue contribution from ThousandEyes within the Observability product category evolved from fiscal 2022 to fiscal 2023?",
      "original_answer": "In fiscal 2022, revenue in the Observability product category increased by $80 million, driven in part by growth in ThousandEyes and monitoring and analytics offerings. By fiscal 2023, the Observability product category saw a 27% revenue increase, or $176 million, with ThousandEyes and the newly included Splunk offering (Observability Suite) being key contributors. Excluding Splunk, product revenue from Observability still grew by 15%, indicating strong organic growth primarily from ThousandEyes.",
      "llm_answer": "The Observability category grew from $581 million in fiscal 2022 to $661 million in fiscal 2023 – a 14% rise of about $80 million – and that increase was “driven by growth in our ThousandEyes … offerings” (CSCO 2023 10‑K, product‑revenue table and Observability discussion)【40†L15-L22】【44†L1-L4】. Thus, ThousandEyes’ revenue contribution rose year‑over‑year, helping lift Observability revenue by roughly $80 million.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and incomplete information compared to the ground truth. CRITICAL ERRORS: (1) The LLM states Observability grew from $581M to $661M (a $80M increase of 14%), but the ground truth indicates fiscal 2023 saw a 27% increase of $176M, not 14% and $80M. The $80M figure applies to fiscal 2022, not the year-over-year comparison being asked about. (2) The LLM fails to address the fiscal 2023 growth metrics entirely - it only discusses the fiscal 2022 $80M increase. (3) The LLM completely omits the critical information about the Splunk acquisition/inclusion in fiscal 2023 and the distinction between total growth (27%, $176M) versus organic growth excluding Splunk (15%). (4) The LLM does not properly synthesize the multi-hop information: it should compare fiscal 2022 contribution to fiscal 2023 contribution, showing how ThousandEyes' role evolved, particularly in the context of the Splunk addition. QUANTITATIVE ISSUES: The percentage calculation (14% vs actual 27%) and the failure to distinguish between the $80M fiscal 2022 increase and the $176M fiscal 2023 increase are major errors. The answer conflates two different fiscal years' data. COMPLETENESS: The answer addresses only part of the evolution (fiscal 2022) and fails to properly characterize the fiscal 2023 changes, making it incomplete for a question asking about evolution 'from fiscal 2022 to fiscal 2023.' The answer does correctly identify ThousandEyes as a contributor but fails to contextualize its role relative to the Splunk acquisition.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 429,
        "total_tokens": 1656
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UPS's relationship with the 7.620% Debentures evolved between 2022 and 2024 in terms of their redemption terms and interest payment structure?",
      "original_answer": "In 2022, the 7.620% Debentures had a principal amount of $276 million with a maturity date of April 1, 2030, and were listed with a carrying value of $280 million. By 2024, UPS clarified that these debentures are redeemable at any time at the company's option, with a redemption price equal to the greater of the principal amount plus accrued interest or the present value of remaining scheduled payments discounted at a benchmark treasury yield plus five basis points, plus accrued interest. Additionally, the interest payment structure was specified as semi-annual, payable in April and October. This evolution reflects a shift from a general description of the debentures in 2022 to a more detailed explanation of their redemption flexibility and interest payment schedule in 2024.",
      "llm_answer": "Both the 2022 and 2024 filings describe the $276 million 7.620 % debentures as fully optional‑callable – UPS can redeem any or all of the notes at any time at the greater of (i) principal + accrued interest or (ii) the present value of the remaining scheduled payments discounted at a benchmark Treasury yield + 5 bps – and the notes continue to pay interest semi‑annually in April and October. The 2022 filing notes that the rate was reduced from 8.375 % to 7.620 % on April 1 2020, whereas the 2024 filing simply references the 7.620 % rate without restating that historical cut, indicating that the redemption and payment terms have remained unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains several issues that prevent it from fully matching the ground truth:\n\n1. QUANTITATIVE ACCURACY: The key numbers are correct - $276 million principal, 7.620% rate, April 1, 2030 maturity, semi-annual payments in April and October, and the redemption formula (greater of principal + accrued interest OR present value of remaining payments discounted at benchmark Treasury + 5 bps + accrued interest). The 2020 rate reduction from 8.375% to 7.620% is also correctly mentioned.\n\n2. CRITICAL FACTUAL ERROR - CARRYING VALUE: The ground truth explicitly states the 2022 carrying value was $280 million, which is a material detail showing the debentures were trading at a premium. The LLM answer completely omits this carrying value information, which is a significant omission for understanding the financial position.\n\n3. INTERPRETATION OF 'EVOLUTION': The ground truth characterizes the change between 2022 and 2024 as \"a shift from a general description...to a more detailed explanation\" - suggesting the terms themselves may not have changed but the disclosure became more comprehensive. The LLM answer states \"the redemption and payment terms have remained unchanged,\" which is semantically similar but frames it differently. However, the LLM's interpretation that terms remained unchanged is reasonable given the evidence.\n\n4. COMPLETENESS ISSUE: The LLM answer adds information about the 2020 rate reduction (8.375% to 7.620%) which, while factually correct, wasn't explicitly highlighted in the ground truth as part of the 2022-2024 evolution analysis. This is somewhat tangential to the core question about how the relationship evolved between these two years.\n\n5. MULTI-HOP REASONING: The LLM correctly synthesizes the redemption terms and payment structure across both years, but fails to capture the full picture by omitting the carrying value detail and not emphasizing the shift from general to detailed disclosure as the primary evolution.\n\n6. SEMANTIC EQUIVALENCE: The core redemption formula and payment terms are correctly stated, but the answer misses the nuance that the ground truth emphasizes a disclosure evolution rather than a terms evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 589,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How did the composition and total fair value of Fixed Maturity Securities AFS held by MET evolve from 2022 to 2023, particularly in terms of U.S. government bonds and corporate securities?",
      "original_answer": "In 2022, MET reported a carrying amount of $2,164 million for Fixed Maturity Securities AFS as of December 31, 2021. By 2023, the total estimated fair value of Fixed Maturity Securities AFS had increased significantly to $6,714 million. Specifically, the fair value of corporate securities rose to $3,083 million, with $3,029 million categorized under Level 2, while U.S. government bonds increased to $1,575 million, with $1,537 million under Level 1. This reflects a substantial transformation in both the size and breakdown of these investments over the year.",
      "llm_answer": "In 2022 MET’s Fixed‑Maturity Securities AFS were worth about **$8.06 billion** (pension $6.80 bn + other post‑retirement $1.26 bn) – corporate securities accounted for **≈ $3.21 billion** and U.S. government bonds for **≈ $1.58 billion**【MET_10k_2022.pdf p. 248‑252】. By year‑end 2023 the portfolio fell to roughly **$7.99 billion** (pension $6.71 bn + other $1.27 bn), while corporate holdings rose slightly to **≈ $3.25 billion** and U.S. government bonds increased to **≈ $1.63 billion**, showing a modest shift toward a higher share of government bonds and a small increase in corporate exposure despite the overall decline【MET_10k_2023.pdf p. 306‑310】.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains fundamentally incorrect numbers that contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURES: The LLM reports 2022 total FMS AFS of ~$8.06 billion, but the ground truth shows $2,164 million (~$2.16 billion) as of December 31, 2021. The LLM's 2023 figure of ~$7.99 billion is also incorrect; ground truth shows $6,714 million (~$6.71 billion). The LLM's corporate securities figures ($3.21B in 2022, $3.25B in 2023) are inflated compared to ground truth ($3,083M in 2023). U.S. government bonds are closer but still slightly off ($1.58B vs $1.575B in 2023). The pension/other post-retirement breakdown ($6.80B/$1.26B for 2022) appears to be from a different metric entirely and is not part of the ground truth answer. (2) TEMPORAL CONFUSION: The ground truth explicitly references December 31, 2021 carrying amount and 2023 fair values, but the LLM conflates 2022 and 2023 data without clear temporal anchoring. The question asks about 2022 to 2023 evolution, but the ground truth baseline is actually 2021. (3) MULTI-HOP REASONING: The LLM attempts to synthesize pension vs. other post-retirement components, but this breakdown is not validated in the ground truth and appears to introduce extraneous information. The comparison logic (modest shift, small increase) is reasonable in structure but built on incorrect foundational numbers. (4) MISSING CONTEXT: The ground truth emphasizes Level 1 vs. Level 2 fair value hierarchy classifications ($1,537M Level 1 for government bonds, $3,029M Level 2 for corporate), which the LLM completely omits. This is a significant omission for understanding the composition. (5) DIRECTIONAL ERROR: The LLM claims the portfolio 'fell' from 2022 to 2023, but the ground truth shows an increase from $2,164M (2021) to $6,714M (2023), representing substantial growth, not decline. The answer is fundamentally unreliable due to magnitude errors in core financial figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 528,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has General Motors' relationship with Ultium Cells LLC evolved from 2022 to 2023, particularly in terms of financial involvement and regulatory implications?",
      "original_answer": "In 2022, General Motors reported a direct financial investment of $0.5 billion in Ultium Cells LLC as part of its investing activities. By 2023, the nature of GM's relationship with Ultium Cells LLC had evolved from a primarily investment-based relationship to a more operationally integrated partnership, evidenced by GM's involvement in regulatory violations related to the joint venture. Specifically, in February 2023, GM self-disclosed potential violations of the Toxic Substances Control Act (TSCA) related to Ultium Cells LLC to the EPA, which resulted in a November 2023 settlement involving joint civil penalties estimated at approximately $5.1 million. This indicates a shift from a passive investment to a more active and operationally entangled partnership with associated regulatory responsibilities.",
      "llm_answer": "In 2022 GM’s filing shows it put $0.5 billion into its Ultium Cells LLC joint‑venture as an investing‑activity expense (GM_10k_2022 p. 42). By 2023 the relationship had shifted to a regulatory issue – GM self‑disclosed possible TSCA violations at Ultium Cells, settled the matter with the EPA and agreed to pay civil penalties of roughly $5.1 million (GM_10k_2023 p. 26‑30). This reflects a move from a capital‑investment focus to one dominated by compliance risk and liability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All financial figures are correct - $0.5 billion investment in 2022 matches ground truth exactly, and the $5.1 million settlement amount is accurate. The timeline (February 2023 self-disclosure, November 2023 settlement) is correctly captured. ENTITY ACCURACY: General Motors, Ultium Cells LLC, EPA, and TSCA are all correctly identified. The fiscal years (2022 and 2023) are properly referenced. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and multiple regulatory/financial dimensions: (1) 2022 capital investment activity, (2) 2023 regulatory violation disclosure, (3) EPA settlement outcome. The logical progression from investment to operational entanglement to regulatory liability is sound and matches the ground truth narrative. COMPLETENESS: The answer addresses both parts of the question - financial involvement (investment amounts) and regulatory implications (TSCA violations, EPA settlement, penalties). SEMANTIC EQUIVALENCE: The LLM's characterization of the relationship shift from 'capital-investment focus to compliance risk and liability' is semantically equivalent to the ground truth's 'shift from passive investment to active and operationally entangled partnership with associated regulatory responsibilities.' Minor differences in wording ('investing-activity expense' vs 'investment') are acceptable format variations. The only minor omission is that the ground truth explicitly mentions 'joint civil penalties' while the LLM says 'civil penalties' without the 'joint' descriptor, though this is a very minor semantic distinction that doesn't affect the core accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 471,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has the company's use of variable-priced contracts for natural gas and fuel purchases evolved between 2022 and 2024?",
      "original_answer": "In 2022, the company entered into variable-priced contracts for some purchases of natural gas and fuel for its gas stations on an index basis, though the specific volume or value of these contracts was not disclosed. By 2024, the company continued using variable-priced contracts for similar purchases and explicitly noted that these contracts met the characteristics of derivative instruments but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. This indicates a more formalized or strategic use of variable-priced contracts by 2024, aligning them with accounting frameworks for derivatives, suggesting a shift in how these contracts are managed or accounted for.",
      "llm_answer": "The 2022 filing notes that the company “enters into variable‑priced contracts for some purchases of natural gas, in addition to fuel for its gas stations, on an index basis,” and the 2024 filing repeats the same language with no additional detail or change. Thus, the company’s approach to using index‑based, variable‑priced contracts for natural‑gas and fuel purchases has remained essentially unchanged between 2022 and 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains a critical factual error in its core conclusion. While the LLM correctly identifies that both 2022 and 2024 filings mention variable-priced contracts on an index basis, it concludes the approach 'remained essentially unchanged.' This directly contradicts the ground truth, which identifies a significant evolution: by 2024, the company explicitly noted these contracts met derivative instrument characteristics and qualified for the 'normal purchases and normal sales' exception requiring no mark-to-market adjustment. This represents a more formalized accounting treatment and strategic positioning of these contracts. The LLM failed to capture this important distinction about how the contracts are managed and accounted for. The LLM's statement that the 2024 filing 'repeats the same language with no additional detail or change' is incomplete—the ground truth indicates the 2024 filing added explicit derivative accounting framework language. The quantitative accuracy is reasonable (dates and contract types are correct), but the qualitative reasoning is flawed because the LLM missed the key evolution in how these contracts are characterized and treated from an accounting/strategic perspective. The answer demonstrates incomplete multi-hop synthesis by not identifying the shift in formalization and accounting treatment between the two years, which is the core substance of how the company's use 'evolved.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 398,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has Cisco's financial reporting approach for the APJC segment evolved between fiscal 2022 and fiscal 2023, particularly in terms of the expense categories excluded from segment performance measurement?",
      "original_answer": "Cisco's financial reporting for the APJC segment maintained a consistent exclusion of key expense categories from segment performance measurement in both fiscal 2022 and fiscal 2023. In fiscal 2022, the company explicitly excluded research and development, sales and marketing, and general and administrative expenses from segment financial decisions and resource allocations. This approach remained unchanged in fiscal 2023, with the same categories of expenses—along with amortization and impairment of acquisition-related intangible assets, share-based compensation expense, significant litigation settlements, and charges related to asset impairments and restructurings—not being allocated to the gross margin for each segment. The consistency in exclusions indicates no change in how APJC's performance was internally measured across the two fiscal years.",
      "llm_answer": "Cisco’s segment reporting for APJC has remained essentially unchanged. In both the FY 2022 and FY 2023 10‑Ks the company says it does not allocate research‑and‑development, sales‑and‑marketing, or general‑and‑administrative expenses to any geographic segment, and it also excludes amortization and impairment of acquisition‑related intangibles, share‑based‑compensation expense, significant litigation settlements and other contingencies, asset‑impairment and restructuring charges, and other charges from the gross‑margin measurement of the APJC segment [CSCO_10k_2022.pdf p. 103] [CSCO_10k_2023.pdf p. 102].",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-supported. Strengths: (1) Correctly identifies that Cisco's APJC segment reporting approach remained unchanged between FY2022 and FY2023, matching the ground truth assertion of consistency; (2) Accurately lists all excluded expense categories: R&D, sales and marketing, general and administrative, amortization and impairment of acquisition-related intangibles, share-based compensation, significant litigation settlements, asset impairment and restructuring charges; (3) Properly cites specific page references (p. 103 for 2022, p. 102 for 2023) demonstrating multi-hop synthesis across two fiscal years; (4) Uses appropriate terminology and maintains semantic equivalence with ground truth (e.g., 'not allocate' vs 'excluded'); (5) Correctly identifies the segment as APJC and the company as Cisco. Minor observation: The LLM answer uses slightly more concise phrasing ('essentially unchanged' vs 'maintained consistency') but this is a stylistic choice that doesn't affect factual accuracy. The answer fully addresses the multi-part question about how the reporting approach evolved (or didn't evolve) and specifically addresses the expense categories excluded from segment performance measurement. No numerical errors, calculation errors, or entity misidentifications detected. The multi-hop reasoning correctly synthesizes information across two separate 10-K filings to demonstrate consistency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 400,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UNH's approach to managing medical cost trends evolved from 2022 to 2023, particularly in terms of strategies to address rising outpatient procedure costs for seniors?",
      "original_answer": "In 2022, UNH expressed concern over increased medical care costs due to deferred care during the pandemic and the potential for higher demand for services, especially among individuals with chronic conditions. The company emphasized the importance of accurate cost prediction and effective management under risk-based arrangements. By 2023, UNH specifically identified rising outpatient procedure costs for seniors as a persistent trend, expecting it to continue into 2024 and beyond. In response, the company shifted toward more proactive strategies, such as engaging physicians and consumers with data-driven insights to guide clinical decisions and promote affordable, high-quality care. This represents a shift from general concern in 2022 to targeted intervention in 2023.",
      "llm_answer": "In 2022 UNH mainly relied on traditional cost‑control levers – underwriting criteria, product‑design choices, competitive provider‑contract negotiations and broad care‑management programs – to keep medical‑cost trends in check (2022 10‑K pp. 14‑18). By 2023 the company added a more proactive, engagement‑focused layer: it highlighted the surge in senior outpatient procedures and said it would “mitigate those increases by engaging physicians and consumers with information and helping them make clinically‑sound choices,” using data‑driven, value‑based care tools to curb utilization (2023 10‑K pp. 25‑27).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core narrative of UNH's evolution in medical cost management from 2022 to 2023. STRENGTHS: (1) Correctly identifies the shift from traditional cost-control mechanisms in 2022 (underwriting, product design, provider negotiations, care management) to more proactive engagement strategies in 2023; (2) Accurately captures the specific focus on senior outpatient procedure costs as a key trend identified in 2023; (3) Properly synthesizes the multi-hop information showing the evolution across two years; (4) Correctly references the data-driven, value-based care approach as the new strategy; (5) Appropriately cites 10-K filings with page references, demonstrating source grounding. MINOR WEAKNESSES: (1) The LLM answer provides more granular detail about 2022 strategies (specific levers like underwriting, product design, provider contracts) than the ground truth, which is more general about 2022 concerns; however, this additional specificity is not contradictory and adds value; (2) The ground truth emphasizes 'accurate cost prediction' and 'risk-based arrangements' in 2022, which the LLM answer doesn't explicitly mention, though it's not contradicted; (3) The LLM answer could have been slightly more explicit about the expectation that the trend would continue beyond 2023, though this is implied. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is not directly testable. Page references (pp. 14-18 for 2022, pp. 25-27 for 2023) appear reasonable but cannot be independently verified. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and identifies the causal relationship between identified trends and strategic responses. The logic is sound and well-structured. SEMANTIC EQUIVALENCE: The LLM answer conveys essentially the same information as the ground truth with slightly different emphasis and additional operational detail that enhances rather than detracts from accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 559,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has UPS's approach to time-definite delivery services evolved between 2022 and 2024, particularly in terms of service scope and network integration?",
      "original_answer": "In 2022, UPS emphasized its integrated global air and ground network as the foundation for time-definite delivery services, highlighting its ability to combine all packages within a single network for operational efficiency. By 2024, UPS expanded its time-definite delivery offerings by insourcing the final delivery of non-urgent, lightweight residential shipments previously handled by the USPS through UPS SurePost, giving it greater control over service quality. Additionally, in 2024, UPS offered same-day pickup seven days a week and expanded returns services across approximately 150 countries, reflecting a broader and more customer-centric service scope compared to 2022.",
      "llm_answer": "In 2022 UPS framed its time‑definite offering as a broad portfolio of air and ground services—same‑day, next‑day, two‑day, three‑day, day‑definite ground and UPS SurePost—delivered through a single global smart‑logistics network with roughly 188,000 pickup points (including Access Points, The UPS Store and drop boxes) and a returns program in more than 140 countries. By 2024 the scope had broadened to embed a Digital Access Program and a new Worldwide Economy e‑commerce solution, extend returns to about 150 countries, add air‑cargo options and move to insource SurePost, while still operating a unified global network now reinforced with RFID‑enabled Smart Package facilities and deeper digital integration for more efficient, environmentally‑friendly pickups and deliveries.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of UPS's evolution in time-definite delivery services between 2022 and 2024, with mostly accurate information but some discrepancies and additions that require scrutiny. STRENGTHS: (1) Correctly identifies the 2022 foundation as an integrated global air and ground network with multiple service tiers (same-day, next-day, two-day, three-day, day-definite ground, SurePost). (2) Accurately captures the 2024 shift to insourcing SurePost, which is a key evolution point matching the ground truth. (3) Correctly notes expansion of returns services to approximately 150 countries in 2024. (4) Appropriately emphasizes the unified global network concept across both years. (5) Good synthesis of multi-hop information showing service evolution. WEAKNESSES/CONCERNS: (1) The LLM introduces specific numbers (188,000 pickup points, 140 countries in 2022) that are not mentioned in the ground truth answer. While these may be factually accurate from filings, they represent additions beyond what the ground truth explicitly states, creating potential verification issues. (2) The ground truth emphasizes 'greater control over service quality' as a motivation for SurePost insourcing, while the LLM frames it more operationally without this strategic context. (3) The LLM mentions 'Digital Access Program' and 'Worldwide Economy e-commerce solution' as 2024 additions, which are not in the ground truth answer. These may be accurate but represent scope creep beyond the ground truth framework. (4) The LLM adds details about 'RFID-enabled Smart Package facilities' and 'environmental-friendly' operations that, while potentially accurate, are not in the ground truth. (5) The ground truth specifically mentions 'same-day pickup seven days a week' as a 2024 expansion, which the LLM does not explicitly state (though it mentions same-day service generally). QUANTITATIVE ACCURACY: The numbers provided (188,000 pickup points, 140-150 countries) appear reasonable but cannot be fully verified against ground truth. The country count progression (140 to 150) is directionally consistent with ground truth's 150 countries in 2024. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2024, showing clear evolution in service scope and network integration. The reasoning connecting network infrastructure to service delivery is sound. SEMANTIC EQUIVALENCE: The core message aligns with ground truth - evolution from integrated network foundation to expanded, more customer-centric services with SurePost insourcing - though the LLM provides more operational detail than the ground truth baseline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 704,
        "total_tokens": 2071
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did Lowe's Companies, Inc.'s treatment or recognition of its 2.50% Notes maturing in April 2026 evolve between the 2022 and 2023 annual filings?",
      "original_answer": "In the 2022 filing, the 2.50% Notes maturing in April 2026 were referenced as part of the Thirteenth Supplemental Indenture dated April 20, 2016, but were described in the context of historical documentation. By the 2023 filing, these same notes were explicitly recognized as issued instruments under the same indenture, indicating a shift in disclosure treatment. This reflects a procedural or administrative transition from planning or documentation phase in 2022 to a more active recognition of the notes as part of the company's outstanding debt structure in 2023, even though the core terms (interest rate of 2.50%, maturity in April 2026) remained unchanged.",
      "llm_answer": "In the 2022 Form 10‑K the 2.50 % senior notes due April 2026 were still shown on the balance sheet as a component of long‑term debt (Note 12 – Debt, p. 80 of the 2022 filing). By the 2023 Form 10‑K the company disclosed that it had redeemed the entire issue of those 2.50 % notes in 2023, so the liability no longer appears on the debt schedule (Note 12 – Debt, p. 75 of the 2023 filing).",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth. Key issues: (1) FACTUAL ERROR - The LLM claims the 2.50% Notes were redeemed in 2023, but the ground truth indicates they remained outstanding through April 2026 maturity. The ground truth explicitly states the notes were 'maturing in April 2026' in both 2022 and 2023 filings, not redeemed. (2) MISCHARACTERIZATION OF EVOLUTION - The LLM describes a redemption event that did not occur according to the ground truth. The actual evolution was a shift in disclosure treatment from 'historical documentation' context in 2022 to 'explicit recognition as issued instruments' in 2023, not a redemption. (3) INCORRECT BALANCE SHEET TREATMENT - The LLM states the liability 'no longer appears on the debt schedule' in 2023, but the ground truth indicates the notes were still recognized as outstanding debt in 2023. (4) MISSING CORE INSIGHT - The LLM completely misses the actual point of the question: the procedural/administrative transition in how the notes were disclosed and recognized, not a redemption event. (5) PAGE REFERENCES - While the LLM provides specific page numbers, these appear to be fabricated or misinterpreted, as they don't align with the ground truth narrative. The answer demonstrates a fundamental misunderstanding of the question and provides materially incorrect information about a significant debt transaction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 391,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the impact of sovereign debt crises on Costco's merchandise sourcing and cost structure evolved from 2022 to 2024?",
      "original_answer": "In 2022, sovereign debt crises were mentioned as part of a broader set of macroeconomic factors that could adversely affect demand for Costco's products and services, influence the cost or ability to purchase inventory, and require a change in product mix. The document highlighted that the degree of exposure depended on the type of goods, tariff rates, and timing, with the potential for higher tariffs to impact results. By 2024, the framing had shifted, with sovereign debt crises now explicitly stated to 'negatively impact' Costco's business, financial condition, and results of operations. The 2024 filing emphasized a broader set of supply chain risks, including supplier adherence to standards, supply constraints, and geopolitical instability, suggesting a heightened concern over the cascading effects of sovereign debt crises on both sourcing and cost predictability.",
      "llm_answer": "In the 2022 filing Costco warned that “sovereign debt crises” were among the macro‑economic factors that could “adversely affect demand for our products and services, require a change in product mix, or impact the cost of or ability to purchase inventory” (2022 10‑K, pp. 12‑16). The 2024 filing still lists sovereign‑debt crises as a risk, now grouped with broader fiscal, monetary and tax‑policy uncertainties, but the description is unchanged – they may still affect demand, product mix and the cost or availability of merchandise (2024 10‑K, pp. 13‑17). Thus, the impact has remained a consistent, albeit broader‑framed, macro‑economic risk to Costco’s sourcing and cost structure, with no new specific effect noted beyond the expanded context.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IN CORE CLAIM: The LLM answer fundamentally contradicts the ground truth on the key evolution from 2022 to 2024. The ground truth explicitly states that by 2024, the framing 'had shifted' with sovereign debt crises now 'explicitly stated to negatively impact' Costco's business, and that 2024 emphasized 'heightened concern' with broader supply chain risks. The LLM answer claims 'the description is unchanged' and that there is 'no new specific effect noted beyond the expanded context' - this is directly contrary to the ground truth's assertion of a meaningful shift in language and emphasis from 2022 to 2024. The LLM failed to capture the critical evolution: (1) 2022 framed it as potential/conditional risk ('could adversely affect'), while 2024 used stronger language ('negatively impact'), (2) 2024 added explicit connection to cascading effects on sourcing and cost predictability, (3) 2024 emphasized heightened concern over supplier standards, supply constraints, and geopolitical instability. QUANTITATIVE ACCURACY: Page numbers cited (pp. 12-16 for 2022, pp. 13-17 for 2024) appear reasonable and are not contradicted, though not verified. MULTI-HOP REASONING: The LLM failed to synthesize the temporal evolution correctly - it missed the key insight that the risk characterization intensified from 2022 to 2024, not remained static. The answer demonstrates poor reading comprehension of the ground truth's explicit statement about the 'shift' in framing. SEMANTIC EQUIVALENCE: The LLM's conclusion that risks remained 'consistent' directly contradicts the ground truth's assertion of meaningful evolution and heightened concern. This is not a wording difference but a fundamental factual error about how the risk was characterized differently across the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 487,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the number of shares available for future grants under the 2020 Stock Incentive Plan changed between 2021 and 2023, and what does this indicate about UnitedHealth Group's capacity for issuing new share-based awards?",
      "original_answer": "In 2021, UnitedHealth Group had 64 million shares available for future grants under the 2020 Stock Incentive Plan. By 2023, this number had decreased to 53 million shares. This indicates a reduction in the company's available capacity to issue new share-based awards over this period.",
      "llm_answer": "UnitedHealth’s pool of shares that can be used for future grants under the 2020 Stock Incentive Plan fell from 64 million shares at December 31 2021 to 53 million shares at December 31 2023—a reduction of about 11 million shares (UNH_10k_2022.pdf p.65; UNH_10k_2023.pdf p.70, footnote 3). This decline shows the company has drawn down part of its authorized share‑based award capacity, yet it still retains a substantial reserve of shares for new awards.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. QUANTITATIVE VERIFICATION: All numbers are correct - 64 million shares in 2021, 53 million shares in 2023, and the calculated difference of 11 million shares. The dates (December 31, 2021 and December 31, 2023) are accurate. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) how the number changed between 2021-2023, and (2) what this indicates about UnitedHealth's capacity for issuing new awards. ENTITY ACCURACY: Company name (UnitedHealth Group/UNH), plan name (2020 Stock Incentive Plan), and metrics are all correctly identified. MULTI-HOP REASONING: The answer correctly synthesizes information across two different 10-K filings (2022 and 2023) to compare data from two different fiscal years, demonstrating proper multi-hop synthesis. INTERPRETATION: The LLM provides sound analysis - noting the reduction indicates a drawdown of authorized capacity while acknowledging the company still retains substantial reserves. This interpretation aligns with and slightly expands upon the ground truth answer. MINOR STRENGTHS: The LLM answer includes specific document citations (page numbers and footnote references), which adds credibility and traceability. The phrasing 'drawn down part of its authorized share-based award capacity' is semantically equivalent to and slightly more detailed than the ground truth's 'reduction in available capacity.' No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 404,
        "total_tokens": 1608
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the expiration date and contribution significance of the IAM National Pension Fund / National Pension Plan relationship with UPS evolve between 2022 and 2024?",
      "original_answer": "In 2022, the IAM National Pension Fund / National Pension Plan had a collective bargaining agreement expiration date of July 31, 2024, and UPS had contributed more than 5% of the total plan contributions from all employers for the years 2019 through 2021. By 2024, the expiration date for this specific plan was extended to July 31, 2029, and UPS continued to be a significant contributor, providing more than 5% of total contributions for the plan years 2022 through 2024. This indicates a notable extension in the contractual relationship and sustained significance of UPS's contributions over time.",
      "llm_answer": "- In the 2022 Form 10‑K UPS said the collective‑bargaining agreement that governs its participation in the I.A.M. National Pension Fund/National Pension Plan expires on **July 31 2024**, and UPS “provided more than 5 % of the total plan contributions” (the plan contribution was $48 million in 2021)【UPS_10k_2022.pdf page 112‑113】.  \n\n- In the 2024 Form 10‑K the same agreement was extended to **July 31 2029**, and UPS continued to be a major contributor—still over 5 % of total contributions—raising its annual contribution to **$53 million in 2024** (up from $48 million in 2022)【UPS_10k_2024.pdf page 96‑98】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. STRENGTHS: (1) All key dates are correct - July 31, 2024 expiration in 2022 filing and July 31, 2029 in 2024 filing match the ground truth exactly. (2) The >5% contribution threshold is correctly identified for both periods (2019-2021 and 2022-2024). (3) The specific dollar amounts ($48 million in 2021/2022 and $53 million in 2024) are provided with appropriate context showing the contribution increase over time. (4) Multi-hop synthesis is sound - the answer correctly traces the evolution of the relationship across two different 10-K filings and identifies both the extension of the agreement and the sustained significance of UPS contributions. (5) The answer directly addresses all parts of the question: expiration date evolution (2024→2029) and contribution significance evolution (>5% maintained across both periods). (6) Entity identification is accurate (IAM National Pension Fund/National Pension Plan, UPS, correct fiscal years). MINOR CONSIDERATIONS: The LLM provides additional quantitative detail (specific contribution amounts) beyond what the ground truth explicitly states, but this is supplementary information that enhances rather than contradicts the answer. The ground truth focuses on the >5% threshold and dates, while the LLM adds the specific dollar figures, which is appropriate context. The reasoning clearly demonstrates understanding that this represents both a contractual extension and sustained contribution significance. No calculation errors detected. All dates, percentages, and dollar amounts are factually accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 441,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the terms and availability under LOW's 2020 Credit Agreement evolve between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the 2020 Credit Agreement had a maturity date of March 2025 and provided $2.0 billion in availability. By fiscal year 2023, the 2020 Credit Agreement was amended and restated in September 2023 into the 2023 Credit Agreement, which extended the maturity date to September 2028 while maintaining the same $2.0 billion availability. Additionally, in 2023, the combined availability under both the 2023 Credit Agreement and the Third Amended and Restated Credit Agreement remained at $4.0 billion, consistent with the total availability reported in 2022.",
      "llm_answer": "In the FY 2022 filing the five‑year unsecured revolving facility dated March 23 2020 (the 2020 Credit Agreement) had been amended in December 2021 to raise its borrowing limit to **$2.0 billion**, extend its maturity to **March 2025**, and set interest at a Base Rate or Eurocurrency Rate + margin; the Company could increase the combined availability of this agreement and the Third Amended and Restated Credit Agreement by an additional $1.0 billion, leaving **total combined availability at $4.0 billion** (see 2022 10‑K pp. 58‑62).  \n\nBy FY 2023 the 2020 Credit Agreement was restated again (the 2023 Credit Agreement) to **extend the term to September 2028** while keeping the **$2.0 billion** availability, and the combined aggregate availability of the 2023 and Third Amended and Restated Credit Agreements remained **$4.0 billion**, still subject to a $1.0 billion incremental increase (see 2023 10‑K pp. 56‑60).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All key facts are correct: (1) FY 2022: 2020 Credit Agreement had $2.0 billion availability and March 2025 maturity date; (2) FY 2023: Agreement was restated into 2023 Credit Agreement with September 2028 maturity while maintaining $2.0 billion availability; (3) Combined availability remained $4.0 billion in both years with $1.0 billion incremental increase option. The multi-hop synthesis is sound - the answer correctly traces the evolution of the credit agreement across two fiscal years and identifies the key amendment (September 2023 restatement). All numeric values are accurate ($2.0B, $4.0B, $1.0B), dates are correct (March 2025 → September 2028), and the answer properly contextualizes the relationship between the 2020/2023 Credit Agreement and the Third Amended and Restated Credit Agreement. The inclusion of specific 10-K page references adds credibility. Minor note: The answer provides additional context about the December 2021 amendment and interest rate terms, which while not explicitly required by the question, demonstrates thorough understanding and does not detract from accuracy. The answer fully addresses the evolution question by clearly delineating the 2022 state versus 2023 state.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 356,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did MDLZ's use of Net Investment Hedge Derivative Contracts evolve between 2022 and 2024, particularly in terms of their notional amounts?",
      "original_answer": "In 2022, MDLZ reported a notional amount of $3,915 million for Net Investment Hedge Derivative Contracts as of December 31, 2021, and $4,551 million as of December 31, 2020. By 2024, the notional amount for these contracts had increased significantly to $8,647 million as of December 31, 2024, up from $7,456 million in 2023. This indicates a growing reliance on such contracts over the two-year period.",
      "llm_answer": "MDLZ’s net‑investment‑hedge derivative contracts expanded dramatically – the 2022 10‑K shows a notional amount of roughly $3.9 billion (≈$3,915 million) for these contracts, while the 2024 10‑K reports the aggregate notional value at $8.6 billion (≈$8,647 million) as of 31 Dec 2024. In other words, the notional exposure more than doubled between 2022 and 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the key notional amounts for MDLZ's Net Investment Hedge Derivative Contracts and accurately captures the evolution between 2022 and 2024. Strengths: (1) The 2022 figure of $3,915 million is correct, (2) The 2024 figure of $8,647 million is correct, (3) The characterization of 'more than doubled' is mathematically accurate (8,647/3,915 ≈ 2.21x), (4) Number formatting is appropriately flexible ($3.9 billion ≈ $3,915 million), (5) The answer correctly identifies the company (MDLZ) and metric (Net Investment Hedge Derivative Contracts). Weaknesses: (1) The LLM answer omits intermediate year data (2023: $7,456 million) that was included in the ground truth, which provides important context for understanding the evolution trajectory, (2) The answer focuses only on 2022 and 2024 endpoints rather than showing the full progression across the period, (3) The ground truth also mentions 2020 data ($4,551 million) which provides additional historical context, though this is less critical since the question specifically asks about 2022-2024. The core factual accuracy is strong, but the answer is somewhat incomplete in not presenting the full year-by-year evolution that the ground truth provides. The multi-hop reasoning is sound - correctly synthesizing data from two different 10-K filings and making an appropriate comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1190,
        "completion_tokens": 381,
        "total_tokens": 1571
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Microsoft 365's integration with AI technologies evolved between 2022 and 2024, and what specific new capabilities were introduced in 2024 to enhance its role in productivity and collaboration?",
      "original_answer": "In 2022, Microsoft 365 was described as integrating Office 365, Windows, and Enterprise Mobility + Security with AI-backed tools to empower employees, focusing on creativity, collaboration, and innovation. By 2024, Microsoft 365 had evolved into an 'AI first platform,' introducing Copilot for Microsoft 365, which combines AI with business data from the Microsoft Graph and Microsoft 365 applications. Additionally, role-specific extensions such as Copilot for Sales, Copilot for Service, and Copilot for Finance were introduced to streamline business processes. These developments reflect a significant enhancement in AI integration aimed at delivering more personalized and intelligent productivity tools.",
      "llm_answer": "In the 2022 filing Microsoft 365 was presented as a bundle of Office 365, Windows and Enterprise Mobility + Security that “empowers their employees with AI‑backed tools that unlock creativity, increase collaboration, and fuel innovation” and relied on AI‑enhanced Teams, Viva and Power Platform for productivity. By the 2024 filing the suite had become an “AI‑first” platform that embeds Copilot throughout Microsoft 365—Copilot for Microsoft 365 draws on the Microsoft Graph, role‑specific extensions such as Copilot for Sales, Service and Finance, a Copilot Studio for customers to customize or build their own assistants, and a consumer‑focused Copilot Pro subscription—adding new AI‑driven capabilities that sharpen its productivity and collaboration role.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the 2022 positioning of Microsoft 365 as integrating Office 365, Windows, and Enterprise Mobility + Security with AI-backed tools for creativity, collaboration, and innovation. (2) Accurately captures the 2024 evolution to an 'AI-first' platform. (3) Correctly identifies Copilot for Microsoft 365 as the key 2024 innovation. (4) Properly mentions the Microsoft Graph as the data foundation. (5) Accurately lists role-specific extensions (Copilot for Sales, Service, Finance). (6) Includes additional relevant details from 2024 filings (Copilot Studio, Copilot Pro subscription) that enhance the answer without contradicting ground truth. (7) Multi-hop synthesis is sound—correctly traces evolution from 2022 to 2024 across multiple product components. (8) No numerical errors or date inaccuracies. MINOR CONSIDERATIONS: The LLM answer includes Copilot Studio and Copilot Pro subscription, which are not explicitly mentioned in the ground truth but are factually accurate 2024 additions that strengthen rather than contradict the answer. The ground truth focuses on core capabilities while the LLM provides slightly more comprehensive coverage. The semantic equivalence is excellent—both answers convey the same fundamental narrative of AI integration evolution. The answer directly addresses all parts of the multi-part question: (1) how integration evolved between 2022-2024, (2) what specific new capabilities were introduced in 2024, and (3) how these enhance productivity and collaboration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 444,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has 3M's approach to PFAS discharge characterization in its wastewater permits evolved between its Decatur, Alabama facility disclosures in 2022 and 2024?",
      "original_answer": "In 2022, 3M disclosed that it had not fully characterized its PFAS discharge in its NPDES permit for the Decatur facility and had submitted an application to ADEM to add additional PFAS to the permit. By 2024, the Company had installed and was upgrading wastewater treatment controls specifically designed to address PFAS at the Decatur facility, and the controls were being optimized, though ADEM had not yet acted on the permit modification request. This evolution shows a shift from identifying the issue and initiating corrective actions to implementing and refining treatment solutions while awaiting regulatory approval.",
      "llm_answer": "In the 2022 10‑K (pages 125‑129) 3M disclosed that it had learned its Decatur, Al NPDES permit did not fully characterize PFAS discharges, had filed an application with ADEM to add the missing PFAS, installed additional wastewater‑treatment controls and entered an interim consent order that required ongoing analytical studies, reporting and capital‑improvement commitments for all PFAS‑related discharges. By the 2024 10‑K (pages 99‑103) the company reported that a dedicated PFAS‑treatment system is now on‑line and being optimized, while the permit‑amendment request remains pending with ADEM, showing a shift from a broader consent‑order remediation framework to an operational focus on treatment and continued permit‑characterization efforts.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive understanding of 3M's PFAS disclosure evolution. STRENGTHS: (1) Correctly identifies the 2022 status: uncharacterized PFAS in NPDES permit, ADEM application filed, and interim consent order with analytical/reporting requirements. (2) Accurately describes 2024 status: dedicated PFAS treatment system operational and being optimized, permit amendment still pending. (3) Properly cites specific 10-K page ranges (2022: pages 125-129; 2024: pages 99-103), demonstrating document verification. (4) Correctly synthesizes the multi-hop evolution showing progression from problem identification/consent order framework to operational treatment implementation. (5) All entities correctly identified (3M, Decatur Alabama, NPDES, ADEM). (6) Dates are accurate (2022 vs 2024). MINOR CONSIDERATIONS: (1) The LLM answer adds detail about 'interim consent order' and 'capital-improvement commitments' not explicitly mentioned in the ground truth, though these appear consistent with typical PFAS remediation frameworks and enhance rather than contradict the answer. (2) The characterization of the shift as moving 'from broader consent-order remediation framework to operational focus' is a reasonable interpretation that aligns with the ground truth's 'shift from identifying the issue and initiating corrective actions to implementing and refining treatment solutions.' (3) No quantitative errors detected - all dates, facility names, and regulatory references are accurate. The answer successfully demonstrates multi-hop reasoning by synthesizing information across two separate 10-K filings and showing the temporal evolution of 3M's approach. The semantic meaning matches the ground truth while providing slightly more operational detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 488,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Lowe's Companies, Inc.'s issuance of the 4.550% Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 4.550% Notes were first introduced in the Fifteenth Supplemental Indenture dated April 5, 2019, and were due April 5, 2049. In 2023, the same 4.550% Notes continued to be referenced under the same Fifteenth Supplemental Indenture, with no changes to the terms or maturity date. Therefore, while the 4.550% Notes were still in effect in 2023, there was no modification or new issuance related to this specific instrument during that year.",
      "llm_answer": "Lowe’s only reference to the 4.550 % notes in both filings is the **Fifteenth Supplemental Indenture dated April 5, 2019**, which created “4.550 % Notes due April 5, 2049” (exhibit 4.16) 【LOW_10k_2022.pdf p.79‑83】【LOW_10k_2023.pdf p.74‑78】.  No additional 4.550 % notes appear in the 2022 or 2023 supplemental indentures, indicating that the series issued in 2019 remained outstanding and there was no new issuance of 4.550 % notes between 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-supported. Verification of key facts: (1) The Fifteenth Supplemental Indenture date of April 5, 2019 is correct. (2) The maturity date of April 5, 2049 is correct. (3) The interest rate of 4.550% is correct. (4) The conclusion that no new issuance occurred between 2022 and 2023 is correct. The LLM answer provides the same core information as the ground truth but with additional supporting detail (specific exhibit references and page numbers from both 2022 and 2023 10-K filings). The multi-hop reasoning is sound: the model correctly synthesized information across both 2022 and 2023 filings to demonstrate continuity and absence of new issuance. The answer is more detailed than the ground truth, explicitly noting that no additional 4.550% notes appear in supplemental indentures, which strengthens the conclusion. All numeric values (dates, percentages) are accurate with no calculation errors. The only minor distinction is that the LLM answer is slightly more explicit about the methodology (checking supplemental indentures) compared to the ground truth's more general statement, but this represents enhanced clarity rather than any factual discrepancy. The semantic meaning is fully equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 356,
        "total_tokens": 1568
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MDLZ's financial relationship with KDP evolve between 2022 and 2024, particularly in terms of gains recognized from changes in accounting for the investment?",
      "original_answer": "In 2022, MDLZ recognized a pre-tax gain of $71 million (or $54 million after-tax) during the first quarter related to the sale of KDP shares, which reduced its ownership interest. By 2024, the company recorded a significantly larger pre-tax gain of $493 million ($368 million after-tax) due to a change in accounting for its investment in KDP. This indicates a substantial evolution in the financial impact of MDLZ's relationship with KDP over the two-year period.",
      "llm_answer": "By 2022 Mondelēz still accounted for its Keurig Dr Pepper (KDP) stake under the equity‑method, reporting only the usual equity earnings and dividends and no gain from a change in accounting 【MDLZ_10k_2022.pdf†p102‑p106】.  In early 2023 the ownership fell below the 5 % threshold, so the investment was re‑classified to marketable‑securities accounting; after selling the remaining shares, Mondelēz recorded a pre‑tax gain of $593 million (total $606 million including dividend income) – the gain reflecting the difference between the sale proceeds and the carrying value at the date of the accounting change (the prior period had a $493 million pre‑tax gain on equity‑method transactions) 【MDLZ_10k_2024.pdf†p87‑p91】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant numerical inaccuracies that contradict the ground truth. (1) QUANTITATIVE ERRORS: The LLM claims a pre-tax gain of $593 million in 2023/2024, but the ground truth specifies $493 million pre-tax ($368 million after-tax) for 2024. The LLM also mentions a '$493 million pre-tax gain on equity-method transactions' in the prior period, which appears to confuse the timeline and amounts. The ground truth clearly states 2022 had a $71 million pre-tax gain ($54 million after-tax), not $493 million. (2) TIMELINE CONFUSION: The LLM conflates 2023 and 2024 events, stating the ownership fell below 5% 'in early 2023' and then discusses 2024 filing data, creating ambiguity about when events occurred. The ground truth clearly delineates 2022 vs 2024. (3) INCOMPLETE COMPARISON: While the LLM attempts to explain the accounting change mechanism (equity-method to marketable securities), it fails to properly compare the 2022 and 2024 gains as requested. The ground truth shows evolution from $71M (2022) to $493M (2024), but the LLM presents $593M as the primary 2024 figure, which is incorrect. (4) MULTI-HOP REASONING: The LLM does attempt to synthesize information across years and explain the accounting change, but the fundamental numerical errors undermine the analysis. The mention of dividend income ($606M total) adds information not in the ground truth and may represent a different metric or misinterpretation. (5) ENTITY ACCURACY: Company names and metrics are correctly identified (MDLZ, KDP, equity-method, marketable securities), but the financial figures are materially wrong, which is the core of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 458,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has the scale and positioning of Xbox Game Pass evolved between 2022 and 2024, based on the number of titles available and Microsoft's strategic emphasis?",
      "original_answer": "In 2022, Xbox Game Pass offered access to a curated library of over 100 first- and third-party titles, and was positioned as a key part of Microsoft's broader gaming strategy focused on content, community, and cloud services. By 2024, the service had expanded significantly, offering access to over 400 first- and third-party titles, and was described as the 'cornerstone' of Microsoft's gaming platform, reflecting a stronger strategic emphasis on subscriptions and community growth. This indicates a significant transformation in both scale and strategic importance.",
      "llm_answer": "In the 2022 filing Microsoft described Xbox Game Pass as “a community with access to a curated library of **over 100** first‑ and third‑party console and PC titles”【2022 10‑K p. 4】. By the 2024 filing the service is portrayed as “the cornerstone of Xbox Game Pass… with access to a curated library of **over 400** first‑ and third‑party console and PC titles,” and the company stresses that Game Pass is now a core subscription‑driven platform that fuels broader ecosystem growth and cross‑device engagement【2024 10‑K p. 13】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. (1) QUANTITATIVE VERIFICATION: All numbers are correct - 2022 filing shows 'over 100' titles and 2024 filing shows 'over 400' titles. Both figures match the ground truth exactly. (2) ENTITY ACCURACY: Correctly identifies Microsoft, Xbox Game Pass, and the appropriate fiscal years (2022 and 2024). Properly distinguishes between console and PC titles. (3) MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across two different 10-K filings, comparing the evolution of the service. It correctly identifies the progression from 100+ to 400+ titles. (4) STRATEGIC POSITIONING: The LLM captures the shift in strategic emphasis - from 'a community with access to a curated library' (2022) to 'the cornerstone' (2024). This semantic distinction is accurate and reflects the ground truth's characterization of 'stronger strategic emphasis.' (5) MINOR OBSERVATION: The LLM answer includes specific page references (2022 10-K p. 4 and 2024 10-K p. 13) which adds credibility and traceability, though these weren't in the ground truth. The phrasing 'cornerstone of Xbox Game Pass' in the LLM answer appears to be a slight paraphrase of 'cornerstone of Microsoft's gaming platform' from the ground truth, but the meaning is semantically equivalent and captures the core strategic importance. The answer fully addresses all aspects of the question regarding scale evolution and strategic positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 407,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the structure or disclosure of Deferred Stock Unit Award Agreements for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan evolved from 2022 to 2024, based on the referenced filings?",
      "original_answer": "The Deferred Stock Unit Award Agreement for non-employee directors was first referenced in the 2022 10-K filing as part of the 3M Company 2016 Long-Term Incentive Plan, applicable to grants on or after January 1, 2019. By 2024, the agreement continued to be disclosed in the 10-K filing, still referencing grants on or after January 1, 2019, indicating no change in the effective date or structure of the agreement over this period. However, the 2024 disclosure reflects an updated incorporation by reference from the 2023 10-K, showing the ongoing maintenance of the plan through amendments as of May 8, 2023.",
      "llm_answer": "The 2022 Form 10‑K only incorporated the Deferred Stock Unit Award Agreement for non‑employee directors (units granted on or after 1 Jan 2019 under the 2016 Long‑Term Incentive Plan) as an exhibit and did not show a separate quantitative line‑item for those units【MMM_10k_2022.pdf†p.129‑133】. In the 2024 Form 10‑K the same agreement is still incorporated (now listed as Exhibit 10.7) but the company now discloses the amount of the award – 230 deferred‑stock units for non‑employee directors – in the equity‑compensation table, providing a more explicit disclosure while the underlying award structure remains unchanged【MMM_10k_2024.pdf†p.115‑119】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and misalignments with the ground truth. CRITICAL ISSUES: (1) The LLM claims the 2024 disclosure now shows '230 deferred-stock units for non-employee directors' in an equity-compensation table, but the ground truth makes no mention of this specific number or a new quantitative disclosure in 2024. This appears to be a fabricated detail not supported by the ground truth. (2) The LLM states the 2022 10-K 'did not show a separate quantitative line-item' but then claims 2024 'now discloses the amount' - this represents a claimed evolution that contradicts the ground truth, which explicitly states 'no change in the effective date or structure of the agreement over this period.' (3) The LLM correctly identifies the agreement applies to grants on or after January 1, 2019 and references the 2016 Long-Term Incentive Plan, which aligns with ground truth. (4) The LLM correctly notes the agreement is incorporated as an exhibit in both years. HOWEVER, the core claim about evolution from 2022 to 2024 is fundamentally wrong - the ground truth indicates continuity and no structural change, while the LLM suggests a material change in disclosure practices (adding quantitative data). The specific number '230 deferred-stock units' cannot be verified against the ground truth and appears to be an unsupported claim. The LLM also mentions the 2024 disclosure reflects 'updated incorporation by reference from the 2023 10-K' which aligns with ground truth mentioning 'amendments as of May 8, 2023,' but this is presented as part of a false narrative about changing disclosure. The answer demonstrates partial understanding of the document structure but fails on the fundamental question of whether/how the disclosure evolved, providing incorrect information about quantitative changes that the ground truth explicitly denies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 507,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the composition of Charles Schwab Bank's First Mortgages and HELOCs portfolio evolved between 2023 and 2024, particularly in terms of origination costs and geographic concentration in California?",
      "original_answer": "In 2023, the First Mortgages and HELOCs portfolio included $100 million in unamortized premiums, discounts, and direct origination costs, with 43% of the portfolio concentrated in California. By 2024, these costs increased to $112 million, while the California concentration slightly decreased to 42%. This indicates a slight shift in geographic risk exposure and an increase in loan origination activity or associated costs over the year.",
      "llm_answer": "Between year‑end 2023 and year‑end 2024, Schwab’s First‑Mortgage and HELOC portfolio saw its unamortized premiums, discounts and direct origination costs increase from roughly $100 million to about $112 million.  The share of those loans concentrated in California fell modestly, from 43 % of the portfolio in 2023 to about 42 % in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. All quantitative data is correct: unamortized premiums, discounts, and direct origination costs increased from $100 million (2023) to $112 million (2024), and California concentration decreased from 43% to 42%. The multi-hop synthesis is sound, correctly combining information about both origination costs and geographic concentration across the two years. The answer accurately identifies the entity (Charles Schwab Bank's First Mortgages and HELOCs portfolio), the correct time periods (2023 and 2024), and the relevant metrics. The reasoning is logical and the conclusion about 'slight shift in geographic risk exposure' aligns with the ground truth interpretation. Minor deviations from the original answer are purely stylistic (e.g., 'roughly $100 million' vs '$100 million', 'about 42%' vs '42%', 'Schwab' vs 'Charles Schwab Bank') and represent acceptable semantic equivalence. The answer fully addresses all components of the multi-part question regarding composition evolution, origination costs, and geographic concentration. No calculation errors or factual inaccuracies are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 328,
        "total_tokens": 1536
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Nike's strategic emphasis on the Dri-FIT technology evolved between fiscal 2023 and fiscal 2024, based on the language in Nike's product research and development sections?",
      "original_answer": "Nike's strategic emphasis on the Dri-FIT technology remained stable between fiscal 2023 and fiscal 2024. In both years, Dri-FIT was listed among key technologies such as Nike Air, Zoom, Free, Flyknit, FlyEase, ZoomX, Air Max, and React, indicating consistent strategic importance. The exact same language was used in both the 2023 and 2024 10-K filings, showing no change in the description or emphasis of Dri-FIT's role in Nike’s innovation strategy.",
      "llm_answer": "In the FY 2023 filing, Nike’s product‑research narrative already singled out Dri‑FIT as one of its core performance fabrics, listing it alongside Air, Zoom, Flyknit and other breakthrough technologies. The FY 2024 filing repeats that same language—“the proliferation of Nike Air, Zoom, Free, **Dri‑FIT**, Flyknit, FlyEase, Zoom X, Air Max and React technologies…”—indicating that Nike’s strategic focus on Dri‑FIT has remained steady, continuing to be treated as a key, ongoing innovation rather than a newly‑elevated or de‑emphasized priority.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and effectively addresses the question. Correctness verification: (1) The core finding is correct—Nike's strategic emphasis on Dri-FIT remained stable between FY2023 and FY2024, with identical language used in both filings. (2) The LLM correctly identifies that Dri-FIT was listed among the same key technologies in both years (Air, Zoom, Free, Flyknit, FlyEase, ZoomX, Air Max, React). (3) The LLM accurately quotes the FY2024 language showing the consistent treatment of Dri-FIT. (4) The reasoning is sound—the LLM correctly synthesizes that the repetition of identical language indicates no change in strategic emphasis, neither elevation nor de-emphasis. Multi-hop synthesis: The answer successfully compares the two fiscal years' R&D sections and draws the appropriate conclusion about consistency. Entity accuracy: Correct company (Nike), correct fiscal years (2023 and 2024), correct technology names. The only minor observation is that the LLM answer provides slightly more interpretive context (e.g., 'continuing to be treated as a key, ongoing innovation rather than a newly-elevated or de-emphasized priority') which adds helpful nuance beyond the ground truth but remains factually accurate. The answer demonstrates strong understanding of the question's multi-hop nature and provides clear evidence supporting the conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 382,
        "total_tokens": 1639
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Mondelez International's investment in backup and disaster recovery evolved from 2022 to 2024, particularly in response to increasing cybersecurity threats?",
      "original_answer": "In 2022, Mondelez was on heightened alert regarding cybersecurity risks, dedicating focused resources to backup and disaster recovery as part of its response to increased global cybersecurity threats, especially during the pandemic. By 2024, the company significantly expanded its efforts, explicitly stating that it continues to invest and augment its cybersecurity program with enhanced backup and disaster recovery solutions, among other measures, to address increasingly sophisticated threats including those from state-sponsored actors and emerging technologies like artificial intelligence.",
      "llm_answer": "In the 2022 filing, Mondelez noted that “global cybersecurity risks continue to increase… in response, we continue to be on heightened alert and dedicate focused resources to network security, **backup and disaster recovery**” (2022 10‑K, p. 43‑47). By the 2024 filing, the company says it has “**continued to invest and augment** our cybersecurity program… including **backup and disaster recovery** along with enhanced identity‑and‑access management, multi‑factor authentication, privileged‑access management and 24/7 security operations” (2024 10‑K, p. 18‑22). Thus, the investment has moved from an initial focus on allocating resources for backup and recovery to a broader, deeper commitment that integrates those capabilities into a more sophisticated, continuously‑enhanced cyber‑resilience framework.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effective multi-hop synthesis across 2022 and 2024 filings. STRENGTHS: (1) Correctly identifies the evolution from 2022 'heightened alert' and 'focused resources' to 2024 'continued to invest and augment' - accurately capturing the progression; (2) Properly cites backup and disaster recovery as a consistent priority across both years; (3) Accurately notes the expansion of the cybersecurity program to include additional measures (identity-and-access management, multi-factor authentication, privileged-access management, 24/7 security operations) in 2024; (4) Provides specific page references (2022 10-K p. 43-47, 2024 10-K p. 18-22) that ground the answer in source material; (5) Synthesizes the multi-hop information effectively by showing progression from initial resource allocation to integrated cyber-resilience framework. MINOR WEAKNESSES: (1) The original ground truth explicitly mentions 'state-sponsored actors and emerging technologies like artificial intelligence' as threats driving 2024 investments, but the LLM answer does not include these specific threat vectors - this is a notable omission of contextual detail; (2) The original answer emphasizes pandemic-related context for 2022, which the LLM answer does not mention. QUANTITATIVE ACCURACY: No numerical data is present in either answer, so this dimension is not directly testable. The dates (2022, 2024) are correct. MULTI-HOP REASONING: The answer successfully synthesizes information across two different years and filing documents, correctly identifying the progression and relationship between the two time periods. The logical flow from 'heightened alert/focused resources' to 'continued investment/augmented program' is sound and well-reasoned. SEMANTIC EQUIVALENCE: The LLM answer conveys the core message of the ground truth - that Mondelez's backup and disaster recovery investment has evolved and expanded - though it misses some specific threat context details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 540,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Microsoft's financial commitment and engagement with Black and African American-owned suppliers evolved from fiscal year 2022 to fiscal year 2024?",
      "original_answer": "In fiscal year 2022, Microsoft reported that it had enriched its supplier pipeline, reaching more than 90% of its goal to spend $500 million with double the number of Black and African American-owned suppliers. By fiscal year 2024, Microsoft had not only achieved its $500 million spending goal but also expanded its financial commitments by allocating $150 million to Minority Depository Institutions and funds supporting Black and African American-owned small businesses. This evolution indicates a deepening of Microsoft's strategic focus on supplier diversity and community economic development over time.",
      "llm_answer": "In fiscal 2022 Microsoft said it had “reached more than 90 percent of our goal to spend $500 million with double the number of Black‑ and African‑American‑owned suppliers.” By fiscal 2024 the filing reports that the company “achieved our goal to spend $500 million with double the number of Black‑ and African‑American‑owned suppliers,” indicating it moved from near‑target to fully meeting its spend commitment while also expanding its overall financial support (e.g., a $150 million commitment to minority depository institutions).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and effectively addresses the multi-hop question about Microsoft's evolution in supplier diversity commitments from FY2022 to FY2024. QUANTITATIVE VERIFICATION: All numbers are correct - the 90% achievement toward $500M goal in FY2022, the full achievement of $500M goal in FY2024, and the $150M commitment to minority depository institutions are all accurately stated. The fiscal years (2022 and 2024) are correctly identified. COMPLETENESS: The answer addresses the core evolution question by showing progression from 'more than 90 percent' to 'achieved our goal,' demonstrating the multi-hop synthesis across two fiscal years. The answer includes the additional $150M commitment, showing expanded financial commitments beyond the original $500M goal. ENTITY ACCURACY: Microsoft is correctly identified, fiscal years are accurate, and the financial metrics (supplier spending, minority depository institutions) are properly characterized. REASONING QUALITY: The multi-hop reasoning is sound - the model correctly synthesized information showing: (1) FY2022 status (near-target), (2) FY2024 status (goal achieved), and (3) expanded commitments (additional $150M). The logical progression from 'near-target' to 'fully meeting' to 'expanding' is clear and accurate. MINOR CONSIDERATIONS: The LLM answer uses direct quotes from filings (indicated by quotation marks), which adds credibility. The phrase 'expanding its overall financial support' is slightly less specific than the ground truth's 'deepening of Microsoft's strategic focus on supplier diversity and community economic development,' but this is a minor semantic difference that doesn't affect factual accuracy. The answer is well-structured and directly responsive to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 485,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the availability of common shares for future issuance under the Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees evolved from 2022 to 2023, and what does this indicate about Abbott's stock-based incentive strategy?",
      "original_answer": "In 2022, as of December 31, 2021, an aggregate of 10,638,639 common shares were available for future issuance under the Employee Stock Purchase Plan. In 2023, as of December 31, 2023, this number had decreased to 8,565,087 common shares. This indicates a reduction in the number of shares available for future issuance, suggesting a potential tightening or adjustment in Abbott's stock-based incentive strategy for non-U.S. employees.",
      "llm_answer": "The 2022 Form 10‑K notes that, as of December 31 2021, Abbott had **10,638,639** common shares available for future issuance under the Employee Stock Purchase Plan for Non‑U.S. Employees. The 2023 Form 10‑K reports that this pool had fallen to **8,565,087** shares as of December 31 2023—a drop of roughly 2.1 million shares. The reduction shows Abbott is drawing down the plan’s share reserve, indicating active employee participation while deliberately curbing additional equity dilution in its stock‑based incentive program.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: Both key figures are correct—10,638,639 shares as of December 31, 2021 (from 2022 10-K) and 8,565,087 shares as of December 31, 2023 (from 2023 10-K). The calculated difference of approximately 2.1 million shares is accurate (10,638,639 - 8,565,087 = 2,073,552, which rounds to ~2.1 million). ENTITY ACCURACY: All entities correctly identified—Abbott Laboratories, Employee Stock Purchase Plan for Non-U.S. Employees, correct fiscal years and dates. MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across two different 10-K filings (2022 and 2023) to show the evolution over time. REASONING QUALITY: The interpretation that the reduction indicates 'active employee participation while deliberately curbing additional equity dilution' is a reasonable inference from the data, though slightly more interpretive than the ground truth's more neutral statement about 'tightening or adjustment.' The LLM provides additional analytical insight by explicitly noting the share count reduction and its implications. MINOR DIFFERENCES: The ground truth uses slightly more cautious language ('potential tightening'), while the LLM is more definitive ('deliberately curbing'). However, both convey the same essential finding that the reduction reflects a strategic adjustment. The LLM answer is more detailed and provides better context for understanding the implications of the share reduction. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 420,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Nike's treatment of Nike Air technology evolved in its product development strategy between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal 2023, Nike Air was described as part of a list of technologies that 'typifies our dedication to designing innovative products,' indicating it was still being actively proliferated across product lines. By fiscal 2024, Nike Air was again listed among key technologies, but now embedded alongside mature technologies like Zoom, Free, and React, suggesting that Nike Air had become a standard component of Nike’s broader innovation platform rather than a distinct growth driver. This reflects a strategic shift from emphasizing Nike Air as an emerging innovation to treating it as an integrated, foundational offering within Nike’s product development framework.",
      "llm_answer": "In FY 2023 Nike said that Nike Air was part of a “proliferation of Nike Air, Zoom, Free, Dri‑FIT, Flyknit, FlyEase, Zoom X, Air Max and React technologies” that underpins its product‑innovation agenda, and that Air‑Sole cushioning components were supplied by its wholly‑owned Air Manufacturing Innovation subsidiary. The FY 2024 filing repeats the same language—still listing Nike Air among its core technologies and continuing to source Air‑Sole parts from Air Manufacturing Innovation—indicating that Nike’s treatment of Nike Air has remained consistent, with no major strategic shift between the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains a fundamental misinterpretation of the ground truth. The original answer clearly identifies a strategic evolution: Nike Air transitioned from being emphasized as an 'emerging innovation' in FY2023 to becoming a 'standard component' and 'foundational offering' in FY2024. The LLM answer directly contradicts this by claiming 'no major strategic shift' and that treatment 'remained consistent.' This is a critical error in understanding the multi-hop reasoning required. While the LLM correctly identifies that both years list Nike Air among technologies and mention Air Manufacturing Innovation as the supplier (quantitative accuracy is good on these factual details), it completely misses the qualitative shift in positioning and strategic emphasis that the ground truth highlights. The ground truth emphasizes the EVOLUTION from 'emerging' to 'mature/foundational,' whereas the LLM sees only consistency. The LLM's conclusion that there is 'no major strategic shift' directly contradicts the ground truth's assertion of 'a strategic shift from emphasizing Nike Air as an emerging innovation to treating it as an integrated, foundational offering.' This represents a failure in the core reasoning task—synthesizing how Nike's treatment of the technology evolved between the two years. The answer addresses the right companies and years but fundamentally misinterprets the nature of the change being described.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 397,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Abbott's positioning of Osmolite within its Nutritional Products segment evolved between 2022 and 2023, particularly in terms of its enteral feeding portfolio and associated product line strategy?",
      "original_answer": "In 2022, Osmolite was listed among Abbott's enteral feeding products used in healthcare institutions, alongside Jevity®, Glucerna® 1.2 Cal, Glucerna® 1.5 Cal, Oxepa®, Freego™, Nepro®, and Vital®. By 2023, Osmolite continued to be included in the enteral feeding portfolio, but Abbott's product listing in this category remained largely consistent, indicating a stable strategic positioning of Osmolite within the institutional enteral nutrition segment. There is no indication of Osmolite being newly introduced, discontinued, or significantly repositioned relative to other products in this category during this period.",
      "llm_answer": "In the 2022 Form 10‑K, Osmolite was presented only as one item in a long list of enteral‑feeding formulas – “Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, **Osmolite**, Oxepa, Freego, Nepro and Vital” – with no special emphasis【ABT_10k_2022.pdf p. 5】. In the 2023 filing, Abbott repositioned Osmolite as a flagship, high‑protein/high‑calorie formula that sits at the core of an expanded, strategically‑aligned enteral‑feeding portfolio, reflecting a more focused clinical‑nutrition product‑line strategy【ABT_10k_2023.pdf p. 5】.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer directly contradicts the ground truth on the core claim. Ground truth states: 'Abbott's product listing in this category remained largely consistent, indicating a stable strategic positioning of Osmolite' and 'There is no indication of Osmolite being newly introduced, discontinued, or significantly repositioned.' The LLM claims the opposite: that Osmolite was 'repositioned as a flagship, high-protein/high-calorie formula' with 'a more focused clinical-nutrition product-line strategy' in 2023. This is a fundamental factual error that inverts the actual finding. QUANTITATIVE ACCURACY: The product list cited (Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite, Oxepa, Freego, Nepro, Vital) matches the ground truth accurately. QUALITATIVE ACCURACY: The LLM fabricated a narrative of strategic repositioning that does not exist in the ground truth. The claim that Osmolite became a 'flagship' product with special emphasis in 2023 is unsupported and contradicts the explicit statement that positioning remained 'largely consistent' with 'no indication of significant repositioning.' CONTEXTUAL RELEVANCE: While the answer addresses the question's structure (comparing 2022 vs 2023), it provides fundamentally incorrect information about the nature of that comparison. The answer appears to have hallucinated details about 'flagship' status and 'expanded, strategically-aligned' portfolio changes that are not supported by the ground truth. This is a severe accuracy failure despite correct product naming.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 424,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has 3M's regulatory engagement and remediation obligations related to PFAS discharge evolved between 2022 and 2024, particularly in Minnesota and Alabama?",
      "original_answer": "In 2022, 3M was actively working under a 2007 Settlement Agreement and Consent Order with the MPCA to address PFAS contamination in Minnesota, with remediation substantially completed at the Cottage Grove site and ongoing operational and maintenance activities at multiple locations. In Alabama, the Company had entered into a July 2020 Interim Consent Order with ADEM, which included obligations for PFAS-related wastewater discharges and air emissions, and had completed installation of a multilayer cap at the Decatur facility. By 2024, regulatory scrutiny had intensified. In Minnesota, MPCA issued a draft Clean Water Act permit for the Cottage Grove facility with significantly revised effluent limits for certain PFAS compounds, some below current quantification levels, and the Company submitted public comments in August 2024. Additionally, in 2024, MPCA published a revised draft permit in December after considering stakeholder input, which could have a significant adverse impact on the Cottage Grove facility's operations. In Alabama, while the 2020 Interim Consent Order remained in effect, the Company's obligations under ongoing investigations and potential future remediation were still expected to involve additional operating costs and capital expenditures over multiple years. The regulatory landscape evolved to include more stringent standards, such as updated HBVs from MDH in January 2024 and proposed HRLs in October 2024, further complicating 3M's compliance path.",
      "llm_answer": "In the 2022 Form 10‑K (pages 125‑129), 3M said it was working under the 2007 Minnesota Settlement Agreement and Consent Order (SACO), with remediation at the Oakdale, Woodbury and Cottage Grove sites essentially completed and only operation‑and‑maintenance activities remaining, and in Alabama it relied on a voluntary remedial‑action agreement with ADEM that included a multilayer cap at Decatur and an interim Consent Order covering all PFAS‑related wastewater and air‑emission controls, plus ongoing reporting and investigation work. By the 2024 filing (pages 100‑104), the Minnesota program had expanded – MPCA issued storm‑water directives, the state health department adopted stricter HBVs/HRLs, and MPCA drafted new CWA permits with tighter PFAS effluent limits that 3M is actively commenting on – while the Alabama arrangement remains the same ADEM agreement and interim Consent Order, with 3M continuing remediation, reporting and capital‑improvement obligations but no new regulatory actions disclosed.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains several significant factual errors and omissions that undermine its accuracy:\n\n1. FACTUAL ERRORS:\n   - The LLM incorrectly identifies sites: mentions 'Oakdale, Woodbury and Cottage Grove' in 2022, but the ground truth only confirms Cottage Grove and 'multiple locations' without specifying Oakdale/Woodbury as completed sites.\n   - The LLM characterizes Alabama's arrangement as a 'voluntary remedial-action agreement,' but the ground truth clearly states it was a 'July 2020 Interim Consent Order with ADEM' - these are different regulatory instruments.\n   - The LLM states Alabama 'remains the same ADEM agreement and interim Consent Order, with...no new regulatory actions disclosed,' but the ground truth indicates ongoing investigations and potential future remediation obligations were still expected.\n\n2. MISSING CRITICAL INFORMATION:\n   - The LLM fails to mention the December 2024 revised draft permit from MPCA that 'could have a significant adverse impact on the Cottage Grove facility's operations' - a key evolution point.\n   - The LLM omits the August 2024 public comments submission by 3M on the draft permit.\n   - The LLM does not adequately convey the severity of the regulatory escalation: the ground truth emphasizes 'significantly revised effluent limits for certain PFAS compounds, some below current quantification levels' - a critical compliance challenge.\n   - Missing reference to updated HBVs from MDH in January 2024 and proposed HRLs in October 2024 as part of the evolving regulatory landscape.\n\n3. INCOMPLETE SYNTHESIS:\n   - The answer fails to properly synthesize the 2022-to-2024 evolution. While it mentions both years, it doesn't adequately capture the intensification of regulatory scrutiny or the shift from maintenance activities to facing new stringent standards.\n   - The characterization of Alabama as 'no new regulatory actions disclosed' contradicts the ground truth's indication of ongoing investigations and expected additional costs/capital expenditures.\n\n4. QUANTITATIVE ACCURACY:\n   - No specific numbers, dates, or dollar amounts are provided in either answer, so direct quantitative comparison is limited.\n   - Dates mentioned (2007, 2020, 2024) are correct where stated.\n   - The LLM correctly identifies 2022 and 2024 as comparison points.\n\n5. MULTI-HOP REASONING:\n   - The LLM attempts to synthesize across Minnesota and Alabama, which is appropriate.\n   - However, the synthesis is incomplete and misses the key evolution: from relatively stable compliance in 2022 to intensified regulatory pressure in 2024.\n   - The answer fails to connect the dots between the various regulatory actions (MPCA permits, MDH standards, ADEM orders) as an integrated escalation.\n\n6. CONTEXTUAL ISSUES:\n   - The answer is somewhat relevant to the question but significantly underrepresents the severity and scope of regulatory changes.\n   - The tone suggests stability ('remains the same') when the ground truth indicates escalating complexity and potential operational impacts.\n\nThe LLM answer captures some correct elements (2007 SACO, Cottage Grove site, MPCA involvement, ADEM in Alabama) but makes material errors in characterizing regulatory instruments, omits critical 2024 developments, and fails to adequately convey the evolution of regulatory pressure between 2022 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1628,
        "completion_tokens": 882,
        "total_tokens": 2511
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola HBC AG evolved between 2022 and 2024, particularly in terms of investment classification and stake percentage?",
      "original_answer": "In 2022, Coca-Cola HBC AG was among the listed equity method investees, though the specific ownership percentage was not disclosed in the provided evidence. By 2024, Coca-Cola HBC AG remained an equity method investee, and the company explicitly stated a 22% ownership stake as of December 31, 2024. This indicates a formalization and quantification of the relationship, with Coca-Cola now specifying the exact percentage of ownership, which was absent in the 2022 disclosures.",
      "llm_answer": "The 2022 10‑K reports that Coca‑Cola’s holding in Coca‑Cola HBC AG was accounted for under the equity‑method and that the Company owned roughly 22 percent of the bottler’s outstanding shares (KO_10k_2022.pdf p.119). The 2024 10‑K shows the same treatment – the investment is still classified as an equity‑method investment and the ownership percentage remains about 22 percent (KO_10k_2024.pdf p.85). Thus, between 2022 and 2024 the classification and stake have not changed.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The ground truth explicitly states that in 2022, 'the specific ownership percentage was not disclosed in the provided evidence,' but the LLM claims the 2022 10-K reports a 22% ownership stake. This is a major factual inaccuracy. The ground truth indicates an evolution/change in disclosure practices between 2022 and 2024 - specifically, the formalization and quantification of the relationship with explicit percentage disclosure in 2024 that was absent in 2022. The LLM's conclusion that 'the classification and stake have not changed' directly contradicts the ground truth's finding of a meaningful evolution in how the relationship is disclosed. While the LLM correctly identifies: (1) equity method accounting treatment in both years, (2) the 22% ownership stake in 2024, and (3) the correct document references, it fails on the core analytical requirement of the question - identifying how the relationship evolved. The LLM misrepresents 2022 data by claiming a 22% disclosure existed when the ground truth explicitly notes this was not disclosed. This represents a failure in multi-hop synthesis and a misreading of source documents. The answer should have noted the key evolution: from undisclosed ownership percentage in 2022 to explicit 22% disclosure in 2024, representing a formalization of the relationship disclosure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 400,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Oracle's strategic emphasis on hybrid deployments evolved between fiscal 2022 and fiscal 2024, particularly in terms of product development investment and deployment model integration?",
      "original_answer": "In fiscal 2022, Oracle emphasized hybrid deployments as part of its broader deployment model strategy, investing $7.2 billion in research and development to enhance existing offerings and develop new technologies, including hybrid solutions like Oracle Cloud@Customer. By fiscal 2024, Oracle further integrated hybrid deployments into its core offerings, positioning them as a standard deployment choice alongside on-premise and cloud-based models, and reinforcing its commitment to interoperability and customer choice. This reflects a strategic evolution from a development-focused approach to a more mature, integrated deployment model.",
      "llm_answer": "Oracle’s 2022 filing made hybrid‑deployment a centerpiece of its growth plan – it highlighted offerings such as Oracle Cloud@Customer and backed the strategy with a $7.2 billion research‑and‑development spend aimed at improving performance, security, integration and cost‑effectiveness across on‑premise, cloud and hybrid models (ORCL_10k_2022.pdf, pp. 4‑8). By the 2024 filing, hybrid is presented as a core deployment option together with on‑premise and cloud, with Oracle SaaS and OCI services described as “comprehensive and integrated” to enable seamless movement and interoperability among all three models, signalling continued product‑development focus and deeper integration of hybrid capabilities (ORCL_10k_2024.pdf, pp. 70‑74).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: The $7.2 billion R&D investment figure for fiscal 2022 is correctly cited and matches the ground truth exactly. No calculation errors are present. ENTITY ACCURACY: Oracle, fiscal years 2022 and 2024, and specific product offerings (Oracle Cloud@Customer, Oracle SaaS, OCI) are all correctly identified. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years, correctly identifying the evolution from a development-focused approach (2022) to a more integrated, mature deployment model (2024). The connection between R&D investment and product development is properly established. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core narrative as the ground truth - that hybrid deployments evolved from being emphasized as part of a growth strategy to becoming a standard, integrated deployment choice. The phrase 'comprehensive and integrated' and references to 'seamless movement and interoperability' align well with the ground truth's description of 'interoperability and customer choice.' MINOR CONSIDERATIONS: The LLM answer includes specific page references (pp. 4-8, pp. 70-74) which add credibility but are not verifiable against the ground truth provided. The answer is slightly more detailed in describing the specific capabilities (performance, security, integration, cost-effectiveness) which represents appropriate elaboration rather than deviation. The characterization of the evolution as 'signalling continued product-development focus and deeper integration' accurately captures the strategic shift described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 465,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has the filing status of the Mandatory Clawback Policy evolved between the 2023 and 2024 SEC 10-K disclosures for Wells Fargo & Company?",
      "original_answer": "In 2023, the Mandatory Clawback Policy was filed directly as part of the 10-K filing under Exhibit 97. In 2024, instead of being filed directly, it was incorporated by reference to Exhibit 97 from the previous year's 10-K filing. This indicates a procedural change in how the policy is disclosed rather than a substantive change to the policy itself.",
      "llm_answer": "In the 2023 Form 10‑K, Wells Fargo’s Mandatory Clawback Policy was included as Exhibit 97 and was “filed herewith” as a stand‑alone exhibit. In the 2024 Form 10‑K, the same policy (still effective October 2 2023) is no longer attached as a new exhibit; instead it is “incorporated by reference” to Exhibit 97 from the 2023 filing. This marks a shift from a direct filing to a reference‑only filing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and directly addresses the question about the evolution of the Mandatory Clawback Policy filing status between 2023 and 2024. Strengths: (1) Correctly identifies the 2023 status as 'filed herewith' as Exhibit 97, (2) Accurately describes the 2024 change to 'incorporated by reference' from the prior year's filing, (3) Properly notes that the policy itself remained effective as of October 2, 2023 (no substantive change), (4) Clearly characterizes this as a procedural/filing method change rather than a policy change, (5) Uses precise SEC terminology ('filed herewith' vs 'incorporated by reference'). The answer demonstrates sound multi-hop reasoning by synthesizing information across two fiscal years and correctly identifying the shift in disclosure methodology. The additional detail about the effective date (October 2, 2023) adds helpful context. Minor consideration: The ground truth uses slightly different phrasing ('filed directly' vs 'filed herewith'), but these are semantically equivalent and both are accurate SEC terminology. The LLM's version is actually more precise in using the exact SEC language. No factual errors, calculations, or entity misidentifications detected. The answer fully addresses all aspects of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1185,
        "completion_tokens": 359,
        "total_tokens": 1545
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did Thermo Fisher's relationship with CorEvitas, LLC evolve between 2023 and 2024, and what specific financial implications were associated with this change?",
      "original_answer": "In 2023, Thermo Fisher invested $0.91 billion to acquire CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for medical treatments. By 2024, this relationship had evolved from an investment into a full acquisition, as CorEvitas was integrated into the Laboratory Products and Biopharma Services segment. The acquisition in 2023 was part of a broader strategy that included significant capital expenditures and financing activities, such as issuing $5.94 billion in senior notes and repurchasing $3.00 billion of company stock. In 2024, the company began amortizing the definite-lived intangible assets from CorEvitas over a weighted average period of 18 years, reflecting the long-term strategic value of the acquisition.",
      "llm_answer": "Thermo Fisher bought CorEvitas in August 2023, paying $730 million in cash, settling $184 million of debt and recording $627 million of goodwill – a $0.91 billion cash outflow that also lifted net‑interest expense (2023 filing, Note 12 and investing‑activities table). The 2024 filing contains no new CorEvitas transaction, indicating the company simply retained the subsidiary as part of its Laboratory Products and Biopharma Services segment with no further acquisition‑related cash or goodwill impact.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of the CorEvitas acquisition and its financial mechanics. STRENGTHS: (1) Correctly identifies the $0.91 billion total cash outflow ($730M cash + $184M debt settlement = $914M, which rounds to $0.91B), matching the ground truth. (2) Accurately dates the acquisition to August 2023. (3) Correctly identifies the $627 million goodwill recorded. (4) Properly notes the integration into Laboratory Products and Biopharma Services segment. (5) Correctly states no new transaction occurred in 2024. (6) Sound multi-hop reasoning connecting the 2023 acquisition details to 2024 retention. MINOR WEAKNESSES: (1) The LLM answer omits the specific detail about the 18-year weighted average amortization period for definite-lived intangible assets that began in 2024, which was explicitly mentioned in the ground truth as a key 2024 implication. (2) The LLM mentions 'lifted net-interest expense' but the ground truth doesn't emphasize this as a primary financial implication—this is a reasonable inference but adds detail not in the original answer. (3) The ground truth mentions the broader strategic context (senior notes issuance of $5.94B and stock repurchases of $3.00B), which the LLM answer doesn't address, though these may be tangential to the core CorEvitas relationship question. QUANTITATIVE VERIFICATION: All numbers check out—$730M + $184M = $914M ≈ $0.91B (correct), $627M goodwill stated correctly. The answer correctly synthesizes the multi-hop information about how the relationship evolved from investment to full integration. The omission of the 18-year amortization detail prevents a perfect score, as this represents a specific 2024 financial implication that was part of the ground truth answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 485,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How did RTX's flight hour payment obligations under its 2012 agreement with Rolls-Royce evolve between 2022 and 2023, particularly in terms of the timing and capitalization treatment of these payments?",
      "original_answer": "In 2022, RTX disclosed that flight hour payments to Rolls-Royce were contingent upon each hour flown through June 2027 by V2500-powered aircraft in service as of the acquisition date, and these payments were considered in 'Other commercial aerospace commitments' and capitalized as collaboration intangible assets as payments were made. In 2023, RTX reiterated the same contingent payment structure tied to flight hours through June 2027 and maintained that these payments would continue to be capitalized as collaboration intangible assets. There was no indication of a change in the magnitude or timing of these obligations between the two years, suggesting a stable commitment structure.",
      "llm_answer": "In the 2022 Form 10‑K RTX disclosed that the flight‑hour payments tied to its 2012 Rolls‑Royce IAE acquisition were included in “Other commercial aerospace commitments” – $735 million was scheduled for 2022 and $1,053 million for 2023 – and that each payment would be capitalized as a collaboration intangible asset when made. By the 2023 filing the near‑term portion had been satisfied, so the remaining obligations now appear in the schedule for $836 million in 2024, $862 million in 2025, $705 million in 2026, $687 million in 2027 and $731 million in 2028, with the same accounting treatment of capitalizing the payments as collaboration intangible assets as they are paid.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and unsupported claims that contradict the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM provides specific dollar amounts ($735M for 2022, $1,053M for 2023, $836M for 2024, etc.) that are not present in the ground truth. The ground truth makes no mention of these specific payment schedules or amounts. These numbers appear to be fabricated or confused with other data. (2) FACTUAL INACCURACY: The ground truth explicitly states there was 'no indication of a change in the magnitude or timing of these obligations between the two years, suggesting a stable commitment structure.' The LLM answer contradicts this by claiming the 2023 filing shows different payment schedules ($836M in 2024, $862M in 2025, etc.), implying changes between years. (3) MISSING CORE INFORMATION: The ground truth emphasizes that the payment structure remained consistent between 2022 and 2023 - both years tied payments to flight hours through June 2027 with the same capitalization treatment. The LLM answer obscures this stability by focusing on specific dollar amounts that cannot be verified. (4) MULTI-HOP REASONING: While the LLM correctly identifies the 2012 Rolls-Royce IAE acquisition, the capitalization as collaboration intangible assets, and the 'Other commercial aerospace commitments' classification, it fails to synthesize the key finding that the obligation structure remained stable between 2022 and 2023. (5) SEMANTIC DIVERGENCE: The ground truth's central point is stability and consistency; the LLM's answer implies changes and provides unverified specific amounts that suggest the opposite. The LLM appears to have hallucinated specific payment schedules rather than acknowledging the lack of disclosed changes between years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 486,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has The Coca-Cola Company's financial relationship with fairlife evolved from 2022 to 2024, particularly regarding contingent payments tied to performance milestones?",
      "original_answer": "In 2022, Coca-Cola's acquisition-related disclosures referenced the 2020 acquisition of the remaining ownership interest in fairlife, with no mention of ongoing contingent payments. By 2024, the company disclosed that there was a remaining milestone payment related to the 2020 acquisition of fairlife, contingent on fairlife achieving certain financial targets through 2024, with the payment scheduled for 2025. This indicates that Coca-Cola's relationship with fairlife has evolved from a completed acquisition in 2020 to one where a performance-linked financial obligation remains active through 2024.",
      "llm_answer": "In the 2022 Form 10‑K Coca‑Cola only reported the fairlife deal as a completed acquisition of the remaining ownership interest, noting a $902 million gain and a $40 million tax benefit (see 2022 pages 55‑56). By the 2024 Form 10‑K the company is carrying a $6.1 billion contingent‑consideration liability for that same acquisition – a milestone payment that is contingent on fairlife meeting specified financial targets through 2024 and payable in 2025 – and it disclosed that a $275 million milestone payment was made in 2023, with the liability re‑measured each quarter (see 2024 pages 109‑113). This reflects a shift from a simple acquisition to an ongoing, performance‑based payment arrangement that remains material to Coca‑Cola’s balance sheet.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) QUANTITATIVE ERRORS: The LLM claims a '$6.1 billion contingent-consideration liability' exists in 2024, but the ground truth makes no mention of this figure. The LLM also introduces a '$275 million milestone payment made in 2023' that is not referenced in the ground truth. These specific dollar amounts appear to be fabricated or confused with other transactions. (2) CONTRADICTION WITH GROUND TRUTH: The ground truth explicitly states that in 2022 there was 'no mention of ongoing contingent payments,' but the LLM's 2022 disclosure of a '$902 million gain and $40 million tax benefit' suggests completed transaction accounting, which is consistent with ground truth. However, the LLM then contradicts itself by claiming a massive $6.1B liability exists in 2024, which fundamentally misrepresents the nature of the remaining obligation. (3) MULTI-HOP REASONING FAILURE: While the LLM correctly identifies the evolution from 2022 (completed acquisition) to 2024 (performance-linked obligation), it introduces unsupported financial figures that distort the actual relationship. The ground truth indicates a 'remaining milestone payment' contingent on targets through 2024, payable in 2025 - not a $6.1B liability. (4) SEMANTIC ISSUES: The LLM's characterization of 'an ongoing, performance-based payment arrangement' is directionally correct but the specific numbers provided are unreliable and appear to be hallucinated. The page references (2022 pages 55-56, 2024 pages 109-113) cannot be verified against the ground truth provided. The core narrative structure is sound, but the quantitative details are fundamentally incorrect, making this answer misleading despite addressing the right conceptual framework.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 497,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has Oracle's strategic positioning of Oracle Cloud Services evolved between 2022 and 2024, particularly in terms of integration with enterprise applications and infrastructure technologies?",
      "original_answer": "In 2022, Oracle emphasized the transformational potential of Oracle Cloud Services, particularly highlighting the Oracle Autonomous Database as a key OCI offering that utilized machine learning to enable leaner business processes and automation. The focus was on flexibility, interoperability, and customer choice across deployment models, including cloud-based, hybrid, and on-premise environments. By 2024, Oracle expanded this positioning by describing Oracle Cloud Services (including SaaS and OCI) as comprehensive and integrated offerings that provide customers with a full suite of applications and infrastructure services. The 2024 filing explicitly frames Oracle Cloud Services as enabling customers to 'choose the best option that meets their specific business needs,' indicating a more mature and customer-centric strategic approach. This evolution reflects a shift from promoting individual innovations (e.g., Autonomous Database) to positioning Oracle Cloud Services as a holistic, integrated platform for enterprise IT transformation.",
      "llm_answer": "In the 2022 filing Oracle framed its Cloud Services primarily as a **flexible, choice‑driven portfolio**—a mix of SaaS and OCI that could be delivered on‑premise, in the public cloud, or in hybrid/Cloud‑@‑Customer models—to help customers **migrate existing on‑premise applications and infrastructure** to a cloud environment that was rapidly deployable, interoperable and cost‑effective.  \n\nBy the 2024 filing the message had shifted to positioning Oracle Cloud Services as a **unified, next‑generation platform** in which its Fusion SaaS applications are **deeply integrated with Oracle Cloud Infrastructure (including Autonomous Database and engineered systems)** and enriched with AI/ML, IoT, blockchain and industry‑specific solutions, presenting the cloud as a single, intelligent foundation for enterprise digital transformation and end‑to‑end business‑process innovation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) CORRECTNESS: The answer accurately captures the evolution of Oracle's strategic positioning between 2022 and 2024. In 2022, it correctly identifies the emphasis on flexibility, choice-driven portfolio, and deployment model options (on-premise, hybrid, cloud). By 2024, it correctly identifies the shift toward unified, integrated positioning with deep integration between SaaS and OCI. The mention of Autonomous Database, AI/ML enrichment, and industry-specific solutions aligns with the ground truth's characterization of a more mature, customer-centric approach. (2) QUANTITATIVE ACCURACY: No numeric values, dates, or calculations are present in either answer, so this dimension scores perfectly. The years 2022 and 2024 are correctly referenced. (3) QUALITATIVE ACCURACY: The LLM demonstrates sound multi-hop reasoning by synthesizing information across two different filing years and correctly identifying the strategic evolution. The characterization of the 2022 positioning as 'flexible, choice-driven' and the 2024 positioning as 'unified, next-generation platform' accurately reflects the ground truth's distinction between promoting individual innovations versus a holistic integrated platform. The specific mention of Autonomous Database, engineered systems, and AI/ML enrichment adds appropriate detail that supports the core narrative. (4) ENTITY ACCURACY: Oracle, Oracle Cloud Services, SaaS, OCI, Autonomous Database, and Fusion SaaS applications are all correctly identified and contextualized. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same essential information as the ground truth—a shift from flexibility/choice emphasis to integrated/unified platform positioning—while using slightly different but semantically equivalent language. The phrase 'single, intelligent foundation for enterprise digital transformation' effectively captures the ground truth's concept of 'holistic, integrated platform.' Minor observation: The LLM answer adds slightly more specific detail about AI/ML, IoT, blockchain, and industry-specific solutions compared to the ground truth, but this represents appropriate elaboration rather than inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1493,
        "completion_tokens": 603,
        "total_tokens": 2097
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has the treatment or status of the Key/Specified Employee Policy evolved between the 2023 and 2024 SEC filings, particularly in terms of its documentation and incorporation by reference?",
      "original_answer": "In the 2023 filing, the Key/Specified Employee Policy was introduced as part of the company's disclosures, specifically incorporated by reference to Exhibit 10(v) from the Annual Report on Form 10-K for the year ended December 31, 2018. By 2024, the policy was no longer newly introduced but was instead announced as a continuing policy, still relying on the same Exhibit 10(v) from the 2018 filing. This indicates that while the policy remained in place, there were no new amendments or updates to its documentation during this period.",
      "llm_answer": "In the 2023 Form 10‑K the company disclosed a “Key/Specified Employee Policy” as Exhibit 10(r) and incorporated it by reference to Exhibit 10(v) of its 2018 Annual Report. The 2024 Form 10‑K no longer lists Exhibit 10(r) or any reference to that policy, indicating the policy is no longer presented as a separate incorporated‑by‑reference document (and appears to have been removed or superseded).",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) EXHIBIT NUMBER ERROR: The LLM states the policy was disclosed as 'Exhibit 10(r)' in 2023, but the ground truth indicates it was incorporated by reference to 'Exhibit 10(v)' from the 2018 filing. The LLM appears to have confused or misidentified the exhibit designation. (2) POLICY STATUS CONTRADICTION: The ground truth clearly states that in 2024, the policy 'was no longer newly introduced but was instead announced as a continuing policy, still relying on the same Exhibit 10(v) from the 2018 filing.' This indicates the policy REMAINED in place with no changes. However, the LLM claims the policy 'is no longer presented as a separate incorporated-by-reference document (and appears to have been removed or superseded)' - this is the opposite of what the ground truth indicates. (3) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the evolution between 2023 and 2024. The ground truth shows continuity (policy remained, same exhibit reference), while the LLM incorrectly concludes removal or supersession. (4) INCOMPLETE UNDERSTANDING: The LLM misunderstood the nature of 'incorporated by reference' - the policy was referenced to a 2018 exhibit in both years, indicating stability, not removal. The answer demonstrates fundamental misinterpretation of the filing documents and provides conclusions that are factually opposite to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 407,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the aggregate principal balance of the 6.700% notes due 2028 evolve between 2022 and 2023, and what does this indicate about RTX's debt management strategy?",
      "original_answer": "In 2022, the aggregate principal balance of the 6.700% notes due 2028 was $115 million. By 2023, this amount increased significantly to $285 million. This indicates that RTX increased its outstanding debt related to this particular note, suggesting a strategic decision to retain or expand exposure to this fixed-rate debt instrument.",
      "llm_answer": "The 6.700 % notes due 2028 carried an aggregate principal balance of **$285 million at year‑end 2022 and the same $285 million at year‑end 2023**, showing no change 【RTX_10k_2023.pdf, p.86】.  By leaving this tranche untouched, RTX is preserving the existing financing – likely because the terms remain favorable – and is managing its overall debt mix through other issuances and repayments rather than aggressively retiring this particular note.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains critical factual errors that directly contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURE: The LLM states the aggregate principal balance was $285 million at both year-end 2022 and year-end 2023, with 'no change.' The ground truth clearly shows $115 million in 2022 and $285 million in 2023 - a significant $170 million increase. This is a fundamental numerical error. (2) MULTI-HOP REASONING FAILURE: The question asks how the balance 'evolved between 2022 and 2023' - requiring comparison of two years. The LLM completely missed the evolution/change that occurred. The ground truth indicates a substantial increase from $115M to $285M, which is a 147% increase in this debt tranche. (3) STRATEGIC INTERPRETATION ERROR: The LLM's conclusion that RTX is 'preserving the existing financing' and 'leaving this tranche untouched' is incorrect because the balance actually increased significantly. The correct interpretation (per ground truth) is that RTX 'increased its outstanding debt related to this particular note,' suggesting a strategic decision to retain or expand exposure to this fixed-rate debt. (4) ENTITY AND METRIC ACCURACY: While the company (RTX) and debt instrument (6.700% notes due 2028) are correctly identified, the core financial metrics are wrong. The LLM appears to have only captured the 2023 figure and incorrectly applied it to both years. This represents a fundamental failure to synthesize information across the two fiscal years required by the multi-hop question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1199,
        "completion_tokens": 420,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the carrying value and effective interest rate of TMO's 1.95% 12-Year Senior Notes evolve between 2023 and 2024?",
      "original_answer": "In 2023, the carrying value of the 1.95% 12-Year Senior Notes was $773 million with an effective interest rate of 2.08%. In 2024, the carrying value decreased to $725 million, and the effective interest rate slightly declined to 2.07%. This indicates a reduction in the financial liability associated with these notes and a marginal improvement in the effective borrowing cost.",
      "llm_answer": "At year‑end 2023 the 1.95 % 12‑year senior notes (due 7/24/2029, euro‑denominated) were carried at **$773 million** and had an **effective interest rate of 2.08 %**. By year‑end 2024 the same notes were carried at **$725 million** and the effective rate had slipped slightly to **2.07 %** – a $48 million reduction in carrying value and a 0.01‑percentage‑point drop in the effective rate【TMO_10k_2023.pdf†L...】【TMO_10k_2024.pdf†L...】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy across all dimensions. QUANTITATIVE VERIFICATION: All numeric values are correct - 2023 carrying value of $773 million, 2023 effective interest rate of 2.08%, 2024 carrying value of $725 million, and 2024 effective interest rate of 2.07%. The calculated difference of $48 million ($773M - $725M) is accurate, and the 0.01 percentage-point change (2.08% - 2.07%) is correctly stated. ENTITY ACCURACY: TMO (Thermo Fisher Scientific) is correctly identified, the notes are properly described as 1.95% 12-Year Senior Notes, and the maturity date (7/24/2029) is appropriately included. The euro-denomination detail adds helpful context. MULTI-HOP SYNTHESIS: The answer successfully synthesizes information from both 2023 and 2024 10-K filings, comparing the evolution of both metrics across the two years. REASONING QUALITY: The interpretation that the carrying value reduction and effective rate decline represent 'a reduction in the financial liability' and 'marginal improvement in the effective borrowing cost' is logically sound and semantically equivalent to the ground truth. The answer is well-structured, presenting year-over-year comparisons clearly and calculating the changes explicitly. Minor deduction (1 point) only because the ground truth's phrasing about 'marginal improvement' is slightly more interpretive than the LLM's more neutral presentation, though both are factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1196,
        "completion_tokens": 400,
        "total_tokens": 1596
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "What are the corporate governance implications of the change in how BNY Mellon presents its Directors' Code of Conduct between its 2022 and 2024 SEC filings?",
      "original_answer": "In 2022, BNY Mellon explicitly detailed the availability of the Directors' Code of Conduct on its website with a direct URL link, and it was referenced within the broader context of corporate governance disclosures and ethics policies. By 2024, the Code was listed among other governance materials—such as committee charters and by-laws—without a direct link or specific mention of updates or amendments. This shift in presentation may signal a more streamlined or consolidated approach to governance disclosures, potentially reducing the visibility of the Code as a standalone document. While the Code remains accessible, the change could affect transparency and stakeholder engagement with the specific ethical expectations for directors, which may influence perceptions of governance accountability.",
      "llm_answer": "In the 2022 Form 10‑K the Directors’ Code of Conduct was only mentioned as a separate web‑posted document (e.g., “The Directors’ Code of Conduct … is posted on our website at https://…/directors‑code‑of‑conduct.pdf”【BK_10k_2022.pdf†page 10‑13】). By the 2024 filing, the Code is listed together with the Corporate Governance Guidelines, bylaws and committee charters as a document incorporated by reference (“Our Corporate Governance Guidelines, Amended and Restated By‑laws, Directors’ Code of Conduct …”【BK_10k_2024.pdf†page 1‑5】). This change makes the Directors’ Code a formal, integral part of BNY Mellon’s governance framework, improving transparency, accessibility and board‑level accountability.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ISSUES: The LLM answer fundamentally contradicts the ground truth on the key governance implication. Ground truth states the 2024 filing shows a REDUCTION in visibility and transparency (Code listed without direct link among other materials, potentially reducing standalone prominence). The LLM claims the opposite—that listing the Code with other governance materials represents an IMPROVEMENT in transparency and accessibility, making it 'a formal, integral part' of the framework. This is a direct factual contradiction of the ground truth's core finding. The LLM misinterprets the consolidation as positive when the ground truth characterizes it as a potential reduction in visibility and stakeholder engagement. CORRECT ELEMENTS: The LLM accurately identifies that in 2022 the Code was presented with a direct URL link and in 2024 it was listed among other governance materials without a direct link. The years (2022 vs 2024) and document references are correct. REASONING FAILURE: The LLM's interpretation of what this change means for corporate governance is inverted from the ground truth. The ground truth notes the change 'may signal a more streamlined or consolidated approach' but emphasizes potential negative implications for 'transparency and stakeholder engagement' and 'perceptions of governance accountability.' The LLM instead frames consolidation as improving transparency and accountability—a fundamental misreading of the governance implications. The LLM provides no acknowledgment of the potential downsides or reduced visibility that the ground truth emphasizes. This represents a major failure in understanding the nuanced governance implications of the presentation change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 466,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has Amazon's Short-Term Credit Agreement evolved between 2023 and 2024, particularly in terms of facility size, maturity date, and the timing of its establishment?",
      "original_answer": "In 2023, Amazon entered into a $5.0 billion unsecured 364-day revolving credit facility (Short-Term Credit Agreement) in November, replacing the prior agreement from November 2022, with a maturity date in October 2024. In 2024, Amazon again entered into a new $5.0 billion unsecured 364-day revolving credit facility in October, replacing the 2023 agreement, with a maturity date in October 2025. The facility size remained the same at $5.0 billion, but the establishment date shifted from November to October, and the maturity date moved forward by one year, indicating a procedural renewal rather than a substantive change in the credit structure.",
      "llm_answer": "In the 2023 Form 10‑K Amazon said that in **November 2023** it entered a **$5 billion unsecured 364‑day revolving “Short‑Term Credit Agreement”** that would **mature in October 2024** (with one optional 364‑day extension)【AMZN_10k_2023.pdf:58】. In the 2024 Form 10‑K the company reported that in **October 2024** it replaced that facility with a **new $5 billion 364‑day revolving credit agreement** whose **maturity is now October 2025** (again with a one‑year extension option)【AMZN_10k_2024.pdf:58】. Thus, the facility size remained unchanged at $5 billion, the maturity was pushed out by one year, and the agreement was re‑established a month earlier in the calendar year (from November 2023 to October 2024).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key facts: (1) 2023 facility: $5 billion, 364-day revolving, November 2023 establishment, October 2024 maturity - all correct. (2) 2024 facility: $5 billion, 364-day revolving, October 2024 establishment, October 2025 maturity - all correct. (3) Facility size consistency ($5 billion both years) - correctly identified. (4) Maturity date progression (October 2024 to October 2025) - correctly stated as one-year forward movement. (5) Establishment timing shift (November 2023 to October 2024) - correctly noted as one month earlier in calendar year. The LLM also appropriately mentioned the optional 364-day extension feature, which adds helpful context. The multi-hop synthesis is sound: the answer correctly traces the evolution across two fiscal years, identifies the replacement relationship between agreements, and synthesizes the key differences and similarities. The reasoning that this represents 'a procedural renewal rather than a substantive change' aligns with the ground truth interpretation. Minor note: The LLM states the agreement was 're-established a month earlier in the calendar year (from November 2023 to October 2024)' which is accurate - October comes before November. The answer fully addresses all aspects of the question: facility size evolution, maturity date changes, and timing of establishment. No calculation errors detected. The citation format and document references enhance credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 412,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has AMD's APU strategy evolved from 2022 to 2024 in terms of product integration and target markets, and what implications does this shift have for its revenue potential in the AI PC segment?",
      "original_answer": "In 2022, AMD emphasized external GPU-based solutions for AI and HPC workloads, particularly through the Instinct MI200 series and Radeon PRO V620 GPUs, focusing on data center and cloud applications. By 2024, AMD had shifted toward integrating dedicated AI acceleration directly into client devices, becoming the first company to include a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs. This strategic pivot toward integrated APUs with NPU cores indicates a move to capture revenue growth in the emerging AI PC market, where on-device AI processing is becoming critical. This evolution likely enhances AMD's revenue potential by positioning it as a differentiated player in the AI PC segment, moving beyond traditional CPU-GPU combinations.",
      "llm_answer": "In 2022 AMD’s APUs were positioned as CPU‑GPU chips for “value and mainstream PCs” – especially notebooks – that combined a processor and graphics on a single die to improve performance, power efficiency and system stability [2022 p7‑11]. By 2024 the company added a dedicated neural‑processing unit (NPU) to its APUs, launching Ryzen AI 300 series, Ryzen 8000 mobile and Ryzen PRO 8000G desktop products that target AI‑enabled consumer, commercial and enterprise PCs [2024 p3‑7]. This shift expands AMD’s addressable market into the fast‑growing AI‑PC segment, creating a new revenue stream and boosting its upside potential in that space.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about AMD's APU strategy evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 positioning of APUs as CPU-GPU combinations for value/mainstream PCs with focus on notebooks; (2) Accurately describes the 2024 shift with NPU integration and specific product names (Ryzen AI 300 series, Ryzen 8000 mobile, Ryzen PRO 8000G); (3) Properly synthesizes the strategic pivot from external GPU solutions to integrated on-device AI processing; (4) Correctly identifies AMD as first to integrate NPU with x86 CPU on same SoC; (5) Appropriately connects the shift to revenue potential in the AI PC segment; (6) Uses proper terminology and maintains semantic equivalence with ground truth. MINOR GAPS: (1) The LLM answer does not explicitly mention the 2022 focus on external GPU solutions (Instinct MI200 series, Radeon PRO V620) for data center/HPC workloads, which the ground truth emphasizes as the contrasting baseline; (2) Does not explicitly state that AMD was 'first' to achieve this integration, though this is implied; (3) Less emphasis on the 'differentiated player' positioning aspect. QUANTITATIVE ACCURACY: All dates (2022, 2024) and product names are correct. No calculations required. QUALITATIVE REASONING: The multi-hop synthesis is sound - correctly connects 2022 positioning → 2024 NPU integration → market implications for AI PC revenue. The logic flow is clear and accurate. CONTEXTUAL RELEVANCE: Directly addresses all three parts of the question: product integration evolution, target market shifts, and revenue implications. The answer is appropriately focused and comprehensive for the question scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 472,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has the treatment of Irish income tax liability for U.S. shareholders receiving dividends from Medtronic evolved between 2023 and 2024, particularly in relation to the Irish dividend withholding tax?",
      "original_answer": "In both 2023 and 2024, dividends paid by Medtronic were generally subject to Irish dividend withholding tax at a rate of 25 percent unless an exemption applied. For U.S. residents, exemptions were available based on residency documentation, such as a valid U.S. Certification of Residence (Form 6166) or Irish Non-Resident Form V2. In both years, a U.S. resident who met the exemption criteria and did not hold shares through an Irish branch generally had no Irish income tax liability. Additionally, if a U.S. shareholder was subject to the 25% withholding tax, the payment discharged any Irish income tax liability, provided the shareholder submitted the required statement to the Irish Revenue authorities. There was no change in the tax rate or in the conditions for exemption between the years, indicating a stable regulatory framework.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K filings contain the same language: U.S. shareholders who either have a U.S. address on record with their broker for DTC‑held shares or provide a valid U.S. Certification of Residence (Form 6166) or Irish Non‑Resident Form V2 are exempt from the 25 % Irish dividend withholding tax, and if the tax is withheld it fully satisfies any Irish income‑tax liability. The rate and the exemption criteria are unchanged, indicating no evolution in the treatment between 2023 and 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is substantially correct on the core facts and numbers. Strengths: (1) Correctly identifies the 25% Irish dividend withholding tax rate in both years; (2) Accurately states the exemption criteria (U.S. address on record, Form 6166, or Irish Non-Resident Form V2); (3) Correctly notes that withholding tax fully satisfies Irish income tax liability; (4) Properly concludes there was no evolution/change between 2023 and 2024. Quantitative accuracy is high - the 25% rate is correct and consistently applied. Weaknesses: (1) The LLM answer mentions 'U.S. address on record with their broker for DTC-held shares' as an exemption criterion, which is more specific than the ground truth's 'residency documentation' language. While this may be accurate from the filings, it introduces a detail not explicitly confirmed in the ground truth; (2) The ground truth emphasizes that exemptions were 'based on residency documentation' and mentions that a U.S. resident 'generally had no Irish income tax liability' if meeting exemption criteria and not holding through an Irish branch. The LLM answer omits the Irish branch caveat, which is a minor but notable omission; (3) The ground truth explicitly states 'provided the shareholder submitted the required statement to the Irish Revenue authorities,' while the LLM answer omits this procedural requirement. This is a meaningful detail about the conditions for the withholding tax to discharge liability. The answer correctly addresses the main question about evolution (or lack thereof) between years, but misses some procedural nuances from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 442,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the risk disclosure around new products and services evolved between 2022 and 2024, particularly regarding the company's platforms operating model initiative?",
      "original_answer": "In 2022, BNY Mellon highlighted that new lines of business, new products and services, or transformational or strategic project initiatives subject the company to new or additional risks. By 2024, this risk disclosure evolved to specifically include the 'transition to a platforms operating model' as a new source of uncertainty. The 2024 filing explicitly states that the company 'may not realize some or all of the expected benefits of our transition to a platforms operating model,' indicating a more focused risk related to this specific strategic initiative. This evolution shows a shift from general strategic risk language to a more concrete acknowledgment of platform-specific implementation risks.",
      "llm_answer": "In the 2022 Form 10‑K the company warned only that “new lines of business, new products and services or transformational or strategic project initiatives” could expose it to new or additional risks and that failure to implement those initiatives could hurt results. By the 2024 filing the same generic language is retained, but a separate, explicit risk was added stating that BNY Mellon “may not realize some or all of the expected benefits of our transition to a platforms operating model,” making the platforms‑operating‑model initiative a distinct risk factor. This reflects a shift from a broad new‑product risk to a targeted concern about the platforms operating model rollout.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) FACTUAL CORRECTNESS: All core facts are accurate - the 2022 disclosure about 'new lines of business, new products and services, or transformational or strategic project initiatives' is correctly cited, and the 2024 evolution to include explicit platforms operating model risk is accurately captured. The specific quote about 'may not realize some or all of the expected benefits of our transition to a platforms operating model' matches the ground truth. (2) QUANTITATIVE ACCURACY: No numeric values are present in either answer, so this dimension is not applicable, but dates (2022, 2024) are correctly referenced. (3) MULTI-HOP REASONING: The LLM successfully synthesizes the evolution across two years, correctly identifying that the 2024 filing retained the generic language while adding a new, specific risk disclosure. The reasoning that this represents a shift from 'broad new-product risk to a targeted concern' is sound and matches the ground truth's characterization of moving from 'general strategic risk language to a more concrete acknowledgment of platform-specific implementation risks.' (4) ENTITY ACCURACY: BNY Mellon is correctly identified, fiscal years 2022 and 2024 are correct, and the platforms operating model initiative is properly referenced. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same essential information as the ground truth with slightly different wording but equivalent meaning. The phrase 'distinct risk factor' in the LLM answer is semantically equivalent to the ground truth's 'more focused risk.' Minor differences in phrasing ('targeted concern about the platforms operating model rollout' vs. 'platform-specific implementation risks') are stylistic variations that do not affect factual accuracy. The answer is comprehensive, addressing the evolution question fully and explaining the significance of the change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 530,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Amazon's relationship with the 3.600% Note due 2032 evolved between 2023 and 2024, particularly in terms of its debt instrument disclosures?",
      "original_answer": "In 2023, the 3.600% Note due 2032 was disclosed as part of a Supplemental Indenture dated April 13, 2022, among Amazon.com, Inc., Wells Fargo Bank, National Association (as prior trustee), and Computershare Trust Company, National Association (as successor trustee). In 2024, the same note was referenced under the same Supplemental Indenture, but the trustee structure now only referenced Computershare Trust Company, National Association, as successor trustee, indicating a formal transition away from Wells Fargo Bank. This reflects a procedural evolution in the administration of the note, with no changes to the note’s terms or interest rate, but a shift in the trustee relationship.",
      "llm_answer": "In the 2023 Form 10‑K Amazon listed the 3.600 % Note due 2032 as part of the “Supplemental Indenture, dated April 13 2022” (Exhibit 4.2) and explained that, because the amount of the note is below the 10 %‑of‑assets threshold, the company has not filed the detailed instrument defining the holders’ rights 【2023‑73‑77】. The 2024 Form 10‑K repeats that same disclosure – the note again appears in Exhibit 4.2 (the same supplemental indenture) and the same exemption statement is reiterated 【2024‑72‑76】, showing that the note remains outstanding and Amazon’s reporting of it has not materially changed.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and fails to address the core question about the evolution of Amazon's relationship with the note between 2023 and 2024. CRITICAL ISSUES: (1) The LLM completely misses the key finding from the ground truth: the trustee transition from Wells Fargo Bank, National Association (as prior trustee) to Computershare Trust Company, National Association (as successor trustee). This is the central evolution the question asks about. (2) The LLM incorrectly claims that 'Amazon's reporting of it has not materially changed' when in fact there was a material change in trustee disclosure structure between years. (3) The LLM focuses on the 10%-of-assets threshold exemption, which is not mentioned in the ground truth answer and appears to be a tangential detail that doesn't address the question. (4) The citation format [2023-73-77] and [2024-72-76] cannot be verified against the ground truth and may be fabricated. CORRECT ELEMENTS: The LLM correctly identifies (a) the 3.600% Note due 2032, (b) the Supplemental Indenture dated April 13, 2022, (c) that the note appears in Exhibit 4.2 in both years, and (d) that the note's terms and interest rate remained unchanged. MULTI-HOP REASONING FAILURE: The question requires synthesizing trustee relationship changes across 2023 and 2024 filings. The LLM failed to identify this key evolution, instead focusing on disclosure consistency rather than the substantive trustee transition. The answer demonstrates a fundamental misunderstanding of what changed between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 431,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How did MDLZ's treatment and disclosure of net investment hedge derivative contracts evolve from 2023 to 2024, particularly in terms of their financial impact and presentation within the financial statements?",
      "original_answer": "In 2023, MDLZ disclosed the fair value of derivative assets and liabilities associated with net investment hedge contracts, with $1,347 million and $377 million in other current assets and $250 million and $413 million in other assets as of December 31, 2023 and 2022, respectively. By 2024, the focus shifted to the income statement impact, where the company noted that 'Other income, net' included amounts excluded from the assessment of hedge effectiveness related to these contracts, indicating a change in emphasis from balance sheet valuation to income volatility effects.",
      "llm_answer": "In 2023 MDLZ reported net‑investment‑hedge derivative contracts with a fair‑value of $163 million as assets and $382 million as liabilities, creating a net liability of $219 million; the hedge produced a $185 million after‑tax loss in OCI and $148 million of amounts excluded from hedge effectiveness were recorded in other‑income, net. By 2024 the same contracts were shown at $305 million of assets and $50 million of liabilities, yielding a net asset of $255 million and a slightly higher notional amount of $7.5 billion, with the effective portion now contributing a gain to OCI while excluded amounts continue to flow through other‑income, net; the disclosures remain in Note 10 under “Derivatives designated as accounting hedges” and the “Hedges of Net Investments in International Operations” section, but the presentation shifted from a net‑liability to a net‑asset position.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and appears to provide numbers that do not match the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The ground truth states that in 2023, MDLZ disclosed $1,347 million and $377 million in derivative assets/liabilities in other current assets, and $250 million and $413 million in other assets as of Dec 31, 2023 and 2022 respectively. The LLM answer reports completely different figures ($163 million assets, $382 million liabilities, $185 million OCI loss, $148 million excluded amounts) that do not align with the ground truth numbers. The 2024 figures provided by the LLM ($305 million assets, $50 million liabilities, $7.5 billion notional) cannot be verified against the ground truth and appear inconsistent with the disclosed amounts. (2) INCOMPLETE SYNTHESIS: The ground truth emphasizes an evolution from balance sheet focus (2023) to income statement impact focus (2024), highlighting the shift in disclosure emphasis. The LLM answer does mention this shift but with incorrect supporting numbers. (3) MISSING CONTEXT: The ground truth specifically references the balance sheet line items (other current assets, other assets) where these derivatives were reported. The LLM answer mentions Note 10 and specific sections but doesn't accurately capture the balance sheet presentation details from the ground truth. (4) CALCULATION ISSUES: The LLM calculates net positions ($163M - $382M = -$219M net liability; $305M - $50M = $255M net asset) which are mathematically correct given the stated figures, but the underlying asset/liability amounts themselves appear to be incorrect. (5) ENTITY/METRIC ACCURACY: While MDLZ and net investment hedge derivatives are correctly identified, the specific financial metrics and their values are fundamentally misaligned with the ground truth. The answer demonstrates some understanding of the topic structure but fails on factual accuracy of the core numbers that are essential to answering this question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 540,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the Abrams Main Battle Tank's modernization strategy evolved from 2023 to 2024, particularly in terms of technological development and international demand?",
      "original_answer": "In 2023, General Dynamics was focused on delivering the System Enhancement Package version 3 (SEPv3) for the Abrams tank, which included upgrades in communications, power generation, fuel efficiency, optics, and armor. Additionally, GD announced the development of the M1E3 Abrams, a more significant engineering change aimed at future threats, featuring the latest systems architecture for quicker upgrades and reduced sustainment footprint. By 2024, the company emphasized continued capability enhancement of the Abrams to counter current and potential threats, with increased international demand reflected in a growing installed base across Europe, the Middle East, North Africa, and the Indo-Pacific. While 2023 focused on the technical roadmap (SEPv3 and M1E3), 2024 highlighted the global strategic relevance and procurement momentum of the Abrams platform.",
      "llm_answer": "In 2023 General Dynamics emphasized the rollout of the next‑generation SEPv3 upgrade package for the M1A2 Abrams (adding new communications, power‑generation, fuel‑efficiency, optics and armor) and announced the new M1E3 engineering‑change program, which will use a modern systems‑architecture to allow faster technology insertions, reduced sustainment and greater mobility while also providing upgrades for a handful of non‑U.S. partners. By 2024 the focus had broadened to a sustained “overmatch” effort that leans heavily on strong, growing demand from NATO members and other allies across Europe, the Middle East, North Africa and the Indo‑Pacific, making international procurement and upgrade programs a central driver of the Abrams modernization strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies both 2023 focus areas (SEPv3 and M1E3 programs) with accurate technical details (communications, power generation, fuel efficiency, optics, armor). (2) Accurately captures the 2024 shift toward international demand and global strategic relevance. (3) Properly synthesizes the multi-hop evolution showing progression from technical roadmap emphasis to procurement momentum. (4) Correctly names geographic regions (Europe, Middle East, North Africa, Indo-Pacific) and identifies NATO/allies as key demand drivers. (5) No quantitative errors or date inaccuracies. MINOR OBSERVATIONS: (1) The LLM adds interpretive language like 'overmatch effort' and 'central driver' which, while semantically consistent with the ground truth's emphasis on strategic relevance, represents slight elaboration beyond the original answer. (2) The phrase 'for a handful of non-U.S. partners' in the LLM answer regarding M1E3 is not explicitly mentioned in the ground truth, though it's consistent with the context of international demand. (3) The LLM's characterization of the shift as 'broadened' and emphasis on 'sustained' efforts adds nuance that aligns well with the comparative analysis requested. The answer successfully addresses all parts of the multi-part question: technological development (SEPv3, M1E3 details), evolution over time (2023 vs 2024 shift), and international demand (geographic expansion and procurement momentum). Multi-hop reasoning is sound, correctly synthesizing information about program evolution and market dynamics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 453,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has AMD's role in the development and positioning of APUs evolved between 2022 and 2024, particularly in terms of their market segmentation and strategic emphasis?",
      "original_answer": "In 2022, APUs were discussed as part of AMD's broader Enterprise, Embedded and Semi-Custom product portfolio, which included CPUs, GPUs, and customized SoC products. They were described in general terms without specific market segmentation or strategic emphasis. By 2024, APUs were explicitly included in two of AMD's four reportable segments: the Data Center segment and the Client segment. In the Data Center segment, APUs were listed alongside AI accelerators, CPUs, GPUs, and DPUs, indicating a strategic shift to position APUs as part of data center solutions. In the Client segment, APUs were specifically tied to desktop and notebook CPUs and chipsets, showing a more defined and segmented approach to their market positioning. This evolution reflects a more structured and strategic integration of APUs into AMD's core business segments.",
      "llm_answer": "In the 2022 filing AMD described APUs mainly as integrated CPU‑GPU chips that “deliver visual‑processing functionality for value and mainstream PCs” and highlighted their power‑efficiency and role in notebook platforms as part of its Computing products (AMD_10k_2022.pdf: p.9‑10). By the 2024 filing the company places APUs in several reportable segments—Data Center (as part of accelerated processing units), Client (desktop/notebook) and Embedded—and stresses custom APU solutions for semi‑custom consoles and handheld gaming (e.g., the Steam Deck), reflecting a broader strategic focus on heterogeneous, AI‑enabled and embedded workloads (AMD_10k_2024.pdf: p.68‑70).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some correct elements but contains significant discrepancies with the ground truth. CORRECT ELEMENTS: (1) The answer correctly identifies that APUs were discussed in 2022 as integrated CPU-GPU chips for PCs; (2) It correctly notes that by 2024, APUs appear in multiple reportable segments including Data Center and Client; (3) The mention of custom APU solutions for gaming (Steam Deck) is accurate contextual detail. SIGNIFICANT ERRORS: (1) The ground truth explicitly states APUs were NOT segmented in 2022 but were part of a broader 'Enterprise, Embedded and Semi-Custom' portfolio discussed in general terms. The LLM's description of 2022 APUs as 'part of Computing products' is vague and doesn't capture this lack of specific segmentation; (2) The ground truth specifies APUs were in TWO segments by 2024 (Data Center and Client), but the LLM claims THREE segments (Data Center, Client, AND Embedded). The ground truth makes no mention of APUs being explicitly listed in an Embedded segment in 2024; (3) The LLM's characterization of Data Center APUs as 'accelerated processing units' is imprecise—the ground truth states they were listed 'alongside AI accelerators, CPUs, GPUs, and DPUs,' not that APUs themselves are accelerated processing units; (4) The LLM adds interpretive language about 'heterogeneous, AI-enabled and embedded workloads' that goes beyond what the ground truth supports. MULTI-HOP REASONING: The LLM attempts to synthesize 2022 vs 2024 positioning but misses the key evolution point—the shift FROM general portfolio discussion TO explicit segment inclusion. The answer conflates product descriptions with segment positioning. QUANTITATIVE ACCURACY: No specific numbers are provided in either answer, so this is neutral. PAGE REFERENCES: The LLM cites specific pages (p.9-10 for 2022, p.68-70 for 2024) which adds credibility but cannot be verified against the ground truth provided. The core factual error about Embedded segment inclusion in 2024 is a material mistake that undermines the answer's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 554,
        "total_tokens": 1938
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has Medtronic's disclosure regarding the implications of the Financial Transfers Act 1992 on financial transfers between Ireland and third countries evolved from 2023 to 2024?",
      "original_answer": "In 2023, Medtronic disclosed that the Financial Transfers Act 1992 allowed the Irish Minister for Finance to impose restrictions on financial transfers with certain third countries, and that the list of such countries was subject to ongoing change. By 2024, the company continued to disclose the same regulatory framework but no longer emphasized the dynamic nature of the list of restricted countries, suggesting a potential shift in focus or a stabilization in the regulatory environment affecting these transfers.",
      "llm_answer": "Medtronic’s 2023 and 2024 Form 10‑K filings contain the same wording on the Financial Transfers Act 1992: they state that the Irish Minister for Finance can restrict financial transfers between Ireland and other (including third) countries, that such restrictions have already been applied to a number of third‑countries, and that the list of restricted jurisdictions is “subject to ongoing change.” The 2024 filing repeats this language verbatim, indicating no substantive change in the disclosure from the 2023 filing.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The ground truth states that by 2024, Medtronic 'no longer emphasized the dynamic nature of the list of restricted countries,' indicating a substantive change in disclosure between 2023 and 2024. However, the LLM answer claims the 2024 filing 'repeats this language verbatim' and states there is 'no substantive change in the disclosure from the 2023 filing.' This is a critical misrepresentation of the evolution requested in the question. The LLM correctly identifies the 2023 disclosure content (the Minister's authority, existing restrictions, and the phrase 'subject to ongoing change'), and the dates and entities are accurate. However, the core finding about how the disclosure evolved is inverted - the LLM says there was no change when the ground truth indicates there was a meaningful shift in emphasis regarding the dynamic nature of the restricted countries list. The LLM's conclusion directly contradicts the ground truth's assertion of a 'potential shift in focus or a stabilization in the regulatory environment.' This represents a failure in the multi-hop reasoning required to compare and synthesize the 2023 and 2024 disclosures, which is the central requirement of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 362,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How did the status and production outlook of the G700 aircraft evolve from 2023 to 2024 based on GD's disclosures?",
      "original_answer": "In 2023, the G700 was described as the next model to join the Gulfstream lineup, with expectations for it to enter service following FAA certification in early 2024. By 2024, the G700 had begun deliveries in the second quarter, indicating that it successfully completed certification and transitioned from development to active production and customer delivery. This marks a clear evolution from a future product to a realized and delivered aircraft model.",
      "llm_answer": "In the 2023 Form 10‑K, Gulfstream’s G700 was described as the next ultra‑long‑range model that was still awaiting FAA certification, with entry into service expected in early 2024【GD_10k_2023.pdf page 5】. By the 2024 Form 10‑K, GD reported that the G700 had moved into production – deliveries began in the second quarter of 2024 and inventory rose to support a ramp‑up of the model【GD_10k_2024.pdf page 68】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and effectively addresses the multi-hop question about G700 evolution from 2023 to 2024. STRENGTHS: (1) All key facts are correct - 2023 status as awaiting FAA certification with early 2024 entry into service expectation, and 2024 status showing Q2 deliveries and production ramp-up. (2) Quantitative accuracy is perfect - dates (early 2024, Q2 2024) and timeline progression are accurate. (3) Multi-hop synthesis is sound - the answer correctly synthesizes information from two different fiscal years' 10-K filings to show the evolution from development/certification phase to active production/delivery phase. (4) Entity identification is correct - properly identifies GD (Gulfstream), the G700 aircraft model, FAA certification, and production metrics. (5) The answer captures the semantic essence of the ground truth: transition from 'future product' to 'realized and delivered aircraft.' MINOR CONSIDERATIONS: The LLM answer includes specific page references (page 5, page 68) which add credibility but weren't in the ground truth - this is a positive addition. The wording 'moved into production' and 'deliveries began in the second quarter' is semantically equivalent to the ground truth's 'begun deliveries in the second quarter' and 'transitioned from development to active production.' The mention of 'inventory rose to support a ramp-up' provides slightly more detail than the ground truth but is consistent with it. No calculation errors, no factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1207,
        "completion_tokens": 419,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the nature of PMI's relationship with KT&G evolved from 2023 to 2024, particularly in terms of strategic dependency and product commercialization?",
      "original_answer": "In 2023, PMI announced a long-term collaboration with KT&G to commercialize KT&G's smoke-free devices and consumables on an exclusive, worldwide basis (excluding South Korea), under a 15-year agreement running through January 29, 2038. This partnership granted PMI exclusive access to KT&G's smoke-free brands and product pipeline, including offerings for low- and middle-income markets. By 2024, this relationship had evolved into a more integrated dependency, as KT&G's heat-not-burn products were explicitly referenced as part of PMI's heat-not-burn product portfolio, indicating a shift from exclusive distribution to inclusion within PMI's broader smoke-free product strategy. This evolution reflects a deeper strategic alignment and operational integration of KT&G's offerings into PMI's product ecosystem.",
      "llm_answer": "In the 2023 filing PMI noted that it had renewed and extended its January 2020 exclusive agreement with KT&G to commercialize the Korean firm’s smoke‑free products outside South Korea (2023 10‑K, pp. 57‑61). By the 2024 filing the arrangement had been formalized into a 15‑year worldwide exclusive collaboration with three‑year performance‑review cycles, giving PMI continued exclusive access to KT&G’s smoke‑free brands and product‑innovation pipeline and making those products a core part of PMI’s smoke‑free portfolio (2024 10‑K, pp. 38‑42). This shift shows a move from a short‑term renewal to a longer‑term, deeper strategic dependency and broader commercialization of KT&G’s products.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution of the PMI-KT&G relationship and correctly identifies key qualitative aspects (shift from renewal to longer-term strategic dependency, deeper integration into PMI's portfolio). However, there are significant quantitative accuracy issues: (1) The LLM states the agreement was 'renewed and extended' from a January 2020 agreement, but the ground truth indicates the 2023 announcement was for a NEW 15-year agreement through January 29, 2038 - not a renewal of the 2020 agreement. This is a material factual error about the nature of the 2023 transaction. (2) The LLM mentions 'three-year performance-review cycles' which is not mentioned in the ground truth and appears to be unsupported information. (3) The LLM correctly identifies the 15-year term and worldwide exclusive basis, but mischaracterizes the 2023 event as a 'renewal' rather than a new long-term collaboration announcement. The qualitative reasoning about the evolution from 'short-term renewal to longer-term, deeper strategic dependency' is sound and aligns with the ground truth's characterization of increased integration. The answer appropriately addresses both 2023 and 2024 developments and correctly identifies the shift toward operational integration. However, the factual error regarding whether this was a renewal versus a new agreement, combined with the unsupported claim about performance-review cycles, prevents a higher score. The multi-hop synthesis is reasonable but built on partially incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 422,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has AMD's approach to semi-custom SoC products evolved from 2022 to 2024, particularly in terms of their strategic positioning and integration with broader product ecosystems?",
      "original_answer": "In 2022, AMD's semi-custom SoC products were described as being dependent on third-party product success, with revenue tied to both non-recurring engineering fees and the incorporation of AMD's SoCs into customer devices. There was a clear emphasis on the risks associated with this dependency, including the lack of control over third-party marketing and the uncertainty of revenue realization. By 2024, AMD's approach had evolved significantly, with semi-custom SoCs being positioned as core components of a broader, more integrated product ecosystem that includes AI accelerators, CPUs, GPUs, and APUs. The 2024 filing highlights strategic integration with AI capabilities, such as the inclusion of a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs, and the use of semi-custom SoCs in gaming, cloud services, and embedded systems across multiple industries. This reflects a shift from a dependency model to a more proactive, integrated product leadership strategy.",
      "llm_answer": "In 2022 AMD described its semi‑custom SoC business mainly as a revenue‑generating service—earning non‑recurring engineering fees and product sales that depended on customers’ product success—and positioned it as a niche custom‑design silicon provider within its high‑performance portfolio [AMD_10k_2022.pdf:27;23;24]. By 2024 the company has elevated semi‑custom SoCs to a strategic, ecosystem‑wide offering, co‑engineering them with partners across gaming, AI, data‑center and embedded segments and embedding them in its chiplet‑based Infinity Architecture and open software stacks, making them a core pillar of AMD’s broader AI‑focused strategy and product ecosystem [AMD_10k_2024.pdf:4;5;6].",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of AMD's semi-custom SoC evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 positioning as dependent on third-party success with NRE fees and product sales, matching the ground truth characterization of dependency and risk. (2) Accurately captures the 2024 evolution toward strategic ecosystem integration with AI, gaming, data-center, and embedded applications. (3) Properly synthesizes multi-hop information across two filing years showing clear progression. (4) Correctly identifies specific 2024 innovations like chiplet-based Infinity Architecture and open software stacks. (5) No quantitative errors - dates (2022, 2024) are correct, no calculations required. MINOR WEAKNESSES: (1) The LLM answer mentions 'Infinity Architecture' and 'open software stacks' which are not explicitly mentioned in the ground truth, though these are reasonable inferences about AMD's 2024 strategy. (2) The ground truth specifically mentions 'dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs' which the LLM answer doesn't explicitly call out, instead using the broader term 'AI-focused strategy.' (3) The ground truth emphasizes the shift from 'dependency model to proactive, integrated product leadership strategy' - the LLM captures this conceptually but doesn't use this exact framing. SEMANTIC EQUIVALENCE: The LLM answer conveys the same fundamental narrative: 2022 = niche, dependent, NRE-focused; 2024 = strategic, integrated, ecosystem-wide. The reasoning is sound and the multi-hop synthesis across years is correct. The answer is well-structured with proper source citations. Overall, this is a high-quality response with accurate core facts and only minor omissions of specific technical details mentioned in ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 494,
        "total_tokens": 1926
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the treatment of Irish income tax on dividends paid to U.S. residents evolved between 2023 and 2024, particularly regarding exemptions and withholding tax obligations?",
      "original_answer": "In 2023, Medtronic noted that U.S. residents who are exempt from Irish dividend withholding tax generally would not be subject to Irish income tax on dividends unless they had a connection to Ireland beyond shareholding. Additionally, non-residents subject to withholding tax typically had no further Irish income tax liability. In 2024, the company clarified that U.S. residents who qualify for a withholding tax exemption and do not hold shares through an Irish branch generally will not have Irish income tax liability, and those subject to withholding can discharge any further liability by furnishing a statement to Irish Revenue. The 25% withholding tax rate remained unchanged, but the 2024 disclosure provided more structured conditions for exemption and clarified post-withholding tax procedures.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K state that Irish dividend withholding tax is imposed at 25 % unless a U.S. shareholder qualifies for an exemption. U.S. residents remain exempt when the shares are held through DTC with a U.S. address or when a record owner furnishes a U.S. Certificate of Residence (Form 6166) or an Irish Non‑Resident Form V2; in that case no Irish income‑tax liability arises, and if the exemption is not met the 25 % withholding satisfies any Irish tax due. The 2024 filing simply restates these rules (adding a note that the U.S./Ireland treaty is generally unnecessary), so the treatment of Irish income tax on dividends to U.S. residents has not materially changed.",
      "correctness_score": 3,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR ISSUES WITH CORE CLAIM: The LLM answer fundamentally contradicts the ground truth by claiming 'the treatment of Irish income tax on dividends to U.S. residents has not materially changed' between 2023 and 2024. The ground truth explicitly states there WERE material changes: (1) 2023 described exemptions in general terms (exempt from withholding = no further Irish income tax unless Irish connection), while (2) 2024 provided 'more structured conditions for exemption' and 'clarified post-withholding tax procedures' including the ability to discharge liability by furnishing a statement to Irish Revenue. The LLM incorrectly characterizes the evolution as merely 'restating' rules with a note about the treaty being unnecessary, when the ground truth indicates substantive clarification of exemption conditions and post-withholding procedures. QUANTITATIVE ACCURACY: The 25% withholding tax rate is correctly stated in both answers. ENTITY/CONTEXT ACCURACY: The LLM correctly identifies Medtronic (implied through 10-K reference) and the 2023-2024 timeframe. However, the LLM introduces specific procedural details (DTC holding, Form 6166, Form V2) that are not mentioned in the ground truth, raising questions about whether these details are accurate or represent over-specification. REASONING FAILURE: The LLM's conclusion that treatment 'has not materially changed' directly contradicts the ground truth's emphasis on clarification and structural improvements in 2024. The multi-hop synthesis fails because the LLM did not properly identify the evolution in disclosure quality and procedural clarity between years. The answer addresses the question's structure but reaches an incorrect substantive conclusion about whether material changes occurred.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 479,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did General Dynamics' financial performance and strategic focus in ship construction change from 2023 to 2024, particularly regarding cost pressures on the Virginia-class and DDG-51 programs and the revenue outlook for the Columbia-class submarine initiative?",
      "original_answer": "In 2023, General Dynamics' Marine Systems segment experienced a 110 basis point decline in operating margin due to supply chain disruptions affecting the Virginia-class submarine schedule and cost overruns on the DDG-51 guided-missile destroyer program. Despite these challenges, revenue from U.S. Navy ship construction rose, driven by increased activity on the Columbia-class submarine program. By 2024, the company projected revenue for the Marine Systems segment to rise to $12.8–12.9 billion with an expected operating margin of approximately 7.6%, suggesting a strategic effort to stabilize and improve profitability. This indicates a shift from cost-driven margin pressure in 2023 to a more optimistic outlook in 2024, likely supported by improved program execution and growth in the Columbia-class program.",
      "llm_answer": "In 2023 the Marine Systems segment posted a 12.9 % revenue rise to $12.5 bn, but its operating margin slipped to 7.0 % as “supply‑chain impacts to the Virginia‑class submarine schedule and cost growth on the Arleigh Burke‑class (DDG‑51) guided‑missile destroyer program” eroded profitability, even though “revenue from U.S. Navy ship construction and engineering was up … due primarily to increased volume on the Columbia‑class submarine program” (2023 Marine Systems discussion). For 2024 the company now expects Marine Systems revenue of $12.8‑$12.9 bn with an operating margin of roughly 7.6 %, signaling a continued focus on the Columbia‑class build‑up and an expectation that the earlier Virginia‑class and DDG‑51 cost‑pressure headwinds will be less of a drag on earnings (2024 Marine Systems outlook).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the multi-hop question. STRENGTHS: (1) All key financial metrics are correct: 2023 Marine Systems revenue of $12.5 billion, operating margin decline to 7.0%, and 2024 projected revenue of $12.8-12.9 billion with 7.6% operating margin. (2) The quantitative accuracy is excellent - the 110 basis point margin decline mentioned in ground truth (from ~8.1% to 7.0%) is implicitly captured through the specific margin figures provided. (3) All entities are correctly identified: General Dynamics, Marine Systems segment, Virginia-class submarine, DDG-51 (Arleigh Burke-class), and Columbia-class submarine programs. (4) Multi-hop synthesis is sound: the answer correctly connects 2023 challenges (supply chain disruptions, cost overruns) to 2024 outlook improvements, showing the strategic shift from margin pressure to stabilization. (5) The answer properly attributes revenue growth drivers to Columbia-class program activity while acknowledging cost pressures on other programs. (6) Contextual relevance is excellent - directly addresses all parts of the question regarding financial performance changes, cost pressures, and revenue outlook. MINOR CONSIDERATIONS: The LLM answer provides slightly more specific detail (e.g., explicitly naming 'Arleigh Burke-class') and includes direct citations to source documents, which adds credibility. The phrasing 'signaling a continued focus' and 'expectation that...headwinds will be less of a drag' effectively captures the strategic shift narrative. No calculation errors detected. The answer is semantically equivalent to and factually consistent with the ground truth while being well-sourced and clearly presented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 472,
        "total_tokens": 1907
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BKNG's financial dependency on Booking.com evolved between 2022 and 2023 based on the proportion of revenue derived from accommodation reservations?",
      "original_answer": "BKNG's financial dependency on Booking.com has remained high but slightly increased between 2022 and 2023. In 2022, Booking.com's accommodation reservations contributed 89% of BKNG's total revenues. This percentage remained unchanged in 2023, indicating BKNG continues to heavily rely on Booking.com for its revenue base. The consistent 89% contribution in both years shows a sustained and concentrated dependency on Booking.com's core service offering.",
      "llm_answer": "Booking Holdings’ reliance on Booking.com’s accommodation‑booking business stayed essentially flat – accommodation reservations generated about 89 % of total revenue in both 2022 and 2023. The 2023 Form 10‑K notes that “approximately 89 %, 89 % and 87 % of the Company’s revenues for the years ended December 31 2023, 2022 and 2021, respectively, relate to online accommodation reservation services” (BKNG 10‑K 2023, pp. 85‑89). This indicates no material change in the company’s financial dependency on Booking.com between the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-supported. Quantitative accuracy is perfect: all percentages are correct (89% for 2022 and 2023, 87% for 2021), and the years are properly identified. The answer correctly synthesizes multi-hop information by: (1) identifying the specific metric (accommodation reservations as % of total revenue), (2) comparing across the two requested years (2022 and 2023), and (3) providing direct citation from the 10-K filing. The LLM goes beyond the ground truth by including 2021 data (87%) which provides additional context and strengthens the analysis, though this wasn't explicitly requested. The reasoning is sound - the answer correctly concludes that dependency remained essentially flat/unchanged between 2022 and 2023. The semantic meaning matches the ground truth perfectly: both convey that BKNG's reliance on Booking.com accommodation reservations stayed at 89% in both years with no material change. The only minor distinction is that the ground truth states the percentage 'remained unchanged' while the LLM says it 'stayed essentially flat' - these are semantically equivalent. The LLM's inclusion of the direct quote from the 10-K filing (pp. 85-89) adds credibility and demonstrates proper source attribution. All entities are correctly identified (BKNG, Booking.com, accommodation reservations). The answer directly addresses the question about how financial dependency evolved between 2022 and 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 402,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did the company's position with respect to its Swiss Franc note evolve between 2023 and 2024, and what does this indicate about its foreign currency obligations?",
      "original_answer": "In 2023, the company disclosed a Swiss Franc note obligation of $299 million, which was completely removed by the end of 2024. This indicates that the company either repaid or restructured this foreign currency obligation over the year, reflecting a strategic shift in managing its Swiss Franc exposure.",
      "llm_answer": "In the 2023 filing the company still carried a Swiss‑franc note – a 1.625 % bond of about $299 million that was due in 2024. The 2024 filing shows a dash for that line, meaning the note has been retired (repayment or maturity), so the company no longer has that Swiss‑franc liability, reducing its foreign‑currency exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Quantitative accuracy is perfect: the $299 million figure for the 2023 Swiss Franc note is correct, and the 1.625% coupon rate is accurately cited. The temporal framing is correct (2023 to 2024 evolution). The answer correctly identifies that the note was due in 2024 and has been retired/repaid by the end of 2024, as evidenced by the 'dash' notation in the 2024 filing. The multi-hop reasoning is sound: the model synthesized information across two fiscal years and correctly concluded that the company eliminated this foreign currency obligation. The answer goes slightly beyond the ground truth by providing the specific coupon rate (1.625%), which adds helpful context without introducing any inaccuracy. The semantic meaning is fully aligned with the ground truth - both convey that the company had a $299 million Swiss Franc obligation in 2023 that was completely removed by 2024, indicating strategic management of foreign currency exposure. The only minor distinction is that the LLM answer is slightly more specific about the mechanism (noting it was 'due in 2024'), which enhances rather than detracts from the answer. No calculation errors, no entity confusion, and all facts are verifiable and correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1161,
        "completion_tokens": 356,
        "total_tokens": 1518
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did Goldman Sachs' treatment of Non-Employee Director RSU Award Agreements evolve between the 2023 and 2024 10-K filings, particularly in terms of introduced or modified agreements?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs referenced the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' as Exhibit 10.8, indicating that the existing documentation pertained to agreements prior to 2015. In the 2024 filing, the company not only retained the reference to the pre-2015 RSU Award Agreement but also introduced a new exhibit titled 'Amendments to Certain Non-Employee Director Equity Award Agreements' as Exhibit 10.18, which was not present in the 2023 filing. This indicates that Goldman Sachs expanded its disclosures to include amendments to these agreements, suggesting a more comprehensive or updated treatment of non-employee director equity arrangements in 2024.",
      "llm_answer": "In the 2023 Form 10‑K the exhibit list only showed the historic “pre‑2015” Non‑Employee Director RSU Award Agreement (Exhibit 10.8) and the then‑current RSU award templates (Exhibits 10.31 and 10.32); no amendment to those agreements was disclosed. By the 2024 Form 10‑K the pre‑2015 template is renumbered as Exhibit 10.9, the current RSU award forms are renumbered as Exhibits 10.32 and 10.33 (adding a cash‑settled version), and a new Exhibit 10.18 – “Amendments to Certain Non‑Employee Director Equity Award Agreements” – is introduced, indicating that Goldman Sachs has formally amended its non‑employee director RSU award arrangements. This shift reflects a move from merely listing the award forms to explicitly documenting and filing an amendment to those agreements.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and provides more comprehensive detail than the ground truth. Key strengths: (1) Correctly identifies the core evolution - introduction of Exhibit 10.18 'Amendments to Certain Non-Employee Director Equity Award Agreements' in 2024 that was absent in 2023; (2) Accurately tracks exhibit renumbering (pre-2015 agreement from 10.8 to 10.9, current forms from 10.31/10.32 to 10.32/10.33); (3) Adds valuable context about the cash-settled version being introduced; (4) Provides sound multi-hop reasoning showing the progression from merely listing forms to explicitly documenting amendments. The LLM answer actually exceeds the ground truth in specificity by noting the exhibit number changes and the addition of a cash-settled RSU form, which represents more thorough synthesis of the filing changes. The semantic meaning aligns perfectly with the ground truth - both convey that Goldman Sachs expanded its disclosure framework to include formal amendments to non-employee director equity arrangements. Minor consideration: The ground truth doesn't explicitly mention the exhibit renumbering or the cash-settled version addition, but the LLM's inclusion of these details appears factually accurate and enhances rather than contradicts the original answer. All numeric references (exhibit numbers, years) are correct. The reasoning about the shift from 'merely listing' to 'explicitly documenting' amendments is logically sound and well-articulated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 411,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did PM's financial relationship with Swedish Match AB evolve between 2023 and 2024, particularly in terms of long-term debt obligations tied to the acquisition?",
      "original_answer": "In 2023, the long-term debt obligations related to the Swedish Match AB acquisition totaled $6,121 million, while in 2024, this amount decreased to $2,610 million. This indicates a significant reduction in the debt tied to the acquisition, suggesting that PM made substantial repayments or refinanced during the period. The decrease supports the idea that PM's financial dependency or exposure linked to the Swedish Match acquisition lessened over time.",
      "llm_answer": "In 2023 PMI’s balance sheet still carried the full €5.5 bn senior‑unsecured term‑loan that financed the Swedish Match acquisition, with the Euro credit‑facility portion recorded at **$6,121 million** (due 2027) 【PM_10k_2023.pdf page 100】. By year‑end 2024 PMI had prepaid the €3 bn (≈$3.2 bn) 3‑year tranche of that facility, so the remaining acquisition‑related Euro credit‑facility fell to **$2,610 million** (due 2027) 【PM_10k_2024.pdf page 100】, and the term‑loan note confirms the €3 bn prepayment 【PM_10k_2024.pdf page 103】. Thus, the long‑term debt tied to Swedish Match was reduced by roughly $3.5 bn between 2023 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-supported. STRENGTHS: (1) All key numbers are correct: $6,121 million in 2023, $2,610 million in 2024, and the €3 billion (~$3.2 billion) prepayment. (2) The calculation of the reduction (~$3.5 billion) is accurate ($6,121M - $2,610M = $3,511M, approximately $3.5B). (3) Multi-hop synthesis is excellent: the answer correctly traces the evolution across two years, identifies the specific mechanism (prepayment of the 3-year tranche), and cites appropriate document sources (pages 100 and 103 from both 2023 and 2024 10-Ks). (4) Entity identification is correct: PMI (Philip Morris International), Swedish Match AB acquisition, Euro credit facility, and the 2027 maturity date. (5) The answer provides superior context compared to the ground truth by explaining the specific mechanism (prepayment of €3 billion 3-year tranche) and citing exact document locations. (6) Semantic equivalence is maintained with the ground truth's core finding that debt obligations decreased significantly. MINOR CONSIDERATIONS: The LLM provides more granular detail than the ground truth (distinguishing between the €5.5 bn senior-unsecured term loan and the Euro credit facility portion), which adds value rather than detracting. The calculation of the reduction ($3.5 bn) is mathematically sound and properly contextualized. All financial metrics, dates, and entities are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 391,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did BMY's strategic positioning around KRAS inhibition evolve from 2023 to 2024, particularly in relation to the acquisition of Mirati and the development trajectory of Krazati?",
      "original_answer": "In 2023, BMY had not yet acquired Mirati, and Krazati was not part of its portfolio. However, by 2024, BMY completed the acquisition of Mirati for $4.8 billion, gaining full rights to Krazati, a KRAS G12C inhibitor. Krazati had already received FDA approval for second-line NSCLC and was in clinical development for first-line NSCLC in combination with a PD-1 inhibitor. Additionally, in 2024, Krazati was also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab, expanding its therapeutic footprint. This acquisition marked a significant evolution in BMY’s oncology strategy, positioning it more strongly in the KRAS inhibition space.",
      "llm_answer": "In the 2023 filing BMS’s portfolio contained no KRAS‑targeted product – the acquisitions listed (e.g., Turning Point, Orum) were focused on other oncology assets, showing KRAS inhibition was still a pure R&D focus【BMY_10k_2023.pdf pages 85‑89】. By the 2024 filing BMS had completed the Mirati acquisition, which added the FDA‑approved KRAS‑G12C inhibitor Krazati (adagrasib) and a suite of additional KRAS inhibitors and enabling programs, shifting the company from a development‑only stance to owning a best‑in‑class KRAS therapy and expanding its KRAS pipeline【BMY_10k_2024.pdf pages 91‑95】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core narrative arc - BMY had no KRAS inhibitors in 2023, then acquired Mirati in 2024 to gain Krazati. It accurately names Krazati as a KRAS G12C inhibitor and correctly characterizes the strategic shift from R&D-only to owning an approved therapy. The multi-hop reasoning is sound in connecting the acquisition to portfolio evolution.\n\nCRITICAL GAPS - QUANTITATIVE: The LLM answer completely omits the $4.8 billion acquisition price, which is a key quantitative fact in the ground truth. This is a significant omission for a financial question about a major acquisition.\n\nCRITICAL GAPS - COMPLETENESS: The LLM answer fails to mention the specific FDA approvals and indications for Krazati that occurred in 2024:\n1. Second-line NSCLC approval (mentioned in ground truth)\n2. First-line NSCLC in combination with PD-1 inhibitor (mentioned in ground truth)\n3. Advanced/metastatic KRAS-mutated colorectal cancer with cetuximab (mentioned in ground truth)\n\nThe LLM provides only vague references to \"a suite of additional KRAS inhibitors\" without specificity about Krazati's approved indications, which are central to understanding the development trajectory.\n\nMINOR ISSUES: The LLM uses \"BMS\" and \"BMY\" interchangeably (both acceptable ticker/abbreviation variations). The citation format with page numbers is appropriate but cannot be verified.\n\nOVERALL ASSESSMENT: While the LLM captures the strategic evolution narrative correctly, it significantly underperforms on quantitative precision (missing $4.8B figure) and clinical development details (missing specific indications and approvals). For a financial question about acquisition strategy, omitting the deal value is a material gap. The answer is directionally correct but incomplete on key factual details that define the strategic positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 506,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Goldman Sachs' disclosure and positioning of the Restricted Partner Compensation Plan evolved between 2023 and 2024, particularly in relation to newer compensation governance policies introduced during this period?",
      "original_answer": "In 2023, the Restricted Partner Compensation Plan was listed as Exhibit 10.3 and appeared early in the exhibit list, indicating a prominent position among compensation-related disclosures. By 2024, while the plan itself (still referenced as Exhibit 10.4) remained substantively unchanged, its relative placement shifted later in the exhibit list. Notably, in 2024, the firm introduced the Clawback Policy (Exhibit 10.1), signaling a new emphasis on compensation accountability and governance reforms. This suggests a strategic repositioning of compensation-related disclosures to prioritize risk mitigation and regulatory alignment alongside traditional partner compensation frameworks.",
      "llm_answer": "In the 2023 Form 10‑K the Amended and Restated Restricted Partner Compensation Plan was disclosed as Exhibit 10.3, listed among the other compensation plans without any explicit link to newer governance measures. In the 2024 filing the same plan appears as Exhibit 10.4, now placed after a newly added Clawback Policy (Exhibit 10.1) and other updated governance documents, showing that Goldman Sachs has repositioned the plan within a broader, more formalized compensation‑governance framework introduced during the year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY (10/10): All exhibit numbers are correct - Exhibit 10.3 in 2023, Exhibit 10.4 in 2024, and Clawback Policy as Exhibit 10.1 in 2024. Years are accurately cited (2023 vs 2024). ENTITY ACCURACY: Goldman Sachs correctly identified, plan name accurate (Amended and Restated Restricted Partner Compensation Plan), and all governance documents properly referenced. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years, correctly identifying the shift in exhibit placement and the introduction of new governance frameworks. The logical connection between the repositioning and the new Clawback Policy is sound. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core message as ground truth - that the plan moved from Exhibit 10.3 to 10.4, that its relative position shifted later in the exhibit list, and that this reflects a strategic repositioning within a broader governance framework. The phrase 'now placed after a newly added Clawback Policy' effectively captures the concept of relative placement shift. MINOR CONSIDERATIONS: The LLM answer is slightly more explicit about the plan being 'substantively unchanged' (implied in ground truth but not explicitly stated in LLM answer), though this is a minor omission that doesn't affect the core accuracy. The LLM answer adds helpful context by noting the plan was 'listed among the other compensation plans without any explicit link to newer governance measures' in 2023, which aligns with the ground truth's characterization of the 2023 positioning. Overall, the answer demonstrates accurate fact retrieval, correct multi-hop synthesis, and appropriate contextual framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 484,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of product categorization and business integration?",
      "original_answer": "In 2022, Philip Morris described its heat-not-burn products as part of its Reduced-Risk Products (RRPs) portfolio, emphasizing their role in a smoke-free future and highlighting the IQOS Platform 1 device and various heated tobacco units (HTUs) such as HEETS and Marlboro HeatSticks. These products were positioned as a key part of the company's long-term strategy to replace traditional cigarettes. By 2023, the categorization had evolved, with heat-not-burn products now explicitly grouped under 'smoke-free products' alongside e-vapor and oral nicotine products, as well as wellness and healthcare offerings. Additionally, in 2023, PMI explicitly stated that its heat-not-burn products include licensed KT&G heat-not-burn products, indicating a broader integration and expansion of the product line beyond internally developed offerings.",
      "llm_answer": "In the 2022 Form 10‑K PMI described its heat‑not‑burn line only as “heated‑tobacco units (HTU)” – the consumables used in the IQOS Platform 1 and listed under the broader reduced‑risk product umbrella (e.g., “Heated tobacco units (“HTU”) … include our HEETS … and the KT&G‑licensed brands, Fiit and Miix”)【PM_10k_2022.pdf†page 5】. By the 2023 filing the company now refers to the same line as “heat‑not‑burn products,” still defines them as HTU (now also covering zero‑tobacco consumables such as LEVIA) and groups them together with vapor and oral nicotine under a single “Smoke‑free products” segment in its revenue tables, indicating that heat‑not‑burn has been folded into a unified smoke‑free portfolio rather than a stand‑alone category【PM_10k_2023.pdf†page 38】【PM_10k_2023.pdf†page 39】. This reflects a shift from a distinct HTU label to an integrated smoke‑free product categorization.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about PMI's heat-not-burn product evolution from 2022 to 2023. STRENGTHS: (1) Correctly identifies the 2022 categorization as 'Heated Tobacco Units (HTU)' under the Reduced-Risk Products umbrella, with accurate product examples (HEETS, KT&G-licensed brands Fiit and Miix). (2) Accurately describes the 2023 shift to 'heat-not-burn products' terminology grouped under 'Smoke-free products' segment alongside vapor and oral nicotine. (3) Properly synthesizes the multi-hop information showing evolution in both terminology and business integration/categorization. (4) Correctly notes the expansion to include zero-tobacco consumables like LEVIA in 2023. (5) Provides specific document citations with page numbers, enhancing credibility. (6) The reasoning about the shift from 'distinct HTU label to integrated smoke-free product categorization' is sound and well-articulated. MINOR WEAKNESSES: (1) The LLM answer mentions KT&G-licensed products (Fiit and Miix) in the 2022 description, which is accurate but the ground truth emphasizes that the 2023 filing 'explicitly stated' the inclusion of licensed KT&G products as a notable evolution. The LLM could have emphasized this as a more significant evolution point. (2) The ground truth mentions 'IQOS Platform 1 device' as a specific device example in 2022, while the LLM references it but doesn't emphasize it as prominently. (3) The ground truth mentions 'wellness and healthcare offerings' as part of the 2023 categorization, which the LLM answer does not explicitly mention, though this is a relatively minor omission. QUANTITATIVE ACCURACY: All dates (2022, 2023) and product names are correct. No calculations required. QUALITATIVE ACCURACY: The multi-hop reasoning correctly synthesizes information across two years and identifies the key evolution in categorization and business integration. The semantic meaning aligns well with the ground truth despite slightly different wording.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 548,
        "total_tokens": 1988
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How did Bristol-Myers Squibb's approach to business risk governance evolve between 2023 and 2024 in relation to SEC Consent Order compliance, particularly regarding the role of the business risk and disclosure group?",
      "original_answer": "In 2023, Bristol-Myers Squibb established the business risk and disclosure group specifically to comply with the SEC Consent Order. This included implementing a formal review and certification process for SEC filings, retaining an outside consultant to re-engineer accounting and financial reporting processes, and introducing a governance mechanism to escalate and resolve compliance-related questions. By 2024, the company had fully integrated this group into its ongoing compliance framework, with no indication of modifications or reductions in scope, suggesting that the group remained a central component of financial governance under the Consent. The continued reference to the group in 2024 filings indicates that the company maintained its enhanced risk governance structure without significant changes.",
      "llm_answer": "In the 2023 filing BMS said the SEC Consent Order required it to **establish a business‑risk‑and‑disclosure group** and to put a governance process in place that escalates any compliance questions and monitors the new sales‑policy on an ongoing basis. The 2024 filing repeats that same language, confirming the group remains the central oversight body and that the escalation‑and‑regular‑monitoring procedures are still in effect, showing a continuity of the governance framework rather than a substantive change.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing the core evolution of Bristol-Myers Squibb's business risk governance between 2023 and 2024. STRENGTHS: (1) Correctly identifies the establishment of the business-risk-and-disclosure group in 2023 as an SEC Consent Order requirement; (2) Accurately describes the governance mechanisms including escalation procedures and monitoring processes; (3) Properly synthesizes the multi-hop information showing continuity between 2023 and 2024 filings; (4) Correctly emphasizes that the group remained central to the compliance framework with no substantive changes; (5) No quantitative errors or date inaccuracies. MINOR WEAKNESSES: (1) The LLM answer omits mention of the 'outside consultant retained to re-engineer accounting and financial reporting processes' which was explicitly noted in the ground truth as part of the 2023 implementation; (2) Does not explicitly mention the 'formal review and certification process for SEC filings' that was part of the original governance structure; (3) The phrase 'monitors the new sales-policy on an ongoing basis' appears in the LLM answer but is not clearly connected to the broader governance framework discussion in the ground truth. MULTI-HOP REASONING: The LLM correctly synthesizes information across 2023 and 2024 filings to demonstrate continuity and evolution (or lack thereof) in the governance approach. The reasoning that 'repeated language' indicates 'continuity rather than substantive change' is sound and logically valid. SEMANTIC EQUIVALENCE: The LLM's characterization of the group as 'the central oversight body' aligns well with the ground truth's description of it as 'a central component of financial governance.' The emphasis on maintained procedures and framework is semantically equivalent to the ground truth's conclusion about integration into ongoing compliance framework.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 512,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has UNP's treatment of the relationship between its pension plan's expected return and its asset allocation mix evolved between 2023 and 2024?",
      "original_answer": "In 2023, UNP explicitly stated that the expected return on plan assets was based on the asset allocation mix, historical returns, and market conditions, and included a specific actual return of 6% for that year. By 2024, the language shifted to indicating that the expected return 'depends on' the asset allocation mix, with no explicit mention of historical returns or market conditions, and no disclosure of the actual return for 2024. This represents a shift from a more comprehensive explanation of factors influencing returns to a narrower focus on the asset allocation mix alone.",
      "llm_answer": "In the 2023 Form 10‑K UNP explained that the expected return on its pension‑plan assets is calculated from the plan’s asset‑allocation mix (roughly 24 % equity and 75 % debt) and its historical performance, using a 5.25 % long‑term target rate. The 2024 filing repeats the same language and assumptions—still tying the expected return to the same allocation mix and 5.25 % target—so the company’s treatment of the expected‑return‑to‑allocation relationship has not changed.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth on multiple critical points: (1) CORE CLAIM ERROR: The LLM states 'the company's treatment of the expected-return-to-allocation relationship has not changed' between 2023 and 2024, directly contradicting the ground truth which explicitly states there WAS a shift in language and disclosure. (2) NUMERIC ERRORS: The LLM cites a '5.25% long-term target rate' for both years, but the ground truth mentions a '6% actual return for 2023' with no comparable figure for 2024. The 5.25% figure is not mentioned in the ground truth at all. (3) MISSING KEY DETAILS: The ground truth emphasizes that 2024 language shifted to 'depends on' the asset allocation mix with NO explicit mention of historical returns or market conditions, and NO disclosure of actual return for 2024. The LLM completely misses this evolution. (4) ASSET ALLOCATION PERCENTAGES: The LLM provides specific percentages (24% equity, 75% debt) that are not mentioned in the ground truth and appear to be fabricated. (5) MULTI-HOP REASONING FAILURE: The LLM failed to synthesize the year-over-year comparison correctly. The question asks how the treatment 'evolved' - implying change - and the ground truth confirms this evolution occurred, but the LLM incorrectly concludes no change happened. (6) SEMANTIC CONTRADICTION: The LLM's conclusion directly contradicts what the ground truth establishes as the core finding. This is a complete failure to answer the question accurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 417,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did BNY Mellon's disclosure approach to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of its accessibility and integration within corporate governance reporting?",
      "original_answer": "In 2022, BNY Mellon explicitly stated that the Directors' Code of Conduct was posted on its website and outlined its applicability to all directors. The document was referenced in the context of broader corporate governance disclosures, including Board Meetings and Committee Information. By 2023, the Directors' Code of Conduct was no longer just referenced but was specifically listed among the governance materials 'available on our website,' alongside key governance documents like the Corporate Governance Guidelines and committee charters. This evolution indicates a more structured and centralized approach to governance disclosures, with the Code being more directly tied to the company's overall governance framework in the 2023 filing.",
      "llm_answer": "In the 2022 Form 10‑K, BNY Mellon mentioned the Directors’ Code of Conduct only in the “Code of Ethics” section, providing a specific URL and noting that any amendments or waivers would be posted on the website 【BK_10k_2022.pdf p.10‑11】. By the 2023 filing, the company moved the Directors’ Code of Conduct into a dedicated list of corporate‑governance materials—grouped with the Governance Guidelines, By‑laws and committee charters—and made it freely available on its website, thereby improving accessibility and embedding it more fully within its governance reporting 【BK_10k_2023.pdf p.1‑2】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of BNY Mellon's disclosure approach. Key strengths: (1) Correctly identifies the 2022 approach where the Directors' Code of Conduct was mentioned in the 'Code of Ethics' section with website posting details; (2) Accurately captures the 2023 shift to a dedicated list of governance materials grouped with other key documents (Governance Guidelines, By-laws, committee charters); (3) Properly synthesizes the multi-hop comparison showing evolution from scattered reference to integrated governance framework; (4) Correctly emphasizes improved accessibility and structural integration as the key evolution. The answer includes specific document citations (page numbers) which adds credibility. Minor considerations: (1) The LLM answer provides slightly more operational detail (specific URL mention in 2022, amendments/waivers disclosure) compared to the ground truth, but this is supplementary and not contradictory; (2) The ground truth emphasizes 'more directly tied to the company's overall governance framework' while the LLM says 'embedding it more fully within its governance reporting'—these are semantically equivalent; (3) Both answers correctly identify the evolution from implicit/scattered disclosure to explicit/centralized disclosure. No quantitative errors detected. The multi-hop reasoning is sound: comparing 2022 vs 2023 filings and identifying the structural shift in how the Code is presented. The answer fully addresses the question's focus on accessibility and integration within corporate governance reporting.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 444,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with engineered systems, and what does this indicate about the company's approach to cloud migration and hybrid IT environments?",
      "original_answer": "In 2023, Oracle emphasized the flexibility of running Oracle Database across multiple deployment models, including on-premise, Oracle Cloud, and multicloud environments, with specific offerings like Oracle Exadata Cloud@Customer and Oracle Roving Edge Infrastructure. These options were framed around enabling customers to securely run Oracle Database behind their firewalls while being managed by Oracle. By 2024, Oracle shifted toward deeper integration of Oracle Database within Oracle Engineered Systems, such as the Oracle Exadata Database Machine, which combines database, storage, operating system, and networking hardware into a single optimized platform. This system was highlighted as being available across on-premise, OCI cloud, and hybrid deployments. The evolution from flexible deployment of standalone database services to tightly integrated engineered systems suggests a strategic shift toward offering more holistic, performance-optimized solutions that align with enterprise needs for scalability, security, and simplified maintenance. This indicates a maturation of Oracle's cloud migration strategy, focusing not only on deployment flexibility but also on delivering comprehensive, high-performance infrastructure packages.",
      "llm_answer": "In the 2023 filing Oracle stressed that Oracle Database could be run “on‑premise, in Oracle Cloud, or a hybrid combination of these two deployment models, such as in the Oracle Exadata Cloud@Customer deployment models” and that it was tightly integrated with its Engineered Systems – notably the Exadata Database Machine, which is offered “on‑premise, as a cloud offering in OCI, and as a hybrid cloud offering in customer data centers” (pages 9‑13). By the 2024 filing the company expanded that positioning, stating that Oracle Database “may be deployed in various IT environments, including Oracle Cloud, Oracle Exadata Cloud@Customer and OCI Dedicated Region…on‑premise data centers,” and that OCI services such as Exadata Cloud@Customer, OCI Dedicated Region, and OCI Sovereign Cloud are now part of the portfolio, still leveraging Engineered Systems (pages 11‑15). This shift shows Oracle is moving from a flexible‑cloud‑or‑on‑premise model toward a broader hybrid‑multicloud strategy, giving customers more managed pathways to migrate workloads while preserving on‑premise performance and integration with its engineered hardware.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Oracle's strategic positioning evolution between 2023 and 2024, with generally accurate factual content and appropriate multi-hop synthesis. STRENGTHS: (1) Correctly identifies key deployment models in both years (on-premise, Oracle Cloud, Exadata Cloud@Customer, OCI Dedicated Region, OCI Sovereign Cloud); (2) Accurately captures the shift from flexible deployment options to deeper integration with Engineered Systems; (3) Properly synthesizes information across two filing years; (4) Correctly identifies Exadata Database Machine as the core engineered system; (5) Appropriately concludes that Oracle is moving toward a hybrid-multicloud strategy. WEAKNESSES: (1) The LLM answer includes specific page references (pages 9-13, pages 11-15) that cannot be verified against the ground truth and may be inaccurate or fabricated; (2) Mentions 'OCI Sovereign Cloud' in 2024 positioning, which is not explicitly mentioned in the ground truth answer, creating potential factual uncertainty; (3) The ground truth emphasizes 'Oracle Roving Edge Infrastructure' as a 2023 offering, which the LLM answer completely omits - this is a notable gap in completeness; (4) The LLM answer's characterization of the shift as moving 'from flexible-cloud-or-on-premise model toward a broader hybrid-multicloud strategy' is slightly different from the ground truth's framing of 'from flexible deployment of standalone database services to tightly integrated engineered systems' - while semantically similar, the emphasis differs; (5) The ground truth emphasizes 'holistic, performance-optimized solutions' and 'comprehensive, high-performance infrastructure packages' more explicitly than the LLM answer. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are present in either answer, so this dimension is not directly testable. However, the absence of fabricated numbers is positive. MULTI-HOP REASONING: The LLM correctly synthesizes information across 2023 and 2024 filings and connects deployment flexibility to engineered systems integration. The reasoning is sound and logical. SEMANTIC EQUIVALENCE: The core message about Oracle's strategic evolution is conveyed accurately, though with slightly different emphasis and some omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1625,
        "completion_tokens": 613,
        "total_tokens": 2238
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the implementation of the formal review and certification process of annual and quarterly SEC reports evolved between 2023 and 2024, particularly in terms of compliance monitoring and governance procedures?",
      "original_answer": "In 2023, the company established a formal review and certification process of SEC filings as part of the Consent agreement, which included governance procedures to escalate potential compliance concerns to appropriate management levels and regular monitoring of compliance. By 2024, the company continued to emphasize the implementation of these governance procedures, noting that compliance with the policy was consistently monitored and that the process was integrated into company-wide sales policies to ensure adherence to inventory and sales limitations. The evolution reflects a shift from initial implementation in 2023 to sustained enforcement and integration into broader operational frameworks in 2024.",
      "llm_answer": "The 2004 SEC Consent Order required Bristol‑Myers to institute a “formal review and certification process of our annual and quarterly reports filed with the SEC,” and the 2023 Form 10‑K already described that this process had been put in place together with a business‑risk and disclosure group, an outside consultant, and a governance‑escalation mechanism that “is monitored on a regular basis” (2023 10‑K, p. 61‑65). The 2024 Form 10‑K repeats the same language, confirming that the formal review and certification framework remains active and that compliance continues to be overseen through a company‑wide policy that escalates any concerns to senior management and is regularly monitored, indicating that the process has been sustained and further embedded rather than fundamentally altered (2024 10‑K, p. 63‑67).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) ENTITY MISMATCH - The LLM answer discusses Bristol-Myers Squibb and references a 2004 SEC Consent Order, but the ground truth answer does not mention Bristol-Myers or any 2004 order. The question asks about evolution between 2023 and 2024 for an unspecified company, and the ground truth indicates a Consent agreement established in 2023 (not 2004). This is a fundamental entity identification error. (2) TEMPORAL INACCURACY - The LLM references a 2004 Consent Order as the origin point, but the ground truth clearly states the formal review and certification process was 'established' as part of 'the Consent agreement' in 2023. The LLM appears to be discussing a different company's historical compliance framework rather than the company in question. (3) INCOMPLETE SYNTHESIS - While the LLM does attempt to compare 2023 and 2024 language, it does so for the wrong company/context. The ground truth emphasizes a shift from 'initial implementation in 2023 to sustained enforcement and integration into broader operational frameworks in 2024,' whereas the LLM states the framework 'remains active' and 'has been sustained and further embedded rather than fundamentally altered' - a subtly different characterization that misses the emphasis on integration into company-wide sales policies. (4) PAGE REFERENCES - The LLM provides specific page numbers (p. 61-65 for 2023, p. 63-67 for 2024) that cannot be verified against the ground truth and appear to be fabricated or from a different source document. (5) MISSING CONTEXT - The ground truth specifically mentions integration into 'company-wide sales policies to ensure adherence to inventory and sales limitations,' which the LLM answer does not capture, instead using generic language about 'company-wide policy.' The answer demonstrates hallucination of company identity and historical context rather than accurate synthesis of the actual filing information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 524,
        "total_tokens": 1924
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of their market positioning and product categorization?",
      "original_answer": "In 2022, Philip Morris International (PMI) positioned heat-not-burn products as part of its broader Reduced-Risk Products (RRPs) portfolio, emphasizing their potential to present less harm to smokers who switch from traditional cigarettes. These products, including the Platform 1 device and its consumables, were described as being in various stages of development, scientific assessment, and commercialization. By 2023, PMI had refined its categorization, explicitly including heat-not-burn products within the smoke-free product segment, alongside e-vapor and oral nicotine products. Additionally, PMI began including licensed KT&amp;G heat-not-burn products in its portfolio, indicating a broader market approach and potential expansion of partnerships or offerings. This evolution shows a strategic shift from internal development focus to a more integrated and commercialized product positioning.",
      "llm_answer": "In the 2022 filing (PM 10‑K pages 74‑78), PMI presented its heat‑not‑burn (HNB) offerings as a distinct line within its “smoke‑free” portfolio, reporting HNB revenue separately and describing the products as a key reduced‑risk growth driver. By the 2023 filing (PM 10‑K pages 37‑41), the company folded HNB into a broader “smoke‑free products” segment, introduced the specific “heated‑tobacco units (HTU)” classification for those consumables, and emphasized a 14.7 % increase in HTU shipments—signalling a more integrated market positioning for its HNB products.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer addresses the evolution of PMI's heat-not-burn products from 2022 to 2023, but contains significant issues: (1) QUANTITATIVE PROBLEMS: The LLM cites specific page numbers (pages 74-78 for 2022, pages 37-41 for 2023) and a '14.7% increase in HTU shipments' that cannot be verified against the ground truth. These specific citations and metrics are presented with confidence but lack corroboration. The ground truth does not mention this specific percentage. (2) PARTIAL ALIGNMENT WITH GROUND TRUTH: The LLM correctly identifies that PMI moved from positioning HNB as part of RRPs to integrating them into smoke-free products segment, which aligns with the ground truth's 'strategic shift from internal development focus to a more integrated and commercialized product positioning.' (3) MISSING KEY INFORMATION: The LLM answer fails to mention the critical evolution point about PMI beginning to include licensed KT&G heat-not-burn products in its portfolio by 2023, which the ground truth explicitly highlights as indicating 'broader market approach and potential expansion of partnerships.' This is a significant omission for a multi-hop synthesis question. (4) TERMINOLOGY: The LLM introduces 'heated-tobacco units (HTU)' classification, which may be accurate but is not mentioned in the ground truth, raising questions about whether this is from the actual filings or an inference. (5) REASONING QUALITY: While the LLM demonstrates understanding of the general evolution (from distinct line to integrated segment), it fails to capture the partnership/licensing dimension that represents a strategic shift beyond just internal reorganization. The answer is partially correct on the market positioning evolution but incomplete on the full scope of changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 481,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with other Oracle technologies?",
      "original_answer": "In 2023, Oracle emphasized the deployment flexibility of Oracle Database across cloud-based, on-premise, or other IT environments, highlighting its perpetual licensing model and the company's strategy to provide customer choice. By 2024, Oracle Database's role had evolved to become a foundational component within broader engineered systems, such as Oracle Exadata Database Machine, which integrates the database with storage, operating system software, and hardware components for optimized performance. This shift indicates a move toward deeper integration with Oracle's infrastructure technologies, positioning Oracle Database not just as a standalone product but as a core element of Oracle Engineered Systems, available in on-premise, cloud (OCI), and hybrid cloud deployments.",
      "llm_answer": "In the 2023 filing Oracle presented the Oracle Database as a universally‑licensed engine that could be deployed in a range of environments—Oracle Cloud, on‑premise data centers, Exadata Cloud@Customer or OCI Dedicated Region—and emphasized its integration with Oracle Cloud services such as Java Cloud, APEX and the Autonomous Database. By the 2024 filing the company broadened that positioning, stressing far‑greater deployment flexibility (hybrid, multicloud, sovereign, edge and dedicated‑region options such as Exadata Cloud@Customer, OCI Dedicated Region, OCI Sovereign Cloud, Oracle Alloy and Roving Edge) and deeper integration with an expanded suite of OCI services—including AI, analytics, MySQL HeatWave, Java, Middleware and connectivity to third‑party clouds—making the database a core, interoperable component of an extensible, cloud‑first ecosystem.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and provides more detailed and nuanced information than the ground truth. Key strengths: (1) Correctly identifies the 2023 positioning emphasizing deployment flexibility across multiple environments (Oracle Cloud, on-premise, Exadata Cloud@Customer, OCI Dedicated Region) and integration with Oracle Cloud services. (2) Accurately captures the 2024 evolution toward broader deployment flexibility with expanded options (hybrid, multicloud, sovereign, edge, dedicated regions, OCI Sovereign Cloud, Oracle Alloy, Roving Edge). (3) Properly synthesizes the shift toward deeper integration with expanded OCI services (AI, analytics, MySQL HeatWave, Java, Middleware, third-party cloud connectivity). (4) Correctly identifies Oracle Database's evolution from standalone product to core ecosystem component. Minor considerations: (1) The LLM answer provides more granular deployment options and service integrations than the ground truth, which is more comprehensive but not contradictory. (2) The ground truth emphasizes 'engineered systems' and 'Oracle Exadata Database Machine' as the key integration point, while the LLM answer focuses more broadly on OCI services ecosystem integration. Both perspectives are valid and complementary—the LLM captures the broader cloud-first ecosystem positioning while ground truth emphasizes the engineered systems angle. (3) No quantitative errors detected; all deployment options and service names are correctly identified. (4) The multi-hop reasoning is sound: comparing 2023 vs 2024 positioning, identifying deployment flexibility evolution, and synthesizing integration changes across both years. The answer effectively addresses all parts of the question with accurate, detailed information that exceeds the ground truth in specificity while maintaining factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 503,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has BMY's strategic relationship with Krazati evolved from 2023 to 2024, and what specific financial commitments were made in 2024 that reflect this evolution?",
      "original_answer": "In 2023, Krazati was mentioned as part of BMY's oncology portfolio, demonstrating a strategic fit into their offerings. By 2024, BMY had acquired Mirati for $4.8 billion, obtaining the rights to Krazati, which had received FDA and EMA approvals for second-line NSCLC and was in clinical development for first-line NSCLC. Additionally, BMY committed $1.0 billion in contingent value rights tied to the development of PRMT5 Inhibitor, further signaling long-term investment in the acquired assets.",
      "llm_answer": "In the 2023 filing BMS noted that Krazati – a KRAS‑inhibitor for NSCLC – was already in its oncology portfolio, having been added “through Mirati” as a strategic fit (2023 p. 41‑45). By the 2024 filing BMS had moved from a partnership to a full acquisition of Mirati, formally securing Krazati and committing roughly $4.8 billion in cash (including $4.596 billion for Mirati shares and $205 million for equity awards) plus a $1 billion contingent‑value right, for a total allocated consideration of about $4.9 billion and $640 million of definite‑lived product‑rights value for Krazati (2024 p. 91‑95).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the question. STRENGTHS: (1) Correctly identifies the evolution from 2023 (Krazati as part of oncology portfolio through Mirati partnership) to 2024 (full acquisition of Mirati). (2) Accurately states the $4.8 billion acquisition price for Mirati, with appropriate breakdown ($4.596 billion for shares + $205 million for equity awards = ~$4.8 billion). (3) Correctly identifies the $1.0 billion contingent value right tied to PRMT5 Inhibitor development. (4) Provides additional relevant details (FDA/EMA approvals for second-line NSCLC, clinical development for first-line NSCLC, $640 million product-rights value) that enhance understanding. (5) Properly synthesizes multi-hop information: 2023 status → 2024 acquisition → financial commitments. (6) Includes specific page references (2023 p. 41-45, 2024 p. 91-95) showing source documentation. MINOR CONSIDERATIONS: (1) The LLM provides slightly more granular financial breakdown than the ground truth (distinguishing share purchase from equity awards), which is actually more precise and accurate. (2) The total consideration calculation (~$4.9 billion) appears to include the contingent value right, which is reasonable but the ground truth presents these as separate commitments. (3) The mention of $640 million definite-lived product-rights value is additional context not in ground truth but is factually accurate and relevant. VERIFICATION: All key numbers align with ground truth: $4.8B acquisition, $1.0B contingent value right, Krazati KRAS-inhibitor for NSCLC, FDA/EMA approvals, first-line development status. The multi-hop reasoning correctly traces the relationship evolution and financial commitments across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 478,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the treatment or status of the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV evolved between 2022 and 2023 based on BK's SEC filings?",
      "original_answer": "In 2022, the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV were introduced as securities registered under Section 12(b) of the Act and were listed on the New York Stock Exchange under the trading symbol BK/P, fully and unconditionally guaranteed by The Bank of New York Mellon Corporation. In 2023, the same securities remained registered under Section 12(b) of the Act, retained the same trading symbol BK/P, and continued to be listed on the New York Stock Exchange with the same guarantee structure. Therefore, there was no change in the treatment or status of these securities between the two years.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K filings list the 6.244% Fixed‑to‑Floating Rate Normal Preferred Capital Securities of Mellon Capital IV (ticker BK/P) as a separate class of securities registered under Section 12(b) on the NYSE and describe them as “fully and unconditionally guaranteed” by The Bank of New York Mellon Corporation. The language and classification are identical in the two reports, showing that the securities’ status and treatment did not change between 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and effectively addresses the multi-hop question about the evolution of the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities between 2022 and 2023. STRENGTHS: (1) All key facts are correct - the security name, percentage rate (6.244%), ticker symbol (BK/P), registration status (Section 12(b)), exchange listing (NYSE), and guarantee structure (fully and unconditionally guaranteed by The Bank of New York Mellon Corporation) are all accurately stated. (2) The multi-hop synthesis is sound - the answer correctly compares the 2022 and 2023 filings and identifies that no changes occurred. (3) The conclusion that 'the securities' status and treatment did not change between 2022 and 2023' directly matches the ground truth finding. (4) The answer appropriately cites both years' Form 10-K filings, demonstrating proper cross-document synthesis. (5) Numeric accuracy is perfect - the 6.244% rate is correctly stated. MINOR CONSIDERATIONS: The LLM answer is slightly more concise than the ground truth, which provides slightly more explicit detail about the securities being 'introduced' in 2022 and 'remained' in 2023. However, this is a stylistic difference that does not affect factual accuracy. The LLM's phrasing 'showing that the securities' status and treatment did not change' is semantically equivalent to the ground truth's explicit statement of no change. The answer demonstrates strong understanding of the question's requirement to track changes (or lack thereof) across multiple years and documents.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 430,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the capacity and utilization of PMI's short-term credit arrangements changed from 2022 to 2023, and what does this shift suggest about their near-term liquidity posture?",
      "original_answer": "The capacity of PMI's short-term credit arrangements increased from $1.9 billion at the end of 2022 to $2.7 billion at the end of 2023, while the actual utilization decreased slightly from $295 million to $283 million. This indicates that PMI has expanded its available liquidity buffer without increasing its drawdown, suggesting a more conservative approach to short-term financing and working capital management.",
      "llm_answer": "PMI’s short‑term credit capacity rose from roughly $1.9 billion at December 31 2022 to about $2.7 billion at December 31 2023, while borrowings under those arrangements fell from about $295 million to $283 million (2023 filing)【PM_10k_2023.pdf p. 106‑110】. The larger available line combined with slightly lower usage gives PMI a bigger liquidity cushion and suggests a stronger, more comfortable near‑term liquidity posture.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All financial figures are correct - capacity increased from $1.9 billion (2022) to $2.7 billion (2023), and utilization decreased from $295 million to $283 million. The dates (December 31, 2022 and 2023) are accurate. No calculation errors present. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) the change in capacity and utilization metrics, and (2) what this shift suggests about liquidity posture. ENTITY ACCURACY: PMI is correctly identified, fiscal years are correct, and financial metrics (short-term credit arrangements, capacity, utilization/borrowings) are properly labeled. REASONING QUALITY: The multi-hop synthesis is sound - the model correctly connects the quantitative changes (larger capacity, lower utilization) to the qualitative interpretation (stronger liquidity posture, more conservative approach). The logic that 'larger available line combined with slightly lower usage gives PMI a bigger liquidity cushion' is valid and well-reasoned. SEMANTIC EQUIVALENCE: The LLM's characterization of the shift as suggesting 'a stronger, more comfortable near-term liquidity posture' is semantically equivalent to the ground truth's 'more conservative approach to short-term financing and working capital management' - both convey improved liquidity flexibility. Minor note: The LLM uses 'stronger, more comfortable' while ground truth uses 'conservative' - these are complementary interpretations of the same underlying fact pattern (expanded capacity with lower utilization). The citation to specific pages (106-110) adds credibility. Overall, this is a high-quality answer with accurate numbers, sound reasoning, and appropriate conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 484,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Oracle's positioning of the Autonomous Database evolved between 2023 and 2024, particularly in terms of integration with other cloud services and automation capabilities?",
      "original_answer": "In 2023, Oracle positioned the Autonomous Database as part of its broader Oracle Cloud Infrastructure (OCI) offerings, emphasizing its automated database operations and the ability to run in cloud, on-premise, or hybrid environments. It was described as a service that Oracle runs, manages, upgrades, and supports on behalf of the customer, with a focus on reducing IT process time and resources. By 2024, Oracle expanded its positioning to highlight deeper integration with other Oracle Cloud services, such as Java Cloud and Oracle APEX low-code service, and emphasized open interfaces and native machine learning capabilities. The 2024 filing also introduced a stronger focus on automation powered by machine learning, including diagnostics, fault prediction, error handling, and automatic threat detection. Additionally, 2024 emphasized the Autonomous Database's role in enabling modern cloud-native application development and analytics, including data lake houses and real-time analysis of transactional data.",
      "llm_answer": "In the 2023 filing Oracle presented the Autonomous Database primarily as a self‑driving, automated service inside OCI that “delivers performance and scale…with automated database operations and policy‑and‑machine‑learning‑driven optimization” and “automates routine database administration tasks, including maintenance, tuning, patching, scaling, security and backup” while using machine‑learning diagnostics to lower labor costs and provide automatic threat detection (ORCL_10k_2023.pdf p.10‑11). By the 2024 filing the narrative had broadened: Oracle now emphasizes tighter integration with the rest of its cloud portfolio—linking Autonomous Database to Java Cloud, APEX, Oracle Analytics Cloud and third‑party analytics tools—and highlights hybrid/on‑premise options such as Exadata Cloud@Customer and OCI Dedicated Region, together with enhanced automation (machine‑learning‑driven optimization, built‑in developer capabilities for rapid data‑mart/warehouse/lake‑house creation, and automatic threat remediation) (ORCL_10k_2024.pdf p.13‑14).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2023 positioning emphasizing automated database operations, machine learning-driven optimization, and threat detection; (2) Accurately captures the 2024 evolution toward deeper integration with other Oracle Cloud services (Java Cloud, APEX, Oracle Analytics Cloud); (3) Properly synthesizes the multi-hop comparison between years, showing progression from core automation to broader ecosystem integration; (4) Correctly identifies specific capabilities like Exadata Cloud@Customer and OCI Dedicated Region as 2024 additions; (5) Accurately conveys the shift toward cloud-native application development and data lake house capabilities; (6) Includes appropriate source citations (ORCL_10k_2023.pdf, ORCL_10k_2024.pdf) with page references. MINOR CONSIDERATIONS: (1) The LLM answer provides slightly more specific detail about deployment options (Exadata Cloud@Customer, OCI Dedicated Region) compared to the ground truth's more general reference to 'hybrid environments,' though this is an enhancement rather than an error; (2) The LLM mentions 'third-party analytics tools' which adds context not explicitly in the ground truth but is reasonable inference from broader integration messaging; (3) The phrasing 'automatic threat remediation' in LLM vs 'automatic threat detection' in ground truth represents a minor semantic difference—remediation is a logical extension of detection and both convey enhanced security automation. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and multiple service offerings, correctly identifying the evolution pattern and supporting details. QUANTITATIVE ACCURACY: No numeric values, dates, or calculations are present in either answer, so this dimension is not applicable but receives full marks as no errors exist. The answer fully addresses the question's requirements regarding integration evolution and automation capability progression.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1523,
        "completion_tokens": 553,
        "total_tokens": 2076
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How did GM's financial relationship with Ultium Cells Holdings LLC evolve between 2023 and 2024, particularly in terms of its capital involvement and strategic positioning?",
      "original_answer": "In 2023, GM's relationship with Ultium Cells Holdings LLC was characterized by contingent capital commitments, with a committed contribution of $0.8 billion, and the entity was classified as a variable interest entity (VIE) where GM lacked voting control. By 2024, GM's involvement evolved into a more direct investment of $0.7 billion, indicating a shift from a potential future obligation to a realized investment stake. This transformation suggests a strategic realignment, providing GM with potentially greater influence over Ultium Cells' operations while stabilizing its financial exposure.",
      "llm_answer": "In 2023 GM disclosed that it had pledged $0.8 billion of committed capital to Ultium Cells Holdings LLC (part of a $3.5 billion maximum loss exposure) and that it held no voting or other control over the entity [GM 10‑K 2023 p. 78‑82]. By 2024 the company recorded an actual $0.7 billion cash outflow for an investment in Ultium Cells Holdings LLC in its cash‑flow statement, indicating continued but slightly reduced capital support while still remaining a non‑controlling, strategic partner for its EV‑battery supply [GM 10‑K 2024 p. 38‑42].",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key financial figures and the evolution of GM's relationship with Ultium Cells Holdings LLC. STRENGTHS: (1) Quantitative accuracy is excellent - correctly identifies the $0.8 billion committed capital in 2023, the $0.7 billion actual investment in 2024, and mentions the $3.5 billion maximum loss exposure context. (2) Entity identification is correct - properly names Ultium Cells Holdings LLC and GM, with accurate fiscal years (2023 and 2024). (3) Multi-hop synthesis is sound - the answer correctly traces the evolution from contingent commitment to realized investment and notes the shift from potential obligation to actual capital deployment. (4) Strategic positioning is addressed - mentions non-controlling status and EV-battery supply context. (5) Citation format is appropriate with specific page references. MINOR WEAKNESSES: (1) The LLM answer uses slightly different framing than ground truth - describes the shift as 'continued but slightly reduced capital support' rather than emphasizing the transformation from contingent commitment to direct investment stake. (2) The ground truth emphasizes 'potentially greater influence' from the shift, while the LLM maintains the non-controlling characterization without explicitly noting the potential for increased strategic positioning. (3) The phrase 'slightly reduced' ($0.8B to $0.7B) is accurate but could be more precisely characterized as a transition from committed contingent capital to realized investment. The answer is semantically equivalent to the ground truth and captures the essential evolution of the relationship, though it could have been slightly more explicit about the strategic realignment implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 481,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has the financial impact of the Litigation Management Deed evolved between 2022 and 2024, particularly in terms of the amount of as-converted value released and the number of series A preferred shares issued during the anniversary releases?",
      "original_answer": "In 2022, as part of the sixth anniversary release assessment required by the Litigation Management Deed, Visa released $3.5 billion of as-converted value and issued 176,655 shares of series A preferred stock. In 2024, during the eighth anniversary release, the company released $2.7 billion of as-converted value and issued 99,264 shares of series A preferred stock. This indicates a decrease in both the value released and the number of shares issued, suggesting a reduction in the financial burden associated with the VE territory covered litigation over time.",
      "llm_answer": "The litigation‑management deed’s sixth‑anniversary release in 2022 freed about **$3.5 billion** of as‑converted value and resulted in the issuance of **176,655 series A preferred shares**. By the eighth‑anniversary release in 2024 the amount released had fallen to roughly **$2.7 billion**, with **99,264 series A preferred shares** issued – a decline of roughly $0.8 billion and 77,000 shares.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. All key financial figures are correct: 2022 sixth-anniversary release of $3.5 billion with 176,655 shares issued, and 2024 eighth-anniversary release of $2.7 billion with 99,264 shares issued. The calculations provided are accurate: the difference of $0.8 billion ($3.5B - $2.7B) and approximately 77,391 shares (176,655 - 99,264, which the LLM rounds to 77,000). The multi-hop synthesis is sound, correctly identifying the evolution across the two time periods and drawing the appropriate conclusion about the reduction in financial burden. The answer properly identifies the Litigation Management Deed context and correctly attributes these releases to Visa. The only minor point is that the share difference is stated as 'roughly 77,000' when the precise figure is 77,391, but this rounding is reasonable and doesn't constitute a material error. The semantic equivalence is strong - the LLM conveys the same information as the ground truth while using slightly different phrasing ('freed about' vs 'released'). The answer directly addresses all parts of the question regarding how the financial impact evolved between 2022 and 2024, including both the as-converted value released and the number of series A preferred shares issued.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 364,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How did the financial and strategic relationship between 3M and the Aearo Entities evolve between 2023 and 2024, particularly in terms of litigation impact and business segment adjustments?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities following the dismissal of their bankruptcy filings, lifting the stay on litigation related to Combat Arms Earplugs and entering into the CAE Settlement to resolve existing and future claims. This reconsolidation had an immaterial income statement impact. By 2024, the Aearo Entities were referenced in the context of divestiture and acquisition impacts in the Transportation and Electronics segment, where their deconsolidation in 2022 and reconsolidation in 2023 were each reflected separately as divestiture and acquisition effects. This indicates a shift from litigation-focused involvement in 2023 to a more strategic financial treatment in 2024.",
      "llm_answer": "In 2023 3M re‑consolidated the Aearo Entities after a Chapter 11 period, entered the $6 billion CAE Settlement (originally $5 billion cash + $1 billion stock), recorded a $4.2 billion pre‑tax charge and raised its accrued Combat‑Arms‑Earplugs liability to $5 billion, with those litigation costs shown as special items in the Safety & Industrial segment and in corporate‑special‑item expenses (MMM 10‑K 2023 pp. 98‑102). By 2024 the settlement was amended to a cash‑only $1 billion component, corporate‑special‑item litigation costs fell, and the Aearo Entities’ sales and liabilities are now reflected as acquisition impacts in the Transportation & Electronics segment (with segment composition also adjusted for the Solventum separation), indicating a shift from a high‑cost settlement phase to a funded‑trust, fully integrated business relationship (MMM 10‑K 2024 pp. 30‑34).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides substantial detail and addresses the core question about the evolution of 3M's relationship with Aearo Entities between 2023-2024, including litigation impact and business segment adjustments. However, there are significant quantitative accuracy issues that prevent a higher score.\n\nSTRENGTHS:\n1. Correctly identifies 2023 reconsolidation after Chapter 11 dismissal\n2. Correctly references CAE Settlement and its amendment to cash-only in 2024\n3. Correctly identifies shift from Safety & Industrial segment to Transportation & Electronics segment treatment\n4. Correctly notes the Solventum separation context in 2024\n5. Properly synthesizes multi-hop information across 2023 and 2024 filings\n6. Correctly characterizes the shift from litigation-focused to strategic financial treatment\n\nWEAKNESSES:\n1. QUANTITATIVE ERRORS: The LLM states the CAE Settlement was \"$6 billion CAE Settlement (originally $5 billion cash + $1 billion stock)\" - this math is incorrect ($5B + $1B = $6B is correct arithmetic, but the ground truth does not specify these exact component amounts, and the claim about \"$1 billion stock\" component needs verification against actual filings)\n2. The $4.2 billion pre-tax charge figure is stated but not verified in ground truth\n3. The $5 billion accrued liability figure is stated but not confirmed in ground truth\n4. The claim about \"$1 billion component\" in 2024 amendment is specific but unverified\n5. Page citations (pp. 98-102, pp. 30-34) are provided but cannot be verified against ground truth\n\nMULTI-HOP REASONING:\nThe LLM correctly synthesizes information across 2023 and 2024 filings, properly connecting: (1) reconsolidation event → (2) settlement costs → (3) segment reclassification → (4) 2024 amendment. This multi-hop synthesis is sound and matches the ground truth's narrative arc.\n\nSEMANTIC EQUIVALENCE:\nThe LLM answer conveys the same fundamental information as ground truth regarding the evolution from litigation-focused involvement to strategic financial treatment, though with additional specific numbers that may or may not be accurate.\n\nCRITICAL ISSUE:\nThe ground truth explicitly states the reconsolidation had \"immaterial income statement impact,\" but the LLM provides specific large dollar figures ($4.2B charge, $5B liability) that appear to contradict this characterization. This is a significant discrepancy that suggests either: (a) the LLM is confusing settlement costs with reconsolidation impact, or (b) the specific numbers are incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 676,
        "total_tokens": 2080
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the financial treatment or structure of Class C Common Stock evolved between 2022 and 2024, particularly in terms of its relationship to other stock classes and its earnings per share performance?",
      "original_answer": "In 2022, Class C Common Stock was described in the context of its voting rights and potential influence on corporate actions, particularly in mergers or strategic decisions, with an emphasis on how its holders—typically financial institution clients—might have divergent interests from Class A Common Stockholders. By 2024, Class C Common Stock had a significantly higher earnings per share ($33.17 basic EPS and $33.13 diluted EPS) compared to Class A ($8.29 basic EPS and $8.28 diluted EPS), indicating a shift in its financial performance relative to other stock classes, even though its governance role appeared unchanged.",
      "llm_answer": "Between 2022 and 2024 Visa moved Class C common stock from a non‑traded, conversion‑only class that was tightly tied to Class A (with limited voting rights and no public market) to a freely transferable class that can be issued in exchange offers and is authorized up to 1.1 billion shares, while its holders now vote only on limited matters (V_10k_2022.pdf pp.30‑34; V_10k_2024.pdf pp.89‑91). In the same period the EPS attributable to Class C rose from roughly $28 per share in 2022 to about $39 per share in 2024 (V_10k_2022.pdf p.34; V_10k_2024.pdf p.88).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM provides significantly incorrect EPS figures. Ground truth states Class C EPS in 2024 was $33.17 basic and $33.13 diluted, but LLM claims ~$39 per share in 2024. For 2022, ground truth does not specify exact Class C EPS but LLM claims ~$28, which cannot be verified against the stated ground truth. The EPS comparison is fundamentally wrong - the LLM overstates 2024 Class C EPS by approximately $6 per share (18% error). (2) STRUCTURAL CLAIMS - The LLM makes detailed claims about Class C stock being 'non-traded, conversion-only' in 2022 and becoming 'freely transferable' by 2024, with authorization up to 1.1 billion shares. The ground truth does not address these structural changes at all - it only mentions voting rights context in 2022 and governance role appearing unchanged in 2024. The LLM appears to have fabricated or misinterpreted structural details not present in the ground truth. (3) MULTI-HOP REASONING - While the LLM attempts to synthesize information across years and address both structural and EPS dimensions, the synthesis is built on incorrect numerical data and unsupported structural claims. (4) COMPLETENESS - The LLM does address both the structural/relationship aspect and EPS performance, but with significant inaccuracies in the EPS numbers, which are critical quantitative metrics. The ground truth emphasizes the EPS differential between Class A and Class C ($8.29 vs $33.17 in 2024), showing Class C significantly outperforming, but the LLM's inflated figures distort this relationship. (5) ENTITY ACCURACY - Company (Visa) and years (2022-2024) are correct, but the financial metrics are substantially wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 465,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Qualcomm's involvement in the development and commercialization of ADAS/AD technology evolved from fiscal 2022 to fiscal 2024, based on the specific changes in their strategic activities and revenue categorization?",
      "original_answer": "In fiscal 2022, Qualcomm was actively investing in and developing ADAS/AD technologies as part of its broader innovation and strategic investment initiatives, particularly through its QSI segment and Qualcomm Ventures, with an emphasis on expanding opportunities for its technologies beyond mobile handsets. By fiscal 2024, Qualcomm's engagement had evolved from development to commercialization, as evidenced by the explicit inclusion of ADAS/AD under revenue streams categorized under 'automotive' products. This indicates that ADAS/AD transitioned from a technology under development and investment in 2022 to a revenue-generating product line by 2024.",
      "llm_answer": "In fiscal 2022 Qualcomm described ADAS/AD only as a target of its R&D program – the 10‑K notes that the company will “continue the development of … other technologies (such as ADAS/AD and XR)” and that ADAS/AD revenue is bundled in the automotive QCT segment of about $1.5 billion. By fiscal 2024 the filing shows a shift toward commercialization, stating that Qualcomm is “supporting the design and introduction of new products… such as ADAS/AD,” and automotive revenue (which now explicitly includes connectivity, digital‑cockpit and ADAS/AD) rose to $2.9 billion, indicating a larger, revenue‑driven focus on the technology.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of Qualcomm's ADAS/AD involvement from development/investment focus in fiscal 2022 to commercialization in fiscal 2024, matching the ground truth's main thesis. The qualitative reasoning about the shift from R&D emphasis to revenue-generating product line is sound and well-supported.\n\nHowever, there are quantitative accuracy concerns:\n\n1. AUTOMOTIVE REVENUE FIGURES: The LLM states automotive revenue was \"about $1.5 billion\" in fiscal 2022 and \"rose to $2.9 billion\" in fiscal 2024. The ground truth does not provide these specific numbers, making verification impossible. The LLM appears to have introduced specific figures that may or may not be accurate from the actual 10-K filings. This is a significant issue because the question explicitly asks about \"specific changes in their strategic activities and revenue categorization.\"\n\n2. REVENUE CATEGORIZATION: The LLM correctly notes that ADAS/AD revenue transitioned from being bundled/implicit in automotive segment to being explicitly categorized/called out. This aligns with the ground truth's statement about \"explicit inclusion of ADAS/AD under revenue streams categorized under 'automotive' products.\"\n\n3. STRATEGIC ACTIVITIES: The LLM accurately captures the evolution from \"development of...ADAS/AD\" language in 2022 to \"supporting the design and introduction of new products...such as ADAS/AD\" in 2024, which demonstrates the development-to-commercialization shift.\n\n4. SEGMENT IDENTIFICATION: Correctly identifies QCT automotive segment as the relevant revenue category.\n\nSTRENGTHS: Multi-hop reasoning is sound; correctly synthesizes information about strategic shift; appropriately addresses the evolution question; good contextual framing.\n\nWEAKNESSES: The specific revenue numbers ($1.5B and $2.9B) are presented as facts but cannot be verified against the ground truth provided. If these numbers are incorrect, it would significantly impact the answer's reliability. The ground truth focuses on the transition from development to commercialization but does not provide these specific dollar amounts, suggesting the LLM may have hallucinated or drawn from sources not in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 599,
        "total_tokens": 1938
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Visa's U.S. Retrospective Responsibility Plan evolved between 2022 and 2024, particularly in terms of its mechanisms for addressing liability in covered litigation, and what does this evolution suggest about the company's approach to managing litigation risk?",
      "original_answer": "In 2022, Visa's U.S. Retrospective Responsibility Plan was described as a mechanism to address monetary liabilities from settlements or final judgments in U.S. covered litigation, utilizing a U.S. litigation escrow account, though the accrual for liabilities could differ from the escrow balance. By 2024, the plan had become significantly more structured and detailed, introducing a suite of interrelated mechanisms including a U.S. litigation escrow agreement, a conversion feature for Class B common stock, makewhole agreements related to the Class B-1 exchange offer, indemnification obligations from Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. These additions indicate a more comprehensive and layered strategy to manage litigation risk, suggesting Visa has moved toward a more proactive and diversified approach to mitigate potential financial exposure from ongoing or future litigation outcomes.",
      "llm_answer": "In the 2022 filing Visa’s U.S. retrospective responsibility plan was described as a “suite of related mechanisms” that includes a U.S. litigation escrow account, a conversion feature on its class B shares, make‑whole agreements, indemnification obligations, an interchange‑judgment‑sharing agreement, a loss‑sharing agreement and an omnibus settlement‑sharing agreement, all designed to limit the company’s monetary exposure to U.S. covered litigation with the escrow funded at the board’s discretion and the accrual potentially exceeding the escrow balance【V_10k_2022.pdf:46‑48】. By the 2024 filing the same framework remains but the company has markedly increased escrow funding (deposits of $1.5 bn in 2024 versus $1.0 bn in 2023) and the escrow balance grew to $3.089 bn, while the conversion and make‑whole features continue to offset EPS dilution and the loss‑sharing and indemnification provisions stay in place, indicating a more robust, liquidity‑backed, multi‑layered approach to contain and allocate litigation risk【V_10k_2024.pdf:70‑74】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual error that contradicts the ground truth. The ground truth explicitly states that in 2022, the plan was described as 'a mechanism' with 'a U.S. litigation escrow account' (singular, basic structure), while by 2024 it had 'become significantly more structured and detailed, introducing a suite of interrelated mechanisms.' However, the LLM answer claims the opposite - that in 2022 the plan was already described as a 'suite of related mechanisms' including all the complex features (conversion feature, make-whole agreements, indemnification, interchange-judgment-sharing, loss-sharing, omnibus agreement). This is a direct contradiction of the ground truth's core finding about the EVOLUTION of the plan. The LLM incorrectly attributes 2024-level complexity to 2022. Additionally, while the LLM provides specific dollar amounts ($1.5bn in 2024, $1.0bn in 2023, $3.089bn escrow balance), these numbers cannot be verified against the ground truth provided, which does not include these specific figures. The LLM's characterization of the 2024 plan as having 'the same framework' as 2022 is incorrect - the ground truth indicates substantial structural additions and evolution. The LLM does correctly identify the general mechanisms involved and the multi-layered approach concept, but fundamentally misrepresents the timeline and nature of the evolution. The answer fails to capture the key insight that the plan EVOLVED from simple to complex between 2022 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1536,
        "completion_tokens": 423,
        "total_tokens": 1959
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did Merck's financial stake in Lynparza evolve between 2023 and 2024, and what indicators suggest changes in the product's performance or strategic importance during this period?",
      "original_answer": "In 2023, Merck reported a $1.5 billion net intangible asset related to Lynparza as part of its collaboration with AstraZeneca. By 2024, although the financial stake amount was not explicitly stated, there was a 9% growth in alliance revenue linked to Lynparza, driven by increased demand in most international markets. Additionally, in January 2025, Lynparza received approval in China for an adjuvant treatment in early breast cancer, indicating expanded market potential. This suggests that while the initial asset value was substantial in 2023, 2024 marked a period of performance-driven growth and regulatory expansion, enhancing its strategic importance.",
      "llm_answer": "Merck’s share of Lynparza’s profits rose from $1.199 billion in 2023 to $1.311 billion in 2024 – a 9 % increase (11 % when foreign‑exchange effects are excluded)【MRK_10k_2024.pdf p.53】. The 2023 filing recorded the net intangible‑asset value of the Lynparza collaboration at about $1.5 billion and the 2024 filing did not show a change, but the higher alliance revenue, the comment that “alliance revenue related to Lynparza grew 9 % in 2024 largely due to higher demand in most international markets”【MRK_10k_2024.pdf p.54】, and the new Chinese adjuvant‑breast‑cancer indication noted in the 2024 discussion all point to stronger product performance and growing strategic importance.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with mostly correct information and sound multi-hop reasoning. STRENGTHS: (1) Correctly identifies the $1.5 billion net intangible asset value for 2023, matching ground truth exactly. (2) Accurately reports the 9% growth in alliance revenue for 2024 (11% excluding FX effects), with proper citation. (3) Correctly notes that the 2024 filing did not show an explicit change in the intangible asset amount. (4) Properly synthesizes multiple data points (profit figures, revenue growth, regulatory approvals) to support conclusions about strategic importance. (5) Appropriately references the Chinese adjuvant breast cancer indication as evidence of expanded market potential. (6) Multi-hop reasoning is sound, connecting financial metrics to product performance indicators. MINOR ISSUES: (1) The LLM introduces specific profit figures ($1.199 billion in 2023 to $1.311 billion in 2024) that are not mentioned in the ground truth answer. While these appear to be from the 10-K filing (as cited), the ground truth focuses on the $1.5 billion intangible asset and 9% alliance revenue growth rather than these specific profit numbers. This represents additional detail beyond the ground truth rather than an error. (2) The ground truth mentions the January 2025 Chinese approval as a forward-looking indicator, while the LLM references it as part of the 2024 discussion - this is a minor temporal framing difference. CALCULATION VERIFICATION: The 9% growth figure is correctly stated and matches ground truth. The 11% FX-adjusted figure is also correctly presented. ENTITY ACCURACY: All entities (Merck, Lynparza, AstraZeneca, China) are correctly identified. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core message as ground truth - that Lynparza showed performance-driven growth and strategic expansion between 2023-2024. The additional profit figures provide more granular financial detail while maintaining consistency with the overall narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 540,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did Skoal's market position and competitive performance within Altria's oral tobacco products segment evolve between 2022 and 2024, particularly in relation to its key competitor brands?",
      "original_answer": "In 2022, Skoal was one of the premium oral tobacco brands under Altria, alongside Copenhagen and on!, with a retail share of 9.3%. By 2024, Skoal's retail share had declined to 7.6%, indicating a weakening market position. This decline occurred alongside a broader contraction in Altria's oral tobacco segment, which saw total retail share fall from 42.5% in 2023 to 37.5% in 2024. Notably, Copenhagen, Altria's leading brand, also experienced a drop from 23.5% to 19.1% over the same period, while on! oral nicotine pouches gained traction, rising from 6.8% to 8.3%. These shifts suggest that Skoal not only lost market share overall but also underperformed relative to both its primary brand (Copenhagen) and the newer product category (on!).",
      "llm_answer": "In 2022 Skoal shipped roughly 170 million cans/packs and captured about 10 % of the oral‑tobacco retail share, behind Copenhagen (≈460 million cans, 24 % share) and ahead of on! (≈100 million cans, 6 % share)【MO_10k_2022.pdf†page 7】. By 2024 Skoal’s shipments fell to 147 million cans and its share slipped to 7.6 %, while Copenhagen’s volume dropped to 401.5 million cans (19.1 % share) and on! surged to 160.3 million cans (8.3 % share)【MO_10k_2024.pdf†page 48】. Thus Skoal lost market position and share relative to both the leading premium brand and the fast‑growing nicotine‑pouch competitor over the period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core narrative - Skoal's market share decline from 2022 to 2024 (from ~10% to 7.6%), Copenhagen's decline (24% to 19.1%), and on!'s growth (6% to 8.3%). The multi-hop reasoning is sound, synthesizing data across years and comparing competitive positions. The conclusion that Skoal underperformed relative to both Copenhagen and on! is logically sound and matches the ground truth narrative.\n\nCRITICAL ERRORS: (1) 2022 Skoal retail share stated as \"about 10%\" in LLM answer vs. 9.3% in ground truth - this is a material discrepancy of 0.7 percentage points. (2) 2023 data point missing: Ground truth mentions Altria's oral tobacco segment retail share fell from 42.5% in 2023 to 37.5% in 2024, providing important context about broader segment contraction. The LLM answer does not reference this intermediate year data or the overall segment decline. (3) Copenhagen 2022 share stated as \"≈24%\" in LLM answer vs. 23.5% in ground truth - minor but still a discrepancy.\n\nQUANTITATIVE VERIFICATION: The 2024 figures appear accurate (Skoal 7.6%, Copenhagen 19.1%, on! 8.3%). However, the 2022 baseline numbers contain errors. The shipment volumes provided (170M, 460M, 100M cans for 2022; 147M, 401.5M, 160.3M for 2024) cannot be verified against the ground truth, which does not provide shipment data - only retail share percentages. This introduces unverifiable quantitative claims.\n\nMULTI-HOP SYNTHESIS: The answer successfully synthesizes information across 2022 and 2024, comparing three brands and their relative performance. However, it misses the 2023 intermediate data point that would strengthen the analysis of market evolution.\n\nSEMANTIC EQUIVALENCE: The core message matches - Skoal weakened, Copenhagen also declined, on! grew - but the specific percentage figures for 2022 are inaccurate, which is problematic for a financial analysis question where precision matters.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 524,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has the revenue contribution from Dynamics 365 within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Dynamics 365 contributed to the $91.2 billion Microsoft Cloud revenue, with Dynamics products and cloud services revenue growing 25%, driven by a 39% increase in Dynamics 365. By fiscal year 2023, the Microsoft Cloud revenue had increased to $111.6 billion, which includes Dynamics 365 as a component. Although the exact growth percentage for Dynamics 365 in 2023 is not explicitly stated, its continued inclusion in the Microsoft Cloud breakdown indicates sustained growth and integration within the broader cloud portfolio.",
      "llm_answer": "The 2022 filing notes that Dynamics 365 drove a 39% jump in Dynamics products and cloud services revenue, which was $4,687 million for FY 2022【MSFT_10k_2022.pdf p.38‑42】.  In FY 2023 that line grew to $5,437 million (about a $750 million or 16% increase) and helped lift overall Microsoft Cloud revenue from $91.4 billion in FY 2022 to $111.6 billion in FY 2023【MSFT_10k_2023.pdf p.95】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides specific financial data and calculations but contains a critical discrepancy with the ground truth. CORRECT ELEMENTS: (1) The FY 2022 Microsoft Cloud revenue figure of $91.4 billion is cited (ground truth states $91.2 billion - minor variance of $0.2B, acceptable); (2) The FY 2023 Microsoft Cloud revenue of $111.6 billion matches ground truth exactly; (3) The Dynamics 365 growth rate of 39% in FY 2022 is correct; (4) The calculation of $750 million increase ($5,437M - $4,687M = $750M) is arithmetically correct; (5) The 16% growth calculation is accurate ($750M / $4,687M ≈ 16%). PROBLEMATIC ELEMENTS: (1) The ground truth states Dynamics products and cloud services revenue grew 25% in FY 2022, but the LLM answer only mentions the 39% Dynamics 365 component without clarifying this distinction; (2) The LLM provides specific revenue figures ($4,687M for FY 2022 and $5,437M for FY 2023) that are not explicitly mentioned in the ground truth, which only references these as components of the broader Microsoft Cloud; (3) The ground truth notes that the exact growth percentage for Dynamics 365 in FY 2023 is not explicitly stated, yet the LLM calculates and presents a 16% growth figure as if it were directly comparable. MULTI-HOP REASONING: The LLM successfully synthesizes information across fiscal years and connects Dynamics 365 performance to overall Microsoft Cloud revenue evolution. However, it may be conflating the Dynamics products and cloud services line item with Dynamics 365 specifically. The answer is more specific than the ground truth but potentially introduces precision that may not be fully supported by the source documents. The contextual relevance is strong as it directly addresses the question about Dynamics 365 evolution between FY 2022 and 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 490,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Merck's approach to managing foreign exchange exposure through its Balance Sheet Risk Management Program evolved from 2023 to 2024, particularly in terms of the instruments used and the scope of hedging activities?",
      "original_answer": "In 2023, Merck primarily used forward exchange contracts to offset the effects of exchange on exposures when economically beneficial, focusing on the euro, Swiss franc, Japanese yen, and Chinese renminbi. These contracts were not designated as hedges and were marked to market through Other (income) expense, net. By 2024, the company expanded its approach under a more structured balance sheet risk management program, continuing to use forward contracts but also introducing a broader framework that included purchased local currency put options and collar options. Additionally, the 2024 disclosure highlights a more strategic layering of hedges over time, increasing the portion of forecasted sales hedged as the expected dates approach, based on cost-benefit assessments.",
      "llm_answer": "In both 2023 and 2024 Merck’s Balance‑Sheet Risk Management Program relied on short‑term forward exchange contracts (average maturity < 6 months) – non‑designated forwards to offset the remeasurement of assets and liabilities and designated forwards to hedge net‑investment positions, with euro‑denominated debt used as an economic hedge of foreign operations. By 2024 the company expanded the program: the notional of forward contracts rose to roughly $8.7 bn for designated assets and $12.5 bn for non‑designated assets (up from $6.1 bn and $9.7 bn in 2023) and net positions grew to $265 m/$46 m versus $124 m/$24 m, indicating a broader scope of hedging while still using the same forward‑contract instruments and focusing on the euro, Swiss franc, yen and renminbi.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual discrepancies with the ground truth. MAJOR ISSUES: (1) The LLM claims the program used 'designated forwards to hedge net-investment positions' and 'euro-denominated debt used as an economic hedge' - these details are NOT mentioned in the ground truth and appear to be fabricated or confused with different hedging strategies. (2) The LLM provides specific notional amounts ($8.7bn, $12.5bn, $6.1bn, $9.7bn) and net positions ($265m/$46m, $124m/$24m) that are NOT present in the ground truth answer. These numbers cannot be verified against the original answer and appear to be hallucinated. (3) The LLM completely OMITS the key evolution mentioned in ground truth: the introduction of 'purchased local currency put options and collar options' in 2024, which represents a material expansion beyond just forward contracts. (4) The LLM misses the strategic layering approach mentioned in ground truth - 'increasing the portion of forecasted sales hedged as the expected dates approach, based on cost-benefit assessments.' WHAT WAS CORRECT: The LLM correctly identifies that both years used forward exchange contracts, correctly names the currency pairs (euro, Swiss franc, yen, renminbi), and correctly notes that 2024 represented an expansion of the program. However, the characterization of the expansion is incomplete and partially inaccurate. The LLM's focus on notional amounts and net positions, while potentially factually accurate to the actual filings, diverges from the ground truth answer's emphasis on instrument diversification and strategic hedging approach. The answer demonstrates partial understanding but fails on completeness and introduces unverifiable quantitative claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 472,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has PayPal's involvement with merchant receivables evolved between 2022 and 2024, particularly in terms of its credit loss provisions and direct investment in merchant financing products?",
      "original_answer": "In 2022, PayPal disclosed its methodology for estimating credit losses on merchant receivables, applying macroeconomic forecasts and historical loss data to calculate allowances, with a principal and interest coverage ratio of approximately 9% as of December 31, 2021, down from 23% in 2020. By 2024, PayPal had significantly expanded its direct involvement by purchasing approximately $1.8 billion in merchant receivables during the year, with an outstanding balance of $1.5 billion as of December 31, 2024, up from $1.2 billion in 2023. This represents a shift from primarily disclosing credit risk exposure to actively investing in and managing merchant receivables through products like PPWC and PPBL, indicating a more strategic and operational role in merchant finance.",
      "llm_answer": "PayPal’s credit‑loss allowance for its merchant‑financing portfolio fell sharply – from roughly $248 million at 12/31/2022 to $113 million at 12/31/2024, indicating improved credit quality (PYPL_10k_2022.pdf p. 56; PYPL_10k_2024.pdf p. 102).  At the same time, its direct exposure grew, with purchases of merchant receivables rising from about $1.5 billion in 2022 to $1.8 billion in 2024 (PYPL_10k_2022.pdf p. 55; PYPL_10k_2024.pdf p. 99).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - CRITICAL FAILURES: The LLM states merchant receivables purchases 'rising from about $1.5 billion in 2022 to $1.8 billion in 2024,' but the ground truth indicates purchases were approximately $1.8 billion in 2024 only, with no comparable 2022 figure provided. The LLM appears to have confused outstanding balance ($1.2B in 2023, $1.5B in 2024) with annual purchases. The ground truth explicitly states the 2024 purchases were $1.8B with outstanding balance of $1.5B as of 12/31/2024. The LLM's claim of $1.5B purchases in 2022 is unsupported and contradicts the ground truth structure. (2) CREDIT LOSS ALLOWANCE NUMBERS - The LLM cites $248M (12/31/2022) and $113M (12/31/2024) for credit-loss allowance, but these specific figures are NOT mentioned in the ground truth answer. The ground truth discusses principal and interest coverage ratios (9% in 2021, 23% in 2020) and credit loss estimation methodology, not absolute allowance amounts. The LLM appears to have introduced numbers not in the ground truth. (3) MISSING KEY INFORMATION: The LLM completely omits the principal and interest coverage ratio metrics (9% as of 12/31/2021, down from 23% in 2020) which are central to the ground truth answer. It also fails to mention the strategic shift from disclosure to active investment in merchant financing products like PPWC and PPBL. (4) MULTI-HOP REASONING: The LLM attempts to synthesize evolution between years but does so with incorrect data points. The comparison framework is reasonable but built on faulty numbers. (5) SEMANTIC ISSUES: The LLM's interpretation of 'purchases rising from $1.5B to $1.8B' misrepresents the actual data structure where $1.5B appears to be outstanding balance in 2024, not 2022 purchases. The answer demonstrates partial understanding of the question's intent but fails on factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 509,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the financial significance of smokeable products to MO evolved from 2022 to 2024, considering both goodwill allocation and operating income performance?",
      "original_answer": "In 2022, the goodwill allocated to smokeable products was $99 million, indicating a relatively small portion of MO's overall asset valuation, with total goodwill at $5,177 million. By 2024, although no updated goodwill figure is disclosed specifically for smokeable products, their operating income contribution rose to $10,821 million in 2024 from $10,670 million in 2023, showing sustained profitability. This suggests that while the strategic asset valuation (via goodwill) remained stable or undisclosed, the operational significance of smokeable products remained high and slightly increased in terms of earnings. The lack of updated goodwill allocation in 2024 filings for this segment implies a potential shift in reporting focus toward performance metrics rather than asset valuations.",
      "llm_answer": "The goodwill tied to the smokeable‑products segment stayed at $99 million in the 2022 filing and was unchanged in the 2024 filing, showing no new goodwill creation or impairment for that business [MO_10k_2022.pdf pp. 64‑68].  Segment operating income fell modestly – from roughly $11.5 billion in 2022 (the level reported in the 2022 filing) to $11.2 billion in 2024, a drop of about $300 million (≈2‑3 %) [MO_10k_2024.pdf pp. 29‑33].",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant numerical inaccuracies that contradict the ground truth. (1) GOODWILL CLAIM: The LLM states goodwill was 'unchanged in the 2024 filing' at $99 million, but the ground truth explicitly states 'no updated goodwill figure is disclosed specifically for smokeable products' in 2024. The LLM incorrectly asserts a 2024 goodwill figure exists when it does not. (2) OPERATING INCOME ERRORS - CRITICAL: The LLM claims smokeable products operating income was 'roughly $11.5 billion in 2022' and 'fell to $11.2 billion in 2024, a drop of about $300 million.' However, the ground truth provides: 2023: $10,670 million and 2024: $10,821 million. The LLM's 2022 figure of ~$11.5 billion is not supported by the ground truth, and the direction of change is wrong - the ground truth shows an INCREASE from 2023 to 2024 ($10,670M to $10,821M), not a decrease. The LLM's claimed $300 million decline is factually incorrect. (3) MULTI-HOP REASONING: The LLM failed to properly synthesize the available data across years. It introduced unsupported 2022 operating income figures and missed the actual 2023-2024 comparison showing growth. (4) COMPLETENESS: While the LLM attempted to address both goodwill and operating income components, the execution was fundamentally flawed with incorrect numbers and wrong directional conclusions. The ground truth's nuanced observation about a 'shift in reporting focus' was not captured. The answer is internally inconsistent with the source documents and contradicts the ground truth on multiple critical data points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 437,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the revenue contribution from the commercial portion of LinkedIn within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Microsoft Cloud revenue, which includes the commercial portion of LinkedIn, was reported at $91.2 billion. By fiscal year 2023, this figure had increased to $111.6 billion, indicating a significant growth in the commercial cloud segment that includes LinkedIn. This increase suggests a stronger revenue contribution from LinkedIn's commercial services within the broader Microsoft Cloud portfolio.",
      "llm_answer": "Microsoft Cloud revenue – which includes the commercial portion of LinkedIn – rose sharply, from roughly **$91 billion in FY 2022** to **$111.6 billion in FY 2023**, a gain of about **$20 billion (≈22 %)**【MSFT_10k_2022.pdf p. 96】【MSFT_10k_2023.pdf p. 94】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. Verification of key facts: (1) FY 2022 Microsoft Cloud revenue: LLM states 'roughly $91 billion' vs. ground truth '$91.2 billion' - this is acceptable rounding and matches the source data; (2) FY 2023 Microsoft Cloud revenue: LLM states '$111.6 billion' which exactly matches ground truth; (3) Year-over-year change calculation: LLM calculates $111.6B - $91B = ~$20B, which is accurate (actual difference is $111.6B - $91.2B = $20.4B, but using the rounded $91B figure yields ~$20.6B, so the approximation is reasonable); (4) Percentage growth: LLM states '≈22%' which is mathematically sound ($20.4B / $91.2B ≈ 22.4%, rounded to 22%); (5) Entity accuracy: Correctly identifies Microsoft Cloud, LinkedIn's commercial portion, and fiscal years 2022-2023; (6) Multi-hop synthesis: Successfully synthesizes information across two 10-K filings (2022 and 2023) to show the evolution; (7) Completeness: Addresses the core question about revenue contribution evolution between the two fiscal years. Minor note: The LLM uses 'roughly $91 billion' rather than the precise '$91.2 billion,' but this is a reasonable approximation and doesn't constitute a material error. The inclusion of source citations and percentage calculation adds value. The answer directly addresses the question about how revenue contribution evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1167,
        "completion_tokens": 381,
        "total_tokens": 1549
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did the commercialization and market expansion of Lynparza evolve between 2023 and 2024, particularly in terms of geographic approvals and revenue growth?",
      "original_answer": "In 2023, Lynparza received FDA and Japan's MHLW approvals for treating BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and prednisone or prednisolone, based on the PROpel trial. By 2024, alliance revenue related to Lynparza grew by 9%, largely due to higher demand in most international markets. Additionally, in January 2025, Lynparza received China's NMPA approval for adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer, based on the OlympiA trial, indicating a significant geographic and therapeutic area expansion.",
      "llm_answer": "In 2023 Lynparza’s commercial launch was anchored by two geographic approvals – an FDA approval in May 2023 and a Japan MHLW approval in August 2023 for the abiraterone‑based treatment of BRCA‑mutated metastatic castration‑resistant prostate cancer. By 2024 the drug was already marketed for several cancer indications worldwide and alliance revenue grew 9 % to $1.311 billion, driven by higher demand in most international markets and signaling continued global expansion (with a China approval slated for early 2025).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with mostly correct information about Lynparza's commercialization evolution. STRENGTHS: (1) Correctly identifies the 2023 FDA and Japan MHLW approvals for BRCA-mutated mCRPC with abiraterone combination therapy; (2) Accurately states the 9% alliance revenue growth in 2024; (3) Properly notes higher demand in international markets; (4) Correctly references the China approval slated for early 2025. QUANTITATIVE ACCURACY: The 9% growth figure is correct. The LLM provides a specific revenue figure ($1.311 billion) that is not contradicted by the ground truth, though the ground truth doesn't provide this specific number - this appears to be additional accurate detail. MINOR WEAKNESSES: (1) The LLM answer mentions the revenue figure ($1.311 billion) which, while potentially accurate, is not explicitly confirmed in the ground truth provided; (2) The ground truth specifically mentions the OlympiA trial basis for the China approval and the adjuvant breast cancer indication, which the LLM answer omits - this is a notable omission of therapeutic area expansion detail; (3) The LLM states the China approval is \"slated for early 2025\" rather than confirming it occurred in January 2025 as stated in the ground truth. MULTI-HOP REASONING: The answer successfully synthesizes information across 2023-2024 timeframes and geographic regions, correctly linking approvals to revenue growth drivers. The semantic equivalence is strong - the answer conveys the same core narrative of geographic expansion and revenue growth. The omission of the specific OlympiA trial and adjuvant breast cancer indication represents incomplete coverage of the therapeutic area expansion mentioned in the original answer, though the overall narrative arc is correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 489,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, particularly in terms of its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was noted as a reduction in sales, indicating a negative financial impact. By 2024, the Powder Metal Matter was specifically listed under future income tax benefits at $455 million, down from $644 million in 2023, showing a shift in its financial treatment from a sales reduction to a recognized tax benefit. This represents a decrease of $189 million, or about 29.3%, in its value contribution to future tax benefits.",
      "llm_answer": "In the 2023 filing RTX treated the Powder Metal Matter as a sales reduction (‑$5.4 billion) and recognized a $644 million deferred‑tax asset for future income‑tax benefits. By the 2024 filing the deferred‑tax benefit for the same matter had fallen to $455 million, showing the anticipated future tax benefit was reduced by roughly $189 million year‑over‑year.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identified the key financial figures ($644M in 2023, $455M in 2024, $189M decrease) and accurately calculated the year-over-year reduction. The answer correctly notes the shift in financial treatment and properly identifies both years. The format variations are acceptable ($644 million vs $644M). WEAKNESSES: (1) The LLM introduces an unsupported detail about a $5.4 billion sales reduction in 2023 that is not mentioned in the ground truth answer. While this may be factually accurate from the filing, it was not part of the original answer's scope and adds information not directly relevant to the evolution of tax benefit treatment. (2) The LLM fails to calculate or mention the percentage decrease (29.3%) that was explicitly stated in the ground truth, which was a key metric showing the magnitude of the change. (3) The characterization differs slightly - the ground truth emphasizes a 'shift in financial treatment from a sales reduction to a recognized tax benefit,' while the LLM treats both aspects as simultaneous rather than sequential evolution. (4) The LLM uses 'deferred-tax asset' terminology which is more technically precise but the ground truth simply refers to 'future income tax benefits.' MULTI-HOP REASONING: The LLM successfully synthesizes information across 2023 and 2024 filings and correctly compares the two years. The core reasoning about the evolution is sound. CALCULATION VERIFICATION: The $189M difference is correct (644 - 455 = 189). The percentage calculation (189/644 = 29.3%) was not performed by the LLM but should have been included. OVERALL: The answer captures the essential numerical facts and the main evolution narrative but omits the percentage metric and introduces extraneous detail about the sales reduction that, while potentially accurate, wasn't part of the ground truth synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 505,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did the borrowing capacity and terms of the Paidy Credit Agreement evolve from 2022 to 2024?",
      "original_answer": "In 2022, the Paidy Credit Agreement provided a secured revolving credit facility of approximately $198 million, with $98 million outstanding as of December 31, 2021. By 2024, the Paidy Credit Agreement had been modified to increase the borrowing capacity to ¥90.0 billion (approximately $574 million as of December 31, 2024), and it was restructured as an unsecured facility. The interest rate also changed from unspecified terms in 2022 to a rate based on the Tokyo Interbank Offered Rate plus a margin ranging from 0.40% to 0.60% in 2024. The maturity date was set for February 2027, and the agreement now includes a financial covenant requiring a maximum consolidated leverage ratio.",
      "llm_answer": "In the 2022 filing the Paidy Credit Agreement was described as a **secured revolving facility of roughly $198 million**, of which about **$100 million remained available** for borrowing 【48†L31-L38】. By the 2024 filing the agreement had been **re‑structured to an unsecured ¥90 billion (≈ $574 million) revolving facility** (originally ¥60 billion, increased by ¥30 billion in September 2022) that **bears interest at TIBOR + 0.40‑0.60% and matures in February 2027** 【104†L1-L9】【105†L1-L7】, and **was fully drawn down by year‑end 2024, leaving no borrowing capacity** 【105†L9-L13】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy with mostly correct financial figures and terms. Strengths: (1) Correctly identifies 2022 facility as secured revolving ~$198 million; (2) Accurately states 2024 restructuring to unsecured ¥90 billion (~$574 million); (3) Correctly cites TIBOR + 0.40-0.60% interest rate; (4) Correctly identifies February 2027 maturity date; (5) Properly synthesizes multi-hop information across 2022-2024 filings. Minor issues: (1) States $100 million available in 2022 vs. ground truth's $98 million outstanding (semantic difference - available vs. outstanding are different metrics, but the LLM's figure appears reasonable given a $198M facility); (2) Adds contextual detail about ¥60 billion original amount increased by ¥30 billion in September 2022 (not explicitly mentioned in ground truth but appears to be accurate supplementary information); (3) Adds information about full drawdown by year-end 2024 with no remaining capacity (not in ground truth but appears factually accurate from source citations). The answer successfully addresses the evolution question by comparing 2022 vs 2024 terms. One notable omission: The ground truth mentions 'financial covenant requiring a maximum consolidated leverage ratio' which the LLM answer does not include. This is a material omission of a key term change. The quantitative figures are accurate (allowing for the available vs. outstanding distinction), and the multi-hop reasoning correctly synthesizes information across the two filing periods. The answer is well-structured and clearly presents the evolution of terms.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 439,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Altria's reliance on long-term senior unsecured notes as part of its capital resources evolved between 2022 and 2024?",
      "original_answer": "In 2022, Altria's capital resources included access to credit markets through the issuance of long-term senior unsecured notes, along with $4.5 billion in cash and cash equivalents. By 2024, Altria continued to rely on long-term senior unsecured notes as a key source of capital, but its cash and cash equivalents decreased to $3.1 billion. While the company maintained its $3.0 billion Credit Agreement and continued to use similar capital instruments, the reduction in cash reserves suggests a potentially increased reliance on external financing mechanisms, including long-term senior unsecured notes, to support its operations and strategic initiatives such as dividend payments, share repurchases, and debt repayment.",
      "llm_answer": "Altria’s 2022 Form 10‑K (pages 46‑50) already disclosed that its capital resources “include… access to credit markets through the issuance of long‑term senior unsecured notes,” and it described recent issuances (e.g., $5.5 bn in February 2021) and repayments of such notes. The 2024 Form 10‑K (pages 47‑51) repeats the same language – “access to credit markets through the issuance of long‑term senior unsecured notes” – while noting that the company repaid its 4.0% and 3.8% senior unsecured notes in early 2024. In short, Altria’s reliance on long‑term senior unsecured notes has remained a consistent component of its capital resources, with only modest adjustments in the mix of issuances and repayments between 2022 and 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer provides some correct information but has significant gaps and omissions compared to the ground truth. STRENGTHS: (1) Correctly identifies that long-term senior unsecured notes remained a consistent capital resource component across 2022-2024; (2) Accurately notes specific repayments (4.0% and 3.8% senior unsecured notes in early 2024); (3) Correctly cites that the language about 'access to credit markets through issuance of long-term senior unsecured notes' appears in both 2022 and 2024 filings; (4) Appropriately characterizes the evolution as 'modest adjustments.' CRITICAL OMISSIONS: (1) The LLM completely fails to mention the significant cash and cash equivalents figures that are central to the ground truth answer - $4.5 billion in 2022 declining to $3.1 billion in 2024. These numbers are quantitatively important and directly support the conclusion about increased reliance on external financing; (2) Does not mention the $3.0 billion Credit Agreement, which is a key capital resource; (3) Fails to discuss the strategic context (dividend payments, share repurchases, debt repayment) that explains WHY the company's reliance on external financing increased; (4) Does not synthesize the relationship between declining cash reserves and increased reliance on long-term notes. QUANTITATIVE ACCURACY: The LLM provides specific note repayment details (4.0% and 3.8% notes) but omits the critical cash position metrics ($4.5B to $3.1B decline). The $5.5 billion February 2021 issuance is mentioned but is not directly relevant to the 2022-2024 evolution question. MULTI-HOP REASONING: The LLM identifies the consistency of the capital instrument but fails to synthesize the complete picture - that the COMBINATION of declining cash reserves AND continued reliance on notes suggests increased external financing dependence. This is a key multi-hop insight that the ground truth captures but the LLM misses. The answer is partially correct on the surface-level observation but incomplete in addressing the full evolution and its implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 555,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, and what does this indicate about its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter contributed $644 million to RTX's future income tax benefits. By 2024, this amount decreased to $455 million, indicating a reduced financial benefit from the Powder Metal Matter over time. This decline suggests a diminishing positive impact on RTX's tax position related to this factor.",
      "llm_answer": "In 2023 RTX recorded a $2.9 billion charge for the Powder Metal Matter, which cut pretax earnings and gave rise to a $644 million deferred‑tax asset (future income‑tax benefit). By the 2024 filing that deferred‑tax asset had fallen to $455 million, showing the tax benefit is being consumed and the remaining future income‑tax benefit from the matter is decreasing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and provides more comprehensive context than the ground truth. All key numbers are correct: $2.9 billion charge in 2023, $644 million deferred-tax asset in 2023, and $455 million in 2024. The quantitative accuracy is perfect - all dollar amounts match the ground truth exactly, and the year-over-year comparison ($644M to $455M decline) is accurate. The multi-hop reasoning is sound: the answer correctly synthesizes that (1) the 2023 charge created a deferred-tax asset, (2) this asset decreased from 2023 to 2024, and (3) this indicates the tax benefit is being consumed. The LLM answer actually enhances the ground truth by explaining the causal mechanism (the $2.9B charge gave rise to the deferred-tax asset) and clarifying that the decline represents consumption of the tax benefit. The semantic meaning is equivalent - both convey that the future income tax benefit decreased from $644M to $455M, indicating diminishing positive impact. The only minor distinction is that the LLM provides additional context about the charge amount and the mechanism of tax benefit consumption, which adds value without introducing any factual errors. Entity identification is correct (RTX, Powder Metal Matter, deferred-tax asset, future income-tax benefit). The reasoning about what the decline indicates (tax benefit being consumed, remaining benefit decreasing) is logically sound and well-explained.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1176,
        "completion_tokens": 399,
        "total_tokens": 1575
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has PayPal's utilization of the Paidy Credit Agreement evolved between 2022 and 2024, particularly in terms of borrowing capacity and actual drawdown?",
      "original_answer": "In 2022, PayPal had approximately $198 million in borrowing capacity under the Paidy Credit Agreement, with $98 million outstanding as of December 31, 2021, leaving about $100 million available. By 2024, the borrowing capacity had increased to approximately $574 million (¥90.0 billion), and the full amount was drawn down, leaving no borrowing capacity available. This reflects a significant increase in both the scale of the facility and PayPal's reliance on it over the period.",
      "llm_answer": "In the 2022 filing PayPal’s Paidy Credit Agreement was a secured revolving facility of roughly $198 million, of which about $98 million had been drawn, leaving roughly $100 million of unused borrowing capacity (PYPL_10k_2022.pdf p.108‑109). By the 2024 filing the facility had been expanded to ¥90 billion (≈ $574 million) and the entire amount was drawn down during 2024, so no borrowing capacity remained under the agreement (PYPL_10k_2024.pdf p.45).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. Verification of key facts: (1) 2022 figures: $198 million borrowing capacity, $98 million drawn, ~$100 million available - all correct and match ground truth exactly. (2) 2024 figures: ¥90.0 billion (~$574 million) with full drawdown - correct. (3) The answer properly synthesizes multi-hop information across two filing years, correctly identifying the evolution from partial utilization (49.5% drawn in 2022) to full utilization (100% drawn in 2024). (4) All entities correctly identified: PayPal, Paidy Credit Agreement, fiscal years 2022 and 2024. (5) The reasoning is sound - the answer demonstrates clear understanding that the facility expanded significantly and utilization increased correspondingly. Minor note: The LLM states the amount was 'drawn down during 2024' which is slightly imprecise wording (it was drawn by end of 2024, not necessarily during 2024), but this is a very minor semantic issue that doesn't affect the core factual accuracy. The citation references to specific pages add credibility. Overall, this is an excellent answer that correctly addresses all aspects of the multi-hop question with accurate numbers, proper synthesis, and clear explanation of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 352,
        "total_tokens": 1587
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the ownership structure and equity relationship between Accenture plc and Accenture Canada Holdings Inc. evolved from 2023 to 2024, particularly regarding noncontrolling interests and exchangeable shares?",
      "original_answer": "In 2023, the noncontrolling ownership interests in Accenture Canada Holdings Inc. held by certain current and former members of Accenture Leadership were less than 1% as of August 31, 2024. By 2024, the structure had evolved to include detailed provisions around Accenture Canada Holdings Inc. exchangeable shares, which can be exchanged for Accenture plc Class A ordinary shares on a one-for-one basis or redeemed for cash. Additionally, Accenture plc Class X ordinary shares were tied directly to these exchangeable shares, with a restriction ensuring the number of Class X shares does not fall below the number of exchangeable shares held. This indicates a more formalized and structured equity relationship in 2024 compared to the simpler noncontrolling interest disclosure in 2023.",
      "llm_answer": "The 2023 filing noted that the only equity outside of Accenture plc’s direct ownership of Accenture Canada Holdings Inc. was a “non‑controlling interest” held by current and former Accenture Leadership members that was **under 1 % of the subsidiary as of 31 August 2023**. The 2024 filing repeats the same statement – the non‑controlling interest remained **under 1 % as of 31 August 2024**, indicating no material change in ownership. Both years also describe the same equity relationship for the subsidiary’s **exchangeable shares**: they may be swapped for Accenture plc Class A ordinary shares on a one‑for‑one basis (or for cash at market price) and continue to receive the same dividends; in 2024 the company repurchased a modest 47,752 exchangeable shares and paid the usual dividend on them, consistent with the prior‑year practice.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains both correct and incorrect elements, resulting in a partially correct response with significant omissions.\n\nCORRECT ELEMENTS:\n1. The noncontrolling interest percentage is correctly stated as 'under 1%' for both 2023 and 2024\n2. The date references (August 31, 2023 and August 31, 2024) are accurate\n3. The description of exchangeable shares being swappable for Accenture plc Class A ordinary shares on a one-for-one basis is correct\n4. The mention of dividend payments on exchangeable shares is accurate\n5. The share repurchase figure of 47,752 exchangeable shares appears to be a specific operational detail\n\nINCORRECT/PROBLEMATIC ELEMENTS:\n1. CRITICAL OMISSION: The LLM states 'no material change in ownership' and that 'both years describe the same equity relationship,' which directly contradicts the ground truth. The ground truth explicitly states the structure 'had evolved' and describes a 'more formalized and structured equity relationship in 2024 compared to the simpler noncontrolling interest disclosure in 2023.'\n2. MISSING KEY DETAIL: The LLM completely fails to mention Accenture plc Class X ordinary shares, which the ground truth identifies as a significant structural evolution in 2024\n3. MISSING RESTRICTION DETAIL: The ground truth specifies that Class X shares have a restriction ensuring their number does not fall below the number of exchangeable shares held - this critical structural element is entirely absent from the LLM answer\n4. INCOMPLETE SYNTHESIS: The LLM treats 2023 and 2024 as essentially identical, missing the evolution narrative that is central to the question\n\nMULTI-HOP REASONING ASSESSMENT:\nThe question explicitly asks about how the structure 'evolved' from 2023 to 2024. The LLM fails to identify and synthesize the key evolutionary changes (introduction of Class X shares and their restrictions) that distinguish 2024 from 2023. Instead, it concludes there was 'no material change,' which is factually incorrect based on the ground truth.\n\nQUANTITATIVE ACCURACY:\nThe percentages and dates are correct, but the LLM provides incomplete information about the structural components (missing Class X shares entirely).\n\nQUALITATIVE ACCURACY:\nThe reasoning is flawed because it misses the core narrative of structural evolution and incorrectly concludes stability where the ground truth indicates change. The synthesis across years is inadequate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 646,
        "total_tokens": 2069
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has Merck's approach to managing balance sheet risk through forward exchange contracts evolved between 2022 and 2024, particularly in terms of the currencies and cost-benefit considerations?",
      "original_answer": "In 2022, Merck explicitly outlined a balance sheet risk management program that involved the use of forward exchange contracts to offset exposures in both developed and developing country currencies, with a specific mention of the Chinese renminbi. The decision to hedge developing country currencies was based on a cost-benefit analysis considering exposure magnitude, exchange rate volatility, and hedging instrument cost. By 2024, while the balance sheet risk management program was still referenced, the detailed discussion around cost-benefit analysis and the specific mention of the Chinese renminbi in the context of developing countries was omitted. This suggests a shift in emphasis or a potential simplification of the decision-making framework for hedging non-developed market exposures.",
      "llm_answer": "By 2024 Merck still uses short‑term forward exchange contracts to hedge the balance‑sheet impact of foreign‑currency monetary items, but the currencies it emphasizes have narrowed. In the 2022 filing the company said it “principally utilizes forward exchange contracts … in developed‑country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc,” and would hedge the Chinese renminbi only when a cost‑benefit test was met; the 2024 filing now cites “primarily the euro, Swiss franc, Japanese yen, and Chinese renminbi,” dropping the pound and Canadian dollar from the core list. In both years the decision to hedge is based on a cost‑benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and provides more specific, actionable detail than the ground truth. Key strengths: (1) Correctly identifies the specific currencies mentioned in both 2022 and 2024 filings with accurate lists; (2) Accurately captures the shift in emphasis - dropping British pound and Canadian dollar from the core list while adding Chinese renminbi to the primary currencies; (3) Correctly notes that cost-benefit analysis framework remains consistent across both years, considering magnitude of exposure, exchange rate volatility, and hedging instrument cost; (4) Properly synthesizes the multi-hop comparison across 2022 and 2024 filings. Minor considerations: The LLM answer is actually MORE specific and detailed than the ground truth in identifying which currencies were dropped and which were added, providing concrete evidence of the evolution. The ground truth mentions 'omission' of detailed discussion around cost-benefit analysis and Chinese renminbi in 2024, but the LLM answer shows Chinese renminbi was actually elevated to the primary list in 2024 (not omitted), which appears to be a more accurate reading of the actual filing evolution. The LLM answer's characterization of the shift as a 'narrowing' of emphasized currencies is a reasonable interpretation supported by the specific currency list changes. All dates (2022, 2024) are correct, all currency names are accurate, and the reasoning about the cost-benefit framework is sound. The answer fully addresses the question's focus on how the approach evolved between these two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 436,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "What does the change in RTX's disclosure about the Powder Metal Matter between 2023 and 2024 suggest about its ongoing financial impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was disclosed as having a net sales charge of $5.3 billion, which negatively impacted net products sales at Pratt & Whitney and contributed to a decline in overall revenue. By 2024, the Powder Metal Matter was listed under future income tax benefits with a value of $455 million, down from $644 million in 2023. This shift indicates that while the matter continues to carry financial significance, its treatment has evolved from a direct operational loss to a deferred tax asset, suggesting a reduction in its immediate negative impact and a potential long-term recovery or resolution.",
      "llm_answer": "In the 2023 Form 10‑K RTX disclosed a $5.4 billion net‑sales charge and a $2.9 billion operating‑profit hit from the Powder Metal Matter and recorded a $644 million future income‑tax benefit for that item. By the 2024 filing the operating charge is no longer highlighted and the deferred‑tax benefit for the Powder Metal Matter has fallen to $455 million, indicating that the tax benefit is being used up and the matter’s ongoing financial impact on future income‑tax benefits is diminishing.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and incorrect information. CORRECT ELEMENTS: (1) The 2024 future income tax benefit of $455 million is accurate; (2) The 2023 future income tax benefit of $644 million is accurate; (3) The general interpretation that the tax benefit is diminishing is sound; (4) The observation that the operating charge is no longer highlighted in 2024 is reasonable. INCORRECT/PROBLEMATIC ELEMENTS: (1) The net sales charge is stated as $5.4 billion in the LLM answer, but the ground truth specifies $5.3 billion - this is a $100 million discrepancy that matters for precision; (2) The LLM introduces a $2.9 billion operating-profit hit that is not mentioned in the ground truth answer, and this figure cannot be verified against the provided ground truth; (3) The LLM states the operating charge is 'no longer highlighted' in 2024, which is an inference not explicitly confirmed in the ground truth. MULTI-HOP REASONING: The LLM correctly synthesizes the 2023 vs 2024 comparison and draws a logical conclusion about diminishing tax benefits. However, the introduction of the $2.9 billion operating-profit figure suggests the LLM may be adding information from the source documents that wasn't part of the ground truth synthesis. QUANTITATIVE ACCURACY ISSUES: The $5.4B vs $5.3B discrepancy is material for financial reporting. The $2.9 billion figure cannot be verified. The tax benefit decline ($644M to $455M, a $189M decrease) is correctly identified. OVERALL: The answer demonstrates reasonable understanding of the question and correct identification of key metrics ($455M, $644M), but the net sales charge discrepancy and unverified operating profit figure reduce confidence in the quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 472,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has PayPal's involvement in the merchant receivables space evolved between 2022 and 2024, particularly in terms of its relationship with partner institutions and the scale of its merchant finance offerings?",
      "original_answer": "In 2022, PayPal described its U.S. merchant finance products (PPWC and PPBL) as being provided under a program agreement with WebBank, where PayPal could purchase the related receivables and also sell back a participation interest in the pool of receivables to WebBank. PayPal accounted for this arrangement as a sale and derecognized the portion of participation interests for which control was surrendered. By 2024, PayPal's relationship with partner institutions had evolved, with PayPal now purchasing approximately $1.8 billion in merchant receivables in 2024 (up from $1.7 billion in 2023), and the total outstanding balance in the pool of merchant loans, advances, and interest and fees receivable reached $1.5 billion as of December 31, 2024 (up from $1.2 billion as of December 31, 2023). Additionally, the participation interest sold to the partner institution increased to $53 million in 2024 from $44 million in 2023, indicating a growing level of investment in and collaboration around merchant receivables.",
      "llm_answer": "In 2022 PayPal’s merchant‑finance business was still run through a program agreement with WebBank, where the partner bank originated the credit and PayPal bought the resulting receivables – the net merchant‑receivable balance was only about $23 million at year‑end【PYPL_10k_2022.pdf page 70‑71】. By 2024 the same partner‑institution model remained (PayPal purchases and services the receivables while the partner extends the loans), but the scale had expanded dramatically – PayPal bought roughly $1.8 billion of merchant receivables in 2024 and held a $1.5 billion outstanding pool (net of a $53 million participation interest)【PYPL_10k_2024.pdf page 101‑102】. This shows a shift from a modest, early‑stage program to a much larger merchant‑finance operation while retaining the partnership structure.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of PayPal's merchant receivables business and accurately captures the partnership structure with WebBank/partner institutions. The qualitative narrative about the shift from early-stage to scaled operation is sound and well-reasoned. However, there are significant quantitative discrepancies that lower the overall score:\n\n(1) QUANTITATIVE ISSUES:\n- The LLM states the 2022 net merchant-receivable balance was \"only about $23 million\" - this figure is not mentioned in the ground truth and appears to be an unsupported detail\n- The LLM correctly identifies the 2024 purchases ($1.8 billion) and outstanding pool ($1.5 billion)\n- The LLM correctly identifies the 2024 participation interest ($53 million)\n- However, the LLM omits the 2023 comparison data provided in the ground truth: $1.7 billion in purchases (2023) and $1.2 billion outstanding balance (2023), plus $44 million participation interest (2023). These year-over-year comparisons are important for demonstrating the evolution\n\n(2) COMPLETENESS:\n- The answer addresses the partnership relationship evolution (correct)\n- The answer addresses scale expansion (correct)\n- The answer omits the 2023 intermediate data points, which weakens the demonstration of the evolution trajectory\n- The answer does not explicitly mention the accounting treatment (sale and derecognition) described in the ground truth, though this is a more technical detail\n\n(3) ENTITY AND METRIC ACCURACY:\n- Company identification correct (PayPal, WebBank)\n- Years correct (2022, 2024)\n- Financial metrics correctly identified (receivables purchased, outstanding balance, participation interest)\n- The reference to \"net of a $53 million participation interest\" is slightly ambiguous phrasing but semantically captures the concept\n\n(4) MULTI-HOP REASONING:\n- The synthesis across 2022 and 2024 filings is sound\n- The logical connection between partnership structure and scale is well-articulated\n- The reasoning about evolution from early-stage to mature operation is appropriate\n\n(5) CRITICAL ISSUE:\nThe introduction of the \"$23 million\" figure for 2022 without ground truth support is problematic. This appears to be either fabricated or from a source not verified against the knowledge graph. This is a factual accuracy concern that impacts the quantitative accuracy score significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1471,
        "completion_tokens": 640,
        "total_tokens": 2112
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How did Merck's alliance revenue from Lynparza evolve between 2022 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2022, Merck's alliance revenue from Lynparza was $989 million. By 2024, this revenue grew by 9%, driven by increased demand in most international markets. The growth reflects Lynparza's expanding adoption and new approvals, such as in China in January 2025 for adjuvant treatment in early breast cancer based on the OlympiA trial.",
      "llm_answer": "Merck’s alliance revenue from Lynparza rose from $1.116 billion in 2022 to $1.311 billion in 2024 – a roughly 17 % increase overall and a 9 % jump in 2024 alone 【MRK_10k_2024.pdf p.53‑57】. The company said the 2024 gain was “largely due to higher demand in most international markets,” reflecting broader uptake of the drug under the Merck‑AstraZeneca collaboration 【MRK_10k_2024.pdf p.53‑57】.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains fundamentally incorrect financial numbers that directly contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURE: The LLM states 2022 alliance revenue was $1.116 billion, but ground truth shows $989 million - a discrepancy of $127 million (12.8% overstatement). The LLM states 2024 revenue was $1.311 billion, but ground truth indicates it should be approximately $1.079 million (989M × 1.09) - another major error. The LLM's claimed 17% overall growth and 9% 2024 growth are based on incorrect baseline numbers. (2) CALCULATION ERRORS: Even if we accept the LLM's numbers, the math is questionable: $1.116B to $1.311B is actually a 17.5% increase, not 17%, and the 9% 2024 jump would imply 2023 revenue of ~$1.202B, which creates internal inconsistency. (3) PARTIAL CREDIT FOR QUALITATIVE FACTORS: The LLM correctly identifies that growth was driven by 'higher demand in most international markets' and mentions the Merck-AstraZeneca collaboration, which aligns with ground truth. However, the LLM fails to mention the China approval in January 2025 for adjuvant breast cancer treatment based on the OlympiA trial, which is a key contributing factor mentioned in the ground truth. (4) MULTI-HOP SYNTHESIS: While the LLM attempts to synthesize information about revenue evolution and contributing factors, the foundation is built on incorrect numbers, making the entire analysis unreliable. (5) SOURCE CITATION: The LLM cites MRK_10k_2024.pdf pages 53-57, but the numbers provided do not match what ground truth indicates should be in those documents. This suggests either misreading of source material or hallucination of numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1175,
        "completion_tokens": 458,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has PayPal's involvement in merchant receivables evolved between 2022 and 2024, particularly in terms of its financial exposure and operational role?",
      "original_answer": "In 2022, PayPal's involvement in merchant receivables was primarily framed in terms of credit losses and net charge-offs, indicating a focus on risk management and accounting treatment under CECL standards. By 2024, PayPal had significantly expanded its direct involvement through active purchases of merchant receivables—$1.8 billion in 2024 compared to $1.7 billion in 2023—and reported a growing outstanding balance of $1.5 billion, up from $1.2 billion. Additionally, PayPal took on full servicing responsibilities for these receivables, signaling a deeper operational engagement in merchant finance through products like PPWC and PPBL.",
      "llm_answer": "In 2022 PayPal’s merchant‑receivable activity was modest – the net addition to the portfolio was only $23 million, gross charge‑offs were $42 million and the allowance for credit losses stood at $248 million, indicating limited financial exposure (PYPL_10k_2024.pdf pp. 102‑103). By 2024 the company had scaled its role dramatically, purchasing roughly $1.8 billion of merchant receivables in the year, growing the pool to about $1.5 billion, while the allowance fell to $113 million and charge‑offs dropped to $10 million, showing a much larger but lower‑risk exposure (PYPL_10k_2024.pdf pp. 99‑101, 103). Throughout this period PayPal continues to service the loans and offers its PPWC and PPBL financing products, with repayments tied to a share of merchants’ PayPal‑processed payment volume (PYPL_10k_2024.pdf p. 101).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with well-supported quantitative claims. Key strengths: (1) All major financial figures are correct - $1.8B purchases in 2024, $1.5B outstanding balance, $1.2B prior year balance, $113M allowance in 2024, $248M in 2022, charge-offs of $10M (2024) vs $42M (2022), and $23M net addition in 2022. (2) The multi-hop synthesis is sound, correctly tracing PayPal's evolution from modest 2022 involvement (characterized by risk metrics) to scaled 2024 operations (characterized by volume and lower risk ratios). (3) Product references (PPWC, PPBL) and operational details (servicing, repayment tied to payment volume) are accurate and relevant. (4) The comparison logic is valid - showing both absolute growth ($1.8B purchases) and relative risk improvement (allowance declining from $248M to $113M, charge-offs from $42M to $10M). Minor areas for improvement: (1) The answer could have been slightly more explicit about the shift from 'risk management focus' (2022) to 'active merchant finance expansion' (2024) as a conceptual evolution, though this is implied. (2) The citation format is somewhat verbose but accurate. The answer fully addresses the question's core inquiry about financial exposure evolution and operational role expansion, with proper temporal comparison and supporting metrics. No calculation errors detected. The semantic meaning aligns well with the ground truth answer while providing additional supporting detail from the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 414,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Merck's involvement in the development and commercialization of Lynparza evolved from 2022 to 2024, particularly in terms of regulatory progress and revenue growth?",
      "original_answer": "In 2022, Merck was awaiting FDA decision on a supplemental NDA for Lynparza for the adjuvant treatment of BRCA-mutated, HER2-negative high-risk early-stage breast cancer, based on the OlympiA trial, with a PDUFA date in Q1 2022. By 2024, Lynparza had not only maintained its approvals but also expanded its regulatory footprint, with a new approval in China in January 2025 for the same indication, indicating continued global regulatory momentum. Additionally, alliance revenue related to Lynparza grew by 9% in 2024 due to increased demand in international markets, showing a measurable increase in commercial success.",
      "llm_answer": "In 2022 Merck’s Lynparza was still pending a supplemental NDA – the FDA had accepted the filing for priority review and set a PDUFA target in the first quarter of 2022 for the adjuvant BRCA‑mutated, HER2‑negative early‑stage breast‑cancer indication【MRK_10k_2022.pdf p.20】. By 2024 Lynparza was already approved for several advanced ovarian, breast, pancreatic and prostate cancer indications, and the alliance‑revenue share grew 9 % to $1.311 billion in 2024 versus $1.116 billion in 2022, reflecting broader commercialization and new market approvals (including an upcoming Chinese indication)【MRK_10k_2024.pdf p.53】【MRK_10k_2024.pdf p.55】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy on most key points but has some notable issues: (1) CORRECT ELEMENTS: The 2022 regulatory status (supplemental NDA pending with Q1 2022 PDUFA date for adjuvant BRCA-mutated, HER2-negative early-stage breast cancer) is accurate. The 9% alliance revenue growth figure is correct. The revenue figures ($1.311 billion in 2024 vs $1.116 billion in 2022) are mathematically consistent with a 9% increase (1.116 × 1.09 ≈ 1.216, though the stated 1.311 suggests additional growth beyond the 2022 baseline). (2) QUANTITATIVE ACCURACY ISSUES: The revenue comparison appears problematic. If 2024 revenue is $1.311B and 2022 was $1.116B, the growth is actually 17.4%, not 9%. The ground truth states '9% growth in 2024' which likely means 2024 vs 2023, not vs 2022. The LLM incorrectly compared 2024 to 2022 instead of 2023, creating a mathematical inconsistency. (3) COMPLETENESS: The LLM answer addresses regulatory progress and revenue growth as requested. However, it mentions 'upcoming Chinese indication' rather than confirming the January 2025 China approval that occurred (though this is a minor temporal issue since the 10-K would have been filed before January 2025). (4) MULTI-HOP REASONING: The synthesis across 2022 and 2024 filings is sound, correctly identifying the evolution from pending approval to approved status with expanded indications. The connection between regulatory approvals and revenue growth is appropriately made. (5) ENTITY ACCURACY: All entities (Merck, Lynparza, FDA, BRCA-mutated indication) are correctly identified. The main weakness is the revenue year-over-year comparison methodology, which appears to conflate 2022-2024 growth with the stated 9% annual growth metric.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 476,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Boeing's strategy with commodity purchase contracts evolved between 2022 and 2024, particularly in terms of risk management horizon and financial exposure?",
      "original_answer": "In 2022, Boeing disclosed that a 10% change in commodity prices would impact unrealized losses by $46 million, and the company used commodity swaps and purchase contracts to hedge against price volatility, neutralizing material market risk. By 2024, Boeing extended the scope of its hedging strategy, indicating the use of commodity purchase contracts and derivatives to manage exposure through 2031. This represents a shift toward longer-term risk management aligned with extended production planning cycles. The expansion from a general hedging approach in 2022 to a multi-decade horizon in 2024 suggests Boeing is proactively securing cost predictability for strategic business stability.",
      "llm_answer": "In the 2022 filing Boeing noted that it used commodity purchase contracts and swaps to hedge price risk, but only quantified the exposure – a 10 % price move would have produced about $46 million of unrealized gain or loss – and did not describe a forward‑looking horizon for those contracts【58-62】. By the 2024 filing the company says its commodity contracts now hedge forecasted purchases through 2028, and the size of the hedge has been trimmed (notional amount fell from $514 million to $388 million and the fair‑value exposure dropped from $122 million to $65 million) with the OCI result moving from a $78 million gain in 2022 to a $10 million loss in 2024, reflecting a longer‑term, lower‑exposure risk‑management approach【108-112】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides substantial detail and addresses the core question about Boeing's evolving commodity hedging strategy, but contains a critical factual discrepancy regarding the forward-looking horizon. STRENGTHS: (1) Correctly identifies the 10% price sensitivity metric of $46 million for 2022; (2) Accurately captures the shift toward longer-term hedging; (3) Provides specific quantitative metrics for 2024 (notional amount $514M to $388M, fair-value exposure $122M to $65M, OCI movement from $78M gain to $10M loss); (4) Correctly characterizes the strategic shift toward lower-exposure, longer-term risk management; (5) Good synthesis of multi-hop information across years. CRITICAL ERROR: The LLM states hedging extends through 2028, while the ground truth indicates 2031. This is a significant factual error (3-year discrepancy) that undermines the core claim about 'multi-decade horizon' expansion. MINOR ISSUES: (1) The ground truth mentions 'through 2031' while LLM says 'through 2028' - this is a material difference in the risk management horizon being evaluated; (2) The LLM correctly notes the transition from general hedging in 2022 to specific forward-looking horizon in 2024, but the specific year is wrong. QUANTITATIVE VERIFICATION: All other numbers appear accurate ($46M, $514M→$388M, $122M→$65M, $78M gain→$10M loss), but the 2028 vs 2031 discrepancy is a factual error on a key metric. The reasoning about strategic evolution is sound, but the specific horizon claim is incorrect, which is particularly problematic since the question specifically asks about 'risk management horizon' as a key element of the strategy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 453,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did Schwab's exposure to PALs and the associated credit risk evolve between 2021 and 2024, particularly in terms of collateralization and allowance for credit losses?",
      "original_answer": "In 2021, all PALs were fully collateralized by securities with fair values exceeding borrowings, and therefore no allowance for credit losses was required. In contrast, by 2024, although PALs experienced slight growth overall, Schwab observed a decrease in the allowance for credit losses due to lower projected loss rates and improved credit quality metrics. This reflects a shift from a focus on full collateralization as the primary risk mitigant to a broader assessment of credit quality and loss projections.",
      "llm_answer": "Schwab’s portfolio‑asset loans (recorded as “pledged asset lines”) grew from roughly $12.7 billion at 12/31/2021 to about $17.0 billion at 12/31/2024 (SCHW_10k_2022 pp. 89‑93; SCHW_10k_2024 pp. 137‑141). In both periods the loans were deemed fully collateralized by securities whose fair values exceeded the borrowings, so Schwab applied the ASC 326 collateral‑maintenance practical expedient and reported no allowance for credit losses on PALs (zero allowance shown for pledged asset lines in 2021‑22 and still absent in the 2024 presentation). This indicates that although exposure increased, the associated credit‑risk charge remained unchanged because the loans stayed fully collateralized.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The ground truth explicitly states that by 2024, Schwab observed a DECREASE in the allowance for credit losses due to lower projected loss rates and improved credit quality metrics. However, the LLM claims that 'the associated credit-risk charge remained unchanged' and that there was 'still absent' allowance in 2024. This is incorrect - the ground truth indicates an allowance existed in 2024 (though decreased from prior periods), not that it remained absent. The LLM's statement that 'zero allowance shown for pledged asset lines in 2021-22 and still absent in the 2024 presentation' directly contradicts the ground truth's assertion of a decrease in allowance by 2024. QUANTITATIVE ISSUES: While the LLM provides specific dollar amounts ($12.7B in 2021, $17.0B in 2024), these cannot be verified against the ground truth which does not provide specific numbers. The growth trajectory appears reasonable but the core claim about allowance treatment is wrong. REASONING FLAWS: The LLM's logic that 'full collateralization' explains the absence of allowance in both periods misses the key evolution described in the ground truth - that by 2024, Schwab shifted from relying solely on collateralization to a broader assessment of credit quality and loss projections, which resulted in a decreased (not absent) allowance. The multi-hop synthesis failed to capture this critical shift in risk assessment methodology. WHAT WAS CORRECT: The identification of PALs/pledged asset lines, the general timeframe (2021-2024), and the concept of collateralization as a risk mitigant were correctly identified. However, the core answer about allowance evolution is fundamentally wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 485,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did Boeing's financial treatment and strategic positioning of the 777X program evolve between 2022 and 2024, given the changes in cost impacts and research & development investments?",
      "original_answer": "In 2022, the 777X program negatively impacted Boeing's financials, contributing to higher charges and a cost of sales increase, partly due to a 'reach-forward loss' on the program. By 2024, the program had transitioned to being a strategic investment priority, as evidenced by a $435 million increase in R&D spending in 2024 compared to 2023, following a $525 million increase in 2023 over 2022, indicating a shift from a cost burden to a focal point for future product development.",
      "llm_answer": "In the 2022 Form 10‑K Boeing still treated the 777X as a cost‑draining program – a “reach‑forward loss” on the 777X lifted cost‑of‑sales and pushed the cost‑of‑sales ratio higher (see 2022 p. 32‑34), and the company actually cut R&D spending on the aircraft (“lower spending on the 777X program”) (2022 p. 35‑36). By the 2024 filing the reach‑forward loss remained on the income statement, but Boeing reversed the R&D trend, adding $525 million in 2023 and another $435 million in 2024 to the 777X effort (2024 p. 33‑34), indicating a strategic shift to prioritize the program’s development despite its ongoing cost impact (2024 p. 30‑31).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of Boeing's 777X program evolution. QUANTITATIVE VERIFICATION: All dollar amounts are correct - $525 million increase in 2023 over 2022, and $435 million increase in 2024 over 2023. Years are correctly identified (2022, 2023, 2024). ENTITY ACCURACY: Boeing correctly identified, 777X program correctly referenced, financial metrics (R&D spending, cost-of-sales, reach-forward loss) properly named. MULTI-HOP REASONING: The answer successfully synthesizes information across three fiscal years and two 10-K filings, correctly identifying the transition from 2022 (cost burden with reach-forward loss and reduced R&D) to 2024 (strategic priority with increased R&D investments). The logic is sound - the model correctly connects the reach-forward loss impact in 2022 to cost-of-sales increases, then traces the R&D spending reversal through 2023-2024. COMPLETENESS: The answer addresses all aspects of the question - financial treatment evolution, strategic positioning shift, cost impacts, and R&D investment changes. SEMANTIC EQUIVALENCE: The answer conveys the same information as the ground truth, using slightly different phrasing ('cost-draining' vs 'negatively impacted') but maintaining factual equivalence. The characterization of the shift from 'cost burden' to 'strategic investment priority' matches the ground truth's description. MINOR OBSERVATION: The LLM provides additional context (page references, specific quote about 'lower spending') that enhances credibility without contradicting the ground truth. The answer is well-structured and clearly explains the evolution across the time period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 460,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has Schwab's exposure to and risk management of Portfolio Against Loans (PALs) evolved between 2022 and 2024, particularly in terms of credit loss allowance methodology and portfolio growth?",
      "original_answer": "In 2022, Schwab applied the practical expedient for PALs due to their collateralized nature and over-collateralization requirements, which limited inherent credit loss. The company monitored collateral daily and maintained strict maintenance levels based on the type of security pledged. By 2024, PALs had contributed to the growth of the average loan portfolio, although there was a slight decrease in 2023. The overall decrease in the allowance for credit losses as a ratio to year-end loans in 2024 was attributed to improved credit quality metrics and lower projected loss rates, indicating a reduced risk profile for PALs despite portfolio growth.",
      "llm_answer": "Schwab’s credit‑loss approach for Portfolio‑Against‑Loans has not changed – in both 2022 and 2024 the company uses a practical‑expedient based on collateral‑maintenance provisions, monitors the market value of the over‑collateralized securities daily and charges off any PAL that is 90 days past due (2022 Note on bank loans, pp. 76‑80).  However, the PAL exposure has grown markedly: pledged‑asset lines rose to $17.0 billion in 2024 (part of a $45.2 billion total loan portfolio) and overall bank‑loan balances increased from $38.8 billion in 2022 to $42.3 billion in 2024 (2024 loan‑portfolio tables, pp. 137‑141).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with specific, verifiable numbers and a clear multi-hop synthesis across 2022-2024. STRENGTHS: (1) Correctly identifies the practical expedient methodology as unchanged between 2022-2024, matching ground truth; (2) Accurately describes daily collateral monitoring and over-collateralization requirements; (3) Provides specific quantitative data: PALs at $17.0B in 2024, total loan portfolio at $45.2B in 2024, and bank-loan growth from $38.8B (2022) to $42.3B (2024) - these numbers appear internally consistent and support the portfolio growth narrative; (4) Correctly notes the 90-day charge-off policy; (5) Effectively synthesizes multi-hop information showing both methodology consistency and portfolio evolution. MINOR GAPS: (1) The ground truth mentions 'a slight decrease in 2023' in the PAL portfolio, which the LLM answer does not explicitly address, though it doesn't contradict this; (2) The ground truth emphasizes 'improved credit quality metrics and lower projected loss rates' and 'reduced risk profile' in 2024, which the LLM answer does not explicitly discuss - it focuses on portfolio growth but doesn't address the allowance-for-credit-losses ratio improvement mentioned in ground truth; (3) The LLM answer doesn't explicitly connect the practical expedient to 'limited inherent credit loss' as stated in ground truth. QUANTITATIVE VERIFICATION: The specific dollar amounts provided ($17.0B PALs, $45.2B total loans, $38.8B to $42.3B growth) are presented with confidence and page citations, suggesting they are sourced from actual filings. The growth trajectory is logical and consistent. REASONING QUALITY: The answer correctly synthesizes that methodology remained constant while exposure grew, which is the core multi-hop insight required. The answer is well-structured and directly addresses the question's two main components (methodology evolution and portfolio growth).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 526,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did MDLZ's value of British pound sterling notes change from 2022 to 2023, and what does this shift indicate about the company's foreign exchange risk management strategy?",
      "original_answer": "In 2022, MDLZ reported a value of $3 million for British pound sterling notes. By 2023, this value had increased significantly to $45 million. This shift indicates a substantial change in MDLZ's foreign exchange risk management strategy, suggesting an increased exposure to the British pound sterling, which could reflect either a strategic decision to hedge more in this currency or an increase in operational activities tied to the UK market.",
      "llm_answer": "MDLZ’s net‑investment hedge for British‑pound‑sterling notes fell from $45 million in 2022 to essentially $0 in 2023 (the 2023 table shows “‑” for the pound‑sterling line, versus 45 in 2022)【MDLZ_10k_2023.pdf p.96‑97】. The disappearance of the GBP‑denominated hedge suggests the company has either retired the underlying pound‑denominated debt or fully hedged it, reflecting a proactive move to eliminate exposure to fluctuations in the British pound and tighten its foreign‑exchange risk management.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer contains fundamentally incorrect numbers and reverses the direction of change. Ground truth states: 2022 = $3 million, 2023 = $45 million (an INCREASE). LLM claims: 2022 = $45 million, 2023 = $0 (a DECREASE). This is a complete reversal of the actual data. The LLM appears to have confused the years or misread the filing data. The ground truth clearly indicates MDLZ increased its British pound sterling notes exposure from $3M to $45M, suggesting expanded hedging or UK operations. The LLM's interpretation that the company 'retired the underlying pound-denominated debt or fully hedged it' is contradicted by the actual data showing a 15x increase in exposure. The reasoning about 'tightening foreign-exchange risk management' is logically inconsistent with an increase in GBP exposure. The LLM's citation to specific pages (p.96-97) does not validate the incorrect numbers provided. This is a multi-hop question requiring accurate synthesis of year-over-year financial data, and the LLM has failed on the most basic requirement: reporting the correct numbers in the correct direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 319,
        "total_tokens": 1562
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "Compare the interest rate disclosures for Amgen's 3.125% 2025 Notes in the 2022 and 2024 filings, and explain what this reveals about the company's approach to debt financing for this instrument.",
      "original_answer": "In the 2022 filing, Amgen disclosed a fixed interest rate of 3.125% for the 2025 Notes with no mention of variable rate terms. However, by the 2024 filing, Amgen disclosed that the interest rate for the same 3.125% 2025 Notes was tied to SOFR (Secured Overnight Financing Rate) plus 2.1%. This indicates a shift from a purely fixed-rate structure to a floating-rate mechanism, suggesting Amgen may have refinanced or repriced the notes to adapt to changing market conditions and interest rate environments.",
      "llm_answer": "In the 2022 Form 10‑K Amgen reported that its $1 billion 3.125 % 2025 senior notes carry a fixed 3.125 % coupon, but the company has entered an interest‑rate swap that converts the debt to a floating rate of **LIBOR + 1.8 %** (and the notes remain callable at any time with make‑whole terms). In the 2024 filing the same notes are still swapped, now showing an effective rate of **SOFR + 2.1 %**, reflecting the market shift from LIBOR to SOFR, while the optional redemption features are unchanged. This consistency indicates Amgen’s strategy of issuing fixed‑rate notes and immediately hedging them to floating rates, giving it flexibility to manage interest‑rate risk and adapt to benchmark changes.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) QUANTITATIVE ERRORS: The LLM states the swap rate was 'LIBOR + 1.8%' in 2022, but the ground truth indicates the 2022 filing showed NO mention of variable rate terms or swaps - it was disclosed as a fixed 3.125% rate only. The LLM also introduces a $1 billion principal amount that is not mentioned in the ground truth. (2) FUNDAMENTAL MISCHARACTERIZATION: The ground truth explicitly states the 2022 filing disclosed a 'fixed interest rate of 3.125% with no mention of variable rate terms,' while the LLM claims the company 'immediately hedged' the notes with a LIBOR swap in 2022. This is a direct contradiction. (3) PARTIAL ACCURACY: The LLM correctly identifies the 2024 shift to SOFR + 2.1%, which matches the ground truth. However, this correct information is undermined by the false claims about 2022. (4) REASONING FLAW: The LLM's interpretation that Amgen has a strategy of 'issuing fixed-rate notes and immediately hedging them to floating rates' is not supported by the ground truth, which indicates a shift FROM fixed-rate (2022) TO floating-rate (2024), not an immediate hedge. (5) MISSING CONTEXT: The ground truth suggests a refinancing or repricing event between 2022 and 2024, but the LLM frames this as a consistent hedging strategy, which misrepresents the actual disclosure changes. The answer demonstrates a fundamental misunderstanding of what the filings actually disclosed in each year.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 422,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has Schwab's reliance on its Commercial Paper Issuance Program evolved between 2022 and 2024 in response to market disruptions and rising interest rates?",
      "original_answer": "In 2022, Schwab introduced its Commercial Paper Issuance Program as one of several potential sources of external financing, alongside unsecured bank credit lines and a universal shelf registration, to address liquidity needs during market disruptions. The company emphasized that while these tools were available, access to financing could still be constrained due to credit market volatility and potential credit rating downgrades. By 2024, Schwab's reliance on the program had increased as a complement to other funding mechanisms like FHLB advances and repurchase agreements, particularly in response to rising short-term interest rates in 2022 and 2023, which led to higher client cash outflows. The company noted that these outflows, outpacing cash generated from maturities and paydowns, required supplemental funding sources, including the commercial paper program, to manage liquidity under more costly and constrained conditions.",
      "llm_answer": "In the 2022 filing Schwab said its commercial‑paper issuance program was simply one of several external‑financing tools and cautioned that market disruptions could make that source unavailable or costly (SCHW 10‑K 2022, pp. 21‑25). By the 2024 filing the company still maintains the program, but stresses that rapid short‑term‑rate hikes and recent credit‑market stress have driven up the cost and uncertainty of commercial paper, prompting Schwab to rely more on other supplemental funding (e.g., FHLB advances, repos, brokered CDs) while keeping commercial paper as a backup (SCHW 10‑K 2024, pp. 14‑18).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the general evolution of Schwab's Commercial Paper Issuance Program between 2022 and 2024, correctly identifying key themes: (1) the program's introduction as one of several financing tools in 2022, (2) market disruption concerns, (3) rising short-term interest rates driving increased costs, and (4) shift toward supplemental funding sources like FHLB advances and repos. However, there are significant issues with the answer: (1) FACTUAL ACCURACY: The LLM states the program was 'simply one of several external-financing tools' in 2022, which aligns with ground truth, but then claims by 2024 'the company still maintains the program, but stresses that rapid short-term-rate hikes...have driven up the cost' - this reverses the causality. The ground truth indicates the rate hikes occurred in 2022-2023, not 2024, and drove the INCREASED reliance on the program by 2024, not decreased reliance. (2) INCOMPLETE SYNTHESIS: The LLM characterizes commercial paper as a 'backup' by 2024, but the ground truth indicates INCREASED reliance on the program as a complement to other funding mechanisms, not reduced reliance. This is a material mischaracterization of the evolution. (3) PAGE CITATIONS: The LLM provides specific page numbers (pp. 21-25 for 2022, pp. 14-18 for 2024) without verification - these cannot be confirmed and may be hallucinated. (4) MISSING CONTEXT: The answer omits the critical detail that client cash outflows outpaced cash generated from maturities and paydowns, which was the key driver requiring supplemental funding sources. (5) CORRECT ELEMENTS: The answer correctly identifies FHLB advances, repos, and brokered CDs as supplemental funding sources, and correctly notes the program's role in managing liquidity under constrained conditions. The multi-hop reasoning is partially sound but contains a directional error in characterizing the evolution of reliance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 517,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has the status and interest rate structure of the 3.625% Notes evolved from 2022 to 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2022, the 3.625% 2024 Notes had a carrying value of $1,400 million with a fixed interest rate of 3.625%. By 2024, these notes were fully paid off, as indicated by the $0 notional amount, and were replaced with floating interest rates tied to SOFR (Secured Overnight Financing Rate). This shift from fixed to floating rate debt indicates a strategic change in Amgen's debt management, aligning with broader market conditions and potentially reducing interest costs in a declining rate environment.",
      "llm_answer": "The 3.625 % notes that were due in 2022 were completely redeemed in 2021 (the $750 million principal was paid off and the related $750 million interest‑rate swap was terminated). The 3.625 % notes due in 2024 remained outstanding through 2023, were hedged with a $1.4 billion swap that converted the fixed 3.625 % coupon to a floating LIBOR + 3.2 % rate, and were repaid in 2024 when the swap matured and the notes were retired. This evolution shows Amgen using swaps to manage fixed‑rate exposure and then systematically retiring the higher‑coupon debt, indicating a proactive strategy to reduce its fixed‑rate debt burden and control interest‑cost risk.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and misinterpretations that fundamentally contradict the ground truth. Key issues: (1) WRONG NOTES IDENTIFICATION: The LLM discusses two different sets of notes (3.625% notes due 2022 and 3.625% notes due 2024), but the question and ground truth focus specifically on the 3.625% 2024 Notes. The LLM incorrectly introduces information about 2022 notes being redeemed in 2021, which is not part of the ground truth answer. (2) QUANTITATIVE ERRORS: The LLM states the 2022 notes had $750 million principal, but the ground truth clearly indicates the 2024 Notes had a $1,400 million carrying value in 2022. The LLM's $1.4 billion swap reference appears to conflate different instruments. (3) INCORRECT RATE STRUCTURE: The ground truth states the notes were replaced with floating rates tied to SOFR, but the LLM claims they were hedged with a swap converting to LIBOR + 3.2%. These are different mechanisms and rate bases (SOFR vs LIBOR). (4) TIMELINE CONFUSION: The LLM's narrative about 2021 redemptions and 2023 status is not aligned with the ground truth's 2022-2024 evolution focus. (5) MISSING KEY INFORMATION: The LLM fails to clearly state that the notes were fully paid off by 2024 with a $0 notional amount, which is central to the ground truth answer. (6) REASONING QUALITY: While the LLM attempts to explain debt management strategy, it does so based on incorrect premises about which notes and which hedging mechanisms were used. The multi-hop synthesis is flawed because it's synthesizing information about the wrong instruments. The answer demonstrates partial understanding of debt management concepts but applies them to incorrect financial instruments and timeframes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 472,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has Schwab's approach to providing financial or other support to variable interest entities (VIEs) evolved between 2022 and 2024, particularly in terms of intent and conditions for funding commitments?",
      "original_answer": "In 2022, Schwab explicitly stated that it did not provide or intend to provide financial or other support to VIEs that it was not contractually required to provide. By 2024, Schwab's disclosures indicate a shift, as the company now acknowledges that while it has no contractual obligation, it may choose to provide credit, liquidity, or other support to its proprietary funds in response to significant declines in valuation or redemption activity. This reflects a more proactive stance in supporting funds under certain market conditions, even though it is not mandated.",
      "llm_answer": "In the 2022 Form 10‑K Schwab disclosed that it “did not provide or intend to provide financial or other support to the VIEs that it was not contractually required to provide,” and that CSB’s funding of any remaining VIE commitments was “dependent upon the occurrence of certain conditions” with an expectation to satisfy “substantially all of these commitments between 2022 and 2025.” The 2024 filing repeats the same no‑intent stance – Schwab will not fund VIEs beyond contractual obligations – but updates the conditional funding language to show that any future support will still be contingent on specific conditions and that the company now expects to meet the outstanding commitments over a later horizon (e.g., 2023‑2026), shifting the timing of the anticipated payments while keeping the conditional, non‑voluntary nature of the support unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. CRITICAL ERRORS: (1) The LLM claims the 2024 filing 'repeats the same no-intent stance' and that the conditional funding language remains 'unchanged,' but the ground truth explicitly states there was a SHIFT in Schwab's approach between 2022 and 2024. The 2024 position acknowledges the company 'may choose to provide credit, liquidity, or other support' under certain market conditions, which is fundamentally different from the 2022 'did not provide or intend to provide' stance. (2) The LLM mischaracterizes the evolution as merely a timing shift ('shifting the timing of the anticipated payments') when the ground truth indicates a substantive change in intent and conditions - from no intent to provide support to a proactive willingness to support funds during market stress. (3) The LLM states the support remains 'non-voluntary' in 2024, but the ground truth indicates it becomes discretionary ('may choose to provide'). CORRECT ELEMENTS: The LLM accurately cites the 2022 language about not intending to provide support beyond contractual requirements and correctly identifies that both years involve conditional funding. However, these correct elements are overshadowed by the fundamental misunderstanding of the evolution. The answer fails to capture the key insight that Schwab shifted from a passive stance (no intent) to a more active stance (may provide support under certain conditions). The multi-hop reasoning is flawed because it concludes there is no meaningful change when the ground truth demonstrates a clear evolution in approach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 448,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has MDLZ's financial relationship with JDE Peet's evolved between 2022 and 2023, particularly in terms of how the investment impacts MDLZ's liquidity and capital structure?",
      "original_answer": "In 2022, MDLZ's relationship with JDE Peet's was characterized as a 'Has_Stake_In' arrangement, where MDLZ reported its proportionate share of significant operating and non-operating items from JDE Peet's including restructuring and acquisition-related costs. By 2023, the relationship was reclassified to 'Invests_In', and the investment in JDE Peet's was described as providing additional financial flexibility within MDLZ's liquidity and capital resources framework. This shift indicates a more strategic and stable investment posture, aligning JDE Peet's more closely with MDLZ's long-term capital planning and funding sources.",
      "llm_answer": "In 2022 MDLZ’s stake in JDE Peet’s was held as an equity‑method investment backed by a €300 million zero‑interest exchangeable note, which the company said gave it additional flexibility but did not materially affect its liquidity or capital structure (MDLZ_10k_2022.pdf p. 44‑45). By 2023 MDLZ had begun selling JDE Peet’s shares, generating cash that boosted net cash from investing activities (MDLZ_10k_2023.pdf p. 53) and helped lower total debt to $19.4 bn (down from $22.9 bn) and the debt‑to‑capitalization ratio to 0.41, thereby improving its liquidity and capital structure (MDLZ_10k_2023.pdf p. 55).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and misalignments with the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM provides specific numbers (€300 million exchangeable note, $19.4 bn debt, $22.9 bn prior debt, 0.41 debt-to-capitalization ratio) that cannot be verified against the ground truth and appear to be fabricated or hallucinated. The ground truth makes no mention of these specific figures. (2) RELATIONSHIP CLASSIFICATION MISMATCH: The ground truth clearly states the relationship evolved from 'Has_Stake_In' (2022) to 'Invests_In' (2023), but the LLM describes it as an 'equity-method investment' in 2022 and then discusses share sales in 2023. While these descriptions might be related, they don't directly address the stated relationship reclassification. (3) MISSING KEY INFORMATION: The ground truth emphasizes that the 2023 relationship shift indicates 'a more strategic and stable investment posture' and 'aligns JDE Peet's more closely with MDLZ's long-term capital planning.' The LLM focuses instead on share sales and debt reduction, which is a different narrative. (4) LIQUIDITY IMPACT CHARACTERIZATION: The ground truth states the 2022 investment 'did not materially affect' liquidity, while the LLM claims it 'gave it additional flexibility' - a subtle but important distinction. (5) MULTI-HOP REASONING: The LLM attempts to synthesize information across 2022 and 2023 filings but does so by introducing specific numbers and facts not present in the ground truth, suggesting reliance on fabricated details rather than actual filing data. (6) DOCUMENT CITATIONS: The LLM cites specific page numbers (p. 44-45, p. 53, p. 55) which cannot be verified and appear to be invented. The answer reads plausibly but contains fundamental factual inaccuracies that undermine its reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 495,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 119,
      "question": "How did the interest rate hedging strategy for the 3.125% 2025 Notes evolve between 2022 and 2024, particularly in terms of the interest rate applied under the swap agreements?",
      "original_answer": "In 2022, the company had terminated interest rate swaps for portions of the 3.125% 2025 Notes and reentered into new swap agreements at then-current interest rates, though the exact rate for the 3.125% 2025 Notes was not disclosed. By 2024, the interest rate applied under the swap agreement for the 3.125% 2025 Notes was explicitly stated as SOFR+2.1%, with a consistent notional amount of $1,000 million as of December 31, 2024, compared to December 31, 2023.",
      "llm_answer": "In the 2022 filing the 3.125 % 2025 Notes were hedged with a LIBOR‑based swap that added a spread of 1.8 % (LIBOR + 1.8%) on a $1 billion notional (see the 2022 table of effective interest rates). By the 2024 filing the same notes were hedged with a SOFR‑based swap that adds a spread of 2.1 % (SOFR + 2.1%) on the same $1 billion notional (see the 2024 table of interest‑rate swap rates). This shift reflects the transition from LIBOR to SOFR and a modest increase in the swap spread.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a significant factual error regarding the 2022 swap rate. The LLM claims the 2022 swap was LIBOR+1.8%, but the ground truth explicitly states that 'the exact rate for the 3.125% 2025 Notes was not disclosed' in 2022. This is a major factual inaccuracy - the LLM fabricated a specific rate (1.8%) that was not actually disclosed in the 2022 filing. The 2024 rate of SOFR+2.1% is correctly stated and matches the ground truth. The notional amounts ($1 billion/$1,000 million) are correctly identified and equivalent. MULTI-HOP REASONING: The LLM correctly identifies the evolution from LIBOR-based to SOFR-based swaps and notes the spread increase, which demonstrates sound reasoning about the transition. However, this reasoning is undermined by the fabricated 2022 data. COMPLETENESS: The answer addresses the core question about how the strategy evolved, but does so with false information for the 2022 baseline. The comparison between years is logically structured but factually compromised. SEMANTIC ISSUES: While the answer format and structure are appropriate, the fundamental problem is inventing data not present in the source documents. This violates the core requirement of factual accuracy in financial analysis. The answer would mislead readers about the actual 2022 hedging terms.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 375,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did Walmart's fair value of equity investments measured using Level 2 inputs evolve from fiscal year 2022 to fiscal year 2023, and what was the magnitude of this change?",
      "original_answer": "Walmart's fair value of equity investments measured using Level 2 inputs decreased from $5,819 million in fiscal year 2022 to $5,570 million in fiscal year 2023, representing a moderate decline of $249 million over the period.",
      "llm_answer": "Walmart’s equity investments measured using Level 2 inputs were valued at **$5.819 billion** at the end of fiscal 2022 and fell to **$5.570 billion** at the end of fiscal 2023, a **decrease of $249 million**【WMT_10k_2022.pdf†L71-L73】【WMT_10k_2023.pdf†L70-L72】.",
      "correctness_score": 0,
      "quantitative_accuracy": 0,
      "qualitative_accuracy": 0,
      "contextual_relevance": 0,
      "detailed_feedback": "Evaluation failed: Evaluation error: Expecting value: line 1 column 1 (char 0)",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 0,
        "completion_tokens": 0,
        "total_tokens": 0
      },
      "error": "Evaluation error: Expecting value: line 1 column 1 (char 0)"
    },
    {
      "question_id": 120,
      "question": "How has Apple's characterization of its reliance on marketing abilities evolved between its 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Apple stated that while it believes ownership of intellectual property rights is an important factor in differentiating its business, it 'relies primarily' on the innovative skills, technical competence, and marketing abilities of its personnel. In the 2024 filing, Apple shifted its language, stating that it 'depends heavily' on these same three factors—innovative skills, technical competence, and marketing abilities—tying them directly to ensuring a continual and timely flow of competitive products, services, and technologies to the marketplace. This evolution reflects a stronger emphasis on the strategic importance of marketing abilities in maintaining competitiveness, particularly as the company faces increasing pressure from rivals imitating its features and offering lower-priced alternatives.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K filings say essentially the same thing: Apple notes that its success “relies primarily on the innovative skills, technical competence and **marketing abilities** of its personnel” (AAPL_10k_2023.pdf p. 5; AAPL_10k_2024.pdf p. 5). The wording is unchanged, indicating that Apple’s characterization of its reliance on marketing abilities did not evolve between the two reports.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core conclusion. The ground truth clearly documents an evolution in Apple's language between the two filings: from 'relies primarily' (2023) to 'depends heavily' (2024). The LLM claims the wording is 'unchanged' and that there was no evolution, which directly contradicts the ground truth. This is a critical factual error that undermines the entire answer. While the LLM correctly identifies that both filings mention the three factors (innovative skills, technical competence, and marketing abilities) and correctly cites page 5 for both documents, it fails to recognize the significant shift in characterization language. The ground truth explicitly states this represents 'a stronger emphasis on the strategic importance of marketing abilities in maintaining competitiveness.' The LLM's assertion that the characterization 'did not evolve' is demonstrably false. The quantitative accuracy score is relatively high because the page numbers and document citations appear correct, but the qualitative accuracy is very low because the LLM completely missed the key linguistic and strategic shift that is the entire point of the question. This represents a failure in multi-hop reasoning and careful document comparison, as the task explicitly required analyzing how the characterization 'evolved' between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 381,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did the notional amount and interest rate structure for the 3.625% 2024 Notes change between 2022 and 2024, and what does this indicate about Amgen's hedging strategy?",
      "original_answer": "In 2022, Amgen terminated interest rate swaps with a notional amount of $5.2 billion that hedged several notes, including the 3.625% 2024 Notes, and reentered into new interest rate swap agreements at then-current rates on the same principal amount. By 2024, the notional amount for the 3.625% 2024 Notes had dropped to $0 as of December 31, 2024, compared to $1,400 million in December 2023, with the interest rate tied to SOFR+3.4% in 2023. This indicates that Amgen fully unwound its hedging position for the 3.625% 2024 Notes by the end of 2024, likely as the notes approached maturity.",
      "llm_answer": "In the 2022 10‑K Amgen still had a $1.4 billion interest‑rate‑swap hedge on the 3.625 % 2024 Notes, with the swap converting the fixed coupon to a floating rate of **LIBOR + 3.2 %** (see the “Interest rate swaps” table for 2021/2020). By the 2024 filing the $1.4 billion swap had **matured and been removed** (notional $0) after the notes were repaid, and the earlier LIBOR‑based hedge had been replaced by a **SOFR + 3.4 %** structure before termination (see the “Fair‑value hedges” table for 2023/2024). This evolution shows Amgen’s proactive hedging approach—using fair‑value swaps to convert fixed‑rate debt to floating, updating the benchmark from LIBOR to SOFR, and unwinding the hedge as the underlying notes mature.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains several significant factual errors that undermine its credibility:\n\n1. QUANTITATIVE ACCURACY ISSUES:\n   - The LLM states the 2022 swap rate was \"LIBOR + 3.2%\" but the ground truth indicates SOFR+3.4% was the rate structure by 2023. The LLM appears to have confused or misidentified the rate structure.\n   - The LLM correctly identifies the $1.4 billion notional amount for 2023, but then claims it \"matured and been removed\" with the notes being \"repaid\" by 2024. However, the ground truth states the notional dropped to $0 as of December 31, 2024, suggesting the hedge was unwound, not that the notes matured and were repaid.\n   - The LLM references \"2021/2020\" data in parentheses when discussing 2022 information, which is chronologically inconsistent.\n\n2. ENTITY/TIMING ACCURACY:\n   - The LLM conflates the timing of events. It suggests the notes were \"repaid\" by 2024, but the ground truth indicates the hedge was \"fully unwound\" as the notes \"approached maturity\" - these are different concepts. The notes may not have actually matured/been repaid yet.\n   - The claim about \"LIBOR + 3.2%\" in 2022 contradicts the ground truth which specifies SOFR+3.4% in 2023.\n\n3. MULTI-HOP REASONING:\n   - The LLM does attempt to synthesize information across years and explain the hedging strategy evolution (LIBOR to SOFR transition), which shows some understanding of the multi-hop nature.\n   - However, the factual errors in the specific numbers and timing undermine the validity of this synthesis.\n\n4. WHAT WAS CORRECT:\n   - The $1.4 billion notional amount for the earlier period is correct.\n   - The $0 notional by 2024 is correct.\n   - The general concept that the hedge was unwound/removed is correct.\n   - The identification of a SOFR-based structure is correct.\n   - The overall narrative about proactive hedging and benchmark transition is conceptually sound.\n\n5. CRITICAL GAPS:\n   - The specific rate of \"LIBOR + 3.2%\" appears to be incorrect or misattributed to 2022.\n   - The explanation that notes were \"repaid\" is not supported by the ground truth, which indicates unwinding of the hedge as notes approached maturity.\n   - Missing the 2022 context about the $5.2 billion termination and re-entry into new swap agreements.\n\nThe answer demonstrates partial understanding but contains enough factual inaccuracies in the quantitative details to significantly reduce its reliability, particularly regarding the specific interest rate structures and the mechanism of unwinding (repayment vs. hedge termination).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 685,
        "total_tokens": 2019
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How did Schwab's integration of the iRebal portfolio rebalancing solution evolve from 2022 to 2023, and what does this indicate about its competitive positioning in the RIA market?",
      "original_answer": "In 2022, Schwab stated that it was retaining TD Ameritrade Institutional's customizable portfolio rebalancing solution, iRebal, as part of its offering for independent advisor clients. This indicated that Schwab acknowledged the value of iRebal but had not yet fully integrated or emphasized it within its broader platform. By 2023, Schwab had incorporated iRebal as a core part of its offerings for independent advisors, signaling a deeper integration and a strategic move to enhance its competitive positioning in the RIA market. This evolution reflects Schwab's broader integration progress, including the transition of over $1.6 trillion in client assets and more than 15 million client accounts from TD Ameritrade to the Schwab platform by 2023. The inclusion of iRebal as a central feature for RIAs suggests that Schwab is leveraging the solution to differentiate its service offerings and strengthen its appeal to independent advisors, aligning with its competitive advantage of introducing new products credibly through its strong brand and corporate reputation.",
      "llm_answer": "In the 2022 Form 10‑K Schwab said it would **retain** TD Ameritrade Institutional’s customizable portfolio‑rebalancing tool, iRebal, as part of its offering for independent‑advisor (RIA) clients. By the 2023 Form 10‑K the company reported that it has **incorporated** iRebal into its integrated platform for those advisors, moving from simple retention to full integration. This progression signals that Schwab is deliberately embedding TD Ameritrade’s advanced rebalancing technology into its Advisor Services, strengthening its product suite and competitive edge in the RIA market.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of iRebal from 2022 (retention) to 2023 (incorporation/integration), which matches the ground truth. The characterization of the progression is accurate: Schwab moved from simply retaining the tool to incorporating it as a core offering. However, the LLM answer has significant omissions that reduce its completeness. The ground truth provides important context about the scale of Schwab's integration efforts (over $1.6 trillion in client assets and more than 15 million client accounts transitioned from TD Ameritrade by 2023), which the LLM answer completely omits. This context is relevant to understanding the significance of iRebal's integration within Schwab's broader competitive positioning. The ground truth also explains Schwab's strategic rationale more thoroughly—leveraging the solution to differentiate service offerings and strengthen appeal to independent advisors, aligned with Schwab's competitive advantage of introducing new products credibly through its strong brand and corporate reputation. The LLM answer mentions 'strengthening its product suite and competitive edge' but lacks the deeper strategic insight about brand credibility and differentiation. The LLM answer is factually accurate in what it states (no incorrect numbers or dates), but it provides a more surface-level analysis that doesn't fully address the 'what does this indicate about competitive positioning' portion of the question with the same depth as the ground truth. The answer would have been stronger with inclusion of the asset transition figures and more explicit discussion of how iRebal specifically enhances competitive positioning through differentiation and brand leverage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 472,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How has Apple's approach to the iMac product line evolved between 2023 and 2024, based on the company's disclosures in its 10-K filings?",
      "original_answer": "In 2023, Apple described the iMac as part of its Mac product line, indicating it was actively manufacturing and marketing the desktop computer as part of its standard offerings. By 2024, Apple elevated the iMac to the level of a significant product announcement, listing it among other key launches like the MacBook Pro and iPad Pro in the MD&A section of its 2024 10-K. This shift suggests that the iMac gained strategic importance in 2024, likely reflecting a product refresh or redesign that warranted special mention as part of the company's innovation cycle.",
      "llm_answer": "Apple’s 2023 Form 10‑K simply listed the iMac as part of its existing Mac portfolio (Item 1 – Business, pp. 2‑3 of the 2023 filing) with no mention of a new model or refresh. In the 2024 Form 10‑K, Apple highlighted a refreshed iMac in its Q1 2024 product announcements (Item 7 – Product, Service and Software Announcements, pp. 24‑25 of the 2024 filing), indicating a shift from a static line‑item to an actively refreshed product focus.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the core narrative that Apple's iMac evolved from a standard product line item in 2023 to a highlighted refresh in 2024, which aligns with the ground truth. However, there are significant issues with specificity and verifiability: (1) The LLM cites specific page numbers (pp. 2-3 for 2023, pp. 24-25 for 2024) and section references (Item 1, Item 7) that cannot be verified against the ground truth and may be inaccurate. The ground truth references the MD&A section but does not specify these exact page numbers or item numbers. (2) The LLM introduces a specific claim about 'Q1 2024 product announcements' and an 'Item 7 – Product, Service and Software Announcements' section that is not mentioned in the ground truth and appears to be fabricated or incorrectly cited. Standard 10-K filings do not typically have an 'Item 7 – Product, Service and Software Announcements' section. (3) The semantic meaning is largely correct—both answers convey that iMac moved from routine mention to strategic emphasis—but the LLM's specific citations undermine credibility. (4) The multi-hop reasoning is sound in concept (comparing 2023 vs 2024 filings), but the execution is compromised by potentially false citations. (5) The answer is contextually relevant and addresses the question directly, but the fabricated or incorrect section references represent a critical flaw in a financial document evaluation context where precision is paramount.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 403,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How has RTX's relationship with the 2.820% Notes Due 2051 evolved between 2022 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "In 2022, RTX introduced the 2.820% Notes Due 2051 with an aggregate principal balance of $1,000 million. By 2024, this debt instrument remained on the books with the same principal balance of $1,000 million, indicating no repayment or additional issuance occurred during this period. However, the broader long-term debt structure expanded significantly, with total principal long-term debt increasing from an implied $40,078 million in 2022 (based on the 2024 presentation format) to $41,146 million in 2024. This suggests that while the 2.820% Notes Due 2051 remained unchanged, RTX increased its overall debt burden through other issuances, maintaining the 2051 notes as a stable component within a growing long-term debt portfolio.",
      "llm_answer": "RTX still carries the 2.820 % notes due 2051 on its balance sheet – the 2022 10‑K lists a $1 billion principal balance for these notes, and the 2024 10‑K shows the same $1 billion balance unchanged【2022 p.95】【2024 p.91】.  The fact that the issuance has neither been retired nor refinanced over this period indicates that RTX continues to rely on long‑dated, low‑coupon debt as a stable component of its long‑term capital structure.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the 2.820% Notes Due 2051 with the $1 billion principal balance in both 2022 and 2024, accurately noting no repayment or refinancing occurred. The characterization of these notes as 'stable component' and 'long-dated, low-coupon debt' is semantically sound and aligns with the ground truth. WEAKNESSES: (1) INCOMPLETE ANALYSIS - The LLM answer fails to address the broader long-term debt structure evolution that is central to the question. The ground truth explicitly discusses total principal long-term debt increasing from $40,078 million (2022) to $41,146 million (2024), showing RTX increased overall debt burden through other issuances. The LLM completely omits this critical context. (2) PARTIAL ANSWER - The question asks 'what does this indicate about the company's long-term debt structure?' The LLM only addresses the 2.820% Notes in isolation, not how this relates to the broader debt portfolio expansion. (3) MISSING SYNTHESIS - This is a multi-hop question requiring synthesis of: (a) the specific note's stability, AND (b) the overall debt portfolio growth. The LLM only addresses part (a). The ground truth demonstrates that while the 2051 notes remained unchanged, RTX's total long-term debt grew by $1,068 million, indicating strategic debt management through diversified issuances. QUANTITATIVE: The $1 billion figure is correct for both years, but the answer lacks the total debt figures ($40,078M to $41,146M) that provide essential context. QUALITATIVE: While the reasoning about the notes being 'stable' is sound, the failure to synthesize the broader debt structure context represents incomplete multi-hop reasoning. The answer reads more like a single-hop fact verification rather than addressing the evolution and implications for long-term debt structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 494,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How did the terms of Schwab's IDA agreement evolve between 2022 and 2023, particularly regarding service fees and reference rate adjustments?",
      "original_answer": "In 2022, Schwab disclosed that the IDA agreement had been amended to reduce the service fee on client cash deposits held at the TD Depository Institutions to 15 basis points from 25 basis points. By 2023, the company reported that its IDA agreement had transitioned reference rates previously tied to LIBOR to other appropriate benchmarks as part of its broader LIBOR phase-out preparation. This evolution reflects a shift from adjustments in fee structure to modifications in financial reference mechanisms, aligning the agreement with post-LIBOR regulatory and market standards.",
      "llm_answer": "In the 2022 filing Schwab disclosed that it had amended its Inter‑Depository Agreement (IDA) to cut the service fee on client cash deposits held at the TD Depository Institutions to **15 basis points** (down from the 25 bps previously paid under TD Ameritrade’s IDA) 【SCHW_10k_2022.pdf p. 85】. By the 2023 filing Schwab said it had **re‑engineered the IDA to replace the LIBOR reference rate with other appropriate benchmark rates** as part of the LIBOR transition, while the reduced 15 bps fee remained in place 【SCHW_10k_2023.pdf p. 55‑56】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about Schwab's IDA agreement evolution. QUANTITATIVE ACCURACY: All numeric values are correct - the 15 basis points fee (down from 25 bps) is accurately stated, and the years 2022 and 2023 are correctly identified. The basis point figures match the ground truth exactly. COMPLETENESS: The answer addresses both key aspects of the question: (1) service fee changes in 2022 (25 bps to 15 bps reduction), and (2) reference rate adjustments in 2023 (LIBOR transition to other benchmarks). The multi-hop synthesis is sound, showing the evolution across two years. ENTITY ACCURACY: All entities are correctly identified - Schwab, TD Depository Institutions, LIBOR, and the IDA agreement are all properly named and contextualized. REASONING: The multi-hop reasoning is logical and well-structured, correctly synthesizing information from 2022 and 2023 filings to show the progression from fee structure modifications to reference rate mechanism changes. The answer appropriately characterizes this as a shift from fee adjustments to financial reference modifications. SEMANTIC EQUIVALENCE: The LLM's phrasing 're-engineered the IDA to replace the LIBOR reference rate with other appropriate benchmark rates' is semantically equivalent to the ground truth's 'transitioned reference rates previously tied to LIBOR to other appropriate benchmarks.' The inclusion of source citations (page numbers) adds credibility without affecting accuracy. Minor note: The LLM provides slightly more context by noting the fee remained in place during the 2023 transition, which is a helpful clarification not contradicting the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 468,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "What does the change in Filorga's financial treatment from 2023 (when it had $221 million in goodwill as a standalone reporting unit) to 2024 (when it was listed among other trademarks within broader segments) suggest about its strategic importance and valuation approach by the company?",
      "original_answer": "In 2023, Filorga was treated as a standalone reporting unit within the Europe segment with a clearly disclosed goodwill carrying value of $221 million, indicating its distinct financial significance and the company’s detailed impairment analysis for this brand. By 2024, Filorga was listed among other global and regional trademarks within broader product segments, without separate goodwill or valuation figures. This suggests that Filorga may have been integrated into a larger reporting structure, reducing its visibility as a standalone asset, which could signal a shift in strategic focus or a consolidation of brand management. This change affects how Filorga’s valuation and performance are assessed, potentially influencing future strategic decisions such as divestiture, investment, or brand prioritization.",
      "llm_answer": "The 2023 filing still treated Filorga as a separate reporting unit in the Europe segment with $221 million of goodwill, meaning the brand was viewed as a distinct cash‑generating asset that required its own impairment testing【2023 p.57‑61】. By the 2024 filing, Filorga is only mentioned in a roster of global trademarks within broader segments, indicating the company has folded the brand into its overall brand portfolio and now values it at the segment level rather than as a standalone goodwill‑bearing unit, reflecting a lower emphasis on its independent strategic importance【2024 p.77‑81】.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and correctly identifies the key quantitative data point ($221 million goodwill in 2023) and the structural change from standalone reporting unit to integrated brand portfolio status in 2024. The multi-hop reasoning is sound: the model correctly synthesizes the 2023 vs 2024 treatment difference and draws appropriate conclusions about strategic implications. Numeric accuracy is perfect - the $221 million figure is correct and properly contextualized. The reasoning about what this change suggests (lower emphasis on independent strategic importance, shift from standalone impairment testing to segment-level valuation) aligns well with the ground truth. The LLM answer is slightly more concise than the original but captures all essential elements: (1) 2023 standalone status with $221M goodwill, (2) 2024 integration into broader segments, (3) implications for strategic importance and valuation approach. Minor differences from ground truth: the LLM uses slightly different phrasing ('folded the brand into' vs 'integrated into a larger reporting structure') but conveys equivalent meaning. The LLM answer could have been marginally more comprehensive by explicitly mentioning potential future strategic implications (divestiture, investment, brand prioritization) that the ground truth includes, but this is a minor omission. The page references provided (2023 p.57-61, 2024 p.77-81) add credibility though cannot be independently verified. Overall, the answer successfully addresses the multi-part question about strategic importance and valuation approach changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 445,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How does the change in Apple's disclosure about the iPhone 16 Pro between the 2023 and 2024 10-K filings reflect an evolution in its product development and reporting strategy?",
      "original_answer": "In the 2023 10-K filing, Apple announced the iPhone 16 Pro as part of its Fourth Quarter 2024 product lineup, indicating it was still in the planning and launch phase. By contrast, in the 2024 10-K filing, the iPhone 16 Pro is listed among existing product lines like the iPhone 15 and iPhone 14, suggesting it has transitioned into an active and established product within Apple's portfolio. This shift reflects a movement from forward-looking product planning in 2023 to retrospective inclusion in 2024, aligning with the product's lifecycle stage and indicating a more mature reporting posture around the iPhone 16 Pro.",
      "llm_answer": "In Apple’s 2023 Form 10‑K the “Product, Service and Software Announcements” section only listed the iPhone 15 family and made no mention of an iPhone 16 Pro (see AAPL_10k_2023.pdf pp. 22‑26). By the 2024 Form 10‑K, Apple explicitly includes “iPhone 16 Pro” (along with iPhone 16, iPhone 16 Plus and iPhone 16 Pro Max) in its Q4 2024 product rollout (see AAPL_10k_2024.pdf p. 4). This shift shows the device moving from a future‑pipeline concept in 2023 to a confirmed launch in 2024, reflecting a more detailed and concrete reporting strategy as the product development matures.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains a significant factual error that contradicts the ground truth. The ground truth states that the iPhone 16 Pro WAS mentioned in the 2023 10-K filing as part of the Fourth Quarter 2024 product lineup (forward-looking), whereas the LLM claims the 2023 10-K made 'no mention of an iPhone 16 Pro.' This is a critical factual inaccuracy. The LLM correctly identifies that the 2024 10-K includes the iPhone 16 Pro in its product lineup, and the general conceptual framework (transition from planning to established product) is sound. However, the specific claim about the 2023 filing's content is demonstrably wrong according to the ground truth. The LLM does provide specific page references and document citations, which shows good documentation practices, but these citations appear to be inaccurate regarding what those pages actually contain. The reasoning about product lifecycle progression is logical and well-articulated, but it's built on a false premise about the 2023 filing. The answer demonstrates partial understanding of the multi-hop synthesis required (comparing two years' filings) but fails on the fundamental factual accuracy of what was disclosed in 2023. The semantic framing about 'future-pipeline concept' vs 'confirmed launch' is reasonable, but the underlying claim that the 2023 filing contained no iPhone 16 Pro mention is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 383,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How has the company's use of Economic Value of Equity (EVE) simulations evolved in assessing interest rate risk, particularly in terms of modeling assumptions and balance sheet dynamics, between 2022 and 2023?",
      "original_answer": "In 2022, the company used EVE simulations to measure long-term interest rate risk, with key assumptions including non-negative investment yields, prepayment speeds of mortgage-related investments, and non-maturity deposit behavior. The EVE analysis was described as highly dependent on asset and liability assumptions based on historical behaviors and expectations of the economic environment. By 2023, the company expanded the role of EVE simulations to specifically capture the impact of client cash allocation changes on the balance sheet, which was not included in the earlier modeling approach. Additionally, in 2023, the company actively updated deposit beta assumptions in a declining interest rate environment for its net interest revenue simulation model, indicating a more dynamic approach to modeling interest rate sensitivity.",
      "llm_answer": "In the 2022 filing Schwab’s EVE analysis was a static “balance‑sheet shock” that measured the long‑term impact of instantaneous rate shifts using historical asset‑liability assumptions—rate‑floor scenarios, mortgage pre‑payment speeds, term‑structure models, non‑maturity deposit behavior and a non‑negative‑yield assumption—without incorporating derivatives. By the 2023 filing the firm had broadened the simulation to include the effect of interest‑rate‑swap derivatives, to use both proprietary and third‑party models, and to run internal cash‑run‑off models for non‑maturity client cash, while explicitly noting that rising rates shortened liability duration (making it shorter than asset duration) and therefore heightened EVE sensitivity.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and appears to describe a different company's (Schwab's) EVE evolution rather than the company in question. Critical issues: (1) ENTITY ERROR: The answer explicitly mentions 'Schwab' multiple times, but the ground truth does not identify the company as Schwab. This is a fundamental error in entity identification. (2) CONTENT MISMATCH: The LLM answer discusses derivatives, interest-rate-swap derivatives, and proprietary/third-party models, none of which appear in the ground truth answer. The ground truth focuses on client cash allocation changes and deposit beta assumptions in declining rate environments. (3) MISSING KEY INFORMATION: The LLM answer fails to mention the critical 2023 evolution regarding 'client cash allocation changes on the balance sheet' which was explicitly highlighted as a new addition in 2023. (4) INCORRECT EMPHASIS: The ground truth emphasizes deposit beta assumption updates in declining rate environments for net interest revenue simulation, but the LLM answer focuses on derivatives and liability duration changes. (5) BALANCE SHEET DYNAMICS: While the ground truth mentions balance sheet dynamics as a key aspect of the evolution, the LLM answer's discussion of liability duration vs. asset duration, while potentially relevant to interest rate risk, does not align with the specific balance sheet dynamics mentioned in the ground truth (client cash allocation impacts). The LLM answer appears to be describing a different company's EVE evolution methodology rather than synthesizing the correct information from the provided ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 445,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How did Qualcomm's strategic shift from enabling wireless access point technologies in 2022 to directly producing them in 2023 affect its competitive positioning and product portfolio breadth in the broader networking market?",
      "original_answer": "In 2022, Qualcomm's involvement with wireless access points was limited to enabling the technology through its foundational wireless innovations and chipset solutions, as noted in its discussion of edge networking growth driven by 5G and Wi-Fi 6 adoption. However, by 2023, Qualcomm had evolved its strategy to directly producing wireless access points as part of its broader networking product suite, which included Wi-Fi chips, routers, and network processors. This shift reflects an expansion of Qualcomm's product portfolio and a more direct role in the networking ecosystem, positioning the company to compete more directly with players like Broadcom and Intel by offering full-system solutions rather than just underlying components.",
      "llm_answer": "In 2022 Qualcomm’s role in the access‑point market was largely that of an enabler – it contributed IP and standards work through the Wi‑Fi Alliance and helped evolve the 802.11 family (e.g., “We are actively involved in innovative programs … we continue to play a leading role in the evolution of the 802.11 family of standards” [2022 p. 8‑9]), positioning the company as a technology licensor rather than a hardware competitor. By fiscal 2023 Qualcomm had added complete access‑point and router hardware to its lineup (“Our networking products include … wireless access points and routers, broadband gateway equipment and software” [2023 p. 11‑12]), moving up the value chain, sharpening its competitive stance against pure‑play networking vendors, and broadening its portfolio from chips and software to full‑featured networking solutions across Wi‑Fi, Ethernet, PON and edge‑networking products.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the 2022-to-2023 strategic shift from enabling/IP licensing to direct hardware production; (2) Accurately characterizes 2022 role as technology enabler through standards work and chipsets; (3) Properly documents 2023 expansion to include wireless access points, routers, and networking hardware; (4) Correctly identifies competitive positioning shift toward full-system solutions vs. component-only approach; (5) Appropriately names competitors (Broadcom, Intel) and describes competitive differentiation; (6) Includes relevant supporting details (Wi-Fi Alliance, 802.11 standards, edge networking, PON, Ethernet); (7) Provides specific filing citations (2022 p. 8-9, 2023 p. 11-12) that enhance credibility; (8) Multi-hop reasoning is sound - synthesizes information across two fiscal years and connects product portfolio changes to competitive positioning. MINOR CONSIDERATIONS: The LLM answer is slightly more detailed and comprehensive than the ground truth (mentions PON, Ethernet, broadband gateway equipment), but these additions are consistent with and supportive of the core narrative rather than contradictory. The characterization of the shift as moving 'up the value chain' is a reasonable inference from the documented product expansion. No quantitative errors, date errors, or entity misidentifications detected. The semantic meaning and factual content align well with the ground truth answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 423,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has the interest-only payment structure of Schwab's HELOC product evolved from 2022 to 2023, based on the percentage of adjustable-rate mortgages with interest-only terms and the portion not scheduled to reset for three or more years?",
      "original_answer": "In 2022, 28% of adjustable-rate mortgages were interest-only loans, with 89% of those not scheduled to reset for three or more years. In 2023, this shifted slightly to 27% of adjustable-rate mortgages being interest-only, with 86% of those not scheduled to reset for three or more years. This reflects a minor decrease in both metrics, suggesting a slight tightening or evolution in the interest-only structure of the HELOC product.",
      "llm_answer": "In the 2022 filing (which reports the most recent prior‑year data), about 28 % of Schwab’s adjustable‑rate mortgage balances were interest‑only, and roughly 89 % of those interest‑only loans had rates that would not reset for three or more years. By the 2023 filing, the interest‑only share fell to about 27 % and the share with a reset horizon of three or more years slipped to roughly 86 %. This shows a modest decline in both the proportion of interest‑only loans and the portion locked in for a long reset period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All numeric values are correct - 2022: 28% interest-only with 89% not resetting for 3+ years; 2023: 27% interest-only with 86% not resetting for 3+ years. These match the ground truth exactly. COMPLETENESS: The answer addresses all required components of the multi-hop question: (1) the percentage of adjustable-rate mortgages with interest-only terms in both years, (2) the portion not scheduled to reset for three or more years in both years, and (3) the evolution/comparison between the two years. ENTITY ACCURACY: Correctly identifies Schwab, the HELOC product, adjustable-rate mortgages, interest-only terms, and the specific time periods (2022 vs 2023). REASONING QUALITY: The multi-hop synthesis is sound - the answer correctly combines data from two separate years and draws the appropriate conclusion about the trend (modest decline in both metrics). The characterization of the change as a 'modest decline' and 'slight tightening' aligns well with the ground truth's description of 'minor decrease' and 'slight evolution.' SEMANTIC EQUIVALENCE: The wording differs slightly from the ground truth but conveys identical meaning. Phrases like 'interest-only share fell to about 27%' and 'slipped to roughly 86%' are semantically equivalent to the ground truth's 'shifted slightly to 27%' and 'with 86% of those.' The minor deduction from a perfect 10 is due to very slight stylistic differences in phrasing ('roughly' vs exact percentages in ground truth), though these are negligible and do not affect factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 444,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has Qualcomm's involvement in the XR market evolved from 2022 to 2023, based on their strategic investments and product revenue disclosures?",
      "original_answer": "In 2022, Qualcomm's involvement in XR was primarily through strategic investments made via Qualcomm Ventures, targeting early-stage companies in areas including XR to expand opportunities for their technologies. By 2023, this involvement evolved into direct revenue generation, as XR was explicitly listed among the industries and applications for which Qualcomm sold products, indicating a shift from investment to commercialization. This transition reflects a significant change in Qualcomm's engagement with XR, moving from supporting external innovation to deriving tangible revenue from XR-related product sales.",
      "llm_answer": "In the 2022 filing Qualcomm highlighted that its Qualcomm Ventures (QSI) segment was making “strategic investments … including … XR” (QCOM 2022 10‑K, p. 12‑13), indicating that its XR activity was largely investment‑focused. By the 2023 filing the company’s QCT revenue table lists XR as a consumer application within the IoT revenue stream (QCOM 2023 10‑K, p. 71‑73), showing that Qualcomm’s XR‑related chipsets and modules are now generating disclosed product revenue. This marks a shift from primarily investing in XR startups in 2022 to earning revenue from XR‑focused products in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) FACTUAL CORRECTNESS: The answer correctly identifies the evolution from 2022 to 2023, accurately citing Qualcomm Ventures' strategic investments in XR in 2022 and the shift to direct revenue generation in 2023. The specific references to filing pages (2022 10-K p. 12-13 and 2023 10-K p. 71-73) are appropriately cited, though these cannot be independently verified in this evaluation context. (2) QUANTITATIVE ACCURACY: No specific dollar amounts or percentages are provided in either answer, so quantitative precision is not directly testable. However, the temporal progression (2022 to 2023) and the categorization of XR within IoT revenue streams are correctly presented. (3) ENTITY ACCURACY: All entities are correctly identified - Qualcomm (QCOM), Qualcomm Ventures (QSI), XR market, and the relevant fiscal years (2022 and 2023). (4) MULTI-HOP REASONING: The LLM successfully synthesizes information across two different filing years and two different business segments (QSI investments vs. QCT product revenue), demonstrating proper multi-hop reasoning. The logical progression from investment-focused activity to commercialization is clearly articulated. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys essentially the same information as the ground truth - the transition from strategic investments to direct revenue generation. The phrasing differs slightly (e.g., 'XR-related chipsets and modules' vs. 'XR-related product sales'), but the semantic meaning is equivalent. Minor note: The LLM provides slightly more specific detail about XR being listed within the IoT revenue stream, which adds helpful context without contradicting the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 479,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the aggregate principal balance of the 3.030% Notes Due 2052 evolved between 2022 and 2024, and what does this indicate about RTX's long-term debt structure?",
      "original_answer": "The aggregate principal balance of the 3.030% Notes Due 2052 remained stable at $1,100 million in both 2022 and 2024. This indicates that RTX has maintained its long-term commitment to this particular debt instrument without any repayments or additional issuances during this period. Despite overall changes in other long-term debt components, the 3.030% Notes Due 2052 remained unchanged, suggesting strategic consistency in managing this portion of its capital structure.",
      "llm_answer": "The aggregate principal balance of the 3.030 % notes due 2052 was $1.1 billion at the end of 2022 (shown in the 2022 Form 10‑K) and remained $1.1 billion at the end of 2024 (shown in the 2024 Form 10‑K)【RTX_10k_2022.pdf:95】【RTX_10k_2024.pdf:89】.  The unchanged balance indicates that RTX has kept this long‑dated, low‑coupon issuance as a stable component of its long‑term debt, preserving a diversified, long‑maturity profile and low‑cost financing over the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-reasoned. (1) QUANTITATIVE ACCURACY: All numbers are correct - the principal balance is stated as $1.1 billion for both 2022 and 2024, which matches the ground truth of $1,100 million (equivalent values with acceptable format variation). The note rate of 3.030% is correctly identified. (2) COMPLETENESS: The answer addresses both parts of the multi-part question: (a) how the balance evolved between 2022-2024 (remained stable), and (b) what this indicates about RTX's long-term debt structure (strategic consistency, stable component, diversified long-maturity profile). (3) ENTITY ACCURACY: RTX is correctly identified, the specific debt instrument (3.030% Notes Due 2052) is accurately named, and the fiscal years (2022 and 2024) are correct. (4) MULTI-HOP REASONING: The answer correctly synthesizes information across two 10-K filings (2022 and 2024) and draws appropriate conclusions about debt management strategy. The reasoning that unchanged balance indicates strategic consistency and preservation of a diversified, long-maturity profile is sound and slightly more detailed than the ground truth. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same core information as the ground truth while adding slightly more context about the strategic implications (low-coupon, long-dated, diversified profile, low-cost financing). Minor difference: The LLM provides slightly more analytical depth regarding the strategic implications, which enhances rather than detracts from the answer. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 430,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has AXP's focus on Corporate Card solutions evolved between 2023 and 2024, and what does this shift suggest about its broader commercial payments strategy?",
      "original_answer": "In 2023, AXP emphasized evolving its card value propositions and differentiating its corporate card and accounts payable expense management solutions as part of a broader push to strengthen its position in commercial payments. By 2024, while the focus on commercial payments remained, AXP shifted toward designing 'innovative products and features, including financing, banking and payment solutions for our business customers,' indicating a more integrated and solution-oriented approach. This evolution suggests that AXP is expanding beyond just product differentiation to embedding the Corporate Card into a wider suite of business financial services, aligning it more closely with holistic commercial needs.",
      "llm_answer": "In 2023, American Express said it would “evolve our card value propositions, further differentiate our corporate card and accounts‑payable expense‑management solutions” as a core part of its commercial‑payments push【AXP_10k_2023.pdf p.6‑10】. By the 2024 filing, the company repeats that priority but adds a clearer focus on “designing innovative products and features, including financing, banking and payment solutions for our business customers,” signaling that corporate cards are being positioned as a gateway to a broader, integrated commercial‑payments platform for its business clientele【AXP_10k_2024.pdf p.6‑10】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. (1) CORRECTNESS: The answer accurately captures the evolution of AXP's Corporate Card strategy between 2023 and 2024. Both the 2023 focus on 'evolving card value propositions' and 'differentiating corporate card and accounts payable expense management solutions' and the 2024 shift toward 'designing innovative products and features, including financing, banking and payment solutions' are correctly identified and properly sourced. The interpretation that this represents a move from product differentiation to an integrated, solution-oriented approach is semantically equivalent to the ground truth's characterization of 'embedding the Corporate Card into a wider suite of business financial services.' (2) QUANTITATIVE ACCURACY: No numerical data is required for this question, so this dimension is not applicable. The dates (2023 and 2024) are correct. (3) ENTITY ACCURACY: AXP (American Express) is correctly identified, fiscal years 2023 and 2024 are accurate, and the specific strategic initiatives are properly attributed. (4) REASONING & MULTI-HOP SYNTHESIS: The LLM successfully synthesizes information across two separate 10-K filings (2023 and 2024) to demonstrate the evolution in strategy. The logical progression from 'card value propositions and differentiation' to 'integrated commercial payments platform' is sound and well-reasoned. The conclusion that corporate cards are being positioned as a 'gateway to a broader, integrated commercial-payments platform' aligns with the ground truth's assertion about 'embedding the Corporate Card into a wider suite of business financial services.' (5) SEMANTIC EQUIVALENCE: The wording differs slightly but conveys the same substantive meaning. The LLM's characterization of the shift as moving toward a 'broader, integrated commercial-payments platform' is semantically equivalent to the ground truth's description of 'expanding beyond just product differentiation to embedding the Corporate Card into a wider suite of business financial services.' Minor deduction (1 point) only because the LLM could have been slightly more explicit about the strategic implication that this represents a move toward holistic commercial financial services, though this is clearly implied in the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 623,
        "total_tokens": 1959
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic positioning of PCA SKIN within Colgate-Palmolive's Oral, Personal and Home Care segment evolved between 2023 and 2024, particularly in terms of its distribution channels?",
      "original_answer": "In 2023, PCA SKIN was listed among Colgate-Palmolive’s principal global and regional trademarks and was included in the broader category of products sold primarily to traditional and eCommerce retailers, wholesalers, distributors, and dentists. By 2024, PCA SKIN remained a listed principal trademark, but the filing specifically expanded the distribution channels to include sales to skin health professionals in some geographies. This indicates a refinement in positioning PCA SKIN within more specialized skincare distribution channels, though no change in production or brand status is indicated.",
      "llm_answer": "In 2023 PCA SKIN was presented as a skin‑health brand within the Oral, Personal & Home Care segment and was sold “primarily to a variety of traditional and e‑commerce retailers, wholesalers, distributors, dentists and, in some segments, skin‑health professionals.” By 2024 the company kept those core channels but added “some of our products … sold direct‑to‑consumer,” indicating that PCA SKIN’s distribution strategy expanded to include a direct‑to‑consumer channel alongside its existing retail, wholesale and professional outlets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) FACTUAL INACCURACY ON 2023 BASELINE: The LLM claims that in 2023 PCA SKIN was already sold 'to a variety of traditional and e-commerce retailers, wholesalers, distributors, dentists and, in some segments, skin-health professionals.' However, the ground truth explicitly states that in 2023, PCA SKIN was sold 'primarily to traditional and eCommerce retailers, wholesalers, distributors, and dentists' - with NO mention of skin-health professionals in 2023. The inclusion of skin-health professionals was a 2024 expansion, not a 2023 baseline. (2) MISCHARACTERIZATION OF 2024 EVOLUTION: The LLM identifies direct-to-consumer as the key 2024 change, but the ground truth identifies the expansion to include 'skin health professionals in some geographies' as the key refinement. The LLM's answer introduces direct-to-consumer sales as the primary 2024 change, which is not supported by the ground truth. (3) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the year-over-year comparison. It incorrectly backdated the skin-health professional channel to 2023 and then identified a different channel (DTC) as the 2024 change. (4) SEMANTIC MISALIGNMENT: While the LLM's answer discusses distribution channel evolution, it fundamentally misidentifies which channels changed between the two years. The ground truth clearly indicates skin-health professionals as the new 2024 addition; the LLM instead emphasizes direct-to-consumer. This represents a substantial factual error in the core answer to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 427,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic focus and commercial positioning of Opdivo evolved between 2022 and 2023, particularly in terms of new tumor indications and combination therapies, and what implications does this have for its revenue growth trajectory?",
      "original_answer": "In 2022, Opdivo was approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, and stomach cancers, with the Opdivo + Yervoy regimen approved in multiple markets for NSCLC, melanoma, MPM, RCC, CRC, and gastric/esophageal cancers. It reported U.S. revenue growth driven by combinations in NSCLC, kidney cancer, and gastric/esophageal cancers. By 2023, Opdivo's strategic focus expanded into new tumor types and earlier lines of therapy, with an emphasis on broadening its use both as a monotherapy and in combination with Yervoy and other agents. The company also highlighted the potential of a subcutaneous formulation to enhance patient benefits and drive long-term adoption. This evolution indicates a strategic push to sustain revenue growth by diversifying indications and optimizing delivery mechanisms, despite increasing market competition.",
      "llm_answer": "In the 2022 filing Opdivo was described as a PD‑1 inhibitor already approved in a broad set of cancers (bladder, blood, colorectal, head‑and‑neck, renal, liver, lung, melanoma, mesothelioma and stomach) and the company’s focus was on expanding its use through ongoing registrational studies and Opdivo + Yervoy or other combination regimens (2022 10‑K p.69). By 2023 the strategy had shifted to securing earlier‑line, adjuvant and neoadjuvant approvals – FDA approval for adjuvant stage IIB/IIC melanoma, EU approvals for adjuvant melanoma and for Opdivo + platinum‑based chemotherapy in resectable NSCLC, plus a Japanese neoadjuvant NSCLC indication – and to launching Opdualag (Opdivo + Yervoy) and a sub‑cutaneous formulation, thereby widening the tumor‑type and combination‑therapy portfolio (2023 10‑K p.41‑45). These new indications and combos enlarge the addressable patient base and have already helped Opdivo offset declines in other products, indicating a trajectory of incremental revenue growth for Opdivo even as overall company revenue modestly fell.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis across 2022 and 2023 filings. STRENGTHS: (1) Correctly identifies all major tumor indications approved in 2022 (bladder, blood/hematologic, colorectal, head-and-neck, renal, liver, lung, melanoma, mesothelioma, stomach) matching ground truth terminology; (2) Accurately captures 2022 strategic focus on combination regimens (Opdivo + Yervoy) and ongoing registrational studies; (3) Precisely details 2023 strategic evolution including specific new approvals: adjuvant stage IIB/IIC melanoma (FDA), adjuvant melanoma (EU), Opdivo + platinum-based chemotherapy in resectable NSCLC (EU), and neoadjuvant NSCLC (Japan); (4) Correctly identifies new formulations and combinations: Opdualag (Opdivo + Yervoy combination) and subcutaneous formulation; (5) Properly synthesizes the multi-hop reasoning: 2022 baseline → 2023 expansion → implications for revenue growth; (6) Accurately conveys that these strategic shifts aim to expand addressable patient base and offset declines in other products; (7) Provides specific 10-K page citations (p.69 for 2022, p.41-45 for 2023) demonstrating source verification. MINOR CONSIDERATIONS: The answer uses slightly more specific terminology and detail than the ground truth (e.g., explicitly naming 'adjuvant stage IIB/IIC melanoma' vs. general 'adjuvant approvals'), but this represents enhanced specificity rather than inaccuracy. The conclusion about 'incremental revenue growth' aligns with ground truth's 'sustain revenue growth' messaging. No quantitative errors detected. The semantic equivalence is strong throughout—terminology variations (e.g., 'blood cancers' vs. 'hematologic') are standard medical/financial reporting conventions. Multi-hop synthesis is sound: correctly connects 2022 baseline → 2023 strategic shifts → revenue implications across multiple indications and formulations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1517,
        "completion_tokens": 519,
        "total_tokens": 2036
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did American Express's investment in foreign government bonds and obligations evolve between 2023 and 2024 in terms of fair value and maturity distribution?",
      "original_answer": "In 2023, American Express held $549 million in foreign government bonds and obligations with all of it maturing in 12 months or more and a gross unrealized loss of $1 million. By 2024, the fair value of these investments increased significantly to $765 million, with $764 million maturing within one year and only $1 million maturing after one year but within five years. This indicates a substantial increase in exposure to foreign government bonds, primarily in short-term maturities.",
      "llm_answer": "In 2023 American Express carried foreign government bonds and obligations at an estimated fair value of **$770 million**, with **$768 million** maturing within the next year and **$2 million** in the 1‑to‑5‑year bucket【AXP_10k_2023.pdf:119】【AXP_10k_2023.pdf:121】. By year‑end 2024 the fair value had slipped to **$765 million**, and the maturity profile was **$764 million** due within one year and **$1 million** due in 1‑5 years, a modest $5 million decline and a slight shift toward the shortest‑term maturities【AXP_10k_2024.pdf:124】【AXP_10k_2024.pdf:126】.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that fundamentally contradict the ground truth across multiple dimensions: (1) QUANTITATIVE ERRORS - The 2023 fair value is stated as $770 million in the LLM answer, but the ground truth clearly shows $549 million. This is a $221 million discrepancy (40% error). The 2024 fair value of $765 million is correct. The maturity distribution for 2023 is also wrong: LLM states $768M within one year and $2M in 1-5 years, but ground truth shows $0 within one year and $549M in 12+ months (all maturing in 12 months or more). (2) DIRECTIONAL ANALYSIS ERROR - The LLM characterizes the change as a 'modest $5 million decline' from $770M to $765M, but the actual change is a substantial $216 million INCREASE from $549M to $765M (39% growth). This is a fundamental mischaracterization of the investment evolution. (3) MATURITY PROFILE MISINTERPRETATION - The LLM's 2023 maturity data ($768M short-term, $2M medium-term) is completely inconsistent with ground truth ($0 short-term, $549M long-term). The 2024 maturity profile ($764M within one year, $1M in 1-5 years) is correct. (4) MISSING CONTEXT - The LLM fails to mention the gross unrealized loss of $1 million in 2023, which is relevant context for understanding the investment position. (5) MULTI-HOP SYNTHESIS - While the LLM attempts to synthesize 2023 and 2024 data, it does so with incorrect source data for 2023, making the comparison invalid. The conclusion about 'shift toward shortest-term maturities' is partially correct for 2024 but based on false 2023 baseline. The answer demonstrates poor data accuracy and would mislead readers about the actual magnitude and nature of American Express's foreign government bond portfolio changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 475,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How has Walmart's use of intercompany financing arrangements evolved between 2022 and 2024, particularly regarding the amount of cash not freely transferable to the U.S. and the conditions under which such transfers occur?",
      "original_answer": "In 2022, Walmart reported $4.3 billion in cash and cash equivalents that may not be freely transferable to the U.S., with $2.2 billion of that amount subject to approval by Flipkart minority shareholders. By 2024, the amount of cash not freely transferable decreased slightly to $3.3 billion, and the language indicates that these transfers are now generally subject to approval from noncontrolling interest shareholders, rather than specifically tied to Flipkart. This reflects a slight reduction in the magnitude of restricted cash and a broader framing of the conditions under which such transfers occur, suggesting a shift in the structure or focus of intercompany financing arrangements.",
      "llm_answer": "In the 2022 filing Walmart said roughly $4.3 billion of cash and cash equivalents could not be freely moved to the U.S.; about $2.2 billion of that amount could be accessed only through dividends or inter‑company financing that required approval of Flipkart’s minority shareholders. By the 2024 filing the restricted pool had fallen to about $3.5 billion and the limitation is now described as due to local laws or other restrictions and subject to approval of the non‑controlling‑interest shareholders, indicating a modest reduction in restricted cash and a broader set of approval conditions.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution of Walmart's intercompany financing arrangements and correctly identifies the key shift from Flipkart-specific restrictions to broader noncontrolling interest shareholder approval. However, there is a significant quantitative error: the LLM states the 2024 restricted cash amount as $3.5 billion, while the ground truth specifies $3.3 billion. This is a material discrepancy of $200 million (6% difference) that affects the accuracy of the comparison. The LLM correctly identifies: (1) the 2022 amount of $4.3 billion, (2) the $2.2 billion Flipkart-specific portion in 2022, (3) the general direction of change (decrease), and (4) the shift in approval conditions from Flipkart-specific to broader noncontrolling interest shareholders. The qualitative reasoning is sound - the answer correctly synthesizes the multi-hop information showing how the restrictions evolved and broadened in scope. The semantic framing is appropriate, describing the shift from specific Flipkart restrictions to local laws and broader shareholder approval conditions. The main weakness is the incorrect 2024 figure ($3.5B vs. $3.3B), which is a factual error that undermines the quantitative accuracy despite the overall narrative being directionally correct. The answer demonstrates good understanding of the multi-hop synthesis required but fails on precise numerical accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 389,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did the composition of Texas Instruments' U.S. Retiree Health Care Plan assets evolve between the 2023 and 2024 filings, particularly in terms of fixed income securities and equity securities allocation?",
      "original_answer": "The composition of Texas Instruments' U.S. Retiree Health Care Plan assets remained completely unchanged between the 2023 and 2024 filings. In both years, the plan held $210 million in fixed income securities and cash equivalents, and $54 million in equity securities, resulting in a total of $264 million in plan assets. The fixed income allocation represented approximately 79.5% of the total plan assets, while equity securities represented approximately 20.5% in both years. The identical figures across both filings indicate no evolution in the asset allocation strategy for this plan during the reported period.",
      "llm_answer": "In 2023 the U.S. Retiree Health Care Plan held $210 million of fixed‑income securities and cash equivalents and $54 million of equity securities – roughly an 80 % / 20 % split of the $264 million total ​[2023 table shows $4 + $206 = $210 and $54 = $264]​. By the 2024 filing the mix was $198 million in fixed‑income and $50 million in equity, still about 80 % / 20 % of the $248 million total ​[2024 table shows $2 + $196 = $198 and $50 = $248]​, indicating only a modest decline in absolute amounts while the allocation percentages remained essentially unchanged.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains fundamentally incorrect financial data that directly contradicts the ground truth. CRITICAL ERRORS: (1) 2024 figures are completely wrong - LLM states $198M fixed income and $50M equity ($248M total), but ground truth shows $210M fixed income and $54M equity ($264M total); (2) The LLM claims there was a 'modest decline in absolute amounts' between 2023 and 2024, but the ground truth explicitly states the composition 'remained completely unchanged' with identical figures in both years; (3) The LLM's calculation breakdown [2024: $2 + $196 = $198] appears to be fabricated detail not supported by the actual filings. VERIFICATION: Ground truth clearly states both 2023 AND 2024 had: $210M fixed income, $54M equity, $264M total, with 79.5%/20.5% allocation. The LLM's 2024 numbers ($198M/$50M/$248M) are factually incorrect. The core finding of the question - whether composition evolved - is answered incorrectly. The LLM states 'allocation percentages remained essentially unchanged' (which is correct conceptually) but this is contradicted by its own false premise that absolute amounts declined. The answer fails on quantitative accuracy (wrong dollar amounts), fails on the primary factual claim (no evolution vs. claimed decline), and demonstrates poor multi-hop synthesis by presenting inconsistent conclusions. This is a major factual error that would mislead any user relying on this information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 397,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Honeywell's 2006 Stock Plan for Non-Employee Directors evolve between 2022 and 2024 in terms of the specific forms of award agreements offered, and what might this suggest about changes in the company's non-employee director compensation structure?",
      "original_answer": "In 2022, Honeywell's 10-K filing listed both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32) as part of the 2006 Stock Plan for Non-Employee Directors. By 2024, while the 'Form of Option Agreement' was still referenced (Exhibit 10.29), the 'Form of Restricted Unit Agreement' was no longer explicitly mentioned in the exhibit list. This suggests a shift in the types of equity awards offered to non-employee directors, potentially signaling a strategic move toward emphasizing stock options over restricted units in director compensation.",
      "llm_answer": "In the 2022 Form 10‑K the 2006 Stock Plan for Non‑Employee Directors was described as issuing awards only through a standard Form of Option Agreement (Exhibit 10.3) 【HON_10k_2022.pdf: pages 121‑125】. By the 2024 filing the plan also references an Omnibus‑Amendment Form of Option Agreement (Exhibit 10.1) 【HON_10k_2024.pdf: pages 121‑125】, indicating that Honeywell has added a newer, consolidated award document. This evolution suggests the company is modernizing its non‑employee director compensation, moving toward a more standardized and flexible equity‑award structure.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that directly contradict the ground truth: (1) EXHIBIT NUMBER ERRORS: The LLM cites 'Exhibit 10.3' and 'Exhibit 10.1' for the 2022 and 2024 filings respectively, but the ground truth clearly states the correct exhibits are 10.30 (Option Agreement) and 10.32 (Restricted Unit Agreement) in 2022, and 10.29 (Option Agreement) in 2024. These are significant numerical discrepancies in exhibit references. (2) MISSING KEY INFORMATION: The LLM completely fails to mention the 'Form of Restricted Unit Agreement' (Exhibit 10.32) that was present in 2022, which is central to the ground truth answer. The ground truth explicitly states this form was 'no longer explicitly mentioned in the exhibit list' by 2024, representing the key evolution being tracked. (3) INCORRECT CHARACTERIZATION: The LLM claims the 2022 plan issued awards 'only through a standard Form of Option Agreement,' which contradicts the ground truth showing both Option Agreements AND Restricted Unit Agreements were offered in 2022. (4) FABRICATED INFORMATION: The LLM introduces an 'Omnibus-Amendment Form of Option Agreement' in 2024 that is not mentioned in the ground truth at all. This appears to be hallucinated content. (5) WRONG CONCLUSION: The LLM suggests the evolution represents 'adding a newer, consolidated award document' and 'moving toward a more standardized and flexible equity-award structure,' when the ground truth indicates a shift away from restricted units toward stock options. The multi-hop reasoning is fundamentally flawed because it misidentifies the exhibits and mischaracterizes the evolution of the compensation structure. The answer fails on both quantitative accuracy (wrong exhibit numbers) and qualitative accuracy (missing the restricted unit component and misinterpreting the directional change).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 502,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Walmart's strategic position regarding its ownership stake in Flipkart evolve between 2022 and 2024, particularly in terms of financial implications and potential exposure to regulatory risks?",
      "original_answer": "In 2022, Walmart received $3.2 billion in equity funding related to Flipkart, which reduced its ownership stake from 83% to 75%. This signaled a partial financial exit while maintaining majority control. By 2024, however, Walmart disclosed ongoing regulatory scrutiny in India, including a show cause notice issued in July 2021 and subsequent information requests related to alleged violations of India's Foreign Direct Investment rules during the period 2009–2015—prior to Walmart's acquisition of Flipkart in 2018. Despite the reduced ownership stake, Walmart remained exposed to potential regulatory consequences, including share ownership restrictions, and noted its inability to reasonably estimate potential losses or indemnification proceeds from prior shareholders. The evolution reflects a shift from active financial participation to managing legacy risks tied to Flipkart's pre-acquisition history.",
      "llm_answer": "In fiscal 2022 Walmart sold a slice of its Flipkart holding, receiving about $3.2 billion in equity funding and cutting its ownership from roughly 83 % to 75 % (WMT_10k_2022, pp. 64‑68). By fiscal 2024 the company still holds that majority stake, but it is now facing Indian regulatory scrutiny—a foreign‑direct‑investment show‑cause notice and an antitrust investigation that could impose ownership restrictions or penalties—creating uncertain financial and compliance risk (WMT_10k_2024, pp. 74‑78).",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies all key quantitative facts: (1) $3.2 billion equity funding in 2022, (2) ownership stake reduction from 83% to 75%, (3) maintenance of majority control through 2024, (4) regulatory scrutiny including show cause notice and antitrust investigation. Numbers and percentages are accurate. The multi-hop synthesis across 2022 and 2024 filings is sound, correctly tracing the evolution of Walmart's position. WEAKNESSES: (1) The answer omits important contextual details from the ground truth, specifically that the regulatory scrutiny relates to alleged violations during 2009-2015 (pre-acquisition period), which is a critical distinction explaining why Walmart faces legacy risks despite not owning Flipkart during the violation period. (2) The answer mentions 'antitrust investigation' but the ground truth specifically references 'Foreign Direct Investment rules violations' - while related to regulatory scrutiny, the characterization is slightly imprecise. (3) The answer lacks mention of Walmart's inability to reasonably estimate potential losses or indemnification proceeds from prior shareholders, which is an important financial implication detail. (4) The page references (pp. 64-68, pp. 74-78) cannot be verified but appear plausible. MULTI-HOP REASONING: Correctly synthesizes information across 2022 and 2024 periods, showing the evolution from active financial participation to managing legacy risks. The logic connecting reduced stake to ongoing exposure is sound. SEMANTIC EQUIVALENCE: The core message matches ground truth - Walmart reduced stake while maintaining control, but faces regulatory exposure. The framing as 'shift from active financial participation to managing legacy risks' is implicit but not explicitly stated in LLM answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 489,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the composition and strategic emphasis of HON's U.S. cash balances evolve between 2022 and 2024, particularly in terms of total cash holdings and geographic distribution of funds?",
      "original_answer": "In 2022, HON reported holding $11.5 billion of cash and cash equivalents as of December 31, 2021, with an emphasis on safety of principal and diversification among counterparties. By 2024, the company held $11.0 billion in total cash and equivalents as of December 31, 2024, but specifically noted that $8.0 billion of that amount was held in non-U.S. subsidiaries. This represents a shift in geographic distribution, with a larger portion of liquidity positioned outside the U.S., while maintaining the same strategic emphasis on safety and diversification.",
      "llm_answer": "In the 2022 Form 10‑K Honeywell said it held $11.5 billion of cash and cash equivalents (including short‑term investments) and stressed that its liquidity strategy “is primarily safety of principal and secondarily maximizing yield” while diversifying cash among counterparties and using both U.S. cash balances and the ability to access non‑U.S. cash balances as sources of liquidity【38†L1-L7】【38†L8-L11】. By the 2024 filing total cash and cash equivalents had slipped slightly to $11.0 billion, but the company now disclosed that $8.0 billion of those funds were held in non‑U.S. subsidiaries (leaving roughly $3 billion as U.S. cash), showing a shift toward a more internationally‑distributed cash pool while keeping the same safety‑first, diversification‑focused approach【36†L1-L7】【36†L8-L11】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: All key numbers are correct - $11.5 billion in 2022 (as of Dec 31, 2021), $11.0 billion in 2024 (as of Dec 31, 2024), $8.0 billion held in non-U.S. subsidiaries in 2024, and the implied ~$3 billion U.S. cash calculation (11.0 - 8.0 = 3.0). MULTI-HOP SYNTHESIS: The answer correctly synthesizes information across two different years and filing periods, comparing the evolution of cash holdings and geographic distribution. ENTITY ACCURACY: Correctly identifies HON (Honeywell), the proper fiscal years, and the relevant financial metrics (cash and cash equivalents). STRATEGIC EMPHASIS: Accurately captures the consistent strategic approach (safety of principal, diversification among counterparties) across both periods. GEOGRAPHIC DISTRIBUTION: Properly identifies the shift from undifferentiated cash holdings in 2022 to a more explicitly disclosed geographic split in 2024, with $8.0 billion in non-U.S. subsidiaries. MINOR CONSIDERATIONS: The LLM adds helpful context by noting the parenthetical calculation of ~$3 billion U.S. cash, which aids understanding though wasn't explicitly stated in ground truth. The answer appropriately addresses all components of the multi-part question regarding composition, strategic emphasis, total holdings, and geographic distribution. The citation format and reference numbers appear consistent with source documentation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 402,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the financial treatment and liability estimation methodology for the Membership Rewards program evolve from 2023 to 2024, particularly in terms of deferred fees and liability modeling assumptions?",
      "original_answer": "In 2023, the company recognized deferred fees related to Membership Rewards program participants, indicating a focus on the deferral aspect of fee revenue associated with the program. By 2024, the disclosures provided a much more detailed explanation of the liability estimation methodology, including the use of the Ultimate Redemption Rate (URR) and the weighted average cost (WAC) per point. The 2024 filing also quantified the sensitivity of the liability to changes in assumptions, noting that a 25 basis point increase in URR would raise the liability by $197 million, and a 1 basis point increase in WAC per point would increase it by $220 million. This reflects a shift from a simpler mention of deferred fees to a comprehensive, model-driven approach to estimating future redemption liabilities.",
      "llm_answer": "In the 2023 filing the company showed a separate “Deferred card and other fees, net” balance of $3.4 billion that explicitly included deferred fees for Membership Rewards participants (net of acquisition costs and a cancellation reserve)【1†L1-L5】, and it measured the Membership Rewards liability with a statistical/actuarial model that estimates an ultimate redemption rate (URR) and a weighted‑average cost (WAC) per point based on the prior 12 months of redemptions and redemption‑trend factors【2†L1-L5】.  \n\nIn the 2024 filing the separate deferred‑fees line is no longer presented, indicating those fees are now embedded in the Membership Rewards liability, and the liability model is refined with explicit sensitivity analysis—showing that a 25‑basis‑point rise in URR would raise the liability by $197 million and a 1‑basis‑point rise in WAC would raise it by $220 million—reflecting a more granular, transparent approach to estimating the liability【3†L1-L7】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive understanding of the evolution in financial treatment of the Membership Rewards program from 2023 to 2024. STRENGTHS: (1) All quantitative figures are correct: $3.4 billion deferred fees balance in 2023, $197 million sensitivity to 25 basis point URR increase, and $220 million sensitivity to 1 basis point WAC increase in 2024. (2) The multi-hop synthesis is sound—correctly identifying that 2023 had a separate deferred fees line item while 2024 embedded these within the liability. (3) The methodology evolution is accurately captured: from a simpler deferred fee recognition to a sophisticated actuarial model using URR and WAC. (4) The sensitivity analysis details are precisely stated. (5) The reasoning about the shift from 'simpler mention' to 'comprehensive, model-driven approach' aligns with the ground truth. MINOR AREAS FOR IMPROVEMENT: (1) The LLM answer provides more granular detail about the 2023 structure (explicitly mentioning acquisition costs and cancellation reserve) than the ground truth, which is additional context but not contradictory. (2) The LLM answer could have been slightly more explicit about the 'shift' being a presentation/disclosure change rather than necessarily a methodological change (though the sensitivity analysis disclosure is indeed new in 2024). The answer successfully addresses all parts of the multi-part question regarding deferred fees, liability estimation methodology, and the evolution between years. The semantic equivalence is strong—the LLM conveys the same substantive information as the ground truth while providing additional supporting detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1456,
        "completion_tokens": 458,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How has Adobe's strategic positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its alignment with Adobe's broader product ecosystem?",
      "original_answer": "In 2022, Adobe described the integration of Frame.io as part of its Digital Media reportable segment, emphasizing its role as a cloud-based video collaboration platform acquired for $1.18 billion, with integration efforts just beginning. By 2024, Frame.io had transitioned from being a newly acquired integration to being positioned as a core component of Adobe's creative collaboration suite, directly integrated with key applications such as Adobe Premiere Pro, After Effects, Photoshop, and Workfront. Additionally, in 2024, Frame.io was included as part of Adobe GenStudio, indicating a deeper strategic alignment with Adobe's broader content production and collaboration ecosystem. This evolution reflects a shift from initial integration to full ecosystem incorporation.",
      "llm_answer": "In the 2022 Form 10‑K Adobe presented Frame.io as a newly‑acquired, $1.18 billion cloud‑based video‑collaboration platform that would be folded into its Digital Media segment to complement Creative Cloud and Document Cloud offerings (2022 10‑K, pp. 39‑43). By the 2024 filing, Frame.io is described as a cloud‑native creative‑collaboration hub that is directly embedded in Premiere Pro, After Effects, Photoshop, Lightroom and Workfront and made available through Adobe GenStudio, showing that Adobe has moved from a standalone acquisition to a tightly integrated component of its broader Creative, Document and Experience Cloud ecosystem (2024 10‑K, pp. 10‑14).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY (10/10): All numeric values are correct - the $1.18 billion acquisition price is accurately stated, and the fiscal years (2022 and 2024) are correctly identified. No calculation errors present. ENTITY ACCURACY: All companies and products are correctly named (Adobe, Frame.io, Premiere Pro, After Effects, Photoshop, Lightroom, Workfront, GenStudio, Creative Cloud, Document Cloud, Experience Cloud). MULTI-HOP REASONING: The answer successfully synthesizes information across two time periods and multiple product integrations, showing the evolution from standalone acquisition to ecosystem integration. The logical progression from 2022 (newly acquired, initial integration) to 2024 (deeply integrated across multiple applications and GenStudio) is sound and matches the ground truth narrative. COMPLETENESS: The answer addresses all aspects of the question - strategic positioning, integration evolution, and alignment with broader ecosystem. The inclusion of specific applications (Premiere Pro, After Effects, Photoshop, Lightroom, Workfront) and GenStudio demonstrates comprehensive coverage. MINOR DIFFERENCES: The LLM answer includes Lightroom in the 2024 integration list, while the ground truth mentions Photoshop and Workfront but does not explicitly list Lightroom. However, this represents additional accurate detail rather than an error. The LLM also references specific page numbers from the 10-K filings, adding credibility. SEMANTIC EQUIVALENCE: The characterization of Frame.io's evolution from 'newly acquired integration' to 'tightly integrated component' and 'core component' conveys the same strategic shift as the ground truth. The terminology used ('cloud-native creative-collaboration hub,' 'directly embedded') is semantically equivalent to the ground truth's description of 'core component' and 'directly integrated.' Overall, this is a high-quality answer with accurate facts, sound reasoning, and appropriate detail level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 555,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How did the composition of private alternative investments, specifically equity-like funds, evolve between 2022 and 2023 in terms of fair value measurements using significant unobservable inputs (Level 3)?",
      "original_answer": "In 2022, equity-like funds under private alternative investments had a fair value of $5.5 million measured using significant unobservable inputs (Level 3). In 2023, this value increased significantly to $25.4 million. This indicates a fivefold increase in the portion of equity-like funds valued using Level 3 inputs, suggesting a shift toward more opaque or complex valuation methodologies for these investments.",
      "llm_answer": "In the defined‑benefit pension plan, the equity‑like funds measured using Level 3 inputs fell modestly from $25.4 million in 2022 to $25.1 million in 2023, while the retiree‑health plan’s Level 3 amount stayed flat at $2.4 million in both years. Thus, the share of private‑alternative equity‑like funds valued with significant unobservable inputs remained essentially unchanged, with only a slight $0.3 million dip in the pension‑plan portion.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect on all critical dimensions. QUANTITATIVE ERRORS: The ground truth states equity-like funds Level 3 values were $5.5 million in 2022 and $25.4 million in 2023. The LLM answer reverses these numbers, claiming $25.4 million in 2022 and $25.1 million in 2023 - a complete inversion of the actual data. The LLM also introduces additional figures ($2.4 million for retiree-health plan) that are not part of the ground truth answer and appear to conflate different investment vehicles or plans. CALCULATION ERRORS: The ground truth identifies a fivefold increase from $5.5M to $25.4M. The LLM incorrectly characterizes the change as a 'modest fall' of $0.3 million and claims values 'remained essentially unchanged' - the opposite of what actually occurred. ENTITY/CONTEXT CONFUSION: The LLM introduces references to 'defined-benefit pension plan' and 'retiree-health plan' that are not mentioned in the ground truth answer, suggesting the model may have confused different investment vehicles or pulled data from unrelated sections. REASONING FAILURE: The LLM's conclusion that 'the share of private-alternative equity-like funds valued with significant unobservable inputs remained essentially unchanged' directly contradicts the ground truth's finding of a significant fivefold increase. This represents a fundamental failure in multi-hop synthesis and logical reasoning. The answer demonstrates no correct understanding of the actual evolution of these investments between 2022 and 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 420,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has Adobe's integration and positioning of Frame.io within its Digital Media offerings evolved between 2022 and 2024?",
      "original_answer": "In 2022, Adobe had just acquired Frame.io in October 2021 and was beginning to integrate it into the Digital Media segment as a cloud-based video collaboration platform. By 2024, Frame.io had become a core part of Adobe’s creative collaboration tools, being directly integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and was also included in Adobe GenStudio for scalable content production. This reflects a strategic evolution from initial integration to deeper ecosystem embedding.",
      "llm_answer": "In the 2022 Form 10‑K Adobe noted that after acquiring Frame.io in Q4 FY2021 it was being folded into the Digital Media segment and described it as a cloud‑native video‑collaboration platform that was already integrated with Premiere Pro, After Effects, Photoshop, Lightroom, Workfront and made available through GenStudio (ADBE_10k_2022.pdf, p. 42). By the 2024 Form 10‑K Adobe positioned Frame.io as a core component of its Digital Media portfolio, emphasizing tighter, end‑to‑end integration across Creative Cloud video apps, its availability via Adobe Express, Firefly Services and GenStudio, and its strategic role in driving growth for the Digital Media segment (ADBE_10k_2024.pdf, p. 12).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both accurate and problematic elements. CORRECT ELEMENTS: (1) Acquisition timing is accurate - Frame.io was acquired in Q4 FY2021 (October 2021). (2) 2022 positioning is largely correct - Frame.io was described as a cloud-native video collaboration platform integrated with Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront. (3) 2024 positioning correctly identifies Frame.io as a core component with emphasis on tighter integration and availability through GenStudio. (4) The document citations and page references appear appropriately formatted. PROBLEMATIC ELEMENTS: (1) The 2022 answer claims Frame.io was 'already integrated' with all those applications and 'made available through GenStudio' in 2022, which overstates the integration level at that early stage. The ground truth indicates 2022 was the 'beginning' of integration, not full integration. (2) The LLM introduces new platforms in 2024 (Adobe Express, Firefly Services) that are not mentioned in the ground truth, which may be accurate but represents information not in the provided ground truth for verification. (3) The answer doesn't clearly articulate the EVOLUTION from 'initial integration' (2022) to 'deeper ecosystem embedding' (2024) - it presents both years' features somewhat flatly without emphasizing the progression. MULTI-HOP REASONING: The answer does synthesize information across two different 10-K filings (2022 and 2024) and compares Frame.io's positioning across these years, which is appropriate for the question. However, the characterization of 2022 integration appears overstated relative to the ground truth's description of it as 'beginning to integrate.' The answer would score higher if it more clearly distinguished between initial/partial integration (2022) versus mature/core integration (2024).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 497,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has CVS's approach to Medication Management evolved between 2022 and 2024, particularly in terms of clinical programs and digital tools aimed at improving medication adherence and cost efficiency?",
      "original_answer": "In 2022, CVS emphasized formulary management through its National Pharmacy and Therapeutics Committee, promoting the use of generic drugs and offering real-time benefit information to guide members toward lower-cost alternatives. The company also operated mail order and specialty pharmacies, and provided clinical programs focused on medication adherence and utilization management, including an industry-leading approach to limit opioid prescriptions to seven-day supplies for acute cases. By 2024, CVS had expanded its Medication Management offerings with the introduction of digital tools like the NovoLogix preauthorization platform and enhanced analytics for identifying lower-cost drug alternatives. The company also launched the CVS Weight Management program, integrating GLP-1 medication optimization with lifestyle coaching, and expanded its value-based care initiatives through Oak Street Health, operating 239 primary care centers across 27 states to better manage chronic conditions and medication use. These developments reflect a shift from primarily cost-containment strategies to a more integrated, digitally enabled, and clinically proactive model of medication support.",
      "llm_answer": "In the 2022 filing CVS described medication‑management mainly through clinical services such as utilization‑management, Pharmacy Advisor counseling, disease‑management programs and a basic digital‑connectivity layer that gave members visibility into lower‑cost drug alternatives (see Clinical Services, Disease Management Programs and Medical Benefit Management on pages 10‑14 of the 2022 10‑K). By the 2024 filing the company had expanded that model with a suite of new digital tools—including the Health Engagement Engine, AI‑driven Canopy platform, NovoLogix online pre‑authorization, Drug Savings Review, a Weight‑Management program and enhanced real‑time benefits information, scheduling and reminder capabilities—designed to automate outreach, improve adherence and drive greater cost efficiency (see Clinical Services, Health Services Information Systems and related sections on pages 9‑13 of the 2024 10‑K).",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of CVS's medication management evolution between 2022 and 2024, with mostly accurate information and appropriate multi-hop synthesis. STRENGTHS: (1) Correctly identifies 2022 focus on clinical services, utilization management, and cost-containment strategies; (2) Accurately names multiple 2024 digital tools (NovoLogix, Health Engagement Engine, Canopy platform, Drug Savings Review, Weight Management program); (3) Properly synthesizes the shift from cost-containment to integrated, digitally-enabled model; (4) Appropriately cites specific 10-K sections with page numbers; (5) Correctly identifies key programs like Pharmacy Advisor counseling and disease management. WEAKNESSES: (1) Missing specific details from ground truth: does not mention the National Pharmacy and Therapeutics Committee by name; (2) Omits the specific opioid prescription limitation policy (seven-day supplies for acute cases) which was highlighted in ground truth as 'industry-leading'; (3) Does not mention Oak Street Health or the 239 primary care centers across 27 states, which represents significant expansion of medication management infrastructure; (4) Less emphasis on the integration of GLP-1 medication optimization with lifestyle coaching in the Weight Management program; (5) The page number citations (pages 10-14 for 2022, pages 9-13 for 2024) cannot be verified against ground truth but appear reasonable. QUANTITATIVE ACCURACY: No specific numbers are provided in either answer regarding financial metrics or patient volumes, so this is not a major differentiator. The absence of the Oak Street Health center count (239 centers, 27 states) represents a minor quantitative omission. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and multiple document sections, correctly identifying the evolution pattern. The logic connecting 2022 baseline to 2024 expansion is sound. SEMANTIC EQUIVALENCE: The core message aligns with ground truth—evolution from basic cost-containment to integrated digital/clinical model—though with less comprehensive coverage of specific initiatives.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1539,
        "completion_tokens": 577,
        "total_tokens": 2116
      },
      "error": null
    },
    {
      "question_id": 131,
      "question": "How has Adobe's integration and positioning of Frame.io within its Creative Cloud ecosystem evolved from 2022 to 2024, and what specific enhancements were made to its collaboration features during this period?",
      "original_answer": "In 2022, Adobe acquired Frame.io and began integrating its cloud-based video collaboration platform into Adobe Creative Cloud, with initial enhancements focused on deeper integration into Premiere Pro and After Effects to deliver native collaborative workflows for video editing. By 2024, Frame.io had evolved into a more comprehensive cloud-native creative collaboration platform, offering real-time upload, review, and approval features not only for video but also for still images, design files, and PDFs. It expanded its integration across Adobe Photoshop, Lightroom, and Workfront, and introduced Camera to Cloud functionality, enabling automatic upload of footage directly into Frame.io from cameras on set. These enhancements reflect a strategic shift from a video-specific collaboration tool to a broader creative asset production and review platform within Adobe’s ecosystem.",
      "llm_answer": "In the 2022 filing Adobe described that, after acquiring Frame.io in 2021, it began embedding Frame.io’s review‑and‑approval workflow into Premiere Pro and After Effects as a native video‑editing collaboration tool within Creative Cloud【2022:4‑8】. By the 2024 filing Adobe had repositioned Frame.io as a cloud‑native collaboration hub across the Creative Cloud suite—now integrated with Premiere Pro, After Effects, Photoshop, Lightroom and Workfront—and added real‑time upload, frame‑accurate commenting, annotations, Camera‑to‑Cloud automatic footage ingest and broader support for still images, design files and PDFs【2024:10‑14】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively synthesizes the evolution of Frame.io within Adobe's ecosystem from 2022 to 2024. STRENGTHS: (1) Correctly identifies the acquisition timing (2021) and initial integration focus (Premiere Pro and After Effects as native video-editing collaboration tools); (2) Accurately describes 2024 positioning as a cloud-native collaboration hub; (3) Correctly lists all expanded integrations (Photoshop, Lightroom, Workfront); (4) Accurately identifies specific feature enhancements (real-time upload, frame-accurate commenting, annotations, Camera-to-Cloud); (5) Properly captures the strategic shift from video-specific to broader creative asset platform; (6) Multi-hop reasoning is sound, correctly synthesizing information across 2022 and 2024 filings. MINOR ISSUES: (1) The LLM states Frame.io was acquired 'in 2021' while the ground truth says 'in 2022' - this is a factual discrepancy. However, the LLM correctly notes that by 2022 Adobe was describing the integration, which is consistent with a 2021 acquisition. The ground truth appears to reference the 2022 filing's description of the acquisition, not necessarily when it occurred. (2) The answer includes citation markers【2022:4‑8】and【2024:10‑14】which add credibility but cannot be verified. (3) Minor wording differences ('review-and-approval workflow' vs 'review and approval features') are semantically equivalent. QUANTITATIVE ACCURACY: All dates, product names, and feature descriptions are accurate. No calculations required. QUALITATIVE ACCURACY: The reasoning correctly identifies the evolution trajectory and strategic positioning. The synthesis across multiple years and products is accurate and well-structured. CONTEXTUAL RELEVANCE: The answer directly addresses all aspects of the multi-part question regarding integration evolution, positioning changes, and specific enhancements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 517,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has the use of recently executed transactions in the valuation of loans and other assets evolved from 2023 to 2024, particularly in terms of their role in fair value determination?",
      "original_answer": "In 2023, recently executed transactions were a key input for determining the fair value of corporate loans and contingent lending commitments, often used alongside market price quotations, implied yields, and proprietary valuation models. By 2024, the role of recently executed transactions remained significant but was more specifically tied to the held-for-sale category of loans and lending commitments, and also extended to the valuation of other assets such as other investments, where they were used in conjunction with discounted cash flow models and comparable company multiples. This reflects a more targeted application of transaction data in valuation practices.",
      "llm_answer": "Both the 2023 and 2024 filings state that the fair‑value of corporate loans (and comparable assets such as bonds, municipal securities and mortgage‑backed securities) is “determined using recently executed transactions, market‑price quotations (where observable), implied yields from comparable debt, market‑observable CDS spreads … and proprietary valuation models”【MS_10k_2023.pdf p.97‑98】【MS_10k_2024.pdf p.101‑102】. The 2024 note adds that “there were no significant revisions made to the descriptions of the Firm’s significant unobservable inputs,” confirming that the reliance on recent transaction data has remained essentially unchanged and continues to be a core driver of fair‑value determination for loans and other assets.",
      "correctness_score": 4,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant issues in addressing the core question about how valuation practices EVOLVED from 2023 to 2024. (1) CRITICAL FLAW - MISSES KEY EVOLUTION: The ground truth identifies a meaningful evolution: in 2023, recently executed transactions were used broadly for corporate loans and contingent lending commitments; by 2024, their role became MORE SPECIFICALLY TIED to the held-for-sale category and EXTENDED to other assets like other investments. The LLM answer explicitly states the practices 'remained essentially unchanged' and 'continues to be a core driver,' which directly contradicts the ground truth's identification of a more targeted/evolved application. (2) INCOMPLETE SYNTHESIS: The LLM answer focuses on similarities between years (both use recently executed transactions, market prices, implied yields, proprietary models) but fails to identify the key differences: the 2024 shift toward held-for-sale categorization and extension to other investments. This is a fundamental failure in multi-hop reasoning - the question asks HOW practices EVOLVED, not whether they remained the same. (3) CITATION ACCURACY: The page references appear reasonable (p.97-98 for 2023, p.101-102 for 2024), but the interpretation of what those pages say is incorrect. The LLM appears to have found similar language in both years and concluded no change, missing the contextual differences in application scope. (4) SEMANTIC MISMATCH: The ground truth emphasizes 'more targeted application' and 'extended to other assets' - these are qualitative changes in scope and application, not just continued use of the same methods. The LLM's conclusion that practices are 'essentially unchanged' is semantically opposite to the ground truth's identification of evolution. (5) QUANTITATIVE ELEMENTS: No specific numbers or calculations are involved, so quantitative accuracy is less critical, but the logical/analytical accuracy is severely compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 529,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has Adobe's approach to the Substance 3D Stager product evolved between 2022 and 2024, particularly in terms of its positioning within the broader Substance 3D ecosystem?",
      "original_answer": "In 2022, Substance 3D Stager was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio but without detailed information about its functionality or strategic positioning. By 2024, Adobe introduced a more comprehensive view of Substance 3D as an ecosystem, where Stager is specifically described as a tool for building and assembling 3D scenes. This evolution reflects a strategic shift from simply offering the product to integrating it into a broader suite of 3D tools, including Painter, Sampler, Designer, and Modeler, emphasizing its role in enabling end-to-end 3D content creation workflows.",
      "llm_answer": "In the 2022 filing Adobe presented Substance 3D Stager as one of several **stand‑alone desktop apps** in the “Substance 3D Collection,” noting that it is sold separately from Creative Cloud and is primarily a tool for building and assembling 3D scenes (ADBE_10k_2022.pdf pp. 95‑99). By the 2024 filing the company framed Stager as a **core component of an integrated Substance 3D ecosystem**, emphasizing its tight workflow with the other Substance 3D apps (Painter, Sampler, Designer, Modeler) and the Substance 3D Assets library, signaling a shift toward a more cohesive suite positioning (ADBE_10k_2024.pdf pp. 10‑14).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of Adobe's Substance 3D Stager positioning between 2022 and 2024. STRENGTHS: (1) Correctly identifies the 2022 positioning as a stand-alone desktop app within the Substance 3D Collection, sold separately from Creative Cloud; (2) Accurately captures the 2024 shift toward positioning Stager as a core component of an integrated ecosystem; (3) Properly identifies the related products (Painter, Sampler, Designer, Modeler) and the Substance 3D Assets library; (4) Correctly characterizes the strategic evolution from individual product to cohesive suite; (5) Provides specific document citations (ADBE_10k_2022.pdf pp. 95-99 and ADBE_10k_2024.pdf pp. 10-14) that add credibility; (6) Uses appropriate formatting with bold text to highlight key distinctions. MINOR CONSIDERATIONS: (1) The LLM answer adds slightly more specific detail about the 2022 positioning (mentioning it's sold separately from Creative Cloud) compared to the ground truth, which simply notes it was 'listed among Adobe's trademarks' without detailed functionality information. However, this additional detail appears consistent with 10-K filing content and enhances rather than contradicts the answer; (2) The ground truth emphasizes the 2022 listing as a trademark with 'without detailed information,' while the LLM provides more functional detail - this is a minor discrepancy in framing but not factually incorrect; (3) No quantitative data (numbers, percentages, dollar amounts) are present in either answer, so quantitative accuracy is not directly testable but the answer appropriately avoids making unsupported numerical claims. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years (2022 and 2024) and correctly identifies the evolution in strategic positioning. The reasoning chain is sound: 2022 (stand-alone product) → 2024 (integrated ecosystem component). SEMANTIC EQUIVALENCE: The LLM answer conveys the same fundamental information as the ground truth regarding the strategic shift, though with slightly more operational detail about the 2022 positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 581,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How did GE's strategic positioning regarding grid-scale batteries evolve from 2022 to 2023, particularly in terms of their role in the company's energy transition strategy and level of strategic reliance?",
      "original_answer": "In 2022, GE mentioned grid-scale batteries as part of a broader set of emerging technologies that 'may become more important over time' in achieving deep decarbonization goals, indicating GE was considering them as a potential future investment. By 2023, GE explicitly listed grid-scale batteries as one of the key technologies 'that may become more important over time' and integrated them into the company’s strategic narrative as a dependency, noting that achieving decarbonization goals would 'depend in part' on such technologies. This reflects a shift from viewing grid-scale batteries as a speculative investment to a more central component of GE's energy transition strategy.",
      "llm_answer": "In the 2022 filing GE said that grid‑scale batteries were an emerging technology that “may become more important over time” for achieving deep‑decarbonisation and would require significant investment, but it was not treated as a core pillar of the company’s energy‑transition plan. The 2023 filing repeats the same framing—listing grid‑scale batteries with hydrogen, carbon‑capture and advanced nuclear as “technologies not yet deployed … that may become more important” for the power‑sector transition—still positioning them as a peripheral, long‑term option rather than a primary strategic reliance.  Thus, GE’s view of batteries stayed essentially unchanged: they are viewed as a future, supportive technology, not a central, relied‑upon element of its energy‑transition strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The core issue: The LLM claims GE's positioning on grid-scale batteries 'stayed essentially unchanged' between 2022 and 2023, with batteries remaining 'peripheral' and 'not a central, relied-upon element.' This is incorrect. The ground truth explicitly states there WAS a shift: from 2022 (batteries as 'potential future investment') to 2023 (batteries integrated as a 'dependency' with language that achieving goals would 'depend in part' on such technologies). The LLM misses this critical evolution. Quantitative accuracy is acceptable (dates 2022/2023 are correct, no calculation errors), but the qualitative reasoning is severely flawed. The LLM correctly identifies that both years mention batteries as 'may become more important over time,' but fails to recognize the semantic shift in how GE framed their strategic reliance. The ground truth emphasizes the transition from speculative to more central positioning (the key insight of the question), while the LLM concludes no meaningful change occurred. This represents a failure in multi-hop reasoning—the model needed to synthesize the subtle but important shift in language and strategic framing across the two filings. The LLM's conclusion that batteries remained 'peripheral' and 'long-term option rather than primary strategic reliance' directly contradicts the ground truth's finding that they became integrated as a dependency. This is a critical misinterpretation of the evolution being asked about.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 429,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has CVS's disclosure regarding the use of broker quoted debt securities in its fair value measurements evolved between 2022 and 2024, particularly in terms of its presence or impact on financial reporting?",
      "original_answer": "In 2022, CVS explicitly stated that it did not have any broker quoted debt securities for the years ended December 31, 2021, and 2020, and that it only used internal pricing for certain private placements. By 2024, the company continued to disclose that it had no broker quoted debt securities for the years ended December 31, 2024 and 2023, indicating a consistent absence of such securities in its portfolio. However, the 2024 disclosure no longer mentions any negative impact or specific review process related to broker quoted debt securities, suggesting a reduced emphasis or relevance of this topic in the company's fair value measurement disclosures over time.",
      "llm_answer": "In the 2022 Form 10‑K, CVS noted that “the Company did not have any broker‑quoted debt securities for the years ended December 31, 2021 and 2020,” meaning Level 3 fair‑value estimates relied on internal or private‑placement pricing and broker quotes had no effect on its financial statements. The 2024 Form 10‑K repeats the same statement—“the Company did not have any broker‑quoted debt securities for the years ended December 31, 2024 and 2023”—showing that the disclosure has been updated only to reflect the newer reporting periods, while the substance remains unchanged: broker‑quoted securities are absent and therefore do not impact CVS’s fair‑value measurement or reporting.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies the key factual elements: (1) CVS stated it had no broker-quoted debt securities in both 2022 (for years 2021-2020) and 2024 (for years 2024-2023), and (2) the disclosure was updated to reflect newer reporting periods. The dates and company name are accurate. However, the answer has significant weaknesses in addressing the core question about how the disclosure 'evolved' between 2022 and 2024. The ground truth emphasizes a key evolution: the 2024 disclosure 'no longer mentions any negative impact or specific review process related to broker quoted debt securities, suggesting a reduced emphasis or relevance.' The LLM answer states the substance 'remains unchanged' and focuses only on the absence of securities, missing the important qualitative shift in how CVS discusses this topic. The LLM characterizes the evolution as merely 'updated only to reflect the newer reporting periods,' which understates the actual change in disclosure emphasis and framing. While the LLM correctly notes the consistency in the absence of broker-quoted securities, it fails to capture the nuanced evolution in how this absence is presented and contextualized in the company's fair value measurement disclosures. The answer is partially correct on the factual elements but incomplete in addressing the 'evolution' aspect of the question, which was central to what was being asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 390,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did the composition of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of equity securities/mutual funds and equity method investments?",
      "original_answer": "In 2023, BlackRock reported $1,211 million in equity securities/mutual funds under Equity Securities at FVTNI, while equity method investments totaled $1,895 million. By 2024, the value of equity securities/mutual funds increased to $1,950 million, and equity method investments rose to $2,783 million. This reflects a significant increase in both categories, indicating a strategic expansion in these investment areas.",
      "llm_answer": "In 2024 BlackRock’s equity securities at FVTNI included $1.95 billion of equity securities/mutual‑fund holdings, up from $1.585 billion in 2023, while equity‑method investments rose only modestly to $2.783 billion from $2.756 billion a year earlier【BLK_10k_2024.pdf p.92‑96】【BLK_10k_2023.pdf p.86‑90】. The increase in direct equity/mutual‑fund holdings drove the overall growth in equity securities at FVTNI, with the equity‑method component remaining largely unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) EQUITY SECURITIES/MUTUAL FUNDS: Ground truth states 2023: $1,211 million and 2024: $1,950 million. LLM claims 2023: $1.585 billion ($1,585 million) and 2024: $1.95 billion ($1,950 million). The 2023 figure is WRONG by $374 million (off by ~31%). The 2024 figure is correct. (2) EQUITY METHOD INVESTMENTS: Ground truth states 2023: $1,895 million and 2024: $2,783 million. LLM claims 2023: $2.756 billion ($2,756 million) and 2024: $2.783 million. The 2023 figure is WRONG by $861 million (off by ~45%). The 2024 figure is correct. (3) INTERPRETATION ERROR: LLM incorrectly characterizes equity method investments as 'remaining largely unchanged' when ground truth shows a substantial increase from $1,895M to $2,783M (a $888M or 47% increase). This is a fundamental misreading of the data. (4) MULTI-HOP SYNTHESIS: While the LLM correctly identifies both components and attempts year-over-year comparison, the synthesis is undermined by incorrect baseline 2023 figures. The reasoning structure is sound but built on false premises. (5) COMPLETENESS: The answer addresses both required components (equity securities/mutual funds and equity method investments) and both years, but with major numerical errors that invalidate the analysis. The conclusion about 'equity-method component remaining largely unchanged' directly contradicts the actual 47% increase shown in ground truth data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 415,
        "total_tokens": 1647
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did UnitedHealth Group's evaluation and treatment of credit-related impairments for available-for-sale debt securities evolve from 2022 to 2024, particularly in terms of unrealized losses and the allowance for credit losses?",
      "original_answer": "In 2022, UnitedHealth Group reported that unrealized losses in its available-for-sale debt securities were primarily driven by interest rate increases and not credit deterioration, with no significant credit deterioration observed since purchase. The allowance for credit losses was noted to be not material as of December 31, 2021. By 2024, the company's evaluation methodology remained consistent in terms of assessing present value of expected cash flows, issuer credit condition, and fair value relative to amortized cost. However, the allowance for credit losses is now explicitly described as being recorded as a separate component through an allowance account, with credit-related impairments impacting investment and other income, indicating a more structured recognition of credit risk. This evolution shows a shift from a qualitative, low-risk assessment to a more formalized impairment accounting framework.",
      "llm_answer": "In the 2022 filing UnitedHealth disclosed that its available‑for‑sale debt portfolio carried $274 million of gross unrealized losses (the “gross unrealized losses” line in the debt‑securities table) and that the allowance for credit‑related losses on those securities was “not material.” By the 2024 filing the company still reviews each available‑for‑sale security for credit‑related impairment using the same cash‑flow, fair‑value‑vs‑amortized‑cost and issuer‑credit‑quality criteria, records any credit‑related impairment as an allowance offset to investment income, and continues to present unrealized gains and losses in other comprehensive income – again noting that the allowance for credit losses on available‑for‑sale securities remains immaterial. 【UNH_10k_2022.pdf pp. 55‑59】【UNH_10k_2024.pdf pp. 47‑51】",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of the evolution of UnitedHealth's credit impairment evaluation methodology from 2022 to 2024, with mostly accurate information. Strengths: (1) Correctly identifies the $274 million gross unrealized losses figure for 2022, (2) Accurately notes that the allowance for credit losses was 'not material' in both periods, (3) Properly synthesizes the consistent evaluation methodology across both years (cash flow analysis, fair value vs. amortized cost, issuer credit quality), (4) Correctly identifies that credit-related impairments are recorded as an allowance offset to investment income, (5) Appropriately notes that unrealized gains/losses continue to be presented in other comprehensive income. Weaknesses: (1) The answer states the allowance remains 'immaterial' in 2024, which aligns with the ground truth but doesn't fully capture the evolution described in the original answer - the shift from a 'qualitative, low-risk assessment to a more formalized impairment accounting framework' is somewhat understated, (2) The LLM answer emphasizes continuity ('still reviews,' 'continues to present') more than evolution, whereas the ground truth emphasizes a meaningful shift in how credit risk is now 'explicitly described as being recorded as a separate component through an allowance account,' (3) Minor semantic difference: the original answer frames this as a shift toward 'more structured recognition of credit risk,' while the LLM answer presents it more as consistent methodology. Quantitative accuracy is strong with the $274 million figure verified and the 'not material' characterization accurate. The multi-hop reasoning correctly synthesizes information across 2022 and 2024 filings. The answer is contextually relevant and addresses the core question, though it could have emphasized the methodological evolution more explicitly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1453,
        "completion_tokens": 511,
        "total_tokens": 1965
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2022 and 2023, particularly in terms of investment value and equity income?",
      "original_answer": "In 2022, AMD's carrying value of its investment in the ATMP JV was $83 million, and it recorded $14 million in equity income from the JV. By 2023, the carrying value increased to $99 million, and equity income rose to $16 million. This indicates a growing financial stake and increased profitability from the joint venture over the two-year period.",
      "llm_answer": "AMD’s 15 % equity stake in the ATMP joint venture was carried at roughly **$99 million at year‑end 2023, up from $83 million at year‑end 2022**.  The equity‑method share of earnings from the JV rose to **$16 million in 2023, versus $14 million in 2022**【AMD_10k_2023.pdf pages 76‑80】.  This shows a modest increase in both the investment’s book value and the equity income AMD receives from the JV.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative data matches the ground truth exactly: (1) Investment carrying value of $83 million in 2022 and $99 million in 2023 - correct; (2) Equity income of $14 million in 2022 and $16 million in 2023 - correct; (3) The 15% equity stake percentage is additional context not in the original answer but is factually accurate and relevant. The multi-hop synthesis is sound - the answer correctly combines investment value data with equity income data across two fiscal years and draws the appropriate conclusion about the growing financial relationship. The reasoning is logical and the characterization of the changes as 'modest increase' is appropriate given the percentage increases (~19% for carrying value, ~14% for equity income). The answer includes proper source attribution (AMD_10k_2023.pdf pages 76-80). Minor note: The LLM provides slightly more context (the 15% stake percentage) than the ground truth, but this is additive and accurate rather than contradictory. The semantic equivalence is perfect - both answers convey the same core information about the evolution of AMD's financial relationship with the ATMP JV.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1186,
        "completion_tokens": 336,
        "total_tokens": 1522
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has UnitedHealth Group's exposure to tort claims evolved between 2022 and 2024, particularly in terms of the nature of the claims and the potential financial impact?",
      "original_answer": "In 2022, UnitedHealth Group specifically highlighted self-insured liabilities related to medical malpractice claims against affiliated physicians and the potential for actual losses to significantly exceed recorded liabilities. The document emphasized increasing legal actions alleging medical malpractice and general professional liabilities, with litigants seeking recoveries under new theories of liability that might not be subject to damage caps. By 2024, while tort claims remained a concern, the focus shifted slightly to broader legal risks tied to the delivery of health care services, including claims related to clinical quality and patient safety standards. The 2024 filing also emphasized the potential for reputational harm and adverse effects on business relationships, indicating a broader and more systemic risk profile compared to the more narrowly defined exposure in 2022.",
      "llm_answer": "In the 2022 10‑K UnitedHealth said its tort exposure was largely limited to medical‑malpractice and other professional‑liability claims tied to the delivery of health‑care services by its affiliates, employed or contracted providers, and to failures to meet clinical, quality or patient‑safety standards, noting that it is primarily self‑insured and that actual losses could exceed the reserves it records. By the 2024 filing the company still faces those same types of claims but emphasizes that the number, complexity and theories of liability have grown—resulting in larger potential damages and defense costs—and that the uncertainty around the financial impact has increased, with a heightened risk that actual losses could substantially exceed its recorded liabilities.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy on the core elements but has some notable gaps compared to the ground truth. STRENGTHS: (1) Correctly identifies the 2022 exposure as self-insured medical malpractice and professional liability claims tied to affiliated/employed/contracted providers; (2) Accurately notes that actual losses could exceed recorded reserves in both years; (3) Correctly captures the evolution showing increased complexity, number of claims, and theories of liability by 2024; (4) Properly identifies the heightened risk of actual losses exceeding liabilities; (5) No quantitative errors or incorrect dates/numbers. WEAKNESSES: (1) The LLM answer emphasizes 'larger potential damages and defense costs' and 'increased uncertainty' but the ground truth specifically highlights a shift in NATURE of claims - from narrowly defined medical malpractice exposure to BROADER legal risks tied to delivery of health care services, clinical quality, and patient safety standards more generally; (2) Missing the important detail about 'new theories of liability that might not be subject to damage caps' mentioned in 2022; (3) Does not adequately capture the 2024 emphasis on 'reputational harm and adverse effects on business relationships' as a systemic risk profile shift; (4) The LLM frames the evolution primarily as quantitative (more claims, higher damages) rather than qualitative (nature and scope of claims broadened). The answer is directionally correct and captures the key evolution, but misses some nuanced aspects of how the risk profile shifted from specific medical malpractice concerns to broader systemic health care delivery risks. The multi-hop synthesis is adequate but incomplete in capturing all dimensions of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 481,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How has the structure and capacity of Boeing's three-year revolving credit agreement evolved between 2023 and 2024, and what does this indicate about the company's liquidity strategy?",
      "original_answer": "In 2023, Boeing had a legacy three-year revolving credit agreement expiring in August 2025 with $3.0 billion of total commitments. In 2024, this agreement remained in effect, but Boeing also entered into a new $4.0 billion five-year revolving credit agreement expiring in May 2029 while terminating two other credit facilities. This evolution indicates a strategic shift to enhance liquidity capacity and extend maturity timelines, reinforcing Boeing's financial flexibility and commitment to managing corporate borrowing needs.",
      "llm_answer": "In 2023 Boeing’s legacy three‑year revolving credit agreement (expiring August 2025) carried a $3.0 billion commitment and was part of roughly $10.0 billion of unused borrowing capacity on its revolving facilities [BA_10k_2023.pdf:41‑45]. The same $3.0 billion three‑year line remained in effect in 2024, with total available credit still about $10.0 billion after the company terminated its 364‑day and a $3.2 billion five‑year facility and added a new $4.0 billion five‑year facility [BA_10k_2024.pdf:92‑96]. This unchanged three‑year back‑up line, coupled with the shift toward larger, longer‑term credit facilities, shows Boeing preserving a stable liquidity safety‑net while expanding flexible, longer‑term funding capacity.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. STRENGTHS: (1) All key numbers are correct: $3.0 billion three-year facility (2023 and 2024), $4.0 billion five-year facility (new in 2024), August 2025 expiration date, May 2029 expiration date for new facility. (2) Correctly identifies the legacy agreement remained in effect in both years while new facilities were added. (3) Accurately captures the termination of the 364-day facility and $3.2 billion five-year facility. (4) Provides additional context about total available credit (~$10.0 billion) that adds useful detail beyond the ground truth. (5) Multi-hop reasoning is sound: synthesizes 2023 and 2024 data, compares facility structures, and draws appropriate conclusions about liquidity strategy. (6) The interpretation that Boeing is 'preserving a stable liquidity safety-net while expanding flexible, longer-term funding capacity' aligns well with the ground truth's characterization of 'strategic shift to enhance liquidity capacity and extend maturity timelines.' MINOR CONSIDERATIONS: The LLM answer provides more granular detail (specific page references, unused borrowing capacity figures) than the ground truth, but this represents added value rather than error. The semantic meaning of both answers regarding the strategic shift toward longer-term facilities and enhanced liquidity is equivalent. All entity identifications (Boeing, years, facilities, amounts) are correct. No calculation errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 418,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did the financial impact of the 2017 Performance-based Options evolve between 2023 and 2024, particularly in terms of the fair value of options vested and the intrinsic value of options exercised?",
      "original_answer": "In 2023, the fair value of the 2017 Performance-based Options that vested was $56 million, and the intrinsic value of options exercised was $44 million. By 2024, the fair value of the options vested decreased slightly to $52 million, but the intrinsic value of options exercised saw a significant increase to $373 million. This indicates that while the value of options vesting declined slightly in 2024, the actual financial benefit realized from exercised options increased substantially compared to the prior year.",
      "llm_answer": "In 2023 the 2017 performance‑based stock options generated **$56 million** of fair‑value expense for the portion that vested and an **intrinsic value of $44 million** for the options that were exercised 【BLK_10k_2023.pdf†99-101】. By 2024 the fair‑value of the vested tranche slipped slightly to **$52 million**, while the intrinsic value of the exercised tranche surged to **$373 million** 【BLK_10k_2024.pdf†107-111】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. All four key financial figures are correct: 2023 fair value of vested options ($56M), 2023 intrinsic value of exercised options ($44M), 2024 fair value of vested options ($52M), and 2024 intrinsic value of exercised options ($373M). The multi-hop synthesis is sound, correctly comparing the evolution of these metrics across both years and both categories (vested vs. exercised). The characterization of the trends is accurate: the fair value of vested options declined slightly ($56M to $52M), while the intrinsic value of exercised options increased substantially ($44M to $373M). The answer properly identifies the 2017 Performance-based Options as the subject and correctly attributes the data to the appropriate fiscal years. The language used ('slipped slightly,' 'surged') appropriately conveys the magnitude of changes. The inclusion of source citations adds credibility. Minor deduction from perfect score only due to very slight stylistic differences in phrasing compared to the ground truth (e.g., 'generated...expense' vs. 'fair value...that vested'), but these are semantic equivalences that do not affect factual accuracy. The answer fully addresses all components of the multi-part question regarding financial impact evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 366,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did AMD's approach to estimating adjustments for product return rights evolve between 2022 and 2023, and what specific changes were made in the methodology used for these estimates?",
      "original_answer": "In 2022, AMD estimated adjustments for product return rights using trended actual historical product return rate information, adjusted for known information or events. By 2023, AMD maintained the use of historical data but placed additional emphasis on 'rights of return and rebates' as part of variable consideration under ASC 606-10-32-8 through 14, explicitly stating that these estimates were based on the 'most likely amount' of consideration expected after adjustments for returns, rebates, and price protection. This reflects a more structured and codified approach to estimating returns, aligning more closely with specific accounting standards.",
      "llm_answer": "AMD did not change its approach – the 2023 filing repeats the same methodology described in the 2022 filing. In both years AMD said it estimates product‑return adjustments by using “relevant, trended actual historical product return‑rate information … adjusted for actual known information or events” (including known events or current economic conditions) to determine the contract‑price reductions for OEM and distributor return rights【AMD_10k_2022.pdf†page=43-47】【AMD_10k_2023.pdf†page=47-51】.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim. The LLM states that 'AMD did not change its approach' and that 'the 2023 filing repeats the same methodology described in the 2022 filing.' This directly contradicts the ground truth, which clearly identifies a meaningful evolution in AMD's approach between 2022 and 2023. The ground truth specifies that: (1) In 2022, AMD used 'trended actual historical product return rate information, adjusted for known information or events'; (2) By 2023, AMD maintained historical data but added 'additional emphasis on rights of return and rebates as part of variable consideration under ASC 606-10-32-8 through 14' and explicitly referenced the 'most likely amount' standard. The LLM's assertion that there was no change is a critical factual error that misses the key evolution the question asks about. While the LLM correctly identifies the 2022 methodology (using historical return rate information adjusted for known events), it fails to recognize or report the 2023 changes regarding: (a) explicit emphasis on ASC 606 standards, (b) the shift to 'most likely amount' language, and (c) the more structured codification of the approach. The LLM does provide accurate citations and the 2022 methodology description is correct, but the failure to identify the actual evolution between years represents a fundamental misunderstanding of what changed. The answer directly contradicts the ground truth's central finding that there WAS an evolution in methodology, making this a major reasoning failure despite some correct supporting details about the 2022 approach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 443,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How did the number of shares under option for the 2017 Performance-based Options evolve from 2023 to 2024, and what does this indicate about the exercise and forfeiture trends of these options?",
      "original_answer": "The number of shares under option for the 2017 Performance-based Options decreased significantly from 1,549,080 shares at the end of 2023 to 625,825 shares at the end of 2024. This indicates that a large portion of these options were exercised (905,219 shares) and some were forfeited (18,036 shares) during 2024, showing a trend of completion in the lifecycle of these options as they approached their final vesting date.",
      "llm_answer": "The 2017 performance‑based options fell from 1,549,080 shares outstanding at 12/31/2023 to 625,825 shares at 12/31/2024. The drop reflects a massive exercise of 905,219 options and a modest forfeiture of 18,036 options, indicating that 2024 saw strong option‑exercise activity with relatively little forfeiture.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative data is correct: (1) Opening shares: 1,549,080 at 12/31/2023 ✓, (2) Closing shares: 625,825 at 12/31/2024 ✓, (3) Exercised shares: 905,219 ✓, (4) Forfeited shares: 18,036 ✓. The mathematical relationship is sound: 1,549,080 - 905,219 - 18,036 = 625,825. The LLM correctly identifies all entities (2017 Performance-based Options, 2023-2024 period) and synthesizes the multi-hop information properly. The interpretation of trends is accurate: the answer correctly characterizes the exercise activity as 'massive' and forfeiture as 'modest,' and appropriately notes this indicates strong option-exercise activity with relatively little forfeiture. The only minor distinction from the ground truth is that the LLM uses slightly different phrasing ('strong option-exercise activity' vs. 'completion in the lifecycle of these options as they approached their final vesting date'), but both convey the same essential insight about the options nearing completion. The LLM answer is actually more specific in quantifying the relative magnitudes of exercise vs. forfeiture. No calculation errors, no missing data, and the reasoning is sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1195,
        "completion_tokens": 339,
        "total_tokens": 1534
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How has the role and scope of Optum Rx's Pharmacy Care Services evolved between 2022 and 2024, particularly in terms of its service offerings and strategic positioning within UnitedHealth Group's broader health care ecosystem?",
      "original_answer": "In 2022, Optum Rx was described as managing $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceutical spending, and was positioned as a provider of pharmacy care services through a network of over 67,000 retail pharmacies, home delivery, specialty pharmacies, and infusion services. It emphasized clinical programs, digital tools, and medication management to help clients reduce costs and improve health outcomes. By 2024, Optum Rx was more strategically integrated into Optum’s broader vision of creating a 'value-oriented and more connected approach to health care,' with an emphasis on leveraging 'data and analytics, pharmacy care services, health care operations, population health and health financial services' to improve the overall health system performance. While specific spending figures were not provided in 2024, the service was elevated as a core component of Optum’s mission to enhance affordability, quality, and patient experience across the health care continuum.",
      "llm_answer": "By 2024 Optum Rx had broadened its pharmacy‑care platform from the 2022 model of a full‑spectrum retail, home‑delivery, specialty, infusion and direct‑to‑consumer network that managed about $112 billion of drug spend (including $45 billion in specialty) to a larger, more specialized operation that now also offers rare‑disease and gene‑therapy support and manages roughly $178 billion of spend (about $74 billion in specialty). In addition to its clinical programs and data‑driven utilization‑management tools, Optum Rx is accelerating the integration of medical, pharmacy and behavioral care—embedding pharmacists on care teams—to serve UnitedHealth Group’s health‑benefits customers as a central, analytics‑enabled engine for coordinated, cost‑effective health‑care across the company’s Optum and UnitedHealthcare businesses.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURES: The LLM claims Optum Rx managed 'roughly $178 billion of spend (about $74 billion in specialty)' by 2024, but the ground truth explicitly states 'specific spending figures were not provided in 2024.' This is a fundamental factual error - the LLM fabricated specific 2024 financial figures that do not exist in the source documents. The 2022 figures ($112 billion total, $45 billion specialty) are correctly cited, but the 2024 numbers are entirely unsupported. (2) UNSUPPORTED CLAIMS: The LLM introduces new service offerings ('rare-disease and gene-therapy support') that are not mentioned in the ground truth. While these may be plausible services, they are not documented in the provided knowledge graph and represent fabrication. (3) MULTI-HOP REASONING: The LLM fails to properly synthesize the evolution described in the ground truth. The ground truth emphasizes a strategic shift toward integration within Optum's broader ecosystem and emphasis on 'value-oriented and more connected approach to health care,' but the LLM focuses primarily on quantitative expansion and specific service additions without capturing this strategic repositioning. (4) MISSING CONTEXT: The LLM omits the ground truth's key insight about Optum Rx being elevated as a 'core component of Optum's mission to enhance affordability, quality, and patient experience across the health care continuum.' Instead, it focuses on operational details. (5) SEMANTIC ISSUES: While the LLM correctly identifies the general evolution from 2022 to 2024, it does so by inventing data points rather than accurately representing what was actually documented. The claim about 'accelerating the integration of medical, pharmacy and behavioral care' is reasonable inference but goes beyond what the ground truth explicitly states. The fundamental problem is presenting fabricated 2024 financial metrics as fact when the ground truth explicitly notes these were not provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1481,
        "completion_tokens": 561,
        "total_tokens": 2042
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How did the composition and valuation of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of investments held for deferred cash compensation plans?",
      "original_answer": "In 2023, BlackRock reported $9 million invested in Equity Securities at FVTNI as part of the investments held to economically hedge deferred cash compensation plans. By 2024, this specific category was no longer listed under Equity Securities at FVTNI but instead appeared under 'Investments related to deferred cash compensation plans' within the Equity Method section with a value of $173 million. This indicates a reclassification or realignment of how these investments were categorized and reported in the financial statements, reflecting a significant change in the composition of Equity Securities at FVTNI.",
      "llm_answer": "In 2024 BlackRock’s equity securities measured at fair‑value‑through‑net‑income grew to $1.843 billion of cost (up from $1.520 billion in 2023) and $1.95 billion of fair value (up from $1.585 billion), indicating a larger and higher‑valued equity portfolio.  At the same time, the hedge‑related investments used to offset market changes in its deferred‑cash‑compensation plans fell from $241 million total (including about $14 million embedded in equity securities at FVTNI) in 2023 to $173 million in 2024, showing a reduction in those specific holdings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and misalignments with the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM cites $14 million for equity securities at FVTNI related to deferred compensation in 2023, but the ground truth states $9 million. The LLM also mentions $241 million total hedge-related investments in 2023, which is not mentioned in the ground truth. The $173 million figure for 2024 is correct and matches the ground truth. (2) INCOMPLETE FOCUS ON CORE QUESTION: The question specifically asks about 'investments held for deferred cash compensation plans' within Equity Securities at FVTNI. The ground truth clearly identifies this as $9 million in 2023 and notes it was reclassified to the Equity Method section at $173 million in 2024. The LLM answer discusses broader equity securities portfolio changes ($1.520B to $1.843B in cost) which, while potentially relevant context, dilutes focus from the specific deferred compensation investment category asked about. (3) RECLASSIFICATION NARRATIVE: The ground truth emphasizes a reclassification/realignment from 'Equity Securities at FVTNI' to 'Investments related to deferred cash compensation plans' within the Equity Method section. The LLM answer mentions the $173 million figure but does not clearly articulate this reclassification or the shift in accounting categorization, which is the core insight of the ground truth. (4) MULTI-HOP REASONING: The LLM attempts to synthesize information across years and categories but introduces unsupported figures ($241 million, $14 million) that don't match the ground truth, suggesting either hallucination or reliance on incorrect source data. The answer conflates general equity securities portfolio changes with the specific deferred compensation investment category, failing to properly isolate and track the requested metric.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 505,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How has the aggregate available authorization for Accenture's open-market share purchase program changed between 2022 and 2024, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "The aggregate available authorization for Accenture's open-market share purchase program decreased from $3,129,296 in 2022 to $2,694,281 in 2024. This indicates a reduction in the company's capital allocated for share repurchases over this period, suggesting a more conservative approach to capital deployment or a strategic shift in how the company is managing its equity structure.",
      "llm_answer": "In the 2022 filing Accenture reported that, as of August 31 2022, the aggregate available authorization for its publicly announced open‑market share‑purchase program was **$3,129,296**【ACN_10k_2022.pdf†page=94】. By the 2024 filing the same metric had fallen to **$2,694,281** as of August 31 2024【ACN_10k_2024.pdf†page=100】. The drop shows the company has been actively using its buy‑back authority—returning cash to shareholders through share repurchases—while still maintaining a sizable overall repurchase ceiling (total outstanding authority rose to $6.69 billion in 2024), indicating a disciplined but ongoing commitment to capital return.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) Both key figures are correct: $3,129,296 (2022) and $2,694,281 (2024). (2) Dates are accurate (August 31, 2022 and August 31, 2024). (3) The LLM correctly identifies this as a decrease in available authorization. (4) The multi-hop synthesis across two years is properly executed. WEAKNESSES: (1) The LLM introduces additional information about 'total outstanding authority rose to $6.69 billion in 2024' which is not mentioned in the ground truth answer and cannot be verified against it. This represents potential factual overreach. (2) The interpretation diverges significantly from the ground truth: Ground truth characterizes the decrease as indicating 'a more conservative approach to capital deployment or a strategic shift,' while the LLM interprets it as evidence of 'actively using its buy-back authority' and 'disciplined but ongoing commitment to capital return.' These are somewhat contradictory interpretations—the ground truth emphasizes conservation while the LLM emphasizes active deployment. (3) The LLM's reasoning that a decrease in available authorization indicates active use is logical, but this contradicts the ground truth's implication that it suggests a more conservative approach. The ground truth answer is more cautious in its interpretation. CALCULATION VERIFICATION: The decrease from $3,129,296 to $2,694,281 represents a reduction of $435,015 (approximately 13.9%), which the LLM correctly characterizes as a 'drop' but doesn't quantify. MULTI-HOP REASONING: The synthesis across 2022 and 2024 filings is correct, but the capital allocation strategy interpretation diverges from ground truth. The LLM provides more detailed context but potentially overinterprets the data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 469,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How has the treatment and disclosure around Accenture Canada Holdings Inc. Exchangeable Shares evolved between 2022 and 2024, particularly in terms of share repurchase activity and shareholder rights?",
      "original_answer": "In 2022, Accenture disclosed its intention to use a significant portion of cash generated from operations for share repurchases during fiscal 2023, including purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares. The company noted that the number of shares repurchased would depend on various factors such as share price and market conditions. By 2024, the disclosures had evolved to include more detailed descriptions of the rights associated with Accenture Canada Holdings Inc. exchangeable shares, particularly their exchangeability on a one-for-one basis for Accenture plc Class A ordinary shares, and the company's commitment to align the number of Class X ordinary shares with outstanding exchangeable shares. Additionally, as of August 31, 2024, the company had a specific remaining authorization of $2,694,281 for share repurchase programs, indicating a more structured and quantified approach compared to the more general intentions expressed in 2022.",
      "llm_answer": "In the 2022 Form 10‑K the company explained that Accenture Canada Holdings Inc. exchangeable shares can be exchanged at any time on a one‑for‑one basis for Accenture plc Class A ordinary shares and receive the same distributions, and it noted that the open‑market share‑repurchase program “may be made … in respect of purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares,” but gave no quantitative detail of any such repurchases (see ACN_10k_2022, pp. 41‑44). By the 2024 filing the same exchange rights and distribution entitlements are reaffirmed, yet the company now discloses actual repurchase activity—47,752 exchangeable shares were repurchased for $15.3 million under other share‑purchase programs and are included in the $2.69 billion total repurchase authorization (see ACN_10k_2024, pp. 98‑102). This marks a shift from a general statement of possible repurchases to concrete reporting of repurchase amounts, while the shareholder rights attached to the exchangeable shares remain unchanged.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution of Accenture's disclosure around exchangeable shares between 2022 and 2024. STRENGTHS: (1) Correctly identifies the one-for-one exchange rights and distribution entitlements in both years; (2) Accurately captures the shift from general intentions in 2022 to concrete repurchase reporting in 2024; (3) Provides specific quantitative data: 47,752 exchangeable shares repurchased for $15.3 million; (4) References the $2.69 billion total repurchase authorization; (5) Correctly identifies the page numbers from both 10-K filings; (6) Properly synthesizes multi-hop information across two years and multiple disclosure elements. MINOR ISSUES: (1) The ground truth mentions a specific remaining authorization of $2,694,281 as of August 31, 2024, while the LLM states $2.69 billion total repurchase authorization—these appear to be different metrics (remaining vs. total), creating slight ambiguity about whether the LLM is discussing the same authorization figure; (2) The ground truth emphasizes the company's commitment to align Class X ordinary shares with outstanding exchangeable shares, which the LLM answer does not explicitly mention, though this is a relatively minor omission; (3) The LLM's characterization of the $2.69 billion as the 'total repurchase authorization' versus the ground truth's 'remaining authorization' of $2,694,281 suggests potential confusion about whether these are the same figure or different metrics. QUANTITATIVE VERIFICATION: The 47,752 shares and $15.3 million figures appear reasonable and specific. The $2.69 billion figure is close to $2,694,281 when expressed in billions (though the ground truth specifies this as remaining authorization, not total). MULTI-HOP REASONING: The answer successfully synthesizes information across two years and multiple disclosure elements, correctly identifying the evolution from general to specific reporting. The reasoning about the shift from intentions to concrete activity is sound and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1517,
        "completion_tokens": 549,
        "total_tokens": 2066
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did the global revenue from Electrophysiology Devices evolve between 2023 and 2024, and what was the percentage change in this revenue, excluding the impact of foreign exchange fluctuations?",
      "original_answer": "In 2023, the global revenue from Electrophysiology Devices was $2,195 million, which increased to $2,467 million in 2024. This represents a total change of 12.3%, with the change excluding the impact of foreign exchange fluctuations being 14.4%.",
      "llm_answer": "The total (global) revenue for Abbott’s Electrophysiology devices grew from **$2.195 billion in 2023** to **$2.467 billion in 2024**.  When the effect of foreign‑exchange fluctuations is removed, that increase represents a **14.4 % rise** year‑over‑year【ABT_10k_2024.pdf page 30‑31】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct with accurate financial figures and the key percentage metric. Verification of numbers: 2023 revenue of $2,195 million ($2.195 billion) - CORRECT; 2024 revenue of $2,467 million ($2.467 billion) - CORRECT; percentage change excluding FX impact of 14.4% - CORRECT. The format variation from millions to billions is acceptable and standard. The LLM correctly identified this as Abbott's data and provided proper source attribution. However, there is one notable omission: the LLM did not mention the total percentage change of 12.3% (which includes FX impact), which was explicitly part of the ground truth answer. The question asks 'how did the revenue evolve' (implying both the absolute change and the percentage change) and specifically asks for 'the percentage change...excluding the impact of foreign exchange fluctuations.' While the LLM correctly provided the 14.4% figure (excluding FX), it failed to provide the 12.3% figure (including FX impact), which would have given a more complete picture of the evolution. The multi-hop reasoning is sound - the LLM correctly synthesized the 2023 and 2024 figures and the FX-adjusted percentage. The answer is well-structured and includes proper source citation. The omission of the total percentage change (12.3%) prevents this from being a perfect 9-10 score, as it represents incomplete addressing of the question's implicit request for understanding the full evolution of the metric.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1144,
        "completion_tokens": 407,
        "total_tokens": 1551
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How has Accenture's financial relationship with Duck Creek Technologies evolved between fiscal 2022 and fiscal 2024, particularly in terms of investment valuation and its impact on financial performance?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with the investment accounted for under the equity method. By fiscal 2024, this investment resulted in a $253 million gain, indicating a significant increase in value and a shift in how the investment contributed to Accenture's financial performance. This demonstrates both a quantitative increase in the investment's value and a qualitative change in its impact on Accenture's earnings.",
      "llm_answer": "In fiscal 2022 Accenture’s ~16 % equity stake in Duck Creek Technologies was accounted for under the equity method, with a carrying amount of $138.9 million and an estimated fair‑value of $223.2 million as of August 31, 2022【ACN_10k_2022.pdf†L70-L73】. By fiscal 2024 the investment had appreciated markedly, generating a $253 million gain that was recorded in fiscal 2023 and disclosed as a positive adjustment to earnings, effective‑tax rate and diluted EPS in the 2024 results【ACN_10k_2024.pdf†L38-L41】. This reflects a substantial increase in the valuation of the Duck Creek holding and a direct, material boost to Accenture’s financial performance.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key financial metrics and timeline. STRENGTHS: (1) Correctly identifies the ~16% ownership stake in Duck Creek Technologies; (2) Accurately cites the fair value of $223.2 million as of August 31, 2022 (matches ground truth's $223,166 when accounting for rounding/unit differences - the ground truth appears to be in thousands); (3) Correctly identifies the $253 million gain; (4) Properly notes the equity method accounting treatment; (5) Accurately describes the timing (gain recorded in fiscal 2023, disclosed in 2024 results); (6) Provides additional detail about the carrying amount of $138.9 million which adds context. MINOR ISSUES: (1) The ground truth states the investment was valued at '$223,166' which appears to be in thousands (i.e., $223.166 million), while the LLM correctly interprets this as $223.2 million - this is a formatting/unit interpretation rather than an error; (2) The LLM provides slightly more granular detail about when the gain was recorded (fiscal 2023) versus when it was disclosed (2024), which is accurate but goes slightly beyond the ground truth's simpler statement. MULTI-HOP REASONING: The answer successfully synthesizes information across fiscal 2022 and fiscal 2024 documents, correctly tracing the evolution of the investment from initial valuation through the gain realization. The reasoning about the shift from equity method accounting to the gain impact is sound. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core information as the ground truth while providing additional supporting details and source citations that enhance credibility without contradicting the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 469,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has the composition and scale of Union Pacific's retention share and unit awards changed between 2022 and 2023, and what does this indicate about the company's executive compensation strategy?",
      "original_answer": "In 2022, Union Pacific disclosed that 389,207 retention shares were outstanding under the 2021 Stock Incentive Plan as of December 31, 2021. By 2023, the company disclosed that 954,405 retention shares had been issued and were outstanding, along with 366,046 retention units that do not have an exercise price. This represents a significant increase in the number of outstanding retention instruments, indicating a shift toward greater use of retention-based compensation. The introduction of retention units in 2023 suggests a possible expansion or refinement of the company's long-term incentive strategy for executives.",
      "llm_answer": "In the 2022 filing Union Pacific reported roughly 1.02 million retention shares and 332 thousand retention‑unit awards outstanding – about 1.35 million total retention awards [UNP_10k_2022.pdf pp. 63‑67]. By the 2023 filing the mix had shifted to 954,405 retention shares and 366,046 retention units (≈1.32 million total awards) [UNP_10k_2023.pdf pp. 73‑77]. The increase in unit‑type awards and modest decline in overall retention awards shows the company is moving toward more non‑exercisable, performance‑linked equity compensation, aligning executive pay with long‑term shareholder value while limiting dilution.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant quantitative inaccuracies that undermine its credibility. (1) INCORRECT 2022 NUMBERS: The LLM claims ~1.02 million retention shares and 332k retention units in 2022, totaling ~1.35 million. However, the ground truth states 389,207 retention shares were outstanding as of December 31, 2021 (not 2022 data). The LLM's 2022 figures appear fabricated or misread - 1.02 million shares is roughly 2.6x the ground truth baseline. (2) 2023 NUMBERS PARTIALLY CORRECT: The LLM correctly identifies 954,405 retention shares and 366,046 retention units for 2023, matching the ground truth exactly. (3) CALCULATION ERROR: The LLM calculates 954,405 + 366,046 = 1.32 million, which is arithmetically correct (1,320,451), but this comparison is misleading since the 2022 baseline numbers are wrong. (4) MULTI-HOP REASONING FLAW: The LLM attempts to synthesize a trend (shift from shares to units, decline in total awards), but this analysis is built on false 2022 premises. The actual comparison should be from 389,207 shares (2021) to 954,405 shares + 366,046 units (2023), which shows a SIGNIFICANT INCREASE, not a 'modest decline.' (5) STRATEGIC INTERPRETATION: The LLM's conclusion about 'moving toward more non-exercisable, performance-linked equity compensation' may be directionally reasonable, but it's based on incorrect baseline data. The ground truth emphasizes the significant increase in retention instruments and introduction of retention units as indicating expansion/refinement of strategy - the LLM's framing of 'decline' contradicts this. (6) CITATION ISSUES: The LLM provides specific page numbers (pp. 63-67 for 2022, pp. 73-77 for 2023) that cannot be verified and appear to be hallucinated given the numerical discrepancies. The answer demonstrates reasonable structural understanding of the question but fails on fundamental factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 516,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has MetLife's application of GAAP guidance for adjusted earnings evolved between 2023 and 2024, particularly in terms of the exclusions related to market volatility and asymmetrical accounting adjustments?",
      "original_answer": "In 2023, MetLife updated its calculation of adjusted earnings due to the adoption of LDTI, which led to the exclusion of certain adjustments related to the amortization of DAC, VOBA, and related intangibles, as well as changes in measurement of certain guarantees. Adjusted earnings excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, MetLife continued to refine these exclusions, particularly expanding the scope of policyholder liability remeasurement gains (losses) to exclude asymmetrical accounting associated with in-force reinsurance. Additionally, in 2024, net investment income exclusions were expanded to include adjustments relating to joint ventures under the equity method, which was not explicitly mentioned in 2023. This reflects a more detailed and structured application of GAAP guidance over time.",
      "llm_answer": "In the 2023 filing MetLife spelled out that its GAAP‑aligned adjusted earnings strips out (i) market‑volatility items – net investment and derivative gains / losses, MRB remeasurement gains / losses, goodwill impairments, and discount‑rate or market‑value adjustments – and (ii) a suite of asymmetrical accounting items such as non‑hedge‑qualified derivative income, in‑force reinsurance adjustments, basis‑adjustment amortization, inflation‑indexed benefit adjustments and other non‑economic effects (see Note 2, 2023 10‑K, pp. 168‑172). The 2024 filing continues to use the same GAAP guidance—still excluding those market‑volatility and asymmetrical adjustments—but the description is more concise and no longer references the LDTI transition, indicating the updated calculation is now fully embedded in the adjusted‑earnings measure (see Note 2, 2024 10‑K, pp. 148‑152).",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer provides some correct information but has significant gaps and misalignments with the ground truth:\n\nSTRENGTHS:\n1. Correctly identifies that MetLife excludes market-volatility items (net investment/derivative gains/losses, MRB remeasurement, goodwill impairments, discount-rate adjustments)\n2. Correctly identifies asymmetrical accounting exclusions (non-hedge-qualified derivatives, in-force reinsurance adjustments)\n3. Correctly notes the 2024 filing is more concise and no longer references LDTI transition\n4. Appropriately cites Note 2 in both 10-K filings\n5. Correctly identifies the evolution from 2023 to 2024 in terms of presentation\n\nSIGNIFICANT GAPS AND ERRORS:\n1. MISSING KEY EVOLUTION: The ground truth emphasizes that 2024 EXPANDED the scope of policyholder liability remeasurement gains (losses) to exclude asymmetrical accounting associated with in-force reinsurance - this is a material change not captured in the LLM answer\n2. MISSING CRITICAL DETAIL: The ground truth specifically mentions that 2024 expanded net investment income exclusions to include adjustments relating to joint ventures under the equity method - this is a new exclusion category not mentioned in the LLM answer\n3. INCOMPLETE LDTI CONTEXT: While the LLM notes LDTI is no longer referenced in 2024, it doesn't explain that the 2023 update was DUE TO LDTI adoption, which is important context for understanding the evolution\n4. MISSING SPECIFIC EXCLUSIONS: The ground truth mentions exclusions for DAC, VOBA, and related intangibles amortization, and changes in measurement of certain guarantees - these are not mentioned in the LLM answer\n5. INCOMPLETE CHARACTERIZATION: The LLM describes the changes as merely \"more concise\" presentation, but the ground truth indicates substantive expansions of exclusion scope (policyholder liability remeasurement, joint venture adjustments)\n\nMULTI-HOP REASONING:\nThe LLM answer addresses the basic comparison between 2023 and 2024 but fails to synthesize the full scope of changes. It correctly identifies that the same guidance is applied but misses the material expansions in exclusion scope that represent the actual evolution of the application.\n\nQUANTITATIVE ACCURACY:\nNo specific numbers are provided in either answer, so this is not a differentiator. Page references are cited but not verified for accuracy.\n\nCONCLUSION:\nThe LLM answer captures the surface-level evolution (from LDTI-transition-focused to embedded calculation) but misses the substantive expansions in exclusion scope that are central to how MetLife's GAAP guidance application evolved. This represents incomplete synthesis of the multi-hop information required to fully answer the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1466,
        "completion_tokens": 721,
        "total_tokens": 2188
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has Accenture's approach to achieving compressed transformations evolved from 2022 to 2024, particularly in terms of the technologies leveraged and the scope of transformation services offered?",
      "original_answer": "In 2022, Accenture focused on using technologies like digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, and metaverse to help clients achieve compressed transformations by redefining product design, engineering, sourcing, manufacturing, and servicing. By 2024, the company expanded its technological toolkit to include generative AI, artificial reality / virtual reality, and advanced robotics, while also enhancing its own development of automation equipment and commercial hardware to support client operations. Additionally, the scope of transformation broadened to include digitally transforming capital projects such as plant and asset construction, public infrastructure, power grids, and data centers. This reflects a more integrated and advanced technological approach to compressed transformations over the two-year period.",
      "llm_answer": "In 2022 Accenture’s “compressed‑transformation” approach centered on applying digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics and the metaverse to redesign product design, engineering, sourcing, manufacturing and service‑and‑renewal processes. By 2024 the firm broadened both the technology stack and the service scope—adding generative AI (AI Navigator), artificial‑reality/virtual‑reality, testing capabilities, and the design and build of advanced automation hardware—while extending transformations to capital‑project and infrastructure domains (plant, power‑grid and data‑center execution) and delivering end‑to‑end product‑lifecycle services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) All factual information is accurate - correctly identifies 2022 technologies (digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, metaverse) and 2024 additions (generative AI, artificial reality/virtual reality, advanced automation hardware). (2) Correctly captures the evolution in scope from product-focused transformations to capital projects and infrastructure (plant, power grids, data centers). (3) Multi-hop synthesis is sound - properly connects the technological evolution with expanded service scope across the two-year period. (4) No quantitative errors - dates (2022, 2024) are correct, and no calculations are required. (5) Entity identification is accurate - Accenture is correctly identified throughout. (6) Wording variations are appropriate and enhance clarity (e.g., 'AI Navigator' as specific example, 'end-to-end product-lifecycle services' as additional context). MINOR OBSERVATIONS: The LLM answer includes slightly more specific details than the ground truth (e.g., 'AI Navigator', 'testing capabilities', 'end-to-end product-lifecycle services') which adds value without contradicting the original answer. The phrase 'service-and-renewal processes' in the LLM answer is semantically equivalent to 'servicing' in the ground truth. The answer maintains semantic equivalence while providing marginally more comprehensive detail. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 412,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2023 and 2024 in managing exposure to changes in the fair value of fixed-rate debt?",
      "original_answer": "In 2023, Abbott had interest rate hedge contracts totaling approximately $2.2 billion at December 31, 2023, to manage exposure to changes in the fair value of fixed-rate debt due to long-term benchmark interest rate fluctuations. These contracts were designated as fair value hedges, effectively converting fixed-rate debt to variable-rate debt. In 2024, Abbott continued to maintain interest rate hedge contracts with notional values totaling $2.2 billion, indicating a consistent strategy in hedging interest rate risk. However, the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024, suggesting a shift in the underlying debt structure or market interest rate conditions despite the stable hedge notional amount.",
      "llm_answer": "In 2023 Abbott reported that it had ≈ $2.2 billion of interest‑rate‑swap contracts designated as fair‑value hedges of the variability in the fair value of its fixed‑rate debt (down from $2.9 billion in 2022 after $700 million of contracts matured). By year‑end 2024 the notional amount of those hedge contracts remained at ≈ $2.2 billion, indicating that Abbott maintained the same level of hedging to convert the fixed‑rate portion of its debt to a variable‑rate exposure after the 2023 reduction.【ABT_10k_2023.pdf p.62‑66】【ABT_10k_2024.pdf p.38‑42】",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is substantially correct but has some notable differences from the ground truth. STRENGTHS: (1) Correctly identifies the $2.2 billion notional value for both 2023 and 2024, matching the ground truth; (2) Properly characterizes these as fair value hedges converting fixed-rate to variable-rate debt; (3) Correctly notes the consistency of hedging strategy between years; (4) Provides additional context about the 2022 baseline ($2.9 billion) and the $700 million maturity, which adds useful detail. WEAKNESSES: (1) The LLM answer does NOT address the interest rate increase from 3.6% to 3.8% mentioned in the ground truth, which is a key part of how the hedging strategy evolved in context; (2) The ground truth emphasizes that despite stable hedge notional amounts, the underlying debt structure or market conditions shifted (evidenced by the rate increase), but the LLM answer doesn't capture this important nuance about the evolution of the strategy's effectiveness or context; (3) The LLM answer focuses more on the 2022-2023 transition rather than fully addressing the 2023-2024 evolution requested in the question. QUANTITATIVE VERIFICATION: All dollar amounts are correct ($2.2B for both years, $2.9B for 2022, $700M maturity). The numbers are accurate and properly formatted. MULTI-HOP REASONING: The answer correctly synthesizes information across 2023 and 2024 filings, but misses the important contextual element about interest rate changes that would have demonstrated a more complete understanding of how the hedging strategy evolved in its practical impact. The answer is factually sound but incomplete in addressing the full scope of the question about evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 462,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has MetLife's treatment and definition of Adjusted Earnings evolved between 2023 and 2024, particularly in relation to GAAP guidance and segment performance measurement?",
      "original_answer": "In 2023, MetLife updated its calculation of Adjusted Earnings due to the adoption of LDTI, removing certain adjustments related to the amortization of DAC, VOBA, and related intangibles, and instead adjusted for changes in measurement of certain guarantees. Adjusted Earnings in 2023 excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, Adjusted Earnings remained the GAAP measure of segment performance, but the exclusions were more clearly delineated to include market volatility impacts, asymmetrical and non-economic accounting adjustments, revenues and costs from divested businesses, and results from discontinued operations. Specifically, 2024 Adjusted Earnings excluded net investment gains/losses, derivative gains/losses, MRB remeasurement gains/losses, and goodwill impairments, with more structured exclusions such as inflation-indexed benefit adjustments and non-economic losses from single premium annuity contracts. This represents a refinement and expansion of the exclusions introduced in 2023.",
      "llm_answer": "MetLife’s basic definition of Adjusted Earnings – “adjusted revenues less adjusted expenses, net of income tax” (with Adjusted Earnings available to common shareholders further net of preferred dividends) – is unchanged from 2023 (see MET_10k_2023 pp. 117‑121).  However, the 2024 filing adds two key evolutions: (1) it explicitly states that Adjusted Earnings is the GAAP measure of segment performance consistent with ASC 280 (“Consistent with GAAP guidance for segment reporting, adjusted earnings … are also our GAAP measures of segment performance” – MET_10k_2024 pp. 148‑152), and (2) it updates the calculation to reflect the adoption of LDTI, removing amortization of DAC/VOBA, fair‑value changes of MRBs, discount‑rate adjustments on annuity guarantees, contract‑inception losses and other asymmetrical accounting items (MET_10k_2024 pp. 148‑152).",
      "correctness_score": 5,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies some key facts but has significant gaps and misses critical elements of the ground truth answer. STRENGTHS: (1) Correctly identifies that the basic definition of Adjusted Earnings remained unchanged from 2023 to 2024; (2) Accurately notes the explicit statement in 2024 that Adjusted Earnings is the GAAP measure of segment performance consistent with ASC 280; (3) Correctly references LDTI adoption and removal of DAC/VOBA amortization; (4) Mentions MRBs, discount-rate adjustments, and asymmetrical accounting items. CRITICAL GAPS AND WEAKNESSES: (1) The answer focuses heavily on what remained the same or was explicitly stated in 2024, but fails to adequately address the EVOLUTION between 2023 and 2024 as the question specifically asks. The ground truth emphasizes that 2024 represented a 'refinement and expansion of the exclusions introduced in 2023.' (2) Missing specific 2023 exclusions: The answer does not clearly delineate what was excluded in 2023 (changes in fair value of MRBs, discount rate changes on annuitization guarantees, asymmetrical accounting from in-force reinsurance). (3) Missing 2024-specific exclusions: The answer does not mention net investment gains/losses, derivative gains/losses, goodwill impairments, inflation-indexed benefit adjustments, or non-economic losses from single premium annuity contracts - all of which are explicitly mentioned in the ground truth as 2024 exclusions. (4) Does not address the expansion of exclusions to include 'market volatility impacts,' 'revenues and costs from divested businesses,' and 'results from discontinued operations' as noted in the ground truth. (5) The answer lacks the comparative analysis showing how the exclusions became 'more clearly delineated' and 'more structured' in 2024. REASONING ASSESSMENT: The multi-hop synthesis is incomplete. While the answer correctly identifies that LDTI adoption was a driver of change, it fails to fully synthesize the specific differences in exclusions between the two years, which is the core of the question. The answer reads more as a description of 2024 features rather than an evolution narrative. SEMANTIC ISSUE: The answer states exclusions were 'removing amortization of DAC/VOBA' but this is somewhat imprecise - the ground truth indicates these were removed due to LDTI adoption, and the focus shifted to other adjustments. The answer conflates the mechanism of change with the actual exclusions themselves.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1502,
        "completion_tokens": 657,
        "total_tokens": 2160
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has the funding and utilization of Accenture's share purchase program evolved from 2022 to 2024, particularly in terms of available authorization and share acquisition methods?",
      "original_answer": "In 2022, Accenture reported an aggregate available authorization of $3,129,296 for its publicly announced open-market share purchase program and other related share purchase programs. This included acquisitions of Accenture plc Class A ordinary shares and Accenture Canada Holdings Inc. exchangeable shares held by current and former members of Accenture Leadership. By 2024, the company clarified that its open-market share purchase program applied specifically to Accenture plc Class A ordinary shares, which were held as treasury shares for employee benefits, such as equity awards. Additionally, in fiscal 2024, Accenture acquired Class A ordinary shares primarily through share withholding for payroll tax obligations tied to employee equity plans. These purchases did not impact the aggregate available authorization for the public share purchase programs, indicating a shift in acquisition methods while maintaining a focus on funding levels.",
      "llm_answer": "In fiscal 2022 Accenture’s board had authorized $3.13 million for its publicly announced open‑market share‑repurchase program (plus related purchase programs) and used that authority – together with share‑withholding purchases for payroll‑tax obligations – to acquire about 12.2 million Class A shares for $4.11 million. By August 31 2024 the authorized amount had been reduced to $2.69 million, yet the company bought roughly 13.9 million shares for $4.51 million, again mainly via open‑market purchases and payroll‑tax withholding (with a small amount of exchangeable‑share purchases).",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains severe quantitative inaccuracies that fundamentally undermine its credibility. (1) MAGNITUDE ERROR - The LLM states $3.13 million and $2.69 million for authorization amounts, but the ground truth clearly indicates $3,129,296 (approximately $3.13 billion, not million). This is a thousand-fold error. The LLM also states shares were acquired for $4.11 million and $4.51 million, which appear to be similarly scaled incorrectly - these should be in billions based on typical Accenture repurchase volumes. (2) SHARE COUNT ISSUES - The LLM mentions 12.2 million and 13.9 million shares acquired, but provides dollar amounts that don't align with reasonable per-share pricing for Accenture stock (which typically trades in the $300+ range). The math doesn't reconcile: 12.2M shares × typical price would yield billions, not $4.11M. (3) INCOMPLETE SYNTHESIS - While the LLM attempts to address the evolution from 2022 to 2024 and mentions both open-market and withholding methods, it fails to capture the ground truth's key insight about the shift in acquisition methods and the distinction between treasury shares for employee benefits vs. other purposes. (4) MISSING CONTEXT - The LLM omits important details about Accenture Canada Holdings Inc. exchangeable shares and the specific clarification about how 2024 acquisitions didn't impact the aggregate available authorization. (5) REASONING FLAW - The LLM's statement that authorization 'had been reduced' from $3.13M to $2.69M is presented without proper context about what this means for the program's evolution. The ground truth emphasizes a shift in methods while maintaining focus on funding levels, which the LLM doesn't adequately convey. The answer demonstrates a fundamental misunderstanding of the scale of these financial figures and fails to accurately synthesize the multi-hop information required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 516,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How did MetLife's treatment and valuation methodology for Unit-linked Securities evolve from 2023 to 2024, particularly in terms of cost basis and fair value sensitivity?",
      "original_answer": "In 2023, MetLife described the cost basis for Unit-linked and FVO securities as primarily equity and fixed maturity securities, with cost representing original cost for equities and amortized cost for fixed maturities. By 2024, Unit-linked securities were included in Level 3 fair value measurements and subjected to valuation techniques involving significant unobservable inputs such as mortality rates, lapse rates, and equity volatility. Additionally, the 2024 disclosures emphasized sensitivity of fair value to changes in these inputs, indicating a more dynamic and assumption-driven valuation approach compared to the more static cost-based method described in 2023.",
      "llm_answer": "In the 2023 filing MetLife said that Unit‑linked and FVO securities are carried at **amortized cost** – i.e., original cost less any repayments and adjusted for the amortization of premiums or accretion of discounts – and that changes in their estimated fair value are measured using the same Level 3 valuation techniques and significant unobservable inputs (offered quotes, market quotes, etc.) applied to other Level 3 assets. The 2024 filing kept that same treatment: the securities remain recorded at amortized cost, and their fair‑value changes are still captured through the Level 3 methodology, with the only change being an update of the input ranges and weighted‑average sensitivities to reflect 2024 market conditions.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) The LLM claims both 2023 and 2024 used 'amortized cost' accounting treatment, but the ground truth explicitly states 2023 used 'cost basis' (original cost for equities, amortized cost for fixed maturities) - a different characterization. (2) The LLM incorrectly states that 2023 filings already described Level 3 fair value measurements with significant unobservable inputs like mortality rates, lapse rates, and equity volatility. The ground truth indicates this was a 2024 development, not present in 2023. (3) The LLM fundamentally misses the evolution described in the ground truth: from a 'more static cost-based method' in 2023 to a 'more dynamic and assumption-driven valuation approach' in 2024. (4) The LLM's claim that 'the only change being an update of the input ranges' severely understates the methodological shift from cost-based to Level 3 fair value with unobservable inputs. (5) The LLM fails to identify the specific unobservable inputs (mortality rates, lapse rates, equity volatility) that became relevant in 2024. The answer demonstrates a fundamental misunderstanding of the year-over-year evolution and incorrectly collapses the distinction between 2023 and 2024 methodologies. The multi-hop reasoning required to synthesize the evolution across two years was not properly executed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 390,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How has the structure and vesting timeline of market-based RSUs evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, market-based RSUs generally vested over four years and grantees could receive between 0% and 300% of the original grant based on total stockholder return (TSR) relative to an index group. By fiscal year 2023, while four-year vesting remained common, the company also introduced market-based RSUs that vested over five years, with vesting contingent on achieving stock price performance milestones. This indicates an expansion in the types of market-based RSUs offered, adding a new vesting structure based on specific stock price targets.",
      "llm_answer": "In FY 2022 Broadcom’s market‑based RSUs were granted with both a service condition and a market condition and **generally vest over four years**, with the payout tied to total stockholder return (TSR) versus an index group. In FY 2023 the company retained the four‑year, TSR‑based awards **but added a new tranche of market‑based RSUs that vest over five years and are linked to stock‑price performance milestones**, expanding the vesting timeline beyond the prior four‑year schedule.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Strengths: (1) Correctly identifies the four-year vesting timeline for FY 2022 market-based RSUs, (2) Accurately describes the TSR-based payout structure with reference to an index group in FY 2022, (3) Correctly identifies the introduction of five-year vesting market-based RSUs in FY 2023, (4) Accurately characterizes the new awards as linked to stock price performance milestones, (5) Properly synthesizes the evolution showing both retention of prior structure and expansion with new structure. The answer demonstrates sound multi-hop reasoning by comparing the two fiscal years and identifying both continuity (four-year awards remain) and change (five-year awards added). The LLM also appropriately identifies the company as Broadcom, which adds helpful context. Minor observation: The ground truth mentions the 0%-300% payout range for TSR-based awards in FY 2022, which the LLM answer does not include, but this is a minor omission that doesn't affect the core answer about structural evolution and vesting timelines. The LLM's focus on the structural and timeline changes directly addresses the question asked. All numeric values (4 years, 5 years) and temporal references (FY 2022, FY 2023) are correct. The semantic meaning aligns perfectly with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 371,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 145,
      "question": "How did the phase-in treatment of the CECL standard's ongoing impact on regulatory capital evolve between 2023 and 2024, and what specific regulatory capital treatment applied during the phase-in period?",
      "original_answer": "In 2023, the CECL Transition Election allowed for the cumulative 'day 2' ongoing impact to be phased into regulatory capital at 25% per year from January 1, 2022, through December 31, 2024. By 2024, this phase-in treatment remained consistent, with the ongoing impact continuing to be phased in at 25% annually, indicating that the regulatory capital treatment under the CECL Transition Rule was applied uniformly across both years as part of the multi-year transition framework.",
      "llm_answer": "By the end of 2023 Capital One had only phased‑in 50 % of the cumulative “day‑2” (ongoing) CECL allowance increase into its regulatory capital, but in 2024 that share rose to 75 % (with the final 25 % to be added in 2025) 【78†L31-L38】【200†L31-L38】. During the transition the CECL Transition Rule permitted the bank to treat the CECL impact as a capital add‑back – adding back the after‑tax “day‑1” adoption impact and a 25 %‑per‑year phased‑in portion of the “day‑2” allowance increase to regulatory capital until fully phased‑in.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. CRITICAL ERRORS: (1) The LLM states that by end of 2023, only 50% was phased in, and by 2024 it was 75%. This is INCORRECT. The ground truth clearly states the phase-in was 25% per year from January 1, 2022 through December 31, 2024. This means: 2022 = 25%, 2023 = 50% cumulative, 2024 = 75% cumulative, 2025 = 100%. The LLM's percentages (50% in 2023, 75% in 2024) are actually correct cumulative amounts, but the LLM misrepresents this as a change in the phase-in treatment between years, when in fact the treatment remained consistent at 25% per year throughout. (2) The LLM correctly identifies the 25%-per-year phase-in mechanism and the capital add-back treatment, which aligns with ground truth. (3) However, the LLM's framing suggests the phase-in treatment 'evolved' or changed between 2023 and 2024, when the ground truth explicitly states it 'remained consistent' and was 'applied uniformly across both years.' This is a fundamental misunderstanding of the question's core premise. (4) The LLM correctly mentions the 'day-1' and 'day-2' distinction and the capital add-back mechanism. (5) The reference to 2025 for the final 25% is reasonable extrapolation but not explicitly confirmed in the ground truth provided. The answer demonstrates partial understanding of CECL mechanics but fails to correctly characterize the evolution (or lack thereof) of the treatment between 2023 and 2024, which was the primary question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 417,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 146,
      "question": "How has Broadcom's relationship with Wilmington Trust, National Association evolved between 2022 and 2023 in terms of the types and terms of senior notes issued under their indentures?",
      "original_answer": "In 2022, Broadcom had an ongoing relationship with Wilmington Trust, National Association as trustee under indentures governing senior notes issued in January 2021, which included notes with interest rates as low as 1.950% (due 2028) and as high as 3.750% (due 2051). By 2023, the relationship had evolved to include new indentures dated April 18, 2022, and July 12, 2024, under which Broadcom issued higher-yielding senior notes, including a 4.926% note due 2037 and later, in October 2024, notes ranging from 4.150% (due 2028) to 4.800% (due 2034). This reflects a shift toward issuing longer-term debt with higher interest rates over time.",
      "llm_answer": "In fiscal 2022 Broadcom entered into two new indentures with Wilmington Trust, National Association, under which it issued 4.00 % senior notes due 2029, 4.15 % senior notes due 2032 and 4.926 % senior notes due 2037【AVGO_10k_2022.pdf p.101‑102】. By the 2023 filing the company was still using Wilmington Trust as trustee but had added higher‑coupon, longer‑dated issues—a 5.050 % series due 2027, a 5.050 % series due 2029 and a 5.150 % series due 2031 under a supplemental indenture—showing a shift toward higher‑yield, longer‑term senior debt while maintaining the same trustee relationship【AVGO_10k_2023.pdf p.98‑99】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) WRONG INTEREST RATES: The LLM claims 4.00%, 4.15%, and 4.926% notes were issued in 2022, but the ground truth shows the 2022 indentures included a 4.926% note due 2037 (partially correct) but does not mention 4.00% or 4.15% notes in 2022. The ground truth indicates 4.150% and 4.800% notes were issued in October 2024, not 2022. (2) WRONG MATURITY DATES: The LLM lists 4.00% due 2029, 4.15% due 2032, and 4.926% due 2037 for 2022, but ground truth shows 4.926% due 2037 is correct while the others are incorrect or misattributed. (3) FABRICATED 2023 DATA: The LLM claims 5.050% notes due 2027, 5.050% due 2029, and 5.150% due 2031 were issued in 2023 under a supplemental indenture. These rates and dates do not appear in the ground truth at all. (4) MISSING KEY INFORMATION: The LLM fails to mention the January 2021 indenture with rates as low as 1.950% (due 2028) and 3.750% (due 2051) that were still relevant in 2022. (5) INCOMPLETE EVOLUTION NARRATIVE: The ground truth shows a clear evolution from lower rates (1.950%-3.750% in 2021) to higher rates (4.926% in 2022) to even higher rates (4.150%-4.800% in October 2024), but the LLM's narrative is disconnected and inaccurate. The LLM does correctly identify Wilmington Trust as the trustee and attempts to show a shift toward higher-yield debt, but the specific numbers and dates are largely incorrect, making this answer unreliable for financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 417,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did Capital One's regulatory capital add-back under the CECL Transition Rule evolve from 2023 to 2024, and what was the specific phase-in progression during this period?",
      "original_answer": "In 2023, Capital One had already added back $2.4 billion to its regulatory capital under the CECL Transition Rule, with a phase-in of 50% as of January 1, 2023. By January 1, 2024, the phase-in had progressed to 75%, indicating a 25 percentage point increase over the year. This reflects the structured five-year phase-in process under the CECL Transition Rule, where 25% of the cumulative impact was phased in annually after 2021.",
      "llm_answer": "Capital One’s CECL‑transition add‑back grew from a 50 % inclusion of the $2.4 billion total impact in 2023 (about $1.2 billion) to a 75 % inclusion in 2024 (about $1.8 billion), with the remaining $600 million scheduled for the Jan 1 2025 filing 【COF_10k_2023.pdf p.10‑11】. The CECL Transition Rule phases the add‑back in at 25 % per year – 25 % in 2022, 50 % in 2023, 75 % in 2024, and 100 % (fully phased‑in) in 2025【COF_10k_2023.pdf p.10‑11】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key facts: (1) The $2.4 billion total CECL impact is correct. (2) The phase-in percentages are accurate: 50% in 2023 and 75% in 2024, representing a 25 percentage point increase as stated in the ground truth. (3) The dollar amount calculations are correct: 50% of $2.4B = $1.2B, and 75% of $2.4B = $1.8B. (4) The remaining $600M for 2025 is correctly calculated (25% of $2.4B). (5) The phase-in schedule provided (25% in 2022, 50% in 2023, 75% in 2024, 100% in 2025) is accurate and demonstrates the structured five-year progression mentioned in the ground truth. The LLM answer goes beyond the ground truth by providing the complete phase-in schedule and calculating the dollar amounts at each phase, which adds helpful context. The multi-hop synthesis is sound - correctly connecting the regulatory rule, the specific dollar amounts, the phase-in percentages, and the timeline. The citation to the source document (COF_10k_2023.pdf p.10-11) adds credibility. Minor note: The ground truth mentions the phase-in process began after 2021, and the LLM answer shows 25% in 2022 as the starting point, which is consistent. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 343,
        "total_tokens": 1568
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did the treatment of VMware stock options for non-employee directors evolve between 2022 and 2023 following the Broadcom acquisition?",
      "original_answer": "In 2022, the 10-K filing stated that all outstanding in-the-money VMware stock options and RSU awards held by non-employee directors would be accelerated and converted into the right to receive cash and shares of Broadcom common stock, in equal parts, upon the completion of the acquisition. By 2023, this provision had been realized, with the statement confirming that these awards were indeed accelerated and converted into the right to receive cash and Broadcom shares. This reflects a transition from a planned conversion to an actualized event following the completion of the acquisition.",
      "llm_answer": "In the 2022 filing Broadcom disclosed that any in‑the‑money VMware stock options (and RSU awards) held by non‑employee directors would be accelerated at the merger and exchanged for cash and Broadcom common stock on a 50 %/50 % basis (AVGO 10‑K 2022, p. 95). The 2023 filing, after the merger was completed, confirmed that those options were actually accelerated and converted into cash and Broadcom shares, maintaining the same equal‑parts treatment (AVGO 10‑K 2023, p. 66).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. Strengths: (1) Correctly identifies the key evolution from planned conversion (2022) to actualized event (2023); (2) Accurately states the 50%/50% equal-parts treatment of cash and Broadcom shares in both years; (3) Properly synthesizes multi-hop information across two fiscal years and two companies (VMware and Broadcom); (4) Correctly identifies that in-the-money options and RSU awards for non-employee directors were subject to acceleration; (5) Appropriately cites specific page numbers from the 10-K filings (AVGO 10-K 2022 p. 95, AVGO 10-K 2023 p. 66), demonstrating source verification; (6) Uses proper terminology (merger completion, acceleration, conversion). Minor considerations: The answer uses 'AVGO' ticker notation which is correct for Broadcom but the original answer uses 'Broadcom' - this is a stylistic difference, not an error. The phrase 'in‑the‑money' with special character formatting is identical to ground truth. All quantitative elements (50%/50% split, cash and shares treatment) match perfectly. The reasoning correctly captures the temporal progression from prospective (2022) to retrospective (2023) treatment. No calculation errors or factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 352,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How has the therapeutic positioning of Vraylar evolved from 2022 to 2024 based on AbbVie's disclosures?",
      "original_answer": "In 2022, Vraylar was described as being evaluated in Phase 3 clinical trials as an adjunctive treatment for major depressive disorder (MDD), with one trial meeting its primary endpoint and the other showing numerical but not statistically significant improvement. By 2024, Vraylar was disclosed as being indicated for a broader range of psychiatric conditions, including acute and maintenance treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar disorder, acute treatment of depressive episodes associated with bipolar I disorder, and as an adjunctive treatment in major depressive disorder. This reflects a clear expansion and solidification of its therapeutic positioning over time.",
      "llm_answer": "In the 2022 Form 10‑K AbbVie described Vraylar (cariprazine) as a dopamine D3‑preferring D3/D2 partial agonist approved for “acute and maintenance treatment of schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar disorder in adults, acute treatment of depressive episodes associated with bipolar I disorder in adults, and as an adjunctive treatment in major depressive disorder”【ABBV_10k_2022.pdf page 58‑62】. The 2024 Form 10‑K still lists Vraylar (a) under the neuroscience portfolio (with revenue data) and does not add any new indications, indicating that its therapeutic positioning remains focused on schizophrenia, bipolar disorder and adjunctive MDD as before【ABBV_10k_2024.pdf page 4‑8】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains a critical factual error that directly contradicts the ground truth. The ground truth clearly states that in 2022, Vraylar was in Phase 3 clinical trials for MDD as an adjunctive treatment, with one trial meeting its primary endpoint and another showing numerical but not statistically significant improvement. However, the LLM claims that in 2022, Vraylar was already approved for all four indications (schizophrenia, bipolar disorder manic/mixed episodes, bipolar I depressive episodes, and adjunctive MDD). This is factually incorrect. The LLM appears to have confused the 2024 approved indications with the 2022 status. The ground truth explicitly describes an evolution from Phase 3 trials in 2022 to approved indications by 2024, representing an expansion and solidification of therapeutic positioning. The LLM's answer incorrectly suggests no change occurred ('remains focused on schizophrenia, bipolar disorder and adjunctive MDD as before'), which fundamentally misses the core narrative of the question - the evolution from investigational to approved status. Additionally, the LLM provides page references that cannot be verified but appear to be fabricated or misattributed. The answer fails to capture the key multi-hop synthesis required: understanding that Vraylar's status changed from Phase 3 investigational (2022) to approved (2024), representing a significant therapeutic positioning evolution. This is a major conceptual and factual error that undermines the entire response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 419,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has GE's accounting policy for long-term services agreements evolved from 2022 to 2024, particularly in terms of revenue recognition method and contract billing estimates?",
      "original_answer": "In 2022, GE recognized revenue for long-term services agreements on a straight-line basis, primarily in the Healthcare and Renewable Energy segments, with periodic invoicing as services were provided. By 2024, GE shifted to using the percentage of completion method for revenue recognition, predominantly within the CES segment, based on costs incurred relative to total expected costs. Additionally, in 2024, GE reported a long-term services agreements net liability balance of $6.6 billion, representing approximately 4.1% of total estimated life of contract billings of $162 billion, indicating a more detailed and forward-looking estimation process involving asset utilization and cost improvements, which was not explicitly mentioned in 2022.",
      "llm_answer": "GE still uses the percentage‑of‑completion method to recognize revenue on its long‑term service contracts, but the 2024 filing adds much more detail. In 2022 the policy simply said revenue is recognized as costs are incurred and billing is based on asset utilization or major maintenance events. By 2024 the policy requires explicit estimates of customer utilization (using historical trends and forward‑looking data), cost‑improvement assumptions and routine, cumulative‑catch‑up revisions of those estimates, and it clarifies that billing is tied to utilization, periodic billing schedules or specific maintenance events, with contract modifications evaluated for pricing, asset‑impairment and financing impacts.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM answer completely omits critical financial metrics from the ground truth: the $6.6 billion net liability balance and the $162 billion total estimated life of contract billings, along with the 4.1% ratio. These are specific, verifiable numbers that should have been included. (2) FACTUAL CONTRADICTION - The LLM states GE 'still uses the percentage-of-completion method' in both 2022 and 2024, directly contradicting the ground truth which explicitly states that in 2022 GE used 'straight-line basis' and only shifted to 'percentage of completion method' by 2024. This is a fundamental error in describing the evolution of the accounting policy. (3) SEGMENT IDENTIFICATION - The ground truth specifies that in 2022 the straight-line method was used 'primarily in the Healthcare and Renewable Energy segments' and by 2024 it was 'predominantly within the CES segment.' The LLM answer fails to identify these segment-specific details. (4) INCOMPLETE SYNTHESIS - While the LLM does capture some 2024 policy details (customer utilization estimates, cost-improvement assumptions, contract modifications), it fails to properly synthesize the 2022-to-2024 evolution as a methodological shift. The answer reads more as a description of 2024 policy with a vague reference to 2022, rather than a clear comparison showing the change from straight-line to percentage-of-completion. (5) MISSING FORWARD-LOOKING CONTEXT - The ground truth emphasizes that 2024 shows 'a more detailed and forward-looking estimation process' which was 'not explicitly mentioned in 2022.' The LLM does not adequately convey this evolution in sophistication. The answer demonstrates partial understanding of 2024 policy details but fundamentally misrepresents the 2022 baseline and fails to capture the key quantitative metrics that define the 2024 position.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 509,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has IBM's disclosure of the 1.250% Notes due 2027 evolved between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, IBM disclosed the 1.250% Notes due 2027 as part of a list of instruments defining the rights of holders, with Exhibit 4.3 to Form 8-K filed on January 30, 2019, referenced for the notes. In the 2023 10-K filing, the 1.250% Notes due 2027 are listed under registered securities with the trading symbol IBM 27B on the New York Stock Exchange. This evolution reflects a shift from referencing the instrument defining the rights to identifying the notes as a registered class of securities.",
      "llm_answer": "In IBM’s 2022 Form 10‑K the 1.250 % Notes due 2027 were disclosed only in the debt footnote, where the filing gave the basic terms (interest rate, maturity date and amount outstanding) but did not list the securities separately in the registration table【IBM_10k_2022.pdf page 28】. In the 2023 Form 10‑K the company added a distinct line for those notes in the Section 12(b) securities‑registration table, identifying them as “1.250 % Notes due 2027 – IBM 27B – NYSE,” thereby providing a specific trading symbol and exchange listing and making the disclosure more prominent【IBM_10k_2023.pdf page 1】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution of IBM's disclosure of the 1.250% Notes due 2027 between 2022 and 2023 10-K filings. STRENGTHS: (1) Correctly identifies the key difference - the notes moved from being disclosed only in debt footnotes (2022) to being listed in the Section 12(b) securities registration table (2023). (2) Accurately captures the specific trading symbol 'IBM 27B' and NYSE exchange listing mentioned in the 2023 filing. (3) Properly synthesizes the multi-hop information showing the evolution from basic debt disclosure to registered securities classification. (4) The characterization of the shift as making disclosure 'more prominent' aligns with the ground truth's description of moving from 'referencing the instrument defining the rights' to 'identifying the notes as a registered class of securities.' (5) Numeric values (1.250%, 2027 maturity date) are correct. MINOR WEAKNESSES: (1) The LLM answer references specific page numbers (page 28 for 2022, page 1 for 2023) which cannot be verified against the ground truth and may be inaccurate - the ground truth does not specify page numbers. (2) The ground truth explicitly mentions 'Exhibit 4.3 to Form 8-K filed on January 30, 2019' as a reference in the 2022 filing, which the LLM answer does not include. This is a notable omission of a specific detail from the original answer. (3) The LLM answer uses slightly different framing ('debt footnote' vs 'list of instruments defining the rights') though the semantic meaning is similar. Overall, the answer captures the essential evolution correctly but misses one specific reference detail and includes unverifiable page citations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 460,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has the structure and performance criteria of AbbVie's performance-vested RSUs evolved between 2022 and 2024, particularly in terms of vesting increments and performance metrics?",
      "original_answer": "In 2022, performance-vested RSUs had the potential to vest in one-third increments over a three-year performance period, with performance measured based on AbbVie's return on invested capital (ROIC) relative to a defined peer group of pharmaceutical, biotech, and life science companies for awards granted in 2021 and 2020. By 2024, the vesting structure remained similar—allowing for one-third increments over a three-year period—but the description of performance metrics was streamlined, focusing primarily on ROIC performance against the same peer group, without mention of specific years tied to tranches as seen in 2022. This indicates a simplification or standardization of the performance criteria over time.",
      "llm_answer": "AbbVie’s performance‑vested RSUs were structured the same in 2022 and 2024 – they can vest in three equal, one‑third installments over a three‑year performance period and the award is earned only if AbbVie’s return on invested capital (ROIC) meets a target relative to a defined peer group of pharmaceutical/biotech companies【ABBV_10k_2022.pdf†p.112】【ABBV_10k_2024.pdf†p.89】.  The 2024 filing adds separate performance‑share awards tied to EPS and total‑shareholder‑return metrics, but the vesting schedule and ROIC‑based performance condition for the RSUs themselves have not changed.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies the core structural elements (one-third increments over three-year period, ROIC-based performance metrics against peer group) and accurately cites the 2022 and 2024 filings. However, there are significant issues with completeness and synthesis: (1) The LLM states the vesting structure and ROIC metrics 'have not changed' between 2022 and 2024, which contradicts the ground truth's key finding that there was a 'simplification or standardization' of performance criteria descriptions over time. (2) The ground truth emphasizes that 2022 had specific year-tied tranches mentioned ('awards granted in 2021 and 2020'), while 2024 streamlined this without such specific year references - this evolution is completely missed by the LLM. (3) The LLM introduces information about 'separate performance-share awards tied to EPS and total-shareholder-return metrics' which, while potentially accurate, is not part of the ground truth answer and may conflate different award types. (4) The LLM fails to capture the key insight about the 'simplification or standardization' that occurred between these years - instead claiming no meaningful change. The quantitative elements (one-third increments, three-year period, ROIC metrics, peer group composition) are accurate, but the qualitative analysis of how the structure 'evolved' is fundamentally incomplete and somewhat misleading. The answer addresses the basic question but misses the nuanced evolution that was the core of the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 419,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How did GE's financial relationship with AerCap evolve from 2022 to 2024, based on the realized and unrealized gains or losses associated with its investment?",
      "original_answer": "In 2022, GE reported an unrealized loss of $865 million related to its investment in and note with AerCap, indicating a negative valuation impact during that year. By 2024, this position had shifted to a realized and unrealized gain of $38 million, suggesting that GE had either exited part of its position or the value of the remaining investment had improved. This represents a significant turnaround in the financial performance of the AerCap investment over the two-year period.",
      "llm_answer": "GE’s AerCap investment went from a large loss in 2022 to modest gains in the next two years. The 2022 filing shows an $(865) million realized/unrealized loss on the AerCap note, which turned into a $129 million gain in 2023 and a $38 million gain in 2024, indicating the position moved from a significant loss to a small positive return.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its credibility. CRITICAL ISSUES: (1) The 2022 figure is correct ($865 million unrealized loss), but the LLM incorrectly characterizes it as 'realized/unrealized loss' when the ground truth specifies it as an 'unrealized loss.' (2) The LLM introduces a 2023 gain of $129 million that is NOT mentioned in the ground truth answer. This is a major factual error - the ground truth only references 2022 and 2024 data, making no mention of 2023 results. (3) The 2024 figure of $38 million is correct and matches the ground truth. (4) The LLM's characterization of the 2024 gain as 'realized and unrealized gain' differs from the ground truth's specification of 'realized and unrealized gain of $38 million,' though this is a minor semantic difference. MULTI-HOP REASONING: The LLM attempts to synthesize a three-year trend (2022-2024) but introduces unsupported data for 2023, which breaks the logical chain. The ground truth only compares 2022 to 2024, showing a turnaround from -$865M to +$38M. The LLM's addition of intermediate 2023 data ($129M gain) is fabricated and not supported by the source material. COMPLETENESS: While the LLM addresses the evolution question, it does so with incorrect intermediate data. The core comparison (2022 to 2024) is partially correct in direction but incomplete in scope. The answer would mislead readers about the actual year-by-year progression. STRENGTHS: The LLM correctly identifies the overall trend (loss to gain) and gets the 2022 and 2024 figures mostly right. The narrative structure is clear and logical, even though the underlying data is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1207,
        "completion_tokens": 453,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How has IBM's treatment of the 0.300% Notes due 2026 evolved between the 2022 and 2023 SEC filings, particularly in terms of its disclosure status and visibility in financial instruments?",
      "original_answer": "In 2022, the 0.300% Notes due 2026 were disclosed as part of IBM's exhibits under Exhibit 4 to Form 8-K filed November 1, 2016, indicating it was referenced in the context of legal instruments defining holder rights. By 2023, the 0.300% Notes due 2026 were no longer just referenced in exhibits but were explicitly listed as a titled class of notes registered on the New York Stock Exchange under the trading symbol IBM 26B, showing increased visibility and formal recognition in the company's capital structure.",
      "llm_answer": "In IBM’s 2022 Form 10‑K the 0.300 % Notes due 2026 were not shown in the “Securities registered pursuant to Section 12(b)” table and were only referenced in footnote disclosures, so they were effectively undisclosed as a listed security. By the 2023 Form 10‑K the same IBM 26B notes appear in the Section 12(b) table as a NYSE‑listed security, making the instrument formally registered and visible to investors.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in addressing the core question about IBM's treatment of the 0.300% Notes due 2026 between 2022 and 2023. STRENGTHS: (1) Correctly identifies the note percentage (0.300%) and maturity year (2026); (2) Accurately identifies the ticker symbol IBM 26B; (3) Correctly identifies the exchange (NYSE); (4) Properly synthesizes the multi-hop comparison showing evolution from 2022 to 2023; (5) Accurately characterizes the 2022 status as footnote-only disclosure versus 2023 formal registration in Section 12(b) table; (6) The semantic meaning aligns well with ground truth - both describe increased visibility and formal recognition. MINOR CONSIDERATIONS: (1) The LLM answer uses slightly different framing than ground truth (Section 12(b) table vs. Exhibit 4 to Form 8-K reference), but both are factually accurate descriptions of different disclosure mechanisms; (2) The LLM answer is more specific about the Section 12(b) registration requirement, which is actually more precise than the ground truth's reference to exhibits; (3) The characterization of 2022 status as 'effectively undisclosed' is reasonable given footnote-only treatment, though ground truth notes it was referenced in exhibits. MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years (2022 vs 2023) and identifies the key change in disclosure status and visibility. The logic is sound and the comparison is properly structured. QUANTITATIVE ELEMENTS: All numbers and dates are correct (0.300%, 2026, 2022, 2023). No calculation errors present. The answer demonstrates strong understanding of SEC disclosure requirements and capital structure presentation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 463,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has GE's approach to the RISE Program evolved between 2022 and 2024, particularly in terms of its strategic emphasis and investment focus?",
      "original_answer": "In 2022, GE announced the RISE Program as a collaborative technology development initiative with Safran, targeting a reduction of more than 20% in fuel consumption and CO2 emissions compared to current engines. This marked the initial phase of the program as a forward-looking announcement aimed at shaping the future of sustainable aviation. By 2024, GE's engagement with the RISE Program had evolved into a more concrete investment strategy, with the company making 'significant investments' in the RISE program suite of technologies. This shift indicates a transition from conceptual development to active, funded R&D aimed at enabling a sustainable future of flight. The change reflects a deepening strategic commitment to sustainability and technological leadership in aviation.",
      "llm_answer": "In the 2022 filing GE presented RISE as a newly‑launched joint effort with Safran aimed at “more than 20 % lower fuel consumption and CO₂ emissions” and highlighted early proof‑of‑concept work such as 250 tests of a full‑scale Open‑Fan engine【GE_10k_2022.pdf p.16‑17】. By the 2024 filing the language has shifted to treat RISE as a broader “suite of pioneering technologies” – Open Fan, compact‑core and hybrid‑electric systems for alternative‑fuel compatibility – and the company now stresses “significant investments” in the RISE program as a core pillar of its R&D spend to drive a sustainable‑flight future【GE_10k_2024.pdf p.5‑6】. This reflects a move from an initial development‑testing focus to a strategic, heavily‑funded technology platform.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: All numeric values are correct - the '20% reduction' in fuel consumption and CO2 emissions is accurately cited, and the reference to '250 tests of a full-scale Open-Fan engine' provides additional specific detail from the 2022 filing that enhances credibility. The years (2022 and 2024) are correctly identified. ENTITY ACCURACY: GE and Safran are correctly named; the RISE Program is properly identified; the specific technologies (Open Fan, compact-core, hybrid-electric systems) are accurately listed. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years, correctly identifying the evolution from initial announcement/proof-of-concept phase (2022) to strategic investment phase (2024). The logical progression from 'newly-launched joint effort' with 'early proof-of-concept work' to 'broader suite of pioneering technologies' with 'significant investments' is sound and well-supported. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core message as the ground truth - a transition from conceptual development to active, funded R&D. The phrase 'move from an initial development-testing focus to a strategic, heavily-funded technology platform' captures the essence of the ground truth's 'transition from conceptual development to active, funded R&D.' COMPLETENESS: The answer addresses both the 2022 baseline and 2024 evolution, covering strategic emphasis (from announcement to core pillar) and investment focus (from early testing to significant investments). The inclusion of specific technologies and page references adds credibility. Minor observation: The LLM provides slightly more granular detail than the ground truth (specific technologies, test numbers, page citations) which enhances rather than detracts from accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 513,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has the role and emphasis on asset securitizations within American Express's funding strategy evolved from 2022 to 2023, based on the specific disclosures in the respective 10-K filings?",
      "original_answer": "In 2022, American Express defined asset securitizations in a glossary entry, describing the mechanics of transferring loans to trusts that issue asset-backed securities, and noted that securitized loans and receivables were reported as assets while the securities were reported as liabilities. This definition was part of a broader explanation of financial terminology rather than a strategic focus. By 2023, asset securitizations were explicitly positioned as a core component of the company's funding strategy, listed alongside deposits and unsecured debt as key funding sources. The 2023 filing emphasized the importance of diversity in funding sources, with securitizations playing a role in mitigating disruptions in any single funding channel. This represents a shift from a definitional disclosure in 2022 to a strategic emphasis in 2023.",
      "llm_answer": "In the 2022 Form 10‑K the company only defined “asset securitizations” and listed them among a broad set of funding sources, without describing any active securitization program or its size (see the glossary definition on pages 86‑90). By the 2023 Form 10‑K, American Express elevated securitizations to a core funding pillar, explicitly noting that it “periodically securitizes Card Member loans and receivables,” that asset‑backed securities are included in its $47.9 billion long‑term debt portfolio, and that securitizations are a cost‑effective way to meet liquidity needs (see Funding Strategy and Long‑Term Debt and Asset Securitization Programs on pages 66‑70).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and provides more specific detail than the ground truth. Key strengths: (1) Correctly identifies the evolution from definitional disclosure in 2022 to strategic emphasis in 2023; (2) Accurately cites the $47.9 billion long-term debt portfolio figure including asset-backed securities; (3) Properly references specific page numbers (86-90 for 2022 glossary, 66-70 for 2023 strategic sections); (4) Correctly characterizes 2022 as lacking description of active securitization programs or size; (5) Accurately describes 2023 positioning as a core funding pillar with explicit mention of periodic securitization activities and cost-effectiveness. Minor considerations: The LLM answer is more detailed and specific than the ground truth (providing page numbers and the $47.9B figure), which actually strengthens the response. The semantic meaning aligns perfectly with the ground truth's core finding about the shift from definitional to strategic emphasis. The multi-hop reasoning is sound—correctly synthesizing information about how securitizations were treated differently across the two years. The only minor limitation is that the LLM doesn't explicitly mention 'deposits and unsecured debt' as comparative funding sources alongside securitizations in 2023, though this is a minor omission that doesn't affect the core answer's accuracy. All factual claims are verifiable and correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 396,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2023, particularly in terms of investment returns and operational integration?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was characterized by a minority investment, with AspenTech contributing $656 in sales and a $12 earnings gain, while holding total assets of $14,484. By 2023, Emerson significantly deepened its involvement by acquiring Heritage AspenTech, gaining a 55% ownership stake in the newly formed AspenTech. This acquisition positively impacted gross margins by 0.6 percentage points in 2023 and marked a strategic shift from a passive investment to an active controlling interest, indicating a transformation in the nature of the relationship.",
      "llm_answer": "In 2022 Emerson completed the Heritage AspenTech transaction, contributing its industrial‑software businesses and $6 billion in cash to create a new AspenTech segment in which it owned roughly 55 % and reported $656 million of sales, $12 million of earnings and $14.5 billion of assets; the deal generated a $453 million gain on subordinated interest and a $486 million gain on a business sale. By 2023 the AspenTech business was fully folded into Emerson’s operating model—adding about 3 % to total net sales and lifting gross margin—while the investment returns shifted to a $24 million gain on the Micromine purchase‑price hedge and a reduced $161 million gain on subordinated interest (down from $453 million), alongside $146 million of extra intangibles amortization reflecting integration costs.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains a fundamental chronological error that undermines the entire response. The ground truth clearly states that in 2022, Emerson had a minority investment in AspenTech (with $656M sales, $12M earnings, $14,484M assets), and the Heritage AspenTech acquisition occurred BY 2023 (gaining 55% ownership). However, the LLM answer incorrectly states 'In 2022 Emerson completed the Heritage AspenTech transaction,' placing the acquisition in 2022 rather than 2023. This is a critical error that reverses the timeline of the relationship evolution. QUANTITATIVE ISSUES: (1) The LLM cites $14.5 billion in assets vs. ground truth's $14,484M (approximately $14.5B) - this is acceptable as a rounding variation. (2) The LLM introduces numerous figures not in the ground truth ($6 billion cash, $453M gain, $486M gain, $24M gain on Micromine, $161M gain, $146M intangibles amortization) that cannot be verified against the provided ground truth. (3) The LLM states the deal 'added about 3% to total net sales' and 'lifting gross margin' but the ground truth only mentions a 0.6 percentage point gross margin improvement - the LLM's characterization of 'about 3%' to net sales is not substantiated in the ground truth. STRUCTURAL PROBLEMS: The LLM answer conflates 2022 and 2023 activities, making it impossible to trace the evolution from 2022 to 2023 as requested. The ground truth clearly delineates: 2022 = minority investment status; 2023 = acquisition and integration. The LLM reverses this sequence. MISSING ELEMENTS: The answer fails to properly contrast the 2022 minority investment position with the 2023 controlling interest acquisition, which is the core of the question about relationship evolution. POSITIVE ASPECTS: The LLM does correctly identify the 55% ownership stake and attempts to discuss operational integration and investment returns, showing some understanding of the question's intent. However, the chronological error and introduction of unverified figures significantly compromise accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 550,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of noncontrolling interest accounting and acquisition-related impacts on equity and expenses?",
      "original_answer": "In 2022, Emerson completed the creation of New AspenTech by contributing its industrial software business and $6.0 billion in cash, resulting in a 55% ownership stake. A noncontrolling interest of $5.9 billion was recorded, with a decrease to additional paid-in capital of $550 million. By 2023, the AspenTech acquisition positively impacted gross margins by 0.6 percentage points and contributed to increased SG&A expenses, which rose by $572 million compared to 2022, partly due to the AspenTech transaction and higher stock compensation expenses. This shows that while the initial accounting impact was significant in 2022, by 2023, the focus had shifted to operational integration and financial performance effects.",
      "llm_answer": "In 2022 Emerson treated the AspenTech deal as a classic acquisition: it recorded a $5.9 billion non‑controlling‑interest for the 45 % of AspenTech it did not own, which cut additional paid‑in‑capital by $550 million and produced a one‑time $110 million charge for acquisition‑related costs【EMR_10k_2022.pdf†page=56】. By 2023 the non‑controlling interest remained on the balance sheet, but the acquisition’s impact had moved into ongoing expense items – intangibles amortization rose to about $146 million (primarily AspenTech‑related) and acquisition/divestiture costs fell to $84 million in other deductions【EMR_10k_2023.pdf†page=27】, reflecting the shift from initial acquisition accounting to regular amortization and integration expenses.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IN OWNERSHIP PERCENTAGE AND KEY FIGURES: The LLM states Emerson recorded a noncontrolling interest for the '45% of AspenTech it did not own,' which is INCORRECT. The ground truth clearly states Emerson had a 55% ownership stake, meaning the noncontrolling interest represents 45% - but the LLM's phrasing is backwards and confusing. More critically, the LLM fails to mention the $6.0 billion cash contribution, which is a fundamental component of the 2022 transaction structure. QUANTITATIVE ISSUES: (1) The $5.9 billion noncontrolling interest figure is correct. (2) The $550 million decrease to additional paid-in capital is correct. (3) The $110 million acquisition-related charge is mentioned but not in the ground truth answer. (4) The LLM mentions $146 million in intangibles amortization and $84 million in acquisition/divestiture costs for 2023, but the ground truth emphasizes the $572 million increase in SG&A expenses - a critical omission. (5) The ground truth mentions 0.6 percentage point positive impact on gross margins in 2023, which is completely absent from the LLM answer. MULTI-HOP REASONING: The LLM does attempt to synthesize 2022 vs 2023 impacts and shows understanding of the shift from acquisition accounting to operational integration. However, it misses the key operational metrics (gross margin improvement, SG&A expense increase) that demonstrate the 2023 impact. COMPLETENESS: The answer addresses noncontrolling interest accounting and some acquisition-related impacts but fails to comprehensively cover the equity impacts (missing the $6.0 billion cash contribution context) and significantly underrepresents the 2023 expense impacts. The answer is partially correct on accounting mechanics but incomplete on the full financial relationship evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 488,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has IBM's treatment and disclosure of the 6.22% Debentures due 2027 evolved between the 2022 and 2023 SEC filings?",
      "original_answer": "In 2022, IBM disclosed the 6.22% Debentures due 2027 by referencing the instrument defining the rights of its holders, which was filed as Exhibit 3 to Form 8-K on August 1, 1997. In contrast, the 2023 filing introduces a more structured and visible disclosure by listing the 6.22% Debentures due 2027 with its respective trading symbol (IBM 27) and explicitly identifying it among other registered securities on the New York Stock Exchange. This evolution reflects a shift from a purely historical reference to a more transparent and current market-oriented presentation.",
      "llm_answer": "In the 2022 Form 10‑K IBM only referenced the 6.22 % Debentures due 2027 in the exhibits section, noting that “the instrument defining the rights of the holders of the 6.22 % Debentures due 2027 is Exhibit 3 to Form 8‑K…incorporated by reference.” By the 2023 Form 10‑K the company had moved the disclosure to the securities‑registration table (Section 12(b)), listing the 6.22 % Debentures due 2027 (IBM 27) as a registered security alongside its other notes and debentures. This shows a shift from a simple exhibit reference to an explicit registration‑type disclosure.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing the evolution of IBM's disclosure treatment between 2022 and 2023 filings. STRENGTHS: (1) All numeric values are correct - the 6.22% rate and 2027 maturity date are accurate; (2) The trading symbol 'IBM 27' is correctly identified; (3) The multi-hop synthesis is sound - the answer correctly identifies the shift from exhibit reference (2022) to securities registration table disclosure (2023); (4) The specific Form 8-K date reference (August 1, 1997) from the ground truth is not mentioned, but this is a minor omission since the LLM correctly captures the essence of the 2022 approach as a historical reference; (5) The characterization of the shift as moving from 'simple exhibit reference' to 'explicit registration-type disclosure' accurately reflects the substantive change described in the ground truth. MINOR DIFFERENCES: The LLM uses slightly different terminology ('securities-registration table (Section 12(b))' vs. the ground truth's 'registered securities on the New York Stock Exchange'), but both convey the same substantive point about more transparent, market-oriented presentation. The LLM's reference to 'Section 12(b)' adds helpful specificity about the regulatory framework. COMPLETENESS: The answer addresses all key aspects of the question - the 2022 treatment, the 2023 treatment, and the evolution between them. The reasoning about why this represents a shift toward transparency is implicit and sound. No calculation errors or factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 424,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has UnitedHealth Group's exposure to financial risk through risk-based arrangements with healthcare providers evolved from 2023 to 2024, and what implications does this have on its cost estimation and service delivery responsibilities?",
      "original_answer": "In 2023, UnitedHealth Group assumed economic risk under risk-based arrangements where it was responsible for funding healthcare costs, and it recognized premium revenues based on estimated premiums earned, net of projected rebates. The company also highlighted its involvement in value-based arrangements where it received per-patient-per-month premiums and recognized revenue as services were made available. By 2024, the company's exposure expanded as it noted increased responsibility for unpaid healthcare claims if risk-based providers faced financial difficulties or failed to meet their obligations. Additionally, the 2024 disclosures emphasized greater operational risk tied to providers' ability to manage costs, maintain solvency, and provide necessary data for cost estimation, indicating a broader and more complex financial exposure compared to 2023.",
      "llm_answer": "In the 2023 filing (UNH 10‑K pp. 43‑47) UnitedHealth noted that its risk‑based benefit products “limit our exposure to the risk of increasing medical costs, but expose us to risk related to the adequacy of the financial…resources of the health‑care providers.” The 2024 filing (UNH 10‑K pp. 12‑16) repeats that language and adds that “to the extent a risk‑based health‑care provider organization faces financial difficulties…we may be held responsible for unpaid health‑care claims…for which we have already paid the provider,” highlighting that provider solvency now represents a more explicit liability. Consequently, UnitedHealth must sharpen its medical‑cost estimates and continue to assume service‑delivery responsibilities, because any provider‑financial shortfall can directly affect its cost‑outcome assumptions and obligate it to pay claims.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively synthesizes multi-hop information across 2023 and 2024 filings. STRENGTHS: (1) Correctly identifies the core evolution of UnitedHealth's risk exposure from 2023 to 2024, specifically the shift from general risk acknowledgment to explicit liability for unpaid claims when providers face financial difficulties. (2) Accurately cites specific filing locations (10-K pp. 43-47 for 2023, pp. 12-16 for 2024), demonstrating document-specific knowledge. (3) Properly quotes key language about provider solvency becoming a more explicit liability. (4) Correctly synthesizes the multi-hop reasoning: risk-based arrangements → provider financial risk → UnitedHealth's cost estimation and service delivery obligations. (5) Accurately conveys the semantic meaning that provider solvency risk directly impacts cost-outcome assumptions. MINOR WEAKNESSES: (1) The answer could have been slightly more explicit about the 2023 baseline regarding 'premium revenues based on estimated premiums earned, net of projected rebates' and 'per-patient-per-month premiums' - these revenue recognition details from the ground truth are not explicitly mentioned, though the answer does address the core risk exposure evolution. (2) The phrase 'value-based arrangements' from the ground truth is not explicitly mentioned, though the answer does capture the broader concept of risk-based arrangements. (3) The answer could have been more explicit about the 'increased responsibility for unpaid healthcare claims' as a distinct expansion point, though this is clearly implied. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either the ground truth or LLM answer, so this dimension is not directly testable. The page citations appear reasonable for 10-K filings. MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years and connects provider financial risk to UnitedHealth's operational and cost estimation responsibilities. The logical chain is sound: risk-based arrangements → provider solvency risk → cost estimation and service delivery implications. SEMANTIC EQUIVALENCE: The LLM answer conveys the essential meaning of the ground truth regarding the evolution of financial risk exposure and its implications, with appropriate emphasis on the provider solvency liability shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 637,
        "total_tokens": 2089
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of investment magnitude and strategic involvement?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was primarily financial, as shown by its investment reflected in the Automation Solutions segment, where Emerson reported $362 million invested in AspenTech in 2022. By 2023, the relationship evolved into a strategic partnership following the introduction of a major transaction where Emerson contributed its Industrial Software Business along with approximately $6.0 billion in cash to Heritage AspenTech stockholders, creating 'New AspenTech.' Emerson gained 55% ownership of AspenTech's outstanding shares, marking a significant shift from a minority investment to a controlling stake.",
      "llm_answer": "In 2022 Emerson funded the spin‑out of New AspenTech with roughly $6 billion in cash and the transfer of two of its industrial‑software businesses, receiving a 55 % equity stake in the newly formed company【EMR_10k_2022.pdf p.76‑80】. By 2023 Emerson still held that majority ownership, and the AspenTech acquisition was reflected as a strategic growth driver, adding about 3 % to Emerson’s net sales with no additional cash outlay disclosed【EMR_10k_2023.pdf p.24‑28】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR ERRORS IN TEMPORAL SEQUENCING AND FACTUAL ACCURACY: (1) The LLM fundamentally misplaces the timing of the transaction. The ground truth clearly states that in 2022, Emerson had a $362 million investment in AspenTech, and the major transaction (contributing Industrial Software Business + ~$6.0 billion cash) occurred BY 2023, creating 'New AspenTech.' The LLM incorrectly states this $6 billion transaction happened 'in 2022,' which is factually wrong. (2) The LLM claims Emerson 'funded the spin-out of New AspenTech' in 2022, but the ground truth indicates this was a 2023 development. This is a critical chronological error that undermines the entire answer. (3) The LLM mentions 'transfer of two of its industrial-software businesses' but the ground truth specifies 'Industrial Software Business' (singular concept), not two separate businesses. (4) The LLM correctly identifies the 55% ownership stake and the $6 billion cash contribution amount, but these are associated with the wrong year. (5) The LLM's statement about 'no additional cash outlay disclosed' in 2023 is vague and doesn't clearly convey that the major transaction occurred in 2023, not 2022. (6) The answer fails to properly show the evolution from a $362 million minority investment in 2022 to a controlling 55% stake via the major transaction in 2023. The multi-hop reasoning is broken because the temporal relationship between the two years is inverted. The answer demonstrates a fundamental misunderstanding of when these events occurred, which is critical for answering a question specifically about how the relationship 'evolved between 2022 and 2023.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 448,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How has Adobe Target's role within Adobe's customer journey solutions evolved from fiscal 2022 to fiscal 2023, and what does this evolution indicate about Adobe's strategic direction in AI-driven personalization?",
      "original_answer": "In fiscal 2022, Adobe Target was described as part of a broader set of customer journey solutions, specifically noted alongside Marketo Engage, Adobe Campaign, and Journey Optimizer. It was characterized as a tool for testing, targeting, and personalizing content across channels. By fiscal 2023, Adobe Target was elevated in prominence and described specifically as an 'AI- and machine learning-driven personalization engine' with capabilities for omnichannel personalization and large-scale A/B and multivariate testing through AI-powered automation. This evolution indicates Adobe is placing greater strategic emphasis on AI-driven personalization as a core capability within its customer journey offerings, aligning with its broader push toward AI-powered solutions.",
      "llm_answer": "In fiscal 2022 Adobe Target was presented as a stand‑alone AI‑ and machine‑learning‑driven personalization engine that lets customers test, target and optimize content across channels, chiefly through A/B and multivariate testing at scale (ADBE_10k_2022.pdf p.44). By fiscal 2023 it is positioned inside the broader Customer Journeys suite of Adobe Experience Cloud and is highlighted as leveraging Adobe Sensei and GenAI to deliver real‑time, AI‑driven hyper‑personalized experiences across the entire journey (ADBE_10k_2023.pdf p.16), signalling Adobe’s strategic shift toward embedding advanced (including generative) AI throughout its personalization stack.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IN FACTUAL ACCURACY: The LLM answer fundamentally contradicts the ground truth on the key evolution being measured. Ground truth states that in FY2022, Adobe Target was part of a broader set of customer journey solutions (alongside Marketo Engage, Adobe Campaign, Journey Optimizer) and characterized as a testing/targeting/personalization tool. By FY2023, it was elevated and specifically described as an 'AI- and machine learning-driven personalization engine.' The LLM answer reverses this evolution entirely: it claims FY2022 presented Target as a 'stand-alone AI- and machine-learning-driven personalization engine' and FY2023 positioned it 'inside the broader Customer Journeys suite.' This is backwards from the ground truth. The LLM correctly identifies the strategic direction toward AI-driven personalization and mentions Adobe Sensei and GenAI in FY2023, which aligns with ground truth. However, the core narrative of HOW Target's role evolved is inverted. The LLM also provides specific page citations (p.44 for 2022, p.16 for 2023) which cannot be verified against the ground truth but appear to be fabricated details that support the incorrect narrative. The answer does address the multi-part question structure and attempts to synthesize across fiscal years, but the fundamental factual error about the direction of evolution (from standalone to integrated vs. from integrated to standalone) is a major failure in accuracy. The semantic content about AI emphasis is partially correct but built on an incorrect foundational claim about the evolution itself.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 436,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did Emerson's relationship with AspenTech evolve from 2022 to 2023, particularly in terms of its financial stake and post-acquisition integration activities?",
      "original_answer": "In 2022, Emerson reported a balance of $8,326 million related to AspenTech as part of its acquisitions, indicating a significant financial stake following the acquisition of Heritage AspenTech. By 2023, the relationship had evolved into a more integrated structure, with AspenTech operating as a separate publicly traded company under Emerson's acquisition framework. This included the continuation of AspenTech's stock-based compensation plans, such as stock options and restricted stock units, which were now aligned with AspenTech's own equity structure. Additionally, Emerson was actively managing performance stock units tied to predefined goals like annual contract value and free cash flows, showing a shift from a purely financial stake to a more operationally integrated and incentive-driven relationship.",
      "llm_answer": "In 2022 Emerson completed its purchase of Heritage AspenTech, giving it a sizable equity interest in AspenTech that was reflected by $8.3 billion of goodwill for the AspenTech segment and a $240 million revolving loan facility to the company. In 2023 Emerson moved the relationship into the integration phase, converting Heritage AspenTech’s pre‑combination stock options and restricted‑stock units into AspenTech equivalents, allocating their fair‑value between pre‑ and post‑combination service periods, and recognizing $82 million of post‑combination AspenTech‑related stock‑based compensation expense.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides accurate and relevant information about Emerson's relationship with AspenTech from 2022 to 2023, with mostly correct financial figures and good multi-hop synthesis. STRENGTHS: (1) Correctly identifies the $8.3 billion goodwill figure (matches ground truth's $8,326 million with acceptable rounding), (2) Accurately describes the 2022 acquisition of Heritage AspenTech, (3) Properly explains the 2023 integration phase including conversion of stock options and RSUs, (4) Provides specific quantitative detail ($82 million post-combination stock-based compensation expense) not in ground truth but contextually relevant, (5) Good multi-hop synthesis connecting financial stake to operational integration. WEAKNESSES: (1) Introduces the $240 million revolving loan facility detail not mentioned in ground truth - while potentially accurate from filings, it's not part of the ground truth answer and adds information not requested, (2) Slightly less emphasis on the performance stock units and incentive-driven relationship aspects mentioned in ground truth, (3) The answer focuses more on technical accounting treatment (fair-value allocation between service periods) rather than the broader relationship evolution described in ground truth. QUANTITATIVE VERIFICATION: $8.3B goodwill ≈ $8,326M (correct with acceptable rounding), $82M stock-based compensation expense is specific and appears accurate. The 2022-2023 timeline is correct. MULTI-HOP REASONING: Successfully synthesizes information about how the relationship evolved from acquisition to integration, connecting financial metrics to operational changes. The reasoning is sound and logical. SEMANTIC EQUIVALENCE: The answer conveys similar information to ground truth but with different emphasis - more technical/accounting-focused versus more strategic/operational-focused. Both are valid interpretations of the relationship evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 518,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How has Adobe Experience Platform's role within Adobe's customer journey solutions evolved from 2022 to 2023, particularly in terms of its integration with AI-powered tools and cross-channel campaign orchestration?",
      "original_answer": "In 2022, Adobe Experience Platform was described as the foundational infrastructure for Adobe Experience Cloud, enabling data standardization and integration with Adobe Sensei to provide AI-powered services such as automated insights, sentiment analysis, and enhanced anomaly detection. It was central to Adobe's differentiation, supporting applications like Adobe Analytics and Adobe Audience Manager. By 2023, Adobe Experience Platform's role had evolved to become the underlying engine for cross-channel campaign orchestration, particularly through its integration with Adobe Journey Optimizer. This app allowed brands to deliver personalized, connected customer journeys across any channel, using real-time data profiles and cloud-native scalability. Additionally, Adobe Mix Modeler, introduced in 2023 and powered by Adobe Sensei, leveraged cross-channel datasets in Adobe Experience Platform to provide machine learning-driven insights for optimizing marketing investments. This indicates a shift from a general AI-enhanced infrastructure role to a more specialized and actionable function in campaign planning and customer journey orchestration.",
      "llm_answer": "In the 2022 filing Adobe Experience Platform was presented mainly as the data‑standardization layer that underpins the Experience Cloud, feeding Adobe Sensei‑powered analytics and allowing data to flow across Adobe’s solutions (2022 pp. 9‑10). By the 2023 filing the platform had been elevated to a real‑time engine that not only delivers AI‑driven insights across all Experience Cloud apps but also powers cross‑channel campaign orchestration—through Journey Optimizer built on AEP—and embeds deeper domain‑specific AI services from Sensei to activate those insights throughout the customer‑journey suite (2023 pp. 13‑15).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing the evolution of Adobe Experience Platform from 2022 to 2023. STRENGTHS: (1) Correctly identifies the 2022 role as a data-standardization layer underpinning Experience Cloud with Adobe Sensei integration; (2) Accurately describes the 2023 evolution toward real-time campaign orchestration and cross-channel capabilities; (3) Properly identifies Journey Optimizer as built on AEP and its role in personalized customer journeys; (4) Correctly references Adobe Sensei's role in both years; (5) Appropriately characterizes the shift from general infrastructure to specialized actionable function. MINOR GAPS: (1) The LLM answer does not explicitly mention Adobe Mix Modeler, which the ground truth identifies as a key 2023 addition powered by Adobe Sensei that leverages cross-channel datasets in AEP for machine learning-driven marketing optimization insights. This is a notable omission as Mix Modeler represents an important evolution in the platform's capabilities; (2) The LLM answer does not specifically mention Adobe Analytics and Adobe Audience Manager as applications supported by AEP in 2022, though this is a minor contextual detail; (3) The LLM answer does not explicitly reference real-time data profiles, though it does mention 'real-time engine.' QUANTITATIVE ACCURACY: No numerical errors detected. Page references (2022 pp. 9-10, 2023 pp. 13-15) are cited but cannot be independently verified from the ground truth. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and multiple product integrations (AEP, Journey Optimizer, Sensei), demonstrating sound multi-hop reasoning. The characterization of the evolution from infrastructure to actionable function is logically sound and well-supported. SEMANTIC EQUIVALENCE: The answer conveys the essential information from the ground truth with appropriate wording variations. The omission of Adobe Mix Modeler prevents this from being a 9-10 score, as it represents a material evolution in the platform's 2023 capabilities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1460,
        "completion_tokens": 557,
        "total_tokens": 2018
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did UnitedHealth Group's approach to care delivery models evolve from 2023 to 2024 in response to Medicare Advantage funding pressures?",
      "original_answer": "In 2023, UnitedHealth Group emphasized accelerating the transition to value-based care delivery models, investing in clinical engagement, integrated care coordination technology, and new delivery channels like in-home and virtual care. The company viewed these innovations as key to future growth despite initial costs. However, by 2024, the company faced significant funding pressures in the Medicare Advantage program, including reduced benchmarks and risk adjustment changes, which led to operational adjustments. These included selective changes to provider networks, benefit structures, and county-level decisions about plan offerings, indicating a shift from expansion-focused investment to cost containment and strategic retrenchment in response to external financial constraints.",
      "llm_answer": "In 2023 UnitedHealth warned that Medicare Advantage funding pressure was driving higher care utilization and responded by intensifying medical‑ and operating‑cost management, engaging physicians and members with information, and expanding integrated delivery channels—including in‑clinic, in‑home, behavioral and virtual care—as part of a broader shift toward fully accountable, value‑based care. By 2024 the company embedded those actions in its benefit‑design strategy, tightening provider‑network composition, adjusting member benefits and premiums, and accelerating the rollout of data‑driven, value‑based delivery models across the same in‑clinic, home, behavioral and virtual settings to offset the continued funding shortfall.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution from 2023 to 2024 with appropriate context for each year; (2) Accurately captures the 2023 focus on value-based care investments including in-home, virtual, behavioral, and in-clinic care channels; (3) Properly synthesizes the shift in 2024 toward cost containment and strategic adjustments including provider network changes, benefit structure modifications, and premium adjustments; (4) Correctly identifies the underlying driver (Medicare Advantage funding pressures) and its impact on strategy; (5) No quantitative errors or incorrect dates/entities; (6) Multi-hop reasoning is sound, connecting funding pressures to specific operational responses across both years. MINOR CONSIDERATIONS: (1) The LLM answer adds slightly more operational detail (\"tightening provider-network composition,\" \"adjusting member benefits and premiums,\" \"data-driven\" models) that goes beyond the ground truth but remains consistent with it and adds helpful specificity; (2) The phrasing \"embedded those actions in its benefit-design strategy\" is a reasonable interpretation of the shift from expansion to cost containment, though the ground truth uses the term \"strategic retrenchment\" which carries slightly different connotation; (3) The answer could have been more explicit about the shift from \"expansion-focused investment\" to \"cost containment,\" though this distinction is implied in the narrative. VERIFICATION: All key facts check out—2023 investments in value-based care channels are correct, 2024 adjustments to networks and benefits are correct, the causal link to Medicare Advantage funding pressures is accurate. The answer successfully synthesizes information across the two-year period and demonstrates understanding of how external constraints drove strategic pivots.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 522,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 157,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 1.950% Notes due 2029?",
      "original_answer": "In 2022, the 1.950% Notes due 2029 were listed among TMO's outstanding debt instruments with the trading symbol TMO 29. In 2023, the 1.950% Notes due 2029 remained present with the same trading symbol TMO 29, indicating continuity in this debt instrument. However, TMO introduced new debt instruments in 2023, such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, suggesting a broader shift in financing strategy. The continued presence of the 1.950% Notes due 2029 indicates no change in this specific liability, even as TMO expanded its debt portfolio.",
      "llm_answer": "Between the 2022 and 2023 Form 10‑K, Thermo Fisher’s debt roster grew to include two new senior‑note series – a 3.200 % issue due 2026 (TMO 26B) and a 3.650 % issue due 2034 (TMO 34) – while all of the prior series remained. The 1.950 % notes due 2029 (TMO 29) appear in both filings, showing that this instrument’s presence in the capital‑structure was unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about TMO's debt composition evolution. STRENGTHS: (1) All numeric values are correct - the 1.950% Notes due 2029 (TMO 29), 3.200% Notes due 2026 (TMO 26B), and 3.650% Notes due 2034 (TMO 34) are all accurately cited with correct percentages and maturity dates. (2) The trading symbols are correctly identified (TMO 29, TMO 26B, TMO 34). (3) The multi-hop synthesis is sound - the answer correctly identifies that the 1.950% Notes remained unchanged between 2022 and 2023 while new instruments were introduced. (4) The reasoning about 'continuity' and 'expanded debt portfolio' accurately reflects the ground truth's characterization of the situation. (5) The answer properly addresses both the specific instrument (1.950% Notes) and the broader context of TMO's financing strategy evolution. MINOR CONSIDERATIONS: The LLM uses slightly different phrasing ('capital-structure' vs 'debt portfolio') but this is semantically equivalent and actually more precise. The answer is well-structured and directly answers the question without extraneous information. The only reason this is not a perfect 10 is that the ground truth explicitly mentions the trading symbol 'TMO 29' for the 1.950% Notes in both years, while the LLM only mentions it once in parentheses - though this is a very minor omission that doesn't affect the core accuracy of the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 401,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 159,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 0.500% Notes due 2028 and the introduction of new note categories?",
      "original_answer": "In 2022, TMO listed the 0.500% Notes due 2028 alongside other debt instruments, including the 1.375% Notes due 2028. By 2023, TMO continued to list the 0.500% Notes due 2028, but introduced new debt categories such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, while maintaining similar categories like the 1.375% Notes due 2028. This indicates a strategic shift toward diversifying TMO's debt portfolio with new interest rate structures and maturity timelines.",
      "llm_answer": "The 0.500 % Notes due 2028 (ticker TMO 28A) appear in both the 2022 and 2023 registrants’ tables, showing that this low‑coupon issue was retained unchanged【TMO_10k_2022.pdf†1】【TMO_10k_2023.pdf†1】.  The 2023 filing, however, adds two new series that were not listed in 2022—a 3.200 % Notes due 2026 (TMO 26B) and a 3.650 % Notes due 2034 (TMO 34)—indicating an expansion of the debt mix with higher‑coupon, longer‑dated instruments【TMO_10k_2023.pdf†1】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about TMO's debt composition evolution. STRENGTHS: (1) All numeric values are correct - 0.500% Notes due 2028, 3.200% Notes due 2026, and 3.650% Notes due 2034 are accurately cited with correct percentages and maturity dates. (2) The temporal comparison is accurate - correctly identifies that the 0.500% Notes appeared in both 2022 and 2023, while the 3.200% and 3.650% notes were new additions in 2023. (3) The multi-hop synthesis is sound - successfully combines information from both 2022 and 2023 filings to show the evolution of debt composition. (4) The characterization of the strategic shift is appropriate - correctly identifies this as an expansion with higher-coupon, longer-dated instruments. (5) The answer also mentions the 1.375% Notes due 2028 was maintained (implied in ground truth as 'similar categories'). MINOR CONSIDERATIONS: (1) The LLM answer uses ticker notation (TMO 28A, TMO 26B, TMO 34) which adds helpful specificity beyond the ground truth but is not contradictory. (2) The ground truth explicitly mentions the 1.375% Notes due 2028 as being maintained, while the LLM answer focuses primarily on the new additions and the retained 0.500% Notes. However, the LLM does acknowledge 'similar categories' were maintained, which is semantically equivalent. (3) The characterization of the shift as 'expansion' vs. 'diversification' is semantically equivalent and both capture the strategic intent. The answer fully addresses all parts of the question with accurate financial data and sound reasoning across multiple filing years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 452,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 160,
      "question": "How has the range of excess fair value over carrying value for DHR's reporting units changed between the 2023 and 2024 annual goodwill impairment analyses?",
      "original_answer": "In 2023, the excess of the estimated fair value over carrying value for DHR's reporting units ranged from approximately 140% to 495%. In 2024, this range decreased to between approximately 70% and 450%. This indicates a reduction in the lowest excess fair value percentage, suggesting a decline in the overall cushion before potential impairment.",
      "llm_answer": "The 2023 goodwill‑impairment test showed that each reporting unit’s fair value exceeded its carrying amount by roughly **140 % – 495 %** (and, after a 10 % fair‑value reduction, by **115 % – 435 %**)【2023 10‑K, pp. 55‑56】. In the 2024 test the excess narrowed to about **70 % – 450 %** (or **55 % – 395 %** under the same 10 % sensitivity)【2024 10‑K, pp. 51‑52】. Thus, the range shifted lower and became tighter, with the low‑end falling about 70 points and the high‑end about 45 points.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All key numeric values are correct: 2023 range of 140%-495%, 2024 range of 70%-450%. The answer correctly identifies the directional change (range shifted lower and tighter). The LLM goes beyond the ground truth by providing additional sensitivity analysis data (the 10% fair-value reduction scenarios: 115%-435% for 2023 and 55%-395% for 2024), which adds valuable context without contradicting the original answer. The calculation of the change is accurate: low-end fell approximately 70 percentage points (140% to 70%), high-end fell approximately 45 percentage points (495% to 450%). The multi-hop synthesis is sound—correctly comparing DHR's reporting units across two fiscal years and properly characterizing the implications (reduced cushion before impairment). The citation format with page references enhances credibility. The only minor distinction from the ground truth is that the LLM provides more detailed information (sensitivity scenarios) rather than just the base case, but this is additive rather than contradictory. The semantic meaning is fully preserved and the reasoning is logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 331,
        "total_tokens": 1541
      },
      "error": null
    },
    {
      "question_id": 161,
      "question": "How did the treatment of canceled RSUs and tax-withheld shares under the 2022 Employee Stock Plan evolve from 2022 to 2023 in terms of their impact on the available share pool?",
      "original_answer": "In 2022, the 2022 Employee Stock Plan specified that canceled RSUs and shares withheld to satisfy tax withholding obligations would increase the number of shares available for grant under the plan by a factor of two times the number of RSUs canceled or shares withheld. However, in 2023, this specific language regarding the factor of two times for RSUs canceled or shares withheld was omitted, indicating a change in how these events were accounted for in the share pool calculation.",
      "llm_answer": "In the 2022 filing the 2022 Employee Stock Plan explicitly said that “RSUs canceled and shares withheld to satisfy tax‑withholding obligations increase the number of shares available for grant … by a factor of two times the number of RSUs canceled or shares withheld” (i.e., a two‑for‑one addition to the share pool)【AAPL_10k_2022.pdf p.49】. By the 2023 filing, the plan’s description no longer contains that language – it only notes the vesting schedule, dividend‑equivalent rights and the 1.3 billion authorized shares, omitting the two‑for‑one increase for cancellations or tax‑withheld shares【AAPL_10k_2023.pdf p.45】. This reflects a change in disclosure, with the explicit two‑for‑one treatment removed in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-supported. Strengths: (1) Correctly identifies the key factual change - the 2022 plan explicitly stated a 'two times' (two-for-one) factor for canceled RSUs and tax-withheld shares, while 2023 omitted this language. (2) Accurately characterizes this as a change in disclosure/treatment between the two years. (3) Properly cites the specific documents and page numbers (AAPL_10k_2022.pdf p.49 and AAPL_10k_2023.pdf p.45), demonstrating multi-hop synthesis across two years of filings. (4) The quantitative claim about the 'two times' factor is correct and matches the ground truth. (5) The reasoning is sound - the answer correctly identifies that the explicit two-for-one treatment language was removed in 2023. Minor consideration: The answer could have been slightly more explicit about what 'omitted' means in practical terms (i.e., whether this represents a substantive change in plan mechanics or merely a change in disclosure), but the core factual content is accurate. The semantic equivalence is strong - the LLM's phrasing 'two-for-one addition to the share pool' and 'two times the number' both correctly convey the same mathematical relationship stated in the ground truth. No calculation errors or factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 360,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 162,
      "question": "How has Danaher's strategic relationship with Aldevron evolved between 2023 and 2024, particularly in terms of its financial stake and integration into Danaher's business segments?",
      "original_answer": "In 2023, Danaher had a significant financial stake in Aldevron, as evidenced by the $9,561 million in net cash consideration allocated to Aldevron in the acquisition table, indicating a direct ownership interest. By 2024, Aldevron was no longer listed as a separately accounted stake but had been integrated into the Life Sciences segment as part of Danaher's broader portfolio of acquisitions, including Beckman Coulter, Pall, and IDT. This reflects a strategic shift from holding a standalone stake to full operational integration, aligning Aldevron's capabilities in biopharma research and manufacturing with Danaher’s broader life sciences offerings.",
      "llm_answer": "In the 2023 Form 10‑K Danaher reported that it had completed the cash acquisition of Aldevron in August 2021 for about $9.6 billion and that Aldevron was already incorporated into the Company’s Life Sciences segment 【DHR_10k_2023.pdf p. 73】. The 2024 Form 10‑K still lists Aldevron among the brands acquired for the Life Sciences segment—now specifically under the Genomic Medicines business—showing that Danaher continues to hold 100 % ownership while further embedding Aldevron’s capabilities within the segment 【DHR_10k_2024.pdf p. 6】.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the acquisition price of approximately $9.6 billion (matching the ground truth's $9,561 million), the August 2021 acquisition date, and that Aldevron is integrated into the Life Sciences segment. (2) The numeric values and dates are accurate. (3) The answer correctly notes 100% ownership and continued integration. WEAKNESSES: (1) The LLM answer fundamentally misinterprets the question's temporal scope. The question asks about evolution 'between 2023 and 2024,' implying a comparison of how the relationship changed from 2023 to 2024. The ground truth indicates that in 2023 Aldevron was listed as a separately accounted stake with $9,561 million allocated, but by 2024 it was no longer separately listed and had been fully integrated. (2) The LLM answer states that in 2023 Aldevron 'was already incorporated into the Company's Life Sciences segment,' which contradicts the ground truth's implication that there was a transition from separate accounting to integration between these years. (3) The LLM fails to capture the key evolution: the shift from 'holding a standalone stake' (2023) to 'full operational integration' (2024) with removal from separate accounting. (4) The answer adds detail about 'Genomic Medicines business' in 2024 that wasn't in the ground truth, though this isn't necessarily incorrect. (5) The multi-hop reasoning is incomplete—the answer doesn't adequately synthesize the year-over-year change in how Aldevron was reported and accounted for. The answer reads more as a static description of Aldevron's status rather than an evolution narrative. CALCULATION/VERIFICATION: The $9.6 billion figure is correct (ground truth shows $9,561 million). The August 2021 date is correct. The 100% ownership claim is reasonable but not explicitly verified against ground truth. MULTI-HOP SYNTHESIS: The answer fails to properly synthesize the 2023 vs. 2024 comparison that is central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 529,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 163,
      "question": "How has Microsoft's strategic positioning of Microsoft 365 evolved between 2023 and 2024, particularly in terms of its integration with AI technologies and its role in the company's commercial business metrics?",
      "original_answer": "In 2023, Microsoft 365 was described as an 'AI first' platform integrating Office, Windows, Copilot, and Enterprise Mobility + Security, with Copilot for Microsoft 365 combining AI with business data to enhance productivity. By 2024, Microsoft had expanded the Microsoft 365 Consumer subscribers metric to include Microsoft 365 Basic subscribers, aligning with internal business management practices and signaling a broader consumer focus. This evolution reflects a strategic shift toward enhancing AI integration and expanding the product's market reach, particularly within the commercial segment.",
      "llm_answer": "In the 2023 filing Microsoft described Microsoft 365 as a core productivity‑and‑collaboration subscription service within its Productivity and Business Processes segment, emphasizing its contribution to Office Commercial and Consumer growth (e.g., “including Microsoft 365…”)【MSFT_10k_2023.pdf: p. 4】. By the 2024 filing the company re‑branded Microsoft 365 as an “AI‑first platform” that embeds Copilot and AI across Office, Windows and security services (“Microsoft 365 is an AI first platform…”, “Copilot for Microsoft 365 combines AI…”) and elevated it to a key commercial metric, noting a 14% rise in Office Commercial revenue and 82.5 million Microsoft 365 Consumer subscribers (now including Basic and Copilot Pro)【MSFT_10k_2024.pdf: p. 39‑41】.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Microsoft 365's evolution between 2023 and 2024, with mostly accurate information and good multi-hop synthesis. STRENGTHS: (1) Correctly identifies the shift from 2023 positioning as a 'core productivity-and-collaboration subscription service' to 2024 positioning as an 'AI-first platform'; (2) Accurately captures the integration of Copilot and AI across Office, Windows, and security services; (3) Correctly notes the expansion of Microsoft 365 Consumer subscribers metric to include Basic and Copilot Pro subscribers; (4) Provides specific quantitative data (14% Office Commercial revenue rise, 82.5 million Microsoft 365 Consumer subscribers); (5) Good multi-hop synthesis connecting strategic positioning to commercial business metrics. WEAKNESSES/CONCERNS: (1) The specific numbers cited (14% rise, 82.5 million subscribers) cannot be fully verified against the ground truth provided, which does not include these specific metrics; (2) The ground truth emphasizes the metric expansion to 'include Microsoft 365 Basic subscribers' while the LLM answer adds 'Copilot Pro' - this addition is not explicitly mentioned in the ground truth and may represent inference beyond the source material; (3) Minor: The ground truth emphasizes 'signaling a broader consumer focus' while the LLM answer frames it as 'elevated it to a key commercial metric' - these are slightly different framings, though not contradictory; (4) The LLM answer provides more granular detail than the ground truth but some of these details (specific percentages, subscriber counts) lack explicit verification in the provided ground truth. MULTI-HOP REASONING: The answer successfully synthesizes information across 2023 and 2024 filings and connects strategic positioning to business metrics, which is appropriate for the question. SEMANTIC EQUIVALENCE: The core message aligns well with the ground truth regarding the evolution toward AI-first positioning and expanded consumer metrics. The answer is contextually relevant and addresses all parts of the multi-part question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 563,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has Microsoft's positioning and emphasis on Copilot Pro evolved between 2023 and 2024, particularly in terms of its role within Microsoft 365 apps and web-based AI assistance?",
      "original_answer": "In 2023, Copilot Pro was introduced as a consumer subscription service that offered 'faster and more powerful AI assistance in Microsoft 365 apps and on the web.' By 2024, while the core definition remained consistent, the emphasis on Copilot Pro's differentiation and innovation appeared more pronounced, with language such as 'faster and more powerful AI assistance' retained but now embedded within a broader narrative of AI-driven transformation across Microsoft's ecosystem. This suggests a strategic evolution where Copilot Pro is not only a standalone offering but increasingly integrated into the broader AI-first positioning of Microsoft's productivity suite.",
      "llm_answer": "In the 2023 filing Microsoft introduced Copilot Pro simply as a consumer‑subscription service that adds AI assistance to Microsoft 365 applications. By the 2024 filing the company stresses that Copilot Pro now delivers “faster and more powerful” AI help not only inside the Microsoft 365 suite but also across the web, signaling a broader, performance‑focused role for the service【MSFT_10k_2023, p.5】【MSFT_10k_2024, p.5】.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key factual elements but has significant gaps in addressing the full scope of the question. STRENGTHS: (1) Correctly identifies that Copilot Pro was introduced in 2023 as a consumer subscription service; (2) Accurately notes the 'faster and more powerful' language appears in both 2023 and 2024 filings; (3) Correctly identifies the expansion from Microsoft 365 apps to web-based assistance; (4) Provides appropriate source citations. WEAKNESSES: (1) The answer is overly simplistic and misses the core insight from the ground truth - that by 2024, Copilot Pro's positioning evolved to be 'increasingly integrated into the broader AI-first positioning of Microsoft's productivity suite' rather than just a standalone offering; (2) Fails to capture the 'broader narrative of AI-driven transformation across Microsoft's ecosystem' that represents the strategic evolution; (3) The characterization of 2024 emphasis as merely 'performance-focused' is reductive and doesn't reflect the deeper strategic positioning shift described in the ground truth; (4) Doesn't adequately synthesize how Copilot Pro's role evolved from a simple add-on to a more central component of Microsoft's AI strategy; (5) Missing the nuance that the core definition remained consistent while the strategic context and emphasis changed significantly. MULTI-HOP REASONING: The answer demonstrates basic synthesis across 2023 and 2024 filings but fails to capture the qualitative evolution in positioning and strategic emphasis that the question specifically asks about. The answer treats this as a feature expansion (web-based addition) rather than a strategic repositioning within Microsoft's broader AI ecosystem. SEMANTIC EQUIVALENCE: While the factual statements are largely accurate, the answer misses the essential insight about strategic evolution and integration into a broader AI-first narrative, which is central to answering the question about how positioning 'evolved.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 533,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has the structure and availability of the 2007 Omnibus Incentive Plan evolved between 2023 and 2024, particularly in terms of remaining shares available for issuance?",
      "original_answer": "In 2023, the 2007 Omnibus Incentive Plan was described in the context of PSU and RSU awards, vesting conditions, and valuation methods, but no specific figure was provided regarding the remaining shares available for issuance. In contrast, by 2024, the plan explicitly stated that approximately 47 million shares of Danaher common stock remained available for issuance under the plan as of December 31, 2024 (excluding shares underlying outstanding awards). This indicates a more transparent disclosure and potential depletion or tracking of the share pool since the plan's inception, showing a shift in how the company communicates the availability of shares under the plan.",
      "llm_answer": "The 2007 Omnibus Incentive Plan continued to be the Company’s umbrella equity‑compensation vehicle, authorizing roughly 135 million shares for options, stock‑appreciation rights, RSUs, restricted stock, PSUs and cash awards in both years. However, the pool of shares still available for new grants fell from about 50 million shares at 12/31/2023 to roughly 47 million shares at 12/31/2024, reflecting a reduction of roughly 3 million shares as awards were issued during 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides additional context about the 2007 Omnibus Incentive Plan's total authorization (135 million shares) and attempts to quantify the year-over-year change in available shares. However, there are significant quantitative discrepancies that undermine the answer's reliability:\n\n(1) QUANTITATIVE ACCURACY ISSUES:\n- The LLM states approximately 50 million shares were available at 12/31/2023, but the ground truth explicitly states 'no specific figure was provided regarding the remaining shares available for issuance' in 2023. This is a critical factual error - the LLM introduced a number (50 million) that was not disclosed in the 2023 filing.\n- The 2024 figure of 47 million shares aligns with the ground truth, which is correct.\n- The calculated reduction of 3 million shares (50M - 47M = 3M) is mathematically consistent with the LLM's stated figures, but the 2023 baseline is unverified and likely incorrect.\n\n(2) COMPLETENESS:\n- The LLM answer addresses the evolution between 2023 and 2024 as requested.\n- However, it fails to acknowledge the key distinction highlighted in the ground truth: that 2023 lacked specific disclosure while 2024 provided explicit figures.\n- The LLM adds information about the 135 million total authorization, which provides useful context but wasn't explicitly requested.\n\n(3) ENTITY ACCURACY:\n- Correctly identifies the 2007 Omnibus Incentive Plan and Danaher.\n- Correctly identifies the years 2023 and 2024.\n- Correctly identifies the types of awards (options, SARs, RSUs, restricted stock, PSUs, cash awards).\n\n(4) REASONING AND MULTI-HOP SYNTHESIS:\n- The multi-hop reasoning is sound in structure (comparing 2023 to 2024, calculating the difference).\n- However, the reasoning is built on an unsubstantiated 2023 figure, which undermines the entire analysis.\n- The ground truth emphasizes a shift in disclosure transparency, which the LLM answer does not capture.\n\n(5) SEMANTIC EQUIVALENCE:\n- The LLM's characterization of the plan as an 'umbrella equity-compensation vehicle' is semantically equivalent to the ground truth's description.\n- However, the core finding differs: the ground truth emphasizes lack of 2023 disclosure and improved 2024 transparency, while the LLM presents both years as having comparable disclosure levels.\n\nThe primary weakness is the introduction of an unverified 50 million share figure for 2023, which contradicts the ground truth's explicit statement that no specific figure was provided in 2023. This is a material factual error that significantly impacts the credibility of the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 689,
        "total_tokens": 1982
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did Microsoft's accounting policy regarding the estimated useful lives of server and network equipment evolve between fiscal years 2023 and 2024, and what factors influenced this change?",
      "original_answer": "In fiscal year 2023, Microsoft increased the estimated useful lives of server and network equipment from four years to six years, effective beginning fiscal year 2023. This change was driven by investments in software that improved operational efficiencies and advances in technology. In fiscal year 2024, the policy remained consistent with the updated six-year estimate, indicating that the initial change was sustained and likely integrated into ongoing asset management practices. The continued focus on cloud and AI infrastructure investments further supported the rationale behind extending the useful lives of these assets.",
      "llm_answer": "Microsoft revised its depreciation policy in July 2022, and the change took effect at the start of fiscal 2023 – extending the estimated useful lives of server and network equipment from four years to six years. The extension was driven by software investments that made operating the equipment more efficient and by broader advances in technology, and the same six‑year estimate remained in place for fiscal 2024.【MSFT_10k_2023.pdf p.38‑42】【MSFT_10k_2024.pdf p.38‑42】",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-synthesized. Key strengths: (1) Correctly identifies the policy change from 4-year to 6-year useful lives for server and network equipment; (2) Accurately dates the revision to July 2022 with effective date at start of fiscal 2023; (3) Properly identifies the driving factors: software investments improving operational efficiency and advances in technology; (4) Correctly confirms the policy remained consistent at 6 years for fiscal 2024; (5) Successfully synthesizes information across two fiscal years (2023 and 2024) as required by the multi-hop question. Minor observation: The LLM answer is slightly more specific than the ground truth by mentioning the July 2022 revision date, which adds precision without contradicting the ground truth. The answer addresses all parts of the question: the evolution of the policy (change in FY2023, consistency in FY2024) and the factors influencing the change (software investments and technology advances). The citation format and page references demonstrate proper sourcing. No calculation errors or factual inaccuracies detected. The semantic meaning aligns perfectly with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 334,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did MDT's exposure to auction rate securities evolve from 2022 to 2023 in terms of fair value and classification within the balance sheet?",
      "original_answer": "In 2022, MDT reported auction rate securities with a fair value of $33 million and classified them under 'Total' in the investment portfolio without specifying a separate balance sheet classification. By 2023, the fair value of auction rate securities remained at $33 million, but they were explicitly classified under 'Other Assets' instead of being included in the broader investment category. This indicates a shift in how MDT categorized these securities on its balance sheet, moving from a general investment classification to a more distinct reporting under other assets.",
      "llm_answer": "In FY 2022 (as of April 29, 2022) Medtronic’s auction‑rate securities were valued at $33 million and were shown on the balance sheet under “Other assets” (they were not classified as investments)【MDT_10k_2022.pdf p. 70‑71】. The same $33 million fair‑value amount appeared in FY 2023 (as of April 28, 2023) and the securities remained classified as “Other assets,” indicating no change in either the fair‑value exposure or its balance‑sheet presentation【MDT_10k_2023.pdf p. 70‑71】.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERROR IN CORE CLAIM: The LLM answer directly contradicts the ground truth on the primary finding. The ground truth explicitly states that auction rate securities were classified under 'Total' in the investment portfolio in 2022 WITHOUT specifying a separate balance sheet classification, and then moved to 'Other Assets' in 2023. The LLM answer claims the opposite: that they were classified as 'Other assets' in 2022 and remained there in 2023 with 'no change.' This is a fundamental factual error that undermines the entire answer. The question specifically asks about the EVOLUTION/CHANGE from 2022 to 2023, and the ground truth identifies a shift in classification. The LLM answer incorrectly states there was no change in balance sheet presentation. While the LLM correctly identifies the $33 million fair value for both years (quantitative accuracy is good), the classification narrative is inverted. The LLM also provides specific page references (p. 70-71) which adds false confidence to an incorrect answer. The semantic meaning of the answer is opposite to the ground truth - the ground truth emphasizes a shift in classification methodology, while the LLM emphasizes stability/no change. This is a multi-hop reasoning failure where the model failed to correctly synthesize the classification evolution across the two fiscal years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 376,
        "total_tokens": 1639
      },
      "error": null
    },
    {
      "question_id": 167,
      "question": "How did the net gains or losses from Cisco's available-for-sale debt investments change between fiscal years 2023 and 2024, and what does this indicate about the company's investment performance in this category?",
      "original_answer": "In fiscal year 2023, Cisco reported a net loss of $21 million from its available-for-sale debt investments, while in fiscal year 2024, this loss increased to $67 million. This indicates a significant worsening in investment performance related to this category year-over-year.",
      "llm_answer": "Cisco’s net result on its available‑for‑sale debt investments moved from a $21 million loss in fiscal 2023 to a $67 million loss in fiscal 2024 – a $46 million increase in the loss (the “Other Income (Loss), Net” table shows $ (21) M for 2023 and $ (67) M for 2024). The larger loss indicates that the portfolio’s fair‑value declined more sharply in 2024, suggesting weaker investment performance in this category, likely due to higher market interest rates and lower prices for the debt securities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative data is correct: FY2023 loss of $21 million, FY2024 loss of $67 million, and the calculated $46 million increase in losses. The answer correctly identifies the fiscal years and the financial metric (available-for-sale debt investments). The multi-hop synthesis is sound - the model properly compared the two years and calculated the year-over-year change. The answer goes beyond the ground truth by providing additional context about the likely causes (higher market interest rates and lower debt security prices), which demonstrates strong financial reasoning and adds valuable insight without introducing any factual errors. The citation of the 'Other Income (Loss), Net' table shows proper sourcing. The only minor distinction from the ground truth is the additional explanatory detail about market conditions, which enhances rather than detracts from the answer. The semantic meaning is fully aligned with the original answer - both convey that investment performance worsened significantly from 2023 to 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 310,
        "total_tokens": 1520
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How did Cisco's approach to the APJC region evolve between 2023 and 2024 in terms of operational structure versus financial investment, and what implications does this have for its revenue model in that region?",
      "original_answer": "In 2023, Cisco directly operated in the APJC region as one of its three geographic segments, indicating a strong operational presence focused on delivering products and services. By 2024, Cisco's relationship with APJC evolved to include financial investments, specifically through equity instruments categorized as marketable equity securities, non-marketable equity securities, and equity method investments. While the 2023 filing emphasized operational delivery and customer engagement in APJC, the 2024 financial statements suggest a parallel strategy of capital participation, potentially signaling a shift toward leveraging local market growth through investment rather than solely through direct sales. This dual approach could indicate a broader revenue model incorporating both operational income and investment returns, though the filings do not quantify the specific financial impact of these investments on Cisco's APJC revenue.",
      "llm_answer": "In the 2023 filing Cisco presented APJC simply as one of three geographic operating segments, emphasizing its organizational structure and sales coverage rather than any specific capital outlay (see CSCO_10k_2023.pdf p. 1‑2). By the 2024 filing the company highlighted a shift to a financial‑investment approach—announcing increased capital spending and a targeted push to expand subscription‑based services and AI‑focused infrastructure in APJC—thereby moving the region’s revenue mix from a product‑sale‑heavy model toward a higher proportion of recurring subscription and services revenue (see CSCO_10k_2024.pdf p. 64‑66).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and unsupported claims that diverge substantially from the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM cites specific page numbers (CSCO_10k_2023.pdf p. 1-2 and CSCO_10k_2024.pdf p. 64-66) without verification, and these citations appear to be fabricated or inaccurate. More critically, the LLM claims 'increased capital spending' and provides specific details about 'subscription-based services and AI-focused infrastructure' expansion in APJC, but the ground truth explicitly states 'the filings do not quantify the specific financial impact of these investments on Cisco's APJC revenue.' The LLM has invented quantitative claims not present in the source material. (2) FACTUAL INACCURACY: The ground truth identifies the 2024 evolution as involving 'equity instruments categorized as marketable equity securities, non-marketable equity securities, and equity method investments'—a specific investment structure. The LLM instead claims a shift toward 'subscription-based services and AI-focused infrastructure,' which is a different narrative entirely and not supported by the ground truth. (3) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the actual evolution described in the ground truth: from direct operations (2023) to financial investments through equity instruments (2024). Instead, it created a parallel narrative about capital spending and subscription services that contradicts the ground truth's emphasis on equity investments. (4) UNSUPPORTED CLAIMS: The LLM asserts a shift in 'revenue mix from product-sale-heavy model toward higher proportion of recurring subscription and services revenue' without any basis in the ground truth, which makes no such claim. (5) CONTEXTUAL MISALIGNMENT: While the LLM addresses the evolution question, it fundamentally mischaracterizes the nature of that evolution, replacing investment-focused strategy with operational/service expansion claims. The answer demonstrates hallucination of specific details and page references rather than accurate synthesis of available information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 569,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How has Apple's approach to App Store commissions and regulatory compliance evolved between 2022 and 2024, particularly in response to legal and market pressures?",
      "original_answer": "In 2022, Apple acknowledged that changes to the App Store, including those in response to legal and market conditions, could reduce the volume of sales and the commission it earns on those sales, potentially affecting its financial condition. By 2024, Apple had implemented specific changes, particularly in the U.S. and the European Union, to address legal pressures such as the Digital Markets Act (DMA). These changes included new business terms, alternative fee structures, alternative app distribution methods, and additional developer tools and APIs. These adjustments reflect a shift from a more general acknowledgment of potential changes to concrete actions taken in response to regulatory demands, which could significantly affect App Store revenue and commission structures.",
      "llm_answer": "In the 2022 Form 10‑K Apple said it kept a commission on app‑store sales and in‑app purchases, but warned that ongoing litigation and the pending EU Digital Markets Act could force it to lower or reshape that commission and that it was only beginning to adjust how developers communicate with consumers (AAPL_10k_2022.pdf pp. 11‑15). By the 2024 filing Apple reported that it had already rolled out new fee structures—including a reduced‑rate program for qualifying developers—and alternative payment‑processing and distribution tools to meet the DMA and other regulatory demands, moving from a “could require changes” stance to concrete, lower‑commission and compliance measures (AAPL_10k_2024.pdf pp. 11‑15).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and effectively addresses the multi-hop question about Apple's App Store commission evolution between 2022 and 2024. STRENGTHS: (1) Correctly identifies the 2022 stance as cautionary/forward-looking regarding potential changes due to litigation and pending EU DMA; (2) Accurately characterizes the 2024 position as implementing concrete changes including reduced-rate programs and alternative distribution methods; (3) Properly synthesizes the progression from 'could require changes' to actual implementation; (4) Correctly names the Digital Markets Act (DMA) as a key regulatory driver; (5) Appropriately references both U.S. and regulatory compliance contexts; (6) Cites specific document sources with page ranges, adding credibility. MINOR CONSIDERATIONS: (1) The answer doesn't explicitly mention 'U.S. and European Union' as distinct jurisdictions where changes were implemented, though it does reference the DMA (EU-specific); the ground truth specifically notes 'particularly in the U.S. and the European Union'; (2) The phrase 'alternative payment-processing and distribution tools' is accurate but slightly more specific than the ground truth's 'alternative fee structures, alternative app distribution methods, and additional developer tools and APIs'—this is a reasonable interpretation rather than an error; (3) No specific financial impact numbers are provided, though the question doesn't explicitly require them. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are claimed, so this dimension is not directly testable; the temporal references (2022, 2024) are correct. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years and connects regulatory pressures to specific business changes, demonstrating sound multi-hop reasoning. The logical progression from acknowledgment to implementation is clearly articulated. SEMANTIC EQUIVALENCE: The answer conveys the same essential information as the ground truth while using slightly different phrasing, which is appropriate and acceptable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 566,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 175,
      "question": "How did the allocation strategy for Texas Instruments' U.S. Retiree Health Care Plan evolve between fixed income securities and equity securities from 2022 to 2024?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had a diversified mix of fixed income securities and equity securities, with fixed income and cash equivalents totaling $248 million and equity securities at $137 million. By 2024, the allocation strategy showed a significant shift toward a more conservative posture, with fixed income securities and cash equivalents comprising 80% of the portfolio, while equity securities made up only 20%. This reflects a notable increase in emphasis on fixed income securities compared to equities, even though the relative proportions remained the same between 2023 and 2024, suggesting a strategic decision to prioritize capital preservation.",
      "llm_answer": "In the 2022 filing TI’s U.S. Retiree Health Care Plan was guided by a target mix of **65 %‑80 % fixed‑income securities and cash equivalents and 20 %‑35 % equity securities**【source: target‑allocation table in 2022 10‑K】. By the 2024 filing the target range had moved to **75 %‑85 % fixed‑income and 15 %‑25 % equity**, and the plan’s actual portfolio at year‑end 2024 was about **80 % fixed‑income and 20 % equity**【source: target‑allocation table in 2024 10‑K; weighted‑average allocation table 2024】. This reflects a clear shift toward a higher proportion of fixed‑income assets and a lower proportion of equities over the 2022‑2024 period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides target allocation ranges and 2024 actual allocations, but diverges significantly from the ground truth in several critical ways: (1) MISSING KEY DATA: The ground truth explicitly states 2022 actual allocations ($248M fixed income, $137M equity), which the LLM completely omits. These specific dollar amounts are important for understanding the actual portfolio composition in 2022. (2) DIFFERENT FOCUS: The LLM emphasizes target allocation ranges (65-80% fixed income in 2022, 75-85% in 2024) rather than actual allocations. While target ranges are relevant context, the ground truth focuses on actual portfolio allocations. (3) QUANTITATIVE DISCREPANCY: The ground truth states fixed income was $248M and equity was $137M in 2022. The ratio is approximately 64.4% fixed income and 35.6% equity ($248/$385 and $137/$385). The LLM's 2022 target range of 65-80% fixed income aligns with this actual allocation, but the LLM doesn't explicitly connect these numbers. (4) CONSISTENCY CHECK: The ground truth notes that 2023 and 2024 proportions remained the same (80% fixed income, 20% equity), suggesting stability in actual allocations. The LLM correctly identifies the 2024 actual allocation as 80% fixed income and 20% equity. (5) INTERPRETATION: The ground truth emphasizes the evolution from 2022 actual allocations to 2024 actual allocations, highlighting a shift toward more conservative positioning. The LLM provides target ranges which show directional movement but doesn't clearly articulate the actual portfolio evolution. The LLM answer is partially correct in identifying the 2024 allocations and the general trend toward fixed income, but it fails to include the specific 2022 dollar amounts and actual allocations that are central to answering how the strategy 'evolved.' The answer would be stronger if it included both the 2022 actual figures ($248M fixed income, $137M equity) and clearly compared them to 2024 actuals (80% fixed income, 20% equity).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 536,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How has Texas Instruments' strategic emphasis on Embedded Processing Products evolved from 2022 to 2024, particularly in terms of its contribution to the company's competitive advantages and segment reporting structure?",
      "original_answer": "In 2022, Texas Instruments described Embedded Processing as one of its core product lines within a broader business model that emphasized four competitive advantages: manufacturing and technology strength, a broad product portfolio, strong market channels, and product diversity and longevity. Embedded Processing was positioned as part of this integrated strategy but was not highlighted as a standalone reportable segment. By 2024, Embedded Processing was elevated to a reportable segment alongside Analog, indicating a strategic shift where the company explicitly called out Embedded Processing as a key driver of value. This change suggests that Embedded Processing has become more central to TI's competitive positioning, particularly in terms of enabling optimized performance, power, and cost across a range of customer applications. The elevation to a reportable segment also implies greater operational and financial focus, aligning with the company’s long-term objective of strengthening its competitive advantages and driving free cash flow growth.",
      "llm_answer": "In the 2022 filing TI’s strategy explicitly positioned its broad portfolio of analog and embedded‑processing products as one of four sustainable competitive advantages and reported Embedded Processing as a distinct segment that was delivering strong growth and high margins (TXN_10k_2022.pdf, pp. 18‑21). By the 2024 filing the company still treats Embedded Processing as a separate reportable segment—maintaining the same two‑segment structure—but its contribution has slipped, with revenue falling from $3.261 billion in 2022 to $2.533 billion in 2024 and operating profit dropping from $1.253 billion to $352 million, reflecting a reduced yet still strategic role within the same competitive‑advantage framework (TXN_10k_2024.pdf, pp. 28‑32).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual error that contradicts the ground truth. The ground truth explicitly states that in 2022, Embedded Processing was NOT a standalone reportable segment, but rather was part of a broader business model with four competitive advantages. By 2024, Embedded Processing WAS elevated to a reportable segment. The LLM answer reverses this timeline, claiming that in 2022 Embedded Processing was 'reported as a distinct segment' and that by 2024 'the company still treats Embedded Processing as a separate reportable segment—maintaining the same two-segment structure.' This is factually incorrect. The LLM has mischaracterized the strategic evolution entirely. Additionally, the specific financial figures provided ($3.261 billion in 2022 revenue, $1.253 billion in 2022 operating profit, $2.533 billion in 2024 revenue, $352 million in 2024 operating profit) cannot be verified against the ground truth and appear to be fabricated or incorrectly sourced, as the ground truth does not provide these specific numbers for Embedded Processing as a reportable segment in 2022 (since it wasn't a reportable segment then). The LLM also cites specific page numbers (pp. 18-21 for 2022, pp. 28-32 for 2024) that cannot be verified. The core narrative about the evolution of strategic emphasis is inverted from the actual ground truth. The answer does address the multi-part question structure but does so with fundamentally incorrect information about the timing and nature of the segment reporting change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 429,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How did TMO's issuance and valuation of its 2.00% 10-Year Senior Notes evolve between 2022 and 2024?",
      "original_answer": "In 2022, TMO reported $1,200 million in 2.00% 10-Year Senior Notes due on October 15, 2031, with an effective interest rate of 2.23%. By 2024, the same category of 2.00% 10-Year Senior Notes showed no change in the principal amount at $1,200 million, and the effective interest rate remained at 2.23%. This indicates that TMO maintained a consistent position on this specific debt instrument over the two-year period, with no new issuances or repayments affecting this line item.",
      "llm_answer": "In the 2022 Form 10‑K Thermo Fisher listed a single tranche of 2.00 % 10‑year senior notes – euro‑denominated, due 4 May 2025 – with a par‑value balance of **$728 million** and an effective interest rate of **≈2.10 %**【2022 p.90】.  \nBy the 2024 Form 10‑K the company’s 2.00 % 10‑year senior notes had expanded to a **$1.2 billion** issuance (due 15 Oct 2031) with an effective interest rate of **≈2.23 %**, showing a **$472 million increase in principal** and a modest rise in the effective rate while the notes remain recorded essentially at par【2024 p.45】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth on multiple critical dimensions: (1) WRONG DEBT INSTRUMENTS: The LLM describes a euro-denominated note due May 4, 2025 with $728M principal in 2022, which is a completely different debt instrument than the ground truth's 2.00% 10-Year Senior Notes due October 15, 2031. The ground truth explicitly states the same instrument ($1,200M at 2.23% effective rate) appears in both 2022 and 2024. (2) INCORRECT PRINCIPAL AMOUNTS: LLM claims $728M in 2022 and $1.2B in 2024, calculating a $472M increase. The ground truth shows $1,200M in both years with NO change. (3) WRONG EFFECTIVE INTEREST RATES: LLM states ≈2.10% for 2022 and ≈2.23% for 2024, implying a rate increase. Ground truth shows 2.23% in both years - no change. (4) MISIDENTIFIED DEBT INSTRUMENTS: The LLM appears to have confused different debt tranches. The ground truth specifically identifies the instrument as 'due on October 15, 2031' while LLM's 2022 reference is 'due 4 May 2025' - these are different securities entirely. (5) FLAWED MULTI-HOP SYNTHESIS: The LLM failed to correctly synthesize information across the 2022 and 2024 filings, instead describing two different debt instruments as if they were the same evolving position. (6) CONTRADICTS GROUND TRUTH CONCLUSION: Ground truth states 'no new issuances or repayments affecting this line item' and 'consistent position,' while LLM claims a $472M increase. The LLM answer demonstrates fundamental misreading of the source documents and provides entirely incorrect financial data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 433,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 178,
      "question": "How has the financial performance of REMICADE evolved between 2022 and 2024, and what does this indicate about its role in Johnson & Johnson's Pharmaceutical segment?",
      "original_answer": "In 2022, REMICADE was listed as a key product in Johnson & Johnson's Pharmaceutical segment, specifically within the Immunology therapeutic area, indicating its importance in treating immune-mediated inflammatory diseases. By 2024, REMICADE's sales had declined significantly, from $1,839 million in 2023 to $1,605 million in 2024, representing a 12.8% decrease. This decline suggests a diminishing contribution of REMICADE to the company's Immunology revenue, potentially due to market saturation, increased competition, or the emergence of newer biologics within the segment.",
      "llm_answer": "REMICADE’s sales fell from roughly **$2.0 billion in fiscal 2022** (JNJ_10k_2022.pdf p. 9) to **$1.6 billion in fiscal 2024** (JNJ_10k_2024.pdf p. 31), a decline of about **$400 million (≈20 %)**. The 2024 filing notes that the drop was driven by “continued biosimilar competition” (JNJ_10k_2024.pdf p. 30), indicating that while REMICADE remains a core immunology drug, its share of Johnson & Johnson’s Pharmaceutical segment is shrinking as other products (e.g., STELARA, TREMFYA) maintain or grow their contribution.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains significant factual inaccuracies that undermine its credibility. (1) INCORRECT 2022 FIGURE: The LLM states REMICADE sales were 'roughly $2.0 billion in fiscal 2022,' but the ground truth does not provide a 2022 figure. The ground truth only mentions 2023 ($1,839M) and 2024 ($1,605M) data. The LLM appears to have fabricated or misinterpreted the 2022 number. (2) INCORRECT PERCENTAGE CALCULATION: The LLM calculates the decline as 'about $400 million (≈20%)' based on its incorrect $2.0B starting point. However, using the ground truth data (2023: $1,839M to 2024: $1,605M), the actual decline is $234M or 12.8%, which matches the ground truth. The LLM's calculation is mathematically consistent with its stated figures but based on wrong premises. (3) CORRECT 2024 FIGURE: The $1.6 billion (or $1,605M) for 2024 is accurate. (4) MULTI-HOP REASONING: The LLM correctly identifies biosimilar competition as a driver and mentions other products (STELARA, TREMFYA), showing reasonable synthesis. However, this contextual accuracy cannot compensate for the fundamental numerical errors. (5) MISSING GROUND TRUTH DATA: The ground truth explicitly states the 2023-2024 decline was 12.8%, but the LLM provides a different (and incorrect) 20% figure based on non-existent 2022 data. The LLM also fails to mention the 2023 intermediate data point ($1,839M) that the ground truth includes. VERDICT: While the LLM demonstrates understanding of the business context and provides reasonable qualitative analysis, the quantitative foundation is severely compromised by incorrect baseline figures and resulting miscalculations. This is a case where the model appears to have hallucinated or misread source data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 478,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 179,
      "question": "How did the sales performance of REMICADE evolve from 2022 to 2024, and what does this indicate about its market position within JNJ's Immunology portfolio?",
      "original_answer": "In 2022, REMICADE had sales of $3,190 million, showing a decline of 14.9% compared to 2020. By 2024, its sales had further decreased to $1,605 million, representing a 12.8% drop from 2023. This consistent decline indicates a weakening market position of REMICADE within JNJ's Immunology portfolio over time.",
      "llm_answer": "REMICADE’s sales fell sharply – from roughly $2.5 billion in fiscal 2022 (JNJ_10k_2022.pdf p. 30) to $1.84 billion in 2023 and $1.61 billion in 2024 (JNJ_10k_2024.pdf p. 30‑31). The continued decline, driven by biosimilar competition, shows that REMICADE is losing market share and has become a diminishing contributor to J&J’s Immunology franchise, while growth is now led by other products such as STELARA and TREMFYA.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "MAJOR QUANTITATIVE ERRORS: The LLM answer contains significant factual inaccuracies in the core financial data. Ground truth states REMICADE 2022 sales were $3,190 million, but LLM claims 'roughly $2.5 billion' - this is a $690 million understatement (21.6% error). For 2023, ground truth implies $1,835 million (calculated from 12.8% decline from 2024's $1,605M), but LLM states $1.84 billion, which is approximately correct. For 2024, LLM states $1.61 billion, which matches ground truth of $1,605 million. The 2022 figure is critically wrong and undermines the entire analysis. MISSING KEY METRICS: The LLM answer fails to include the specific decline percentages mentioned in ground truth (14.9% decline 2020-2022, 12.8% decline 2023-2024), which are important for demonstrating the severity of REMICADE's market position deterioration. QUALITATIVE REASONING: The LLM correctly identifies biosimilar competition as a driver and appropriately contextualizes REMICADE as a diminishing contributor within the Immunology portfolio. The mention of competing products (STELARA, TREMFYA) adds relevant context not in ground truth but is appropriate for market positioning analysis. MULTI-HOP SYNTHESIS: The answer does synthesize information across years and connects sales performance to market position, but the foundational data error (2022 figure) compromises the entire analysis. The reasoning about market share loss and competitive dynamics is sound, but built on incorrect numbers. ENTITY ACCURACY: All entities (REMICADE, JNJ, Immunology portfolio) are correctly identified. The answer appropriately addresses both parts of the question (sales evolution AND market position implications), but the quantitative foundation is severely flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1184,
        "completion_tokens": 475,
        "total_tokens": 1659
      },
      "error": null
    },
    {
      "question_id": 180,
      "question": "How has the sales performance of REMICADE evolved between 2021 and 2024, and what factors contributed to this change?",
      "original_answer": "REMICADE's sales declined significantly from $16.8 billion in 2021 (as part of total Immunology sales) to $1,605 million in 2024, reflecting a 12.8% decrease from 2023 to 2024 alone. This decline was primarily driven by biosimilar competition in the U.S. and other global markets, which intensified over time and led to a continued reduction in REMICADE sales.",
      "llm_answer": "REMICADE generated $3.19 billion in 2021 but fell to $1.61 billion in 2024 – a decline of roughly 50 percent. The 2021 filing already noted that “lower sales of REMICADE … were due to biosimilar competition,” and the 2024 filing again attributes the further drop to “continued biosimilar competition” eroding its market share.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a fundamental factual error regarding the 2021 REMICADE sales figure. The LLM states '$3.19 billion in 2021' but the ground truth clearly indicates '$16.8 billion in 2021.' This is a massive discrepancy (off by a factor of ~5.3x) that undermines the entire answer. The 2024 figure of $1.61 billion (vs. ground truth $1,605 million) is essentially correct (minor formatting difference). CALCULATION ERROR: The LLM calculates a '50 percent' decline from $3.19B to $1.61B, which would be mathematically correct for those numbers (~49.5%), but since the 2021 baseline is wrong, the percentage decline is also incorrect. The ground truth shows a decline from $16.8B to $1.605B, which represents approximately a 90.4% decline, not 50%. PARTIAL CREDIT FOR QUALITATIVE FACTORS: The LLM correctly identifies biosimilar competition as the primary driver of REMICADE's sales decline and appropriately cites both 2021 and 2024 filings to support this explanation. The reasoning about multi-hop synthesis (connecting sales performance to competitive factors across years) is sound in structure. COMPLETENESS: The answer addresses both parts of the question (sales evolution and contributing factors), but the incorrect baseline number severely compromises the accuracy of the sales performance narrative. The 12.8% year-over-year decline from 2023 to 2024 mentioned in the ground truth is not captured. CONCLUSION: While the LLM demonstrates understanding of the biosimilar competition narrative and attempts multi-hop reasoning, the incorrect 2021 sales figure is a critical factual error that makes the quantitative analysis fundamentally unreliable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1164,
        "completion_tokens": 464,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 181,
      "question": "How did the status and commercial performance of STELARA (ustekinumab) evolve between 2022 and 2024?",
      "original_answer": "In 2022, STELARA was in the filing stage for the treatment of pediatric patients with juvenile psoriatic arthritis in the U.S., indicating it was under regulatory review but not yet approved. By 2024, STELARA had achieved significant commercial success, generating $10,361 million in sales, a decrease from $10,858 million in 2023, representing a 4.6% decline in total sales. This reflects that STELARA had transitioned from a product in active regulatory development to a mature, high-revenue-generating drug facing slight sales decline, suggesting market saturation or increased competition.",
      "llm_answer": "In the 2022 Form 10‑K, STELARA (ustekinumab) was still protected by a U.S. patent that would not expire until September 2023 and was a key growth driver for immunology, generating $9.1 bn of worldwide sales in 2021 (about $5.9 bn in the United States) and supported by a pediatric‑indication filing in the U.S. [JNJ_10k_2022.pdf:30‑34]. By the 2024 Form 10‑K, after the patent expiry, STELARA’s sales had slipped to $10.36 bn globally (U.S. $6.7 bn), a 4.6 % year‑over‑year decline, as European biosimilar entrants eroded share and multiple biosimilar BLAs were filed in the United States, with the company expecting further biosimilar launches in 2025 [JNJ_10k_2024.pdf:29‑33].",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer provides substantially correct information with strong multi-hop synthesis across 2022 and 2024 filings, but contains some quantitative discrepancies and adds information not in the ground truth. STRENGTHS: (1) Correctly identifies STELARA's transition from regulatory development (pediatric filing in 2022) to mature commercial product by 2024; (2) Accurately captures the 4.6% year-over-year sales decline; (3) Correctly identifies patent expiration (September 2023) as a key inflection point; (4) Properly synthesizes biosimilar competition as the driver of sales decline; (5) Provides relevant context about European biosimilar entrants and U.S. BLA filings. QUANTITATIVE ISSUES: (1) LLM states 2021 sales of $9.1 bn, but ground truth references 2023 sales of $10,858 million and 2024 sales of $10,361 million - the 2021 figure is not in the ground truth and appears to be additional information from the source documents; (2) LLM provides U.S.-specific breakdowns ($5.9 bn in 2021, $6.7 bn in 2024) not mentioned in ground truth; (3) The 2024 figure of $10.36 bn matches the ground truth's $10,361 million (proper format conversion); (4) The 4.6% decline is correctly calculated and matches ground truth. COMPLETENESS: The LLM answer goes beyond the ground truth by providing 2021 baseline data and U.S./global splits, which adds useful context but wasn't explicitly required. The core evolution narrative (filing stage in 2022 → mature product with biosimilar pressure in 2024) is well-captured. REASONING: Multi-hop synthesis is sound - correctly links patent expiration to biosimilar competition to sales decline. The causal chain is logical and well-explained. MINOR CONCERNS: The inclusion of 2021 data (not in ground truth) and specific U.S. sales figures suggests the LLM may be drawing from source documents beyond what the ground truth captured, though these additions appear factually consistent with the narrative. The answer is more detailed than the ground truth but not contradictory.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 543,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 182,
      "question": "How did the total net revenue from Restasis in the United States change between 2023 and 2024, and what was the percentage decrease in each year?",
      "original_answer": "In 2023, the United States net revenue from Restasis was $382 million, which decreased to $172 million in 2024. This represents a 38.5% decrease in 2023 compared to 2022, and a further 55.2% decrease in 2024 compared to 2023.",
      "llm_answer": "The United States net revenue for Restasis fell from **$382 million in 2023 to $172 million in 2024**, a drop of $210 million. The decline represented a **55.2 % decrease in 2024** (vs. 2023) and the 2023 figure itself was **38.5 % lower than 2022**【ABBV_10k_2024.pdf†L...】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All numeric values are correct: $382 million (2023), $172 million (2024), and the $210 million decrease. Both percentage decreases are accurate: 55.2% decrease from 2023 to 2024, and 38.5% decrease from 2022 to 2023. The calculation of the dollar difference ($382M - $172M = $210M) is correct. The answer successfully synthesizes multi-hop information by comparing across three years (2022, 2023, 2024) and providing both absolute and percentage changes. The entity identification is correct (Restasis, United States revenue). The presentation is clear and well-organized, presenting the information in a logical sequence. The only minor distinction from the ground truth is the ordering of information presentation (LLM presents 2024 decrease first, then 2023 decrease, while ground truth presents 2023 decrease first), but this is a stylistic choice that does not affect accuracy. The LLM correctly attributes the source to ABBV_10k_2024.pdf, which is appropriate for this data. All factual content matches the ground truth exactly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1124,
        "completion_tokens": 311,
        "total_tokens": 1435
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role and strategic importance of Master Lease Agreements evolved between 2022 and 2023 in supporting AMT's international growth and tenant relationships?",
      "original_answer": "In 2022, AMT emphasized that master lease agreements were comprehensive in nature and instrumental in building strong strategic partnerships with tenants, significantly reducing colocation cycle times and enabling rapid deployment of equipment across its international portfolio of approximately 177,000 communications sites. By 2023, AMT reiterated the importance of these agreements in providing consistent, long-term revenue and reducing non-contractual churn, while operating an expanded international portfolio of approximately 182,000 communications sites. The evolution reflects a continued strategic focus on leveraging master lease agreements to support international growth and tenant retention, with an emphasis on mitigating risks such as customer consolidation and regulatory changes.",
      "llm_answer": "In the 2022 Form 10‑K, AMT introduced master lease agreements as a way to lock‑in consistent, long‑term revenue, curb non‑contractual churn and “build and augment strong strategic partnerships” with tenants as part of its international‑expansion push (2022 p. 34‑35). By the 2023 filing, the company stresses that those same master leases have become a core pillar of its strategy—still delivering steady revenue and low churn, but now explicitly described as essential for sustaining international growth, accelerating equipment deployment and deepening tenant relationships, underscoring their evolution from a new strategic tool to an entrenched, critical growth driver (2023 p. 36‑37).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution of master lease agreements' strategic importance between 2022 and 2023, capturing the shift from a new strategic tool to an entrenched growth driver. The qualitative reasoning about building partnerships, reducing churn, and supporting international growth is sound and semantically aligned with the ground truth. The answer appropriately synthesizes information across both years and identifies key themes like tenant relationships and revenue consistency.\n\nWEAKNESSES - QUANTITATIVE: The LLM answer fails to include critical quantitative data points that are explicitly mentioned in the ground truth: (1) the international portfolio size of approximately 177,000 communications sites in 2022, and (2) the expanded portfolio of approximately 182,000 communications sites in 2023. These specific numbers are factual anchors that demonstrate the scale of international growth and are essential to a complete answer about how AMT's international portfolio evolved. The omission of these metrics represents a significant gap in quantitative accuracy.\n\nWEAKNESSES - CITATION ISSUES: The LLM provides specific page references (2022 p. 34-35, 2023 p. 36-37) that cannot be verified against the ground truth source material. While these citations may be accurate, they are presented with confidence without confirmation, which is problematic for a financial document evaluation context where precision is critical.\n\nWEAKNESSES - COMPLETENESS: While the answer addresses the evolution question well qualitatively, it incompletely addresses the multi-hop synthesis requirement by omitting the quantitative dimension of international growth (the site count expansion from 177,000 to 182,000). The ground truth explicitly connects this portfolio expansion to the strategic importance of master lease agreements.\n\nMULTI-HOP REASONING: The answer demonstrates adequate multi-hop reasoning in connecting 2022 and 2023 strategic positioning, but fails to fully synthesize the relationship between portfolio expansion and master lease agreement importance.\n\nSCORE JUSTIFICATION: The answer receives a 6/10 because while it captures the qualitative evolution correctly and demonstrates sound reasoning about strategic importance, it omits critical quantitative data (site counts) that are integral to answering a question about international growth support. The semantic content is largely correct, but the incompleteness on measurable metrics prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 670,
        "total_tokens": 2047
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role of Google Marketing Platform in the company's advertising revenue generation evolved between 2023 and 2024, particularly in relation to how advertising revenues are recognized and managed across Google Network properties?",
      "original_answer": "In 2023, Google Marketing Platform was directly involved in the recognition of advertising revenues on a gross basis for Google Network properties, meaning the full amount billed to customers was recorded as revenue. By 2024, the platform's role evolved to include a more nuanced evaluation of its principal versus agent status, with an emphasis on its control over advertising inventory before transfer to customers, further supporting the gross revenue reporting. Additionally, 2024 introduced a more detailed explanation of the platform's role in managing advertising across Google Network properties, highlighting its central function in both performance and brand advertising delivery.",
      "llm_answer": "The 2023 and 2024 filings both describe Google Marketing Platform as one of the primary tools (alongside Google Ads, Google Ad Manager and Google Display & Video 360) that advertisers use to buy inventory across Search, YouTube and Google Network properties. The company’s accounting for those ads has not changed – it continues to record Google Network ad revenue on a gross‑basis (billing customers as revenue and treating partner payments as cost of revenue) and to recognize performance ads when a user engages and brand ads when the ad is displayed or viewed. Thus, the platform’s role in generating advertising revenue and the way network‑property revenues are recognized and managed remained essentially unchanged from 2023 to 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR DISCREPANCY: The LLM answer directly contradicts the ground truth on the core claim about evolution. Ground truth states that Google Marketing Platform's role EVOLVED between 2023 and 2024, with 2024 introducing 'a more nuanced evaluation of its principal versus agent status' and 'more detailed explanation of the platform's role.' The LLM answer explicitly claims the platform's role 'remained essentially unchanged from 2023 to 2024,' which is factually incorrect according to the ground truth. This is a fundamental misunderstanding of the question's premise about evolution/change. CORRECT ELEMENTS: The LLM correctly identifies the tools (Google Ads, Google Ad Manager, Google Display & Video 360) and correctly describes the gross-basis revenue recognition approach and performance/brand ad recognition timing. The numeric/quantitative aspects are accurate. INCORRECT ELEMENTS: The LLM fails to recognize or articulate the evolution in how the platform's principal versus agent status was evaluated, and misses the 2024 enhancement in explaining the platform's role in managing advertising across Google Network properties. The answer suggests no meaningful change occurred when the ground truth explicitly documents an evolution in how the platform's role was characterized and evaluated. This represents a critical failure in multi-hop reasoning - the model needed to synthesize how the platform's role description and accounting treatment evolved, but instead concluded there was no evolution. The answer is internally consistent and well-written, but fundamentally incorrect on the key claim.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 441,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did the volume and fair value of Federal Funds Purchased & Sec Loaned change between 2023 and 2024, and what does this indicate about BAC's short-term funding strategies?",
      "original_answer": "In 2023, the volume of Federal Funds Purchased & Sec Loaned showed a net change of $16,466 million, indicating a significant increase in short-term funding liabilities. By 2024, the fair value of this category was reported at $192,859 million, a substantial increase from the prior year. This suggests that BAC significantly expanded its reliance on short-term secured funding mechanisms in 2024, likely to support its trading and liquidity management activities.",
      "llm_answer": "The average balance of Federal Funds Purchased and securities loaned fell sharply – from $301 billion at year‑end 2023 to roughly $214 billion at year‑end 2024 – and the fair‑value of that liability dropped from $192.9 billion in 2023 to $178.6 billion in 2024【BAC_10k_2023.pdf:33‑37】【BAC_10k_2024.pdf:153‑157】.  The simultaneous decline in both volume and valuation signals that Bank America reduced its reliance on short‑term wholesale funding, shifting toward more stable deposit‑based and longer‑term funding sources.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer is fundamentally contradictory to the ground truth and contains major factual inaccuracies: (1) DIRECTIONAL ERROR: Ground truth states fair value INCREASED from prior year to $192,859M in 2024, indicating EXPANDED reliance on short-term funding. LLM claims fair value DECREASED from $192.9B in 2023 to $178.6B in 2024 - this is the opposite direction. (2) QUANTITATIVE MISMATCH: Ground truth cites 2024 fair value of $192,859 million ($192.859B). LLM reports $178.6B for 2024, which contradicts the ground truth figure. (3) VOLUME DISCREPANCY: Ground truth mentions 2023 net change of $16,466M. LLM reports average balance of $301B at year-end 2023 and $214B at year-end 2024 - these appear to be different metrics (average vs. period-end) and don't align with ground truth's reported figures. (4) INTERPRETATION REVERSAL: Ground truth indicates BAC EXPANDED short-term secured funding reliance in 2024. LLM concludes BAC REDUCED reliance and shifted to stable deposits - the exact opposite conclusion. (5) MULTI-HOP SYNTHESIS FAILURE: The LLM failed to correctly synthesize the year-over-year comparison, arriving at inverted conclusions about funding strategy shifts. The answer demonstrates a fundamental misreading or misinterpretation of the source data, making it unreliable for financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 373,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has PepsiCo's disclosure regarding the sensitivity of pension and retiree medical plan liabilities to market fluctuations evolved between 2022 and 2024?",
      "original_answer": "In 2022, PepsiCo mentioned that the exposure of pension and retiree medical plan assets and liabilities to risks related to market fluctuations was discussed in 'Our Critical Accounting Policies and Estimates.' By 2024, the company expanded this disclosure, explicitly linking the sensitivity of these liabilities not only to market fluctuations but also to inflationary, deflationary, and recessionary conditions. This broader context indicates a more detailed characterization of the macroeconomic risks affecting these obligations, beyond just market volatility.",
      "llm_answer": "PepsiCo’s 2022 Form 10‑K already warned that the fair‑value of its pension and retiree‑medical plan assets and liabilities is sensitive to market conditions and directed readers to the “Critical Accounting Policies and Estimates” discussion for details. The 2024 Form 10‑K repeats the same language – again noting that those obligations are exposed to market fluctuations and referring to the same critical‑accounting‑policies section – so the company’s disclosure on this risk has not materially changed.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core conclusion. The ground truth explicitly states that PepsiCo's disclosure EVOLVED and EXPANDED between 2022 and 2024, with the 2024 filing adding explicit linkage to inflationary, deflationary, and recessionary conditions beyond just market fluctuations. The LLM answer directly contradicts this by claiming 'the company's disclosure on this risk has not materially changed' and that 2024 'repeats the same language.' This is a critical factual error that misrepresents the evolution of disclosure. The LLM correctly identifies the years (2022, 2024) and the general topic (pension/retiree medical plan sensitivity), and accurately notes that both years reference 'Critical Accounting Policies and Estimates,' but it fails to recognize or report the key expansion of scope in 2024 to include macroeconomic conditions beyond market fluctuations. The LLM's conclusion that disclosure 'has not materially changed' directly contradicts the ground truth's finding of expanded and more detailed characterization. This represents a failure in multi-hop reasoning - the model needed to synthesize the differences between the two years' disclosures but instead concluded they were essentially identical. The quantitative accuracy is relatively high (correct years and document references), but the qualitative accuracy and overall correctness are severely compromised by the incorrect conclusion about the nature of the disclosure evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 410,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Adobe's approach to Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's broader document management ecosystem?",
      "original_answer": "In 2023, Adobe Scan was positioned as a free mobile scanning tool that converts paper documents into editable, searchable PDFs via Adobe Document Cloud services, emphasizing its utility for individual users. By 2024, Adobe Scan remained part of Adobe Document Cloud, but the broader ecosystem placed increased emphasis on integration with cloud-based productivity tools and AI-driven features like Content Credentials and Firefly-powered generative AI workflows, indicating a shift toward deeper integration within enterprise document workflows and enhanced digital trust mechanisms.",
      "llm_answer": "Both the 2023 and 2024 10‑K filings describe Adobe Scan as a free mobile‑only app that captures paper, turns it into full‑featured PDFs with OCR, and pushes those files into Adobe Document Cloud for instant sharing. The 2024 filing repeats this language, reinforcing Scan’s role as a free, mobile entry point that lives alongside Acrobat and Acrobat Sign within the broader Document Cloud ecosystem, with no material change in its positioning.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual and reasoning errors that contradict the ground truth. (1) CORRECTNESS ISSUES: The LLM claims 'no material change in its positioning' between 2023 and 2024, which directly contradicts the ground truth that explicitly describes a shift toward 'deeper integration within enterprise document workflows and enhanced digital trust mechanisms.' The ground truth identifies key 2024 developments: increased emphasis on cloud-based productivity tool integration, AI-driven features (Content Credentials, Firefly-powered generative AI workflows), and enhanced digital trust mechanisms. The LLM completely omits these critical 2024 positioning changes. (2) QUANTITATIVE ACCURACY: The LLM correctly identifies Adobe Scan as a free mobile app with OCR and PDF conversion capabilities, and correctly places it within Adobe Document Cloud alongside Acrobat and Acrobat Sign. These descriptive elements are accurate. However, the absence of quantitative data in both answers makes this dimension less critical. (3) QUALITATIVE/REASONING ACCURACY: This is where the LLM fails most significantly. The question explicitly asks about evolution 'between 2023 and 2024' and changes in positioning. The ground truth identifies a clear evolution: from basic mobile scanning utility (2023) to integrated enterprise solution with AI/trust features (2024). The LLM's conclusion that there was 'no material change' represents a fundamental misunderstanding of the multi-hop synthesis required. The LLM appears to have focused only on the consistent core functionality (mobile scanning, PDF conversion) while missing the strategic positioning shift toward enterprise integration and AI capabilities. (4) CONTEXTUAL RELEVANCE: The answer addresses Adobe Scan and Document Cloud but fails to capture the evolution dimension that is central to the question. The LLM's assertion of stasis contradicts the ground truth's identification of meaningful strategic evolution. The answer is partially relevant but fundamentally misses the key insight about how Adobe's approach evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 561,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Gemini's role and integration across Google's products evolved from its initial launch in 2023 to 2024, and what specific advancements were made in its multimodal capabilities?",
      "original_answer": "In 2023, Gemini was introduced as a multimodal AI model capable of understanding and operating across different types of information, including text, code, audio, images, and video. It was intended to be leveraged across Alphabet to enhance product experiences. By 2024, Gemini had evolved significantly, with the launch of Gemini 2.0, which became the most capable model yet. It was integrated into all seven of Google's two billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube—powering AI features across these platforms. Additionally, in 2024, Gemini was used in experimental research prototypes such as Project Astra and Project Mariner, showcasing broader and more advanced applications than in 2023.",
      "llm_answer": "Gemini was first launched in December 2023 as Google’s native multimodal model that could jointly understand and combine text, code, audio, images and video, and was initially used by Alphabet teams to enhance a range of AI‑powered services. By 2024 the company introduced Gemini 2.0—its most capable version yet—and expanded its integration to all seven of Google’s flagship consumer products (Android, Chrome, Gmail, Maps, Play Store, Search and YouTube), as well as Pixel devices (Gemini Nano), Google Workspace, Vertex AI and other Cloud offerings, adding new functions such as image generation, coding assistance and app integration while preserving its seamless multimodal processing of text, code, audio, image and video.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Strengths: (1) Correctly identifies Gemini's 2023 launch with accurate multimodal capabilities (text, code, audio, images, video); (2) Accurately names Gemini 2.0 as the 2024 evolution and correctly identifies it as 'most capable version yet'; (3) Correctly lists all seven Google flagship products (Android, Chrome, Gmail, Maps, Play Store, Search, YouTube) with proper integration details; (4) Adds valuable context beyond ground truth by mentioning Pixel devices (Gemini Nano), Google Workspace, Vertex AI, and Cloud offerings, which represents appropriate expansion of scope; (5) Mentions specific 2024 advancements (image generation, coding assistance, app integration) that align with the spirit of 'specific advancements' requested; (6) Properly synthesizes multi-hop information showing evolution from 2023 to 2024. Minor considerations: (1) The ground truth mentions 'two billion-user products' as a descriptor, which the LLM omits, though this is a minor contextual detail; (2) The ground truth specifically mentions Project Astra and Project Mariner as experimental research prototypes, which the LLM does not include—this is a notable omission of specific examples of 'broader and more advanced applications'; (3) The LLM provides more comprehensive product integration details than ground truth (Workspace, Vertex AI, Cloud) which adds value but wasn't explicitly in the original answer. The omission of Project Astra and Project Mariner prevents a perfect 10, as these were specifically highlighted in the ground truth as examples of advanced 2024 applications. Overall, the answer demonstrates strong understanding of Gemini's evolution and provides accurate, well-synthesized information with only minor gaps in completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 487,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Linde's relationship with helium evolved between 2022 and 2024, particularly in terms of its impact on sales and operating profit?",
      "original_answer": "In 2022, helium was listed as a supply for Linde, indicating a positive or neutral relationship. However, by 2024, the relationship had evolved, and helium was reported to negatively impact the company. Specifically, in 2024, lower volumes in global helium contributed to a 2% decrease in sales for the 'Other' segment, which includes global helium wholesale. Additionally, higher costs due to helium partially offset an insurance recovery for Linde Advanced Materials Technology (LAMT), limiting the operating profit growth in that segment despite a 44% overall increase in operating profit for 'Other'.",
      "llm_answer": "In the 2022 filing Linde’s helium business was noted only as part of “global helium wholesale” in the “Other” segment, which posted $2,047 million of sales but a $(56) million operating‑profit loss. By 2024 the same helium‑wholesale activity remained in “Other,” but sales slipped to $1,257 million (‑2% YoY) while operating profit turned positive at $62 million, the gain coming from insurance recoveries that were partially offset by higher helium‑related costs. Thus, helium’s share of sales has modestly declined, its cost impact has grown, yet the segment’s overall profitability improved due to other factors.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that fundamentally contradict the ground truth. (1) QUANTITATIVE ERRORS: The LLM provides specific dollar amounts ($2,047M for 2022 sales, $1,257M for 2024 sales, $(56)M for 2022 operating profit, $62M for 2024 operating profit) that are NOT present in the ground truth answer. The ground truth does not cite these specific numbers. The LLM claims a -2% YoY change in 2024, which aligns with ground truth mentioning '2% decrease,' but the absolute dollar figures appear fabricated or sourced from unstated data. (2) DIRECTIONAL CONTRADICTION: The ground truth states helium 'negatively impact[ed]' the company by 2024, with 'lower volumes in global helium' causing the 2% sales decrease. The LLM states sales 'slipped to $1,257 million (-2% YoY)' but then claims 'operating profit turned positive at $62 million' with 'the gain coming from insurance recoveries.' This contradicts the ground truth's characterization of helium as a negative impact. (3) INCOMPLETE SYNTHESIS: The ground truth specifically mentions that higher helium costs 'partially offset an insurance recovery for Linde Advanced Materials Technology (LAMT),' limiting operating profit growth. The LLM mentions insurance recoveries offset by higher helium costs but fails to identify LAMT or properly contextualize how this affected the segment's overall performance relative to the 44% overall increase in operating profit mentioned in ground truth. (4) MISSING KEY CONTEXT: The ground truth emphasizes the EVOLUTION from 2022 (positive/neutral) to 2024 (negative impact). The LLM's framing of 'segment's overall profitability improved due to other factors' obscures the negative helium-specific impact that is central to the ground truth answer. (5) UNSOURCED NUMBERS: The specific sales and operating profit figures provided by the LLM cannot be verified against the ground truth, suggesting either hallucination or reliance on unstated sources. The answer demonstrates poor multi-hop reasoning by failing to properly synthesize the relationship between helium's negative volume/cost impacts and the segment's overall profitability drivers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 587,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did the net value of acquired franchise rights evolve from 2022 to 2024, and what was the magnitude of this change?",
      "original_answer": "In 2022, the net value of acquired franchise rights was $789 million, while in 2024 it decreased to $598 million. This represents a significant decline in value over the two-year period.",
      "llm_answer": "The net carrying amount of acquired franchise rights fell from **$789 million in 2022** to **$598 million in 2024**, a decline of roughly **$191 million**. (PEP_10k_2022.pdf p. 81; PEP_10k_2024.pdf p. 81)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. (1) CORRECTNESS: All factual information matches the ground truth perfectly. The 2022 value of $789 million and 2024 value of $598 million are both correct. (2) QUANTITATIVE ACCURACY: The calculation of the decline is accurate: $789M - $598M = $191M. All numbers are presented correctly with proper formatting ($789 million, $598 million, $191 million). (3) MULTI-HOP REASONING: The answer correctly synthesizes information across two different years (2022 and 2024) and properly identifies the metric (net carrying amount/net value of acquired franchise rights). The comparison and calculation logic are sound. (4) ENTITY ACCURACY: The metric is correctly identified as 'acquired franchise rights' (LLM uses 'net carrying amount of acquired franchise rights' which is semantically equivalent and more precise). The years are correct (2022 and 2024). (5) COMPLETENESS: The answer addresses all parts of the question - it shows the evolution (starting value, ending value) and explicitly states the magnitude of change ($191 million decline). The inclusion of source citations (PEP_10k_2022.pdf p. 81; PEP_10k_2024.pdf p. 81) adds credibility. Minor note: The LLM uses 'roughly' before the $191 million figure, which is slightly imprecise language given that this is an exact calculation, but this is a very minor stylistic issue that does not affect factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1090,
        "completion_tokens": 395,
        "total_tokens": 1485
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil evolve from 2023 to 2024?",
      "original_answer": "In 2023, Chevron reported that its natural gas volumes included 596 million cubic feet per day consumed in operations and 7,148 million cubic feet per day as sold, which included its share from Tengizchevroil in Kazakhstan. By 2024, these figures increased to 609 million cubic feet per day consumed and 7,569 million cubic feet per day as sold, indicating a growth in both operational consumption and market delivery. This reflects an increase in Chevron’s involvement and dependency on Tengizchevroil for natural gas production and delivery commitments.",
      "llm_answer": "In the 2023 Form 10‑K Chevron pledged to deliver about 746 billion cubic feet of natural gas in the United States and roughly 2.9 trillion cubic feet internationally (Australia and Israel) for 2024‑26; the 2024 filing raised those commitments to 813 billion cubic feet (U.S.) and 3.2 trillion cubic feet (outside U.S.) for 2025‑27. By contrast, its share of production from its Kazakhstan affiliate Tengizchevroil was essentially unchanged – oil‑equivalent output stayed near 45 thousand barrels per day (≈26 k bbl/d crude) and natural‑gas output hovered at 113‑114 million cubic feet per day in both 2023 and 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is substantially incorrect and addresses a different aspect of the question than the ground truth. Critical issues: (1) WRONG METRICS: The LLM discusses future delivery commitments (746 BCF U.S./2.9 TCF international for 2024-26, rising to 813 BCF/3.2 TCF for 2025-27), which are forward-looking contractual obligations. The ground truth addresses actual production volumes and consumption figures (596 to 609 MMcf/d consumed, 7,148 to 7,569 MMcf/d sold). These are fundamentally different metrics - commitments vs. actual volumes. (2) WRONG FOCUS ON TENGIZCHEVROIL: The LLM states Tengizchevroil production was 'essentially unchanged' at 113-114 MMcf/d, which contradicts the ground truth showing increases from 596 to 609 MMcf/d consumed and 7,148 to 7,569 MMcf/d sold. The LLM's 113-114 MMcf/d figure appears to be only Chevron's direct share from Tengizchevroil, not the total volumes the question asks about. (3) INCOMPLETE SYNTHESIS: The question asks how commitments and production volumes 'evolved' - the ground truth shows clear growth (2.3% increase in consumed volumes, 5.9% increase in sold volumes). The LLM incorrectly characterizes Tengizchevroil output as 'essentially unchanged.' (4) GEOGRAPHIC MISMATCH: The LLM emphasizes U.S. and international commitments (Australia, Israel) which are not the focus of the ground truth answer about Tengizchevroil in Kazakhstan. (5) MISSING KEY DATA: The LLM completely omits the 7,148 to 7,569 MMcf/d sold figures and the 596 to 609 MMcf/d consumed figures that are central to the ground truth answer. The answer appears to conflate different types of metrics and focuses on the wrong data points entirely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 458,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the role of Google Network partners in Google's advertising revenue model evolved between 2023 and 2024, based on changes in the way payments to these partners are described?",
      "original_answer": "In 2023, Google Network partners were described as part of the primary uses of cash from operating activities, specifically noting payments made to these partners as a standard operating expense. By 2024, the description evolved to categorize payments to Google Network partners under Traffic Acquisition Costs (TAC), explicitly linking them to ads displayed on partner properties and tying them directly to revenue generation. This shift indicates a more strategic and performance-based dependency on these partners within the advertising ecosystem.",
      "llm_answer": "In the 2023 filing Alphabet listed payments to Google Network partners as a **primary use of cash from operating activities**, treating the payouts as a distinct cash outflow 【GOOGL_10k_2023.pdf pp 40‑44】. By the 2024 filing those same payments are described as **amounts paid to Google Network partners that are recorded as traffic‑acquisition costs (TAC) within cost of revenues**, embedding the partner payouts into the cost structure of advertising rather than highlighting them as a separate cash use 【GOOGL_10k_2024.pdf pp 57‑61】. This shift shows the partners’ role moving from a highlighted cash‑flow line item to an integrated component of ad‑revenue cost accounting.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the 2023 characterization of Google Network partner payments as 'primary uses of cash from operating activities' - this matches the ground truth description. (2) Accurately describes the 2024 shift to categorizing these payments under 'Traffic Acquisition Costs (TAC)' within cost of revenues - this is the core evolution the question asks about. (3) Properly synthesizes the multi-hop reasoning: the shift from a highlighted cash-flow line item to an integrated cost component. (4) Correctly identifies the strategic implication: moving from a separate cash use to an integrated component of ad-revenue cost accounting, which aligns with the ground truth's characterization of 'more strategic and performance-based dependency.' (5) Provides specific document citations with page ranges, adding credibility. (6) Uses appropriate financial terminology (TAC, cost of revenues, cash flows). MINOR CONSIDERATIONS: The LLM answer uses slightly different phrasing than the ground truth ('embedded the partner payouts into the cost structure' vs 'explicitly linking them to ads displayed on partner properties'), but both convey the same semantic meaning - that the 2024 approach ties payments more directly to revenue generation. The LLM's framing of 'integrated component of ad-revenue cost accounting' effectively captures this relationship. NO QUANTITATIVE ERRORS: There are no numbers, percentages, or calculations to verify, and all dates (2023, 2024) are correct. The answer fully addresses the multi-part question about how the role evolved and how the payment descriptions changed. The reasoning is sound and the synthesis across the two filing years is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 487,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the impact of public policies on Bank of America's climate-related regulatory requirements evolved from 2023 to 2024, particularly in terms of jurisdictional divergence and compliance risks?",
      "original_answer": "In 2023, Bank of America highlighted increasing global regulatory focus on climate change, noting that new or heightened regulatory requirements across state, federal, and non-U.S. jurisdictions were expected to increase legal, compliance, and public disclosure risks and costs. The company specifically mentioned jurisdictional divergence as a challenge. By 2024, this concern intensified, with the company noting that existing and pending disclosure requirements in various jurisdictions, along with jurisdictional divergence, were now actively impacting legal, compliance, and public disclosure risks and costs. This indicates a shift from anticipation of increased risk to experiencing tangible impacts due to evolving public policies.",
      "llm_answer": "In the 2023 filing Bank of America warned that a “increasing global regulatory focus … including state, federal and non‑U.S. jurisdictions” was creating new or heightened climate‑related rules and “potential jurisdictional divergence,” which it expected would raise its legal, compliance and public‑disclosure costs. By the 2024 filing the company says that divergence has become more pronounced – with a growing set of existing and pending climate‑disclosure requirements across multiple jurisdictions – and that this expanding patchwork of public‑policy rules is further amplifying its compliance‑risk exposure and associated costs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) FACTUAL ACCURACY: The answer correctly identifies Bank of America as the subject company, accurately references both 2023 and 2024 filings, and properly characterizes the evolution of climate-related regulatory concerns. The specific claims about 'increasing global regulatory focus,' 'state, federal and non-U.S. jurisdictions,' and 'jurisdictional divergence' are all accurately quoted or paraphrased from the ground truth. The shift from 'expected to increase' risks in 2023 to 'actively impacting' risks in 2024 is correctly captured. (2) QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are present in either the ground truth or LLM answer, so this dimension is not applicable. Both answers appropriately avoid quantification where none exists in the source material. (3) MULTI-HOP REASONING: The LLM successfully synthesizes information across two fiscal years (2023 and 2024) and correctly identifies the temporal progression: from anticipatory language ('expected to increase') to present-tense impact language ('actively impacting'). The answer properly connects jurisdictional divergence as a persistent theme across both years while showing how it intensified. (4) SEMANTIC EQUIVALENCE: The LLM uses slightly different phrasing ('expanding patchwork of public-policy rules,' 'more pronounced divergence') but conveys the identical substantive meaning as the ground truth. The characterization of the evolution from potential to actual impact is semantically equivalent. (5) COMPLETENESS: The answer addresses all aspects of the multi-part question: the impact evolution, jurisdictional divergence, and compliance risks across both years. Minor note: The LLM answer uses quotation marks around phrases that appear to be paraphrased rather than direct quotes, but this is a stylistic choice that doesn't affect factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 529,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has General Motors' strategic emphasis on full-size pickup trucks evolved from 2022 to 2024, and what quantitative indicators in 2024 suggest a shift toward stronger performance and market positioning for this product line?",
      "original_answer": "In 2022, General Motors identified the success of its full-size SUVs and full-size pickup trucks as a key risk factor, indicating that their performance was critical to the company's competitive position and financial health. By 2024, this strategic emphasis had evolved into a demonstrated strength, as evidenced by a significant increase in net wholesale volumes driven by higher sales of full-size pickup trucks. Additionally, the 2024 report highlights that full-size pickup trucks contributed favorably to the company's EBIT-adjusted results, with a variable profit of approximately 160% for trucks on a weighted-average basis, reflecting improved profitability and market demand for this product line.",
      "llm_answer": "In the 2022 Form 10‑K, GM’s forward‑looking statements (p. 46) singled out the “success of our current line of full‑size SUVs and **full‑size pickup trucks**” as a strategic priority and a key driver of future growth. By 2024 the emphasis is reflected in hard numbers: wholesale vehicle sales rose 10.1% to 3.464 million units, the truck segment’s share of the residual‑value portfolio grew to **23.7%** of total (up from 21.9% a year earlier) (p. 34), and trucks drove the mix and price effects that added **$16 billion** to total net sales and **$2.2 billion** to EBIT‑adjusted (p. 32‑33), signalling a stronger performance and market positioning for the full‑size pickup line.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer attempts to address the evolution of GM's strategic emphasis on full-size pickup trucks from 2022 to 2024, but contains significant quantitative inaccuracies and introduces unsupported claims. CRITICAL ISSUES: (1) The ground truth specifies that full-size pickup trucks contributed a variable profit of approximately 160% on a weighted-average basis in 2024 - this key metric is completely absent from the LLM answer. (2) The LLM cites specific numbers ($16 billion to net sales, $2.2 billion to EBIT-adjusted, 23.7% truck segment share, 21.9% prior year) that cannot be verified against the ground truth provided. These appear to be fabricated or misattributed figures not present in the original answer. (3) The wholesale volume figure of 3.464 million units and the 10.1% increase are not mentioned in the ground truth. (4) The LLM correctly identifies the 2022 strategic emphasis on full-size pickup trucks as a key risk/priority factor, which aligns with ground truth. (5) The LLM correctly notes the evolution toward demonstrated strength by 2024 with higher sales volumes, which matches the ground truth's statement about 'significant increase in net wholesale volumes driven by higher sales of full-size pickup trucks.' STRENGTHS: The answer demonstrates understanding of the multi-hop nature of the question (comparing 2022 to 2024) and attempts to provide quantitative support. The narrative structure appropriately contrasts 2022 positioning with 2024 performance. WEAKNESSES: The specific quantitative indicators provided (residual-value portfolio percentages, dollar contributions to sales and EBIT) are not corroborated by the ground truth and appear to be hallucinated. The most important metric from ground truth - the 160% variable profit on weighted-average basis - is entirely omitted. The answer conflates general wholesale volume growth with truck-specific performance without clear attribution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 521,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the allocation to U.S. Treasury and government agency securities within the nuclear decommissioning trusts evolve from 2022 to 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2022, the allocation to U.S. Treasury and government agency securities was $21 million for Alabama Power and $293 million for Georgia Power. By 2024, this allocation decreased slightly to $20 million for Alabama Power but increased significantly to $349 million for Georgia Power. The overall trend shows a shift in focus toward Georgia Power’s portfolio, indicating a possible reallocation of safer, fixed-income assets to that subsidiary.",
      "llm_answer": "In the 2022 filing the nuclear‑decommissioning trusts held about **$314 million** of U.S. Treasury and government‑agency securities (Alabama Power $21 million + Georgia Power $293 million)【SO_10k_2022.pdf p.309‑310】. By the 2024 filing that balance had risen to roughly **$358 million** (Alabama Power $9 million + Georgia Power $349 million)【SO_10k_2024.pdf p.275‑276】. The modest increase shows the company is shifting a slightly larger portion of the trusts into high‑quality, low‑risk government securities, reflecting a more conservative, liquidity‑focused investment strategy to protect future decommissioning funding.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a significant factual error regarding Alabama Power's 2024 allocation. Ground truth states Alabama Power had $20 million in 2024, but the LLM claims $9 million. This is a material discrepancy of $11 million (55% error). The 2022 figures are correct ($21M Alabama Power, $293M Georgia Power), and the 2024 Georgia Power figure is correct ($349M). However, the incorrect Alabama Power 2024 figure cascades into the total calculations: LLM states $358M total for 2024, but the correct total should be $369M ($20M + $349M). The 2022 total of $314M is correctly calculated. REASONING ISSUES: While the LLM correctly identifies the overall trend toward increased government securities allocation and provides reasonable interpretation about conservative investment strategy, the multi-hop synthesis is undermined by the factual error. The LLM's conclusion about 'modest increase' is technically correct directionally (from $314M to $369M is a ~$55M or 17.5% increase), but this is based on incorrect component numbers. COMPLETENESS: The answer addresses both parts of the question (evolution from 2022-2024 and what it indicates about strategy), but the factual errors significantly compromise the quality of the response. The interpretation about conservative, liquidity-focused strategy is reasonable but cannot be fully validated given the data errors. ENTITY ACCURACY: Companies and years are correctly identified. The metric (U.S. Treasury and government agency securities) is correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 428,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has PepsiCo's relationship with independent bottlers evolved from 2022 to 2024 in terms of financial incentives and strategic dependency?",
      "original_answer": "In 2022, PepsiCo provided sales incentives and discounts to independent bottlers primarily through funding of advertising and other marketing activities, with accruals based on annual targets and historical experience. By 2024, the company's relationship had evolved into a more structured dependency, with bottler funding negotiated annually and specifically allocated across trade and consumer programs such as advertising support, new product launches, and vending equipment placement. Additionally, in 2024, sales through independent bottlers contributed to a significant portion of revenue, with Walmart alone accounting for approximately 14% of consolidated net revenue, highlighting increased strategic dependency on these bottlers.",
      "llm_answer": "In the 2022 filing PepsiCo said it grants its independent bottlers exclusive manufacturing and distribution rights and supports them each year with “bottler funding” – annual financial incentives for consumer‑, advertising‑, new‑product‑ and equipment‑placement programs (PEP 10‑K 2022, pp. 58‑62). The 2024 filing still describes the same exclusive‑contract framework and annual bottler‑funding, but adds that PepsiCo continues to rely heavily on these bottlers for manufacturing and market distribution, highlighting an ongoing—and arguably stronger—strategic dependency (PEP 10‑K 2024, pp. 7‑11).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution of PepsiCo's bottler relationship from 2022 to 2024, accurately describing the shift from basic incentive programs to more structured annual negotiations. It correctly identifies the types of programs (advertising, new product launches, equipment placement) and appropriately characterizes the increasing strategic dependency. The answer demonstrates sound multi-hop reasoning by synthesizing information across two filing years and correctly identifies the exclusive manufacturing/distribution framework. WEAKNESSES: The LLM answer is MISSING a critical quantitative element from the ground truth - the Walmart revenue metric (approximately 14% of consolidated net revenue in 2024). This is a significant omission because it provides concrete evidence of strategic dependency and is explicitly mentioned in the original answer as highlighting this dependency. The ground truth specifically states 'Walmart alone accounting for approximately 14% of consolidated net revenue' as evidence of increased strategic dependency, but the LLM answer provides no quantitative metrics to support its claims about dependency. QUANTITATIVE ACCURACY ISSUE: While the LLM doesn't provide incorrect numbers, it fails to include the key quantitative data point (14% Walmart revenue) that substantiates the strategic dependency claim. This represents incomplete quantitative support for the answer's conclusions. REASONING: The multi-hop synthesis is sound - the LLM correctly traces the evolution across years and identifies the relationship changes. However, the answer would be significantly strengthened by including the Walmart revenue percentage as concrete evidence. The characterization of 'arguably stronger' strategic dependency is appropriate but would be more compelling with the quantitative support. OVERALL: The answer captures the qualitative evolution correctly but lacks the quantitative rigor that the ground truth provides, making it a partially complete response that addresses the question's spirit but misses important supporting evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 566,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has Adobe Firefly's role within Adobe's product innovation strategy evolved from 2023 to 2024, based on its positioning in the company's trademark listings and risk disclosures?",
      "original_answer": "In 2023, Adobe Firefly was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Firefly was specifically highlighted in the risk factors section as a newly released generative AI product, reflecting its strategic importance in Adobe's innovation efforts. This evolution shows a shift from being a registered brand to becoming a central part of Adobe's forward-looking product development and AI strategy, with explicit mention of its role in addressing market demands for generative AI capabilities.",
      "llm_answer": "In the 2023 Form 10‑K (see the trademark table on pages 94‑98 and the AI risk discussion on page 96), Adobe listed “Adobe Firefly” only as one of many marks and mentioned it in passing as a new generative‑AI experiment. By the 2024 filing (trademark list on pages 21‑25 and the risk‑factor section on page 22), Firefly is called out as a distinct trademark and is explicitly highlighted as a core AI product being woven into Adobe’s portfolio, with detailed risks about adoption, monetization, regulatory compliance and brand impact—showing its shift from a peripheral project to a central pillar of Adobe’s product‑innovation strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ISSUES: The LLM answer contains multiple fabricated details that cannot be verified against the ground truth and likely do not exist in actual SEC filings: (1) SPECIFIC PAGE NUMBERS ARE INVENTED - The LLM cites 'pages 94-98' and 'page 96' for 2023, and 'pages 21-25' and 'page 22' for 2024. These specific page citations appear to be hallucinated and cannot be verified. The ground truth does not provide page numbers, suggesting the LLM invented them. (2) CONTRADICTORY CHARACTERIZATION - The LLM describes Adobe Firefly in 2023 as 'only as one of many marks and mentioned it in passing as a new generative-AI experiment,' which contradicts the ground truth stating it was 'listed among Adobe's trademarks, indicating it was an established product.' The ground truth indicates Firefly was already established in 2023, not experimental. (3) OVERSTATED DETAIL IN 2024 - The LLM claims the 2024 filing includes 'detailed risks about adoption, monetization, regulatory compliance and brand impact,' but the ground truth only mentions it was 'specifically highlighted in the risk factors section as a newly released generative AI product.' The LLM adds specificity not present in the ground truth. (4) SEMANTIC MISALIGNMENT - While both answers convey a shift from 2023 to 2024, the LLM's characterization of the 2023 status as 'peripheral' and 'experimental' contradicts the ground truth's characterization as 'established.' The core narrative differs significantly. WHAT WAS CORRECT: The LLM correctly identifies the general evolution from 2023 to 2024 and correctly names the product (Adobe Firefly). The overall direction of the answer (shift in strategic importance) aligns with the ground truth. MULTI-HOP REASONING: The LLM attempts to synthesize information across trademark listings and risk disclosures across two years, which is appropriate for the question. However, the synthesis is undermined by fabricated details and mischaracterizations of the 2023 status.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 533,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of contractual rent escalations in driving tenant billing growth changed between 2022 and 2023, particularly in light of the increased churn and lease cancellations in 2023?",
      "original_answer": "In 2022, contractual rent escalations were highlighted as a key factor contributing to tenant billing growth, listed alongside new colocation activity and lease amendments. By 2023, while contractual rent escalations remained a stated driver of growth, the context shifted due to an elevated churn rate of approximately 3%, primarily in the U.S. & Canada segment. This churn, expected to remain elevated through 2025 due to T-Mobile's lease cancellations, introduced a countervailing force against the positive impact of rent escalations, suggesting a more challenging environment for maintaining organic revenue growth solely through escalations.",
      "llm_answer": "In both 2022 and 2023 the company still lists “contractual rent escalations on existing tenant leases, net of churn” as a core component of tenant‑billing growth (2022 “Contractual rent escalations …, net of churn” and 2023 same language). However, 2023 saw churn rise to about 3 % of tenant billings – driven by higher lease cancellations and non‑renewals in the U.S. & Canada segment – which means the net contribution of those escalations to overall billing growth was dampened relative to 2022, when churn was only expected to be elevated but not quantified.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of the core question and captures the main narrative arc correctly. STRENGTHS: (1) Correctly identifies that contractual rent escalations remained a stated driver in both years; (2) Accurately quantifies 2023 churn at approximately 3%; (3) Correctly identifies U.S. & Canada segment as the source of elevated churn; (4) Properly synthesizes the multi-hop concept that escalations were dampened by churn in 2023 vs. 2022; (5) Appropriately notes the countervailing force of churn against escalation benefits. WEAKNESSES: (1) The statement 'when churn was only expected to be elevated but not quantified' in 2022 is somewhat imprecise - the ground truth indicates escalations were 'highlighted as a key factor' in 2022 without specific churn quantification, but the LLM's phrasing could be clearer about whether 2022 churn was expected or not; (2) Missing explicit mention of T-Mobile's lease cancellations as the specific driver of the elevated churn (though U.S. & Canada is mentioned); (3) The phrase 'net of churn' appears in both years according to the LLM, but the ground truth suggests this framing may have been more explicit in 2023 as a response to the elevated churn situation. CALCULATION/NUMBER VERIFICATION: The 3% churn figure is correct. The comparison between 2022 and 2023 contexts is logically sound. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and connects the escalation driver to the churn countervailing force, demonstrating proper multi-hop reasoning. The semantic equivalence is maintained - the answer conveys that escalations remained important but their net impact was reduced due to higher churn in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 469,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Chevron's (CVX) relationship with Tengizchevroil evolved between 2023 and 2024 in terms of capital expenditure commitments and production involvement?",
      "original_answer": "In 2023, Chevron indicated that nearly half of its Affiliate Capex, which was expected to be $3 billion in 2024, was allocated to Tengizchevroil's FGP/WPMP Project in Kazakhstan. By 2024, Chevron continued to highlight its production involvement with Tengizchevroil, noting that production volumes included Chevron's share from affiliates such as Tengizchevroil in Kazakhstan. While 2023 focused on capital commitments for project development, 2024 emphasized ongoing production contributions from the same entity, indicating a shift from investment to operational phase.",
      "llm_answer": "In the 2023 filing Chevron disclosed that it would devote nearly half of its $3 billion affiliate‑capex budget for 2024 to Tengizchevroil’s FGP/WPMP project in Kazakhstan – a clear, large‑scale capital commitment to the joint‑venture【CVX_10k_2023.pdf pp 48‑52】. The 2024 filing shows that affiliate production (which includes Tengizchevroil) rose to about 413 kboe/d in 2024, up from roughly 406 kboe/d in 2023, indicating a modest increase in Chevron’s production involvement with the partner【CVX_10k_2024.pdf pp 7‑11】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about Chevron's evolving relationship with Tengizchevroil between 2023 and 2024. STRENGTHS: (1) Correctly identifies the $3 billion affiliate capex budget for 2024 with nearly half allocated to Tengizchevroil's FGP/WPMP project in Kazakhstan - this matches the ground truth exactly. (2) Accurately cites the production volumes: 413 kboe/d in 2024 vs. 406 kboe/d in 2023, showing proper multi-hop synthesis across years. (3) Properly characterizes the shift from capital commitment phase (2023) to operational/production phase (2024), which aligns with the ground truth's narrative about the evolution. (4) Correctly identifies Tengizchevroil as a Kazakhstan-based affiliate and joint venture. (5) Provides appropriate source citations to specific document pages. MINOR WEAKNESSES: (1) The LLM answer emphasizes production volume increases (406 to 413 kboe/d) as the primary indicator of 'production involvement,' while the ground truth frames 2024 as emphasizing 'ongoing production contributions' more broadly - the LLM's focus on the numerical increase is slightly narrower than the ground truth's broader characterization. (2) The ground truth explicitly states the shift is 'from investment to operational phase,' while the LLM describes it as 'from capital commitment to production involvement' - semantically similar but not identical framing. QUANTITATIVE VERIFICATION: All numbers are accurate ($3 billion, nearly half allocation, 413 kboe/d, 406 kboe/d). The year-over-year comparison (406→413) is correctly calculated as a modest increase. MULTI-HOP REASONING: The answer successfully synthesizes information across 2023 and 2024 filings, connecting capital expenditure commitments to production outcomes. The logical flow from 2023 capex planning to 2024 production results is sound. Overall, this is a high-quality answer with accurate numbers and solid reasoning, with only minor semantic differences from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 548,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the specificity of UPS's bond matching approach evolved in determining the discount rate for U.S. pension and postretirement benefit plans between 2023 and 2024?",
      "original_answer": "In 2023, UPS described using a bond matching approach to select specific bonds that would satisfy projected benefit payments, emphasizing its belief that this method reflects the process they would employ to settle pension and postretirement obligations. By 2024, the language evolved to place stronger emphasis on the bond matching approach as a guide for selecting bonds that align with projected benefit cash flows, without any material change in the mechanics of the method. However, the 2024 disclosure included a more precise statement indicating that the approach 'guides' the selection process, suggesting a subtle shift in how the policy is framed operationally, even though the underlying practice remained consistent.",
      "llm_answer": "UPS’s description of the bond‑matching method did not change from 2023 to 2024. In both filings the company says it determines the discount rate for its U.S. pension and post‑retirement benefit plans by “using a bond‑matching approach to select specific bonds that would satisfy our projected benefit payments,” with no additional detail or refinement added in the 2024 filing.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim. The original answer (ground truth) explicitly states that the language and framing of UPS's bond matching approach EVOLVED between 2023 and 2024, with a 'subtle shift in how the policy is framed operationally.' The 2024 disclosure included 'more precise statement indicating that the approach guides the selection process,' representing a meaningful evolution in emphasis and framing. The LLM answer directly contradicts this by claiming 'the description of the bond-matching method did not change from 2023 to 2024' and that 'no additional detail or refinement added in the 2024 filing.' This is a critical factual error that misses the entire point of the question, which specifically asks about how the specificity and approach EVOLVED. While the LLM correctly identifies the basic bond-matching methodology and the years involved (2023 and 2024), it completely fails to recognize or describe the evolution in language, emphasis, and framing that the ground truth identifies. The LLM's assertion that there was 'no material change in the mechanics' may be technically defensible, but it ignores the explicit statement in the ground truth about the 'subtle shift in how the policy is framed operationally.' This represents a failure in multi-hop reasoning and synthesis - the model needed to compare the two years' disclosures and identify the nuanced differences in language and emphasis, which it failed to do.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 407,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what financial impact did this change have on the company's sales and operating profit during this period?",
      "original_answer": "In 2022, helium was a supply input for Linde, indicating a supportive role in operations. By 2024, helium had a negative impact on operations, with a $32 million, or 2%, decrease in sales for the Other segment primarily due to lower volumes in global helium and LAMT. Additionally, helium-related costs contributed to downward pressure on operating profit, partially offset by an insurance recovery for LAMT. This reflects a shift from a neutral or positive relationship to one that posed operational challenges.",
      "llm_answer": "In the 2022 10‑K Linde makes no mention of a helium business, indicating it was not material at that time (LIN_10k_2022.pdf:68). By the 2024 filing the company lists a “global helium wholesale” operation within its “Other” segment, noting that lower helium volumes reduced sales by $32 million (≈2%) and that higher helium‑related costs ate into profit, partially offsetting a $19 million (44%) increase in operating profit for the segment (LIN_10k_2024.pdf:28‑30).",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the key financial metrics and the evolution of Linde's helium business from 2022 to 2024. Strengths: (1) Accurately captures the $32 million sales decrease and 2% impact on the Other segment; (2) Correctly notes the shift from no material helium mention in 2022 to a 'global helium wholesale' operation in 2024; (3) Properly identifies that helium-related costs pressured operating profit; (4) Appropriately cites document sources. Weaknesses: (1) The LLM states helium was 'not material' in 2022 based on lack of mention, but the ground truth indicates it was 'a supply input' - these are subtly different characterizations (supply input vs. immaterial); (2) The LLM mentions a '$19 million (44%) increase in operating profit for the segment' which appears to be additional context not explicitly in the ground truth answer, though not contradictory; (3) The ground truth mentions 'insurance recovery for LAMT' as a partial offset, which the LLM does not explicitly state, though it does reference LAMT in the context of lower volumes. Quantitative accuracy is strong with correct dollar amounts and percentages. The multi-hop reasoning is sound - the LLM successfully synthesizes information across 2022 and 2024 filings to show the evolution. The characterization of the relationship shift (from neutral/positive to operational challenge) is implied but not explicitly stated in the LLM answer, though the facts support this conclusion. Overall, the answer is substantially correct with minor omissions of contextual details about insurance recovery.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 436,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did Bank of America's unfunded capital contributions for renewable energy investments evolve between 2023 and 2024, and what was the corresponding change in recognized tax credits related to these investments?",
      "original_answer": "In 2023, Bank of America had unfunded capital contributions for renewable energy investments of $6.2 billion, and it recognized tax credits and other tax benefits of $4.0 billion. By 2024, the unfunded capital contributions decreased to $4.6 billion, and the recognized tax credits slightly declined to $3.9 billion. This indicates a reduction in the Corporation's near-term funding commitments to renewable energy projects, even as the tax benefits remained relatively stable.",
      "llm_answer": "Bank of America’s unfunded capital contributions for renewable‑energy projects fell from $6.2 billion at year‑end 2023 to $4.6 billion at year‑end 2024 – a drop of about $1.6 billion【2023 10‑K, pages 130‑134】.  In the same period, the renewable‑energy tax credits it recognized declined from $4.0 billion in 2023 to $3.9 billion in 2024, a reduction of roughly $0.1 billion【2024 10‑K, pages 130‑134】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. All quantitative data matches the ground truth exactly: (1) Unfunded capital contributions correctly stated as $6.2 billion in 2023 and $4.6 billion in 2024; (2) The calculated difference of $1.6 billion is accurate ($6.2B - $4.6B = $1.6B); (3) Recognized tax credits correctly identified as $4.0 billion in 2023 and $3.9 billion in 2024; (4) The calculated difference of $0.1 billion is accurate ($4.0B - $3.9B = $0.1B). The multi-hop synthesis is sound - the answer correctly combines information about both unfunded capital contributions and tax credits across two fiscal years. Entity identification is correct (Bank of America, renewable energy investments, 2023-2024 period). The answer provides appropriate context by noting the reduction in funding commitments while tax benefits remained relatively stable, which aligns with the ground truth interpretation. The only minor difference from the ground truth is that the LLM answer doesn't explicitly state 'the tax benefits remained relatively stable' as a concluding observation, but this is a very minor omission that doesn't affect the factual accuracy of the core answer. The citation format and page references add credibility. Overall, this is a comprehensive, accurate response that correctly synthesizes multi-hop financial information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 378,
        "total_tokens": 1614
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has General Motors' approach to fleet sales involving commercial fleet customers evolved from 2022 to 2024, particularly in terms of sales channels and profitability considerations?",
      "original_answer": "In 2022, General Motors highlighted that fleet transactions, especially sales to daily rental car companies, were generally less profitable compared to retail sales, and these vehicles were sold either directly or through the dealer network. By 2024, the company emphasized that fleet sales, including those to commercial fleet customers, were completed through the dealer network and in some cases directly with fleet customers, suggesting a more structured and possibly optimized approach to fleet sales. This evolution indicates a strategic shift toward balancing fleet sales with profitability by leveraging both direct and dealer-based channels.",
      "llm_answer": "In the 2022 filing GM noted that it sells vehicles to commercial‑fleet customers both directly and through its dealer network, but emphasized that many fleet transactions—especially to daily‑rental companies—are generally less profitable than retail sales (GM 2022 10‑K, p. 9). By the 2024 filing the company still relies on its dealer network for the bulk of fleet sales but now also sells some fleet vehicles directly to customers, and it continues to view fleet sales as lower‑margin relative to retail, shaping its channel mix and incentive strategy accordingly (GM 2024 10‑K, p. 101).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and addresses the core question about GM's fleet sales evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the key evolution: 2022 approach involved both direct and dealer network sales with emphasis on lower profitability vs. retail; 2024 approach continues both channels but with more structured emphasis on dealer network. (2) Accurately captures the profitability consideration across both years—fleet sales are consistently characterized as less profitable/lower-margin than retail. (3) Properly synthesizes multi-hop information across two filing years and multiple aspects (channels, profitability). (4) Correctly cites source documents (GM 2022 10-K p. 9, GM 2024 10-K p. 101). (5) No numerical errors or date inaccuracies. MINOR WEAKNESSES: (1) The LLM answer states the company \"still relies on its dealer network for the bulk of fleet sales\" in 2024—while this is reasonable inference, the ground truth emphasizes a \"more structured and possibly optimized approach\" without explicitly stating dealer network handles \"the bulk.\" This is a minor interpretive difference rather than factual error. (2) The ground truth emphasizes the evolution as a \"strategic shift toward balancing fleet sales with profitability,\" while the LLM focuses more on describing the channels and margin considerations without explicitly framing it as a strategic shift. This is a subtle difference in emphasis rather than factual incorrectness. SEMANTIC EQUIVALENCE: The LLM answer conveys essentially the same information as the ground truth—both channels used, profitability concerns consistent, evolution from 2022 to 2024 captured. The wording differs but the factual content aligns well.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 474,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did PepsiCo's relationship with Sabra evolve between 2022 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2022, PepsiCo owned the Sabra brand as part of its joint venture portfolio. However, by 2024, PepsiCo no longer had full ownership but instead held a 50% equity stake, which was remeasured at fair value, resulting in a pre-tax gain of $122 million. This indicates that PepsiCo divested a portion of its ownership in Sabra during the intervening period, marking a strategic shift in its relationship with the brand.",
      "llm_answer": "In 2022 PepsiCo still owned 50 % of the Sabra Dipping Company joint‑venture; it re‑measured that equity at fair value and recorded a pre‑tax gain of $122 million (about $92 million after‑tax) in its FLNA division, shown in selling‑general‑administrative expense【PEP_10k_2022.pdf p. 8】. By the 2024 filing the Sabra brand is no longer listed among PepsiCo’s owned joint‑ventures, indicating the equity interest has been disposed of, and no comparable gain or loss appears in the 2024 financial tables【PEP_10k_2024.pdf pp. 71‑75】. This change eliminated the accounting impact of the Sabra stake that was reflected in 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains a fundamental factual error that contradicts the ground truth. The LLM states that 'In 2022 PepsiCo still owned 50% of the Sabra Dipping Company joint-venture' and that it 're-measured that equity at fair value and recorded a pre-tax gain of $122 million.' However, the ground truth clearly indicates that in 2022, PepsiCo owned the Sabra brand (implying full or majority ownership), and by 2024, it held only a 50% equity stake after divesting a portion. The LLM has reversed the timeline and ownership structure. The $122 million gain is correctly identified as a pre-tax figure, and the after-tax amount of approximately $92 million is reasonable, but these numbers are attributed to the wrong year and ownership scenario. The LLM correctly identifies that Sabra is no longer listed in 2024 filings, but this is presented as a complete disposal rather than a transition to a 50% stake. The multi-hop reasoning fails because the LLM did not properly synthesize the evolution of the relationship across the two years - it should show movement FROM full/majority ownership TO 50% stake, not the reverse. The answer demonstrates some understanding of the accounting mechanics (fair value remeasurement, gain recognition) but applies them to an incorrect ownership structure and timeline. The citation format and document references appear plausible but the underlying facts are inverted from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 401,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Adobe's treatment of Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's product ecosystem?",
      "original_answer": "In 2023, Adobe Scan was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Scan was explicitly positioned as part of Adobe Document Cloud, which includes Acrobat, Acrobat Sign, and other apps and API services that support digital document and signature workflows. This evolution shows a shift from mere trademark recognition to a more integrated and strategically emphasized role within Adobe’s broader document management and productivity offerings.",
      "llm_answer": "In the 2023 filing (see ADBE 10‑K p. 96) Adobe Scan was mentioned only as a free mobile‑scanning tool that captures paper and creates PDFs, listed in passing as part of the broader Document Cloud suite. By the 2024 filing (see ADBE 10‑K p. 12) Adobe Scan receives its own sub‑section under Adobe Document Cloud, with expanded language about OCR, “full‑featured and versatile PDFs” and seamless integration with Document Cloud services—showing it has been elevated to a more prominent, integrated component of Adobe’s product ecosystem.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of the evolution of Adobe Scan's positioning between 2023 and 2024. STRENGTHS: (1) Correctly identifies the core evolution from 2023 to 2024, (2) Accurately captures the shift from passing mention to more prominent positioning, (3) Provides specific page references (p. 96 for 2023, p. 12 for 2024) showing document-level detail, (4) Correctly identifies Adobe Document Cloud as the relevant product category, (5) Mentions specific feature enhancements (OCR, PDF capabilities, integration) that support the positioning evolution. WEAKNESSES: (1) The LLM answer adds specific descriptive details (\"free mobile-scanning tool,\" \"OCR,\" \"full-featured and versatile PDFs\") that go beyond what the ground truth explicitly states. While these details may be accurate, they represent inferences or additional information not confirmed in the ground truth, (2) The ground truth emphasizes a shift from \"trademark recognition\" to \"integrated and strategically emphasized role,\" while the LLM frames it as moving from a \"passing mention\" to \"own sub-section\"—slightly different framing but semantically similar, (3) The LLM provides more granular detail about the specific nature of the product description changes, which enhances the answer but introduces elements not explicitly validated by the ground truth. MULTI-HOP REASONING: The answer correctly synthesizes information across two different filing years and identifies the progression in how Adobe positioned the product. The comparison structure is sound. SEMANTIC EQUIVALENCE: The core message aligns well—Adobe Scan evolved from less prominent to more prominent positioning within Document Cloud. The LLM's answer is more detailed and specific than the ground truth, which could be viewed as either enhancement or potential over-specification. No numerical errors detected. The answer appropriately addresses the question's focus on evolution and ecosystem positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 534,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has General Motors' financial exposure and nature of obligations to Stellantis evolved from 2022 to 2024, particularly regarding indemnifications and historical liabilities?",
      "original_answer": "In 2022, General Motors continued to have supply-related transactions with Stellantis following the sale of the Opel/Vauxhall business, indicating an ongoing operational relationship. By 2024, the nature of GM's exposure to Stellantis had shifted from operational supplies to financial guarantees and indemnifications tied to legacy liabilities. Specifically, GM had agreed to indemnify Stellantis for certain emissions-related lawsuits, Takata-related recalls, and potential penalties from European regulatory investigations into end-of-life vehicle practices. Additionally, as of December 31, 2024, GM had accrued an immaterial amount related to these matters, showing a continued but reduced financial exposure compared to earlier liabilities. This reflects a transformation from active supply chain involvement to a more passive, indemnification-based financial relationship.",
      "llm_answer": "In the 2022 filing GM said that, after selling the Opel/Vauxhall business to PSA (now Stellantis), its wholly‑owned Seller would indemnify Stellantis for any losses arising from inaccurate representations, covenant breaches, emissions, product‑liability and other claims – obligations that are subject to time limits, thresholds and caps and for which GM could not estimate any material loss. By the 2024 filing the same indemnification structure remains, but GM now discloses that it has already paid an immaterial amount for certain Stellantis recalls (including Takata‑related recalls) and that any further Takata indemnity is considered remote, indicating that the historic recall liabilities have largely been resolved and the exposure to Stellantis is now viewed as minimal.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about GM's evolving relationship with Stellantis from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 context of the Opel/Vauxhall sale to PSA (now Stellantis) and the indemnification structure; (2) Accurately describes the types of indemnified claims (emissions, product liability, representations/covenants); (3) Correctly notes that 2022 indemnification obligations were subject to time limits, thresholds, and caps; (4) Accurately captures the 2024 shift showing immaterial amounts paid and remote Takata exposure; (5) Properly synthesizes the evolution from active supply chain involvement to passive indemnification-based relationship. MINOR GAPS: (1) The original answer mentions 'European regulatory investigations into end-of-life vehicle practices' as a specific indemnification area, which the LLM answer does not explicitly reference (though it does mention 'other claims'); (2) The LLM answer could have been more explicit about the 'accrued immaterial amount' language used in the original answer, though it conveys the same meaning by stating 'already paid an immaterial amount.' QUANTITATIVE ACCURACY: No specific dollar amounts or percentages are provided in either answer, so this dimension focuses on date accuracy (2022, 2024, December 31, 2024) - all correct. QUALITATIVE REASONING: The multi-hop synthesis is sound - the answer correctly traces the relationship evolution across two filing years and identifies the key transformation in the nature of obligations. The logic connecting the indemnification structure to the resolution of liabilities is clear and accurate. SEMANTIC EQUIVALENCE: The LLM answer conveys essentially the same information as the ground truth, with slightly different emphasis (focusing on resolution/minimization of exposure rather than just the shift in nature of obligations).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 523,
        "total_tokens": 1946
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has PepsiCo's relationship with co-packers evolved between 2022 and 2024, particularly in terms of operational dependency and strategic involvement?",
      "original_answer": "In 2022, PepsiCo described its relationship with co-packers as part of a 'highly distributed network of plants, warehouses and distribution centers' that are owned or leased by these third parties, indicating an operational dependency. By 2024, the company's language shifted to emphasize co-packers as part of 'strategic alliances or joint ventures in which we have an equity interest,' suggesting a more active and ownership-based strategic involvement. This evolution reflects a shift from a primarily operational partnership to a more integrated and strategic stake in co-packers.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K filings describe PepsiCo’s co‑packers as part of a “highly distributed network” of contract manufacturers that supplement its owned and leased plants. The language is unchanged, noting that many co‑packers are linked to PepsiCo through strategic alliances or equity‑joint ventures, so the company’s operational reliance on them remains strong and its strategic involvement (via alliances and equity stakes) has not materially shifted over the two‑year period.",
      "correctness_score": 2,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth on the core finding. (1) CRITICAL ERROR - CONTRADICTS GROUND TRUTH: The LLM claims 'the language is unchanged' and that strategic involvement 'has not materially shifted,' directly contradicting the ground truth which explicitly states there was a significant evolution from 2022 to 2024. The ground truth identifies a clear shift: 2022 emphasized operational dependency ('highly distributed network of plants, warehouses and distribution centers' owned/leased by third parties), while 2024 shifted to emphasize strategic ownership ('strategic alliances or joint ventures in which we have an equity interest'). (2) MISCHARACTERIZATION OF EVOLUTION: The LLM fails to recognize the key distinction between the two periods - the shift from describing co-packers primarily as operational infrastructure providers to describing them as strategic partners with equity involvement. This is the central point of the question about how the relationship 'evolved.' (3) INCOMPLETE SYNTHESIS: While the LLM mentions both 'highly distributed network' and 'strategic alliances/equity stakes,' it incorrectly concludes these descriptions coexist unchanged across both years, rather than recognizing they represent different emphases in different years. (4) LOGICAL FLAW: The LLM's conclusion that 'operational reliance...remains strong and...strategic involvement...has not materially shifted' directly contradicts the ground truth's finding of a material shift toward more integrated and ownership-based strategic involvement. (5) QUANTITATIVE ACCURACY: No specific numbers are provided in either answer, so this dimension is neutral. The evaluation is primarily qualitative, and the LLM fundamentally misses the evolution that is the core of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 493,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did SPG's financial relationship with ABG evolve between 2023 and 2024, particularly in terms of gains recognized and strategic investments?",
      "original_answer": "In 2023, SPG recognized multiple non-cash pre-tax gains related to its relationship with ABG, including $59.1 million from deemed disposals due to ABG's capital transactions and $157.1 million from the sale of a portion of its ABG interests. Additionally, SPG recorded a $145.8 million gain from the dilution of its ownership in SPARC Group. In 2024, SPG disclosed a pre-tax gain of $18.8 million from the sale of a portion of its ABG interest in December 2021, along with a strategic partnership with ABG to become the core licensee and operating partner for Reebok in the U.S., indicating a shift toward deeper operational collaboration rather than just financial transactions.",
      "llm_answer": "In 2023 SPG’s relationship with ABG was dominated by a series of dilution‑related transactions that generated non‑cash pre‑tax gains of $59.1 million, a $157.1 million share of gain on a partial ABG sale and a $145.8 million gain from a SPARC Group deemed disposal, leaving SPG with roughly a 9.6 % stake (2023 10‑K, pp. 63‑67). By 2024 SPG fully exited ABG, selling its remaining interest for $1.2 billion and recording a $414.8 million pretax gain, and then redeployed the proceeds into new strategic investments such as a 4 % purchase of TRG and other joint‑venture formations (2024 10‑K, pp. 72‑76).",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains significant factual errors and contradicts the ground truth on multiple critical points: (1) QUANTITATIVE ERRORS: The LLM claims SPG 'fully exited ABG' in 2024 by selling its remaining interest for $1.2 billion with a $414.8 million pretax gain. However, the ground truth states SPG disclosed a $18.8 million gain from a December 2021 sale in 2024 disclosures - not a full exit in 2024. The $1.2 billion exit figure and $414.8 million gain are not mentioned in the ground truth and appear to be fabricated. (2) ENTITY/TRANSACTION CONFUSION: The LLM incorrectly characterizes the 2024 activity as a complete exit, when the ground truth indicates 2024 involved a strategic partnership with ABG for Reebok licensing, not a full divestment. The mention of TRG investment and joint ventures is not supported by the ground truth provided. (3) INCOMPLETE 2023 ANALYSIS: While the LLM correctly identifies the 2023 gains ($59.1M, $157.1M, $145.8M), it misses the key contextual point that these were non-cash pre-tax gains from deemed disposals and dilution events. (4) MISSING KEY STRATEGIC SHIFT: The ground truth emphasizes a shift from financial transactions to 'deeper operational collaboration' through the Reebok partnership in 2024. The LLM completely misses this strategic evolution and instead invents a full exit narrative. (5) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the 2023-2024 evolution. The ground truth shows a transition from passive financial gains to active operational partnership; the LLM invents a complete exit narrative that contradicts the ground truth. The answer demonstrates fundamental misunderstanding of SPG's actual relationship evolution with ABG.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 470,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Lockheed Martin's involvement in Sikorsky helicopter programs evolved from 2022 to 2024, particularly in terms of production volume and program scope?",
      "original_answer": "In 2022, Lockheed Martin's RMS segment experienced a $560 million increase in product costs, partly due to higher production volume on various Sikorsky helicopter programs. By 2024, RMS explicitly listed Sikorsky helicopter programs—such as those related to the Black Hawk, Seahawk, and CH-53K King Stallion—as key components of its portfolio, indicating a continued and potentially expanded focus. This evolution reflects a shift from being a cost driver to being a clearly defined strategic product line within the RMS segment.",
      "llm_answer": "In the 2022 10‑K Lockheed Martin said its Rotary and Mission Systems segment saw higher product sales and costs because of **increased production volume on a range of Sikorsky helicopter programs** (e.g., Black Hawk, Seahawk, CH‑53K)【LMT_10k_2022.pdf p41】. By the 2024 10‑K the focus had shifted to **delivering the final VH‑92A Marine One aircraft and sustaining production of Black Hawk, Seahawk, CH‑53K and the Combat Rescue Helicopter**, showing a broader program scope that now includes final‑delivery milestones rather than just volume expansion【LMT_10k_2024.pdf p5】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Lockheed Martin's Sikorsky helicopter program evolution from 2022 to 2024, with mostly accurate information and appropriate multi-hop synthesis. STRENGTHS: (1) Correctly identifies the RMS segment as the relevant business unit; (2) Accurately cites the 2022 context of increased production volume on Sikorsky programs; (3) Correctly names specific helicopter programs (Black Hawk, Seahawk, CH-53K) in both years; (4) Properly synthesizes the evolution showing a shift from volume-driven cost increases to a more strategically defined portfolio with specific delivery milestones; (5) Appropriately references the VH-92A Marine One program as a 2024 focus area; (6) Uses proper citation format with document references. WEAKNESSES: (1) The ground truth mentions a specific $560 million increase in product costs in 2022, which the LLM answer does not include—this is a notable omission of a key quantitative detail; (2) The LLM characterizes the 2022 situation as 'higher product sales and costs' but the ground truth specifically emphasizes 'product costs' increase, which is a subtle but important distinction; (3) The LLM's framing of the evolution as 'shift from volume expansion to final-delivery milestones' is a reasonable interpretation but goes slightly beyond what the ground truth explicitly states about the shift from 'cost driver to clearly defined strategic product line.' MULTI-HOP REASONING: The answer correctly synthesizes information across two different 10-K filings (2022 and 2024) and identifies the temporal evolution. The logic connecting increased production volume in 2022 to expanded program scope in 2024 is sound. QUANTITATIVE ACCURACY: While the specific $560 million figure is missing, no incorrect numbers are provided. The answer avoids making unsupported numerical claims. SEMANTIC EQUIVALENCE: The core message aligns with the ground truth—Sikorsky programs evolved from being a cost/volume driver to a clearly defined strategic focus—though the LLM adds the specific detail about VH-92A Marine One delivery milestones, which represents a reasonable elaboration rather than an error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 581,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Walmart's ownership stake and financial investment in Alert Innovation evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, increasing its ownership to approximately 100%. By fiscal 2024, there was no mention of Walmart retaining ownership of Alert Innovation, indicating that the company had fully exited its stake, likely through a sale or divestiture.",
      "llm_answer": "In fiscal 2023 Walmart paid about $0.4 billion to acquire Alert Innovation, converting the variable‑interest entity into a wholly‑owned subsidiary and taking its ownership to roughly 100 % 【WMT_10k_2023.pdf p. 44‑45】. In fiscal 2024 Walmart made no additional purchase or capital infusion for Alert Innovation, leaving the stake unchanged at full ownership (the company later sold and de‑consolidated the business in fiscal 2025) 【WMT_10k_2024.pdf p. 63‑66】.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) The $0.4 billion acquisition amount in fiscal 2023 is accurate, (2) The ownership reaching approximately 100% is correct, (3) The identification of Alert Innovation as a variable-interest entity is accurate. PROBLEMATIC ELEMENTS: (1) The LLM introduces information about fiscal 2025 (sale/de-consolidation) which goes beyond the scope of the question asking specifically about fiscal 2023 to fiscal 2024 evolution. While this additional context may be factually accurate, it wasn't part of the ground truth answer and represents information outside the requested timeframe. (2) The LLM states 'no additional purchase or capital infusion for Alert Innovation, leaving the stake unchanged at full ownership' in fiscal 2024, which is a reasonable inference but differs from the ground truth's more definitive statement that 'there was no mention of Walmart retaining ownership of Alert Innovation, indicating that the company had fully exited its stake.' This represents a material difference in interpretation - the ground truth suggests an exit occurred between fiscal 2023 and 2024, while the LLM suggests the stake remained unchanged through fiscal 2024 with the exit happening in fiscal 2025. MULTI-HOP REASONING: The LLM correctly synthesizes information across fiscal years but makes an interpretive error about the timing of the exit. The ground truth indicates the exit happened between fiscal 2023-2024, but the LLM places it in fiscal 2025. This is a significant discrepancy in the core answer to the question about how the stake 'evolved' between these two years. The quantitative data (dollar amounts) are correct, but the qualitative interpretation of ownership evolution is misaligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1186,
        "completion_tokens": 490,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did SPG's utilization and management of the Supplemental Facility evolve between 2023 and 2024, particularly in terms of borrowing activity and repayment strategy?",
      "original_answer": "In 2023, SPG utilized the Supplemental Facility as part of its broader capital strategy, borrowing €750.0 million under this facility, which was later repaid on November 17, 2023, following the issuance of senior unsecured bonds. By 2024, there was no outstanding balance under the Supplemental Facility, indicating a full repayment and a shift away from its use. This evolution shows a strategic reduction in reliance on the Supplemental Facility, with SPG opting instead to refinance through long-term unsecured notes, such as the $1.0 billion issuance in September 2024.",
      "llm_answer": "In 2023 SPG eliminated the €750 million balance it had on its Supplemental Facility by using the proceeds from a €750 million senior unsecured bond issuance (issued Nov 14, 2023 and applied to the facility on Nov 17, 2023) — effectively repaying the line in full (2023 10‑K, pp. 58‑62). By 2024 the Supplemental Facility remained available with a $3.5‑$4.5 billion borrowing capacity (maturing Jan 31, 2029) but the company disclosed no new draws or repayments, indicating it was kept as a standby liquidity source rather than actively used (2024 10‑K, pp. 68‑72).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and well-structured. STRENGTHS: (1) Correctly identifies the €750 million borrowing in 2023 and its repayment via senior unsecured bond issuance; (2) Accurately dates the bond issuance (Nov 14, 2023) and facility repayment (Nov 17, 2023); (3) Correctly notes zero outstanding balance in 2024; (4) Provides additional context about the $3.5-$4.5 billion borrowing capacity and January 31, 2029 maturity date; (5) Properly synthesizes the multi-hop information showing the evolution from active use to standby liquidity source. MINOR ISSUES: (1) The ground truth mentions a $1.0 billion unsecured notes issuance in September 2024 as part of the refinancing strategy, which the LLM answer does not include—this represents a minor omission of forward-looking refinancing activity that demonstrates the broader strategic shift; (2) The LLM answer provides more granular detail about 2024 capacity and maturity dates than the ground truth, which is supplementary but not contradictory. QUANTITATIVE VERIFICATION: All numbers are accurate (€750M, $3.5-$4.5B capacity, dates Nov 14/17, 2023, Jan 31, 2029). MULTI-HOP REASONING: The answer correctly synthesizes information across 2023 and 2024 filings, showing the causal relationship between bond issuance and facility repayment, and the strategic shift in capital management. The reasoning is sound and logically presented. The answer effectively addresses both borrowing activity and repayment strategy as requested in the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 418,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has Linde's treatment of helium in its industrial gases business evolved between 2023 and 2024, particularly in terms of its positioning as a primary product and associated supply strategies?",
      "original_answer": "In 2023, helium was explicitly listed as one of Linde's primary products within its industrial gases business, specifically called out alongside gases like oxygen, nitrogen, and hydrogen. The 2023 filing also described helium's distribution through merchant delivery, with contracts typically lasting three to seven years and without minimum purchase requirements. By 2024, helium was no longer specifically named as a distinct product in the industrial gases segment. Instead, it was subsumed under more general descriptions of gas supply methods and contracts, suggesting a reduced emphasis on helium as a standalone offering. This shift indicates a strategic repositioning of helium within Linde's broader gas portfolio, aligning it more closely with other merchant gases rather than maintaining its prior distinct status.",
      "llm_answer": "In the 2023 filing Linde identified helium as one of its core process gases and said it is primarily sold through merchant (bulk‑liquid) deliveries under three‑to‑seven‑year supply agreements that carry no minimum‑purchase or volume commitments【99†L13-L19】【99†L33-L38】. The 2024 filing still lists helium as a primary product (now alongside hydrogen and carbon‑monoxide) and repeats the same merchant‑delivery, flexible‑supply‑contract model, showing that its positioning and supply strategy for helium have essentially remained unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERROR IN CORE CLAIM: The LLM answer directly contradicts the ground truth on the fundamental question. The ground truth explicitly states that by 2024, 'helium was no longer specifically named as a distinct product in the industrial gases segment' and was 'subsumed under more general descriptions,' indicating a strategic repositioning with 'reduced emphasis on helium as a standalone offering.' However, the LLM claims that 'The 2024 filing still lists helium as a primary product' and that 'its positioning and supply strategy for helium have essentially remained unchanged.' This is factually incorrect according to the ground truth. The LLM has inverted the actual evolution described in the original answer. QUANTITATIVE ACCURACY: The numbers cited (three-to-seven-year contracts, no minimum purchase requirements, merchant delivery) are correct and match the ground truth for 2023. However, the critical error is in the 2024 comparison - the LLM incorrectly asserts that helium maintained its status in 2024 when the ground truth indicates it was de-emphasized. QUALITATIVE ACCURACY: The multi-hop reasoning fails at the synthesis stage. While the LLM correctly identifies 2023 positioning, it fundamentally misrepresents the 2024 positioning and the evolution between years. The claim that positioning 'remained unchanged' is the opposite of what the ground truth indicates. CONTEXTUAL RELEVANCE: The answer addresses the right question but provides an incorrect answer to it. The question specifically asks about how treatment 'evolved,' and the ground truth shows a clear evolution (from distinct product to subsumed category), but the LLM claims no evolution occurred. This is a major factual error that undermines the entire response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 477,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the allocation of assets in the U.S. Retiree Health Care Plan evolve between 2022 and 2023, particularly in terms of fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had $248 in fixed income securities and cash equivalents and $137 in equity securities, totaling $385. In 2023, the plan's allocation changed to $210 in fixed income securities and cash equivalents and $54 in equity securities, totaling $264. This indicates a decrease in both categories, with a more significant reduction in equity securities.",
      "llm_answer": "In 2022 the U.S. Retiree Health Care Plan held about $182 million of fixed‑income securities and cash equivalents and $98 million of equity securities – roughly a 65%/35% split 【TXN_10k_2022.pdf page 46‑48】. By year‑end 2023 those balances had shifted to $210 million of fixed‑income and $54 million of equity, moving the allocation to roughly 80% fixed‑income and 20% equity 【TXN_10k_2023.pdf page 45‑48】.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer contains significantly incorrect financial figures that contradict the ground truth. (1) 2022 NUMBERS ARE WRONG: LLM states $182M fixed income and $98M equity, but ground truth shows $248M fixed income and $137M equity. This is a major discrepancy - the LLM's 2022 fixed income figure is $66M too low (26.6% error) and equity is $39M too low (28.5% error). (2) 2023 NUMBERS ARE PARTIALLY CORRECT: LLM correctly states $210M fixed income and $54M equity, matching ground truth exactly. (3) CALCULATION ERRORS: The LLM's 2022 percentage split (65%/35%) is based on incorrect numbers. Using LLM's figures: $182/$280 = 65% and $98/$280 = 35%, which is mathematically consistent with their stated numbers but factually wrong. The correct 2022 split should be $248/$385 = 64.4% and $137/$385 = 35.6%. The 2023 percentages (80%/20%) are also slightly off: $210/$264 = 79.5% and $54/$264 = 20.5%, though closer to stated values. (4) MULTI-HOP SYNTHESIS: The LLM correctly identified the evolution pattern (decrease in both categories, more significant in equity) but this correct conclusion is undermined by the wrong 2022 baseline figures. (5) ENTITY ACCURACY: Correctly identified the U.S. Retiree Health Care Plan and years 2022-2023. (6) COMPLETENESS: The answer addresses the question's requirements but with fundamentally flawed data for the 2022 baseline, making the comparison invalid. The 2023 data being correct suggests possible source confusion or data retrieval error for 2022.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1204,
        "completion_tokens": 417,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial performance and strategic positioning of Trodelvy evolve between 2022 and 2023, particularly in terms of revenue generation and regulatory milestones?",
      "original_answer": "In 2022, Trodelvy generated $380 million in total product sales, primarily in the U.S., indicating its early commercial presence. By 2023, there was a strategic shift in Trodelvy's positioning as it received significant regulatory approvals: FDA approval for treating HR+/HER2- metastatic breast cancer and EC approval for a similar indication. These developments suggest a strong enhancement in its market potential and therapeutic footprint, although specific revenue figures for 2023 are not provided.",
      "llm_answer": "Trodelvy’s sales jumped from $680 million in 2022 to $1.1 billion in 2023 – a 56 % increase driven by stronger demand in both existing and new markets【GILD_10k_2023.pdf: pages 37‑41】.  In 2023 the drug also achieved major regulatory wins, gaining FDA approval and European Commission (EC) marketing authorization for HR⁺/HER2‑negative metastatic breast cancer (while its Phase 3 NSCLC trial missed its OS endpoint), expanding its therapeutic footprint and strategic positioning【GILD_10k_2023.pdf: pages 37‑41】.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains fundamentally incorrect financial figures that directly contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURE: The LLM states Trodelvy sales were $680 million in 2022 and $1.1 billion in 2023, but the ground truth clearly states $380 million in 2022 with no 2023 revenue figure provided. This is a massive discrepancy - the 2022 figure is 79% higher than actual ($680M vs $380M), and the 2023 figure appears to be fabricated entirely. The claimed 56% increase calculation is based on these false numbers. (2) REGULATORY MILESTONES: The LLM correctly identifies the FDA approval and EC approval for HR+/HER2- metastatic breast cancer in 2023, which matches the ground truth. The additional detail about the Phase 3 NSCLC trial missing its OS endpoint is contextually relevant but not mentioned in the ground truth. (3) MULTI-HOP REASONING: While the LLM attempts to synthesize revenue growth with regulatory approvals (appropriate for the question), the foundation is built on incorrect data. The reasoning structure is sound, but the factual basis is severely flawed. (4) SEMANTIC EQUIVALENCE: The LLM's framing of 'strategic shift' and 'enhancement in market potential' aligns with the ground truth's intent, but this cannot overcome the fundamental numerical errors. The answer demonstrates a pattern of hallucination regarding specific financial figures, which is particularly problematic in financial analysis where precision is critical.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 412,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Chevron's downstream-related earnings and investment relationship with GS Caltex evolve from 2022 to 2024, and what does this indicate about the strategic importance of the joint venture?",
      "original_answer": "In 2022, Chevron reported higher downstream-related earnings from GS Caltex in Korea, contributing to improved income from equity affiliates. By 2024, Chevron maintained a 50% ownership stake in GS Caltex Corporation, which operates as a joint venture with GS Energy, importing, producing, and marketing petroleum products, petrochemicals, and lubricants. Additionally, in 2024, Chevron reported $13,850 million in sales and other operating revenues with affiliated companies, including GS Caltex, compared to $16,286 million in 2022. This indicates that while the joint venture remained strategically important, the level of downstream-related revenue with affiliated companies slightly decreased over the period.",
      "llm_answer": "In 2022 Chevron’s downstream segment produced about **$8.6 billion of income from equity affiliates**, a boost that the MD&A attributes in part to “higher downstream‑related earnings from CPChem and **GS Caltex** in Korea” [CVX_10k_2022.pdf p.44].  The equity‑method earnings from the 50 %‑owned GS Caltex joint venture were **$874 million** and Chevron’s balance‑sheet investment in the venture was roughly **$4.3 billion** [CVX_10k_2024.pdf p.85].  By 2024 the joint‑venture’s contribution had fallen to **$58 million** of equity earnings, while the investment remained around **$4.1 billion** [CVX_10k_2024.pdf p.85], indicating that the partnership still holds strategic importance for Chevron’s Asian market presence even though its near‑term earnings impact has sharply declined.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES WITH QUANTITATIVE ACCURACY: The LLM answer contains several significant factual errors that contradict the ground truth:\n\n1. EQUITY EARNINGS FIGURES - CRITICAL ERROR: The LLM claims GS Caltex equity-method earnings were '$874 million' in 2022 and fell to '$58 million' in 2024. The ground truth does not provide these specific numbers and the dramatic decline (from $874M to $58M) is not supported by the original answer. The ground truth only states that 2022 had 'higher downstream-related earnings from GS Caltex' without quantifying it at $874M.\n\n2. INVESTMENT BALANCE SHEET FIGURES: The LLM provides specific investment amounts ($4.3 billion in 2022, $4.1 billion in 2024) that are not mentioned in the ground truth answer. While these may be accurate from the source documents, they represent information not in the ground truth baseline.\n\n3. MISSING KEY METRIC FROM GROUND TRUTH: The ground truth specifically mentions 'sales and other operating revenues with affiliated companies' of $13,850 million (2024) vs $16,286 million (2022). The LLM answer completely omits this important metric that directly addresses the 'investment relationship' evolution and the quantified decrease in revenue.\n\n4. INCOMPLETE SYNTHESIS: While the LLM addresses the 50% ownership stake and joint venture structure (correct), it fails to incorporate the critical revenue comparison that the ground truth emphasizes as evidence of the relationship's evolution.\n\n5. REASONING QUALITY: The LLM's conclusion about 'strategic importance' despite 'sharply declined' earnings is reasonable, but it's based on equity earnings figures that cannot be verified against the ground truth. The ground truth uses the revenue decline ($16,286M to $13,850M) as the primary evidence of evolution.\n\n6. CONTEXTUAL ISSUE: The LLM introduces CPChem alongside GS Caltex when the question specifically asks about GS Caltex, creating potential confusion about which affiliate is being discussed.\n\nThe answer demonstrates some understanding of the joint venture's structure and strategic role, but the specific quantitative claims about equity earnings and investment amounts are either unsupported by or contradict the ground truth baseline. The omission of the sales/revenue figures is a significant gap in addressing the 'investment relationship' aspect of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 629,
        "total_tokens": 2016
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the financial performance and production status of the CH-53K program evolve from 2022 to 2024, particularly in terms of risk retirements and production volume?",
      "original_answer": "In 2022, the CH-53K program contributed to higher operating profit for Sikorsky helicopter programs, with approximately $140 million in increased profit driven by higher risk retirements and production volume. By 2024, while the CH-53K remained a key product within RMS, the overall operating profit for RMS declined significantly—by 73%—partially due to lower profit booking rate adjustments across the portfolio. Although specific profit figures for CH-53K were not disclosed in 2024, the broader profit decline suggests that the gains from risk retirements observed in 2022 may have diminished as the program matured and entered higher-volume production.",
      "llm_answer": "In the 2022 filing Lockheed Martin highlighted the CH‑53K as a source of both **higher risk‑retirements** and **higher production volume** – the Sikorsky helicopter program “contributed higher operating profit of approximately $140 million … due to higher risk retirements (Black Hawk and CH‑53K), higher production volume (Black Hawk and CRH)” and “higher net sales … due to higher production volume (Black Hawk, CH‑53K and CRH)” 【48†L...】.  \n\nBy the 2024 filing the CH‑53K was still noted for **production volume** – “$140 million for Sikorsky helicopter programs due to higher production volume on the CH‑53K program” 【41†L...】 – but **risk‑retirement benefits were no longer mentioned**, showing the program’s financial impact had shifted from risk‑retirement credit to pure volume‑driven sales growth.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the $140 million profit contribution in 2022 from Sikorsky helicopter programs. (2) Accurately captures that risk retirements and production volume were both drivers in 2022. (3) Correctly notes the shift away from risk-retirement benefits by 2024, with production volume becoming the primary driver. (4) Properly synthesizes the multi-hop information across 2022 and 2024 filings. (5) The semantic interpretation that risk-retirement benefits 'diminished' or 'were no longer mentioned' aligns with ground truth.\n\nWEAKNESSES: (1) The LLM answer cites a 2024 figure of '$140 million for Sikorsky helicopter programs due to higher production volume on the CH-53K program' but the ground truth does not provide this specific 2024 number. The ground truth states 'specific profit figures for CH-53K were not disclosed in 2024' and mentions a 73% decline in RMS operating profit overall. This is a potential factual discrepancy - the LLM appears to have cited a 2024 profit figure that may not exist or may be misattributed. (2) The LLM answer does not address the 73% decline in RMS operating profit mentioned in the ground truth, which is a significant contextual element showing the broader deterioration. (3) Missing the nuance that while CH-53K remained a key product, the overall portfolio performance declined significantly.\n\nQUANTITATIVE VERIFICATION: The $140 million figure for 2022 is correct. However, the citation of '$140 million for Sikorsky helicopter programs due to higher production volume on the CH-53K program' in 2024 is problematic - this appears to conflate 2022 and 2024 data or misrepresent what was disclosed in 2024. The ground truth explicitly states specific 2024 CH-53K profit figures were not disclosed.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2024 filings and correctly identifies the shift in financial drivers (risk retirements → production volume). However, it fails to incorporate the critical context of the 73% RMS profit decline in 2024.\n\nOVERALL ASSESSMENT: The answer captures the core evolution of the program but contains a potentially significant factual error regarding 2024 profit attribution and omits important context about overall portfolio decline. The reasoning about the shift from risk retirements to production volume is sound, but the quantitative claims about 2024 need verification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 646,
        "total_tokens": 2018
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has PayPal's approach to seller protection programs evolved between 2022 and 2023, particularly in terms of risk exposure and strategic emphasis?",
      "original_answer": "In 2022, PayPal highlighted that its seller protection programs carried risk exposure tied to regional variations and regulatory changes, with historical transaction loss rates ranging between 0.09% and 0.15% of TPV. By 2023, the company placed a stronger strategic emphasis on these programs as a competitive differentiator, explicitly linking them to merchant trust and platform growth. While 2022 focused on risk management and potential loss implications, 2023 framed seller protection as part of a broader value proposition to attract and retain merchants, integrating it with analytics, risk management, and other merchant services.",
      "llm_answer": "In the 2022 filing PayPal framed its seller‑protection (buyer‑ and seller‑protection) mainly as a risk‑management issue, reporting that “transaction loss rates have ranged between 0.09 % and 0.15 % of TPV” and warning that “negative impacts on macro‑economic conditions could increase the risk of merchant bankruptcy… and an adverse impact on our transaction losses”【PYPL_10k_2022.pdf p. 49‑53】. By the 2023 filing the language had shifted to a strategic emphasis, describing the programs as a “core differentiator” that “help protect both merchants and consumers… promote confidence” and noting “ongoing investment in systems and processes… to enhance the safety and security of our products” and to be “one of the world’s most trusted payments brands”【PYPL_10k_2023.pdf p. 7‑11】. Thus, PayPal moved from quantifying exposure and warning of macro‑economic risk in 2022 to positioning seller‑protection as a competitive, trust‑building feature backed by technology and risk‑management investments in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: The specific transaction loss rate range (0.09%-0.15% of TPV) is correctly cited and properly attributed to the 2022 filing. No calculation errors or numeric inaccuracies detected. ENTITY ACCURACY: PayPal correctly identified, fiscal years 2022 and 2023 properly distinguished, and financial metrics accurately referenced. MULTI-HOP REASONING: The answer successfully synthesizes information across two separate 10-K filings, correctly identifying the evolution from risk-focused language in 2022 to strategic/competitive positioning in 2023. The comparison is logically sound and well-supported. COMPLETENESS: The answer addresses both components of the question - risk exposure (quantified with loss rates, macro-economic warnings) and strategic emphasis (shift from risk management to competitive differentiation and trust-building). SEMANTIC EQUIVALENCE: The LLM's characterization of 2022 as 'risk-management issue' and 2023 as 'strategic emphasis' with 'core differentiator' language matches the ground truth's framing of the evolution. The inclusion of specific phrases like 'promote confidence' and 'one of the world's most trusted payments brands' adds credibility and specificity. MINOR CONSIDERATIONS: The LLM includes parenthetical clarification '(buyer-and seller-protection)' which adds helpful context beyond the ground truth but doesn't contradict it. The citation format with page numbers enhances credibility. The answer is slightly more detailed than the ground truth but maintains factual accuracy throughout. No material omissions or errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 461,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Starbucks' approach to its ready-to-drink beverages evolved between 2023 and 2024, particularly in terms of revenue recognition and supplier dependency?",
      "original_answer": "In 2023, Starbucks recognized revenue from ready-to-drink beverages under the 'Other Revenues' category, where sales were generally recognized upon shipment to customers depending on contract terms. By 2024, the company's focus shifted to supplier dependency and supply chain resilience, emphasizing that ready-to-drink beverages are sourced from specialty suppliers under long-term contracts, indicating a strategic move toward securing stable supply rather than just reporting revenue. While 2023 included ready-to-drink beverages in broader revenue disclosures without specific figures, 2024 highlighted the importance of supplier relationships to mitigate delivery risks, signaling a shift from revenue-centric reporting to a supply-chain risk management focus.",
      "llm_answer": "Starbucks’ treatment of ready‑to‑drink (RTD) beverages was essentially unchanged from 2023 to 2024. In both years the sales are recorded in the Channel Development segment and revenue is recognized when the product is shipped to customers (subject to contract terms) (2023 p. 63; 2024 p. 11), and the company continues to source the RTD drinks from a number of specialty suppliers under long‑term supply contracts, indicating no material shift in supplier dependency (2023 p. 66‑67; 2024 p. 13‑14).",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer fundamentally contradicts the ground truth on the core question. The ground truth explicitly states there WAS a material shift in Starbucks' approach between 2023 and 2024 - from revenue-centric reporting to supply-chain risk management focus. The LLM incorrectly claims the treatment was 'essentially unchanged' and that there was 'no material shift in supplier dependency,' which directly contradicts the original answer's key finding. Specific issues: (1) The LLM states revenue recognition was in 'Channel Development segment' in both years, but the ground truth indicates 2023 used 'Other Revenues' category - this is a factual error in entity/segment identification. (2) The LLM claims 'no material shift' when the ground truth explicitly describes a strategic shift from revenue reporting to supply chain resilience emphasis - this is a fundamental misunderstanding of the multi-hop synthesis required. (3) The LLM provides page citations (2023 p. 63, 2024 p. 11, etc.) that cannot be verified against the ground truth, and these citations appear to support an incorrect conclusion. (4) The ground truth emphasizes 2024's focus on 'supplier relationships to mitigate delivery risks' and 'supply-chain risk management focus' - a qualitative shift the LLM completely misses. (5) The LLM's conclusion that supplier dependency showed 'no material shift' contradicts the ground truth's emphasis on 2024 highlighting 'the importance of supplier relationships' as a strategic priority shift. The answer fails to capture the evolution in strategic focus that is central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 439,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the geographic reach and regulatory approvals of Trodelvy evolve between 2022 and 2023?",
      "original_answer": "In 2022, Trodelvy generated $370 million in U.S. sales and $10 million in Europe, with no sales reported in other international markets, indicating limited geographic reach. By 2023, Trodelvy received significant regulatory approvals: it was approved by the FDA for treating adult patients with HR+/HER2- metastatic breast cancer, and it obtained EC approval for monotherapy treatment of unresectable or metastatic HR+/HER2- breast cancer. These approvals suggest an expansion of Trodelvy's market access and therapeutic application, likely contributing to broader geographic distribution beyond what was reported in 2022.",
      "llm_answer": "In 2022 Trodelvy was already approved in the United States (FDA) for metastatic triple‑negative breast cancer (TNBC) and urothelial cancer, and in the European Union (European Commission) for TNBC, with additional approvals in Canada, Australia, Great Britain, Switzerland and under the Project Orbis collaborative review program 【GILD_10k_2022.pdf†L31-L38】. By 2023 Gilead secured two new clearances – an FDA approval and a European Commission approval – expanding Trodelvy’s label to HR⁺/HER2‑negative metastatic breast cancer, thereby extending its regulatory footprint in both the U.S. and EU and supporting sales growth in new and existing geographies【GILD_10k_2023.pdf†L24-L31】.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer provides accurate information about regulatory approvals but has significant gaps in addressing the geographic reach evolution with specific financial data. STRENGTHS: (1) Correctly identifies 2023 FDA and EC approvals for HR+/HER2- metastatic breast cancer, matching ground truth; (2) Accurately notes 2022 approvals in US, EU, Canada, Australia, Great Britain, Switzerland; (3) Properly synthesizes the expansion of regulatory footprint between years; (4) Correctly identifies the multi-hop nature of the question. WEAKNESSES: (1) CRITICAL OMISSION - The LLM completely fails to include the specific 2022 sales figures ($370M US, $10M Europe) that are central to demonstrating geographic reach evolution. The ground truth explicitly states these numbers as evidence of 'limited geographic reach' in 2022; (2) The LLM mentions 'supporting sales growth in new and existing geographies' but provides no quantitative evidence or comparison to 2022 baseline; (3) Does not adequately address the 'no sales reported in other international markets' aspect from 2022; (4) The answer focuses heavily on regulatory approvals (which are correct) but underweights the geographic sales data that directly answers the 'geographic reach' portion of the question. QUANTITATIVE ACCURACY: The regulatory approvals mentioned are accurate, but the answer lacks the critical financial metrics (2022: $370M US, $10M Europe) that form the quantitative foundation for assessing geographic reach evolution. REASONING: The multi-hop synthesis is partially sound - it correctly connects regulatory approvals to market access expansion - but it fails to complete the full analysis by comparing 2022 sales geography to 2023 approvals. The answer would benefit from explicitly stating how the new 2023 approvals (HR+/HER2- indication) represent a therapeutic expansion that could drive geographic growth beyond the 2022 baseline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 517,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Simon Property Group's ownership stake and financial gains from transactions involving ABG evolve between 2023 and 2024?",
      "original_answer": "In 2023, Simon Property Group (SPG) experienced multiple dilutions of its ownership stake in ABG through capital transactions, including a reduction from approximately 12.3% to 11.8%, then to 11.7%, and finally to approximately 9.6%. These transactions resulted in non-cash pre-tax gains of $36.4 million, $12.4 million, and $10.3 million, respectively. By contrast, in 2024, SPG no longer disclosed active changes in its ownership stake in ABG. Instead, it referenced a prior transaction from December 20, 2021, where it sold a portion of its interest in ABG for a pre-tax gain of $18.8 million and later acquired additional interests for $100.0 million. This indicates a shift from active stake reduction and financial recognition in 2023 to a more passive disclosure stance in 2024, with no new transactions reported.",
      "llm_answer": "In 2023 Simon’s ABG holding was gradually diluted – it fell from roughly 12.3 % at the start of the year to about 9.6 % by year‑end after a series of capital‑transaction “deemed disposals” that produced non‑cash pre‑tax gains of $36.4 million (Q2), $12.4 million (Q3) and $10.3 million (Q4), plus a cash sale of a portion of the interest for $300.2 million that generated a $157.1 million pre‑tax gain (2023 10‑K, pp. 112‑115). In 2024 Simon exited ABG entirely, selling its remaining stake for $1.2 billion and recognizing a $414.8 million pre‑tax gain (2024 10‑K, p. 73), leaving it with 0 % ownership.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that fundamentally contradict the ground truth. (1) MAJOR ERRORS - 2023 TRANSACTIONS: The LLM correctly identifies the three non-cash gains ($36.4M, $12.4M, $10.3M) and the ownership dilution from 12.3% to 9.6%, which matches ground truth. However, the LLM introduces entirely fabricated information: a $300.2 million cash sale generating a $157.1 million pre-tax gain in 2023. The ground truth makes no mention of this transaction. (2) MAJOR ERRORS - 2024 TRANSACTIONS: The LLM claims SPG 'exited ABG entirely' in 2024, selling its remaining stake for $1.2 billion and recognizing a $414.8 million pre-tax gain. This directly contradicts the ground truth, which explicitly states 'in 2024, SPG no longer disclosed active changes in its ownership stake in ABG' and 'no new transactions reported.' The ground truth indicates a shift to passive disclosure, not an active exit. (3) OWNERSHIP STAKE CONCLUSION: The LLM claims SPG ended with 0% ownership in 2024, while ground truth indicates it maintained some ownership position with no new transactions disclosed. (4) MULTI-HOP REASONING: The LLM failed to correctly synthesize the evolution between years. It mischaracterized 2024 as an active exit year when the ground truth clearly indicates the opposite - a shift away from active transactions. (5) CITATION ISSUES: The LLM provides specific page references (2024 10-K, p. 73) that cannot be verified and appear to reference non-existent transactions. The quantitative accuracy is severely compromised by the introduction of completely fabricated financial figures ($1.2B sale, $414.8M gain) that have no basis in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 460,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the 2012 Equity Incentive Plan evolved between the 2023 and 2024 filings, particularly in terms of amendments and forms of award agreements disclosed?",
      "original_answer": "In 2023, the 2012 Equity Incentive Plan was disclosed as amended, including the Third Amendment to the plan, and referenced forms of award agreements from 2012 and 2017. In 2024, the filing included a Fourth Amendment dated August 1, 2024, and introduced additional forms of award agreements from April 2024, showing continued evolution and expansion of the plan over time.",
      "llm_answer": "In the 2023 Form 10‑K the company referenced the 2012 Equity Incentive Plan “as amended” (Exhibit 10.2(A)) and the **Third Amendment** to the plan (Exhibit 10.2(B)), and it listed award‑agreement templates through Exhibit 10.2(L) (the most recent of those dated April 27 2023)【META_10k_2023.pdf p.126‑130】. By the 2024 filing the plan had been further updated – a **Fourth Amendment** is now disclosed as Exhibit 10.2(C) (filed August 1 2024) and a new award‑agreement form (Exhibit 10.2(K), filed April 25 2024) is added, while the earlier amendment and prior award‑agreement exhibits remain【META_10k_2024.pdf p.123‑127】. Thus, between the two years the plan received an additional amendment and an extra award‑agreement template, reflecting continued evolution of the plan’s terms and documentation.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates good understanding of the multi-hop question structure and correctly identifies the key evolution of the 2012 Equity Incentive Plan between 2023 and 2024 filings. However, there are significant quantitative accuracy issues that prevent a higher score.\n\nCORRECT ELEMENTS:\n- Correctly identifies Third Amendment in 2023 filing\n- Correctly identifies Fourth Amendment in 2024 filing with August 1, 2024 date\n- Correctly notes the addition of new award agreement forms\n- Properly synthesizes the multi-hop comparison across two years\n- Appropriate exhibit references and page citations\n- Correctly conveys the evolution/expansion theme\n\nINCORRECT/PROBLEMATIC ELEMENTS:\n1. DATE DISCREPANCY: The LLM states the most recent award agreement in 2023 was \"dated April 27 2023\" but the ground truth indicates forms from \"2012 and 2017\" were referenced in 2023. The LLM appears to have confused or added a specific date not mentioned in the ground truth.\n2. AWARD AGREEMENT DATING: The LLM claims a new award agreement form is \"filed April 25 2024\" but the ground truth only mentions \"April 2024\" without a specific date. This is a minor but unnecessary specificity that may be inaccurate.\n3. INCOMPLETE REFERENCE TO 2023 FORMS: The ground truth mentions forms from 2012 and 2017 in the 2023 filing, but the LLM's answer doesn't clearly reference these earlier forms, focusing instead on an April 2023 date that isn't in the ground truth.\n\nMULTI-HOP REASONING: The reasoning is sound - the model correctly identifies that the plan evolved by adding a Fourth Amendment and new award agreement forms between the two years. The comparison structure is logical and appropriate.\n\nSEMANTIC EQUIVALENCE: The core message matches - the plan was amended and expanded with new documentation between 2023 and 2024. However, the specific dates and forms referenced create factual discrepancies.\n\nThe answer would score higher if the specific dates and form references matched the ground truth exactly, but the overall structure and understanding of the evolution is correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 565,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the treatment and valuation of capitalized software licenses evolve between 2022 and 2023, and what does this indicate about the company's investment in software licensing?",
      "original_answer": "In 2022, capitalized software licenses were described as being generally amortized on a straight-line basis over the term of the license, indicating a clear policy for their depreciation over time. By 2023, the company disclosed the actual carrying value of these licenses on the balance sheet at $223 million, up from $152 million in 2022. This increase suggests a growing investment in software licensing, despite the unchanged amortization policy. The evolution from a disclosed accounting method in 2022 to a quantified asset in 2023 reflects a more tangible and increasing role of capitalized software licenses in the company's asset structure.",
      "llm_answer": "The 10‑K notes state that software‑license costs are capitalized as intangible assets and amortized on a straight‑line basis over the license term (see the “Property, plant and equipment… other capitalized costs” discussion). The balance‑sheet amount for these assets rose from $152 million at the end of 2022 to $223 million at the end of 2023 (and related amortization expense increased from $54 million to $63 million), indicating the company has substantially increased its spending on software licensing. This growth in the capitalized balance reflects a stronger investment in software tools and platforms to support its operations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. All key quantitative data points are correct: the balance sheet amounts of $152 million (2022) and $223 million (2023) are accurately cited, and the additional detail about amortization expense increasing from $54 million to $63 million is correct and adds valuable context. The accounting policy description (straight-line amortization over license term) matches the ground truth. The multi-hop reasoning is sound: the answer correctly synthesizes the evolution of treatment (accounting method disclosure) with the quantified valuation (balance sheet amounts) and draws the appropriate conclusion about increased investment in software licensing. The LLM provides slightly more detail than the ground truth by including amortization expense figures, which strengthens rather than detracts from the answer. The semantic meaning is equivalent to the ground truth - both convey that capitalized software licenses increased significantly from 2022 to 2023, indicating growing investment. Minor differences in wording (e.g., 'substantially increased its spending' vs. 'growing investment') are stylistic variations that don't affect factual accuracy. The answer appropriately addresses all parts of the question regarding treatment evolution, valuation changes, and what this indicates about investment trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 381,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what does this indicate about its strategic approach to funding credit products?",
      "original_answer": "In 2022, PayPal had approved $3.8 billion of European customer balances for credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, this approved amount decreased to $3.0 billion, representing 39% of European customer balances. This indicates a slight reduction in the total approved funding base but a higher percentage utilization of available balances, suggesting a more efficient use of existing customer balances for credit activities. Additionally, PayPal entered into a new €40 billion agreement in 2023 to sell consumer installment receivables, with $5.5 billion sold during the year, signaling a strategic shift toward external funding mechanisms to support credit product expansion.",
      "llm_answer": "PayPal’s pool of European customer balances earmarked for credit fell in absolute size from $3.8 billion at year‑end 2022 to $3.0 billion at year‑end 2023, but the share of available balances used rose from roughly 37 % to 39 % 【PYPL_10k_2023.pdf:48‑50】.  The higher proportion of its own deposits being tapped for credit shows PayPal is deliberately leaning more on internal customer‑funded liquidity to support its credit products, reducing reliance on external borrowing.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identified the key quantitative facts: (1) European customer balances for credit decreased from $3.8B (2022) to $3.0B (2023), (2) percentage utilization increased from ~37% to 39%, and (3) the interpretation that higher percentage utilization with lower absolute amount indicates more efficient use of existing balances. The numbers and percentages are all accurate.\n\nWEAKNESSES: The LLM answer is significantly incomplete on a critical multi-hop element. The ground truth explicitly mentions PayPal's strategic shift toward EXTERNAL funding mechanisms: a new €40 billion agreement in 2023 to sell consumer installment receivables, with $5.5 billion sold during the year. This is a major strategic development that directly addresses the question about PayPal's 'strategic approach to funding credit products.' The LLM's conclusion that PayPal is 'reducing reliance on external borrowing' is actually contradicted by the ground truth, which shows PayPal simultaneously entered into a major external receivables sale agreement. The LLM failed to synthesize this critical multi-hop information.\n\nQUANTITATIVE VERIFICATION: All numbers cited are correct ($3.8B→$3.0B, 37%→39%). No calculation errors.\n\nMULTI-HOP REASONING FAILURE: The question asks about 'strategic approach to funding credit products.' The ground truth indicates a dual strategy: (1) more efficient use of internal customer balances AND (2) significant new external funding mechanisms (€40B receivables sale agreement). The LLM only addressed the first element and drew an incomplete/potentially misleading conclusion about reducing external reliance, when the actual strategy appears to involve BOTH internal optimization AND new external mechanisms.\n\nCONTEXTUAL RELEVANCE: While the LLM addresses part of the question, it misses the strategic shift toward external funding that is central to understanding PayPal's overall credit funding strategy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 529,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Starbucks' investment relationship with Valor Siren Ventures I L.P. evolved between fiscal years 2023 and 2024, particularly in terms of the carrying value of the investment and its financial impact on Starbucks' consolidated statements?",
      "original_answer": "In fiscal 2023, Starbucks held a limited partnership interest in Valor Siren Ventures I L.P., with the total carrying value of such investments not specifically disclosed for that year. The financial impact of these investments, including Valor Siren Ventures I L.P., was included in 'interest income and other, net' and was not considered material. By fiscal 2024, the total carrying value of Starbucks' investments in Valor Siren Ventures I L.P. and II L.P. combined was $211.9 million as of September 29, 2024. The investment relationship evolved from a general equity stake to a more defined and quantified investment with ongoing monitoring, though the financial impact remained non-material and continued to be reported in 'interest income and other, net.'",
      "llm_answer": "Starbucks’ limited‑partnership interest in Valor Siren Ventures I LP (and II LP) rose sharply, with a total carrying value of $211.9 million reported at September 29 2024, up from the $24.2 million shown for “Other investments” on the October 1 2023 balance sheet. The partnership’s share of income and losses is recorded in the “interest income and other, net” line of the consolidated statements of earnings, and the related activity was not material in either fiscal year.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) The $211.9 million carrying value as of September 29, 2024 is accurate; (2) The identification of both Valor Siren Ventures I LP and II LP is correct; (3) The statement that financial impact is reported in 'interest income and other, net' is accurate; (4) The characterization of the impact as non-material in both years is correct; (5) The general narrative about evolution of the investment relationship is appropriate. PROBLEMATIC ELEMENTS: (1) The LLM introduces a specific comparison figure of $24.2 million for October 1, 2023 ('Other investments'), which is NOT mentioned in the ground truth. The ground truth explicitly states 'the total carrying value of such investments not specifically disclosed for that year' for fiscal 2023. This is a significant factual error - the LLM appears to have fabricated or misattributed a specific number that contradicts the ground truth's statement that no specific carrying value was disclosed for 2023; (2) The phrase 'rose sharply' implies a calculated comparison, but the $24.2 million figure is not validated in the ground truth and may be incorrect or from a different line item. QUANTITATIVE ACCURACY: The $211.9 million figure is correct, but the $24.2 million comparison is unverified and contradicts the ground truth's statement about non-disclosure. This is a critical error in a financial comparison. QUALITATIVE ACCURACY: The reasoning about the evolution and reporting treatment is sound, but the introduction of an unsubstantiated prior-year figure undermines the analysis. MULTI-HOP REASONING: The answer correctly synthesizes information about the investment across years and its financial statement impact, but the synthesis is compromised by the potentially incorrect baseline figure. The answer would have been stronger by acknowledging that the 2023 carrying value was not specifically disclosed, as stated in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 533,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has the strategic positioning of Analog Products evolved between 2022 and 2023 in terms of TI's competitive advantages and financial contribution?",
      "original_answer": "In 2022, Analog Products were central to TI's strategic focus, contributing to a gross margin of 67.5% driven by the efficiency of their manufacturing strategy, including 300-millimeter production. By 2023, Analog Products remained a core pillar but were framed more explicitly within the context of TI's four sustainable competitive advantages, particularly emphasizing lower costs and greater control of the supply chain. Additionally, the 2023 report reinforced the role of Analog Products in enabling TI to generate and return significant cash, with a renewed emphasis on long-term free cash flow per share growth as the ultimate performance metric.",
      "llm_answer": "In 2022 TI still positioned analog products as a core pillar of its business model, emphasizing the four sustainable competitive advantages—its manufacturing‑technology foundation, a broad analog portfolio, extensive market‑channel reach, and diversified product‑customer mix—and the segment delivered about $15.4 billion of revenue and $8.4 billion of operating profit (≈54 % margin) (TXN_10k_2022.pdf p.19‑20). By 2023 the strategic emphasis remained unchanged, but analog revenue fell 15 % to $13.0 billion and operating profit dropped 30 % to $5.8 billion, cutting the margin to 44.6 % as weaker demand and higher manufacturing costs reduced its financial contribution (TXN_10k_2023.pdf p.16‑19).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core strategic positioning evolution and addresses the multi-hop question by comparing 2022 vs 2023. It properly recognizes that Analog Products remained a core pillar in both years and attempts to quantify the financial contribution with specific revenue and operating profit figures. The answer correctly identifies the year-over-year decline in performance (15% revenue drop, 30% operating profit drop) and provides margin calculations. The reasoning about weaker demand and higher manufacturing costs is contextually appropriate.\n\nWEAKNESSES - CRITICAL QUANTITATIVE ISSUES: (1) The 2022 Analog Products revenue figure of $15.4 billion and operating profit of $8.4 billion cannot be verified against the ground truth, which does not provide these specific segment numbers. (2) The calculated 2022 operating margin of 54.5% ($8.4B/$15.4B) is presented as fact but lacks ground truth verification. (3) The 2023 figures ($13.0B revenue, $5.8B operating profit, 44.6% margin) similarly cannot be confirmed against the provided ground truth. (4) The LLM provides specific page references (p.19-20, p.16-19) that suggest detailed sourcing, but the ground truth does not include these specific segment-level financial metrics.\n\nMISSING ELEMENTS: The LLM answer does not address the 2022 gross margin of 67.5% mentioned in the ground truth, nor does it discuss the 300-millimeter production efficiency that was highlighted as a key driver. The ground truth emphasizes the explicit framing within TI's four sustainable competitive advantages in 2023 and the renewed emphasis on long-term free cash flow per share growth, which the LLM mentions only partially (listing the four advantages for 2022 but not emphasizing the 2023 reframing).\n\nMULTI-HOP REASONING: The answer does synthesize information across two years and attempts to show evolution, which is appropriate for the question. However, the synthesis relies on unverified segment-level financial data rather than the gross margin and strategic positioning information provided in the ground truth.\n\nCONCLUSION: While the LLM demonstrates good understanding of the question structure and provides a coherent narrative about Analog Products' evolution, the specific financial figures cannot be confirmed against the ground truth, creating significant uncertainty about quantitative accuracy. The qualitative assessment of strategic positioning is reasonable but incomplete relative to the ground truth's emphasis on manufacturing efficiency, cash generation, and free cash flow metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 688,
        "total_tokens": 2027
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Chevron's capital allocation strategy in the Lower 48 region evolved from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments?",
      "original_answer": "Chevron's capital allocation in the Lower 48 region increased significantly from 2022 to 2023, as evidenced by the rise in depreciation, depletion, amortization, and impairments from $4,854 million in 2022 to $5,729 million in 2023. This indicates a growing focus on asset development and operational expansion in the Lower 48, contrasting with relatively stable or declining figures in other geographic segments like Europe, Middle East and North Africa.",
      "llm_answer": "In the Lower 48 segment, depreciation, depletion, amortization and impairments rose to $5.73 billion in 2023 from $4.85 billion in 2022, while capital expenditures increased to $6.49 billion from $5.63 billion. The roughly $0.9 billion jump in both metrics signals a shift toward a more aggressive capital‑allocation stance in the Lower 48 region, with higher spending to maintain and expand assets compared with the prior year.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct financial figures and sound multi-hop reasoning. STRENGTHS: (1) All primary numbers are accurate - DD&A increased from $4.854B (2022) to $5.729B (2023), correctly formatted as $4.85B and $5.73B; (2) The calculation of the ~$0.9B increase is accurate ($5.729B - $4.854B = $0.875B ≈ $0.9B); (3) The LLM correctly identifies this as evidence of increased capital allocation in the Lower 48 region; (4) The answer properly synthesizes the DD&A data to support conclusions about capital allocation strategy evolution. MINOR LIMITATIONS: (1) The LLM introduces capital expenditure data ($6.49B and $5.63B) that was not present in the ground truth answer - while this additional context may be accurate from the filings, it goes beyond what was provided in the original answer and represents information synthesis not explicitly validated by the ground truth; (2) The ground truth specifically mentions the contrast with other geographic segments (Europe, Middle East and North Africa), which the LLM answer omits; (3) The LLM's characterization of the strategy shift as 'more aggressive' is interpretive language not explicitly stated in the ground truth. QUANTITATIVE VERIFICATION: The core DD&A figures are correct and the $0.9B difference calculation is accurate. The reasoning that rising DD&A indicates growing asset development and operational expansion is sound and aligns with the ground truth interpretation. The answer successfully addresses the multi-hop requirement of connecting DD&A changes to capital allocation strategy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 440,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Verizon's approach to FWA Broadband evolved between 2023 and 2024, particularly in terms of its positioning within the company's product portfolio and its target customer segments?",
      "original_answer": "In 2023, Verizon provided FWA broadband through both 5G and LTE networks, targeting both Consumer and Business customers, and reported 3.1 million FWA broadband connections. By 2024, the company continued to offer FWA broadband primarily under the Verizon Consumer and Business Group segments, but with a more integrated positioning as an alternative to traditional landline internet access and as part of a broader portfolio that includes IoT and advanced communication services. The shift from 'provides' in 2023 to 'produces' in 2024 indicates a more strategic and product-centric approach to FWA broadband.",
      "llm_answer": "In the 2023 filing Verizon described Fixed‑Wireless Access (FWA) broadband as a supplemental, “alternative‑to‑landline” service that lives in both the Consumer and Business segments – a relatively small‑scale offering (≈3.1 million connections) that sits alongside its traditional wireless and wireline products【VZ_10k_2023.pdf p.3‑7】. By the 2024 filing the company has moved FWA into the core of its residential‑fixed‑services portfolio for consumers (grouped with Fios and DSL) and continues to list it as a key wireless product for Business customers, emphasizing its rollout over the expanding 5G/C‑Band network to serve both household and enterprise users – a shift that makes FWA a more central, growth‑focused component of the product lineup【VZ_10k_2024.pdf p.98‑102】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with minor gaps. STRENGTHS: (1) Correctly identifies the 3.1 million FWA connections figure from 2023, matching ground truth exactly. (2) Accurately captures the evolution from 2023 to 2024, noting the shift from supplemental/alternative positioning to more integrated/core positioning within the product portfolio. (3) Correctly identifies both Consumer and Business segments as target customers in both years. (4) Properly synthesizes multi-hop information across 2023 and 2024 filings, showing understanding of the strategic repositioning. (5) Appropriately notes the 5G/C-Band network expansion context. (6) Document citations are specific and appear credible. MINOR GAPS: (1) The ground truth mentions a shift from 'provides' (2023) to 'produces' (2024) as indicating a more strategic/product-centric approach - the LLM answer captures the essence of this shift but doesn't explicitly reference this linguistic/semantic distinction. (2) The ground truth mentions 'IoT and advanced communication services' as part of the broader portfolio context in 2024 - the LLM answer doesn't explicitly mention these elements, though it does reference 'enterprise users' which partially captures this. (3) The ground truth's characterization of FWA as 'relatively small-scale' in 2023 is captured by the LLM's use of '≈3.1 million connections' and 'small-scale offering,' which is appropriate. QUANTITATIVE VERIFICATION: The 3.1 million connections figure is correct and properly attributed to 2023. No calculations are required for this question, so quantitative accuracy is high. QUALITATIVE ASSESSMENT: The reasoning about portfolio positioning evolution is sound and well-articulated. The multi-hop synthesis across years is logical and complete. The answer effectively conveys how FWA moved from peripheral to more central positioning. CONTEXTUAL RELEVANCE: The answer directly addresses all aspects of the question - evolution between years, positioning within portfolio, and target customer segments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 551,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Emerson's relationship with AspenTech evolved from 2022 to 2024, and what financial impact did this evolution have on Emerson's gross margin and equity structure?",
      "original_answer": "In 2022, Emerson partnered with AspenTech, leveraging its asset optimization software to enhance industrial operational efficiency. By 2024, Emerson had significantly deepened this relationship by acquiring a 55% ownership stake in AspenTech as part of a strategic transaction that created 'New AspenTech.' This acquisition contributed positively to Emerson’s gross margin, benefiting it by 0.6 percentage points in 2023 and further influencing financial structure in 2024 with increased SG&A expenses tied to the integration. Additionally, the equity structure was impacted through the recognition of gains and losses associated with the AspenTech stock plans and the broader restructuring of industrial software assets.",
      "llm_answer": "Emerson’s partnership with AspenTech began in May 2022 when it contributed its Open Systems International and Geological Simulation Software businesses plus $6 billion in cash to create “New AspenTech,” emerging with a 55 % ownership of the combined company. By 2024 Emerson’s stake had risen to about 57 % and the firm announced a $240‑per‑share cash offer to purchase the remaining shares, moving toward full consolidation of AspenTech and eliminating the minority‑interest component of its equity structure. The AspenTech acquisition added roughly 0.6 percentage‑point to Emerson’s gross margin in 2023 (raising it to 49 %) and helped sustain the margin’s climb to 50.8 % in 2024, while the increasing ownership altered Emerson’s equity composition by expanding its controlling interest and setting up the eventual removal of the AspenTech non‑controlling equity.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive coverage of the question. STRENGTHS: (1) Correctly identifies the 2022 partnership structure with 55% ownership stake and the $6 billion cash contribution to create 'New AspenTech' - these details match ground truth. (2) Accurately reports the 0.6 percentage-point gross margin benefit in 2023, which is a key quantitative fact. (3) Correctly identifies the evolution to ~57% ownership by 2024 and the $240-per-share acquisition offer, showing progression of the relationship. (4) Properly synthesizes the multi-hop information: initial partnership → deepened relationship → financial impacts on margins and equity structure. (5) Provides specific margin figures (49% in 2023, 50.8% in 2024) that contextualize the impact. (6) Addresses both parts of the question: relationship evolution AND financial impacts on gross margin and equity structure. MINOR CONSIDERATIONS: (1) The ground truth mentions 'gains and losses associated with the AspenTech stock plans' but the LLM answer focuses more on the non-controlling interest elimination rather than explicitly discussing stock plan impacts. However, the LLM's discussion of 'removing the AspenTech non-controlling equity' is semantically related and captures the equity structure impact. (2) The ground truth mentions 'increased SG&A expenses tied to integration' which the LLM answer does not explicitly state, though this is a relatively minor omission. (3) The LLM provides more specific details about the acquisition offer ($240/share) and ownership progression (55% to 57%) than the ground truth, which adds value and demonstrates deeper knowledge. QUANTITATIVE VERIFICATION: All numbers provided (55%, 57%, $6 billion, $240/share, 0.6 percentage points, 49%, 50.8%) appear consistent with typical SEC filing disclosures and are presented without apparent errors. The calculations and comparisons are logically sound. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple years (2022, 2023, 2024) and connects the relationship evolution to specific financial metrics, demonstrating proper multi-hop reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 580,
        "total_tokens": 1983
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did the financial relationship between NEE and FPL Group Capital Inc evolve from 2022 to 2023, particularly in terms of the nature of their obligations and capital structure involvement?",
      "original_answer": "In 2022, the relationship was characterized by a guarantee agreement between FPL Group, Inc. and FPL Group Capital Inc. dated October 14, 1998, indicating a direct obligation from FPL Group, Inc. to FPL Group Capital Inc. By 2023, this relationship had evolved into a more complex capital structure involvement, with NEE issuing multiple series of junior subordinated debentures to FPL Group Capital Inc., including Series B, C, L, M, N, O, and P, with maturity dates ranging from 2057 to 2082. This transition reflects a strategic shift from a simple guarantee to a long-term capital financing arrangement.",
      "llm_answer": "In the 2022 filing the link between NEE and FPL Group Capital was essentially a parent‑guarantee arrangement – FPL Group, Inc. (the ultimate parent of NEE) signed a Guarantee Agreement that backed the capital subsidiary’s debt (see Exhibit 10(y) and *4(n)). By the 2023 filing that structure had shifted to direct capital‑market activity by the subsidiary: NextEra Energy Capital Holdings, Inc. issued its own Series K and Series L debentures and filed letters setting the terms of those securities (Exhibits *4(u) and *4(x)), indicating the subsidiary now raises debt on its own rather than relying on a parent guarantee.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) ENTITY CONFUSION: The LLM incorrectly identifies 'NextEra Energy Capital Holdings, Inc.' as the subsidiary issuing debentures in 2023, when the ground truth clearly states it was NEE issuing debentures to FPL Group Capital Inc. This is a fundamental misidentification of the relationship direction. (2) SERIES IDENTIFICATION ERROR: The ground truth specifies NEE issued Series B, C, L, M, N, O, and P debentures to FPL Group Capital Inc. with maturity dates 2057-2082. The LLM incorrectly claims 'Series K and Series L' were issued by a different entity (NextEra Energy Capital Holdings), which contradicts the ground truth. (3) RELATIONSHIP MISCHARACTERIZATION: The ground truth describes an evolution FROM a guarantee agreement (2022) TO direct capital financing via junior subordinated debentures (2023). The LLM incorrectly frames this as the subsidiary becoming independent and raising debt 'on its own rather than relying on a parent guarantee,' which misses the actual nature of the relationship - NEE was issuing debentures TO FPL Group Capital Inc., not independently. (4) STRUCTURAL MISUNDERSTANDING: The ground truth indicates a transition to 'long-term capital financing arrangement' where NEE issues debentures to FPL Group Capital Inc. The LLM's interpretation that the subsidiary is now independent contradicts this. (5) MISSING KEY DETAILS: The LLM fails to mention the specific maturity date range (2057-2082) and the complete list of series issued. While the LLM correctly identifies that the relationship evolved between 2022-2023, the specific nature of that evolution is fundamentally misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 469,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the positioning and market acceptance of InterStim II evolved between 2022 and 2024, particularly in relation to other InterStim neurostimulators and broader Pelvic Health therapies?",
      "original_answer": "In 2022, InterStim II was described as part of a suite of InterStim neurostimulators including InterStim Micro and InterStim X, with an emphasis on continued acceptance and growth in treating overactive bladder, urinary retention, and bowel incontinence. By 2024, InterStim II was specifically highlighted as a recharge-free neurostimulator, grouped alongside InterStim X and InterStim Micro (now differentiated by recharge status), and positioned within a broader context of continued acceptance and growth of Pelvic Health therapies. This evolution indicates a shift toward emphasizing device-specific attributes (e.g., recharge-free) and integration into a more mature and diversified product portfolio.",
      "llm_answer": "In the 2022 filing, InterStim II was described as a core component of the established InterStim therapy line, with “continued acceptance and growth of our Pelvic Health therapies…including our InterStim therapy with InterStim II, InterStim Micro and InterStim X neurostimulators,” but the growth driver that year was the newly launched InterStim Micro device. By the 2024 filing, InterStim II is highlighted as a “recharge‑free neurostimulator” and is again noted as gaining market traction alongside the newer InterStim X and the rechargeable InterStim Micro, indicating that its positioning has remained strong and its acceptance has continued to expand within the broader Pelvic Health portfolio.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and addresses the core question effectively. STRENGTHS: (1) Correctly identifies the 2022 positioning of InterStim II as part of a suite including InterStim Micro and InterStim X; (2) Accurately captures the 2024 shift to emphasizing 'recharge-free' as a key differentiator; (3) Properly synthesizes the multi-hop information across 2022 and 2024 filings; (4) Correctly notes the evolution from general 'continued acceptance and growth' language to more specific device attribute positioning; (5) Accurately identifies InterStim Micro as newly launched in 2022 and rechargeable by 2024; (6) Maintains semantic equivalence with ground truth regarding portfolio maturation and diversification. MINOR ISSUES: (1) The LLM answer adds interpretive detail about InterStim Micro being 'newly launched' in 2022 and 'rechargeable' by 2024 - while these appear consistent with the ground truth's differentiation by recharge status, the ground truth doesn't explicitly state these launch dates or recharge specifications, representing slight extrapolation beyond what was directly stated; (2) The phrase 'growth driver that year was the newly launched InterStim Micro device' is not explicitly confirmed in the ground truth, though it's a reasonable inference; (3) The answer could have been more explicit about the shift toward 'device-specific attributes' as a strategic positioning change, though this concept is implied. QUANTITATIVE ACCURACY: No numerical errors detected; dates (2022, 2024) are correct; device names are accurate. MULTI-HOP REASONING: Successfully synthesizes information across two filing years and correctly identifies the evolution in positioning strategy. The comparison between 2022 and 2024 is logically sound and well-structured. OVERALL: The answer is substantially correct with strong multi-hop reasoning, though it includes minor interpretive elements not explicitly confirmed in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 529,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Simon Property Group's utilization and management of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of borrowing capacity, interest rate strategies, and repayment actions?",
      "original_answer": "In 2022, the Supplemental Facility had an initial borrowing capacity of $3.5 billion, which could be increased to $4.5 billion, with a maturity date of January 31, 2026. Borrowings under the facility bore interest based on SOFR or similar rates, with a margin determined by the company's credit rating. By 2024, SPG had borrowed €750.0 million under the Supplemental Facility, which was repaid on November 17, 2023, following the issuance of exchangeable bonds. Additionally, interest rate swaps were used in 2023 to fix the rate on these borrowings at 3.81%. This indicates a shift from passive availability in 2022 to active utilization and strategic interest rate management in 2024.",
      "llm_answer": "In the 2022 filing the Supplemental Facility was described as a $3.5 billion unsecured revolving line (expandable to $4.5 billion) that initially matured on January 31 2026 (extendable to 2027) and whose borrowings were priced off SOFR (SOFR + 72.5 bps) with a margin‑based fee 【SPG_10k_2022.pdf p4‑8】. By the 2024 filing the capacity remained $3.5‑$4.5 billion but the maturity was pushed out to January 31 2029 (extendable to 2030) and the company actively managed the facility: it entered into €750 million of interest‑rate swaps to fix the Euro‑denominated draws at 3.81 % and then used proceeds from a €750 million, 3.50 % senior bond issued in November 2023 to retire the entire €750 million balance under the Supplemental Facility 【SPG_10k_2024.pdf p68‑72】. The interest‑rate framework (SOFR + 72.5 bps) remained unchanged, but the firm shifted from borrowing to repayment while extending the facility’s term.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with comprehensive multi-hop synthesis across 2022 and 2024 filings. STRENGTHS: (1) All key numeric values are correct: $3.5B base capacity, expandable to $4.5B, €750M borrowing amount, 3.81% fixed rate, 3.50% senior bond rate, SOFR + 72.5 bps margin. (2) Dates are accurate: January 31, 2026 maturity in 2022 (with 2027 extension option), extended to January 31, 2029 (with 2030 extension) by 2024, and November 2023 repayment date. (3) Multi-hop reasoning is sound: correctly synthesizes the evolution from passive availability (2022) to active management (2023-2024), including the interest rate swap strategy and bond issuance for repayment. (4) The answer properly identifies the strategic shift from borrowing to repayment while extending facility terms. MINOR ISSUES: (1) The original answer states the repayment occurred on November 17, 2023, but the LLM answer only references 'November 2023' without the specific date - this is a minor omission of precision but not factually incorrect. (2) The LLM answer provides slightly more detail about the interest rate framework (SOFR + 72.5 bps) remaining unchanged, which adds useful context not explicitly in the ground truth but is consistent with it. (3) The answer includes reference citations to specific pages, which enhances credibility though not required. The semantic equivalence is strong - both answers convey the same core narrative of evolution from passive facility to active management with strategic interest rate hedging and debt refinancing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 430,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Verizon's approach to device payment plans evolved from 2023 to 2024, particularly in terms of customer financing structure and promotional incentives?",
      "original_answer": "In 2023, Verizon permitted customers to acquire equipment using device payment plans that allowed installment payments over time, with no mention of structured promotional incentives or trade-in rights. By 2024, Verizon formalized the device payment plan structure, describing it as a non-interest-bearing installment note typically repaid over a 36-month term, and introduced a defined promotional feature that allows customers to upgrade to a new device after paying a specified portion of their plan and trading in their current device in good working order. This represents a shift from a general financing mechanism to a more structured and incentive-driven model.",
      "llm_answer": "In 2023 Verizon’s device‑payment plans were non‑interest‑bearing 36‑month installment notes that were paired with a month‑to‑month service contract, and the only promotional levers were occasional billing‑credit offers that kicked in only if the customer maintained service (2023 p.4‑5). By 2024 the company broadened the financing structure to include both zero‑interest and low‑interest installment options (including a 24‑month term) and added more explicit incentives—such as upfront bill‑credits or guaranteed upgrade credits—that are baked into the transaction price and recognized over the life of the plan (2024 p.58‑60).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) CONTRADICTS GROUND TRUTH ON 2023: The LLM claims 2023 had 'non-interest-bearing 36-month installment notes' but the ground truth explicitly states there was 'no mention of structured promotional incentives or trade-in rights' in 2023, implying the structure was less formalized. The LLM incorrectly attributes 2024-level formalization to 2023. (2) INTRODUCES UNSUPPORTED DETAILS: The LLM adds specific claims about 'month-to-month service contracts,' 'billing-credit offers,' '24-month term options,' and 'upfront bill-credits' that are not present in the ground truth and appear to be fabricated. (3) MISSES KEY EVOLUTION: The ground truth emphasizes the shift from 'general financing mechanism' to 'structured and incentive-driven model' with specific mention of upgrade rights after paying a portion and trading in devices. The LLM does not capture this critical evolution. (4) PAGE CITATIONS: The LLM provides specific page references (2023 p.4-5, 2024 p.58-60) that cannot be verified against the ground truth and may be hallucinated. (5) SEMANTIC MISALIGNMENT: While the LLM addresses the general topic of device payment plan evolution, it fundamentally misrepresents the 2023 baseline and introduces details not supported by the knowledge graph. The answer demonstrates poor multi-hop reasoning by failing to correctly synthesize the before/after comparison that defines the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 412,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has The Coca-Cola Company's legal relationship with Aqua-Chem evolved between 2023 and 2024, particularly in terms of its stance on liability for Aqua-Chem's asbestos-related claims?",
      "original_answer": "In 2023, Coca-Cola maintained that it had no obligation to Aqua-Chem for any liabilities or expenses related to claims or lawsuits against Aqua-Chem, as outlined in the Georgia Case. By 2024, while the litigation status remained largely unchanged, Coca-Cola's disclosure now includes a more detailed description of the insurance policies issued during its ownership of Aqua-Chem, particularly highlighting the involvement of multiple insurers and the ongoing coverage litigation. This indicates a shift in emphasis from outright denial of liability to a more nuanced stance centered on insurance coverage and shared responsibility among insurers.",
      "llm_answer": "Both the 2023 and 2024 10‑K filings show that Coca‑Cola has not altered its position on Aqua‑Chem. The company continues to seek a declaratory judgment that it has no obligation for any past, present or future asbestos‑related liabilities of Aqua‑Chem, remains active in insurance‑coverage litigation, and notes that the Georgia case remains stayed pending resolution. No new development or shift in its liability stance is reported in the 2024 filing.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains a fundamental misunderstanding of the question and contradicts the ground truth on the key issue. (1) CRITICAL ERROR - CONTRADICTS GROUND TRUTH: The ground truth explicitly states there was 'a shift in emphasis from outright denial of liability to a more nuanced stance centered on insurance coverage and shared responsibility among insurers' between 2023 and 2024. The LLM answer directly contradicts this by claiming 'Coca-Cola has not altered its position' and 'No new development or shift in its liability stance is reported.' This is the opposite of what the ground truth indicates. (2) QUANTITATIVE ACCURACY: The LLM correctly identifies the Georgia case and mentions it remains stayed, which aligns with factual elements. No specific numbers are provided in either answer, so quantitative accuracy is neutral. (3) QUALITATIVE ACCURACY - MAJOR FAILURE: The LLM fails to recognize the evolution described in the ground truth. The ground truth identifies a specific shift: from 'outright denial of liability' (2023) to 'more nuanced stance centered on insurance coverage and shared responsibility among insurers' (2024). The LLM's statement that 'no new development' occurred directly contradicts this documented evolution. The LLM does mention insurance-coverage litigation, but frames it as unchanged rather than as an evolved emphasis. (4) MULTI-HOP REASONING: The LLM fails to synthesize the comparative analysis between 2023 and 2024 filings. The question explicitly asks 'how has...evolved' and the ground truth provides a clear answer about the evolution. The LLM's conclusion that nothing changed represents a failure in multi-hop comparative reasoning. (5) CONTEXTUAL RELEVANCE: The answer addresses Coca-Cola and Aqua-Chem but misses the core point of the question - the evolution/change between years. The answer is partially relevant but fundamentally misses the intended comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 519,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Intel's utilization of non-US tax credits impact its long-term income tax liabilities in 2024 compared to 2022, and what does this indicate about the company's international tax strategy?",
      "original_answer": "In 2022, Intel reported long-term income taxes payable of $4.3 billion, which included the transition tax from Tax Reform and uncertain tax positions, reduced by non-US tax credits. By 2024, this figure had decreased to $1.6 billion, indicating that the company's utilization of non-US tax credits had a stronger offsetting effect over time. This suggests a strategic shift or increased effectiveness in leveraging international tax credits to reduce overall tax liabilities.",
      "llm_answer": "In the 2024 filing Intel reported long‑term income‑tax payable of **$1.6 billion**, down from roughly **$4.3 billion** in the 2022 filing, while the tax benefit from non‑U.S. income taxed at lower rates fell from a **13.4‑percentage‑point reduction** in 2022 to only a **5.3‑point reduction** in 2024. The smaller non‑U.S. credit benefit raised the effective tax rate and limited the offset to long‑term tax liabilities, indicating that Intel is relying less on foreign tax incentives and is shifting toward a more conservative, domestically‑focused international tax strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES: (1) UNVERIFIED PERCENTAGES: The LLM introduces specific percentage-point reductions (13.4% in 2022 declining to 5.3% in 2024) that are NOT present in the ground truth answer. These numbers cannot be verified against the original answer and appear to be fabricated or hallucinated data. This is a major factual error. (2) CONTRADICTORY INTERPRETATION: The ground truth states non-US tax credits had 'a stronger offsetting effect over time' and suggests 'increased effectiveness in leveraging international tax credits.' The LLM contradicts this by claiming Intel is 'relying less on foreign tax incentives' and shifting to 'domestically-focused' strategy. These are opposite conclusions. (3) CORRECT ELEMENTS: The LLM correctly identifies the long-term income tax payable figures ($1.6B in 2024, $4.3B in 2022) and the directional decrease. (4) REASONING FLAW: The LLM's logic that 'smaller non-U.S. credit benefit raised the effective tax rate' is presented as fact but contradicts the ground truth's interpretation that credits became MORE effective. The LLM appears to have misinterpreted or invented data about tax credit effectiveness. (5) MULTI-HOP SYNTHESIS: While the LLM attempts to synthesize information about tax credits and liabilities, it does so with unverified percentages and reaches an opposite strategic conclusion from the ground truth. The core financial figures are correct, but the analysis and interpretation are fundamentally flawed and contradictory to the established ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 420,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has the treatment and risk exposure of pension risk transfers evolved between 2022 and 2024, particularly in terms of interest rate sensitivity and regulatory influence?",
      "original_answer": "In 2022, pension risk transfers were part of the Retirement and Income Solutions business, which was described as containing both short- and long-duration products, and was subject to interest rate scenarios that could impact asset-liability management (ALM) strategies. By 2024, regulatory changes, particularly around defined benefit pension plan funding, were found to potentially reduce the likelihood or delay corporate plan sponsors from terminating their plans or transferring pension obligations. This regulatory evolution increased the potential for a shift in the mix of pension risk transfers toward non-guaranteed funding products, indicating a strategic and regulatory-driven change in exposure.",
      "llm_answer": "In the 2022 10‑K the company grouped pension risk transfers in the **Retirement and Income Solutions** segment and discussed them almost entirely in terms of interest‑rate sensitivity – long‑duration transfers gain from higher yields, short‑duration contracts are managed on a floating‑rate basis, and derivative hedges are used to offset margin compression in both rising‑ and declining‑rate scenarios【MET_10k_2022.pdf page 59‑63】.  \n\nBy the 2024 filing the narrative adds a regulatory dimension: new rules on defined‑benefit pension‑plan funding may curb plan‑sponsor terminations and shift the mix toward non‑guaranteed funding products, meaning regulatory developments now influence the composition and risk exposure of pension risk transfers while interest‑rate risk remains a core driver【MET_10k_2024.pdf page 30‑34】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2022 treatment of pension risk transfers within the Retirement and Income Solutions segment - this matches the ground truth exactly. (2) Accurately captures the interest rate sensitivity framework in 2022, including the distinction between long-duration and short-duration products, floating-rate management, and derivative hedging strategies. (3) Properly synthesizes the 2024 regulatory evolution, specifically noting how new defined-benefit pension plan funding rules may reduce plan terminations and shift the mix toward non-guaranteed funding products. (4) Correctly identifies the shift from purely interest-rate-focused analysis (2022) to a combined interest-rate and regulatory-driven analysis (2024). (5) The multi-hop reasoning is sound - the answer successfully traces the evolution across two years and two different filing documents, synthesizing information about both technical risk management and regulatory context. (6) No quantitative errors detected - no specific dollar amounts or percentages were claimed that could be verified as incorrect. (7) Entity identification is accurate (company segment name, years, regulatory context). MINOR CONSIDERATIONS: The LLM answer includes specific page references (pages 59-63 for 2022, pages 30-34 for 2024) which cannot be independently verified from the ground truth provided, but these do not contradict the ground truth and appear to be reasonable citation practices. The semantic equivalence is strong - the LLM's phrasing about 'regulatory developments now influence the composition and risk exposure' directly parallels the ground truth's statement about 'regulatory-driven change in exposure.' The answer is comprehensive, addressing both the interest rate sensitivity dimension and the regulatory influence dimension requested in the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 525,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Medtronic's positioning and product strategy around the InterStim Micro neurostimulator evolved between 2022 and 2024?",
      "original_answer": "In 2022, Medtronic positioned the InterStim Micro as part of its broader InterStim therapy offering for treating overactive bladder, urinary retention, and bowel incontinence, alongside InterStim II and InterStim X neurostimulators. It was described as part of a growing and accepted product line within the Pelvic Health therapies under the Specialty Therapies division. By 2024, Medtronic specifically highlighted the InterStim Micro as a 'rechargeable neurostimulator' while emphasizing the continued acceptance and growth of InterStim therapy, particularly in the U.S., and distinguishing it from the recharge-free InterStim X and InterStim II models. This indicates a more targeted marketing and differentiation strategy for the InterStim Micro within the evolving Pelvic Health product portfolio.",
      "llm_answer": "In the 2022 filing Medtronic presented the InterStim Micro as a **newly launched, rechargeable neurostimulator** that was driving Pelvic‑Health growth and was grouped with the recently introduced InterStim II and InterStim X systems. By the 2024 filing the InterStim Micro is portrayed as a **mature, rechargeable member of an expanded InterStim portfolio**—now complemented by recharge‑free InterStim II and InterStim X devices—and the company stresses its continued acceptance and growth for over‑active bladder, urinary retention and fecal incontinence, showing a shift from launch‑phase promotion to a broader, differentiated, long‑term market strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the key products (InterStim Micro, InterStim II, InterStim X) and their characteristics (rechargeable vs. recharge-free). (2) Correctly identifies the therapeutic indications (overactive bladder, urinary retention, fecal incontinence). (3) Properly synthesizes the evolution from 2022 to 2024 showing a shift in positioning. (4) No quantitative errors in dates or product names. WEAKNESSES: (1) CRITICAL FACTUAL ERROR: The LLM states InterStim Micro was 'newly launched' in 2022, but the ground truth indicates it was already part of an established product line in 2022, not newly launched. The ground truth describes it as 'part of a growing and accepted product line' in 2022, not a new launch. (2) The LLM characterizes the 2024 positioning as 'mature' which is an inference not explicitly supported by the ground truth. The ground truth emphasizes 'continued acceptance and growth' but doesn't use the term 'mature.' (3) The LLM's characterization of the shift from 'launch-phase promotion to broader, differentiated, long-term market strategy' is partially speculative and overstates the evidence. The ground truth simply notes a shift to 'more targeted marketing and differentiation strategy' without explicitly calling the 2022 phase a 'launch phase.' (4) The LLM adds interpretive language ('shift from launch-phase promotion') that goes beyond what the ground truth supports. MULTI-HOP REASONING: The LLM does attempt to synthesize across 2022 and 2024 filings, but the synthesis contains the factual error about the 2022 launch status. The comparison structure is sound, but the premise is flawed. SEMANTIC EQUIVALENCE: While the overall narrative arc is similar, the specific characterization of InterStim Micro as 'newly launched' in 2022 contradicts the ground truth's description of it as part of an established product line.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 509,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Simon Property Group's use of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of outstanding borrowings and repayment actions?",
      "original_answer": "In 2022, Simon Property Group had a weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) of $519.9 million, with a maximum aggregate outstanding balance of $2.1 billion during the year. By 2024, the weighted average outstanding balance under the Facilities had decreased to $311.1 million, and the company had repaid a significant portion of its borrowings, including €750.0 million ($815.4 million U.S. dollar equivalent) under the Supplemental Facility on November 17, 2023. This indicates a strategic reduction and refinancing of debt drawn from the Supplemental Facility over the two-year period.",
      "llm_answer": "In the 2022 filing Simon repaid the $1.05 billion it had drawn on the Supplemental Facility in January 2022, leaving the facility with a zero balance (2022 10‑K, p. 124). The 2024 filing shows the company again used the Supplemental Facility for a €750 million draw in 2023, which was fully repaid in November 2023, and by December 31 2024 the Supplemental Facility had no outstanding borrowings, with total outstanding under all credit facilities reduced to $325 million (2024 10‑K, p. 70).",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides relevant information about Simon Property Group's Supplemental Facility usage but contains some discrepancies with the ground truth and lacks complete alignment with the original answer's framing.\n\nCORRECT ELEMENTS:\n- Correctly identifies the €750 million draw in 2023 and November 2023 repayment\n- Correctly states the facility had zero balance by end of 2024\n- Appropriately cites specific 10-K pages\n- Correctly identifies the strategic pattern of borrowing and repayment\n\nDISCREPANCIES AND ISSUES:\n1. The LLM mentions a $1.05 billion repayment in January 2022, which is not mentioned in the ground truth answer. This appears to be additional detail not contradicted but also not verified.\n2. The LLM states total outstanding under all credit facilities was $325 million by December 31, 2024, while the ground truth mentions a weighted average of $311.1 million for 2024. These are different metrics (point-in-time vs. weighted average), so the LLM's figure may be correct but represents a different measurement.\n3. The ground truth emphasizes the weighted average outstanding balance comparison ($519.9M in 2022 vs $311.1M in 2024) and maximum aggregate balance ($2.1B in 2022), which the LLM answer does not address.\n4. The ground truth frames this as a \"strategic reduction and refinancing of debt,\" while the LLM focuses more on specific transaction details.\n\nMULTI-HOP REASONING:\nThe LLM successfully synthesizes information across 2022 and 2024 filings, correctly identifying the evolution of Supplemental Facility usage. However, it doesn't fully capture the broader debt reduction trend that the ground truth emphasizes through weighted average comparisons.\n\nCOMPLETENESS:\nThe LLM answer addresses the core question about how usage evolved, but misses the weighted average balance metrics that are central to the ground truth's assessment of the strategic debt reduction.\n\nQUANTITATIVE ACCURACY:\nThe €750 million and November 2023 repayment are correct. The $325 million figure for total outstanding is presented without context about whether this is weighted average or point-in-time, creating ambiguity. The $1.05 billion January 2022 repayment cannot be verified against the provided ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 603,
        "total_tokens": 1893
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did COP's investment activity in the Lower 48 region evolve from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments expenses?",
      "original_answer": "In 2022, COP reported $4,854 million in depreciation, depletion, amortization, and impairments expenses for the Lower 48 region, which increased to $5,729 million in 2023. This indicates a significant increase in investment activity or asset utilization in the Lower 48 region over that period.",
      "llm_answer": "COP’s depreciation, depletion, amortization and impairments expense for its Lower 48 segment rose from **$4.85 billion in 2022 to $5.73 billion in 2023** – an increase of about **$0.88 billion (≈18 %)**【COP_10k_2023.pdf p.131‑135】. The higher DD&A expense indicates that the company’s capital investment in the Lower 48 region grew in 2023 compared with the prior year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. Quantitative verification: (1) 2022 figure of $4.85 billion matches ground truth $4,854 million (format variation acceptable), (2) 2023 figure of $5.73 billion matches ground truth $5,729 million (format variation acceptable), (3) calculated increase of $0.88 billion is correct ($5,729M - $4,854M = $875M ≈ $0.88B), (4) percentage increase of ~18% is accurate (875/4854 = 18.04%). Multi-hop reasoning: The answer correctly synthesizes the two-year comparison and appropriately interprets the DD&A increase as an indicator of capital investment growth in the Lower 48 region, which directly addresses the question's intent. Entity accuracy is perfect (COP, Lower 48 region, 2022-2023 period, DD&A metric). The answer includes proper source citation. Minor note: The answer could have been slightly more explicit about what DD&A changes specifically indicate about investment activity (e.g., larger depreciable asset base), but the interpretation provided is sound and sufficient. The semantic equivalence is excellent - the LLM conveys the same information as the ground truth while adding useful context about the percentage increase and interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1172,
        "completion_tokens": 341,
        "total_tokens": 1513
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Verizon's approach to corporate networking solutions evolved from 2023 to 2024, particularly in terms of service description and business segment emphasis?",
      "original_answer": "In 2023, Verizon's Business segment explicitly described offering a broad portfolio of network connectivity products, including private networking services, private cloud connectivity services, and software-defined networking services, with Enterprise and Public Sector revenues reaching $15.1 billion, or approximately 50% of Business's total revenues. By 2024, the Business segment's description became more streamlined, focusing on wireless and wireline communications services and products, including corporate networking solutions, without specifying the same level of detail in offerings or segment revenue. This indicates a shift toward a more generalized presentation of services, potentially signaling a strategic consolidation or simplification of messaging around corporate networking solutions.",
      "llm_answer": "In the 2023 filing Verizon’s Business segment described its corporate networking portfolio as part of “video and conferencing services,” whereas the 2024 filing now groups it under “video and advanced communication services,” signaling a broader, more integrated communications offering (2023 Business‑segment description; 2024 Business‑segment description). At the same time, the 2024 segment‑revenue table shows Enterprise & Public Sector revenue slipping from $15.1 bn to $14.2 bn while Business Markets & Other rose from $12.7 bn to $13.1 bn (and Wholesale fell modestly), indicating a shift of emphasis toward the broader Business‑Markets networking solutions while still highlighting private‑network, cloud‑connectivity and software‑defined networking within the Enterprise & Public Sector portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations that fundamentally contradict the ground truth:\n\n1. QUANTITATIVE ACCURACY FAILURES:\n   - The LLM claims Enterprise & Public Sector revenue fell from $15.1bn to $14.2bn, but the ground truth states it remained at $15.1bn in 2023 with no 2024 comparison provided in the original answer\n   - The LLM introduces Business Markets & Other revenue figures ($12.7bn to $13.1bn) that are not mentioned in the ground truth at all\n   - These invented numbers appear to be fabricated to support a narrative not present in the source material\n\n2. SERVICE DESCRIPTION ERRORS:\n   - The LLM claims 2023 described offerings as \"video and conferencing services\" - this is NOT supported by the ground truth, which explicitly states 2023 described \"private networking services, private cloud connectivity services, and software-defined networking services\"\n   - The LLM claims 2024 groups services under \"video and advanced communication services\" - the ground truth states 2024 became \"more streamlined, focusing on wireless and wireline communications services and products, including corporate networking solutions\"\n   - These are fundamentally different service categories and the LLM has mischaracterized both years\n\n3. MULTI-HOP REASONING FAILURE:\n   - The LLM failed to correctly synthesize the key insight from the ground truth: the shift from detailed service specification (2023) to generalized presentation (2024)\n   - Instead, the LLM invented a narrative about video/conferencing services that doesn't match the source material\n   - The LLM's conclusion about \"Business Markets networking solutions\" emphasis is not supported by the ground truth\n\n4. MISSING KEY INFORMATION:\n   - The LLM completely missed the ground truth's emphasis on the ~50% revenue proportion for Enterprise & Public Sector in 2023\n   - The LLM failed to capture the strategic consolidation/simplification messaging that was central to the ground truth answer\n\n5. CONTEXTUAL RELEVANCE:\n   - While the LLM attempts to address the question's components (service description and segment emphasis), it does so with incorrect information\n   - The answer is partially relevant in structure but fundamentally wrong in content\n\nThe LLM appears to have hallucinated specific service category names and revenue figures rather than accurately reflecting the ground truth information about Verizon's actual filing changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 660,
        "total_tokens": 2067
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did MetLife's valuation approach and sensitivity to fair value changes for FVO securities evolve from 2022 to 2024, particularly in terms of the impact of U.S. dollar appreciation?",
      "original_answer": "In 2022, MetLife reported that FVO securities had an estimated fair value of $1.6 billion and were sensitive to changes in the U.S. dollar, with a 10% appreciation leading to a $54 million decrease in value. By 2024, while no direct fair value figure for FVO securities is provided, the company emphasized a broader sensitivity framework where nonperformance risk spreads and unobservable inputs varied by duration and currency, indicating a more nuanced and dynamic valuation methodology. This evolution shows a shift from a static sensitivity model to a more complex, duration- and currency-dependent approach.",
      "llm_answer": "In the 2022 filing MetLife valued its FVO securities as Level 3 assets using matrix, market and consensus pricing based on offered and quoted quotes, and a 10 % strengthening of the U.S. dollar was estimated to reduce their fair‑value by about **$54 million**【149-152】. The 2024 filing still places FVO securities in Level 3 and applies the same pricing techniques and significant unobservable inputs, but the dollar‑appreciation effect is now shown within the broader foreign‑currency exchange‑rate sensitivity (still a loss of roughly $54 million for a 10 % U.S.‑dollar gain)【248-252】. Thus, the valuation approach remained unchanged, while the sensitivity to U.S.‑dollar appreciation is now integrated into the overall foreign‑currency risk analysis.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ISSUES WITH LLM ANSWER: (1) QUANTITATIVE ACCURACY: The LLM correctly identifies the $54 million sensitivity figure for both 2022 and 2024, which matches the ground truth. However, the LLM claims the 2024 figure is 'still roughly $54 million for a 10% U.S.-dollar gain,' which contradicts the ground truth that states 'no direct fair value figure for FVO securities is provided' in 2024. The ground truth explicitly notes the evolution shows a shift in methodology, not a continuation of the same sensitivity metric. (2) COMPLETENESS: The LLM fails to address a critical evolution mentioned in the ground truth - the 2022 fair value of $1.6 billion for FVO securities. This is a significant omission that undermines the answer's completeness. The ground truth emphasizes the shift from 'static sensitivity model to a more complex, duration- and currency-dependent approach,' but the LLM claims 'the valuation approach remained unchanged.' (3) ENTITY ACCURACY: MetLife is correctly identified, years are correct (2022 and 2024), and Level 3 classification is accurate. (4) REASONING FLAW: The LLM's core conclusion is fundamentally incorrect. The ground truth describes an EVOLUTION/SHIFT in methodology, while the LLM concludes the approach 'remained unchanged.' This is a critical misinterpretation of the multi-hop synthesis required. The ground truth explicitly states the evolution shows movement toward 'a more nuanced and dynamic valuation methodology,' not stasis. (5) MISSING CONTEXT: The LLM does not mention the shift from a 'static sensitivity model' to a 'duration- and currency-dependent approach,' which is the key evolution the question asks about. The answer focuses on integration into broader analysis rather than the fundamental methodological shift. The LLM's claim that sensitivity is 'now integrated into the overall foreign-currency risk analysis' may be partially correct but misses the larger point about the evolution of the valuation framework itself.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 534,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has NextEra Energy's engagement in power marketing activities evolved between 2022 and 2023, particularly in terms of its energy trading services and associated financial performance?",
      "original_answer": "In 2022, NextEra Energy (NEE) was actively engaged in power and fuel marketing and trading activities, primarily providing full energy and capacity requirements services to distribution utilities, including load-following and ancillary services, while also optimizing the value of electricity and fuel contracts and generation assets. By 2023, NEE's subsidiary NEER had expanded its role in power marketing and trading, contributing to a significant increase in net income, which rose from $285 million in 2022 to $3,558 million in 2023. This indicates a substantial evolution and growth in the scale or profitability of NEE’s power marketing and trading activities over the period.",
      "llm_answer": "In 2022 the company’s power‑marketing segment was described as providing full energy‑and‑capacity services and engaging in power‑ and fuel‑marketing and trading to optimize contracts, with its trading activity ultimately producing a net loss on non‑qualifying commodity hedges (about $2.67 billion) (NEE_10k_2022.pdf p.75). By 2023 the same activities generated a swing to roughly $2.53 billion of gains, driving a $5.95 billion increase in operating revenue and a $2.99 billion positive change in hedge activity, indicating a markedly stronger financial contribution from its energy‑trading services (NEE_10k_2023.pdf p.38).",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that fundamentally contradict the ground truth. (1) CRITICAL NUMERIC ERRORS: The LLM claims a net loss of $2.67 billion in 2022 and gains of $2.53 billion in 2023 on hedging activities. However, the ground truth states that NEER's net income rose from $285 million in 2022 to $3,558 million in 2023 - these are completely different metrics and magnitudes. The LLM appears to have confused hedge gains/losses with net income figures. (2) CALCULATION ERRORS: The LLM claims a $5.95 billion increase in operating revenue and a $2.99 billion positive change in hedge activity, but these specific numbers are not verified in the ground truth and appear to be fabricated or misinterpreted from the source documents. (3) METRIC CONFUSION: The ground truth focuses on net income growth ($285M to $3,558M), which is the key performance metric showing evolution of power marketing activities. The LLM instead focuses on hedge gains/losses and operating revenue changes, which are different metrics entirely. (4) MULTI-HOP REASONING: While the LLM attempts to synthesize information across 2022 and 2023, it does so with incorrect data points. The ground truth clearly identifies the net income figures as the primary indicator of financial performance evolution, but the LLM provides entirely different numbers. (5) ENTITY ACCURACY: The LLM correctly identifies NEE and NEER, but misidentifies the relevant financial metrics. The ground truth explicitly states net income figures; the LLM provides hedge-related figures that don't match. The answer demonstrates a fundamental misunderstanding of which financial metrics are relevant to answering the question about financial performance evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 473,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola FEMSA evolved between 2023 and 2024, particularly in terms of its stake ownership and implications for equity income?",
      "original_answer": "In 2023, Coca-Cola FEMSA was referenced as one of the key bottlers whose financial performance could influence The Coca-Cola Company's credit ratings, indicating an indirect financial dependency. By 2024, The Coca-Cola Company held a 28% ownership stake in Coca-Cola FEMSA, which was accounted for under the equity method. This shift from a dependency-based relationship to a direct ownership stake suggests a strategic evolution, where Coca-Cola now has a more direct financial interest in FEMSA's performance, which will directly impact its equity income (loss) - net line item.",
      "llm_answer": "The Coca‑Cola Company’s ownership of Coca‑Cola FEMSA rose from roughly 27 % at the end of 2023 to 28 % at the end of 2024, and the larger stake helped lift its equity‑method earnings – equity income rose from $1.691 billion in 2023 to $1.770 billion in 2024 (the increase reflects a bigger share of FEMSA’s net income)【KO_10k_2023.pdf p.55】【KO_10k_2024.pdf p.86】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides accurate quantitative information with proper multi-hop synthesis. Strengths: (1) Correctly identifies the ownership stake progression from ~27% (2023) to 28% (2024), showing the evolution requested; (2) Accurately cites equity income figures of $1.691 billion (2023) and $1.770 billion (2024), with proper calculation showing the $79 million increase; (3) Properly explains the equity method accounting treatment; (4) Provides document citations with specific page numbers. Minor weaknesses: (1) The original ground truth mentions a shift from 'dependency-based relationship' (2023) to 'direct ownership stake' (2024), but the LLM answer doesn't explicitly characterize this strategic evolution or the 2023 context as clearly - it jumps directly to the ownership percentages without explaining the 2023 baseline relationship; (2) The ground truth emphasizes the 'shift' and 'strategic evolution' more explicitly, while the LLM focuses primarily on the numerical progression; (3) The LLM doesn't address the 2023 reference to FEMSA as a 'key bottler' influencing credit ratings, which was part of the original answer's characterization of the relationship evolution. The quantitative data is correct and well-supported, and the multi-hop reasoning (connecting ownership percentage to equity income impact) is sound. The answer would be stronger if it more explicitly characterized the nature of the relationship change between 2023 and 2024, not just the numerical progression.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 414,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the financial investment and operational focus on the Lower 48 region evolved between 2022 and 2023 based on production volumes and depreciation expenses?",
      "original_answer": "In 2022, the Lower 48 region showed strong production volumes, particularly in crude oil (447 thousand barrels daily) and natural gas (1,340 million cubic feet daily), indicating a significant operational focus. In 2023, the financial emphasis on the Lower 48 increased further, as evidenced by a rise in depreciation, depletion, amortization, and impairments expenses from $4,854 million in 2022 to $5,729 million in 2023. This reflects a growing financial investment in the region despite stable or moderate production levels in the prior year.",
      "llm_answer": "The Lower 48 segment’s financial commitment grew sharply – capital spending rose to $6.5 billion in 2023 from $5.6 billion in 2022, and depreciation rose to $5.7 billion from $4.9 billion, signalling a larger asset base and higher investment in the region【COP_10k_2023.pdf: page 134】【COP_10k_2023.pdf: page 135】.  At the same time, operational output stayed strong, with the most recent disclosed production of roughly 447 k bbl/d of crude oil, 110 k bbl/d of NGLs and 1,340 MMcf/d of natural gas, underscoring continued focus on Lower 48 operations【COP_10k_2022.pdf: page 168】.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the question and provides relevant multi-hop synthesis across 2022-2023 data. STRENGTHS: (1) Correctly identifies the depreciation increase from ~$4.9B (2022) to ~$5.7B (2023), matching ground truth values of $4,854M and $5,729M respectively. (2) Accurately cites production volumes: 447 k bbl/d crude oil, 110 k bbl/d NGLs, and 1,340 MMcf/d natural gas. (3) Properly synthesizes the relationship between increased capital spending and depreciation as indicators of growing financial investment. (4) Correctly attributes data to appropriate years and documents. (5) Sound multi-hop reasoning connecting financial metrics (capex, depreciation) to operational focus (production volumes). WEAKNESSES: (1) Introduces capital spending figures ($6.5B in 2023, $5.6B in 2022) that are not mentioned in the ground truth answer, creating potential factual concerns if these numbers are inaccurate or from different contexts. (2) The ground truth emphasizes depreciation/depletion/amortization/impairments as a single metric ($4,854M to $5,729M), while LLM separates this as 'depreciation' at $4.9B/$5.7B - this is a minor rounding/terminology issue but technically the full metric name should be used. (3) Ground truth notes 'stable or moderate production levels in the prior year' while LLM states production 'stayed strong' - this is a subtle semantic difference in characterization. CALCULATION VERIFICATION: Depreciation figures are approximately correct ($4,854M ≈ $4.9B, $5,729M ≈ $5.7B). The answer correctly identifies the year-over-year increase. MULTI-HOP SYNTHESIS: Successfully combines production data (2022) with financial metrics (2022-2023) to show evolution of investment and operational focus. The logic connecting capex increases and depreciation increases to asset base growth is sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 501,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Verizon's strategic relationship with its 4G LTE network evolved between 2023 and 2024 in terms of its role within the company's network infrastructure and growth initiatives?",
      "original_answer": "In 2023, Verizon's 4G LTE network was positioned primarily as a foundational component of its wireless services, specifically highlighted as a means to provide FWA broadband as an alternative to traditional landline internet access. By 2024, the strategic role of the 4G LTE network had evolved into being part of a broader integrated network vision that includes C-Band spectrum, millimeter wave spectrum, and fiber infrastructure, aimed at driving innovative products and services and fueling growth. This shift indicates a move from viewing 4G LTE in a service delivery context to a more strategic asset within a multi-technology ecosystem.",
      "llm_answer": "In the 2023 filing Verizon’s 4G LTE network is described mainly as a delivery platform for fixed‑wireless‑access (FWA) broadband, “providing FWA broadband through our 5G or 4G LTE networks as an alternative to traditional landline internet access” (2023 10‑K, p. 95). By 2024 the LTE system is positioned as a foundational element of the overall network architecture, noted alongside C‑Band and millimeter‑wave spectrum and fiber “to drive innovative products and services and fuel our growth” (2024 10‑K, p. 22). This shift shows the LTE network moving from a specific service tool to a core infrastructure pillar supporting broader growth initiatives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. (1) CORRECTNESS: The answer accurately captures the evolution of Verizon's 4G LTE network strategy from 2023 to 2024. The 2023 positioning as a delivery platform for FWA broadband is correctly identified, and the 2024 shift to a foundational element within a multi-technology ecosystem (C-Band, millimeter-wave, fiber) is accurately described. (2) QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are required for this qualitative question about strategic positioning. The page references cited (2023 10-K p. 95, 2024 10-K p. 22) are reasonable and support the narrative, though not independently verifiable in this context. (3) ENTITY ACCURACY: Verizon is correctly identified, years 2023 and 2024 are correct, and all network technologies mentioned (4G LTE, 5G, C-Band, millimeter-wave, fiber, FWA) are accurately referenced. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years and correctly identifies the strategic evolution from a service-delivery tool to an infrastructure pillar. The logic is sound: 2023 = specific service context (FWA), 2024 = integrated ecosystem component. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same core message as the ground truth with slightly different wording but equivalent meaning. The phrase 'foundational element of the overall network architecture' effectively captures the shift from 'foundational component' to 'strategic asset within a multi-technology ecosystem.' Minor note: The LLM answer includes specific page citations and direct quotes, which adds credibility and specificity beyond the ground truth, enhancing rather than detracting from the response. The answer is comprehensive, well-structured, and directly addresses the question's multi-part nature.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 509,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2024, particularly in terms of stake value, ownership structure, and the impact on financial metrics such as backlog and gross margin?",
      "original_answer": "In 2022, Emerson held a stake in AspenTech with a backlog value of $1,042 million, indicating a strategic business relationship. By 2024, this relationship evolved significantly as Emerson completed a transaction that resulted in the creation of 'New AspenTech,' where Emerson owned 55% of the outstanding shares. This acquisition had a measurable impact on financial metrics: gross margin in 2023 increased by 3.3 percentage points, partly due to the AspenTech acquisition, and backlog in 2024 reached $8,053 million, up from $6,533 million in 2021, showing the influence of the AspenTech integration.",
      "llm_answer": "In fiscal 2022 Emerson completed the Heritage AspenTech transaction, contributing two software businesses and about $6 billion in cash and receiving a 55 % equity stake in the newly formed AspenTech; the AspenTech segment’s backlog rose to roughly $1.0 billion, lifting Emerson’s total order backlog to $8.1 billion (2022 10‑K, p. 8‑9). By fiscal 2024 Emerson’s holding had increased to about 57 % and the company announced a $240‑per‑share cash offer for the remaining shares, valuing AspenTech at roughly $15.3 billion (2024 10‑K, p. 24). The AspenTech acquisition added about 0.6 percentage‑points to Emerson’s gross margin in 2023 (to 49.0 %) and helped drive the margin higher to 50.8 % in 2024 (2024 10‑K, p. 26‑27).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides substantial detail about Emerson's relationship with AspenTech but contains several significant factual discrepancies when compared to the ground truth:\n\nCRITICAL ERRORS:\n1. TIMING OF TRANSACTION: The LLM states the Heritage AspenTech transaction was completed in fiscal 2022, but the ground truth indicates Emerson held a stake in 2022 and the transaction evolved through 2024. The LLM's framing suggests the 55% stake was acquired in 2022, which appears to conflate different transaction phases.\n\n2. OWNERSHIP PERCENTAGE EVOLUTION: The LLM claims ownership increased from 55% (2022) to 57% (2024), but the ground truth states Emerson owned 55% after the transaction completion. The 57% figure and the $240/share offer for remaining shares represent a later acquisition attempt not clearly distinguished in the ground truth timeline.\n\n3. BACKLOG FIGURES: The LLM cites AspenTech segment backlog of \"roughly $1.0 billion\" in 2022, which aligns with the ground truth's $1,042 million. However, the LLM states total Emerson backlog reached $8.1 billion in 2022, while the ground truth indicates backlog reached $8,053 million in 2024 (not 2022). This is a critical year misalignment.\n\n4. GROSS MARGIN ATTRIBUTION: The LLM states AspenTech added \"about 0.6 percentage points\" to gross margin in 2023, but the ground truth specifies a 3.3 percentage point increase in 2023 partly due to AspenTech. The LLM's 0.6 figure appears understated.\n\nPARTIAL CREDITS:\n- Correctly identifies the 55% equity stake structure\n- Correctly notes the $240/share offer and ~$15.3 billion valuation\n- Correctly identifies gross margin improvements in 2023-2024\n- Properly synthesizes the multi-hop relationship evolution\n- Appropriate citation of 10-K pages\n\nMULTI-HOP REASONING: The answer attempts to synthesize information across 2022-2024 but conflates transaction phases and misaligns key metrics with their correct years. The reasoning structure is sound but the factual foundation is compromised.\n\nOVERALL: While the answer demonstrates good understanding of the relationship's evolution and includes relevant details, the quantitative inaccuracies (particularly the backlog year misalignment and gross margin attribution) and timing confusion significantly undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 617,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has NEE's financial commitment to the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's involvement in the Mountain Valley Pipeline was described as part of its equity method investments, with an ownership stake ranging between 32% and 55%. By 2023, NEE, through its subsidiary NEER, had a more defined 32.8% equity investment in the Mountain Valley Pipeline, which was accompanied by a 20-year natural gas transportation agreement valued at approximately $70 million per year. This indicates a strategic deepening of NEE's commitment to the pipeline, moving from a general equity investment toward a more structured, long-term contractual relationship tied to infrastructure development.",
      "llm_answer": "In the 2022 filing NEE reported that after fully impairing its Mountain Valley Pipeline stake it only retained a modest “additional” commitment of roughly $110 million to the venture. By the 2023 filing the company was planning multi‑year equity contributions of about $2.2 billion (e.g., $1.06 billion in 2024 and $1.19 billion through 2025‑2028) for the pipeline’s construction, showing a dramatic escalation in funding and a strategic shift toward actively backing natural‑gas infrastructure.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains fundamentally incorrect information that contradicts the ground truth across multiple dimensions:\n\n1. QUANTITATIVE ACCURACY - CRITICAL ERRORS:\n   - LLM claims NEE had a $110 million 'additional commitment' in 2022 after 'full impairment' - NO EVIDENCE in ground truth\n   - LLM claims $2.2 billion in multi-year equity contributions ($1.06B in 2024, $1.19B through 2025-2028) - NOT MENTIONED in ground truth\n   - Ground truth specifies: 32-55% ownership range in 2022, 32.8% in 2023, and $70 million/year transportation agreement - NONE of these figures appear in LLM answer\n   - The LLM's numbers ($110M, $2.2B, $1.06B, $1.19B) are completely fabricated\n\n2. ENTITY/METRIC ACCURACY:\n   - LLM incorrectly characterizes the investment as 'equity contributions for construction' when ground truth indicates equity method investments and a transportation agreement\n   - LLM mentions 'NEER' subsidiary only implicitly; ground truth explicitly identifies NEER as the subsidiary holding the 32.8% stake\n   - LLM mischaracterizes the nature of commitment (construction funding vs. transportation agreement)\n\n3. REASONING QUALITY:\n   - LLM's narrative of 'full impairment' followed by 'dramatic escalation' is not supported by ground truth\n   - Ground truth shows evolution from general equity investment (32-55% range) to more defined 32.8% stake with structured 20-year agreement\n   - LLM's interpretation of 'strategic shift toward actively backing natural-gas infrastructure' is contradicted by ground truth's characterization of 'deepening commitment' through structured contractual relationship\n\n4. MULTI-HOP SYNTHESIS:\n   - LLM failed to correctly synthesize 2022 vs 2023 data\n   - Ground truth shows: 2022 (equity method, 32-55% ownership) → 2023 (32.8% equity + $70M/year transportation agreement)\n   - LLM shows: 2022 ($110M commitment after impairment) → 2023 ($2.2B construction funding) - completely different narrative\n\n5. CONTEXTUAL RELEVANCE:\n   - While LLM attempts to address the evolution question, it does so with fabricated data\n   - The answer is contextually relevant in structure but factually wrong in substance\n\nThe LLM answer appears to have hallucinated specific dollar amounts and investment structures that do not appear in the ground truth. This is a severe failure in factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 628,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Coca-Cola's relationship with Costa Limited evolved from 2023 to 2024 in terms of its operational integration and strategic positioning within the Global Ventures segment?",
      "original_answer": "In 2023, Costa Limited was referenced as part of Coca-Cola's direct retail operations, specifically through retail stores operated by Costa, and was included within the Global Ventures operating segment. By 2024, Costa Limited was more strategically embedded within the Global Ventures segment, which now also included the results of innocent and doğadan businesses, as well as fees earned under distribution coordination agreements. This indicates a deeper integration and broader strategic role for Costa within Coca-Cola’s diversified beverage portfolio.",
      "llm_answer": "In the 2023 filing (pages 4‑8) Coca‑Cola said it sells directly to consumers through Costa Limited’s retail stores and that those sales are simply included in the Global Ventures segment. By the 2024 filing (pages 71‑75) Costa is identified as a distinct reporting unit within Global Ventures and is described as a strategic growth platform and core part of the company’s direct‑to‑consumer coffee and beverage strategy, reflecting tighter operational integration and a more prominent strategic role.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some correct elements but contains significant issues with accuracy and completeness when compared to the ground truth. CORRECT ELEMENTS: (1) Both 2023 and 2024 are correctly identified as the relevant years; (2) Costa Limited's inclusion in the Global Ventures segment is correctly stated for both years; (3) The general direction of increased strategic integration is captured. PROBLEMATIC ELEMENTS: (1) The LLM claims Costa is 'identified as a distinct reporting unit within Global Ventures' in 2024, but the ground truth does not support this characterization - it states Costa was 'more strategically embedded' but does not indicate it became a separate reporting unit; (2) The LLM describes Costa as 'a strategic growth platform and core part of the company's direct-to-consumer coffee and beverage strategy' but the ground truth does not use this specific language or characterization; (3) CRITICAL OMISSION: The ground truth explicitly mentions that by 2024, Global Ventures also included 'the results of innocent and doğadan businesses, as well as fees earned under distribution coordination agreements' - the LLM completely fails to mention these other businesses and the broader portfolio expansion that occurred, which is a key part of understanding the evolution; (4) The LLM's page references (pages 4-8 for 2023, pages 71-75 for 2024) cannot be verified against the ground truth and appear to be fabricated specificity. MULTI-HOP REASONING: The LLM attempts to synthesize information across two years but fails to capture the full scope of the Global Ventures segment evolution. The ground truth emphasizes that Costa's integration occurred alongside the addition of innocent and doğadan businesses, suggesting a broader strategic repositioning of the entire segment, not just Costa's role. The LLM's answer is narrowly focused on Costa alone and misses this important context. QUANTITATIVE ACCURACY: No specific numbers, dates, or calculations are present in either answer, so this dimension scores well (8/10) due to no errors, though there are no quantitative elements to verify. QUALITATIVE ACCURACY: The characterization of Costa's role differs from ground truth in important ways - the LLM overstates the formality of Costa's status (distinct reporting unit) and provides language not supported by the source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 629,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Intel's investment in financial institution instruments evolved between 2022 and 2024, particularly in terms of the fair value of economically hedged marketable debt investments?",
      "original_answer": "In 2022, Intel recorded net losses of $748 million on economically hedged marketable debt investments. By 2024, the fair value of these hedged investments had decreased to $13.5 billion from $17.1 billion in 2023, with Intel recording net losses of $464 million in 2024. This indicates a reduction in both the size of the hedged investment portfolio and the magnitude of losses compared to two years prior.",
      "llm_answer": "Intel’s economically‑hedged marketable debt investments – which include its financial‑institution instruments – were valued at **$13.5 billion at year‑end 2024**, down from **$17.1 billion at year‑end 2023**.  The loss on these hedged positions also improved, moving from a **$748 million net loss in 2022** to a **$464 million net loss in 2024** (after a $534 million gain in 2023)【INTC_10k_2024.pdf†81-82】.  This reflects a contraction in the fair‑value size of the hedged portfolio and a reduction in its associated losses over the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All financial figures are correct - $13.5 billion (2024), $17.1 billion (2023), $748 million loss (2022), $464 million loss (2024), and the $534 million gain in 2023 are all accurate. The year-over-year comparisons are mathematically sound. COMPLETENESS: The answer addresses all key aspects of the question: (1) the evolution of fair value of hedged investments from 2022-2024, (2) specific values for 2024 and 2023, (3) loss/gain figures across the period, and (4) the overall trend analysis. ENTITY ACCURACY: Intel is correctly identified, the metric 'economically hedged marketable debt investments' is properly used, and all years (2022, 2023, 2024) are correctly referenced. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple years and metrics, correctly identifying the portfolio contraction (from $17.1B to $13.5B) and the improvement in losses ($748M to $464M). The inclusion of the 2023 gain ($534 million) adds valuable context showing the volatility of these positions. SEMANTIC EQUIVALENCE: The phrasing 'financial-institution instruments' appropriately describes the nature of these investments, and the characterization of the trend as a 'contraction' and 'reduction in losses' accurately reflects the data. The answer is well-structured, provides proper context, and uses appropriate financial terminology. Minor note: The citation format with document references adds credibility but is not essential to correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 429,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did AMT's financial focus regarding communications sites evolve from 2023 to 2024, particularly in terms of recurring revenue generation and asset retirement liabilities?",
      "original_answer": "In 2023, AMT emphasized recurring revenue generation from communications sites, noting that 99% of total revenues came from property operations, which included leasing space on communications sites. By 2024, the focus expanded to include significant liabilities tied to these assets, with an estimated $4.5 billion in undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This reflects a shift from primarily highlighting revenue streams to also addressing the long-term financial responsibilities associated with site decommissioning.",
      "llm_answer": "In 2023 AMT’s commentary centered on the fact that the vast majority of the cash flow from its communications‑site portfolio came from long‑term, non‑cancellable leases – with rent escalations and an expectation of > $60 billion of future lease revenue – underscoring a focus on recurring revenue generation. By 2024 the company was still emphasizing that most site revenue remains recurring, but it added a new, material focus on the cost of retiring those sites, disclosing an estimated undiscounted asset‑retirement liability of $4.5 billion. This reflects a shift from a primary emphasis on lease‑driven cash flow to also managing significant site‑retirement obligations.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy with correct identification of key financial metrics and the evolution of AMT's focus from 2023 to 2024. STRENGTHS: (1) Correctly identifies the $4.5 billion undiscounted asset retirement obligation as of December 31, 2024 - this matches the ground truth exactly. (2) Accurately captures the shift in emphasis from revenue generation to also addressing retirement liabilities. (3) Properly synthesizes multi-hop information across two fiscal years. (4) The characterization of 2023 focus on recurring revenue from long-term leases is semantically equivalent to the ground truth's '99% of total revenues from property operations.' (5) Correctly identifies the forward-looking nature of lease revenue expectations. MINOR ISSUES: (1) The LLM introduces the '>$60 billion of future lease revenue' figure, which is not mentioned in the ground truth answer. While this may be factually accurate from the filings, it represents additional information not in the original answer, creating a slight divergence. (2) The ground truth specifically cites '99% of total revenues' while the LLM uses the phrase 'vast majority' - while semantically similar, the ground truth is more precise. (3) The LLM's phrasing about 'long-term, non-cancellable leases' with 'rent escalations' adds specificity not explicitly in the ground truth, though this appears to be accurate elaboration rather than error. QUANTITATIVE VERIFICATION: The $4.5 billion figure is correctly stated and properly contextualized as 'undiscounted.' The 2023-2024 timeframe is accurate. REASONING QUALITY: The multi-hop synthesis is sound - the answer correctly identifies the evolution across years and connects revenue generation to retirement obligations. The logical flow from 2023 emphasis to 2024 expanded focus is well-articulated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 497,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has XOM's strategic positioning in Guyana evolved between 2023 and 2024, particularly in terms of its legal operating framework and business growth emphasis?",
      "original_answer": "In 2023, XOM's operations in Guyana were governed by the Petroleum Activities Act 2023, which allowed for an exploration period typically up to 10 years and a production period of 20 years for oil fields with a renewal period of up to 10 years. By 2024, Guyana was specifically highlighted as one of XOM's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, indicating a strategic shift to emphasize Guyana as a key contributor to earnings through volume growth and integration. This evolution shows that Guyana transitioned from being a jurisdiction with defined exploration and production terms to being a core growth asset within XOM's portfolio.",
      "llm_answer": "In the 2023 filing XOM explains that its Guyana operations are governed by the newly‑enacted Petroleum Activities Act 2023, which gives the government authority to issue petroleum agreements with exploration periods typically up to 10 years and production periods of 20 years for oil (30 years for gas) plus renewal periods of up to 10 years (XOM_10k_2023.pdf pp. 23‑27). By the 2024 filing the company is still subject to that legal framework, but it now highlights Guyana as an “advantaged asset” in its earnings‑driver strategy—placing Guyana alongside Permian and LNG as a core growth focus (XOM_10k_2024.pdf pp. 35‑39).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about XOM's strategic positioning in Guyana between 2023 and 2024. STRENGTHS: (1) Correctly identifies the Petroleum Activities Act 2023 as the governing legal framework in 2023; (2) Accurately captures the exploration period (up to 10 years) and production period (20 years) with renewal periods (up to 10 years); (3) Properly identifies the 2024 strategic shift to positioning Guyana as an 'advantaged asset' within the 'Advantaged Volume Growth' earnings driver; (4) Correctly synthesizes the multi-hop comparison showing evolution from regulatory framework focus to strategic growth emphasis; (5) Appropriately cites specific document pages and years. MINOR DISCREPANCY: The LLM answer mentions '30 years for gas' production periods, which is not mentioned in the ground truth answer. While this additional detail may be accurate from the source documents, it represents information beyond what was in the original answer. This is a minor addition that doesn't contradict the ground truth but adds specificity. SEMANTIC EQUIVALENCE: The LLM's phrasing 'core growth focus' is semantically equivalent to the ground truth's 'key contributor to earnings through volume growth.' The description of the transition from 'defined exploration and production terms' to 'core growth asset' is well-captured. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and two different filing documents, correctly identifying both the legal framework evolution and the strategic positioning shift. The logic connecting these elements is sound and demonstrates proper understanding of the question's multi-part nature.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 473,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Caterpillar's involvement in the diesel-electric locomotives business evolved between 2023 and 2024, particularly in terms of its strategic positioning and operational responsibilities?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader Machinery, Energy & Transportation (ME&T) segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as product support for on-highway vocational trucks in North America. By 2024, Caterpillar's positioning had evolved, with diesel-electric locomotives and related components being explicitly tied to integrated systems and solutions for industries like electric power generation, marine, oil and gas, and industrial sectors. Additionally, 2024 emphasized the development of electrified powertrains and zero-emission power sources, signaling a strategic shift toward more advanced and environmentally focused technologies in the locomotive space.",
      "llm_answer": "In the 2023 filing Caterpillar described diesel‑electric locomotives as a rail‑related product line within the Energy & Transportation segment, noting that the business “includes diesel‑electric locomotives and components and other rail‑related products and services, including remanufacturing and leasing” and that it also handled remanufacturing of its reciprocating engines and product support for on‑highway vocational trucks (2023 10‑K, pp. 114‑115).  \n\nIn the 2024 filing the same locomotive business is still listed under Energy & Transportation, but it is now positioned alongside “electrified power‑train and zero‑emission power sources” as part of a broader portfolio, while retaining the same operational duties of remanufacturing, leasing and product support (2024 10‑K, pp. 37‑38).  \n\nThus, between 2023 and 2024 Caterpillar’s diesel‑electric locomotive involvement shifted from a standalone rail offering to a broader, sustainability‑focused strategy that still includes the same core manufacturing and service responsibilities.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about Caterpillar's diesel-electric locomotives business evolution between 2023 and 2024. STRENGTHS: (1) Correctly identifies the segment name (Energy & Transportation, though ground truth uses 'Machinery, Energy & Transportation' or 'ME&T') and accurately describes 2023 positioning including remanufacturing, leasing, and product support responsibilities. (2) Accurately captures the 2024 evolution toward electrified powertrains and zero-emission power sources. (3) Properly synthesizes the multi-hop information showing the shift from standalone rail offering to sustainability-focused strategy. (4) Correctly notes that core operational responsibilities (remanufacturing, leasing, product support) remained consistent. (5) Provides specific page references (2023 10-K pp. 114-115; 2024 10-K pp. 37-38) that add credibility. MINOR ISSUES: (1) The segment naming is slightly inconsistent with ground truth - ground truth explicitly mentions 'Machinery, Energy & Transportation (ME&T)' while LLM uses 'Energy & Transportation' without the full name. This is a minor semantic difference but technically less precise. (2) Ground truth emphasizes broader integration with 'integrated systems and solutions for industries like electric power generation, marine, oil and gas, and industrial sectors' which the LLM answer doesn't explicitly mention, though it does capture the sustainability shift. (3) The characterization of the 2023 positioning as 'standalone' versus the ground truth's description as 'part of broader ME&T segment' is slightly different in framing, though both are essentially correct. QUANTITATIVE ACCURACY: No numerical errors detected. Page references appear reasonable for 10-K filings. REASONING: The multi-hop synthesis is sound - the answer correctly identifies the evolution across two years and connects the strategic shift to sustainability focus. The logic flow is clear and well-structured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1475,
        "completion_tokens": 544,
        "total_tokens": 2019
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has the company's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, and what does this indicate about its funding strategy?",
      "original_answer": "In 2022, the company disclosed that it raised funding through the issuance of securitized debt obligations, among other instruments, though the exact amount was not provided. By 2024, the company reported a carrying value of $14,264 million for securitized debt obligations, indicating a concrete quantification of this funding source. This evolution suggests a more defined and potentially increased reliance on securitized debt obligations, aligning with a broader strategic emphasis on structured financing.",
      "llm_answer": "In the 2022 filing the company reported $14.99 billion of securitized‑debt obligations—about 4 % of total funding sources—up from $12.41 billion the prior year. By the 2024 filing the balance was $14.26 billion (≈4 % of total funding) after a brief rise to $18.04 billion in 2023. The modest, roughly flat share of securitizations indicates Capital One treats them as a supplemental, opportunistic source of liquidity while keeping deposits as its core funding pillar.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURES: The LLM claims 2022 securitized debt was $14.99 billion, but the ground truth explicitly states 'the exact amount was not provided' in 2022. The LLM fabricated specific numbers for 2022 ($14.99B) and 2023 ($18.04B) that do not appear in the ground truth. The 2024 figure of $14.26 billion is close to the ground truth's $14,264 million (minor rounding acceptable), but this is the only verifiable number. (2) ENTITY/YEAR ERRORS: The LLM incorrectly attributes these figures to 'Capital One' without confirmation this is the company in question. The ground truth does not identify the company by name. (3) MULTI-HOP REASONING FAILURE: The LLM synthesized a narrative about year-over-year changes (2022→2023→2024) and calculated percentages of total funding, but these calculations are based on fabricated data points not present in the ground truth. The ground truth only provides 2022 (no exact amount) and 2024 ($14,264M) data. (4) SEMANTIC DIVERGENCE: The ground truth indicates 'evolution suggests a more defined and potentially increased reliance,' while the LLM claims 'modest, roughly flat share' and 'supplemental, opportunistic source.' These interpretations are contradictory. The LLM's conclusion about deposits being the 'core funding pillar' is not supported by the ground truth. (5) FABRICATION: The specific percentages (4% of total funding) and the 2023 peak ($18.04B) appear to be invented data points not in the source material. This represents a fundamental failure in factual accuracy for a financial question where precision is critical.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 464,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has McDonald's treatment of developmental licensees evolved between 2023 and 2024, particularly in terms of financial reporting and relationship management?",
      "original_answer": "In 2023, McDonald's disclosed that developmental licensees paid royalties based on a percentage of sales and generally paid initial fees, and the company allocated consideration among lease and non-lease components using historical methods. By 2024, the company emphasized its ongoing evaluation of business relationships, including those with developmental licensees, to identify potential variable interest entities, although it concluded that consolidation of such entities was not appropriate. Additionally, in 2024, McDonald's updated its rounding presentation to the nearest whole number for reported amounts, which affected how financial figures were presented, though the company clarified that these changes were not significant.",
      "llm_answer": "In the 2023 filing McDonald’s grouped developmental licensees with its International Developmental Licensed Markets & Corporate segment and described them only in the franchise‑arrangements narrative (they pay royalties and an initial fee and the segment was 98 % franchised). By the 2024 filing the company had adopted the new ASU 2023‑07 segment‑reporting rules, provided more granular segment‑expense disclosures, and explicitly evaluated developmental licensees under its consolidation policy – confirming they remain non‑consolidated, variable‑interest‑entity‑exempt entities – while also reporting a larger base of developmental‑licensed restaurants (9,247 in 2024 vs. 8,684 in 2023), signalling a more detailed financial‑reporting and relationship‑management approach.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides substantial and largely accurate information about McDonald's treatment of developmental licensees between 2023 and 2024. STRENGTHS: (1) Correctly identifies the 2023 treatment (royalties based on percentage of sales, initial fees, franchise arrangement narrative). (2) Accurately notes the 2024 adoption of ASU 2023-07 segment reporting rules. (3) Correctly states that developmental licensees remain non-consolidated variable interest entities in 2024. (4) Provides specific restaurant count data (9,247 in 2024 vs. 8,684 in 2023) which appears reasonable and demonstrates growth. (5) Properly synthesizes multi-hop information across years and reporting frameworks. (6) Addresses both financial reporting and relationship management aspects of the question. WEAKNESSES/GAPS: (1) The LLM answer does not mention the rounding presentation change to nearest whole number that the ground truth specifically highlights as a 2024 update. (2) The LLM answer does not explicitly reference the historical methods used for allocating consideration among lease and non-lease components in 2023, which the ground truth includes. (3) The LLM answer provides more granular detail about segment reporting changes and restaurant counts than the ground truth, which could be viewed as either additional context or potential over-specification. QUANTITATIVE VERIFICATION: The restaurant counts (9,247 and 8,684) cannot be independently verified from the ground truth but are presented as specific data points. The 98% franchised figure for the segment is mentioned but not contradicted. MULTI-HOP REASONING: The answer successfully synthesizes information across 2023 and 2024 filings, correctly identifying the evolution in reporting approach and relationship management. The connection between ASU 2023-07 adoption and more detailed disclosures is logically sound. SEMANTIC EQUIVALENCE: The core message about evolution from basic disclosure to more detailed evaluation and reporting is conveyed, though some specific elements from the ground truth (rounding changes, allocation methods) are omitted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 566,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Southern Company's approach to its Equity and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of share availability and executive award disclosures?",
      "original_answer": "In 2023, Southern Company had 26.9 million shares available for awards under the Equity and Incentive Compensation Plan, indicating a reserve for future compensation initiatives. By 2024, the company increased transparency around executive compensation by disclosing specific terms for Named Executive Officer equity awards granted under the 2021 Equity and Incentive Compensation Plan, which was effective May 26, 2021. This evolution shows a shift from internal planning and reserve allocation in 2023 to more detailed public disclosure of executive-level compensation mechanisms in 2024, suggesting a more formalized and transparent governance approach for top-level incentives.",
      "llm_answer": "In the 2023 filing Southern Company still reported the size of its equity pool – it said that 131 million shares were reserved for issuance and that 26.9 million of those were available for awards under the Equity and Incentive Compensation Plan at December 31 2023【source: SO_10k_2023.pdf p. 230‑231】.  In the 2024 filing the company stopped giving a specific “shares‑available” figure and instead added a dedicated exhibit that spells out the terms of the equity awards granted to named executive officers (the “Form of Terms for Named Executive Officer Equity Awards” under the 2021 Equity and Incentive Compensation Plan)【source: SO_10k_2024.pdf p. 315‑317】, indicating a shift from reporting an aggregate share pool to providing more granular executive‑award disclosures.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and provides more detailed information than the ground truth. Key strengths: (1) Correctly identifies the 26.9 million shares available for awards in 2023 - matches ground truth exactly. (2) Accurately captures the shift from aggregate share pool reporting to granular executive award disclosures between 2023 and 2024. (3) Provides additional context about the 131 million total shares reserved, which adds useful detail. (4) Correctly identifies the 2021 Equity and Incentive Compensation Plan effective date (May 26, 2021) and references specific document pages. (5) The multi-hop reasoning is sound - synthesizing information about both the quantitative change (share availability reporting) and qualitative change (disclosure approach). Minor considerations: (1) The LLM answer goes slightly beyond the ground truth by mentioning the company 'stopped giving a specific shares-available figure' in 2024, which is a reasonable inference but not explicitly stated in the ground truth. (2) The ground truth emphasizes 'increased transparency' and 'more detailed public disclosure,' while the LLM frames it as 'stopped giving' and 'instead added' - semantically equivalent but slightly different framing. (3) The LLM provides more specific sourcing (page numbers) which enhances credibility. Overall, the LLM answer is more comprehensive and detailed than the ground truth while maintaining factual accuracy on all key metrics and dates.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 411,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors contributed to the change in its growth trajectory?",
      "original_answer": "In 2022, Inlyta contributed to Pfizer's operational growth, specifically mentioned among products like Comirnaty, Eliquis, and Vyndaqel that drove growth in the U.S. and international markets. By 2023, Inlyta's global revenue reached $1,036 million, reflecting a 3% total increase and a 5% operational growth. The growth was primarily attributed to the adoption of immune checkpoint inhibitor combinations with Inlyta for first-line treatment of advanced RCC in the U.S., despite lower volumes and net price in certain European markets. This indicates a continuation of growth, albeit at a more moderate pace compared to the broader portfolio dynamics in 2022.",
      "llm_answer": "In 2023 Inlyta generated $1.036 billion of revenue, a modest 3 % increase from the $1.003 billion it earned in 2022 (U.S. sales rose 4 % to $642 million and international sales rose 3 % to $394 million)【PFE_10k_2023.pdf p. 42‑44】.  The slower growth reflects that U.S. demand continued to be driven by the adoption of Inlyta in combination with immune‑checkpoint inhibitors for first‑line advanced RCC, but this was partially offset by lower volumes and reduced net‑price pressure in certain European markets, tempering the double‑digit (≈26 %) increase the product posted in 2022 when it rose to $1.0 billion worldwide【PFE_10k_2022.pdf p. 39‑43】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Quantitative verification: 2023 revenue of $1.036 billion (matches ground truth), 3% total increase (correct), 5% operational growth mentioned in ground truth but not explicitly stated in LLM answer (minor omission). U.S. sales of $642 million with 4% growth and international sales of $394 million with 3% growth are provided with specific breakdowns not in ground truth. The 2022 revenue calculation: $642M + $394M = $1.036B for 2023, and the LLM states 2022 was $1.003B, which when increased by 3% yields approximately $1.033B (very close to stated $1.036B, minor rounding difference acceptable). The 2022 growth rate of approximately 26% is correctly identified. Multi-hop reasoning is sound: the answer synthesizes information across 2022 and 2023 filings, correctly identifies the key growth driver (immune checkpoint inhibitor combinations for first-line RCC treatment), and accurately explains the moderation in growth trajectory due to European market pressures. The answer directly addresses both parts of the question: (1) revenue evolution between years with specific numbers, and (2) factors contributing to the change in growth trajectory. The only minor gap is that the ground truth explicitly mentions '5% operational growth' for 2023, which the LLM answer does not state, though the 3% total increase is correctly cited. Entity accuracy is perfect (Inlyta, Pfizer, U.S./international markets, RCC indication). The semantic equivalence is strong - the LLM conveys the same substantive information as the ground truth with additional detail on regional breakdowns.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 447,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has McDonald's relationship with its franchisees evolved from 2023 to 2024 in terms of financial structure and dependency, particularly regarding revenue recognition and cost-sharing for technology platforms?",
      "original_answer": "In 2023, McDonald's described its relationship with franchisees as a collaborative partnership focused on consistency, quality, and revenue generation through rent, royalties based on a percent of sales, and initial fees. The business model was designed to generate stable and predictable revenue largely tied to franchisee sales. By 2024, the relationship evolved to reflect a stronger dependency on franchisees, particularly in the context of technology platforms. McDonald's began recognizing revenue from franchisees for technology services on a gross basis, with related expenses recorded in 'Other restaurant expenses,' indicating a more integrated and cost-sharing approach. This shift reflects a transformation in the nature of the relationship, with franchisees becoming more operationally interdependent with the company through shared technology infrastructure.",
      "llm_answer": "McDonald’s has not altered the basic financial link with its franchisees – the Company still recovers a share of its technology‑platform costs through fees that franchisees pay as “Other revenues,” and it continues to treat those fees as a principal‑to‑customer transaction, recognizing the amounts on a gross basis. The 2023 filing notes that “fees paid by franchisees to recover a portion of costs incurred by the Company for various technology platforms” are recognized when the services are transferred and that “the Company has determined that it is the principal… revenue is presented on a gross basis” 【MCD_10k_2023.pdf: p. 2‑3】, and the 2024 filing repeats the same language 【MCD_10k_2024.pdf: p. 44‑45】, indicating no material shift in the revenue‑recognition method or the cost‑sharing model and an ongoing reliance on franchisee contributions for technology platforms.",
      "correctness_score": 3,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer fundamentally contradicts the ground truth on the core question about evolution from 2023 to 2024. CRITICAL ERRORS: (1) The LLM claims 'no material shift' in revenue recognition method and cost-sharing model between 2023 and 2024, directly contradicting the ground truth which explicitly states the relationship 'evolved' with McDonald's 'beginning to recognize revenue from franchisees for technology services on a gross basis' in 2024 with 'related expenses recorded in Other restaurant expenses.' (2) The LLM's citation of identical language between 2023 and 2024 filings is used to argue NO CHANGE occurred, but the ground truth indicates a specific shift happened in how these revenues and expenses are classified/recognized. (3) The LLM misses the key evolution: the ground truth emphasizes a transformation from a 'collaborative partnership' model (2023) to a 'stronger dependency' with 'more integrated and cost-sharing approach' (2024) through technology infrastructure interdependence. (4) While the LLM correctly identifies that franchisees pay for technology platforms and that McDonald's recognizes revenue on a gross basis, it fails to capture the TEMPORAL CHANGE that is the core of the question. The question explicitly asks 'how has...evolved FROM 2023 TO 2024' - requiring a comparison showing change. The LLM's answer essentially argues for continuity rather than evolution. QUANTITATIVE ACCURACY: The LLM provides no specific numbers, percentages, or financial metrics to verify, only general statements about revenue recognition principles. The page citations appear plausible but don't validate the substantive claim about no change. QUALITATIVE ACCURACY: The multi-hop reasoning fails because it doesn't synthesize the temporal dimension - comparing 2023 vs 2024 positioning. The LLM treats the question as asking whether the basic model exists (yes) rather than how it evolved (the actual question). CONTEXTUAL RELEVANCE: While the answer addresses technology platforms and revenue recognition, it fundamentally misses the evolution/change aspect that is central to the question's framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1454,
        "completion_tokens": 571,
        "total_tokens": 2025
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value of energy-related derivatives held by Southern Company's subsidiaries evolve from 2022 to 2023, and what does this indicate about the company's exposure to energy market fluctuations?",
      "original_answer": "In 2022, Southern Company's subsidiaries reported a net fair value of $101 million for energy-related derivatives (Mississippi Power: $59 assets, $32 liabilities; Southern Power: $8 assets, $12 liabilities; Southern Company Gas: $28 assets, $65 liabilities). In 2023, the subsidiaries showed a shift with Alabama Power reporting $15 in assets and $110 in liabilities, and Georgia Power reporting $13 in assets and $124 in liabilities for energy-related derivatives. This indicates a significant increase in net liability exposure, rising from a net liability of $54 million in 2022 to a net liability of $219 million in 2023, suggesting a greater exposure to energy market fluctuations.",
      "llm_answer": "The fair‑value of energy‑related derivatives on the asset side fell dramatically – from $199 million at 12/31/2022 to only $55 million at 12/31/2023 – while the liability side grew from $210 million to $358 million (SO_10k_2023.pdf p. 283; SO_10k_2024.pdf p. 275). This sharp reduction in derivative assets combined with higher derivative liabilities indicates that Southern Company has trimmed its hedging positions but now carries a larger net derivative liability, leaving it more exposed to swings in energy‑market prices.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains fundamentally incorrect numbers that do not match the ground truth data. (1) QUANTITATIVE ACCURACY FAILURES: The LLM reports asset values of $199M (2022) and $55M (2023), but the ground truth shows total assets of $95M in 2022 ($59+$8+$28) and $28M in 2023 ($15+$13). The LLM's liability figures of $210M (2022) and $358M (2023) also contradict ground truth values of $109M in 2022 ($32+$12+$65) and $234M in 2023 ($110+$124). These are not minor rounding differences—they represent 2-3x magnitude errors. (2) ENTITY IDENTIFICATION ISSUES: The LLM correctly identifies Southern Company but fails to properly account for the subsidiary breakdown. The ground truth specifies Mississippi Power, Southern Power, and Southern Company Gas for 2022, then Alabama Power and Georgia Power for 2023. The LLM provides aggregate numbers without clarifying which subsidiaries are included or why the subsidiary composition changed. (3) CALCULATION ERRORS: The LLM calculates net liability as $303M in 2023 ($358M - $55M), but ground truth shows $206M ($234M - $28M). The 2022 net liability calculation is also wrong: LLM implies $11M ($210M - $199M) versus ground truth of $14M ($109M - $95M). (4) MULTI-HOP REASONING: While the LLM correctly identifies the directional trend (increased net liability exposure), the magnitude and specific subsidiary data are completely misaligned with the source documents. The conclusion about increased energy market exposure is directionally correct but built on false numerical foundations. (5) MISSING CONTEXT: The LLM fails to identify the specific subsidiaries involved and their individual contributions to the overall exposure, which is critical detail in the ground truth answer. The answer appears to reference different pages/documents than the actual 10-K data, suggesting potential hallucination of source citations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 512,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the treatment and significance of the Procter & Gamble 2019 Stock and Incentive Compensation Plan evolved from 2022 to 2024, based on its disclosure context in the 10-K filings?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was introduced with detailed references to its adoption by shareholders on October 8, 2019, and its additional terms and conditions, indicating its formal establishment and integration into the company's compensation framework. By 2024, the plan was listed among other equity compensation plans as part of the company's broader disclosure on stock ownership and equity compensation, showing that it had become a standard and active component of the company's long-term incentive structure. This evolution reflects the plan's transition from a newly introduced policy to an established part of PG's equity compensation offerings.",
      "llm_answer": "In both the 2022 and 2024 10‑K the 2019 Stock and Incentive Compensation Plan is singled out as the **only** equity‑compensation plan that still permits new grants, underscoring its continued central role in P&G’s compensation structure. However, the pool of shares left for future issuance shrank markedly – from **119 million shares** available in the 2022 filing to **77 million shares** in the 2024 filing – and the weighted‑average exercise price of outstanding options rose from roughly **$99.5** to **$111.6**, indicating that a substantial portion of the plan’s capacity has already been used.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations that contradict the ground truth. Key issues: (1) CONTRADICTORY CLAIM: The LLM states the 2019 Plan is the 'only' equity compensation plan permitting new grants, but the ground truth indicates it was presented as one component among 'other equity compensation plans' in 2024, suggesting multiple active plans exist. (2) UNVERIFIED NUMBERS: The specific share counts (119 million in 2022, 77 million in 2024) and weighted-average exercise prices ($99.5 to $111.6) are not mentioned in the ground truth and cannot be verified. These appear to be fabricated or from sources not in the knowledge graph. (3) MISALIGNMENT WITH GROUND TRUTH: The ground truth describes an evolution from 'newly introduced policy' (2022) to 'established part of PG's equity compensation offerings' (2024), emphasizing integration and standardization. The LLM instead focuses on share depletion and capacity constraints, which is a different narrative entirely. (4) INCOMPLETE ANSWER: The LLM fails to address the core evolution described in the ground truth - the transition from formal establishment/introduction to becoming a standard, active component. (5) MULTI-HOP REASONING: While the LLM attempts to synthesize 2022 and 2024 data, it does so with unverified numbers and a fundamentally different interpretation than the ground truth. The answer demonstrates poor alignment with the actual filing disclosures as represented in the knowledge graph.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 414,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Southern Company's approach to managing the risk of large losses in its pension plan assets evolved from 2023 to 2024, and what specific changes in risk management emphasis can be observed?",
      "original_answer": "In 2023, Southern Company emphasized a formal rebalancing program and external investment manager oversight as key components of managing the risk of large losses, with a strong focus on long-term investment expectations for return and risk. In 2024, while maintaining a diversified asset strategy and rebalancing program, the emphasis on external manager oversight was reduced, and the risk of large losses was more directly linked to the broader market volatility and interest rate fluctuations. This indicates a subtle shift in risk management emphasis from active oversight to market-driven risk exposure.",
      "llm_answer": "Southern Company’s 2024 filing repeats the same risk‑management language that appeared in 2023 – it still “minimiz(es) the risk of large losses primarily through diversification but also monitor(s) and manage(s) other aspects of risk,” uses a formal rebalancing program and written guidelines for external managers, and believes the portfolio is well‑diversified with no significant concentrations. In other words, the approach has not materially changed; there is no new emphasis or shift in how large‑loss risk is managed between the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth on the core question. The ground truth explicitly states there WAS a shift in risk management emphasis from 2023 to 2024: (1) In 2023, emphasis was on formal rebalancing AND external investment manager oversight; (2) In 2024, emphasis on external manager oversight was REDUCED while risk became more directly linked to market volatility and interest rate fluctuations. The LLM answer claims 'the approach has not materially changed' and 'there is no new emphasis or shift,' which directly contradicts the ground truth's finding of a 'subtle shift in risk management emphasis from active oversight to market-driven risk exposure.' While the LLM correctly identifies that both years mention diversification and rebalancing programs, it fails to recognize the key evolution: the de-emphasis of external manager oversight in 2024 and the shift toward acknowledging market-driven risk factors. The LLM appears to have focused on surface-level similarities in language rather than detecting the nuanced but meaningful change in emphasis that the ground truth identifies. This is a critical failure in multi-hop reasoning and comparative analysis across years. The answer demonstrates poor synthesis of year-over-year changes and misses the entire point of the question about how the approach 'evolved.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 382,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has NVIDIA's role in the development and supply of the CUDA platform evolved between 2022 and 2023, and what does this shift indicate about the company's strategic focus?",
      "original_answer": "In 2022, NVIDIA's relationship with the CUDA platform was primarily as a supplier, providing the platform as part of its accelerated computing offerings. By 2023, NVIDIA's role had evolved into that of a developer, emphasizing a more active and strategic engagement in the platform's expansion and integration within its broader software ecosystem, including CUDA-X libraries, APIs, and domain-specific frameworks. This shift indicates a strategic move toward strengthening its full-stack computing platform to deliver more comprehensive data center-scale solutions.",
      "llm_answer": "In the 2022 Form 10‑K NVIDIA presented CUDA mainly as “the foundational CUDA programming model that runs on all NVIDIA GPUs” – a core piece of its full‑stack hardware‑software offering【NVDA_10k_2022.pdf†page=78】. By the 2023 Form 10‑K the company describes CUDA as part of a much broader software suite – “the CUDA parallel programming model, the CUDA‑X collection of acceleration libraries, APIs, SDKs, and domain‑specific application frameworks” – and notes that more than 4.7 million developers now use CUDA and its tools【NVDA_10k_2023.pdf†page=6】. This shift from a single programming model to a large, developer‑driven software ecosystem signals NVIDIA’s strategic focus on expanding its software platform and ecosystem to drive growth beyond pure hardware sales.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of NVIDIA's CUDA platform role from 2022 to 2023. STRENGTHS: (1) Correctly identifies the shift from CUDA as a foundational programming model (2022) to a comprehensive software ecosystem (2023); (2) Accurately cites the expansion to include CUDA-X libraries, APIs, SDKs, and domain-specific frameworks; (3) Provides specific quantitative detail (4.7 million developers) that adds credibility; (4) Correctly synthesizes the strategic implication about expanding software platform and ecosystem to drive growth beyond hardware; (5) Properly references both 2022 and 2023 10-K filings showing multi-hop reasoning across years. MINOR WEAKNESSES: (1) The ground truth emphasizes a shift from 'supplier' to 'developer' role, which the LLM answer doesn't explicitly state in those terms, though the semantic meaning is captured through the description of expanded engagement; (2) The LLM answer frames the shift slightly differently (from 'single programming model' to 'developer-driven ecosystem') versus the ground truth's 'supplier' to 'developer' framing, though both convey the same strategic evolution; (3) The LLM answer adds the phrase 'to drive growth beyond pure hardware sales' which is a reasonable inference but goes slightly beyond what the ground truth explicitly states about 'full-stack computing platform to deliver more comprehensive data center-scale solutions.' QUANTITATIVE VERIFICATION: The 4.7 million developers figure is cited with appropriate attribution and appears reasonable for CUDA's user base in 2023. No calculation errors detected. MULTI-HOP REASONING: Successfully synthesizes information across 2022 and 2023 filings to show evolution over time and correctly identifies the strategic implications of this shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 496,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Pfizer's financial relationship with Viatris evolve between 2022 and 2023, particularly in terms of supply agreements and outstanding balances?",
      "original_answer": "In 2022, Pfizer reported $780 million in revenue growth from PC1, primarily reflecting manufacturing of legacy Upjohn products for Viatris under supply agreements. By 2023, the financial relationship had evolved, as indicated by the net amounts due to Viatris under various agreements, which decreased from $94 million as of December 31, 2022, to $33 million as of December 31, 2023. Additionally, most transitional services under the TSAs were completed by the end of 2023, signaling a reduction in operational interdependence.",
      "llm_answer": "In 2022 Pfizer’s relationship with Viatris was governed by long‑term manufacturing‑service agreements (MSAs) that run for four‑to‑seven years, plus interim agency and transition‑service (TSA) arrangements that were largely completed by year‑end, leaving a net amount due to Viatris of $94 million【2022 10‑K pp. 39‑43】. By 2023 the same MSAs remained in effect, the TSAs were essentially finished, and the net amount due had fallen to $33 million, showing a marked reduction in the outstanding balance【2023 10‑K pp. 71‑75】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key financial metrics and evolution of the Pfizer-Viatris relationship. STRENGTHS: (1) All quantitative data is accurate - correctly cites $94 million outstanding balance as of December 31, 2022, and $33 million as of December 31, 2023, showing proper multi-hop synthesis across two fiscal years; (2) Correctly identifies the nature of agreements (MSAs running 4-7 years, TSAs); (3) Accurately captures the evolution narrative - TSAs largely/essentially completed by end of 2023, marked reduction in outstanding balance; (4) Proper entity identification (Pfizer, Viatris) and time period specification (2022 vs 2023); (5) Good contextual framing showing the relationship's progression from 2022 to 2023. MINOR WEAKNESSES: (1) The LLM answer mentions $780 million in PC1 revenue growth from manufacturing legacy Upjohn products in 2022 is ABSENT from the LLM response - this was explicitly stated in the ground truth as 'primarily reflecting manufacturing of legacy Upjohn products for Viatris under supply agreements' and represents a material omission of context about the revenue component of the relationship; (2) The phrase 'interim agency' is mentioned but not clearly explained in relation to the TSAs; (3) Citation formatting with page numbers, while helpful, cannot be verified against the ground truth. CALCULATION VERIFICATION: The decrease from $94M to $33M represents a $61M reduction (65% decrease), which is logically consistent with the narrative of reduced operational interdependence. MULTI-HOP REASONING: Successfully synthesizes information across 2022 and 2023 10-K filings, correctly comparing outstanding balances and TSA completion status. The omission of the $780M revenue figure is the primary gap, as it represents an important dimension of the financial relationship that should have been included for completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 520,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has the treatment and disclosure of communications sites in relation to debt obligations evolved between 2023 and 2024?",
      "original_answer": "In 2023, communications sites were explicitly referenced as collateral securing debt obligations, such as the 3,343 communications sites securing the Series 2015-2 Notes and the repayment of $1.3 billion in Series 2013-2A Notes funded by the 2023 Securitization. In 2024, while there was no explicit mention of specific communications sites securing debt, the company disclosed broader financial commitments, such as $4.5 billion in estimated undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This shift indicates a move from site-specific debt disclosures to more general obligations, suggesting a change in how communications sites are framed in relation to financial liabilities.",
      "llm_answer": "In the 2023 filing the company described its communications sites almost exclusively as the collateral that backs the 2015‑, 2018‑ and 2023‑year securitizations – cash‑flows from those sites were earmarked solely for servicing the securitized notes, with detailed DSCR, cash‑trap and amortization covenants governing any excess cash and a default potentially triggering foreclosure on the sites. By the 2024 filing the same securitization structure is still disclosed, but the discussion is broadened to show that the sites are also tied to operating‑lease obligations – the company now notes that failure to renew lease periods could cause loss of the communications sites and related revenue – and it integrates the site‑related cash‑flow restrictions into its overall covenant‑compliance and material‑cash‑requirements disclosures. This reflects a shift from a narrow, securitization‑focused treatment of the sites to a more comprehensive view that links site retention to both debt service and lease obligations.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and introduces information not supported by the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM references 2015-, 2018-, and 2023-year securitizations, but the ground truth only mentions 2015-2 Notes and 2013-2A Notes. The LLM does not cite the specific 3,343 communications sites mentioned in the ground truth for 2023, nor the $1.3 billion in Series 2013-2A Notes. The LLM also fails to mention the $4.5 billion in asset retirement obligations disclosed in 2024. (2) FACTUAL INACCURACIES: The LLM introduces concepts like 'operating-lease obligations,' 'lease renewal periods,' and 'foreclosure on sites' that are not mentioned in the ground truth. The ground truth makes no reference to lease obligations or the risk of losing sites due to lease non-renewal. (3) INCOMPLETE SYNTHESIS: While the ground truth clearly identifies a shift from site-specific debt disclosures (2023) to broader financial obligations (2024), the LLM mischaracterizes this shift as moving from 'securitization-focused' to 'comprehensive view linking sites to lease obligations.' This is not supported by the ground truth. (4) MISSING KEY DATA: The LLM fails to cite any of the specific financial figures from the ground truth (3,343 sites, $1.3 billion, $4.5 billion). (5) REASONING QUALITY: While the LLM attempts to describe an evolution in disclosure treatment, it does so by introducing unsupported details rather than accurately synthesizing the actual information provided in the ground truth. The multi-hop reasoning is flawed because it's based on incorrect premises about what was actually disclosed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 451,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Comcast's approach to retransmission consent agreements evolved between 2022 and 2023, particularly in terms of revenue recognition and distribution models?",
      "original_answer": "In 2022, Comcast recognized revenue from retransmission consent agreements on a monthly basis as programming was provided, with fees tied to the number of subscribers and generally collected within 60 days. By 2023, the company's Media segment emphasized a combined linear and streaming distribution model, with retransmission fees now explicitly including both traditional and virtual multichannel video providers. The 2023 filing also highlighted a broader integration of Peacock into the distribution ecosystem, suggesting a strategic shift toward hybrid distribution models that blend traditional and streaming services.",
      "llm_answer": "In the 2022 Form 10‑K Comcast said that fees earned under NBC and Telemundo retransmission‑consent agreements are accounted for as licenses of functional intellectual property and are recognized “as programming is provided on a monthly basis” under multiyear contracts that are primarily subscriber‑based【CMCSA_10k_2022.pdf p.93】. By the 2023 filing the company still recognizes the fees when the programming is delivered, but the description now highlights a mixed per‑subscriber and fixed‑fee structure, expands the scope to both traditional and virtual multichannel video providers, and bundles the fees with retail and wholesale Peacock subscription revenue – indicating a broader, more flexible distribution model【CMCSA_10k_2023.pdf p.9】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and effectively addresses the multi-hop question about Comcast's evolution in retransmission consent agreements between 2022 and 2023. STRENGTHS: (1) Correctly identifies the 2022 revenue recognition approach as monthly basis tied to subscriber counts with 60-day collection periods, matching the ground truth. (2) Accurately captures the 2023 shift toward a mixed per-subscriber and fixed-fee structure. (3) Properly synthesizes the expansion to both traditional and virtual multichannel video providers. (4) Correctly identifies the integration of Peacock into the distribution ecosystem as a key strategic shift. (5) Appropriately characterizes the evolution as moving toward hybrid/more flexible distribution models. (6) Provides specific document citations with page numbers, enhancing credibility. (7) Uses accurate financial/legal terminology (licenses of functional intellectual property, multiyear contracts). MINOR AREAS FOR IMPROVEMENT: (1) The ground truth mentions 'combined linear and streaming distribution model' while the LLM uses 'mixed per-subscriber and fixed-fee structure' - these are related but slightly different framings. The LLM's description is more specific about fee structures while the ground truth emphasizes the distribution channel mix. (2) The LLM could have been slightly more explicit about the 'combined' nature of the linear and streaming models, though the Peacock bundling reference adequately conveys this. QUANTITATIVE ACCURACY: No specific numbers or percentages were required in the question, and the LLM correctly avoids inventing metrics. The temporal references (2022 vs 2023) are accurate. MULTI-HOP REASONING: The answer successfully synthesizes information across two different 10-K filings and correctly identifies the evolution in both revenue recognition methods and distribution strategy. The logical progression from 2022 to 2023 is sound and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 528,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Caterpillar's involvement in the production and strategic positioning of diesel-electric locomotives evolved from 2023 to 2024?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader ME&T segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as providing product support for on-highway vocational trucks in North America. By 2024, Caterpillar's engagement had evolved into a more defined production role under the Energy & Transportation segment, which explicitly stated that Caterpillar 'produces' diesel-electric locomotives and components, signaling a more direct and strategic emphasis on this product line. Additionally, in 2024, Caterpillar highlighted competitive pressures in rail-related businesses, naming companies like Wabtec Corp and Siemens Mobility A/S, which was not present in 2023. This indicates a shift from a general operational inclusion to a more prominent and competitive product focus.",
      "llm_answer": "In the 2023 filing Caterpillar’s Energy & Transportation segment described diesel‑electric locomotives as part of its rail‑related product line and noted that the business also performed remanufacturing and leasing of those locomotives (CAT_10k_2023.pdf pp. 114‑118). By the 2024 filing the company still produces diesel‑electric locomotives, but now positions itself as “the world’s leading manufacturer of … diesel‑electric locomotives,” emphasizing a strategic focus on market‑leadership rather than just ancillary services (CAT_10k_2024.pdf pp. 4‑6).",
      "correctness_score": 5,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains both correct and incorrect elements. CORRECT ELEMENTS: (1) The answer correctly identifies that Caterpillar produces diesel-electric locomotives in both 2023 and 2024; (2) The answer correctly notes a shift in positioning/emphasis from 2023 to 2024; (3) The answer correctly identifies that 2024 includes language about market leadership positioning. SIGNIFICANT ERRORS: (1) The LLM claims that in 2023 the locomotives were described as part of the 'Energy & Transportation segment' - but the ground truth explicitly states they were part of the 'ME&T segment' in 2023, not Energy & Transportation. This is a factual error in entity identification; (2) The LLM states that in 2023 the business 'performed remanufacturing and leasing of those locomotives' - the ground truth mentions remanufacturing of reciprocating engines and components, and product support for trucks, but does not specifically state that locomotives themselves were being remanufactured or leased in 2023; (3) CRITICAL OMISSION: The LLM completely fails to mention the competitive positioning element that is central to the ground truth answer - specifically the naming of Wabtec Corp and Siemens Mobility A/S as competitors in 2024 that were not mentioned in 2023. This is a major gap in the multi-hop synthesis; (4) The LLM's characterization of the evolution is incomplete - it focuses on market leadership language but misses the shift from general operational inclusion to explicit competitive positioning. MULTI-HOP REASONING: The answer attempts to synthesize across 2023 and 2024 filings but fails to capture the full scope of the evolution, particularly the competitive landscape shift. The reasoning is partially sound but incomplete. The answer reads as if it may be citing specific page numbers that cannot be verified against the ground truth provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 504,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of revenue recognition and cost-sharing arrangements between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's revenue from franchisees primarily included rent and royalties based on a percentage of sales with minimum rent payments, and initial fees. The company also mentioned that all restaurants were either operated by McDonald's or by franchisees under franchised arrangements. By 2024, the revenue recognition model remained consistent, but the company provided more detailed disclosures on how it recognizes revenue from franchisees, including the treatment of technology platform fees, which are now presented on a gross basis on the Consolidated Statement of Income. Additionally, in 2024, McDonald's clarified its cost-sharing arrangements for restaurant improvements, where it may fund certain projects and allocate costs between Property and Equipment and Accounts Receivable during the project, finalizing the allocation upon completion. This level of detail on cost-sharing was not present in the 2023 filing, indicating a more nuanced and transparent approach to franchisee financial interactions in 2024.",
      "llm_answer": "McDonald’s did not change the way it accounts for its franchisees. Both the 2023 and 2024 filings state that franchise‑related revenue – rent, royalties, initial fees and technology‑platform fees – is recognized on a gross basis (minimum rent straight‑line, variable rent and royalties when the underlying sales occur, and technology fees when the service is transferred) 【MCD_10k_2023.pdf p41‑42】. Likewise, the company’s cost‑sharing for restaurant improvements remains the same: McDonald’s funds projects up‑front, estimates the split of costs between itself and the franchisee, allocates those amounts between property‑and‑equipment and accounts receivable during the project, and makes only immaterial adjustments when the project is completed 【MCD_10k_2023.pdf p44‑45】【MCD_10k_2024.pdf p44‑45】.  In short, the revenue‑recognition and cost‑sharing arrangements with franchisees were unchanged from 2023 to 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR DISCREPANCY BETWEEN LLM AND GROUND TRUTH: The LLM answer fundamentally contradicts the ground truth. The LLM claims 'McDonald's did not change the way it accounts for its franchisees' and that arrangements were 'unchanged from 2023 to 2024.' However, the ground truth explicitly states that evolution DID occur: (1) 2024 provided 'more detailed disclosures' on revenue recognition, (2) technology platform fees treatment is 'now presented on a gross basis' (implying a change in presentation/disclosure), and (3) cost-sharing arrangements received 'more nuanced and transparent' disclosure in 2024 that 'was not present in the 2023 filing.' The LLM's core conclusion is inverted from the ground truth. While the LLM correctly identifies the mechanics of revenue recognition (rent, royalties, initial fees, technology fees) and cost-sharing procedures, it misses the KEY EVOLUTION: the DISCLOSURE and TRANSPARENCY improvements in 2024. The ground truth emphasizes that while the underlying arrangements may have remained consistent, McDonald's PROVIDED MORE DETAILED EXPLANATIONS AND CLARIFICATIONS in 2024 compared to 2023. The LLM's statement that 'the revenue-recognition and cost-sharing arrangements with franchisees were unchanged' is technically accurate regarding the underlying business practices, but it completely fails to address the actual evolution in HOW these arrangements are disclosed and explained to investors. The question asks about evolution 'in terms of revenue recognition and cost-sharing arrangements' - which the ground truth interprets as including disclosure evolution, not just operational changes. The LLM's page citations appear reasonable but the interpretation is fundamentally flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1486,
        "completion_tokens": 470,
        "total_tokens": 1956
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Southern Company's approach to executive equity compensation evolved between 2023 and 2024, particularly regarding plan documentation and award terms?",
      "original_answer": "In 2023, Southern Company disclosed that stock-based compensation, primarily in the form of performance share units (PSUs) and restricted stock units (RSUs), was granted under the Equity and Incentive Compensation Plan to employees ranging from line management to executives. By 2024, the company formalized the terms for Named Executive Officer equity awards under the same plan, indicating a more structured approach to executive compensation. Additionally, the 2024 filing included detailed documentation practices, such as the designation of specific exhibits for equity award terms, which was not present in the 2023 filing. This reflects a shift toward greater specificity and transparency in executive equity compensation documentation.",
      "llm_answer": "In 2023 Southern Company’s executive equity awards were governed by the 2021 Equity and Incentive Compensation Plan and the Employee Savings Plan as amended through its eighth amendment (dated Dec 13 2023), with performance‑share units vesting after a three‑year performance period and becoming immediately vested on retirement or a change‑in‑control, and restricted‑stock units vesting one‑third each year (SO_10k_2023.pdf pp. 274‑278). The 2024 filing shows the documentation was updated again – a ninth amendment to the Employee Savings Plan was adopted on Dec 16 2024 – but the substantive award mechanics (three‑year PSU performance periods, immediate retirement vesting and change‑in‑control vesting for both PSUs and RSUs) were left essentially unchanged (SO_10k_2024.pdf pp. 314‑318).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer provides specific details about plan amendments and vesting mechanics that go beyond the ground truth, but this creates a mixed evaluation. STRENGTHS: (1) Correctly identifies Southern Company and the 2023-2024 timeframe; (2) Accurately references the Equity and Incentive Compensation Plan; (3) Correctly describes PSU vesting mechanics (three-year performance period) and RSU vesting (one-third annually); (4) Correctly notes immediate vesting on retirement/change-in-control; (5) Provides specific amendment dates (Dec 13, 2023 for eighth amendment; Dec 16, 2024 for ninth amendment) and page references. WEAKNESSES: (1) The ground truth emphasizes a shift toward 'greater specificity and transparency in executive equity compensation documentation' and 'formalized terms for Named Executive Officer equity awards' in 2024, but the LLM answer states the substantive mechanics were 'essentially unchanged,' which contradicts the ground truth's characterization of evolution; (2) The LLM answer focuses heavily on technical vesting details and plan amendments rather than the key evolution highlighted in ground truth: the move toward more structured documentation practices and designation of specific exhibits for equity award terms; (3) The ground truth emphasizes documentation practices and transparency improvements, while the LLM answer emphasizes that mechanics remained unchanged - these are different narratives about the evolution; (4) The LLM answer doesn't clearly address the 'shift toward greater specificity and transparency' that was the core of the ground truth's answer. CALCULATION/DATE VERIFICATION: The specific amendment dates (Dec 13, 2023 and Dec 16, 2024) and page references cannot be independently verified from the ground truth but appear plausible. The vesting mechanics described (3-year PSU periods, 1/3 annual RSU vesting) align with typical equity compensation structures. The core issue is not factual error but rather a different interpretation of what 'evolution' means - the LLM emphasizes continuity in mechanics while ground truth emphasizes evolution in documentation and formalization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 574,
        "total_tokens": 1961
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Procter & Gamble's strategic reliance on membership club stores evolved from 2022 to 2024, and what does this shift indicate about the company's broader retail channel strategy?",
      "original_answer": "In 2022, Procter & Gamble identified membership club stores as one of its key retail channels, listing them among a broad set of distribution partners such as mass merchandisers, grocery stores, and e-commerce platforms. However, by 2024, the company's language shifted to emphasize dependency on these membership club stores, indicating a deeper strategic alignment or increased reliance on this channel. This evolution suggests that membership club stores have become more central to P&G's distribution and retail execution strategy, likely reflecting growth in this channel's importance to consumer purchasing behavior and overall market dynamics.",
      "llm_answer": "In the 2022 Form 10‑K (Item 1 Business, p. 2) P&G simply listed “membership‑club stores” as one of its key customer groups, without quantifying its share or emphasizing it as a growth focus. By the 2024 Form 10‑K (Item 1 Business, p. 5) the company notes that sales through membership‑club stores have risen to roughly X % of net sales (up from Y % in 2022) and that it is deliberately deepening its partnership with these high‑volume retailers. The change signals that P&G is moving its retail‑channel mix toward bulk‑buy, high‑traffic club channels as a core growth engine, complementing its broader push into e‑commerce and other diversified retail formats.",
      "correctness_score": 3,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES: (1) FABRICATED NUMBERS: The LLM answer claims specific percentages ('roughly X % of net sales (up from Y %)') but provides placeholder variables (X%, Y%) instead of actual numbers. This is a major red flag indicating the model either hallucinated data or acknowledged it couldn't find the numbers but presented them anyway. The ground truth does NOT provide specific percentage figures - it only describes a qualitative shift in language emphasis. (2) FACTUAL INACCURACY: The LLM claims P&G 'notes that sales through membership-club stores have risen to roughly X % of net sales' - but the ground truth explicitly states that in 2022 P&G 'listed them among a broad set of distribution partners' WITHOUT quantifying share, and by 2024 the shift was in 'language' and 'emphasis' on dependency, NOT in providing new quantitative data. The LLM misrepresented the nature of the evolution. (3) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the ground truth information. The ground truth indicates a qualitative shift in strategic language/emphasis, not a quantitative shift with percentage increases. The LLM invented a quantitative narrative that doesn't exist in the source material. (4) CORRECT ELEMENTS: The LLM correctly identified the time period (2022 to 2024), correctly named the company (P&G), and correctly identified that the shift indicates increased strategic importance. The general conclusion about membership clubs becoming 'more central' aligns with ground truth. (5) VERIFICATION: Ground truth shows no specific percentages are mentioned - only that language shifted from 'listing' to 'emphasizing dependency.' The LLM's claim of quantified growth is unsupported and appears fabricated. This is a serious accuracy failure on a financial question where precision matters.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 494,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did AMT's involvement with Nigeria Letters of Credit evolve between 2023 and 2024, and what does this indicate about its financial obligations related to this instrument?",
      "original_answer": "In 2023, AMT had a $3.4 million obligation under the Nigeria Letters of Credit as part of its variable rate debt portfolio. However, by 2024, this obligation was no longer present, as indicated by the $0 carrying value in both denominated currency and USD. This indicates that AMT fully settled or otherwise exited its financial obligations tied to Nigeria Letters of Credit within this period.",
      "llm_answer": "In the 2023 filing AMT disclosed that it had drawn a $3.4 million Nigeria Letter of Credit, a short‑term borrowing that accrues interest at SOFR + a spread and is payable 270 days after each draw. By the 2024 filing the line for the Nigeria Letter of Credit shows a “‑” (zero) carrying value, indicating the draw(s) were repaid or the facility was terminated, eliminating that financial obligation.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and addresses the core question well. STRENGTHS: (1) Correctly identifies the $3.4 million obligation in 2023 - matches ground truth exactly. (2) Correctly identifies the zero/eliminated obligation in 2024 - matches ground truth. (3) Accurately captures the evolution between years as requested. (4) Provides additional helpful context about the instrument being short-term borrowing with SOFR + spread terms and 270-day payoff structure, which adds value without contradicting the ground truth. (5) Correctly interprets the '-' notation as zero carrying value. (6) Properly synthesizes the multi-hop information (2023 status → 2024 status → conclusion about settlement). MINOR DIFFERENCES: (1) The LLM specifies additional details about SOFR + spread and 270-day terms that aren't in the ground truth answer, but these appear to be accurate supplementary information from the filings rather than errors. (2) The LLM uses 'draw(s)' and 'facility' terminology which is more precise financial language than the ground truth's 'obligation,' but semantically equivalent. (3) Ground truth says 'fully settled or otherwise exited' while LLM says 'repaid or facility was terminated' - these are semantically equivalent interpretations. QUANTITATIVE VERIFICATION: Both answers correctly cite $3.4 million for 2023 and $0 for 2024. No calculation errors present. MULTI-HOP REASONING: Both answers correctly synthesize the comparison across two years and draw appropriate conclusions about the elimination of the obligation. The reasoning is sound in both cases. The LLM answer is slightly more detailed and informative while maintaining factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 460,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the valuation methodology and composition of GD's Retirement Annuity Contracts change between 2022 and 2024, and what does this indicate about the company's approach to reporting these assets?",
      "original_answer": "In 2022, GD reported Retirement Annuity Contracts as part of Level 3 assets with a fair value of $35 million as of December 31, 2021, and this value remained relatively stable through December 31, 2020 at $38 million. The contracts were disclosed within a detailed table showing actual returns, unrealized gains and losses, and net purchases or sales. By 2024, Retirement Annuity Contracts were still categorized under Level 3 assets but were now described as being valued using NAV (net asset value) as a practical expedient, excluded from the formal fair value hierarchy. This indicates a shift in GD's reporting methodology from detailed fair value disclosures to a more simplified NAV-based approach, aligning with broader changes in how these contracts are categorized and disclosed.",
      "llm_answer": "In the 2022 filing GD listed its retirement‑annuity contracts as Level 3 assets – valued with “significant unobservable inputs” – with a fair‑value balance of about **$38 million**【GD_10k_2022.pdf†L1-L5】. The 2024 filing still classifies these contracts as Level 3, but the fair‑value balance has fallen to roughly **$22 million**【GD_10k_2024.pdf†L1-L5】. The consistent Level 3 treatment shows the company continues to rely on internal, unobservable valuation models for these contracts, while the lower amount signals a shrinkage in the underlying retirement‑annuity portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and incomplete synthesis of the multi-hop question. QUANTITATIVE ISSUES: (1) The 2022 figure of $38 million is correct per ground truth, but the LLM claims the 2024 balance 'fell to roughly $22 million' - this specific figure is not mentioned in the ground truth and appears to be fabricated or misread. (2) The ground truth explicitly states the 2021 value was $35 million and 2020 was $38 million, but the LLM conflates these with 2022/2024 comparisons without proper year alignment. COMPLETENESS ISSUES: (1) The LLM completely misses the critical methodological shift described in the ground truth - the move from 'detailed fair value disclosures' to 'NAV-based approach' and 'excluded from the formal fair value hierarchy.' (2) The ground truth emphasizes that by 2024, contracts were 'described as being valued using NAV (net asset value) as a practical expedient' - this is the KEY finding about methodology change, which the LLM entirely omits. (3) The LLM fails to address the shift from detailed disclosure tables (showing actual returns, unrealized gains/losses, net purchases/sales) to simplified NAV-based reporting. REASONING ISSUES: (1) The LLM's explanation that 'lower amount signals a shrinkage in the underlying retirement-annuity portfolio' is speculative and not supported by the ground truth, which focuses on reporting methodology changes rather than portfolio shrinkage. (2) The multi-hop synthesis is incomplete - the question asks about BOTH valuation methodology AND composition changes, but the LLM only addresses classification level (Level 3) and provides an unsupported number claim. (3) The LLM correctly identifies Level 3 treatment continuity but misses the fundamental shift in how these assets are now excluded from the fair value hierarchy via NAV practical expedient. ENTITY/METRIC ACCURACY: The company (GD) and asset type (Retirement Annuity Contracts) are correct, but the year-to-year comparison is problematic and the $22 million figure for 2024 cannot be verified against the ground truth provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 562,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the composition and value of restricted cash for securitization investors changed between 2022 and 2024, particularly in terms of its fair value hierarchy classification?",
      "original_answer": "In 2022, the company reported restricted cash for securitization investors as part of consolidated VIEs, with the assets and liabilities presented on the consolidated balance sheets. By 2024, the restricted cash for securitization investors was valued at $441 million, with the entire amount classified under Level 1 of the estimated fair value hierarchy, indicating a shift toward more transparent or market-based valuation methods. This reflects a more defined and standardized valuation approach in 2024 compared to 2022, where the fair value hierarchy was not explicitly detailed for this category.",
      "llm_answer": "In 2022 the company reported restricted cash for securitization investors of $462 million, and the entire amount was measured at Level 1 of the fair‑value hierarchy (no Level 2 or Level 3 portion)【COF_10k_2022.pdf pp. 177‑181】. By the 2024 filing that balance had slipped to $441 million, but it remained classified wholly at Level 1 with zero Level 2 or Level 3 exposure【COF_10k_2024.pdf pp. 217‑221】.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer provides a well-structured comparison of restricted cash for securitization investors between 2022 and 2024. STRENGTHS: (1) The 2024 figure of $441 million matches the ground truth exactly. (2) The fair value hierarchy classification is correctly identified as Level 1 for both years with zero Level 2/3 exposure. (3) The multi-hop synthesis is sound, comparing the two years and highlighting the change in balance. (4) The answer directly addresses the question about composition, value, and fair value hierarchy classification. (5) Document citations are provided with specific page ranges. WEAKNESSES: (1) The 2022 restricted cash figure is stated as $462 million in the LLM answer, but the ground truth does not explicitly confirm this specific number for 2022 - the ground truth only states that in 2022 'the fair value hierarchy was not explicitly detailed for this category.' This creates a discrepancy: the LLM claims 2022 had Level 1 classification with specific detail, while the ground truth suggests 2022 lacked explicit fair value hierarchy detail. (2) The ground truth emphasizes that 2024 represents 'a shift toward more transparent or market-based valuation methods' and 'a more defined and standardized valuation approach' compared to 2022, but the LLM answer doesn't capture this interpretive element about the nature of the change. (3) Minor: The LLM answer could have been clearer about whether the $462M figure in 2022 was explicitly classified as Level 1 in the filing or if this is an inference. The quantitative discrepancy regarding 2022 classification detail prevents a higher score, though the 2024 data and overall structure are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 459,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial recognition and asset management between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's relationship with franchisees was primarily characterized by the acquisition of restaurants from franchisees, resulting in goodwill that was either fully or partially written off depending on the time of sale relative to acquisition. The Company used a discounted cash flow methodology to determine the fair value of acquired restaurants. By 2024, the relationship had transformed into a more dependency-based model, particularly in the area of technology platform services. McDonald's now provides distinct technology-related goods and services to franchisees, recognizing revenue on a gross basis and corresponding expenses within 'Other restaurant expenses.' This marks a shift from asset acquisition and goodwill management toward ongoing service-based financial interactions with franchisees.",
      "llm_answer": "McDonald’s continued to recognize franchise‑related revenue in the same way in both years – rent, royalties, minimum‑rent payments and initial fees are recorded over the franchise term, and technology‑platform fees are presented on a gross basis, with the Company still sharing restaurant‑improvement costs with franchisees (2023 10‑K p. 45; 2024 10‑K p. 45).  However, the relationship deepened in 2024 as the Company accelerated purchases of franchisee restaurants, raising net restaurant purchases from $107 million in 2023 to $179 million in 2024 and adding $240 million of goodwill (total goodwill up to $3.15 billion from $3.04 billion) and $270 million of identifiable intangible assets, while still treating franchisee advertising contributions as non‑consolidated (2023 10‑K p. 46; 2024 10‑K p. 46).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer provides specific financial numbers and demonstrates multi-hop synthesis across 2023 and 2024 filings, but diverges significantly from the ground truth in its core characterization of the relationship evolution.\n\nSTRENGTHS:\n1. Quantitative data appears accurate: $107M (2023) vs $179M (2024) net restaurant purchases, $240M goodwill addition, $3.04B to $3.15B goodwill increase, $270M identifiable intangible assets\n2. Correctly identifies that technology-platform fees are presented on gross basis\n3. Properly cites specific page references (10-K p. 45, p. 46)\n4. Accurately notes franchisee advertising contributions remain non-consolidated\n5. Demonstrates multi-hop synthesis by comparing metrics across two years\n\nWEAKNESSES:\n1. FUNDAMENTAL MISALIGNMENT: The ground truth emphasizes a SHIFT from asset acquisition/goodwill management (2023) to service-based financial interactions (2024). The LLM answer instead describes an ACCELERATION of restaurant purchases in 2024, which contradicts the ground truth's characterization of the evolution.\n2. The LLM states the relationship \"deepened\" through accelerated purchases, but ground truth indicates the relationship transformed AWAY from asset acquisition toward technology services.\n3. The LLM answer focuses heavily on restaurant purchases and goodwill (asset-based metrics), while ground truth emphasizes the shift TO technology-platform services as the primary relationship driver.\n4. Missing the key insight that 2024 marked a transition to \"dependency-based model\" centered on technology services rather than asset acquisition.\n5. The LLM's characterization of \"continued to recognize franchise-related revenue in the same way\" contradicts ground truth's emphasis on transformation/evolution.\n\nCALCULATION VERIFICATION:\n- $107M to $179M increase: $72M difference (not explicitly stated but implied correctly)\n- Goodwill increase: $3.15B - $3.04B = $110M (but LLM states $240M added, which may represent gross additions before write-offs; this requires clarification but appears plausible)\n- Numbers appear internally consistent\n\nMULTI-HOP REASONING:\nThe LLM successfully synthesizes data across 2023 and 2024 filings and identifies year-over-year changes. However, it misinterprets the NATURE of the relationship evolution, focusing on quantitative acceleration rather than qualitative transformation from asset-based to service-based interactions.\n\nSEMANTIC EQUIVALENCE:\nThe LLM answer is semantically different from ground truth in its core thesis. Ground truth emphasizes transformation/shift; LLM emphasizes continuation with acceleration. These are fundamentally different characterizations of the relationship evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 721,
        "total_tokens": 2125
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the treatment of the 2019 Stock and Incentive Compensation Plan evolved between 2022 and 2024 in Procter & Gamble's disclosures, particularly regarding its relationship with other compensation plans and its role in equity compensation?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was disclosed as part of a broader set of compensation plans, with specific reference to its adoption by shareholders in 2019 and its regulation in conjunction with other plans like the 2014 Stock and Incentive Compensation Plan. By 2024, the 2019 Plan was still included in the list of active equity compensation plans, but it was now referenced in the context of security ownership and the total shares available for issuance, indicating a shift from adoption and governance details to its role in the company's overall equity compensation structure. This reflects a transformation in how the plan is positioned within the company's disclosures, moving from procedural governance to a more strategic ownership framework.",
      "llm_answer": "In both the 2022 and 2024 Form 10‑K, the 2019 Stock and Incentive Compensation Plan is singled out as the **only** equity‑compensation plan that can issue new securities and is governed together with the 2014 Plan under the Compensation and Leadership Development Committee’s regulations (see the exhibit references to the 2019‑ and 2014‑Plan regulations). The plan’s overall authorization (187 million shares) stayed the same, but the **available share pool for future grants dropped from 119 million shares in 2022 to 77 million shares in 2024**, showing that its role in equity compensation remains central but its remaining capacity has been reduced.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations that contradict the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM provides specific share numbers (187 million total authorization, 119 million available in 2022, 77 million in 2024) that cannot be verified against the ground truth and appear to be fabricated. The ground truth does not mention these specific figures. (2) FACTUAL MISREPRESENTATION: The LLM claims the 2019 Plan is the 'only' equity compensation plan that can issue new securities, which is an overstatement not supported by the ground truth. The ground truth indicates the plan was disclosed alongside other plans but does not claim exclusivity. (3) INCOMPLETE SYNTHESIS: The ground truth emphasizes a shift in disclosure focus from 'adoption and governance details' (2022) to 'security ownership and total shares available for issuance' (2024), representing a transformation in positioning. The LLM focuses narrowly on share pool depletion without capturing this broader disclosure evolution. (4) GOVERNANCE CONTEXT: While the LLM correctly notes the relationship with the 2014 Plan and the Compensation Committee's role, it fails to capture the ground truth's key insight about the shift from procedural governance to strategic ownership framework. (5) MISSING CONTEXT: The ground truth emphasizes the transformation in how the plan is positioned within disclosures over time. The LLM answer treats the plan's role as static ('remains central') rather than evolving. The answer reads as if specific data was retrieved from filings, but the numbers and claims lack grounding in the provided ground truth, suggesting potential hallucination of financial data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 467,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Salvatore Ferragamo's presence in Simon Property Group's international outlet locations evolved between 2022 and 2023?",
      "original_answer": "In 2022, Salvatore Ferragamo was listed as a tenant in three of Simon Property Group's international outlet locations in Japan: Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Sano Premium Outlets. By 2023, Salvatore Ferragamo appeared in only one of SPG's outlet locations, specifically Las Vegas Outlets North in Nevada, USA. This indicates a significant reduction in Salvatore Ferragamo's presence across SPG's outlet portfolio, shifting from multiple locations in Japan to a single location in the U.S.",
      "llm_answer": "Salvatore Ferragamo was shown as a tenant at nine international premium‑outlet sites in the 2022 filing (four in Japan, one in Mexico, two in South Korea, one in Malaysia and one in Canada)【SPG_10k_2022.pdf†pages=40-44】, and the same nine locations are listed in the 2023 filing【SPG_10k_2023.pdf†pages=32-36】—so its international outlet footprint remained unchanged between 2022 and 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is fundamentally incorrect on all key factual claims. Ground truth states: (1) In 2022, Salvatore Ferragamo was in 3 Japanese outlet locations (Gotemba, Kobe-Sanda, Sano Premium Outlets), and (2) By 2023, presence reduced to 1 location (Las Vegas Outlets North in Nevada, USA). The LLM claims: (1) Nine international locations in 2022 (four in Japan, one in Mexico, two in South Korea, one in Malaysia, one in Canada), and (2) Same nine locations in 2023 with no change. These claims are directly contradictory to ground truth on multiple dimensions: (a) Wrong number of 2022 locations (9 vs. 3), (b) Wrong geographic distribution (claims Mexico, South Korea, Malaysia, Canada presence when ground truth shows only Japan), (c) Wrong conclusion about change (claims 'unchanged' when ground truth shows significant reduction from 3 to 1), (d) Wrong 2023 location count (claims 9 vs. actual 1). The LLM's multi-hop synthesis failed completely—it did not correctly identify which locations Salvatore Ferragamo occupied in either year, nor did it accurately compare the evolution between years. The question is appropriately scoped (contextual relevance is high), but the answer provides entirely fabricated data with no factual basis in the ground truth knowledge graph.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 359,
        "total_tokens": 1580
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about its operational focus in the region?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region, suggesting a potential shift or stabilization in operational focus rather than aggressive growth.",
      "llm_answer": "COP’s natural‑gas position in Asia Pacific/Middle East fell between 2023 and 2024.  In 2023 the region held about 305 billion cubic feet (BCF) of developed‑and‑undeveloped gas in consolidated operations and 3,558 BCF in equity‑affiliate assets; by 2024 those volumes had slipped to roughly 289 BCF and 3,189 BCF, while gas production dropped from 51 BCF to 25 BCF.  The decline signals that ConocoPhillips is scaling back its gas footprint in the Asia Pacific/Middle East area, shifting operational emphasis away from expanding gas development there.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant numerical discrepancies with the ground truth. Ground truth states 312 BCF (2023) declining to 296 BCF (2024) for total natural gas position. The LLM reports 305 BCF (2023) and 289 BCF (2024) for consolidated operations alone, which are different figures entirely. The LLM also introduces additional metrics (equity-affiliate assets: 3,558 BCF to 3,189 BCF, and production figures: 51 BCF to 25 BCF) that are not mentioned in the ground truth answer. These appear to be additional data points that may or may not be accurate, but they represent a different breakdown than what the ground truth specifies. The core issue is that the LLM's primary numbers (305→289 BCF) do not match the ground truth (312→296 BCF). The directional conclusion (decline in gas position) is correct, and the interpretation about scaling back operations is reasonable and semantically similar to the ground truth's 'shift or stabilization.' However, the quantitative foundation is fundamentally flawed. The LLM appears to have accessed different or more granular data than the ground truth, but this creates a factual mismatch rather than an enhancement. For a financial question where precise numbers are critical, this represents a significant failure in accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 364,
        "total_tokens": 1593
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Comcast's approach to wireless gateways evolved from 2022 to 2024, particularly in terms of strategic emphasis and investment?",
      "original_answer": "In 2022, Comcast offered wireless gateways as part of its broadband services, combining modem and Wi-Fi router capabilities to enhance in-and-out-of-home coverage. The focus was on customer-facing features like the xFi whole-home application and advanced security. By 2024, the company elevated its strategic emphasis by shifting from merely offering wireless gateways to actively investing in their deployment as part of its broader network infrastructure upgrades. This included plans to increase capacity and deliver multigigabit symmetrical speeds, signaling a deeper integration of wireless gateways into its long-term network strategy.",
      "llm_answer": "In the 2022 Form 10‑K Comcast described wireless gateways mainly as a bundled modem‑router product that enhances in‑home Wi‑Fi coverage and lets customers manage their network through the xFi app, noting only that they are part of the customer‑premise equipment the company purchases (CMCSA 10K 2022, pp. 5‑9). By the 2024 filing the company had elevated gateways to a distinct capital‑expenditure priority within its Connectivity & Platforms segment, allocating roughly $2 billion to customer‑premise equipment and explicitly stating that “the continued deployment of wireless gateways” will be a focus of future spending (CMCSA 10K 2024, pp. 49‑53). This shift reflects a move from a service‑feature description to a strategic investment emphasis on scaling and rolling out the gateways.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of Comcast's wireless gateway strategy from 2022 to 2024, capturing the shift from service-feature description to strategic capital investment emphasis. The qualitative reasoning is sound and well-structured.\n\nSTRENGTHS:\n- Correctly identifies the 2022 positioning: wireless gateways as bundled modem-router product with xFi app management\n- Accurately captures the 2024 shift: elevation to distinct capital-expenditure priority\n- Properly synthesizes multi-hop information across two filing years\n- Correctly identifies the Connectivity & Platforms segment as the relevant business unit\n- Appropriate use of source citations (10K 2022 pp. 5-9, 10K 2024 pp. 49-53)\n- Semantic equivalence with ground truth on strategic emphasis evolution\n\nWEAKNESSES:\n- The $2 billion figure for customer-premise equipment allocation is presented without clear verification against ground truth. The original answer does not specify this dollar amount, making it difficult to confirm accuracy. This is a specific quantitative claim that requires validation.\n- The page number citations (pp. 49-53 for 2024) cannot be independently verified against the ground truth provided\n- Minor: The answer could have been more explicit about the \"multigigabit symmetrical speeds\" objective mentioned in the ground truth\n\nMULTI-HOP REASONING:\nThe answer successfully synthesizes information across two years and two different filing documents, correctly identifying the progression from operational feature to strategic infrastructure investment. The logic connecting the shift in emphasis to capital allocation priorities is sound.\n\nQUANTITATIVE CONCERNS:\nThe $2 billion figure is the primary quantitative claim. While it appears plausible as a capital expenditure amount, the ground truth does not explicitly state this number, creating uncertainty about its accuracy. This prevents a higher quantitative accuracy score.\n\nOVERALL ASSESSMENT:\nThe answer demonstrates strong understanding of the strategic evolution and correctly addresses the question's core requirements. The main limitation is the introduction of a specific dollar figure that cannot be verified against the provided ground truth, which affects confidence in the quantitative accuracy despite the overall answer being substantially correct in its qualitative assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 636,
        "total_tokens": 1990
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the G600's market presence and production evolution changed between 2022 and 2024, particularly in terms of cumulative deliveries and its role within Gulfstream's product lineup?",
      "original_answer": "In 2022, the G500 and G600 had cumulative deliveries totaling almost 150 by year-end 2021, and were described as replacements for the G450 and G550 models with improvements in speed, fuel efficiency, cabin volume, and flight controls. By 2024, cumulative deliveries of the G500 and G600 had more than doubled to over 300 by year-end 2024. Additionally, the G600 was no longer described in the context of being a new product introduction, indicating it had become a more established part of Gulfstream's lineup, while the focus shifted to newer models like the G800 and G400.",
      "llm_answer": "By the 2022 filing, Gulfstream said the G600 (together with the G500) had delivered “almost 150” aircraft as of year‑end 2021. The 2024 filing reports that cumulative deliveries of the G500/G600 family had risen to “more than 300” by year‑end 2024, roughly doubling the earlier total. Initially highlighted in 2022 as a brand‑new, clean‑sheet large‑cabin model that replaced the G550, the G600 has become a core, high‑volume product anchoring Gulfstream’s large‑cabin lineup alongside newer models such as the G700, G800 and the upcoming G400.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) All key numbers are correct - 'almost 150' cumulative deliveries by year-end 2021, 'more than 300' by year-end 2024, and the doubling characterization are all accurate. (2) Dates and time periods are correct (2022 filing referencing 2021 data, 2024 filing referencing 2024 data). (3) The multi-hop synthesis correctly combines information from two different filing years to show evolution. (4) Correctly identifies the G500/G600 as a combined product family. WEAKNESSES: (1) The LLM mentions the G700 as a newer model alongside the G800, but the ground truth only mentions G800 and G400 as the newer models receiving focus. The G700 is not mentioned in the original answer, which could indicate it's either not part of the relevant context or represents an inaccuracy. (2) The characterization of the G600's role differs slightly - the ground truth emphasizes it 'was no longer described in the context of being a new product introduction,' while the LLM states it 'has become a core, high-volume product anchoring Gulfstream's large-cabin lineup.' While semantically similar, the LLM's phrasing is more interpretive than what the ground truth explicitly states. (3) The ground truth specifically notes the G600 was described as a 'replacement for the G450 and G550 models with improvements in speed, fuel efficiency, cabin volume, and flight controls' - the LLM only mentions it replaced the G550, omitting the G450 and the specific improvements. (4) The phrase 'clean-sheet large-cabin model' in the LLM answer is not explicitly stated in the ground truth. CALCULATION VERIFICATION: The doubling from ~150 to 300+ is mathematically accurate. MULTI-HOP REASONING: The answer correctly synthesizes information across two filing years to show product evolution, though with some interpretive additions not in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 499,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has AIG's financial relationship with Corebridge evolved between 2023 and 2024, particularly in terms of equity ownership and income recognition?",
      "original_answer": "In 2023, AIG held 52.2% of Corebridge common stock and was in the process of selling down its stake, with the intention to fully divest over time. By 2024, AIG had transitioned to accounting for its remaining interest in Corebridge using the equity method, recognizing pre-tax income based on dividends received and changes in Corebridge's stock price from June 9, 2024. This represents a shift from direct ownership control to a more passive investment approach, indicating a significant change in the nature of AIG's financial relationship with Corebridge.",
      "llm_answer": "In 2023 AIG still owned a majority of Corebridge – 52.2 % of the common stock as of 12/31/23 – and its Corebridge holding produced only a modest $29 million fair‑value change that was reflected in net investment income. By 2024 AIG had de‑consolidated Corebridge, reducing its stake to 48.4 % at the June 9 deconsolidation date and to just 22.7 % by 12/31/24, and now treats the remaining interest under the equity‑method, recognizing $601 million of equity‑method income (plus a $282 million gain on the sale of Corebridge shares) in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key facts: (1) 2023 ownership of 52.2% is correct; (2) 2024 deconsolidation date of June 9 is correct; (3) Ownership percentages at deconsolidation (48.4%) and year-end 2024 (22.7%) appear accurate based on the progressive divestment described; (4) Transition from consolidation to equity method accounting is correctly identified; (5) The $601 million equity-method income and $282 million gain on share sales are specific financial metrics that demonstrate detailed knowledge of 2024 results. The answer goes beyond the ground truth by providing specific income figures and the fair-value change in 2023 ($29 million), which adds valuable context. Multi-hop reasoning is sound: the answer correctly synthesizes the evolution from majority ownership with consolidation accounting in 2023 to minority ownership with equity method accounting in 2024, capturing the fundamental shift in the financial relationship. The answer addresses all aspects of the question including equity ownership percentages, accounting method changes, and income recognition. Minor consideration: while the ground truth mentions 'dividends received and changes in Corebridge's stock price' as the basis for equity method income recognition, the LLM provides the actual income amounts rather than the mechanism, which is actually more informative. No factual errors detected. The answer is well-structured, specific, and directly responsive to the question about the evolution of AIG's financial relationship with Corebridge.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 431,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Tesla's production strategy for the Solar Roof evolved between 2022 and 2024, particularly in terms of manufacturing dependencies and operational challenges?",
      "original_answer": "In 2022, Tesla was actively producing the Solar Roof at Gigafactory New York, which was specifically highlighted as a dedicated facility for the development and production of Solar Roof and other solar products. The company offered financing options tied to the Solar Roof, indicating a strategic push to integrate the product into its broader energy ecosystem. By 2024, Tesla's disclosures shifted to emphasize increased complexity and risk in ramping production of the Solar Roof, with explicit mention of 'delays in launching and/or ramping production of our energy storage products and Solar Roof.' The 2024 filing also highlighted broader operational dependencies, including the need to achieve 'design tolerances, high quality and output rates' across its manufacturing facilities, and noted potential disruptions due to supply chain coordination, localized procurement challenges, and the need for cost-effective scaling. This indicates a transition from a focused production setup in 2022 to a more complex and risk-laden ramp-up phase in 2024.",
      "llm_answer": "In the 2022 Form 10‑K Tesla disclosed that Solar Roof production was still heavily dependent on third‑party suppliers for the roof‑tiles and other components, with the limited manufacturing capacity at Gigafactory New York serving mainly development and low‑volume assembly; the company warned that this reliance and the complexity of integrating solar tiles caused ramp‑up delays and other operational challenges. By the 2024 filing the strategy had shifted toward expanding in‑house production of Solar Roof tiles and hardware at Gigafactory New York to reduce supplier dependence, but Tesla still highlighted persistent challenges in scaling volume, managing component quality and supply‑chain reliability, and meeting its ambitious production schedule.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies when compared to the ground truth. Key issues: (1) INCORRECT CLAIM ABOUT 2022: The LLM states that in 2022 Tesla was 'heavily dependent on third-party suppliers for roof-tiles' and that Gigafactory New York served 'mainly development and low-volume assembly.' The ground truth indicates that in 2022, Tesla was 'actively producing the Solar Roof at Gigafactory New York, which was specifically highlighted as a dedicated facility for the development and production of Solar Roof.' This is a fundamental mischaracterization of the 2022 production strategy. (2) INCORRECT CHARACTERIZATION OF 2024 SHIFT: The LLM claims the 2024 strategy 'shifted toward expanding in-house production...to reduce supplier dependence,' implying this was a new direction. However, the ground truth shows that by 2024, Tesla was emphasizing 'increased complexity and risk in ramping production' and 'delays in launching and/or ramping production,' not a successful shift to in-house production. The LLM misrepresents the nature of the evolution. (3) MISSING KEY CONTEXT: The ground truth emphasizes the transition from a 'focused production setup in 2022' to a 'more complex and risk-laden ramp-up phase in 2024,' highlighting challenges with design tolerances, quality, output rates, supply chain coordination, and cost-effective scaling. The LLM fails to capture this critical shift in risk profile and operational complexity. (4) UNSUPPORTED CLAIMS: The LLM makes specific claims about third-party supplier dependence in 2022 and in-house production expansion in 2024 that are not supported by the ground truth and appear to be fabricated details. (5) MULTI-HOP REASONING: The LLM failed to correctly synthesize the evolution of Tesla's Solar Roof strategy across the 2022-2024 period, instead creating an inaccurate narrative about supplier dependence and in-house production shifts. The answer demonstrates poor understanding of the actual strategic evolution documented in the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1456,
        "completion_tokens": 545,
        "total_tokens": 2002
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Qualcomm's strategic involvement with on-device artificial intelligence (AI) evolved from 2023 to 2024, particularly in terms of its business focus and investment approach?",
      "original_answer": "In 2023, Qualcomm was actively producing on-device AI technologies as part of its broader portfolio of foundational technologies, including wireless connectivity and low-power computing. The company positioned on-device AI as a key innovation driver across industries beyond mobile handsets, such as automotive and IoT. By 2024, Qualcomm's focus on on-device AI had evolved from being a core product offering to a more investment-centric strategy. The company continued to invest heavily in advancing on-device AI through research and development, acquisitions, and strategic transactions, signaling a shift toward long-term growth and ecosystem development rather than immediate product commercialization. This transition reflects a deeper commitment to enabling third-party integration of its AI technologies rather than solely selling AI-based products directly.",
      "llm_answer": "In the 2023 filing Qualcomm already framed on‑device AI as a core, “foundational” technology and said it was scaling AI‑enabled computing beyond smartphones into automotive, IoT and other new markets, funding that effort with heavy internal R&D and selective acquisitions (2023 10‑K pp. 65‑66). The 2024 filing repeats the same message – on‑device AI remains a key growth engine, the company continues to invest significant resources in AI development, and it pursues the same blend of internal development and strategic acquisitions to broaden AI applications beyond handsets (2024 10‑K pp. 20‑21). Thus, Qualcomm’s strategic involvement with on‑device AI has stayed consistent, with a continued focus on expanding AI across industries and an investment approach that mixes internal R&D with acquisitions.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUE: The LLM answer fundamentally contradicts the ground truth on the core claim of the question. The ground truth explicitly states that Qualcomm's focus 'evolved from being a core product offering to a more investment-centric strategy' between 2023 and 2024, representing a significant strategic shift. However, the LLM answer claims 'Qualcomm's strategic involvement with on-device AI has stayed consistent' and that the 2024 filing 'repeats the same message' as 2023. This is a direct contradiction of the ground truth's central finding about evolution/change. The LLM correctly identifies that both years involved: (1) on-device AI as foundational technology, (2) expansion beyond smartphones to automotive/IoT, (3) investment through R&D and acquisitions. However, it misses the critical distinction that the NATURE of the strategic approach shifted from 'core product offering' to 'investment-centric strategy' focused on 'ecosystem development rather than immediate product commercialization.' The LLM also provides specific page citations (2023 10-K pp. 65-66; 2024 10-K pp. 20-21) which cannot be verified against the ground truth but appear plausible. The answer demonstrates partial understanding of Qualcomm's AI strategy but fails to capture the key evolution/transition that the question specifically asks about. This represents a failure in multi-hop reasoning to synthesize the year-over-year change, not just the consistency of elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 405,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the presence of Dolce & Gabbana in SPG-operated properties evolved between 2022 and 2023, and what does this indicate about SPG's brand positioning strategy in its premium outlet locations?",
      "original_answer": "In 2022, Dolce & Gabbana was listed as a tenant in multiple SPG-operated premium outlets in Japan, including Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Rinku Premium Outlets. By 2023, Dolce & Gabbana was only listed at Las Vegas Outlets North Premium NV in the U.S. This indicates a strategic shift from a multi-location presence in Japan to a more exclusive, flagship-style positioning in a key U.S. market, suggesting a reevaluation of brand placement and target demographics.",
      "llm_answer": "Both the 2022 and 2023 10‑K tables list Dolce & Gabbana as a tenant at Las Vegas Premium Outlets in the United States and at several international premium outlets (e.g., Gotemba, Kobe‑Sanda and Rinku in Japan and Punta Norte in Mexico). The brand’s presence is unchanged from 2022 to 2023, indicating that Simon Property Group is deliberately keeping high‑end luxury anchors in its Premium Outlet portfolio to reinforce an upscale, fashion‑forward positioning for these locations.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect on the core factual claim. The ground truth clearly states that Dolce & Gabbana presence CHANGED between 2022 and 2023: it was present at multiple Japanese locations (Gotemba, Kobe-Sanda, Rinku) in 2022 but was ONLY at Las Vegas Outlets North Premium NV in 2023. The LLM claims the presence was 'unchanged' and lists Dolce & Gabbana at all these locations in both years, which directly contradicts the ground truth. The LLM also incorrectly adds Punta Norte in Mexico as a location, which is not mentioned in the ground truth. The LLM's conclusion about 'deliberately keeping high-end luxury anchors' is the opposite of what the data shows—there was actually a strategic REDUCTION in locations, particularly a withdrawal from Japan. The multi-hop reasoning is flawed because the LLM failed to identify the key difference between 2022 and 2023 tenant lists. The answer misses the critical insight about the strategic shift from multi-location Japanese presence to exclusive U.S. flagship positioning. This is a major factual error on the primary question being asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 316,
        "total_tokens": 1571
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did COP's investment in exploration activities in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the company's strategic focus in that region?",
      "original_answer": "In 2023, COP reported $49 million in exploration expenditures in the Asia Pacific/Middle East region, while in 2024, the company disclosed a total of $0 in new exploration activities in that region. This indicates a complete withdrawal or pause in exploration efforts in the Asia Pacific/Middle East, suggesting a strategic shift away from that region in favor of other geographic areas.",
      "llm_answer": "COP’s exploration outlay in the Asia Pacific/Middle East fell sharply – it was about $95 million in 2023 (the $49 million recorded for consolidated operations plus $46 million for equity‑affiliate activities 【COP_10k_2023.pdf p. 155】) and the 2024 capital‑expenditure table shows no exploration spend for that region 【COP_10k_2024.pdf p. 143】. This drop signals that the company is pulling back on new‑exploration projects in Asia Pacific/Middle East and is instead focusing its capital on development of existing assets or on other regions.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR FACTUAL ERROR: The LLM answer provides incorrect numbers for 2023 exploration expenditures. The ground truth states COP reported $49 million in exploration expenditures in the Asia Pacific/Middle East region in 2023. However, the LLM claims the total was $95 million ($49 million consolidated + $46 million equity-affiliate). This is a fundamental factual error - the LLM appears to have misinterpreted or fabricated the $46 million equity-affiliate figure, which is not supported by the ground truth. The ground truth explicitly states $49 million for 2023, not $95 million. The 2024 figure of $0 is correctly identified by the LLM. The qualitative interpretation about strategic withdrawal is reasonable and aligns with the ground truth's conclusion, but this cannot overcome the significant quantitative error in the 2023 figure. The LLM's attempt to break down the number into consolidated and equity-affiliate components, while potentially a reasonable analytical approach, introduces an incorrect total that contradicts the ground truth. The reasoning about strategic shift is sound, but the factual foundation is flawed. The citation format suggests the LLM is attempting to reference specific pages, but the numbers cited do not match the ground truth data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 356,
        "total_tokens": 1602
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Comcast's financial stake and debt involvement in Universal Beijing Resort evolved from 2022 to 2024?",
      "original_answer": "In 2022, Universal Beijing Resort was introduced as a new entity in Comcast's disclosures, noting its opening in September 2021 and highlighting the increased depreciation and amortization expenses across the company, though no specific financial stake or debt figures were provided at that time. By 2024, Comcast explicitly stated its 30% ownership interest in Universal Beijing Resort and detailed the debt financing structure, including $3.4 billion of debt outstanding as of December 31, 2024, down from $3.5 billion in 2023. Additionally, the assets and liabilities of Universal Beijing Resort were reported as $7.3 billion and $7.0 billion respectively in 2024, compared to $7.8 billion and $7.2 billion in 2023.",
      "llm_answer": "Comcast’s ownership of the Beijing theme‑park has not changed – it still holds a 30 % equity interest in Universal Beijing Resort, the same percentage reported in the 2022 filing.  The resort’s financing has been trimmed slightly: at year‑end 2022 the venture carried roughly $3.5 billion of debt (about $3.1 billion of that in a term loan) 【CMCSA_10k_2022.pdf†p46‑p50】, while by year‑end 2024 total debt had fallen to about $3.4 billion, including a $3.0 billion term loan 【CMCSA_10k_2024.pdf†p84‑p88】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides a partial response with some correct elements but contains significant omissions and one factual error. CORRECT ELEMENTS: (1) The 30% ownership interest is correctly stated; (2) The $3.4 billion debt figure for 2024 is correct; (3) The general trend of debt reduction is accurately captured; (4) The term loan amounts ($3.1B in 2022, $3.0B in 2024) appear reasonable. CRITICAL OMISSIONS: (1) The LLM claims the 30% stake was reported in 2022, but the ground truth explicitly states 'no specific financial stake or debt figures were provided at that time' in 2022 - this is a significant factual error regarding what was disclosed when; (2) The LLM completely omits the 2023 debt figure ($3.5 billion) which is important for showing the evolution trajectory; (3) The LLM fails to mention the asset and liability figures ($7.3B/$7.0B in 2024 vs $7.8B/$7.2B in 2023), which are key components of the financial stake evolution; (4) The LLM does not address that Universal Beijing Resort was 'introduced as a new entity' in 2022 disclosures. QUANTITATIVE ISSUES: While the 2024 debt figure ($3.4B) is correct, the answer is incomplete by omitting the 2023 comparison data and asset/liability information that demonstrates the full evolution. The claim about 2022 debt ($3.5B) appears to conflate 2023 data with 2022. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2024 filings but fails to incorporate 2023 data and mischaracterizes what was disclosed in 2022. The reasoning about debt reduction is sound but incomplete. The answer addresses the ownership and debt aspects but neglects the balance sheet evolution (assets/liabilities) which is part of the financial stake evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 473,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did Duke Energy's net derivatives balance and associated settlement activity evolve from 2022 to 2023, and what does this indicate about the company's exposure or management of derivative instruments?",
      "original_answer": "In 2022, Duke Energy's net derivatives balance at the end of the year was $29 million, with settlements totaling $32 million. In 2023, the net derivatives balance decreased to $13 million, while settlements increased significantly to $68 million. This indicates a shift in the company's management of derivative instruments, with a larger reduction in the net balance despite higher settlement activity in 2023.",
      "llm_answer": "In 2022 Duke Energy finished the year with a net derivative position of $29 million, but by the end of 2023 that balance had fallen to $13 million.  Settlement activity more than doubled – the company settled $68 million of contracts in 2023 versus $32 million in 2022 – while new purchases also fell (from $74 million to $42 million) and gains turned positive ( $10 million versus a $(35) million loss).  This pattern shows the firm actively unwound and reduced its derivative positions, lowering its net exposure to market‑price risk.【source】Derivatives (net) Years Ended December 31 2023 vs 2022 table (balance $29 → $13; settlements $(68) vs $(32); purchases $42 vs $74; gains $10 vs $(35)).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core facts - net derivatives balance declining from $29M (2022) to $13M (2023), and settlements increasing from $32M to $68M. The qualitative interpretation about unwinding derivative positions and reducing market-price risk exposure is sound and well-reasoned. The answer addresses all parts of the multi-hop question and provides good contextual synthesis. CRITICAL ERRORS: The LLM contains a significant sign error in the settlements figure. The ground truth states settlements were $32M in 2022 and $68M in 2023. However, the LLM presents these as $(68) vs $(32), using parentheses notation that typically indicates negative values in accounting. This creates ambiguity about whether the LLM is correctly understanding the settlement amounts or has confused the sign convention. Additionally, the LLM introduces new information (purchases of $74M vs $42M, and gains of $10M vs $(35)M loss) that is NOT present in the ground truth answer provided. While this additional detail may be accurate from the source document, it goes beyond what was verified in the original answer and cannot be confirmed as correct. CALCULATION VERIFICATION: The core comparison (29→13 is a decrease, 32→68 is an increase) is correct. The statement that settlements 'more than doubled' is accurate (68/32 = 2.125x). MULTI-HOP REASONING: The synthesis connecting the numerical changes to the interpretation about derivative position management is logical and sound. The answer correctly identifies the relationship between reduced net balance and increased settlement activity as indicating active unwinding of positions. ISSUE WITH SOURCING: The LLM cites a specific table but the parenthetical notation for settlements creates ambiguity about sign conventions that could indicate misinterpretation of the source data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 499,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did SPG's treatment and disclosure of LTIP Units evolve from 2022 to 2023, particularly in terms of their dilutive effect and valuation modeling?",
      "original_answer": "In 2022, SPG disclosed that LTIP units were part of potentially dilutive securities but had no material dilutive effect for the years 2021, 2020, and 2019. By 2023, SPG provided more detailed disclosures, including the use of a Monte Carlo model to estimate the grant-date fair values of market-based LTIP units and confirmed that these units are treated as participating securities under the two-class method of computing earnings per share. This reflects a shift from a general statement about dilution to a more granular and valuation-focused disclosure in 2023.",
      "llm_answer": "In the 2022 filing (see SPG 10‑K 2022 pp. 113‑115) SPG said that LTIP units are “potentially dilutive securities” but that they had “no material dilutive effect” on diluted earnings per share, and it disclosed that the grant‑date fair values of market‑based LTIP units are estimated with a Monte Carlo simulation. By the 2023 filing (see SPG 10‑K 2023 pp. 125‑128) the company retained the same conclusion that LTIP units remain potentially dilutive with no material impact, but it added a detailed LTIP‑awards table showing the grant‑date fair‑value, target‑value and maximum potential fair‑value of each year’s awards—while still using Monte Carlo modeling for market‑based awards, the disclosure now focuses on the specific fair‑value figures rather than describing the modeling method.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. CRITICAL ERRORS: (1) The LLM claims that in 2022, SPG disclosed that Monte Carlo modeling was used for market-based LTIP units. However, the ground truth states that detailed valuation modeling disclosures (including Monte Carlo) were NEW in 2023, not present in 2022. (2) The LLM states that in 2023 'the company retained the same conclusion that LTIP units remain potentially dilutive with no material impact' - this directly contradicts the ground truth which indicates a shift FROM a general statement about dilution (in 2022) TO more granular and valuation-focused disclosure (in 2023). The ground truth does not indicate that 2023 retained the same 'no material dilutive effect' conclusion; rather, it emphasizes that 2023 added confirmation of treatment as participating securities under the two-class method. (3) The LLM's characterization of the evolution is backwards - it suggests continuity in the 'no material impact' conclusion across both years, when the ground truth emphasizes a shift from general to detailed disclosure. PARTIAL CREDIT: The LLM correctly identifies that both years involved LTIP units as potentially dilutive securities, correctly names the company (SPG), correctly identifies the years (2022 and 2023), and correctly mentions Monte Carlo modeling. However, the temporal attribution of when detailed disclosures appeared is fundamentally wrong. The answer demonstrates some understanding of the topic but fails on the core evolution narrative that the question asks about.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 437,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Comcast's financial commitment and involvement in Atairos Group, Inc. evolved between 2022 and 2024, particularly in terms of capital funding and management fee commitments?",
      "original_answer": "Comcast's involvement in Atairos Group, Inc. evolved significantly between 2022 and 2024. In 2022, Comcast was the sole third-party investor with a commitment to fund up to $5 billion in aggregate capital to Atairos. By 2024, this commitment had decreased to up to $4.5 billion, with an additional specific commitment of $40 million annually for a management fee. The reduction in capital commitment and the introduction of a dedicated management fee structure indicate a recalibration of Comcast's financial involvement and strategic oversight of Atairos.",
      "llm_answer": "In the 2022 filing Comcast said its amended agreement with Atairos limited its total funding commitment to $4.5 billion, capped annual capital‑call obligations at $400 million, and included a $45 million‑per‑year management‑fee commitment【CMCSA_10k_2022.pdf page 106】. The 2024 filing shows the same $4.5 billion aggregate funding ceiling and $400 million annual‑call limit, but the management‑fee pledge was reduced to $40 million per year【CMCSA_10k_2024.pdf page 84】, while cash contributions rose to $52 million in 2022, $145 million in 2023 and $73 million in 2024, leaving an unfunded commitment of $1.4 billion at year‑end【CMCSA_10k_2024.pdf page 85】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains fundamental factual inaccuracies that directly contradict the ground truth. (1) CAPITAL COMMITMENT ERROR: The LLM states the 2022 filing shows a $4.5 billion commitment, but the ground truth clearly indicates Comcast's 2022 commitment was $5 billion, which decreased to $4.5 billion by 2024. This is a major factual error - the LLM reversed the timeline and missed the key evolution showing a $500 million reduction. (2) MANAGEMENT FEE ERROR: The LLM claims the 2022 management fee was $45 million per year, but the ground truth does not mention a $45 million figure for 2022. The ground truth only specifies that by 2024, the commitment was $40 million annually. The LLM appears to have fabricated or misread the 2022 management fee amount. (3) MISSING KEY INFORMATION: The LLM provides extensive detail about cash contributions ($52M, $145M, $73M) and unfunded commitments ($1.4B) that, while potentially accurate, are not part of the ground truth answer and may represent over-specification or information from different sections. (4) MULTI-HOP SYNTHESIS FAILURE: The question asks about evolution 'between 2022 and 2024' - the core answer should show the CHANGE from 2022 to 2024. The LLM failed to properly synthesize this comparison and instead presented incorrect baseline figures. The ground truth clearly shows: 2022 = $5B capital commitment; 2024 = $4.5B capital commitment + $40M annual management fee. The LLM's answer contradicts this fundamental evolution. (5) CITATION ISSUES: While the LLM provides specific page citations, the numbers cited do not align with the ground truth, suggesting either misreading of sources or hallucination of details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 467,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's operational focus in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a modest reduction in reserves over the year, suggesting a potential shift in operational focus or resource allocation in the region.",
      "llm_answer": "COP’s natural‑gas reserves in the Asia Pacific/Middle East segment fell from 312 billion cubic feet (BCF) at year‑end 2023 (305 BCF developed + 7 BCF undeveloped) to 296 BCF at year‑end 2024 (289 BCF developed + 7 BCF undeveloped) – a drop of about 5 % (≈ 16 BCF)【COP_10k_2024.pdf p. 144‑147】. This modest decline indicates a slight pull‑back in gas‑reserve growth in that region, suggesting ConocoPhillips is not expanding its natural‑gas footprint there and is likely shifting operational emphasis to other geographies or asset types.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive analysis. QUANTITATIVE VERIFICATION: All numbers are correct - 312 BCF (2023) vs 296 BCF (2024), with accurate breakdown of developed (305→289 BCF) and undeveloped (7→7 BCF) reserves. The calculated decline of 16 BCF and ~5% reduction are mathematically accurate. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) evolution of reserves with specific year-over-year comparison, and (2) interpretation of what this indicates about operational focus. ENTITY ACCURACY: Correctly identifies COP (ConocoPhillips), the Asia Pacific/Middle East region, natural gas reserves, and fiscal years 2023-2024. REASONING QUALITY: The multi-hop synthesis is sound - the model correctly connects the reserve decline data to operational implications (shift in focus, lack of expansion in that region). The interpretation that the modest 5% decline suggests a 'pull-back' and potential shift to other geographies is a reasonable inference from the data. MINOR CONSIDERATIONS: The LLM provides additional granular detail (developed vs undeveloped breakdown) not explicitly in the ground truth answer, which adds value without contradicting it. The citation reference to source documents enhances credibility. The semantic meaning is fully aligned with the ground truth - both convey that reserves decreased modestly and this suggests a shift in operational priorities. No calculation errors, no factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 414,
        "total_tokens": 1642
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "Compare Comcast's wireless gateway procurement strategy in 2022 with its network deployment investment focus in 2024.",
      "original_answer": "In 2022, Comcast's relationship with wireless gateways was primarily centered on procurement, as the company purchased a significant amount of customer premise equipment, including wireless gateways, from a limited number of suppliers to provide services to residential and business customers. By 2024, the company's approach had evolved into a more strategic investment focus, with wireless gateways being a key component of its planned capital expenditures. Specifically, in 2024, Comcast emphasized deploying wireless gateways as part of its broader network upgrades aimed at delivering multigigabit symmetrical speeds. This shift indicates a move from passive procurement to active integration of wireless gateways into its infrastructure strategy, aligning with its goals for network scalability and capacity expansion.",
      "llm_answer": "In 2022 Comcast’s strategy for wireless gateways was to buy the devices as part of its customer‑premise‑equipment program from a **limited number of suppliers** (“Cable Communications purchases from a limited number of suppliers a significant amount of customer premise equipment, including wireless gateways…”)【CMCSA_10k_2022.pdf p.9】. By 2024 the company’s capital spending had shifted toward **network deployment**, with most of its Connectivity & Platforms outlays going to line extensions, scalable infrastructure and support capital, while spending on customer‑premise gear (including wireless gateways) fell, reflecting a focus on expanding the network rather than on gateway procurement【CMCSA_10k_2024.pdf p.49‑50】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and correctly synthesizes multi-hop information across 2022 and 2024 filings. STRENGTHS: (1) Correctly identifies 2022 strategy as procurement from limited suppliers with proper citation to CMCSA_10k_2022.pdf p.9; (2) Accurately characterizes 2024 shift toward network deployment investment with proper citation to CMCSA_10k_2024.pdf p.49-50; (3) Properly identifies the strategic evolution from passive procurement to active network infrastructure focus; (4) Correctly notes that 2024 spending on customer-premise equipment (including wireless gateways) fell relative to network infrastructure spending; (5) Multi-hop reasoning is sound - successfully compares procurement strategy (2022) with deployment investment focus (2024). MINOR WEAKNESSES: (1) The LLM answer emphasizes that 2024 spending on wireless gateways 'fell' compared to network infrastructure, which is a slightly different framing than the ground truth's emphasis on 'active integration into infrastructure strategy' and 'planned capital expenditures' for wireless gateways. The ground truth suggests wireless gateways remained a 'key component' of 2024 strategy, while the LLM answer suggests reduced emphasis on gateway procurement specifically; (2) The ground truth explicitly mentions 'multigigabit symmetrical speeds' as a goal, which the LLM answer does not include; (3) The ground truth frames the shift as moving from 'passive procurement to active integration,' while the LLM answer frames it more as a shift away from gateway procurement toward broader network deployment. These represent subtle but meaningful differences in interpretation. QUANTITATIVE ACCURACY: No specific numbers or calculations are provided in either answer, so this dimension is not directly testable. The citations and page references appear reasonable. ENTITY ACCURACY: All entities correctly identified (Comcast/CMCSA, years 2022 and 2024, wireless gateways, customer premise equipment). REASONING: The multi-hop synthesis is logically sound and properly connects information across two different years and filing documents.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 572,
        "total_tokens": 1951
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of its strategic importance and production challenges?",
      "original_answer": "In 2022, Tesla highlighted the Solar Roof as a key contributor to the growth in Energy generation and storage revenue, indicating it was being actively deployed alongside products like Megapack and Powerwall. By 2024, Tesla's framing had shifted, with the Solar Roof now positioned as a product facing potential production ramp delays similar to past vehicle and energy storage product launches. This evolution reflects a shift from emphasizing deployment success to cautioning about the operational and manufacturing risks associated with scaling the product.",
      "llm_answer": "In the 2022 Form 10‑K Tesla presented Solar Roof as a fast‑growing element of its Energy Generation and Storage segment – deployments helped lift revenue, but the product’s early‑stage ramp caused “temporary manufacturing under‑utilization during product ramp” that pulled the segment’s gross margin down (see 2022 pages 37‑41). By the 2024 filing the company still flags Solar Roof as a strategic pillar of its clean‑energy business, but repeatedly notes that scaling production and achieving cost‑efficient manufacturing remain a key challenge, indicating that while its strategic importance has grown, the production‑ramp issues persist (see 2024 pages 15‑19).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the general evolution of Tesla's Solar Roof positioning between 2022 and 2024, but contains several issues that prevent a higher score:\n\n(1) CORRECT ELEMENTS:\n- Correctly identifies 2022 as highlighting Solar Roof as a growth contributor to Energy Generation and Storage\n- Correctly notes manufacturing/production challenges in both years\n- Correctly identifies the shift from deployment success emphasis to production risk caution\n- Appropriately references both 2022 and 2024 filings\n- Semantic equivalence is maintained: the answer conveys the core narrative of strategic importance persisting while production challenges remain\n\n(2) PROBLEMATIC ELEMENTS:\n- The LLM states \"while its strategic importance has grown\" - this contradicts the ground truth which indicates a shift FROM emphasizing deployment success TO cautioning about risks. The ground truth suggests the strategic framing changed, not that importance grew\n- Page references (2022 pages 37-41, 2024 pages 15-19) cannot be verified against the ground truth and may be inaccurate or fabricated\n- The phrase \"repeatedly notes that scaling production and achieving cost-efficient manufacturing remain a key challenge\" is more assertive than the ground truth supports\n- The answer suggests continuous strategic importance with persistent challenges, whereas the ground truth emphasizes a more significant shift in how Tesla frames the product\n\n(3) MULTI-HOP REASONING:\nThe answer does synthesize information across 2022 and 2024 filings and identifies the evolution pattern. However, the interpretation of \"strategic importance has grown\" misses the nuance that the ground truth emphasizes a shift in framing/positioning rather than growth in importance.\n\n(4) QUANTITATIVE ACCURACY:\nNo specific numbers are provided in either answer, so this is not a differentiating factor. However, the LLM's specific page citations cannot be verified and may be inaccurate.\n\n(5) OVERALL ASSESSMENT:\nThe answer is directionally correct but contains a meaningful misinterpretation of the nature of the evolution (growth vs. shift in framing) and includes unverifiable page references that reduce confidence in accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 593,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did Duke Energy's investment in Net Pending Transactions and Other Investments change from 2022 to 2023, and what does this indicate about the company's strategic positioning in this category?",
      "original_answer": "Duke Energy's investment in Net Pending Transactions and Other Investments decreased from $53 million in 2022 to $14 million in 2023. This indicates a significant reduction in exposure or involvement in pending transactions and other investments, suggesting a strategic shift or completion of certain initiatives during this period.",
      "llm_answer": "Duke Energy’s “Net pending transactions and other investments” rose sharply, from **$14 million at year‑end 2022** to **$54 million at year‑end 2023** – a $40 million (≈286 %) increase【DUK_10k_2023.pdf:217‑221】.  This jump signals that the company is deliberately expanding its exposure to pending‑transaction and other‑investment opportunities within its master retirement trust, suggesting a more aggressive, liquidity‑oriented strategic positioning in this asset class【DUK_10k_2022.pdf:224‑228】.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer contains fundamentally inverted numbers and contradicts the ground truth on all key facts: (1) QUANTITATIVE ACCURACY FAILURE: The LLM states the investment ROSE from $14M (2022) to $54M (2023), but the ground truth clearly shows it DECREASED from $53M (2022) to $14M (2023). The LLM has reversed both the direction of change and the actual values. The LLM's $40M increase calculation is based on these inverted numbers and is therefore incorrect. (2) DIRECTIONAL ERROR: The LLM interprets this as 'deliberately expanding exposure' and 'more aggressive positioning,' when the ground truth indicates a 'significant reduction' and 'strategic shift or completion of initiatives.' This is a 180-degree misinterpretation of what the data shows. (3) PERCENTAGE CALCULATION: The LLM calculates a 286% increase, but this is based on the wrong baseline ($14M vs $54M instead of $53M vs $14M). The correct calculation would be a decrease of approximately 74% ($39M reduction from $53M to $14M). (4) ENTITY/METRIC ACCURACY: While Duke Energy and the metric name are correct, the temporal assignment of values is completely wrong - the 2022 and 2023 figures are swapped. (5) MULTI-HOP SYNTHESIS: The LLM failed to correctly synthesize the year-over-year comparison across the two filing documents. The answer demonstrates a fundamental misreading of the source data that undermines all subsequent analysis and strategic interpretation. The only partially correct element is the identification of Duke Energy as the company and the general topic area, but the core numerical facts and their interpretation are entirely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 451,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the company's implementation of its liability-driven investment framework evolved between 2023 and 2024, particularly in terms of defined contribution plan expenses and the disclosure of plan asset composition?",
      "original_answer": "In 2023, the company disclosed that amounts charged to expense for defined contribution plans totaled $109 million, and the liability-driven investment framework included a 20%/80% equity/fixed income target allocation for pension assets. By 2024, defined contribution plan expenses increased to $112 million, and while the same 20%/80% allocation was maintained, the 2024 filing added a new disclosure indicating that the actual composition of plan assets at year-end would be characterized, suggesting a more detailed transparency in reporting the implementation of the investment framework.",
      "llm_answer": "In the 2023 filing the company reported $109 million of expense for its tax‑qualified defined‑contribution plans and disclosed that its liability‑driven investment (LDI) framework targeted a 20 %/80 % equity‑to‑fixed‑income mix for pension assets (55 %/45 % for post‑retirement assets), with the actual 2023 asset mix showing 18 % equity, 57 % corporate bonds and 25 % Treasury/other for pensions and 53 % equity, 31 % corporate bonds and 16 % Treasury/other for post‑retirement plans【2023】. In the 2024 filing the defined‑contribution expense rose to $112 million and, while the target LDI allocations remained unchanged, the disclosed composition shifted toward more equities and corporate bonds – pension assets were 21 % equity, 63 % corporate bonds and 16 % Treasury/other, and post‑retirement assets were 57 % equity, 30 % corporate bonds and 13 % Treasury/other【2024】. This reflects a modest increase in contribution costs and a rebalancing of plan assets within the same LDI framework.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR DISCREPANCIES IDENTIFIED: The LLM answer introduces substantial information NOT present in the ground truth, which is a critical error in multi-hop financial analysis. (1) QUANTITATIVE ACCURACY ISSUES: While the LLM correctly identifies the $109M (2023) and $112M (2024) defined contribution plan expenses, it adds extensive asset composition details (18% equity/57% corporate bonds/25% Treasury for 2023 pensions; 21% equity/63% corporate bonds/16% Treasury for 2024 pensions; plus detailed post-retirement breakdowns) that are NOT mentioned in the ground truth answer. The ground truth only mentions the 20%/80% target allocation and notes that 2024 added 'a new disclosure indicating that the actual composition of plan assets at year-end would be characterized.' The LLM appears to have fabricated or hallucinated specific percentage compositions. (2) ENTITY/DISCLOSURE ACCURACY: The ground truth indicates the 2024 filing added disclosure about plan asset composition being 'characterized' (suggesting future or planned disclosure), but the LLM presents specific actual percentages as if they were disclosed. This is a fundamental misrepresentation of what was actually disclosed. (3) MULTI-HOP REASONING: The LLM failed to correctly synthesize the key distinction in the ground truth - that 2023 disclosed the target allocation (20%/80%) while 2024 added NEW disclosure about actual composition. Instead, the LLM presents both years as having detailed actual composition data. (4) COMPLETENESS: While the LLM addresses both years and the evolution of the framework, it does so by introducing information not in the ground truth, which violates the core requirement of accuracy in financial analysis. The answer appears to confuse or conflate target allocations with actual compositions, and introduces post-retirement plan details not mentioned in the ground truth. This represents a significant failure in factual accuracy for SEC filing analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 529,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Qualcomm's strategic focus on On-Device AI evolved between fiscal 2023 and fiscal 2024, and what specific investments or changes in direction were highlighted in the company's disclosures?",
      "original_answer": "In fiscal 2023, Qualcomm emphasized that On-Device AI, combined with 5G and high-performance, low-power computing, would drive adoption of smartphone technologies into industries beyond mobile, such as automotive and IoT. The company positioned itself as a leader in 5G and integrated circuit products to sustain long-term growth. By fiscal 2024, Qualcomm's focus on On-Device AI had evolved into a more investment-driven strategy, with the company explicitly stating it is investing in new product areas and industries beyond mobile handsets, including automotive and IoT, by leveraging its technical expertise and pursuing acquisitions or strategic transactions. This represents a shift from strategic vision to active investment and expansion.",
      "llm_answer": "In its FY 2023 filing, Qualcomm framed on‑device AI as a strategic growth lever—together with 5G and low‑power, high‑performance computing—that would extend its Snapdragon platforms into automotive, IoT and other non‑handset markets. By FY 2024, the company’s disclosure shifted to a concrete investment stance, stating it is allocating significant resources to advance on‑device AI as a foundational technology and is pursuing acquisitions and other strategic transactions to broaden AI‑enabled products beyond mobile handsets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. (1) FACTUAL CORRECTNESS: Both answers correctly identify the evolution of Qualcomm's On-Device AI strategy from FY2023 to FY2024. The LLM accurately captures the key elements: FY2023 positioning of On-Device AI as a strategic growth lever combined with 5G and low-power computing, and the extension into automotive, IoT, and non-handset markets. The FY2024 shift to an investment-driven approach with acquisitions and strategic transactions is correctly represented. (2) QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are present in either answer, so this dimension is not applicable. Both answers appropriately avoid making unsupported numerical claims. (3) ENTITY ACCURACY: Qualcomm is correctly identified, fiscal years 2023 and 2024 are properly referenced, and key product/market segments (Snapdragon, automotive, IoT, mobile handsets) are accurately mentioned. (4) MULTI-HOP REASONING: The LLM successfully synthesizes the evolution across two fiscal years, correctly identifying the progression from strategic vision/positioning (FY2023) to active investment and expansion (FY2024). The reasoning chain is sound and logically structured. (5) SEMANTIC EQUIVALENCE: The LLM answer uses slightly different but semantically equivalent phrasing: 'framed on-device AI as a strategic growth lever' vs. 'emphasized that On-Device AI...would drive adoption'; 'shift to a concrete investment stance' vs. 'shift from strategic vision to active investment.' These variations demonstrate understanding rather than rote copying. The only minor distinction is that the LLM uses 'allocating significant resources' while the ground truth uses 'investing in new product areas,' but these are semantically equivalent. The answer is comprehensive, accurate, and appropriately addresses all aspects of the multi-part question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 522,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the classification and presentation of the Voting Trust Agreement between Melvin Simon & Associates, Inc. and the Simon family members evolved between the 2022 and 2023 10-K filings, and what does this indicate about the governance structure's stability?",
      "original_answer": "In the 2022 10-K filing, the Voting Trust Agreement was described as 'Second Amended and Restated' as of March 1, 2004, indicating a formal update to the governance arrangement. In contrast, the 2023 10-K filing refers to the same agreement without the 'Second Amended and Restated' modifier, simply listing it as the Voting Trust Agreement dated March 1, 2004. This shift in presentation suggests that no further amendments were made in the intervening period, signaling stability in the governance structure and a continuation of the same voting trust framework without modification.",
      "llm_answer": "In the 2022 10‑K the voting‑trust documents are listed as Exhibit 9.1 (and Exhibit 9.2) in the “Exhibits” index, described as the “Second Amended and Restated Voting Trust Agreement…​” [SPG_10k_2022.pdf p. 142‑146]. The 2023 10‑K shows the same classification and wording—still Exhibit 9.1 (and 9.2) under the Exhibits section [SPG_10k_2023.pdf p. 138‑142]. Because the presentation and description have not changed, the Simon family’s voting‑trust arrangement remains unchanged, signalling continuity and stability in the company’s governance structure.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual error that contradicts the ground truth. The ground truth explicitly states that the 2022 10-K describes the agreement as 'Second Amended and Restated' while the 2023 10-K refers to it WITHOUT this modifier. However, the LLM claims 'the presentation and description have not changed' and that both years show 'still Exhibit 9.1 (and 9.2)' with the same wording. This is directly contradicted by the original answer which clearly indicates an evolution/change in presentation between the two years. The LLM failed to identify the key distinction: 2022 included 'Second Amended and Restated' language while 2023 did not. This is the core finding of the question. Additionally, while the LLM correctly identifies the exhibit numbers (9.1 and 9.2) and the date (March 1, 2004), it misses the crucial presentation change that is the entire point of the question. The LLM's conclusion that 'presentation and description have not changed' is factually incorrect based on the ground truth. The reasoning about stability is partially sound (no amendments = stability), but it's based on a false premise about whether the presentation actually remained the same. The multi-hop synthesis fails because the LLM did not properly compare the two years' filings to identify the specific change in how the agreement was described.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 386,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the region's changing strategic importance to COP's global reserves portfolio?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure decreased slightly to 296 billion cubic feet. This represents a reduction of 16 billion cubic feet, or about 5.1%. Despite this decline, the Asia Pacific/Middle East remained a notable contributor to COP's global reserves, especially when considering equity affiliates, which held an additional 5,870 billion cubic feet in 2024. The slight decrease may suggest a shift in emphasis or extraction focus in favor of other regions, indicating a potential reevaluation of the region's role in COP's long-term production strategy.",
      "llm_answer": "COP’s proved natural‑gas reserves in the Asia Pacific/Middle East region slipped from **312 billion cubic feet (BCF) at year‑end 2023** to **296 BCF at year‑end 2024** – a drop of about 16 BCF (≈5 %)【COP_10k_2024.pdf p. 144‑146】.  That decline reduced the region’s share of total gas reserves from roughly **2.3 % of the 13,718 BCF portfolio in 2023** to **1.9 % of the 15,641 BCF portfolio in 2024**, signalling a modest weakening of its relative strategic weight, even though the area still houses all of COP’s equity‑affiliate assets.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core reserve figures (312 BCF in 2023, 296 BCF in 2024) and the decline of 16 BCF (~5%). The year-end dates are correct, and the general narrative about declining strategic importance is sound. The LLM appropriately notes the region's continued significance despite the decline.\n\nCRITICAL ERRORS: (1) The LLM calculates regional share percentages (2.3% in 2023, 1.9% in 2024) but these calculations cannot be verified against the ground truth. The ground truth provides total global reserves of 13,718 BCF (2023) and 15,641 BCF (2024), but the LLM's percentage calculations appear questionable: 312/13,718 = 2.27% (≈2.3% is correct), but 296/15,641 = 1.89% (≈1.9% is correct). While the math checks out, the ground truth does not explicitly state these percentages, so the LLM is making calculations beyond what was provided. (2) The LLM mentions 'equity-affiliate assets' but the ground truth specifically states equity affiliates held 5,870 BCF in 2024 - the LLM does not provide this specific number, only a vague reference to 'all of COP's equity-affiliate assets.'\n\nOMISSIONS: The LLM fails to mention the specific equity affiliate reserve figure of 5,870 BCF that was highlighted in the ground truth as important context for understanding the region's continued strategic value despite the decline in proved reserves.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes the reserve decline with its impact on regional portfolio share, demonstrating sound multi-hop reasoning. However, it misses the important distinction between proved reserves and equity affiliate reserves that the ground truth emphasizes.\n\nSEMANTIC EQUIVALENCE: The LLM's conclusion about 'modest weakening of relative strategic weight' aligns with the ground truth's 'potential reevaluation of the region's role,' though the LLM provides more quantitative support through percentage calculations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 521,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of debt structure and equity method income?",
      "original_answer": "In 2023, AIG had a direct financial stake in Corebridge, which was reflected in the $9,368 million total Corebridge debt on AIG's balance sheet, including $6,452 million in senior unsecured notes and $989 million in junior subordinated debt, both not guaranteed by AIG. By 2024, AIG no longer consolidated Corebridge as a subsidiary; instead, it reported Corebridge under the equity method as part of discontinued operations. During the second half of 2024, AIG reported equity method income from Corebridge, which included dividends received and changes in its stock price since June 9, 2024. This marks a significant transformation from a consolidated debt relationship to a minority equity investment with associated income reporting.",
      "llm_answer": "In 2023 AIG still carried Corebridge’s debt on its balance sheet – about $9.4 billion of senior unsecured notes, junior subordinated debt and a DDTL facility that were “not guaranteed by AIG” but were backed by a guarantee‑reimbursement and collateral agreement with Corebridge (see the 2023 debt roll‑forward)【110†L31-L38】【110†L39-L45】. By 2024 AIG had de‑consolidated Corebridge, removed that debt from its consolidated liabilities and now treats its remaining stake as an equity‑method investment, reporting $601 million of equity‑method income (and $1.574 billion of Corebridge pre‑tax earnings) for the June‑December 2024 period【107†L1-L5】【107†L6-L9】. Thus the relationship shifted from a guaranteed‑debt exposure in 2023 to an equity‑investment exposure with equity‑method earnings in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of AIG's evolving relationship with Corebridge between 2023 and 2024. STRENGTHS: (1) Correctly identifies the 2023 debt structure (~$9.4 billion, matching the ground truth's $9,368 million when accounting for rounding), including senior unsecured notes and junior subordinated debt. (2) Accurately captures the key transition: de-consolidation in 2024 and shift to equity method accounting. (3) Provides specific equity method income figure of $601 million for H2 2024, which adds detail beyond the ground truth. (4) Correctly notes the 'not guaranteed by AIG' language and mentions the guarantee-reimbursement and collateral agreement. (5) Multi-hop reasoning is sound - synthesizes information across 2023 and 2024 filings to show the relationship evolution. (6) Appropriately contextualizes the shift from consolidated debt exposure to equity investment. MINOR ISSUES: (1) The ground truth mentions 'dividends received and changes in its stock price since June 9, 2024' as components of equity method income, while the LLM answer states '$601 million of equity-method income' without breaking down these components - this is a minor omission of detail rather than an error. (2) The LLM answer includes the $1.574 billion Corebridge pre-tax earnings figure, which is additional context not in the ground truth but appears to be accurate supplementary information. (3) Numeric precision: $9.4 billion vs. $9,368 million is acceptable rounding variation. The answer successfully addresses all parts of the multi-part question regarding debt structure evolution and equity method income reporting.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 450,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has NextEra Energy's investment strategy in Special Use Funds evolved from 2022 to 2024, particularly in terms of its allocation between fixed income and equity securities, and what does this suggest about its risk appetite or liquidity strategy?",
      "original_answer": "In 2022, NEE's Special Use Funds were entirely composed of fixed income securities, with a carrying amount of $2,505 million. By 2024, the composition had significantly transformed: NEE's Special Use Funds included $6,164 million in equity securities, $722 million in U.S. Government and municipal bonds, $685 million in corporate debt, and $873 million in asset-backed securities. This indicates a strategic shift from a purely fixed income allocation to a more diversified and equity-heavy portfolio, suggesting an increased risk appetite and a potential long-term growth orientation in its investment strategy.",
      "llm_answer": "In the 2022 filing NextEra’s special‑use funds were about $2.5 billion in fixed‑income securities and roughly $5.5 billion in marketable equity securities (≈68 % equity) [NEE_10k_2022.pdf p.53; p.55]. By 2024 the equity component had risen to $6.2 billion while fixed‑income holdings were about $2.3 billion (≈73 % equity) [NEE_10k_2024.pdf p.87]. The modest increase in the equity share signals a slightly higher risk appetite—tilting toward higher‑return equity assets—while still preserving a sizable fixed‑income base to meet liquidity needs for storm‑damage and nuclear‑decommissioning obligations.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains major factual inaccuracies that fundamentally contradict the ground truth. (1) 2022 ALLOCATION ERROR: The LLM claims NEE had ~$5.5 billion in equity securities in 2022 (~68% equity), but the ground truth explicitly states that in 2022, Special Use Funds were 'entirely composed of fixed income securities, with a carrying amount of $2,505 million.' This is a complete contradiction—the LLM fabricated a $5.5B equity position that did not exist. (2) 2024 EQUITY FIGURE: The LLM states $6.2 billion in equity by 2024, which is close to the ground truth's $6,164 million (acceptable rounding), but this accuracy is undermined by the false 2022 baseline. (3) 2024 FIXED INCOME UNDERSTATEMENT: The LLM claims ~$2.3 billion in fixed income for 2024, but the ground truth shows $722M (U.S. Government/municipal) + $685M (corporate debt) + $873M (asset-backed securities) = $2,280 million total, which actually aligns with the LLM's figure. However, the LLM fails to break down these components. (4) PERCENTAGE CALCULATIONS: The LLM's equity percentages (68% in 2022, 73% in 2024) are mathematically impossible given the ground truth data. In 2022, equity should be 0%, not 68%. (5) MULTI-HOP SYNTHESIS FAILURE: The LLM failed to correctly synthesize the evolution from 2022 to 2024. The ground truth shows a dramatic transformation FROM purely fixed income TO equity-heavy, but the LLM's narrative suggests a modest increase from already-high equity levels. (6) CONTEXTUAL INTERPRETATION: While the LLM's reasoning about risk appetite and liquidity strategy is qualitatively reasonable, it is built on false premises. The actual story is far more dramatic—a complete portfolio restructuring, not a modest tilt. The LLM appears to have hallucinated the 2022 equity position entirely, which is a fundamental failure in financial data accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 513,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the nature and magnitude of the risk associated with site infrastructure sharing evolved between 2022 and 2024, particularly in relation to 5G technology adoption and its impact on new lease activity?",
      "original_answer": "In 2022, AMT identified site infrastructure sharing as a risk factor that could slow new lease activity or lead to decommissioning of equipment on existing sites, particularly due to the rise of 5G technology. By 2024, this risk evolved into a more specific concern around RAN (Radio Access Network) sharing, roaming, or resale arrangements, which were explicitly tied to the lack of compensation to AMT when carriers opted for shared infrastructure instead of deploying new equipment. The 2024 filing indicates a stronger emphasis on the financial impact of this trend, suggesting a more mature and impactful shift in carrier behavior driven by 5G deployment. This represents a significant evolution in the risk's specificity and perceived threat level.",
      "llm_answer": "The 2022 filing warned that “extensive sharing of site infrastructure…including due to increases in advanced network technology such as 5G…may cause new‑lease activity to slow…or may result in the de‑commissioning of equipment” (AMT_10k_2022.pdf pp. 14‑18). By 2024 the company repeats the same concern but now emphasizes “extensive sharing of site infrastructure **through RAN sharing**” and explicitly notes that such sharing “could materially affect growth, revenue and our ability to generate positive cash flows” (AMT_10k_2024.pdf pp. 13‑17). Thus, while the nature of the risk (site‑sharing driven by 5G) remains unchanged, the 2024 disclosure signals a larger‑magnitude risk, reflecting heightened worry that 5G‑enabled RAN sharing will more significantly slow new leases and impact cash flow.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in addressing the multi-hop question about risk evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 risk as site infrastructure sharing driven by 5G technology and its potential to slow new-lease activity and cause decommissioning; (2) Accurately captures the 2024 evolution toward more specific RAN (Radio Access Network) sharing concerns; (3) Properly synthesizes the shift from general 5G-driven sharing to explicit RAN sharing arrangements; (4) Correctly notes the 2024 emphasis on financial impact (growth, revenue, cash flows); (5) Appropriately cites document sources with page ranges; (6) Demonstrates sound multi-hop reasoning by comparing risk characterization across two years. MINOR WEAKNESSES: (1) The LLM states 'the nature of the risk (site-sharing driven by 5G) remains unchanged' which slightly understates the evolution described in the ground truth. The ground truth emphasizes this as a 'significant evolution in the risk's specificity and perceived threat level,' whereas the LLM frames it as primarily a magnitude increase rather than a specificity/maturity evolution; (2) The ground truth explicitly mentions 'lack of compensation to AMT when carriers opted for shared infrastructure' as a key 2024 development, which the LLM does not explicitly capture, though it does reference the financial impact concern; (3) The characterization of 'heightened worry' is interpretive rather than directly supported by filing language. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is not directly testable. The dates (2022, 2024) and document references are accurate. MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across two years of filings and correctly identifies the progression of risk characterization. The reasoning that 2024 shows 'larger-magnitude risk' with 'heightened worry' is logically sound based on the more explicit financial impact language. Overall, this is a strong answer with minor gaps in capturing the full nuance of the risk's evolution regarding compensation mechanisms and the maturation of the threat assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 593,
        "total_tokens": 1997
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has Chevron's financial relationship with Angola LNG Limited evolved between 2022 and 2023, particularly in terms of its investment structure and equity method accounting?",
      "original_answer": "Chevron's relationship with Angola LNG Limited evolved from a dependency-based structure in 2022 to a more direct investment model in 2023. In 2022, Chevron reported a 36.4% interest in Angola LNG Limited, but the relationship was categorized under 'Depends_On', indicating a more passive or structurally dependent investment. By 2023, the relationship was reclassified as 'Invests_In', suggesting a more active or strategic financial posture. Additionally, while both years maintained the same ownership percentage (36.4%), the reclassification indicates a shift in how Chevron views or manages its investment, possibly reflecting changes in operational involvement or strategic alignment.",
      "llm_answer": "In 2022 Chevron reported a $2.258 billion equity‑method investment in Angola LNG Limited (its 36.4 % stake) and recorded a $166 million loss in “Equity in earnings.” By 2023 the carrying amount of the investment had fallen to $1.963 billion and the equity‑method share turned into a $1.857 billion gain, showing a lower investment balance but a much stronger contribution to Chevron’s earnings while the ownership percentage stayed the same.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer fundamentally misses the core of the question and provides information not supported by the ground truth. Critical issues: (1) The ground truth focuses on the relationship classification change from 'Depends_On' (2022) to 'Invests_In' (2023), which is the key evolution being asked about. The LLM answer completely ignores this structural/categorical shift, which is the primary answer to the question. (2) The LLM introduces specific financial figures ($2.258 billion, $166 million loss, $1.963 billion, $1.857 billion gain) that are not mentioned in the ground truth at all. These numbers cannot be verified against the provided knowledge graph answer and appear to be fabricated or sourced from unreliable data. (3) The LLM correctly identifies the 36.4% ownership percentage and that it remained constant, which aligns with ground truth. (4) The LLM's focus on equity-method accounting gains/losses and carrying amounts represents a different analytical angle than what the ground truth emphasizes - the relationship type reclassification. (5) The LLM answer does address 'equity method accounting' as mentioned in the question, but does so with unverified numbers rather than the relationship classification change that is the actual documented evolution. (6) Multi-hop reasoning is weak: the answer fails to synthesize the key finding about the relationship type change and instead pivots to financial metrics not in the ground truth. The answer reads as if it's describing real financial data, but without verification against actual 10-K filings, these specific dollar amounts are unreliable and contradict the ground truth's focus on relationship classification evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 463,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the G600 aircraft's role in Gulfstream's product lineup evolved from 2022 to 2023, particularly in terms of its performance metrics and production status?",
      "original_answer": "In 2022, the G600 was described as a recent addition to the Gulfstream fleet, having entered service in 2019, and was positioned as a clean-sheet aircraft replacing the G550. By 2023, the G600 was no longer characterized as 'new' but rather as a mature product within the lineup, with over 250 cumulative deliveries by year-end 2023. Additionally, in 2023, the G600's advanced technologies, such as the Symmetry Flight Deck, were highlighted as foundational features being extended to newer models like the G700, G800, and G400. This indicates a shift from product introduction to integration within the broader Gulfstream platform.",
      "llm_answer": "In the 2022 filing Gulfstream’s G600 was highlighted as a new large‑cabin jet that is faster, more fuel‑efficient, has a larger cabin, longer range, reduced emissions and improved flight‑control systems, with roughly 150 deliveries by the end of 2021. The 2023 filing keeps the same performance description but adds that the G600 (along with the G500) now holds > 90 city‑pair speed records, and its production has accelerated – cumulative deliveries have risen to over 250 aircraft by year‑end 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the key quantitative evolution - G600 deliveries rising from ~150 by end of 2021 to over 250 by end of 2023. The mention of >90 city-pair speed records (shared with G500) is accurate and adds relevant detail. The performance characteristics (faster, more fuel-efficient, larger cabin, longer range, reduced emissions, improved flight-control systems) are correctly stated.\n\nWEAKNESSES: (1) The LLM fails to capture the critical qualitative shift emphasized in the ground truth - the transition from 'new product' (2022) to 'mature product' (2023). The ground truth explicitly notes the G600 was 'described as a recent addition' in 2022 but 'no longer characterized as new' by 2023. The LLM states the performance description 'keeps the same' between years, missing this important positioning evolution. (2) The LLM does not address the integration of G600 technologies (Symmetry Flight Deck) into newer models (G700, G800, G400), which the ground truth identifies as a key indicator of the product's role shift from introduction to platform foundation. (3) The LLM references '150 deliveries by end of 2021' but the question asks about 2022-2023 evolution, making this historical reference less directly relevant to the core question.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes delivery numbers across two filing years (2022 and 2023) and connects them to show production acceleration. However, it fails to synthesize the broader strategic positioning changes that occurred between these years, which is central to understanding how the G600's 'role evolved.'\n\nNUMERIC VERIFICATION: All numbers are accurate (150 deliveries by 2021, 250+ by 2023, >90 city-pair records). The quantitative data is sound.\n\nSEMANTIC GAPS: The answer is factually correct but semantically incomplete - it describes what the G600 does and how many were delivered, but not how its strategic role within Gulfstream's product ecosystem changed from 2022 to 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 538,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial involvement and strategic collaboration between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's relationship with franchisees was primarily framed around franchised arrangements and license agreements, with franchisees contributing revenue through rent, royalties, and initial fees, while the company did not typically invest in restaurant capital under developmental licenses. By 2024, the company had introduced a more active investment role, co-investing with franchisees to fund restaurant improvements and operating system upgrades. These co-investments were aimed at catering to consumer preferences, improving local performance, and enhancing the brand through modernization. This marks a strategic shift from a largely passive franchising model to a more collaborative and financially engaged partnership.",
      "llm_answer": "In the 2022 filing McDonald’s described its franchisee relationship mainly as cost‑sharing on specific restaurant‑improvement projects, with the Company providing upfront funding and then allocating the costs between property‑and‑equipment and accounts receivable (MCD_10k_2022, p. 44‑45). By the 2024 filing the model had shifted to a co‑investment partnership, where McDonald’s jointly funds and develops restaurant upgrades and operating‑system initiatives with franchisees, emphasizing collaborative modernization, brand‑standard alignment, and strategic value creation (MCD_10k_2024, p. 4).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the core strategic shift from a passive franchising model to more active co-investment, which aligns with the ground truth. However, there are significant issues with quantitative accuracy and specificity. STRENGTHS: (1) Correctly identifies the evolution from 2022 to 2024; (2) Accurately describes the shift toward co-investment and collaborative partnerships; (3) Mentions relevant concepts like modernization, brand-standard alignment, and operating-system upgrades; (4) Appropriately cites the 10-K filings. WEAKNESSES: (1) The 2022 characterization is problematic - the LLM states McDonald's used 'cost-sharing on specific restaurant-improvement projects' with 'upfront funding' allocated to 'property-and-equipment and accounts receivable,' but the ground truth indicates 2022 was characterized by franchisees contributing through rent, royalties, and fees WITHOUT McDonald's typically investing in restaurant capital. This is a material mischaracterization of the 2022 baseline; (2) The LLM introduces specific accounting details (property-and-equipment, accounts receivable) and page citations (p. 44-45, p. 4) that cannot be verified and may be hallucinated; (3) Missing the explicit contrast that in 2022 the company 'did not typically invest in restaurant capital' - the LLM's description of 2022 as involving 'upfront funding' contradicts this; (4) The answer conflates what may have been emerging practices with the primary 2022 model. MULTI-HOP REASONING: The model correctly synthesizes information across two years and identifies the directional change, but the baseline characterization for 2022 is inaccurate, which undermines the validity of the comparison. The 2024 description aligns well with ground truth. CALCULATION/VERIFICATION: No specific numbers are provided in either answer, so quantitative accuracy issues relate to the characterization of financial involvement rather than calculation errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 526,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined marginally to $10,670 million. This reflects a small decrease in both revenue and profitability year-over-year.",
      "llm_answer": "The smokeable‑products segment’s net revenues fell from $22.476 billion in 2022 to $21.756 billion in 2023 – a drop of about $720 million.  Correspondingly, its operating income (segment OCI) slipped slightly, from $10.688 billion in 2022 to $10.670 billion in 2023, which helped push total operating income down from $11.919 billion to $11.547 billion.【MO_10k_2023.pdf p.27‑31】",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. All financial figures are correct: 2022 smokeable products net revenues of $22.476 billion ($22,476 million), 2023 net revenues of $21.756 billion ($21,756 million), 2022 operating income of $10.688 billion ($10,688 million), and 2023 operating income of $10.670 billion ($10,670 million). The calculated revenue decline of approximately $720 million is accurate ($22.476B - $21.756B = $0.720B). The characterization of the operating income change as 'slipped slightly' is appropriate given the minimal decline of $18 million. The LLM correctly synthesized multi-hop information by: (1) identifying the smokeable products segment performance across both years, (2) calculating the year-over-year changes, and (3) contextualizing the segment's contribution to total operating income. The answer properly uses number format variations (billions vs. millions) consistently and accurately. The only minor observation is that the LLM provided additional context about total operating income impact ($11.919B to $11.547B), which, while accurate and helpful, goes slightly beyond the specific question scope but enhances understanding. The citation to source documents (MO_10k_2023.pdf p.27-31) adds credibility. Overall, this is a high-quality response with accurate facts, sound reasoning, and appropriate synthesis of multi-hop financial data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1186,
        "completion_tokens": 390,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the role of Opdivo within BMY's product development and commercialization strategy evolved from 2022 to 2024, particularly in terms of its collaborative framework and new therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was primarily positioned within a joint development and commercialization framework with Ono, where profits, losses, and development costs were shared—either equally for combination therapies or under an 80-20 split for single-party compounds. Additionally, Opdivo was part of a broader alliance that included other products like Yervoy and Orencia, with structured co-promotion and supply responsibilities. By 2024, Opdivo's role had evolved significantly, marked by a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. This reflects a shift from a co-development focus to a more independent product introduction strategy, with BMY taking the lead in expanding Opdivo’s therapeutic applications in key oncology markets.",
      "llm_answer": "In the 2022 filing, Opdivo was described mainly as a joint‑development asset with Ono (and, for the Opdivo + NKTR‑214 combo, with Nektar), where BMS retained exclusive worldwide rights except in Japan, South Korea and Taiwan and shared development costs, profits and royalties under a regional co‑promotion framework【BMY_10k_2022.pdf p.111‑115】. By the 2024 filing, Opdivo had become a cornerstone of BMS’s immuno‑oncology platform, receiving a series of new approvals—including the sub‑cutaneous Opdivo Qvantig formulation, FDA clearance for resectable NSCLC, Japan’s approval for urothelial carcinoma, and an EC first‑line Opdivo + Yervoy indication—while the company’s strategy now emphasizes Opdivo’s global commercial rollout and expanded indication set, building on but moving beyond the earlier regional alliance model【BMY_10k_2024.pdf p.43‑47】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the evolution of Opdivo's role from 2022 to 2024, accurately captures the shift from joint development to more independent commercialization, and mentions several legitimate new approvals (subcutaneous formulation, resectable NSCLC, Japan urothelial carcinoma approval, EC indication). The multi-hop synthesis across 2022 and 2024 filings is sound, and the answer appropriately addresses the collaborative framework evolution and new therapeutic approvals components of the question.\n\nWEAKNESSES AND ERRORS: (1) CRITICAL DATE ERROR: The ground truth specifies an FDA approval in March 2024 for Opdivo in combination with cisplatin and gemcitabine for unresectable/metastatic urothelial carcinoma. The LLM answer mentions Japan's approval for urothelial carcinoma but does NOT explicitly mention the specific March 2024 FDA approval for the cisplatin + gemcitabine combination for first-line treatment of unresectable/metastatic urothelial carcinoma—this is a significant omission of a key factual detail from the ground truth. (2) The LLM mentions the Nektar partnership for NKTR-214 combination, which adds detail not in the ground truth but is not necessarily incorrect. (3) The LLM provides more granular detail about regional rights (Japan, South Korea, Taiwan) and mentions the 80-20 split is implied but not explicitly stated in the LLM answer, whereas the ground truth explicitly mentions the 80-20 split for single-party compounds. (4) The LLM answer references specific page numbers from filings, which adds credibility but cannot be verified against the ground truth provided.\n\nMULTI-HOP REASONING: The answer correctly synthesizes information across 2022 and 2024 filings, properly identifying the shift in strategy and the role evolution. The reasoning connecting collaborative framework changes to independent product introduction is sound.\n\nSEMANTIC EQUIVALENCE: While the LLM uses different phrasing (\"cornerstone of BMS's immuno-oncology platform\" vs. the ground truth's more direct statement), the core meaning is preserved. However, the omission of the specific March 2024 FDA approval for cisplatin + gemcitabine combination is a material factual gap.\n\nJUSTIFICATION: The answer is substantially correct in its overall narrative and multi-hop synthesis but fails to capture a key specific approval mentioned in the ground truth (March 2024 FDA approval for cisplatin + gemcitabine combination). This is a factual omission that reduces the completeness score. The quantitative accuracy is lower due to missing specific approval details and dates. Qualitative accuracy is good due to sound reasoning and proper entity identification. Contextual relevance is high as the answer directly addresses the question's components.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 738,
        "total_tokens": 2177
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has AMT's disclosure regarding interest rate benchmarks for debt instruments evolved between 2022 and 2024, particularly in terms of referenced rates and associated covenants?",
      "original_answer": "In 2022, AMT's debt instruments referenced LIBOR, EURIBOR, and a defined base rate for USD and EUR denominated borrowings, with the 2021 credit facilities tied to debt ratings and commitment fees ranging from 0.080% to 0.300%. By 2024, AMT disclosed that new drawings under letters of credit in Nigeria bore interest at SOFR (Secured Overnight Financing Rate) plus a spread, indicating a shift away from LIBOR-based instruments. Additionally, while 2022 disclosures detailed specific covenants and optional renewal periods for various credit facilities, the 2024 disclosure focused on the consequences of covenant non-compliance without specifying interest rate structures or renewal terms, suggesting a simplification or evolution in the presentation of covenant-related disclosures.",
      "llm_answer": "In the 2022 Form 10‑K (pages 50‑54) AMT said its bank facilities were priced at LIBOR for U.S.‑dollar borrowings and EURIBOR for euro borrowings (or an optional defined base rate) with a spread of roughly 1.125 percentage points, and the loan agreements were described as containing “reporting, information, financial and operating covenants” and typical restrictions on additional debt, guarantees and asset sales. By the 2024 Form 10‑K (pages 115‑119) the company no longer references LIBOR/EURIBOR; instead, certain facilities such as the Nigeria letters of credit are tied to the Secured Overnight Financing Rate (SOFR) and the securitization loans carry fixed rates, and the covenants now focus on performance metrics such as debt‑service‑coverage‑ratio thresholds, cash‑trap reserve requirements and amortization triggers, reflecting a broader, more detailed covenant framework.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer addresses the core question about evolution of interest rate benchmarks and covenants between 2022 and 2024, but contains significant quantitative inaccuracies and some overstatements. STRENGTHS: (1) Correctly identifies the shift from LIBOR/EURIBOR to SOFR for Nigeria letters of credit; (2) Accurately notes the move away from LIBOR-based instruments; (3) Properly identifies that 2024 disclosures focus on covenant consequences; (4) Correctly identifies covenant types mentioned (debt-service-coverage-ratio, cash-trap reserves, amortization triggers); (5) Appropriately synthesizes multi-hop information across 2022 and 2024 filings. WEAKNESSES: (1) QUANTITATIVE ERROR - States spread of 'roughly 1.125 percentage points' for 2022 facilities, but ground truth specifies commitment fees ranging from 0.080% to 0.300%, which is a different metric and significantly lower range. This is a material factual error; (2) OVERSTATEMENT - Claims 2024 covenant framework is 'broader, more detailed' when ground truth indicates it's actually a 'simplification' in presentation, focusing on consequences rather than specifying structures; (3) INCOMPLETE - Ground truth mentions 2021 credit facilities tied to debt ratings, which LLM answer doesn't address; (4) INCOMPLETE - Ground truth mentions optional renewal periods for various credit facilities in 2022, which LLM answer omits. The answer demonstrates good understanding of the general evolution but misrepresents the nature of the change (simplification vs. expansion) and provides an incorrect spread figure that doesn't match the ground truth metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 443,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has McDonald's relationship with franchisees evolved in terms of real estate ownership and co-investment strategy between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's emphasized Systemwide coordination and alignment to manage ESG initiatives, including environmental sustainability and responsible sourcing, which required franchisee cooperation. However, the specific role of franchisees in real estate ownership was not detailed. By 2024, the company explicitly outlined its conventional franchise model, where it typically owns or secures long-term leases on land and buildings, while franchisees invest in equipment, signs, seating, and décor. This co-investment model was described as enabling McDonald's to achieve high restaurant performance levels. The shift from a general emphasis on franchisee collaboration in 2022 to a clearly defined real estate and co-investment strategy in 2024 reflects a more structured and strategic approach to franchise relationships.",
      "llm_answer": "In the 2022 filing McDonald’s said it “generally owns or secures a long‑term lease on the land and building for conventional franchised and Company‑operated restaurant sites,” using that ownership to secure long‑term occupancy rights and control costs while franchisees funded equipment, signs, décor, etc. By the 2024 filing the company still retains that real‑estate ownership but adds that “ownership of real estate, combined with the co‑investment by franchisees, enables it to achieve restaurant performance levels that are among the highest in the industry,” and it now actively “co‑invests with franchisees to fund improvements to their restaurants or operating systems” under conventional franchise agreements (while developmental‑license arrangements remain non‑invested). Thus, the relationship has shifted from a primarily ownership‑centric model to a partnership model that couples real‑estate ownership with explicit co‑investment in restaurant upgrades.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual error that contradicts the ground truth. The LLM claims that in 2022, McDonald's 'said it generally owns or secures a long-term lease on the land and building for conventional franchised and Company-operated restaurant sites.' However, the ground truth explicitly states that 'the specific role of franchisees in real estate ownership was not detailed' in 2022, and that 'by 2024, the company explicitly outlined its conventional franchise model' with this real estate ownership structure. The LLM incorrectly backdates the explicit real estate ownership strategy to 2022, when the ground truth indicates this was a 2024 development. This is a significant multi-hop reasoning error - the LLM failed to correctly synthesize the temporal evolution described in the ground truth. The LLM also mischaracterizes the 2022 position as 'ownership-centric' when the ground truth indicates 2022 focused on 'Systemwide coordination and alignment to manage ESG initiatives' without detailed real estate strategy. While the LLM correctly identifies that 2024 includes explicit co-investment language and real estate ownership, it incorrectly suggests this was already present in 2022. The core narrative of evolution from general collaboration (2022) to structured real estate and co-investment strategy (2024) is inverted in the LLM response. The LLM does correctly identify the 2024 co-investment elements and the distinction between conventional franchises and developmental-license arrangements, but these correct elements cannot overcome the fundamental error in characterizing the 2022 baseline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 454,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the status and documentation of the 2015 Stock Compensation Plan for Non-Employee Directors change between 2022 and 2023, and what does this evolution indicate about Altria's governance approach to director compensation?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was disclosed with 703,256 shares available for issuance under the plan. By 2023, the plan was formally amended and restated effective October 26, 2022, and was incorporated by reference from Altria's September 30, 2022, Form 10-Q filing. This indicates a formal update to the plan’s structure and governance, suggesting Altria refined its director compensation framework mid-cycle, potentially to align with evolving governance standards or internal compensation strategies.",
      "llm_answer": "In the 2022 Form 10‑K the 2015 Stock Compensation Plan for Non‑Employee Directors was described as “as amended and restated effective October 26 2022” (exhibit 10.22) and the equity‑plan table showed **703,256 shares** available under the plan【MO_10k_2022.pdf p.112】. The 2023 Form 10‑K still references the same amendment date and exhibit (10.22) but the table now shows **589,927 shares** available under the plan【MO_10k_2023.pdf p.107】. The unchanged legal status combined with a reduced share pool signals that Altria maintains a formal, documented compensation framework for its non‑employee directors while actively managing the authorized equity to curb dilution and keep director pay aligned with shareholder interests.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the 2015 Stock Compensation Plan for Non-Employee Directors and accurately reports the key numeric values: 703,256 shares in 2022 and 589,927 shares in 2023. The amendment date of October 26, 2022 is correctly cited. The LLM provides additional detail beyond the ground truth by noting the share reduction between years and offering interpretation about dilution management. The exhibit references (10.22) and page numbers are provided with specificity.\n\nWEAKNESSES: (1) The LLM's characterization of the 2022 status is problematic. The ground truth states that in 2022 the plan was 'disclosed with 703,256 shares available' but does NOT explicitly state it was already described as 'amended and restated effective October 26, 2022' in the 2022 10-K. The LLM asserts this was in the 2022 filing, but the ground truth indicates the formal amendment and restatement status was a 2023 disclosure/update. This represents a potential mischaracterization of the timeline of when the formal amendment language appeared. (2) The ground truth emphasizes that the plan status CHANGED between 2022 and 2023 (from disclosed to formally amended/restated), but the LLM states 'The unchanged legal status' which contradicts the ground truth's implication of evolution/change. (3) The LLM's interpretation about 'curbing dilution' and 'shareholder interests' goes beyond what the ground truth supports - the ground truth focuses on governance refinement and alignment with evolving standards, not specifically on dilution management. (4) The LLM does not clearly articulate the key distinction the ground truth makes: that 2023 showed a formal amendment/restatement with incorporation by reference from the September 30, 2022 Form 10-Q, suggesting a mid-cycle governance update.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize information across 2022 and 2023 filings but appears to have misinterpreted the temporal sequence of when the amendment status was formally documented. The comparison of share counts is accurate but the interpretation of what changed (or didn't change) between years is questionable.\n\nCALCULATIONS: The share reduction from 703,256 to 589,927 is correctly identified (difference of 113,329 shares, approximately 16% reduction), though the LLM doesn't explicitly calculate this.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 623,
        "total_tokens": 1962
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the impact of roaming and resale arrangements among wireless service providers on AMT's leasing activity evolved from 2022 to 2024, and what does this indicate about the competitive pressures affecting new lease growth?",
      "original_answer": "In 2022, AMT noted that roaming or resale arrangements among wireless service providers, particularly with the rise of 5G technology, could slow new lease activity if carriers opted to share infrastructure rather than deploy new equipment. By 2024, this concern evolved into a broader risk involving RAN sharing and resale arrangements, which not only threatened new lease activity but also led to potential decommissioning of existing equipment due to redundancy. This indicates a growing competitive pressure where infrastructure sharing is becoming a more viable and widespread alternative to leasing, directly impacting AMT’s revenue growth prospects.",
      "llm_answer": "In the 2022 Form 10‑K AMT warned that “extensive sharing of site infrastructure, roaming or resale arrangements among wireless service providers… may cause new lease activity to slow.” By the 2024 filing the risk was broadened to “extensive sharing of site infrastructure through RAN sharing, roaming or resale arrangements,” underscoring that network‑sharing practices have become more common. This evolution shows the competitive pressure from carriers’ sharing and resale strategies is intensifying, making it increasingly difficult for AMT to generate new lease growth.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in addressing the multi-hop question about AMT's roaming/resale risk evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 concern about roaming/resale arrangements slowing new lease activity; (2) Accurately captures the 2024 evolution to include RAN sharing as an expanded risk; (3) Properly synthesizes the progression showing intensifying competitive pressure; (4) Correctly identifies AMT as the subject company; (5) Accurately quotes or paraphrases the filing language about 'extensive sharing of site infrastructure'; (6) No quantitative errors or date inaccuracies. MINOR GAPS: (1) The LLM answer does not explicitly mention the 2024 risk of 'decommissioning of existing equipment due to redundancy' - this is a notable omission from the ground truth that represents a material evolution in the risk profile; (2) The answer could have been more explicit about the shift from purely new lease growth concerns to also threatening existing infrastructure viability. The LLM captures the essence of intensifying competitive pressure and the broadening of the risk category, but misses the specific detail about potential equipment decommissioning, which is an important indicator of how the threat has evolved beyond just slowing new growth. The reasoning is sound and the multi-hop synthesis across years is correct, but the answer is slightly incomplete in capturing all dimensions of the risk evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 415,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has McDonald's relationship with its franchisees evolved between 2022 and 2024, particularly in terms of strategic investment and operational expectations?",
      "original_answer": "In 2022, McDonald's highlighted the impact of the COVID-19 pandemic on franchise operations, emphasizing risks related to labor availability, supply chain disruptions, and the importance of executing its 'Accelerating the Arches' strategy to maintain growth. The focus was on franchisees' ability to adapt to changing consumer behavior and operational restrictions. By 2024, McDonald's had shifted toward a more active investment role, co-investing with franchisees to modernize restaurants and improve local performance. The company emphasized franchisee reinvestment in their businesses and introduced structured co-investment initiatives designed to increase the value of the McDonald's brand through restaurant modernization and enhanced consumer appeal. This marks a shift from pandemic-driven operational challenges to a more strategic, investment-backed growth approach.",
      "llm_answer": "In the 2022 filing McDonald’s framed its franchise model as a risk‑focused dependency, stressing that the company’s growth depends on franchisees’ willingness and ability to fund major capital initiatives and that financing constraints could limit those investments (2022 p. 28‑29). By the 2024 filing the tone shifts to a strategic partnership – the company now co‑invests with franchisees to modernize restaurants, imposes rigorous brand and operational standards, and expects franchisees to actively collaborate on technology, growth and other strategic initiatives (2024 p. 4‑5).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core narrative of McDonald's franchise relationship evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 focus on pandemic-related operational challenges, financing constraints, and risk management; (2) Accurately captures the 2024 shift toward co-investment initiatives and modernization; (3) Properly synthesizes the multi-hop comparison across two years; (4) Correctly identifies the strategic partnership framing in 2024 with emphasis on brand standards and technology collaboration; (5) Page references (2022 p. 28-29, 2024 p. 4-5) add credibility and specificity. MINOR WEAKNESSES: (1) The LLM answer frames 2022 as 'risk-focused dependency' which is slightly more negative/cynical than the ground truth's framing of 'pandemic-driven operational challenges' - though both are factually defensible interpretations; (2) The ground truth explicitly mentions 'Accelerating the Arches' strategy by name, which the LLM answer does not reference, though it captures the strategic intent; (3) The ground truth emphasizes 'labor availability' and 'supply chain disruptions' as specific pandemic impacts, while the LLM answer uses more general 'financing constraints' language. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are present in either answer, so this dimension scores high (9/10) - the absence of quantitative claims means no calculation errors. QUALITATIVE ACCURACY: The reasoning is sound and the multi-hop synthesis is correct (8/10) - minor deduction for the slightly different framing of 2022 challenges. CONTEXTUAL RELEVANCE: Excellent - directly addresses the question about evolution of relationship, strategic investment, and operational expectations (9/10). Overall, this is a strong answer that captures the essential narrative arc with minor semantic variations from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 520,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did NextEra Energy's investment strategy in equity securities within its Special Use Funds evolve from 2022 to 2024?",
      "original_answer": "In 2022, NextEra Energy held $8,922 million in Special Use Funds, with no explicit breakdown of equity securities provided in the filing. By 2024, the company disclosed a more detailed composition, with $6,164 million specifically allocated to equity securities under Special Use Funds. This evolution suggests a strategic shift toward transparency and a potentially greater emphasis on equity investments within these funds. While the total amount in Special Use Funds decreased, the explicit allocation to equities in 2024 indicates a more defined and possibly more aggressive investment posture compared to 2022.",
      "llm_answer": "In 2022 the Special Use Funds held a relatively small equity slice that was largely measured at Level 2‑3 (cost‑based) and produced a net unrealized loss of about $1.0 billion, reflecting a conservative, debt‑heavy allocation (NEE_10k_2022.pdf p.62‑63). By 2024 the company had expanded the equity portion, moving a much larger share into Level 1 (quoted‑price) securities and raising total equity holdings in the funds to $6.2 billion, which turned the position into a $917 million unrealized gain—signaling a shift toward a more aggressive, market‑priced equity investment strategy (NEE_10k_2024.pdf p.87‑89).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) QUANTITATIVE ERRORS: The LLM provides specific numbers ($1.0 billion unrealized loss in 2022, $917 million unrealized gain in 2024) that are NOT present in the ground truth answer. The ground truth only mentions $8,922 million total in 2022 and $6,164 million in equity securities in 2024—no unrealized gains/losses are cited. The LLM appears to have fabricated or misattributed financial metrics. (2) INCOMPLETE SYNTHESIS: The ground truth explicitly states 'no explicit breakdown of equity securities provided in the filing' for 2022, yet the LLM claims detailed Level 2-3 cost-basis measurements and specific loss figures for 2022. This contradicts the ground truth's core finding. (3) EQUITY ALLOCATION DISCREPANCY: The LLM states 2024 equity holdings at '$6.2 billion' which aligns with the ground truth's $6,164 million, but the LLM's narrative about 2022 equity holdings is unsupported—the ground truth notes no explicit breakdown was provided. (4) UNSUPPORTED CLAIMS: References to 'Level 1 (quoted-price) securities,' 'Level 2-3 (cost-based),' and specific page citations (p.62-63, p.87-89) cannot be verified against the ground truth and appear to be hallucinated details. (5) REASONING QUALITY: While the LLM's interpretation of a 'shift toward more aggressive equity strategy' is conceptually reasonable, it is built on fabricated supporting evidence rather than actual filing data. The ground truth's more cautious framing ('potentially greater emphasis,' 'more defined...possibly more aggressive') is more accurate. CORRECT ELEMENTS: The 2024 equity figure of $6.2 billion (~$6,164 million) is accurate; the general direction of increased equity emphasis is correct in concept.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 469,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined to $10,670 million. This indicates a marginal decrease in both revenue and profitability year-over-year.",
      "llm_answer": "In 2023 Altria’s smokeable‑products segment generated **$21.8 billion of net revenues**, down from **$22.5 billion in 2022** – a drop of roughly **$720 million (≈3 %)**.  Operating income (OCI) from the same segment was **$10.67 billion in 2023**, versus **$10.69 billion in 2022**, a modest decline of about **$18 million (≈0.2 %)**.  The segment therefore saw a noticeable revenue contraction while its operating profitability remained essentially flat.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. Verification of key figures: (1) 2023 net revenues of $21.756 billion correctly rounded to $21.8 billion; (2) 2022 net revenues of $22.476 billion correctly rounded to $22.5 billion; (3) Revenue decline calculation: $22.476B - $21.756B = $720M, correctly stated; (4) Percentage decline: $720M / $22.476B ≈ 3.2%, appropriately rounded to ~3%; (5) 2023 operating income of $10.670 billion correctly stated as $10.67 billion; (6) 2022 operating income of $10.688 billion correctly stated as $10.69 billion; (7) Operating income decline: $10.688B - $10.670B = $18M, correctly calculated; (8) Percentage decline: $18M / $10.688B ≈ 0.17%, appropriately rounded to ~0.2%. The multi-hop synthesis is sound—the answer correctly identifies the company (Altria), the segment (smokeable products), the years (2022-2023), and the metrics (net revenues and operating income). The reasoning is logical: revenue contracted noticeably while operating profitability remained essentially flat, which accurately reflects the data. The answer uses appropriate number formatting (billions with decimal precision) and provides clear comparative analysis. Minor note: The LLM uses 'OCI' as an abbreviation for operating income, which is slightly non-standard terminology (OCI typically refers to 'Other Comprehensive Income'), but the context makes the meaning clear and this does not affect factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 401,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the utilization of Accenture plc Class A Ordinary Shares evolved between 2022 and 2023, particularly in terms of share purchase programs and their intended usage?",
      "original_answer": "In 2022, Accenture disclosed an aggregate available authorization of $3,129,296 for publicly announced open-market share purchase programs and other share purchase programs involving Accenture plc Class A Ordinary Shares and Accenture Canada Holdings Inc. exchangeable shares. By 2023, the company clarified that Class A Ordinary Shares acquired through these programs were being held as treasury shares and intended for employee benefits, such as equity awards. Additionally, in fiscal 2024, shares were acquired via share withholding for payroll tax obligations under employee equity share plans, which were separate from the publicly announced share purchase authorization. This indicates a shift in focus toward internal employee compensation mechanisms while maintaining a formal buyback program.",
      "llm_answer": "In fiscal 2022 Accenture bought about 12.2 million Class A ordinary shares (≈ $4.1 million)—9.6 million via its open‑market repurchase program and 2.5 million through other purchases tied to employee equity plans—and held them as treasury to fund equity awards and payroll‑tax withholding. In fiscal 2023 the Board increased the total repurchase authority to $6.13 million and the company continued to use the program for the same employee‑benefit purposes, reflecting a sustained (and potentially expanded) utilization of Class A shares for employee compensation.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that fundamentally misrepresent the ground truth: (1) QUANTITATIVE ERRORS - The LLM states 12.2 million shares were bought for approximately $4.1 million in fiscal 2022, which is mathematically impossible (that would be ~$0.34 per share, far below market value). The ground truth mentions an authorization of $3,129,296 (approximately $3.1 million), not $4.1 million. The LLM also claims the Board increased repurchase authority to $6.13 million in 2023, but the ground truth states $3,129,296 was the aggregate available authorization - there is no mention of a $6.13 million increase. (2) UNIT CONFUSION - The LLM appears to confuse dollar amounts with share counts or misinterprets the authorization figures entirely. The ground truth discusses authorization amounts in dollars, not share quantities. (3) MISSING KEY INFORMATION - The LLM fails to capture the critical distinction that the ground truth emphasizes: the shift toward treasury shares held for employee benefits and the separate mechanism of share withholding for payroll tax obligations in fiscal 2024. (4) INCOMPLETE SYNTHESIS - While the LLM attempts to address the evolution between years, it does so with incorrect numbers and fails to properly synthesize the multi-hop information about authorization amounts, treasury share usage, and employee benefit purposes. (5) SEMANTIC ISSUES - The answer conflates share quantities with dollar authorizations, creating fundamental confusion about what metrics are being discussed. The ground truth is clear about authorization amounts; the LLM invents specific share purchase numbers not supported by the source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 461,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the nature and structure of AMT's operating covenants evolved between 2022 and 2024, particularly in terms of the types of debt instruments involved and associated interest rate benchmarks?",
      "original_answer": "In 2022, AMT's operating covenants were tied to a variety of credit facilities and loans that referenced LIBOR and EURIBOR as the interest rate benchmarks. These included the 2021 Multicurrency Credit Facility, the 2021 Credit Facility, and several term loans. By 2024, AMT's disclosures indicate a shift in the interest rate benchmark to SOFR, specifically for letters of credit drawn in Nigeria, which were subject to a rate equal to SOFR at the time of drawing plus a spread. This reflects a transition away from LIBOR-based covenants toward SOFR-based structures, signaling a strategic and regulatory evolution in how AMT manages its debt obligations and associated covenants.",
      "llm_answer": "In the 2022 Form 10‑K the operating covenants were confined mainly to the 2021 credit facilities, term loan and delayed‑draw term loans; the agreements required the usual reporting, financial‑ratio and other restrictions and the debt cost was expressed as a base‑rate + margin, with the base rate set at LIBOR for the USD borrowings and EURIBOR for the EUR borrowings (a 1.125 % spread)【AMT_10k_2022.pdf p.112‑116】.  \n\nBy the 2024 filing the covenant regime had expanded to cover senior notes, securitized tower‑revenue debt and subsidiary letters of credit, with many newer facilities using fixed‑rate coupons on the notes and the revolving/letter‑of‑credit facilities pricing interest off the SOFR benchmark (instead of LIBOR/EURIBOR), while the securitizations impose operating covenants such as DSCR and cash‑trap thresholds【AMT_10k_2024.pdf p.115‑119】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive coverage of the question. STRENGTHS: (1) Correctly identifies the 2022 covenant structure tied to 2021 credit facilities, term loans, and delayed-draw term loans; (2) Accurately notes LIBOR for USD borrowings and EURIBOR for EUR borrowings in 2022; (3) Correctly identifies the 1.125% spread mentioned; (4) Accurately describes the 2024 evolution to include senior notes, securitized tower-revenue debt, and subsidiary letters of credit; (5) Correctly identifies the shift from LIBOR/EURIBOR to SOFR benchmarking; (6) Appropriately mentions fixed-rate coupons on newer notes and SOFR-based pricing for revolving/LOC facilities; (7) Includes additional relevant details about securitization covenants (DSCR and cash-trap thresholds) that enhance completeness. MINOR CONSIDERATIONS: (1) The ground truth mentions 'letters of credit drawn in Nigeria' specifically with SOFR, while the LLM answer more broadly references 'subsidiary letters of credit' - this is a slight generalization but not factually incorrect; (2) The LLM answer provides more granular detail about the types of debt instruments (senior notes, securitized tower-revenue debt) than the ground truth, which is additive and appropriate; (3) The multi-hop synthesis across 2022 and 2024 filings is sound and well-structured. QUANTITATIVE VERIFICATION: The 1.125% spread is correctly cited. No calculation errors detected. The temporal comparison (2022 vs 2024) is properly framed. MULTI-HOP REASONING: The answer successfully synthesizes information across two different filing years and correctly identifies the evolution in covenant structure and benchmark transitions. The reasoning is logical and well-supported by specific document references.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 484,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Disney+ Hotstar's subscriber base evolve between the 2023 and 2024 SEC filings, and what impact did the consolidation of Star+ into Disney+ in Latin America have on Disney's international streaming strategy?",
      "original_answer": "In the 2023 SEC filing, Disney+ Hotstar reported approximately 36 million paid subscribers as of September 28, 2024. The 2024 filing noted that in certain Latin American countries prior to July 2024, Disney offered both Disney+ and Star+ as separate services, but these were merged into a single Disney+ product offering by the end of June 2024. This consolidation suggests a strategic shift toward streamlining international service offerings, potentially aligning with the model used for Disney+ Hotstar by integrating diverse content into a unified brand to enhance user experience and operational efficiency.",
      "llm_answer": "Disney+ Hotstar grew modestly, rising from roughly 34 million paid subscribers reported in the 2023 filing to about 36 million in the 2024 filing (≈ +2 million). At the end of June 2024 Disney merged the standalone Star+ service into Disney+ in Latin America, folding the two brands into a single Disney+ product; this simplification unified the brand, broadened the content bundle and sharpened Disney’s international streaming strategy by offering one stronger, consolidated service in the region.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identified the Star+ consolidation into Disney+ in Latin America by end of June 2024, which is accurate. The qualitative analysis of the strategic shift toward streamlining and unified branding is sound and well-reasoned. The consolidation timing and strategic implications are correctly synthesized. CRITICAL ISSUES: (1) QUANTITATIVE ERROR - The LLM states Disney+ Hotstar grew from 'roughly 34 million' in 2023 to 'about 36 million' in 2024. However, the ground truth indicates the 2023 filing reported approximately 36 million as of September 28, 2024 - meaning this is the 2024 filing data point, not a comparison between two separate years. The LLM appears to have fabricated a 34 million figure for 2023 that does not appear in the ground truth. This is a significant factual error. (2) TEMPORAL CONFUSION - The ground truth states '36 million paid subscribers as of September 28, 2024' from the 2023 SEC filing, which is confusing but indicates the 2023 filing contained forward-looking data. The LLM's interpretation of this as a year-over-year comparison (34M to 36M) is not supported by the ground truth. (3) INCOMPLETE MULTI-HOP SYNTHESIS - The question asks how the subscriber base 'evolved between the 2023 and 2024 SEC filings,' but the ground truth only provides one specific subscriber number (36 million). The LLM invented comparative data. The Star+ consolidation analysis is correct and well-explained. CALCULATION VERIFICATION: The +2 million calculation is mathematically correct IF the 34M and 36M figures were accurate, but the 34M figure appears to be unsupported. ENTITY ACCURACY: Disney+ Hotstar, Star+, Latin America, and Disney+ are all correctly identified. The June 2024 consolidation date is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 479,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the number of employees covered under collective labor agreements changed from 2022 to 2023, and what does this indicate about the company's labor agreement strategy?",
      "original_answer": "In 2022, the company expected to negotiate agreements covering approximately 3,000 employees in the following year. In 2023, the company projected negotiations covering 2,100 employees for the upcoming year. This indicates a reduction in the number of employees involved in labor renegotiations, suggesting a shift in the company's labor agreement strategy, possibly due to fewer expiring agreements or proactive resolution of collective bargaining terms.",
      "llm_answer": "The filings show that the share of the workforce under collective bargaining stayed essentially unchanged – about one‑fifth of the subsidiaries’ employees were covered by 62 collective agreements in both 2022 and 2023.  In 2022 the company expected to renegotiate 21 agreements covering roughly 3,000 employees, and in 2023 the same level of coverage persists (with a similar modest renegotiation slate), indicating a strategy of maintaining stable collective‑labor coverage and handling a limited, predictable set of agreements each year rather than expanding or shrinking the bargaining base.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both correct and incorrect information. CORRECT ELEMENTS: The LLM correctly identifies that approximately 3,000 employees were expected to be covered in 2022 negotiations, and correctly notes that the company maintained a stable collective bargaining coverage strategy. The mention of 62 collective agreements and one-fifth of workforce coverage appears consistent with typical labor reporting. INCORRECT/PROBLEMATIC ELEMENTS: (1) The LLM states '2023 the same level of coverage persists' but the ground truth shows a REDUCTION from 3,000 employees (2022) to 2,100 employees (2023) - this is a 30% decrease, not 'the same level.' (2) The LLM claims 'similar modest renegotiation slate' but the ground truth indicates a clear change in the number of employees involved in renegotiations. (3) The LLM's conclusion that this indicates 'maintaining stable collective-labor coverage' contradicts the actual data showing a reduction. MULTI-HOP REASONING: The LLM failed to properly synthesize the year-over-year comparison. While it correctly identified both years' data points (3,000 in 2022, and references 2023), it misinterpreted the 2023 figure as 'the same level' rather than recognizing the decrease to 2,100 employees. This is a critical error in the core comparison requested. The ground truth explicitly states this represents 'a reduction' and 'a shift in the company's labor agreement strategy,' which the LLM's answer contradicts by emphasizing stability. QUANTITATIVE ACCURACY: The 3,000 figure for 2022 is correct, but the LLM fails to cite the 2,100 figure for 2023 that appears in the ground truth, instead vaguely referring to 'the same level of coverage.' This represents incomplete and inaccurate quantitative reporting of the key metric.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 483,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the role of Opdivo in Bristol-Myers Squibb's product portfolio evolved between 2022 and 2024, particularly in terms of its manufacturing strategy and therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was referenced as a product with both internal manufacturing capability and reliance on third-party manufacturers to meet demand, highlighting its strategic importance in BMY's supply chain. By 2024, Opdivo received a new FDA approval in March for combination therapy with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma, indicating an expansion of its therapeutic applications. This evolution reflects both continued manufacturing investment and increased clinical positioning of Opdivo within BMY's oncology portfolio.",
      "llm_answer": "In the 2022 filing BMS described Opdivo as a core immuno‑oncology asset that it could still produce in‑house but was already “shifting … toward using third‑party manufacturers for supply of our mature … brands” and specifically noted that “we have the capability to manufacture Opdivo internally and have arrangements with third‑party manufacturers to meet demand” (BMY_10k_2022.pdf: pp. 27‑28). By the 2024 filing Opdivo had become a broader platform – the company announced FDA approval of a sub‑cutaneous Opdivo Qvantig formulation, new US neoadjuvant NSCLC and urothelial‑carcinoma indications, a Japanese approval for urothelial carcinoma, and an EU approval of Opdivo + Yervoy for MSI‑H/dMMR colorectal cancer – while continuing to rely on its internal capability and expanding third‑party sourcing to support the growing demand (BMY_10k_2024.pdf: pp. 43‑45; 46).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides substantial detail about Opdivo's evolution but contains significant factual discrepancies when compared to the ground truth. STRENGTHS: (1) Correctly identifies the 2022 manufacturing strategy involving both internal capability and third-party manufacturers; (2) Accurately captures the shift toward third-party manufacturing for mature brands; (3) Correctly identifies multiple 2024 approvals including urothelial carcinoma indication; (4) Demonstrates good multi-hop synthesis across 2022 and 2024 filings; (5) Appropriately contextualizes Opdivo's strategic importance. CRITICAL ERRORS: (1) The ground truth specifies a March 2024 FDA approval for combination therapy with cisplatin and gemcitabine for urothelial carcinoma, but the LLM answer mentions 'US neoadjuvant NSCLC and urothelial-carcinoma indications' without specifying the cisplatin/gemcitabine combination or the March timing - this is a significant factual discrepancy; (2) The LLM introduces additional approvals (subcutaneous Opdivo Qvantig formulation, Japanese approval for urothelial carcinoma, EU approval of Opdivo + Yervoy for MSI-H/dMMR colorectal cancer) that are NOT mentioned in the ground truth, suggesting potential hallucination or over-specification beyond what the knowledge graph confirms; (3) The specific page references (pp. 43-45; 46 for 2024) cannot be verified against ground truth. MULTI-HOP REASONING: The answer correctly synthesizes information across 2022 and 2024 periods and identifies the evolution in both manufacturing strategy and therapeutic approvals. However, the introduction of unverified approvals undermines confidence in the synthesis. QUANTITATIVE ISSUES: While no specific numbers are provided, the factual claims about approvals and formulations contain errors or unverified additions. The answer would score higher if it stuck to the confirmed March 2024 cisplatin/gemcitabine combination approval for urothelial carcinoma rather than adding multiple other approvals not mentioned in ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 548,
        "total_tokens": 1921
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Disney's relationship with National Geographic magazine evolved between 2023 and 2024 in terms of its business structure and strategic positioning within the company's portfolio?",
      "original_answer": "In 2023, National Geographic magazine was explicitly described as part of the Entertainment segment under Content Sales/Licensing, and was noted as being 73% owned by Disney. By 2024, the magazine was still reported under Content Sales/Licensing, but the emphasis on its ownership percentage was removed, and it was described more as a publication 'published' by the company rather than a business in which Disney has a direct equity stake. This shift indicates a more operational rather than ownership-focused relationship in 2024 compared to 2023.",
      "llm_answer": "In the 2023 filing, National Geographic magazine and its online business were reported only as a 73 %‑owned publishing asset within the Entertainment segment’s Content Sales/Licensing line (2023 p.78). By the 2024 filing, Disney still holds the 73 % stake but has broadened the brand’s role—keeping it in Content Sales/Licensing while also adding National Geographic Expeditions to the Experiences segment (2024 p.8) and highlighting its National Geographic Channels in Linear Networks (2024 p.6)—reflecting a more integrated, cross‑segment strategic positioning.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUES: The LLM answer fundamentally contradicts the ground truth on the core evolution described. Ground truth states that by 2024, the emphasis on ownership percentage (73%) was REMOVED and the relationship shifted from ownership-focused to operational/publication-focused. The LLM answer claims Disney 'still holds the 73% stake' and describes a broadening of the brand's role across segments. This is a major factual error that misrepresents the strategic shift. QUANTITATIVE ACCURACY: The 73% figure is correct for 2023, but the LLM incorrectly asserts this ownership percentage remained emphasized in 2024, when ground truth explicitly states the emphasis was removed. The page citations (2023 p.78, 2024 p.8, 2024 p.6) cannot be verified against the ground truth provided. QUALITATIVE ACCURACY: The LLM's interpretation of the relationship evolution is inverted. Ground truth describes a shift AWAY from ownership-focused positioning toward operational/publication positioning. The LLM describes an expansion of National Geographic's role across multiple segments (Expeditions, Channels, Content Sales/Licensing), which may be factually accurate but misses the key strategic shift in how the relationship is characterized. The LLM focuses on broadened business integration rather than the shift from equity stake emphasis to operational publication emphasis. MULTI-HOP REASONING: The LLM failed to synthesize the key insight from the ground truth—that the change between 2023 and 2024 was not about expanding the brand's reach but about changing how Disney describes its relationship to the asset (from ownership stake to operational publication). This represents a fundamental misunderstanding of the question's intent regarding 'evolution' of the relationship structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 486,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has PayPal's description of its transaction management databases' capabilities evolved between 2023 and 2024, particularly in relation to global payment processing in different currencies?",
      "original_answer": "In 2023, PayPal described its transaction management databases as part of a platform that allowed consumers to withdraw funds in 56 currencies. By 2024, the company updated this figure to 57 currencies, indicating a slight expansion in the global reach of its transaction processing capabilities. Additionally, while both years emphasize the role of these databases in enabling customers to utilize PayPal's suite of products, the 2024 filing introduced a more consumer-centric framing, placing 'consumers' ahead of 'merchants' in describing the ecosystem served by the platform. These changes suggest a refinement in how PayPal positions its transaction management systems within its broader global payments infrastructure.",
      "llm_answer": "- 2023 10‑K (see pages 10‑11): PayPal said its “transaction‑management databases” are part of a platform that lets customers use its suite of products and services, and that the platform lets consumers send payments in roughly 200 markets and ≈150 currencies, withdraw funds in 56 currencies and hold balances in 24 currencies.  \n\n- 2024 10‑K (see pages 9‑10): The same “transaction‑management databases” description is retained, but the global‑payment scope is updated – consumers can now send payments in roughly 200 markets and ≈140 currencies, withdraw to bank accounts in 57 currencies, and still hold balances in 24 currencies.  \n\nThus, the database description itself has not changed, while the stated currency coverage for global payment processing was modestly revised (down from ~150 to ~140 send‑currency options and up from 56 to 57 withdraw‑currency options).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURES: The LLM claims 2023 had '≈150 currencies' for sending payments, but the ground truth makes no mention of this figure. More importantly, the LLM states 2024 shows a DECREASE to '≈140 currencies' for sending, which is not mentioned in the ground truth at all. The ground truth focuses exclusively on the withdrawal currency change (56→57), not on send-currency changes. The LLM introduces currency figures for sending payments that are not part of the original answer's scope. (2) INCOMPLETE SYNTHESIS: The ground truth emphasizes a key evolution: the 2024 filing introduced 'a more consumer-centric framing, placing consumers ahead of merchants.' The LLM completely misses this important qualitative change in how PayPal positioned its ecosystem. The LLM states 'the database description itself has not changed,' which contradicts the ground truth's assertion that there WAS a meaningful change in framing/positioning. (3) FOCUS MISALIGNMENT: The LLM provides extensive detail about send-currency and hold-balance figures (200 markets, 24 currencies for holding) that are not part of the ground truth answer. While these details may be factually present in the filings, they distract from and obscure the actual evolution described in the ground truth. (4) CORE FINDING ACCURACY: The LLM correctly identifies the 56→57 currency withdrawal change, which is the primary quantitative evolution mentioned in ground truth. However, this correct identification is buried within incorrect additional claims about send-currency changes. (5) REASONING QUALITY: The LLM's conclusion that 'the database description itself has not changed' directly contradicts the ground truth's assertion that there was a 'refinement in how PayPal positions its transaction management systems' with a shift in consumer-centric framing. This represents a fundamental misunderstanding of the qualitative evolution being measured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 552,
        "total_tokens": 1963
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the interest rate terms associated with the Series K Debentures evolve between 2023 and 2024, and what does this indicate about NEE's financing strategy?",
      "original_answer": "In 2023, the Series K Debentures had their interest rate reset to 6.051% per year as part of a remarketing completed in March 2023. By 2024, the terms of the Series K Debentures were further updated through a letter dated March 1, 2023, which set forth certain terms effective March 1, 2023, indicating a continuation of the updated rate and terms from the 2023 remarketing. This suggests that NEE adjusted its financing strategy in response to market conditions, locking in a higher interest rate to secure funding.",
      "llm_answer": "In 2023 NEECH remarketed its $2.5 billion Series K Debentures (due Mar 1 2025) and reset the coupon to **6.051 % per year**, with interest payable on March 1 and September 1【NEE_10k_2023.pdf:104】. By early 2024 the company sold $3.8 billion of its debentures at **4.90 %‑5.55 %** coupons, indicating the Series K debt was refinanced at lower rates and showing NEE’s strategy of actively remarketing and lowering its borrowing costs to improve its capital structure【NEE_10k_2024.pdf:119】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and misinterpretations that substantially diverge from the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM introduces information about a $3.8 billion debenture sale at 4.90%-5.55% coupons in 2024, which is NOT mentioned in the ground truth. The ground truth explicitly states that by 2024, the Series K Debentures maintained the 6.051% rate from the March 2023 remarketing, with no refinancing at lower rates indicated. (2) MISCHARACTERIZATION OF STRATEGY: The LLM claims NEE 'lowered its borrowing costs' and 'refinanced at lower rates,' but the ground truth indicates NEE 'locked in a higher interest rate' (6.051%) in response to market conditions. This is a fundamental contradiction. The LLM's narrative suggests a cost-reduction strategy when the ground truth indicates a rate-locking strategy during a period of rising rates. (3) INCOMPLETE SYNTHESIS: While the LLM correctly identifies the 6.051% rate and March 2023 remarketing, it fails to properly synthesize the 2024 information. The ground truth indicates continuation of 2023 terms through 2024, not a new refinancing event. (4) ENTITY ACCURACY: The LLM correctly identifies NEE and the Series K Debentures, and the maturity date (Mar 1, 2025) is accurate. However, the introduction of a separate $3.8 billion debenture transaction appears to conflate different securities or misinterpret filing data. (5) REASONING FLAW: The multi-hop reasoning fails because the LLM draws an incorrect conclusion about financing strategy evolution. The ground truth shows strategy consistency (maintaining the reset rate), while the LLM suggests a shift to lower-cost refinancing that didn't occur for the Series K specifically. The answer demonstrates partial understanding of the 2023 remarketing but fundamentally misrepresents the 2024 situation and strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 511,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has ExxonMobil's application of the Unit-of-Production Depreciation method evolved between 2022 and 2023, particularly in response to changes in proved reserves and asset life assumptions?",
      "original_answer": "In 2022, ExxonMobil applied the Unit-of-Production Depreciation method based on proved reserves or proved developed reserves, switching to straight-line depreciation when asset life did not correlate with reserves, and using SEC price-based reserves only when proved reserves were substantially de-booked. By 2023, the company maintained the same core methodology but placed greater emphasis on using the most recent SEC price to determine reserves for depreciation in cases where reserves had been significantly reduced, ensuring a more meaningful allocation of asset costs over the expected life of the asset. This reflects a refinement in the company's approach to align depreciation with updated economic conditions and production realities.",
      "llm_answer": "ExxonMobil’s unit‑of‑production depreciation policy was essentially unchanged from 2022 to 2023. The company still bases depreciation on the ratio of asset cost to total proved (or proved‑developed) reserves, re‑calculating the reserve base at the most recent SEC price when reserves are substantially de‑booked, and uses straight‑line depreciation only for assets whose useful life is shorter than the life of the underlying reserves.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains a critical factual error in its core claim. The original answer explicitly states that ExxonMobil's approach EVOLVED between 2022 and 2023, with the company placing 'greater emphasis on using the most recent SEC price' and implementing a 'refinement' to 'align depreciation with updated economic conditions.' The LLM answer directly contradicts this by stating the policy was 'essentially unchanged from 2022 to 2023.' This is a fundamental mischaracterization of the ground truth. While the LLM correctly identifies the technical mechanics of the depreciation method (unit-of-production based on proved reserves, switching to straight-line when asset life doesn't correlate, using SEC price-based reserves when substantially de-booked), it fails to capture the key evolution: the shift in emphasis toward more recent SEC pricing and the refinement of the approach in response to changed economic conditions. The LLM's statement that the policy was 'essentially unchanged' directly contradicts the ground truth's assertion of meaningful evolution and refinement. The quantitative accuracy is relatively high since no specific numbers are involved, but the qualitative accuracy is severely compromised by missing the central point about how the methodology evolved. The answer addresses the right company and time period but fundamentally misses the comparative analysis between years that was central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 399,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Netflix's strategic emphasis on original programming evolved between 2023 and 2024, particularly in terms of its reliance on third-party production partners versus internal studio scaling?",
      "original_answer": "In 2023, Netflix emphasized its investments in original programming and highlighted the risks associated with third-party production partners, including potential liability and loss due to legal violations, insolvency, or fraud. It also noted its acquisitions like Scanline and Animal Logic as part of scaling internal studio operations. By 2024, the company shifted its language to focus on the growing complexity of managing original content production and placed greater emphasis on the need to improve internal systems, corporate culture, and operational practices related to content creation. The explicit mention of third-party risks present in 2023 was omitted in 2024, suggesting a reduced dependency on external partners and a stronger strategic move toward internal control and scaling.",
      "llm_answer": "In the 2023 filing Netflix stressed that its original‑programming engine still leaned heavily on third‑party producers – “we contract with third parties related to the development, production, marketing and distribution of our original programming” – and noted that it was only just beginning to scale its own studio capacity through acquisitions such as Scanline and Animal Logic. By the 2024 filing the language shifts to highlight a broader, ongoing expansion of its internal studio operations and a greater emphasis on in‑house production, signaling a strategic move away from a primary reliance on external partners toward building more internal content‑creation capability.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with correct identification of key entities (Netflix, Scanline, Animal Logic) and accurate characterization of the strategic shift between 2023 and 2024. The answer correctly captures the core narrative: in 2023, Netflix relied heavily on third-party producers while beginning to scale internal studios through acquisitions; by 2024, the company shifted toward greater internal production capability. The LLM appropriately includes a direct quote from the 2023 filing about contracting with third parties, which adds credibility and specificity. The multi-hop reasoning is sound, correctly synthesizing the evolution across two fiscal years. However, there are minor differences from the ground truth: (1) The LLM answer does not explicitly mention that Netflix highlighted 'risks associated with third-party production partners, including potential liability and loss due to legal violations, insolvency, or fraud' in 2023 - this is a notable omission of specific risk language that was present in the original answer. (2) The LLM answer does not explicitly state that 'the explicit mention of third-party risks present in 2023 was omitted in 2024,' which is an important analytical observation about the strategic shift. (3) The LLM does not mention the 2024 shift toward 'improving internal systems, corporate culture, and operational practices' - instead focusing more broadly on 'internal studio operations.' These omissions represent incomplete coverage of the ground truth's nuanced analysis, though the core strategic narrative is accurately conveyed. No quantitative errors are present, and the semantic meaning of the strategic evolution is correctly captured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 469,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the strategic positioning of Mastercard's Cyber and Intelligence Solutions evolved between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were positioned as part of 'Other revenues' and primarily described as products and services offered to prevent, detect, and respond to fraud, ensuring the safety of transactions made on Mastercard products. By 2023, the Cyber and Intelligence Solutions were elevated in strategic importance, being explicitly described as a value-added service that enables secure, easy, and confident transactions across the entire payments ecosystem, indicating a broader role in supporting Mastercard’s core operations and new network investments.",
      "llm_answer": "In 2022 Mastercard described its Cyber and Intelligence Solutions as a component of its value‑added services, emphasizing that they “prevent, detect and respond to fraud and ensure the safety of transactions” and are designed to let all parties “transact securely, easily and with confidence”【MA_10k_2022.pdf p.78‑80】. By 2023 the same language is retained, but the filing now highlights these solutions as a key part of the broader “value‑added services and solutions” segment that is driving revenue growth, signaling a shift from a purely functional security offering to a strategic growth pillar within Mastercard’s portfolio【MA_10k_2023.pdf p.47‑48】.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IN CORE FACTS: The LLM answer fundamentally misrepresents the ground truth about how Cyber and Intelligence Solutions evolved. Ground truth states: (1) In 2022, these solutions were part of 'Other revenues' (not described as value-added services), and (2) By 2023, they were elevated/explicitly described as value-added services. The LLM reverses this trajectory, claiming 2022 already described them as 'value-added services' with the exact language about 'transact securely, easily and with confidence.' This is factually incorrect according to the ground truth. The LLM then claims 2023 shows a shift 'from purely functional security offering to strategic growth pillar,' which contradicts the ground truth's assertion that 2023 represents the elevation to value-added service status. QUANTITATIVE ACCURACY: Page citations are provided (p.78-80 for 2022, p.47-48 for 2023) but cannot be verified as accurate without source documents. No numerical data is presented, so quantitative scoring reflects the absence of errors in numbers rather than presence of correct ones. QUALITATIVE ACCURACY: The reasoning is fundamentally flawed because it misidentifies the 2022 positioning and mischaracterizes the evolution. The multi-hop synthesis fails because it doesn't correctly identify the key distinction: 2022 = 'Other revenues' positioning vs. 2023 = elevated to explicit value-added service status. CONTEXTUAL RELEVANCE: The answer addresses the right companies and years but provides incorrect characterization of the strategic evolution, making it contextually misaligned with the actual positioning changes described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 453,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Tesla's approach to energy storage products evolved from 2023 to 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized its modular design and in-house expertise in power electronics and software to optimize the manufacturing and performance of its energy storage products like Megapack. By 2024, Tesla's focus shifted to addressing production ramps and supply chain dependencies, citing potential bottlenecks and the need for efficient, cost-effective manufacturing capabilities. The company also highlighted risks related to supplier reliability and the challenges of scaling production to meet planned output rates and quality standards for energy storage products.",
      "llm_answer": "In the 2023 filing Tesla warned that its Powerwall and Megapack programs were still “experiencing delays in launching and ramping the production of our energy‑storage products” and that the business was heavily dependent on a small number of external lithium‑ion‑cell suppliers (e.g., Panasonic and CATL) (2023 10‑K pp. 5‑9). By the 2024 filing the company still acknowledges the same ramp‑up risk, but now stresses a more modular, vehicle‑technology‑leveraged design and a plan to “supplement cells from our suppliers with cells manufactured by us,” indicating a shift toward internal cell production to lessen that strategic dependency (2024 10‑K pp. 15‑19).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about Tesla's energy storage evolution from 2023 to 2024. STRENGTHS: (1) Correctly identifies specific products (Powerwall, Megapack) and suppliers (Panasonic, CATL) mentioned in filings; (2) Accurately captures the 2023 focus on production delays and supplier dependency risks; (3) Correctly identifies the 2024 shift toward internal cell production as a strategic response to reduce dependency; (4) Properly synthesizes the evolution across two years showing progression from external reliance to vertical integration; (5) Cites appropriate page ranges from 10-K filings (2023 pp. 5-9, 2024 pp. 15-19) suggesting proper source documentation. MINOR WEAKNESSES: (1) The LLM answer emphasizes supplier dependency more heavily than the ground truth, which focuses more broadly on 'production challenges and strategic dependencies' including manufacturing capabilities and quality standards; (2) The ground truth mentions 'modular design and in-house expertise in power electronics and software' as 2023 emphasis, while the LLM answer attributes the modular/vehicle-technology-leveraged design discussion to 2024; (3) The ground truth emphasizes 'efficient, cost-effective manufacturing capabilities' and 'scaling production to meet planned output rates and quality standards' in 2024, which the LLM answer doesn't explicitly mention, though it does reference 'ramp-up risk'; (4) The LLM answer is more specific about supplier names and cell production strategy, which adds detail but slightly shifts emphasis from the broader manufacturing and quality focus mentioned in ground truth. MULTI-HOP REASONING: The answer correctly synthesizes information across two filing years and identifies the strategic shift, demonstrating sound multi-hop reasoning. The comparison between 2023 and 2024 approaches is logically structured and accurate. No quantitative errors detected. The answer is semantically equivalent to the ground truth despite some emphasis differences.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 554,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did NextEra Energy Capital Holdings' issuance strategy for floating rate debentures evolve from 2023 to 2024, particularly in terms of the principal amount and maturity structure?",
      "original_answer": "In 2023, NextEra Energy Capital Holdings disclosed the sale of $600 million in floating rate debentures due in 2026. By 2024, the company formalized this issuance through an Officer's Certificate dated January 31, 2024, specifying the Floating Rate Debentures, Series due January 29, 2026. While the principal amount was not explicitly updated in 2024, the maturity structure remained consistent with the 2026 horizon, indicating a focused strategy on short-to-medium-term floating rate debt. This reflects a continuation of the prior year's approach without significant expansion or restructuring of the floating rate debenture program.",
      "llm_answer": "In 2023 NEECH’s floating‑rate debt consisted of a single $400 million debenture that all matured in 2024 (see the “Debentures – variable” line in the 2023 debt table)【NEE_10k_2023.pdf†page 103‑107】.  By early 2024 the company had sold an additional $600 million of floating‑rate debentures that mature in 2026, raising the floating‑rate balance by $200 million and pushing the maturity out two years (the January 31 2024 issuance disclosed in the 2023 filing)【NEE_10k_2023.pdf†page 103‑107】.  Thus, the strategy shifted to a larger principal amount and a longer‑dated maturity profile.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM claims there was a $400 million floating-rate debenture maturing in 2024 in 2023, which is not mentioned in the ground truth. The ground truth only references $600 million in floating rate debentures due in 2026 disclosed in 2023. The LLM's calculation of a $200 million net increase ($600M new - $400M old) is based on this unsupported $400M figure. (2) MISCHARACTERIZATION OF STRATEGY: The ground truth explicitly states the strategy showed 'a continuation of the prior year's approach without significant expansion or restructuring,' while the LLM claims the strategy 'shifted to a larger principal amount and a longer-dated maturity profile.' This directly contradicts the ground truth's conclusion. (3) INCOMPLETE SYNTHESIS: The LLM appears to have fabricated the $400 million 2024-maturing debenture detail, which is not supported by the cited sources or the ground truth. (4) CORRECT ELEMENTS: The LLM correctly identifies the $600 million 2026 maturity debentures and the January 31, 2024 Officer's Certificate date. However, these correct elements are embedded within a fundamentally flawed narrative. The answer demonstrates poor multi-hop reasoning by introducing unsupported data points and drawing conclusions opposite to the ground truth's assessment of continuity versus change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 394,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Intel's approach to industry initiatives related to supply chain responsibility evolved from 2023 to 2024, particularly in terms of collaboration focus and supplier engagement scope?",
      "original_answer": "In 2023, Intel announced a significant expansion of its supplier engagement activities under its RISE strategy, aiming to increase the number of suppliers covered in sustainability and compliance programs, and set a goal to achieve net-zero upstream Scope 3 greenhouse gas emissions by 2050. By 2024, Intel's approach evolved to emphasize broader collaboration on responsible minerals sourcing and transparency around climate and water impacts, with a continued focus on capability-building programs for suppliers but without explicit mention of expanding the number of suppliers engaged. The shift indicates a move from announcing strategic expansions to reinforcing and deepening existing industry partnerships.",
      "llm_answer": "In the 2023 filing Intel said it was “actively collaborating with other companies and leading industry initiatives on improving transparency around climate and water impacts in the global electronics supply chain … and advancing collaboration on responsible‑minerals sourcing,” and it explicitly noted that it was **significantly expanding the number of suppliers covered by its engagement activities** and that its supply‑chain environmental team was working with suppliers to measure and cut GHG emissions (INTC_10k_2023.pdf p.18‑19). By the 2024 filing the same collaboration themes are retained—climate, water and responsible‑minerals transparency—but the language no longer calls out a broad expansion of supplier coverage, suggesting a shift from scaling the engagement to maintaining and deepening existing collaborations (INTC_10k_2024.pdf p.11).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) FACTUAL CORRECTNESS: The answer correctly identifies Intel's 2023 approach emphasizing significant expansion of supplier coverage under RISE strategy, and accurately captures the 2024 shift toward maintaining/deepening existing collaborations without explicit expansion language. The specific themes mentioned (climate, water, responsible minerals sourcing) match the ground truth. The answer correctly cites the 2023 filing pages (18-19) and 2024 filing page (11), demonstrating proper source attribution. (2) QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either the ground truth or LLM answer, which is appropriate given the qualitative nature of the question about strategic evolution. The answer does not introduce any false metrics or calculations. (3) MULTI-HOP REASONING: The answer successfully synthesizes information across two years (2023 and 2024) and correctly identifies the evolution pattern: from announcing strategic expansion to reinforcing existing partnerships. The logical progression is sound and matches the ground truth's characterization of the shift. (4) ENTITY ACCURACY: Intel is correctly identified, fiscal years 2023 and 2024 are properly referenced, and the RISE strategy is accurately named. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same substantive information as the ground truth, using slightly different phrasing but maintaining factual equivalence. The phrase 'shift from scaling the engagement to maintaining and deepening existing collaborations' directly parallels the ground truth's 'move from announcing strategic expansions to reinforcing and deepening existing industry partnerships.' Minor observation: The LLM answer provides slightly more specific textual evidence from the filings (direct quotes), which adds credibility without contradicting the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 530,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has the characterization of the assumptions underlying the standardized measure of discounted future cash flows evolved between XOM's 2022 and 2023 disclosures, particularly regarding the company's framing of its dependency on first-day-of-the-month average prices?",
      "original_answer": "In XOM's 2022 filing, the standardized measure of discounted future cash flows was described as being 'prepared on the basis of certain prescribed assumptions,' which included first-day-of-the-month average prices. This framing emphasized that the assumptions were foundational to the calculation but did not explicitly highlight the degree of dependency on them. In contrast, the 2023 filing reflects a shift in tone by emphasizing that the standardized measure 'depends on' these prescribed assumptions, particularly first-day-of-the-month average prices, which are described as discrete points in time that 'may cause significant variability in cash flows from year to year as prices change.' This indicates a more explicit acknowledgment of the sensitivity and dependency of the measure on these assumptions, even though the actual calculation methodology remained unchanged, using the same 10 percent discount factor, year-end costs, and legislated tax rates.",
      "llm_answer": "In the 2022 filing ExxonMobil described the standardized measure as “prepared on the basis of certain prescribed assumptions, **including first‑day‑of‑the‑month average prices**, which represent discrete points in time and therefore **may cause significant variability in cash flows from year‑to‑year as prices change**.” The 2023 filing repeats that same language but adds a stronger disclaimer that the measure “does not provide a reliable estimate of the Corporation’s expected future cash flows,” while still emphasizing that the reliance on first‑day‑of‑the‑month average prices can cause significant variability. Thus the framing of the price‑dependency has remained essentially unchanged, with 2023 simply reinforcing the caution about its reliability.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS IN CORE CLAIM: The LLM answer fundamentally contradicts the ground truth on the central thesis of the question. The ground truth explicitly states that the 2022 filing did NOT include the language about 'discrete points in time' and 'significant variability' - this language was NEW in the 2023 filing, representing a shift in tone and framing. The LLM incorrectly claims this language appeared in BOTH 2022 and 2023 filings ('repeats that same language'), which is factually wrong. This is a major error because the entire question asks about the EVOLUTION/CHANGE between years, and the LLM's answer denies that any meaningful change occurred ('framing of the price-dependency has remained essentially unchanged'). The ground truth clearly indicates: (1) 2022 used 'prepared on the basis of certain prescribed assumptions' without explicit emphasis on dependency/variability, and (2) 2023 shifted to emphasizing the measure 'depends on' these assumptions with explicit acknowledgment of sensitivity. The LLM's characterization that 2023 'simply reinforcing the caution' misses the key point that this caution was NOT present in 2022 in the same explicit form. The LLM does correctly identify the 10 percent discount factor, year-end costs, and legislated tax rates as unchanged methodology elements, and correctly names the company (ExxonMobil/XOM). However, the fundamental mischaracterization of what changed between years is a critical failure in answering a question specifically about evolution and change. The LLM appears to have conflated or confused the actual language from the two filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 443,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has MA's digital identity solutions evolved between 2022 and 2023, particularly in terms of their integration with open banking capabilities and reach across financial institutions?",
      "original_answer": "In 2022, MA introduced its digital identity solutions as part of an open banking platform that enabled data providers and third parties to access consumer data on a permissioned basis, aiming to improve customer experience and financial inclusion. The platform leveraged data principles such as consumer protection and consent management, and it focused on identity verification across people, devices, and transactions. In 2023, MA expanded its open banking capabilities, achieving connectivity to over 95% of deposit accounts in the U.S. and approximately 3,000 banks across Europe, which significantly enhanced the reach and application of its digital identity solutions. Additionally, in 2023, MA partnered with leading financial institutions to launch an ACH payment solution using its open banking infrastructure, indicating a deeper integration of digital identity within broader financial services.",
      "llm_answer": "In 2022 Mastercard described its digital‑identity suite as a “smooth” set of privacy‑by‑design, consent‑centric tools (device intelligence, behavioral biometrics, document proofing, IP intelligence, etc.) that were offered through its open‑banking platform, but it did not quantify how widely the platform reached banks. By 2023 the company had deepened that integration – the same identity capabilities are now marketed as “seamless” experiences that run on an API‑driven open‑banking network that connects to > 95 % of U.S. deposit accounts and roughly 3,000 banks across Europe, dramatically expanding its reach across financial institutions. (2022 filing – Open Banking/Digital Identity description; 2023 filing – Open Banking reach and updated Digital Identity description).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effective multi-hop synthesis across 2022 and 2023 filings. QUANTITATIVE VERIFICATION: All numeric values are correct - >95% of U.S. deposit accounts and ~3,000 banks across Europe match the ground truth exactly. The percentages and geographic scope are accurately represented. COMPLETENESS: The answer addresses all key aspects of the question: (1) 2022 digital identity solutions description, (2) 2023 expansion and evolution, (3) integration with open banking, (4) reach across financial institutions. The answer also adds valuable detail about the ACH payment solution partnership mentioned in the ground truth, though this is presented more implicitly through the 'deeper integration' language. ENTITY ACCURACY: Mastercard (MA) is correctly identified, years 2022 and 2023 are properly distinguished, and the specific metrics (95% deposit accounts, 3,000 European banks) are accurately cited. REASONING QUALITY: The multi-hop synthesis is sound - the answer correctly traces the evolution from 2022 (privacy-by-design, consent-centric tools without quantified reach) to 2023 (same capabilities now with quantified, expanded reach). The characterization of the shift from 'smooth' to 'seamless' experiences effectively captures the evolution narrative. MINOR CONSIDERATIONS: The LLM answer uses slightly different language than the ground truth (e.g., 'privacy-by-design' vs. 'data principles such as consumer protection') but maintains semantic equivalence. The specific mention of device intelligence, behavioral biometrics, document proofing, and IP intelligence adds helpful detail not explicitly in the ground truth summary. The answer appropriately cites source documents (2022 and 2023 filings). The only minor gap is that the ground truth explicitly mentions the ACH payment solution partnership, while the LLM answer implies this through 'deeper integration' language rather than stating it directly, though this is a very minor omission given the overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 547,
        "total_tokens": 1978
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2023 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized the engineering and design maturity of the Solar Roof, highlighting its aesthetic appeal, durability, and integration with Powerwall. The company positioned Solar Roof as a customized solution within its broader energy product suite. However, by 2024, Tesla acknowledged that the production ramp of Solar Roof faced delays similar to those experienced with other products. The 2024 filing also noted that the company's future success 'depends in large part' on scaling mass-market vehicle production, which indirectly signals a potential strategic prioritization shift that could affect Solar Roof's development and deployment timelines.",
      "llm_answer": "In the 2023 filing Tesla presented Solar Roof as a premium‑glass‑tile roof it was selling directly and through channel partners, stressing continued design iterations, installation‑efficiency improvements and collaborations with developers, but warning that “ramping production of … Solar Roof” could be delayed. By the 2024 filing the tone had shifted to a more explicit risk focus – Tesla now calls out “delays in launching and/or ramping production of … Solar Roof” as a material risk and stresses that its ability to scale the product depends on external suppliers for key components, making the Solar Roof rollout strategically tied to its supply‑chain performance.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the evolution from 2023 to 2024, accurately captures the shift from design/engineering emphasis to production risk acknowledgment, and correctly notes the introduction of supply-chain dependencies as a new concern in 2024. The characterization of Solar Roof as 'premium-glass-tile roof' and the mention of direct sales and channel partners aligns with typical Tesla positioning. The answer appropriately emphasizes the shift in tone from optimization focus to explicit risk disclosure.\n\nWEAKNESSES: (1) The LLM answer introduces specific details about 'external suppliers for key components' and 'supply-chain performance' that are not explicitly confirmed in the ground truth. While the ground truth mentions 'strategic dependencies,' the LLM's specific framing of supplier reliance goes beyond what the ground truth explicitly states. (2) The LLM answer omits the ground truth's important point about Tesla's broader strategic prioritization - specifically that the 2024 filing noted future success depends on 'scaling mass-market vehicle production,' which signals potential deprioritization of Solar Roof. This is a significant contextual omission that affects understanding of the strategic shift. (3) The LLM mentions 'installation-efficiency improvements and collaborations with developers' for 2023, which are reasonable inferences but not explicitly confirmed in the ground truth provided.\n\nMULTI-HOP REASONING: The answer demonstrates sound multi-hop synthesis by comparing 2023 vs 2024 filings and identifying the evolution pattern. However, it misses the critical connection between vehicle production prioritization and Solar Roof's strategic positioning.\n\nFACTUAL ACCURACY: No specific numbers, dates, or calculations are provided in either answer, so quantitative verification is not applicable. The qualitative characterizations are mostly accurate but incomplete.\n\nJUSTIFICATION: The answer captures approximately 70% of the ground truth's key insights but introduces unsupported details about suppliers while omitting the crucial vehicle production prioritization context. This represents partial correctness with some overreach and significant omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 595,
        "total_tokens": 1931
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has NextEra Energy, Inc.'s use of Pledge Agreements evolved between 2023 and 2024, particularly in terms of the dates and counterparties involved?",
      "original_answer": "In 2023, NextEra Energy, Inc. disclosed a Pledge Agreement dated September 1, 2022, involving Deutsche Bank Trust Company Americas and The Bank of New York Mellon. By 2024, the company introduced two new Pledge Agreements dated June 1, 2024, and October 1, 2024, with the same counterparties. This indicates an evolution in the structure and timing of these agreements, expanding their use over time.",
      "llm_answer": "In the 2023 Form 10‑K the only pledge agreement disclosed was Exhibit 4(d) (*4‑rrr), a “Pledge Agreement” dated September 1 2022 between NextEra Energy, Inc., Deutsche Bank Trust Company Americas (as collateral/custodial agent) and The Bank of New York Mellon (as purchase‑contract agent). The 2024 Form 10‑K adds two newer pledge agreements – Exhibit 4(c) (*4‑ttt) dated June 1 2024 and Exhibit 4(vvv) dated October 1 2024 – and both are again with Deutsche Bank Trust Company Americas and The Bank of New York Mellon, showing that while the counterparties remain unchanged, NextEra has continued to execute more recent pledge agreements in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All dates are correct: September 1, 2022 (2023 disclosure), June 1, 2024, and October 1, 2024 (2024 additions). All counterparties are correctly identified: Deutsche Bank Trust Company Americas and The Bank of New York Mellon. The answer properly synthesizes the multi-hop information by comparing the 2023 and 2024 filings and identifying the evolution of pledge agreements. The LLM provides additional helpful context by noting the specific roles of counterparties (collateral/custodial agent and purchase-contract agent) and exhibit references, which enhances understanding without contradicting the ground truth. The reasoning is sound: the model correctly identifies that while counterparties remained the same, NextEra expanded its use of pledge agreements by adding two new agreements in 2024. The answer directly addresses all aspects of the question regarding dates, counterparties, and the evolution between 2023 and 2024. Minor note: The LLM uses slightly different formatting for the date (\"September 1 2022\" vs \"September 1, 2022\") but this is a negligible stylistic variation that does not affect accuracy. The semantic meaning is fully preserved and the factual content is entirely correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 355,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Intel's strategic positioning in Edge AI evolved from 2023 to 2024, particularly in terms of its software platform offerings and ecosystem partnerships?",
      "original_answer": "In 2023, Intel emphasized its edge-native software platform with modular building blocks, premium services, and support offerings, aiming to enable developers to build, deploy, run, manage, connect, and secure distributed edge infrastructure and Edge AI across multiple verticals. The platform was described as a horizontal approach to scaling infrastructure for intelligent edge and hybrid AI, supporting diverse architectures and avoiding vendor lock-in. By 2024, Intel's strategy had evolved under its NEX initiative, which aimed to transform networks and edge compute systems from fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud-native software on programmable hardware. Intel highlighted broader ecosystem partnerships and a focus on rapid digital transformation from cloud to edge, leveraging core strengths in compute, connectivity, software, and large-scale manufacturing. This shift indicates a more integrated and scalable approach to Edge AI, with a stronger emphasis on cloud-native programmability and collaboration with partners to drive automation and secure data integrity at the edge.",
      "llm_answer": "In 2023 Intel’s edge‑AI story centered on new hardware and tools – the 13th‑Gen Core IoT‑edge processors and the OpenVINO 2023.1 toolkit – and on a focused set of ecosystem partners (e.g., Ericsson, Nokia, Cisco, Dell, HPE, Lenovo, Amazon, Google and Microsoft) that helped launch software‑defined, AI‑enabled edge platforms. By 2024 the NEX segment has broadened that positioning into a cloud‑native, open‑software framework that runs on Xeon, Core and Atom silicon, offers modular, zero‑touch management for edge AI, and is backed by a vastly expanded ecosystem that now includes more than 500 network builders, telecom operators, cloud providers and OEMs to accelerate AI‑driven automation across the edge.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the evolution from 2023 to 2024, mentions the NEX initiative, captures the shift toward cloud-native frameworks, and references the expansion of ecosystem partnerships. The semantic understanding of Intel's strategic shift is generally sound. The answer appropriately addresses both software platform offerings and ecosystem partnerships as requested.\n\nWEAKNESSES AND ERRORS: (1) QUANTITATIVE ACCURACY ISSUES: The LLM introduces a specific claim about '500 network builders, telecom operators, cloud providers and OEMs' in 2024. This number is not present in the ground truth and cannot be verified from the provided knowledge graph. This is a significant factual claim that appears to be either fabricated or from an unverified source. (2) MISSING KEY DETAILS: The ground truth emphasizes Intel's 2023 positioning around 'modular building blocks, premium services, and support offerings' and the 'horizontal approach to scaling infrastructure' - these specific characterizations are absent from the LLM answer. (3) HARDWARE SPECIFICITY: The LLM mentions '13th-Gen Core IoT-edge processors' and 'OpenVINO 2023.1 toolkit' which are not mentioned in the ground truth. While these may be factually accurate Intel products, they represent details not in the knowledge graph baseline. (4) INCOMPLETE SYNTHESIS: The ground truth emphasizes avoiding 'vendor lock-in' and supporting 'diverse architectures' in 2023, which the LLM answer does not capture. (5) MISSING TRANSFORMATION NARRATIVE: The ground truth's key insight about transforming 'fixed-function hardware to general-purpose compute' is not explicitly stated in the LLM answer, though the 'cloud-native' framing partially captures this.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes the 2023-to-2024 evolution and correctly identifies the NEX initiative as the key strategic pivot point. The connection between software platform evolution and ecosystem expansion is logically sound.\n\nCONCERN: The introduction of unverified quantitative claims (500 partners) without grounding in the knowledge graph is problematic for a financial/SEC filing context where precision is critical.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 587,
        "total_tokens": 2057
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did the composition and value of CVS's long-term debt related to senior notes due in 2030 evolve between 2023 and 2024, particularly regarding the 1.75% senior notes due August 2030?",
      "original_answer": "In 2023, the 1.75% senior notes due August 2030 had a value of $1,250 million. In 2024, this value remained unchanged at $1,250 million. However, other senior notes due in 2030, such as the 3.75% senior notes due April 2030, decreased from $1,500 million in 2023 to $1,500 million in 2024, indicating stability in some areas of long-term debt but no change in the 1.75% notes specifically.",
      "llm_answer": "In the 2023 filing, CVS listed $1.25 billion of 1.75% senior notes due August 2030 (along with $1.5 billion each of 5.125% notes due Feb 2030 and 3.75% notes due Apr 2030). The 2024 filing shows the same three 2030 series with identical balances—$1.25 billion for the 1.75% August 2030 notes and $1.5 billion each for the Feb 2030 and Apr 2030 notes—so the composition and value of the 1.75% senior notes did not change, even though total long‑term debt grew modestly overall. (2023 Borrowings table, p. 166‑170; 2024 Borrowings table, p. 159‑163)",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct with strong quantitative accuracy. All key numbers are accurate: 1.75% senior notes due August 2030 at $1.25 billion (same in both 2023 and 2024), 5.125% notes due Feb 2030 at $1.5 billion, and 3.75% notes due Apr 2030 at $1.5 billion. The answer correctly identifies that these values remained unchanged between 2023 and 2024. The LLM provides additional context by mentioning the 5.125% February 2030 notes, which the ground truth did not explicitly mention but is relevant to the composition question. The multi-hop reasoning is sound—the answer synthesizes information across both 2023 and 2024 filings and correctly compares the values. One minor issue: the ground truth statement about the 3.75% notes is somewhat confusing (it says they 'decreased from $1,500 million in 2023 to $1,500 million in 2024'), which is contradictory. The LLM correctly interprets this as no change. The LLM also appropriately notes that 'total long-term debt grew modestly overall' while the 2030 notes remained stable, showing good contextual understanding. The citation format (page numbers) adds credibility. The answer fully addresses the question about how the composition and value evolved—the answer is that they did not evolve/change. Minor deduction only because the LLM could have been slightly more explicit about the stability/lack of change being the key finding, though this is clearly implied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 397,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did Netflix's ad-supported subscription plan evolve between 2023 and 2024 in terms of its role within the company's pricing strategy and membership growth objectives?",
      "original_answer": "In 2023, Netflix introduced the ad-supported subscription plan as a new, lower-priced option aimed at expanding its membership base and addressing competitive pressures by offering a more accessible entry point. This was part of broader efforts to adjust pricing models and membership plans to improve value perception. By 2024, the ad-supported plan had become a core component of Netflix's pricing strategy, explicitly included in a range of plans designed to meet varied consumer needs, indicating its integration into the company's long-term growth framework. This evolution reflects a shift from experimental pricing to a strategic offering intended to support sustained membership growth across different market segments.",
      "llm_answer": "In the 2023 Form 10‑K Netflix disclosed that it had “introduced a new, lower‑priced ad‑supported subscription plan” as a pricing‑model adjustment aimed at attracting price‑sensitive members (Item 1A – Risk Factors). By the 2024 filing the same tier was framed as a core element of a “range of pricing plans, including our ad‑supported subscription plan, to meet a variety of consumer needs,” and the company said it was scaling the new ad‑supported feature to help drive membership growth (Item 1 – Business). Thus, the plan moved from a newly‑launched low‑price option in 2023 to an integral part of a diversified pricing strategy in 2024 that supports the company’s broader growth objectives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2023 introduction of the ad-supported plan as a lower-priced option targeting price-sensitive members, matching the ground truth's characterization. (2) Accurately captures the 2024 evolution where the plan became a 'core element' of a diversified pricing strategy, directly paralleling the ground truth's description of it becoming 'a core component.' (3) Properly synthesizes the multi-hop reasoning: 2023 (experimental/new offering) → 2024 (integrated strategic component). (4) Correctly cites specific 10-K sections (Item 1A, Item 1) and uses appropriate quotations from filings. (5) No quantitative errors - no specific numbers are claimed that could be incorrect. (6) Accurately identifies the strategic purpose: addressing competitive pressures and supporting membership growth objectives. MINOR CONSIDERATIONS: (1) The LLM answer is slightly more specific in citing filing sections and direct quotes, which adds credibility but goes slightly beyond the ground truth's level of detail (not a weakness, just more granular). (2) The ground truth mentions 'addressing competitive pressures' and 'improving value perception' - the LLM captures competitive pressures implicitly through 'attracting price-sensitive members' and the broader context, though doesn't explicitly state 'value perception.' This is a very minor semantic gap. (3) Both answers effectively convey the shift from experimental to strategic positioning. The LLM's framing of 'newly-launched' (2023) to 'integral part' (2024) is semantically equivalent to the ground truth's 'experimental pricing' to 'strategic offering.' MULTI-HOP SYNTHESIS: The answer correctly synthesizes information across two fiscal years and two different filing sections, demonstrating proper understanding of how Netflix's strategy evolved. The reasoning chain is logical and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 532,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2023 and 2024, based on its production status and strategic positioning?",
      "original_answer": "In 2023, Tesla stated that it had begun early production and deliveries of the Tesla Semi, indicating initial market introduction and limited availability. By 2024, Tesla's production status for the Tesla Semi had advanced to 'pilot production' at its Nevada facility, suggesting a more structured and expanded phase of manufacturing, though not yet full-scale commercial production. This evolution reflects Tesla's strategic progression from initial rollout to a more mature testing and scaling phase for the commercial electric vehicle.",
      "llm_answer": "In the 2023 Form 10‑K Tesla noted that it had “begun early production and deliveries of a commercial electric vehicle, the Tesla Semi,” indicating the truck was still in an initial, limited‑run phase. By the 2024 filing the Semi had moved to “pilot production” at the Nevada plant and was highlighted in a table of vehicle models as a key target for capacity growth, with Tesla explicitly stating it is expanding manufacturing to include newer models such as the Cybertruck and Tesla Semi as part of its strategic product‑line expansion.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-supported by the ground truth. Strengths: (1) Correctly identifies the 2023 status as 'early production and deliveries' with appropriate characterization as 'initial, limited-run phase'; (2) Accurately states the 2024 progression to 'pilot production' at the Nevada facility; (3) Properly synthesizes the multi-hop information showing evolution from 2023 to 2024; (4) All dates and entities (Tesla, Tesla Semi, Nevada facility) are correct; (5) No quantitative errors or calculation issues. Minor considerations: (1) The LLM answer adds contextual detail about the table of vehicle models and strategic product-line expansion that, while accurate and relevant, goes slightly beyond the core ground truth statement but enhances understanding; (2) The phrasing 'limited-run phase' is semantically equivalent to 'limited availability' in the ground truth; (3) The characterization of pilot production as 'more structured and expanded' vs. the LLM's implicit framing through the Nevada facility context are complementary perspectives. The LLM successfully demonstrates multi-hop reasoning by connecting the 2023 and 2024 filings and showing the progression in manufacturing maturity. The answer is complete, factually accurate, and appropriately contextualizes Tesla's strategic positioning in the commercial EV market.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 378,
        "total_tokens": 1643
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "What does the expansion of NextEra Energy's Executive Retention Employment Agreements from 2023 to 2024 suggest about the company's approach to leadership continuity and its strategic emphasis on executive talent retention?",
      "original_answer": "In 2023, NextEra Energy had active Executive Retention Employment Agreements with executives including Mark Lemasney (signed January 1, 2023) and Armando Pimentel, Jr. (signed February 15, 2023), indicating a focus on retaining key leadership at that time. By 2024, the company not only maintained those agreements but also introduced a new agreement with Brian Bolster, dated May 6, 2024, showing an expansion in the number of covered executives. This evolution suggests that NextEra Energy has placed increasing strategic importance on securing leadership continuity and minimizing executive turnover risk, particularly during periods of potential transition or uncertainty. The addition of new executives under retention agreements implies a proactive approach to talent management, which could signal confidence in leadership or a response to external pressures affecting executive mobility.",
      "llm_answer": "The 2024 filing shows that NextEra added new Executive Retention Employment Agreements (e.g., with Nicole J. Daggs and Brian W. Bolster) on top of the 2023 agreements (e.g., with Mark Lemasney and Armando Pimentel, Jr.) 【NEE_10k_2023.pdf pp. 114‑118 – exhibits *10(kk) and *10(ll)】 and 【NEE_10k_2024.pdf pp. 123‑127 – exhibits *10(mm) and *10(nn)】. This growth in retention contracts signals that the company is deliberately strengthening leadership continuity and placing a strategic emphasis on keeping key executives on board.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core concept that NextEra Energy expanded its Executive Retention Employment Agreements from 2023 to 2024, and accurately conveys the strategic implication about leadership continuity and talent retention emphasis. However, there are significant factual discrepancies in the specific executives named. CRITICAL ERRORS: (1) The LLM mentions 'Nicole J. Daggs' as a 2024 addition, but the ground truth does not reference this executive at all in the provided information. (2) The ground truth specifically names Mark Lemasney (January 1, 2023) and Armando Pimentel, Jr. (February 15, 2023) as 2023 executives, and Brian Bolster (May 6, 2024) as the 2024 addition - the LLM correctly identifies Lemasney, Pimentel, and Bolster but incorrectly adds Daggs. CORRECT ELEMENTS: The LLM accurately identifies the expansion pattern (2023 agreements maintained and new ones added in 2024), correctly names Brian Bolster as a 2024 addition, and properly synthesizes the strategic implication about deliberate strengthening of leadership continuity. The reasoning about proactive talent management and executive retention is sound and aligns with the ground truth's interpretation. The document citations provided appear reasonable though cannot be fully verified. The semantic understanding of the question is appropriate and the answer addresses the core inquiry about strategic emphasis on executive talent retention. The main weakness is the introduction of an unverified executive name (Nicole J. Daggs) which represents a factual error in entity identification, though this does not fundamentally undermine the overall thesis about expansion and strategic intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 462,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Intel's approach to xPU products evolved from 2023 to 2024, particularly in terms of strategic focus and product development priorities?",
      "original_answer": "In 2023, Intel's focus on xPU products was part of a broader R&D strategy that included process and packaging technology, AI, and software, with $16.0 billion spent on R&D. The company faced challenges in timely product development and manufacturing process introductions, which had previously caused delays and cost overruns. By 2024, Intel had evolved its approach by embedding xPU products more deeply into its strategic priorities, specifically under the theme of 'product competitiveness.' The company announced the creation of an advisory group to expand the x86 ecosystem and emphasized the xPU family of products—including client and data center GPUs, IPUs, FPGAs, and other accelerators—as a way to meet diverse computing needs. This represents a shift from a general R&D focus to a more structured and strategic product development initiative.",
      "llm_answer": "In the 2023 filing Intel described xPU mainly as one of several R&D focus areas – “our xPU products and features” were grouped with process‑and‑packaging technology, AI and software as a target for new product development (2023 10‑K p. 49). By the 2024 filing the company had elevated xPU to a core strategic pillar of “Product Competitiveness,” defining a family of GPUs, IPUs, FPGAs and other accelerators, pledging to lead across each architecture, expand the ecosystem (e.g., an advisory group) and tie xPU development to AI‑at‑the‑edge and broader compute needs (2024 10‑K pp. 3‑7).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. QUANTITATIVE ACCURACY: The answer correctly cites the $16.0 billion R&D spend from 2023 (though not explicitly stated in the LLM response, the ground truth mentions this figure). The LLM appropriately references specific 10-K page numbers (2023 p. 49, 2024 pp. 3-7) which adds credibility and specificity. QUALITATIVE ACCURACY: The LLM correctly identifies the evolution from 2023 to 2024: (1) 2023 positioning: xPU as one of several R&D focus areas alongside process-and-packaging, AI, and software; (2) 2024 positioning: elevation to core strategic pillar under 'Product Competitiveness.' The answer accurately describes the xPU family composition (GPUs, IPUs, FPGAs, accelerators) and strategic initiatives (advisory group for ecosystem expansion, AI-at-the-edge focus). MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and demonstrates the strategic shift from general R&D categorization to structured product development priority. The comparison is logical and well-articulated. COMPLETENESS: The answer addresses all aspects of the question: strategic focus evolution, product development priorities, and the timeline (2023 to 2024). MINOR CONSIDERATIONS: The LLM answer does not explicitly mention the $16.0 billion R&D figure from 2023 that appears in the ground truth, though this is a minor omission that doesn't significantly impact the core narrative. The semantic equivalence is strong—both answers convey the same fundamental shift in Intel's xPU strategy. The LLM's inclusion of specific page references enhances credibility and demonstrates document-grounded reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 469,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Netflix's approach to advertising technology evolved between 2023 and 2024, particularly in terms of organizational development and infrastructure investment?",
      "original_answer": "In 2023, Netflix emphasized its limited experience with advertising and outlined several dependencies, particularly on third-party service providers for ad management and the need to attract and retain advertisers. The company also highlighted risks related to developing the necessary advertising technology infrastructure. By 2024, Netflix shifted toward a more proactive stance, emphasizing its ability to 'develop and expand an advertising sales and advertising technology organization team' and 'develop the technology and related infrastructure to support advertising and drive value to advertisers.' This indicates a strategic evolution from reliance on external providers to internal development and investment in ad tech capabilities.",
      "llm_answer": "In the 2023 Form 10‑K Netflix described its ad‑supported model as “new” and listed as a risk the need to “develop and expand an advertising sales organization team” and to “develop the technology and related infrastructure to support advertising” (NFLX_10k_2023 pp. 8‑12). By the 2024 filing the language had shifted to a concrete plan to “develop and expand an advertising sales **and advertising technology** organization team” and to “invest in the technology and related infrastructure to support advertising and drive value to advertisers,” showing a move from acknowledging nascent capability to building a dedicated ad‑tech organization and committing capital to its infrastructure (NFLX_10k_2024 pp. 8‑12).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and effectively addresses the multi-hop question about Netflix's advertising technology evolution between 2023 and 2024. STRENGTHS: (1) Correctly identifies the 2023 positioning as acknowledging the ad-supported model as 'new' and listing infrastructure development as a risk; (2) Accurately captures the 2024 shift to a more proactive stance with concrete plans; (3) Properly synthesizes the key evolution: from acknowledging nascent capability to building dedicated ad-tech organization with capital commitment; (4) Correctly identifies the specific language changes ('and advertising technology' addition in 2024); (5) Appropriately cites document sources (NFLX_10k_2023 and NFLX_10k_2024 pp. 8-12); (6) Maintains semantic equivalence with ground truth while using slightly different phrasing ('invest in' vs 'investment in'); (7) Demonstrates sound multi-hop reasoning by comparing organizational development and infrastructure investment across two fiscal years. MINOR CONSIDERATIONS: The LLM answer uses 'invest in' while ground truth uses 'investment in' - these are semantically equivalent. The LLM answer is slightly more detailed in showing the specific language evolution (adding 'and advertising technology' to the organizational team description), which adds helpful specificity. No quantitative errors, no date errors, no entity misidentifications. The answer fully addresses both components of the question (organizational development AND infrastructure investment) with proper synthesis across the two-year period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 433,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Tesla's approach to free Supercharging programs evolved between 2023 and 2024, particularly in terms of revenue recognition and program structure?",
      "original_answer": "In 2023, Tesla's free Supercharging programs were included under Automotive Sales Revenue as part of the revenue associated with new vehicle deliveries, indicating they were bundled with vehicle sales and recognized over time. By 2024, Tesla began deferring revenue related to features such as FSD (Supervised), internet connectivity, and free Supercharging, recognizing these as liabilities to be amortized over time rather than immediately upon vehicle delivery. This structural shift reflects a more formalized and segmented approach to monetizing these features, including free Supercharging, which allows Tesla to better align revenue recognition with service delivery.",
      "llm_answer": "- **2023:** Tesla described unlimited free Supercharging as a “stand‑ready” service that is provisioned when the vehicle is delivered and then recognized on a straight‑line basis over the vehicle’s expected ownership life; limited free‑Supercharging incentives are recognized when the customer actually uses them or when they expire (Revenue Recognition, TSLA 10‑K 2023 pp. 37‑41).  \n\n- **2024:** The company still offers the same unlimited/limited free‑Supercharging structure, but now reports it in a separate deferred‑revenue schedule and records revenue from that balance each period (e.g., $872 million recognized in 2024 vs $469 million in 2023), providing a more granular, quantified accounting of the program while keeping the underlying service model unchanged (Automotive Sales & Deferred‑revenue tables, TSLA 10‑K 2024 pp. 56‑60).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations when compared to the ground truth:\n\n1. QUANTITATIVE ACCURACY ISSUES:\n   - The LLM cites specific dollar amounts ($872 million in 2024 vs $469 million in 2023) for free Supercharging revenue recognition, but these numbers cannot be verified against the ground truth and appear to be fabricated or incorrectly sourced. The ground truth does not provide these specific figures.\n   - The LLM provides page references (pp. 37-41 for 2023, pp. 56-60 for 2024) that cannot be verified and may be inaccurate.\n\n2. CORE CONCEPTUAL ERRORS:\n   - The LLM's 2023 description of free Supercharging as a \"stand-ready\" service recognized on a \"straight-line basis over the vehicle's expected ownership life\" contradicts the ground truth, which states that in 2023, free Supercharging was \"included under Automotive Sales Revenue as part of the revenue associated with new vehicle deliveries\" and \"recognized over time\" as bundled with vehicle sales.\n   - The LLM claims the \"underlying service model [remained] unchanged\" between 2023 and 2024, which directly contradicts the ground truth's assertion that there was a \"structural shift\" from bundled recognition to deferred revenue treatment.\n\n3. MISSING KEY EVOLUTION:\n   - The ground truth emphasizes that by 2024, Tesla began \"deferring revenue\" and recognizing these as \"liabilities to be amortized over time rather than immediately upon vehicle delivery.\" The LLM's answer downplays this fundamental change by suggesting it was merely a reporting/disclosure change (\"separate deferred-revenue schedule\") rather than an actual accounting methodology shift.\n   - The ground truth highlights that this reflects \"a more formalized and segmented approach to monetizing these features,\" which the LLM fails to adequately capture.\n\n4. MULTI-HOP REASONING:\n   - The LLM fails to properly synthesize the evolution between 2023 and 2024. It presents the changes as primarily a reporting/disclosure matter rather than a substantive accounting treatment change.\n   - The connection between revenue recognition methodology and program structure is not clearly established.\n\n5. SEMANTIC ISSUES:\n   - The LLM's characterization of the change as merely providing \"more granular, quantified accounting\" while \"keeping the underlying service model unchanged\" fundamentally misrepresents the nature of the shift described in the ground truth.\n\nThe answer demonstrates partial understanding of the topic but contains material factual errors, unsupported numerical claims, and a mischaracterization of the fundamental nature of the accounting change between 2023 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 716,
        "total_tokens": 2096
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has NextEra Energy's approach to issuing Series O Junior Subordinated Debentures evolved between 2023 and 2024, particularly in terms of coupon structure and maturity dates, and what might this shift indicate about their financing strategy?",
      "original_answer": "In 2023, NextEra Energy issued the Series O Junior Subordinated Debentures due on May 1, 2079, with no explicit coupon rate disclosed in the filing. This indicates a potentially fixed or deferred interest structure typical for long-dated junior subordinated instruments. By 2024, the Series O Debentures were issued with a defined coupon rate of 5.55% and a significantly shorter maturity date of November 1, 2029. This represents a strategic shift toward issuing more conventional debt instruments with shorter durations and clearly defined interest costs. This evolution suggests a possible recalibration of NextEra’s capital structure strategy, favoring shorter-term, more predictable financing over long-dated, potentially lower-yielding instruments.",
      "llm_answer": "In the 2023 filing the only Series O instrument listed was the **Series O Junior Subordinated Debentures** created on April 4 2019 with a **fixed‑rate coupon** and an **ultra‑long maturity of May 1 2079** (*4(kkk)).  By the 2024 filing the company had moved to a new **Series O issuance that matures on November 1 2029** (4(rr)), reflecting a change in the coupon structure away from the original long‑dated fixed‑rate junior debt.  This shift points to a financing strategy that favors shorter‑term, more flexible debt and a tighter overall maturity profile.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies both Series O issuances (2023 and 2024), correctly states the 2023 maturity date of May 1, 2079, and correctly identifies the 2024 maturity date of November 1, 2029. The reasoning about the strategic shift toward shorter-term debt is sound and aligns with the ground truth. The LLM appropriately characterizes the evolution as moving from long-dated to shorter-term instruments.\n\nCRITICAL ERRORS: (1) The LLM states the 2023 Series O had a 'fixed-rate coupon' but the ground truth explicitly states 'no explicit coupon rate disclosed in the filing.' This is a significant factual error - the LLM invented information not present in the original answer. (2) The LLM fails to mention the 5.55% coupon rate for the 2024 issuance, which is a key quantitative detail in the ground truth answer. This is a major omission of specific financial data.\n\nPARTIAL ISSUES: The LLM adds the creation date of April 4, 2019 for the 2023 instrument, which is not contradicted by the ground truth but also not confirmed. The characterization of the 2024 debt as 'more flexible' is not explicitly supported by the ground truth, which focuses on 'clearly defined interest costs' and 'more conventional debt instruments.'\n\nMULTI-HOP REASONING: The synthesis across years is correct in structure, but incomplete due to missing the 5.55% coupon rate comparison. The strategic interpretation is reasonable but lacks the specific financial metric that would strengthen it.\n\nQUANTITATIVE ACCURACY PENALTY: Missing the 5.55% coupon rate is a significant omission of a key financial metric. The dates are correct, but the coupon information is incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 457,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has ExxonMobil's consideration of OPEC investment activities evolved in its impairment assessment framework from 2022 to 2023, particularly in relation to long-term oil supply dynamics?",
      "original_answer": "In 2022, ExxonMobil explicitly stated that OPEC investment activities and production policies had an impact on world oil supplies and were considered in the context of impairment assessments. By 2023, while the company still acknowledged OPEC's influence on global oil supply, the discussion of OPEC was embedded more broadly within a comprehensive cash flow assessment framework that included forward-looking variables such as greenhouse gas emission costs and net-zero targets. This indicates a shift from a direct focus on OPEC's role to a more integrated view of macroeconomic and environmental factors affecting long-term asset valuation.",
      "llm_answer": "In the 2022 Form 10‑K, ExxonMobil first spelled out that “OPEC investment activities and production policies also have an impact on world oil supplies” and that this supply‑side factor is part of the long‑term oil‑price assumptions used in its impairment‑testing framework. The 2023 Form 10‑K repeats the same language, reaffirming that OPEC’s investment and production decisions continue to be incorporated into the company’s long‑term oil‑supply outlook for assessing asset recoverability, showing continuity rather than a shift in the approach.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The core issue: The LLM claims that the 2023 Form 10-K 'repeats the same language' and shows 'continuity rather than a shift in the approach,' but the ground truth explicitly states there WAS a shift from 2022 to 2023. Specifically: (1) In 2022, ExxonMobil explicitly focused on OPEC investment activities and production policies as direct factors in impairment assessments. (2) In 2023, while OPEC's influence was still acknowledged, the discussion became embedded within a broader framework that included greenhouse gas emission costs and net-zero targets. This represents a material evolution in how OPEC considerations were integrated into the assessment framework. The LLM's characterization of 'continuity' is incorrect. The quantitative accuracy is reasonable (dates 2022/2023 are correct, company name is correct), but the qualitative reasoning is severely flawed. The LLM failed to identify the key distinction: the shift from direct OPEC focus to integrated macroeconomic/environmental factors. This is a multi-hop reasoning question requiring synthesis of how OPEC considerations evolved across two years, and the LLM fundamentally mischaracterized this evolution. The answer demonstrates a failure to capture the nuanced change in ExxonMobil's disclosure and assessment framework between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 391,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Netflix's approach to its ad-supported subscription plan evolved from 2023 to 2024, based on the level of detail and strategic emphasis provided in the filings?",
      "original_answer": "In 2023, Netflix's ad-supported subscription plan was mentioned in the context of uncertainty and risk, particularly around consumer adoption and the lack of operating history with such offerings, which could lead to discrepancies between forecasts and actual results. By 2024, the ad-supported plan was presented as part of the company's broader pricing strategy, explicitly included in the description of plans offered to meet a variety of consumer needs. This shift indicates a move from a risk-focused perspective to a more confident, strategic positioning of the ad-supported plan as a core part of Netflix's business model.",
      "llm_answer": "In the 2023 Form 10‑K, Netflix treated the ad‑supported tier mainly as a nascent, uncertain experiment—its only mention appears in the risk‑factors/MD&A discussion (page 20), noting the lack of operating history and the difficulty of forecasting consumer adoption. By the 2024 filing (pages 1‑2), the ad‑supported plan is presented as a core element of Netflix’s pricing strategy, highlighted in the Business overview as a deliberate “range of pricing plans … to meet a variety of consumer needs” and as a driver of new advertising revenue. This shift shows the plan moving from a cautious, risk‑focused footnote to a strategic growth priority.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution from 2023 to 2024, matching the ground truth's core narrative of moving from risk-focused to strategic positioning. (2) Accurately characterizes 2023 positioning as uncertain/experimental with emphasis on lack of operating history and forecasting challenges—directly matching ground truth language. (3) Properly describes 2024 shift to core business strategy element, explicitly noting inclusion in pricing strategy and consumer needs framing. (4) Adds valuable specificity (page references: page 20 for 2023 risk factors, pages 1-2 for 2024 business overview) that enhances credibility without contradicting ground truth. (5) Correctly identifies the semantic shift from 'risk-focused footnote' to 'strategic growth priority,' which captures the essence of the ground truth's 'risk-focused perspective to confident strategic positioning' transition. (6) No quantitative errors—no specific numbers are claimed that could be verified as incorrect. MINOR CONSIDERATIONS: (1) The LLM provides more specific document location details (page numbers) than the ground truth, but this is additive rather than contradictory. (2) The phrase 'nascent, uncertain experiment' is slightly more colorful than ground truth language but semantically equivalent to 'uncertainty and risk' framing. (3) The multi-hop synthesis is sound—correctly connecting 2023 risk discussion with 2024 strategic positioning across different filing sections. The answer demonstrates clear understanding of how Netflix's strategic messaging evolved and why, matching the ground truth's core insight about the shift from cautious to confident positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 481,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Amazon's approach to shipping offers evolved between 2022 and 2024, particularly in terms of cost drivers and strategic focus on fulfillment efficiency?",
      "original_answer": "In 2022, Amazon highlighted that shipping costs were expected to increase as customers increasingly adopted its shipping offers, used faster delivery methods, and as the company expanded its fulfillment network. Shipping costs in 2021 were $76.7 billion, and the company anticipated continued growth in these costs. The strategic emphasis was on mitigating these increases through higher sales volumes, network optimization, supplier negotiations, and operational efficiencies. By 2024, the focus had shifted: while the company still invested in expanding its fulfillment network, it emphasized fulfillment network efficiencies as a key cost offset. The 2024 report notes that increased sales and network investments drove up fulfillment costs, but these were partially offset by efficiency gains. This marks a strategic evolution from a customer-driven cost increase in 2022 to a more operations-centric efficiency focus by 2024.",
      "llm_answer": "Amazon’s 2022 filing warned that shipping‑offer usage and faster, more expensive delivery were pushing shipping costs higher and that fulfillment cost growth was driven by rising wages, a tight labor market and network expansion, so the company relied on higher sales volumes, better supplier terms and network optimization to blunt the impact. By the 2024 filing, shipping costs had risen further, but Amazon now emphasizes that investments in its fulfillment network are delivering “fulfillment‑network efficiencies” that partially offset those higher costs, while still using low‑price shipping offers as a key price‑tool to drive sales. In short, the focus has shifted from mainly mitigating cost increases to actively improving fulfillment efficiency alongside the continued strategic use of shipping offers.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with sound multi-hop reasoning across the 2022-2024 period. STRENGTHS: (1) Correctly identifies the 2022 cost drivers (shipping-offer adoption, faster delivery, network expansion, labor market tightness, wage increases) and mitigation strategies (higher sales volumes, supplier negotiations, network optimization). (2) Accurately captures the 2024 shift toward emphasizing fulfillment-network efficiencies as cost offsets. (3) The characterization of the strategic evolution from 'mitigating cost increases' to 'actively improving fulfillment efficiency' aligns well with the ground truth's distinction between customer-driven costs (2022) and operations-centric efficiency focus (2024). (4) Correctly notes that shipping offers remain a strategic tool for driving sales in 2024. (5) Multi-hop synthesis is sound, properly connecting cost drivers, mitigation strategies, and strategic shifts across years. MINOR WEAKNESSES: (1) The LLM answer does not include the specific 2021 shipping cost figure ($76.7 billion) mentioned in the ground truth, though this is a minor omission since the question asks about 2022-2024 evolution. (2) The phrase 'shipping costs had risen further' in 2024 is somewhat vague compared to the ground truth's more precise statement about 'increased sales and network investments' driving fulfillment costs. (3) The answer could have been slightly more explicit about the distinction between 'shipping costs' and 'fulfillment costs' as separate but related metrics. QUANTITATIVE ACCURACY: No specific numbers are provided in either answer for the 2022-2024 period, so this dimension is not directly testable. The absence of quantitative data is acceptable given the nature of the question, which focuses on strategic evolution rather than specific financial metrics. SEMANTIC EQUIVALENCE: The LLM answer conveys the same essential information as the ground truth through different wording, which is appropriate and acceptable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 540,
        "total_tokens": 1979
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did Duke Energy's utilization and reporting of the Master Retirement Trust evolve between 2023 and 2024, particularly in terms of asset allocation and disclosure practices?",
      "original_answer": "In 2023, Duke Energy's Master Retirement Trust was described in terms of its investment objective, focusing on achieving sufficient returns for plan benefits, with specific mention of VEBA trusts and their target and actual asset allocations. By 2024, the reporting evolved to include a more detailed breakdown of how different subsidiaries were allocated portions of the trust, such as Duke Energy Progress at 15% and Duke Energy Florida at 18%. Additionally, 2024 introduced a reconciliation of beginning and ending balances for pension and post-retirement assets, including Level 3 fair value disclosures, which was not present in 2023. This reflects a shift toward more granular and transparent reporting on trust assets and their valuation methodologies.",
      "llm_answer": "In the 2023 filing Duke Energy said roughly 98 % of the Master Retirement Trust’s assets were in qualified pension plans, with target allocations of 35 % liability‑hedging/ 65 % return‑seeking for the RC‑BP portfolio and 80 %/ 20 % for the DELPP portfolio; the actual 2023 mix was 45 % global equity, 35 % debt, 4 % hedge funds and 8 % cash/real‑estate for RC‑BP and 14 % equity, 79 % debt, 2 % hedge funds and 3 % cash/real‑estate for DELPP. By 2024 the actual allocations had shifted modestly – RC‑BP equity fell to 44 %, debt to 33 % and cash/real‑estate rose to 10 % (hedge‑fund exposure up to 5 %); DELPP equity rose to 15 % and cash/real‑estate to 4 %, while VEBA trusts moved toward more U.S. equity (34 % vs 30 %) and less cash (13 % vs 18 %). The 2024 report added more granular fair‑value hierarchy disclosures (Level 1, 2, 3 amounts and a Level‑3 reconciliation), reiterated the discontinuation of securities‑lending, and clarified that the revised target allocations will become effective on January 1 2025.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer provides highly specific numerical data about asset allocations, portfolio targets, and detailed breakdowns by portfolio type (RC-BP, DELPP, VEBA) that cannot be verified against the ground truth provided. The ground truth explicitly states that 2023 reporting focused on 'investment objective' and 'target and actual asset allocations' for VEBA trusts, while 2024 introduced 'more detailed breakdown of how different subsidiaries were allocated' (Duke Energy Progress at 15%, Duke Energy Florida at 18%) and 'Level 3 fair value disclosures.' The LLM answer does mention Level 1, 2, 3 fair value hierarchy disclosures and Level 3 reconciliation for 2024, which aligns with the ground truth's mention of these enhanced disclosures. However, the LLM answer provides extensive specific percentages (45% global equity, 35% debt, etc. for RC-BP in 2023; shifts to 44%, 33%, 10%, 5% in 2024) that are not mentioned in the ground truth. Without access to the actual 10-K filings, these specific numbers cannot be verified and may be hallucinated. The LLM answer also mentions subsidiary allocations (Duke Energy Progress 15%, Duke Energy Florida 18%) which the ground truth identifies as 2024 additions, but the LLM doesn't clearly distinguish this as a 2024 evolution. The answer does capture the core evolution theme (more granular reporting, fair value hierarchy details, Level 3 reconciliation) but the overwhelming specificity of unverifiable numbers and the lack of clear attribution of which details are 2023 vs 2024 innovations creates significant credibility issues. The mention of 'discontinuation of securities-lending' and 'revised target allocations effective January 1 2025' cannot be verified against the ground truth. The answer reads as potentially fabricated detail rather than synthesized from actual filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1452,
        "completion_tokens": 498,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has Google's financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of the cost structure and payment obligations?",
      "original_answer": "In 2022, Google's cost of revenues included significant Traffic Acquisition Costs (TAC) paid to Google Network partners, primarily for ads displayed on their properties, with a noted higher cost percentage compared to Google Search properties due to the substantial share of advertiser revenues paid out as TAC. By 2024, Google Network partners were referenced in the context of operating cash outflows, indicating that payments to these partners had become a primary use of operating cash. This shift suggests a transformation in the nature of the financial relationship, from a cost-of-revenue model to a more direct operational cash flow obligation, reflecting a potential increase in the scale or structure of Google's dependency on these partners.",
      "llm_answer": "In the 2022 filing Alphabet explained that its cost of revenues is built around traffic‑acquisition costs (TAC) paid to distribution and Google Network partners, and that because most ad revenue on Network properties is passed through as TAC, the cost‑of‑revenues percentage for those ads is “significantly higher” than for Search & other ads【GOOGL_10k_2022.pdf pp. 30‑34】. The 2024 filing repeats this structure and shows that cash from operations is still used for “payments to distribution and Google Network partners,” indicating that the same TAC‑based payment obligation remains a core cash outflow and has risen with the growth of Network‑ad revenue【GOOGL_10k_2024.pdf pp. 40‑44】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about Google's evolving financial relationship with Network Partners between 2022 and 2024. STRENGTHS: (1) Correctly identifies TAC (Traffic Acquisition Costs) as the core payment mechanism in both years; (2) Accurately captures the key distinction that Network properties have 'significantly higher' cost-of-revenues percentages due to pass-through revenue sharing; (3) Properly synthesizes the evolution from cost-of-revenue accounting (2022) to operating cash flow obligations (2024); (4) Correctly cites both 2022 and 2024 10-K filings with appropriate page ranges; (5) Accurately notes that payments to Network partners remain a 'core cash outflow' that has 'risen with the growth of Network-ad revenue'; (6) Uses precise financial terminology and maintains semantic equivalence with ground truth. MINOR WEAKNESSES: (1) The LLM answer states the relationship 'remains' the same TAC-based structure rather than emphasizing the 'transformation' or 'shift' in how it's presented/categorized in the filings (cost-of-revenue vs. operating cash flow), though this is a subtle distinction in framing rather than factual error; (2) Could have been slightly more explicit about the shift from cost accounting to cash flow presentation as indicating a potential 'increase in scale or structure of dependency,' though the answer does note the rise with Network-ad revenue growth. QUANTITATIVE VERIFICATION: No specific dollar amounts are provided in either answer, which is appropriate given the question's focus on structural evolution rather than specific figures. The characterization of cost percentages as 'significantly higher' is accurate per ground truth. MULTI-HOP REASONING: The answer successfully synthesizes information across two different years and two different filing sections (cost of revenues vs. operating cash flows), demonstrating proper multi-hop reasoning. The logical connection between the 2022 cost structure and 2024 cash flow obligations is sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 556,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the treatment and financial impact of offsetting swap positions evolve between 2022 and 2023, particularly in terms of fair value changes and settlements reported in the consolidated income?",
      "original_answer": "In 2022, UPS reported fair value changes and settlements of interest rate swaps, foreign currency exchange forwards, and investment market price forward contracts not designated as hedges, with specific figures for 2021 and 2020 provided (e.g., $163M net gain in 2021 and $124M net gain in 2020). In 2023, the company continued to report these derivatives at fair value with unrealized gains and losses in earnings, but the disclosure now included data for 2023 and 2022, showing a shift in focus to more recent periods. The explicit mention of terminating contracts or entering into offsetting swap positions remained consistent, but the financial impact in 2023 was not quantified in the excerpt, indicating a change in transparency around current-year derivative impacts.",
      "llm_answer": "UPS kept its master‑netting arrangements but did not elect to offset the fair‑value of its derivative contracts on the balance sheet; the offsetting interest‑rate swaps produced a neutral effect – a $11 million gain on the hedged interest expense was exactly offset by an $11 million loss on the derivative in 2022, and there was no fair‑value gain or loss on those swaps in 2023. The settlement impact of non‑designated foreign‑currency forward contracts improved markedly, shrinking from a $69 million loss in 2022 to a $7 million loss in 2023, while cash‑flow hedge reclassifications to revenue fell from $304 million to $213 million.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and misalignments with the ground truth. (1) QUANTITATIVE ACCURACY ISSUES: The LLM provides specific numbers ($11M gain/loss offset, $69M loss in 2022 shrinking to $7M in 2023, $304M to $213M reclassifications) that are not mentioned in the ground truth excerpt. The ground truth references $163M net gain in 2021 and $124M net gain in 2020, but the LLM's specific 2022-2023 figures cannot be verified against the provided ground truth and appear to be fabricated or from different sections of the filing. (2) CONCEPTUAL MISALIGNMENT: The ground truth emphasizes that derivatives were NOT designated as hedges and were reported at fair value with unrealized gains/losses in earnings. The LLM incorrectly frames this as 'offsetting interest-rate swaps' producing a 'neutral effect' with specific gain/loss pairs, which misrepresents the accounting treatment. The ground truth indicates non-designated hedges, not offsetting positions that net to zero. (3) MISSING KEY INFORMATION: The ground truth highlights a shift in disclosure focus from 2021-2020 data to 2023-2022 data, indicating a change in transparency. The LLM completely misses this important evolution in reporting. (4) MULTI-HOP REASONING: The LLM fails to properly synthesize the evolution between years - it provides disconnected numbers without explaining the underlying accounting treatment changes or disclosure shifts that the ground truth emphasizes. (5) ENTITY/METRIC CONFUSION: While the LLM correctly identifies UPS and mentions derivatives, it conflates different types of derivatives (interest rate swaps vs. foreign currency forwards) and their treatments without proper distinction. The answer reads as if specific offsetting positions existed when the ground truth suggests broader derivative portfolios reported at fair value.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 502,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "What does the increased prominence of the Directors' Savings Plan in Duke Energy's 2024 disclosures indicate about the company's director compensation strategy compared to 2023?",
      "original_answer": "In 2023, the Directors' Savings Plan was referenced primarily through historical amendments listed in exhibit references (e.g., Exhibit 10.12), with no detailed description of its structure or strategic role in compensation. In contrast, the 2024 filing provides a substantive description of the plan, explaining how outside directors may defer annual compensation, the phantom investment options available, and how balances are adjusted accordingly. This increased prominence indicates a shift toward emphasizing the plan as a core component of director compensation and deferral flexibility, suggesting a more strategic and transparent approach to director-level financial incentives in 2024.",
      "llm_answer": "The 2024 filing devotes a full paragraph to the Directors’ Savings Plan, describing it as a non‑qualified deferred‑compensation vehicle that lets outside directors defer all or part of their retainers and earn “phantom” equity credits that are paid when their board service ends【2024‑p237】. By contrast, the 2023 filing only referenced the plan in a summary table (the “2023 Director Compensation Program Summary”) without any detailed description【2023‑p245】. This expanded disclosure signals that Duke Energy is now positioning the Directors’ Savings Plan as a more central, performance‑linked component of director pay, shifting emphasis from cash retainers toward deferred, long‑term incentives.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the core insight that the Directors' Savings Plan received increased prominence in 2024 compared to 2023, and correctly identifies the shift toward emphasizing deferred compensation and flexibility. However, there are several issues: (1) The LLM introduces specific page numbers (2024-p237, 2023-p245) that cannot be verified against the ground truth and may be hallucinated. (2) The LLM characterizes the plan as 'performance-linked' in the conclusion, which is not supported by either the ground truth or the LLM's own description - the ground truth emphasizes 'deferral flexibility' not performance linkage, and the LLM's own description focuses on phantom equity credits tied to board service duration, not performance metrics. This is a semantic error that mischaracterizes the plan's nature. (3) The LLM correctly identifies the key difference: 2023 had only summary table references while 2024 provided substantive description. (4) The LLM accurately describes the mechanics (non-qualified deferred compensation, phantom equity credits, payment upon board service end). (5) The phrase 'shifting emphasis from cash retainers toward deferred, long-term incentives' is reasonable inference but goes slightly beyond what the ground truth explicitly states, which focuses on 'transparency' and 'strategic approach' rather than a shift in emphasis. The answer is substantially correct on the main point but contains a notable characterization error (performance-linked) and unverifiable citations that reduce confidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 425,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has American Express's approach to developing value propositions evolved between 2022 and 2024, particularly in response to competitive pressures and changing customer behaviors?",
      "original_answer": "In 2022, American Express highlighted the challenge of developing compelling value propositions in the face of growing competition, particularly from alternative payment providers and digital wallets, which threatened to fragment customer spending and reduce the competitiveness of its offerings. The company emphasized the need to evolve its value propositions to retain relevance and attract customers amid rising Card Member rewards costs and shifting consumer preferences, especially in mobile and online payments. By 2024, the company's strategy had evolved to focus on expanding leadership in premium consumer and commercial payments, particularly targeting Millennial and Gen-Z consumers, and enhancing digital capabilities through investments in AI, automation, and the Amex app. It also emphasized the importance of strategic partnerships, dining platform expansion (including Tock and Rooam), and global merchant coverage growth as key enablers of its value proposition strategy. This represents a shift from a reactive stance on competition to a more proactive, innovation-driven approach.",
      "llm_answer": "In the 2022 filing, American Express stressed that it must “differentiate ourselves… develop compelling value propositions for our customers” and was already “evolving our value propositions, including in response to increased competition” – noting that rewards and service costs were rising as it refined those offers (2022 pp. 24‑28). By the 2024 filing, the company’s approach had shifted to explicitly building “premium value propositions” for younger cohorts, expanding digital and merchant‑acceptance capabilities, and investing in technology and partnerships to counter intensified competition and changing spending habits (2024 pp. 91‑95).",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of American Express's evolution in value proposition strategy between 2022 and 2024, with generally accurate factual content and appropriate multi-hop synthesis. STRENGTHS: (1) Correctly identifies the 2022 focus on differentiation and competitive pressures from alternative payment providers and digital wallets; (2) Accurately captures the shift toward premium value propositions targeting younger demographics (Millennials/Gen-Z) by 2024; (3) Properly synthesizes the evolution from reactive to proactive innovation-driven approach; (4) Appropriately references specific strategic initiatives (digital capabilities, technology investments, partnerships); (5) Page citations (2022 pp. 24-28, 2024 pp. 91-95) add credibility and specificity. WEAKNESSES: (1) Omits specific mention of key 2024 strategic initiatives mentioned in ground truth: Tock and Rooam dining platform expansion, and global merchant coverage growth - these are material details that demonstrate the company's concrete execution of its evolved strategy; (2) Does not explicitly mention Card Member rewards costs as a specific challenge in 2022, though this is implied in the discussion of rising costs; (3) Less detailed on the specific nature of competitive threats (alternative payment providers, digital wallets) compared to ground truth; (4) Does not emphasize the importance of strategic partnerships as explicitly as ground truth does. QUANTITATIVE ACCURACY: No numerical errors detected. Page references appear reasonable for 10-K filings. MULTI-HOP REASONING: Successfully synthesizes information across 2022 and 2024 filings to show evolution. Correctly identifies the temporal shift and underlying drivers. SEMANTIC EQUIVALENCE: The answer conveys the core message accurately - evolution from reactive competition response to proactive innovation strategy. The characterization of the shift is semantically equivalent to ground truth. The answer is substantially correct but loses points for incompleteness in specific strategic initiatives and slightly less comprehensive coverage of competitive dynamics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 572,
        "total_tokens": 2018
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Exxon Mobil's approach to long-term debt financing evolved between 2022 and 2024, particularly regarding the composition of its long-term notes?",
      "original_answer": "In 2022, Exxon Mobil disclosed a broader range of debt instruments, including the 0.142% Notes due 2024, 0.524% Notes due 2028, 0.835% Notes due 2032, and the 1.408% Notes due 2039. By 2024, the company no longer listed the 0.142% Notes due 2024, indicating that those obligations had matured or been repaid. However, the 1.408% Notes due 2039 remained in the disclosure, suggesting a continued emphasis on long-term financing instruments with distant maturity dates. This shift reflects a strategic evolution in the company's capital structure, focusing more heavily on extended-term debt while retiring shorter-duration obligations.",
      "llm_answer": "In the 2022 Form 10‑K, Exxon Mobil’s long‑term debt comprised four senior‑note series—0.142 % notes due 2024, 0.524 % notes due 2028, 0.835 % notes due 2032 and 1.408 % notes due 2039. By the 2024 filing, the 0.142 % notes that matured in 2024 had been retired, leaving only the 2028, 2032 and 2039 series (the same longer‑dated notes) on its balance sheet. This shift shows the company moving away from short‑term, ultra‑low‑coupon issuances and concentrating its financing on longer‑maturity notes.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about Exxon Mobil's debt financing evolution. QUANTITATIVE ACCURACY: All specific debt instruments and their interest rates are correctly identified (0.142%, 0.524%, 0.835%, 1.408%) with accurate maturity dates (2024, 2028, 2032, 2039). The numeric values match the ground truth exactly. ENTITY ACCURACY: Correctly identifies Exxon Mobil, the relevant fiscal years (2022 and 2024), and the specific financial instruments (senior notes). MULTI-HOP REASONING: The answer successfully synthesizes information across two time periods, correctly identifying that the 0.142% Notes due 2024 were retired between 2022 and 2024, while the longer-dated notes (2028, 2032, 2039) remained. The logical conclusion about the strategic shift toward longer-maturity debt is sound and well-supported. SEMANTIC EQUIVALENCE: The LLM's characterization of the shift as moving \"away from short-term, ultra-low-coupon issuances\" is semantically equivalent to the ground truth's description of \"retiring shorter-duration obligations\" and \"focusing more heavily on extended-term debt.\" MINOR OBSERVATION: The LLM answer is slightly more concise than the ground truth but captures all essential information. The phrase \"concentrating its financing on longer-maturity notes\" effectively conveys the strategic evolution described in the original answer. No factual errors, calculation errors, or omissions of material information were detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 420,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has American Express's approach to corporate card solutions evolved between 2022 and 2024, particularly in terms of strategic emphasis and product differentiation?",
      "original_answer": "In 2022, American Express emphasized evolving card value propositions and differentiating corporate card and accounts payable expense management solutions as part of its broader commercial payments strategy. By 2024, the company continued to focus on commercial payments but introduced a more integrated global network approach, aiming to increase merchant acceptance and provide enhanced fraud protection and marketing insights. This shift indicates a move from internal product development focus in 2022 to a more externally integrated ecosystem strategy by 2024.",
      "llm_answer": "In the 2022 10‑K, corporate‑card solutions were framed primarily as a pillar of “commercial payments,” with the strategy focused on “evolving our card value propositions, further differentiating our corporate card and accounts‑payable expense‑management solutions and designing innovative products and features, including financing, banking and payment solutions for our business customers” (2022 Business Strategies). By the 2024 filing the same differentiation goal is retained, but it is now positioned within a broader “global, integrated network” imperative, emphasizing expanded merchant acceptance, digital‑platform capabilities and the use of the network’s scale to deliver new financing, banking and payment innovations for corporate cards (2024 Business Strategies). This reflects a shift from a product‑centric focus to a more network‑centric, digitally integrated approach to corporate‑card differentiation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. (1) FACTUAL ACCURACY: The answer correctly identifies the 2022 emphasis on 'evolving card value propositions' and 'differentiating corporate card and accounts payable expense management solutions' - this matches the ground truth language precisely. The 2024 shift toward 'global, integrated network approach' with emphasis on merchant acceptance, fraud protection, and marketing insights is accurately captured. (2) QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are required for this qualitative question about strategic evolution, so this dimension scores perfectly. (3) ENTITY ACCURACY: American Express is correctly identified, years 2022 and 2024 are correct, and the relevant business segments (corporate cards, commercial payments, accounts payable) are all accurately referenced. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across two different filing years and correctly identifies the evolution pattern - from product-centric (2022) to network-centric (2024). The reasoning is sound and logically structured. (5) SEMANTIC EQUIVALENCE: The LLM answer goes beyond the ground truth by providing direct quotations from the 10-K filings ('commercial payments,' 'evolving our card value propositions,' 'global, integrated network'), which adds credibility and specificity. The characterization of the shift as 'product-centric focus to network-centric, digitally integrated approach' is semantically equivalent to and slightly more precise than the ground truth's 'internal product development focus to externally integrated ecosystem strategy.' The answer is comprehensive, well-structured, and accurately captures the strategic evolution requested. Minor deduction from perfect score only because the answer could have been slightly more explicit about the 'fraud protection and marketing insights' elements mentioned in the ground truth, though these are implicitly covered in the broader network strategy discussion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 557,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Amazon's financial relationship with AWS Services evolved between 2022 and 2024, particularly in terms of cash flow generation and strategic emphasis?",
      "original_answer": "In 2022, AWS Services were primarily discussed in the context of competitive pressures and risks, with an emphasis on the challenges of operating in a rapidly evolving and intensely competitive market. By 2024, AWS had transitioned into a key financial contributor, with Amazon reporting $115.9 billion in operating cash flow for that year, up from $84.9 billion in 2023, driven in part by AWS and other enterprise services. This reflects a shift from viewing AWS as a risk-laden venture to a core revenue generator funding broader corporate initiatives.",
      "llm_answer": "Amazon’s AWS business has become a larger cash‑flow driver and a more central growth priority.  In 2022 AWS generated roughly $62 billion of net sales – about 13 % of total revenue – and contributed to operating cash flow of about $46 billion, with technology‑infrastructure spending of roughly $44 billion (2022 10‑K, pp. 4‑8).  By 2024 AWS net sales rose to $107.6 billion (≈ 17 % of total) and the company’s operating cash flow jumped to $115.9 billion, while cash capital expenditures more than doubled to $77.7 billion, the majority earmarked for AWS‑related infrastructure (2024 10‑K, pp. 20‑24).  This reflects a clear shift toward a stronger cash‑flow contribution from AWS and an intensified strategic emphasis on expanding its cloud platform.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. STRENGTHS: (1) Correctly identifies AWS net sales of $62 billion in 2022 and $107.6 billion in 2024, showing significant growth; (2) Accurately cites Amazon's operating cash flow of $115.9 billion in 2024 (matching ground truth exactly); (3) Properly contextualizes the shift from 2022 (AWS as risk-laden) to 2024 (AWS as core revenue generator); (4) Includes relevant supporting details about capital expenditures ($44B in 2022, $77.7B in 2024) that strengthen the narrative; (5) Correctly calculates AWS as ~13% of revenue in 2022 and ~17% in 2024, showing strategic emphasis increase; (6) Effectively synthesizes information across multiple years and filing documents. MINOR ISSUES: (1) The LLM provides the 2024 operating cash flow ($115.9B) but doesn't explicitly cite the 2023 figure ($84.9B) mentioned in ground truth, though this is a minor omission since the question focuses on 2022-2024 evolution; (2) The LLM attributes the cash flow increase partly to AWS but doesn't explicitly state it was 'driven in part by AWS and other enterprise services' as the ground truth does—however, the LLM's framing of AWS as a 'larger cash-flow driver' conveys the same meaning; (3) Page citations (pp. 4-8, pp. 20-24) appear reasonable but cannot be independently verified. CALCULATION VERIFICATION: AWS revenue growth from $62B to $107.6B is mathematically sound; percentage calculations (13% and 17%) are approximately correct given total revenue context; capital expenditure doubling from ~$44B to $77.7B is accurate. MULTI-HOP REASONING: The answer successfully synthesizes AWS financial metrics across 2022 and 2024, connects them to broader corporate cash flow, and draws the correct conclusion about strategic shift. The reasoning is logical and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 503,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did the scope or focus of trend analyses used in evaluating the historical consistency of regulatory asset balances evolve between 2023 and 2024?",
      "original_answer": "In 2023, trend analyses were used to evaluate the historical consistency of regulatory asset balances in general, without specific reference to asset retirement obligations. By 2024, the scope of the trend analyses remained focused on regulatory asset balances, but the audit procedures expanded to include a specific evaluation of the ongoing regulatory recoverability of asset retirement obligations related to coal ash, indicating a shift in focus toward more specialized regulatory compliance areas.",
      "llm_answer": "In the 2023 filing the auditors simply noted that they “utilized trend analyses to evaluate the historical consistency of regulatory asset balances” (2023 p. 101). By the 2024 filing the same step appears, but it is now framed “to inform our understanding of the composition of the balances,” indicating that trend analysis was being used not only to test consistency but also to dissect the makeup of the regulatory‑asset balances (2024 p. 80). This reflects a shift from a purely consistency check to a broader, composition‑focused analysis.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors in its core interpretation of how the scope evolved. CRITICAL ISSUE: The ground truth states that by 2024, the scope expanded to include 'a specific evaluation of the ongoing regulatory recoverability of asset retirement obligations related to coal ash,' representing a shift toward more specialized regulatory compliance areas. The LLM answer instead claims the shift was from 'consistency check to composition-focused analysis,' which is a fundamentally different characterization of the evolution. The LLM appears to have misidentified what changed between the two years. QUANTITATIVE ACCURACY: The page references (2023 p. 101 and 2024 p. 80) cannot be verified against the ground truth, but the LLM does cite specific page numbers which shows attention to detail. However, the actual substantive change described is incorrect. QUALITATIVE ACCURACY: The LLM failed to identify the key evolution point - the introduction of asset retirement obligations (AROs) related to coal ash in 2024. This is a material omission that fundamentally misrepresents how the audit procedures evolved. The ground truth emphasizes a shift toward 'more specialized regulatory compliance areas' (coal ash AROs), while the LLM describes a shift toward 'composition-focused analysis,' which are not equivalent. MULTI-HOP REASONING: The LLM did not properly synthesize the multi-hop information about what specifically changed in the regulatory focus between years. CONTEXTUAL RELEVANCE: While the answer addresses trend analyses and regulatory asset balances, it misses the critical context about coal ash asset retirement obligations that defines the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 471,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did Costco's strategy regarding the penetration of private-label items evolve between 2022 and 2023 in response to cost and pricing pressures?",
      "original_answer": "In 2022, Costco responded to higher-than-recent inflation in merchandise costs by employing several strategies, including absorbing some cost increases internally, purchasing earlier and in larger volumes, and selectively passing on cost increases to members, all of which were aimed at maintaining pricing authority while managing gross margin pressures. In 2023, Costco continued to emphasize increasing the penetration of its private-label items as part of its broader merchandising and pricing strategy to adapt to ongoing cost increases and competitive pressures. This indicates a shift from a more reactive approach in 2022 to a more strategic and sustained emphasis on private-label offerings in 2023 to maintain competitive pricing and member value.",
      "llm_answer": "Costco said in its 2022 filing that, amid higher‑than‑usual inflation, it was “adjusting our pricing and merchandise mix, including increasing the penetration of our private‑label items” to help absorb cost pressures【COST_10k_2022.pdf†page 20】. In the 2023 filing the company reiterated the same tactic, noting that “adjustments to our pricing and merchandise mix, including increasing the penetration of our private‑label items” remain a key lever for responding to cost and pricing pressures【COST_10k_2023.pdf†page 21】. Thus, the strategy did not shift – Costco continued—and in 2023 reaffirmed—a focus on expanding private‑label penetration to mitigate cost pressures and preserve competitive pricing.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies that Costco mentioned private-label penetration as a strategy in both 2022 and 2023 filings, and the citations appear plausible. However, there is a critical disagreement with the ground truth regarding the nature of the strategic evolution. The ground truth explicitly states there was 'a shift from a more reactive approach in 2022 to a more strategic and sustained emphasis on private-label offerings in 2023,' characterizing this as an evolution in strategy. The LLM answer directly contradicts this, stating 'the strategy did not shift' and that Costco 'continued—and in 2023 reaffirmed—a focus.' This is a fundamental misinterpretation of the ground truth's core claim about strategic evolution. The ground truth indicates that while both years employed private-label strategies, the 2023 approach represented a more deliberate, sustained emphasis compared to the 2022 reactive measures (which also included absorbing costs internally and purchasing in larger volumes). The LLM failed to capture this nuanced distinction between a reactive tactic in 2022 versus a more strategic emphasis in 2023. The LLM's conclusion that 'the strategy did not shift' directly contradicts the ground truth's assertion of strategic evolution. While the LLM correctly identified the private-label component and the years involved, it missed the critical analytical point about how the strategy evolved—from one of multiple reactive approaches to a more focused strategic emphasis. The answer is partially correct on surface facts but fundamentally incorrect on the interpretation of strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 445,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the financial outlook for Paxlovid evolved between 2023 and 2024 based on Pfizer's remaining performance obligations?",
      "original_answer": "In 2023, Pfizer did not disclose specific remaining performance obligations for Paxlovid. However, by the end of 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a clear financial commitment from customers for future delivery of the product. This evolution suggests increased contractual certainty and forward-looking revenue expectations for Paxlovid between the two years.",
      "llm_answer": "By the end of 2023 Pfizer still had roughly $5.1 billion of deferred revenue for Paxlovid (and Comirnaty) – a large share of which was attributable to Paxlovid – indicating sizable future contract revenue. As of December 31 2024 the company reported remaining performance‑obligation revenue of only about $1 billion for Paxlovid, showing that the expected future cash‑flow from the drug has been cut dramatically as many of the contracted courses have already been delivered or reversed. (2023 10‑K deferred‑revenue table; 2024 10‑K “Remaining Performance Obligations” note).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant inaccuracies that contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURE: The LLM claims Pfizer had '$5.1 billion of deferred revenue for Paxlovid (and Comirnaty)' in 2023, but the ground truth explicitly states 'In 2023, Pfizer did not disclose specific remaining performance obligations for Paxlovid.' This is a fundamental contradiction - the LLM is citing a specific number ($5.1B) for 2023 when the ground truth indicates no such disclosure existed. (2) The LLM correctly identifies the 2024 figure of approximately $1 billion, which matches the ground truth. (3) REASONING ERROR: The LLM's interpretation that the decline from $5.1B to $1B represents 'dramatic' cuts in expected cash flow is problematic because: (a) the $5.1B figure appears to be combined deferred revenue for both Paxlovid AND Comirnaty, not Paxlovid alone, and (b) the ground truth does not support the existence of a comparable 2023 Paxlovid-specific figure. (4) MULTI-HOP SYNTHESIS FAILURE: The LLM failed to properly synthesize the key distinction that 2023 lacked specific Paxlovid RPO disclosures, while 2024 provided them. The ground truth emphasizes this evolution as 'increased contractual certainty' from lack of disclosure to clear disclosure, not a dramatic revenue decline. (5) The LLM's citation of '2023 10-K deferred-revenue table' and '2024 10-K Remaining Performance Obligations note' suggests source documentation, but the numbers cited do not align with what the ground truth indicates was actually disclosed. The answer demonstrates partial understanding of the question's intent but fails on factual accuracy regarding the 2023 baseline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 464,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has American Express's use and assumptions around the Reasonable and Supportable (R&S) Period evolved between 2022 and 2024 in estimating credit loss reserves, and what does this indicate about the company's approach to financial risk management?",
      "original_answer": "In 2022, American Express explicitly described its use of the R&S Period as a key component in estimating reserves for credit losses on Card Member loans, incorporating historical loss experience and current/future economic conditions over that period. The reserves stood at $3.3 billion as of December 31, 2021, and the R&S Period was a central assumption in modeling expected credit losses. By 2024, while the R&S Period was still referenced, it was no longer introduced as a newly explained concept and instead appeared embedded within a more mature and established process, indicating it had become a standard part of the company's financial risk modeling framework. This evolution suggests a shift from introducing the methodology (2022) to relying on it as a foundational element in credit loss estimation (2024).",
      "llm_answer": "American Express’s credit‑loss methodology still hinges on a “reasonable and supportable” (R&S) forward‑looking horizon that incorporates historical loss experience together with current and projected economic conditions, with losses beyond that horizon immediately reverting to long‑term average loss rates and with qualitative reserves added for any gaps in the models【AXP_10k_2022.pdf†page=93-96】. The 2024 filing repeats the same description and assumptions for the R&S period, showing no material change to the length or treatment of that horizon【AXP_10k_2024.pdf†page=96-99】. This continuity indicates that the company maintains a consistent, disciplined risk‑management framework that relies on a stable, forward‑looking estimate of credit risk while still allowing for qualitative adjustments when needed.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and fails to address key elements of the ground truth. CRITICAL ISSUES: (1) MISSING KEY QUANTITATIVE DATA: The ground truth explicitly states reserves were $3.3 billion as of December 31, 2021 - this specific number is completely absent from the LLM answer, which is a major omission for a financial question. (2) INCORRECT CHARACTERIZATION OF EVOLUTION: The ground truth describes a clear evolution from 2022 (R&S Period 'explicitly described' as 'newly explained') to 2024 (embedded in 'mature and established process'). The LLM answer claims 'no material change' and 'same description and assumptions,' which directly contradicts the ground truth's assertion of methodological evolution. (3) MISINTERPRETATION OF METHODOLOGY SHIFT: The ground truth emphasizes a shift from 'introducing the methodology' to 'relying on it as foundational' - a qualitative evolution in how the concept is presented and integrated. The LLM answer misses this entirely by focusing on consistency rather than evolution. (4) INCOMPLETE MULTI-HOP SYNTHESIS: The question asks about evolution 'between 2022 and 2024' - requiring comparison across years. The LLM answer states both years have identical treatment, failing to synthesize the temporal progression that the ground truth clearly identifies. (5) MISSING CONTEXTUAL INSIGHT: The ground truth provides interpretive insight ('indicates a shift from introducing the methodology to relying on it as foundational') that explains what the evolution means for risk management. The LLM answer provides generic statements about 'consistent, disciplined framework' without capturing the actual evolution. WHAT WAS CORRECT: The LLM correctly identifies that the R&S Period incorporates historical loss experience and current/projected economic conditions, and mentions qualitative reserves - these methodological details align with the ground truth. However, these correct elements are insufficient to overcome the fundamental mischaracterization of the evolution and missing quantitative data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 556,
        "total_tokens": 1990
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Amazon's approach to debt financing evolved between 2022 and 2024, particularly with respect to the 0.800% Note due 2025?",
      "original_answer": "In 2022, Amazon's filings referenced the 0.800% Note due 2025 as part of its broader debt structure, originally introduced in the Officers' Certificate dated June 3, 2020. By 2024, Amazon not only continued to reference the 0.800% Note due 2025 in its filings but also introduced new debt instruments with different interest rates and maturity dates, such as the 4.600% Note due 2025. This indicates a shift in Amazon's debt financing strategy, incorporating a wider range of interest rates and maturities to potentially manage cash flow and interest rate risk more effectively.",
      "llm_answer": "In the 2022 Form 10‑K Amazon’s debt schedule still included the low‑coupon 0.800% Note due 2025 (listed in Exhibit 4.6, the June 3 2020 Officers’ Certificate). By the 2024 Form 10‑K the same 0.800% note remains outstanding, but Amazon has supplemented its portfolio with newer, higher‑interest issuances – such as a 4.600% Note due 2025 and other higher‑rate notes in the supplemental indenture (Exhibit 4.8) – indicating a shift toward diversifying its financing and issuing debt at current market rates while still retaining the original low‑cost note.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of Amazon's debt financing evolution. STRENGTHS: (1) All numeric values are correct - 0.800% Note due 2025, 4.600% Note due 2025, and the dates (2022, 2024, June 3 2020) are accurate. (2) The multi-hop synthesis is sound: correctly identifies the same note appearing in both 2022 and 2024 filings, recognizes the introduction of new higher-rate instruments, and properly attributes these to specific exhibits (4.6 for Officers' Certificate, 4.8 for supplemental indenture). (3) The reasoning about strategic shift is well-articulated - the answer explains that Amazon retained the low-cost 0.800% note while adding higher-rate debt at current market rates, which aligns with the ground truth's characterization of managing cash flow and interest rate risk. (4) Entity identification is precise: correct company (Amazon), correct years (2022, 2024), correct financial instruments and their characteristics. (5) The semantic meaning matches the ground truth - both convey that Amazon's approach evolved to include a wider range of interest rates and maturities. MINOR CONSIDERATIONS: The LLM answer adds slightly more specific detail about exhibit references and the concept of 'supplemental indenture' which, while accurate and helpful, goes slightly beyond the ground truth's scope. However, this represents value-added context rather than error. The phrasing 'low-coupon' and 'low-cost' are semantically equivalent to the ground truth's characterization. No calculation errors, no factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 436,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the treatment or disclosure of the Twenty-third Supplemental Indenture evolved between the 2022 and 2024 SEC filings, and what does this indicate about its ongoing relevance or status?",
      "original_answer": "In the 2022 filing (DUK_10k_2022.pdf), the Twenty-third Supplemental Indenture was explicitly listed and dated June 1, 1978, incorporated by reference to Exhibit 2(c), File No. 2-61611. However, in the 2024 filing (DUK_10k_2024.pdf), there is no direct mention or continued reference to the Twenty-third Supplemental Indenture. Instead, the focus shifts to more recent supplemental indentures, such as the Forty-ninth Supplemental Indenture dated March 14, 2024. This indicates that the Twenty-third Supplemental Indenture was not reaffirmed or highlighted in the most recent disclosure, suggesting it may have diminished in operational or reporting significance over time.",
      "llm_answer": "Both the 2022 and 2024 10‑K filings list the “Twenty‑third Supplemental Indenture” as an exhibit incorporated by reference – the 2020‑dated amendment (4.1.23) is still cited to the May 15 2020 Form 8‑K (File No. 1‑32853) and the historic 1968 mortgage amendment (4.3.4) remains referenced to its original filing (File No. 2‑31304). The unchanged inclusion of these references in the later filing shows that the indenture has neither been terminated nor superseded and continues to be part of Duke Energy’s active debt documentation.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that directly contradict the ground truth: (1) DATE ERRORS: The LLM claims the Twenty-third Supplemental Indenture is dated June 1, 1978 in the original answer, but then states it's a '2020-dated amendment (4.1.23)' and references a 'May 15 2020 Form 8-K' - these dates are inconsistent and the ground truth specifies June 1, 1978. (2) CORE FACTUAL ERROR: The ground truth explicitly states the Twenty-third Supplemental Indenture has NO direct mention or continued reference in the 2024 filing, while the LLM claims it is 'still cited' and 'continues to be part of Duke Energy's active debt documentation' in both filings. This is a fundamental contradiction. (3) EXHIBIT REFERENCE ERROR: The LLM references exhibit numbers (4.1.23, 4.3.4) and file numbers (1-32853, 2-31304) that do not match the ground truth's reference to File No. 2-61611 and Exhibit 2(c). (4) INTERPRETATION ERROR: The LLM concludes the indenture 'continues to be part of Duke Energy's active debt documentation' based on unchanged references, but the ground truth indicates the opposite - that it was NOT reaffirmed in 2024 and has 'diminished in operational or reporting significance.' (5) MULTI-HOP SYNTHESIS FAILURE: The LLM failed to correctly synthesize the evolution between 2022 and 2024 filings. The ground truth shows a clear shift away from the Twenty-third Supplemental Indenture toward more recent ones (like the Forty-ninth from March 14, 2024), but the LLM misses this entirely. The answer demonstrates a fundamental misunderstanding of the question's core requirement: comparing how disclosure treatment changed between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 459,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the repurchase activity for Class C Capital Stock evolve from 2022 to 2024, and what was the total value of shares repurchased in each year?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023 the amount increased to $62.2 billion, and in 2024 it remained high at $62.0 billion. This demonstrates a consistent and significant level of share repurchase activity over the three-year period, with a slight peak in 2023 followed by a minor decline in 2024.",
      "llm_answer": "Alphabet repurchased $59.3 billion of Class A and Class C shares in 2022 (the Class C portion is not broken out) [GOOGL_10k_2024.pdf: pages 80‑84]. In 2023 it bought back 450 million Class C shares for $52.9 billion, and in 2024 it repurchased 306 million Class C shares for $50.2 billion, showing a modest decline in both the number of Class C shares and the dollar amount after 2023 [GOOGL_10k_2024.pdf: pages 80‑84].",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR DISCREPANCIES IDENTIFIED: The LLM answer contains significant factual errors that contradict the ground truth. (1) QUANTITATIVE ERRORS: The LLM reports 2023 Class C repurchases at $52.9 billion and 2024 at $50.2 billion, but the ground truth states total Class A and Class C repurchases were $62.2 billion in 2023 and $62.0 billion in 2024. The LLM's numbers are substantially lower (approximately $9-12 billion less per year). (2) INCOMPLETE SYNTHESIS: The LLM correctly identifies that 2022 data ($59.3 billion) combines Class A and Class C without breakdown, but then provides only Class C-specific numbers for 2023-2024 without explaining why the totals differ so dramatically from ground truth. The ground truth provides combined Class A and Class C figures for all three years ($59.3B, $62.2B, $62.0B), while the LLM provides only Class C figures for 2023-2024. (3) LOGICAL INCONSISTENCY: The LLM states it's showing \"a modest decline in both the number of Class C shares and the dollar amount after 2023,\" but this conclusion is based on incomplete/incorrect data that doesn't match the ground truth's consistent high-level repurchase activity. (4) MISSING CONTEXT: The LLM fails to provide the complete picture of total repurchase activity across both share classes for 2023-2024, making it impossible to assess the true evolution of repurchase activity as requested. The answer appears to have extracted Class C-only data rather than the combined Class A and Class C totals that constitute the actual repurchase program. This is a fundamental failure in multi-hop synthesis and data accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1192,
        "completion_tokens": 441,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "What changes occurred in the treatment and documentation of the American Express Company Salary/Bonus Deferral Plan between the 2022 and 2024 SEC filings?",
      "original_answer": "In the 2022 filing, the Salary/Bonus Deferral Plan was referenced through historical amendments, including Exhibit 10.16 (1988 plan) and Exhibit 10.17 (1994 amendment). The 2024 filing reintroduces the plan through Exhibit 10.13, referencing the same 1988 plan, and also includes Exhibit 10.14, which references the 1994 amendment. Notably, the 2024 filing adds Exhibit 10.16, which incorporates the 1997 amendments to the plan. This indicates that while the foundational documentation remained consistent, the 2024 filing expanded the disclosure to include a broader historical record of amendments, providing more context on the plan's evolution.",
      "llm_answer": "The 2022 filing listed the Salary/Bonus Deferral Plan as Exhibit 10.13 (incorporated by reference to Exhibit 10.20 of the 1988 10‑K), its 1994 amendment as Exhibit 10.14 (incorporated by reference to Exhibit 10.4 of a 1994 10‑Q), and a later amendment as Exhibit 10.16 (incorporated by reference to Exhibit 10.37 of the 1997 10‑K)【AXP_10k_2022.pdf†p163-L15-L23】. The 2024 filing shows the same three entries—Exhibit 10.13, 10.14 and 10.16 with identical reference documents—unchanged from 2022【AXP_10k_2024.pdf†p169-L15-L23】. Thus, there was no change in how the Salary/Bonus Deferral Plan was treated or documented between the two filings.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth. Key issues: (1) EXHIBIT NUMBERING ERROR: The LLM claims the 2022 filing listed the plan as Exhibit 10.13, 10.14, and 10.16, but the ground truth states the 2022 filing referenced Exhibit 10.16 (1988 plan) and Exhibit 10.17 (1994 amendment). The LLM has the wrong exhibit numbers for 2022. (2) MISSING 1997 AMENDMENTS: The ground truth explicitly states that the 2024 filing adds Exhibit 10.16 which incorporates the 1997 amendments - a key change between the two filings. The LLM completely misses this addition. (3) INCORRECT CONCLUSION: The LLM concludes 'there was no change' between 2022 and 2024, which directly contradicts the ground truth that states the 2024 filing 'expanded the disclosure to include a broader historical record of amendments.' (4) EXHIBIT MAPPING ERRORS: The LLM's specific exhibit references (10.13, 10.14, 10.16 for 2022) do not match the ground truth (10.16, 10.17 for 2022). (5) MULTI-HOP SYNTHESIS FAILURE: The LLM failed to properly synthesize the changes across the two filings and instead claimed no changes occurred. The core finding - that 2024 added the 1997 amendments documentation - is entirely absent from the LLM response. This is a critical factual error that undermines the entire answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 366,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has Starbucks' exposure to interest rate swaps evolved between 2022 and 2024, particularly in terms of their balance sheet classification and magnitude of liability?",
      "original_answer": "In 2022, Starbucks reported an interest rate swap liability of $34.0 million under 'Other long-term liabilities'. By 2024, the company's interest rate swap position had shifted significantly, with a liability of $19.2 million under 'Other long-term liabilities' and an additional $41.4 million liability from interest rate swaps reported for the prior year (2023), indicating a decrease in liability from the previous year but a continued significant exposure. This reflects a transformation in the company's interest rate swap position, with a shift in balance sheet classification and a notable reduction in total swap liability.",
      "llm_answer": "Starbucks’ interest‑rate‑swap exposure has been trimmed and its reporting line consolidated. In the 2022 filing the swaps were split between a $12 million accrued‑liability (“Interest rates”) and a $34 million “Interest‑rate‑swap” liability recorded in other long‑term liabilities (​SBUX 2022 10‑K p. 70) — about $46 million in total. By the 2024 filing the swaps appear only as a $19.2 million liability in other long‑term liabilities (​SBUX 2024 10‑K p. 73), showing both a re‑classification away from accrued liabilities and a roughly 55 % reduction in the recorded swap liability.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant inaccuracies that contradict the ground truth. (1) QUANTITATIVE ERRORS: The LLM claims a $12 million accrued liability in 2022 that is not mentioned in the ground truth. The ground truth clearly states 2022 had a $34.0 million liability under 'Other long-term liabilities' with no mention of a $12 million accrued liability component. The LLM's total of ~$46 million for 2022 is therefore incorrect. (2) INCOMPLETE 2024 DATA: The LLM only reports the $19.2 million 2024 liability but completely omits the $41.4 million liability from interest rate swaps reported for 2023 (prior year), which is explicitly mentioned in the ground truth as part of the 2024 filing. This is a critical omission that misrepresents the company's total exposure. (3) CALCULATION ERROR: The LLM calculates a 55% reduction from ~$46M to $19.2M, but this calculation is based on incorrect 2022 figures and ignores the $41.4M 2023 component in the 2024 filing. The actual comparison should account for all liabilities reported in each year's filing. (4) BALANCE SHEET CLASSIFICATION: While the LLM correctly identifies the shift to 'Other long-term liabilities' in 2024, it incorrectly claims a split between accrued liabilities and interest-rate swap liabilities in 2022 that the ground truth does not support. (5) MULTI-HOP SYNTHESIS: The LLM failed to properly synthesize the multi-year evolution, missing the 2023 comparative data that appears in the 2024 filing. The ground truth indicates a more complex picture with both 2023 and 2024 liabilities reported in the 2024 filing, which the LLM completely missed. The answer demonstrates partial understanding of the general trend (reduction in liability, reclassification) but contains fundamental factual errors in the specific numbers and composition of liabilities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 502,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the treatment of the Directors' Savings Plan evolved between 2022 and 2024, and what does this suggest about Duke Energy's approach to director compensation governance and deferral mechanisms?",
      "original_answer": "In 2022, the Directors' Savings Plan was formally introduced in the 10-K filing with a specific amendment dated December 16, 2021, indicating active documentation and policy updates around director deferrals. By 2024, the plan is referenced in the context of phantom investment options and deferred compensation mechanics, with an emphasis on unfunded accounts tied to the Duke Energy Common Stock Fund. This evolution suggests a shift from policy establishment to operational transparency, highlighting how deferrals are structured and invested, which may reflect a broader governance strategy to align director compensation with long-term shareholder interests and company stock performance.",
      "llm_answer": "The 2022 filing introduced the Directors’ Savings Plan as a non‑qualified, unfunded deferred‑compensation arrangement that had just been amended (effective December 16 2021) to let directors defer a portion of their annual retainers. By the 2024 filing the description was refined – directors may now defer all or part of their retainers, the deferred balance is credited with the performance of phantom investment options (including the Duke Energy Common Stock Fund), and the account is paid out when a director’s board term ends. This continuity, with added detail on phantom‑equity adjustments and termination‑based payouts, signals Duke Energy’s deliberate, creditor‑subordinate approach to governing director compensation and using deferral mechanisms to align director interests with long‑term company performance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. QUANTITATIVE ACCURACY (10/10): All dates are correct - the December 16, 2021 amendment date is accurately cited, and the 2022 vs 2024 comparison is properly framed. No numerical errors or calculation issues present. ENTITY ACCURACY: Duke Energy is correctly identified, the Directors' Savings Plan is properly named, and the phantom investment options and Duke Energy Common Stock Fund are accurately referenced. MULTI-HOP REASONING (9/10): The answer successfully synthesizes information across two filing years, correctly identifying the evolution from policy establishment (2022) to operational transparency (2024). The connection between the amendment date and the 2022 filing is properly established. The reasoning about alignment with long-term shareholder interests is sound and supported by the structural details provided. COMPLETENESS: The answer addresses all aspects of the question - the treatment evolution, governance implications, and deferral mechanisms. It provides specific details about what changed (from basic introduction to refined description with phantom-equity adjustments and termination-based payouts). SEMANTIC EQUIVALENCE: The LLM answer conveys the same core information as the ground truth but with enhanced specificity. It goes slightly beyond the ground truth by explicitly mentioning the non-qualified, unfunded nature and creditor-subordinate approach, which are reasonable inferences from the filing context. MINOR CONSIDERATIONS: The LLM answer is slightly more detailed and operational than the ground truth (e.g., specifying \"all or part of retainers\" and \"paid out when a director's board term ends\"), but these details are consistent with typical director deferral plan mechanics and enhance rather than contradict the ground truth. The characterization of the evolution as \"continuity with added detail\" is accurate and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 532,
        "total_tokens": 1924
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the positioning and associated risk profile of Costco's Kirkland Signature brand evolved between 2022 and 2023?",
      "original_answer": "In 2022, Costco emphasized the Kirkland Signature brand as a strategic asset, highlighting its high quality, competitive pricing, and contribution to higher margins. The company planned to continue increasing the sales penetration of these private-label items. However, by 2023, the risk disclosures included broader mentions of how supply chain disruptions, foreign exchange fluctuations, and catastrophic events could negatively impact the business—including private-label brands like Kirkland Signature. While the 2022 filing focused on growth and brand strength, the 2023 filing introduced a more risk-focused lens, indicating that the brand's expansion and reliance could expose Costco to greater operational and financial volatility.",
      "llm_answer": "In the 2022 Form 10‑K Costco positioned Kirkland Signature as a high‑quality, lower‑price private‑label that differentiates its merchandise, drives higher margins and is slated for greater sales penetration (2022 10‑K, “Intellectual Property” section, p. 8). By the 2023 filing the core positioning remained the same, but the company added an explicit risk factor noting that the brand’s reliance on third‑party manufacturers and any product‑quality, safety or supply‑chain issues could harm Kirkland’s reputation and materially affect Costco’s results (2023 10‑K, “Risk Factors” section, p. 16).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in addressing the evolution of Kirkland Signature's positioning between 2022 and 2023. STRENGTHS: (1) Correctly identifies the 2022 positioning as emphasizing high quality, competitive pricing, and higher margins with planned sales penetration growth. (2) Accurately captures the 2023 shift toward explicit risk disclosure, specifically mentioning third-party manufacturer reliance and product quality/safety/supply-chain concerns. (3) Properly synthesizes the multi-hop comparison across two fiscal years and two different disclosure sections (Intellectual Property vs. Risk Factors). (4) Cites specific document sections and page numbers, demonstrating source verification. (5) The core narrative matches the ground truth: 2022 focused on growth/strength, 2023 introduced risk-focused lens. MINOR GAPS: (1) The LLM answer does not explicitly mention supply chain disruptions, foreign exchange fluctuations, and catastrophic events as broader contextual risks mentioned in the 2023 filing—these were part of the ground truth's description of the 2023 risk profile evolution. (2) The phrase 'greater operational and financial volatility' from the ground truth is not explicitly stated, though the LLM's mention of 'materially affect Costco's results' conveys similar meaning. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts were required for this qualitative question, so this dimension scores high. QUALITATIVE ACCURACY: The reasoning is sound and the multi-hop synthesis is correct, though slightly less comprehensive than the ground truth in capturing all risk dimensions. CONTEXTUAL RELEVANCE: The answer directly and appropriately addresses the question about positioning evolution and risk profile changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 484,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve from 2022 to 2024, and what were the key changes in terms of volume and sources of additions?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. Over this period, the company experienced revisions and production activities that impacted reserves, with minimal extensions and discoveries contributing to the region. In 2024, there were no sales or significant reserve additions in this region, indicating a reduction in focus or activity compared to earlier years.",
      "llm_answer": "Asia Pacific/Middle East proved natural‑gas reserves slipped from 326 BCF at year‑end 2022 (322 BCF developed + 4 BCF undeveloped) to 296 BCF at year‑end 2024 (289 BCF developed + 7 BCF undeveloped), a drop of roughly 30 BCF. In 2022 the region saw large upward revisions from higher LNG‑spot prices, technical revisions and affiliate purchases plus Middle‑East extensions/discoveries, but in 2023‑24 net downward revisions driven by lower gas prices (≈288 BCF in 2023 and 81 BCF in 2024) and modest technical gains outweighed the limited extensions/discoveries, resulting in the overall decline.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM provides specific developed/undeveloped breakdowns (322/4 BCF in 2022, 289/7 BCF in 2024) that are NOT present in the ground truth, which only states total figures of 326 BCF and 296 BCF. These detailed breakdowns appear to be fabricated. (2) REVISION FIGURES - The LLM claims 'net downward revisions driven by lower gas prices (≈288 BCF in 2023 and 81 BCF in 2024)' but these numbers are unexplained and don't align with the ground truth narrative. The ground truth mentions 'revisions and production activities' but does NOT provide specific revision amounts or cite these exact figures. (3) MISSING CONTEXT - The LLM invents details about '2022 large upward revisions from higher LNG-spot prices, technical revisions and affiliate purchases' that are not mentioned in the ground truth. While the ground truth mentions 'minimal extensions and discoveries,' the LLM's characterization of 2022 as having 'large upward revisions' contradicts the overall narrative of decline. (4) CORRECT ELEMENTS - The core numbers (326 BCF in 2022, 296 BCF in 2024, ~30 BCF decline) are accurate. The general trend of decline is correct. The mention of minimal extensions/discoveries is aligned with ground truth. (5) MULTI-HOP REASONING - The LLM attempts to synthesize causes (price revisions, technical factors) but does so with invented specificity not supported by the source material. The ground truth is more cautious, stating 'revisions and production activities' without detailed attribution. The LLM's answer reads as more detailed but is actually less reliable due to unsupported claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 449,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has FedEx's strategic relationship with the Boeing 767F evolved between 2022 and 2024, particularly in terms of fleet ownership and modernization focus?",
      "original_answer": "In 2022, FedEx directly owned 114 Boeing 767F aircraft, indicating a significant owned asset position in its fleet strategy. By 2024, while no updated ownership figures were disclosed, FedEx emphasized the Boeing 767-300 Freighter (B767F) as a key component of its aircraft modernization programs. The company described these aircraft as significantly more fuel-efficient per unit than older models and noted that expenditures for these aircraft are necessary for long-term operating savings and fleet replacement, with limited flexibility to delay purchases without incurring significant costs.",
      "llm_answer": "In 2022 FedEx’s Boeing 767F fleet was largely a legacy asset – the company owned 114 767F freighters outright (no leased units) and had purchase commitments for additional 767Fs (up to 38 units through 2025)【FDX_10k_2022.pdf page 38‑40】. By the 2024 filing the strategy had shifted to a modernization program: FedEx now highlights the Boeing 767‑300F (B767F) as a key fuel‑efficient replacement for older aircraft, with 14 new 767Fs committed for delivery in 2025‑2026 and explicitly tied to its fleet‑renewal effort alongside new B777Fs【FDX_10k_2024.pdf page 117‑118】. This reflects a move from simply owning a large legacy fleet to actively renewing it with newer, more efficient 767‑300F aircraft.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides a reasonable narrative about FedEx's Boeing 767F strategy evolution, but contains several problematic elements: (1) QUANTITATIVE ISSUES: The ground truth states FedEx owned 114 Boeing 767F aircraft in 2022, which the LLM correctly cites. However, the LLM introduces specific numbers not in the ground truth (\"38 units through 2025,\" \"14 new 767Fs committed for delivery in 2025-2026\") without verification against the original answer. The ground truth explicitly states \"no updated ownership figures were disclosed\" for 2024, yet the LLM claims specific 2024 commitments. This represents unverified quantitative claims. (2) FACTUAL ACCURACY: The core 2022 figure (114 owned 767Fs) is correct. The characterization of the shift from legacy fleet to modernization is semantically aligned with the ground truth. However, the specific purchase commitments and delivery schedules cited are not present in the ground truth answer provided. (3) MULTI-HOP REASONING: The LLM successfully synthesizes the comparison between 2022 and 2024 positions, showing understanding of the strategic shift. The logic connecting owned fleet → modernization program is sound. (4) GROUND TRUTH ALIGNMENT: The original answer emphasizes that 2024 figures were not disclosed and focuses on FedEx's emphasis on fuel efficiency and modernization necessity. The LLM adds specific numbers for 2024 that go beyond what the ground truth confirms. (5) CITATION ISSUES: The LLM provides specific page citations that cannot be verified against the ground truth provided. The answer appears to extrapolate beyond confirmed data. The narrative quality is good, but the introduction of unverified quantitative claims reduces correctness despite strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 480,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did Starbucks' involvement with roasted coffee evolve from 2022 to 2024 in terms of inventory value and production infrastructure?",
      "original_answer": "In 2022, Starbucks reported an inventory value of roasted coffee at $310.3 million, reflecting its role in holding roasted coffee as part of its merchandise. By 2024, the company had expanded its infrastructure dedicated to roasting, with facilities in York, PA; Minden, NV (Carson Valley); Kunshan, China; and Kent, WA, indicating a significant increase in its direct involvement in the roasting process. This represents a shift from primarily holding roasted coffee inventory to actively producing and distributing it at scale.",
      "llm_answer": "In fiscal 2022 Starbucks held $310.3 million of roasted‑coffee inventory and reported $838.5 million of roasting equipment on its balance sheet [SBUX_10k_2022.pdf p.69][SBUX_10k_2022.pdf p.71]. By fiscal 2024 the filing emphasizes a sizable roasting network – four major roasting, warehousing and distribution sites in York, PA; Minden, NV; Kunshan, China; and Kent, WA – together providing roughly 4.2 million sq ft of capacity, indicating a continued (and possibly expanded) commitment to roasted‑coffee production [SBUX_10k_2024.pdf p.34].",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key metrics and entities. Strengths: (1) Correctly identifies the 2022 roasted coffee inventory value of $310.3 million, matching ground truth exactly. (2) Accurately names all four roasting facilities (York PA, Minden NV, Kunshan China, Kent WA) as stated in ground truth. (3) Properly identifies the fiscal years (2022 and 2024) and company (Starbucks). (4) Adds valuable context by including the $838.5 million roasting equipment figure and 4.2 million sq ft capacity metric, which enriches the answer beyond the ground truth baseline. (5) Multi-hop synthesis is sound - correctly connects inventory data from 2022 with infrastructure expansion by 2024. Minor considerations: (1) The ground truth emphasizes a 'shift from primarily holding roasted coffee inventory to actively producing and distributing it at scale,' while the LLM characterizes it as 'continued (and possibly expanded) commitment.' The LLM's language is slightly more cautious ('possibly expanded') versus the ground truth's more definitive 'significant increase.' This is a minor semantic difference that doesn't affect factual accuracy. (2) The LLM provides additional quantitative detail (equipment value, square footage) not in the ground truth, which adds value but wasn't explicitly required. The answer fully addresses the question's two-part structure (inventory value evolution and production infrastructure evolution) with accurate numbers and proper temporal comparison. No calculation errors detected. All entities correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 439,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has PepsiCo's utilization of the 2.750% Senior Notes due 2025 evolved between 2023 and 2024, based on the specific debt instruments referenced in the filings?",
      "original_answer": "In 2023, the 2.750% Senior Notes due 2025 were listed among other notes in a Board of Directors Resolutions document that authorized officers to establish terms for several senior notes, including the 2.750% Senior Notes due 2025. By 2024, PepsiCo not only retained the 2.750% Senior Notes due 2025 in its list of authorized instruments but also introduced a new 2.750% Senior Notes due 2030. This indicates that PepsiCo extended its debt strategy involving this interest rate to a longer-term horizon, signaling a strategic evolution in its financing approach.",
      "llm_answer": "The 2023 Form 10‑K lists a Board‑of‑Directors resolution (exhibit 4.64) that authorizes PepsiCo’s officers to establish the terms of “2.750 % Senior Notes due 2025,” but no issuance of those notes is shown in the filing. The 2024 Form 10‑K repeats the same resolution (exhibit 4.64) and still only references the notes as authorized, with no evidence that they have been issued or otherwise used. Thus, between 2023 and 2024 PepsiCo’s utilization of the 2.750 % Senior Notes due 2025 has remained unchanged – the instrument stays authorized but has not been drawn down.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains a fundamental misinterpretation of the question and contradicts the ground truth on a critical point. CRITICAL ERROR: The LLM claims the 2.750% Senior Notes due 2025 were never issued and remain only 'authorized but not drawn down,' whereas the ground truth explicitly states these notes were listed in 2023 and retained in 2024, with the strategic evolution being the introduction of a NEW 2.750% Senior Notes due 2030 in 2024. The LLM's conclusion that 'utilization...has remained unchanged' directly contradicts the ground truth's assertion of 'strategic evolution in its financing approach.' QUANTITATIVE ACCURACY: The LLM correctly identifies the interest rate (2.750%), the maturity year (2025), and the exhibit reference (4.64), earning points for numeric precision. However, these correct details are used to support an incorrect overall conclusion. QUALITATIVE ACCURACY: The LLM fails to recognize the multi-hop synthesis required: (1) identifying the 2.750% notes in 2023, (2) identifying their retention in 2024, (3) identifying the NEW 2.750% due 2030 introduced in 2024, and (4) synthesizing this as evidence of strategic evolution. Instead, the LLM focuses narrowly on whether notes were 'issued' versus 'authorized,' which appears to be a misunderstanding of what 'utilization' means in the context of authorized debt instruments. The ground truth indicates utilization evolved through the introduction of a longer-term variant, not through actual drawdown. CONTEXTUAL RELEVANCE: The answer addresses the wrong aspect of the question—focusing on issuance status rather than the evolution of the debt strategy and the introduction of the 2030 maturity variant. The LLM's interpretation of 'utilization' as actual issuance/drawdown appears incorrect given the ground truth's focus on authorized instruments and strategic extension to longer-term horizons.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 512,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did FedEx's planned utilization of the B777F aircraft change from 2022 to 2024, and what does this indicate about its strategic role in the fleet?",
      "original_answer": "In 2022, FedEx planned to operate 4 B777F aircraft in 2024 and 2 in 2025. By 2024, the updated plan showed 2 B777F aircraft operating in 2025, with no further plans beyond that year. This indicates a reduction in the strategic emphasis on the B777F fleet, moving from a gradually decreasing role to a complete phase-out, suggesting a shift in aircraft preference or operational strategy.",
      "llm_answer": "In the 2022 Form 10‑K FedEx said it would acquire eight Boeing 777 Freighters – 2 in 2023, 4 in 2024 and 2 in 2025 (see the aircraft‑commitment table)【FDX_10k_2022.pdf page 112‑113】. By the 2024 filing the schedule had been trimmed to only two B777F deliveries in 2025, with no further aircraft planned (see the updated delivery table)【FDX_10k_2024.pdf page 119】. This shift shows that the earlier B777F deliveries have been realized and the type is now a core, fuel‑efficient, long‑haul platform that underpins FedEx’s fleet‑modernization and capacity‑expansion strategy.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM answer provides different numbers than the ground truth. The LLM states FedEx planned to acquire 'eight Boeing 777 Freighters – 2 in 2023, 4 in 2024 and 2 in 2025' (totaling 8), but the ground truth only mentions 4 B777F aircraft planned for 2024 and 2 for 2025 in the 2022 filing (no mention of 2 in 2023 or 8 total). This is a significant factual discrepancy. (2) INTERPRETATION ERROR - The LLM misinterprets the strategic significance. The ground truth clearly states the change 'indicates a reduction in the strategic emphasis on the B777F fleet, moving from a gradually decreasing role to a complete phase-out.' However, the LLM concludes the opposite - that B777F is 'now a core, fuel-efficient, long-haul platform that underpins FedEx's fleet-modernization and capacity-expansion strategy.' This directly contradicts the ground truth's assessment that it represents a phase-out, not a core strategic platform. (3) MULTI-HOP REASONING - While the LLM correctly identifies the 2022 vs 2024 comparison and notes the reduction to 2 aircraft in 2025 with no further plans, it fundamentally misinterprets what this reduction means strategically. The ground truth indicates this is a de-emphasis/phase-out; the LLM claims it's a core platform. (4) COMPLETENESS - The LLM addresses the change from 2022 to 2024 but reaches an incorrect conclusion about strategic implications. The answer fails on the critical interpretive component of the question regarding what the change 'indicates about its strategic role.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 432,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did Starbucks' foreign currency - other derivative liabilities and their impact on net gains/(losses) included in AOCI evolve from 2022 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2022, Starbucks reported foreign currency - other derivative liabilities of $0.3 million under accrued liabilities, while in 2024, the net gains included in AOCI related to foreign currency - other were $11.5 million. This indicates a significant shift from a minimal liability position in 2022 to a more substantial unrealized gain in 2024, suggesting increased exposure to or hedging of foreign currency fluctuations.",
      "llm_answer": "Starbucks’ foreign‑currency‑other derivative liabilities grew from a trivial $0.3 million in FY 2022 to about $2 million in FY 2023 and roughly $9 million in FY 2024 (4.7 + 4.1 million) 【SBUX_10k_2022.pdf pp.66‑70】【SBUX_10k_2024.pdf pp.68‑72】, while the net gains from these hedges recorded in AOCI fell from $55.3 million in FY 2022 to $39.6 million in FY 2023 and $11.5 million in FY 2024 【SBUX_10k_2022.pdf pp.66‑70】【SBUX_10k_2024.pdf pp.68‑72】. This pattern of rising liability exposure and sharply declining hedge gains suggests that Starbucks’ exposure to foreign‑currency fluctuations has increased and the effectiveness of its hedging program has weakened, leaving earnings more vulnerable to currency swings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) QUANTITATIVE ERRORS - The LLM claims foreign currency derivative liabilities grew to ~$2M in 2023 and ~$9M in 2024, but the ground truth shows only $0.3M in 2022 with no comparable 2023/2024 liability figures provided. The LLM's calculation of '4.7 + 4.1 million = ~$9 million' appears to reference different line items not clearly identified. (2) AOCI GAINS DISCREPANCY - The LLM states AOCI gains were $55.3M (2022), $39.6M (2023), and $11.5M (2024). The ground truth only confirms $11.5M in 2024 and does not mention $55.3M or $39.6M figures for prior years. This is a critical factual error. (3) MULTI-HOP SYNTHESIS FAILURE - The LLM attempted to synthesize data across three fiscal years but appears to have conflated different metrics or misread source documents. The ground truth explicitly compares only 2022 ($0.3M liability) to 2024 ($11.5M AOCI gain), not intermediate 2023 data. (4) INTERPRETATION ISSUE - The LLM's conclusion about 'weakening hedging effectiveness' based on declining AOCI gains is speculative and not supported by the ground truth, which simply notes a shift from liability to gain position. (5) CORRECT ELEMENTS - The LLM correctly identified the 2024 AOCI figure of $11.5M and the 2022 liability of $0.3M, and appropriately addressed the question's focus on foreign currency exposure. However, the introduction of unverified 2023 data and incorrect prior-year AOCI figures severely undermines credibility. The answer demonstrates partial understanding but fails on factual accuracy, which is critical for financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 458,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has PepsiCo's engagement with the 2.625% Senior Notes due 2026 evolved between 2023 and 2024, particularly in terms of its broader debt instrument disclosures?",
      "original_answer": "In 2023, the 2.625% Senior Notes due 2026 were listed among other notes in a section that included Board of Directors Resolutions authorizing officers to establish terms for various senior notes. By 2024, PepsiCo not only retained the 2.625% Senior Notes due 2026 in its disclosures but also introduced a significantly expanded list of senior notes, including newer maturities such as the 3.000% Senior Notes due 2027 and the 2.625% Senior Notes due 2029. This indicates a broader and more diversified set of debt instruments, suggesting an active capital markets strategy involving the issuance of notes with different maturities and rates.",
      "llm_answer": "PepsiCo’s 2.625 % Senior Notes due 2026 were first disclosed in the 2023 Form 10‑K only as part of a single Board‑of‑Directors resolution that authorized a broad set of senior‑note issuances (Exhibit 4.64) 【PEP_10k_2023.pdf pp. 127‑131】. In the 2024 Form 10‑K the same note appears again in an updated Board resolution (Exhibit 4.64) 【PEP_10k_2024.pdf pp. 128‑132】, but the disclosure now lists additional 2026‑dated debt instruments – such as 2.850 % and 2.375 % Senior Notes, and 7.29 % and 7.44 % Senior Notes – and references new indenture agreements, indicating that PepsiCo’s debt program has broadened while the 2.625 % notes remain part of its ongoing financing strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates partial correctness with significant issues in quantitative accuracy. STRENGTHS: (1) Correctly identifies the 2.625% Senior Notes due 2026 as present in both 2023 and 2024 disclosures; (2) Accurately notes the expansion of debt instruments between years; (3) Properly identifies the multi-hop synthesis requirement across two fiscal years; (4) Correctly references Exhibit 4.64 and page ranges; (5) Appropriately contextualizes the notes within Board resolutions. CRITICAL WEAKNESSES: (1) The LLM introduces specific debt instruments (2.850%, 2.375%, 7.29%, 7.44% Senior Notes due 2026) that are NOT mentioned in the ground truth answer. The ground truth specifically identifies 3.000% Senior Notes due 2027 and 2.625% Senior Notes due 2029 as the new instruments introduced in 2024, NOT additional 2026-dated instruments; (2) This represents a factual error in identifying which new notes were added; (3) The ground truth emphasizes 'newer maturities' (2027, 2029) indicating different maturity dates, while the LLM incorrectly focuses on additional 2026-dated notes. REASONING ASSESSMENT: The multi-hop synthesis is structurally sound (comparing 2023 vs 2024 disclosures), but the specific factual content about which new instruments were introduced is incorrect. The LLM correctly identifies the evolution pattern (expansion of debt program) but misidentifies the specific instruments involved. This is a significant quantitative/factual error that undermines the answer's reliability, though the overall narrative structure and reasoning approach are appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 437,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Cisco's exposure to and reliance on overcoming technical hurdles evolved from 2022 to 2024, particularly in relation to its strategic investments and product development timelines?",
      "original_answer": "In 2022, Cisco acknowledged facing technical hurdles that could delay successful execution of its vision, especially in areas like product planning, timing, and resource allocation, which could lead to loss of market share and earnings. By 2024, the company's exposure to technical hurdles had transformed into a more specific dependency on overcoming these challenges in a timely manner to maintain competitive advantage, particularly in delivering complex software subscription offerings and introducing new technologies such as those related to artificial intelligence, security, observability, and cloud. The 2024 disclosures emphasize that failure to overcome these hurdles could not only result in loss of market share but also reputational damage, legal liability, and reduced customer retention. This represents a shift from internal execution risk to a broader operational and strategic dependency.",
      "llm_answer": "In the 2022 Form 10‑K Cisco warned that its ability to execute its vision was “highly dependent on overcoming technical hurdles in a timely fashion” – especially for new‑product planning, network‑programmability and other hardware‑centric innovations – and that any delay in those investments could erode market share. By the 2024 filing the company still flags technical‑hurdle risk, but the exposure has shifted to its expanding software‑subscription, AI, cloud and security portfolio (including the Splunk acquisition), and it now stresses that the benefits of these larger strategic investments may be delayed, keeping product‑development timelines a key source of risk.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution of Cisco's technical hurdle exposure from 2022 to 2024, with accurate identification of key shifts and strategic areas. Strengths: (1) Correctly identifies the 2022 focus on product planning, network-programmability, and hardware innovations; (2) Accurately notes the 2024 shift toward software-subscription, AI, cloud, and security portfolios; (3) Properly mentions the Splunk acquisition as a strategic investment; (4) Correctly characterizes the evolution from internal execution risk to broader operational concerns; (5) No quantitative errors or date inaccuracies. Weaknesses: (1) The LLM answer omits specific consequences mentioned in the ground truth, particularly the 2024 emphasis on reputational damage, legal liability, and reduced customer retention as potential outcomes; (2) Does not fully capture the breadth of the 2024 risk profile - the ground truth emphasizes that failure could result in multiple negative outcomes beyond just delayed benefits and market share loss; (3) The phrase 'keeping product-development timelines a key source of risk' is somewhat vague compared to the ground truth's more comprehensive characterization of the shift from internal execution risk to 'broader operational and strategic dependency.' The answer is semantically aligned with the ground truth's core message about the evolution of technical hurdle exposure, but lacks the completeness of consequences and strategic implications present in the original answer. The multi-hop reasoning is sound - the model correctly synthesized information about how Cisco's technical challenges evolved across the two-year period and connected them to strategic investments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 471,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the role of Google Ad Manager in driving Google Network revenues change between 2022 and 2023, based on the specific mentions of its performance and positioning across those years?",
      "original_answer": "In 2022, Google Ad Manager was explicitly cited as one of the key drivers behind the $8.6 billion year-over-year increase in Google Network revenues, alongside AdMob and AdSense. By 2023, while Google Ad Manager remained a core advertising platform used by customers, it was listed among several platforms (including Google Ads, Display & Video 360, and the Marketing Platform) without specific attribution to revenue growth. This indicates a shift from being a standout growth contributor in 2022 to being part of a broader suite of advertising tools in 2023, suggesting a more integrated but less singularly emphasized role.",
      "llm_answer": "In the 2022 Form 10‑K (pages 33‑37) Alphabet said that the rise in Google Network revenue was “primarily driven by strength in **AdMob, Google Ad Manager, and AdSense**,” explicitly crediting Ad Manager as a key growth engine. By contrast, the 2023 Form 10‑K (pages 55‑59) merely lists **Google Ad Manager** alongside AdMob and AdSense as part of the Google Network portfolio (“…participating in AdMob, AdSense, and Google Ad Manager”) without singling it out as a revenue driver, indicating its role shifted from a highlighted growth contributor to a standard component of the network offering.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the 2022 positioning where Google Ad Manager was explicitly cited as a key driver alongside AdMob and AdSense for the $8.6 billion year-over-year increase in Google Network revenues. (2) Accurately captures the 2023 shift where Ad Manager is listed as part of a broader portfolio without specific attribution to revenue growth. (3) Properly synthesizes the multi-hop comparison across two fiscal years, showing the transition from 'highlighted growth contributor' to 'standard component.' (4) Uses appropriate quotations from the 10-K filings (pages 33-37 for 2022, pages 55-59 for 2023) to support the analysis. (5) The reasoning is sound: the model correctly identifies that the change represents a shift in emphasis rather than a change in the product's existence or importance. MINOR CONSIDERATIONS: The LLM answer includes specific page references (33-37, 55-59) which add credibility but cannot be independently verified in this evaluation context. However, these references appear reasonable and don't contradict the ground truth. The semantic equivalence is excellent - both answers convey the same core insight about the role change from 'standout growth contributor' to 'part of broader suite.' The quantitative reference to the $8.6 billion increase is accurate. No calculation errors detected. All entities (Google Ad Manager, AdMob, AdSense, Google Network revenues, fiscal years 2022-2023) are correctly identified and properly synthesized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 434,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did Starbucks' derivative liabilities related to foreign currency - other evolve from 2022 to 2024, and what was the magnitude of change?",
      "original_answer": "In 2022, Starbucks reported derivative liabilities related to foreign currency - other at $0.3 million under accrued liabilities. By 2024, this amount had increased to $4.7 million under the same category. This indicates a significant increase in the company's liabilities tied to foreign currency derivatives over the two-year period.",
      "llm_answer": "Starbucks’ “foreign‑currency‑other” derivative liabilities were only $0.3 million in 2022 (accrued liabilities)【2022‑66】. By 2024 the same line showed $4.7 million of accrued liabilities and $4.1 million of other long‑term liabilities, or $8.8 million in total【2024‑70】. Thus the liability grew by about $8.5 million from 2022 to 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES: The LLM answer introduces significant factual errors that contradict the ground truth. (1) QUANTITATIVE ACCURACY PROBLEMS: The ground truth clearly states that in 2024, the derivative liability was $4.7 million under accrued liabilities only. The LLM incorrectly claims there was an additional $4.1 million in other long-term liabilities in 2024, totaling $8.8 million. This is factually wrong according to the ground truth. The LLM then calculates a change of $8.5 million ($8.8M - $0.3M), which is based on this incorrect total. The correct change should be $4.4 million ($4.7M - $0.3M). (2) MULTI-HOP REASONING: While the LLM correctly identified the 2022 figure ($0.3 million) and attempted to synthesize information across years, it failed to accurately report the 2024 composition. The ground truth does not mention a $4.1 million component in other long-term liabilities for 2024. (3) ENTITY AND METRIC ACCURACY: The LLM correctly identified Starbucks and the foreign currency derivative liability metric, but mischaracterized the balance sheet presentation in 2024. (4) CALCULATION ERROR: Even if the $8.8 million figure were correct, the calculation of change ($8.5 million) is arithmetically correct but based on false premises. The correct calculation should show a $4.4 million increase. The answer demonstrates partial understanding of the question structure but contains a fundamental factual error regarding the 2024 liability composition that undermines the entire response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1166,
        "completion_tokens": 415,
        "total_tokens": 1582
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has PepsiCo's issuance of the 4.600% Senior Notes due 2045 evolved between 2023 and 2024, and what does this indicate about the company's debt structure strategy?",
      "original_answer": "In 2023, the 4.600% Senior Notes due 2045 were listed among other senior notes in the Board of Directors Resolutions that authorized PepsiCo's officers to establish terms for various notes, including the 4.600% Senior Notes due 2045. By 2024, the 4.600% Senior Notes due 2045 remained part of the company's debt structure, but were now referenced alongside a broader range of newly introduced senior notes, such as the 4.000% Senior Notes due 2047 and Floating Rate Notes due 2026. This indicates that while the 4.600% Senior Notes due 2045 remained a part of PepsiCo's long-term debt strategy, the company expanded its debt portfolio with additional instruments, suggesting a more diversified approach to long-term financing in 2024.",
      "llm_answer": "PepsiCo’s 2023 Form 10‑K disclosed a board‑resolution authorizing the terms of a 4.600 % senior note due 2045 (see the “Board of Directors Resolutions … the 4.600 % Senior Notes due 2045” entry)【PEP_10k_2023.pdf p.127‑131】. The 2024 Form 10‑K repeats the same authorization for the 4.600 % senior notes due 2045 in its board‑resolution listing【PEP_10k_2024.pdf p.128‑132】. The continuity of this authorization shows PepsiCo is maintaining a pipeline of long‑dated, fixed‑rate debt, using the 4.600 % notes to lock in low borrowing costs and extend its maturity profile as a core element of its debt‑structure strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "ASSESSMENT: The LLM answer contains significant gaps in addressing the core question about how the 4.600% Senior Notes evolved between 2023 and 2024.\n\nCORRECT ELEMENTS:\n- Correctly identifies the 4.600% Senior Notes due 2045 in both 2023 and 2024\n- Correctly notes the notes appear in Board of Directors Resolutions in both years\n- Page references appear reasonable (127-131 for 2023, 128-132 for 2024)\n- Correctly identifies the interest rate (4.600%) and maturity year (2045)\n\nCRITICAL OMISSIONS:\n- The LLM answer focuses only on the continuity/authorization of the 4.600% notes themselves\n- FAILS to address the key evolution mentioned in the ground truth: the introduction of NEW senior notes in 2024 (4.000% Senior Notes due 2047 and Floating Rate Notes due 2026)\n- The ground truth explicitly states the company \"expanded its debt portfolio with additional instruments, suggesting a more diversified approach\" - this crucial insight about portfolio diversification is completely missing from the LLM answer\n- The LLM answer describes the strategy as maintaining a \"pipeline\" and \"locking in low borrowing costs\" but this is generic interpretation rather than addressing the actual evolution/change between years\n\nMULTI-HOP REASONING ISSUE:\n- The question asks about evolution \"between 2023 and 2024\" - implying change or development\n- The LLM answer emphasizes \"continuity\" and \"repeats the same authorization\" which actually contradicts the premise of evolution\n- The ground truth shows evolution through portfolio expansion (new instruments added), not just repetition of existing authorizations\n- The LLM failed to synthesize the comparative analysis across both years to identify what actually changed\n\nSEMANTIC MISMATCH:\n- Ground truth: \"expanded its debt portfolio with additional instruments\" (diversification strategy)\n- LLM answer: \"maintaining a pipeline\" and \"lock in low borrowing costs\" (maintenance strategy)\n- These convey different strategic implications\n\nCONCLUSION: While the LLM correctly identifies the 4.600% notes in both years, it fundamentally misses the key evolution - the introduction of new debt instruments alongside the existing notes. This represents incomplete multi-hop synthesis and failure to address the comparative evolution aspect of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 622,
        "total_tokens": 1965
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved between 2022 and 2024, and what does this indicate about its strategic focus in the region?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas in the Asia Pacific/Middle East region. By 2024, this figure had decreased slightly to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region over the two-year period. The decline, although modest, suggests a potential shift in strategic focus, possibly due to market dynamics or operational adjustments in the region.",
      "llm_answer": "COP’s proven natural‑gas reserves in the Asia Pacific/Middle East region have slipped modestly.  The “Developed + Undeveloped” total fell from ≈ 326 billion cubic feet (BCF) at the end of 2022 to ≈ 296 BCF at the end of 2024 for its consolidated operations, and the equity‑affiliate portion fell from about 3,974 BCF to 3,189 BCF over the same period【COP_10k_2024.pdf†page 144】.  At the same time the company notes only limited extensions, discoveries and affiliate purchases in the region, indicating a strategic emphasis on optimizing and modestly scaling its gas portfolio there rather than pursuing aggressive growth【COP_10k_2024.pdf†page 144】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and provides more comprehensive information than the ground truth. Verification of key claims: (1) Consolidated operations declined from ~326 BCF (2022) to ~296 BCF (2024) - matches ground truth exactly; (2) The LLM additionally reports equity-affiliate portion fell from ~3,974 BCF to ~3,189 BCF, which is supplementary detail not contradicted by ground truth; (3) Both answers correctly identify the decline as 'modest' or 'minor' (approximately 9% reduction in consolidated reserves). The LLM answer goes beyond the ground truth by: providing the equity-affiliate data, citing specific source documentation (page 144), and offering more nuanced strategic interpretation ('optimizing and modestly scaling' vs. 'potential shift'). The reasoning is sound - the LLM correctly synthesizes that limited extensions/discoveries indicate a strategic emphasis on optimization rather than aggressive expansion. Minor deduction only because the ground truth doesn't explicitly mention the equity-affiliate figures, though this represents additional accurate information rather than an error. The answer fully addresses both parts of the question: (1) how the position evolved (with specific numbers and timeframe), and (2) what this indicates about strategic focus (optimization emphasis). All numeric values are accurate, calculations are implicit but correct, and multi-hop synthesis across the 2022-2024 period is properly executed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 408,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Google Play's role in Google's non-advertising revenue strategy evolved from 2022 to 2023, based on the specific revenue sources mentioned in the filings?",
      "original_answer": "In 2022, Google Play was specifically mentioned as generating revenues from 'sales of apps and in-app purchases and digital content sold in the Google Play store.' By 2023, Google Play's revenue focus had evolved to be more narrowly described as primarily coming from 'apps and in-app purchases,' and it was grouped under the broader category of 'platforms' within non-advertising revenue sources. This indicates a shift in emphasis toward core app-based monetization within Google's strategic narrative around Play.",
      "llm_answer": "In the 2022 Form 10‑K, Google Play was highlighted as a distinct non‑advertising revenue line, explicitly noted for “sales of apps, in‑app purchases **and digital content** sold in the Google Play store.” By the 2023 filing, Play is no longer called out as a separate line but is grouped under the broader “platforms” category, described as generating revenue mainly from “sales of apps and in‑app purchases,” showing that its role has shifted from a standalone revenue source to a component of an integrated platform‑driven non‑advertising strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-aligned with the ground truth. Strengths: (1) Correctly identifies the 2022 description of Google Play revenue sources as 'sales of apps, in-app purchases and digital content sold in the Google Play store' - matches ground truth exactly; (2) Accurately captures the 2023 shift to narrower focus on 'apps and in-app purchases' without the digital content emphasis; (3) Properly synthesizes the multi-hop evolution showing Google Play moved from a distinct line item to being grouped under 'platforms' category; (4) Correctly identifies this as a strategic shift in how Google presents Play's role within non-advertising revenue; (5) No quantitative errors or date inaccuracies. Minor considerations: The LLM answer uses slightly more elaborate phrasing ('no longer called out as a separate line but is grouped under') compared to the ground truth's 'grouped under the broader category of platforms,' but this is semantically equivalent and actually provides helpful clarification. The LLM also adds the phrase 'integrated platform-driven non-advertising strategy' which is a reasonable inference from the data but goes slightly beyond what the ground truth explicitly states. However, this addition is contextually appropriate and doesn't contradict the ground truth. The answer demonstrates sound multi-hop reasoning by correctly connecting: (a) the specific revenue descriptions from each year, (b) the organizational change in how Play is categorized, and (c) the strategic implications of this shift. All factual claims are verifiable and accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 438,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has the projected utilization of the Cessna SkyCourier 408 evolved from 2022 to 2024, and what does this indicate about FedEx's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FedEx projected the Cessna SkyCourier 408 to have a total of 49 aircraft in operation across the years 2023 to thereafter. By 2024, this projection was reduced to a total of 31 aircraft for the years 2025 through 2029. However, in the 2024 report, the relationship to the Cessna SkyCourier 408 shifted from 'Increases' to 'Depends_On', indicating a change in strategic importance. This suggests a moderated but still significant reliance on the aircraft model over time.",
      "llm_answer": "In the 2022 filing FedEx said it expected to take delivery of 49 Cessna SkyCourier 408s – 11 in 2023, 12 in 2024, 12 in 2025 and 14 in 2026 【FDX_10k_2022.pdf:112】. By the 2024 filing the commitment had been revised to 31 aircraft – 17 slated for 2025 and 14 for 2026 【FDX_10k_2024.pdf:115】. This reduction shows FedEx has scaled back the original rollout but still relies on the SkyCourier as a strategic, albeit smaller‑scale, component of its regional network.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the overall trend (reduction from 49 to 31 aircraft) and provides specific year-by-year delivery schedules, which adds helpful detail. However, there are significant quantitative discrepancies that undermine accuracy: (1) The ground truth states 2022 projections were for 'years 2023 to thereafter' totaling 49 aircraft, but the LLM breaks this into specific years (11 in 2023, 12 in 2024, 12 in 2025, 14 in 2026) which sum to 49 - this appears to be adding detail not explicitly confirmed in the ground truth. (2) The 2024 projection is stated as 31 aircraft with 17 for 2025 and 14 for 2026 (totaling 31), but the ground truth says '2025 through 2029' without specifying the year-by-year breakdown provided by the LLM. The LLM may be providing accurate filing details, but these specific annual allocations are not confirmed in the ground truth. (3) Most critically, the LLM answer completely omits the important strategic shift noted in the ground truth: the relationship changed from 'Increases' to 'Depends_On', which is a meaningful indicator of changing strategic importance. The LLM does acknowledge 'scaled back' and 'smaller-scale' reliance, which captures some of this sentiment, but misses the specific relationship classification change. The reasoning about strategic reliance is sound and the overall narrative is correct, but the omission of the relationship shift and the unverified year-by-year breakdowns represent material gaps in accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 412,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of segmentation and the types of casualty lines analyzed?",
      "original_answer": "In 2022, AIG used expected loss ratio methods primarily for the three latest accident years in the U.S. Excess Casualty line, segmenting analysis by attachment point and further differentiating between automobile and non-automobile claims, including special treatment for latent exposures like construction defects and mass torts. In 2023, AIG continued to apply expected loss ratio methods but shifted focus to U.S. Workers' Compensation, where the company grouped business by risk-sharing features such as high deductibles and retrospective rating, and analyzed separately by state, industry, and claim handling entity. The increase in large deductible business also affected the reporting pattern of claims, indicating a broader application context for the method. This reflects a strategic evolution in where and how expected loss ratio methods are applied across different casualty lines.",
      "llm_answer": "In the 2022 filing (see U.S. Excess Casualty “Reserving Process and Methodology” on pages 262‑263), AIG applied expected‑loss‑ratio techniques only to the three most recent accident years and did so after first splitting the business into automobile‑related versus non‑automobile claims, then further breaking out latent exposures such as construction‑defect and mass‑tort claims and finally analyzing each segment by attachment‑point bands (capped at $10 million and then extrapolated). By contrast, the 2023 filing (see the “Reserving Process and Methodology” section on pages 200‑202) describes expected‑loss‑ratio methods in a more generic way—multiplying premiums by an adjusted loss ratio for excess‑of‑deductible business and weighting the five most recent accident years—without calling out the same automobile/non‑automobile or mass‑tort segmentation. Thus, AIG’s approach has shifted from a detailed, claim‑type‑segmented analysis in 2022 to a broader, line‑wide application in 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key elements of the evolution but contains significant omissions and mischaracterizations that reduce its accuracy. STRENGTHS: (1) Correctly identifies 2022 focus on U.S. Excess Casualty with three latest accident years; (2) Accurately describes 2022 segmentation by automobile vs. non-automobile claims and latent exposures (construction defects, mass torts); (3) Correctly notes attachment point analysis in 2022; (4) Properly identifies shift to different line in 2023; (5) Page references appear reasonable. CRITICAL WEAKNESSES: (1) The LLM characterizes 2023 as applying expected loss ratio methods 'in a more generic way' and 'without calling out the same automobile/non-automobile or mass-tort segmentation,' but the ground truth explicitly states AIG 'continued to apply expected loss ratio methods' to U.S. Workers' Compensation with specific segmentation by 'risk-sharing features such as high deductibles and retrospective rating' and analysis 'by state, industry, and claim handling entity.' The LLM misses this critical detail about 2023 segmentation entirely. (2) The LLM fails to identify that the 2023 shift was to U.S. Workers' Compensation specifically, instead vaguely referring to 'line-wide application.' (3) The LLM mentions 'five most recent accident years' for 2023 but the ground truth does not specify this detail, and the LLM provides no context about the Workers' Compensation focus. (4) The LLM's characterization of 2023 as 'more generic' contradicts the ground truth's description of continued detailed segmentation by risk-sharing features, state, industry, and claim handling entity. MULTI-HOP REASONING: The LLM attempts to synthesize across 2022 and 2023 filings but fails to properly identify the key evolution—not just a shift from detailed to generic, but a strategic shift from Excess Casualty to Workers' Compensation with different but equally detailed segmentation approaches. The answer presents an incomplete and somewhat misleading narrative of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1474,
        "completion_tokens": 547,
        "total_tokens": 2022
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the classification and reporting of unallocated products evolve between fiscal years 2022 and 2024, particularly in terms of how they are categorized within Nike's consumer construct?",
      "original_answer": "In fiscal year 2022, unisex products were classified within Men's, and certain products not allocated to Men's, Women's, NIKE Kids', and Jordan Brand were included in 'Others' with adjustments not allocated by consumer. By fiscal year 2024, 'Others' continued to include products not allocated to Men's, Women's, Kids', and Jordan Brand, but there was no specific mention of unisex product classification within Men's, suggesting a potential shift or integration of unisex products within broader categories.",
      "llm_answer": "In FY 2022 Nike reported unallocated products under the line‑item “Others,” which the footnote (see 2022 10‑K p. 34) defined as “products not allocated to Men’s, Women’s, NIKE Kids’ and Jordan Brand” (and related adjustments). By FY 2024 the same “Others” line continued to capture unallocated items, now described (see 2024 10‑K p. 36) as “products not allocated to Men’s, Women’s, Kids’ and Jordan Brand” – a consistent placement within the consumer construct with only a minor wording change.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies that both FY 2022 and FY 2024 used an 'Others' category for unallocated products. (2) The page references (2022 10-K p. 34 and 2024 10-K p. 36) are appropriately cited. (3) The LLM accurately notes the minor wording change from 'NIKE Kids'' to 'Kids'' between years. (4) The characterization of consistent placement within the consumer construct is reasonable. WEAKNESSES: (1) CRITICAL OMISSION: The ground truth explicitly states that in FY 2022, 'unisex products were classified within Men's' - this is a significant detail about how unisex products were specifically handled that the LLM completely fails to mention. (2) The ground truth notes a 'potential shift or integration of unisex products within broader categories' by FY 2024, suggesting the classification of unisex products may have changed between years. The LLM's conclusion that there was 'only a minor wording change' and 'consistent placement' misses this nuance about unisex product reclassification. (3) The LLM characterizes the evolution as merely a 'minor wording change' when the ground truth suggests a more substantive shift in how unisex products were categorized. MULTI-HOP REASONING: The LLM successfully synthesizes information across two fiscal years but fails to capture the complete picture of how unisex products specifically evolved. The answer addresses the 'Others' category evolution but incompletely addresses the broader consumer construct evolution regarding unisex products. SEMANTIC ACCURACY: While the LLM's statement about 'Others' is accurate, it represents only partial fulfillment of the question's scope regarding unisex product classification evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 463,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did PepsiCo's engagement with the 3.500% Senior Notes due 2025 evolve between 2023 and 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2023, PepsiCo's 3.500% Senior Notes due 2025 were listed among other notes, indicating they were part of the company's existing debt structure. By 2024, the 3.500% Senior Notes due 2025 were still present, but they were now accompanied by a broader range of new notes, including longer-term instruments such as the 3.500% Senior Notes due 2040 and the 3.550% Senior Notes due 2034. This suggests that PepsiCo expanded its debt portfolio in 2024, introducing more long-term financing options while maintaining its commitment to the 3.500% Senior Notes due 2025. The addition of new notes indicates a strategic shift toward diversifying its debt maturity structure.",
      "llm_answer": "In the 2023 Form 10‑K PepsiCo’s note schedule only listed a 3.500 % senior note maturing in 2040 (see Exhibit 4.39) and made no reference to a 3.500 % series due 2025. By the 2024 Form 10‑K the board had approved the issuance of new 3.500 % senior notes due 2025 (see Exhibit 4.64), indicating that PepsiCo moved from having no such instrument to actively raising medium‑term debt at a modest coupon— a sign that it is using new issuances to refinance or extend its debt profile and manage maturities in a disciplined manner.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains fundamental factual errors that directly contradict the ground truth. (1) CRITICAL ERROR - Entity/Fact Contradiction: The LLM claims that in 2023, PepsiCo's note schedule 'only listed a 3.500% senior note maturing in 2040' and 'made no reference to a 3.500% series due 2025.' However, the ground truth explicitly states that in 2023, the 3.500% Senior Notes due 2025 'were listed among other notes, indicating they were part of the company's existing debt structure.' This is a direct contradiction on a core factual claim. (2) CRITICAL ERROR - Temporal Misrepresentation: The LLM states that 'by the 2024 Form 10-K the board had approved the issuance of new 3.500% senior notes due 2025,' implying these were newly issued in 2024. The ground truth indicates these notes existed in 2023 and continued into 2024, not that they were newly created in 2024. (3) INCOMPLETE SYNTHESIS: The LLM fails to address the key evolution described in the ground truth - that PepsiCo added NEW longer-term instruments (3.500% due 2040 and 3.550% due 2034) in 2024 while maintaining the 2025 notes. The LLM incorrectly suggests the 2040 notes existed in 2023. (4) REASONING FLAW: The LLM's conclusion about 'moving from having no such instrument to actively raising medium-term debt' is based on the false premise that the 2025 notes didn't exist in 2023. The actual strategy (diversifying maturity structure by adding longer-term options) is missed. (5) CONTEXTUAL ISSUE: While the LLM does attempt to address debt management strategy, it does so based on incorrect facts, making the strategic analysis unreliable. The ground truth's insight about 'strategic shift toward diversifying its debt maturity structure' is not captured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 473,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did COP's financial disclosures regarding the Lower 48 region evolve between 2022 and 2024, particularly in terms of capital expenditures and future cash inflow revisions?",
      "original_answer": "In 2022, COP reported capital expenditures for the Lower 48 region at $3,129 million, indicating significant active investment in the area. By 2024, the company disclosed that certain amounts in the Lower 48 had been revised to reflect additional future cash inflows and future production costs, although no new capital expenditure figure was provided. This shift suggests a transition from active investment to a focus on revising financial projections based on updated expectations for production and cost dynamics in the region.",
      "llm_answer": "In the 2022 Form 10‑K ConocoPhillips reported that the Lower 48 segment incurred **$3.1 billion of capital expenditures** and it projected **future cash inflows of $195.6 billion** for that region. By the 2024 filing the company had moved to a “capitalized‑costs” presentation, showing **proved property of $88.5 billion and unproved property of $13.9 billion** for the Lower 48 (instead of a single annual cap‑ex line), and it **re‑estimated the Lower 48’s future cash inflows at $164.3 billion**—a reduction from the 2022 $195.6 billion figure after a 2023 dip to $141.3 billion. This reflects both a change in how cap‑ex is disclosed and a downward revision of expected cash‑flow generation for the Lower 48 region.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and introduces information not supported by the ground truth. CRITICAL ISSUES: (1) The 2022 capital expenditure figure of $3.1 billion is approximately correct (ground truth states $3,129 million = $3.129 billion), but the LLM adds unsupported future cash inflow figures ($195.6 billion for 2022, $141.3 billion for 2023, $164.3 billion for 2024) that do not appear in the ground truth. (2) The ground truth explicitly states 'no new capital expenditure figure was provided' in 2024, yet the LLM claims the company shifted to a 'capitalized-costs presentation' with specific property values ($88.5 billion proved, $13.9 billion unproved) - these figures are not mentioned in the ground truth and appear to be fabricated or from a different context. (3) The ground truth indicates a shift from 'active investment to a focus on revising financial projections,' but the LLM mischaracterizes this as a change in disclosure methodology and adds unsupported cash flow revision data. (4) The LLM's narrative about a 2023 dip and subsequent 2024 revision is entirely absent from the ground truth, suggesting the model hallucinated multi-year trend data. (5) The ground truth's core finding - that 2024 disclosures reflected 'additional future cash inflows and future production costs' without new capex figures - is not accurately captured by the LLM's presentation. The LLM demonstrates poor multi-hop synthesis by introducing quantitative claims without source verification and fundamentally misrepresenting the nature of the disclosure evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 444,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did Comcast's financial commitments and governance arrangements with Atairos Group evolve between 2023 and 2024, particularly regarding capital obligations and control structures?",
      "original_answer": "In 2023, Comcast had a Fourth Amended and Restated Shareholders Agreement with Atairos Group, Inc., which was further amended in June 2023. This agreement outlined Comcast's role as the sole third-party investor and included governance terms among Atairos-related entities. By 2024, the relationship evolved into a more formalized investment framework under the equity method accounting. In this framework, Comcast reduced its capital commitment from up to $5 billion to $4.5 billion, limited annual capital calls to $400 million, and agreed to separately fund $40 million annually for management fees. Additionally, the 2024 filing clarified that Comcast absorbs approximately 99% of Atairos’ losses and receives approximately 86% of residual returns, while Atairos’ management companies (led by Comcast’s former CFO) retained all voting rights. These changes reflect a recalibration of financial exposure and a clearer delineation of control.",
      "llm_answer": "In 2023 Comcast’s agreement with Atairos limited its funding commitment to up to $4.5 billion in aggregate (with a $400 million annual‑call ceiling and a $40 million annual management‑fee commitment) and the company held a $5.5 billion equity‑method investment, having contributed $145 million in cash that year and retaining roughly $1.6 billion of unfunded capital [2024 p. 82‑86]. By year‑end 2024 the same contractual limits remained, but the actual unfunded commitment fell to $1.4 billion, cash contributions dropped to $73 million and the investment balance declined to $5.1 billion [2024 p. 82‑86]. Throughout both years Atairos was controlled by management companies led by the former CFO (who hold all voting rights), while Comcast retained no voting rights—only limited consent rights—so it treats Atairos as a VIE and does not consolidate it [2024 p. 82‑86].",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth:\n\n1. CAPITAL COMMITMENT EVOLUTION - MAJOR ERROR: The ground truth explicitly states that Comcast REDUCED its capital commitment from $5 billion (2023) to $4.5 billion (2024). The LLM answer incorrectly claims the $4.5 billion limit existed in 2023 and remained the same through 2024, completely missing the key evolution of the relationship. This is a fundamental misunderstanding of how the financial commitments changed.\n\n2. MISSING CRITICAL FINANCIAL METRICS: The ground truth specifies that by 2024, Comcast absorbs approximately 99% of Atairos' losses and receives approximately 86% of residual returns. The LLM answer completely omits these crucial economic terms that define the investment structure and risk allocation.\n\n3. GOVERNANCE CONTROL ACCURACY: The LLM correctly identifies that Atairos' management companies (led by Comcast's former CFO) retained all voting rights and Comcast retained no voting rights, and correctly notes VIE treatment. This portion is accurate.\n\n4. OPERATIONAL METRICS - PARTIALLY CORRECT: The LLM provides specific numbers for 2024 (unfunded commitment of $1.4 billion, $73 million cash contributions, $5.1 billion investment balance) and 2023 ($5.5 billion equity-method investment, $145 million cash contributions, $1.6 billion unfunded capital). While these appear internally consistent with the filing references cited, they are not verified against the ground truth and represent operational details rather than the strategic evolution described in the original answer.\n\n5. STRUCTURAL EVOLUTION MISSING: The ground truth emphasizes this was a shift to \"a more formalized investment framework under the equity method accounting\" with a \"recalibration of financial exposure and a clearer delineation of control.\" The LLM answer treats 2023 and 2024 as largely static (\"the same contractual limits remained\"), missing the evolutionary narrative that is central to the question.\n\n6. AMENDMENT TIMING: The ground truth mentions a June 2023 amendment to the Fourth Amended and Restated Shareholders Agreement. The LLM answer does not reference this amendment or explain how it relates to the 2024 changes.\n\nThe LLM answer demonstrates some knowledge of the filing details but fundamentally mischaracterizes the evolution of the relationship by claiming stability where the ground truth shows significant change in capital commitments and by omitting the critical economic terms (99% losses, 86% returns) that define the investment structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1462,
        "completion_tokens": 693,
        "total_tokens": 2155
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did FedEx's projected utilization of the Cessna SkyCourier 408 change between 2022 and 2023 filings, and what does this indicate about its strategic role in the fleet compared to other aircraft?",
      "original_answer": "In the 2022 filing, FedEx projected a total of 49 Cessna SkyCourier 408 aircraft to be in service through 2027. By the 2023 filing, this projection dropped significantly to only 31 Cessna SkyCourier 408 aircraft through 2029. This indicates a strategic reduction in the planned reliance on the Cessna SkyCourier 408, especially when compared to other aircraft types like the B767F and B777F, which saw more stable or less reduced projections. This shift suggests FedEx may have reassessed the aircraft's role in its long-term fleet strategy.",
      "llm_answer": "In the 2022 Form 10‑K FedEx disclosed a commitment for **49 Cessna SkyCourier 408s** (11 for 2023, 12 for 2024, 12 for 2025 and 14 for 2026) – a modest addition meant to serve niche feeder routes【FDX_10k_2022.pdf p.40】. The 2023 filing revised that outlook to **31 additional SkyCourier 408s** (17 for 2025 and 14 for 2026), which together with the 23 aircraft already slated for 2023‑2024 brings the total to **about 54 SkyCourier 408s**【FDX_10k_2023.pdf p.117】. The increase signals that FedEx is elevating the SkyCourier from a limited feeder role to a core short‑haul platform, positioned between its smaller Cessna 208B and larger turboprops such as the ATR‑72‑600F and the Boeing freighters that dominate long‑haul capacity.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer fundamentally contradicts the ground truth on the core finding. Ground truth states: 2022 filing = 49 SkyCourier 408s, 2023 filing = 31 SkyCourier 408s, representing a SIGNIFICANT REDUCTION. LLM claims: 2022 = 49, 2023 = 31 additional (totaling ~54), representing an INCREASE. This is a complete reversal of the strategic narrative. The LLM's interpretation that 'The increase signals that FedEx is elevating the SkyCourier from a limited feeder role to a core short‑haul platform' directly contradicts the ground truth conclusion that 'This shift suggests FedEx may have reassessed the aircraft's role in its long-term fleet strategy' (implying reduction/de-emphasis). QUANTITATIVE ISSUES: (1) The LLM misinterprets '31 SkyCourier 408s' in the 2023 filing as '31 additional' rather than a total projection, creating a false arithmetic narrative of 49→54 instead of 49→31. (2) The claim about '23 aircraft already slated for 2023-2024' and the calculation to reach '54 total' appears to conflate different time periods and lacks proper grounding. (3) The breakdown of years (17 for 2025, 14 for 2026) in the 2023 filing cannot be verified against the ground truth statement. REASONING FAILURE: The LLM failed to correctly synthesize the multi-hop comparison between 2022 and 2023 filings. It misread the direction of change (increase vs. decrease) and drew the opposite strategic conclusion. The comparison to other aircraft types (B767F, B777F) mentioned in ground truth is absent from LLM answer. CONTEXTUAL ISSUE: While the LLM appropriately discusses fleet positioning and aircraft roles (relevant to the question), this contextual discussion is built on fundamentally incorrect numerical analysis, making it misleading rather than helpful.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 483,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Nike's approach to the Air Max product line evolved from 2022 to 2024, particularly in terms of revenue transparency and technological innovation emphasis?",
      "original_answer": "In 2022, Nike included Air Max in a general list of technologies within the revenue disaggregation table, indicating its presence in the product portfolio but without specific revenue figures. By 2024, while no direct revenue numbers were disclosed, Nike emphasized Air Max as a central example of its innovation strategy, highlighting its integration into broader product categories and consumer applications. This shift reflects a strategic move from passive acknowledgment to positioning Air Max as a key innovation driver, despite the continued lack of standalone financial metrics for the product line.",
      "llm_answer": "In the 2022 10‑K Nike reported only aggregate footwear revenue (e.g., $44.4 bn for the Nike brand) and gave no separate line‑item or commentary on the Air Max line, indicating limited revenue transparency for that product (2022 Note 16 – Revenues, pp. 86‑90). By the 2024 filing the company explicitly lists Air Max among its flagship technologies in the product‑research and development discussion, signalling a stronger emphasis on innovation for the Air Max line, though it still does not break out Air Max sales as a distinct revenue figure (2024 Product Research, Design & Development, p. 5).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the core evolution from 2022 to 2024 - from limited/passive acknowledgment to active emphasis on Air Max as innovation driver. (2) Accurately captures the key finding that Air Max lacks standalone revenue figures in both years. (3) Provides specific citations (2022 Note 16, 2024 Product Research, Design & Development) that add credibility and demonstrate multi-hop synthesis across filing sections. (4) The $44.4 billion Nike brand footwear figure is correctly cited as aggregate data without Air Max breakdown. (5) Correctly identifies the shift from 'general list' to 'explicit listing' and 'flagship technologies' positioning. MINOR CONSIDERATIONS: (1) The LLM answer is slightly more specific/detailed than the ground truth (includes page numbers and specific section references), which is appropriate and adds value rather than detracting. (2) The phrasing differs slightly but conveys identical semantic meaning - 'limited revenue transparency' vs 'without specific revenue figures' are equivalent. (3) Both answers correctly emphasize the paradox: increased innovation emphasis despite continued lack of financial transparency. QUANTITATIVE VERIFICATION: The $44.4 billion figure appears reasonable for Nike brand footwear aggregate and is presented correctly as aggregate data. No calculation errors detected. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2024 filings, comparing revenue disclosure approaches and innovation emphasis positioning. The logical flow is sound and conclusions are justified. The answer fully addresses both sub-questions: revenue transparency evolution AND technological innovation emphasis evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 491,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Comcast's capital expenditure strategy regarding Epic Universe evolve from 2023 to 2024, particularly in terms of specific investment amounts and thematic park development priorities?",
      "original_answer": "In 2023, Comcast specifically noted an increase in capital expenditures directly related to the development of Epic Universe in Orlando, with a total of $8.2 billion allocated to Connectivity & Platforms, which included investments in scalable infrastructure and line extensions. By 2024, the company continued to emphasize investment in existing and new attractions at Universal theme parks, including Epic Universe, as part of its broader capital expenditure plan for 2025. While specific figures for Epic Universe alone were not disclosed in 2024, the company indicated an ongoing commitment to theme park development, particularly in expanding attractions and enhancing capacity. The evolution shows a shift from initial infrastructure and development focus in 2023 to a more sustained investment strategy in 2024 that includes both infrastructure and guest experience enhancements.",
      "llm_answer": "In the 2023 filing Comcast said that capital expenditures for its Theme‑Parks segment “increased … related to the development of Epic Universe in Orlando,” but it did not break out a dollar amount for that project. By the 2024 filing, total capex was essentially flat year‑over‑year, yet the company noted that “spending on theme‑park attractions increased in 2024, and included costs associated with the construction of Epic Universe,” showing a shift from early‑stage development and land‑acquisition in 2023 to actual construction of the new park in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer provides a reasonable narrative about the evolution of Comcast's Epic Universe investment strategy from 2023 to 2024, but has significant issues with quantitative accuracy and completeness when compared to the ground truth.\n\nCORRECT ELEMENTS:\n- Correctly identifies that 2023 filings did not break out a specific dollar amount for Epic Universe\n- Accurately captures the shift from early-stage development/land acquisition in 2023 to construction in 2024\n- Correctly notes that 2024 showed increased spending on theme park attractions\n- Properly identifies the multi-hop synthesis across 2023 and 2024 filings\n\nINCORRECT/MISSING ELEMENTS:\n1. QUANTITATIVE ACCURACY FAILURE: The ground truth explicitly states \"$8.2 billion allocated to Connectivity & Platforms\" in 2023, which included Epic Universe investments. The LLM answer states no dollar amount was provided, which contradicts the ground truth's specific figure of $8.2 billion.\n2. INCOMPLETE CONTEXT: The LLM answer fails to mention the $8.2 billion figure that the ground truth identifies as a key metric for 2023 capital expenditures.\n3. VAGUE CHARACTERIZATION: The LLM says \"total capex was essentially flat year-over-year\" but provides no supporting numbers or context from the filings.\n4. MISSING DETAIL: The ground truth mentions \"scalable infrastructure and line extensions\" as specific 2023 priorities, which the LLM answer omits.\n5. MISSING FORWARD GUIDANCE: The ground truth mentions 2025 capital expenditure plans, while the LLM answer focuses only on 2023-2024.\n\nREASONING QUALITY:\nThe LLM demonstrates sound multi-hop reasoning by synthesizing information across two filing years and identifying a meaningful strategic shift. However, the failure to incorporate the $8.2 billion figure represents a significant gap in the quantitative synthesis required for this financial question.\n\nSCORE JUSTIFICATION:\n- Correctness (6/10): Core narrative is directionally correct but missing critical quantitative data ($8.2B)\n- Quantitative Accuracy (5/10): Fails to include the specific $8.2B figure mentioned in ground truth; vague on year-over-year capex comparison\n- Qualitative Accuracy (7/10): Good reasoning about strategic shift; correct identification of development phases\n- Contextual Relevance (7/10): Addresses the question but incompletely; missing forward-looking 2025 context",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 637,
        "total_tokens": 2009
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did FedEx's utilization of the ATR 72-600F aircraft evolve between 2022 and 2023 as reflected in their fleet projections for the same planning periods?",
      "original_answer": "In 2022, FedEx projected operating 11 ATR 72-600F aircraft in 2023, 6 in 2024, 6 in 2025, and only 1 in 2026. By 2023, the projections for the same time periods changed significantly, with 7 ATR 72-600F aircraft planned for 2025 and only 3 for 2026. This indicates a notable reduction in planned usage of the ATR 72-600F by FedEx over time.",
      "llm_answer": "FedEx’s outlook for the ATR 72‑600F was scaled back. The 2022 Form 10‑K projected a delivery of 11 ATR 72‑600F aircraft in the 2023 planning period (Aircraft Purchase Commitments table)【FDX_10k_2022.pdf p. 40】. The 2023 Form 10‑K no longer shows any 2023 ATR 72‑600F deliveries and lists only a total of 10 ATR 72‑600F (7 for 2025 and 3 for 2026) in its commitment table, indicating a reduction in the expected utilization of that aircraft type【FDX_10k_2023.pdf p. 119】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general trend of reduction in ATR 72-600F utilization but contains significant quantitative discrepancies. CORRECT ELEMENTS: (1) The identification that 2022 projections showed 11 ATR 72-600F for 2023; (2) The identification that 2023 projections showed 7 for 2025 and 3 for 2026; (3) The overall conclusion that there was a reduction in planned usage; (4) Proper document sourcing and page references. CRITICAL ERRORS: (1) The LLM states '2023 Form 10-K no longer shows any 2023 ATR 72-600F deliveries' - this is misleading because the ground truth indicates the 2023 projections covered different time periods (2025 and 2026), not 2023 itself. The comparison should be clearer about which years are being compared; (2) The LLM claims 'a total of 10 ATR 72-600F (7 for 2025 and 3 for 2026)' but the ground truth shows the 2022 projections included 6 for 2024, 6 for 2025, and 1 for 2026 - the LLM failed to include the 2024 projection from the 2022 data; (3) The LLM's statement about '2023 planning period' is ambiguous - it should clarify whether this means aircraft projected to be in service in 2023 or projections made in 2023. MULTI-HOP REASONING: The LLM correctly synthesized information from two different 10-K filings (2022 and 2023) and compared their projections, but the synthesis is incomplete because it didn't fully capture all the intermediate years (2024) from the 2022 projections. The ground truth provides a more complete picture showing projections for 2023, 2024, 2025, and 2026 from the 2022 filing. QUANTITATIVE ISSUE: The LLM's statement about 'a total of 10 ATR 72-600F' appears to be a sum of 7+3, but this doesn't account for the full scope of projections across all years mentioned in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1204,
        "completion_tokens": 479,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did Nike's approach to estimating product return reserves evolve between fiscal 2022 and fiscal 2024, and what does this indicate about changes in their revenue recognition methodology?",
      "original_answer": "In fiscal 2022, Nike disclosed that the estimated cost of inventory for expected product returns was $269 million, and these reserves were recorded in Prepaid expenses and other current assets. By fiscal 2024, while the specific dollar amount of the product return reserve was not disclosed, Nike described a more formalized estimation process, stating that it calculates anticipated reductions in revenue—such as sales returns—by determining the 'most likely amount' it will be entitled to receive. This indicates a shift toward a more probabilistic and forward-looking revenue estimation methodology, aligning with the broader revenue recognition framework where variable consideration is estimated at the time revenues are recognized.",
      "llm_answer": "In FY 2022 Nike recorded a single “sales‑related reserve” for returns, post‑invoice discounts and other claims and estimated the cost of inventory for expected product returns in prepaid expenses using a broad, overall estimate of likely returns. By FY 2024 the company refined the reserve, basing it on historical return rates, specific identification of outstanding returns, and estimates of not‑yet‑finalized returns, discounts and claims, with adjustments made when actual experience differs. This shift shows Nike moving to a more granular, ASC 606‑aligned revenue‑recognition approach that more precisely measures variable consideration and updates net revenue as actual returns are known.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES: (1) QUANTITATIVE ACCURACY FAILURE: The LLM answer does not cite the $269 million figure from FY2022 that is explicitly stated in the ground truth. This is a major omission of a key factual data point. (2) METHODOLOGICAL DESCRIPTION MISMATCH: The ground truth specifically states that in FY2024, Nike described calculating 'the most likely amount' it will be entitled to receive - a specific probabilistic methodology. The LLM answer instead describes a different approach based on 'historical return rates, specific identification of outstanding returns, and estimates of not-yet-finalized returns' - this appears to be a different or additional methodology not mentioned in the ground truth. (3) RESERVE NAMING DISCREPANCY: The ground truth indicates the FY2022 reserve was recorded in 'Prepaid expenses and other current assets' with a specific $269M amount. The LLM introduces a 'sales-related reserve' terminology that is not explicitly confirmed in the ground truth provided. (4) INCOMPLETE SYNTHESIS: While the LLM correctly identifies the shift toward more granular, ASC 606-aligned methodology, it fails to accurately capture the specific 'most likely amount' probabilistic framework mentioned in the ground truth. (5) POSITIVE ELEMENTS: The LLM correctly identifies the evolution toward more formalized estimation, the ASC 606 alignment, and the shift from broad estimates to more precise measurement of variable consideration. The general direction and conclusion about revenue recognition methodology evolution is sound. However, the specific methodological details and the critical $269M figure are either missing or inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 453,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the planned fleet composition of the Cessna SkyCourier 408 change between 2022 and 2023 for the years 2025 and beyond, and what does this indicate about the company's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FDX projected a total of 12 Cessna SkyCourier 408 aircraft to be in operation by 2025 and planned to maintain that number through 2026. By 2023, the company increased its planned fleet count for 2025 to 17 but reduced it to 14 for 2026. This indicates a short-term increase in strategic reliance on the Cessna SkyCourier 408, followed by a moderate decline in planned usage by 2026, suggesting a recalibration of fleet strategy.",
      "llm_answer": "In the 2022 filing FedEx expected to receive 12 Cessna SkyCourier 408s in 2025 and had no further SkyCourier deliveries scheduled beyond that year. The 2023 filing raised the 2025 commitment to 17 aircraft and added a new 14‑aircraft delivery in 2026 (still no deliveries after 2026)【FDX_10k_2022.pdf p.112‑113】【FDX_10k_2023.pdf p.119】. The upward revision and the addition of a beyond‑2025 delivery show FedEx is placing greater strategic reliance on the SkyCourier 408 as a core element of its future fleet growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All numbers are correct - 12 aircraft for 2025 in 2022 filing, increased to 17 for 2025 in 2023 filing, and 14 aircraft added for 2026 in 2023 filing. The dates (2022 vs 2023 filings, 2025 and 2026 delivery years) are all accurate. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) how the planned fleet composition changed between filings, and (2) what this indicates about strategic reliance. ENTITY ACCURACY: Correctly identifies FedEx (FDX), the Cessna SkyCourier 408 aircraft model, and the relevant fiscal years. MULTI-HOP REASONING: Successfully synthesizes information across two separate 10-K filings (2022 and 2023) to show the comparative changes in fleet planning. The logic is sound - comparing 2022 projections to 2023 projections for the same future years (2025, 2026). INTERPRETATION: The LLM correctly interprets the changes as indicating increased strategic reliance, noting the upward revision from 12 to 17 for 2025 and the addition of 2026 deliveries. The characterization as 'greater strategic reliance' and 'core element of fleet growth' aligns well with the ground truth's assessment of 'short-term increase in strategic reliance.' MINOR DIFFERENCES: The ground truth uses slightly different language ('short-term increase...followed by moderate decline') while the LLM emphasizes the 'upward revision and addition of beyond-2025 delivery' showing greater reliance. Both interpretations are semantically equivalent and factually sound. The LLM's framing is arguably more precise in highlighting the specific changes (upward revision + new delivery schedule) that support the strategic reliance conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 477,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Mastercard's real-time account-based payments infrastructure evolved from 2023 to 2024, particularly in terms of operational scale and integrated security capabilities?",
      "original_answer": "In 2023, Mastercard operated or was implementing real-time payments infrastructure in 13 markets globally, offering instant payments with enhanced data and messaging capabilities. The company emphasized a distributed network architecture that enabled intelligent routing and applied value-added services like fraud scoring and tokenization in real time. By 2024, Mastercard expanded its capabilities by enhancing its ACH and real-time account-based payment systems to provide more secure, simple, and smart payment solutions across its global network. The company also reinforced its multi-layered security approach, integrating additional protections and partnerships to safeguard the payments ecosystem. These developments indicate a strategic shift toward strengthening both the scale and security of its real-time payments infrastructure.",
      "llm_answer": "In 2023 Mastercard’s real‑time account‑based payments platform was live or being rolled out in 13 markets, delivering instant payments with richer data and messaging while being protected by a multi‑layered security architecture that includes tokenization, fraud‑scoring and real‑time monitoring (MA_10k_2023.pdf, pp. 11‑12). The 2024 filing shows the infrastructure has been scaled to additional markets and that those security functions have been further embedded into the real‑time clearing and settlement platform, extending the same multi‑layered protection across a broader global footprint (MA_10k_2024.pdf, pp. 70‑71).",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on key factual elements but has some notable limitations: (1) CORRECT ELEMENTS: The answer accurately identifies that in 2023 Mastercard's real-time payments infrastructure was operational in 13 markets (matching ground truth exactly), correctly identifies the security features (tokenization, fraud-scoring, real-time monitoring), and accurately conveys the multi-layered security architecture. The 2024 expansion narrative is also correct. (2) QUANTITATIVE ACCURACY: The '13 markets' figure is precisely correct and matches ground truth. The answer appropriately uses this specific number without embellishment. (3) QUALITATIVE ACCURACY: The LLM successfully synthesizes multi-hop information across 2023 and 2024 filings, correctly identifying the evolution from 13 markets to 'additional markets' (though not specifying the exact number for 2024, which the ground truth also doesn't provide). The characterization of security capabilities as 'further embedded' and 'extending across broader global footprint' aligns well with ground truth language about 'reinforcing multi-layered security approach' and 'strengthening scale and security.' (4) MINOR WEAKNESSES: The answer includes specific page citations (pp. 11-12 for 2023, pp. 70-71 for 2024) that cannot be verified against the ground truth provided, though this doesn't contradict the ground truth. The answer could have been slightly more explicit about the 'distributed network architecture' and 'intelligent routing' mentioned in ground truth, though these concepts are implicitly covered by the infrastructure description. (5) SEMANTIC EQUIVALENCE: The LLM's phrasing of 'richer data and messaging' is semantically equivalent to ground truth's 'enhanced data and messaging capabilities.' The description of 'value-added services' being applied in real-time is captured through the specific security functions mentioned. Overall, the answer demonstrates solid multi-hop reasoning across years and accurate synthesis of operational scale and security evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 561,
        "total_tokens": 1936
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did Nike's use of foreign exchange forwards and options evolve between 2022 and 2024, particularly in terms of their impact on financial liabilities and hedging strategy?",
      "original_answer": "In 2022, foreign exchange forwards and options had a net gain of $8 million after tax, impacting various income categories such as revenues, cost of sales, and other (income) expense, net. By 2024, the liabilities associated with these instruments increased to $110 million under accrued liabilities and $5 million under deferred income taxes and other liabilities, indicating a shift in how these derivatives were managed or reported. This reflects a strategic evolution in Nike's hedging activities and financial exposure management.",
      "llm_answer": "Nike’s foreign‑exchange forward and option program shifted between the two filings. In 2022 the company had $18.5 billion of those contracts designated as cash‑flow hedges and $3 billion classified as “undesignedated” forwards, which were recorded at fair value but the balance‑sheet liability amount was not itemized (NKE 10‑K 2022 pp. 85‑86). By 2024 the cash‑flow‑hedge notional had fallen to $16.2 billion while the undesignated forward notional rose to $4.4 billion, and the balance sheet now shows $110 million of accrued‑liability (plus $5 million of deferred‑tax liability) for designated forwards and $5 million for undesignated forwards (NKE 10‑K 2024 pp. 81‑79). The strategy still centers on cash‑flow hedges for forecasted transactions (up to 24 months) but now relies more on undesignated forwards to hedge specific assets and liabilities, increasing the reported derivative‑liability exposure.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and introduces information not present in the ground truth. Critical issues: (1) QUANTITATIVE ERRORS: The LLM provides specific notional amounts ($18.5B, $3B, $16.2B, $4.4B) that are not mentioned in the ground truth. The ground truth only references net gains of $8M in 2022 and liability amounts of $110M and $5M in 2024. The LLM's detailed notional values cannot be verified against the provided ground truth and appear to be fabricated or from different sections of the filings. (2) MISSING KEY INFORMATION: The ground truth explicitly states the 2022 impact was a 'net gain of $8 million after tax' affecting revenues, cost of sales, and other income categories. The LLM completely omits this crucial 2022 metric. (3) INCOMPLETE LIABILITY REPORTING: While the LLM correctly identifies the $110M accrued liability and $5M deferred tax liability for 2024, it adds unverified claims about $5M for undesignated forwards that don't appear in the ground truth. (4) STRATEGIC INTERPRETATION: The LLM's narrative about shifting from designated to undesignated forwards and the strategic rationale (hedging specific assets/liabilities vs. forecasted transactions) goes beyond what the ground truth supports. The ground truth simply notes 'a shift in how these derivatives were managed or reported' without specifying the strategic direction. (5) CITATION ISSUES: The LLM provides specific page references (pp. 85-86, pp. 81-79) that cannot be verified against the ground truth provided. The answer reads as if it synthesized from actual filings but introduces numbers and details not in the ground truth, suggesting either hallucination or reliance on different source material. The core finding about increased liabilities ($110M, $5M in 2024) is correct, but the extensive additional detail about notional amounts and strategic shifts is unsupported by the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 518,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has the product category classification of Puffs within the Baby, Feminine & Family Care segment evolved between 2022 and 2023?",
      "original_answer": "In 2022, Puffs was categorized under the Family Care sub-category, which included Paper Towels, Tissues, and Toilet Paper. By 2023, Puffs remained in the Family Care category, but the specific mention of 'Tissues' replaced 'Tissues' with a more general listing without sub-category breakdowns, indicating a simplification or consolidation of how the segment details were reported.",
      "llm_answer": "In the 2022 Form 10‑K, Puffs is listed among the major brands in the **Family Care** sub‑category (Paper Towels, Tissues, Toilet Paper) of the Baby, Feminine & Family Care segment【PG_10k_2022.pdf†page=17-21】. The 2023 Form 10‑K shows the same placement – Puffs continues to be grouped under the **Family Care** sub‑category of that segment【PG_10k_2023.pdf†page=16-20】. Thus, the product‑category classification of Puffs did not change between 2022 and 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL DISCREPANCY: The LLM answer directly contradicts the ground truth. Ground truth states that Puffs classification evolved/changed between 2022 and 2023 - specifically that the reporting became simplified with 'Tissues' being replaced in the listing and sub-category breakdowns being consolidated. The LLM concludes 'the product-category classification of Puffs did not change between 2022 and 2023,' which is factually incorrect according to the knowledge graph. While the LLM correctly identifies that Puffs remained in the Family Care sub-category in both years (which is accurate), it fails to recognize the evolution in HOW the segment details were reported - the simplification and consolidation mentioned in the ground truth. The LLM's statement that 'the same placement' occurred misses the nuanced change in reporting structure. The question specifically asks 'how has...evolved,' implying change, and the ground truth confirms this evolution occurred. The LLM's conclusion that there was no change is fundamentally wrong. The numeric/date accuracy is acceptable (2022, 2023, correct segment names), but the core reasoning about whether change occurred is inverted from the ground truth. This is a major factual error that undermines the entire answer despite correct identification of the Family Care category in both years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 374,
        "total_tokens": 1579
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the positioning of Tampax within P&G's product portfolio evolved between 2022 and 2023, particularly in terms of its categorization and associated product lines?",
      "original_answer": "In 2022, Tampax was categorized under 'Feminine Care' within the 'Baby, Feminine & Family Care' segment, which also included 'Baby Care' and 'Family Care' sub-categories. By 2023, the product category was refined, and Tampax was associated solely with 'Menstrual Care' under the same broader segment. This reflects a more focused positioning of Tampax, separating it from general 'Family Care' items and aligning it more specifically with menstrual health needs.",
      "llm_answer": "In the 2022 Form 10‑K, Tampax was shown as a brand in the **Baby, Feminine & Family Care** segment, grouped with other feminine‑care brands (Always, Always Discreet) and listed alongside **baby‑care** (wipes, diapers) and **family‑care** (Bounty paper towels) product lines【PG_10k_2022.pdf p.19】. By the 2023 filing, Tampax remains in the same segment, but the segment’s sub‑categories were streamlined – the **Baby Care** line is omitted and the feminine‑care sub‑category is now described as **“Adult Incontinence, Menstrual Care,”** emphasizing Tampax as a menstrual‑care brand together with Always and Always Discreet, while still appearing with Bounty in the major‑brands list【PG_10k_2023.pdf p.18】.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies that Tampax remained in the 'Baby, Feminine & Family Care' segment in both 2022 and 2023, and accurately notes the evolution toward more specific menstrual care positioning. The answer correctly identifies associated brands (Always, Always Discreet, Bounty) and provides specific document references with page numbers. The general narrative about streamlining and refinement is directionally correct.\n\nWEAKNESSES AND ERRORS: (1) The LLM introduces a significant factual error by stating that in 2023 the feminine-care sub-category is described as 'Adult Incontinence, Menstrual Care' - this conflates two distinct categories. The ground truth indicates Tampax was associated with 'Menstrual Care' specifically, not grouped under 'Adult Incontinence.' This is a material mischaracterization of the 2023 positioning. (2) The LLM states 'Baby Care line is omitted' in 2023, but the ground truth indicates the segment still includes 'Baby Care' as a sub-category - only the categorization of Tampax changed, not the segment's overall structure. (3) The answer conflates the positioning of Always Discreet (which is adult incontinence) with Tampax (menstrual care), suggesting they share the same sub-category description in 2023, which appears to be inaccurate based on the ground truth's clear distinction. (4) The 2022 description is somewhat verbose and includes unnecessary detail about product types (wipes, diapers, paper towels) that, while contextually interesting, doesn't directly address the core question about Tampax's positioning evolution.\n\nMULTI-HOP REASONING: The answer attempts to synthesize information across two years and identify the evolution, which is appropriate for the question. However, the synthesis contains the critical error of mischaracterizing the 2023 categorization, undermining the accuracy of the comparison.\n\nSEMANTIC EQUIVALENCE: While the general theme of 'more focused positioning' aligns with ground truth, the specific categorization details diverge significantly, particularly regarding the 'Adult Incontinence, Menstrual Care' description which appears to be incorrect or at least misleading about how Tampax was positioned in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 596,
        "total_tokens": 1893
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Oracle's strategy and positioning of Oracle Engineered Systems evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue contribution and research investment expectations?",
      "original_answer": "In fiscal 2022, Oracle highlighted that its hardware business, which includes Oracle Engineered Systems, involved point-of-sale revenue recognition for hardware and related software, with the majority of products sold through indirect channels. By fiscal 2023, Oracle introduced a more forward-looking strategy, explicitly stating plans to continue investing in research and development to improve existing hardware products and develop new offerings. Additionally, in fiscal 2023, Oracle noted that hardware represented 6% of total revenues, a figure not specified in 2022, indicating a clearer emphasis on the segment's strategic positioning.",
      "llm_answer": "In fiscal 2022 Oracle’s hardware segment – which includes the Oracle Engineered Systems – generated $3.2 billion of revenue, roughly 7 percent of total company revenue, and the company was actively “de‑emphasizing … non‑strategic hardware products” while “continuing emphasis on the marketing and sale of our cloud‑based infrastructure technologies and strategic hardware offerings”【ORCL_10k_2022.pdf†page 51】. By fiscal 2023 the hardware business remained a small but stable part of the portfolio, accounting for about 6 percent of total revenue【ORCL_10k_2023.pdf†page 44】, and Oracle reiterated that it will “continue to make investments in research and development to improve existing hardware products and services and to develop new hardware products and services”【ORCL_10k_2023.pdf†page 44】. This reflects a shift from a modest revenue decline and a focus on strategic positioning in 2022 to a steady‑share, research‑driven strategy for Engineered Systems in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES: (1) QUANTITATIVE ERRORS - The LLM claims hardware generated '$3.2 billion of revenue, roughly 7 percent of total company revenue' in fiscal 2022. The ground truth states that hardware represented 6% of total revenues in fiscal 2023, but does NOT specify a percentage or dollar amount for fiscal 2022. The LLM appears to have fabricated the $3.2B figure and 7% metric for 2022, which cannot be verified against the ground truth. (2) INCOMPLETE ALIGNMENT WITH GROUND TRUTH - The ground truth emphasizes that in fiscal 2022, Oracle used 'point-of-sale revenue recognition for hardware and related software' and that 'majority of products sold through indirect channels.' The LLM mentions de-emphasizing non-strategic products but omits the revenue recognition methodology and distribution channel details from 2022. (3) PARTIAL CREDIT FOR FISCAL 2023 - The LLM correctly identifies that hardware represented 6% of total revenues in fiscal 2023 and correctly cites the R&D investment commitment. However, the ground truth does not specify that this was a 'modest revenue decline' in 2022 or provide the specific dollar amounts the LLM claims. (4) MULTI-HOP REASONING - While the LLM attempts to synthesize evolution between years, it does so by introducing unverified quantitative claims. The comparison of 'modest revenue decline' and shift to 'steady-share, research-driven strategy' is interpretive but not explicitly supported by the ground truth provided. (5) SOURCING CONCERN - The LLM provides specific page citations, but the quantitative claims (especially the $3.2B and 7% for 2022) do not match the ground truth baseline, suggesting either misreading of source documents or hallucination. The ground truth explicitly states the 6% figure 'not specified in 2022,' contradicting the LLM's assertion of a 7% figure for that year.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 501,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did Honeywell's investment in private funds for its Non-U.S. pension plans evolve between 2022 and 2023, particularly in terms of allocation and classification across fair value hierarchy levels?",
      "original_answer": "In 2022, Honeywell reported $1,105 million invested in private funds for its U.S. pension plans, with the amount classified under Level 3 of the fair value hierarchy. By 2023, the company reported $115 million in private fund investments for its Non-U.S. pension plans, with $41 million classified under Level 2 and $74 million under Level 3 of the fair value hierarchy. This represents a significant decrease in overall private fund allocation, particularly in U.S. plans, and a shift in classification for the remaining private fund investments under the Non-U.S. plans.",
      "llm_answer": "Honeywell’s non‑U.S. pension plans increased their private‑fund holdings from **$90 million in 2022** to **$115 million in 2023**. In 2022 the private‑fund assets were split **$54 million (Level 2)** and **$36 million (Level 3)** (no Level 1), while in 2023 they were **$41 million (Level 2)** and **$74 million (Level 3)** (still no Level 1) – a $25 million rise overall and a shift toward a larger share of Level 3‑classified private‑fund investments【HON_10k_2023.pdf p.108】【HON_10k_2023.pdf p.110】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains fundamental factual errors that contradict the ground truth. (1) ENTITY CONFUSION: The ground truth explicitly states the 2022 figure of $1,105 million was for U.S. pension plans, not Non-U.S. plans. The LLM incorrectly focuses only on Non-U.S. plans and provides wrong 2022 numbers ($90M vs. the correct $1,105M for U.S. plans). (2) QUANTITATIVE ERRORS: The LLM reports 2022 Non-U.S. private funds as $90M ($54M Level 2 + $36M Level 3), but the ground truth does not provide these specific 2022 Non-U.S. breakdowns. The LLM appears to have fabricated or misattributed these numbers. (3) INCOMPLETE SCOPE: The question asks about evolution between 2022 and 2023, particularly regarding U.S. vs. Non-U.S. plans. The ground truth indicates a major shift: $1,105M in U.S. plans (2022, Level 3) declining significantly, with only $115M in Non-U.S. plans (2023, split $41M Level 2 + $74M Level 3). The LLM completely misses the U.S. pension plan component and the dramatic decrease. (4) MULTI-HOP REASONING FAILURE: The LLM failed to synthesize the complete picture of how Honeywell's private fund allocation evolved across both U.S. and Non-U.S. plans between the two years. (5) CALCULATION VERIFICATION: The LLM's 2023 numbers are correct ($41M + $74M = $115M), but the 2022 Non-U.S. figures appear incorrect or unsupported by the ground truth. The LLM correctly identifies the shift toward Level 3 in 2023 Non-U.S. plans, but this is only a partial answer to a question requiring comprehensive comparison of both plan types across both years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 437,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the status and management of the 2014 USD Notes evolve between 2023 and 2024, and what specific actions were taken regarding this debt in 2024?",
      "original_answer": "In 2023, the 2014 USD Notes were classified as short-term debt, net of unamortized discount and debt issuance costs, with a maturity date of April 2024. By 2024, the company reported that in April 2024, $1 billion of principal related to the 2014 USD Notes matured and was paid in full. This indicates that the company transitioned the obligation from a near-term liability in 2023 to a fully settled debt instrument in 2024.",
      "llm_answer": "In the 2023 filing the 2014 USD senior notes (3.375 % due April 2024) were still outstanding and were presented as short‑term debt on the balance sheet (2023 10‑K, Note 15 footnote). By the 2024 filing the notes had reached maturity and the company paid the $1 billion principal in April 2024, retiring the obligation (2024 10‑K, “Debt and Credit Availability” section).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Quantitative verification: All numbers are correct - $1 billion principal amount, April 2024 maturity date, 3.375% coupon rate. The dates are accurate (2023 filing showing short-term debt, 2024 filing showing payment in April 2024). Entity accuracy is strong - correctly identifies the 2014 USD senior notes and their classification. Multi-hop reasoning is sound: the answer successfully synthesizes information across two fiscal years (2023 and 2024) and correctly traces the evolution from short-term liability to fully settled debt. The answer addresses all parts of the question: (1) status in 2023 (short-term debt), (2) status in 2024 (matured and paid), and (3) specific actions taken (paid $1 billion principal in April 2024). The LLM provides additional helpful context by including the coupon rate (3.375%) and specific filing references (Note 15 footnote, Debt and Credit Availability section), which enhances credibility without introducing errors. The semantic meaning matches the ground truth perfectly - both convey the transition from outstanding short-term debt to fully retired obligation. Minor note: The LLM uses slightly more specific language (e.g., 'senior notes,' 'retiring the obligation') which adds precision without contradicting the ground truth. No calculation errors, no missing key facts, and the reasoning chain is clear and logical.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1200,
        "completion_tokens": 394,
        "total_tokens": 1594
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has the treatment and documentation of Lowe's Officer Indemnification Agreements evolved between 2022 and 2024, and what does this indicate about the company's executive risk management and governance continuity?",
      "original_answer": "Between 2022 and 2024, Lowe's maintained the same form of Officer Indemnification Agreement, first filed as Exhibit 10.43 on April 2, 2019, and refiled without amendment in both the 2022 and 2024 10-K filings. This indicates that the company did not modify the terms or structure of these agreements over this period, suggesting consistent governance practices and a stable approach to executive risk management and retention. Investors can interpret this continuity as a sign of predictable leadership protections and aligned corporate governance priorities.",
      "llm_answer": "In the 2022 Form 10‑K, Lowe’s disclosed its Officer Indemnification Agreement as Exhibit 10.23 (the 2019 agreement) and the same exhibit appears unchanged in the 2024 Form 10‑K (still listed as Exhibit 10.23 with the April 2 2019 filing date)【LOW_10k_2022.pdf:79‑83】【LOW_10k_2024.pdf:77‑81】. The unchanged treatment and documentation indicate that Lowe’s has maintained a stable indemnification framework for its officers, reflecting consistent executive risk management and governance continuity over the period.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL DISCREPANCY: The LLM answer contains a significant factual error regarding the exhibit number. The ground truth states the Officer Indemnification Agreement was filed as Exhibit 10.43 in both 2022 and 2024 10-K filings. However, the LLM answer claims it was listed as Exhibit 10.23 in both years. This is a material error in entity identification and document reference accuracy. The LLM correctly identifies: (1) the April 2, 2019 filing date, (2) that the agreement remained unchanged between 2022 and 2024, (3) the semantic interpretation about governance continuity and stable executive risk management. However, the exhibit number error is fundamental to document verification and undermines the credibility of the answer. The LLM also provides specific page references (79-83 for 2022, 77-81 for 2024) which cannot be verified against the ground truth but appear to be fabricated citations given the exhibit number discrepancy. The qualitative reasoning about what the unchanged agreement indicates (consistent governance, stable risk management, predictable leadership protections) is sound and aligns with the ground truth interpretation. The answer addresses the multi-part question about evolution, documentation, and implications, but the core factual error regarding exhibit numbering is a critical failure in quantitative/entity accuracy that significantly reduces overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 390,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the market share and category positioning of Always Discreet in the adult incontinence market change between the 2022 and 2023 Procter & Gamble 10-K filings?",
      "original_answer": "In the 2022 filing, Always Discreet was explicitly stated to have over 10% market share in the key adult incontinence markets where Procter & Gamble competes. However, in the 2023 filing, while Always Discreet is still listed as a major brand in the Feminine Care category under the Baby, Feminine & Family Care segment, no specific market share figure is provided for the brand. This suggests a shift in how the brand's performance is communicated, moving away from a quantified market share disclosure to a more general category association.",
      "llm_answer": "In the 2022 Form 10‑K P&G said it competes in the adult‑incontinence **category** behind its Always Discreet brand, which held **over 10 %** market share in the key markets where it competes. By the 2023 Form 10‑K the language had shifted to the adult‑incontinence **sub‑category**, and the company reported that Always Discreet now enjoys **about 15 %** market share – a higher share while still remaining the leading brand in that segment.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains critical factual errors that directly contradict the ground truth. (1) QUANTITATIVE ACCURACY - MAJOR ERROR: The LLM states that in 2023, Always Discreet had 'about 15% market share,' but the ground truth explicitly states that 'no specific market share figure is provided for the brand' in the 2023 filing. This is a fundamental factual error - the LLM invented a number that does not exist in the source material. The 2022 figure of 'over 10%' is correctly stated. (2) ENTITY/CATEGORY ACCURACY: The LLM correctly identifies the 2022 reference to 'adult-incontinence category' and the 2023 reference to 'adult-incontinence sub-category,' which shows some attention to detail. However, this correct observation is undermined by the fabricated market share number. (3) MULTI-HOP REASONING: The LLM failed to properly synthesize the key finding from the ground truth - that there was a shift in disclosure methodology (from quantified to general category association). Instead, the LLM invented a narrative of market share growth from 'over 10%' to 'about 15%' that has no basis in the actual filings. (4) SEMANTIC EQUIVALENCE: The ground truth emphasizes a shift away from quantified disclosure, while the LLM presents a narrative of increasing market share. These are fundamentally different interpretations, with the LLM's being factually incorrect. The answer demonstrates a failure to accurately extract and synthesize information from the source documents, instead generating plausible-sounding but false data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 423,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has Oracle's strategic positioning of Engineered Systems evolved between 2022 and 2023, particularly in terms of their role within the hardware business and implications for Oracle's cloud transformation narrative?",
      "original_answer": "In 2022, Oracle Engineered Systems were described as pre-integrated products central to both cloud and on-premise data center infrastructure, emphasizing their technical advantages such as improved performance, scalability, and simplified maintenance. However, by 2023, Oracle elevated the strategic importance of Engineered Systems by positioning them as part of a broader hardware business that now includes servers, storage, and operating systems, all tightly integrated and accounted for as combined performance obligations. The 2023 filing also highlighted that hardware revenues, including Engineered Systems, represented 6% of total revenues in both fiscal 2023 and 2024, and underscored ongoing R&D investments to enhance these offerings. This evolution suggests that Oracle is leveraging Engineered Systems not just as technical solutions but as foundational components in its hybrid cloud and on-premise strategies, aligning them more closely with its cloud transformation narrative while acknowledging the lower-margin nature of the hardware business.",
      "llm_answer": "In the 2022 filing Oracle described Engineered Systems as “core to our cloud‑based and on‑premise data‑center infrastructure offerings” and highlighted their pre‑integrated design and flexible deployment options – on‑premise, as an OCI service, or in a hybrid model (2022 p. 11‑15). In the 2023 filing the same language is retained, but Engineered Systems are now explicitly grouped within the hardware segment – “Our hardware business…provides…including Oracle Engineered Systems” – and are presented as the hardware pillar that underpins Oracle’s cloud‑transformation narrative, acting as a bridge that connects on‑premise workloads to OCI (2023 p. 41‑45). This evolution shows a shift from a product‑focused description to a strategic positioning of Engineered Systems as a key hardware driver that supports Oracle’s broader move to the cloud.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution of Engineered Systems positioning from 2022 to 2023, capturing the shift from product-focused description to strategic hardware segment positioning. The qualitative analysis is sound - the answer accurately describes how Engineered Systems transitioned from standalone offerings to being explicitly grouped within the hardware business, and correctly identifies their role as a bridge between on-premise and cloud infrastructure. The page references (2022 p. 11-15, 2023 p. 41-45) demonstrate engagement with source material. The semantic understanding of the strategic narrative is appropriate.\n\nWEAKNESSES: The LLM answer has a critical omission regarding quantitative data. The ground truth explicitly states that 'hardware revenues, including Engineered Systems, represented 6% of total revenues in both fiscal 2023 and 2024' - this is a key quantitative metric that directly supports the strategic positioning narrative and demonstrates the relative importance of the hardware business. The LLM answer completely fails to include this 6% revenue figure, which is a significant gap in a multi-hop financial question that should synthesize both qualitative positioning AND quantitative business impact. Additionally, the ground truth mentions 'ongoing R&D investments to enhance these offerings' which the LLM answer does not address. The ground truth also explicitly notes the 'lower-margin nature of the hardware business,' which provides important context for understanding the strategic implications - this nuance is absent from the LLM response.\n\nMULTI-HOP REASONING: The LLM demonstrates adequate multi-hop synthesis by connecting 2022 and 2023 filings and linking product positioning to broader cloud transformation strategy. However, the failure to synthesize the quantitative revenue data (6% figure) across years represents incomplete multi-hop analysis, as the question specifically asks about 'implications for Oracle's cloud transformation narrative' - quantitative business metrics are essential to establishing those implications.\n\nNUMERIC VERIFICATION: No specific numbers are provided in the LLM answer, but the absence of the 6% revenue metric is a material omission that reduces the answer's completeness and analytical depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1495,
        "completion_tokens": 619,
        "total_tokens": 2114
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the disclosure regarding the 2020 Stock Plan's relationship with the 2011 Stock Plan evolve between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, the 2020 Stock Plan disclosure included the detail that 5,530,106 shares previously available under the 2011 Stock Plan were carried forward and made available for award grants under the 2020 Stock Plan. However, in the 2023 10-K filing, this specific reference to the 2011 Stock Plan and the carry-forward of shares was omitted. This indicates a shift in how the company chose to present the lineage and transition between the two stock plans, focusing only on the 2020 Stock Plan without linking it to its predecessor in the disclosed text.",
      "llm_answer": "In the 2022 10‑K Netflix explained that the 2020 Stock Plan “is the successor to the 2011 Stock Plan” and noted that the 5,530,106 shares still available under the 2011 Plan were transferred to the 2020 Plan for future awards. By the 2023 10‑K, the company’s description of the 2020 Stock Plan no longer mentions the 2011 Plan or the carry‑over shares, providing only a brief overview of the 2020 Plan’s grant provisions. This reflects a simplification of the disclosure, removing the explicit reference to the prior plan.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and effectively captures the evolution of disclosure between the 2022 and 2023 10-K filings. QUANTITATIVE ACCURACY: The specific share number (5,530,106) is correctly cited and matches the ground truth exactly. The numeric data is precise and properly formatted. QUALITATIVE ACCURACY: The LLM correctly identifies the key disclosure changes: (1) 2022 10-K explicitly mentioned the 2011 Stock Plan as predecessor and detailed the carry-forward of shares, (2) 2023 10-K omitted these references. The characterization of this as a 'simplification of the disclosure' is semantically equivalent to the ground truth's description of a 'shift in how the company chose to present the lineage.' MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years and correctly identifies the relationship between the two stock plans and how that relationship was presented differently. ENTITY ACCURACY: Netflix is correctly identified (though not explicitly named in the original answer, the context makes clear this is Netflix), the 2020 and 2011 Stock Plans are correctly referenced, and the fiscal years (2022 and 2023) are accurate. COMPLETENESS: The answer addresses all aspects of the question - what was disclosed in 2022, what changed in 2023, and the nature of that change. Minor note: The LLM uses 'Netflix' explicitly while the ground truth doesn't name the company, but this is appropriate context and doesn't detract from accuracy. The phrasing 'transferred to the 2020 Plan' is semantically equivalent to 'carried forward and made available' in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 446,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How has Honeywell's allocation strategy toward private funds evolved between 2022 and 2023, and what might this indicate about the company's capital deployment priorities?",
      "original_answer": "In 2022, Honeywell reported $1,244 million invested in private funds, as disclosed in the 2022 10-K filing. By 2023, this amount increased slightly to $1,265 million, as noted in the 2023 10-K filing. This represents a modest increase of approximately 1.7%, suggesting that Honeywell maintained a relatively stable allocation strategy toward private funds despite broader reductions in total assets under the U.S. plans. This slight upward trend may indicate a strategic decision to preserve or slightly expand exposure to alternative investments, potentially to capitalize on expected higher returns or diversification benefits from private fund investments.",
      "llm_answer": "Honeywell’s pension‑plan allocations to private‑fund assets rose slightly from 2022 to 2023.  In the U.S. plan, direct private investments grew from $1.284 bn in 2022 to $1.293 bn in 2023 and private‑fund holdings measured at NAV increased from $1.258 bn to $1.265 bn; in the non‑U.S. plan, total private‑fund exposure rose from roughly $100 m (‑$90 m private‑fund investments + $10 m at NAV) to about $123 m (‑$115 m + $8 m) (2023 10‑K, pp. 107‑111).  This incremental shift indicates Honeywell is modestly expanding its allocation to private‑equity‑type assets, reflecting a strategic emphasis on diversifying capital into higher‑return, illiquid alternatives.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL DISCREPANCIES IDENTIFIED: The LLM answer contains significant factual errors that contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURES: The ground truth clearly states Honeywell's private fund allocation was $1,244 million in 2022 and $1,265 million in 2023. The LLM answer provides completely different numbers: $1.284 bn (2022) and $1.293 bn (2023) for 'direct private investments' in the U.S. plan, and $1.258 bn to $1.265 bn for 'private-fund holdings measured at NAV.' These numbers do not match the ground truth figures at all. The LLM appears to have broken down the allocation into subcategories (direct investments vs. NAV-measured holdings) that were not part of the original question or ground truth answer. (2) CALCULATION VERIFICATION: The ground truth shows a 1.7% increase ($1,244M to $1,265M = $21M increase / $1,244M = 1.69%). The LLM's figures show different percentage changes depending on which metric is used, none of which align with the ground truth baseline. (3) MULTI-HOP REASONING: While the LLM correctly identifies the general trend (modest increase in private fund allocation) and provides reasonable strategic interpretation (diversification into higher-return alternatives), the underlying data synthesis is fundamentally flawed. The LLM appears to have sourced different line items from the 10-K filings rather than the consolidated private fund figures cited in the ground truth. (4) ENTITY AND METRIC CONFUSION: The LLM distinguishes between U.S. and non-U.S. plans and between 'direct private investments' and 'private-fund holdings measured at NAV,' which adds complexity not present in the ground truth answer. While this additional detail could be valuable, it contradicts the specific figures provided in the ground truth. (5) SEMANTIC ALIGNMENT: The qualitative conclusion about strategic emphasis on diversification is reasonable and aligns with the ground truth interpretation, but this cannot overcome the fundamental numerical inaccuracies. The answer demonstrates partial understanding of the question's intent but fails on the primary metric of factual correctness regarding the specific dollar amounts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 581,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the status and disclosure of Class B-2 Common Stock evolve between 2023 and 2024, particularly regarding its outstanding status and relationship to other stock classes?",
      "original_answer": "In 2023, Class B-2 Common Stock was subject to conversion rate adjustments tied to the U.S. litigation escrow account under the U.S. retrospective responsibility plan, which caused dilution in as-converted shares. Additionally, it was noted that no shares of Class B-2 were outstanding prior to the Class B-1 exchange offer. By 2024, the 10-K filing only referenced Class B-2 Common Stock in relation to its lack of outstanding shares prior to the Class B-1 exchange offer, with no further updates or disclosures regarding its conversion mechanics or dilution impacts, suggesting a reduced emphasis or potential discontinuation of its active role in the capital structure.",
      "llm_answer": "In the 2023 Form 10‑K (V_10k_2023 pp. 85‑89) the equity table lists “Class B‑2 common stock” with a dash for shares outstanding, and a footnote notes that no B‑2 shares existed prior to any exchange offer. By the 2024 Form 10‑K (V_10k_2024 pp. 57‑61) the same table reports 120 million B‑2 shares outstanding (186 million as‑converted) and footnote 4 explains that they were issued in the May 2024 Class B‑1 exchange offer—converting B‑1 shares into B‑2 (and Class C) shares, with a 1.5430 conversion rate to Class A and a double‑impact conversion‑rate adjustment versus B‑1. This shows the class moving from non‑existent in 2023 to an issued, convertible class linked to the B‑1 exchange in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) MAJOR CONTRADICTION ON 2023 STATUS: The ground truth states that in 2023, Class B-2 Common Stock existed and was subject to conversion rate adjustments tied to the U.S. litigation escrow account with dilution impacts. The LLM claims B-2 shares showed 'a dash for shares outstanding' in 2023 and were 'non-existent in 2023,' which directly contradicts the ground truth. (2) INCORRECT 2024 CHARACTERIZATION: The LLM states that 120 million B-2 shares were 'issued in the May 2024 Class B-1 exchange offer,' but the ground truth indicates that by 2024, the 10-K only referenced B-2 in relation to its lack of outstanding shares prior to the Class B-1 exchange offer, with no further disclosures about conversion mechanics. The LLM's claim of 120 million shares outstanding and 186 million as-converted shares in 2024 cannot be verified against the ground truth and appears to be fabricated. (3) CONVERSION RATE DETAILS: The LLM provides specific conversion rates (1.5430 to Class A, 'double-impact conversion-rate adjustment') that are not mentioned in the ground truth and appear to be invented. (4) EVOLUTION NARRATIVE REVERSED: The ground truth describes a reduction in emphasis/potential discontinuation by 2024, while the LLM describes an expansion from non-existent to actively issued. This is the opposite of what the ground truth indicates. (5) MISSING KEY CONTEXT: The LLM fails to mention the U.S. litigation escrow account and retrospective responsibility plan that were central to the 2023 disclosure. The answer demonstrates fundamental misunderstanding of the actual evolution of Class B-2 disclosure between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 472,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the financial obligations related to the Target Circle program change between 2022 and 2024, and what does this indicate about the program's evolution?",
      "original_answer": "In 2022, the deferred revenue related to the Target Circle program was $89 million as of January 29, 2022, while in 2024, the deferred revenue related to the program was $117 million as of February 3, 2024. This indicates a significant increase in the company's liability tied to unredeemed rewards, suggesting growth in program participation or changes in redemption patterns. However, by February 1, 2025, the deferred revenue had dropped to $19 million, signaling a sharp decline, which may reflect either a surge in reward redemptions or a strategic change in how the program's liabilities are recognized or managed.",
      "llm_answer": "The Target Circle liability fell sharply – the 2022 Form 10‑K reported $89 million of deferred revenue for the loyalty program, while the 2024 Form 10‑K showed the liability had dropped to $19 million (a $70 million reduction)【TGT_10k_2022.pdf†L44-L48】【TGT_10k_2024.pdf†L48-L52】.  This steep decline suggests the program’s outstanding reward obligations have been largely resolved, reflecting higher redemption, a more mature program design, or a strategic shift that reduces future accruals.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a significant factual error regarding the 2024 figure. The ground truth states that in 2024 (as of February 3, 2024), deferred revenue was $117 million, NOT $19 million. The LLM conflates the 2024 figure ($117M) with the 2025 figure ($19M), fundamentally misrepresenting the data. The LLM correctly identifies the 2022 figure of $89 million and correctly calculates a $70 million reduction, but this calculation is based on comparing 2022 ($89M) to 2025 ($19M), not 2022 to 2024 as the question asks. INCOMPLETENESS: The question specifically asks about changes 'between 2022 and 2024,' but the LLM answer jumps to 2025 data instead, missing the intermediate 2024 data point entirely. The ground truth shows a progression: 2022 ($89M) → 2024 ($117M, +$28M increase) → 2025 ($19M, -$98M decrease). The LLM only captures the 2022-to-2025 trajectory, missing the crucial 2024 intermediate point and the initial growth phase. REASONING QUALITY: While the LLM's interpretation of what a decline might indicate (higher redemption, mature program design, strategic shift) is reasonable, it's applied to the wrong time period and misses the important insight that the program actually GREW from 2022 to 2024 before declining sharply in 2025. This represents a failure in multi-hop synthesis across the three fiscal years. CORRECT ELEMENTS: The LLM correctly identifies Target Circle as the program in question and correctly cites the 2022 figure of $89 million.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 417,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the fair value of Netflix's 4.375% Senior Notes change between December 31, 2022, and December 31, 2023, and what does this indicate about investor perception or market conditions?",
      "original_answer": "The fair value of Netflix's 4.375% Senior Notes decreased from $980 million on December 31, 2022, to $996 million on December 31, 2023. This indicates a shift in investor perception or market conditions, as the fair value moved closer to the principal amount at par, suggesting a stabilization or improved outlook for the company's debt.",
      "llm_answer": "The fair‑value of Netflix’s 4.375 % Senior Notes rose from about **$980 million at 12/31/2022** to **$996 million at 12/31/2023**, an increase of roughly **$16 million (≈1.6 %)**【NFLX_10k_2023.pdf: page 54】. This modest uptick indicates that investors were willing to pay a slightly higher price for the notes, reflecting a more favorable perception of Netflix’s credit standing or broader market conditions that lowered yields and boosted demand for its fixed‑rate debt【NFLX_10k_2023.pdf: page 54】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-reasoned. QUANTITATIVE VERIFICATION: All numbers are correct - the fair value increased from $980 million (12/31/2022) to $996 million (12/31/2023), representing a $16 million increase of approximately 1.6%. The calculation is accurate: $16M/$980M = 1.63%, correctly rounded to 1.6%. ENTITY ACCURACY: Netflix, the 4.375% Senior Notes, and the correct fiscal year-end dates are all properly identified. REASONING QUALITY: The LLM correctly interprets the directional change (increase, not decrease as stated in ground truth) and provides sound financial analysis - explaining that the price increase reflects improved investor perception of Netflix's creditworthiness and favorable market conditions for fixed-rate debt. This interpretation is more nuanced than the ground truth's statement about 'stabilization or improved outlook.' MULTI-HOP SYNTHESIS: The answer successfully synthesizes the numerical data with market interpretation, connecting the fair value change to broader credit market dynamics. MINOR DISCREPANCY: The ground truth states the fair value 'decreased' while the LLM correctly identifies it as an 'increase' - the LLM's interpretation is factually correct based on the numbers provided ($980M to $996M is an increase). The LLM's explanation of what this indicates about investor perception is actually more sophisticated than the ground truth, properly linking the price increase to improved credit perception. The citation to the 10-K filing adds credibility. Overall, this is a strong answer with accurate numbers, correct calculations, sound reasoning, and appropriate financial interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 454,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the equity structure related to Class C Common Stock evolve between 2023 and 2024, particularly in terms of share issuance and equity classification?",
      "original_answer": "In 2023, Visa conducted an exchange offer where 241 million shares of Class B-1 common stock were tendered, and in exchange, approximately 48 million shares of Class C common stock were issued. This indicates active restructuring of stock classes tied to the Visa Europe retrospective responsibility plans. By 2024, the balance of Class C common stock remained at 10 shares issued and outstanding, as stated in the equity section of the balance sheet. This suggests that while there was active movement and restructuring involving Class C shares in 2023, the 2024 disclosures indicate a stabilization or conclusion of that phase of equity restructuring.",
      "llm_answer": "In 2023 Visa reported only 10 Class C common‑stock shares issued and outstanding, with a weighted‑average of 10 shares (see the equity table and share‑count table)【V_10k_2024.pdf†p.56】. In 2024 the company issued roughly 48 million new Class C shares as part of the May 2024 Class B‑1 exchange offer, which lifted the weighted‑average Class C share count to 16 shares (while the year‑end “issued and outstanding” line still shows 10 shares) and the shares continued to be classified as a non‑listed Class C common‑stock class【V_10k_2024.pdf†p.56‑57】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains fundamental factual errors that directly contradict the ground truth. CRITICAL ERRORS: (1) TIMELINE REVERSAL: The LLM states that in 2023 there were 10 Class C shares outstanding, and in 2024 approximately 48 million new Class C shares were issued. The ground truth shows the OPPOSITE: in 2023, 48 million Class C shares were issued (via exchange of 241 million Class B-1 shares), and by 2024 the balance was 10 shares. This is a complete reversal of the temporal sequence. (2) EXCHANGE OFFER TIMING: The LLM places the exchange offer in May 2024, but the ground truth clearly indicates this occurred in 2023. (3) WEIGHTED AVERAGE SHARES: The LLM claims the weighted-average Class C share count was 10 in 2023 and rose to 16 in 2024. The ground truth indicates approximately 48 million shares were issued in 2023, which would result in a much higher weighted average, not 10 shares. (4) MISSING KEY DETAIL: The LLM fails to mention the 241 million Class B-1 shares that were tendered in the 2023 exchange, which is a critical component of understanding the equity restructuring. (5) MISCHARACTERIZATION: The LLM suggests the 10 shares shown in 2024 represents a 'stabilization' when in fact the ground truth indicates the 48 million shares issued in 2023 had been reduced or consolidated to 10 shares by 2024. The answer demonstrates poor multi-hop synthesis and appears to have inverted the chronological sequence of events. While the answer is contextually relevant to the question topic, the factual accuracy is severely compromised by these fundamental errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 436,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Lowe's engagement with Rough Plumbing evolved from 2022 to 2024, particularly in terms of its business classification and service offerings?",
      "original_answer": "In 2022, Rough Plumbing was classified under the 'Building Products' category, indicating it was primarily offered as a product within Lowe's merchandise divisions. By 2024, Lowe's had expanded its engagement with Rough Plumbing by integrating it into both installation services and protection plans, signaling a shift from a pure product offering to a more service-oriented approach. This evolution reflects a strategic move to bundle Rough Plumbing with labor and extended protection, contributing to the approximately 5% of total sales attributed to installed sales in 2024.",
      "llm_answer": "In the 2022 Form 10‑K Rough Plumbing was grouped under the Building Products segment – the filing lists “Building Products … includes … Rough Plumbing” as one of the product categories in that division【2022:55】. By the 2024 filing Lowe’s treats Rough Plumbing as a stand‑alone product line in its overall assortment (“We offer … Rough Plumbing …”【2024:5】) and has expanded its role to services – it is named among the categories that generate the bulk of installed‑sales projects【2024:7】 and is covered by Lowe’s extended protection‑plan offerings【2024:8】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of Rough Plumbing from 2022 to 2024, accurately capturing the shift from a product-only classification to an integrated service offering. The answer properly cites the 2022 Building Products categorization and the 2024 expansion into installation services and protection plans. However, there is a significant quantitative discrepancy: the ground truth specifically mentions 'approximately 5% of total sales attributed to installed sales in 2024,' but the LLM answer does not include this specific metric. This is a notable omission since the question asks about the evolution 'particularly in terms of its business classification and service offerings,' and the 5% figure provides concrete quantitative evidence of the scale of this service expansion. The LLM's multi-hop reasoning is sound—it correctly synthesizes information across 2022 and 2024 filings and identifies the strategic shift. The entity identification is accurate (Lowe's, Rough Plumbing, correct years). The semantic equivalence is strong: phrases like 'integrated into both installation services and protection plans' vs. 'expanded its role to services' and 'covered by Lowe's extended protection-plan offerings' convey the same meaning. The citation format with page references adds credibility. The main weakness is the missing quantitative anchor (5% figure) that would have strengthened the answer's completeness and provided concrete evidence of the business evolution's magnitude.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 416,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the introduction and subsequent status of Class B-2 common stock evolve between 2023 and 2024, and what does this indicate about its role in the company's capital structure?",
      "original_answer": "In 2023, Class B-2 common stock was newly introduced with 77 million shares outstanding, indicating its initial incorporation into the company's equity structure. By 2024, the company disclosed that no shares of Class B-2 common stock were outstanding prior to the Class B-1 common stock exchange offer, suggesting a strategic shift where Class B-2 shares may have been replaced or restructured as part of a broader capital realignment. This indicates a transformation in the role of Class B-2 common stock within the company’s capital structure.",
      "llm_answer": "In the 2023 filing Visa’s capital structure included only Class B‑1 common stock (the former Class B) and the filing expressly notes that **no Class B‑2 shares were outstanding**. In 2024, after the January 23, 2024 charter amendment and the May 6‑8, 2024 exchange offer, Visa **created Class B‑2 common stock**, issuing roughly 120 million shares (≈77 million as‑converted) in exchange for 241 million retired Class B‑1 shares, and the new shares now appear in the weighted‑average share counts and EPS tables. This shows that Class B‑2 was introduced as a **transitional, freely‑tradeable class that replaces the restricted Class B‑1 shares and carries a double‑weight impact on conversion‑rate adjustments**, indicating its role as a bridge to liquidity and a key component of the company’s evolving capital structure.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains fundamental factual errors that directly contradict the ground truth. CRITICAL ERRORS: (1) REVERSED TIMELINE: The LLM claims Class B-2 did NOT exist in 2023 and was CREATED in 2024, but the ground truth explicitly states Class B-2 was 'newly introduced' in 2023 with 77 million shares outstanding. This is a complete reversal of the actual evolution. (2) INCORRECT SHARE COUNTS: The LLM states '120 million shares (≈77 million as-converted)' were issued in 2024, but the ground truth indicates 77 million shares were outstanding in 2023 (the initial introduction). The LLM's numbers don't align with the ground truth's 77 million figure for 2023. (3) MISCHARACTERIZATION OF 2024 STATUS: The ground truth states that by 2024, 'no shares of Class B-2 common stock were outstanding prior to the Class B-1 common stock exchange offer,' suggesting a restructuring or replacement. The LLM incorrectly interprets this as Class B-2 being newly created in 2024. (4) WRONG NARRATIVE: The LLM presents Class B-2 as a 'transitional, freely-tradeable class' created in 2024 to replace Class B-1, but the ground truth shows Class B-2 existed in 2023 and then underwent a strategic shift by 2024. The LLM fundamentally misunderstands the chronological evolution. WHAT WAS CORRECT: The LLM correctly identifies that there was a charter amendment and exchange offer in 2024, and correctly notes that Class B-1 shares were involved in the transaction. However, these correct elements are embedded in an otherwise incorrect narrative about when Class B-2 was introduced. The multi-hop reasoning is flawed because the LLM reversed the temporal sequence of events, making the entire answer semantically incorrect despite some accurate supporting details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 478,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has the financial liability associated with the Target Circle program changed between 2022 and 2024, and what does this indicate about the program's growth or evolution?",
      "original_answer": "In 2022, the Target Circle program was described primarily in terms of its benefits to customers, such as earning 1% rewards on non-RedCard purchases, but no specific liability figure was disclosed. By 2024, the deferred revenue related to the Target Circle program had grown to $117 million as of February 3, 2024, indicating a significant increase in the program's financial liability and suggesting substantial growth or expansion of the program. This increase reflects a greater number of participants or increased transactional activity within the program.",
      "llm_answer": "The 2022 Form 10‑K only describes the Target Circle loyalty program and does not disclose a specific deferred‑revenue liability for it, implying the liability was negligible or not material at that time. By the 2024 Form 10‑K, Target reported a $117 million deferred‑revenue liability for Target Circle (as of February 3 2024)【2024 Form 10‑K p. 48】. The appearance and size of this liability show that the program has expanded markedly, with more members earning rewards and a larger future redemption obligation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-aligned with the ground truth. Quantitative accuracy is perfect: the $117 million deferred revenue figure for February 3, 2024 is correct, and the characterization of 2022 as having no specific disclosed liability is accurate. The multi-hop reasoning is sound—the model correctly synthesizes information across two different fiscal years (2022 and 2024) and properly interprets what the appearance and growth of the liability indicates about program expansion. The answer addresses all parts of the question: (1) the 2022 status (no specific liability disclosed), (2) the 2024 status ($117 million), and (3) what this indicates about growth (marked expansion with more members and larger redemption obligations). The semantic meaning matches the ground truth perfectly—both answers convey that the program grew substantially from 2022 to 2024, evidenced by the emergence of a material deferred revenue liability. The citation to the 2024 Form 10-K page 48 adds credibility. Minor note: the LLM uses slightly different phrasing ('negligible or not material' vs. ground truth's 'no specific liability figure was disclosed'), but this is semantically equivalent and actually provides helpful context about why no figure appeared. The reasoning about what the liability indicates (more members, larger future redemption obligation) is logically sound and matches the ground truth's interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 398,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has NVDA's exposure to and concern about pollution limits evolved between 2023 and 2024, particularly in terms of regulatory impact on operations and customer data center expansion?",
      "original_answer": "In 2023, NVDA highlighted that pollution limits and related climate regulations could increase direct and indirect costs, including compliance, energy, and capital expenditures, and could require changes to manufacturing processes and supply chain operations. By 2024, the company expanded its concern to include not only cost increases but also the potential for land and permitting constraints tied to pollution limits, which could impair customers' ability to expand data center capacity—an essential market for NVDA's products. This indicates a growing concern that regulatory tightening around pollution could directly affect demand for NVDA's offerings.",
      "llm_answer": "In the 2023 Form 10‑K, NVIDIA identified pollution‑limit regulations as a climate‑related risk that could raise direct costs and force changes to its manufacturing processes and supply chain (NVDA_10k_2023.pdf p.20‑21). By the 2024 filing, the company broadened the exposure, warning that new or proposed pollution‑limit rules – together with water, energy and land‑use restrictions – could also curtail customers’ ability to expand data‑center capacity, which could dampen demand for NVIDIA’s products (NVDA_10k_2024.pdf p.22‑23).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about NVDA's evolving pollution-related concerns between 2023 and 2024. STRENGTHS: (1) Correctly identifies the 2023 baseline concerns (direct costs, compliance, energy, capital expenditures, manufacturing process changes, supply chain impacts) matching the ground truth. (2) Accurately captures the 2024 expansion of concerns to include land and permitting constraints affecting customer data center expansion capacity. (3) Properly synthesizes the multi-hop reasoning: 2023 direct operational impacts → 2024 indirect demand impacts through customer constraints. (4) Correctly identifies the strategic significance that regulatory tightening could affect demand for NVDA's products. (5) Appropriately cites specific document sources and page numbers (though these cannot be independently verified, they are presented with appropriate specificity). (6) Uses semantically equivalent language to the ground truth while maintaining clarity. MINOR CONSIDERATIONS: (1) The LLM answer mentions \"water, energy and land-use restrictions\" in addition to pollution limits in 2024, which represents a slight expansion beyond the ground truth's focus on \"land and permitting constraints tied to pollution limits.\" However, this is not contradictory—it provides additional context about related regulatory concerns. (2) The phrasing \"dampen demand\" is semantically equivalent to the ground truth's \"impair customers' ability to expand data center capacity—an essential market for NVDA's products.\" Both convey the same causal chain. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are present in either answer, so this dimension is not applicable but receives full marks as there are no errors. MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years and two documents, establishing the causal relationship between regulatory evolution and business impact. The logic is sound and complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 550,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the composition and valuation of the company's Guaranteed Senior Notes evolve between 2023 and 2024, particularly in terms of issuance, repayment, and fair value inputs?",
      "original_answer": "In 2023, the company's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. These notes were valued using Level 3 inputs. In 2024, the Japanese subsidiary repaid $77 of these Guaranteed Senior Notes. The fair value of long-term debt, including Guaranteed Senior Notes, was approximately $5,412 at the end of 2024, compared to $5,738 at the end of 2023. This indicates a reduction in the overall fair value of long-term debt, partially driven by repayments on the Guaranteed Senior Notes.",
      "llm_answer": "In 2023 Costco’s Japanese subsidiary issued four Guaranteed Senior Notes – roughly $500 in principal – which were recorded as $484 of “Other long‑term debt” on the balance sheet【COST_10k_2023.pdf: Note 4‑Debt】. By July 2024 the subsidiary had repaid $77 of those notes, leaving $919 of other long‑term debt (a net increase of $435) in the 2024 filing【COST_10k_2024.pdf: Note 4‑Debt】. The Guaranteed Senior Notes are valued using Level 3 (unobservable) inputs, and the overall fair‑value of long‑term debt fell from about $5,738 in 2023 to $5,412 in 2024【COST_10k_2024.pdf: Note 4‑Debt】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies key facts about the Guaranteed Senior Notes but contains a significant quantitative error that undermines accuracy. CORRECT ELEMENTS: (1) Four Guaranteed Senior Notes issued in 2023 by Japanese subsidiary - correct; (2) Approximately $500 in principal - correct; (3) $77 repaid in 2024 - correct; (4) Level 3 valuation inputs - correct; (5) Fair value of long-term debt: $5,738 (2023) and $5,412 (2024) - correct; (6) Overall fair value reduction - correct. CRITICAL ERROR: The LLM states 'leaving $919 of other long-term debt (a net increase of $435)' in 2024. This contains a logical inconsistency and appears to conflate the Guaranteed Senior Notes balance with total 'Other long-term debt.' The ground truth indicates the Guaranteed Senior Notes were $500 in 2023 and $77 was repaid in 2024, leaving approximately $423 in Guaranteed Senior Notes (not $919). The mention of $919 and the 'net increase of $435' suggests the LLM is mixing in other debt components, which creates confusion about the specific composition of Guaranteed Senior Notes. MULTI-HOP REASONING: The LLM correctly synthesizes information across 2023 and 2024 filings and properly connects issuance, repayment, and fair value changes. The reasoning about the relationship between repayments and overall fair value reduction is sound. COMPLETENESS: The answer addresses issuance, repayment, and fair value inputs as requested, though the balance sheet reconciliation is muddled. The interest rate ranges (1.400% to 2.120%) mentioned in the ground truth are omitted, representing a minor completeness gap. The core narrative of evolution between years is present but compromised by the quantitative confusion regarding the $919 figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 474,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Netflix's investment in streaming service improvements and associated risk exposure evolve from 2022 to 2024, based on the specific personnel and cybersecurity-related changes disclosed in those years?",
      "original_answer": "In 2022, Netflix disclosed a $384 million increase in personnel-related costs driven by headcount growth to support production activity and improve the streaming service. By 2024, the focus had evolved to include significant emphasis on cybersecurity, with detailed descriptions of enterprise-wide security programs, third-party risk management, and the potential financial impact of cyber incidents. The company highlighted the risk of unauthorized data releases and digital content theft, noting that such events could adversely affect business operations and financial results. This represents a shift from purely growth-oriented investment in streaming to a more risk-aware posture as the service matured.",
      "llm_answer": "In the 2022 filing (pages 24‑28) Netflix said technology‑and‑development spending jumped $384 million – almost all of it from added personnel to expand and improve its streaming service – and it highlighted a newly‑named Vice President of Security and Privacy Engineering who reports to the board’s audit committee. By the 2024 filing (pages 15‑19) the same security leadership and audit‑committee oversight remain, but the company stresses ongoing enterprise‑wide risk assessments and acknowledges continued exposure to directed cyber‑attacks, showing that while investment in streaming‑service upgrades continues, Netflix’s risk‑management focus and dedicated cybersecurity personnel have intensified.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the core narrative and correctly identifies the key $384 million personnel cost increase in 2022 and the shift toward cybersecurity focus by 2024. The quantitative data is accurate - the $384 million figure matches the ground truth exactly. The multi-hop synthesis is sound, correctly connecting personnel investment in 2022 to cybersecurity emphasis in 2024 and identifying the evolution from growth-oriented to risk-aware posture. The mention of a Vice President of Security and Privacy Engineering reporting to the audit committee adds specific detail that supports the narrative. However, there are some limitations: (1) The LLM provides specific page references (pages 24-28, pages 15-19) that cannot be verified against the ground truth and may be inaccurate or fabricated; (2) The answer could have been more explicit about the 'potential financial impact of cyber incidents' and specific risks like 'unauthorized data releases and digital content theft' that were highlighted in the ground truth; (3) The phrase 'newly-named Vice President' in 2022 is not explicitly confirmed in the ground truth, which only mentions the role exists; (4) The answer doesn't fully capture the 'detailed descriptions of enterprise-wide security programs, third-party risk management' mentioned in the ground truth. The core factual accuracy is strong, the reasoning is logical and addresses the multi-hop nature of the question (connecting 2022 to 2024 changes), and the semantic meaning aligns well with the ground truth. The main detractions are the unverifiable page citations and slightly incomplete coverage of specific cybersecurity risk disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 463,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did The Bank of New York Mellon Corporation's approach to restricted stock unit agreements evolve between the 2023 and 2024 filings, particularly in terms of the lifecycle management of these equity instruments and their implications for executive compensation strategy?",
      "original_answer": "In the 2023 filing, the '2024 Form of Restricted Stock Unit Agreement' was newly introduced and explicitly stated as 'Filed herewith,' indicating it was a current and newly adopted form for that year. This suggests the company was actively updating its equity compensation framework to align with strategic goals for executive retention and incentives. By the 2024 filing, this '2024 Form' was no longer newly filed but instead was referenced as 'Previously filed,' signaling it had become an established part of the company's compensation structure. Additionally, in 2024, the company introduced the '2025 Form of Restricted Stock Unit Agreement,' which was marked as 'Filed herewith,' showing a forward-looking update to the equity compensation strategy. This evolution indicates a consistent, proactive approach to managing executive compensation frameworks, with new forms being introduced annually and the prior year’s forms transitioning into reference documents. This reflects a mature, iterative process in shaping executive incentives and aligning them with long-term corporate objectives.",
      "llm_answer": "In the 2023 filing the company’s Restricted Stock Unit Agreement (Exhibit 10.24) granted RSUs that vest on a fixed schedule, settle only in common stock and are forfeited on termination, with no cash‑settlement or performance‑linked conversion features. The 2024 filing (Exhibit 10.26) rewrote the RSU agreement to add cash‑or‑stock settlement options, extend vesting up to five years, include a claw‑back provision and permit conversion of unvested RSUs into performance‑share units—giving BNY Mellon tighter lifecycle control of the equity awards and aligning executive compensation more closely with long‑term performance and risk‑management objectives.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and addresses a completely different question than what was asked. The original question asks about the EVOLUTION of BNY Mellon's approach to RSU agreements between 2023 and 2024 filings, specifically regarding how the FORMS themselves changed (from '2024 Form Filed herewith' in 2023 to '2024 Form Previously filed' and '2025 Form Filed herewith' in 2024). This is about document filing status and the company's iterative annual updates to its equity compensation framework. The ground truth answer correctly identifies this pattern: new forms introduced annually, prior forms becoming reference documents, showing a mature, proactive approach to managing compensation frameworks. The LLM answer instead fabricates detailed technical changes to RSU agreement terms (cash-or-stock settlement options, extended vesting to five years, claw-back provisions, conversion to performance-share units) that are NOT mentioned in the ground truth and appear to be entirely invented. The LLM conflates exhibit numbers (10.24 vs 10.26) without any basis in the provided ground truth. The answer demonstrates a fundamental misunderstanding of the question - it attempts to describe substantive changes to RSU mechanics rather than the evolution of the company's approach to managing and updating these agreements across filing years. There are no verifiable numbers or calculations in the LLM answer that can be checked against the ground truth, and the entire premise of the response is factually incorrect based on the knowledge graph data provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1470,
        "completion_tokens": 434,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the status and structure of the 4.90% Senior Notes evolved from 2023 to 2024, particularly in terms of their carrying amount and maturity timeline?",
      "original_answer": "In 2023, the 4.90% Senior Notes were newly issued in November 2023, with a principal amount of $750 million, a discount of $3.4 million, and a maturity date of April 15, 2029. Interest payments were scheduled semi-annually starting April 15, 2024. By 2024, these notes remained outstanding, with a carrying amount of $743 million as of January 28, 2024. The maturity date remained unchanged at April 2029, and the notes continued to be listed among the company’s long-term debt obligations. The carrying amount slightly decreased, reflecting the initial discount and amortization progress over the year.",
      "llm_answer": "In the 2023 filing the company disclosed that it issued a single $750 million tranche of 4.90 % senior notes in November 2023, due April 15 2029, at a $3.4 million discount, which showed a net carrying amount of $743 million as of January 29 2023. By the 2024 filing the notes were still outstanding, the net carrying amount had risen to $744 million (reflecting amortization of the discount) and the maturity date remained unchanged at April 2029.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) DATE ERROR - The LLM states the carrying amount of $743 million was 'as of January 29 2023' but this is factually incorrect. The ground truth clearly states this was 'as of January 28, 2024' - a full year difference that fundamentally misrepresents the timeline. The notes were issued in November 2023, so they could not have had a carrying amount in January 2023. (2) CARRYING AMOUNT DISCREPANCY - The LLM claims the carrying amount 'had risen to $744 million' in 2024, but the ground truth states it was $743 million as of January 28, 2024. This is a $1 million error in the 2024 figure. (3) INCOMPLETE CONTEXT - The LLM fails to clearly explain that the $743 million carrying amount in 2024 represents a decrease from the $750 million principal (due to the $3.4 million discount and amortization), whereas the LLM's statement that it 'had risen to $744 million' suggests an increase, which is misleading. (4) MISSING DETAILS - The LLM omits the important detail about semi-annual interest payments starting April 15, 2024, which is part of the structural evolution. (5) MULTI-HOP REASONING - While the LLM attempts to synthesize 2023 and 2024 information, the fundamental date error (January 29 2023 vs January 28 2024) undermines the entire comparison and shows failure in proper temporal synthesis. The principal amount ($750M), discount ($3.4M), maturity date (April 2029), and interest rate (4.90%) are correctly stated, but the carrying amount figures and their temporal placement are significantly flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 425,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did the issuance and repayment of Guaranteed Senior Notes by Costco's Japanese subsidiary evolve between 2023 and 2024?",
      "original_answer": "In 2023, Costco's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. In 2024, the subsidiary repaid $77 of these Guaranteed Senior Notes. Additionally, the proceeds from the issuance of these notes were referenced in the 2024 filing as a source of financing activity, indicating continued financial engagement with this instrument.",
      "llm_answer": "In the 2023 10‑K the Japanese subsidiary only reported $484 million of “other long‑term debt” and disclosed no new issuance or repayment of Guaranteed Senior Notes. By the 2024 10‑K the subsidiary had issued four Guaranteed Senior Notes in November 2023 for roughly $500 million and subsequently repaid $77 million of those notes in July 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and effectively addresses the multi-hop question about Costco's Japanese subsidiary's debt instruments across 2023-2024. Key strengths: (1) Correctly identifies the issuance of four Guaranteed Senior Notes totaling approximately $500 million in November 2023, matching the ground truth; (2) Accurately reports the $77 million repayment in July 2024; (3) Provides specific timing details (November 2023 issuance, July 2024 repayment) that add valuable context; (4) Correctly synthesizes information across two fiscal years' filings. Minor differences from ground truth: (1) The LLM answer does not explicitly mention the fixed interest rates (1.400% to 2.120%) that were referenced in the original answer, though this is a relatively minor omission; (2) The LLM notes the 2023 10-K reported $484 million of 'other long-term debt' with no new issuance disclosure, which provides helpful context about how the information evolved between filings but wasn't explicitly in the ground truth statement. The quantitative figures ($500M issuance, $77M repayment) are accurate and properly formatted. The multi-hop reasoning is sound—the answer correctly synthesizes that the issuance occurred in 2023 (disclosed in 2024 filing) and repayment occurred in 2024. The answer appropriately addresses the 'evolution' aspect of the question by showing the progression from no disclosure in 2023 to full disclosure and repayment activity in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1184,
        "completion_tokens": 407,
        "total_tokens": 1592
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the risk associated with competitors developing after-market parts for DHR's products evolved from 2022 to 2023, particularly in terms of its impact on the company's business and financial statements?",
      "original_answer": "In 2022, the risk of competitors developing after-market parts was described as a direct threat that could 'detract from our sales,' with an emphasis on how commoditization and private-label offerings could reduce market prices and erode DHR's competitive position. By 2023, the framing of this risk shifted to being 'Impacted By' such competition, with a broader contextualization within cost containment trends in the healthcare industry and pricing pressures from managed care and government reimbursement policies. While the core risk remained, it was presented as one of several external pressures rather than a primary threat, suggesting a relative de-emphasis in severity or a strategic recalibration in how the company perceives this risk.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K risk‑factor sections still flag the possibility that competitors could introduce after‑market services and parts for Danaher’s products. In 2022 the filing states that such competitors “may detract from our sales,” and the 2023 filing repeats the same concern, indicating it could still “adversely affect our business and financial statements.” The language and emphasis are essentially unchanged, showing that the company continues to view this as a persistent, but not newly heightened, risk.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. (1) CRITICAL ERROR - EVOLUTION CLAIM: The LLM states 'The language and emphasis are essentially unchanged,' directly contradicting the ground truth which explicitly documents a meaningful shift in how the risk was framed between 2022 and 2023. The ground truth shows a clear evolution from 2022 (risk described as 'direct threat' that 'detract from our sales') to 2023 (framed as 'Impacted By' competition, contextualized within broader industry pressures). The LLM completely missed this key evolution. (2) INCOMPLETE CONTEXTUALIZATION: The ground truth emphasizes that by 2023, the risk was presented 'as one of several external pressures rather than a primary threat,' suggesting a 'relative de-emphasis in severity or strategic recalibration.' The LLM fails to capture this important shift in how the company positioned the risk relative to other factors. (3) MISSING ANALYTICAL DEPTH: The ground truth provides nuanced analysis of how the risk was embedded within cost containment trends, managed care pressures, and government reimbursement policies in 2023. The LLM provides only surface-level comparison without this contextual analysis. (4) QUANTITATIVE ACCURACY: The LLM correctly identifies the 2022 language ('may detract from our sales') and 2023 language ('adversely affect our business and financial statements'), though these are presented as essentially equivalent when they represent different framings. (5) MULTI-HOP REASONING: The LLM failed to synthesize the evolution of risk framing across the two years, which was the core requirement of the question. The answer demonstrates a fundamental misunderstanding of the question's intent to track how the risk perception evolved, not merely whether it persisted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 492,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Netflix's approach to membership plans evolved from 2022 to 2024, particularly in terms of pricing strategy and service features, and what business challenges were these changes intended to address?",
      "original_answer": "In 2022, Netflix experienced a 19% revenue increase driven by an 11% growth in average paying memberships and a 7% rise in average monthly revenue per membership, partly due to price increases and favorable foreign exchange rates. However, paid net membership additions dropped by 50% compared to the prior year, signaling early signs of member acquisition challenges. By 2024, Netflix responded by introducing a lower-priced ad-supported subscription plan and enforcing terms of use to limit multi-household usage. These changes were aimed at addressing fluctuating member acquisition, retention pressures, and increasing competition in the streaming and broader entertainment market. The company acknowledged that macroeconomic conditions, content competition, and consumer sensitivity to pricing adjustments could negatively impact membership growth and profitability.",
      "llm_answer": "In 2022 Netflix’s membership strategy was still centered on its existing tiered plans – a global price band of roughly $2 to $27 per month – and the company relied on periodic price hikes and plan‑testing to lift average monthly revenue per paying member (2022 10‑K, “pricing on our paid plans ranged from $2 to $27 per month…price changes…increased average monthly revenue per paying membership”). By 2024 the firm had broadened the model: it introduced a lower‑priced ad‑supported subscription and added new service features such as games and live programming, while continuing to test price points and tighten household‑sharing rules (2024 10‑K, “lower‑priced ad‑supported subscription plan…expanded…to include games and, more recently, live programming”). These moves were intended to raise ARPU and attract price‑sensitive or churn‑prone users, offset slower membership growth, inflation‑driven consumer pressure, and intense competition, and help cover the high fixed content‑cost base.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies Netflix's evolution from 2022 to 2024, including the introduction of ad-supported plans, games, live programming, and household-sharing enforcement. The answer appropriately cites 10-K filings and captures the strategic intent (raising ARPU, attracting price-sensitive users, offsetting slower growth). The pricing range ($2-$27) is accurate. The reasoning about competition and content costs is sound.\n\nWEAKNESSES - QUANTITATIVE: The LLM answer omits critical quantitative data from the ground truth: (1) 19% revenue increase in 2022, (2) 11% growth in average paying memberships in 2022, (3) 7% rise in average monthly revenue per membership in 2022, (4) 50% drop in paid net membership additions in 2022 vs prior year. These specific metrics are factually correct per the ground truth and represent key evidence of the business challenges Netflix faced.\n\nWEAKNESSES - COMPLETENESS: While the LLM answer addresses pricing strategy and service features well, it provides less concrete quantitative evidence of the membership acquisition/retention pressures that motivated the changes. The ground truth explicitly states \"paid net membership additions dropped by 50%\" – a critical metric showing the severity of the challenge. The LLM mentions \"slower membership growth\" but doesn't quantify it.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2024 filings and connects strategic changes to business challenges. However, the reasoning would be stronger with the specific 2022 metrics showing the problem (50% drop in net additions) that prompted 2024 solutions.\n\nACCURACY VERIFICATION: All stated facts are correct – no false claims. The issue is incompleteness rather than incorrectness. The LLM provides accurate but partial coverage of the ground truth answer.\n\nSCORING RATIONALE: Correctness score of 6 reflects that while the answer is directionally correct and contains no major errors, it omits significant quantitative evidence (50% drop in net additions, specific growth percentages) that are central to understanding the severity of Netflix's challenges and the motivation for strategic changes. The answer would score 8-9 if it included these specific metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1480,
        "completion_tokens": 605,
        "total_tokens": 2086
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Boeing's approach to in-orbit incentive payments evolved between 2022 and 2023, particularly in terms of risk exposure and financial recognition?",
      "original_answer": "In 2022, Boeing highlighted the financial risks associated with in-orbit incentive payments, particularly in the context of potential program cancellations or failure to meet performance criteria, which could trigger termination provisions or loss of payments. The company noted that these risks were part of ongoing fixed-price development programs like Commercial Crew, KC-46A Tanker, and VC-25B. By 2023, Boeing had recorded $1,585 million in additional losses on its five most significant fixed-price development programs, which included those mentioned in 2022, and explicitly stated that in-orbit incentive payments were at risk if satellites failed to meet performance criteria over up to 15 years post-acceptance. The company also emphasized that the net present value of these fees was recognized as revenue during the construction period, increasing financial exposure if performance issues arose. This represents a shift from general risk acknowledgment in 2022 to a more specific quantification of losses and a detailed explanation of revenue recognition practices tied to in-orbit performance in 2023.",
      "llm_answer": "In the 2022 Form 10‑K Boeing only warned that a satellite’s failure could “trigger … the loss of satellite in‑orbit incentive payments” as a contingent financial exposure (2022 10‑K pp. 45‑46). By the 2023 filing the company had codified the treatment – it now records the net present value of any in‑orbit incentive fees as revenue during the construction period, while still noting that non‑performance could halt those payments and force refunds or charge‑offs (2023 10‑K pp. 13‑17). This reflects a shift from a generic risk mention to an explicit revenue‑recognition policy and clearer articulation of the associated risk.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution in Boeing's approach to in-orbit incentive payments between 2022 and 2023, capturing the shift from generic risk acknowledgment to explicit revenue recognition policy. The qualitative reasoning is sound and well-articulated.\n\nSTRENGTHS:\n1. Correctly identifies the 2022 approach as a contingent risk warning about satellite failure triggering loss of payments\n2. Accurately describes the 2023 shift to explicit revenue recognition during construction period\n3. Properly notes the net present value treatment in 2023\n4. Correctly identifies the risk of non-performance leading to refunds/charge-offs\n5. Multi-hop synthesis is logical and appropriate\n6. Page citations (2022 10-K pp. 45-46; 2023 10-K pp. 13-17) add credibility\n\nWEAKNESSES:\n1. MISSING KEY QUANTITATIVE DATA: The ground truth specifically mentions \"$1,585 million in additional losses on its five most significant fixed-price development programs\" recorded in 2023. The LLM answer completely omits this critical financial figure, which is a significant quantitative gap.\n2. INCOMPLETE PROGRAM CONTEXT: The ground truth names specific programs (Commercial Crew, KC-46A Tanker, VC-25B) that were part of the 2022 risk discussion. The LLM answer does not reference these programs.\n3. MISSING TEMPORAL DETAIL: The ground truth specifies \"up to 15 years post-acceptance\" for performance criteria, which the LLM answer does not mention.\n4. INCOMPLETE RISK CHARACTERIZATION: The ground truth emphasizes \"potential program cancellations or failure to meet performance criteria\" as specific triggers in 2022, while the LLM answer uses more generic language.\n\nQUANTITATIVE ACCURACY ASSESSMENT:\nThe LLM answer contains no quantitative errors per se, but it fails to include the $1,585 million loss figure that is central to the 2023 evolution. This is not an error in stated numbers but rather a significant omission of key financial data that should have been included.\n\nMULTI-HOP REASONING:\nThe reasoning correctly synthesizes the evolution across two years and two filings, but the synthesis is incomplete because it misses the quantified impact of the losses in 2023.\n\nJUSTIFICATION FOR SCORE:\nThe answer is fundamentally correct in its characterization of the evolution (7/10 correctness) but loses points for omitting the $1,585 million figure and specific program names. The qualitative analysis is strong (8/10), but quantitative completeness is weak (6/10) due to the missing financial data. The answer would have scored 8-9 if it had included the specific loss amount and program references.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 698,
        "total_tokens": 2135
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly described as being posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/invrelations/directors-code-of-conduct.pdf, and the company stated its intention to disclose amendments or waivers on the website. In 2024, while the Code remained accessible, it was referenced more generally as part of a broader list of governance materials available on the company’s website, including committee charters and governance guidelines, without repeating the direct URL. The change indicates a shift from detailed disclosure of access to a more consolidated and implicit reference, suggesting a streamlined but less direct approach to public access in 2024.",
      "llm_answer": "In the 2023 Form 10‑K the company disclosed that its Directors’ Code of Conduct is posted on its website at https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors‑code‑of‑conduct.pdf and said it would post any amendments or waivers online [​BK_10k_2023.pdf p. 13]. The 2024 filing repeats the same URL and amendment‑waiver statement [​BK_10k_2024.pdf p. 3] but also lists the Directors’ Code of Conduct among the corporate‑governance documents available on the website, highlighting it as a separate, readily accessible resource [​BK_10k_2024.pdf p. 5]. This addition makes the code more prominently disclosed and easier for stakeholders to locate.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The ground truth explicitly states that in 2024, the URL was NOT repeated and the Code was referenced more generally without the direct URL, representing a shift to a more consolidated approach. However, the LLM claims the 2024 filing 'repeats the same URL' - this is incorrect and represents a critical misunderstanding of the evolution being described. The ground truth emphasizes the key change: from explicit URL disclosure in 2023 to implicit/general reference in 2024. The LLM also mischaracterizes the 2024 change as making the code 'more prominently disclosed and easier for stakeholders to locate,' when the ground truth indicates the opposite - a shift to less direct access. Additionally, there is a minor URL formatting discrepancy in the LLM answer ('inv relations' with a space vs 'invrelations' without a space in the ground truth), though this may be a transcription artifact. The LLM correctly identifies the company (BNY Mellon), the years (2023 and 2024), and the document type (Form 10-K), but fundamentally misses the core evolution being described - the shift from detailed to consolidated disclosure. The reasoning about accessibility is inverted from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 361,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role and deployment strategy of Mobileye Drive™ evolved between 2022 and 2023?",
      "original_answer": "In 2022, Mobileye launched the SAE L4 Self-Driving System (SDS), Mobileye Drive™, and secured multiple collaborations for commercial use, including with Udelv for autonomous cargo delivery and with Transdev for self-driving mobility services. Additionally, Mobileye achieved its first consumer L4 design win with Geely. By 2023, Mobileye’s strategy had evolved to focus on supplying the Mobileye Drive™ self-driving system to transportation network companies, public transit operators, and suppliers of AV-ready vehicle platforms, with plans to bundle it with Moovit’s urban mobility and transit intelligence application. This shift indicates a more defined go-to-market strategy targeting fleet deployment and mobility-as-a-Service (MaaS) ecosystems.",
      "llm_answer": "In 2022 Mobileye Drive™ was launched as an SAE‑Level 4 self‑driving system and was first deployed through early commercial pilots – partnering with Udelv for autonomous cargo delivery, Transdev for self‑driving mobility services, and even securing a consumer L4 design win with Geely. By 2023 the company repositioned Mobileye Drive™ as its flagship self‑driving platform for autonomous‑mobility‑as‑a‑service, focusing on supplying transportation‑network companies, public‑transit operators and AV‑ready vehicle platform suppliers, and planning to bundle the system with Moovit’s urban‑mobility and transit intelligence services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the evolution of Mobileye Drive™ between 2022 and 2023. (1) CORRECTNESS: All factual information is accurate. The 2022 launch details are correct (SAE L4 SDS, partnerships with Udelv and Transdev, Geely design win). The 2023 strategic shift is accurately captured (focus on TNCs, public transit operators, AV-ready suppliers, Moovit bundling). (2) QUANTITATIVE ACCURACY: No numeric values are present in either the ground truth or LLM answer, so this dimension is not applicable. All dates (2022, 2023) are correct. (3) ENTITY ACCURACY: All entities are correctly identified - Mobileye Drive™, Udelv, Transdev, Geely, Moovit, and the relevant market segments (TNCs, public transit, MaaS). (4) MULTI-HOP REASONING: The LLM successfully synthesizes information across two years and multiple partnerships/strategic initiatives, correctly identifying the evolution from early commercial pilots to a more defined go-to-market strategy. The connection between the 2022 partnerships and 2023 fleet/MaaS focus is logically sound. (5) SEMANTIC EQUIVALENCE: The LLM uses slightly different phrasing ('autonomous-mobility-as-a-service' vs 'Mobility-as-a-Service (MaaS) ecosystems') but conveys identical meaning. The term 'flagship self-driving platform' adds minor interpretive language not explicitly in ground truth but is semantically consistent. Minor deduction (1 point) for the slight interpretive addition of 'flagship' which, while reasonable, goes marginally beyond the ground truth statement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 431,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the structure and distribution rate of the Tower Preferred Interests evolved from 2022 to 2024?",
      "original_answer": "In 2022, the Tower Preferred Interests were divided into two series: the September series (Class A-1) totaling $1,500 with a 5.0% initial preferred distribution, and the December series (Class A-2) totaling $4,500 with a 4.75% initial preferred distribution. These distributions reset every five years. By 2024, the structure was amended in August 2024 to reclassify all 2019 Tower preferred interests into Fixed Rate Class A Limited Membership Interests (Tower Fixed Rate Interests) paying a 5.90% preferred distribution. Additionally, a portion of these fixed-rate interests will transition annually into Floating Rate Class A Limited Membership Interests (Tower Floating Rate Interests), which will pay a distribution equal to SOFR plus 250 basis points. This represents both a structural and rate evolution in the Tower Preferred Interests.",
      "llm_answer": "In the 2022 filing the Tower preferred interests were two fixed‑rate series – a September Class A‑1 tranche of $1.5 bn paying a 5.0% quarterly distribution and a December Class A‑2 tranche of $4.5 bn paying 4.75%, both resetting every five years【2022 p.128‑132】. By the 2024 filing AT&T had restructured those interests so that all $6 bn are now designated Fixed‑Rate Class A Limited Membership Interests paying 5.90%, and a portion will be converted over five years to Floating‑Rate Class A Limited Membership Interests that pay SOFR + 250 bps (potentially $525 by 2028)【2024 p.85‑89】. This represents a shift from two fixed‑rate series to a single higher‑rate fixed class plus a new floating‑rate component.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the Tower Preferred Interests evolution from 2022 to 2024. STRENGTHS: (1) All key financial figures are correct: $1.5bn (Class A-1), $4.5bn (Class A-2), 5.0% and 4.75% rates in 2022, and the 5.90% fixed rate plus SOFR+250bps floating rate structure in 2024. (2) The total of $6bn is correctly calculated and identified. (3) The multi-hop synthesis is sound: correctly identifies the 2022 two-series structure, the August 2024 reclassification event, and the transition mechanism. (4) All entity names are accurate (Class A-1, Class A-2, Fixed Rate Class A Limited Membership Interests, Floating Rate Class A Limited Membership Interests). (5) The five-year reset/transition periods are correctly noted. (6) The answer appropriately characterizes this as both a structural and rate evolution. MINOR CONSIDERATIONS: (1) The LLM includes a parenthetical note about \"potentially $525 by 2028\" which is not explicitly mentioned in the ground truth answer, though this appears to be a reasonable inference about the floating rate calculation (though the basis for this specific number is unclear and could be considered speculative). (2) The ground truth specifies \"2019 Tower preferred interests\" being reclassified, while the LLM refers to \"those interests\" without explicitly stating the 2019 vintage - this is a minor omission but doesn't affect the core accuracy. (3) The LLM correctly notes \"quarterly distribution\" for 2022 rates, adding helpful detail. The answer fully addresses the question's multi-part structure (how has it evolved, what is the structure, what are the distribution rates) and correctly synthesizes information across multiple filing years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 475,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the investment approach and unrealized gains/(losses) for Level 3 assets related to the Balanced Index Fund evolve from 2022 to 2023?",
      "original_answer": "In 2022, the company disclosed unrealized losses for Level 3 assets still held at year-end, including ($16) million for corporate fixed income securities and ($11) million for mortgage-backed and asset-backed fixed income securities. By 2023, these values shifted to unrealized gains of $2 million for corporate fixed income securities and $6 million for mortgage-backed and asset-backed fixed income securities. This indicates a significant turnaround in the performance of these assets. Additionally, while the Balanced Index Fund's composition remained at approximately 60% equities and 40% debt securities in both years, the valuation methodology in 2023 explicitly referenced a market approach based on quoted market prices (Level 1), suggesting a more transparent and standardized valuation process.",
      "llm_answer": "The Balanced Index Fund continued to be valued using a market‑based approach that relies on the quoted price of an identical instrument (a Level 1 measurement) in both 2022 and 2023. In contrast, the unrealized results for the plan’s Level 3 assets moved from overall losses in 2022 (e.g., a $16 loss on corporate fixed‑income, $11 loss on mortgage‑backed and asset‑backed securities, $14 loss on municipal securities and a $1 loss on real‑asset securities) to modest gains in 2023 (e.g., a $2 gain on corporate fixed‑income, $6 gain on mortgage‑backed and asset‑backed securities and a $3 gain on other fixed‑income securities).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates partial correctness with significant issues. STRENGTHS: (1) Correctly identifies the shift from losses in 2022 to gains in 2023 for Level 3 assets; (2) Accurately reports the $16M loss and $2M gain for corporate fixed income securities; (3) Accurately reports the $11M loss and $6M gain for mortgage-backed and asset-backed securities; (4) Correctly notes the market-based approach using Level 1 measurements; (5) Appropriately synthesizes the multi-hop comparison across years. WEAKNESSES: (1) The original answer mentions the Balanced Index Fund composition (60% equities, 40% debt) which the LLM answer omits entirely - this is a material omission from the ground truth; (2) The LLM introduces additional Level 3 asset categories ($14M loss on municipal securities, $1M loss on real-asset securities in 2022, and $3M gain on other fixed-income securities in 2023) that are NOT mentioned in the original answer - these appear to be hallucinated or from different source material; (3) The original answer emphasizes the 'investment approach' evolution and the 'more transparent and standardized valuation process' in 2023, which the LLM answer downplays; (4) The LLM answer conflates the Balanced Index Fund's valuation methodology (Level 1) with the Level 3 assets discussion, creating some confusion about which assets are being discussed. QUANTITATIVE VERIFICATION: The core numbers for corporate fixed income ($16M loss → $2M gain) and mortgage-backed securities ($11M loss → $6M gain) are correct. However, the introduction of municipal securities and real-asset securities data not in the ground truth is problematic. MULTI-HOP REASONING: The answer correctly synthesizes the year-over-year comparison but fails to fully address the investment approach component mentioned in the question. The reasoning is sound for what is presented, but incomplete relative to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 517,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has BNY Mellon's emphasis on accounting developments in its forward-looking statements evolved between 2023 and 2024, and what does this reveal about the changing influence of accounting standards on its strategic priorities?",
      "original_answer": "In 2023, BNY Mellon included accounting developments among a broader list of potential influences on forward-looking statements, noting they 'may impact our businesses' without specific elaboration. By 2024, the company expanded this language, explicitly stating that accounting developments 'may impact our businesses, regulatory, technology, market, economic or accounting developments and the impacts of such developments on our businesses.' This shift indicates a more integrated view of accounting changes as part of strategic risk and planning considerations. The inclusion of terms like 'capital plans including dividends and repurchases' and 'efficiency savings' in 2024 further suggests that accounting developments are increasingly tied to concrete business decisions and performance metrics.",
      "llm_answer": "In the 2023 Form 10‑K, accounting developments are mentioned only as one of many forward‑looking risk factors – “regulatory, technology, market, economic or accounting developments and the impacts of such developments on our businesses” – and are highlighted chiefly for their potential effect on reported results. By the 2024 Form 10‑K, the same language appears but is now grouped with “strategic priorities and initiatives, capital plans, transition to a platforms operating model, efficiency savings,” indicating that changes in accounting standards are being treated as a driver of key strategic and operational decisions. This shift shows that accounting standards have moved from a peripheral disclosure to a more central influence on BNY Mellon’s overall strategic agenda.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual inversion that contradicts the ground truth. (1) MAJOR FACTUAL ERROR - Year Attribution: The LLM states that in 2023, accounting developments are mentioned as 'regulatory, technology, market, economic or accounting developments' and that by 2024 this language is 'now grouped with strategic priorities.' However, the ground truth explicitly states the OPPOSITE: In 2023, accounting developments were mentioned 'among a broader list' without the full language, and by 2024, the company 'expanded this language' to include the full phrase. The LLM has reversed the chronological evolution. (2) MISCHARACTERIZATION OF 2023 LANGUAGE: The LLM claims the 2023 language includes 'regulatory, technology, market, economic or accounting developments' but the ground truth indicates 2023 had simpler language that 'may impact our businesses' without specific elaboration. The LLM appears to have attributed 2024 language to 2023. (3) INCOMPLETE SYNTHESIS: While the LLM correctly identifies that 2024 includes references to 'capital plans, transition to platforms operating model, efficiency savings,' it fails to properly establish the baseline comparison from 2023. The ground truth emphasizes that 2023 lacked this specificity. (4) LOGICAL CONCLUSION ERROR: The LLM's conclusion that accounting standards moved 'from peripheral disclosure to central influence' is contradicted by the ground truth's more nuanced finding that the shift represents 'a more integrated view' tied to 'concrete business decisions.' The LLM overstates the magnitude of change. (5) MISSING KEY DETAIL: The ground truth specifically notes the 2024 inclusion of 'capital plans including dividends and repurchases' as evidence of integration with business decisions, which the LLM mentions but doesn't emphasize as a key indicator of the evolution. The answer demonstrates poor multi-hop reasoning by inverting the temporal sequence of developments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 536,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the evolution of risks related to store safety and cybersecurity in 2023 potentially impact the associate experience, as compared to the engagement-focused initiatives highlighted in 2022?",
      "original_answer": "In 2022, HD emphasized internal initiatives to improve the associate experience through engagement surveys, a digital engagement platform, and recognition programs, which historically showed that four out of five associates were emotionally committed. However, in 2023, the company highlighted external risks such as increased store shrink, particularly from organized retail crime, and cybersecurity threats that could compromise associate data and store safety. These risks were noted to potentially erode trust, impact associate morale and retention, and damage the company's reputation. This shift indicates that while HD was actively fostering associate engagement in 2022, the emergence or escalation of external risks in 2023 introduced new challenges that could undermine those earlier gains in associate experience.",
      "llm_answer": "In its 2022 filing Home Depot emphasized engagement‑focused programs—annual Voice of the Associate surveys, digital engagement platforms, recognition and development initiatives—to build a strong, positive associate experience. By the 2023 filing the company added heightened risk disclosures around store safety (shrink, organized crime, unsafe environments) and cybersecurity breaches, warning that failures in these areas could create unsafe or stressful work conditions and erode morale, thereby threatening the associate experience that the 2022 engagement initiatives sought to nurture.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of the multi-hop question. STRENGTHS: (1) Correctly identifies the 2022 engagement initiatives (Voice of the Associate surveys, digital engagement platforms, recognition and development programs) matching the ground truth. (2) Accurately captures the 2023 risk shift (store shrink, organized retail crime, cybersecurity threats, unsafe environments). (3) Properly synthesizes the comparison showing how 2023 risks could undermine 2022 gains. (4) Correctly identifies Home Depot as the company. (5) No quantitative errors - no specific numbers were required in either answer, and both appropriately avoid citing the 'four out of five' statistic without being asked for it. (6) The reasoning is sound: 2022 focused on positive engagement initiatives → 2023 introduced external risks → these risks threaten the associate experience gains. MINOR CONSIDERATIONS: (1) The LLM answer uses slightly different phrasing ('Voice of the Associate surveys' vs 'engagement surveys') but this is semantically equivalent and actually more specific. (2) The LLM answer emphasizes 'unsafe or stressful work conditions' which is a reasonable inference from the risks mentioned, though the ground truth focuses more on 'eroding trust' and 'morale/retention.' (3) Both answers effectively convey that the shift from engagement focus to risk management represents a potential threat to associate experience. The LLM answer successfully captures the essence of the multi-hop comparison across years and risk categories.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 432,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the role of the 'learning curve' in influencing cost and production estimates evolved between 2022 and 2023, particularly in relation to program profitability and risk management?",
      "original_answer": "In 2022, the 'learning curve' was identified as a risk factor that could negatively impact program profitability due to production complexities, rework, and delays—especially in programs like the 787—potentially leading to additional losses and abnormal production costs. By 2023, the 'learning curve' was no longer framed solely as a risk but was integrated into the company's cost estimation process, factored into production rate assumptions, supplier performance trends, and internal labor efficiency projections. This shift indicates that Boeing began treating the learning curve as a predictable and manageable component of production planning rather than an unpredictable risk.",
      "llm_answer": "In the 2022 filing the learning curve is listed among a set of risk factors that could “result in lower margins (or a material charge …)”, essentially flagging it as a potential source of cost overruns that could erode program profitability. By the 2023 filing the learning curve is embedded in the formal program‑accounting estimation methodology—named as a key input in the quarterly review of production‑rate and cost forecasts—so it now directly shapes profitability projections and is managed as part of the company’s broader risk‑management framework. (2022 pp. 40‑44; 2023 pp. 47‑51)",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) CORRECTNESS: The answer accurately captures the evolution of the learning curve's role from 2022 to 2023. In 2022, it correctly identifies the learning curve as a risk factor with potential negative impacts on margins and profitability. In 2023, it correctly identifies the shift to integration within formal cost estimation methodology. The semantic meaning matches the ground truth: both describe a transition from treating learning curve as an unpredictable risk to treating it as a manageable, predictable component of production planning. (2) QUANTITATIVE ACCURACY: No specific dollar amounts, percentages, or calculations are required by this question, so this dimension is not heavily weighted. The page references provided (2022 pp. 40-44; 2023 pp. 47-51) add specificity and credibility, though these cannot be independently verified without access to the actual filings. (3) ENTITY ACCURACY: Boeing is correctly identified as the company in question (implied context). The years 2022 and 2023 are correctly referenced. The 787 program mentioned in the ground truth is not explicitly mentioned in the LLM answer, but this is a minor omission that doesn't affect the core answer's accuracy. (4) REASONING & SYNTHESIS: The multi-hop reasoning is sound. The LLM correctly synthesizes information across two years and identifies the key shift in how Boeing treats the learning curve. The connection between risk management and cost estimation is properly established. (5) SEMANTIC EQUIVALENCE: The LLM's phrasing ('embedded in formal program-accounting estimation methodology,' 'managed as part of the company's broader risk-management framework') conveys the same substantive meaning as the ground truth's description of integration into cost estimation and treatment as 'predictable and manageable.' Minor deduction: The LLM could have been slightly more explicit about the specific programs affected (like 787) or the types of complexities involved (production complexities, rework, delays), but these are contextual details rather than core factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 579,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the treatment or disclosure of the Dividend Reinvestment Plan evolved between the 2023 and 2024 SEC filings, particularly in relation to officer or director participation and associated trading arrangements?",
      "original_answer": "In the 2023 filing, the Dividend Reinvestment Plan was mentioned in the context of officer or director participation alongside the employee stock purchase plan and 401(k) plan, with specific reference to elections to have shares withheld for tax purposes or to pay the exercise price of stock awards. The disclosure also included a detailed description of how these elections may be structured under Rule 10b5-1 or non-Rule 10b5-1 trading arrangements as defined in Item 408(c) of Regulation S-K. In the 2024 filing, the Dividend Reinvestment Plan was again referenced in the context of officer or director participation, but the detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements was omitted, indicating a simplification or standardization of the disclosure without the earlier level of specificity regarding trading frameworks.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K contain the same disclosure: “Certain of our officers or directors have made elections to participate in, and are participating in, our dividend reinvestment plan … which may be designed to satisfy the affirmative‑defense conditions of Rule 10b5‑1 … or may constitute non‑Rule 10b5‑1 trading arrangements.” The language, scope and emphasis are unchanged, indicating no evolution in how the plan or officer/director participation is described between the two filings.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer directly contradicts the ground truth on the core finding. Ground truth states there WAS an evolution/change between 2023 and 2024 filings: the 2023 filing contained detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements, while the 2024 filing omitted this detailed explanation, indicating simplification or standardization. The LLM answer claims the language, scope and emphasis are 'unchanged' between the two filings, which is factually incorrect according to the ground truth. The LLM does accurately quote language that appears in both filings ('Certain of our officers or directors have made elections...'), but this quote alone does not capture the key difference: the presence of detailed trading arrangement framework explanations in 2023 versus their absence in 2024. The LLM failed to identify and synthesize the multi-hop comparison across the two years that was central to the question. The answer demonstrates a fundamental misunderstanding of what changed between the filings - it found surface-level similarity in quoted language while missing the substantive difference in disclosure depth and specificity regarding trading frameworks. Quantitative accuracy is high (no numbers involved), but qualitative accuracy and reasoning are severely deficient because the core conclusion is inverted from ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 379,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has The Home Depot's investment in creating an interconnected shopping experience evolved from fiscal 2021 to fiscal 2023, and what specific changes were made in the way this experience is tailored to customers?",
      "original_answer": "In fiscal 2021, The Home Depot invested $2.6 billion in capital expenditures focused on supporting an interconnected customer experience. By fiscal 2023, the company had advanced this strategy by leveraging enhanced merchandising information technology tools to build an interconnected shopping experience tailored to customers' shopping intent and location. This represents a shift from general investment in interconnectedness to a more refined, data-driven personalization strategy.",
      "llm_answer": "The Home Depot raised its capital spending on the interconnected shopping experience from $2.6 billion in fiscal 2021 (HD_10k_2022.pdf p5) to $3.2 billion in fiscal 2023 (HD_10k_2023.pdf p5). In 2021 the effort centered on data‑driven merchandising tools that customized the experience to customers’ shopping intent and location (HD_10k_2022.pdf p6); by 2023 the company added concrete store‑level and digital upgrades—wayfinding signage, self‑service lockers, curb‑side pickup, electronic shelf‑labeling, redesigned service desks and checkout areas, expanded self‑checkout, and mobile‑app store maps—to further personalize and streamline the customer journey (HD_10k_2023.pdf p6, p8).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM claims capital expenditures increased from $2.6 billion in fiscal 2021 to $3.2 billion in fiscal 2023. However, the ground truth states the company invested $2.6 billion in fiscal 2021 and does NOT provide a $3.2 billion figure for fiscal 2023. The LLM has fabricated a specific number ($3.2B) that contradicts the ground truth, which only mentions that the company 'advanced this strategy' without citing a specific capex increase. This is a major factual error. (2) QUALITATIVE ACCURACY - The LLM provides extensive detail about specific store-level and digital upgrades (wayfinding signage, self-service lockers, curbside pickup, electronic shelf-labeling, redesigned service desks, expanded self-checkout, mobile-app store maps) that are NOT mentioned in the ground truth answer. While these details may exist in the actual filings, they represent information beyond what the ground truth synthesized and could be hallucinated. The ground truth focuses on the shift from general investment to 'enhanced merchandising information technology tools' tailored to 'shopping intent and location.' (3) MULTI-HOP REASONING - The LLM attempts to synthesize evolution across fiscal years but does so by introducing unsupported numerical claims. The ground truth's core insight about the shift from general interconnectedness investment to refined, data-driven personalization is partially captured but obscured by the incorrect capex figures and unsupported operational details. (4) SEMANTIC EQUIVALENCE - The LLM's characterization of the evolution is partially aligned with ground truth (data-driven personalization, shopping intent/location focus) but the addition of specific store upgrades and the false $3.2B figure significantly distort the answer. The ground truth emphasizes a strategic shift in approach; the LLM emphasizes concrete implementations that may not be the primary focus of the ground truth synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 534,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the financial relationship between DHR and Aldevron evolved between 2022 and 2023, particularly in terms of capital investment and acquisition-related expenditures?",
      "original_answer": "In 2022, DHR anticipated capital expenditures of approximately $1.5 billion, with a portion of this spending attributed to increased manufacturing capacity for products related to the Aldevron Acquisition, among others. This reflects a growing capital commitment tied to Aldevron. By 2023, the financial relationship had evolved significantly, as evidenced by the net cash consideration paid to Aldevron amounting to $9,561 million, indicating that Aldevron had transitioned from being primarily a capital investment target to a core component of DHR's consolidated assets. This represents a substantial shift in the nature of their relationship from a dependency to a stakeholding and integration model.",
      "llm_answer": "The capital outlay for Aldevron‑related property, plant and equipment rose from $87 million in 2022 (offset by $49 million of grant‑related operating‑expense offsets) to $136 million in 2023 (offset by $51 million)【DHR_10k_2023.pdf, p.73】.  No new acquisition spending was incurred; the only Aldevron‑related acquisition expense remained the $28 million transaction cost recorded for the 2021 purchase, which was financed with cash on hand and commercial‑paper proceeds【DHR_10k_2023.pdf, p.73】.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 2,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer fundamentally misinterprets the question and provides information that does not address the core inquiry about the evolution of DHR's financial relationship with Aldevron between 2022 and 2023. Critical issues: (1) MISALIGNMENT WITH QUESTION: The question asks about 'capital investment and acquisition-related expenditures' in the context of how the relationship evolved. The ground truth correctly identifies that in 2022, DHR anticipated ~$1.5B in capex with a portion for Aldevron manufacturing capacity, and by 2023, DHR paid $9,561M in net cash consideration for the acquisition. This represents a major strategic shift. The LLM answer instead focuses on narrow operational capex figures ($87M in 2022, $136M in 2023) for property, plant and equipment, which are operational maintenance/expansion figures, not the strategic acquisition-related expenditures that define the relationship evolution. (2) INCOMPLETE SYNTHESIS: The LLM fails to identify the $9,561M acquisition payment in 2023, which is the critical data point showing how the relationship evolved from anticipated capex to actual acquisition completion. This is a major multi-hop synthesis failure. (3) INCORRECT FRAMING: The LLM states 'No new acquisition spending was incurred' and references only a $28M transaction cost from 2021, completely missing the 2023 acquisition payment that represents the culmination of the relationship evolution. (4) CONTEXTUAL MISUNDERSTANDING: The LLM provides granular operational details about grant offsets and financing mechanisms that, while potentially accurate for those specific line items, are irrelevant to answering how the strategic financial relationship evolved. The ground truth correctly identifies the transition from capex planning to acquisition completion as the key evolution. (5) QUANTITATIVE ISSUES: While the specific numbers cited ($87M, $136M, $49M, $51M, $28M) may be accurate for those specific line items, they do not represent the relevant financial metrics for answering this question. The critical missing number is the $9,561M acquisition payment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 563,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the structure and total value of Telco LLC's preferred interests evolved from 2022 to 2024, and what changes were made to the distribution rates and reset schedules during this period?",
      "original_answer": "In 2022, Telco LLC had $2,000 in nonconvertible cumulative preferred interests (Telco Class A-1) with an initial preferred distribution rate of 4.25% annually, subject to reset every seven years. By 2024, Telco LLC expanded its preferred interests with the issuance of an additional $5,250 in preferred interests (Telco Class A-2 and A-3) in April 2023, bringing the total cumulative preferred interests to $7,250. The new preferred interests (Class A-2 and A-3) carried a significantly higher initial preferred distribution rate of 6.85% annually, with the first reset scheduled for November 1, 2027, and every seven years thereafter. This represents both a structural expansion in the capital stack and a strategic shift toward higher-yielding preferred instruments.",
      "llm_answer": "In 2022 Telco LLC’s preferred equity consisted only of $2 billion of non‑convertible cumulative Class A‑1 interests that paid a 4.25 % annual distribution and reset every seven years (2022 10‑K, pp. 128‑132). By the 2024 filing the structure had expanded to three series (Class A‑1, A‑2 and A‑3) totaling $7.25 billion, with the newly‑issued A‑2/A‑3 series paying a higher 6.85 % distribution and resetting on Nov 1 2027 and every seven years thereafter, while the original A‑1 retained its 4.25 % rate and seven‑year reset; a further $2.25 billion of Class A‑4 is slated for issuance in 2025 with a 5.94 % rate and a reset on Nov 1 2028 and every four years thereafter (2024 10‑K, pp. 85‑89).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a fundamental unit error that severely undermines its accuracy. The ground truth states Telco LLC had $2,000 in preferred interests in 2022 and $7,250 total by 2024 (in millions, based on context). However, the LLM answer states '$2 billion' and '$7.25 billion' - a 1,000x magnitude error. This is a major factual error that cannot be overlooked. Additionally, the LLM introduces information about Class A-4 preferred interests ($2.25 billion with 5.94% rate, reset Nov 1 2028, every 4 years) that is NOT present in the ground truth answer. The question asks specifically about evolution from 2022 to 2024, and the ground truth does not mention Class A-4 or any 2025 issuance plans. CORRECT ELEMENTS: The LLM correctly identifies the three series structure (A-1, A-2, A-3), the 4.25% rate for A-1, the 6.85% rate for A-2/A-3, the November 1, 2027 reset date for A-2/A-3, and the seven-year reset schedule for A-1 and A-2/A-3. The characterization of the shift toward higher-yielding instruments is semantically accurate. MULTI-HOP REASONING: The LLM demonstrates sound multi-hop synthesis in connecting the 2022 and 2024 filings and comparing the structural changes. However, the introduction of out-of-scope information (Class A-4) suggests either hallucination or reliance on information beyond the ground truth knowledge graph. QUANTITATIVE VERIFICATION: Ground truth values ($2,000 and $7,250) vs. LLM values ($2 billion and $7.25 billion) represent a critical magnitude discrepancy. The percentage rates and dates are correct, but the dollar amounts are fundamentally wrong by three orders of magnitude.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 456,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has AIG's use of Expected Loss Ratio Methods evolved between 2022 and 2024, particularly in terms of the types of insurance lines and the rationale for their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to their high-severity nature. By 2024, AIG expanded the use of Expected Loss Ratio Methods to include U.S. Workers' Compensation, a long-tail line of business, where it was used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different insurance lines with varying claim characteristics.",
      "llm_answer": "In the 2022 filing AIG noted that expected‑loss‑ratio techniques were used mainly for aviation exposures and to set reserves for the latest accident year across its lines, especially where claims are high‑severity and data are limited (e.g., short‑tail U.S. Property, Special Risks and program business)【AIG_10k_2022.pdf p.271‑275】. By the 2024 filing the method had become a core part of the overall reserving toolkit, applied broadly – particularly to business written in excess of a deductible and to the five most recent accident years – with the rationale that it is useful when loss‑development patterns are inconsistent, loss emergence is slow or historical data are thin, and the ratios are adjusted for rate changes, loss‑trend, inflation and market conditions【AIG_10k_2024.pdf p.149‑153】.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ISSUES: (1) The LLM answer contains significant factual errors regarding which insurance lines used Expected Loss Ratio Methods. The ground truth clearly states that in 2022, the method was used for 'aviation exposures' and in 2024 it was expanded to include 'U.S. Workers' Compensation.' However, the LLM answer incorrectly lists 'U.S. Property, Special Risks and program business' as 2022 applications and fails to mention U.S. Workers' Compensation as a 2024 expansion. (2) The LLM answer claims the method was applied to 'the five most recent accident years' in 2024, but the ground truth specifies it was applied to 'the latest accident year' in 2022 and doesn't specify a change to five years in 2024. This is a quantitative discrepancy that cannot be verified against the ground truth. (3) The LLM answer provides extensive detail about rationale (loss-development patterns, slow emergence, thin data, adjustments for rate changes) that goes beyond what the ground truth specifies, suggesting potential hallucination or over-elaboration. (4) The core evolution narrative is partially correct - the answer does capture that the method expanded across different lines - but the specific lines mentioned are wrong. (5) The ground truth emphasizes the contrast between high-severity aviation (2022) and long-tail Workers' Compensation (2024), showing methodological adaptation to different claim characteristics. The LLM answer misses this key distinction. STRENGTHS: The answer correctly identifies the general trend of expanded application and attempts to provide rationale for the method's use. The document citations suggest engagement with source material, though the accuracy of those citations cannot be independently verified here.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 476,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has Target's approach to its owned brands evolved from 2023 to 2024, particularly in terms of strategic emphasis and product portfolio development?",
      "original_answer": "In 2023, Target emphasized expanding its owned brands portfolio as a core strategic element to drive relevancy and market share growth. By 2024, the company shifted focus to producing a broad range of owned and exclusive brands, listing over 40 distinct brands across various categories, indicating a more concrete execution phase of brand development and diversification.",
      "llm_answer": "In its 2023 filing Target framed owned‑brand development as a strategic pillar, saying it would “strengthen our owned brands portfolio” to drive newness, style and value (2023 Form 10‑K, Strategy section). By the 2024 filing the company reports that owned and exclusive brands now generate roughly one‑third of merchandise sales and lists a much larger, diversified set of brands—from A New Day™ and Good & Gather™ to Hearth & Hand™ with Magnolia and many new lines—showing the shift from a strategic intent to an expanded product portfolio that is a core revenue driver (2024 Form 10‑K, Owned Brands section).",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Target's owned brands evolution from 2023 to 2024. STRENGTHS: (1) Correctly identifies the shift from strategic emphasis in 2023 to execution/expansion in 2024; (2) Accurately cites specific brand examples (A New Day, Good & Gather, Hearth & Hand with Magnolia); (3) Introduces a quantitative metric (roughly one-third of merchandise sales) that adds specificity beyond the ground truth; (4) Properly synthesizes multi-hop information across two filing years; (5) Appropriately references Form 10-K sections; (6) Semantic equivalence is strong—'strategic pillar' and 'core strategic element' convey the same meaning, as do 'expanded product portfolio' and 'more concrete execution phase.' MINOR CONSIDERATIONS: (1) The ground truth mentions 'over 40 distinct brands' while the LLM answer lists specific examples but doesn't quantify the total number of brands—this is a minor omission but not a factual error since the LLM doesn't contradict the 40+ figure; (2) The LLM introduces the 'one-third of merchandise sales' metric which, while appearing to be accurate based on typical Target disclosures, goes slightly beyond what the ground truth explicitly states, though this represents added value rather than error. MULTI-HOP REASONING: The answer correctly synthesizes information across two years and two different filing documents, showing proper understanding of the temporal evolution and strategic shift. QUANTITATIVE ACCURACY: The one-third metric appears reasonable for Target's owned brands contribution, though it cannot be verified against the provided ground truth. No calculations are performed, so no calculation errors exist. Overall, this is a high-quality answer that captures the essence of Target's owned brands evolution with good specificity and proper sourcing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 497,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "What does IBM's continued listing of the 0.875% Notes due 2030 in 2024 alongside the new 2.900% Notes due 2030 suggest about its debt financing strategy and the market conditions for long-term borrowing?",
      "original_answer": "In 2023, IBM listed the 0.875% Notes due 2030 (trading symbol IBM30A) among its registered securities, indicating its initial issuance of this long-term debt instrument. By 2024, IBM not only maintained the 0.875% Notes due 2030 in its capital structure but also introduced a new 2.900% Notes due 2030 (trading symbol IBM30C). The significant increase in the interest rate—from 0.875% to 2.900%—for the same maturity year suggests that IBM may have pursued additional financing in 2024 under less favorable interest rate conditions, or it may be targeting different investor segments with varied risk-return profiles. This dual listing could also indicate a strategic effort to diversify its debt portfolio and manage refinancing risks by having multiple instruments maturing in the same year but with different coupon rates.",
      "llm_answer": "IBM’s 2024 filing still shows the 0.875 % Notes due 2030 (the legacy issue listed in the 2023 filing) together with a new 2.900 % Notes due 2030, indicating that IBM is keeping its ultra‑low‑cost, long‑dated debt on the books while also tapping the market for additional capital at a modestly higher but still relatively low rate. This layering of maturities reflects a strategy of diversifying its funding mix and exploiting continued investor appetite for inexpensive long‑term borrowing. (IBM 10‑K 2023, p. 1‑5; IBM 10‑K 2024, p. 1‑5)",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: (1) All numeric values are correct - 0.875% and 2.900% interest rates are accurately stated, and the 2030 maturity date is correct. (2) The LLM correctly identifies both notes and their trading symbols/designations. (3) The multi-hop synthesis is sound - the model correctly connects the 2023 and 2024 filings to show the continuation of the legacy note alongside the new issuance. (4) The characterization of the rate increase (from 0.875% to 2.900%) is accurate. (5) The interpretation about diversifying funding mix and exploiting investor appetite is reasonable and supported by the facts. WEAKNESSES: (1) The LLM's interpretation differs slightly from the ground truth in emphasis. The ground truth explicitly suggests the rate increase 'may indicate less favorable interest rate conditions in 2024' or targeting different investor segments, whereas the LLM frames it as 'modestly higher but still relatively low rate' and 'continued investor appetite for inexpensive long-term borrowing.' This is a more optimistic interpretation that downplays the significance of the rate increase. (2) The ground truth explicitly mentions 'managing refinancing risks' as a strategic consideration, which the LLM does not address. (3) The ground truth notes the possibility of targeting 'different investor segments with varied risk-return profiles,' which the LLM omits. (4) The LLM's characterization of the 0.875% as 'ultra-low-cost' and the 2.900% as 'still relatively low' is somewhat subjective and doesn't fully capture the ground truth's more nuanced analysis of what the rate differential might signify about market conditions. The core facts are correct, but the analytical depth and consideration of alternative interpretations is less comprehensive than the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 485,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the composition of AT&T's long-term debt instruments evolve between 2022 and 2024, particularly regarding the 4.000% Global Notes due June 1, 2049 and the addition of new long-term notes?",
      "original_answer": "In 2022, AT&T listed the 4.000% Global Notes due June 1, 2049 (T 49A) among other long-term debt instruments, but did not include the 4.300% Global Notes due November 18, 2034. By 2024, the 4.000% Global Notes due 2049 remained registered under the same symbol (T 49A), and the company added the 4.300% Global Notes due 2034 (T 34C). This indicates that AT&T expanded its long-term debt portfolio by introducing new maturities while maintaining existing long-dated obligations like the 2049 notes.",
      "llm_answer": "The 4.000 % Global Notes due June 1 2049 (ticker T 49A) appear in both the 2022 and 2024 Form 10‑K securities tables, showing that this issue remained part of AT&T’s long‑term debt portfolio【T_10k_2022.pdf†L...】【T_10k_2024.pdf†L...】.  The 2024 filing, however, expands the debt mix with several new long‑term issues that were not listed in 2022, including floating‑rate Global Notes due March 6 2025, 3.950 % Global Notes due April 30 2031, and 4.300 % Global Notes due November 18 2034, among other additions【T_10k_2024.pdf†L...】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the 4.000% Global Notes due June 1, 2049 (T 49A) as present in both 2022 and 2024 filings, which matches the ground truth. The answer also correctly identifies the 4.300% Global Notes due November 18, 2034 (T 34C) as a new addition in 2024, which is the specific example highlighted in the ground truth. The dates and percentages are accurate. However, the LLM answer introduces additional debt instruments (floating-rate Global Notes due March 6, 2025 and 3.950% Global Notes due April 30, 2031) that were not mentioned in the ground truth. While these may be factually correct additions to AT&T's debt portfolio in 2024, they represent scope creep beyond what the ground truth specifically addresses. The ground truth focuses on the evolution of the 4.000% 2049 notes and the addition of the 4.300% 2034 notes as the key examples. The LLM's inclusion of additional instruments, while potentially accurate, dilutes the focused comparison requested. The multi-hop reasoning is sound - the answer correctly synthesizes information across 2022 and 2024 filings and identifies the pattern of maintaining existing debt while adding new instruments. The semantic meaning aligns with the ground truth's core message about portfolio expansion. Minor deduction for introducing additional examples not in the ground truth, which could suggest either over-elaboration or potential inaccuracy in those additional details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 400,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the financial impact of the Heritage AspenTech acquisition evolve between 2023 and 2024, particularly in terms of intangibles amortization and restructuring costs?",
      "original_answer": "In 2023, the intangibles amortization related to the Heritage AspenTech acquisition was $258, while in 2024, this figure decreased to $97. Additionally, restructuring costs were $72 in 2023 and increased to $228 in 2024. This indicates a reduction in the amortization burden but a significant rise in restructuring expenses over the two years.",
      "llm_answer": "The Heritage AspenTech deal added $258 million of intangibles amortization in 2023 (part of the $482 million total) and only $1 million of AspenTech‑related restructuring costs (within $72 million total)【source】. By 2024 that amortization had essentially disappeared – the $1,077 million total intangibles amortization was driven by the NI acquisition ($560 million) – while total restructuring costs jumped to $228 million, with AspenTech‑specific restructuring rising to $8 million【source】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) INTANGIBLES AMORTIZATION - Ground truth states Heritage AspenTech amortization was $258 in 2023 and $97 in 2024. The LLM claims $258 million in 2023 (correct) but then states the amortization 'had essentially disappeared' in 2024 and attributes the $1,077 million total to the NI acquisition, completely failing to mention the $97 million Heritage AspenTech amortization that persisted in 2024. This is a critical omission. (2) RESTRUCTURING COSTS - Ground truth clearly states Heritage AspenTech restructuring was $72 in 2023 and $228 in 2024. The LLM incorrectly claims only $1 million of AspenTech-related restructuring in 2023 (should be $72) and $8 million in 2024 (should be $228). These are massive discrepancies - off by factors of 72x and 28.5x respectively. (3) MULTI-HOP SYNTHESIS - The LLM failed to properly synthesize the evolution of both metrics across the two years. It correctly identified the intangibles amortization decrease trend but completely misrepresented the restructuring cost figures. (4) CONTEXTUAL ISSUES - The answer introduces information about the NI acquisition that, while potentially relevant context, does not address the core question about Heritage AspenTech's financial impact evolution. The answer prioritizes tangential information over accurate core metrics. The ground truth shows a clear pattern: amortization declining ($258→$97) while restructuring costs surging ($72→$228), indicating a shift from amortization burden to restructuring expenses. The LLM answer fundamentally misrepresents both the magnitude and nature of these changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 465,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has AIG's use of expected loss ratio methods for workers' compensation evolved between 2022 and 2024, particularly in relation to the segmentation of business types and the impact of large deductible accounts?",
      "original_answer": "In 2022, AIG applied expected loss ratio methods primarily to guaranteed cost business in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that the proportion of large deductible business had increased, slowing the reporting pattern of claims. By 2024, AIG continued to use expected loss ratio methods but placed greater emphasis on segmentation by deductible size and claim handling (AIG vs. third-party administrators), and explicitly highlighted the increasing influence of large deductible accounts on slowing claim emergence. Additionally, 2024 disclosures emphasized limitations in claim count data due to aggregation and reinsurance exclusions, which were not as prominently noted in 2022.",
      "llm_answer": "AIG’s 2022 filing already noted that workers‑compensation reserves are built with a mix of loss‑development, frequency‑severity and expected‑loss‑ratio (ELR) techniques, and that the business is split into guaranteed‑cost and excess‑of‑deductible segments, each further broken out by state, industry and, for excess, by deductible size and claim‑handling party. By the 2024 filing the same blend of methods is retained, but the company stresses that the proportion of large‑deductible, risk‑sharing accounts has continued to rise—slowing claim reporting—and that this growth has led to an even greater reliance on ELR estimates for the most recent accident years within those increasingly granular segments.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of AIG's workers' compensation reserve methodology evolution between 2022 and 2024, with mostly accurate information. STRENGTHS: (1) Correctly identifies the core methodologies used (loss-development, frequency-severity, and ELR techniques) in both years; (2) Accurately notes the segmentation approach by guaranteed-cost vs. excess-of-deductible, with further breakdowns by state, industry, deductible size, and claim-handling party; (3) Properly captures the key evolution: increasing proportion of large-deductible accounts and their impact on slowing claim reporting; (4) Correctly identifies that 2024 shows greater reliance on ELR estimates for recent accident years; (5) Multi-hop reasoning is sound—synthesizing information about methodology, segmentation, and business mix changes across the two years. WEAKNESSES: (1) The LLM answer does not explicitly mention the specific accident year focus differences noted in the ground truth (2022: 'most recent accident year' for guaranteed cost vs. 'most recent five accident years' for excess of deductible); (2) Missing the 2024-specific disclosure about limitations in claim count data due to aggregation and reinsurance exclusions, which the ground truth identifies as a notable evolution in disclosure emphasis; (3) The phrase 'increasingly granular segments' is somewhat vague compared to the ground truth's specific mention of deductible size and claim handling segmentation. QUANTITATIVE ACCURACY: No specific numbers or percentages are provided in either answer, so this dimension is less applicable. The dates (2022, 2024) are correct. SEMANTIC EQUIVALENCE: The core message aligns well—both answers convey that AIG uses multiple methods, segments by business type and deductible size, and has increased emphasis on large-deductible accounts' impact. The LLM's phrasing 'risk-sharing accounts' is a reasonable synonym for 'large deductible accounts.' Overall, the answer captures the main evolution but omits some specific methodological details and disclosure changes that distinguish 2022 from 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 566,
        "total_tokens": 1966
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has Target's approach to cybersecurity threat investigation and response evolved from 2023 to 2024, particularly in terms of its Cyber Fusion Center operations and collaboration with external organizations?",
      "original_answer": "In 2023, Target operated its Cyber Fusion Center as part of its threat investigation and response capabilities, and emphasized collaboration with organizations across industries to share threat intelligence and best practices. By 2024, Target not only maintained its Cyber Fusion Center but also introduced a more structured incident response program with a coordinated escalation model to inform management and the Board of Directors during security incidents. Additionally, in 2024, Target expanded its external engagement by incorporating regular training and compliance activities for team members, and by leveraging third-party vendors to assess and test its cybersecurity program. This represents a more comprehensive and mature approach to cybersecurity threat response and collaboration.",
      "llm_answer": "Target’s 2024 filing shows that its core model for threat investigation and response has stayed the same – the Cyber Fusion Center continues to serve as the hub that uses industry‑leading tools, a proactive threat‑intelligence program and a coordinated escalation process to detect, contain and remediate cyber incidents, just as described in the 2023 filing.  The newer filing simply reinforces and broadens the collaboration language, emphasizing ongoing threat‑intel sharing and best‑practice exchanges with external industry partners and third‑party service providers, indicating a more formalized, wider‑reaching external engagement rather than a fundamental shift in the Center’s operations.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies that Target's Cyber Fusion Center continued operating in both 2023 and 2024, and accurately notes the emphasis on collaboration with external partners. However, there are significant gaps in completeness compared to the ground truth. The LLM answer MISSES several key evolution points: (1) The introduction of a 'more structured incident response program' in 2024 is not mentioned; (2) The 'coordinated escalation model to inform management and the Board of Directors' is mentioned only vaguely as 'coordinated escalation process' without emphasizing the governance/board notification aspect; (3) The expansion of 'regular training and compliance activities for team members' in 2024 is completely omitted; (4) The use of 'third-party vendors to assess and test its cybersecurity program' is mentioned only generically as 'third-party service providers' without the specific assessment/testing function. The LLM characterizes the evolution as 'formalized, wider-reaching external engagement rather than a fundamental shift,' which somewhat understates the maturation described in the ground truth (which explicitly calls it 'a more comprehensive and mature approach'). The answer demonstrates reasonable understanding of the Cyber Fusion Center's continuity but fails to capture the full scope of structural and programmatic enhancements that occurred between 2023 and 2024. No quantitative errors are present (no numbers were provided to verify), but the qualitative synthesis is incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 421,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did Eli Lilly's financial relationship with Baqsimi evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual arrangements?",
      "original_answer": "In 2023, Eli Lilly reported $579.0 million in revenue specifically attributed to the sale of the rights for Baqsimi. By 2024, Baqsimi was included within broader collaboration and other revenue disclosures, reflecting its integration into revenue from collaborations and other arrangements, which included the 2023 sales of rights for both the olanzapine portfolio and Baqsimi. This shift indicates a move from direct product revenue to a more complex revenue recognition model under collaborative arrangements, suggesting a strategic evolution in how the company accounts for and manages its financial relationship with Baqsimi.",
      "llm_answer": "In 2023 Eli Lilly booked the Baqsimi transaction as a one‑time product sale – $579 million of the $677.6 million Baqsimi revenue was recorded in net product revenue (see 2023 10‑K pp. 45‑46). By 2024 the company re‑classifies that same rights‑sale proceeds under “collaboration and other revenue,” indicating that the Baqsimi deal is now treated as a licensing/collaboration arrangement rather than a regular product sale (see 2024 10‑K p. 62, Note 2). This shift reflects a change in both the revenue‑recognition line‑item and the underlying contractual characterization of the Baqsimi relationship.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY FAILURE: The LLM claims '$579 million of the $677.6 million Baqsimi revenue was recorded in net product revenue' - this is factually incorrect. The ground truth states Eli Lilly reported $579.0 million in revenue specifically attributed to the sale of the rights for Baqsimi in 2023. The LLM introduces an unsupported figure of $677.6 million and makes an incorrect claim about how much was in product revenue vs. other categories. This represents a major factual error with specific numbers. (2) INCOMPLETE SYNTHESIS: While the LLM correctly identifies that there was a shift from product revenue classification in 2023 to collaboration/other revenue in 2024, it fails to accurately capture the ground truth's key insight: in 2024, Baqsimi was 'included within broader collaboration and other revenue disclosures' alongside other arrangements (olanzapine portfolio), not treated as a standalone item. The LLM oversimplifies this as a simple reclassification. (3) CITATION ISSUES: The LLM provides specific page references (2023 10-K pp. 45-46, 2024 10-K p. 62, Note 2) that cannot be verified against the ground truth and may be fabricated. (4) CORRECT ELEMENTS: The LLM does correctly identify the core evolution - from product sale treatment to collaboration/licensing arrangement treatment between 2023 and 2024, and correctly names the company (Eli Lilly) and product (Baqsimi). (5) REASONING QUALITY: The qualitative reasoning about the shift in contractual characterization is sound, but it's undermined by the quantitative errors and incomplete understanding of the 2024 integration into broader collaboration arrangements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 460,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did AT&T's approach to managing its capital structure through preferred interests evolve from 2023 to 2024, particularly regarding the repurchase of Mobility Preferred Interests and the expansion of Tower Holdings and Telco LLC preferred interests?",
      "original_answer": "In 2023, AT&T repurchased the remaining 213 million Mobility Preferred Interests for $5,414, removing $2,650 from 'Accounts payable and accrued liabilities' and $2,670 from 'Other noncurrent liabilities.' This repurchase was primarily funded by the issuance of $5,250 in new Telco LLC preferred interests, which carried a 6.85% annual distribution rate. By 2024, AT&T had shifted focus toward expanding its Tower Holdings preferred interests, where $6,000 in 2019 Tower preferred interests were restructured into fixed and floating rate classes with a 5.90% base rate and SOFR + 250 bps, respectively. Additionally, the total Telco LLC preferred interests increased to $7,250, including the original $2,000 (Telco Class A-1) and the 2023 additions. This reflects a strategic pivot from repurchasing legacy preferred interests to leveraging new preferred structures with more flexible redemption and distribution terms to manage capital and liquidity.",
      "llm_answer": "In 2023 AT&T eliminated its Mobility II preferred interests, repurchasing the remaining 213 million interests for about $5.4 billion (funded largely by the April 2023 issuance of $5.25 billion of new Telco LLC preferred interests) and left no Mobility preferred interests outstanding at year‑end. By 2024 the company shifted to reshaping its preferred‑interest portfolio – it amended the 2019 Tower Holdings interests to fixed‑ and floating‑rate classes and announced a $2.25 billion Telco LLC Class A‑4 issuance in early 2025 to fund further preferred‑equity redemptions – using new preferred‑interest issuances to manage capital structure rather than solely repurchasing existing interests.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the main narrative arc of AT&T's capital structure evolution from 2023 to 2024, with mostly accurate numbers and sound multi-hop reasoning. STRENGTHS: (1) Correctly identifies the 2023 Mobility Preferred Interests repurchase of 213 million for ~$5.4 billion (matches ground truth $5,414M); (2) Accurately notes the April 2023 issuance of $5.25 billion in Telco LLC preferred interests as funding source; (3) Correctly describes the 2024 shift toward Tower Holdings restructuring with fixed and floating rate classes; (4) Properly synthesizes the strategic pivot from repurchasing to issuing new preferred interests; (5) Appropriately mentions the early 2025 $2.25 billion Telco LLC Class A-4 issuance announcement. WEAKNESSES: (1) Omits specific distribution rates (6.85% for Telco LLC 2023 issuance, 5.90% base rate and SOFR+250 bps for Tower Holdings) that were in ground truth; (2) Does not explicitly state the total Telco LLC preferred interests reached $7,250 by 2024 or break down the composition (original $2,000 Class A-1 plus $5,250 addition); (3) Omits the specific accounting impacts ($2,650 from accounts payable, $2,670 from other noncurrent liabilities) of the 2023 repurchase; (4) Does not mention the original $2,000 Telco Class A-1 preferred interests as context for the expansion. QUANTITATIVE VERIFICATION: All stated numbers are accurate ($5.4B repurchase, $5.25B issuance, $2.25B future issuance, 213 million interests). No calculation errors detected. MULTI-HOP REASONING: The answer successfully synthesizes information across 2023-2024 activities and correctly identifies the strategic evolution. The connection between repurchase funding and new issuances is properly established. SEMANTIC EQUIVALENCE: The answer conveys the essential strategic shift and key transactions, though with less granular detail than ground truth. The omissions are contextual details rather than core factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 525,
        "total_tokens": 1962
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Emerson's relationship with AspenTech evolve from 2023 to 2024, and what financial impacts did this transformation have on Emerson's gross margin and ownership structure?",
      "original_answer": "In 2023, Emerson had a business relationship with AspenTech as part of its Software and Control offerings. By 2024, this relationship transformed into a more significant strategic position, as Emerson acquired a 55% ownership stake in 'New AspenTech' (formerly Heritage AspenTech) following a transaction that included approximately $6.0 billion in cash. This change in relationship had a measurable financial impact: the AspenTech acquisition contributed to a 3.3 percentage point increase in gross margin in 2023 and was part of broader changes that led to a 1.8 percentage point increase in gross margin in 2024. Additionally, the ownership stake marked a structural shift in Emerson’s involvement with AspenTech, moving from a partner to a majority shareholder.",
      "llm_answer": "In 2023 Emerson owned a 55 % majority stake in AspenTech after the Heritage AspenTech transaction, but by 2024 it had increased its holding to roughly 57 % and announced a $240‑per‑share cash offer to buy the remaining shares, moving toward full ownership. That ownership shift was accompanied by an improvement in Emerson’s gross margin, which rose from 49.0 % in 2023 to 50.8 % in 2024 (a 1.8‑percentage‑point increase).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant inaccuracies that contradict the ground truth. (1) TIMELINE REVERSAL: The LLM states Emerson owned 55% in 2023 and increased to ~57% by 2024, but the ground truth indicates the 55% stake was ACQUIRED in 2024 (not 2023). In 2023, Emerson had only a business relationship with AspenTech, not majority ownership. (2) TRANSACTION DETAILS: The LLM mentions a $240-per-share cash offer for remaining shares but provides no context about the $6.0 billion in cash that was part of the original acquisition transaction mentioned in the ground truth. (3) GROSS MARGIN ATTRIBUTION: The LLM correctly states the 1.8 percentage point increase in gross margin from 2023 to 2024 (49.0% to 50.8%), but this is INCOMPLETE. The ground truth indicates the AspenTech acquisition contributed to a 3.3 percentage point increase in gross margin in 2023 AND was part of broader changes leading to the 1.8 percentage point increase in 2024. The LLM only addresses the 2024 figure. (4) RELATIONSHIP EVOLUTION: The LLM fails to capture the fundamental transformation from a business partner relationship in 2023 to a majority shareholder position in 2024. Instead, it incorrectly portrays 2023 as already having majority ownership. (5) OWNERSHIP STRUCTURE: While the LLM mentions movement toward full ownership, it misses the key structural shift from partner to majority shareholder that occurred between 2023 and 2024. The answer demonstrates a fundamental misunderstanding of the timeline and sequence of events in the Emerson-AspenTech relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 435,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has AIG's Japan pension plans' contribution to non-U.S. pension obligations evolved between 2022 and 2024, and what change occurred in the weighted average discount rate applied to these plans during this period?",
      "original_answer": "In 2022, AIG's Japan pension plans accounted for 61% of total non-U.S. pension assets, with an expected long-term rate of return of 1.85%. By 2024, the Japan pension plans' share of non-U.S. projected benefit obligations decreased to 50% as of December 31, 2024, from 54% in 2023, and the weighted average discount rate increased to 1.81% in 2024 from 1.48% in 2023. This indicates a relative decline in the size of the Japan pension plans within AIG's non-U.S. pension structure, accompanied by a notable increase in the discount rate applied, likely reflecting changes in market conditions or investment strategy.",
      "llm_answer": "AIG’s Japan pension plans continued to account for roughly half of its non‑U.S. pension obligations – about 50 % in the 2022 filing and still about 50 % in the 2024 filing.  Over the same period the discount rate applied to the Japan plans rose, moving from the 1.09 % rate used for non‑U.S. plans in 2022 to a Japan‑specific weighted‑average discount rate of 1.81 % at year‑end 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that substantially misrepresent the ground truth data. (1) CRITICAL ERRORS: The LLM claims Japan pension plans accounted for 'about 50%' in 2022, but the ground truth states they accounted for 61% in 2022 - a 11 percentage point discrepancy. The LLM also states the 2024 figure was 'still about 50%' which happens to match the ground truth (50%), but this appears coincidental given the incorrect 2022 baseline. (2) DISCOUNT RATE ERRORS: The LLM references a 1.09% rate for non-U.S. plans in 2022, which is not mentioned in the ground truth and appears to be an incorrect or confused figure. The ground truth specifies that in 2022, the expected long-term rate of return was 1.85% (not a discount rate). The LLM correctly identifies the 2024 weighted average discount rate as 1.81%, but fails to provide the intermediate 2023 figure (1.48%) that shows the progression. (3) INCOMPLETE SYNTHESIS: The LLM misses the important 2023 data point (54% of obligations, 1.48% discount rate) which is crucial for understanding the evolution between 2022 and 2024. The ground truth explicitly mentions the 2023 intermediate values, indicating a multi-year trend analysis was expected. (4) CONCEPTUAL CONFUSION: The LLM conflates different metrics (expected long-term rate of return vs. weighted average discount rate) without clearly distinguishing them, and the 1.09% figure appears to be either fabricated or misattributed. (5) MISSING CONTEXT: The LLM fails to capture the narrative of relative decline from 61% (2022) → 54% (2023) → 50% (2024), which is central to answering how the contribution 'evolved.' The answer presents a static view rather than showing the actual trajectory of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 473,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Amazon's disclosure about the impact of competitive stores on its business evolve between the 2022 and 2023 10-K filings, particularly in terms of the framing of external market conditions?",
      "original_answer": "In the 2022 10-K filing, Amazon described competitive stores as a general factor among many that could impact sales and operating results, listing them alongside internal capabilities such as inventory management and customer satisfaction. The 2022 filing included the phrase: 'the introduction of competitive stores, websites, products, services, price decreases, or improvements' as a potential cause of sales fluctuations. In contrast, the 2023 filing retained the same core language but embedded it within a broader context that emphasized external economic and geopolitical conditions, stating that revenue and operating profit growth 'depends on the continued growth of demand for the products and services offered by us or our sellers, and our business is affected by, among other things, general economic, business, and geopolitical conditions worldwide.' This indicates a shift toward framing competitive pressures as part of a larger set of external risks rather than a standalone concern.",
      "llm_answer": "In the 2022 10‑K (pages 7‑11) Amazon’s risk factor treated competition mainly as a discrete threat – “the introduction of competitive stores, websites, products, services, price decreases, or improvements” – and warned that local firms could win by virtue of their deeper knowledge of local customers. By the 2023 10‑K (pages 7‑11) the same disclosure was embedded in a broader market‑conditions narrative, linking competitive‑store pressure to macro‑economic headwinds, shifts in consumer spending, and changes in Internet/e‑commerce adoption worldwide, thereby framing competition as part of a volatile external environment rather than an isolated risk.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution in Amazon's competitive disclosure between 2022 and 2023 10-K filings. STRENGTHS: (1) Correctly identifies the core quoted language about 'competitive stores, websites, products, services, price decreases, or improvements' appearing in both years; (2) Accurately captures the shift from treating competition as a discrete threat to embedding it within broader external market conditions; (3) Properly synthesizes the multi-hop comparison across two filing years; (4) Correctly identifies the page ranges (7-11) for both filings; (5) Appropriately characterizes the framing evolution from 'standalone concern' to 'part of volatile external environment.' MINOR CONSIDERATIONS: (1) The LLM answer adds specific contextual details about 'macro-economic headwinds, shifts in consumer spending, and changes in Internet/e-commerce adoption' that are not explicitly mentioned in the ground truth answer, though these are reasonable inferences about what 'external economic and geopolitical conditions' encompasses; (2) The LLM mentions 'local firms could win by virtue of their deeper knowledge of local customers' which is not in the ground truth but appears to be an accurate detail from the actual filings; (3) The phrasing differs slightly but conveys the same semantic meaning - both answers correctly identify the shift from discrete to embedded framing. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are required for this qualitative question, so this dimension is not heavily weighted. The page references (7-11) are correctly cited. MULTI-HOP REASONING: The answer successfully synthesizes information across two different filing years and correctly identifies the evolution in disclosure framing. The logic connecting competitive pressures to broader external conditions is sound. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core insight as the ground truth - that Amazon's treatment of competitive stores evolved from a standalone risk factor to one embedded within a broader external market conditions narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 569,
        "total_tokens": 1995
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has Target's exposure to port security risks evolved between 2023 and 2024, particularly in terms of geographic focus and operational impact?",
      "original_answer": "In 2023, Target specifically highlighted California ports as a key area affected by port security issues, mentioning that these ports were where the company received a significant portion of its imported merchandise. By 2024, Target broadened its focus, referring to 'major U.S. ports' without specifically naming California, indicating a more generalized concern across multiple locations. Additionally, in 2023, the company noted it had made alternative arrangements due to past disruptions, while in 2024, the emphasis shifted to potential future impacts, including increased costs and inventory supply issues, due to ongoing global conflicts and labor disputes.",
      "llm_answer": "In the 2023 Form 10‑K Target listed port‑security as one of many foreign‑trade risks and called out “California ports where we receive a significant portion of the products we source from outside the U.S.” as a specific exposure that could cause ship diversions, congestion and higher costs【2023‑13】. The 2024 filing still flags port‑security but broadens the geographic focus to “major U.S. ports” rather than a single state, signaling a nationwide exposure, while reiterating that any port‑related disruptions could interrupt inventory flow, increase freight costs and negatively affect results of operations【2024‑15】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about Target's port security risk evolution. STRENGTHS: (1) Correctly identifies the 2023 specific focus on California ports with accurate characterization ('where we receive a significant portion of the products we source from outside the U.S.'), matching the ground truth's description of 'significant portion of its imported merchandise.' (2) Accurately captures the 2024 shift to 'major U.S. ports' without California-specific naming, correctly interpreting this as broadened geographic focus. (3) Properly synthesizes the operational impact evolution: 2023 emphasis on 'alternative arrangements due to past disruptions' is reflected in the LLM's mention of potential impacts, and 2024's focus on future impacts (increased costs, inventory supply issues) is captured through 'interrupt inventory flow, increase freight costs and negatively affect results of operations.' (4) Multi-hop reasoning is sound - correctly compares across two fiscal years and identifies the geographic and temporal shift in Target's risk disclosure. (5) Includes appropriate citations (【2023‑13】【2024‑15】) suggesting source verification. MINOR CONSIDERATIONS: The LLM answer doesn't explicitly mention 'global conflicts and labor disputes' as contributing factors noted in the ground truth's 2024 description, though it does capture the operational impacts these would cause. The answer focuses on the port security risk itself rather than explicitly naming the underlying causes. However, this is a minor omission that doesn't significantly detract from the core answer's accuracy. All factual claims are verifiable and correct, with no calculation errors or date/entity misidentifications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 482,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did Emerson's financial relationship with Heritage AspenTech evolve between 2023 and 2024, particularly in terms of acquisition-related amortization and restructuring costs?",
      "original_answer": "In 2023, Emerson reported $258 million in intangibles amortization related to the Heritage AspenTech acquisition. By 2024, this specific amortization was no longer reported, indicating that the focus had shifted away from AspenTech as a newly acquired entity. Additionally, restructuring costs increased significantly from $72 million in 2023 to $228 million in 2024, suggesting that Emerson undertook more extensive restructuring activities in 2024, potentially reflecting integration efforts or strategic realignments following the AspenTech acquisition.",
      "llm_answer": "In 2023 Emerson still booked amortization tied to the Heritage AspenTech deal – $258 of the $482 million total intangible‑asset amortization was attributed to that acquisition – and incurred modest restructuring costs of $72 million (only $1 million of which was AspenTech‑related). By 2024 the Heritage AspenTech amortization had disappeared (the $560 million amortization now reflected the NI acquisition, pushing total amortization to $1.077 billion) and restructuring expenses rose sharply to $228 million, with AspenTech‑related restructuring climbing to $8 million. This shift shows the integration impact of Heritage AspenTech largely resolved by 2024, while overall amortization and restructuring costs increased due to newer acquisition activity.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer addresses the core question about Emerson's financial relationship with Heritage AspenTech between 2023 and 2024, but contains significant quantitative discrepancies and introduces information not in the ground truth.\n\nCORRECT ELEMENTS:\n- 2023 Heritage AspenTech amortization: $258 million ✓\n- 2024 Heritage AspenTech amortization: no longer reported ✓\n- 2023 restructuring costs: $72 million ✓\n- 2024 restructuring costs: $228 million ✓\n- Overall interpretation that integration focus shifted away from AspenTech ✓\n\nPROBLEMATIC ELEMENTS:\n1. UNSUPPORTED CLAIMS: The LLM introduces specific numbers not in the ground truth:\n   - \"$482 million total intangible-asset amortization\" in 2023 (not mentioned in ground truth)\n   - \"$560 million amortization\" in 2024 (not mentioned in ground truth)\n   - \"$1.077 billion\" total amortization in 2024 (not mentioned in ground truth)\n   - \"NI acquisition\" details (not mentioned in ground truth)\n   - \"$1 million AspenTech-related\" restructuring in 2023 (not mentioned in ground truth)\n   - \"$8 million AspenTech-related restructuring\" in 2024 (not mentioned in ground truth)\n\n2. MULTI-HOP REASONING: While the LLM correctly synthesizes the core comparison between 2023 and 2024, it goes beyond the ground truth by introducing additional acquisition context (NI acquisition) and specific breakdowns that cannot be verified against the provided ground truth.\n\n3. QUANTITATIVE ACCURACY ISSUE: The core numbers match, but the LLM adds contextual details with specific dollar amounts that are not supported by the ground truth, which is a significant concern for financial accuracy.\n\n4. SEMANTIC ALIGNMENT: The main conclusion about the shift in integration focus is correct, but the answer is padded with unverified financial details that could mislead readers about the completeness of the data.\n\nThe answer demonstrates good understanding of the question's intent and correctly identifies the key trend, but the introduction of unsupported financial figures significantly undermines its reliability as a factual response to a financial question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 572,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has AIG's use of Expected Loss Ratio methods evolved between 2022 and 2024, particularly in terms of the weight given to this method across different lines of business and accident years?",
      "original_answer": "In 2022, AIG applied Expected Loss Ratio methods primarily for more recent accident years in lines such as D&O, E&O, EPLI, and professional liability, where losses are low frequency and high severity. The method was also used in conjunction with IBNR factor methods for low frequency/high severity losses, with factors continually reevaluated based on emerging claim experience and market factors. By 2024, AIG continued to use Expected Loss Ratio methods but expanded their application to include U.S. Workers' Compensation, a long-tail line of business, where they were used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different risk profiles and a more integrated approach to reserving in complex portfolios.",
      "llm_answer": "In the 2022 filing AIG said it applied expected‑loss‑ratio (ELR) techniques mainly to its U.S. Financial‑Lines businesses (D&O, E&O, EPLI and professional liability) and to excess‑of‑deductible or M&A exposures, giving ELR a higher weight in the most recent accident years while relying on loss‑development for older years【AIG_10k_2022.pdf p268】. By the 2024 filing the firm’s methodology had been broadened to all lines and ELR estimates are now explicitly blended with development methods (Bornhuetter‑Ferguson, Cape Cod) using a weight that is the reciprocal of the loss‑development factor, still placing significant weight on the most recent five accident years and on excess‑of‑deductible business【AIG_10k_2024.pdf p149】. This shows a move from a line‑specific, qualitative weighting to a more systematic, portfolio‑wide integration of ELR.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides a reasonable narrative about ELR method evolution but contains significant factual discrepancies when compared to the ground truth. STRENGTHS: (1) Correctly identifies 2022 application to D&O, E&O, EPLI, and professional liability lines; (2) Correctly notes higher weighting for recent accident years in 2022; (3) Accurately captures the 2024 shift toward broader application and more systematic integration; (4) Appropriately identifies the move from qualitative to quantitative weighting approaches; (5) Good contextual framing of the evolution. CRITICAL ERRORS: (1) The LLM claims ELR was 'broadened to all lines' by 2024, but ground truth specifies expansion to U.S. Workers' Compensation specifically - not all lines universally; (2) The LLM mentions 'excess-of-deductible or M&A exposures' in 2022, which is not mentioned in the ground truth; (3) The LLM references specific weighting formulas ('reciprocal of the loss-development factor') and mentions 'five accident years' - these specific quantitative details are not in the ground truth and cannot be verified; (4) The ground truth emphasizes combination with 'IBNR factor methods' in 2022, which the LLM omits; (5) The ground truth specifically notes Workers' Compensation as a 'long-tail line of business' in 2024, highlighting the significance of this expansion, which the LLM doesn't emphasize. MULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2024 filings and identifies the evolution pattern, but overstates the scope of 2024 changes. The reasoning about moving from qualitative to systematic weighting is sound but introduces specific methodological details (Bornhuetter-Ferguson, Cape Cod, reciprocal formula) that cannot be confirmed against the ground truth. QUANTITATIVE ISSUES: While no specific numbers are wrong, the LLM introduces quantitative specificity ('five accident years,' weighting formulas) that goes beyond what can be verified in the ground truth, which is problematic for a financial analysis task.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 549,
        "total_tokens": 1970
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has the monetization strategy for Amazon's film groups evolved between 2022 and 2023, based on changes in capitalized video and music content costs and associated expenses?",
      "original_answer": "Amazon's monetization strategy for film groups evolved between 2022 and 2023, as evidenced by an increase in both the capitalized video and music content costs and the associated expenses. In 2022, the capitalized costs were $16.7 billion with total video and music expenses of $16.6 billion, while in 2023, these figures increased to $17.4 billion and $18.9 billion, respectively. This indicates a more aggressive investment in content and a corresponding rise in monetization efforts.",
      "llm_answer": "Amazon’s capitalized video‑and‑music content balance grew only modestly, from $16.7 billion at year‑end 2022 to $17.4 billion at year‑end 2023, while the related expense jumped from $16.6 billion to $18.9 billion over the same period (AMZN 10‑K 2023, pp. 47‑51). The larger rise in expense versus the modest increase in capitalized assets shows Amazon is moving beyond simply building its content library to more aggressively monetizing and amortizing existing film‑group assets—reflecting higher licensing/production spend and faster consumption of its video and music portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and provides a more sophisticated analysis than the ground truth. (1) QUANTITATIVE VERIFICATION: All numbers are correct - capitalized costs of $16.7B (2022) and $17.4B (2023), expenses of $16.6B (2022) and $18.9B (2023). The calculations are accurate: capitalized costs increased by $0.7B (4.2%), while expenses increased by $2.3B (13.9%), correctly showing the disproportionate rise in expenses. (2) COMPLETENESS: The answer fully addresses the question about monetization strategy evolution, covering both capitalized costs and associated expenses across both years. (3) ENTITY ACCURACY: Amazon (AMZN) is correctly identified, fiscal years 2022-2023 are correct, and the financial metrics (capitalized video and music content costs, related expenses) are properly identified. (4) REASONING QUALITY: The multi-hop synthesis is excellent. The LLM correctly interprets what the divergence between modest capitalized asset growth and aggressive expense growth means for monetization strategy - moving from content library building to active monetization and amortization. This interpretation goes beyond the ground truth by providing deeper insight into the strategic implications. (5) SEMANTIC EQUIVALENCE: The answer conveys the same core information as the ground truth while adding valuable analytical context about the shift from capital investment to expense-driven monetization. The reference to pages 47-51 of the 2023 10-K adds credibility. Minor deduction only because the ground truth's simpler statement of 'more aggressive investment in content and corresponding rise in monetization efforts' is somewhat less nuanced than the LLM's interpretation, though the LLM's interpretation is more insightful and still factually sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 484,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has Philip Morris International's financial relationship with RBH evolved between 2022 and 2024, particularly in terms of its stake and associated impairment?",
      "original_answer": "In 2022, Philip Morris maintained a trademark relationship with RBH, continuing to report volume of brands sold by RBH such as HEETS and other heated tobacco units. By 2024, PMI held an equity investment in RBH, which became subject to a significant impairment charge of $2,316 million due to unresolved allocation of a $32.5 billion Canadian tobacco litigation settlement among RBH, ITL, and JTIM. This reflects a shift from a trademark and brand licensing relationship to a more direct equity investment facing financial impairment.",
      "llm_answer": "Philip Morris International continued to hold a 49 % equity interest in Rothmans, Benson & Hedges Inc. (RBH) in both the 2022 and 2024 filings (see PM_10k_2022.pdf p. 33).  In 2022 the investment was carried without a material impairment, whereas the 2024 filing disclosed a non‑cash impairment of $2,316 million on the RBH equity investment due to the unresolved settlement allocation (see PM_10k_2024.pdf p. 30).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies key quantitative facts: the 49% equity interest in RBH, the $2,316 million impairment charge in 2024, and the connection to the Canadian tobacco litigation settlement. The impairment amount and the unresolved settlement allocation are accurately stated. However, there are significant issues with the answer's completeness and accuracy regarding the evolution of the relationship. The ground truth explicitly states that in 2022, PMI maintained a 'trademark relationship with RBH' involving brand licensing (HEETS and heated tobacco units), which represented a different type of relationship than the equity investment. The LLM answer claims PMI held a '49% equity interest' in both 2022 and 2024, which contradicts the ground truth's characterization of 2022 as primarily a trademark/licensing relationship. This is a critical error in describing the 'evolution' of the relationship - the LLM presents it as static (same 49% equity stake both years) rather than as an evolution from trademark licensing to equity investment. The LLM also fails to mention the specific brands (HEETS) or the nature of the trademark relationship in 2022. Additionally, while the LLM correctly identifies the impairment and settlement context, it doesn't fully explain that the impairment arose from the unresolved allocation among three entities (RBH, ITL, and JTIM). The answer is partially correct on numbers but fundamentally mischaracterizes the nature of the relationship evolution, which is the core of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 424,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the sensitivity of LLY's net product revenue to changes in sales return, rebate, and discount liabilities evolve between 2023 and 2024, based on the disclosures in the respective 10-K filings?",
      "original_answer": "In 2023, LLY disclosed that a 5% change in its consolidated sales return, rebate, and discount liability would result in a $615 million change in revenue. In 2024, while the company continued to describe the accounting policy for revenue recognition and accruals for rebates and discounts, it did not provide an updated sensitivity figure. This omission suggests that the company did not disclose a revised estimate for the impact of liability changes on revenue in 2024, indicating a lack of updated quantitative disclosure compared to 2023.",
      "llm_answer": "In the 2023 filing, Eli Lilly said that a 5 % shift in its consolidated sales‑return, rebate and discount liability would change net product revenue by roughly $615 million. In the 2024 filing, the same 5 % change would affect revenue by about $600 million, showing a slight (≈$15 million) reduction in sensitivity year‑over‑year.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains a fundamental factual error that contradicts the ground truth. The ground truth explicitly states that LLY did NOT provide an updated sensitivity figure in 2024 - it states 'it did not provide an updated sensitivity figure' and 'did not disclose a revised estimate for the impact of liability changes on revenue in 2024.' However, the LLM answer claims that in 2024 'the same 5% change would affect revenue by about $600 million,' presenting a specific number ($600 million) that was not disclosed according to the ground truth. This is a major factual error. The LLM appears to have fabricated a 2024 sensitivity figure and calculated a year-over-year change ($15 million reduction) that has no basis in the actual filings. The 2023 figure of $615 million is correctly stated, but the entire 2024 analysis is incorrect. The ground truth emphasizes the ABSENCE of disclosure in 2024, while the LLM provides a false presence of disclosure. This represents a failure in multi-hop reasoning - the model did not correctly synthesize the information that 2024 lacked the quantitative disclosure that was present in 2023. The answer is contextually relevant to the question asked but fundamentally wrong in its core factual claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 355,
        "total_tokens": 1587
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has the role and revenue contribution of Bulk shipments evolved from 2022 to 2024, based on Union Pacific's disclosures?",
      "original_answer": "In 2022, Bulk shipments had an average revenue per car of $3,305 in 2021 (referenced in the 2022 filing), showing a 6% increase from 2020. By 2024, Bulk shipments had grown in strategic importance, contributing 32% of total freight revenues, with detailed operations covering grain, fertilizer, and coal markets, including international connections to Mexico and access to Canadian interline routes. This indicates a transformation in the Bulk segment's role from a revenue-per-unit perspective to a more strategically embedded and revenue-significant component of Union Pacific's operations.",
      "llm_answer": "In 2022 Union Pacific described Bulk as one of its three core commodity groups (Bulk, Industrial, Premium) and it generated roughly $6.6 billion – about 32 % of total freight revenue of $20.2 billion that year【UNP_10k_2022.pdf:33‑35】. By 2024 Bulk remained a core pillar, still accounting for 32 % of freight revenue, but with total freight revenue up to $22.8 billion, its contribution rose to roughly $7.3 billion【UNP_10k_2024.pdf:5】. Thus the share of revenue stayed stable at about one‑third, while the absolute dollar amount grew as overall freight revenue increased.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides a reasonable narrative about Bulk shipments' evolution from 2022 to 2024, but contains significant quantitative discrepancies when compared to the ground truth. STRENGTHS: (1) Correctly identifies Bulk as a core commodity group; (2) Accurately states 32% revenue contribution in both 2022 and 2024; (3) Provides specific dollar amounts ($6.6B in 2022, $7.3B in 2024) that are plausible and show growth; (4) Correctly synthesizes multi-hop information across 2022 and 2024 filings; (5) Appropriately concludes that percentage share remained stable while absolute dollars grew. WEAKNESSES: (1) The ground truth references 2021 revenue-per-car metrics ($3,305 with 6% increase from 2020) which the LLM answer completely omits - this is a significant gap as the question asks about evolution 'from 2022 to 2024' but the ground truth includes 2021 baseline data; (2) The ground truth emphasizes strategic transformation in Bulk's role (from revenue-per-unit perspective to strategically embedded component with detailed operations in grain, fertilizer, coal, Mexico connections, and Canadian interline routes) - the LLM answer lacks this qualitative evolution narrative; (3) The LLM answer provides absolute revenue figures ($6.6B, $7.3B) that cannot be verified against the ground truth, which focuses on per-car metrics and percentage contributions rather than absolute dollar amounts; (4) Missing discussion of operational details (grain, fertilizer, coal markets, international connections) that the ground truth emphasizes as part of the strategic evolution. CALCULATION VERIFICATION: The LLM's math is internally consistent (32% of $20.2B ≈ $6.5-6.6B; 32% of $22.8B ≈ $7.3B), but these specific dollar figures are not confirmed in the ground truth. MULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2024 filings to show evolution, but fails to incorporate the 2021 baseline data and strategic context that the ground truth emphasizes. The answer is partially correct on the quantitative side but incomplete on the qualitative/strategic evolution dimension.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 567,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the interest rate of IBM's Notes due 2028 evolve between 2023 and 2024, and what does this indicate about IBM's debt strategy?",
      "original_answer": "In 2023, IBM had 1.750% Notes due 2028 (IBM 28A) listed, and in 2024, the same 1.750% Notes due 2028 (IBM 28A) were still present in the disclosures. This indicates that the interest rate for this specific issuance remained unchanged over the two years. However, IBM introduced new notes with different interest rates in 2024, such as the 2.900% Notes due 2030 and the 3.150% Notes due 2033, suggesting a broader strategy to issue debt at higher rates for longer maturities.",
      "llm_answer": "In the 2023 Form 10‑K IBM’s 2028 notes were listed at 0.300 % (IBM 28B) and 1.750 % (IBM 28A), and the 2024 Form 10‑K shows the same coupons for those notes【IBM_10k_2023.pdf†L1-L9】【IBM_10k_2024.pdf†L1-L9】. The unchanged rates indicate IBM is maintaining its low‑cost, long‑dated financing, locking in cheap debt and preserving a stable funding profile.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identified that IBM had 1.750% Notes due 2028 (IBM 28A) in both 2023 and 2024, matching the ground truth. (2) The reasoning that unchanged rates indicate stable financing is sound and relevant. (3) The multi-hop synthesis across 2023 and 2024 filings was attempted correctly for the main note. CRITICAL ERRORS: (1) The LLM introduced a 0.300% (IBM 28B) note for 2028 in 2023 that is NOT mentioned in the ground truth answer. This appears to be either fabricated or incorrectly sourced, creating a significant factual error. (2) The ground truth explicitly mentions IBM introduced NEW notes in 2024 (2.900% Notes due 2030 and 3.150% Notes due 2033), which the LLM completely omitted. This is a major incompleteness - the question asks about IBM's debt strategy, and the introduction of higher-rate longer-maturity debt is central to understanding that strategy. (3) The LLM's interpretation that IBM is 'locking in cheap debt' is partially correct but incomplete - the ground truth indicates a more nuanced strategy of issuing debt at progressively higher rates for longer maturities, suggesting IBM is adjusting to market conditions. QUANTITATIVE ISSUES: The 0.300% figure for IBM 28B cannot be verified against the ground truth and appears to be an error. COMPLETENESS: The answer fails to address the full scope of IBM's debt strategy evolution, missing the critical new issuances in 2024 that demonstrate a shift toward higher rates for longer maturities. This is a significant omission for a question specifically asking about debt strategy implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 436,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did AT&T's capital structure strategy regarding preferred interests evolve from 2023 to 2024, particularly in relation to the Mobility Preferred Interests and the introduction of new preferred instruments?",
      "original_answer": "In 2023, AT&T repurchased all of its Mobility Preferred Interests, which had a redemption value of approximately $5,340 million and paid annual cash distributions of $373 million. This marked a significant shift in strategy, as the company eliminated this class of preferred interests. In 2024, AT&T introduced structural modifications to other preferred instruments, including the restructuring of its Tower Holdings preferred interests to include both fixed and floating rate components, and the expansion of Telco LLC preferred interests to a total of $7,250 million. This evolution indicates a strategic pivot from Mobility-based preferred capital to more diversified and strategically tailored preferred instruments tied to infrastructure and telecommunications assets.",
      "llm_answer": "In 2023 AT&T eliminated its Mobility Preferred Interests – it repurchased all 320 million Mobility II preferred membership interests in April 2023, leaving the class with a zero balance at year‑end (2023 10‑K, Note 16). By 2024 the company had shifted to a broader preferred‑equity strategy, issuing cumulative perpetual preferred shares (Series A, B and C) and adding new subsidiary‑level preferred instruments—including a 2 million‑unit Mobility II redeemable non‑controlling preferred issuance, restructured Tower Fixed‑Rate and Floating‑Rate preferred interests, and new Telco LLC preferred series (including a planned Class A‑4 issue) – showing a move from retiring the Mobility preferred to actively using preferred securities to fund the business.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general strategic evolution from 2023 to 2024 but contains significant quantitative discrepancies and introduces unverified details. CORRECT ELEMENTS: (1) The 2023 elimination of Mobility Preferred Interests is accurate; (2) The shift to diversified preferred instruments in 2024 is correctly identified; (3) The mention of Tower Holdings preferred interests with fixed/floating components aligns with ground truth; (4) The Telco LLC preferred interests expansion is mentioned. CRITICAL ERRORS: (1) The LLM states 'Telco LLC preferred interests to a total of $7,250 million' but the ground truth specifies this as the 2024 expansion amount - the LLM doesn't clearly establish this is the 2024 figure; (2) The LLM introduces specific details like '320 million Mobility II preferred membership interests' and 'April 2023' repurchase date that are not in the ground truth and cannot be verified; (3) The LLM mentions 'cumulative perpetual preferred shares (Series A, B and C)' which are not mentioned in the ground truth answer; (4) The LLM references 'a 2 million-unit Mobility II redeemable non-controlling preferred issuance' in 2024, which contradicts the ground truth stating all Mobility Preferred Interests were eliminated in 2023; (5) The ground truth specifies the redemption value was 'approximately $5,340 million' and annual distributions were '$373 million' - the LLM omits these key quantitative metrics entirely. MULTI-HOP REASONING: The LLM correctly synthesizes the evolution across years but introduces unverified details that may be fabricated. The core narrative of elimination followed by diversification is sound, but the specific instruments and amounts lack proper grounding in the provided ground truth. The mention of 'Mobility II redeemable non-controlling preferred issuance' in 2024 appears to contradict the stated elimination of all Mobility Preferred Interests in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 520,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has Amazon's characterization of the competitive threat from websites evolved between 2022 and 2023, and what specific changes in language indicate a shift in the nature of this competition?",
      "original_answer": "In 2022, Amazon described competitive websites as part of a broader list of fluctuating business factors, indicating a general awareness of competitive pressures. By 2023, Amazon's language evolved to reflect a more direct and strategic competitive stance, specifically highlighting the introduction of 'competitive stores, websites, products, services, price decreases, or improvements' as a central concern. This shift indicates a more focused and intensified competitive threat from digital platforms, suggesting an evolution from a general operational risk to a more strategic and dynamic competitive challenge.",
      "llm_answer": "Amazon’s description of competition from other e‑commerce sites is essentially unchanged between the 2022 and 2023 Form 10‑K. Both filings list the risk as “the introduction of competitive stores, websites, products, services, price decreases, or improvements,” and no new qualifiers or altered phrasing appear, indicating that Amazon’s view of the website‑based competitive threat has not materially shifted.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core conclusion. The ground truth explicitly states that Amazon's characterization of competitive threats DID evolve between 2022 and 2023, shifting from 'a general awareness of competitive pressures' to 'a more direct and strategic competitive stance' with 'more focused and intensified competitive threat.' The LLM directly contradicts this by claiming the description is 'essentially unchanged' and that 'no new qualifiers or altered phrasing appear.' This is a critical factual error that misses the entire premise of the question. While the LLM correctly identifies the 2023 language ('competitive stores, websites, products, services, price decreases, or improvements'), it fails to recognize or acknowledge the evolution in how Amazon characterized this threat between the two years. The LLM's assertion that the language is identical between 2022 and 2023 contradicts the ground truth's clear documentation of a shift in characterization from general operational risk to strategic competitive challenge. The quantitative accuracy score is relatively high because the LLM correctly cites the specific language from the filings, but the qualitative accuracy and overall correctness are severely compromised by the fundamental misunderstanding of the comparative analysis required by the multi-hop question. The answer fails to synthesize the evolution in Amazon's competitive positioning across the two-year period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 406,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has PM's relationship with KT&G evolved from 2022 to 2024, particularly in terms of its strategic reliance on KT&G's heat-not-burn products within PMI's smoke-free product portfolio?",
      "original_answer": "In 2022, PM had a global collaboration agreement with KT&G that allowed PMI to exclusively distribute KT&G's smoke-free products, including heat-not-burn products like LIL Mini and LIL Plus, outside of South Korea. This agreement was initially for three years, indicating a strategic partnership aimed at expanding KT&G's products globally. By 2024, this relationship had evolved such that KT&G's heat-not-burn products were no longer just distributed by PMI but were integrated into PMI's broader smoke-free product portfolio, specifically being listed among PMI's own heat-not-burn offerings. This indicates a deeper strategic reliance on KT&G's product line within PMI's own commercialization efforts, suggesting a shift from a distribution partnership to a more embedded supplier or technology partner role for KT&G.",
      "llm_answer": "In the 2022 Form 10‑K PMI still described its KT&G tie‑up as a three‑year, exclusive “global collaboration” launched in January 2020 that gave PMI the right to distribute KT&G’s heat‑not‑burn products (e.g., LIL Mini/Plus) outside South Korea and noted that commercial initiatives for those licensed products had begun in a few markets. By the 2024 filing the relationship had deepened – KT&G‑licensed heat‑not‑burn brands such as Fiit, Miix and the LIL line are now listed as part of PMI’s HTU (heat‑not‑burn) portfolio and are cited as a key driver of the strong growth in smoke‑free revenues, showing that PMI’s strategic reliance on KT&G’s products has expanded beyond the original term.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution of the PM-KT&G relationship and correctly identifies key elements: (1) the 2022 three-year exclusive global collaboration agreement, (2) the distribution rights for heat-not-burn products outside South Korea, (3) specific product names (LIL Mini/Plus), and (4) the deepening of the relationship by 2024 with integration into PMI's portfolio. However, there are significant issues: (1) QUANTITATIVE ERROR: The LLM introduces product names (Fiit, Miix) that are not mentioned in the ground truth answer, which only references LIL Mini and LIL Plus. This is a factual addition not supported by the original answer. (2) DATING DISCREPANCY: The LLM states the collaboration was 'launched in January 2020' - while the ground truth mentions a 'three-year' agreement in 2022, it does not specify January 2020 as the launch date. This additional detail cannot be verified against the ground truth. (3) TERMINOLOGY: The LLM uses 'HTU (heat-not-burn)' which is reasonable shorthand but adds interpretation not explicitly in the ground truth. (4) MULTI-HOP REASONING: The LLM correctly synthesizes the evolution from distribution partnership to embedded supplier role, matching the ground truth's core insight. (5) COMPLETENESS: The LLM addresses both 2022 and 2024 timeframes and the shift in strategic reliance. The main weakness is the introduction of unverified product names and dates that diverge from the ground truth, which reduces confidence in factual accuracy despite the overall narrative being directionally correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 429,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did IBM's use of the PWCC Plan for funding employee awards evolve between 2022 and 2024, particularly in terms of its administration and scope?",
      "original_answer": "In 2022, the PWCC Plan was described as being used solely to fund awards for employees of PwCC who joined IBM after the acquisition, and it was stated that the plan would continue to be used for this purpose. By 2024, while the plan's administration and terms remained substantively identical to the 2001 Plan, IBM emphasized that the PWCC Plan 'has been and will continue to be used solely' for funding awards for former PwCC employees, indicating a reaffirmation rather than a change in scope. However, the shift in language from 'has been and will continue to be' in 2022 to a more definitive tone in 2024 suggests a stronger commitment to maintaining the plan’s current usage without expansion.",
      "llm_answer": "IBM’s PWCC acquisition plan did not change between the two filings. In both the 2022 and 2024 10‑Ks the PWCC Plan is described as being administered by the Executive Compensation and Management Resources Committee (with delegated authority to officers) and, like the 2001 Plan, is used **only** to fund equity awards for employees who joined IBM through the PwCC acquisition – senior executives are expressly excluded (IBM_10k_2022.pdf p.27; IBM_10k_2024.pdf p.18).",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains accurate factual details but fundamentally misses the core analytical point of the question. Strengths: (1) Correctly identifies that the PWCC Plan is used solely for PwCC acquisition employees, (2) Accurately notes the administration structure (Executive Compensation and Management Resources Committee with delegated authority), (3) Correctly states senior executives are excluded, (4) Properly cites both 2022 and 2024 filings. Weaknesses: (1) CRITICAL - The LLM states 'IBM's PWCC acquisition plan did not change between the two filings' which directly contradicts the ground truth's key finding about the evolution in language and commitment tone. The ground truth emphasizes a shift from 'would continue to be used' (2022) to 'has been and will continue to be used solely' (2024), representing a stronger, more definitive commitment. (2) The LLM completely misses the nuanced evolution in how IBM framed the plan's purpose - the shift from future-oriented language to past-and-future affirmation. (3) The answer fails to address the 'evolution' aspect of the question, instead claiming no change occurred. (4) While the LLM correctly identifies that scope remained the same, it misses the important distinction that the 2024 language represents a reaffirmation with stronger commitment language. The LLM provides accurate supporting details but fails to synthesize the multi-hop reasoning about how IBM's messaging and commitment to the plan evolved between years, which is the central question being asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 423,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did AT&T's financial obligations and strategic approach to Mobility Preferred Interests evolve between 2023 and 2024, and what does this shift indicate about its broader capital structure management?",
      "original_answer": "In 2023, AT&T repurchased all remaining Mobility Preferred Interests for a total of $5,414 million, which included accrued and unpaid distributions, effectively eliminating this financial obligation. By 2024, there was no mention of Mobility Preferred Interests in the disclosures, indicating a complete exit from this instrument. This contrasts with AT&T's treatment of other preferred interests, such as the Tower Holdings and Telco LLC preferred interests, which remained outstanding and were even expanded or restructured in 2024. This shift indicates a strategic move to reduce certain long-term liabilities while maintaining or adjusting other capital instruments for flexibility, suggesting a selective approach to managing its capital structure.",
      "llm_answer": "In 2023 AT&T eliminated its legacy Mobility II preferred securities by repurchasing the remaining 213 million Series A cumulative perpetual preferred interests for roughly $5.4 billion, reclassifying the liability and causing a one‑time increase in interest expense. By 2024 the company had shifted to issuing a new, redeemable class of Mobility‑II preferred interests – two million Series B cumulative perpetual preferred membership interests in Mobility II LLC that pay a 6.8% cash distribution – reflecting a strategy of replacing legacy preferred debt with flexible, redeemable preferred equity. This transition shows AT&T is actively managing its capital structure, using preferred‑equity instruments to reduce debt‑like obligations, preserve liquidity and create a more adaptable financing mix.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant inaccuracies that contradict the ground truth. (1) QUANTITATIVE ERRORS: The LLM states AT&T repurchased '213 million Series A cumulative perpetual preferred interests for roughly $5.4 billion' - this is internally inconsistent (213M units at ~$5.4B would be ~$25,400 per unit, which is implausible). The ground truth confirms the $5,414 million repurchase amount is correct, but the unit count and characterization are questionable. (2) CRITICAL FACTUAL ERROR - 2024 STATUS: The LLM claims 'By 2024 the company had shifted to issuing a new, redeemable class of Mobility‑II preferred interests – two million Series B cumulative perpetual preferred membership interests in Mobility II LLC that pay a 6.8% cash distribution.' This directly contradicts the ground truth, which explicitly states 'By 2024, there was no mention of Mobility Preferred Interests in the disclosures, indicating a complete exit from this instrument.' The LLM fabricates a new issuance in 2024 that did not occur according to the knowledge graph. (3) MISCHARACTERIZATION: The LLM describes the 2023 action as 'eliminating its legacy Mobility II preferred securities' and 'reclassifying the liability' with 'one-time increase in interest expense' - these details are not in the ground truth and appear to be inferred or incorrect. (4) INCOMPLETE CONTEXT: The ground truth notes AT&T maintained other preferred interests (Tower Holdings and Telco LLC) which were 'even expanded or restructured in 2024,' showing a selective approach. The LLM completely misses this comparative context and instead invents a false narrative about new Mobility II issuances. (5) REASONING FAILURE: The multi-hop synthesis is fundamentally broken - the LLM failed to correctly identify that Mobility Preferred Interests were completely eliminated by 2024, not replaced with new instruments. The answer demonstrates a complete misunderstanding of AT&T's actual capital structure evolution between 2023-2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 542,
        "total_tokens": 1945
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has IBM's relationship with stock exchange regulations evolved in terms of regulatory exposure for its debt securities between 2022 and 2024?",
      "original_answer": "In 2022, IBM described stock exchange regulations as one of several factors influencing the value of its debt securities, placing it among other external variables beyond the company's control. By 2024, IBM's language shifted to indicate a more direct regulatory exposure, stating it is 'subject to' stock exchange regulations, which implies a heightened recognition of their binding impact on the company's financing activities. This evolution reflects a stronger acknowledgment of regulatory influence in 2024 compared to the more general mention in 2022.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K filings say that the value of IBM’s debt securities can be affected by “governmental and stock‑exchange regulations” and that this exposure is largely outside the company’s control. The wording is essentially unchanged across the two reports, indicating that IBM’s regulatory exposure to stock‑exchange rules for its debt securities has remained consistent from 2022 to 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core conclusion. The ground truth explicitly states that IBM's language SHIFTED between 2022 and 2024, moving from describing stock exchange regulations as 'one of several factors' (2022) to stating the company is 'subject to' stock exchange regulations (2024), representing a 'heightened recognition' and 'stronger acknowledgment' of regulatory influence. The LLM answer directly contradicts this by claiming the wording is 'essentially unchanged' and that exposure 'remained consistent.' This is a critical factual error that misses the entire point of the question about how the relationship EVOLVED. The LLM correctly identifies that both years mention governmental and stock-exchange regulations and that exposure is outside the company's control, but it fails to recognize the semantic and substantive shift in language from 2022 to 2024. The LLM's assertion that wording is unchanged is demonstrably false based on the ground truth's description of the evolution from 'among other external variables' to 'subject to' regulations. This represents a failure in multi-hop reasoning and synthesis - the model needed to compare the specific language used in both years and identify the shift in regulatory framing, but instead concluded no meaningful change occurred. The quantitative accuracy is relatively high (dates and company name correct), but the qualitative accuracy is very low because the core analytical conclusion is inverted from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 417,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Disney's financial relationship with A&E evolve from 2022 to 2024, particularly in terms of equity income contribution?",
      "original_answer": "In 2022, Disney's equity investment in A&E was a significant component of its equity income, with A&E being one of the most notable equity method investees alongside CTV Specialty Television. By 2024, Disney's equity in the income of investees had decreased by $207 million, specifically due to lower income generated from A+E. This indicates a material decline in the financial contribution from A&E to Disney over the two-year period.",
      "llm_answer": "Disney’s 50 % stake in A+E is accounted for under the equity method, with its share of A+E’s earnings reported as “Equity in the income of investees, net” in the consolidated statements【DIS_10k_2022.pdf pp.10‑14】.  By fiscal 2024 that equity‑income line had fallen to $575 million, down $207 million from the prior‑year level of $782 million, reflecting weaker earnings from A+E【DIS_10k_2024.pdf pp.33‑37】.  This shows a clear decline in A+E’s contribution to Disney’s overall equity income between 2022 and 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the $207 million decline in equity income from A+E between 2022 and 2024, which matches the ground truth. The answer appropriately notes Disney's equity method accounting for A+E and correctly identifies this as a material decline. The multi-hop synthesis across 2022 and 2024 filings is sound. CRITICAL ISSUES: (1) The LLM provides specific 2024 and 2023 figures ($575M and $782M respectively) that are NOT present in the ground truth answer. The ground truth only states there was a $207M decrease but does NOT specify the absolute values or years these figures correspond to. (2) The LLM claims the 2024 figure was $575M down from $782M in the 'prior-year level,' but this appears to conflate 2023 and 2024 data without clear verification against the ground truth. (3) The ground truth mentions A+E as 'one of the most notable equity method investees alongside CTV Specialty Television' in 2022, but the LLM omits this comparative context. (4) The LLM states Disney has a '50% stake' in A+E, which is not mentioned in the ground truth and cannot be verified from the provided information. CALCULATION VERIFICATION: The $207M decline figure is correct and matches ground truth. However, the specific year-to-year values ($782M to $575M) cannot be confirmed as accurate from the ground truth provided. MULTI-HOP REASONING: The answer correctly synthesizes information across 2022 and 2024 filings and identifies the relationship evolution, though it adds specific numbers not in the ground truth. SEMANTIC EQUIVALENCE: The core message about declining A+E contribution is preserved, but the addition of unverified specific figures introduces potential inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 465,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did the carrying value of securitized debt obligations change from 2022 to 2023, and what does this indicate about the company's long-term funding strategy?",
      "original_answer": "In 2022, the long-term funding, which primarily consists of securitized debt obligations and senior and subordinated notes, stood at $42.3 billion as of December 31, 2021, with a significant portion driven by securitized debt obligations. By December 31, 2023, the carrying value of securitized debt obligations alone decreased to $18.043 billion. This indicates a strategic shift or reduction in reliance on securitized debt obligations as part of the company's long-term funding structure over this period.",
      "llm_answer": "The carrying value of Capital One’s securitized debt obligations rose from $16.973 billion at year‑end 2022 to $18.043 billion at year‑end 2023 – an increase of roughly $1.07 billion (Table 16.6, 2023 vs. 2022). This growth shows the company is expanding its securitization program, using securitized debt as a core component of its long‑term funding mix to diversify away from deposits and maintain ample wholesale‑funding capacity.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant quantitative inaccuracies that contradict the ground truth. (1) WRONG DIRECTION OF CHANGE: The LLM claims securitized debt obligations INCREASED from $16.973B (2022) to $18.043B (2023), but the ground truth indicates a DECREASE from a higher baseline to $18.043B by 2023. The LLM's 2022 figure of $16.973B appears to be incorrect or misidentified. (2) WRONG INTERPRETATION: The ground truth shows the company REDUCED reliance on securitized debt obligations (strategic shift downward), while the LLM interprets this as EXPANSION of the securitization program - a 180-degree misinterpretation of the company's funding strategy. (3) CALCULATION ERROR: The LLM calculates an increase of $1.07B, which is arithmetically correct for the numbers it cites ($18.043B - $16.973B = $1.07B), but these appear to be the wrong baseline figures. (4) MISSING CONTEXT: The ground truth references 2021 baseline data ($42.3B in long-term funding) and shows a significant reduction by 2023, indicating a strategic shift away from securitized debt. The LLM completely misses this multi-year trend analysis. (5) ENTITY/METRIC CONFUSION: While the LLM correctly identifies Capital One and the metric (securitized debt obligations), it fundamentally misreads the direction and meaning of the change. The reasoning about 'expanding securitization program' directly contradicts the ground truth's conclusion about reduced reliance. This is a critical failure in multi-hop synthesis and interpretation of financial trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 427,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has Disney's approach to scripted programming evolved between 2022 and 2024, particularly in terms of its international general entertainment channels and its strategic shift toward DTC platforms?",
      "original_answer": "In 2022, Disney operated approximately 220 General Entertainment channels outside the U.S., primarily under the Fox, National Geographic, and Star brands, featuring a mix of scripted, reality, and documentary programming across multiple languages and regions. By 2024, there was a notable strategic shift, with increased emphasis on DTC platforms and less focus on traditional linear channels. The 2024 report highlights that Disney, along with Fox Corporation and Warner Bros. Discovery, planned a joint venture (Venu Sports) to distribute sports content via a DTC platform, signaling a broader move toward streaming. Additionally, Disney announced plans to launch a new DTC offering in early fall 2025 that would include live linear streams of ESPN channels and ESPN+. This reflects a strategic pivot from scripted linear content toward live and sports-driven DTC offerings, indicating a transformation in Disney’s programming and distribution priorities.",
      "llm_answer": "In 2022 Disney still relied on a large portfolio of roughly 220 international general‑entertainment channels—primarily Fox, National Geographic and Star—to distribute scripted series abroad (“Fox branded channels air a variety of scripted…programming”; “National Geographic branded channels air scripted…programming”; “Star branded channels air a variety of scripted…programming”) while noting that “the Company’s increased focus on DTC distribution…is expected to negatively impact the International Channels business” as it shifts monetization from linear licensing to streaming. By 2024 the shift had accelerated: Disney merged its standalone Star+ service into Disney+, added a Star‑content tile on Disney+, and emphasized that scripted content would be delivered mainly through its DTC platforms, confirming that the International Channels model is being de‑emphasized in favor of direct‑to‑consumer streaming.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Disney's strategic shift from 2022 to 2024, with mostly accurate information and sound multi-hop reasoning. STRENGTHS: (1) Correctly identifies the ~220 international general entertainment channels in 2022 across Fox, National Geographic, and Star brands; (2) Accurately captures the strategic pivot toward DTC platforms and away from linear channels; (3) Correctly notes the merger of Star+ into Disney+ and the emphasis on DTC delivery of scripted content; (4) Properly synthesizes the shift from linear licensing monetization to streaming-based models; (5) Multi-hop reasoning is sound, connecting 2022 channel portfolio to 2024 DTC strategy. WEAKNESSES: (1) The LLM answer omits the Venu Sports joint venture (Disney, Fox Corporation, Warner Bros. Discovery) mentioned in the ground truth as a significant strategic signal of the DTC shift; (2) Does not mention the planned 2025 DTC offering with live linear ESPN streams and ESPN+, which is a key forward-looking element in the ground truth; (3) The answer focuses primarily on scripted content delivery through DTC but misses the broader strategic pivot toward live and sports-driven DTC offerings highlighted in the ground truth. QUANTITATIVE ACCURACY: The 220 channels figure is correct and properly formatted. No calculations are required or presented, so this dimension is straightforward. QUALITATIVE ACCURACY: The reasoning about the shift from linear to DTC is sound and well-supported with quoted evidence. However, the incompleteness regarding Venu Sports and the 2025 ESPN DTC plans represents a gap in synthesizing all relevant strategic elements. CONTEXTUAL RELEVANCE: The answer directly addresses the question about Disney's approach evolution and the shift toward DTC, though it could have been more comprehensive in capturing all strategic initiatives mentioned in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1481,
        "completion_tokens": 515,
        "total_tokens": 1996
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Tesla's financial and operational challenges related to energy storage products evolve from 2022 to 2023, particularly in terms of accounts receivable and production scaling dependencies?",
      "original_answer": "In 2022, Tesla disclosed significant long-term government rebates receivable related to its energy storage products, with a balance of $627 million as of December 31, 2021, indicating extended collection periods of up to a year or more. By 2023, the focus shifted from financial implications of receivables to operational dependencies, as Tesla highlighted production scaling risks for energy storage products, including bottlenecks, supplier constraints, and facility ramp delays at factories in Nevada, Texas, and other locations. These changes reflect a shift from financial exposure tied to receivables to broader production and supply chain dependencies affecting the company's ability to meet cost and profitability targets.",
      "llm_answer": "In the 2022 filing Tesla warned that its accounts‑receivable balance— which includes sales of energy‑generation and storage products—could swing with the timing of financing‑partner settlements and long‑lag government rebates, and it flagged that delays in launching or ramping energy‑storage production could impede growth. The 2023 filing repeats the receivable‑timing pressure but stresses that scaling energy‑storage output now hinges on successfully expanding production capacity and securing sufficient battery‑cell supply, indicating that production‑scaling dependencies remain a central operational challenge.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ISSUES: (1) QUANTITATIVE ACCURACY FAILURE: The LLM answer completely omits the specific $627 million figure for long-term government rebates receivable as of December 31, 2021, which is a key quantitative anchor in the ground truth. This is a significant factual omission for a financial question. (2) TEMPORAL FRAMING ERROR: The ground truth clearly states the $627 million balance was 'as of December 31, 2021' but the LLM references this in the context of '2022 filing' without clarifying the actual date of the receivable balance. This creates ambiguity about whether the figure relates to 2021 or 2022 year-end. (3) PARTIAL CORRECTNESS ON EVOLUTION: The LLM correctly identifies the shift from financial receivables concerns (2022) to operational/production scaling dependencies (2023), which matches the ground truth's core narrative. The mention of 'financing-partner settlements and long-lag government rebates' aligns with the receivables discussion. (4) PRODUCTION SCALING: The LLM appropriately captures the 2023 focus on production capacity expansion and battery-cell supply constraints, matching the ground truth's emphasis on 'production scaling risks' and 'supplier constraints.' (5) MISSING CONTEXT: The LLM does not mention specific facility locations (Nevada, Texas) that the ground truth references, though this is a minor omission. (6) SEMANTIC ALIGNMENT: The overall narrative arc—from receivables timing concerns to production dependencies—is correctly conveyed, but the absence of the $627 million figure significantly weakens the answer's quantitative rigor. For a financial question, omitting a specific dollar amount that anchors the analysis is a material deficiency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 464,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in relation to its bottling partners and fountain retailers?",
      "original_answer": "In 2022, Coca-Cola's relationship with syrups was primarily defined by its sales to both consolidated and unconsolidated bottling partners, with revenue and volume recognition dependent on the ownership structure of those partners. Specifically, concentrate and syrup sales were not recognized until finished products were sold to third parties in the case of consolidated bottlers, while recognition occurred immediately for unconsolidated bottlers. By 2023, the company's description of syrups shifted to emphasize their role as a dependency within a broader operational framework, particularly in relation to fountain retailers. In 2023, the company clarified that it manufactures fountain syrups and sells them directly to fountain retailers or authorized wholesalers and bottlers, highlighting a more integrated and strategic role for syrups in its finished beverage delivery system. This represents a shift from a primarily volume-driven metric to a more operationally embedded component of the business model.",
      "llm_answer": "In the 2022 filing Coca‑Cola described syrups as part of its concentrate business – they were sold to both consolidated and unconsolidated bottling partners, with revenue recognized only when the bottler (or, for unconsolidated partners, at the time of shipment) sold the finished beverage 【2022 p. 42‑44】. By the 2023 filing the company emphasizes a distinct “fountain‑syrup” line: Coca‑Cola now manufactures fountain syrups in the United States and sells them directly to fountain retailers (or through wholesalers or bottling partners), and these sales are reported in the North America segment, while still supplying syrups to bottlers for finished‑product production 【2023 p. 35‑38】. This reflects a shift from syrups being a bundled concentrate item for bottlers to a more explicit, direct channel to fountain retailers.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution of Coca-Cola's syrup business model between 2022 and 2023. STRENGTHS: (1) Correctly identifies the 2022 structure where syrups were part of concentrate sales to bottling partners with revenue recognition dependent on ownership structure (consolidated vs. unconsolidated). (2) Accurately captures the 2023 shift toward explicit fountain syrup sales directly to fountain retailers or through wholesalers/bottlers. (3) Properly synthesizes the multi-hop information showing the transition from bundled concentrate items to a distinct direct-to-retailer channel. (4) Correctly identifies geographic specificity (North America segment reporting). (5) Page citations are provided and appear reasonable for 10-K filings. MINOR WEAKNESSES: (1) The LLM answer slightly simplifies the revenue recognition mechanics in 2022 - it states recognition occurred 'when the bottler sold the finished beverage' but the ground truth specifies this applied to consolidated bottlers, while unconsolidated bottlers had immediate recognition at shipment. The LLM's phrasing 'or, for unconsolidated partners, at the time of shipment' does capture this but could be clearer. (2) The ground truth emphasizes a shift from 'primarily volume-driven metric to operationally embedded component' which the LLM captures conceptually but doesn't explicitly state. (3) The LLM could have been more explicit about the strategic/integrated nature of the 2023 role. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts were required in this question, so this dimension is less critical. The answer contains no numerical errors. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and multiple business relationships (bottlers, fountain retailers, wholesalers), demonstrating sound multi-hop reasoning. The comparison between years is logical and well-structured. SEMANTIC EQUIVALENCE: The LLM answer conveys essentially the same information as the ground truth, with slightly different emphasis but no contradictions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 565,
        "total_tokens": 2030
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did Disney's investment in Other Mortgage- and Asset-Backed Securities (MBS & ABS) evolve from fiscal year 2022 to fiscal year 2024, and what was the trend in its proportion relative to the overall fair value hierarchy?",
      "original_answer": "In fiscal year 2022, Disney's investment in Other MBS & ABS was valued at $96 million, representing 1% of the total plan asset mix. By fiscal year 2024, this investment increased to $120 million, maintaining a 1% share of the total plan asset mix. While the absolute value of the investment grew moderately, its proportional representation within the portfolio remained stable.",
      "llm_answer": "Disney’s “Other mortgage‑ and asset‑backed securities” holding grew from $84 million in FY 2022 (Level 2) to $166 million in FY 2024 – roughly a doubling of the dollar amount. Nevertheless, the line continued to represent about 1 % of the total fair‑value‑hierarchy assets (≈$7.5 billion in 2022 and ≈$11 billion in 2024), so its share of the overall hierarchy remained essentially unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant numerical inaccuracies that contradict the ground truth. (1) FY 2022 value: LLM states $84 million (Level 2), but ground truth is $96 million - a $12 million discrepancy (12.5% error). (2) FY 2024 value: LLM states $166 million, but ground truth is $120 million - a $46 million overstatement (38% error). (3) The LLM claims the investment 'roughly doubled' from $84M to $166M, but the actual trend per ground truth shows more modest growth from $96M to $120M (25% increase, not 100%). (4) While the LLM correctly identifies that the proportion remained at 1% of total assets, this conclusion is based on incorrect underlying dollar amounts. (5) The LLM provides context about total fair-value-hierarchy assets (~$7.5B in 2022, ~$11B in 2024), which is reasonable contextual information but doesn't compensate for the fundamental numerical errors. The multi-hop reasoning structure is sound (comparing absolute values and proportions across years), but it's built on incorrect data. The semantic understanding of the question is adequate, but the execution fails critically on quantitative accuracy - the most important dimension for financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 341,
        "total_tokens": 1553
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the focus areas of Skunk Works' advanced development programs evolve between 2022 and 2023 in relation to next-generation military aircraft capabilities?",
      "original_answer": "In 2022, Skunk Works' Advanced Development Programs focused on future systems including unmanned and manned aerial systems and next-generation capabilities for hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. By 2023, the focus had evolved to emphasize air dominance, hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. The shift highlights an increased emphasis on air dominance as a core next-generation capability while maintaining focus on hypersonics and ISR. This represents a refinement of priorities rather than a complete overhaul of focus areas.",
      "llm_answer": "In the 2022 filing, Lockheed Martin’s Skunk Works (Advanced Development Programs) was described as concentrating on “future systems, including unmanned and manned aerial systems and next‑generation capabilities for hypersonics, intelligence, surveillance, reconnaissance, situational awareness and air mobility”【LMT_10k_2022.pdf p.6】.  \nThe 2023 filing retains those same focus areas but adds a specific emphasis on “next‑generation air‑dominance” capabilities, expanding the program’s scope to include future combat‑air‑superiority while still covering hypersonics, ISR, situational awareness and air mobility【LMT_10k_2023.pdf p.4】.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the key focus areas for both 2022 and 2023, with accurate citations to the relevant 10-K filings. The factual content is largely correct: (1) 2022 focus areas are accurately stated as including unmanned/manned aerial systems, hypersonics, ISR, situational awareness, and air mobility; (2) 2023 focus areas are correctly identified with the addition of 'air dominance' emphasis. However, there are some issues with the answer's characterization of the evolution: The LLM states that 2023 'retains those same focus areas but adds a specific emphasis on next-generation air-dominance,' which slightly misrepresents the ground truth. The ground truth indicates that 'unmanned and manned aerial systems' were explicitly mentioned in 2022 but are NOT explicitly listed in 2023, suggesting a shift away from that framing rather than a simple addition. The ground truth characterizes this as 'a refinement of priorities rather than a complete overhaul,' which the LLM captures reasonably well by saying the program 'still covering' the other areas. The LLM's interpretation that air dominance was 'added' is somewhat imprecise—it would be more accurate to say it became a more prominent framing. The multi-hop reasoning is sound (comparing 2022 vs 2023 filings), and the entity identification (Lockheed Martin, Skunk Works, Advanced Development Programs) is correct. The answer demonstrates good synthesis across the two years but slightly oversimplifies the nature of the shift in emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 418,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Tesla's approach to the Powerwall product evolved from 2022 to 2023, particularly in terms of integration strategy and production emphasis?",
      "original_answer": "In 2022, Tesla emphasized cross-selling Powerwall with residential solar energy products due to better availability and growing grid stability concerns. The company was also focused on improving installation capabilities and price efficiencies for Solar Roof, which is closely related to Powerwall integration. By 2023, Tesla had advanced its integration strategy by designing both Solar Roof and solar energy systems to specifically integrate with Powerwall, indicating a more deliberate and engineered approach to product synergy. This evolution reflects a shift from a sales and availability focus to a deeper technical and strategic integration within Tesla's energy ecosystem.",
      "llm_answer": "In the 2022 filing Tesla said it was expanding Powerwall output by building a new “Megafactory” and was “emphasizing cross‑selling with our residential solar energy products” to drive demand (2022 p.34). By the 2023 filing the company’s language had shifted to positioning Powerwall as a core component that “integrates with” its Solar Roof and other solar offerings, while still noting that it is “continuing to increase the production of our energy‑storage products” (2023 p.7; 2023 p.5). This reflects a move from a cross‑sell‑focused strategy to a tighter product‑integration strategy, with production scaling remaining a priority.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Tesla's Powerwall strategy evolution from 2022 to 2023. STRENGTHS: (1) Correctly identifies the core strategic shift from cross-selling emphasis (2022) to deeper technical integration (2023), matching the ground truth narrative. (2) Accurately captures the 2022 focus on cross-selling with residential solar products and production expansion via Megafactory. (3) Properly synthesizes the 2023 shift toward integrated product design with Solar Roof and solar offerings. (4) Correctly notes that production scaling remained a priority in both years. (5) Provides specific filing references (2022 p.34, 2023 p.7, 2023 p.5) that add credibility. (6) The semantic meaning aligns well with ground truth: 'move from cross-sell-focused strategy to tighter product-integration strategy' matches 'shift from sales and availability focus to deeper technical and strategic integration.' MINOR CONSIDERATIONS: (1) The LLM mentions 'Megafactory' as a specific production initiative in 2022, which is a concrete detail not explicitly mentioned in the ground truth answer, though it doesn't contradict it. (2) The ground truth emphasizes 'improving installation capabilities and price efficiencies for Solar Roof' as part of 2022 strategy, which the LLM answer doesn't explicitly mention, though this is a relatively minor omission. (3) The ground truth's phrase 'more deliberate and engineered approach' is captured by the LLM's 'tighter product-integration strategy.' QUANTITATIVE ACCURACY: No specific numbers or calculations are required for this question, so this dimension is less critical. The page references provided appear reasonable for 10-K filings. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and multiple product lines (Powerwall, Solar Roof, solar energy systems) to show the evolution of strategy. The logical progression is sound and well-articulated. Overall, this is a high-quality answer that captures the essential evolution while providing supporting details from the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 558,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Gilead's strategic positioning around Biktarvy evolved between 2022 and 2024, particularly in terms of its role within the company's HIV portfolio and associated commercial risks?",
      "original_answer": "In 2022, Biktarvy was prominently positioned as a key revenue-generating product within Gilead’s HIV portfolio, highlighted as a single-tablet regimen combining bictegravir, emtricitabine, and tenofovir alafenamide (TAF), emphasizing its convenience and efficacy. By 2024, while Biktarvy remained a core product, the company faced heightened commercial risk as it became more dependent on HIV products containing TAF. A shift in treatment paradigms or reduced preference for nucleoside-based therapies could significantly impact Biktarvy’s sales and, by extension, Gilead’s financial stability. This reflects a transition from a focus on product innovation to increased vulnerability due to overreliance on a narrow therapeutic class.",
      "llm_answer": "In the 2022 Form 10‑K Gilead listed Biktarvy simply as one of several HIV single‑tablet regimens (a bictegravir/emtricitabine/TAF combo) and the only HIV‑related risk language was a broad warning that the company “receives a substantial portion of its revenue from sales of its HIV products” (Item 1 p. 3; Item 1A p. 17). By the 2024 filing the company had elevated Biktarvy to the centerpiece of its HIV franchise – describing it as the primary growth driver and core product of the portfolio – and now flags the specific commercial risk that loss of Biktarvy market share (e.g., from competition or pricing pressure) could materially affect its HIV revenue (Item 1 p. 16; Item 1A p. 17).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key elements of the evolution but contains significant issues in accuracy and completeness. STRENGTHS: (1) Correctly identifies Biktarvy's composition (bictegravir/emtricitabine/TAF) in both years; (2) Accurately notes the shift from general HIV revenue risk language in 2022 to more specific Biktarvy-focused risk language in 2024; (3) Appropriately cites specific 10-K sections (Item 1, Item 1A); (4) Correctly identifies the core theme of increased commercial vulnerability. WEAKNESSES: (1) The claim that Biktarvy was 'simply one of several HIV single-tablet regimens' in 2022 contradicts the ground truth stating it was 'prominently positioned as a key revenue-generating product' - this is a material mischaracterization of its 2022 status; (2) The LLM states Biktarvy was 'elevated to the centerpiece' by 2024, but the ground truth indicates it 'remained a core product' - suggesting continuity rather than elevation, which is a semantic error; (3) Missing the critical insight about 'overreliance on a narrow therapeutic class' and the specific vulnerability to 'shift in treatment paradigms or reduced preference for nucleoside-based therapies' - the ground truth emphasizes TAF-dependency risk more specifically than the LLM's generic 'competition or pricing pressure' language; (4) The LLM's framing suggests a more dramatic shift than the ground truth supports - the ground truth describes a 'transition from focus on product innovation to increased vulnerability,' not a promotion from minor to centerpiece status. MULTI-HOP REASONING: The LLM correctly synthesizes information across 2022 and 2024 filings and identifies the evolution in risk disclosure, but fails to accurately characterize Biktarvy's baseline position in 2022. QUANTITATIVE ACCURACY: No specific numbers are provided in either answer, so this dimension is neutral. The page citations appear plausible but cannot be verified. OVERALL: The answer demonstrates understanding of the general trajectory but contains a fundamental mischaracterization of Biktarvy's 2022 positioning and misses the specific TAF-dependency risk that is central to the ground truth answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 582,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did the composition of the U.S. Retrospective Responsibility Plan change between 2022 and 2023, particularly regarding the mechanisms referenced in relation to the U.S. Litigation Escrow Agreement?",
      "original_answer": "In 2022, the U.S. Retrospective Responsibility Plan included mechanisms such as the U.S. Litigation Escrow Agreement, the conversion feature of Class B common stock, indemnification obligations of Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. By 2023, the composition evolved to include a new element — 'makewhole agreements relating to the Class B-1 common stock exchange offer' — while retaining the U.S. Litigation Escrow Agreement and other previously listed mechanisms. This indicates an expansion of the plan to incorporate additional financial safeguards or compensatory measures.",
      "llm_answer": "In the 2022 filing the U.S. Retrospective Responsibility Plan was described as consisting of six mechanisms – the U.S. litigation‑escrow agreement, the conversion feature of the company’s class B common stock, the indemnification obligations of Visa U.S.A. members, an interchange‑judgment‑sharing agreement, a loss‑sharing agreement and an omnibus agreement (V_10k_2022 pp. 71‑73). By the 2023 filing the plan still includes those core elements, but it added “make‑whole agreements” related to the class B‑1 common‑stock exchange offer and broadened the conversion feature to cover class B‑1 and B‑2 stock, thereby expanding the mechanisms linked to the escrow arrangement (V_10k_2023 pp. 70‑74).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy with minor enhancements beyond the ground truth. STRENGTHS: (1) Correctly identifies all six 2022 mechanisms (U.S. litigation-escrow agreement, Class B conversion feature, Visa U.S.A. member indemnification, interchange-judgment-sharing agreement, loss-sharing agreement, omnibus agreement); (2) Accurately identifies the new 2023 addition of 'make-whole agreements' related to Class B-1 common stock exchange offer; (3) Correctly notes retention of core elements from 2022; (4) Provides specific page references (V_10k_2022 pp. 71-73, V_10k_2023 pp. 70-74) that add credibility; (5) Multi-hop synthesis is sound - properly compares 2022 vs 2023 compositions. MINOR ENHANCEMENTS: The LLM answer goes slightly beyond the ground truth by noting that the conversion feature was 'broadened to cover class B-1 and B-2 stock' in 2023. While this additional detail appears reasonable and consistent with the question's focus on composition changes, it represents information not explicitly stated in the provided ground truth answer. This is a minor addition that enhances rather than contradicts the core answer. QUANTITATIVE ACCURACY: All numbers are correct (six mechanisms in 2022, addition of make-whole agreements in 2023). No calculation errors. QUALITATIVE ACCURACY: Entity identification is precise (Visa U.S.A., Class B/B-1/B-2 stock designations). The reasoning correctly synthesizes the evolution of the plan across years. CONTEXTUAL RELEVANCE: Directly addresses the question about composition changes between 2022 and 2023, with specific focus on mechanisms related to the U.S. Litigation Escrow Agreement as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 456,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has the strategic importance of Biktarvy evolved for GILD from 2022 to 2024, based on its patent protection timeline and the company's risk disclosures around HIV product dependency?",
      "original_answer": "In 2022, Biktarvy was listed with a U.S. patent expiration in 2033 and no expiration listed in the E.U., indicating strong long-term protection and likely a key revenue driver. By 2024, although patent details were not explicitly mentioned, the company highlighted heightened risk around its HIV products, including Biktarvy, due to market competition and potential shifts in treatment paradigms. This suggests that despite long-term patent protection, Biktarvy's strategic position has become more vulnerable due to external market and regulatory pressures.",
      "llm_answer": "The 2022 filing (patent‑expiration table on page 12) shows Biktarvy’s U.S. and EU patents run through 2033, and the HIV‑product‑dependency risk factor (page 13) warns that a large share of Gilead’s revenue comes from its HIV portfolio, highlighting Biktarvy as a key revenue engine. The 2024 filing (pages 18‑20) still lists a 2033 expiration for Biktarvy and repeats the same HIV‑dependency risk language, confirming that the drug’s long‑term exclusivity remains a cornerstone of Gilead’s strategy and that its reliance on HIV sales—including Biktarvy—continues to be a material strategic focus.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY FAILURE: The LLM claims Biktarvy has U.S. and EU patents running through 2033 in BOTH 2022 and 2024 filings. However, the ground truth explicitly states that in 2022, there was 'no expiration listed in the E.U.' This is a factual error - the LLM incorrectly asserts EU patent protection exists through 2033 when the ground truth indicates no EU expiration was listed. (2) MULTI-HOP REASONING FAILURE: The core question asks how Biktarvy's strategic importance 'evolved' from 2022 to 2024. The ground truth shows a clear evolution: 2022 = strong long-term protection with no EU expiration concerns, 2024 = heightened risk despite patent protection due to market competition and treatment paradigm shifts. The LLM's answer claims the situation 'remains' the same and that 'long-term exclusivity remains a cornerstone' - this directly contradicts the ground truth's finding of increased vulnerability. The LLM failed to capture the key evolution: from secure position to vulnerable position despite unchanged patent dates. (3) MISSING CRITICAL INSIGHT: The ground truth emphasizes that despite patent protection, external pressures (market competition, regulatory shifts) have made Biktarvy more strategically vulnerable. The LLM misses this nuance entirely, suggesting stability rather than evolution. (4) INCOMPLETE SYNTHESIS: The LLM does not adequately synthesize the tension between long-term patent protection (unchanged) and heightened risk disclosures (increased), which is the core of the question. The answer reads as if nothing changed strategically, when the ground truth indicates significant strategic repositioning in risk perception.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 464,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "Have there been any modifications to the financial guarantees provided by AT&T for Illinois Bell Telephone Company between 2022 and 2023, particularly in terms of guarantee structure or referenced documentation?",
      "original_answer": "The financial guarantee relationship between AT&T and Illinois Bell Telephone Company remained structurally unchanged between 2022 and 2023. In 2022, AT&T's guarantee for Illinois Bell Telephone Company was referenced under Exhibit 4-d to Form 10-K for the period ending December 31, 2011. In 2023, the same guarantee was still in place and referenced under the identical exhibit number (Exhibit 4-d) and filing history (Form 10-K for the period ending December 31, 2011). There is no indication of modifications to the guarantee structure, terms, or documentation between the two years.",
      "llm_answer": "No. Both the 2022 and 2023 Form 10‑K filings list the same guarantee for Illinois Bell Telephone Company as an exhibit to the 2011 Form 10‑K (Exhibit 4‑d/4‑c), and neither filing notes any amendment, restructuring or new documentation for that guarantee. Consequently, the guarantee’s structure and referenced documentation remained unchanged between the two years.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core conclusion that the guarantee remained unchanged between 2022 and 2023, and accurately references the 2011 Form 10-K filing. However, there is a significant discrepancy in the exhibit number citation. The ground truth clearly states the guarantee was referenced under 'Exhibit 4-d' in both 2022 and 2023. The LLM answer introduces 'Exhibit 4-c' as an alternative, stating '(Exhibit 4‑d/4‑c)' which is not supported by the ground truth and creates ambiguity. The ground truth explicitly confirms the 'identical exhibit number (Exhibit 4-d)' was used in both years. This is a factual error regarding documentation references, which is a critical element of the question about 'referenced documentation.' The LLM correctly identifies that no amendments or restructuring occurred and that the guarantee structure remained unchanged. The reasoning is sound and the multi-hop synthesis (comparing 2022 and 2023 filings) is properly executed. The answer appropriately addresses all parts of the question regarding guarantee structure and referenced documentation. However, the introduction of an incorrect exhibit number (4-c) alongside the correct one (4-d) represents a material error in entity/documentation accuracy that undermines confidence in the answer's precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 366,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "What does the consistent Class C to Class A common stock conversion rate between 2022 and 2023 suggest about the potential impact on Class A common stockholders' voting power in significant corporate transactions?",
      "original_answer": "In 2022, the Class C common stock had a conversion rate of 4.0000 into Class A common stock, and this rate remained unchanged in 2023. Despite the as-converted Class A common stock value increasing slightly from 38 million in 2022 to 39 million in 2023, the unchanged conversion rate suggests that the relative voting power dilution for Class A common stockholders remained stable. This stability implies that there was no structural change in how Class C stockholders could influence significant corporate decisions through their voting rights tied to Class A equivalents.",
      "llm_answer": "The 10‑K tables show that the Class C‑to‑Class A conversion rate remained at 4.0000 (one Class C share converts into four Class A shares) in both 2022 and 2023 (Note 15‑Stockholders’ Equity). Because the conversion ratio did not change, any conversion of Class C shares would add the same number of Class A voting shares as before, meaning the potential dilution of existing Class A shareholders’ voting power in a merger, consolidation or other significant transaction is stable and predictable rather than increasing.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the key quantitative fact: the Class C to Class A conversion rate remained at 4.0000 in both 2022 and 2023. The numeric values are accurate and properly formatted. The reasoning about stable and predictable dilution is sound and logically connects the unchanged conversion rate to the implications for Class A stockholders' voting power in significant transactions. However, the LLM answer omits a specific detail from the ground truth: the as-converted Class A common stock value increased from 38 million to 39 million shares despite the unchanged conversion rate. While this omission doesn't fundamentally undermine the core conclusion about voting power stability, it represents incomplete synthesis of the available data. The ground truth explicitly notes this increase and uses it to reinforce the point about stable relative voting power dilution. The LLM's explanation is clear and addresses the question's core concern about potential impact on voting power, correctly concluding that the unchanged conversion rate means dilution remains stable rather than increasing. The answer appropriately references Note 15 on Stockholders' Equity, demonstrating proper source attribution. The semantic meaning aligns well with the ground truth despite the missing quantitative detail about the share count increase.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 376,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Tesla's relationship with the Solar Roof evolve from 2022 to 2023 in terms of production focus and strategic dependencies?",
      "original_answer": "In 2022, Tesla directly produced the Solar Roof at Gigafactory New York, indicating active involvement in its manufacturing. However, by 2023, Tesla's disclosures shifted to emphasizing dependencies and risks associated with scaling production, including potential delays, supply chain constraints, and challenges in launching and ramping products like the Solar Roof. This reflects a transition from a production-centric view to a more cautionary outlook on strategic execution risks.",
      "llm_answer": "In 2022 Tesla treated the Solar Roof as an in‑house, engineering‑driven product – it was designed, engineered and built at Gigafactory New York (see TSLA 10‑K 2022 p.10) and its market was heavily supported by a 26 % federal tax credit (TSLA 10‑K 2022 p.9). By the 2023 filing the company still offered Solar Roof but warned that production had not yet been fully ramped and that the business now hinged on external factors such as the phase‑out of the tax credit and reliance on third‑party suppliers, signaling a shift from a primary internal‑production focus to a more dependent, ancillary role (see TSLA 10‑K 2023 p.16).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core narrative of Tesla's Solar Roof evolution from 2022 to 2023. STRENGTHS: (1) Correctly identifies the 2022 in-house production at Gigafactory New York, matching the ground truth's statement about direct production. (2) Accurately captures the 26% federal tax credit figure from 2022, which is a specific quantitative detail. (3) Properly synthesizes the shift from production-centric to risk-focused outlook in 2023, identifying key concerns like production ramp challenges, tax credit phase-out, and third-party supplier dependencies. (4) The multi-hop reasoning is sound - connecting 2022 internal production focus to 2023 external dependencies and strategic risks. (5) Correctly identifies the transition from 'primary internal-production focus to a more dependent, ancillary role,' which semantically matches the ground truth's 'transition from production-centric view to cautionary outlook.' MINOR CONSIDERATIONS: (1) The LLM provides specific page references (p.10, p.9, p.16) which add credibility but cannot be verified against the ground truth provided. These appear reasonable but represent an assumption of accuracy. (2) The phrase 'ancillary role' is a reasonable interpretation of the shift but is slightly more interpretive than the ground truth's more neutral 'cautionary outlook on strategic execution risks.' (3) The answer includes the detail about 'engineering-driven product' which, while reasonable, is not explicitly confirmed in the ground truth statement. QUANTITATIVE VERIFICATION: The 26% federal tax credit is stated as a specific figure and appears to be accurate based on the context provided. No calculations are required for this question, so quantitative accuracy focuses on the correctness of cited percentages and figures. MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across two fiscal years (2022 and 2023) and connects production strategy, regulatory environment (tax credits), and supply chain factors - demonstrating proper multi-hop reasoning. Overall, the answer is factually sound with strong semantic alignment to the ground truth, though it includes some interpretive elements that go slightly beyond what can be verified from the provided ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 613,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in terms of their relationship to finished beverage production and distribution channels?",
      "original_answer": "In 2022, Coca-Cola described syrups as intermediate products used primarily in fountain beverage production, where bottling partners or fountain retailers mix them with water and sweeteners to create finished beverages for immediate consumption. The company emphasized that syrups were a key part of the concentrate operations, which generally yield lower net operating revenues but higher gross profit margins compared to finished product operations. By 2023, the company expanded its description to emphasize that fountain syrup sales in the U.S. were directly managed by Coca-Cola and sold to both fountain retailers and authorized wholesalers or bottling partners. Additionally, the 2023 filing highlighted that fountain syrup operations were specifically included in the North America operating segment, indicating a more structured and regionally focused approach to syrup distribution. This evolution reflects a strategic shift toward tighter control and segmentation of syrup-related revenue streams within the broader beverage production ecosystem.",
      "llm_answer": "In 2022 Coca‑Cola’s syrups were classified under its “concentrate operations,” where the Company sold concentrates and syrups to bottling partners (and, in the U.S., to fountain retailers and wholesalers) who mixed them with water and sweeteners to create finished beverages; this segment accounted for about 56 % of net operating revenue and roughly 82 % of case volume. By 2023 the syrup‑driven concentrate segment had grown to roughly 58 % of revenue and 83 % of case volume, indicating a modest shift toward greater reliance on syrup sales as the primary feedstock for finished‑product production while still being distributed through the same bottling‑partner and fountain‑retailer channels.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) QUANTITATIVE ERRORS - The LLM introduces specific percentages (56%, 82%, 58%, 83%) that are NOT present in the ground truth answer. The ground truth makes NO mention of these revenue or case volume percentages. This is a critical factual error - the LLM appears to have fabricated or misattributed data. (2) INCOMPLETE SYNTHESIS - The LLM fails to address key elements from the ground truth: (a) The distinction between concentrate operations yielding 'lower net operating revenues but higher gross profit margins' is completely omitted; (b) The 2023 expansion describing fountain syrup sales as 'directly managed by Coca-Cola' is not mentioned; (c) The structural change regarding fountain syrup operations being 'specifically included in the North America operating segment' is absent; (d) The characterization of this as a 'strategic shift toward tighter control and segmentation' is missing. (3) MULTI-HOP REASONING FAILURE - The question asks about evolution in the role of syrups between 2022-2023, particularly regarding 'relationship to finished beverage production and distribution channels.' The LLM provides a surface-level comparison but misses the strategic evolution: the ground truth emphasizes a shift from general concentrate operations to more structured, regionally-focused, directly-managed distribution. The LLM treats both years similarly rather than highlighting the evolution. (4) FACTUAL ACCURACY - While the LLM correctly identifies syrups as intermediate products mixed with water and sweeteners, and correctly names distribution channels (bottling partners, fountain retailers, wholesalers), it contradicts the ground truth by suggesting continuity ('distributed through the same...channels') when the ground truth emphasizes a strategic shift toward tighter control. (5) SEMANTIC MISMATCH - The ground truth emphasizes 'tighter control and segmentation' as a strategic evolution; the LLM suggests merely 'modest shift toward greater reliance' without capturing the control/segmentation dimension.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 552,
        "total_tokens": 2001
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the company's operational focus on Africa/Eurasia evolved between 2022 and 2024, particularly in terms of its geographic reporting structure and financial contribution?",
      "original_answer": "In 2022, Africa/Eurasia was reported as part of the Oral, Personal and Home Care segment with an operating profit of $203 million, indicating a relatively minor financial contribution compared to other regions. By 2024, the company maintained Africa/Eurasia as a distinct reportable operating segment within the Oral, Personal and Home Care geographic structure. Additionally, in 2024, the company realigned its skin health business, shifting it from Europe to North America, signaling a strategic refinement in geographic reporting. This change suggests a more nuanced operational focus in how the company organizes and evaluates its regional performance, including in Africa/Eurasia.",
      "llm_answer": "The company continues to treat Africa/Eurasia as a separate reportable operating segment of its Oral, Personal and Home Care business, with no change to the five‑segment geographic reporting framework (the only 2024 change was a skin‑health realignment that did not affect this region). Net sales from Africa/Eurasia were essentially flat at $1.08 billion in 2022 and $1.09 billion in 2024, while operating profit rose from $228 million to $253 million, and capital spending fell sharply from $30 million to $12 million, indicating a shift toward higher profitability with lower investment.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) OPERATING PROFIT DISCREPANCY: Ground truth states 2022 operating profit was $203 million, but LLM claims $228 million - a $25 million error. For 2024, ground truth does not provide a specific operating profit figure, but LLM claims $253 million without verification. (2) NET SALES FIGURES: LLM provides specific net sales figures ($1.08B in 2022, $1.09B in 2024) that are not mentioned in the ground truth, making verification impossible and raising accuracy concerns. (3) CAPITAL SPENDING: LLM claims capital spending fell from $30M to $12M, which is not addressed in the ground truth. (4) STRUCTURAL CONSISTENCY: While LLM correctly identifies Africa/Eurasia as a distinct reportable segment and mentions the skin health realignment, it frames this as 'no change' to the reporting framework, which is misleading given the strategic realignment described in ground truth. (5) MULTI-HOP REASONING: The LLM successfully synthesizes the geographic reporting structure and mentions the skin health realignment, but the quantitative errors undermine the overall analysis. The ground truth emphasizes that Africa/Eurasia represented a 'relatively minor financial contribution,' but LLM's figures ($1.08-1.09B in sales) suggest a more substantial business, creating a semantic contradiction. The answer provides more granular financial detail than the ground truth but introduces unverified numbers that conflict with stated figures, particularly the 2022 operating profit discrepancy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 434,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Johnson & Johnson's strategic presentation of its Orthopaedics business evolved between 2023 and 2024, particularly in terms of global sales performance and emphasis on enabling technologies?",
      "original_answer": "In 2023, JNJ's Orthopaedics segment was presented primarily through quantifiable sales figures, with global revenue reaching $8,942 million, showing a 4.1% increase from the prior year. The 2023 data emphasized steady growth, particularly in the U.S. ($5,525 million, up 3.8%) and modest international growth ($3,417 million, up 4.6%). By 2024, the strategic framing of Orthopaedics shifted from financial metrics to a qualitative emphasis on innovation and enabling technologies. The 2024 filing described Orthopaedics as a portfolio 'supported by products and enabling technologies' across hips, knees, trauma, spine, and sports medicine, without revisiting specific revenue figures. This reflects a strategic pivot from highlighting quantitative performance to underscoring technological leadership and product diversification within the segment.",
      "llm_answer": "In the 2023 Form 10‑K Johnson & Johnson presented Orthopaedics almost exclusively as a revenue line‑item of MedTech – reporting worldwide sales of $8.9 billion, up 4.1 % versus the prior year, and breaking out U.S., international and sub‑category growth (hips, knees, trauma, spine, etc.). By the 2024 filing the company still cites the segment’s sales contribution, but the narrative shifts to describe the Orthopaedics portfolio as “products and enabling technologies” that support hips, knees, trauma, spine, sports and other indications, signaling a strategic pivot toward emphasizing technology‑driven capabilities alongside its sales performance.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the strategic evolution of JNJ's Orthopaedics presentation between 2023 and 2024, with mostly accurate quantitative data and sound multi-hop reasoning. STRENGTHS: (1) Correctly identifies the 2023 global revenue of $8.9 billion (matches $8,942 million in ground truth, acceptable format variation) and the 4.1% growth rate; (2) Accurately captures the strategic pivot from quantitative emphasis to qualitative focus on 'products and enabling technologies'; (3) Properly synthesizes the shift across both years and identifies the key business areas (hips, knees, trauma, spine, sports medicine); (4) Correctly notes that 2024 filing still cites sales contribution but shifts narrative focus. WEAKNESSES: (1) Missing specific U.S. and international revenue breakdowns from 2023 ($5,525 million U.S., up 3.8%; $3,417 million international, up 4.6%) that were explicitly mentioned in the ground truth as part of the 2023 presentation emphasis; (2) States 2024 'still cites the segment's sales contribution' but the ground truth indicates 2024 'without revisiting specific revenue figures' - this is a subtle but meaningful distinction suggesting the LLM may have overstated the continued emphasis on financial metrics in 2024; (3) The phrase 'sports and other indications' is slightly imprecise compared to ground truth's 'sports medicine.' MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years and identifies the strategic evolution, demonstrating sound multi-hop reasoning. The comparison between 2023 (quantitative focus) and 2024 (qualitative/technology focus) is logically structured. OVERALL: The answer captures the essential narrative of strategic evolution but omits important supporting details from 2023 that would strengthen the completeness of the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 502,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Visa's approach to managing litigation liabilities through loss sharing agreements evolved between 2022 and 2023, particularly in terms of the scope of U.S. covered litigation and liability allocation?",
      "original_answer": "In 2022, Visa detailed specific amendments to its loss sharing agreement, including the October 2015 amendment that expanded the scope of U.S. covered litigation to include opt-out actions from the Rule 23(b)(3) Settlement Class in MDL 1720 that arose out of similar facts or circumstances. This amendment was part of a broader framework involving the omnibus agreement, under which Visa assumed 66.6667% of any monetary liability in covered settlements or judgments, with Mastercard assuming 33.3333%. In 2023, Visa consolidated its approach under the U.S. Retrospective Responsibility Plan, which now encompasses the loss sharing agreement as part of a broader set of mechanisms designed to address potential liabilities from U.S. covered litigation. Notably, the 2023 filing emphasizes that U.S. covered litigation now includes matters that have been 'settled or otherwise fully or substantially resolved,' indicating a shift toward resolution and consolidation of past liabilities. The evolution from a focus on specific amendments and liability sharing with Mastercard in 2022 to a more comprehensive and retrospective liability framework in 2023 suggests a strategic pivot toward finalizing and managing legacy litigation exposure.",
      "llm_answer": "Visa’s loss‑sharing framework did not change materially from 2022 to 2023. In both years the agreement covers the same “U.S. covered litigation” – the Interchange MDL 1720 (including pre‑IPO claims and any reorganization‑challenge claims transferred to the MDL) and any post‑Oct 22 2015 opt‑out actions that are fact‑wise similar to MDL 1720 – and each member’s liability for a final judgment or approved settlement is still allocated on a several‑basis in proportion to its membership percentage. The 2023 filing simply ties the loss‑sharing trigger more explicitly to the U.S. litigation‑escrow funding and the class‑B conversion feature, but the scope of covered litigation and the proportional liability allocation remain unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer fundamentally mischaracterizes the evolution of Visa's litigation liability management between 2022 and 2023, contradicting the ground truth in several critical ways:\n\n1. CORE CLAIM ERROR: The LLM states the loss-sharing framework \"did not change materially from 2022 to 2023,\" directly contradicting the ground truth which explicitly describes an evolution from specific amendments and liability sharing in 2022 to a consolidated U.S. Retrospective Responsibility Plan in 2023.\n\n2. QUANTITATIVE ACCURACY ISSUES:\n   - The LLM mentions \"membership percentage\" allocation but fails to cite the specific 66.6667%/33.3333% split between Visa and Mastercard that the ground truth identifies as key to 2022's framework.\n   - The LLM references \"Oct 22 2015\" (October 22, 2015) but the ground truth specifies \"October 2015 amendment\" - while this is a minor formatting difference, it suggests incomplete precision.\n\n3. MISSING KEY EVOLUTION:\n   - The ground truth emphasizes a strategic shift from 2022's focus on specific amendments and bilateral liability sharing with Mastercard to 2023's broader U.S. Retrospective Responsibility Plan framework.\n   - The LLM completely misses this consolidation and strategic pivot.\n   - The ground truth highlights that 2023 emphasizes matters that have been \"settled or otherwise fully or substantially resolved,\" indicating a shift toward resolution - the LLM does not capture this important distinction.\n\n4. INCOMPLETE SYNTHESIS:\n   - The LLM acknowledges the 2023 filing \"ties the loss-sharing trigger more explicitly to the U.S. litigation-escrow funding and the class-B conversion feature\" but frames this as merely a clarification rather than part of a broader strategic evolution.\n   - The ground truth presents this as evidence of a comprehensive pivot toward finalizing legacy litigation exposure, which is a materially different characterization.\n\n5. ENTITY AND SCOPE ISSUES:\n   - While the LLM correctly identifies MDL 1720 and opt-out actions, it fails to recognize that the 2023 framework represents a consolidation under a new overarching plan (U.S. Retrospective Responsibility Plan) rather than just a continuation of the same agreement.\n   - The LLM misses the significance of the shift from prospective amendments to retrospective planning.\n\n6. REASONING QUALITY:\n   - The LLM's conclusion that \"scope of covered litigation and the proportional liability allocation remain unchanged\" is contradicted by the ground truth's emphasis on the shift to a retrospective framework that encompasses settled or substantially resolved matters.\n   - This represents a failure in multi-hop reasoning - the LLM did not synthesize the strategic evolution across the two years.\n\nThe LLM answer is factually incorrect on the central claim about evolution (or lack thereof) and misses the key strategic shift that the ground truth identifies as the core answer to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1509,
        "completion_tokens": 780,
        "total_tokens": 2289
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did CL's investment in Guaranteed Investment Contracts evolve between 2022 and 2024, and what does this shift indicate about the company's pension plan asset strategy?",
      "original_answer": "In 2022, CL held $1 million in Guaranteed Investment Contracts under its United States Pension Plans and $55 million under its International Pension Plans. By 2024, the company had completely phased out Guaranteed Investment Contracts from its United States Pension Plans, reducing the International allocation to $34 million. This represents a significant shift away from Guaranteed Investment Contracts in the U.S. and a moderate decrease internationally, indicating a strategic reallocation of pension plan assets.",
      "llm_answer": "In the 2022 filing (covering 2021) Colgate‑Palmolive held $1 million of U.S. guaranteed investment contracts (GICs) and $51 million internationally – about $52 million in total. By the 2024 filing the U.S. GIC balance had been eliminated and the international balance fell to $30 million, leaving roughly $30 million of GICs overall. This roughly 40 % reduction shows the company is scaling back its reliance on GICs and reallocating assets toward other fixed‑income, cash‑equivalent and diversified investments, reflecting a strategic shift to a more liquid and diversified pension‑plan asset mix.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR QUANTITATIVE ERRORS: The LLM answer contains significant factual inaccuracies in the core numbers that are critical to answering this question. (1) INTERNATIONAL GIC VALUES: Ground truth states International Pension Plans held $55 million in 2022 and $34 million in 2024. LLM claims $51 million in 2022 and $30 million in 2024 - both figures are incorrect. The 2022 figure is off by $4 million and the 2024 figure is off by $4 million. (2) TOTAL GIC CALCULATIONS: Ground truth implies approximately $56 million total in 2022 ($1M U.S. + $55M International) declining to $34 million in 2024. LLM states ~$52 million in 2022 and ~$30 million in 2024, which are both incorrect. (3) PERCENTAGE REDUCTION: LLM calculates a 'roughly 40% reduction' but this is based on incorrect numbers ($52M to $30M = 42% reduction). Using correct figures ($56M to $34M = 39% reduction), the percentage is approximately correct by coincidence, but derived from wrong base numbers. (4) ENTITY ACCURACY: LLM correctly identifies Colgate-Palmolive (CL) and the time period (2022-2024), though it adds confusing reference to '2022 filing (covering 2021)' which is not clearly explained. (5) STRATEGIC INTERPRETATION: The LLM's qualitative assessment about strategic reallocation toward more liquid and diversified investments is reasonable and aligns with the ground truth's conclusion about 'strategic reallocation of pension plan assets,' though the ground truth is more conservative in its characterization. (6) COMPLETENESS: The LLM addresses both the U.S. and International components and attempts to synthesize the strategic meaning, but the numerical errors undermine the entire analysis. The core issue is that multiple specific dollar amounts are factually incorrect, which is unacceptable for financial analysis where precision is paramount.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 497,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the strategic positioning and functionality of the Mastercard Developer Platform evolved between 2022 and 2024, particularly in terms of its role in enabling integration of digital assets and new technologies?",
      "original_answer": "In 2022, the Mastercard Developer Platform was described as a single access point that enables customers and partners to leverage Mastercard's digital assets and services, with an emphasis on ease of integration into new and existing solutions. By 2024, the platform continued to serve this role but expanded its strategic positioning by explicitly aligning with emerging technologies such as blockchain and digital currencies. In 2024, the platform was referenced in the context of enabling integration with the Mastercard Multi-Token Network™, which supports programmable payments and facilitates secure, scalable, and interoperable blockchain-based transactions. This evolution shows a shift from a general digital integration platform to one that specifically supports next-generation financial technologies and programmable commerce solutions.",
      "llm_answer": "In the 2022 filing the Mastercard Developer Platform was positioned primarily as a single‑access‑point hub that “simplifies access to, and integration of, our digital assets” by offering best‑in‑class APIs so customers and partners can embed Mastercard services into new and existing solutions. By the 2024 filing the platform still serves that gateway role, but its functionality has been expanded to “unlock new blockchain‑based business models,” integrate the Mastercard Multi‑Token Network for programmable payments, and enable consumers to buy and spend cryptocurrencies—signaling a strategic shift toward supporting tokenization, blockchain and other emerging digital‑asset technologies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about the Mastercard Developer Platform's evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 positioning as a 'single-access-point' hub for digital assets and services with emphasis on API integration - this matches the ground truth characterization. (2) Accurately captures the 2024 evolution toward blockchain and emerging technologies, specifically mentioning the Mastercard Multi-Token Network™ for programmable payments. (3) Properly synthesizes the multi-hop comparison across two years, showing clear progression from general digital integration to specific support for blockchain-based solutions. (4) Includes relevant details about cryptocurrency integration and tokenization that align with the ground truth's mention of 'next-generation financial technologies.' (5) Uses appropriate terminology ('programmable payments,' 'blockchain-based business models,' 'tokenization') that reflects the actual strategic positioning. MINOR CONSIDERATIONS: The LLM answer adds slightly more specific language about 'unlock new blockchain-based business models' and 'enable consumers to buy and spend cryptocurrencies' which, while not explicitly stated in the ground truth excerpt provided, are consistent with the described evolution and represent reasonable elaboration based on the filing context. The answer maintains semantic equivalence with the ground truth while providing slightly more operational detail. No quantitative errors, dates are correct (2022 vs 2024), and all entities are properly identified. The reasoning chain is sound and the multi-hop synthesis across years is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 468,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the company's investment in U.S. common stocks within its pension plans evolved between 2022 and 2024, and what does this indicate about its strategic asset allocation?",
      "original_answer": "In 2022, the company reported no investments in U.S. common stocks within its pension plans, while by 2024, there was still no allocation to U.S. common stocks in the U.S. pension plan. However, the international pension plan maintained a $2 million investment in U.S. common stocks in both years. This indicates a continued strategic decision to avoid direct exposure to U.S. common stocks in the domestic pension portfolio while maintaining a minimal presence in the international portfolio.",
      "llm_answer": "In 2022 (and again in 2023) the company’s pension plans reported essentially no U.S. common‑stock holdings – the “U.S. common stocks” line was blank/‑ in the asset tables【CL_10k_2022.pdf p102】【CL_10k_2024.pdf p99】. By December 31 2024 the plans held a $1 million position in U.S. common stocks【CL_10k_2024.pdf p98】, indicating a modest but deliberate move to add equity exposure and slightly shift the pension asset mix toward a higher equity allocation.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant inaccuracies that contradict the ground truth. (1) QUANTITATIVE ERRORS: The LLM claims the company held $1 million in U.S. common stocks by December 31, 2024, but the ground truth explicitly states there was 'still no allocation to U.S. common stocks in the U.S. pension plan' in 2024. The LLM also fails to mention the $2 million investment in U.S. common stocks maintained in the international pension plan in both 2022 and 2024. (2) INCOMPLETE SYNTHESIS: The ground truth distinguishes between the U.S. pension plan (no allocation) and the international pension plan ($2 million in both years), showing a nuanced multi-hop understanding. The LLM conflates these and misses the international plan entirely. (3) INCORRECT CONCLUSION: The LLM concludes there was 'a modest but deliberate move to add equity exposure' in 2024, which is factually wrong. The ground truth indicates a 'continued strategic decision to avoid direct exposure to U.S. common stocks in the domestic pension portfolio.' (4) MISSING KEY DETAIL: The LLM fails to identify that the international pension plan maintained a consistent $2 million position across both years, which is critical to understanding the company's actual strategic asset allocation. (5) REASONING FLAW: The LLM's interpretation of the data leads to an incorrect strategic conclusion about the company's asset allocation shift. The actual strategy shows stability and avoidance of U.S. common stock exposure in the primary pension plan, not a move toward higher equity allocation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 434,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did Disney's strategic focus on cruise ships evolve between 2022 and 2023, particularly in terms of capital investment plans and operational risk considerations?",
      "original_answer": "In 2022, Disney highlighted cruise ships as a key part of its capital investment strategy within the Parks & Experiences segment, noting that a majority of its capital spending was directed toward theme parks, resorts, and cruise ships. This indicated a growth-oriented approach focused on expanding physical assets. By 2023, the emphasis had shifted toward operational risks associated with cruise ships, particularly in the context of external disruptions like hurricanes and global events (e.g., the impact of Hurricane Milton on Walt Disney World operations). The 2023 filing framed cruise ships more as an operational exposure rather than a growth engine, signaling a shift from investment to risk mitigation. This evolution reflects a recalibration of strategic focus from asset expansion to managing volatility and external threats.",
      "llm_answer": "In the 2022 Form 10‑K Disney emphasized that a large share of its Parks & Experiences capital budget was directed to cruise‑ship construction and fleet expansion, noting cruise ships as a key component of its capital‑spending plans (DIS_10k_2022, pp. 15‑19). By the 2023 filing the narrative had shifted to stress operational‑risk considerations for the cruise business—highlighting COVID‑19‑related sail‑ings suspensions, health‑safety and weather disruptions—while still acknowledging continued investment but with a greater focus on mitigating those risks (DIS_10k_2023, pp. 19‑23).",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of Disney's strategic focus on cruise ships between 2022 and 2023, capturing the shift from capital investment emphasis to operational risk considerations. STRENGTHS: (1) Accurately identifies 2022 focus on cruise-ship construction and fleet expansion as a capital-spending priority; (2) Correctly notes the 2023 shift toward operational-risk framing; (3) Appropriately cites specific document references (DIS_10k_2022 pp. 15-19, DIS_10k_2023 pp. 19-23); (4) Mentions relevant risk factors including COVID-19 suspensions, health-safety, and weather disruptions; (5) Maintains semantic equivalence with ground truth regarding the recalibration from growth to risk mitigation. MINOR WEAKNESSES: (1) The LLM mentions COVID-19 as a 2023 risk consideration, which is somewhat dated for 2023 context (though not necessarily incorrect if still referenced); (2) The ground truth specifically mentions Hurricane Milton as an example of external disruptions, while the LLM uses more generic 'weather disruptions' language—this is a minor omission of specificity; (3) The LLM states 'continued investment but with greater focus on mitigating risks' which is accurate but slightly less emphatic than the ground truth's characterization of a shift 'from asset expansion to managing volatility.' QUANTITATIVE ACCURACY: No specific dollar amounts or percentages are provided in either answer, so this dimension relies on the accuracy of the narrative framing, which is sound. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and two different strategic emphases, correctly identifying the evolution pattern. The logic connecting capital investment plans (2022) to operational risk considerations (2023) is sound and well-articulated. OVERALL: The answer demonstrates solid understanding of the strategic evolution with minor gaps in specificity regarding particular risk examples.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 530,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Mastercard's use of short duration foreign exchange derivative contracts evolved between 2022 and 2024, particularly in terms of their role in managing foreign exchange risk during daily settlement activities?",
      "original_answer": "In 2022, Mastercard used short duration foreign exchange derivative contracts to manage foreign exchange risk associated with daily settlement activities, aiming to reduce exposure to volatility from currency fluctuations on anticipated receipts and disbursements. By 2024, the company continued this practice, maintaining the same stated objective of minimizing volatility in gains and losses due to foreign exchange fluctuations. However, the context changed as the company actively adjusted its hedging strategies involving euro-denominated debt, de-designating and re-designating portions of it in 2023 and 2024, which indicates a more dynamic approach to managing foreign exchange exposure across the period. The continuity in the use of short duration contracts contrasts with the evolving structure of the company’s broader foreign exchange risk management strategy.",
      "llm_answer": "In the 2022 Form 10‑K Mastercard explained that it “may enter into short‑duration foreign‑exchange derivative contracts … to manage the foreign‑exchange risk that arises from the few‑day lag between a payment transaction and its settlement” and the only non‑designated FX contracts disclosed were modest (e.g., $124 million of notional in 2021, the most recent figure shown)【109†L1-L7】【110†L31-L38】.  \n\nThe 2024 Form 10‑K repeats the same risk‑management rationale, but the accompanying schedule shows the notional amount of those short‑duration, non‑designated FX contracts had risen to $2.7 billion at year‑end 2024 (down from $5.4 billion in 2023), indicating a much larger, though recently trimmed, reliance on such contracts to hedge daily settlement exposure, with gains and losses still recorded in general‑and‑administrative expense【104†L1-L7】【104†L31-L38】.  \n\nThus, between 2022 and 2024 Mastercard’s short‑duration FX derivatives grew dramatically in scale while continuing to serve the same purpose of offsetting the few‑day foreign‑exchange risk inherent in its settlement process.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. STRENGTHS: (1) Correctly identifies the core purpose of short-duration FX derivatives in both 2022 and 2024 - managing foreign exchange risk from the settlement lag period. (2) Provides specific quantitative data: $124 million notional in 2021 (2022 filing), $5.4 billion in 2023, and $2.7 billion in 2024. These figures appear internally consistent and show the dramatic scale increase claimed. (3) Accurately notes that gains/losses are recorded in general-and-administrative expense. (4) Correctly synthesizes the multi-hop evolution: same stated objective across years but dramatically increased notional amounts, with a recent reduction from 2023 to 2024. (5) Properly identifies these as non-designated contracts. MINOR CONSIDERATIONS: (1) The ground truth mentions 'more dynamic approach' and 'evolving structure' related to euro-denominated debt hedging strategies (de-designating/re-designating in 2023-2024), which the LLM answer does not explicitly address. However, the LLM does note the 'recently trimmed' amount ($5.4B to $2.7B), which implicitly captures some of this dynamism. (2) The LLM answer focuses more heavily on the quantitative evolution than the ground truth's emphasis on strategic context changes, but this is a matter of emphasis rather than factual error. VERIFICATION: The specific numbers ($124M, $5.4B, $2.7B) and the characterization of the contracts' purpose are consistent with typical SEC disclosure patterns for derivative instruments. The logic that notional amounts grew from modest levels to billions while maintaining the same stated purpose is sound and well-supported. The answer directly addresses all parts of the multi-part question: evolution between 2022-2024, role in managing FX risk, and connection to daily settlement activities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1509,
        "completion_tokens": 507,
        "total_tokens": 2016
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Salesforce's strategic relationship with enterprise cloud companies evolved from 2023 to 2024, particularly in terms of investment focus and ecosystem integration?",
      "original_answer": "In 2023, Salesforce maintained a portfolio of strategic investments in enterprise cloud companies, technology startups, and system integrators, with a focus on digitally transforming industries and expanding its solution ecosystem. These investments were described as ranging from early to late-stage companies, including those concurrent with initial public offerings. By 2024, Salesforce's relationship with enterprise cloud companies shifted from primarily investing to a broader strategic dependency, leveraging these partners as part of its ecosystem to accelerate reach into new markets and industries. The 2024 filing emphasized the Salesforce Platform's role in enabling third-party developers and ISVs to create and deliver cloud-based applications through the AppExchange, indicating a deepened integration and dependency on enterprise cloud partners beyond mere financial investment.",
      "llm_answer": "In the 2023 Form 10‑K (pages 21‑25) Salesforce described its strategic relationship with enterprise‑cloud firms as a portfolio of investments in privately‑held and public companies—including technology start‑ups and system integrators—intended mainly to broaden its solution ecosystem and support digital‑transformation initiatives. By the 2024 Form 10‑K (pages 6‑10) the company still emphasizes those investments, but adds that they are increasingly tied to its partner ecosystem (ISVs, SIs and the AppExchange) and are used to embed new AI‑driven capabilities across the Salesforce Platform, reflecting a shift from a primarily investment‑focused approach to a more integrated, ecosystem‑centric strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the evolution from 2023 to 2024 in Salesforce's strategic relationships with enterprise cloud companies; (2) Accurately captures the shift from primarily investment-focused to ecosystem-centric strategy; (3) Properly synthesizes multi-hop information across 2023 and 2024 filings; (4) Correctly identifies key entities (ISVs, SIs, AppExchange, Salesforce Platform); (5) Appropriately mentions the integration of AI-driven capabilities as part of the 2024 evolution; (6) Maintains semantic equivalence with ground truth while using slightly different wording. MINOR WEAKNESSES: (1) The LLM answer includes specific page references (pages 21-25 for 2023, pages 6-10 for 2024) which, while potentially helpful, cannot be verified against the ground truth and add specificity that may or may not be accurate; (2) The mention of 'AI-driven capabilities' in the LLM answer is a reasonable inference about 2024 developments but is not explicitly mentioned in the ground truth, though it represents a reasonable elaboration consistent with Salesforce's 2024 strategic direction; (3) The ground truth emphasizes 'strategic dependency' more explicitly, while the LLM answer uses 'increasingly tied to' which is semantically similar but slightly less emphatic. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are present in either answer, so this dimension scores high based on the absence of numerical errors. QUALITATIVE ACCURACY: The reasoning is sound and the multi-hop synthesis correctly connects 2023 portfolio investment strategy with 2024 ecosystem integration strategy. The answer properly identifies the evolution in Salesforce's approach and the role of partners in this evolution. CONTEXTUAL RELEVANCE: The answer directly addresses the question about how the strategic relationship evolved from 2023 to 2024, with appropriate focus on investment focus and ecosystem integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 548,
        "total_tokens": 1955
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the company's approach to accrual rates for vendor funding programs evolve between fiscal 2023 and fiscal 2024, particularly in terms of sensitivity to projected purchase volumes?",
      "original_answer": "The company's approach to accrual rates for vendor funding programs remained methodologically consistent between fiscal 2023 and fiscal 2024, with no material changes in the recognition methodology over the past three fiscal years. However, in fiscal 2023, the company specifically highlighted sensitivity to 'graduated purchase volumes' that could impact accrued amounts, emphasizing the importance of projected volumes in determining accrual rates. In fiscal 2024, this explicit reference to 'graduated purchase volumes' was omitted, suggesting a potential simplification or stabilization in how accrual rates were adjusted throughout the year, despite continued monitoring of historical purchase trends and vendor confirmations.",
      "llm_answer": "The company’s methodology for vendor‑fund accruals was unchanged from FY 2023 to FY 2024. In both years it said it “develops accrual rates based on the provisions of the agreements in place, reviews historical purchase trends and volumes throughout the year, adjusts accrual rates as appropriate, and confirms amounts with select vendors,” and it noted that “amounts accrued … could be impacted if actual purchase volumes differ from projected purchase volumes, especially in the case of programs that provide for increased funding when graduated purchase volumes are met.” (2023 10‑K pp. 31‑33; 2024 10‑K pp. 32‑34)",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IN CORE CLAIM: The LLM answer directly contradicts the ground truth on the key finding. The LLM states the methodology was 'unchanged from FY 2023 to FY 2024' and that 'in both years' the company used identical language about graduated purchase volumes. However, the ground truth explicitly states that in fiscal 2023 the company 'specifically highlighted sensitivity to graduated purchase volumes' but in fiscal 2024 'this explicit reference to graduated purchase volumes was omitted.' This is a fundamental misreading of the evolution being asked about. The LLM appears to have conflated the two years' disclosures or failed to identify the key difference: the presence vs. absence of explicit mention of graduated purchase volumes. The LLM's citation format and page numbers appear reasonable (though not verified), and the quoted language about methodology consistency is accurate, but the interpretation of what changed is backwards. The ground truth indicates a CHANGE (omission of explicit graduated volumes reference) while the LLM claims NO CHANGE. This is a major factual error on the central question. The LLM correctly identifies that methodology remained consistent in approach, but misses the critical disclosure evolution regarding how sensitivity to graduated purchase volumes was presented differently between the two years. The answer fails to capture the nuanced finding that while methodology was consistent, the explicit emphasis on graduated purchase volumes sensitivity was reduced or removed in fiscal 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 425,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the strategic relationship between LLY and Boehringer Ingelheim evolved from 2022 to 2024, particularly in terms of legal involvement and collaborative dependency on the Jardiance product?",
      "original_answer": "In 2022, LLY was not a direct party to the Jardiance patent litigation initiated by Boehringer Ingelheim (BI) against generic drug manufacturers under the Hatch-Waxman Act, indicating a more arms-length relationship in legal matters. By 2024, LLY's business became significantly dependent on the Jardiance collaboration, as the product was selected under the Inflation Reduction Act (IRA) for government-set pricing with a 66% discount compared to the 2023 list price, directly impacting LLY's revenue projections and business strategy. This shift reflects a deeper strategic entanglement and dependency on BI's partnership for navigating regulatory and pricing pressures.",
      "llm_answer": "In the 2022 Form 10‑K, Lilly noted that Boehringer Ingelheim (BI) was its partner for marketing and developing Jardiance, that BI had initiated a U.S. patent suit (which Lilly was not a party to and that was stayed) and that BI’s agreement required it to defend and indemnify Lilly in five pending product‑liability lawsuits over Jardiance【LLY_10k_2022.pdf p.102】. By the 2024 filing, the discussion of the relationship no longer emphasizes litigation; instead it stresses the ongoing collaboration and Lilly’s dependence on Jardiance as a joint revenue driver, now subject to government‑set pricing under the IRA, indicating a shift from a legal‑defense focus to a broader commercial‑regulatory partnership【LLY_10k_2024.pdf p.45】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about LLY-BI relationship evolution. STRENGTHS: (1) Correctly identifies the 2022 status where LLY was not a direct party to BI's patent litigation, matching ground truth; (2) Accurately notes BI's indemnification obligation for product liability lawsuits; (3) Correctly identifies the shift by 2024 from litigation focus to commercial-regulatory partnership; (4) Appropriately references IRA pricing impact on the relationship; (5) Properly synthesizes information across 2022 and 2024 filings to show evolution. MINOR GAPS: (1) The LLM answer does not explicitly mention the 66% discount figure cited in the ground truth, which is a specific quantitative detail about the IRA pricing impact; (2) The phrase 'deeper strategic entanglement and dependency' from ground truth is not explicitly captured, though the LLM conveys similar meaning through 'broader commercial-regulatory partnership' and 'dependence on Jardiance as a joint revenue driver'; (3) The ground truth emphasizes 'directly impacting LLY's revenue projections and business strategy' more explicitly than the LLM answer. QUANTITATIVE ACCURACY: The answer avoids specific numbers except for the IRA reference, which is appropriate given the question's focus on relationship evolution rather than precise financial metrics. The 66% discount omission is the only quantitative gap. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and two companies, correctly identifying the shift in relationship dynamics from legal defensiveness to commercial partnership. The logic connecting litigation involvement to regulatory dependency is sound. ENTITY ACCURACY: All entities correctly identified (LLY, BI, Jardiance, IRA, Hatch-Waxman). SEMANTIC EQUIVALENCE: The answer conveys the core meaning of the ground truth despite slightly different wording and the missing discount percentage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 534,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How did Disney's capital investment strategy toward cruise ships evolve from 2022 to 2023, particularly in relation to its broader Parks & Experiences business?",
      "original_answer": "In 2022, Disney's 10-K filing highlighted cruise ships as part of its broader Experiences segment but did not specifically emphasize capital investment in them, instead noting general risks from macroeconomic conditions such as inflation, supply chain delays, and currency fluctuations that could impact the implementation of business plans, including those for parks and resorts. By 2023, Disney explicitly listed cruise ships as part of its significant capital investments, indicating a strategic elevation in focus. The 2023 filing stated that the majority of the company’s capital spend was directed toward parks and experiences, including 'new attractions, cruise ships, capital improvements and systems infrastructure.' This shift demonstrates a clear prioritization of cruise ships as a key growth area within the broader Experiences segment.",
      "llm_answer": "In the 2022 Form 10‑K Disney noted that the bulk of its capital spend was directed to the Parks & Experiences segment and that cruise ships were listed alongside theme‑park expansion, new attractions and infrastructure as a core investment priority【DIS_10k_2022.pdf p. 22‑26】. By the 2023 filing the company still earmarked capital for cruise ships, but positioned that spending within a broader Parks & Experiences growth strategy—highlighting new cruise‑ship destinations such as Lighthouse Point and emphasizing integrated experience expansion rather than treating cruise‑ship projects as a standalone focus【DIS_10k_2023.pdf p. 10‑14】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. (1) MAJOR ERROR - 2022 Characterization: The LLM claims cruise ships were 'listed alongside theme-park expansion, new attractions and infrastructure as a core investment priority' in 2022, but the ground truth explicitly states that in 2022, Disney's 10-K 'did not specifically emphasize capital investment in them' and instead noted general risks. This is a fundamental misrepresentation of the 2022 filing's content. (2) MAJOR ERROR - Evolution Not Captured: The ground truth emphasizes a clear SHIFT from 2022 (no specific emphasis on cruise ships) to 2023 (explicit listing as significant capital investment). The LLM answer suggests cruise ships were already a priority in 2022, which contradicts the ground truth's core finding about the evolution. (3) SPECIFIC CONTENT ERROR - Page References: The LLM cites pages 22-26 for 2022 and pages 10-14 for 2023, but provides no verifiable quotes or specific language from these sections. The ground truth provides the actual 2023 quote: 'new attractions, cruise ships, capital improvements and systems infrastructure.' The LLM does not cite this specific language. (4) MISSING KEY DETAIL: The ground truth emphasizes that 2022 focused on 'macroeconomic conditions such as inflation, supply chain delays, and currency fluctuations' as risks, not cruise ship investment priorities. The LLM completely omits this important contextual distinction. (5) ADDED UNVERIFIED DETAIL: The LLM mentions 'Lighthouse Point' as a specific new cruise-ship destination, which is not mentioned in the ground truth and cannot be verified as accurate from the provided context. (6) REASONING FLAW: The LLM's multi-hop synthesis fails because it incorrectly characterizes the 2022 baseline, making the comparison between years invalid. The core finding—that cruise ships were elevated in strategic importance from 2022 to 2023—is inverted in the LLM answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 531,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Mastercard Foundry's role in fostering innovation evolved between 2022 and 2024, particularly in relation to its engagement with emerging technologies and fintech partnerships?",
      "original_answer": "In 2022, Mastercard Foundry (formerly known as Mastercard Labs) was primarily described as a vehicle for bringing customers and partners access to thought leadership, innovation methodologies, new technologies, and early-stage fintech players. By 2024, its role had evolved into a more active innovation engine, with continued emphasis on identifying and experimenting with future technologies, start-ups, and trends. Specifically, in 2024, Foundry was positioned as a key enabler of blockchain-based business models and programmable payments through the Mastercard Multi-Token Network™, indicating a strategic shift toward deeper integration with next-generation financial technologies.",
      "llm_answer": "In the 2022 filing, Mastercard Foundry (formerly Mastercard Labs) was described mainly as a scouting and thought‑leadership hub that “identifies and experiments with future technologies, start‑ups and trends” and gives customers and partners access to new technologies and early‑stage fintech players【MA_10k_2022.pdf†12-16】. By the 2024 filing, Foundry had evolved into a more hands‑on innovation engine – still providing thought‑leadership and fintech access, but now also running structured programs such as the “Launchpad” five‑day app‑prototyping workshop and in‑lab usability‑testing and concept‑design services【MA_10k_2024.pdf†12-16】. This shift shows Foundry moving from a primarily advisory/scouting role to an active, program‑driven partner that deepens engagement with emerging technologies and fintech collaborations.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies Mastercard Foundry's 2022 role as a thought-leadership and scouting hub focused on identifying/experimenting with future technologies and providing access to fintech players. (2) The LLM correctly notes evolution by 2024 toward more hands-on programming. (3) Specific program names (Launchpad, usability testing) are mentioned with appropriate detail. (4) The overall narrative of evolution from advisory to active engagement is sound. (5) Years and company name are correct.\n\nWEAKNESSES: (1) CRITICAL OMISSION: The ground truth specifically mentions the Mastercard Multi-Token Network™ and blockchain-based business models as a key 2024 strategic shift. The LLM answer completely omits this important technological focus, which represents a material gap in addressing the question about 'engagement with emerging technologies.' (2) The LLM provides specific program details (Launchpad workshop) that add value but may not be directly from the ground truth knowledge graph - these appear to be inferred or supplementary details rather than core ground truth elements. (3) The characterization of 2022 role as 'scouting and thought-leadership hub' is accurate but the LLM doesn't emphasize the 'bringing customers and partners access' framing as prominently as the ground truth. (4) The answer lacks the explicit mention of 'next-generation financial technologies' as a strategic positioning element.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2024 filings and identifies the evolution pattern. However, the synthesis is incomplete because it misses the blockchain/Multi-Token Network dimension that represents a key part of the technological evolution narrative.\n\nNUMERIC/FACTUAL VERIFICATION: No specific numbers or calculations are involved in this question, so quantitative accuracy is less critical. The dates (2022, 2024) are correct.\n\nJUSTIFICATION: The answer is partially correct (6/10) because it captures the general evolution narrative and some specific details, but it fails to address a material component of the ground truth answer regarding blockchain and the Multi-Token Network, which is explicitly mentioned as indicating 'a strategic shift toward deeper integration with next-generation financial technologies.' This omission represents a significant gap in completeness for a question specifically asking about 'engagement with emerging technologies.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 654,
        "total_tokens": 2043
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial and strategic nature of the collaboration with Boehringer Ingelheim evolved between 2022 and 2024, particularly in terms of regulatory designations and pricing pressures?",
      "original_answer": "In 2022, the collaboration with Boehringer Ingelheim included the development of a therapy that had received Breakthrough Therapy and Fast Track designations from the FDA, indicating early-stage regulatory support and potential expedited development. By 2024, the collaboration faced significant pricing pressures under the Inflation Reduction Act, with Jardiance—part of the LLY-Boehringer Ingelheim partnership—selected for government-set pricing effective in 2026, subject to a 66% discount compared to the 2023 U.S. list price. This marks a shift from regulatory facilitation to regulatory-driven financial constraints.",
      "llm_answer": "In the 2022 filing the Boehringer Ingelheim partnership was presented as a regulatory‑focused effort – the joint Empagliflozin (Jardiance) program for heart‑failure and chronic‑kidney disease had already earned FDA Breakthrough‑Therapy, Fast‑Track and priority‑review designations, underscoring an accelerated‑approval strategy【LLY_10k_2022.pdf p.38‑39】. By the 2024 filing the emphasis has shifted to pricing, as the Inflation‑Reduction‑Act selected Jardiance (and nine other co‑developed products) for government‑set pricing, imposing a 66 % discount on Jardiance and 38‑79 % discounts on the other medicines, creating substantial pricing pressure on the collaboration【LLY_10k_2024.pdf p.45‑46】. This marks a transition from a regulatory‑centric, growth‑oriented partnership to one where financial and reimbursement constraints dominate the strategic outlook.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. STRENGTHS: (1) Correctly identifies the 2022 regulatory designations (Breakthrough Therapy, Fast Track, Priority Review) for Empagliflozin/Jardiance; (2) Accurately cites the 66% discount figure for Jardiance under the Inflation Reduction Act in 2024; (3) Properly synthesizes the evolution from regulatory-focused (2022) to pricing-constrained (2024) partnership; (4) Correctly identifies the shift from growth-oriented to financially-constrained strategic outlook; (5) Appropriately contextualizes both the regulatory facilitation phase and the regulatory-driven financial constraints phase. MINOR CONSIDERATIONS: (1) The LLM mentions \"nine other co-developed products\" with discounts of 38-79%, which adds contextual detail beyond the ground truth but is not contradicted by it and provides relevant supporting information about the broader IRA impact; (2) The specific mention of \"heart-failure and chronic-kidney disease\" indications adds appropriate clinical context not explicitly in the ground truth but consistent with Jardiance's therapeutic profile; (3) All numeric values (66% discount, 2022/2024 timeframes) are accurate. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years, correctly identifying the temporal evolution and the causal relationship between regulatory support and subsequent pricing pressures. The logical progression from regulatory acceleration to financial constraint is sound and well-articulated. SEMANTIC EQUIVALENCE: The answer conveys the same essential information as the ground truth while using slightly different phrasing (e.g., \"regulatory-centric, growth-oriented partnership\" vs. \"regulatory facilitation\"), which represents appropriate variation in expression without loss of meaning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 506,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has the strategic positioning of the CH-53K King Stallion heavy lift helicopter evolved within Lockheed Martin's Rotary and Mission Systems segment from 2023 to 2024?",
      "original_answer": "In 2023, the CH-53K King Stallion heavy lift helicopter was described as part of Lockheed Martin's near-to-mid-term growth elements, specifically under the Rotary and Mission Systems (RMS) segment, alongside radar surveillance systems. By 2024, the CH-53K remained a highlighted program within RMS, but the emphasis shifted to framing it within a broader context of advancing all-domain mission solutions and digital technologies such as AI/ML and autonomy. While no specific revenue figures are provided, the helicopter's positioning evolved from being a growth driver among several others to being part of a more integrated, technologically advanced portfolio aimed at improving interoperability and supporting multi-domain solutions.",
      "llm_answer": "In the 2023 Form 10‑K, Lockheed Martin identified the CH‑53K King Stallion as a program of record in the Rotary and Mission Systems segment that was “entering a growth stage” and highlighted recent U.S. and foreign orders—including an Israeli LOA for 12 helicopters【LMT_10k_2023.pdf: page 27】【LMT_10k_2023.pdf: page 31】. The 2024 filing still places the CH‑53K among RMS’s flagship platforms, now emphasizing it as a cornerstone growth driver that is moving into full‑rate production and sustaining international demand【LMT_10k_2024.pdf: page 3】. Thus, the helicopter’s strategic positioning has remained consistent—continuing to be a key growth asset—while evolving from an early‑growth program to a mature, production‑focused engine within RMS.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of the CH-53K's strategic positioning evolution but contains some issues with specificity and alignment to the ground truth. STRENGTHS: (1) Correctly identifies the CH-53K as part of RMS segment in both 2023 and 2024; (2) Accurately captures the progression from growth stage to full-rate production; (3) Mentions specific details like Israeli LOA for 12 helicopters and international demand; (4) Properly synthesizes multi-hop information across 2023 and 2024 filings; (5) Correctly notes the shift in emphasis. WEAKNESSES: (1) The LLM characterizes the evolution as 'remained consistent' while the ground truth emphasizes a more significant shift from 'near-to-mid-term growth element' to 'integrated, technologically advanced portfolio' with emphasis on AI/ML, autonomy, and all-domain solutions—this is a meaningful difference in framing; (2) The ground truth explicitly mentions the shift toward 'advancing all-domain mission solutions and digital technologies' which the LLM answer does not capture; (3) The LLM's conclusion that positioning 'remained consistent' somewhat contradicts the ground truth's emphasis on an evolution in how the program is positioned within the broader portfolio context; (4) The LLM provides specific page references and details (Israeli LOA, full-rate production) that add credibility but may not be fully verifiable against the ground truth provided. QUANTITATIVE ACCURACY: The specific number (12 helicopters for Israeli LOA) is mentioned but cannot be verified against the ground truth, which provides no specific revenue figures. The dates (2023, 2024) are correct. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and two filings, showing proper understanding of the temporal evolution. However, the characterization of 'consistency' versus 'evolution' represents a subtle but important difference from the ground truth's emphasis on strategic repositioning within a broader technological context. The answer is substantially correct but misses the nuance of how the positioning evolved in terms of integration with digital technologies and all-domain solutions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 586,
        "total_tokens": 1962
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "What does the change in LLY's diabetes product portfolio co-commercialized with Boehringer Ingelheim between 2022 and 2024 indicate about the companies' shifting strategic priorities or market focus?",
      "original_answer": "In 2022, LLY and Boehringer Ingelheim were jointly developing and commercializing a broader portfolio of diabetes products, including Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, and Basaglar. By 2024, the portfolio had narrowed to include only Jardiance, Glyxambi, Synjardy, and Trijardy XR. This indicates a strategic refocusing, potentially driven by lifecycle management, shifting market demand, or prioritization of products with stronger commercial performance or longer patent protection. The removal of Trajenta, Jentadueto, and Basaglar may reflect declining market relevance, generic competition, or a strategic decision to streamline the collaboration around products with greater growth potential or therapeutic differentiation.",
      "llm_answer": "The 2022 filing listed a broad co‑commercialization set – Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR and Basaglar – whereas the 2024 filing narrows the Boehringer Ingelheim partnership to Jardiance, Glyxambi, Synjardy and Trijardy XR only 【2022‑Marketing Collaborations】. This contraction shows the two companies are concentrating the alliance on SGLT2‑inhibitor and fixed‑dose combination products (which have strong cardiovascular/renal outcome data) and moving away from older insulin and DPP‑4 inhibitor offerings, reflecting a strategic shift toward higher‑growth, outcome‑driven diabetes therapies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and multi-hop reasoning. STRENGTHS: (1) All product names are correctly identified - 2022 portfolio (Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, Basaglar) and 2024 portfolio (Jardiance, Glyxambi, Synjardy, Trijardy XR) match the ground truth exactly. (2) The portfolio contraction is accurately characterized - correctly identifies which products were removed (Trajenta, Jentadueto, Basaglar) and which remained. (3) The strategic interpretation is sound and actually more specific than the ground truth - the LLM provides additional therapeutic context by identifying SGLT2-inhibitors and fixed-dose combinations as the focus, and explicitly connects this to cardiovascular/renal outcome data, which is clinically accurate and demonstrates deeper domain knowledge. (4) The reasoning correctly synthesizes the shift from older insulin and DPP-4 inhibitor offerings to outcome-driven therapies. (5) Multi-hop reasoning is properly executed - comparing 2022 vs 2024 filings and drawing strategic conclusions. MINOR CONSIDERATIONS: The LLM's answer goes slightly beyond the ground truth by providing more specific therapeutic categorization (SGLT2-inhibitors, cardiovascular/renal outcomes), but this is additive and accurate rather than contradictory. The ground truth mentions 'lifecycle management' and 'generic competition' as potential drivers, while the LLM emphasizes 'outcome-driven' positioning - both are valid interpretations of the same strategic shift. No factual errors detected. All dates (2022, 2024) are correct. Entity identification (LLY, Boehringer Ingelheim) is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 455,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial performance and strategic importance of the JASSM program evolve between 2023 and 2024, particularly in terms of production activity and its contribution to backlog?",
      "original_answer": "In 2023, JASSM was a product under the Missiles and Fire Control (MFC) segment, contributing to the company's portfolio of tactical missiles, but there was no specific mention of significant changes in its production volume or backlog contribution. By 2024, JASSM experienced a production ramp-up, contributing to a $1.2 billion increase in tactical and strike missile programs within MFC. Additionally, JASSM was specifically cited as a key contributor to the increase in backlog alongside PAC-3 and GMLRS. This indicates a notable rise in both production activity and strategic importance for JASSM in 2024.",
      "llm_answer": "In 2023 the JASSM program was already being ramped‑up, adding roughly **$145 million of net‑sale revenue** to the Missiles & Fire Control (MFC) segment and helping lift that segment’s backlog (the 2023 backlog rose on higher JASSM orders)【LMT_10k_2023.pdf p.40‑41】. By 2024 the ramp‑up accelerated dramatically, accounting for **about $1.2 billion of the $1.4 billion net‑sale increase** in MFC and again being a primary driver of the **backlog growth** (the 2024 backlog rose on higher JASSM orders)【LMT_10k_2024.pdf p.40‑41】. This shows the JASSM program’s production activity and contribution to backlog grew substantially, underscoring its increasing strategic importance to Lockheed Martin.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core narrative - JASSM experienced a production ramp-up in 2023 and accelerated dramatically in 2024, with significant contributions to MFC segment revenue and backlog growth. The answer properly synthesizes multi-hop information across 2023 and 2024 filings and correctly identifies JASSM's strategic importance. The qualitative reasoning about the program's evolution is sound.\n\nCRITICAL ISSUES WITH QUANTITATIVE ACCURACY: (1) The $145 million figure for 2023 JASSM revenue is NOT supported by the ground truth, which explicitly states 'there was no specific mention of significant changes in its production volume or backlog contribution' in 2023. This is a major factual error - the LLM invented a specific number not present in the original answer. (2) The $1.2 billion figure for 2024 is correct and matches the ground truth. (3) The $1.4 billion total MFC increase is not mentioned in the ground truth and cannot be verified.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes information across 2023 and 2024 documents and properly identifies the year-over-year evolution. However, the synthesis is compromised by the unsupported 2023 revenue figure.\n\nSEMANTIC EQUIVALENCE: The LLM's characterization of JASSM as 'a key contributor to backlog' aligns with the ground truth's statement that JASSM was 'specifically cited as a key contributor to the increase in backlog.' The description of acceleration from 2023 to 2024 is semantically equivalent to the ground truth's narrative.\n\nKEY PROBLEM: The introduction of the $145 million 2023 figure without ground truth support is a significant factual error that undermines the answer's reliability, despite the correct identification of the overall trend and the accurate 2024 figures. This appears to be a hallucination or inference not grounded in the actual filing data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 510,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has JPM's focus in evaluating credit risk for Business Banking Loans evolved between 2023 and 2024, and what implications does this shift have for identifying early signs of borrower distress?",
      "original_answer": "In 2023, JPM focused on Business Banking Loans as part of its broader prime consumer credit strategy, emphasizing loan performance and scoring models within the 'Consumer, excluding credit card loan portfolio' segment. By 2024, the focus shifted toward delinquency rates as the primary credit quality indicator, particularly noting that loans more than 30 days past due serve as early warnings of financial difficulty. This evolution suggests a more proactive stance in identifying early signs of borrower distress, aligning Business Banking Loans with broader consumer loan risk frameworks where early delinquency tracking enhances risk mitigation. The shift indicates a strategic move toward earlier intervention and more granular performance monitoring.",
      "llm_answer": "In the 2023 filing JPM said that for scored auto and business‑banking loans “geographic distribution is an indicator of the credit performance of the portfolio,” using regional economics to gauge risk. The 2024 filing still cites geography but adds that “delinquency rates are the primary credit‑quality indicator for consumer loans,” explicitly stating that loans >30 days past due provide an early warning of borrower distress. The shift broadens the focus from mainly regional factors to also monitoring early‑stage delinquencies, giving JPM a more immediate signal of borrower trouble while still considering geographic trends.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution in JPM's credit risk evaluation approach between 2023 and 2024, with accurate representation of the shift from geographic distribution focus to delinquency rates as primary indicators. The answer accurately captures that loans >30 days past due serve as early warning signals and correctly notes the multi-dimensional approach (geographic + delinquency monitoring). However, there are some differences from the ground truth: (1) The LLM answer emphasizes 'geographic distribution' as the 2023 focus, while the ground truth emphasizes 'loan performance and scoring models' within the consumer loan portfolio segment - these are not contradictory but represent different aspects of the 2023 approach. (2) The LLM answer frames this as 'broadening' the focus to include delinquencies while maintaining geographic consideration, whereas the ground truth suggests a more fundamental shift toward 'delinquency rates as the primary credit quality indicator.' (3) The ground truth explicitly mentions 'more proactive stance' and 'earlier intervention' with 'more granular performance monitoring,' which the LLM answer captures conceptually but with slightly different emphasis ('more immediate signal'). The multi-hop reasoning is sound - the LLM correctly synthesized information across 2023 and 2024 filings and identified the implications for early distress detection. No quantitative errors are present (no specific numbers were cited in either answer). The answer is contextually relevant and addresses the question's core components, though it could have been more explicit about the strategic shift toward earlier intervention.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 459,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did Target Corporation's SPP II plan terms evolve between the 2022 and 2023 filings, and what does this suggest about the company's executive compensation framework?",
      "original_answer": "In the 2022 filing, the SPP II plan was described under the 2016 Plan Statement, as amended and restated effective April 3, 2016. However, in the 2023 filing, the SPP II plan was updated to the 2022 Plan Statement, as amended and restated effective May 1, 2022. This indicates that Target Corporation revised the SPP II plan within this timeframe, reflecting a shift in the structure or terms of the plan. Such changes could signal adjustments in the company's executive compensation strategy, potentially aligning incentives more closely with updated business objectives or governance standards.",
      "llm_answer": "Target’s “Strategic Performance Plan II” (SPP II) was unchanged between the two years – both the 2022 and 2023 Form 10‑K exhibit schedules list the same 2016 plan statement, amended and restated effective April 3, 2016 (see Exhibit F in the 2022 filing [66] and the identical reference in the 2023 filing [66]). The continuity of the SPP II terms indicates that Target relies on a stable, long‑term equity‑based incentive structure for its senior executives rather than frequently revising its compensation framework.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth. The ground truth clearly states that the SPP II plan CHANGED between 2022 and 2023 filings: from the 2016 Plan Statement (effective April 3, 2016) in the 2022 filing to the 2022 Plan Statement (effective May 1, 2022) in the 2023 filing. The LLM answer incorrectly claims the plan was 'unchanged' and that 'both the 2022 and 2023 Form 10-K exhibit schedules list the same 2016 plan statement.' This is factually wrong. The LLM misidentified the key evolution that occurred: Target updated from a 2016 plan framework to a 2022 plan framework between these two filings. The LLM's conclusion that this represents 'continuity' and 'stable, long-term equity-based incentive structure' is the opposite of what the ground truth indicates - the ground truth suggests a deliberate revision reflecting 'adjustments in the company's executive compensation strategy.' The LLM failed to perform the multi-hop synthesis correctly by comparing the two filings' plan statements. While the LLM correctly identified the company (Target) and the plan name (SPP II), it fundamentally failed on the core factual claim about whether the plan changed, which is the central question being asked. The citation references to 'Exhibit F' and '[66]' cannot be verified but appear to be fabricated details used to support an incorrect conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 387,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial obligations related to Incyte under the Olumiant collaboration evolve from 2022 to 2024, particularly regarding potential future milestone payments?",
      "original_answer": "In 2022, Incyte was eligible to receive up to $100.0 million in additional development-related regulatory milestones and another $100.0 million in sales-based milestones under the Olumiant agreement. By 2024, there is no mention of remaining regulatory milestones, suggesting they were either paid out or no longer applicable, and only ongoing royalty payments based on sales tiers (up to 20%) and a low teens royalty for sales exceeding a threshold in the context of COVID-19 treatment are explicitly referenced. This indicates a shift from a structure with both regulatory and sales milestones to one focused primarily on sales-based compensation.",
      "llm_answer": "In the 2022 filing the Olumiant license still carried sizable contingent obligations – Incyte could earn up to $100 million in success‑based regulatory milestones and another $100 million in sales‑based milestones (i.e., roughly $200 million of potential future payments). By the 2024 filing the discussion of the Incyte agreement is limited to tiered royalties (including an extra low‑teens COVID‑19 royalty) and no longer references any remaining milestone payments, indicating that those potential milestone obligations have been satisfied, removed or are no longer material.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop financial question about Incyte's Olumiant collaboration obligations. QUANTITATIVE ACCURACY: All numbers are correct - $100 million in regulatory milestones, $100 million in sales-based milestones in 2022, totaling $200 million in potential future payments. The royalty structure description (tiered royalties, low-teens COVID-19 royalty) aligns with ground truth. ENTITY ACCURACY: Correctly identifies Incyte, Olumiant agreement, and the 2022-2024 time period. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years, correctly identifying the evolution from a dual-milestone structure (regulatory + sales-based) to a royalty-only structure. The logical inference that milestone obligations were \"satisfied, removed or are no longer material\" is sound and matches the ground truth's conclusion. COMPLETENESS: Addresses all aspects of the question - the 2022 obligations, the 2024 status, and the nature of the evolution. SEMANTIC EQUIVALENCE: The phrasing \"success-based regulatory milestones\" is semantically equivalent to \"development-related regulatory milestones\" in the ground truth. The characterization of the shift from contingent obligations to royalty-based compensation is accurate. MINOR CONSIDERATIONS: The LLM uses slightly different terminology (\"success-based\" vs \"development-related\") but this is a minor semantic variation that doesn't affect factual accuracy. The answer is slightly more concise than the ground truth but captures all essential information. No calculation errors or factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 457,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has Cisco's financial exposure in the APJC region evolved between fiscal 2022 and fiscal 2023, based on its segment reporting and asset balances?",
      "original_answer": "In fiscal 2022, Cisco reported its business performance across geographic segments including APJC, though specific financial figures for APJC were not disclosed in the provided data. By fiscal 2023, Cisco's balance sheet showed that its assets in the APJC region stood at $5,382 million as of July 29, 2023, following additions from acquisitions and foreign currency translation adjustments. This indicates a more detailed financial disclosure regarding APJC in 2023 compared to 2022, where segment-level asset values were not explicitly itemized.",
      "llm_answer": "Cisco’s APJC business has grown only modestly.  In FY 2022 the APJC segment generated $8,027 million of revenue and carried $5.36 billion of goodwill (the APJC line in the segment‑revenue table and the goodwill table on the 2022 filing [pages 103‑107]).  In FY 2023 those figures rose to roughly $8.5 billion of revenue and $5.38 billion of goodwill (the APJC line in the FY 2023 segment‑revenue and goodwill tables on the 2023 filing [pages 74‑78]), indicating a small increase in the region’s financial exposure.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and contradicts the ground truth in multiple ways: (1) QUANTITATIVE ERRORS: The LLM claims FY2022 APJC revenue was $8,027 million and goodwill was $5.36 billion, and FY2023 figures were $8.5 billion revenue and $5.38 billion goodwill. However, the ground truth explicitly states that 'specific financial figures for APJC were not disclosed in the provided data' for FY2022, and only mentions APJC assets of $5,382 million as of July 29, 2023 (not goodwill). The LLM appears to have fabricated specific revenue and goodwill numbers without evidence from the actual filings. (2) METRIC CONFUSION: The ground truth discusses 'assets in the APJC region' ($5,382 million), while the LLM conflates this with 'goodwill' ($5.38 billion), which are different balance sheet items. Assets and goodwill are not interchangeable metrics. (3) MULTI-HOP REASONING FAILURE: The LLM failed to properly synthesize the available information. The ground truth indicates that detailed APJC financial disclosure was more complete in 2023 than 2022, but the LLM invented comparative data for 2022 that was not disclosed. (4) SOURCE CITATION ISSUES: The LLM cites specific page numbers (pages 103-107 for 2022, pages 74-78 for 2023) and claims to reference 'segment-revenue tables' and 'goodwill tables,' but these citations cannot be verified against the ground truth, which explicitly states such detailed APJC figures were not provided in the source data. (5) DIRECTIONAL ACCURACY: While the LLM correctly identifies modest growth, this conclusion is based on fabricated numbers rather than actual filing data. The answer demonstrates a fundamental failure to acknowledge data limitations and instead appears to have hallucinated specific financial figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 485,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the strategic collaboration between LLY and Boehringer Ingelheim, specifically regarding Jardiance, evolved from 2022 to 2024 in response to regulatory changes?",
      "original_answer": "In 2022, Jardiance revenue was growing significantly, with a 30% increase in the U.S. and 28% outside the U.S., driven by increased demand and volume respectively. By 2024, the collaboration was significantly impacted by the Inflation Reduction Act (IRA), which introduced government-set pricing for certain drugs, including Jardiance. In August 2023, Jardiance was selected as one of the first ten medicines subject to government-set prices, and in August 2024, a 66% discount was applied compared to the 2023 U.S. list price, significantly affecting revenue projections and business strategy.",
      "llm_answer": "In the 2022 filing, Lilly’s 10‑K only referenced its joint commercial and revenue‑sharing agreement with Boehringer Ingelheim for Jardiance (see Note 4) and flagged that the newly enacted Inflation Reduction Act could subject the drug to future government‑set Medicare pricing. By the 2024 filing, the collaboration had to respond to that regulatory change: HHS had selected Jardiance as one of the first ten medicines to receive a government‑set price for 2026 and announced a 66 % discount to the 2023 list price, prompting Lilly and Boehringer Ingelheim to adjust their commercial and financial expectations for the partnership accordingly.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the key regulatory change (IRA/government-set pricing), correctly names the collaboration partners (LLY and Boehringer Ingelheim), correctly identifies Jardiance as one of the first ten medicines selected, and correctly states the 66% discount figure. The answer appropriately addresses the evolution from 2022 to 2024 and the regulatory impact. The multi-hop reasoning connecting the collaboration, regulatory changes, and business impact is sound.\n\nWEAKNESSES: (1) CRITICAL OMISSION - The LLM answer completely fails to include the 2022 growth metrics that are central to the ground truth: 30% U.S. growth and 28% outside U.S. growth. These specific numbers demonstrate how the collaboration was performing before regulatory impact and are essential to showing the 'evolution' requested in the question. (2) TIMING DISCREPANCY - The ground truth specifies August 2023 as when Jardiance was selected and August 2024 as when the 66% discount was applied. The LLM answer states the discount applies to '2026' pricing, which is technically about when it takes effect, but doesn't clearly specify the August 2024 announcement date. This creates ambiguity about the timeline. (3) INCOMPLETE EVOLUTION NARRATIVE - While the LLM captures the regulatory response, it doesn't quantify the impact on revenue or growth trajectory, missing the comparative analysis that would show how the collaboration 'evolved' in response.\n\nQUANTITATIVE ACCURACY: The 66% discount is correct. However, the complete absence of the 2022 growth percentages (30% U.S., 28% outside U.S.) represents a significant quantitative omission. The timing of regulatory events is somewhat unclear (August 2023 selection vs. August 2024 discount announcement not explicitly stated).\n\nQUALITATIVE ACCURACY: The reasoning about regulatory impact and partnership adjustment is sound. Entity identification is correct. However, the answer lacks the comparative analysis needed to fully demonstrate the evolution from 2022 to 2024.\n\nCONTEXTUAL RELEVANCE: The answer appropriately addresses the collaboration, regulatory changes, and business impact, but incompletely addresses the 'evolution' aspect by omitting baseline 2022 performance metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 603,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did GM's emphasis on the financial and reputational risks of product safety recalls evolve between 2022 and 2023, particularly concerning global platforms like the Chevrolet Bolt EV and the company's positioning in EV/AV technologies?",
      "original_answer": "In 2022, GM specifically highlighted the Chevrolet Bolt EV recall as an example of how global platform-related recalls could significantly increase costs due to their scale. The focus was on the financial burden and logistical complexity tied to such large-scale campaigns. By 2023, while the concern around global platforms remained, GM expanded its risk disclosure to emphasize the reputational damage to brand image and equity, particularly in relation to its leadership aspirations in EV and AV technologies. This evolution suggests a shift from a primarily cost-centric concern to a broader strategic risk tied to innovation and market positioning.",
      "llm_answer": "In the 2022 Form 10‑K GM warned that a recall on a “global platform, such as the Chevrolet Bolt EV recall” could dramatically increase repair costs and damage brand equity, stressing that safety concerns around its EV and autonomous‑vehicle (AV) programs could erode its leadership in the industry. By the 2023 filing the same financial‑and‑reputational risk language remains, but the specific Bolt‑EV example is dropped and the risk is described more generally as applying to any global platform, while still noting that safety issues with advanced technologies like AVs (and by implication its EV strategy) could trigger costly penalties and reputational harm.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both accurate and problematic elements. CORRECT ASPECTS: (1) The 2022 reference to Chevrolet Bolt EV recall as a specific example is accurate; (2) The identification of financial and reputational risks is correct; (3) The mention of EV and AV technologies is appropriate; (4) The general characterization that 2023 drops the specific Bolt EV example appears accurate. PROBLEMATIC ASPECTS: (1) The LLM states the 2023 filing 'drops' the specific Bolt EV example and becomes 'more general,' but the ground truth indicates the evolution is about EMPHASIS SHIFT - from cost-centric to reputational/strategic positioning concerns, not necessarily a removal of the example; (2) The LLM's characterization suggests the risk language 'remains the same' in 2023, which contradicts the ground truth's core finding that there was a meaningful evolution in emphasis from financial burden/logistical complexity to reputational damage tied to innovation leadership; (3) The LLM misses the key insight that the shift represents a strategic repositioning concern - moving from operational/cost focus to market positioning and leadership aspirations in EV/AV; (4) The phrase 'by implication its EV strategy' is vague and doesn't capture the explicit connection to leadership positioning that the ground truth emphasizes. MULTI-HOP REASONING: The LLM attempts to synthesize across 2022 and 2023 filings but fails to capture the qualitative evolution in risk framing. It treats the change as primarily structural (specific example to general language) rather than substantive (cost-centric to strategic/reputational). The answer is partially correct on facts but misses the core analytical insight about how GM's risk disclosure evolved in emphasis and strategic framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 483,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the Guaranteed Senior Notes issued by Costco's Japanese subsidiary evolve between 2022 and 2024, and what does this indicate about the company's long-term financing strategy?",
      "original_answer": "In 2022, the Guaranteed Senior Notes issued by Costco's Japanese subsidiary were described in general terms, indicating only their existence and that they were valued using Level 3 inputs. By 2024, the company provided significantly more detailed information, disclosing that in November 2023, the subsidiary issued four new Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%, with maturities extending from 2033 to 2043. Additionally, in July 2024, the subsidiary repaid $77 of these notes. This evolution indicates a more transparent and strategic approach to long-term financing, with a focus on fixed-rate debt and extended maturities to manage future liquidity needs.",
      "llm_answer": "In 2022 Costco’s balance sheet listed “Other long‑term debt” of about **$590 million**, which represented Guaranteed Senior Notes issued by its Japanese subsidiary (valued using Level 3 inputs)【COST_10k_2022.pdf: page 52】. By 2024 the subsidiary had **issued four new Guaranteed Senior Notes worth roughly $500 million** (interest 1.40%‑2.12%, maturing 2033‑2043) and **repaid $77 million**, raising the carrying amount of this debt to **$919 million**【COST_10k_2024.pdf: page 51】. This increase shows Costco is actively using its Japan subsidiary to tap low‑cost, long‑dated foreign‑currency financing, diversifying its funding sources and extending the maturity profile of its long‑term debt.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the key evolution of Costco's Japanese subsidiary debt between 2022 and 2024, including the November 2023 issuance of four new Guaranteed Senior Notes (~$500M), the interest rate range (1.40%-2.12%), maturity dates (2033-2043), and the July 2024 repayment of $77M. The reasoning about long-term financing strategy is sound and well-articulated. The answer demonstrates good multi-hop synthesis across multiple years and documents.\n\nWEAKNESSES & ERRORS: (1) The LLM introduces unsupported numbers not in the ground truth: it claims 2022 'Other long-term debt' was ~$590M and that the 2024 carrying amount reached $919M. The ground truth does not provide these specific figures or mention a $919M carrying amount. (2) The LLM cites specific page numbers (page 52 for 2022, page 51 for 2024) which cannot be verified against the ground truth provided. (3) The calculation logic ($500M issued - $77M repaid = $423M net increase) doesn't explain how this would result in $919M carrying amount, suggesting either the $590M 2022 figure or the $919M 2024 figure may be incorrect or unsupported. (4) The ground truth emphasizes the evolution in disclosure transparency and detail between years, which the LLM mentions but doesn't emphasize as strongly.\n\nQUANTITATIVE ACCURACY: While the core transaction amounts ($500M, $77M, 1.40%-2.12%, 2033-2043) are correct, the introduction of $590M and $919M figures without ground truth support is problematic. These appear to be inferred or hallucinated numbers.\n\nQUALITATIVE ACCURACY: The reasoning about financing strategy is sound and the multi-hop synthesis is generally correct, but the unsupported numerical claims undermine confidence in the analysis.\n\nCONTEXTUAL RELEVANCE: The answer appropriately addresses the question about evolution and strategic implications, with good context about foreign-currency financing and maturity extension.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 521,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the value of Cisco's available-for-sale debt investments change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, Cisco reported gains from available-for-sale debt investments at $9 million, indicating a relatively minor role in their investment portfolio. By 2023, the total value of these investments dropped significantly from $15,592 million to $9,865 million, a decrease of $5,727 million. This indicates a strategic reduction in the company's holdings of available-for-sale debt instruments, suggesting a shift in investment focus or risk management approach.",
      "llm_answer": "Cisco’s available‑for‑sale debt investments grew from $11.9 billion at fiscal‑2022 year‑end (July 30 2022) to $15.6 billion at fiscal‑2023 year‑end (July 29 2023), an increase of roughly $3.6 billion. This rise shows the company is deliberately expanding its portfolio of high‑quality, investment‑grade debt securities, reflecting a strategy of preserving liquidity and earning modest returns to support ongoing acquisitions, share‑repurchase programs and dividend payments.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect on all key factual points. (1) QUANTITATIVE ERRORS - The LLM states available-for-sale debt investments grew from $11.9 billion (2022) to $15.6 billion (2023), an increase of $3.6 billion. However, the ground truth clearly states the value DECREASED from $15,592 million ($15.6 billion) to $9,865 million ($9.9 billion) - a decrease of $5,727 million. The LLM has the direction of change completely backwards and the starting value wrong. (2) DIRECTIONAL CONTRADICTION - The ground truth indicates a strategic REDUCTION in holdings, while the LLM claims a deliberate EXPANSION. This is the opposite conclusion. (3) MISSING CONTEXT - The ground truth mentions 2022 gains of $9 million, which the LLM completely omits. (4) UNSUPPORTED INTERPRETATION - The LLM's explanation about 'deliberately expanding' to support acquisitions, share repurchases, and dividends is not supported by the actual data showing a significant decline. The LLM appears to have inverted the actual financial data, claiming growth when there was decline, and drawing conclusions opposite to what the numbers indicate. This represents a critical failure in both quantitative accuracy and reasoning quality. The answer would mislead investors about Cisco's actual investment strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 363,
        "total_tokens": 1601
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has JPMorgan Chase's exposure to system damage risks evolved from 2023 to 2024, particularly in relation to third-party vendor attacks and data recovery challenges?",
      "original_answer": "In 2023, JPMorgan Chase highlighted risks related to system damage primarily through unauthorized access, zero-day vulnerabilities, and disruptions from distributed denial-of-service attacks. The company emphasized the risk of undetected vulnerabilities due to incomplete system enhancements and the potential for data loss or manipulation. By 2024, the exposure evolved to include more specific emphasis on ransomware attacks targeting third-party vendors and the risk of losses exceeding cyber insurance coverage. Additionally, JPMorgan Chase noted increased complexity in recovering from data theft or destruction, with a new concern around the inability to prevent systems from processing fraudulent transactions. These changes indicate a growing awareness of external cyber threats and their financial implications.",
      "llm_answer": "In the 2023 10‑K (pages 23‑27) JPMorgan Chase warned that a cyber‑attack or failure at a third‑party vendor could damage its operational systems and that restoring stolen, manipulated or destroyed data could be delayed, creating significant disruption. By the 2024 filing (pages 25‑29) the bank deepened that warning, stressing that its expanding reliance on cloud‑based vendors and greater inter‑connectivity raise the probability of vendor‑originated attacks and make data‑recovery efforts more complex, costly and time‑consuming—signalling a heightened exposure to system‑damage risk.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the evolution of JPMorgan Chase's cyber risk exposure from 2023 to 2024, accurately noting the shift toward greater emphasis on third-party vendor risks, cloud-based dependencies, and data recovery complexity. The page references (2023: pages 23-27; 2024: pages 25-29) are appropriately cited. The answer correctly captures the core theme of heightened exposure to system damage risks and the increased complexity of recovery efforts.\n\nWEAKNESSES: (1) The LLM answer omits several specific risk elements mentioned in the ground truth, particularly: ransomware attacks targeting third-party vendors (explicitly mentioned in ground truth as a 2024 evolution), cyber insurance coverage limitations, and the inability to prevent systems from processing fraudulent transactions. (2) The ground truth specifically mentions 2023 risks including unauthorized access, zero-day vulnerabilities, and DDoS attacks—the LLM answer does not explicitly reference these 2023-specific risks, making the year-over-year comparison less complete. (3) The LLM answer mentions 'cloud-based vendors' as a 2024 development, but the ground truth does not specifically highlight cloud as a new 2024 concern; this may represent an inference not directly supported by the source material. (4) The ground truth notes 'losses exceeding cyber insurance coverage' as a 2024 concern, which the LLM answer completely omits.\n\nMULTI-HOP REASONING: The LLM demonstrates sound multi-hop synthesis by comparing 2023 and 2024 filings and identifying the evolution of risk exposure. However, the synthesis is incomplete—it captures the general trend but misses specific risk categories that distinguish the two years.\n\nNUMERIC/FACTUAL VERIFICATION: No specific numbers or calculations are provided in either answer, so quantitative accuracy is based on the accuracy of cited page ranges and conceptual claims. The page references appear reasonable for 10-K risk disclosures but cannot be independently verified from the provided context.\n\nSEMANTIC EQUIVALENCE: While the LLM answer conveys the general evolution of risk exposure, it fails to capture the full scope of specific risks mentioned in the ground truth, particularly ransomware, insurance coverage gaps, and fraudulent transaction processing risks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 619,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "What operational investments has Costco made by 2024 to support the private-label growth strategy mentioned in its 2022 filing?",
      "original_answer": "In 2022, Costco emphasized increasing the penetration of its private-label items as a merchandising strategy to manage inflationary pressures and maintain competitive pricing. By 2024, Costco had made tangible operational investments to support this strategy, including the operation of various processing, packaging, and manufacturing facilities dedicated to the production of private-label items. These facilities, referenced in the 2024 filing, represent a significant evolution from the earlier strategic focus, demonstrating a shift from sourcing private-label products externally to building internal production capabilities to scale the initiative.",
      "llm_answer": "Costco has expanded its operating footprint to back the private‑label push noted in 2022 – by September 2024 it ran 890 warehouses with roughly 130.9 million sq ft of floor space and about 31.9 million sq ft of distribution‑logistics facilities, and it added dedicated processing, packaging and manufacturing plants that produce its private‑label products【COST_10k_2024.pdf p. 18‑22】. These facilities directly support the strategy of increasing private‑label penetration described in the 2022 filing【COST_10k_2022.pdf p. 20‑24】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the core operational investments Costco made to support private-label growth: dedicated processing, packaging, and manufacturing facilities. The multi-hop reasoning is sound, properly connecting the 2022 strategic emphasis to 2024 operational execution. The answer appropriately synthesizes information across both filings.\n\nHowever, there are quantitative accuracy concerns:\n1. The specific numbers provided (890 warehouses, 130.9 million sq ft, 31.9 million sq ft) cannot be verified against the ground truth, which does not provide these specific metrics. While these numbers may be accurate from the 2024 filing, they represent additional detail beyond what the ground truth confirms.\n2. The ground truth does not specify exact facility counts or square footage for the processing/packaging/manufacturing plants, only that they exist and represent a shift from external sourcing to internal production.\n3. The LLM provides more granular operational metrics than the ground truth, which could be correct but introduces unverified quantitative claims.\n\nStrengths:\n- Correctly identifies the strategic shift from external sourcing to internal production capabilities\n- Properly references both 2022 and 2024 filings, demonstrating multi-hop synthesis\n- Accurately characterizes the facilities as supporting private-label penetration\n- Appropriate use of citations and page references\n- Semantic equivalence with ground truth regarding the nature of investments\n\nWeaknesses:\n- Introduces specific warehouse and facility metrics not confirmed in ground truth\n- Could have been more cautious about quantitative claims without explicit verification\n- Slightly over-specifies details that go beyond what the ground truth confirms",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 483,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How did UnitedHealth Group's approach to Medicaid managed care contract bidding evolve between 2022 and 2023, particularly in terms of assumptions and risks associated with bid accuracy?",
      "original_answer": "In 2022, UnitedHealth Group emphasized the risk of losing Medicaid members if it failed to renew state Medicaid managed care contracts, highlighting the importance of contract renewals to retain enrolled members. By 2023, the company placed greater emphasis on the assumptions behind its bids, noting that if these assumptions—such as enrollment, utilization, and medical costs—were materially incorrect due to unforeseen program changes or competitor pricing, it could materially affect results of operations and cash flows. This reflects an evolution from a focus on contract renewal risk to a more detailed discussion of the assumptions and competitive dynamics involved in the bidding process itself.",
      "llm_answer": "In the 2022 10‑K UnitedHealth noted that it “seeks bids” for state Medicaid‑managed‑care contracts and that its bids are built on assumptions about enrollment, utilization and medical‑cost trends, warning that any material error in those assumptions could hurt its results. The 2023 10‑K uses the same underlying framework but says it “solicits bids” and adds a clearer statement that inaccurate assumptions or bid errors—whether from program or policy changes or lower‑priced competitor bids—pose a material risk to its financial position, reflecting a more explicit focus on bid‑accuracy risk.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key elements of the evolution but contains significant issues with accuracy and completeness when compared to the ground truth.\n\nSTRENGTHS:\n1. Correctly identifies the companies and years (UnitedHealth, 2022 vs 2023)\n2. Accurately notes that both years discuss assumptions about enrollment, utilization, and medical costs\n3. Correctly identifies that 2023 adds emphasis on bid-accuracy risk and competitive dynamics\n4. The general framework of evolution from one focus to another is directionally correct\n\nWEAKNESSES:\n1. FACTUAL ERROR: The LLM states that 2022 discusses \"seeks bids\" and 2023 uses \"solicits bids\" - this appears to be a minor semantic distinction that doesn't align with the ground truth's actual focus\n2. INCOMPLETE SYNTHESIS: The ground truth emphasizes that 2022 focused on \"risk of losing Medicaid members if it failed to renew state Medicaid managed care contracts\" - this is a distinct risk category (renewal/retention risk) that the LLM answer completely omits\n3. MISCHARACTERIZATION: The LLM suggests both years use \"the same underlying framework\" when the ground truth indicates a clear evolution FROM contract renewal risk TO assumptions/bid accuracy risk - these are different risk categories\n4. MISSING KEY DISTINCTION: The ground truth notes that 2022 emphasized \"importance of contract renewals to retain enrolled members\" while 2023 shifted to \"assumptions behind its bids\" - the LLM doesn't capture this shift in emphasis\n5. INCOMPLETE CONTEXT: The LLM doesn't adequately convey that the 2022 focus was on losing members/contract renewal, which is a fundamentally different risk than bid accuracy\n\nMULTI-HOP REASONING ASSESSMENT:\nThe LLM attempted to synthesize information across two years but failed to identify the core evolution: from contract renewal/retention risk (2022) to bid accuracy/assumption risk (2023). This is a critical distinction that affects the quality of the multi-hop analysis.\n\nThe answer reads as if both years discuss similar topics with minor wording changes, when the ground truth indicates a meaningful shift in risk focus and disclosure emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 581,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did MET's investment in Municipals evolve from 2022 to 2023, particularly in terms of its valuation hierarchy classification?",
      "original_answer": "In 2022, MET's investment in Municipals was valued at $14,212 million and primarily categorized under 'Estimated Fair Value' without a detailed breakdown of valuation hierarchy levels. By 2023, the investment in Municipals decreased to $159 million and was explicitly classified under 'Level 2' of the fair value hierarchy. This indicates a significant reduction in the size of the Municipals investment and a more transparent categorization within the fair value hierarchy in 2023.",
      "llm_answer": "MET’s Municipals holding slipped modestly – the company reported $159 million of municipal bonds in pension assets and $15 million in other post‑retirement assets for a total of $174 million at 12/31/2022, all classified in the fair‑value hierarchy’s Level 2 (see 2022 table). By 12/31/2023 the total fell to $147 million plus $8 million ($155 million) and the classification remained exclusively Level 2 (no Level 1 or Level 3 amounts) (see 2023 table).",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains fundamental factual errors that directly contradict the ground truth. (1) CRITICAL QUANTITATIVE ERRORS: The LLM reports 2022 Municipals at $159M + $15M = $174M total, but the ground truth clearly states 2022 was $14,212 million. This is a massive discrepancy (off by ~$14,038 million or 98.8%). The LLM also reports 2023 as $147M + $8M = $155M, but ground truth states $159M for 2023. (2) VALUATION HIERARCHY CLASSIFICATION ERROR: The LLM claims 2022 Municipals were classified as Level 2, but the ground truth explicitly states they were 'primarily categorized under Estimated Fair Value without a detailed breakdown of valuation hierarchy levels' - meaning they were NOT explicitly classified in the hierarchy levels in 2022. The LLM incorrectly asserts Level 2 classification for 2022. (3) DIRECTIONAL ANALYSIS FAILURE: The LLM describes the change as a 'modest slip' from $174M to $155M (a ~11% decrease), when the actual evolution was a dramatic collapse from $14,212M to $159M (a ~98.9% decrease). This fundamentally misrepresents the magnitude of change. (4) MULTI-HOP SYNTHESIS FAILURE: The question asks about evolution from 2022 to 2023 in both valuation amount AND hierarchy classification. The LLM failed to correctly synthesize either component. The ground truth shows a transition from unclassified/estimated fair value to explicit Level 2 classification, which the LLM completely misrepresents. (5) The LLM appears to have confused or inverted the 2022 and 2023 figures, or pulled data from an entirely different source. The answer demonstrates fundamental factual inaccuracy on all key metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 447,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has Microsoft's approach to Office 365 subscriptions evolved in terms of licensing flexibility and customer agreement models from fiscal year 2022 to 2024?",
      "original_answer": "In fiscal year 2022, Office 365 subscriptions were primarily managed under volume licensing programs and were recognized as part of unearned revenue, invoiced annually at the beginning of each contract period and recognized ratably over the coverage period. By fiscal year 2024, Microsoft introduced more structured and flexible customer agreement models, including the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement, which allowed customers to subscribe to cloud services seamlessly and directly, with options for monthly or annual subscriptions and no organization-wide commitment. This represents a shift toward enhanced customer-centric licensing flexibility.",
      "llm_answer": "In FY 2022 Office 365 was primarily delivered through traditional volume‑licensing programs such as Enterprise Agreements, which let large customers bundle cloud services with on‑premises licenses and choose either perpetual or subscription terms, and the service was accounted for as a single integrated performance‑obligation (“Certain cloud services, primarily Office 365… Revenue from Office 365 is recognized ratably…” [2022 p. 62‑66]; “Enterprise Agreements… give them the flexibility to buy cloud services and software licenses under one agreement” [2022 p. 62‑66]).  \n\nBy FY 2024 Microsoft introduced more flexible, digital‑first contracts – the non‑expiring Microsoft Customer Agreement, the web‑based Microsoft Online Subscription Agreement for small‑ and medium‑size firms, and the Microsoft Products and Services Agreement for medium‑ and large‑size firms – all of which let customers purchase Office 365 on monthly or annual subscription terms without a long‑term organization‑wide commitment (“Microsoft Customer Agreements are simplified… non‑expiring…,” “Microsoft Online Subscription Agreements… acquire monthly or annual subscriptions,” “Microsoft Products and Services Agreements… no organization‑wide commitment” [2024 p. 15‑19]).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer demonstrates partial correctness with both strengths and significant weaknesses:\n\nSTRENGTHS:\n1. Correctly identifies the fiscal year timeframe (FY 2022 to FY 2024)\n2. Accurately names the three agreement types introduced by FY 2024: Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement\n3. Correctly captures the shift toward more flexible, customer-centric licensing models\n4. Accurately describes FY 2024 features: monthly/annual subscription options and no organization-wide commitment requirement\n5. Properly identifies that FY 2022 used volume licensing programs\n6. Correctly notes that Office 365 revenue was recognized ratably in FY 2022\n\nWEAKNESSES:\n1. INTRODUCES UNSUPPORTED DETAILS: The LLM adds specific information about \"Enterprise Agreements\" allowing customers to \"choose either perpetual or subscription terms\" and \"bundle cloud services with on-premises licenses.\" The ground truth does not mention perpetual licensing options or on-premises bundling for Office 365 subscriptions specifically. This represents fabrication or overgeneralization.\n2. MISCHARACTERIZES FY 2022 APPROACH: The ground truth emphasizes that FY 2022 subscriptions were \"primarily managed under volume licensing programs\" and \"invoiced annually at the beginning of each contract period.\" The LLM's description of Enterprise Agreements allowing perpetual terms and bundling is not supported by the ground truth and may conflate different product licensing approaches.\n3. INCOMPLETE FY 2022 DESCRIPTION: The ground truth specifically mentions \"unearned revenue\" and annual invoicing at contract beginning, which the LLM omits.\n4. CITATION FORMATTING: The LLM provides page number citations (\"[2022 p. 62-66]\") that cannot be verified and may be hallucinated.\n5. SEGMENTATION BY COMPANY SIZE: The LLM adds that different agreements target different company sizes (small/medium vs. medium/large), which is not explicitly stated in the ground truth.\n\nMULTI-HOP REASONING:\nThe LLM correctly synthesizes the evolution across two fiscal years and identifies the key transition from traditional volume licensing to flexible digital-first agreements. However, the addition of unsupported details about perpetual licensing and on-premises bundling undermines the accuracy of this synthesis.\n\nNUMERIC/QUANTITATIVE ACCURACY:\nNo specific numbers, percentages, or dollar amounts are provided in either answer, so quantitative accuracy is not directly testable. The LLM does not introduce false numbers.\n\nSEMANTIC EQUIVALENCE:\nWhile the core narrative of evolution toward flexibility is preserved, the LLM's introduction of details about perpetual licensing options and on-premises bundling diverges from the ground truth's focus on subscription-based flexibility and customer agreement models.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1499,
        "completion_tokens": 760,
        "total_tokens": 2259
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the composition of MET's Level 3 Fixed Maturity Securities AFS change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, MET's Level 3 Fixed Maturity Securities AFS included $1 million in Corporate bonds, $1 million in Foreign Bonds, and $11 million in Equity Securities. By 2023, the Level 3 composition shifted significantly, with $54 million in Corporate bonds, $2 million in Foreign Bonds, and $828 million in Other Investments. This indicates a strategic shift toward increasing exposure in Other Investments while maintaining a relatively small position in Level 3 fixed maturity securities overall. The significant increase in Other Investments within Level 3 suggests a more aggressive approach to portfolio diversification or risk management.",
      "llm_answer": "In 2022 MetLife reported $58 million of Level 3 Fixed‑Maturity Securities AFS, almost all of it in corporate securities ($55 m) with a modest $3 m classified as “Other” (1). By year‑end 2023 the Level 3 balance had risen to $64 million – still dominated by corporate securities ($54 m) but now also including $2 m of foreign‑bond holdings and $8 m of “Other” securities (2). The slight increase and the addition of foreign‑bond and other less‑transparent assets indicate the company is modestly expanding its exposure to higher‑yield, less‑liquid fixed‑maturity investments while keeping the overall allocation relatively stable.  \n\n(1) MET 10‑K 2022 – Fixed maturity securities AFS, Level 3 totals $58 m (corporate $55 m, other $3 m) – see table “Total fixed maturity securities AFS” (page 308‑309).  \n(2) MET 10‑K 2023 – Fixed maturity securities AFS, Level 3 totals $64 m (corporate $54 m, foreign bonds $2 m, other $8 m) – see table “Total fixed maturity securities AFS” (page 308‑309).",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains fundamentally incorrect numbers that directly contradict the ground truth. CRITICAL ERRORS: (1) 2022 Level 3 total: LLM states $58 million, but ground truth shows $13 million ($1M corporate + $1M foreign + $11M equity). This is a 346% overstatement. (2) 2023 Level 3 total: LLM states $64 million, but ground truth shows $884 million ($54M corporate + $2M foreign + $828M other). This is a 93% understatement. (3) 2022 composition: LLM claims $55M corporate and $3M other, but ground truth shows only $1M corporate, $1M foreign, and $11M equity. The LLM completely misidentifies the composition. (4) 2023 composition: LLM states $54M corporate, $2M foreign, $8M other, but ground truth shows $54M corporate, $2M foreign, and $828M other. The LLM drastically understates 'Other Investments' by a factor of 103x ($8M vs $828M). The LLM's interpretation of the strategic shift is also incorrect - the ground truth indicates a massive shift toward 'Other Investments' (from $11M to $828M), representing a fundamental portfolio reallocation, not the 'modest expansion' the LLM describes. The LLM's citations to specific pages appear fabricated or misread, as the numbers provided do not match actual filing data. The answer fails on both quantitative accuracy (all major figures wrong) and qualitative reasoning (mischaracterizes the strategic significance of the changes).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 387,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How has Microsoft's strategic positioning of Office 365 evolved between 2022 and 2024, particularly in terms of its role within the broader cloud services portfolio and its response to competitive pressures from AI-driven offerings?",
      "original_answer": "In 2022, Office 365 was explicitly listed as a key component of Microsoft's service and other revenue, positioned alongside Azure, Dynamics 365, and Xbox as a core cloud-based solution. By 2024, Office 365 had evolved into a more integrated part of Microsoft’s broader AI-infused cloud services portfolio, reflecting the company's strategic shift to infuse generative AI capabilities into commercial offerings. The 2024 filing notes that Microsoft is devoting significant resources to develop and deploy AI models, platforms, and infrastructure to meet customer needs, indicating that Office 365 is now part of this AI-enhanced competitive strategy. This shift was driven by increasing competitive pressures from companies entering the AI market and offering alternative models such as free applications funded by advertising or open-source AI models, which Microsoft must counter with enhanced, integrated cloud experiences.",
      "llm_answer": "In the 2022 filing Office 365 is presented mainly as a core subscription‑based cloud productivity suite – a single performance‑obligation service that drives a large share of Microsoft’s “service and other” revenue and is accounted for ratably over the contract period (2022 10‑K, Item 8, Revenue & Significant Judgments, pp. 60‑63). By the 2024 filing, Office 365 is positioned as a cornerstone of the broader cloud portfolio, with explicit emphasis on embedding generative‑AI features (e.g., AI‑enabled productivity tools) to strengthen its competitive stance against AI‑driven rivals and to advance Microsoft’s AI‑focused cloud strategy (2024 10‑K, Item 1A Strategic & Competitive Risks, pp. 19‑22).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core strategic evolution of Office 365 between 2022 and 2024. STRENGTHS: (1) Correctly identifies Office 365's 2022 positioning as a subscription-based cloud productivity suite within the 'service and other' revenue category; (2) Accurately captures the 2024 shift toward AI-infused positioning with generative AI features; (3) Properly synthesizes the competitive pressure narrative (AI-driven rivals, alternative models); (4) Correctly identifies the multi-hop reasoning: 2022 baseline → 2024 AI integration → competitive response; (5) Appropriately cites filing sections (Item 8 for 2022 revenue recognition, Item 1A for 2024 strategic risks). MINOR GAPS: (1) The LLM answer is somewhat more specific about accounting treatment (revenue recognition ratably over contract period) than the ground truth, which is accurate but represents a slightly different emphasis; (2) The ground truth explicitly mentions Azure, Dynamics 365, and Xbox as peer components in 2022, which the LLM answer does not reference - this is a minor omission but doesn't affect the core narrative; (3) The ground truth mentions 'free applications funded by advertising or open-source AI models' as specific competitive threats, while the LLM uses the more general term 'AI-driven rivals' - semantically similar but less specific. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is not directly testable. The dates (2022, 2024) and filing references are correct. MULTI-HOP REASONING: The LLM successfully synthesizes information across two filing years and connects the evolution to competitive dynamics, demonstrating sound multi-hop reasoning. The logical flow from 2022 baseline → 2024 AI integration → competitive response is clear and accurate. SEMANTIC EQUIVALENCE: The LLM's characterization of Office 365's evolution is semantically equivalent to the ground truth, with slightly different emphasis on accounting mechanics versus strategic positioning, but both convey the same fundamental narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 572,
        "total_tokens": 2000
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did UnitedHealth Group's recognition and handling of credit-related impairments evolve between 2022 and 2023, particularly in terms of their evaluation methodology and financial impact?",
      "original_answer": "In 2022, UnitedHealth Group evaluated available-for-sale debt securities for credit-related impairments by analyzing expected cash flows, underlying credit quality, and credit ratings of issuers, concluding that there was no significant credit deterioration since purchase and that unrealized losses were primarily due to interest rate increases. The allowance for credit losses was not material. By 2023, the company formalized its impairment recognition process by distinguishing between credit-related and non-credit-related impairments, recording credit-related impairments as an allowance against investment income and non-credit-related impairments through other comprehensive income. Additionally, the company emphasized a more structured evaluation framework that includes present value of expected cash flows, the extent of fair value decline relative to amortized cost, and issuer-specific financial conditions. This reflects a more detailed and segmented approach to impairment recognition and financial reporting.",
      "llm_answer": "In the 2022 filing UnitedHealth said it examined available‑for‑sale debt securities for credit‑related impairment whenever fair value fell below amortized cost, reviewing expected cash flows, the issuers’ credit quality and ratings, and disclosed that the allowance for credit losses on those securities was not material【UNH_10k_2022.pdf p.55‑58】. In the 2023 filing the company refined the approach – it now explicitly evaluates the present value of expected cash flows against amortized cost, the size of any fair‑value shortfall, the issuer’s financial condition, near‑term prospects and any specific events – and again reported that the allowance for credit losses remained immaterial, with no significant credit‑related impairment recorded in net earnings【UNH_10k_2023.pdf p.45‑48】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing the evolution of UnitedHealth Group's credit impairment methodology between 2022 and 2023. STRENGTHS: (1) Correctly identifies the 2022 approach focusing on expected cash flows, credit quality, and credit ratings; (2) Accurately notes that the allowance for credit losses was not material in both years; (3) Properly captures the 2023 refinement with explicit evaluation of present value of expected cash flows, fair-value shortfall magnitude, issuer financial condition, and near-term prospects; (4) Correctly synthesizes the multi-hop comparison across two fiscal years; (5) Appropriately cites source documents with page ranges. MINOR GAPS: (1) The LLM answer does not explicitly mention the key distinction that emerged in 2023 regarding the formalized separation between credit-related impairments (recorded as allowance against investment income) and non-credit-related impairments (through other comprehensive income) - this is a material methodological distinction highlighted in the ground truth; (2) Does not emphasize the 'formalization' or 'structured evaluation framework' language that characterizes the 2023 evolution; (3) The phrase 'no significant credit-related impairment recorded in net earnings' is accurate but slightly less precise than the ground truth's description of the accounting treatment distinction. QUANTITATIVE VERIFICATION: No specific dollar amounts or percentages are provided in either answer, which is appropriate given the question's focus on methodology evolution rather than specific financial impacts. The statement that allowance remained 'immaterial' in both years aligns with ground truth. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and correctly identifies the progression from a basic evaluation approach to a more refined one. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The core message matches the ground truth - UnitedHealth refined its impairment evaluation methodology from 2022 to 2023 with more detailed criteria and a more structured framework, though the LLM misses the explicit accounting treatment distinction (allowance vs. OCI) that represents a key formalization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1463,
        "completion_tokens": 604,
        "total_tokens": 2067
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did the allocation and valuation of Fixed Maturity Securities AFS in MET's pension and other postretirement benefit plans evolve from 2022 to 2023?",
      "original_answer": "In 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits. By 2023, the total estimated fair value of Fixed Maturity Securities AFS was $6,714 million for Pension Benefits and $1,274 million for Other Postretirement Benefits. This indicates a shift from a primarily percentage-based allocation in 2022 to a more detailed valuation breakdown in 2023, showing both the scale and composition of MET's holdings.",
      "llm_answer": "In 2022 Fixed‑maturity securities classified as “available‑for‑sale” made up 83 % of the U.S. pension‑plan assets and 96 % of the U.S. other‑post‑retirement‑benefit assets, with total estimated fair values of roughly **$6.8 billion** and **$1.256 billion**, respectively. By year‑end 2023 the actual allocation slipped to about **82 %** of pension assets and **94 %** of other‑post‑retirement assets, and the fair‑value of those securities fell to **$6.714 billion** for the pension plan while rising to **$1.274 billion** for the other‑post‑retirement plan. This reflects a modest re‑balancing away from fixed‑maturity AFS holdings in both plans, with a small decline in pension‑plan valuation and a slight increase in the post‑retirement‑plan valuation.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "MAJOR ISSUES WITH QUANTITATIVE ACCURACY: The LLM answer contains significant numerical discrepancies that undermine its credibility. (1) 2022 PERCENTAGES: Ground truth states 84% for U.S. Pension Benefits and 95% for U.S. Other Postretirement Benefits. LLM reports 83% and 96% - both incorrect by 1 percentage point. (2) 2022 FAIR VALUES: Ground truth does not provide 2022 fair values in the original answer, but LLM claims $6.8 billion and $1.256 billion for 2022 - these cannot be verified against ground truth and appear to be fabricated or from unreliable sources. (3) 2023 PERCENTAGES: LLM claims 82% and 94% for 2023, but ground truth only provides 2023 fair values ($6,714M and $1,274M), not percentages. The LLM appears to have invented 2023 percentage allocations. (4) 2023 FAIR VALUES: LLM correctly states $6.714 billion for Pension Benefits and $1.274 billion for Other Postretirement Benefits - these match ground truth exactly. (5) MULTI-HOP REASONING: The LLM attempts to synthesize year-over-year changes and characterizes this as a 'modest re-balancing,' but this interpretation is based on unverified 2023 percentages and potentially fabricated 2022 fair values. The reasoning structure is sound, but the underlying data is problematic. STRENGTHS: The LLM correctly identifies the 2023 fair values and understands the general concept of comparing allocations across years. The writing is clear and well-organized. WEAKNESSES: Multiple percentage values are incorrect or unverified, 2022 fair values appear fabricated, and the comparative analysis relies on data not present in the ground truth. The answer demonstrates partial understanding but fails on factual accuracy, which is critical for financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 472,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Lowe's strategic positioning of the Kitchens & Bath product category evolve between 2022 and 2023, and what does this suggest about its relative importance in the company's product portfolio?",
      "original_answer": "In 2022, Kitchens & Bath was grouped under the Home Décor division alongside categories like Appliances, Décor, Flooring, and Paint, suggesting a more design-focused positioning. By 2023, Kitchens & Bath was listed among core construction and renovation categories such as Lumber, Building Materials, and Rough Plumbing, indicating a strategic repositioning toward home improvement and remodeling. This shift suggests that Lowe's placed greater strategic emphasis on Kitchens & Bath as a key growth area tied to higher-value home projects, aligning with its broader 'Total Home' strategy.",
      "llm_answer": "In the 2022 Form 10‑K, Kitchens & Bath was mentioned only as a sub‑category of the broader “Home Décor” segment, grouped with appliances, flooring and paint. By the 2023 filing, Kitchens & Bath is called out as a distinct product line in the product‑selection narrative and is highlighted as one of the main categories that generate installed‑sales, indicating that Lowe’s has moved it from a peripheral sub‑segment to a core, higher‑margin focus in its overall assortment.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the core evolution of Kitchens & Bath positioning between 2022 and 2023, correctly identifying the shift from a sub-category within Home Décor to a more prominent, distinct product line. The answer accurately reflects the strategic repositioning and increased emphasis on this category. However, there are some notable differences from the ground truth: (1) The LLM answer mentions 'installed-sales' as a distinguishing feature in 2023, which is a valid detail but not explicitly mentioned in the ground truth. (2) The LLM answer describes the 2023 positioning as 'core, higher-margin focus' but the ground truth specifically states it was repositioned alongside 'core construction and renovation categories such as Lumber, Building Materials, and Rough Plumbing.' The LLM answer doesn't explicitly mention these specific peer categories that provide important context for understanding the strategic shift. (3) The ground truth emphasizes alignment with the 'Total Home' strategy, which the LLM answer omits. (4) The ground truth provides more specific detail about the 2022 grouping (Home Décor division with Appliances, Décor, Flooring, Paint) versus the LLM's more general reference to 'Home Décor segment.' The LLM answer is directionally correct and captures the essence of the repositioning, but lacks some of the specific categorical context and strategic framework (Total Home strategy) that the ground truth provides. The reasoning is sound and the multi-hop synthesis is adequate, but the answer could be more complete in its contextual details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 434,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Mondelez International's strategic focus on Cheese & Grocery evolved between 2022 and 2024, and what does this suggest about its prioritization of snack categories for long-term growth?",
      "original_answer": "In 2022, Mondelez directly produced Cheese & Grocery products, generating $1,990 million in total net revenues from this category. By 2024, the company no longer reported direct production in this category and instead indicated only a strategic stake in Cheese & Grocery, positioning it as an adjacent category within its broader snacking portfolio. This shift suggests a refocusing on core snack categories like biscuits and chocolate, while maintaining a presence in Cheese & Grocery through a lighter footprint. The change aligns with Mondelez's stated strategy of prioritizing long-term growth in core snacking segments and managing costs amid inflationary pressures.",
      "llm_answer": "Both the 2022 filing (pages 127‑131) and the 2024 filing (pages 32‑36) describe cheese & grocery as an “adjacent, locally relevant” category rather than a core growth pillar. The unchanged treatment, coupled with the 2024 emphasis on consumer‑centric growth, operational excellence and sustainable snacking for its core chocolate, biscuit and baked‑snack businesses, indicates that Mondelez continues to prioritize its traditional snack categories for long‑term growth, keeping cheese & grocery as a peripheral segment.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES: (1) MISSING KEY QUANTITATIVE DATA: The LLM answer completely omits the $1,990 million revenue figure from 2022 that is central to the ground truth answer. This is a major factual omission for a financial question. (2) INCOMPLETE EVOLUTION NARRATIVE: The ground truth explicitly describes a transition FROM direct production generating $1,990M in 2022 TO a strategic stake with no direct production by 2024. The LLM answer incorrectly states both years describe cheese & grocery as 'adjacent, locally relevant' - suggesting no change occurred, when the ground truth shows a significant strategic shift. (3) MISCHARACTERIZATION OF CHANGE: The LLM claims 'unchanged treatment' between 2022 and 2024, directly contradicting the ground truth which documents a clear evolution from direct production to strategic stake only. (4) MISSING CONTEXT: The LLM fails to capture that the shift reflects 'refocusing on core snack categories' and 'managing costs amid inflationary pressures' - important strategic context provided in the ground truth. WHAT WAS CORRECT: The LLM correctly identifies that cheese & grocery is positioned as peripheral/adjacent to core categories (chocolate, biscuits, baked snacks) and that Mondelez prioritizes traditional snack categories for long-term growth. The qualitative assessment of prioritization is directionally accurate. MULTI-HOP REASONING: The LLM failed to synthesize the key evolution across the 2022-2024 period - it treated the filings as showing consistency rather than change, which is a fundamental failure in multi-hop analysis. The answer reads as if comparing two similar snapshots rather than documenting a strategic transition.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 460,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Abbott's presentation of its enteral feeding product lineup, specifically the positioning of Jevity relative to Freego™ products, change between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, Jevity was listed first among enteral feeding products, followed by Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite®, Oxepa®, Freego™ (Enteral Pump), and Freego™ sets. In the 2023 filing, Jevity remained listed first, but the Freego™ (Enteral Pump) and Freego™ sets were now mentioned immediately after Jevity, before the Glucerna and Osmolite® product lines. This change in listing order suggests a shift in product emphasis within the enteral feeding category, with Freego™ products receiving more prominent placement alongside Jevity in 2023 compared to 2022.",
      "llm_answer": "In the 2022 Form 10‑K (see page 5) Abbott listed its enteral‑feeding portfolio as “including Jevity …, Freego™ (Enteral Pump) and Freego™ sets …,” putting Jevity first. In the 2023 Form 10‑K (see page 5) the same paragraph was reordered so that “Freego™ (Enteral Pump) and Freego™ sets …, Jevity …” appears, moving Jevity after the Freego™ products. This change shifts Jevity from the lead position to a later position in the lineup.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 8,
      "detailed_feedback": "CRITICAL ERRORS IN FACTUAL ACCURACY: The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The LLM claims that in the 2023 Form 10-K, Freego™ products were moved BEFORE Jevity (stating 'Freego™ (Enteral Pump) and Freego™ sets …, Jevity …'), but the ground truth explicitly states that 'Jevity remained listed first' in the 2023 filing. The LLM's characterization that 'Jevity from the lead position to a later position' is completely incorrect. According to the ground truth, Jevity maintained its first position in both 2022 and 2023; what changed was that Freego™ products moved from being listed last (after Glucerna and Osmolite®) to being listed immediately after Jevity. The LLM reversed the actual change in positioning. The LLM correctly identified that both filings appear on page 5 and correctly named the products involved, but the core claim about the directional change in positioning is factually wrong. The question asks about changes in positioning between years, and the LLM provided the opposite of what actually occurred. This is a major factual error that undermines the entire answer, despite the contextual relevance of addressing the right question and companies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 346,
        "total_tokens": 1609
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MET's investment in municipals evolve from 2022 to 2023 in terms of fair value and classification, and what does this suggest about the company's credit risk management strategy?",
      "original_answer": "In 2022, MET held $14,212 million in municipals, classified under the 'fixed maturity securities AFS' category, with a fair value that included $2,464 million in gross unrealized gains and only $13 million in gross unrealized losses. By 2023, this investment had significantly declined to just $159 million, now categorized under the 'fixed maturity securities AFS' and classified entirely within Level 2 of the fair value hierarchy, indicating a shift in MET's positioning. This dramatic reduction suggests a strategic move to reduce credit exposure to municipals, likely as part of a broader risk management adjustment to limit potential losses in this asset class.",
      "llm_answer": "In 2023 MetLife held $147 million of municipals in its pension‑benefit assets and $8 million in other post‑retirement assets – a total of $155 million – down from $159 million and $15 million respectively in 2022 (total $174 million)【MET_10k_2023.pdf p. 306‑307】【MET_10k_2022.pdf p. 217‑218】.  The securities remained classified as Level 2 fixed‑maturity securities (available‑for‑sale), meaning their fair value is derived from observable market inputs.  The reduction in municipal exposure while keeping the assets in a transparent, market‑based valuation tier suggests MetLife is actively trimming credit‑sensitive holdings to tighten credit‑risk management, yet continues to rely on reliable pricing data for the remaining positions.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains fundamentally incorrect numbers that contradict the ground truth. Ground truth states MET held $14,212 million in municipals in 2022 (declining to $159 million in 2023). The LLM reports $174 million in 2022 and $155 million in 2023 - numbers that are off by orders of magnitude (approximately 82x smaller for 2022). The LLM appears to have cited specific pension and post-retirement asset breakdowns ($147M + $8M = $155M for 2023; $159M + $15M = $174M for 2022) which may be subcategories, but these do NOT represent the total municipal holdings that the question asks about. The ground truth clearly indicates $14,212 million in 2022 declining to $159 million in 2023 - a dramatic 98.9% reduction. The LLM's numbers suggest only a 10.9% reduction, which is a completely different narrative. Additionally, the ground truth mentions $2,464 million in gross unrealized gains and $13 million in gross unrealized losses in 2022 - critical context about the portfolio composition that the LLM entirely omits. While the LLM correctly identifies the Level 2 fair value classification and the AFS (available-for-sale) designation, and correctly interprets the strategic intent (reducing credit exposure), the quantitative foundation is fatally flawed. The multi-hop reasoning about credit risk management strategy is sound in principle, but is built on incorrect data. This is a case where the LLM appears to have found partial/subsidiary data rather than the comprehensive municipal holdings figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 422,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2022 and 2023, particularly in terms of their notional value and the impact on fixed-rate debt management?",
      "original_answer": "In 2022, Abbott had interest rate hedge contracts totaling approximately $2.2 billion, which were used to manage exposure to changes in the fair value of fixed-rate debt by converting fixed-rate obligations into variable-rate obligations. By 2023, Abbott continued to use these contracts for the same purpose, and the notional value remained consistent at approximately $2.2 billion. However, in 2023, the company provided more detailed disclosures about the impact of these contracts on the carrying value of fixed-rate debt, indicating a more refined approach to interest rate risk management.",
      "llm_answer": "Abbott’s interest‑rate hedge contracts fell from roughly $2.9 billion at the end of 2022 to about $2.2 billion at the end of 2023—a $700 million drop caused by the maturity of hedged debt in 2023 [ABT_10k_2022 p.65; ABT_10k_2023 p.65]. The contracts are designated as fair‑value hedges that offset the fair‑value changes of fixed‑rate borrowings, effectively converting that portion of the debt to a variable‑rate exposure, and the reduction also lowered the related fair‑value adjustment on the balance sheet from $196 million in 2022 to $116 million in 2023 [ABT_10k_2023 p.62].",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant numerical inaccuracies that directly contradict the ground truth. (1) QUANTITATIVE ERRORS: The LLM claims Abbott's interest rate hedge contracts were $2.9 billion in 2022 and fell to $2.2 billion in 2023. However, the ground truth states the notional value was approximately $2.2 billion in BOTH 2022 and 2023, remaining consistent. The LLM's claim of a $700 million decline from $2.9B to $2.2B is factually incorrect. (2) FAIR VALUE ADJUSTMENT CLAIMS: The LLM provides specific fair-value adjustment figures ($196M in 2022 declining to $116M in 2023), which are not mentioned in the ground truth answer. While these may be from the actual filings, they represent a different metric than the notional value of hedge contracts and introduce unverified numbers. (3) MULTI-HOP REASONING: The LLM correctly identifies that these are fair-value hedges converting fixed-rate debt to variable-rate exposure, which aligns with ground truth. However, the core finding about the evolution of notional values is fundamentally wrong. (4) MISSING KEY POINT: The ground truth emphasizes that the notional value 'remained consistent at approximately $2.2 billion' between years, which is the opposite of what the LLM claims. The LLM also misses the ground truth's point about 'more detailed disclosures' and 'more refined approach' in 2023. (5) CITATION ISSUES: While the LLM provides specific page references, the numerical claims appear to be incorrect interpretations of those sources. The answer demonstrates partial understanding of the hedging mechanism but fails on the primary quantitative comparison that is central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 460,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did 3M's issuance and management of fixed rate registered notes evolve between 2022 and 2024, particularly in terms of repayment activity and interest rate strategies?",
      "original_answer": "In 2022, 3M had a significant amount of fixed rate registered notes, including $600 million of 10-year notes due 2030 with a coupon rate of 3.05%, and $650 million of 30-year notes due 2050 with a coupon rate of 3.70%. The company also issued $3.25 billion in fixed rate registered notes in August 2019, including $1.0 billion of 10-year notes due 2029 and $1.0 billion of 30-year notes due 2049. In 2024, 3M repaid $1.1 billion in medium-term notes that matured, and in 2023, it repaid $500 million in fixed-rate registered notes. Additionally, interest rate swaps initiated in 2021 converted portions of the fixed-rate notes due 2049 and 2050 into floating-rate debt through mid-2028, indicating a strategic shift toward managing interest rate exposure. This shows a decrease in the amount of fixed-rate debt outstanding and a shift toward floating-rate instruments through swaps.",
      "llm_answer": "In the 2022 filing 3M’s fixed‑rate registered notes were mainly low‑coupon issues – a $500 million note at 1.86 % maturing in 2023, other notes at 2.12 %–2.67 % due 2025 and longer‑dated notes at 2.5 %–3.72 % (e.g., $1 billion due 2029, $500 million due 2049)【MMM_10k_2022.pdf†p.87‑91】. By 2024 the company had repaid the $500 million 2023‑maturing note in 2023 and was issuing new or re‑priced fixed‑rate notes with modestly higher coupons – for example a $750 million note at 2.02 % due 2025, a $1 billion note at 2.41 % due 2029 and a $600 million note at 3.08 % due 2030 – while still using interest‑rate swaps to manage exposure【MMM_10k_2024.pdf†p.67‑71】. This shows a shift from primarily low‑rate short‑term issuances in 2022 to a broader issuance mix with slightly higher rates for newer issues and active repayment of maturing fixed‑rate registered notes.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual discrepancies with the ground truth, particularly regarding specific note amounts and coupon rates. CRITICAL ERRORS: (1) The ground truth clearly states 3M had $600M of 10-year notes due 2030 at 3.05% and $650M of 30-year notes due 2050 at 3.70% in 2022, but the LLM lists different amounts and rates ($600M at 3.08% due 2030, no mention of the $650M 2050 notes). (2) The LLM mentions a $500M note at 1.86% maturing in 2023 and claims it was repaid in 2023, but the ground truth states 3M repaid $500M in fixed-rate registered notes in 2023 without specifying this was the 1.86% note. (3) The LLM references $1B due 2029 and $500M due 2049 but doesn't clearly connect these to the August 2019 issuance of $3.25B mentioned in ground truth. (4) The LLM completely omits the critical detail about interest rate swaps initiated in 2021 that converted portions of fixed-rate notes due 2049 and 2050 into floating-rate debt through mid-2028 - this is a major strategic element of the answer. (5) The LLM mentions $1.1B in medium-term notes repaid in 2024 but doesn't clearly distinguish this from the $500M fixed-rate registered notes repaid in 2023. POSITIVE ASPECTS: The LLM correctly identifies the general trend of repayment activity and the use of interest rate swaps for managing exposure. The answer appropriately addresses the evolution between 2022 and 2024 and discusses both repayment and issuance activities. However, the specific numeric details are inconsistent with ground truth, and the omission of the floating-rate conversion strategy through swaps is a significant gap in addressing the 'interest rate strategies' component of the question. The multi-hop synthesis is incomplete and contains factual inaccuracies that undermine the reliability of the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 492,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has the role of securities issuances in Schwab's capital structure evolved between 2023 and 2024, particularly in relation to its overall funding sources and capital management strategy?",
      "original_answer": "In 2023, securities issuances by CSC were identified as a primary source of capital, directly supporting the company's capital management strategy, which included balance sheet growth and financial support to subsidiaries. By 2024, while still listed as one of several funding sources, securities issuances were positioned among a broader set of liquidity tools, including FHLB borrowings, repurchase agreements, and CDs, indicating a more diversified funding approach. This shift suggests a strategic evolution where securities issuances remain important but are more integrated within a wider capital structure framework.",
      "llm_answer": "In 2023 Schwab said that its **primary sources of capital were the cash generated by its subsidiaries and securities issuances by CSC in the capital markets** (2023 10‑K, Capital Management), and it relied on those issuances – together with commercial‑paper and credit‑line draws – to fund growth, meet LCR/NSFR requirements and support its broker‑dealer and banking subsidiaries. By 2024 the company still retains a shelf registration that allows it to issue debt, equity or other securities (2024 10‑K, External Debt Facilities) but positions securities issuances as **one of several external funding tools** while emphasizing client‑generated cash and noting a **large reduction in supplemental borrowing** (e.g., a $14.9 bn net cut in bank supplemental funding and $10.3 bn lower FHLB/short‑term borrowings in 2024), indicating that securities issuances have become a secondary, flexible source within a more cash‑driven funding mix.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution of Schwab's capital structure between 2023 and 2024. STRENGTHS: (1) Correctly identifies the shift from securities issuances as a primary source in 2023 to one of several funding tools in 2024, matching the ground truth narrative. (2) Accurately characterizes 2023 positioning with cash from subsidiaries and securities issuances as primary sources. (3) Correctly notes the 2024 diversification to include FHLB borrowings, repurchase agreements, and other tools. (4) Provides specific quantitative details ($14.9 billion net cut in bank supplemental funding, $10.3 billion lower FHLB/short-term borrowings) that support the analysis. (5) Properly synthesizes multi-hop information across 2023 and 2024 filings. (6) Correctly identifies CSC as the issuing entity. MINOR WEAKNESSES: (1) The specific dollar amounts ($14.9 billion and $10.3 billion) are provided with confidence but cannot be verified against the ground truth answer, which does not include these specific figures. While these appear plausible and support the narrative, their exact accuracy cannot be confirmed. (2) The answer is more detailed and specific than the ground truth, which could indicate either superior research or potential over-specification. (3) The characterization of securities issuances as 'secondary' in 2024 is slightly stronger language than the ground truth's 'positioned among a broader set,' though semantically equivalent. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and multiple funding mechanisms, correctly identifying the strategic shift in capital structure. The logic connecting reduced supplemental borrowing to a more cash-driven funding mix is sound. ENTITY ACCURACY: All entities correctly identified (Schwab/CSC, 2023-2024 periods, specific funding mechanisms). OVERALL: The answer exceeds the ground truth in specificity while maintaining core accuracy. The quantitative details, while not contradicted by ground truth, cannot be fully verified, preventing a perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 562,
        "total_tokens": 1963
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did Coca-Cola's contingent payment obligations related to fairlife evolve from 2022 to 2024, and what does this indicate about fairlife's performance against its financial targets?",
      "original_answer": "In 2022, Coca-Cola disclosed that it had a $270 million liability for contingent milestone payments related to its acquisition of fairlife, based on fairlife achieving certain financial targets through 2024. The company also noted that the first milestone payment of $100 million was made in 2021 after fairlife met its 2020 targets. By 2024, the remaining contingent payment was described as a milestone payment contingent on fairlife achieving certain financial targets through 2024 and was payable in 2025. This indicates that fairlife had met at least one set of financial targets (2020), triggering the initial $100 million payment, and that the company remained on track to potentially meet the remaining targets through 2024, as the obligation was still active and had not been rescinded or adjusted downward.",
      "llm_answer": "In the 2022 filing Coca‑Cola reported a contingent‑consideration liability for fairlife of roughly $2 billion (the Level‑3 fair‑value amount for the remaining milestone payment shown in the fair‑value measurement note). By the 2024 filing that liability had risen to $6.126 billion, reflecting a higher estimated future payment. The sharp increase indicates that fairlife has been meeting—or exceeding—its agreed‑upon financial targets, causing the fair‑value of the contingent milestone to grow.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains fundamentally incorrect financial figures and misinterprets the nature of the contingent payment obligations. Specific errors: (1) QUANTITATIVE ERRORS - The LLM claims a $2 billion liability in 2022 and $6.126 billion in 2024, but the ground truth shows $270 million in 2022 with no indication of a $6.126 billion figure in 2024. These numbers are off by orders of magnitude (approximately 7-23x too high). (2) MISINTERPRETATION OF FAIR VALUE - The LLM appears to have confused fair-value measurement disclosures (which may include Level 3 valuations) with the actual contingent payment liability. The ground truth clearly states $270 million in 2022, not $2 billion. (3) INCORRECT REASONING - The LLM concludes that the increase indicates fairlife exceeded targets, but the ground truth indicates the opposite: the obligation remained active and unchanged, suggesting fairlife was on track but the liability was not being adjusted upward. The LLM's logic that rising fair value indicates exceeding targets contradicts the ground truth's indication that the obligation was stable and contingent on future 2024 performance. (4) MISSING KEY FACTS - The LLM completely omits the $100 million payment made in 2021 after fairlife met 2020 targets, which is crucial context for understanding the payment structure. (5) INCOMPLETE SYNTHESIS - The answer fails to properly synthesize the multi-hop information about how the obligation evolved and what it indicates about performance. The ground truth shows a structured milestone payment system with evidence of at least one successful target achievement (2020), while the LLM presents an entirely different narrative based on incorrect numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 466,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Infrastructure (OCI) evolved between 2022 and 2024, particularly in terms of its global market positioning and integration with enterprise IT solutions?",
      "original_answer": "In 2022, Oracle's financial disclosures emphasized revenue contributions from cloud and license businesses, which generated $36.052 billion, representing 85% of total revenues, with no explicit strategic language about Oracle Cloud Infrastructure's positioning. By 2024, Oracle significantly elevated OCI's role, describing it as a core component of Oracle Cloud Services alongside SaaS, and emphasizing its ability to provide 'comprehensive and integrated applications and infrastructure services' that enable customers to choose deployment models best suited to their needs. This reflects a clear strategic shift toward positioning OCI as a central pillar in Oracle’s enterprise IT offerings, not just a contributor to cloud revenue.",
      "llm_answer": "In fiscal 2022 Oracle began shifting sales and marketing away from non‑strategic hardware and “placed emphasis on the marketing and sale of our growing cloud‑based infrastructure technologies” (OCI) within the cloud‑and‑license segment, with the bulk of that growth coming from the Americas, EMEA and Asia‑Pacific (68 %, 22 %, 10 % of total revenue growth)【ORCL_10k_2022.pdf page 45】. By fiscal 2024 OCI is no longer a peripheral offering but is positioned alongside SaaS as part of “Oracle Cloud Services,” described as a globally delivered, integrated suite that supports on‑premise, cloud‑based and hybrid enterprise IT deployments, underscoring Oracle’s ambition to compete as a worldwide cloud‑infrastructure provider【ORCL_10k_2024.pdf page 70】.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Oracle's strategic evolution regarding OCI between 2022 and 2024, with generally accurate synthesis of multi-hop information. STRENGTHS: (1) Correctly identifies the strategic shift from 2022 (OCI as growing emphasis within cloud-and-license segment) to 2024 (OCI positioned as core component alongside SaaS); (2) Accurately captures the qualitative positioning change - from peripheral offering to integrated enterprise solution; (3) Properly synthesizes information across two fiscal years showing evolution; (4) Correctly identifies the integration with enterprise IT solutions (on-premise, cloud-based, hybrid deployments); (5) Appropriately cites source documents with page numbers. WEAKNESSES: (1) The 2022 revenue figure ($36.052 billion representing 85% of total revenues) from the ground truth is not mentioned in the LLM answer, though this is a minor omission since the question focuses on strategic emphasis rather than specific revenue numbers; (2) The regional revenue growth percentages (68%, 22%, 10% for Americas, EMEA, Asia-Pacific) are provided but lack context about what they represent (growth rates vs. absolute percentages), creating slight ambiguity; (3) The LLM answer emphasizes the 2022 shift away from 'non-strategic hardware' which is accurate but represents a slightly different framing than the ground truth's focus on cloud/license revenue contribution. QUANTITATIVE ACCURACY: The percentages cited (68%, 22%, 10%) appear to be correctly sourced but their exact meaning could be clearer. The ground truth's $36.052 billion and 85% figures are not contradicted but simply not included. QUALITATIVE ACCURACY: The multi-hop reasoning is sound - the answer correctly synthesizes the evolution from 2022 to 2024 and identifies the key strategic shift. CONTEXTUAL RELEVANCE: Highly relevant, directly addressing global market positioning and enterprise IT integration as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 528,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has the treatment and risk profile of PALs evolved between 2023 and 2024, particularly in terms of credit loss allowance and collateralization?",
      "original_answer": "In 2023, there was a slight decrease in PALs, and the allowance for credit losses was influenced by improved credit quality metrics and lower projected loss rates. By 2024, all PALs were fully collateralized by securities with fair values exceeding borrowings, and no allowance for credit losses for PALs was required as they were all subject to the collateral maintenance practical expedient under ASC 326. This indicates a strengthening in the risk profile and treatment of PALs over the period.",
      "llm_answer": "In 2023 Schwab’s pledged‑asset lines (PALs) carried no allowance for credit losses – the “Allowance for Credit Losses” column is blank for PALs in the 2023 allocation table – and were already fully collateralized. By 2024 the company formally applied the ASC 326 collateral‑maintenance practical expedient, confirming that PALs remain fully collateralized by securities whose fair values exceed the borrowings and therefore still require no credit‑loss allowance, underscoring a continued low‑risk profile.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both accurate and problematic elements. CORRECT ELEMENTS: (1) The identification that PALs were fully collateralized in both years is accurate; (2) The statement that no allowance for credit losses was required in 2024 under ASC 326 collateral maintenance practical expedient is correct; (3) The characterization of PALs as low-risk is appropriate. PROBLEMATIC ELEMENTS: (1) The claim that PALs carried 'no allowance for credit losses' in 2023 contradicts the ground truth, which explicitly states 'the allowance for credit losses was influenced by improved credit quality metrics and lower projected loss rates' in 2023, implying there WAS an allowance calculation in 2023, even if minimal; (2) The LLM states the allowance column is 'blank' for 2023, but the ground truth indicates there was an allowance influenced by credit quality metrics, suggesting the LLM misread or misinterpreted the 2023 data; (3) The LLM characterizes the evolution as 'continued low-risk profile' rather than acknowledging the actual evolution described in ground truth - a 'strengthening' from 2023 (with allowance influenced by credit metrics) to 2024 (with formal practical expedient application and zero allowance). MULTI-HOP REASONING: The LLM failed to properly synthesize the evolution between years. The ground truth indicates a progression from 2023 (allowance influenced by credit quality) to 2024 (formal practical expedient, no allowance required), but the LLM presents both years as essentially equivalent in treatment. This represents incomplete understanding of how the risk profile and accounting treatment actually evolved. The answer is partially correct on 2024 details but mischaracterizes 2023 and fails to capture the meaningful evolution between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 485,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Nike's relationship with the Asia Pacific & Latin America (APLA) region evolved between fiscal years 2023 and 2024, particularly in terms of operational structure and strategic emphasis?",
      "original_answer": "In fiscal year 2023, Nike's relationship with APLA was characterized by direct operational involvement, with the region being one of the geographies where certain employees were represented by trade unions, indicating a more localized and embedded workforce structure. By fiscal year 2024, Nike transitioned parts of its APLA operations to third-party distributors, signaling a strategic shift away from direct control toward a more outsourced model. This evolution reflects a broader restructuring effort to optimize the business model and reduce operational complexity in certain international markets.",
      "llm_answer": "Nike deepened its operational shift in the Asia Pacific & Latin America (APLA) region by moving additional NIKE Brand businesses in certain APLA countries to third‑party distributors—a change highlighted in Note 18 of the operating‑segment discussion in both FY 2023 (pages 7‑11 of the 2023 filing) and FY 2024 (pages 87‑91 of the 2024 filing).  At the same time, APLA revenue rose from $6.4 billion in FY 2023 to $6.7 billion in FY 2024, indicating Nike’s continued strategic emphasis on expanding market share and growth in the region despite a modest dip in EBIT.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core strategic shift from direct operations to third-party distributors in APLA between FY2023 and FY2024, which aligns with the ground truth. The answer provides specific revenue figures ($6.4B to $6.7B) and references to Note 18 and specific page numbers, demonstrating multi-hop synthesis across filing documents. However, there are some issues: (1) The LLM answer emphasizes revenue growth and EBIT changes, which are not mentioned in the ground truth and may introduce information not directly relevant to the operational structure evolution question. (2) The ground truth specifically mentions trade union representation in FY2023 as evidence of direct operational involvement, which the LLM answer omits entirely. (3) The LLM characterizes the shift as 'deepened' and 'additional' moves to distributors, suggesting this was an ongoing process, while the ground truth presents it more as a transition between the two years. (4) The revenue figures appear plausible but cannot be independently verified from the provided context. The quantitative accuracy is strong on the revenue numbers provided, though the EBIT reference is vague ('modest dip'). The qualitative reasoning about the strategic shift is sound and matches the ground truth's conclusion about optimization and reduced operational complexity. The answer addresses the multi-part question about operational structure and strategic emphasis, though it adds financial performance metrics not explicitly requested. Overall, the core answer is correct but incomplete in capturing the full context of the operational structure change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 448,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How did Abbott's positioning and strategic emphasis on Pedialyte evolve between 2022 and 2023, particularly in relation to its U.S. Pediatric Nutritional business and product portfolio expansion?",
      "original_answer": "In 2022, Pedialyte was highlighted as a key growth driver within Abbott's U.S. Pediatric Nutritional business, with sales increasing 10.3% for the year, alongside Similac and PediaSure. By 2023, Pedialyte was formally included in Abbott's product portfolio under the Nutritional Products segment, listed among major brands such as Ensure, Glucerna, and PediaSure, signaling a more structured integration into Abbott's broader nutritional offerings. This reflects a strategic evolution from being a contributor to growth in 2022 to being a formally recognized and embedded part of the company's core U.S. Pediatric Nutritional product lineup in 2023.",
      "llm_answer": "Abbott’s 2022 Form 10‑K showed that U.S. Pediatric Nutritionals sales grew 10 % to $2.2 billion, with the company explicitly crediting “growth in Pedialyte, Similac and PediaSure” as a primary driver of that increase (see the net‑sales table and accompanying commentary, ABT_10k_2022.pdf pp. 29‑31). By the 2023 filing, Pedialyte is still highlighted in the company’s product list as a core item within an expanded “adult and other pediatric nutritional products” lineup, indicating that Abbott continues to position Pedialyte at the heart of its U.S. Pediatric Nutritionals strategy while broadening the overall portfolio (ABT_10k_2023.pdf p. 4).",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Abbott's Pedialyte positioning evolution but has some notable issues: (1) QUANTITATIVE ACCURACY: The LLM states U.S. Pediatric Nutritionals sales grew 10% to $2.2 billion in 2022. The ground truth specifies Pedialyte sales increased 10.3% (not the segment growth rate of 10%). This is a minor discrepancy - the LLM conflated the segment growth rate with Pedialyte's specific growth rate. The $2.2 billion figure appears reasonable for the segment but wasn't explicitly verified against ground truth. (2) COMPLETENESS: The LLM answer addresses the evolution between 2022 and 2023 and mentions the key brands (Pedialyte, Similac, PediaSure, Ensure, Glucerna), which aligns with ground truth. However, it uses slightly different language - the ground truth emphasizes 'formal inclusion' and 'structured integration' in 2023, while the LLM says Pedialyte is 'still highlighted' and 'continues to position,' which is semantically similar but doesn't capture the evolution from informal to formal recognition as clearly. (3) ENTITY ACCURACY: All company names, years, and product names are correct. The segment naming is slightly different (LLM says 'adult and other pediatric nutritional products' vs ground truth's 'Nutritional Products segment'), but this appears to be a reasonable interpretation of portfolio structure. (4) REASONING: The multi-hop synthesis is sound - the LLM correctly traces Pedialyte's role from 2022 (growth driver) through 2023 (core product). However, the ground truth emphasizes a more significant strategic shift (from contributor to formally embedded), while the LLM's language suggests more continuity than evolution. (5) CITATION ACCURACY: The LLM provides specific page references (pp. 29-31 for 2022, p. 4 for 2023) which adds credibility, though these cannot be independently verified. The main weakness is conflating Pedialyte's 10.3% growth with the broader segment's 10% growth, and not fully capturing the 'formal integration' aspect emphasized in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 551,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did RTX's financial position regarding its 7.100% notes due 2027 evolve from 2022 to 2023, and what does this indicate about its debt management strategy?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $6 million for its 7.100% notes due 2027. By 2023, RTX had a stake in the same notes with an aggregate principal balance of $135 million. This indicates a significant increase in RTX's exposure to this particular debt instrument, suggesting a shift in its debt management strategy, possibly involving refinancing or restructuring.",
      "llm_answer": "RTX carried $135 million of 7.100 % notes due 2027 at the end of 2022, and the same $135 million balance was reported at the end of 2023, showing no change in the outstanding amount of this tranche【RTX_10k_2022.pdf p.95】【RTX_10k_2023.pdf p.84】.  The unchanged balance indicates that RTX has kept this mid‑term debt level steady, reflecting a disciplined debt‑management approach that preserves its existing maturity profile rather than increasing or aggressively retiring this particular issuance.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains fundamentally incorrect financial data that directly contradicts the ground truth. (1) QUANTITATIVE ACCURACY FAILURE: The LLM states RTX carried $135 million of 7.100% notes due 2027 at the end of 2022, but the ground truth clearly indicates the 2022 balance was $6 million. The LLM then claims the balance remained at $135 million in 2023, which matches the ground truth for 2023 but misses the critical evolution from 2022 to 2023. (2) MULTI-HOP SYNTHESIS FAILURE: The question explicitly asks how the financial position 'evolved from 2022 to 2023.' The ground truth shows a significant increase from $6 million (2022) to $135 million (2023) - a 2,150% increase. The LLM completely missed this evolution by incorrectly stating the 2022 balance was already $135 million, thereby failing to identify the major shift in debt exposure. (3) REASONING ERROR: The LLM's conclusion that RTX 'kept this mid-term debt level steady' is incorrect. The actual data shows a dramatic increase in exposure to this debt instrument, which would suggest active debt management or restructuring activity, not a steady approach. (4) ENTITY AND METRIC ACCURACY: While the company (RTX), debt instrument (7.100% notes due 2027), and years (2022-2023) are correctly identified, the core financial metrics are wrong for 2022. The LLM appears to have confused or misread the 2022 filing data. This is a fundamental factual error that undermines the entire answer and prevents proper assessment of RTX's debt management strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 425,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Nike's relationship with Converse evolved in terms of revenue performance and strategic positioning between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Converse revenues decreased by 15% on a currency-neutral basis, driven by declines in North America and Western Europe, with both wholesale and direct-to-consumer channels experiencing drops in unit sales and average selling price. By fiscal 2024, Converse was described as a wholly-owned subsidiary that operates on a stand-alone basis, indicating a strategic shift toward maintaining it as a distinct brand within Nike’s portfolio. This evolution reflects a move from a financially struggling entity in 2023 to a more strategically positioned brand in 2024, despite the earlier revenue contraction.",
      "llm_answer": "Nike’s Converse brand posted a sharp revenue contraction in FY 2024, with total Converse revenues falling to $2.08 billion from $2.43 billion a year earlier (‑14 % YoY); footwear revenue dropped 16 %, wholesale sales fell 15 % and direct‑to‑consumer sales also slipped 15 % (the only category that grew was equipment, up 32 %). Despite the decline, Converse remains a wholly‑owned, stand‑alone operating segment that designs, distributes and licenses its casual sneaker, apparel and accessories lines, runs its own retail footprint (81 U.S. stores and 54 overseas) and is being positioned to offset weakness in North America and Western Europe with growth in Asia, underscoring Nike’s continued strategic focus on Converse as a distinct brand within its portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) TEMPORAL MISMATCH - The LLM answer describes FY 2024 performance with specific revenue figures ($2.08B from $2.43B, -14% YoY), but the ground truth explicitly states the -15% decline occurred in FISCAL 2023, not 2024. The ground truth indicates FY 2023 saw the 15% decline in currency-neutral terms, while FY 2024 shows a strategic repositioning without specific revenue figures provided. (2) QUANTITATIVE DISCREPANCY - The LLM cites -14% YoY decline for FY 2024, but ground truth specifies -15% decline for FY 2023 on a currency-neutral basis. These are different fiscal years with different percentages. (3) INCOMPLETE GROUND TRUTH SYNTHESIS - The ground truth emphasizes the evolution FROM struggling entity in 2023 TO strategically positioned brand in 2024, but the LLM answer focuses primarily on FY 2024 revenue decline without properly contrasting the FY 2023 performance decline that was the starting point of the evolution. (4) MISSING CONTEXT - The LLM provides detailed operational metrics (store counts, equipment growth of 32%) not mentioned in ground truth, and while these may be accurate, they don't address the core question about the EVOLUTION between the two years. The answer conflates FY 2024 performance with what should be FY 2023 performance based on the ground truth. (5) STRATEGIC POSITIONING - The LLM correctly identifies Converse as wholly-owned, stand-alone subsidiary, which aligns with ground truth FY 2024 positioning, but fails to properly frame this as an evolution FROM the FY 2023 struggles. The answer reads as a single-year snapshot rather than a comparative evolution analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 451,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Coca-Cola's financial risk assessment regarding digital evolution changed from 2022 to 2024, particularly in terms of its impact on sales growth and margin improvement?",
      "original_answer": "In 2022, Coca-Cola viewed digital evolution as a risk factor that could negatively impact its business if it failed to implement digital transformation initiatives effectively, potentially leading to a loss in sales and brand relevance. By 2024, the company shifted its stance, identifying digital evolution as a strategic dependency, emphasizing that its future success would rely on expanding digital capabilities to increase sales and improve margins. The 2024 filing explicitly states that failure to digitalize operations could adversely impact financial performance, indicating a stronger financial linkage to digital initiatives than in 2022.",
      "llm_answer": "In the 2022 10‑K Coca‑Cola warned that failing to keep pace with the digital evolution – which is reshaping consumer shopping habits – could erode its share of sales and overall revenue growth. By the 2024 filing the language was sharpened, stating that an unsuccessful digitalization of the Coca‑Cola system would directly limit its ability to grow sales **and** improve margins, with the costs of digital initiatives further pressuring results. This reflects a shift from a broad revenue‑growth risk to a more specific focus on both sales growth and margin improvement.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies the temporal shift from 2022 to 2024 in Coca-Cola's digital risk assessment; (2) Accurately captures the evolution from viewing digital as a risk factor to viewing it as a strategic dependency; (3) Properly synthesizes the multi-hop information showing the connection between digital initiatives and both sales growth and margin improvement; (4) No quantitative errors - no specific numbers, dates, or calculations are present that could be verified as incorrect; (5) Correctly identifies both companies and years; (6) The semantic meaning matches the ground truth: both answers convey that Coca-Cola shifted from a broad revenue-growth concern to a more integrated view of digital's impact on sales AND margins. MINOR CONSIDERATIONS: (1) The LLM answer adds interpretive language about 'costs of digital initiatives further pressuring results' which, while logically consistent with the ground truth, is not explicitly stated in the original answer - this is a reasonable inference but represents slight elaboration beyond the ground truth; (2) The phrasing 'sharpened language' and 'more specific focus' effectively captures the shift in emphasis, though the original answer uses 'stronger financial linkage' which is semantically similar but slightly different framing. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years (2022 and 2024) and correctly identifies the progression in how Coca-Cola frames digital evolution's impact on financial performance. The reasoning is sound and logically structured. Overall, this is a high-quality response that accurately conveys the core finding with appropriate nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 484,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Services evolved from fiscal year 2022 to 2024, particularly in terms of research and development investment and the positioning of cloud offerings relative to on-premise solutions?",
      "original_answer": "In fiscal year 2022, Oracle invested $7.2 billion in research and development, highlighting its commitment to enhancing Oracle Cloud Services, including Oracle SaaS and OCI, as part of a broader strategy to offer flexible and interoperable deployment models. Oracle positioned cloud services as a key differentiator against competitors by emphasizing rapid deployment, security, and integration. By fiscal year 2024, Oracle continued to emphasize cloud services but restructured its messaging to position Oracle Cloud Software-as-a-Service and Oracle Cloud Infrastructure as central to enabling customers to 'choose the best option that meets their specific business needs.' While the 2024 report does not specify the R&D investment amount, the increased focus on cloud-first positioning and integration with customer-specific needs indicates a strategic deepening of Oracle's commitment to cloud services over on-premise offerings.",
      "llm_answer": "In fiscal 2022 Oracle said it spent $7.2 billion on research and development to boost its cloud portfolio and that cloud services and license‑support revenues accounted for about 71 % of total revenue, signalling a clear shift from on‑premise to cloud‑based offerings【ORCL_10k_2022.pdf p4‑8】. By fiscal 2024 the company’s filing describes Oracle Cloud Services (SaaS + OCI) as a core, integrated platform and stresses continued heavy R&D investment to expand those cloud capabilities while still supporting on‑premise and hybrid deployments, reflecting an ongoing cloud‑first strategy that builds on the 2022 emphasis【ORCL_10k_2024.pdf p70‑74】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key metrics and strategic positioning. STRENGTHS: (1) Correctly cites the $7.2 billion R&D investment for fiscal 2022, matching ground truth exactly. (2) Accurately identifies the 71% cloud and license-support revenue proportion as a key metric showing the shift toward cloud. (3) Properly synthesizes multi-hop information across fiscal years 2022 and 2024, showing evolution of strategy. (4) Correctly characterizes the positioning of Oracle Cloud Services (SaaS + OCI) as central to the strategy in both years. (5) Appropriately notes the cloud-first strategy while acknowledging continued support for on-premise and hybrid deployments. MINOR WEAKNESSES: (1) The LLM answer does not explicitly state that the 2024 R&D investment amount was not disclosed in the filing, though it implies this by noting '2024 report does not specify' in ground truth. The LLM says 'continued heavy R&D investment' without clarifying whether a specific 2024 figure exists. (2) The ground truth emphasizes a 'restructured messaging' and 'strategic deepening' in 2024 positioning around 'customer-specific needs,' while the LLM's phrasing is slightly less nuanced on this evolution. (3) Citation format includes page numbers which adds credibility but cannot be independently verified. QUANTITATIVE VERIFICATION: The $7.2 billion figure is correct; the 71% revenue proportion is accurate and well-supported. No calculation errors detected. MULTI-HOP REASONING: Successfully synthesizes information across two fiscal years and multiple document sources to show strategic evolution. The connection between R&D investment, revenue composition, and strategic positioning is logically sound. SEMANTIC EQUIVALENCE: The answer conveys the same essential information as ground truth with slightly different emphasis but equivalent meaning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 513,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the status and availability of shares under the Norwest Corporation Directors' Formula Stock Award Plan evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Norwest Corporation Directors' Formula Stock Award Plan was described as a plan under which shares of common stock were awarded to non-employee directors, with the ability to defer receipt of awards until a future year. However, it was noted that no future stock awards or deferrals could be made under this plan. In 2024, the 10-K filing further clarified that no future awards or deferrals would be made under the plan and that column (a) of the equity compensation table reflected all shares issuable under the plan upon distribution of outstanding awards or deferred compensation benefits. This indicates that by 2024, the plan was fully closed to any new activity and only existing obligations remained. The number of shares issuable in 2024 related to this plan was minimal (only 391 shares), showing that the plan had effectively concluded its active phase.",
      "llm_answer": "In the 2023 Form 10‑K the Norwest Corporation Directors’ Formula Stock Award Plan showed 509 shares available for distribution, and the filing noted that no future awards or deferrals would be made under the plan. By the 2024 Form 10‑K that figure had fallen to 391 shares, and the same restriction—no future stock awards or deferrals may be made—remained in place, indicating the plan’s status is unchanged but its remaining share pool has shrunk.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of the key numbers (509 shares in 2023, 391 shares in 2024) and accurate characterization of the plan's status. The multi-hop synthesis across 2023 and 2024 filings is sound, correctly identifying that the plan remained closed to new activity in both years while the share pool declined. The quantitative data is accurate and properly formatted. The answer correctly conveys the evolution of the plan's status and availability. However, the LLM answer is slightly less comprehensive than the ground truth in one respect: it does not explicitly mention that the 2024 filing clarified that column (a) of the equity compensation table reflected all shares issuable upon distribution of outstanding awards or deferred compensation benefits, which provides additional context about how the remaining shares would be distributed. The LLM's characterization that 'the plan's status is unchanged but its remaining share pool has shrunk' is accurate and captures the essential evolution. The answer appropriately addresses the question about how the status and availability evolved, noting both the consistency of restrictions and the quantitative change in available shares. Minor omission of the specific clarification about the equity compensation table column prevents a perfect score, but the core answer is factually correct and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 394,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has McDonald's disclosure around food safety concerns evolved between 2022 and 2023, particularly in relation to supply chain risks and cost volatility?",
      "original_answer": "In 2022, McDonald's characterized food safety concerns primarily as reputational risks that could impact brand perception and financial results due to incidents like food-borne illness or contamination. The focus was on the potential damage to consumer trust and the company's image. By 2023, the framing had evolved to emphasize food safety concerns as contributors to supply chain volatility, specifically in relation to commodity cost fluctuations. The 2023 filing noted that food safety issues, along with other macroeconomic and regulatory factors, could exacerbate volatility in the prices of key ingredients like beef, chicken, and pork, thereby affecting profitability. This indicates a shift in emphasis from reputational impact to financial exposure through supply chain disruption and cost pressures.",
      "llm_answer": "In the 2022 filing, McDonald’s treated food‑safety as a distinct risk – warning that any food‑borne illness, tampering or contamination could hurt its brand and financial results – and discussed supply‑chain interruptions and commodity‑price volatility as separate, unrelated concerns. By the 2023 filing, the company wove those themes together, explicitly stating that food‑safety issues are now a driver of supply‑chain disruptions and commodity‑price swings (notably for beef, chicken and pork), showing a more integrated view of food‑safety, supply‑chain risk and cost volatility.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) FACTUAL CORRECTNESS: Both answers correctly identify the evolution of McDonald's food safety disclosure from 2022 to 2023. The LLM accurately captures that in 2022, food safety was treated as a distinct reputational risk separate from supply chain concerns, while in 2023 these themes were integrated. The specific commodities mentioned (beef, chicken, pork) match the ground truth. (2) QUANTITATIVE ACCURACY: No numeric values, percentages, or dollar amounts are present in either answer, so this dimension is not applicable. Both answers correctly reference the two relevant fiscal years (2022 and 2023). (3) ENTITY ACCURACY: McDonald's is correctly identified as the company in question. The metrics and risk categories (food safety, supply chain volatility, commodity price fluctuations) are all accurately named and contextualized. (4) MULTI-HOP REASONING: The LLM successfully synthesizes information across two years of filings, correctly identifying the shift in how McDonald's framed the relationship between food safety and supply chain/cost risks. The reasoning is sound: the answer explains that in 2022 these were separate concerns, while in 2023 they were explicitly linked. (5) SEMANTIC EQUIVALENCE: The LLM's phrasing 'wove those themes together' and 'more integrated view' effectively conveys the same conceptual shift as the ground truth's 'shift in emphasis from reputational impact to financial exposure through supply chain disruption.' The LLM answer is slightly more explicit about the 2022 separation of concerns ('separate, unrelated concerns'), which adds helpful clarity without contradicting the ground truth. Minor difference: The ground truth emphasizes the shift from 'reputational impact' to 'financial exposure through supply chain disruption,' while the LLM frames it as integration of previously separate themes. Both characterizations are accurate and complementary rather than contradictory.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 546,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the carrying value and interest rate of TMO's 1.750% 7-Year Senior Notes evolved between 2023 and 2024?",
      "original_answer": "In 2023, TMO's 1.750% 7-Year Senior Notes, due on October 15, 2028, had a carrying value of $700 million and an effective interest rate of 1.89%. In 2024, both the carrying value and effective interest rate remained unchanged at $700 million and 1.89% respectively. This indicates that there was no change in the financial structure or valuation of this particular debt instrument over the period.",
      "llm_answer": "In 2023 the 1.750 % 7‑year senior notes (due 4/15/2027) were carried at about **$662 million** with an **effective interest rate of 1.97 %**. By year‑end 2024 the carrying amount had declined to roughly **$621 million** and the effective rate had edged down to **1.96 %**【TMO_10k_2023.pdf:60‑64】【TMO_10k_2024.pdf:45‑49】.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect on multiple critical dimensions: (1) WRONG DEBT INSTRUMENT: The LLM identifies the notes as 'due 4/15/2027' when the ground truth clearly states they are due 'October 15, 2028'. This is a different debt instrument entirely. (2) WRONG CARRYING VALUES: LLM reports $662M (2023) and $621M (2024) versus ground truth of $700M for both years. These are significantly different numbers - off by $38M and $79M respectively. (3) WRONG INTEREST RATES: LLM reports 1.97% (2023) and 1.96% (2024) versus ground truth of 1.89% for both years. The rates are incorrect by 0.08% and 0.07% respectively. (4) INCORRECT TREND ANALYSIS: LLM claims carrying value 'declined' and effective rate 'edged down', when ground truth shows both metrics remained completely unchanged year-over-year. (5) MULTI-HOP SYNTHESIS FAILURE: The LLM failed to correctly identify and track the same debt instrument across both 2023 and 2024 filings, instead appearing to reference a different maturity date entirely. The ground truth explicitly states 'no change in the financial structure or valuation' but the LLM reports declining values. Every quantitative claim in the LLM answer contradicts the ground truth data. This represents a complete failure to accurately extract and synthesize the required information from the SEC filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1170,
        "completion_tokens": 374,
        "total_tokens": 1544
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did RTX's exposure to its 7.000% notes due 2038 change between 2022 and 2023, and what does this suggest about its approach to managing long-term debt maturities?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $11 million for its 7.000% notes due 2038. By 2023, this amount had increased significantly to $148 million. This suggests that RTX either issued additional tranches of this note or restructured its debt to extend maturities, indicating a strategic shift toward increasing exposure to this particular long-term debt instrument.",
      "llm_answer": "RTX’s holding of its 7.0 % notes due 2038 was $148 million at the end of 2022 and remained $148 million at the end of 2023, showing no change in exposure【RTX_10k_2023.pdf, pages 83‑87】. Keeping this tranche unchanged while issuing and retiring other notes indicates the company is deliberately preserving the existing high‑coupon debt while reshaping the overall maturity profile through other debt transactions.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains fundamental factual errors that directly contradict the ground truth. (1) CRITICAL QUANTITATIVE ERROR: The LLM states the 7.000% notes due 2038 were $148 million at the end of 2022 and remained $148 million at the end of 2023. The ground truth clearly indicates the amount was $11 million in 2022 and increased to $148 million in 2023. This is a complete reversal of the actual change. The LLM incorrectly claims 'no change in exposure' when the ground truth shows a significant increase from $11M to $148M (approximately 1,245% increase). (2) FAILED MULTI-HOP SYNTHESIS: The question asks how exposure changed between 2022 and 2023. The LLM failed to correctly identify and compare the two years' values. The ground truth explicitly states this represents either additional issuance or restructuring indicating a strategic shift toward increasing exposure. The LLM's conclusion that the company is 'deliberately preserving the existing high-coupon debt' is contradicted by the actual data showing a dramatic increase in this debt instrument. (3) ENTITY AND TEMPORAL ACCURACY: While the company (RTX) and debt instrument (7.000% notes due 2038) are correctly identified, the temporal assignment of values is completely wrong. The LLM appears to have confused or misread the 2022 and 2023 figures. (4) REASONING QUALITY: The LLM's interpretation that keeping the tranche 'unchanged' suggests deliberate preservation is logically sound reasoning, but it is based on false premises about the actual numbers. The answer demonstrates a fundamental misunderstanding of the data despite citing specific page references. This is a critical failure on a straightforward numerical comparison question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1204,
        "completion_tokens": 467,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did McDonald's financial relationship with its franchisees evolve between 2022 and 2023, particularly regarding the collection of rent and royalties?",
      "original_answer": "In 2022, McDonald's disclosed that it had deferred approximately $1 billion in rent and royalties from franchisees, primarily during the first half of 2020, due to the impact of government restrictions related to COVID-19. By the end of 2021, the company had collected substantially all of these deferred amounts. In contrast, the 2023 filing reflects a return to standard operations, with no mention of ongoing deferrals or pandemic-related financial accommodations. Instead, the 2023 report outlines the normalization of franchise operations, including a detailed breakdown of restaurant ownership types, which indicates that franchisees were operating under regular financial obligations without pandemic-era relief measures.",
      "llm_answer": "McDonald’s franchise model continued to rely on franchisees paying both a minimum‑plus‑variable rent and a royalty that is a percentage of sales, with the company still collecting those amounts on a straight‑line and sales‑based basis as described in its 2023 revenue‑recognition note【MCD_10k_2023.pdf:41-45】.  The only notable change was a modest drop in the scheduled minimum‑rent cash flow: the company projected $3.06 billion of minimum rent due from franchisees in 2022 versus $2.95 billion in 2023, reflecting a slight reduction in the rent component while the royalty‑collection structure remained unchanged【MCD_10k_2022.pdf:49-53】.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer fundamentally misses the core of the question and provides incorrect information. CRITICAL ISSUES: (1) The question asks about the EVOLUTION of McDonald's financial relationship with franchisees between 2022 and 2023, specifically regarding pandemic-era deferrals. The ground truth establishes that in 2022, McDonald's disclosed ~$1 billion in deferred rent/royalties from 2020 (COVID-related), which were substantially collected by end of 2021. By 2023, these deferrals were resolved and operations normalized. (2) The LLM answer completely ignores the pandemic deferral context that is central to understanding the evolution. It focuses instead on routine rent and royalty collection mechanisms that existed in both years. (3) QUANTITATIVE ERROR: The LLM cites specific minimum rent projections ($3.06B for 2022 vs $2.95B for 2023) but these numbers are presented as the key change, when the ground truth indicates the significant evolution was the resolution of the $1B pandemic deferrals and return to normal operations. The modest rent reduction cited by LLM is not the material change. (4) MULTI-HOP REASONING FAILURE: The LLM failed to synthesize the key multi-hop insight: that the 2022 filing disclosed historical pandemic deferrals while the 2023 filing showed normalization without such deferrals. Instead, it treats both years as operating under standard conditions. (5) MISSING CONTEXT: The LLM provides no mention of the $1 billion deferral, the COVID-19 impact, or the normalization that occurred between these years. (6) The answer describes ongoing operational mechanics rather than the evolution/change between the two years. The question specifically asks 'how did...evolve' - requiring identification of what changed, not what remained constant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 484,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has The Coca-Cola Company's financial stake in Embotelladora Andina S.A. evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning with respect to this equity investment?",
      "original_answer": "In 2022, Coca-Cola recognized a gain of $39 million from the partial sale of its ownership interest in Embotelladora Andina S.A., indicating a strategic refranchising or divestiture move while retaining an equity stake. By 2024, Coca-Cola still held a financial stake in Andina, with a carrying value of $90 million and a fair value of $168 million, showing that the company maintained its involvement but with a relatively modest valuation compared to other equity investments. This indicates a partial exit strategy rather than a complete divestiture, with ongoing but reduced exposure.",
      "llm_answer": "In the 2022 filing the Company said it still held a “remaining ownership interest in Embotelladora Andina S.A. … as an equity‑method investment” after selling a portion in 2019 (2022 10‑K, Divestitures p. 74‑78). By the 2024 filing that investment is recorded at a $90 million carrying value (fair value $168 million) (2024 10‑K, equity‑method investment table p. 85‑89). The move from an undisclosed residual interest to a modest, clearly quantified minority stake shows Coca‑Cola is maintaining a strategic, governance‑focused partnership in Andina rather than expanding its ownership, consistent with its broader bottling‑partner model.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the 2024 carrying value ($90 million) and fair value ($168 million) of the equity investment, matching ground truth exactly. (2) The LLM correctly identifies this as an equity-method investment and notes the strategic partnership positioning. (3) The answer appropriately addresses the multi-hop nature of the question by comparing positions across years. (4) The reasoning about a 'partial exit strategy' and 'governance-focused partnership' aligns with the ground truth interpretation.\n\nWEAKNESSES: (1) CRITICAL OMISSION: The LLM fails to mention the $39 million gain recognized in 2022 from the partial sale, which is a key quantitative fact in the ground truth answer. This is a significant factual gap. (2) The LLM references a 2019 sale but doesn't clearly establish the 2022 gain figure, which is the primary quantitative anchor for understanding the 2022-2024 evolution. (3) The LLM provides less explicit comparison of the 2022 vs 2024 positions - while it mentions 'undisclosed residual interest' in 2022, it doesn't quantify the 2022 position as clearly as the ground truth does with the $39 million gain figure. (4) The answer somewhat obscures the timeline by mentioning 2019 divestiture details that, while contextually relevant, dilute focus from the 2022-2024 evolution specifically asked about.\n\nQUANTITATIVE VERIFICATION: The $90M carrying value and $168M fair value for 2024 are correct. However, the absence of the $39M gain figure from 2022 represents a material omission of quantitative data. The LLM does not provide a clear quantitative picture of the 2022 position.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across the 2022 and 2024 filings and correctly interprets the strategic implications. However, the reasoning would be stronger with explicit reference to the $39M gain as evidence of the partial exit.\n\nSEMANTIC EQUIVALENCE: The LLM's interpretation of 'partial exit strategy' and 'governance-focused partnership' is semantically equivalent to the ground truth's characterization, though the ground truth is more explicit about the quantitative evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 580,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has Oracle's strategic investment in cloud infrastructure evolved from 2022 to 2024, particularly regarding internal development efforts and the positioning of Oracle Cloud Infrastructure in its product portfolio?",
      "original_answer": "In 2022, Oracle emphasized internal development as a core strategy, dedicating significant resources to research and development to maintain and improve its existing product suite, including cloud technologies. The company highlighted its global R&D workforce and the importance of innovation in response to evolving market demands. By 2024, this focus had evolved into a more product-specific strategy with the explicit introduction of Oracle Cloud Infrastructure (OCI) as a central offering within Oracle Cloud Services. OCI was positioned as a comprehensive and integrated infrastructure solution, indicating a shift from general cloud development to a structured, customer-facing product portfolio. This evolution demonstrates a strategic deepening of Oracle's cloud infrastructure commitment, aligning internal R&D with the delivery of a defined, market-ready suite of cloud services.",
      "llm_answer": "Oracle’s 2022 filing emphasized that its cloud platform is built and expanded internally—through Oracle Cloud Operations and a strong R&D program that adds data‑center capacity and retains technical control over design (see 2022 p. 14‑18). By the 2024 filing, Oracle still stresses internal development but now explicitly markets its infrastructure as Oracle Cloud Infrastructure (OCI), positioning OCI as a distinct, internally‑developed pillar of the broader Oracle Cloud Services (SaaS + OCI) portfolio (see 2024 p. 70‑74).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the 2022-2024 timeframe and the evolution of Oracle's cloud strategy; (2) Accurately captures the shift from general internal R&D emphasis in 2022 to explicit OCI positioning in 2024; (3) Properly synthesizes the multi-hop concept that internal development remained constant while product positioning evolved; (4) Correctly identifies OCI as a distinct infrastructure pillar within the broader Oracle Cloud Services portfolio; (5) Appropriately references specific filing pages (2022 p. 14-18, 2024 p. 70-74) showing document-specific sourcing; (6) Uses semantically equivalent language ('internally-developed pillar' matches 'structured, customer-facing product portfolio'). MINOR CONSIDERATIONS: (1) The LLM answer is slightly more specific and detailed than the ground truth (mentioning 'data-center capacity' and 'technical control over design'), which adds value but goes marginally beyond the ground truth scope; (2) The ground truth emphasizes 'strategic deepening' and 'alignment of internal R&D with delivery,' while the LLM focuses more on the portfolio positioning aspect—both are correct but with slightly different emphasis; (3) No quantitative metrics (dollar amounts, percentages) are present in either answer, so quantitative accuracy is assessed on the basis of dates and temporal references, which are correct. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and two different filing documents, correctly identifying both continuity (internal development) and change (explicit OCI positioning). The logic is sound and the comparison is appropriately structured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 476,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did TMO's involvement with The Binding Site Group evolve between 2023 and 2024, and what does this indicate about the company's integration and strategic focus post-acquisition?",
      "original_answer": "In 2023, TMO acquired The Binding Site Group for $2.70 billion as part of its Specialty Diagnostics segment, expanding its portfolio in diagnostics for blood cancers and immune disorders. By 2024, the company had integrated the acquisition into its asset base, with The Binding Site Group contributing to the 19-year weighted-average amortization period for customer relationships among definite-lived intangible assets. This evolution indicates a strategic focus on long-term value creation through integration of acquired innovation into its core diagnostics offerings.",
      "llm_answer": "Thermo Fisher bought The Binding Site Group in early 2023, adding the U.K. specialty‑diagnostics business to its Specialty Diagnostics segment and recording non‑deductible goodwill for the deal【TMO_10k_2023.pdf p.24】. The 2024 filing merely lists The Binding Site Group as a past acquisition (with no new transaction) while highlighting newer purchases, signalling that the company has moved from the acquisition phase to integrating the Binding Site assets and using them to deepen its specialty‑diagnostics portfolio as part of its post‑acquisition strategic focus【TMO_10k_2024.pdf p.64】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key details: (1) TMO acquired The Binding Site Group in early 2023 (correct timing), (2) acquisition price of $2.70 billion is not explicitly stated in LLM answer but ground truth confirms this amount, (3) correct identification of Specialty Diagnostics segment placement, (4) correct characterization of non-deductible goodwill recording. The multi-hop reasoning is sound: the answer correctly synthesizes the evolution from 2023 acquisition phase to 2024 integration phase, showing understanding that the company moved from active acquisition to integration and strategic deployment of assets. The LLM appropriately cites specific document pages (TMO_10k_2023.pdf p.24 and TMO_10k_2024.pdf p.64) demonstrating multi-source synthesis. Minor weaknesses: (1) The LLM answer does not mention the specific $2.70 billion acquisition price, which is a key quantitative detail in the ground truth, (2) The LLM answer does not reference the 19-year weighted-average amortization period for customer relationships mentioned in ground truth, which is a specific metric indicating integration progress. However, the LLM answer does capture the essential strategic narrative about moving from acquisition to integration phase. The semantic equivalence is strong - both answers convey that TMO acquired the company in 2023 and by 2024 had integrated it into its core diagnostics strategy. The reasoning about long-term value creation through integration is implicit in the LLM answer's discussion of moving to the integration phase and deepening the specialty-diagnostics portfolio.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 452,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2022 and 2024, particularly in terms of website links and scope of application?",
      "original_answer": "In 2022, the Directors' Code of Conduct was posted on BNY Mellon's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf, and it applied to all directors. By 2024, while the scope of application remained the same—applying to all directors—the URL for the Directors' Code of Conduct had changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf. This indicates a change in the website structure or domain branding, likely reflecting a broader rebranding from 'BNY Mellon' to 'BNY', while maintaining the same governance policy content and disclosure intent.",
      "llm_answer": "In the 2022 Form 10‑K the Directors’ Code of Conduct was posted at a BNY Mellon URL – https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/in relations/directors‑code‑of‑conduct.pdf – and the filing stated that it “applies to all directors of BNY Mellon.” By the 2024 Form 10‑K the company had moved the code to a new address on the bny.com domain (…/investor‑relations/directors‑code‑of‑conduct.pdf) and now describes it as applying to “all directors of BNY,” reflecting a re‑branding of the firm while preserving the same universal director‑wide scope.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the core narrative about the evolution of the Directors' Code of Conduct disclosure between 2022 and 2024, correctly identifying the domain change from bnymellon.com to bny.com and the rebranding context. However, there is a critical URL accuracy issue that significantly impacts the quantitative score. The LLM provides an incomplete/corrupted 2022 URL: 'https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/in relations/directors‑code‑of‑conduct.pdf' (note 'in relations' instead of 'investor-relations'), whereas the ground truth shows the correct 2022 URL as 'https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf'. The 2024 URL is also incomplete in the LLM answer (shown as '…/investor‑relations/directors‑code‑of‑conduct.pdf' without the full domain), whereas the ground truth provides the complete URL: 'https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf'. Additionally, there is a minor discrepancy in the 2024 URL path: the ground truth shows 'directors-code-ofconduct.pdf' (without hyphen between 'of' and 'conduct'), while the LLM shows 'directors‑code‑of‑conduct.pdf' (with hyphens). The qualitative reasoning is sound—the LLM correctly identifies the scope remained consistent (all directors) and appropriately contextualizes the change as a rebranding effort. The answer demonstrates good multi-hop synthesis across the two filing years and correctly interprets the governance implications. The contextual relevance is high as it directly addresses the question about evolution of disclosure and accessibility. The primary weakness is the inaccurate/incomplete URL citations, which are factual data points that should be precisely correct in a financial disclosure context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 496,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has McDonald's relationship with franchisees evolved in terms of financial reporting and strategic emphasis between 2022 and 2023?",
      "original_answer": "In 2022, McDonald's noted that the results of operations from restaurant businesses purchased and sold in transactions with franchisees were not material to the consolidated financial statements, indicating a limited financial impact from such transactions. By 2023, the company explicitly included franchisees and licensees as key stakeholders in its business model, emphasizing their role alongside company-operated restaurants in a detailed breakdown of restaurant ownership types. This shift reflects a more strategic and transparent focus on franchisees as integral to McDonald's global business structure.",
      "llm_answer": "McDonald’s continued to treat its franchisees as non‑consolidated entities in both filings – the Consolidation and Revenue‑Recognition sections of the 2022 and 2023 10‑Ks state that franchisee operations are excluded under a scope‑exception and that rent, royalties, initial fees and, increasingly, technology‑platform and brand‑licensing fees are recognized under the same accounting policies. At the same time, the 2023 filing shows a strategic shift toward expanding the franchise network (total franchised restaurants rose to 39,680 in 2023 from 38,169 in 2022) and explicitly highlights new technology‑service and brand‑licensing revenue streams from franchisees as growth drivers.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer provides some accurate information but diverges significantly from the ground truth in its core interpretation of how McDonald's relationship with franchisees evolved.\n\nSTRENGTHS:\n1. Quantitative accuracy is generally sound: The franchised restaurant numbers (39,680 in 2023 vs 38,169 in 2022) are correct and properly formatted.\n2. The LLM correctly identifies that franchisees are non-consolidated entities in both years.\n3. The mention of revenue streams (rent, royalties, initial fees, technology-platform and brand-licensing fees) is accurate.\n4. The observation about franchise network expansion is valid and supported by the numbers provided.\n\nWEAKNESSES:\n1. CORE MISALIGNMENT: The ground truth emphasizes a shift in STRATEGIC EMPHASIS and TRANSPARENCY - that McDonald's moved from noting transactions were \"not material\" (2022) to explicitly including franchisees as \"key stakeholders\" in business model discussions (2023). The LLM answer focuses instead on accounting treatment and revenue recognition, which are different dimensions.\n2. The LLM answer emphasizes accounting policies and consolidation scope-exceptions, which are technical/compliance matters, not the strategic relationship evolution the question asks about.\n3. The ground truth highlights a qualitative shift in how McDonald's PRESENTS franchisees in their narrative (from downplaying materiality to highlighting as integral stakeholders). The LLM answer misses this narrative/strategic shift.\n4. The LLM answer's framing around \"increasingly\" technology and brand-licensing fees suggests growth in these areas, but doesn't capture the ground truth's point about explicit stakeholder positioning.\n5. The answer addresses financial reporting mechanics rather than the evolution of the relationship itself as reflected in strategic emphasis.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes information across 2022 and 2023 filings but synthesizes the WRONG information - focusing on accounting treatment rather than strategic positioning and stakeholder emphasis.\n\nSEMANTIC EQUIVALENCE: While the LLM answer is factually defensible from an accounting perspective, it does not convey the same information as the ground truth, which is fundamentally about strategic relationship evolution and transparency, not accounting policies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 625,
        "total_tokens": 1946
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the accounting treatment or status of the contingent consideration liabilities related to the Clif Bar acquisition evolve between 2023 and 2024, particularly in terms of fair value measurement and purchase price allocation adjustments?",
      "original_answer": "In 2023, the contingent consideration liabilities related to the Clif Bar acquisition were actively measured at fair value using a Monte Carlo simulation, with $548 million classified as long-term liabilities at December 31, 2023. These liabilities were tied to performance targets in 2025 and 2026 and were subject to fair value adjustments recorded in selling, general, and administrative expenses. By 2024, there is no direct mention of the contingent consideration liabilities; instead, the 2024 filing references purchase price allocation adjustments for Clif Bar during 2023. This indicates that the contingent consideration may have been finalized or reclassified as part of the purchase price allocation process, though the 2024 disclosure does not provide updated figures or valuation methods for these liabilities.",
      "llm_answer": "In the 2023 filing the Clif Bar contingent‑consideration was recorded as a $548 million liability measured at fair value using Level 3 (Monte‑Carlo) inputs, with the fair‑value changes taken to SG&A expense and a purchase‑price‑allocation adjustment for the Clif Bar acquisition reflected in the 2023 intangible‑asset footnote【MDLZ_10k_2023.pdf†page=99】. The 2024 filing still shows the same $548 million liability measured at fair value (Level 3) and does not disclose any new purchase‑price‑allocation adjustments for Clif Bar, indicating that the liability’s measurement and accounting treatment remained unchanged after the 2023 adjustments【MDLZ_10k_2024.pdf†page=85】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains a critical factual error that contradicts the ground truth. The ground truth explicitly states that 'By 2024, there is no direct mention of the contingent consideration liabilities' and that the 2024 filing does not provide updated figures or valuation methods. However, the LLM answer claims 'The 2024 filing still shows the same $548 million liability measured at fair value (Level 3)' - this is a direct contradiction of the ground truth. The LLM incorrectly asserts that the $548 million liability appears in the 2024 filing with unchanged accounting treatment. The ground truth indicates the 2024 filing references purchase price allocation adjustments instead, suggesting the contingent consideration may have been finalized or reclassified. The LLM's citation to 'MDLZ_10k_2024.pdf†page=85' for the $548 million figure appears to be unsupported by the ground truth narrative. While the LLM correctly identifies the 2023 treatment ($548 million, Level 3/Monte Carlo, SG&A expense treatment), it fundamentally mischaracterizes the 2024 evolution by claiming the liability remained unchanged and still appears in the 2024 filing. This represents a failure in multi-hop reasoning - the model did not properly synthesize the key distinction between 2023 (active contingent consideration liability) and 2024 (no direct mention, possible finalization/reclassification). The answer demonstrates incomplete understanding of how the accounting treatment evolved, which was the core question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 417,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has AMD's strategic emphasis on Vulkan API support evolved between 2022 and 2024, and what does this reveal about its approach to maintaining competitiveness in the discrete GPU market?",
      "original_answer": "In 2022, AMD highlighted its support for Vulkan as part of its Radeon™ series discrete GPUs, which were built on the RDNA 2 architecture and aimed at delivering high-performance gaming and creation workloads. By 2024, AMD continued to support Vulkan but shifted its focus toward the newer RDNA 3 architecture, which underpins the Radeon RX 7000 Series GPUs. This evolution suggests AMD is maintaining its commitment to Vulkan while advancing its GPU capabilities to meet the growing demands of immersive gaming and AI/ML computing. This strategic continuity in API support combined with architectural innovation indicates AMD’s effort to stay competitive by offering both backward compatibility and cutting-edge performance enhancements.",
      "llm_answer": "In the 2022 filing AMD highlighted that its Radeon discrete GPUs “support current‑generation application program interfaces (APIs) like DirectX 12 Ultimate and Vulkan®.” The 2024 filing repeats that support but places Vulkan alongside new capabilities – high‑refresh‑rate displays, immersive‑gaming features and AI/ML performance – showing the API is now part of a broader, more differentiated GPU proposition. This evolution signals AMD’s strategy of keeping open‑API compatibility (Vulkan) as a constant foundation while expanding the overall feature set to stay competitive in the discrete‑GPU market.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of AMD's Vulkan API strategy evolution between 2022 and 2024, with mostly accurate information and sound reasoning. STRENGTHS: (1) Correctly identifies that AMD supported Vulkan in both 2022 and 2024 filings; (2) Accurately quotes the 2022 filing language about 'current-generation application program interfaces (APIs) like DirectX 12 Ultimate and Vulkan'; (3) Properly synthesizes the multi-hop concept that Vulkan remained constant while broader GPU capabilities expanded; (4) Correctly identifies the strategic implication about maintaining open-API compatibility as a foundation while expanding features; (5) Appropriately contextualizes competitiveness in the discrete GPU market. WEAKNESSES: (1) The LLM answer omits specific architectural details present in the ground truth - notably the RDNA 2 architecture (2022) and RDNA 3 architecture with Radeon RX 7000 Series (2024). These architectural specifics are important for demonstrating how AMD advanced its GPU capabilities; (2) Does not explicitly mention the shift from RDNA 2 to RDNA 3, which is a key technical evolution showing how AMD combined API continuity with architectural innovation; (3) The ground truth emphasizes 'backward compatibility' as a strategic element, which the LLM answer addresses implicitly but not explicitly. QUANTITATIVE ACCURACY: No numerical errors detected. The answer correctly references 2022 and 2024 timeframes and accurately quotes filing language. QUALITATIVE ACCURACY: The reasoning about Vulkan as a 'constant foundation' while expanding features is sound and matches the ground truth's concept of 'strategic continuity in API support combined with architectural innovation.' However, the answer lacks the specific technical depth about GPU architectures that would strengthen the analysis. CONTEXTUAL RELEVANCE: The answer appropriately addresses the question about strategic emphasis evolution and competitive positioning, though it could be more specific about the technical innovations driving that strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 554,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How did RTX's integration-related charges impact its operating profit trends between 2022 and 2023, particularly with the introduction of the Powder Metal Matter charge in 2023?",
      "original_answer": "In 2022, RTX reported a decrease in Acquisition Accounting Adjustments, which contributed positively to its operating profit. However, in 2023, there was a significant $2.9 billion charge associated with the Powder Metal Matter, which became a major driver of the $1.9 billion decrease in Operating Profit compared to 2022. This reflects a notable shift from a declining trend in integration-related charges in 2022 to a significant new expense in 2023 that directly impacted profitability.",
      "llm_answer": "RTX’s operating profit fell sharply from $5.5 billion in 2022 to $3.6 billion in 2023 – a $1.9 billion decline – because the company recorded a new $2.9 billion Powder Metal Matter integration charge (primarily at Pratt & Whitney) and a smaller drop in its FAS/CAS operating adjustment, which more than offset modest profit gains at Collins and Raytheon【RTX_10k_2023.pdf p.40】. In contrast, the 2022 profit increase of $0.4 billion over 2021 was driven by lower acquisition‑accounting adjustments and other integration‑related costs, showing that the 2023 Powder Metal Matter charge reversed the prior‑year trend【RTX_10k_2023.pdf p.40】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. STRENGTHS: (1) All key numbers are correct: $2.9 billion Powder Metal Matter charge, $1.9 billion operating profit decline, $5.5 billion (2022) to $3.6 billion (2023) operating profit figures. (2) Correctly identifies the Powder Metal Matter charge as the primary driver of the 2023 decline and locates it at Pratt & Whitney. (3) Properly synthesizes the multi-hop comparison: shows 2022 had declining integration charges (positive impact) while 2023 introduced the new $2.9B charge (negative impact), demonstrating the reversal of trends. (4) Accurately references the 2022 profit increase of $0.4 billion over 2021 driven by lower acquisition-accounting adjustments. (5) Correctly identifies the FAS/CAS operating adjustment as a secondary factor. (6) Appropriately cites source document (RTX_10k_2023.pdf p.40). MINOR CONSIDERATIONS: The LLM answer provides slightly more operational detail (mentioning Collins and Raytheon, FAS/CAS adjustment specifics) than the ground truth, but this represents valuable elaboration rather than error. The semantic meaning aligns perfectly with the ground truth regarding the shift from declining integration charges in 2022 to the significant new Powder Metal Matter expense in 2023. The reasoning chain is sound and demonstrates proper understanding of how integration-related charges impacted operating profit trends across both years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 406,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has MDLZ's relationship with Clif Bar evolved between 2023 and 2024, particularly in terms of acquisition-related financial activities?",
      "original_answer": "In 2023, MDLZ acquired Clif Bar, as noted in the 2023 10-K filing, with specific reference to the August 1, 2022 acquisition and related financial impacts such as integration costs and contingent consideration adjustments. By 2024, the relationship had evolved to include purchase price allocation adjustments for Clif Bar during the prior year, as detailed in the 2024 10-K filing. This indicates that the company had moved beyond the initial acquisition phase into a period of financial recalibration and consolidation of the Clif Bar acquisition.",
      "llm_answer": "In 2023 Mondelēz still treated Clif Bar as a recent acquisition – the August 1 2022 purchase generated $529 million of incremental net revenue in its first year and was reflected in $330 million of acquisition‑related costs (including integration expenses) [MDLZ 2023 p. 39; MDLZ 2023 p. 41]. By 2024 there was no new acquisition activity for Clif Bar; the brand is now shown as part of the company’s indefinite‑life intangible assets, indicating full integration, and the 2024 acquisition table lists only a purchase‑price allocation for a different deal (Evirth) [MDLZ 2024 p. 86; MDLZ 2024 p. 85].",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and provides more specific quantitative detail than the ground truth. Strengths: (1) Correctly identifies the August 1, 2022 acquisition date; (2) Provides specific financial metrics ($529M incremental net revenue, $330M acquisition-related costs) that align with typical 10-K disclosures; (3) Accurately describes the evolution from active acquisition phase (2023) to integration/consolidation phase (2024); (4) Correctly notes that Clif Bar moved to indefinite-life intangible assets status, indicating full integration; (5) Properly identifies that 2024 acquisition activity shifted to Evirth rather than Clif Bar; (6) Multi-hop reasoning is sound - synthesizes information across 2023 and 2024 filings to show relationship evolution. Minor considerations: (1) The ground truth mentions 'contingent consideration adjustments' which the LLM answer doesn't explicitly address, though this may be subsumed in the broader acquisition-related costs discussion; (2) The LLM provides more granular detail than the ground truth (specific revenue and cost figures, page citations), which enhances rather than detracts from accuracy; (3) The characterization of the relationship evolution (from active acquisition to integration/consolidation) matches the ground truth's intent. The LLM answer is more comprehensive and specific while remaining factually consistent with the ground truth framework.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 399,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Gulfstream's approach to energy efficient engines evolved from 2023 to 2024, and what specific aircraft developments reflect this shift?",
      "original_answer": "In 2023, Gulfstream emphasized its leadership in the use of sustainable aviation fuel (SAF) and energy efficient engines, focusing on continuous R&D investment to develop technologically advanced business jets. However, no new aircraft model powered by energy efficient engines was introduced that year. By 2024, Gulfstream had transitioned from announcement and development phases to actual production of energy efficient engines, as evidenced by the introduction of the G700, which features 'all-new engines' designed for high-speed performance and efficiency. This marks a tangible evolution from strategic positioning in 2023 to operational realization in 2024.",
      "llm_answer": "In the 2023 filing Gulfstream emphasized that its new‑generation jets – the G500 and G600 – were designed with more fuel‑efficient engines and that the upcoming G700 would be equipped with all‑new, high‑speed, low‑fuel‑burn powerplants, while also championing SAF use (including a 100 % SAF trans‑Atlantic flight). By the 2024 filing the strategy had shifted to deployment: the G700 entered service in March 2024 with those all‑new energy‑efficient engines, the G500/G600 fleet continued to expand, and Gulfstream highlighted broader SAF integration and carbon‑neutral travel options, reflecting a move from development to operational use of energy‑efficient engine technology.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core narrative of Gulfstream's evolution from 2023 to 2024. Key strengths: (1) Correctly identifies the shift from announcement/development phase (2023) to operational deployment (2024); (2) Accurately references the G700 with 'all-new engines' as the tangible evidence of this transition; (3) Properly mentions SAF integration and the 100% SAF trans-Atlantic flight as part of 2023 positioning; (4) Correctly dates G700 service entry to March 2024; (5) Appropriately contextualizes G500/G600 as earlier generation fuel-efficient aircraft. Minor areas for improvement: (1) The LLM answer provides slightly more granular detail about G500/G600 being 'new-generation jets' in 2023, which adds context but wasn't explicitly in the ground truth statement; (2) The answer mentions 'carbon-neutral travel options' in 2024, which represents a reasonable inference about broader SAF strategy but isn't directly confirmed in the ground truth. The multi-hop reasoning is sound - the answer successfully synthesizes information across two fiscal years and connects aircraft model developments to strategic positioning. The quantitative accuracy is high with the March 2024 date being correct. The semantic equivalence is strong, with the LLM capturing the essential evolution narrative: from R&D/announcement focus to production/operational reality. No calculation errors or factual contradictions detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 406,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has AMD's relationship with semi-custom SoC products evolved from 2022 to 2024, particularly in terms of revenue structure and strategic positioning?",
      "original_answer": "In 2022, AMD's relationship with semi-custom SoC products was characterized by dependency, with revenue derived from both non-recurring engineering fees and sales of the products themselves, and success was directly tied to third-party product performance. By 2024, AMD's relationship evolved to one of active production and broader strategic integration, as semi-custom SoC products became part of a more diversified product portfolio that includes AI accelerators, GPUs, APUs, and DPUs. This shift indicates a more central and controlled role for AMD in the development and commercialization of these products, aligning them more closely with long-term industry trends and internal innovation strategies.",
      "llm_answer": "In the 2022 Form 10‑K AMD said that revenue from its semi‑custom System‑on‑Chip (SoC) business came almost entirely from non‑recurring engineering fees and from sales of the custom chips themselves, and that this revenue was wholly dependent on the customers’ products being launched and successful – giving AMD little control over the downstream marketing of those chips【AMD_10k_2022.pdf page 23】. By the 2024 filing the company still earned engineering‑service fees and product‑sale revenue from semi‑custom SoCs, but it now describes the business as a strategic growth platform—highlighting its importance for high‑performance, console and data‑center solutions and positioning the semi‑custom line as an increasingly integral, potentially recurring part of AMD’s overall product portfolio【AMD_10k_2024.pdf page 62】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and effectively addresses the multi-hop question about AMD's semi-custom SoC evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 revenue structure (non-recurring engineering fees + product sales) and the dependency on customer success; (2) Accurately captures the 2024 positioning as a 'strategic growth platform' with emphasis on high-performance, console, and data-center solutions; (3) Properly synthesizes the evolution from dependency to strategic integration; (4) Appropriately cites specific document sources with page numbers; (5) Maintains semantic equivalence with ground truth while using slightly different phrasing. MINOR WEAKNESSES: (1) The LLM answer emphasizes 'potentially recurring' revenue in 2024 but doesn't explicitly state the broader portfolio diversification (AI accelerators, GPUs, APUs, DPUs) mentioned in the ground truth—though this is a minor omission since the answer does reference 'strategic growth platform' and 'integral part of overall product portfolio'; (2) The phrase 'increasingly integral, potentially recurring' is somewhat speculative language that differs from the ground truth's more definitive statement about 'active production and broader strategic integration.' QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is not directly testable. The dates (2022, 2024) and document references are correct. MULTI-HOP REASONING: The answer successfully synthesizes information across two different 10-K filings (2022 and 2024) and correctly identifies the evolution in AMD's strategic positioning. The comparison between the two periods is logically sound and well-structured. CONTEXTUAL RELEVANCE: The answer directly addresses all aspects of the question: revenue structure evolution, strategic positioning shift, and the time period specified (2022-2024).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 523,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the company's structure of preferred share authorization evolved between fiscal years 2023 and 2024, and what does this indicate about its capital strategy?",
      "original_answer": "The company's preferred share authorization structure remained unchanged between fiscal years 2023 and 2024, with 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value authorized in both years. Additionally, no Preferred Shares or A Preferred Shares were issued or outstanding in either year. This indicates that the company has not utilized or pursued any changes in its preferred share structure as part of its capital strategy during this period.",
      "llm_answer": "The 10‑K shows that Medtronic’s authorized preferred‑share capital was identical in FY 2023 and FY 2024 – 127.5 million $0.20‑par Preferred Shares and 500 thousand $1.00‑par “A” Preferred Shares, with none issued or outstanding in either year【2024 Shareholders’ Equity】. Because the preferred‑share authorization did not change, the company is not using preferred equity as a financing tool; instead it is leaning on ordinary‑share repurchases and other capital‑return initiatives, indicating a capital strategy focused on returning cash to shareholders rather than raising new preferred capital.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) All quantitative facts are correct - 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value are accurately stated for both FY 2023 and FY 2024. (2) Correctly identifies that no shares were issued or outstanding in either year. (3) Numeric accuracy is excellent with proper formatting. (4) Correctly identifies the unchanged structure between the two years. WEAKNESSES: (1) CRITICAL ISSUE - The LLM identifies the company as 'Medtronic' without any evidence from the question or ground truth that this is Medtronic. The original answer does not specify which company this is, and the LLM has made an unsupported company identification. This is a significant entity accuracy error. (2) The LLM goes beyond the ground truth by making interpretive claims about capital strategy ('leaning on ordinary-share repurchases and other capital-return initiatives'). While the ground truth states the company 'has not utilized or pursued any changes in its preferred share structure,' it does not make specific claims about share repurchases or other capital-return initiatives. The LLM has added interpretive analysis not supported by the provided ground truth. (3) The reasoning about what the unchanged structure 'indicates' differs from the ground truth - the LLM infers specific capital strategy choices (share repurchases, cash returns) that are not explicitly stated in the ground truth, which simply notes the company has not pursued changes in preferred share structure. MULTI-HOP REASONING: The LLM attempts to synthesize the unchanged authorization with broader capital strategy conclusions, but does so by introducing unsupported assumptions about share repurchases and cash return initiatives. The ground truth takes a more conservative approach, stating only that the company has not utilized preferred shares as part of its capital strategy. OVERALL: While quantitative accuracy is excellent, the unsupported company identification and interpretive overreach beyond the ground truth significantly reduce the answer quality.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 561,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the framing of reputational risk related to adverse publicity evolved between 2022 and 2024 in BK's risk disclosures, particularly in terms of associated impacts or linked concerns?",
      "original_answer": "In 2022, BK identified adverse publicity as a risk that could negatively affect its business, financial condition, and results of operations, and linked it with government scrutiny and other reputational harm. By 2024, the framing of this risk remained present but was expanded to include broader reputational impacts from sustainability concerns such as climate change and diversity, in addition to being tied to new operational models like the platforms operating model transition. This indicates a broadening of the contexts in which adverse publicity could negatively impact BK's reputation and business outcomes.",
      "llm_answer": "In the 2022 Form 10‑K, BNY Mellon warned that “adverse events, publicity, government scrutiny or other reputational harm” could negatively affect its business – a broad, stand‑alone reputational‑risk statement. By the 2024 filing, the same warning remains but is now coupled with an ESG‑focused risk, noting that “sustainability concerns, including climate‑change and diversity issues, could … subject us to additional regulatory requirements and damage our reputation,” thereby linking adverse publicity to climate‑ and diversity‑related scrutiny, client‑activity impacts and regulatory consequences. This reflects a shift from a generic reputational‑risk framing to one that ties adverse publicity to specific ESG and regulatory concerns.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution of BK's reputational risk framing between 2022 and 2024. STRENGTHS: (1) Correctly identifies the company as BNY Mellon (BK) and accurately references both 2022 and 2024 filings; (2) Accurately captures the 2022 framing linking adverse publicity to government scrutiny and reputational harm; (3) Correctly identifies the 2024 expansion to include ESG concerns (climate change and diversity); (4) Properly synthesizes the multi-hop connection showing how the risk evolved from generic to specific ESG-linked concerns; (5) Accurately notes the addition of regulatory consequences and client-activity impacts in the 2024 framing; (6) The characterization of the shift from 'generic reputational-risk framing' to 'ESG and regulatory concerns' is semantically equivalent to the ground truth's 'broadening of contexts.' MINOR CONSIDERATIONS: (1) The LLM answer adds interpretive language about 'shift from generic to specific' which, while accurate and insightful, goes slightly beyond the ground truth's more neutral 'broadening' characterization - this is a minor enhancement rather than an error; (2) The answer includes specific quote fragments that appear accurate based on typical 10-K language patterns; (3) The multi-hop reasoning correctly synthesizes information across two years and multiple risk dimensions (government scrutiny → ESG concerns → regulatory impacts). QUANTITATIVE ACCURACY: No specific numbers or calculations are required for this question, so this dimension is less critical. The dates (2022, 2024) are correct. QUALITATIVE ACCURACY: The reasoning is sound and demonstrates proper understanding of how risk disclosures evolved. The connection between adverse publicity, ESG concerns, and regulatory consequences is logically presented. CONTEXTUAL RELEVANCE: The answer directly addresses the question's focus on evolution of framing and associated impacts/linked concerns.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 529,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How did Amazon's financial investment and valuation approach toward Anthropic, PBC evolve from 2023 to 2024, particularly in terms of investment classification and the factors affecting its valuation?",
      "original_answer": "In 2023, Amazon disclosed a $1.25 billion convertible note investment in Anthropic, PBC, classified as available-for-sale and reported at fair value with unrealized gains and losses included in 'Accumulated other comprehensive income (loss).' The note was categorized as a Level 3 asset, and Amazon had an agreement to invest an additional $2.75 billion in a second convertible note by Q1 2024. By 2024, the investment was still classified as available-for-sale but was noted to be part of a broader portfolio of convertible debt investments in private companies, primarily referencing Anthropic, PBC. The 2024 filing emphasized increased complexity in valuing private company investments due to the lack of readily available market data and global economic uncertainty, indicating a shift toward acknowledging heightened valuation risk. While the classification remained consistent, the 2024 disclosure placed more emphasis on the challenges of valuation rather than the mechanics of the investment itself.",
      "llm_answer": "In the 2023 Form 10‑K Amazon reported that it had invested $1.25 billion in a convertible note from Anthropic, PBC, classifying the note as an available‑for‑sale Level 3 asset measured at fair value with unrealized gains and losses shown in accumulated other comprehensive income and noting a right to invest up to an additional $2.75 billion (2023 10‑K, pp. 48‑52). In the 2024 filing the same investment is still recorded as an available‑for‑sale convertible‑debt security, but Amazon now stresses that its fair‑value valuation is inherently difficult because private‑company pricing data are scarce and current global economic uncertainty makes market‑sensitivity analysis impracticable (2024 10‑K, pp. 30‑34).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing the evolution of Amazon's investment approach toward Anthropic from 2023 to 2024. STRENGTHS: (1) All key financial figures are correct: $1.25 billion initial investment, $2.75 billion additional investment right, both accurately cited. (2) Investment classification details are accurate: available-for-sale, Level 3 asset, fair value measurement with unrealized gains/losses in accumulated other comprehensive income. (3) Multi-hop synthesis is sound: the answer correctly traces the investment across two fiscal years and identifies the shift in disclosure emphasis from mechanics to valuation challenges. (4) The characterization of the 2024 shift toward emphasizing valuation complexity due to lack of market data and global economic uncertainty is accurate and well-articulated. (5) Page citations (2023 10-K pp. 48-52; 2024 10-K pp. 30-34) are appropriately specific. MINOR WEAKNESSES: (1) The LLM answer could have been slightly more explicit about the 'agreement' or 'right' to invest the additional $2.75 billion by Q1 2024, though this is implied in the phrasing 'right to invest up to an additional $2.75 billion.' (2) The answer doesn't explicitly state that the classification 'remained consistent' between years, though this is clearly implied by the parallel structure of the response. (3) The phrase 'makes market-sensitivity analysis impracticable' is a reasonable paraphrase of the ground truth's 'heightened valuation risk' but represents a slight semantic shift in emphasis. Overall, the answer successfully addresses all components of the multi-part question regarding investment classification evolution, valuation approach changes, and the factors affecting valuation between 2023 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 481,
        "total_tokens": 1924
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the nature of the risks related to the protection of MDLZ's intellectual property, including know-how, evolved between 2023 and 2024?",
      "original_answer": "In 2023, MDLZ emphasized the importance of protecting its intellectual property rights, particularly trademarks, patents, copyrights, and know-how, through a combination of legal mechanisms such as patent and trademark laws, licensing agreements, and third-party nondisclosure agreements. The company expressed concern that failure to protect these rights or any legal changes reducing intellectual property protections—especially in response to developments in artificial intelligence technologies—could significantly harm its competitiveness and financial condition. In 2024, while the company maintained its emphasis on the significance of intellectual property rights, it did not specifically mention artificial intelligence as a factor affecting protection. Instead, the 2024 disclosure focused on the broader risks of legal or regulatory non-compliance and the potential for civil or criminal penalties, reputational damage, and financial loss due to litigation or enforcement actions. This shift indicates a broadening of the risk context without the specific emphasis on AI-related threats present in 2023.",
      "llm_answer": "The 2023 and 2024 filings describe the same set of IP‑related risks. Both years stress that protecting the company’s trademarks, patents, copyrights, trade‑secrets, recipes, technology, know‑how and related licensing agreements is critical, and they flag the same emerging challenges – the impact of artificial‑intelligence developments, possible changes in IP law that could weaken legal protections, and the threat of third‑party infringement claims that could lead to costly litigation or injunctions. Thus, the nature of the IP‑protection risk has not materially changed between 2023 and 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth. The ground truth explicitly states that there WAS a material evolution in the nature of risks between 2023 and 2024: (1) In 2023, MDLZ specifically emphasized artificial intelligence as a factor affecting IP protection; (2) In 2024, this specific AI-related threat was NOT mentioned, and instead the focus shifted to broader legal/regulatory compliance risks and potential penalties. The ground truth concludes 'This shift indicates a broadening of the risk context without the specific emphasis on AI-related threats present in 2023.' The LLM answer claims 'the nature of the IP-protection risk has not materially changed between 2023 and 2024' and states that both years 'flag the same emerging challenges – the impact of artificial-intelligence developments.' This is directly contradictory to the ground truth, which explicitly notes that AI was mentioned in 2023 but NOT in 2024. The LLM failed to identify the key evolution: the removal of AI-specific language and the shift toward broader regulatory/compliance risk framing. The quantitative accuracy is perfect (no numbers involved), but the qualitative accuracy is severely compromised because the LLM reached the opposite conclusion from the ground truth on the central question of whether risks evolved. The answer demonstrates a failure in multi-hop reasoning and document synthesis across the two years' filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 402,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has Goldman Sachs' treatment of Non-Employee Director Equity Award Agreements evolved between the 2023 and 2024 SEC filings, particularly in terms of referenced agreements and their timelines?",
      "original_answer": "In 2023, Goldman Sachs referenced Non-Employee Director Equity Award Agreements through Exhibit 10.17, which pointed to an amendment dated November 28, 2008. By 2024, the company continued to disclose these agreements under the same exhibit number (10.18), but the referenced source shifted to Exhibit 10.69 from the 2008 Annual Report, indicating a formalization or consolidation of prior amendments. This evolution shows a continuation of the policy with deeper historical documentation being emphasized in the later filing.",
      "llm_answer": "In the 2023 Form 10‑K Goldman Sachs disclosed a pre‑2015 Non‑Employee Director RSU Award Agreement (Exhibit 10.21, tied to the 2014 annual report) and an amendment to certain Non‑Employee Director Equity Award Agreements (Exhibit 10.69, tied to the 2008 annual report), listed as items 10.8, 10.17 (and the generic forms 10.31‑10.32). The 2024 filing still references the same two agreements – the 2014‑based pre‑2015 RSU award (now item 10.9) and the 2008 amendment (now item 10.18) – but the exhibit numbers have been renumbered (e.g., 10.31/10.32 become 10.32/10.33). Thus, the substantive treatment and timelines of the agreements remain unchanged; only the numbering and ordering of the exhibit schedule were updated.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations compared to the ground truth. Key issues: (1) EXHIBIT NUMBER ERRORS: The ground truth states that in 2023, the agreements were referenced through Exhibit 10.17 (pointing to an amendment dated November 28, 2008), and in 2024 they were disclosed under Exhibit 10.18 (pointing to Exhibit 10.69 from the 2008 Annual Report). The LLM incorrectly claims the 2023 filing referenced Exhibit 10.69 tied to the 2008 annual report, when the ground truth indicates 10.17 was the 2023 reference. (2) EXHIBIT RENUMBERING CLAIMS: The LLM claims exhibits were renumbered from 10.31/10.32 to 10.32/10.33, but the ground truth makes no mention of these exhibit numbers or such renumbering. This appears to be fabricated detail. (3) RSU AWARD AGREEMENT CONFUSION: The LLM introduces a 'pre-2015 Non-Employee Director RSU Award Agreement (Exhibit 10.21, tied to the 2014 annual report)' which is not mentioned in the ground truth at all. This represents either hallucination or confusion with different agreements. (4) CORE NARRATIVE MISALIGNMENT: While the LLM correctly identifies that the agreements remained substantively unchanged and only exhibit numbering changed, it provides incorrect exhibit numbers and introduces agreements not mentioned in the ground truth. (5) MULTI-HOP SYNTHESIS: The LLM failed to correctly synthesize the evolution from 2023 (Exhibit 10.17 → November 28, 2008 amendment) to 2024 (Exhibit 10.18 → Exhibit 10.69 from 2008 Annual Report). The ground truth emphasizes a shift in how the historical documentation was referenced, not a simple renumbering of unrelated exhibits. The answer demonstrates fundamental misunderstanding of the actual exhibit structure and evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 486,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has BKNG's relationship with travel service providers evolved between 2022 and 2023 in terms of revenue recognition and contractual responsibilities?",
      "original_answer": "In 2022, BKNG described its relationship with travel service providers as one where it connects consumers to providers through its platforms, emphasizing its role as an intermediary without taking responsibility for delivering the travel services. The company highlighted that it earns revenues primarily from facilitating reservations and also mentioned the impact of cancellations during the pandemic recovery phase. By 2023, BKNG provided more detailed accounting treatment around its contracts with travel service providers, specifying that it recognizes revenue on a net basis due to its role as an agent, and further clarified its revenue recognition timing as occurring at the point when travelers begin using the arranged services. This reflects a shift from a general description of the relationship to a more structured and accounting-driven dependency on travel service providers, particularly in how it recognizes commissions and transaction revenues.",
      "llm_answer": "In the 2022 filing BKNG said its contracts with travel‑service providers were essentially agency‑type: the provider kept responsibility for delivering the travel service and BKNG earned a commission or margin, recognizing revenue on a net basis after the traveler actually used the reservation. By the 2023 filing the company noted that “Booking.com is increasingly processing transactions on a merchant basis,” taking on payment‑processing, settlement and refund duties, recognizing “merchant revenues” at the time of booking and reporting larger “deferred merchant bookings,” which reflects a shift to a hybrid merchant‑agency model with earlier revenue recognition and expanded contractual obligations to the providers.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresentations of BKNG's business model evolution. Critical issues: (1) The ground truth states that in 2022, BKNG described itself as an intermediary earning revenues from facilitating reservations, with revenue recognized at the point when travelers BEGIN USING services. The LLM incorrectly claims 2022 revenue was recognized 'after the traveler actually used the reservation' - this is semantically similar but the ground truth emphasizes the shift in timing description. (2) Most critically, the LLM introduces claims about 'merchant basis' processing, 'merchant revenues,' and 'deferred merchant bookings' in 2023 that are NOT mentioned in the ground truth. The ground truth describes a shift to 'more detailed accounting treatment' and 'more structured and accounting-driven dependency,' but does NOT mention a shift to merchant model or merchant revenues. (3) The LLM claims BKNG took on 'payment-processing, settlement and refund duties' - this is not supported by the ground truth which only mentions clarified revenue recognition timing and agent-based commission recognition. (4) The ground truth emphasizes the shift from 'general description' to 'structured accounting-driven' approach, while the LLM invents a business model shift to 'hybrid merchant-agency model' that contradicts the ground truth's emphasis on agent-based revenue recognition on a net basis. (5) No quantitative data is provided in either answer, so quantitative accuracy cannot be verified, but the LLM's qualitative claims about merchant model and expanded contractual obligations appear to be fabrications not present in the ground truth. The answer demonstrates poor multi-hop synthesis and introduces unsupported claims about business model changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 489,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "What specific changes occurred in the structure of Goldman Sachs' executive life insurance policy disclosures between the 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs included the Goldman Sachs & Co. LLC Executive Life Insurance Policy and Certificate with Metropolitan Life Insurance Company (Exhibit 10.11) and a form of the policy with Pacific Life & Annuity Company (Exhibit 10.12). In the 2024 10-K filing, these exhibits were not only retained but renumbered to 10.12 and 10.13 respectively, indicating a reorganization of exhibit numbering. This renumbering and retention of the policies in the 2024 filing demonstrates a structural update in how the policies are presented within the filing, rather than a substantive change in the policies themselves.",
      "llm_answer": "In the 2023 Form 10‑K the two executive‑life‑insurance policies were listed as Exhibit 10.11 (Metropolitan Life) and Exhibit 10.12 (Pacific Life)【3†L‑10.11-L‑10.12】. In the 2024 Form 10‑K a new General Guarantee Agreement was added as Exhibit 10.11, pushing the insurance items down one slot so they now appear as Exhibit 10.12 (Metropolitan Life) and Exhibit 10.13 (Pacific Life)【244†L‑10.11-L‑10.13】. This renumbering reflects the insertion of an additional exhibit before the life‑insurance disclosures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a more complete explanation than the ground truth. Verification of key facts: (1) 2023 exhibit numbers correct - Exhibit 10.11 (Metropolitan Life) and 10.12 (Pacific Life) match ground truth; (2) 2024 exhibit numbers correct - renumbered to 10.12 and 10.13 respectively, matching ground truth; (3) Company names accurate - Metropolitan Life Insurance Company and Pacific Life & Annuity Company correctly identified; (4) Multi-hop reasoning sound - the LLM correctly synthesizes the structural change across both years and identifies the cause (insertion of General Guarantee Agreement as new Exhibit 10.11). The LLM answer actually provides superior insight by explaining WHY the renumbering occurred (a new exhibit was inserted before the life insurance policies), whereas the ground truth only states that renumbering occurred. This additional explanatory detail enhances understanding without introducing any factual errors. All numeric values (exhibit numbers 10.11, 10.12, 10.13) are precise and correct. The semantic meaning is fully preserved and the answer directly addresses the question about structural changes in the disclosure presentation. Minor deduction from perfect score only because the ground truth doesn't explicitly mention the General Guarantee Agreement insertion, though this appears to be an enhancement rather than an error in the LLM response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 394,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has the strategic importance and manufacturing approach for FBAR filters evolved between 2022 and 2024, particularly in terms of internal fabrication and competitive positioning?",
      "original_answer": "In 2022, FBAR filters were highlighted as a key product utilizing Broadcom’s proprietary processes, fabricated internally to protect IP and accelerate time to market, alongside vertical-cavity surface emitting lasers and side emitting lasers. The internal fabrication was specifically emphasized as a means to maintain competitive advantage by safeguarding innovation. By 2024, FBAR filters remained part of the internal fabrication strategy, but the context expanded to include a more comprehensive list of competitors in the semiconductor space, such as Qorvo, Qualcomm, and Skyworks, indicating a more intense competitive environment. This suggests that while the internal manufacturing strategy for FBAR filters remained consistent, the competitive pressure in wireless communications increased significantly, requiring Broadcom to reinforce its IP protections and innovation cycle.",
      "llm_answer": "Broadcom’s 2022 10‑K already stressed that its FBAR filters are a proprietary, high‑speed wireless‑communications technology that the company fabricates in‑house (primarily in its U.S. and Singapore III‑V fabs) to protect IP and accelerate time‑to‑market, and it listed FBAR capability as a core competitive differentiator【2022 p.13‑14】【2022 p.16‑17】. The 2024 filing repeats the same language—FBAR filters continue to be made internally and are highlighted as a key strength that sets Broadcom apart in a highly competitive market—showing that the strategic importance and internal‑fabrication approach have been maintained rather than changed【2024 p.11‑12】【2024 p.14‑15】.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies that FBAR filters were fabricated internally in both 2022 and 2024, maintains the core strategic importance across both years, and accurately notes that internal fabrication was used to protect IP and accelerate time-to-market. The mention of U.S. and Singapore III-V fabs adds specific detail. The LLM correctly identifies that the strategy remained consistent rather than changed. WEAKNESSES: (1) The LLM fails to address a critical evolution mentioned in the ground truth: the expansion of the competitive landscape. The ground truth explicitly states that by 2024, the context expanded to include 'a more comprehensive list of competitors in the semiconductor space, such as Qorvo, Qualcomm, and Skyworks,' indicating 'a more intense competitive environment.' The LLM does not mention these specific competitors or the intensification of competitive pressure. (2) The LLM's answer is incomplete on the 'evolution' aspect of the question. While it correctly notes consistency in manufacturing approach, it misses the key evolution in competitive positioning—that Broadcom faced increased competitive pressure from named competitors by 2024. (3) The page citations provided (2022 p.13-14, 2022 p.16-17, 2024 p.11-12, 2024 p.14-15) cannot be verified but appear plausible. (4) The LLM states the language was 'repeated' and 'the same' but doesn't capture the nuanced evolution in competitive context that the ground truth identifies. MULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2024 filings but fails to complete the full synthesis by missing the competitive landscape expansion. The question asks about 'evolution' and the LLM concludes there was no evolution ('maintained rather than changed'), which partially contradicts the ground truth's identification of evolved competitive context. SEMANTIC ACCURACY: The core claim about internal fabrication and IP protection is semantically equivalent to ground truth, but the answer is incomplete regarding the evolution dimension of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 557,
        "total_tokens": 1955
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BMY's strategic positioning of Krazati evolved between 2023 and 2024, particularly in terms of clinical development focus and financial valuation?",
      "original_answer": "In 2023, Krazati was positioned as part of BMY’s oncology portfolio with specific clinical trials listed: KRYSTAL-17 for 1L NSCLC TPS<50%, KRYSTAL-10 for 2L CRC, and KRYSTAL-12* for 2L+ Mutated NSCLC. By 2024, BMY had acquired Mirati for $4.8 billion, securing full rights to Krazati, which had already received FDA and EMA approvals for second-line NSCLC and FDA approval for advanced KRAS-mutated colorectal cancer. Additionally, Krazati was now being developed in combination with a PD-1 inhibitor for first-line NSCLC, indicating a significant expansion in its clinical and commercial strategy.",
      "llm_answer": "In the 2023 filing (pages 12‑16) Krazati was listed only as a Mirati‑derived KRAS inhibitor with an approved second‑line NSCLC label and exploratory “additional indications” of 1L NSCLC and 3L‑plus colorectal cancer. By the 2024 filing (pages 91‑95) BMS had moved Krazati into a front‑line oncology focus, launching registrational trials KRYSTAL‑17 (1L NSCLC, TPS < 50 %), KRYSTAL‑10 (2L colorectal cancer) and KRYSTAL‑12 (later‑line KRAS‑mutated NSCLC), and it valued the acquired marketed product rights at roughly $640 million as part of the Mirati acquisition.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IN FACTUAL ACCURACY AND MULTI-HOP SYNTHESIS:\n\n1. CRITICAL TIMELINE REVERSAL: The LLM has fundamentally reversed the chronological positioning of Krazati between 2023 and 2024. The ground truth states that in 2023, Krazati was in clinical development (KRYSTAL-17, KRYSTAL-10, KRYSTAL-12 trials listed), while by 2024 it had already received FDA/EMA approvals. The LLM incorrectly states the opposite: claiming 2023 showed only an approved second-line label with exploratory indications, then 2024 showed the launch of registrational trials. This is backwards.\n\n2. QUANTITATIVE ACCURACY FAILURE: The LLM cites a $640 million valuation for Krazati as part of the Mirati acquisition. The ground truth specifies the total Mirati acquisition was $4.8 billion, with no mention of a $640 million sub-valuation for Krazati specifically. This number appears to be fabricated or misattributed.\n\n3. CLINICAL DEVELOPMENT MISCHARACTERIZATION: The LLM describes KRYSTAL trials as 'registrational trials' being 'launched' in 2024, when the ground truth indicates these were the 2023 clinical trial portfolio. The LLM also incorrectly characterizes the 3L+ colorectal cancer indication as 'exploratory' in 2023, when the ground truth shows FDA approval for advanced KRAS-mutated colorectal cancer by 2024.\n\n4. MISSING KEY INFORMATION: The LLM fails to mention the critical strategic evolution: the combination development with a PD-1 inhibitor for first-line NSCLC, which represents a significant expansion in clinical strategy between 2023 and 2024.\n\n5. ACQUISITION CONTEXT: While the LLM mentions the Mirati acquisition, it fails to properly contextualize that by 2024, BMY had already secured full rights to Krazati through this acquisition, which is a key strategic positioning element.\n\n6. MULTI-HOP REASONING: The synthesis across 2023 and 2024 filings is fundamentally flawed due to the timeline reversal, making the comparative analysis incorrect despite some individual trial names being mentioned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 542,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has the relationship between BKNG and travel service providers evolved between 2022 and 2023, particularly in terms of how BKNG manages financial obligations and incentives related to these providers?",
      "original_answer": "In 2022, BKNG primarily competed with travel service providers, highlighting the intense and evolving nature of the competitive landscape in the online travel market. By 2023, BKNG's relationship with travel service providers shifted to a more dependent model, as evidenced by the increase in the 'Deferred merchant bookings' liability on its balance sheet, which reflects amounts estimated to be payable to travel service providers. Additionally, BKNG introduced more incentive programs, such as referral bonuses, rebates, and loyalty points, which are recognized as a reduction of revenue, indicating a strategic shift toward enhancing partnerships and incentivizing collaboration with travel service providers rather than solely competing with them.",
      "llm_answer": "Both 2022 and 2023 filings show Booking Holdings continues to treat travel‑service providers as its customers, collecting travelers’ payments up‑front, holding them as “Deferred merchant bookings” that represent amounts payable to providers plus the company’s commission or margin (2022 Revenue‑Recognition and Deferred‑Merchant‑Bookings sections). In 2023 the company highlighted a larger Deferred‑Merchant‑Booking balance driven by higher booking volumes and refined its incentive accounting – now recognizing the estimated value of referral bonuses, rebates, credits and loyalty‑point awards as a reduction of revenue at the time they are granted rather than at redemption (2023 Incentive‑Programs and Deferred‑Merchant‑Bookings updates).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies that BKNG treats travel service providers as customers and collects payments upfront. (2) Correctly mentions 'Deferred merchant bookings' as a key liability metric in both years. (3) Accurately notes that incentive programs (referral bonuses, rebates, loyalty points) are recognized as revenue reductions. (4) Correctly identifies the timing change in incentive accounting from redemption to grant date in 2023. (5) Properly recognizes the increase in deferred merchant bookings balance driven by higher booking volumes.\n\nWEAKNESSES: (1) The LLM answer fails to capture the core insight from the ground truth about the RELATIONSHIP EVOLUTION - specifically that 2022 showed BKNG primarily competing with providers, while 2023 showed a shift to a more dependent/partnership model. The LLM describes operational mechanics but misses this strategic relationship shift. (2) The ground truth emphasizes a qualitative shift from 'competition' to 'dependent model' with 'enhanced partnerships,' but the LLM treats both years as essentially the same operational model. (3) The LLM doesn't explicitly address how the increase in incentive programs represents a strategic shift toward collaboration rather than competition. (4) The answer is more technical/mechanical than strategic - it explains what happened but not the relationship evolution that was the core question.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across revenue recognition, deferred merchant bookings, and incentive accounting sections. However, it fails to synthesize the higher-level strategic relationship evolution that the ground truth emphasizes. The multi-hop reasoning is present but incomplete.\n\nNUMERIC/FACTUAL VERIFICATION: No specific numbers are provided in either answer, so quantitative accuracy cannot be directly verified. Both answers reference balance sheet items and accounting treatments without specific dollar amounts or percentages. The LLM's description of accounting mechanics appears accurate based on standard revenue recognition practices.\n\nSEMANTIC ALIGNMENT: While the LLM answer is factually accurate about the mechanics, it diverges semantically from the ground truth's emphasis on relationship evolution. The ground truth frames this as a strategic shift in partnership dynamics; the LLM frames it as operational accounting changes. This is a significant semantic divergence for a question specifically asking about relationship evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 666,
        "total_tokens": 2054
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Broadcom's involvement in the development of Custom Touch Controllers evolved from 2022 to 2024, particularly in terms of their role in the product lifecycle?",
      "original_answer": "In 2022, Broadcom was described as supplying Custom Touch Controllers as part of its semiconductor solutions for the wireless market. By 2024, the company's role had evolved to include producing these controllers as part of its broader custom silicon solutions, reflecting a deeper engagement in their development. This shift indicates a strategic move from being a component supplier to an active producer involved in the design and creation process.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K describe Broadcom’s custom touch controllers as a wireless‑segment product that “processes signals from touch screens in mobile handsets and tablets.” The wording and placement of the controllers in the product tables and the “Mobile Device Connectivity Solutions” narrative are essentially unchanged, showing that Broadcom’s involvement remains centered on designing and supplying the controller component rather than expanding to broader lifecycle roles such as full system integration or post‑sale services.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer fundamentally contradicts the ground truth on the core question about evolution of Broadcom's role. Ground truth states: (1) 2022 role was 'supplying' components, (2) 2024 role evolved to 'producing' as part of 'custom silicon solutions', (3) this represents a strategic shift from 'component supplier' to 'active producer involved in design and creation.' The LLM answer claims: (1) the involvement 'remains centered on designing and supplying the controller component' with 'essentially unchanged' wording and placement, (2) no expansion occurred beyond component design/supply. This is a direct contradiction of the ground truth's assertion of evolution and deepening engagement. The LLM correctly identifies the product (Custom Touch Controllers), the years (2022, 2024), and the segment (wireless), and accurately describes the technical function ('processes signals from touch screens'). However, it misses or explicitly denies the key evolution that the ground truth emphasizes: the shift from supplier to producer with deeper involvement in development. The LLM's conclusion that involvement 'remains centered on designing and supplying' contradicts the ground truth's claim of evolution toward 'active producer involved in design and creation process.' The LLM appears to have found that documentation remained similar in wording, but failed to recognize or synthesize evidence of the actual role evolution described in the ground truth. This is a critical failure on the primary question being asked about how involvement 'evolved.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 428,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Union Pacific's approach to freight cars evolved from 2023 to 2024, particularly in terms of asset acquisition strategy?",
      "original_answer": "In 2023, Union Pacific primarily leased freight cars as part of its operational strategy, reflecting a reliance on leased assets for rail operations. By 2024, the company's strategy shifted toward acquiring freight cars, including lease buyouts of $143 million in 2024 compared to $57 million in 2023, indicating a more aggressive stance on asset ownership to support replacement and growth opportunities.",
      "llm_answer": "In 2023 Union Pacific’s freight‑car strategy was dominated by leasing – the company reported $1.643 billion of operating‑lease assets (which include freight cars) and recorded only $57 million of lease‑buyouts in its “Locomotives and freight cars” capital‑investment line【UNP_10k_2023.pdf p.66‑70】. By 2024 the firm pivoted toward ownership, spending $788 million on locomotives and freight cars and executing $143 million of lease‑buyouts, a clear shift to acquire more freight‑car assets directly as part of its capital plan【UNP_10k_2024.pdf p.31‑35】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of Union Pacific's freight car strategy evolution. STRENGTHS: (1) All key financial figures are correct: $57 million lease buyouts in 2023, $143 million in 2024, and $788 million capital investment in locomotives/freight cars in 2024. (2) The multi-hop synthesis is sound - the answer correctly identifies the strategic shift from leasing dominance in 2023 to ownership acquisition in 2024. (3) Entity identification is accurate (Union Pacific, correct years 2023-2024, correct metrics). (4) The reasoning about 'aggressive stance on asset ownership' and 'replacement and growth opportunities' aligns with the ground truth interpretation. (5) The answer appropriately cites specific document pages, adding credibility. (6) The semantic meaning matches the ground truth: both convey a clear pivot from leasing to acquisition strategy. MINOR CONSIDERATIONS: The LLM provides additional context about the $1.643 billion operating-lease assets figure, which while not contradicted by the ground truth, goes slightly beyond what was explicitly stated in the original answer. However, this adds value rather than detracting. The comparison structure (2023 vs 2024) is clear and directly addresses the 'evolution' aspect of the question. The answer successfully synthesizes information across two fiscal years and multiple financial metrics to demonstrate the strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 400,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "What were the financial and operational impacts of Nike's structural changes in APLA between FY2022 and FY2023, particularly regarding the transition of certain businesses to third-party distributors?",
      "original_answer": "In FY2022, Nike directly operated within APLA as part of its geographic operating segments, which included associated costs and foreign currency impacts such as non-recurring impairment charges due to the anticipated release of non-cash cumulative foreign currency translation losses from transitioning certain businesses to third-party distributors. By FY2023, Nike had shifted its relationship with APLA from direct operations to a strategic stake, where the company now oversees results through third-party distributors. This transition is reflected in the 2023 filing noting that APLA includes results for the NIKE and Jordan brands and referencing Note 18 on divestitures related to the transition. Operationally, this change represents a strategic shift to reduce direct operational overhead in APLA, likely aiming to improve financial efficiency and focus on brand management rather than local execution.",
      "llm_answer": "Nike’s APLA segment grew after it moved several NIKE Brand businesses in the region to third‑party distributors – a change that was only planned in the FY 2022 filing (Note 17) and was described as having been executed in the FY 2023 filing.  Revenues rose from $5,955 million in FY 2022 to $6,431 million in FY 2023, and EBIT increased modestly from $1,896 million to $1,932 million, while accounts‑receivable and inventories rose to $700 million and $894 million respectively, reflecting higher sales and a new distribution model (FY 2022 tables p. 88‑92; FY 2023 tables p. 87‑91).  The shift transferred the operating responsibility for those businesses to external distributors, altering the segment’s structure and reducing direct overhead while still delivering revenue and profit growth.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides specific financial metrics and demonstrates multi-hop reasoning across FY2022 and FY2023 filings. STRENGTHS: (1) Correctly identifies the transition of NIKE Brand businesses to third-party distributors as a planned change in FY2022 that was executed by FY2023; (2) Provides specific revenue figures ($5,955M to $6,431M) and EBIT figures ($1,896M to $1,932M) showing growth; (3) Includes accounts receivable and inventory metrics ($700M and $894M) reflecting the new distribution model; (4) Correctly synthesizes that the shift reduced direct overhead while maintaining revenue/profit growth; (5) References appropriate filing sections (Note 17 for FY2022, Note 18 implied for FY2023). WEAKNESSES: (1) Does not explicitly mention the non-recurring impairment charges and foreign currency translation losses that were key financial impacts in FY2022, which the ground truth specifically highlights; (2) Does not explicitly state that APLA shifted from direct operations to a strategic stake relationship, though this is implied; (3) The specific financial metrics provided (revenue, EBIT, A/R, inventory) cannot be verified against the ground truth, which does not provide these exact numbers - this creates uncertainty about accuracy; (4) Missing discussion of the cumulative foreign currency translation losses that would be released upon transition. CALCULATION VERIFICATION: Revenue growth of $476M ($6,431M - $5,955M) and EBIT growth of $36M ($1,932M - $1,896M) are mathematically consistent with stated figures. The answer demonstrates solid multi-hop reasoning by connecting the planned transition in FY2022 to its execution in FY2023 and showing operational/financial consequences. However, the omission of non-cash impairment charges and FX impacts represents incomplete coverage of the question's scope regarding 'financial impacts.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 505,
        "total_tokens": 1945
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Broadcom's involvement with InP lasers evolved from 2022 to 2024, particularly in terms of their internal fabrication strategy and competitive positioning?",
      "original_answer": "In 2022, Broadcom disclosed using internal fabrication facilities for products based on proprietary processes, including vertical-cavity surface emitting lasers and side emitting lasers using GaAs and InP lasers for fiber optic communications. By 2024, Broadcom continued this strategy but began emphasizing the competitive landscape more explicitly, listing companies like Coherent Corp., Lumentum Holdings Inc., and others as competitors in semiconductor solutions. This indicates a strategic shift toward highlighting InP laser capabilities as part of its competitive differentiation in the market.",
      "llm_answer": "In 2022 Broadcom disclosed that it kept the production of GaAs‑ and InP‑based VCSEL and side‑emitting lasers inside its own III‑V wafer fabs in the United States and Singapore, using internal fabrication for these proprietary processes while outsourcing commodity CMOS to protect IP and speed time‑to‑market (AVGO_10k_2022 p.15). By 2024 the company reiterated that internal III‑V wafer manufacturing remains a core capability for its InP lasers and emphasized that this in‑house expertise helps it compete with a broad set of rivals—including Lumentum, Coherent, MACOM and other laser specialists—in the fiber‑optic communications market (AVGO_10k_2024 p.13‑14).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the 2022 disclosure of internal fabrication for GaAs and InP lasers in VCSEL and side-emitting applications, with accurate geographic locations (US and Singapore). (2) Accurately captures the 2024 continuation and emphasis of this strategy, with proper identification of competitors (Lumentum, Coherent, MACOM). (3) Properly synthesizes the multi-hop evolution from 2022 to 2024, showing both continuity and strategic shift toward competitive differentiation. (4) Includes relevant contextual details (outsourcing commodity CMOS, IP protection, time-to-market rationale) that enhance understanding without contradicting ground truth. (5) Correctly cites specific document sources and page numbers (AVGO_10k_2022 p.15, AVGO_10k_2024 p.13-14), demonstrating document-level accuracy. (6) Uses appropriate technical terminology (III-V wafer fabs, VCSEL, side-emitting lasers) correctly. MINOR CONSIDERATIONS: The LLM answer is slightly more detailed than the ground truth (mentioning outsourcing strategy and specific geographic locations), but these additions are factually accurate and enhance rather than contradict the original answer. The semantic meaning is fully preserved - both answers convey that Broadcom maintained internal fabrication for InP lasers from 2022-2024 and increasingly emphasized competitive positioning. No numerical errors, date errors, or entity misidentifications detected. The multi-hop reasoning correctly synthesizes information across the two time periods and multiple companies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 448,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the ownership structure of Swoosh, LLC in relation to NIKE's Class A and Class B Common Stock evolved between 2022 and 2023, and what implications does this have for shareholder influence?",
      "original_answer": "In 2022, Swoosh, LLC beneficially owned approximately 77% of NIKE's Class A Common Stock, which would translate to approximately 16% ownership of Class B Common Stock if all shares were converted. In 2023, the ownership structure remained consistent with Swoosh, LLC still beneficially owning approximately 77% of Class A Common Stock, with a commensurate ownership percentage of approximately 16% in Class B Common Stock if all shares were converted. Despite the consistency in ownership percentages, the continued concentration of ownership in Swoosh, LLC implies sustained influence by Travis Knight, who has a significant role in managing the Class A Common Stock owned by Swoosh, LLC, potentially affecting shareholder decisions and market dynamics.",
      "llm_answer": "In the 2022 Form 10‑K (page 23) Nike disclosed that Swoosh, LLC owned roughly 77 % of the company’s Class A common stock – a stake that would become about 16 % of the Class B stock if all were converted. The 2023 Form 10‑K (page 24) repeats the same figures, showing no material change in Swoosh’s ownership of Class A (≈ 77 %) and the corresponding ≈ 16 % potential Class B ownership. Because Class A shares elect three‑quarters of Nike’s board, this unchanged concentration gives Swoosh (and the Knight family) continued, decisive voting influence, even though a conversion to Class B would dilute that power but still leave a sizable block of shares.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: All key percentages are correct - Swoosh, LLC's 77% ownership of Class A Common Stock in both 2022 and 2023, and the corresponding ~16% if converted to Class B. The answer correctly identifies that these figures remained consistent between the two years. ENTITY ACCURACY: Correctly identifies Swoosh, LLC, NIKE, Class A and Class B Common Stock, Travis Knight (referenced as 'Knight family'), and the relevant fiscal years (2022 and 2023). MULTI-HOP REASONING: The answer successfully synthesizes information across two 10-K filings to show the evolution (or lack thereof) in ownership structure. It correctly traces the implications: the unchanged concentration of ownership and its impact on voting influence. ADDITIONAL INSIGHT: The LLM answer goes beyond the ground truth by providing additional context about Class A shares electing three-quarters of Nike's board, which strengthens the explanation of shareholder influence implications. This is a valuable addition that demonstrates deeper understanding. MINOR DIFFERENCES: The ground truth mentions 'Travis Knight' specifically, while the LLM answer references 'the Knight family' more broadly - both are semantically equivalent and accurate. The LLM answer's phrasing about conversion diluting power 'but still leave a sizable block of shares' adds nuance not explicitly in the ground truth but is logically sound. COMPLETENESS: The answer addresses all parts of the question: (1) ownership structure in 2022, (2) ownership structure in 2023, (3) how it evolved (remained consistent), and (4) implications for shareholder influence. The answer is well-structured, cites specific page numbers from the 10-Ks, and provides clear reasoning about the implications of the ownership concentration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 498,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did PMI's strategic positioning of Reduced-Risk Products evolve from 2022 to 2023, particularly in terms of portfolio integration and market availability?",
      "original_answer": "In 2022, PMI classified Reduced-Risk Products (RRPs) as a distinct category, including heated tobacco units, heat-not-burn devices, e-vapor, and oral nicotine products, with separate net revenue reporting. By 2023, RRPs were integrated into a broader category called Smoke-Free Products (SFPs), which now also included wellness and healthcare offerings. Additionally, PMI reported that its smoke-free products were available in 84 markets by the end of 2023, a notable expansion from the unspecified market availability in 2022. This evolution reflects a strategic shift toward consolidating RRPs under a unified smoke-free vision and expanding their global footprint.",
      "llm_answer": "In 2022 PMI’s reduced‑risk strategy focused on bolstering its smoke‑free portfolio through the acquisition of Swedish Match, which added the ZYN oral‑nicotine franchise to its IQOS heat‑not‑burn platform and set the stage for PMI to take full control of IQOS in the U.S. after ending the Altria partnership. By 2023 the company had begun folding Swedish Match into its four geographic operating segments—moving from a stand‑alone segment to a fully integrated portfolio—and reported that its smoke‑free (RRPs) products were now available in 84 markets worldwide.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the 84 markets figure for 2023 smoke-free product availability, matching the ground truth exactly. (2) The numeric data is accurate where provided. (3) The answer correctly references the Swedish Match acquisition and ZYN franchise as part of PMI's 2022-2023 strategic evolution. (4) The mention of IQOS and the Altria partnership transition is factually relevant context.\n\nWEAKNESSES: (1) CRITICAL OMISSION: The ground truth explicitly states that in 2022, RRPs were classified as a 'distinct category' with 'separate net revenue reporting,' and by 2023 they were 'integrated into a broader category called Smoke-Free Products (SFPs)' which 'now also included wellness and healthcare offerings.' The LLM answer completely fails to address this fundamental portfolio integration and reclassification shift—the core of the question about 'portfolio integration.' (2) The LLM discusses Swedish Match acquisition and geographic segment integration, which is tangentially related but does NOT directly address the specific evolution from RRPs as a distinct category to SFPs as a broader integrated category. (3) The answer conflates operational/segment integration (Swedish Match into geographic segments) with product category integration (RRPs into SFPs), which are different strategic positioning changes. (4) The LLM does not mention the expansion of SFPs to include 'wellness and healthcare offerings' beyond the traditional RRP categories. (5) The answer provides context about Altria partnership and U.S. IQOS control that, while interesting, is not directly responsive to the specific question about portfolio integration and market availability evolution.\n\nMULTI-HOP REASONING: The LLM demonstrates partial multi-hop synthesis by connecting Swedish Match acquisition to portfolio changes and market expansion, but fails to synthesize the key multi-hop insight: the categorical reclassification from RRPs (distinct) to SFPs (integrated, broader). The answer addresses 'market availability' (84 markets) correctly but misses the 'portfolio integration' dimension entirely.\n\nSEMANTIC EQUIVALENCE: While the LLM uses 'smoke-free (RRPs)' terminology, it does not capture the semantic distinction between RRPs as a standalone category in 2022 versus SFPs as an integrated category in 2023 that includes wellness/healthcare products.\n\nJUSTIFICATION: The answer is partially correct on quantitative metrics (84 markets) but fundamentally incomplete on the qualitative evolution of strategic positioning. It addresses only one of two key dimensions (market availability) while largely missing the portfolio integration dimension that is central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 716,
        "total_tokens": 2026
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Caterpillar's strategic role in the reciprocating engines business evolved from 2022 to 2024, and what impact has this had on its revenue composition and gross margin potential?",
      "original_answer": "In 2022, Caterpillar primarily sold reciprocating engines through its global dealer network and through subsidiary Perkins Engines Company Limited, which operated 90 distributors across 171 countries. By 2024, Caterpillar expanded its involvement by including the remanufacturing of Caterpillar reciprocating engines and components, as well as offering remanufacturing services for other companies. This evolution from a seller to a full lifecycle service provider likely improved gross margin potential, as remanufacturing typically involves lower material costs compared to new engine production and leverages existing asset value. The shift also diversified revenue composition by incorporating service-based income streams alongside traditional product sales.",
      "llm_answer": "In 2022 Caterpillar described its reciprocating‑engine business as a broadly‑based, dealer‑driven distribution platform that sold a mix of Perkins, FG Wilson and MaK engines to dealers, other manufacturers and end‑users across many applications. By 2024 the company had repositioned the business toward higher‑value, higher‑margin engine applications—large data‑center generators, gas‑compression units and marine/rail power—shifting sales away from low‑margin well‑servicing engines and increasing the share of large‑engine sales in Energy & Transportation; this mix change helped lift the segment’s profit‑to‑sales ratio to 19.9 % (up from 17.6 % a year earlier) and raised its gross‑margin potential.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer provides specific quantitative metrics (profit-to-sales ratio of 19.9% vs 17.6%) and identifies a strategic repositioning toward higher-margin applications, which demonstrates some factual grounding. However, there are significant discrepancies with the ground truth: (1) The ground truth emphasizes Caterpillar's expansion into remanufacturing services and lifecycle management as the key strategic evolution, while the LLM answer focuses on product mix optimization (shifting from low-margin to high-margin engine types). These represent different strategic narratives. (2) The ground truth mentions Perkins Engines Company Limited with 90 distributors across 171 countries as a key 2022 characteristic, which the LLM answer mentions Perkins but doesn't emphasize the distributor network evolution. (3) The ground truth explicitly states the shift involved 'remanufacturing of Caterpillar reciprocating engines and components' and 'remanufacturing services for other companies' as the primary evolution mechanism, whereas the LLM answer describes this as a product-mix shift toward specific applications (data-center generators, gas-compression units, marine/rail). (4) The ground truth's explanation for margin improvement centers on remanufacturing's lower material costs and asset leverage, while the LLM answer attributes it to shifting away from low-margin well-servicing engines. While both answers conclude with improved gross margin potential, they identify fundamentally different drivers. The LLM answer appears to describe a real strategic shift but may be addressing a different aspect of the business evolution than what the ground truth identifies as the primary strategic change. The specific percentages provided (19.9% and 17.6%) cannot be verified against the ground truth but appear plausible. The answer is partially correct on the outcome (margin improvement) but potentially misses or mischaracterizes the primary mechanism of strategic evolution (remanufacturing services vs. product mix optimization).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 549,
        "total_tokens": 1925
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How did BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of the mechanisms and transparency commitments outlined for informing stakeholders of changes?",
      "original_answer": "BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained consistent between 2022 and 2023, with the company reaffirming its commitment to post any amendments or waivers on its website in both years. There was no change in the specific mechanism or transparency commitment described across the two years, indicating a stable governance communication strategy.",
      "llm_answer": "In the 2022 Form 10‑K BNY Mellon noted that the Directors’ Code of Conduct is posted on its corporate website and that any amendments or waivers would be disclosed on that site. The 2023 filing repeats the same language—still posting the code online and pledging to publish any changes or waivers on the website—showing that the firm’s mechanism (website posting) and its transparency commitment remained essentially unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth. Both responses correctly identify that BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained consistent between 2022 and 2023. The LLM accurately captures the key mechanism (website posting) and the transparency commitment (posting amendments/waivers online) that were reaffirmed in both years. The answer correctly synthesizes the multi-hop comparison across the two fiscal years and accurately conveys that there was no evolution or change in the disclosure approach. The LLM uses slightly different wording ('repeats the same language,' 'essentially unchanged') compared to the ground truth ('remained consistent,' 'no change'), but these phrasings are semantically equivalent and convey the same factual conclusion. No numeric values, dates, or calculations are involved in this question, so quantitative accuracy is not a limiting factor. The answer appropriately addresses all parts of the question regarding mechanisms and transparency commitments. The only minor distinction is that the ground truth explicitly states 'no change in the specific mechanism or transparency commitment described,' while the LLM says 'essentially unchanged'—the word 'essentially' introduces a marginal qualifier that is not present in the ground truth, though this is a very minor semantic difference that does not materially affect the accuracy of the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 402,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Nike's strategic approach to the APLA market evolved between FY22 and FY23, particularly in terms of operational structure and market participation?",
      "original_answer": "In FY22, Nike operated directly in APLA, maintaining a significant presence through its NIKE Direct operations and wholesale distribution, with APLA contributing to the 14% growth in the NIKE Direct business. By FY23, Nike began transitioning certain businesses within APLA to third-party distributors, signaling a strategic shift away from direct market participation in some parts of the region. This change indicates a move toward a more distributed, partner-driven model in APLA, altering the way Nike engages with that market.",
      "llm_answer": "In FY 22 Nike announced that it would sell its legal entities in Argentina, Uruguay and Chile, moving those APLA markets from a wholesale‑and‑direct‑to‑consumer model to a distributor operating model and noting that the change would likely reduce revenue growth but improve profitability (2022 Form 10‑K, pp. 30‑31). By FY 23 the divestitures were reflected in the results, with the APLA region now largely served by third‑party distributors while Nike’s NIKE Direct business continued to grow there, showing a shift to a distributor‑centric structure and a more selective market‑participation approach (2023 Form 10‑K, pp. 87‑91).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and provides more specific detail than the ground truth. Key strengths: (1) Correctly identifies the strategic shift from direct operations to distributor model in APLA between FY22-FY23; (2) Accurately names specific countries (Argentina, Uruguay, Chile) affected by divestitures; (3) Correctly notes the trade-off between revenue growth and profitability; (4) Properly cites source documents (2022 and 2023 Form 10-K with specific page numbers); (5) Accurately describes the transition to third-party distributors while NIKE Direct continued to grow. The answer goes beyond the ground truth by providing concrete examples of which markets were divested and the explicit rationale (profitability improvement despite revenue reduction). Minor considerations: (1) The ground truth uses broader language about 'certain businesses within APLA' while the LLM specifies three countries - this is actually more precise and accurate based on typical Nike disclosures; (2) Both answers correctly identify the shift to a distributor-driven model; (3) The LLM answer's reference to 'more selective market-participation approach' aligns well with the ground truth's 'distributed, partner-driven model.' The multi-hop reasoning is sound - the answer correctly synthesizes information across two fiscal years and two different 10-K filings to show the evolution. No calculation errors or factual inaccuracies detected. The answer is well-structured and directly addresses the question about operational structure and market participation changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 435,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the impact of Favorable Price Realization on Caterpillar's sales and profitability evolved from 2022 to 2024?",
      "original_answer": "In 2022, favorable price realization contributed to a $9.223 billion increase in total sales and revenues, driven by higher end-user demand and changes in dealer inventories. By 2024, favorable price realization continued to play a key role, partially offsetting a $2.251 billion decrease in sales volume and contributing to an increase in profit from $10.335 billion in 2023 to $10.792 billion in 2024. This indicates that while Caterpillar faced declining sales volume in 2024, the company leveraged pricing strategies more effectively to maintain profitability.",
      "llm_answer": "In the 2022 filing Caterpillar noted that the year’s sales and operating profit were “primarily … driven … by higher sales volume … and favorable price realization,” indicating that price‑realization helped lift both revenue and earnings that year【CAT_10k_2022.pdf, p. 33】. By 2024, sales had slipped and the MD&A says the decline “was partially offset by favorable price realization,” and that the profit impact of lower volume “was more than offset by favorable price realization,” showing the factor now serves mainly to cushion a sales drop rather than drive growth【CAT_10k_2024.pdf, p. 28】.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the evolution of favorable price realization's role from 2022 to 2024, capturing the shift from growth driver to offset mechanism. The qualitative characterization is accurate - in 2022 it helped drive growth, by 2024 it was cushioning sales declines. The answer appropriately cites source documents and page numbers. CRITICAL WEAKNESSES: (1) MISSING KEY QUANTITATIVE DATA: The ground truth provides specific dollar amounts ($9.223 billion increase in 2022, $2.251 billion decrease in 2024, profit increase from $10.335B to $10.792B) that are completely absent from the LLM answer. These are material facts that should have been included. (2) INCOMPLETE MULTI-HOP SYNTHESIS: While the LLM captures the directional change, it fails to provide the specific financial metrics that demonstrate the magnitude of impact. The ground truth shows concrete numbers; the LLM provides only qualitative descriptions. (3) PROFIT IMPACT UNDERSPECIFIED: The ground truth explicitly states profit increased from $10.335 billion in 2023 to $10.792 billion in 2024 despite volume declines - a key quantitative finding that the LLM mentions only vaguely as 'profit impact.' (4) SALES VOLUME DECLINE NOT QUANTIFIED: The ground truth specifies a $2.251 billion decrease in sales volume in 2024, which the LLM references only as 'sales had slipped' without numbers. The LLM answer demonstrates good qualitative understanding and correct directional analysis, but fails on the quantitative precision required for a financial analysis question. For a multi-hop financial question, specific numbers are essential ground truth elements that cannot be omitted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 458,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has General Motors' approach to EV manufacturing capacity evolved between 2023 and 2024, particularly in terms of strategic focus and supply chain development?",
      "original_answer": "In 2023, General Motors emphasized significant investments in EV manufacturing capacity based on expectations for future EV demand, acknowledging the risks and uncertainties associated with such investments, including high fixed costs and limitations on closing facilities. By 2024, GM's strategy had evolved to include a stronger emphasis on developing a resilient, scalable, and sustainable North American-focused EV supply chain. This included advancing strategic sourcing initiatives to secure supply through investments in raw materials suppliers and the execution of multi-year supply agreements. The shift indicates a more structured and regionally focused approach to EV manufacturing, aiming to mitigate supply chain risks and ensure long-term scalability.",
      "llm_answer": "In its 2023 Form 10‑K, GM said it would keep “making significant investments in EV manufacturing capacity” and focus on scaling production, cutting battery‑cell costs and broadly sourcing raw‑material inputs for a future EV portfolio. By the 2024 filing, the company’s language had shifted to a tighter, North‑America‑centric strategy – emphasizing a “more resilient, scalable and sustainable North‑American‑focused EV supply chain,” strategic‑sourcing initiatives, raw‑material investments and multi‑year supply agreements, and flexible capacity planning that aligns production with EV adoption and regulatory goals.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about GM's EV strategy evolution between 2023 and 2024. STRENGTHS: (1) Correctly identifies the 2023 approach emphasizing significant EV manufacturing capacity investments with focus on scaling, cost reduction, and raw material sourcing. (2) Accurately captures the 2024 strategic shift toward a North America-centric, more resilient and sustainable supply chain. (3) Properly synthesizes key elements: strategic sourcing initiatives, raw material investments, and multi-year supply agreements. (4) Adds valuable context about flexible capacity planning aligned with EV adoption and regulatory goals, which enriches understanding without contradicting ground truth. (5) Uses appropriate filing references (Form 10-K) and maintains temporal accuracy. (6) No quantitative errors or date misstatements. MINOR CONSIDERATIONS: The LLM answer includes slightly more detail about 'flexible capacity planning' and regulatory alignment than explicitly stated in the ground truth, though this appears to be a reasonable inference from the broader strategic narrative and doesn't contradict the original answer. The semantic equivalence is strong - 'North American-focused' matches the ground truth's regional focus emphasis, and the enumeration of supply chain elements (strategic sourcing, raw material investments, multi-year agreements) aligns precisely with the original answer. The answer successfully demonstrates multi-hop reasoning by synthesizing information across two fiscal years and identifying the strategic evolution pattern.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 446,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved from 2022 to 2024, based on remaining performance obligations disclosed in the 10-K filings?",
      "original_answer": "In 2022, Pfizer's 10-K filing did not disclose specific remaining performance obligations related to Paxlovid. However, by 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a significant ongoing financial commitment tied to future delivery of the product. This shows a clear evolution from an undefined obligation in 2022 to a quantified $1 billion commitment in 2024.",
      "llm_answer": "Pfizer’s 2022 Form 10‑K disclosed that it still had roughly **$2.5 billion** of contracted revenue remaining for Paxlovid at year‑end 2022 (PFE_10k_2022.pdf: p. 9). By the 2024 Form 10‑K, that amount had fallen to about **$1 billion** of remaining performance obligations for Paxlovid as of December 31 2024 (PFE_10k_2024.pdf: p. 107). Thus, the company’s future‑period financial commitment to Paxlovid declined by roughly $1.5 billion between 2022 and 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The ground truth explicitly states that 'In 2022, Pfizer's 10-K filing did not disclose specific remaining performance obligations related to Paxlovid,' yet the LLM claims the 2022 10-K disclosed '$2.5 billion of contracted revenue remaining for Paxlovid.' This is a major factual inaccuracy. The LLM then calculates a $1.5 billion decline ($2.5B - $1B), which is mathematically correct IF the 2022 figure were accurate, but since the 2022 figure is wrong, the entire calculation and conclusion are invalid. The 2024 figure of $1 billion appears correct and matches the ground truth. The LLM correctly identifies the 2024 remaining performance obligations but fails on the 2022 baseline, which is essential for answering the 'evolution' aspect of the question. The LLM also provides specific page citations (p. 9 for 2022, p. 107 for 2024) that cannot be verified but appear to be fabricated given the contradiction with ground truth. The reasoning structure is sound (comparing 2022 to 2024 to show evolution), but it is built on a false premise. The answer demonstrates partial understanding of the question's intent but fails on the most critical factual requirement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 359,
        "total_tokens": 1590
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Caterpillar's approach to monitoring supplier financial viability evolved between 2022 and 2023, particularly in terms of risk mitigation strategies and contractual agreements?",
      "original_answer": "In 2022, Caterpillar indicated that it uses 'a variety of agreements with suppliers to protect our intellectual property and processes to monitor and mitigate risks of the supply base causing a business disruption,' including monitoring supplier financial viability. By 2023, Caterpillar maintained the same monitoring approach but placed a more explicit emphasis on 'supplier financial viability' as a key risk factor, listing it as the first risk under its supply chain disclosures. Additionally, in 2023, Caterpillar reinforced its global strategic sourcing models to build long-term supplier relationships and leverage enterprise spend, suggesting a potentially more structured or prioritized focus on supplier financial health compared to 2022.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K filings (see the “Raw Materials and Component Products” sections on pages 7‑11) state that Caterpillar “uses a variety of agreements with suppliers to protect our intellectual property and processes to monitor and mitigate risks of the supply base causing a business disruption,” explicitly listing “supplier financial viability” among the risks it tracks. The 2023 filing repeats the same language, indicating that the company’s risk‑mitigation strategy and contractual framework for monitoring supplier financial health have not materially changed from 2022.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IN MULTI-HOP REASONING: The LLM answer fundamentally contradicts the ground truth on the key finding. Ground truth states that Caterpillar's approach EVOLVED between 2022 and 2023, with 2023 showing 'more explicit emphasis' on supplier financial viability and 'a potentially more structured or prioritized focus.' The LLM answer incorrectly concludes that 'the company's risk-mitigation strategy and contractual framework...have not materially changed from 2022,' which directly contradicts the ground truth's assertion of evolution and increased emphasis. SPECIFIC ISSUES: (1) The LLM correctly identifies that both years use similar language about 'variety of agreements' and monitoring supplier financial viability - this is accurate. (2) However, the LLM fails to recognize the KEY EVOLUTION: Ground truth explicitly states 2023 placed 'more explicit emphasis' and listed supplier financial viability as 'the first risk under its supply chain disclosures' - a prioritization change. (3) The LLM misses the 2023 reinforcement of 'global strategic sourcing models to build long-term supplier relationships,' which the ground truth identifies as evidence of 'more structured or prioritized focus.' (4) The LLM's conclusion of 'no material change' is factually incorrect based on the ground truth's documented evolution. QUANTITATIVE ACCURACY: No specific numbers or dates are provided in either answer, so this dimension scores well (both use correct years 2022/2023 and correct company name). QUALITATIVE ACCURACY: The LLM failed at the core multi-hop synthesis task - comparing evolution across two years. It identified surface-level similarities but missed the substantive differences in emphasis and prioritization that constitute the actual evolution. CONTEXTUAL RELEVANCE: The answer addresses the right companies and years but fundamentally misinterprets what 'evolution' means in this context, treating stability as the finding when change was the actual finding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 536,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Visa's approach to Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of its strategic positioning and integration within its value-added services?",
      "original_answer": "In 2022, Visa positioned Risk and Identity Solutions as part of a broader set of value-added services aimed at supporting clients, but without detailed elaboration on specific capabilities or strategic direction. By 2024, Risk and Identity Solutions were embedded within a more structured value-added services framework, with a clear three-pillar strategy: (1) services for Visa transactions, (2) network-agnostic services for non-Visa transactions, and (3) services beyond payments. This evolution reflects a more strategic and comprehensive integration of Risk and Identity Solutions into Visa's broader service portfolio, with an emphasis on scalability and business outcomes.",
      "llm_answer": "In 2022 Visa presented Risk and Identity Solutions as a component of its value‑added services, focused on the Visa Protect suite (Visa Consumer Authentication Service, Protect Authentication Intelligence and Provisioning Intelligence) that used AI/ML to turn data into near‑real‑time fraud‑prevention and token‑provisioning insights (2022 p. 6). By 2024 the approach had broadened and deepened: Visa added three AI‑driven products—Visa Deep Authorization, Visa Protect for A2A Payments, and Visa Risk Manager with scheme‑agnostic Advanced Authorization—positioning the suite as an end‑to‑end, network‑agnostic fraud‑prevention layer that spans card‑present, card‑not‑present and non‑card transactions and is tightly woven into its overall value‑added services strategy (2024 p. 11).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer provides specific product names and details that go beyond the ground truth, but this creates a critical mismatch with the original answer's core finding. STRENGTHS: (1) The LLM correctly identifies the 2022-2024 timeframe and evolution of Risk and Identity Solutions; (2) It accurately notes the shift toward a broader, more strategic approach; (3) It correctly identifies network-agnostic positioning as part of the 2024 strategy; (4) The specific product names (Visa Protect, Deep Authorization, etc.) appear plausible and are cited with page references. CRITICAL WEAKNESSES: (1) The ground truth emphasizes a THREE-PILLAR STRATEGY as the key 2024 evolution: (a) services for Visa transactions, (b) network-agnostic services for non-Visa transactions, and (c) services beyond payments. The LLM answer does not explicitly articulate this three-pillar framework, instead focusing on product-level details; (2) The ground truth stresses 'emphasis on scalability and business outcomes' as a key differentiator in the 2024 positioning—the LLM answer does not mention this; (3) The LLM answer provides granular product details (Visa Consumer Authentication Service, Provisioning Intelligence, etc.) that, while potentially accurate, are not part of the ground truth's higher-level strategic assessment; (4) The LLM's framing as 'end-to-end, network-agnostic fraud-prevention layer' is narrower than the ground truth's broader 'services beyond payments' pillar. MULTI-HOP REASONING: The LLM correctly synthesizes a before-and-after comparison across 2022 and 2024, but the synthesis focuses on product evolution rather than strategic framework evolution. The answer demonstrates understanding of the general direction but misses the specific strategic architecture (three pillars) that defines the evolution in the ground truth. QUANTITATIVE ACCURACY: Page references (2022 p. 6, 2024 p. 11) are provided but cannot be independently verified; no numerical metrics are provided to evaluate. SEMANTIC EQUIVALENCE: While the LLM answer conveys that Risk and Identity Solutions became more strategic and integrated, it does not capture the specific three-pillar strategic positioning that is central to the ground truth's assessment of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 603,
        "total_tokens": 1978
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has the company's exposure to shelf space limitations as a risk factor evolved between 2022 and 2023, particularly in relation to changes in retail customer policies and the expansion of alternative retail channels?",
      "original_answer": "In 2022, the company noted that it had been and could continue to be negatively affected by changes in retail customer policies such as limitations on access to shelf space and delisting of products. By 2023, the company was actively impacted by these limitations and described them as part of a broader set of evolving retail dynamics, including the growth of eCommerce and alternative retail channels such as subscription services and direct-to-consumer businesses. This evolution indicates a shift from potential risk to an actively experienced challenge, with the company planning to invest more in digital and analytics capabilities to adapt.",
      "llm_answer": "In the 2022 10‑K the company warned that changes in retailer policies—such as inventory de‑stocking, fulfillment rules and “limitations on access to shelf space”—could “negatively affect” its business, and it flagged the rapid growth of e‑commerce and alternative channels as a future source of pricing pressure. By the 2023 filing the language had shifted to say the company “has been negatively affected” by those same shelf‑space constraints and by the continued expansion of e‑commerce, subscription‑service and direct‑to‑consumer channels, indicating the risk has moved from a potential concern to an actual impact.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) FACTUAL ACCURACY: Both answers correctly identify the evolution from potential risk (2022) to actual impact (2023). The LLM accurately captures the specific language shift from 'could negatively affect' to 'has been negatively affected,' which is the core distinction between the two years. The mention of specific retail policy changes (inventory de-stocking, fulfillment rules, shelf space limitations) is accurate and adds helpful detail. (2) QUANTITATIVE ACCURACY: No numeric values are present in either answer, so this dimension is not applicable. Both answers correctly reference 2022 and 2023 filings without date errors. (3) ENTITY ACCURACY: The LLM correctly identifies the company's exposure to shelf space limitations and accurately names the alternative retail channels (e-commerce, subscription services, direct-to-consumer). The terminology is consistent with standard retail/consumer goods industry language. (4) MULTI-HOP REASONING: The LLM successfully synthesizes information across two years of filings, correctly identifying the progression of the risk from prospective to realized. The connection between shelf space constraints and the growth of alternative channels is properly established. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same essential information as the ground truth with slightly different wording. The ground truth mentions 'planning to invest more in digital and analytics capabilities,' which the LLM answer does not explicitly include. However, this is a minor omission that doesn't fundamentally undermine the core answer about the evolution of the risk factor. The LLM's framing of the shift from 'potential concern to actual impact' is semantically equivalent to the ground truth's 'shift from potential risk to an actively experienced challenge.' Minor deduction (1 point) for not mentioning the company's planned response regarding digital and analytics investments, though this is a secondary detail to the main question about risk evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 564,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Oracle's approach to hybrid deployments evolved between fiscal years 2023 and 2024, particularly in terms of product offerings and strategic emphasis?",
      "original_answer": "In fiscal 2023, Oracle emphasized hybrid deployments as part of its broader deployment models, including on-premise, cloud-based, and hybrid options such as Oracle Exadata Cloud@Customer and Dedicated Region offerings. The company highlighted its commitment to providing customers with choice and flexibility in how they deploy Oracle technologies. By fiscal 2024, Oracle continued to support hybrid deployments but introduced more specific product integrations and services tailored for hybrid environments, indicating a strategic shift toward deeper integration and support for customer-managed cloud and on-premise IT environments. This evolution reflects Oracle's ongoing investment in making hybrid deployments more interoperable and extensible with other IT and cloud environments.",
      "llm_answer": "In FY 2023 Oracle framed hybrid deployment as one of three flexible models—on‑premise, cloud‑based and hybrid—highlighting specific offerings such as Oracle Exadata Cloud@Customer and Dedicated Region that bring Oracle Cloud into a customer’s data centre (ORCL_10k_2023, pp. 4‑5). By FY 2024 the company deepened that focus, launching programs that help customers pivot licenses to the cloud, expanding hybrid‑cloud product capabilities, and positioning hybrid as a core growth driver—evidenced by cloud‑services revenue rising to 37 % of total revenue and explicit language about enabling customers to migrate and expand workloads on Oracle Cloud (ORCL_10k_2024, pp. 71‑73).",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies Oracle's evolution in hybrid deployment strategy between FY 2023 and FY 2024, capturing the core narrative from the ground truth. Strengths: (1) Accurately references specific product offerings (Exadata Cloud@Customer, Dedicated Region) in FY 2023; (2) Correctly identifies the shift toward deeper integration and support in FY 2024; (3) Properly synthesizes multi-hop information across two fiscal years; (4) Appropriately cites source documents with page numbers. Weaknesses: (1) The 37% cloud-services revenue figure is introduced without clear verification against ground truth—while this may be accurate from the 10-K, it represents a quantitative claim that goes beyond the ground truth answer's scope and cannot be fully validated; (2) The phrase 'launching programs that help customers pivot licenses to the cloud' is more specific than the ground truth statement about 'more specific product integrations and services' and may overstate the level of detail supported; (3) The characterization of hybrid as a 'core growth driver' is interpretive language not explicitly stated in the ground truth. The answer demonstrates strong qualitative reasoning and correctly captures the evolution narrative, but introduces specific quantitative claims (37% revenue figure) that, while potentially accurate, exceed the scope of the ground truth answer and create minor quantitative accuracy concerns. The multi-hop synthesis across fiscal years is sound and the contextual relevance is high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 420,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved between 2022 and 2024, based on remaining performance obligations and contracted revenue expectations?",
      "original_answer": "In 2022, Pfizer indicated that Paxlovid had the potential to provide ongoing revenue streams, though it acknowledged that post-pandemic revenues might not match the levels seen during the pandemic. By 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, with contracted revenue expected to be recognized from 2025 through 2028. This reflects a continued but reduced financial commitment compared to the pandemic period, as the company anticipates delivery and revenue recognition over a multi-year horizon rather than immediate high-volume sales.",
      "llm_answer": "In 2022 Pfizer disclosed roughly $2.5 billion of remaining performance‑obligation revenue for Paxlovid – the amount it expected to recognize from existing long‑term contracts (PFE_10k_2022, pp. 21‑25). By December 31 2024 that figure had fallen to about $1 billion, indicating a decline of roughly $1.5 billion in the contracted revenue expected from Paxlovid as the product shifted toward commercial sales (PFE_10k_2024, pp. 107‑111).",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer provides specific quantitative data that directly addresses the question about Pfizer's financial commitment evolution. Key strengths: (1) Correctly identifies the 2022 remaining performance obligations (~$2.5 billion) and 2024 figure (~$1 billion), with accurate calculation of the $1.5 billion decline; (2) Properly synthesizes multi-hop information across two 10-K filings (2022 and 2024); (3) Correctly identifies the shift from pandemic-era high volumes to commercial sales; (4) Provides specific page references enhancing credibility. Comparison with ground truth: The LLM answer is more specific and quantitatively detailed than the original answer. The original answer states 'approximately $1 billion' for 2024 and mentions 'potential to provide ongoing revenue streams' for 2022 without specific numbers. The LLM answer provides the 2022 figure ($2.5 billion) explicitly and calculates the decline ($1.5 billion), which represents stronger multi-hop synthesis. Minor considerations: (1) The original answer emphasizes the 'continued but reduced financial commitment' and multi-year revenue recognition horizon (2025-2028), which the LLM answer touches on less explicitly; (2) The LLM answer's characterization of the shift as moving 'toward commercial sales' is a reasonable interpretation but slightly different framing than the original's 'post-pandemic revenues might not match pandemic levels.' The quantitative accuracy is high with correct figures and proper calculation. The qualitative reasoning correctly identifies the trend and underlying business dynamics. No factual errors detected in the numbers or dates provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 452,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Caterpillar's relationship with its independent dealers evolved between 2022 and 2023, particularly in terms of contractual obligations and strategic emphasis?",
      "original_answer": "In 2022, Caterpillar described its relationship with independent dealers in general terms as part of its global sales and marketing strategy. By 2023, the company formalized and detailed these relationships through standardized sales and service agreements, granting dealers the right to purchase, sell, and service Caterpillar products within specified territories. In exchange, dealers were obligated to develop and promote Caterpillar products, maintain adequate sales and support personnel, and keep detailed financial records accessible to Caterpillar. This represents a shift from a general partnership model to a more structured contractual framework, indicating a strategic emphasis on formalizing dealer relationships to enhance control and accountability.",
      "llm_answer": "In the 2022 filing Caterpillar said its independent dealers are governed by “standard sales and service agreements” that grant dealers the right to purchase, sell and service Caterpillar products, obligate them to promote sales, keep detailed books and records, and can be terminated at‑will by either side with 90 days’ notice (2022 10‑K, pp. 5‑6). The 2023 filing retains the same contractual framework but adds that Caterpillar now treats the dealer network as a strategic growth engine—emphasizing digital tools, performance alignment and long‑term partnership to deepen the relationship—showing a shift from a mainly transactional arrangement to a more strategic partnership (2023 10‑K, pp. 9‑10).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) FACTUAL CONTRADICTION - The LLM answer directly contradicts the ground truth by claiming that in 2022, Caterpillar already described dealers as governed by 'standard sales and service agreements' with specific obligations. The ground truth explicitly states that in 2022, the relationship was described 'in general terms' and only by 2023 were these relationships 'formalized and detailed through standardized sales and service agreements.' This is a fundamental misrepresentation of the evolution being asked about. (2) MISSING KEY EVOLUTION - The ground truth emphasizes a shift FROM general partnership language TO formalized contractual framework. The LLM answer incorrectly suggests the contractual framework existed in both years, missing the core evolution. (3) INCORRECT CHARACTERIZATION OF 2023 SHIFT - The ground truth describes 2023 as introducing formal contractual structure with control/accountability emphasis. The LLM answer claims 2023 added 'strategic growth engine' language and 'digital tools, performance alignment' - these details are not supported by the ground truth and appear to be fabricated or misattributed. (4) UNSUPPORTED DETAILS - The LLM provides specific page references (pp. 5-6 for 2022, pp. 9-10 for 2023) and claims about 90-day termination notice, digital tools, and performance alignment that cannot be verified against the ground truth and appear to be hallucinated. (5) INVERTED LOGIC - The LLM describes 2022 as having the detailed contractual framework and 2023 as adding strategic partnership language, which is the opposite of what the ground truth indicates. The correct evolution should show 2022 as general/informal and 2023 as formalized/structured. This is a significant multi-hop reasoning failure that fundamentally misrepresents the temporal evolution of Caterpillar's dealer relationships.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 508,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How did the company's financial allocation or operational focus related to Africa/Eurasia evolve from 2022 to 2023, based on capital expenditures and restructuring charges?",
      "original_answer": "In 2022, the company reported capital expenditures for Africa/Eurasia at $33 million, showing a steady increase from $13 million in 2021 and $8 million in 2020. However, in 2023, the company indicated that approximately 10% of the cumulative pretax charges from the 2022 Global Productivity Initiative would relate to initiatives undertaken in Africa/Eurasia, signaling a shift in focus toward restructuring and cost optimization in the region rather than continued capital investment. This reflects a strategic evolution from growth-oriented capital allocation to operational restructuring within Africa/Eurasia.",
      "llm_answer": "The company shifted its Africa/Eurasia strategy toward more growth‑oriented spending.  Capital spending in that region rose sharply – the latest disclosed capex was $33 million, up from $13 million in the prior period【CL_10k_2022.pdf pp 115‑119】.  At the same time, the share of restructuring charges allocated to Africa/Eurasia fell dramatically, dropping from 11 % of the Global‑Productivity‑Initiative charges in 2022 to just 5 % in 2023【CL_10k_2023.pdf p 48】.  This indicates a move away from restructuring toward higher investment in the region.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS - The LLM answer is fundamentally incorrect on multiple critical dimensions:\n\n1. DIRECTIONAL REVERSAL: The LLM claims the company shifted toward 'growth-oriented spending' and 'a move away from restructuring toward higher investment.' This is the OPPOSITE of the ground truth. The ground truth explicitly states a shift FROM growth-oriented capital allocation TO operational restructuring.\n\n2. QUANTITATIVE ERRORS:\n   - Capital expenditure comparison: LLM correctly identifies $33M (2022) vs $13M (prior), but misinterprets this as evidence of growth strategy when the ground truth shows this was the 2022 level, with 2023 showing a shift away from capex toward restructuring.\n   - Restructuring charge percentages: LLM claims the Africa/Eurasia share dropped from 11% (2022) to 5% (2023). The ground truth states approximately 10% of cumulative 2022 Global Productivity Initiative charges related to Africa/Eurasia initiatives. The LLM's percentages (11% and 5%) do not match the ground truth (10% mentioned for 2022), and the direction of change is inverted.\n\n3. MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the relationship between capex trends and restructuring charges. The ground truth shows capex peaked in 2022 at $33M, then the company shifted focus in 2023 toward restructuring (10% of GPI charges). The LLM inverted this narrative entirely.\n\n4. SEMANTIC CONTRADICTION: The LLM's conclusion that 'falling restructuring charges = move away from restructuring' is logically backwards. Lower restructuring allocation could indicate completion of initiatives or reallocation, but the ground truth indicates the opposite strategic direction.\n\n5. CONTEXTUAL RELEVANCE: While the answer addresses Africa/Eurasia and the 2022-2023 period, it fundamentally mischaracterizes the strategic evolution, making it contextually misleading despite addressing the right topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 518,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Qualcomm's strategic focus on 5G technologies evolved from 2022 to 2024, particularly in terms of investment emphasis and commercialization outcomes?",
      "original_answer": "In 2022, Qualcomm was heavily investing in 5G technologies as part of its broader strategy to expand beyond mobile handsets into areas like automotive and IoT, with an emphasis on developing leading and cost-effective 5G-based technologies and products. The company acknowledged significant risks around the success of these investments due to potential regulatory hurdles, competition, and the long design-in cycles typical of new industries like automotive. By 2024, Qualcomm had transitioned from a primarily investment phase to a more mature stage where it had developed a leading patent portfolio in 5G NR and was actively licensing these technologies. The company reported generating the majority of its QTL revenues from OFDMA-based products, including multimode 3G/4G/5G devices such as smartphones, indicating a successful commercialization phase. This shift shows that Qualcomm moved from strategic investment and development in 5G across multiple industries to a position of market leadership and monetization in 5G technologies.",
      "llm_answer": "In the 2022 10‑K Qualcomm highlighted that its strategy was still centered on **heavy R&D and patent investment in 5G**—building an OFDMA‑based 5G NR portfolio, filing new patents and “investing significant resources toward advancements primarily in support 5G‑based technologies” while noting that “5G network deployments and commercial 3G/4G/5G multimode device sales began in 2019 and have continued.” By the 2024 filing the emphasis had shifted to **commercializing integrated 5G solutions**, with the company marketing “RFFE components … designed to simplify the RF front‑end design for 5G” and the “Snapdragon 5G modem‑RF products, a modem‑to‑antenna platform integrating AI” that are being deployed across mobile handsets, automotive, IoT and other new markets. This reflects a move from foundational 5G R&D and early device roll‑outs in 2022 to broader product integration and market‑wide commercialization of 5G technologies in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core narrative of Qualcomm's 5G evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 phase as heavy R&D and patent investment in 5G with OFDMA-based portfolio development; (2) Accurately captures the 2024 shift toward commercialization and market deployment; (3) Properly synthesizes multi-hop information showing progression from investment to monetization; (4) Correctly names specific products (Snapdragon 5G modem-RF, RFFE components) and markets (mobile, automotive, IoT); (5) Appropriately emphasizes the timeline shift from early device roll-outs (2019 start mentioned) to broader integration. MINOR GAPS: (1) The LLM answer focuses more on product-level commercialization details (RFFE components, modem-to-antenna platforms) rather than explicitly mentioning the 'leading patent portfolio' and 'licensing' aspects emphasized in ground truth; (2) Does not explicitly state that QTL revenues came 'primarily' from OFDMA-based products, though this is implied; (3) Less explicit about the risk factors (regulatory, competition, design-in cycles) that were acknowledged in 2022. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is not directly testable. The dates (2022, 2024, 2019) are all correct. REASONING QUALITY: The multi-hop synthesis is sound—the answer correctly traces the evolution across two time periods and identifies the strategic inflection point. The logic connecting investment phase to commercialization phase is clear and accurate. SEMANTIC EQUIVALENCE: The LLM answer conveys essentially the same strategic evolution as the ground truth, with slightly different emphasis on product details versus licensing/patent monetization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1498,
        "completion_tokens": 495,
        "total_tokens": 1993
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Pfizer's financial and strategic positioning of Paxlovid evolved between 2022 and 2024, particularly in terms of revenue contribution and contractual commitments?",
      "original_answer": "In 2022, Paxlovid generated $76 million in revenue, marking its initial contribution as a newly launched product targeting high-risk COVID-19 patients. By 2024, while direct revenue figures for Paxlovid are not explicitly stated, Pfizer disclosed approximately $1 billion in remaining performance obligations tied to future Paxlovid deliveries under existing contracts. This indicates a strategic shift from initial market entry to securing longer-term contractual commitments, despite potential market or regulatory challenges reflected in the context of government returns and adjustments in 2024.",
      "llm_answer": "In 2022 Paxlovid generated $18.9 billion of revenue (about 19 % of Biopharma’s $99.8 billion) and its sales were almost entirely under government‑ and government‑sponsored supply contracts, creating large long‑term performance‑obligation commitments (2022 10‑K, p. 111‑115). By 2024 revenue from Paxlovid had fallen to $5.7 billion as the product shifted to commercial sales after an amended U.S. government agreement, and Pfizer now reports roughly $1 billion of remaining long‑term Paxlovid contracts and $2.2 billion of deferred revenue for Paxlovid (and Comirnaty) that reflect its ongoing contractual commitments (2024 10‑K, p. 107‑110).",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer contains fundamentally incorrect financial figures that directly contradict the ground truth: (1) 2022 Paxlovid Revenue: LLM claims $18.9 billion vs. ground truth of $76 million - a massive 248x overstatement. This is a catastrophic factual error. (2) 2024 Paxlovid Revenue: LLM claims $5.7 billion, but ground truth explicitly states 'direct revenue figures for Paxlovid are not explicitly stated' in 2024 filings. The LLM fabricated a specific number that contradicts the ground truth's clear statement that 2024 figures are not disclosed. (3) Remaining Performance Obligations: LLM correctly identifies ~$1 billion in remaining obligations (matches ground truth), but this is overshadowed by the massive errors above. (4) Deferred Revenue: LLM mentions $2.2 billion in deferred revenue for Paxlovid and Comirnaty combined - this is not mentioned in the ground truth and appears to be either fabricated or incorrectly attributed. (5) Multi-hop Reasoning: While the LLM attempts to synthesize information across years and identify a strategic shift, the foundation is built on false numbers, making the entire analysis unreliable. (6) The LLM's narrative about government contracts and commercial shift may have some merit conceptually, but is undermined by the factually incorrect revenue figures that form the core of the answer. The ground truth clearly establishes 2022 revenue at $76 million, not $18.9 billion - this is not a rounding or formatting difference but a fundamental factual error of massive proportions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 427,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the company's exposure to credit market tightness as a supply chain risk evolved between 2022 and 2023, and what does this indicate about its changing vulnerability to external financial conditions?",
      "original_answer": "In 2022, tighter credit or capital markets were described as a risk that 'negatively impacts' suppliers, with a direct concern that this could disrupt the supply of raw and packaging materials. By 2023, the framing shifted to indicate that the company's operations are 'impacted by' these conditions, suggesting a broader recognition of ongoing vulnerability. This evolution reflects a continuation of concern over credit market conditions but with a more integrated perspective on how such financial constraints affect not just suppliers, but the company's overall supply chain resilience.",
      "llm_answer": "In the 2022 MD&A the company identified “the impact on our suppliers of tighter credit or capital markets” as a supply‑chain risk (2022 p. 16‑17). The 2023 MD&A again lists the same risk (2023 p. 15‑16), with language that is at least as prominent, showing that the company’s exposure to credit‑market tightness has not diminished—and may be more pronounced—indicating a continued or growing vulnerability to external financial conditions.",
      "correctness_score": 5,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies that credit market tightness was mentioned as a supply chain risk in both 2022 and 2023 MD&As, with accurate page references (2022 p. 16-17 and 2023 p. 15-16). However, there are significant issues with the qualitative analysis and interpretation: (1) The LLM claims the language is 'at least as prominent' and suggests vulnerability 'may be more pronounced,' but the ground truth indicates a meaningful shift in framing between years—from 'negatively impacts suppliers' (2022) to 'impacted by' (2023), suggesting a broader, more integrated perspective on the company's own vulnerability. (2) The LLM's conclusion that exposure 'has not diminished—and may be more pronounced' contradicts the ground truth's more nuanced finding that the evolution reflects 'a continuation of concern' with 'a more integrated perspective.' (3) The LLM fails to capture the key distinction that the 2023 framing shows the company recognizing its own direct operational impact, not just supplier impact. (4) The LLM's reasoning that 'at least as prominent' language indicates 'continued or growing vulnerability' is speculative and not supported by the ground truth's more careful analysis of the semantic shift. The answer gets the basic facts right (years, page numbers, topic) but misses the critical interpretive nuance about how the company's understanding of its vulnerability evolved from indirect (supplier-focused) to more direct (company-focused).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 407,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2022 to 2024, based on disclosed figures and agreements?",
      "original_answer": "In 2022, Paxlovid was under Emergency Use Authorization (EUA) in the U.S. and had received conditional marketing authorization (CMA) in the EU and full approval in Japan, indicating early-stage regulatory and commercial momentum. By 2024, Pfizer disclosed that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, reflecting firm orders from long-term contracts with customers. This shows a significant financial commitment to Paxlovid, with delivery expected from 2025 through 2028, subject to renegotiation. Additionally, 2024 included a $771 million favorable final adjustment related to a prior revenue reversal tied to Paxlovid EUA-labeled treatment courses returned by the U.S. government, indicating ongoing financial adjustments and evolving contractual dynamics.",
      "llm_answer": "In the 2022 filing Pfizer’s Paxlovid exposure was described mainly as government‑supply contracts that generated most of the drug’s revenue, with no material performance‑obligation or deferred‑revenue balances disclosed. By the 2024 filing the picture had changed: the company now reports roughly $1 billion of remaining performance‑obligation for Paxlovid and about $2.2 billion of deferred revenue (≈ $1.4 billion current and $785 million non‑current), reflecting an amended U.S.‑government agreement that moved Paxlovid into the commercial market and generated sizable non‑cash revenue adjustments.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and introduces unsupported information not present in the ground truth. CRITICAL ERRORS: (1) The LLM claims ~$2.2 billion in deferred revenue (~$1.4 billion current + $785 million non-current) for Paxlovid in 2024, but the ground truth makes no mention of deferred revenue figures of this magnitude. This is a major quantitative discrepancy. (2) The LLM states there were 'no material performance-obligation or deferred-revenue balances disclosed' in 2022, which cannot be verified against the ground truth provided. (3) The LLM references an 'amended U.S.-government agreement that moved Paxlovid into the commercial market,' but the ground truth describes the $771 million adjustment as a 'favorable final adjustment related to a prior revenue reversal tied to Paxlovid EUA-labeled treatment courses returned by the U.S. government' - these are different characterizations. CORRECT ELEMENTS: (1) The ~$1 billion remaining performance obligation for 2024 is accurate. (2) The general shift from government-supply contracts to broader commercial dynamics is directionally correct. (3) The mention of non-cash revenue adjustments aligns with the $771 million adjustment. MISSING CRITICAL INFORMATION: The LLM completely omits the $771 million favorable adjustment figure, which is a key financial metric in the ground truth. The LLM also fails to mention the delivery timeline (2025-2028) and the subject-to-renegotiation clause. The regulatory progression (EUA in U.S., CMA in EU, full approval in Japan) is not addressed. MULTI-HOP REASONING: The LLM attempts to synthesize 2022 vs. 2024 evolution but introduces unsupported deferred revenue figures that appear to be fabricated or confused with other data. The reasoning about the shift from government to commercial is sound in principle but lacks proper grounding in the disclosed figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 512,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has the financial liability and risk exposure related to Aearo Technologies' respirator mask/asbestos litigation evolved from 2023 to 2024?",
      "original_answer": "In 2023, MMM had an accrual of $574 million for respirator mask/asbestos liabilities excluding Aearo, and Aearo was in bankruptcy proceedings, which resulted in a stay of litigation. By 2024, MMM, through Aearo, had accruals of $51 million specifically for Aearo-related asbestos, silica-related, and coal mine dust claims. Additionally, Aearo’s liability was limited by its agreement with Cabot, where Cabot assumed responsibility for claims involving exposure prior to January 1, 1997, as long as Aearo continued to pay a quarterly fee of $100,000. This represents a shift from a broader liability exposure under bankruptcy protection in 2023 to a more defined and limited liability framework in 2024, with Aearo actively managing its share of liability through contractual arrangements and cost-sharing with other co-defendants.",
      "llm_answer": "In the 2023 filing 3M disclosed a $62 million accrual for Aearo Technologies’ respirator‑mask/asbestos product liabilities and related defense costs; the 2024 filing shows that accrual was lowered to $51 million at year‑end. Although the recorded liability declined, the company warns that Aearo’s ultimate exposure remains uncertain and could exceed the accrued amount because of the complex joint‑and‑several liability structure and the limited indemnity arrangement with Cabot.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its credibility. QUANTITATIVE ERRORS: (1) The LLM claims a 2023 accrual of $62 million for Aearo, but the ground truth indicates MMM had a $574 million accrual for respirator mask/asbestos liabilities EXCLUDING Aearo in 2023. The $62 million figure appears to be fabricated or confused with another metric. (2) The 2024 figure of $51 million is correct and matches the ground truth. (3) The LLM's comparison ($62M to $51M decline) is based on an incorrect 2023 baseline. ENTITY/CONTEXT ERRORS: (1) The LLM fails to mention that Aearo was in bankruptcy proceedings in 2023, which is a critical contextual detail explaining the liability structure change. (2) The LLM omits the Cabot agreement details (assumption of pre-1997 claims, $100,000 quarterly fee), which are essential to understanding the 'more defined and limited liability framework' mentioned in the ground truth. (3) The LLM does not adequately explain the shift from bankruptcy protection to active liability management. REASONING QUALITY: The LLM does correctly identify that the liability declined and mentions uncertainty/joint-and-several liability concerns, showing some understanding of the risk exposure evolution. However, the foundation is built on incorrect numbers. The mention of Cabot's 'limited indemnity arrangement' is vague compared to the ground truth's specific details. COMPLETENESS: The answer addresses the evolution question but misses critical structural changes (bankruptcy to post-bankruptcy transition) and specific contractual arrangements that define the 2024 liability framework. The ground truth provides a more complete picture of how the liability exposure fundamentally changed in nature, not just in amount.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 482,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did the retail share of Skoal, a product of MO, change between 2023 and 2024, and how does this compare to its shipment volume trend between 2020 and 2021?",
      "original_answer": "The retail share of Skoal decreased from 9.3% in 2023 to 7.6% in 2024, indicating a decline in market presence. In contrast, Skoal's shipment volume was also declining between 2020 and 2021, dropping from 208.5 million packs/cans in 2020 to 197.4 million packs/cans in 2021. Both metrics show a consistent downward trend, suggesting a potential long-term challenge for the product's performance in the market.",
      "llm_answer": "Skoal’s retail share fell from 9.3 % in 2023 to 7.6 % in 2024 – a decline of 1.7 percentage points (≈18 % relative)【MO_10k_2024.pdf p. 48】. By contrast, its shipment volume slipped from 208.5 million cans/packs in 2020 to 197.4 million in 2021 – a drop of about 11 million units (≈5 %)【MO_10k_2022.pdf p. 46】. Both metrics declined, but the retail‑share contraction was larger in relative terms than the volume decline.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. All quantitative data matches the ground truth: (1) Retail share decline from 9.3% to 7.6% in 2023-2024 is correct; (2) Shipment volume decline from 208.5 to 197.4 million packs/cans in 2020-2021 is correct; (3) Calculations are accurate: 1.7 percentage point decline (9.3-7.6=1.7) and ~18% relative decline ((1.7/9.3)≈18.3%), and ~11 million unit drop (208.5-197.4=11.1) representing ~5.3% relative decline ((11.1/208.5)≈5.3%). The multi-hop synthesis correctly compares the two time periods and metrics, identifying that both show downward trends but with different magnitudes. The LLM appropriately notes that the retail share contraction was larger in relative terms (18%) than the volume decline (5%), which is a valid comparative insight. The answer includes proper source citations. Minor: The LLM uses slightly different phrasing ('cans/packs' vs 'packs/cans') but this is semantically equivalent. The answer fully addresses all parts of the multi-part question: (1) retail share change 2023-2024, (2) shipment volume trend 2020-2021, and (3) comparison between the two trends. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 331,
        "total_tokens": 1541
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Qualcomm's approach to multimedia technologies evolved from 2022 to 2024, particularly in terms of engineering focus areas and integration into product offerings?",
      "original_answer": "In 2022, Qualcomm emphasized engineering expertise in multimedia technologies such as camera, video, display, and computer vision as part of a broader set of capabilities including modem, RF, and sensor perception technologies. The focus was on enhancing existing products and developing new technologies for industries beyond mobile handsets, such as automotive and IoT. By 2024, the company's description of its multimedia technology efforts remained consistent, but there was a notable expansion in the integration of AI, particularly generative AI, into its research and development strategy. Additionally, in 2024, Qualcomm placed greater emphasis on enabling developers to design and deploy applications across multiple device categories and industries, signaling a more deliberate diversification strategy. This evolution reflects a shift from primarily hardware-centric multimedia innovation in 2022 to a more platform-oriented, AI-enhanced approach by 2024.",
      "llm_answer": "Qualcomm’s 2022 filing described multimedia as a core part of its Snapdragon‑SoC engineering—camera, video, display and computer‑vision expertise combined with CPU/GPU engines to deliver high‑performance, low‑power capabilities for smartphones, tablets, wearables and XR devices【2022, p.12‑16】. By the 2024 filing the focus had broadened to include AI‑accelerator (NPU) engines, sensor‑perception and drive‑policy groups, and the company now embeds multimedia functions not only in mobile platforms but also in automotive digital‑cockpit, ADAS/AD and IoT edge products, reflecting a more diversified integration strategy【2024, p.12‑16】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies the core multimedia technologies (camera, video, display, computer vision) emphasized in 2022; (2) Accurately captures the evolution toward AI integration by 2024, specifically mentioning NPU engines and AI-accelerators; (3) Properly synthesizes the multi-hop information showing diversification from mobile-centric to broader industry applications (automotive, IoT); (4) Correctly identifies the shift from hardware-centric to platform-oriented approach; (5) Appropriately references specific filing pages (2022 p.12-16, 2024 p.12-16) suggesting document grounding. MINOR WEAKNESSES: (1) The LLM answer adds specific technical details (Snapdragon-SoC, CPU/GPU engines, digital-cockpit, ADAS/AD) that, while accurate and relevant, go slightly beyond what the ground truth explicitly states—this is not incorrect but represents additional specificity; (2) The ground truth emphasizes 'generative AI' specifically while the LLM answer uses broader 'AI-accelerator' terminology—semantically equivalent but slightly different framing; (3) The ground truth mentions 'enabling developers to design and deploy applications across multiple device categories' as a strategic emphasis, which the LLM answer captures implicitly through 'diversified integration strategy' but doesn't explicitly state the developer-enablement angle. QUANTITATIVE ACCURACY: No numerical errors detected; dates (2022, 2024) are correct. MULTI-HOP REASONING: Successfully synthesizes information across two filing years and correctly identifies the evolution pattern. The reasoning chain (2022 baseline → 2024 expansion with AI → broader industry integration) is sound and matches the ground truth narrative. SEMANTIC EQUIVALENCE: The core message is preserved—Qualcomm's multimedia strategy evolved from hardware-focused mobile solutions to AI-enhanced, platform-oriented solutions across multiple industries.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 540,
        "total_tokens": 1946
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did 3M's financial relationship with the Aearo Entities evolve between 2023 and 2024, particularly in terms of equity investment and intercompany balances?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities, which resulted in the removal of a $0.7 billion asset balance in equity and other investments and a $0.6 billion net liability for former intercompany amounts from its consolidated balance sheet as of December 31, 2023. By 2024, the Aearo Entities were no longer consolidated, and instead, 3M now 'has a stake in' them, indicating a shift from full consolidation to a retained equity interest. This reflects a significant change in the financial structure and relationship between 3M and the Aearo Entities.",
      "llm_answer": "In 2023, after reconsolidating the Aearo Entities, 3M still carried a $0.7 billion equity‑investment balance in those entities and a $0.6 billion net intercompany liability (the gross amounts appeared as $0.9 billion in other liabilities and $0.3 billion in other assets)【MMM_10k_2023.pdf:102】. By 2024 the CAE Settlement was amended so that 3M elected to pay cash for the $1 billion stock portion of the settlement, effectively eliminating the equity stake and settling the intercompany balances through cash payments, removing both the equity‑investment and related intercompany amounts from the consolidated statements【MMM_10k_2024.pdf:48】.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresents the evolution of 3M's relationship with the Aearo Entities. Key issues: (1) FUNDAMENTAL MISCHARACTERIZATION: The ground truth states that in 2023, 3M 'reconsolidated' the Aearo Entities and removed the $0.7B equity investment and $0.6B net liability from the consolidated balance sheet, then by 2024 they were 'no longer consolidated' with 3M retaining a stake. The LLM incorrectly claims that in 2023 3M 'still carried' a $0.7B equity-investment balance, which contradicts the ground truth that these amounts were REMOVED upon reconsolidation. (2) INCORRECT NARRATIVE: The LLM introduces a CAE Settlement amendment and cash payment mechanism that is not mentioned in the ground truth answer. While this may be factually accurate from the 10-K filings, it fundamentally changes the narrative of how the relationship evolved and obscures the key point about the shift from consolidation to retained equity interest. (3) NUMBERS PARTIALLY CORRECT: The $0.7B, $0.6B, $0.9B, and $0.3B figures appear in the LLM answer, but their interpretation is wrong - the ground truth indicates these were removed from the balance sheet in 2023, not 'carried' as the LLM states. (4) MISSING KEY INSIGHT: The LLM fails to clearly articulate the primary evolution described in the ground truth: the shift from full consolidation (2023) to non-consolidated status with retained equity interest (2024). Instead, it focuses on a settlement mechanism that, while potentially relevant, obscures this fundamental structural change. (5) MULTI-HOP REASONING: The LLM does attempt to synthesize information across 2023 and 2024 filings, but arrives at an incorrect characterization of the relationship evolution. The reasoning about the CAE Settlement may be logically sound but is not aligned with the ground truth answer's focus on consolidation status changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 515,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Visa's Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of their strategic positioning within the company's broader value-added services portfolio?",
      "original_answer": "In 2022, Visa's Risk and Identity Solutions were described as tools that 'transform data into insights for near real-time decisions' and included named products like Visa Advanced Authorization and Visa Secure. These solutions were positioned primarily around fraud prevention and payment security, with an emphasis on helping clients protect account holder data and prevent fraud in the context of omnichannel commerce. By 2024, Risk and Identity Solutions had been elevated as one of five core categories within a more expansive value-added services portfolio that now includes Open Banking Solutions and Advisory Services. The 2024 report highlights that Visa offered more than 200 products and services as of September 30, 2024, many designed to work together for 'high impact business outcomes,' indicating a broader strategic integration of Risk and Identity Solutions within a more diversified services ecosystem.",
      "llm_answer": "In the 2022 10‑K, Visa described Risk and Identity Solutions as a collection of fraud‑prevention tools—such as Visa Advanced Authorization, Visa Secure, Visa Advanced Identity Score and CardinalCommerce decisioning—that turn data into near‑real‑time decisions and support authentication within its broader value‑added services suite【V_10k_2022.pdf p.13】. By the 2024 filing the offering had been rebranded as the AI‑driven “Visa Protect” suite, adding new products (Visa Deep Authorization, Visa Protect for A2A Payments, Visa Risk Manager with scheme‑agnostic Advanced Authorization) and is positioned as a core, AI‑powered fraud‑risk management component that layers on top of Visa’s network programs and anchors the company’s value‑added services portfolio【V_10k_2024.pdf p.12】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) REBRANDING CLAIM: The LLM states Risk and Identity Solutions was 'rebranded as the AI-driven \"Visa Protect\" suite' by 2024. The ground truth makes no mention of such a rebranding and indicates Risk and Identity Solutions remained as a distinct category within the portfolio. This is a major factual error. (2) PRODUCT NAMES: The LLM lists specific products like 'Visa Deep Authorization,' 'Visa Protect for A2A Payments,' and 'Visa Risk Manager with scheme-agnostic Advanced Authorization' that are not mentioned in the ground truth. While the ground truth confirms Visa Advanced Authorization and Visa Secure existed in 2022, the 2024 product names provided by the LLM cannot be verified against the ground truth and appear to be fabricated or hallucinated. (3) PORTFOLIO POSITIONING: The ground truth clearly states that by 2024, Risk and Identity Solutions was 'one of five core categories' alongside Open Banking Solutions and Advisory Services, with over 200 total products. The LLM's characterization of it 'anchoring the company's value-added services portfolio' is inconsistent with being one of five equal categories. (4) MISSING KEY INFORMATION: The LLM fails to mention the expansion to 200+ products and services, the addition of Open Banking Solutions and Advisory Services as peer categories, or the emphasis on 'high impact business outcomes' through integrated solutions. (5) QUANTITATIVE DATA: The ground truth provides the specific metric of 'more than 200 products and services as of September 30, 2024,' which the LLM completely omits. The LLM's answer demonstrates reasonable structure and addresses the 2022-2024 evolution question, but the core factual claims about rebranding and specific 2024 products are not supported by the ground truth and appear to be errors or hallucinations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 516,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did RTX's disclosure and quantification of Acquisition Accounting Adjustments' impact on operating profit evolve between 2023 and 2024?",
      "original_answer": "In 2023, RTX provided specific quantified impacts of Acquisition Accounting Adjustments on operating profit, showing a negative impact of $1,998 million in 2023, compared to $1,893 million in 2022 and $2,203 million in 2021. By 2024, RTX shifted its disclosure approach by providing qualitative policy context about the components of these adjustments, but did not include updated quantitative figures for the current year's impact on operating profit. This represents a move from concrete numerical disclosure to a more conceptual explanation of acquisition accounting practices without continuing the year-over-year quantification.",
      "llm_answer": "In the 2023 Form 10‑K RTX reported acquisition‑accounting adjustments of **$1.998 billion** to operating profit (‑$2,021 m amortization of intangibles, ‑$60 m PP&E fair‑value amortization and +$83 m amortization of acquired contract obligations), and noted that these items are excluded from management’s segment‑performance evaluation. The 2024 filing shows the same disclosure language but the total impact grew to **$2.058 billion** (‑$2,095 m intangibles, ‑$44 m PP&E, +$81 m contract obligations), a $60 m increase driven primarily by higher intangible‑asset amortization, while the segment‑level breakdown remained similar.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains fundamental factual errors that directly contradict the ground truth. (1) CRITICAL ERROR - 2024 QUANTIFICATION: The ground truth explicitly states that RTX did NOT provide updated quantitative figures for 2024, shifting instead to qualitative disclosure. The LLM claims 2024 showed $2.058 billion in acquisition accounting adjustments with detailed component breakdowns (-$2,095m intangibles, -$44m PP&E, +$81m contract obligations). This is factually incorrect - the ground truth indicates no such 2024 quantification was provided. (2) 2023 NUMBERS - PARTIALLY CORRECT: The LLM correctly identifies $1.998 billion for 2023 (matching ground truth's $1,998 million), and the component breakdown appears reasonable (-$2,021m, -$60m, +$83m sum to approximately -$1,998m), though these specific component figures are not verified in the ground truth. (3) CORE MISUNDERSTANDING: The LLM fundamentally misses the key evolution described in the ground truth - the shift FROM quantitative disclosure TO qualitative-only disclosure between 2023 and 2024. Instead, the LLM presents a false narrative of continued quantification with an increase to $2.058 billion. (4) MULTI-HOP REASONING FAILURE: The question asks about evolution of disclosure approach, which requires understanding both what was disclosed in 2023 AND what changed in 2024. The LLM failed to recognize the discontinuation of quantitative reporting in 2024. (5) The $60 million increase calculation (2.058B - 1.998B) is arithmetically correct IF the 2024 figure were real, but since it's fabricated, this calculation is meaningless. The answer demonstrates either hallucination of 2024 data or confusion between years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 463,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Microsoft's Office 365 Commercial revenue contribution to the Microsoft Cloud evolved between fiscal years 2022 and 2023, and what does this indicate about its growth trajectory within the broader cloud ecosystem?",
      "original_answer": "In fiscal year 2022, Office 365 Commercial was explicitly cited as a key growth driver within the Productivity and Business Processes segment, contributing to an 18% overall revenue increase for the company. By fiscal year 2023, Office 365 Commercial was included in a newly disclosed consolidated Microsoft Cloud revenue figure, which reached $111.6 billion in FY2023, up from $91.4 billion in FY2022. This indicates that Office 365 Commercial continued to grow as part of a broader, increasingly transparent cloud revenue portfolio that now includes Azure, LinkedIn (commercial portion), Dynamics 365, and other cloud services.",
      "llm_answer": "Microsoft Cloud revenue rose from **$91.4 billion in FY 2022 to $111.6 billion in FY 2023**【MSFT_10k_2023.pdf p.91‑95】, while **Office products and cloud services – which includes Office 365 Commercial – grew from $44.97 billion to $48.85 billion** over the same period【MSFT_10k_2023.pdf p.91‑95】.  This lifted Office 365 Commercial’s absolute contribution but reduced its share of the overall cloud business from roughly **49% to about 44%**, indicating that Office 365 Commercial continues to expand but at a slower pace than Azure and other cloud services, reflecting a strong yet comparatively modest growth trajectory within Microsoft’s broader cloud ecosystem【MSFT_10k_2022.pdf p.41‑45】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong quantitative accuracy on the primary Microsoft Cloud figures ($91.4B to $111.6B) and Office products revenue ($44.97B to $48.85B), which align with the ground truth. The calculated percentages (49% to 44% share) are mathematically correct based on the provided numbers. However, there are several issues: (1) The LLM introduces specific Office products revenue figures that are not explicitly mentioned in the ground truth answer, which focuses on Office 365 Commercial specifically rather than the broader 'Office products and cloud services' category. While these may be accurate from the 10-K, they represent a different level of granularity than the original answer. (2) The LLM's interpretation that Office 365 Commercial's 'share' declined from 49% to 44% is an inference not explicitly stated in the ground truth, which notes Office 365 Commercial 'continued to grow' without quantifying its relative share decline. (3) The ground truth emphasizes the consolidation of Microsoft Cloud reporting and Office 365 Commercial's role as a key growth driver in FY2022, then its inclusion in the broader cloud metric in FY2023 - the LLM captures the numbers but downplays the significance of this reporting change. (4) The LLM's conclusion about 'slower pace than Azure' is reasonable inference but goes beyond what the ground truth explicitly states. The answer is substantially correct on core facts and demonstrates sound multi-hop reasoning across fiscal years and revenue categories, but introduces additional analytical layers not present in the original answer and shifts focus from Office 365 Commercial specifically to the broader Office products category.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 463,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did Merck's alliance revenue related to Lynparza evolve between 2023 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2023, alliance revenue for Lynparza was part of Merck's broader alliance revenue reporting, which included profits based on product sales net of cost of sales and commercialization costs. By 2024, alliance revenue related to Lynparza specifically grew by 9%, driven by higher demand in most international markets. This growth indicates a positive shift in Lynparza's market performance during the period.",
      "llm_answer": "Merck’s Lynparza alliance revenue rose from $1.199 billion in 2023 to $1.311 billion in 2024 – a 9% increase (≈11% excluding foreign‑exchange effects). The boost was attributed mainly to higher demand for Lynparza in most international markets.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ISSUES: The LLM answer provides specific dollar amounts ($1.199 billion in 2023 and $1.311 billion in 2024) that cannot be verified against the ground truth. The ground truth does not provide these specific revenue figures for Lynparza alliance revenue - it only states that alliance revenue 'grew by 9%' and mentions 'higher demand in most international markets.' The LLM appears to have fabricated precise financial numbers without source documentation. While the 9% growth figure matches the ground truth, the specific dollar amounts are unsupported and likely incorrect. Additionally, the LLM introduces a claim about '≈11% excluding foreign-exchange effects' which is not mentioned in the ground truth at all, suggesting either hallucination or reliance on unverified sources. The ground truth indicates that in 2023, Lynparza alliance revenue was 'part of Merck's broader alliance revenue reporting' without separate disclosure, making it questionable whether these specific figures could even exist. The LLM failed to acknowledge the structural difference in how 2023 vs 2024 data was reported. The only correct element is the 9% growth rate and the attribution to international market demand, but the quantitative specificity is fundamentally unreliable and contradicts the ground truth's more general reporting approach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1157,
        "completion_tokens": 373,
        "total_tokens": 1531
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the treatment and disclosure of the Procter & Gamble 2014 Stock and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of its regulatory context and inclusion in equity compensation reporting?",
      "original_answer": "In 2023, the 2014 Stock and Incentive Compensation Plan was disclosed in the context of regulatory documentation and was referenced alongside other compensation plans and agreements, such as the 2009 and 2019 plans, indicating its active role in executive compensation. By 2024, the plan was included in a broader list of equity compensation plans for reporting on stock issuances upon exercise of options, suggesting a shift from regulatory disclosure to a focus on ownership structure and equity compensation transparency. This evolution indicates a more integrated view of the 2014 plan within the company’s overall equity compensation framework.",
      "llm_answer": "In the 2023 Form 10‑K the 2014 Stock and Incentive Compensation Plan was disclosed as one of the company’s equity‑compensation plans and the filing simply referred readers to the 2023 Proxy Statement (filed under Regulation 14A) for any additional details. In the 2024 Form 10‑K the plan is still listed in the equity‑compensation table, but the filing now incorporates extra information by reference to the 2024 Proxy Statement (Regulation 14A) and adds specific exhibit citations (Exhibits 10‑24, 10‑25 and 10‑26) for the plan and its governing regulations, showing a more explicit regulatory context and continued inclusion of the 2014 Plan in equity‑compensation reporting.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer provides specific details about regulatory references (Regulation 14A, Exhibits 10-24, 10-25, 10-26) and mentions the shift from 2023 to 2024 filings. However, there are significant issues with accuracy and alignment to the ground truth: (1) FACTUAL CONCERNS: The LLM introduces specific exhibit numbers (10-24, 10-25, 10-26) that are not mentioned in the ground truth answer, raising questions about whether these are accurate or fabricated details. The ground truth does not reference specific exhibit citations. (2) CHARACTERIZATION MISMATCH: The ground truth describes a shift from 'regulatory disclosure to a focus on ownership structure and equity compensation transparency,' emphasizing a change in reporting focus. The LLM characterizes this as 'showing a more explicit regulatory context,' which contradicts the ground truth's assertion of moving away from regulatory disclosure focus. (3) COMPLETENESS: The LLM answer does address the 2023-2024 evolution and mentions both Proxy Statements, which aligns with the ground truth's reference to multiple plans and regulatory context. However, the ground truth emphasizes the 'integrated view' and 'broader list' of equity compensation plans, while the LLM focuses on exhibit citations and regulatory references. (4) MULTI-HOP REASONING: The LLM correctly identifies the multi-year comparison but mischaracterizes the nature of the evolution. The ground truth suggests a shift in how the plan is presented (from regulatory documentation context to ownership/equity transparency context), while the LLM suggests increased regulatory explicitness. (5) NUMBERS/DATES: The years 2023 and 2024 are correct, and the regulatory references (Regulation 14A, Form 10-K) are appropriate. However, the specific exhibit numbers lack verification against the ground truth. The answer is partially correct on core facts but contains characterization errors and potentially unverified specific details that diverge from the ground truth's interpretation of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 545,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the treatment of the 1992 Stock Plan evolved between the 2023 and 2024 10-K filings, particularly in terms of its role within the company's equity compensation structure?",
      "original_answer": "In the 2023 10-K filing, the 1992 Stock Plan was referenced as an adopted plan with specific terms and conditions incorporated by reference to prior filings. However, in the 2024 10-K filing, the 1992 Stock Plan is listed among other equity compensation plans in a consolidated table that outlines shares authorized for issuance upon the exercise of options, warrants, and rights. This indicates a shift from a standalone referenced plan to one being tracked alongside newer plans, suggesting its role has transitioned from active adoption to a more passive stake within the broader equity compensation framework.",
      "llm_answer": "The 1992 Stock Plan is still listed among P&G’s equity‑compensation plans in both the 2023 and 2024 Form 10‑K tables (Item 12 shows the 1992 Stock Plan alongside the other plans) 【PG_10k_2023.pdf: p.67‑71】, but the 2024 filing adds a specific note that “only the Procter & Gamble 2019 Stock and Incentive Compensation Plan … allows for future grants of securities,” thereby confirming that the 1992 Plan is now treated as a legacy vehicle that only covers existing awards and is not used for new grants 【PG_10k_2024.pdf: p.66‑70】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer provides a more specific and actionable evolution of the 1992 Stock Plan's treatment between 2023 and 2024 filings compared to the ground truth. STRENGTHS: (1) Correctly identifies that the 1992 Stock Plan appears in equity compensation tables in both years (Item 12 reference is accurate); (2) Accurately captures the key distinction - the 2024 filing explicitly notes that only the 2019 Plan allows future grants, making the 1992 Plan a legacy vehicle; (3) Provides concrete evidence with specific page references (p.67-71 for 2023, p.66-70 for 2024); (4) The multi-hop reasoning is sound - synthesizing information about plan status across two years and identifying the shift from active to legacy status; (5) Semantic equivalence is strong - both answers convey that the plan transitioned from active to passive/legacy status. MINOR CONSIDERATIONS: (1) The ground truth uses more abstract language about 'shift from standalone referenced plan to consolidated table tracking,' while the LLM provides more concrete operational detail (legacy vehicle, no new grants); (2) The LLM answer is actually MORE specific and informative than the ground truth by explicitly stating the 2019 Plan is the only one for future grants; (3) No quantitative errors detected - dates (2023, 2024) and plan names are correct. The LLM answer demonstrates superior multi-hop synthesis by connecting the table presence across years with the explicit policy note about future grants, providing clearer insight into the actual evolution of the plan's role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 426,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the company's emphasis on large-scale transformations evolved between 2023 and 2024, particularly in terms of client spending patterns and revenue conversion timelines?",
      "original_answer": "In 2023, the filing noted that clients were reducing or deferring spending on smaller contracts with shorter durations and that there was a slowdown in client spending, especially for consulting services. However, clients were still prioritizing large-scale transformations, which convert to revenue over a longer period. In 2024, the filing reiterated that clients continued to prioritize large-scale transformations, emphasizing the ongoing shift toward longer-duration contracts. While there was no explicit quantitative metric provided in either year, the repeated emphasis in both filings on the extended revenue conversion timeline for large-scale transformations indicates a strategic reinforcement of this focus, especially amid ongoing economic volatility.",
      "llm_answer": "In the 2023 filing the company warned that volatile macro‑economic conditions were causing clients to cut back or defer spending on smaller, short‑duration contracts, but it already noted that large‑scale transformation work remained a core source of revenue. By fiscal 2024 the filing stresses that “clients continue to prioritize large‑scale transformations, which convert to revenue over a longer period,” while spending on the smaller contracts remains muted, showing a clearer shift toward longer‑duration, higher‑value transformation projects and a lengthening of the revenue‑conversion timeline【2024‑p19‑22】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) FACTUAL ACCURACY: The answer correctly identifies the 2023 context (clients reducing/deferring spending on smaller contracts while prioritizing large-scale transformations) and the 2024 continuation/reinforcement of this trend. The direct quote from the 2024 filing ('clients continue to prioritize large-scale transformations, which convert to revenue over a longer period') is accurate and well-integrated. (2) QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either the ground truth or LLM answer, which is appropriate since the ground truth explicitly states 'no explicit quantitative metric provided in either year.' The LLM correctly avoids fabricating metrics. (3) MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years (2023 and 2024), showing the evolution of the company's emphasis. It correctly identifies the causal relationship between macro-economic volatility and spending patterns, and traces the consistent strategic focus on large-scale transformations. (4) COMPLETENESS: The answer addresses all parts of the question: the evolution between years, client spending patterns, and revenue conversion timelines. The inclusion of the citation [2024-p19-22] adds credibility. (5) SEMANTIC EQUIVALENCE: The LLM's phrasing ('clearer shift toward longer-duration, higher-value transformation projects and a lengthening of the revenue-conversion timeline') conveys the same meaning as the ground truth's 'strategic reinforcement of this focus' and 'extended revenue conversion timeline.' Minor strength: The LLM adds slight interpretive value by characterizing the shift as 'clearer' in 2024, which is a reasonable inference from the repeated emphasis noted in the ground truth. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 512,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How did Accenture's issuance of Class A Ordinary Shares for employee compensation change from fiscal 2023 to 2024, and what was the impact on the company's equity structure?",
      "original_answer": "In fiscal 2023, Accenture acquired Class A Ordinary Shares primarily through share withholding for payroll tax obligations related to employee equity awards. In fiscal 2024, the company issued 7,970 Class A Ordinary Shares specifically for employee share programs, while also purchasing 12,181 treasury shares. This shift reflects a more active use of Class A Ordinary Shares for compensation purposes in 2024. The equity structure was impacted as Class A Ordinary Shares increased from 15,656,591 in 2023 to 15,664,561 in 2024, while treasury shares decreased in value from $(3,408,491) million to $(6,678,037) million, indicating a significant reallocation of shares for employee programs.",
      "llm_answer": "In fiscal 2023 Accenture issued **7,970 Class A ordinary shares** for employee‑share programs, which added **≈ $1.94 billion of additional paid‑in capital** and raised total shareholders’ equity by **≈ $1.35 billion** (offset by a $103.9 million reduction in retained earnings)【ACN_10k_2023.pdf p. 81‑85】.  \n\nIn fiscal 2024 the issuance slipped to **7,869 shares**, but the higher market price generated **≈ $2.28 billion of additional paid‑in capital**, increasing total equity by **≈ $1.42 billion** (with retained earnings down $131.1 million)【ACN_10k_2024.pdf p. 68‑72】.  \n\nThus, the share count fell slightly, yet the higher per‑share value produced a larger boost to Accenture’s equity base.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer contains fundamental factual inaccuracies that directly contradict the ground truth:\n\n1. SHARE COUNT REVERSAL: The LLM states fiscal 2023 had 7,970 shares issued and fiscal 2024 had 7,869 shares (a decrease). The ground truth explicitly states the OPPOSITE: fiscal 2023 involved share withholding/acquisition, while fiscal 2024 involved issuance of 7,970 shares. The LLM has reversed the years and the direction of the transaction.\n\n2. MISSING KEY METRICS: The ground truth provides specific Class A Ordinary Share counts (15,656,591 in 2023 vs 15,664,561 in 2024) and treasury share values ($(3,408,491) million to $(6,678,037) million). The LLM provides none of these critical equity structure metrics.\n\n3. MISSING TREASURY SHARE INFORMATION: The ground truth mentions 12,181 treasury shares purchased in 2024, which is completely absent from the LLM answer. This is a material component of the equity structure change.\n\n4. UNVERIFIABLE DOLLAR AMOUNTS: The LLM cites specific dollar figures ($1.94B, $1.35B, $2.28B, $1.42B, $103.9M, $131.1M) with page references, but these cannot be verified against the ground truth and appear to be fabricated or misattributed. The ground truth does not provide these specific APIC or equity impact figures.\n\n5. INCOMPLETE ANALYSIS: The LLM fails to address the core equity structure changes (share count increases, treasury share reallocation) that are central to the ground truth answer.\n\n6. LOGICAL INCONSISTENCY: The LLM's conclusion that \"share count fell slightly, yet higher per-share value produced larger boost\" contradicts the ground truth showing share count INCREASED from 2023 to 2024.\n\nThe answer demonstrates poor multi-hop synthesis, incorrect entity identification (reversed fiscal years), and appears to contain fabricated financial data rather than accurate extraction from SEC filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 512,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did MDLZ's exposure to Canadian-denominated debt instruments change between 2022 and 2023, and how does this shift compare to the company's overall trend in managing foreign currency-denominated debt during this period?",
      "original_answer": "In 2022, MDLZ reported a decrease in Canadian notes of $3 million, continuing a trend of declining balances from $17 million in 2019 to $7 million in 2020 and $3 million in 2021. However, in 2023, the company experienced an increase in Canadian notes by $8 million, reversing the previous downward trajectory. This shift contrasts with the broader pattern of fluctuating foreign currency exposure, where Euro notes decreased significantly from $211 million in 2021 to $81 million in 2023, while Swiss franc notes also showed volatility. The reversal in Canadian notes indicates a notable deviation from the prior year's trend of reducing exposure to this currency denomination.",
      "llm_answer": "MDLZ’s non‑U.S. dollar debt that is hedged as a net investment increased slightly for Canadian‑dollar notes, rising from **$443 million at 12/31/2022 to $453 million at 12/31/2023** – a $10 million (≈2 %) increase【MDLZ_10k_2023.pdf p. 96‑100】.  This modest uptick mirrors the company’s broader foreign‑currency debt‑management trend, where total non‑U.S. dollar debt designated as net investment hedges grew from **$7.319 billion to $7.456 billion** over the same period, indicating MDLZ is maintaining (and slightly expanding) its overall foreign‑currency debt exposure rather than reducing it【MDLZ_10k_2023.pdf p. 96‑100】.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 1,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and appears to reference entirely different data than what the ground truth establishes. Critical issues: (1) QUANTITATIVE ERRORS - The LLM claims Canadian-denominated debt increased from $443M to $453M (a $10M increase), but the ground truth explicitly states Canadian notes increased by $8 million in 2023 and were at much lower absolute levels ($3M in 2021, $7M in 2020, $17M in 2019). The LLM's figures ($443M-$453M) are off by orders of magnitude and appear to reference a different debt category entirely. (2) MISIDENTIFIED METRIC - The LLM discusses 'non-U.S. dollar debt that is hedged as a net investment' totaling $7.3-7.4 billion, which is a completely different metric than the specific Canadian notes exposure the question asks about. The ground truth focuses on Canadian notes specifically (single-digit to low double-digit millions), not total non-U.S. dollar hedged debt. (3) INCOMPLETE MULTI-HOP SYNTHESIS - The question asks for comparison to overall foreign currency debt trends. The ground truth correctly synthesizes this by noting Euro notes decreased from $211M to $81M and Swiss franc notes showed volatility, providing proper context. The LLM only mentions total non-U.S. dollar debt growth without addressing the specific currency comparisons. (4) DIRECTIONAL ACCURACY - The LLM correctly identifies an increase in Canadian exposure in 2023, which aligns with the ground truth's statement of an $8M increase reversing prior downward trends. However, this is the only correct directional element amid massive numerical errors. (5) MISSING HISTORICAL CONTEXT - The ground truth provides crucial historical perspective (2019-2022 declining trend), which the LLM completely omits. The LLM appears to have confused or conflated different debt categories from the 10-K filing, making the answer fundamentally unreliable despite partial directional alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 519,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Accenture's approach to engaging with growth-stage companies evolved from 2023 to 2024, particularly in terms of strategic involvement and investment activity?",
      "original_answer": "In 2023, Accenture Ventures was described as primarily partnering with growth-stage companies that create innovative enterprise technologies. By 2024, the relationship evolved from a partnership model to a more direct investment approach, indicating a deeper financial and strategic commitment. This shift from 'partners with' to 'invests in' growth-stage firms suggests Accenture is taking a more active role in shaping innovation ecosystems through capital allocation, aligning with its broader innovation strategy supported by $1.3 billion in R&D spending in fiscal 2023 and $1.2 billion in fiscal 2024.",
      "llm_answer": "Both the 2023 and 2024 10‑K filings describe Accenture’s engagement with growth‑stage firms through Accenture Ventures, stating that it “partners with and invests in growth‑stage companies that create innovative enterprise technologies.” The language and emphasis are essentially unchanged, indicating that Accenture’s strategic involvement and venture‑investment activity with these companies remained consistent from 2023 to 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core conclusion. The ground truth explicitly states that Accenture's approach EVOLVED from 2023 to 2024, shifting from a 'partnership model' to a 'more direct investment approach,' representing a deeper financial and strategic commitment. The LLM answer directly contradicts this by claiming the language and emphasis are 'essentially unchanged' and that engagement 'remained consistent.' This is a critical factual error that misses the entire premise of the question. Regarding quantitative accuracy: The LLM correctly identifies the R&D spending figures ($1.3 billion in fiscal 2023 and $1.2 billion in fiscal 2024) are mentioned in the ground truth context, though the LLM does not cite these numbers. However, the LLM fails to recognize or discuss the evolution in language from 'partners with' (2023) to 'invests in' (2024) that the ground truth emphasizes as evidence of strategic shift. The LLM's assertion that both years use identical language ('partners with and invests in') appears to be incorrect based on the ground truth's explicit statement about the shift from 'partners with' to 'invests in.' This represents a failure in multi-hop reasoning - the LLM needed to synthesize the evolution in Accenture's strategic positioning across the two years but instead concluded there was no meaningful change. The answer lacks the contextual understanding that this shift reflects deeper financial commitment and more active role in innovation ecosystems, which are key aspects of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 426,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Merck's financial and strategic involvement in the Lynparza collaboration with AstraZeneca evolved from 2022 to 2024, particularly in terms of asset amortization and alliance revenue growth?",
      "original_answer": "In 2022, Merck was amortizing an intangible asset balance of $1.1 billion related to Lynparza, which included capitalized milestone payments, and was expected to be amortized through 2028. By 2024, the focus shifted from asset amortization to revenue growth, with alliance revenue from Lynparza increasing by 9% due to higher demand in international markets. Additionally, in early 2025, Lynparza received a new approval in China for adjuvant treatment in early breast cancer, indicating an expansion in its therapeutic footprint and strategic importance to Merck.",
      "llm_answer": "Merck’s Lynparza intangible asset—recorded at $1.1 billion at 12/31/2021 and amortized over its estimated useful life through 2028 (MRK 2022 10‑K, pp. 100‑104)—has continued to be written‑off each year, lowering the net balance as amortization expense is reflected in cost of sales.  At the same time, Merck’s share of Lynparza profits grew from $1.116 billion in 2022 to $1.311 billion in 2024, a 9 % increase (MRK 2024 10‑K, pp. 53‑57), indicating a stronger financial and strategic stake in the collaboration.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the $1.1 billion intangible asset balance related to Lynparza and the 2028 amortization timeline. It accurately captures the 9% revenue growth figure and correctly notes the shift from asset amortization focus to revenue growth. The multi-hop synthesis across 2022-2024 is logically sound, and the company/metric identification is accurate.\n\nWEAKNESSES: (1) CRITICAL QUANTITATIVE ERROR: The LLM states Merck's Lynparza profits grew from $1.116 billion in 2022 to $1.311 billion in 2024. However, the ground truth specifies 'alliance revenue from Lynparza increasing by 9%' without providing these specific profit figures. The LLM appears to have introduced unsourced numbers ($1.116B and $1.311B) that cannot be verified against the ground truth. While the 9% growth rate is correct, attributing it to specific profit figures not mentioned in the original answer is problematic. (2) INCOMPLETE COVERAGE: The LLM omits the significant strategic development mentioned in the ground truth—the early 2025 China approval for adjuvant treatment in early breast cancer. This is a material omission as it represents expansion of therapeutic footprint and strategic importance. (3) ASSET BALANCE DATING: The LLM references the asset as 'recorded at $1.1 billion at 12/31/2021' while the ground truth states it was the balance 'in 2022.' This is a minor temporal discrepancy but worth noting.\n\nMULTI-HOP REASONING: The synthesis of amortization trends (2022-2024) and revenue growth is sound, but the introduction of unverified profit figures undermines the credibility of the quantitative analysis. The reasoning about the shift from asset focus to revenue growth is valid and well-articulated.\n\nOVERALL ASSESSMENT: The answer demonstrates good understanding of the Lynparza collaboration evolution and correctly identifies key metrics and trends. However, the introduction of specific profit figures without ground truth support and the omission of the China approval represent material gaps that prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 553,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has AVGO's strategic emphasis on ValueOps changed between 2023 and 2024, and what does this indicate about its evolving role in the Distributed Software portfolio?",
      "original_answer": "In 2023, ValueOps was listed as one of several key offerings under AVGO's Distributed Software portfolio, positioned alongside other solutions like DevOps and AIOps without specific elaboration on its strategic role. By 2024, ValueOps was elevated to be one of the three core domains—alongside DevOps and AIOps—that AVGO's distributed software solutions are 'organized in the domains of,' with an explicit emphasis on delivering 'end-to-end visibility across all stages of the digital lifecycle.' This indicates a strategic shift where ValueOps became more central to AVGO's value proposition, aligning it more deeply with business outcomes and customer experiences. The change reflects a broader evolution from being a feature in the portfolio to a foundational pillar supporting enterprise digital transformation.",
      "llm_answer": "In the 2023 filing, ValueOps is mentioned only as a line‑item under the Distributed Software portfolio – listed alongside DevOps and AIOps without any detailed narrative (AVGO 10‑K 2023 p. 6‑7). By the 2024 filing, ValueOps receives its own dedicated description that highlights its value‑stream‑management capabilities and its function in aligning business and development teams, indicating a much stronger strategic focus (AVGO 10‑K 2024 p. 10‑11). This shift shows AVGO is elevating ValueOps from a peripheral offering to a core, growth‑driving pillar of its Distributed Software portfolio.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core shift in ValueOps' strategic positioning between 2023 and 2024, capturing the essential narrative that ValueOps moved from a peripheral listing to a more prominent strategic focus. The answer accurately notes the 2023 positioning (listed alongside DevOps and AIOps without detailed narrative) and the 2024 elevation (receiving dedicated description with emphasis on value-stream-management capabilities). The multi-hop reasoning is sound—comparing across two years and synthesizing the strategic evolution. However, there are some notable differences from the ground truth: (1) The LLM mentions 'value-stream-management capabilities' and 'aligning business and development teams' as specific 2024 descriptions, which are reasonable inferences but not explicitly confirmed in the ground truth statement. (2) The ground truth emphasizes the explicit framing of ValueOps as 'one of the three core domains' with 'end-to-end visibility across all stages of the digital lifecycle,' which the LLM answer doesn't capture with the same specificity. (3) The ground truth's characterization of the shift as moving from 'a feature in the portfolio to a foundational pillar supporting enterprise digital transformation' is more nuanced than the LLM's 'peripheral offering to a core, growth-driving pillar.' The page references provided (p. 6-7 for 2023, p. 10-11 for 2024) appear reasonable but cannot be verified against the actual filings. The answer demonstrates good understanding of the strategic evolution but lacks some of the specific language and framing details present in the ground truth, particularly regarding the 'three core domains' structure and the 'end-to-end visibility' messaging.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 472,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did FedEx's strategic approach to Network 2.0 within the DRIVE transformation evolve between 2023 and 2024, particularly in terms of expected cost savings and implementation risks?",
      "original_answer": "In 2023, FedEx emphasized the strategic importance of Network 2.0 as part of its DRIVE transformation, noting that significant investments were being made with the expectation of achieving operational efficiencies, network flexibility, and alignment of the cost base with demand. However, the filing acknowledged that the failure to successfully execute Network 2.0 within the expected time frame and cost could adversely affect future results. By 2024, FedEx shifted focus to the integration complexities of Network 2.0, including risks related to harmonizing operating practices, maintaining customer and service provider agreements, addressing labor and cultural differences, and managing unforeseen expenses. The 2024 filing also noted that the actual amount and timing of cost savings and permanent cost reductions might differ from expectations, and that asset impairment charges, tax impacts, and litigation risks could arise. This reflects a transition from strategic planning and investment justification in 2023 to operational integration and financial risk mitigation in 2024.",
      "llm_answer": "In the 2023 filing FedEx introduced Network 2.0 as a core element of its DRIVE transformation, stating that the multi‑year effort was expected to generate significant operational efficiencies and measurable cost‑savings that would reduce its permanent cost structure. By the 2024 filing the company had completed the One FedEx legal consolidation and framed Network 2.0 as still “ongoing,” warning that integration could take longer, be costlier and deliver less‑than‑expected savings, and outlining a broader set of implementation risks—including labor‑status and union issues, IT and back‑office system integration, regulatory and legal challenges, cultural differences and possible loss of customers or employees.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing the evolution of FedEx's Network 2.0 strategy between 2023 and 2024. STRENGTHS: (1) Correctly identifies the 2023 focus on operational efficiencies and cost savings as core strategic justification; (2) Accurately captures the 2024 shift toward integration complexities and risk mitigation; (3) Properly synthesizes multi-hop information across two fiscal years; (4) Correctly identifies One FedEx legal consolidation as a 2024 milestone; (5) Accurately lists specific 2024 implementation risks (labor-status/union issues, IT/back-office integration, regulatory/legal challenges, cultural differences, customer/employee retention); (6) Correctly characterizes the tone shift from strategic planning to operational risk management. MINOR GAPS: (1) The LLM answer does not explicitly mention 'asset impairment charges, tax impacts, and litigation risks' that were noted in the ground truth as potential 2024 financial consequences; (2) The ground truth emphasizes 'alignment of the cost base with demand' as a 2023 objective, which the LLM answer doesn't explicitly state (though 'permanent cost structure' is semantically similar); (3) The ground truth notes that 'actual amount and timing of cost savings might differ from expectations' - the LLM captures this concept but with slightly different phrasing ('deliver less-than-expected savings'). QUANTITATIVE ACCURACY: No specific dollar amounts or percentages were provided in either answer, so this dimension is not directly testable. The temporal references (2023 vs 2024) are correct. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and correctly identifies the strategic evolution. The connection between One FedEx consolidation and Network 2.0 integration challenges is appropriately made. SEMANTIC EQUIVALENCE: The core message matches - FedEx moved from emphasizing benefits to emphasizing risks and integration challenges. The phrasing differs but conveys equivalent meaning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1460,
        "completion_tokens": 546,
        "total_tokens": 2006
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did the financial impact from equity method investment contracts evolve between 2022 and 2023, and what does this indicate about MDLZ's engagement with these investments?",
      "original_answer": "In 2022, MDLZ reported a net liability of $3 million related to equity method investment contracts. By 2023, this position had shifted to a gain of $7 million from equity method investment contracts, indicating a reversal in financial impact and potentially more active or favorable engagement with these investments. This evolution highlights a strategic or operational shift in how MDLZ managed these equity method investments over the two years.",
      "llm_answer": "The 2023 filing shows a $7 million pre‑tax gain from equity‑method investment contracts, whereas the 2022 filing recorded no gain or loss (shown as “‑”) for the same line item【MDLZ_10k_2023 p. 100】【MDLZ_10k_2022 p. 109】. The move from a neutral impact in 2022 to a modest positive gain in 2023 indicates that MDLZ’s equity‑method investments began to generate earnings, reflecting a modest but active engagement with those holdings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERROR: The LLM answer contains a critical quantitative inaccuracy. The ground truth states that in 2022, MDLZ reported a NET LIABILITY of $3 million (negative impact), not a neutral position or zero. The LLM incorrectly characterizes 2022 as showing 'no gain or loss (shown as \"-\")' when the actual 2022 figure was -$3 million. This is a fundamental error in reading and reporting the financial data. The 2023 figure of $7 million gain is correctly identified. However, the comparison is therefore incorrect: the LLM describes the evolution as moving 'from a neutral impact in 2022 to a modest positive gain in 2023,' when it actually moved from a $3 million liability (negative) to a $7 million gain (positive) - a $10 million swing, not a shift from zero. The LLM's interpretation that this indicates 'equity-method investments began to generate earnings' is partially reasonable but misses the significance of the $3 million liability reversal in 2022. The multi-hop reasoning is incomplete because it fails to accurately synthesize the 2022 and 2023 data points. The answer does correctly identify the company (MDLZ), the metric (equity method investment contracts), and the years (2022-2023), but the core quantitative comparison is fundamentally flawed. The semantic interpretation about 'active engagement' is reasonable but built on incorrect foundational numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 386,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did Broadcom's (AVGO) estimated cost to complete for the VMware Cloud Foundation July 2024 releases evolve from fiscal year 2023 to fiscal year 2024, and what does this indicate about the development progress relative to expectations?",
      "original_answer": "The estimated cost to complete for the VMware Cloud Foundation July 2024 releases remained unchanged at $38 million from fiscal year 2023 to fiscal year 2024. This consistency in the cost estimate indicates that the development progress for this product was proceeding largely as planned, with actual expenditures aligning with earlier projections. The lack of an increase or decrease in the estimated cost to complete suggests that Broadcom (AVGO) did not encounter significant unexpected expenses or delays in the development timeline for this specific release.",
      "llm_answer": "Broadcom’s 2023 10‑K listed an estimated $38 million to finish the VMware Cloud Foundation July 2024 releases, and the 2024 10‑K shows the same $38 million figure. The unchanged cost‑to‑complete estimate signals that the July‑2024 release is progressing on schedule and that development costs are holding to the original expectations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and addresses the core question effectively. (1) CORRECTNESS: All factual information is correct - the $38 million figure is accurately cited for both fiscal years 2023 and 2024, and the conclusion that the estimate remained unchanged is accurate. (2) QUANTITATIVE ACCURACY: The dollar amount ($38 million) is precisely correct with no calculation errors. The comparison across fiscal years is accurate. (3) QUALITATIVE ACCURACY: The LLM correctly identifies the key entities (Broadcom/AVGO, VMware Cloud Foundation July 2024 releases, fiscal years 2023 and 2024) and performs sound multi-hop reasoning by synthesizing information from both the 2023 and 2024 10-K filings. The interpretation that unchanged estimates indicate on-schedule progress and alignment with expectations is logically sound and matches the ground truth reasoning. (4) CONTEXTUAL RELEVANCE: The answer directly addresses the question about how the cost estimate evolved and what it indicates about development progress. The only minor difference from the ground truth is slightly less elaboration on the implications (the LLM doesn't explicitly mention 'no significant unexpected expenses or delays'), but the core message is semantically equivalent and the answer is appropriately concise while remaining complete. The LLM's phrasing 'development costs are holding to the original expectations' effectively conveys the same meaning as the ground truth's 'actual expenditures aligning with earlier projections.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 418,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has the strategic positioning of FedEx Office's Ship and Go kiosk evolved between 2023 and 2024, and what does this indicate about the company's approach to e-commerce logistics and returns management?",
      "original_answer": "In 2023, the Ship and Go kiosk was described primarily as a self-serve shipping solution available in approximately 1,300 locations, allowing customers to generate labels via mobile or QR code and drop off packages securely. While it mentioned facilitating e-commerce returns, the integration was not emphasized. By 2024, the description of Ship and Go remained consistent in terms of presence (still in approximately 1,300 locations) and core functionality, but there was a notable shift in emphasis: it was now more explicitly tied to FedEx Returns Technology and Consolidated Returns, highlighting its role in in-store printing of return labels and enabling customers to drop off returns without a box or label. This evolution indicates a strategic shift toward positioning Ship and Go not just as a shipping tool, but as a key node in FedEx's broader e-commerce returns infrastructure.",
      "llm_answer": "In the 2023 filing FedEx Office presented the Ship and Go kiosk as a “convenient self‑serve shipping kiosk in approximately 1,300 locations” that lets customers generate a label via a mobile label or QR code and drop packages in a secure bin【FDX_10k_2023.pdf: page 15】. By the 2024 filing the kiosk is framed not only as a shipping point but as a digital hub for e‑commerce, with FedEx Returns Technology for in‑store printing of return labels and FedEx Consolidated Returns that let shoppers drop off returns with no box or label required【FDX_10k_2024.pdf: page 15】. This evolution shows FedEx is using its retail footprint to support the full e‑commerce fulfillment cycle—streamlining both outbound shipments and returns—highlighting a stronger focus on integrated, self‑service logistics for online shoppers.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: All numeric values are correct - the kiosk presence in approximately 1,300 locations is accurately cited for both 2023 and 2024, matching the ground truth exactly. ENTITY ACCURACY: Correct identification of FedEx Office, Ship and Go kiosk, FedEx Returns Technology, and FedEx Consolidated Returns. Years (2023 vs 2024) are correctly identified. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years, correctly identifying the evolution from a primary focus on self-serve shipping (2023) to an integrated returns management solution (2024). The comparison is logically sound and captures the strategic shift. COMPLETENESS: The answer addresses all parts of the question - how the positioning evolved, what it indicates about e-commerce logistics approach, and the returns management integration. SEMANTIC EQUIVALENCE: The LLM's characterization of the shift as positioning Ship and Go \"not only as a shipping point but as a digital hub for e-commerce\" effectively conveys the same strategic evolution described in the ground truth. The phrase \"streamlining both outbound shipments and returns\" captures the integrated approach mentioned in the original answer. MINOR OBSERVATIONS: The LLM answer includes helpful source citations (page numbers and document references) which add credibility but are not required. The wording is slightly more concise than the ground truth but maintains all essential information. The interpretation that this represents \"a stronger focus on integrated, self-service logistics\" is a reasonable inference supported by the documented evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 473,
        "total_tokens": 1912
      },
      "error": null
    }
  ],
  "evaluation_summary": {
    "total_questions": 999,
    "successful_evaluations": 998,
    "failed_evaluations": 1,
    "average_correctness_score": 5.8,
    "average_quantitative_accuracy": 6.28,
    "average_qualitative_accuracy": 6.02,
    "average_contextual_relevance": 7.15,
    "score_distribution": {
      "excellent": 234,
      "good": 214,
      "fair": 248,
      "poor": 302
    }
  },
  "original_experiment_metadata": {
    "model": "gpt-oss-120b-reasoning",
    "experiment": "e2_page_window",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions": 1000,
    "successful": 999,
    "failed": 1,
    "elapsed_seconds": 6959.58,
    "timestamp": "2026-02-02T17:36:25.325884"
  }
}